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Methods appendix to “Global, regional, and national incidence, 
prevalence, and years lived with disability for 328 diseases and injuries 
for 195 countries, 1990–2016: a systematic analysis for the Global 
Burden of Disease Study 2016” 
 
Preamble 
This appendix provides further methodological detail for “Global, regional, and national incidence, 
prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a 
systematic analysis for the Global Burden of Disease Study 2016” This study complies with the 
Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) recommendations. It 
includes detailed tables and information on data in an effort to maximize transparency in our estimation 
processes and provide a comprehensive description of analytical steps. We intend this appendix to be a 
living document, to be updated with each iteration of the Global Burden of Disease Study. 
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Section 1. GBD overview 
 
1.1 GATHER statement 
This study complies with the Guidelines for Accurate and Transparent Health Estimates Reporting 
(GATHER) recommendations. We have documented the steps involved in our analytical procedures and 
detailed the data sources used in compliance with the GATHER. For additional GATHER reporting, please 
refer to Appendix Table 1 in Section 4.  
 
1.2 Locations of the analysis 
The locations included in GBD 2016 have been arranged into a hierarchy of seven super-regions and a 
further nested set of 21 regions containing 195 countries and territories. These countries and territories 
for which GBD estimated global, regional, and national cause-specific mortality and years of life lost (YLLs) 
have not changed since GBD 2015. New subnational locations estimated for GBD 2016 were the local 
government areas of England and provinces of Indonesia. Subnational assessments for GBD 2016 
included 26 states and one federal district for Brazil, 33 provinces and municipalities for China, nine 
regions and 150 local government areas for England, 31 states and union territories by urbanicity for 
India, 34 provinces for Indonesia, 47 prefectures for Japan, 47 counties for Kenya, 31 states and one 
federal district for Mexico, two areas for Sweden, nine provinces for South Africa, 13 states for the 
Kingdom of Saudi Arabia, and 50 states and one federal district for the United States. Combined, there 
were 335 locations at the first subnational unit level. Subnational Level 2 only applies to India (urban and 
rural populations by state) and England (the upper tier local health authorities). For this paper we present 
data at the national and territory level.  Please refer to Appendix table 2 for more information.   
 
1.3 Time period of the analysis 
A complete set of cause-specific incidence, prevalence, and YLD numbers and rates were computed for 
the years 1990, 1995, 2000, 2005, 2010, and 2016.  All GBD 2016 results and online data visualisations 
are available at http://vizhub.healthdata.org/gbd-compare1 with access to results for all GBD metrics. 
 
1.4 GBD Cause List 
The GBD cause and sequelae list is organised hierarchically (see Appendix Table 3) to accommodate 
different purposes and needs of various users.  
The first two levels aggregate causes into general grouping. At Level 1 there are three cause groups: 
communicable, maternal, neonatal, and nutritional diseases (CMNNDs); non-communicable diseases 
(NCDs); and injuries. These Level 1 aggregates are subdivided at Level 2 of the hierarchy into 21 cause 
groupings (e.g., neonatal disorders, neurological disorders, and transport injuries). The disaggregation 
into Levels 3 and 4 contains the finest level of detail for causes captured in GBD 2016. The greatest detail 
available for some causes, such as anxiety disorders or rheumatoid arthritis, is at Level 3 of the hierarchy 
while other specific causes are at Level 4 of the hierarchy with an aggregate category at Level 3 (for 
example, depressive disorders at Level 3 which encompasses major depressive disorders and dysthymia 
at Level 4). Sequelae of diseases and injuries are organised at Levels 5 and 6 of the hierarchy. In GBD, 
sequelae are defined as distinct, mutually exclusive, categories of health consequences that can be 
directly attributed to a cause. For example, both neuropathy and blindness due to diabetic retinopathy 
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are sequelae of diabetes; stroke and ischaemic heart disease are not, as these consequences cannot be 
categorically ascribed to diabetes in an individual despite good evidence for increased risk of these 
outcomes. The finest detail for all sequelae estimated in GBD is at Level 6 and is aggregated into summary 
sequelae categories (Level 5) for causes with large numbers of sequelae. Examples include the grouping 
of the infectious disease episodes and long-term sequelae of meningitis, and the grouping of 47 injury 
sequelae into seven summary categories (for example all fractures, spinal cord lesions, and head injuries). 
Sequelae in GBD are mutually exclusive and collectively exhaustive and thus our YLD estimates at each 
level of the hierarchy sum to the total of the level above. Prevalence aggregation is estimated at the level 
of individuals who may have more than one sequela or disease, and therefore are not additive. 
The GBD cause list continues to evolve to reflect the policy relevance, public health, and medical care 
importance of the causes of major losses of health. The cause and sequelae list expanded following 
feedback from GBD 2015 and input from GBD 2016 collaborators. (Appendix Table 3). The incorporation 
of these changes expanded the cause list from the 310 causes with nonfatal estimates examined in GBD 
2015 to 328 causes with nonfatal estimates and from 2,337 to 2,498 unique sequelae at Level 6 of the 
hierarchy. As in GBD 2015, we made no estimates of YLDs for just five causes, either because no disability 
is possible, as is the case with sudden infant death syndrome; because disability may occur rarely but at 
levels too low for accurate estimation given the data, as for aortic aneurysm; or because the disability is 
captured by the complicating causes that led to that cause of death, as for indirect maternal deaths, late 
maternal deaths, and maternal deaths aggravated by HIV/AIDS. Appendix Table 4 provides a list of 
International Classification of Diseases version 9 (ICD-9) and International Classification of Diseases 
version 10 (ICD-10) codes for all GBD causes and the nature of injury categories. 
 
1.5 GBD results  
Results from the Global Burden of Disease Study (GBD 2016) are now measured in terabytes. Results are 
available in an interactive data downloading tool on the Global Health Data exchange (GHDx). The tool 
contains the complete set of results from all summary papers; however, specialised tables from the 
papers are available as separate entries in the GHDx as were made available for GBD 2015. 
 
The current version of the data download tool is available in the GHDx and contains core summary results 
for the Global Burden of Disease Study 2016 (GBD 2016): http://ghdx.healthdata.org/gbd-results-tool. 
The core summary results include deaths, YLLs, YLDs, and DALYs. It includes data for causes, risks, cause-
risk attribution, aetiologies, and impairments. 
 
In the GBD 2016 version, the tool also contains measures such as prevalence and incidence as well as rate 
of change data. Data above a certain size cannot be viewed online but can be downloaded. Depending on 
the size of the download, users may need to enter an email address and a download location will be sent 
to them when the files are prepared. 
 
1.6 Data input sources 
GBD 2016 incorporated a large number and wide variety of input sources to estimate mortality, causes 
of death and illness, and risk factors for 195 countries and territories from 1990 to 2016 and interpolated. 
These input sources are accessible through an interactive citation tool available in IHME’s GHDx. 
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Users can retrieve citations for a specific GBD component, cause or risk, and location by choosing from 
the available selection boxes. They can then view and access GHDx records for input sources and export a 
CSV file that includes the GHDx metadata, citations, and information about where the data were used in 
GBD. Additional metadata for each input source are available through the citation tool, as required by the 
GATHER statement. 
 
The citation tool is accessible through the GHDx at http://ghdx.healthdata.org/global-burden-disease-
study-2016 
 
1.7 List of Acronyms  
Adol: adolescent 
Air poll mort: mortality attributable to air pollution 
ANC: Antenatal care 
ART: antiretroviral therapy 
BTL: basic tabulation list 
CDR: crude death rates 
CHERG: Child Health Epidemiology Research Group 
CKD: chronic kidney disease 
CKD-DM: chronic kidney disease deaths attributable to diabetes  
COD: causes of death 
CODEm: cause of death ensemble modelling  
COPD: chronic obstructive pulmonary disease  
CR: cancer registry 
CVD: cardiovascular disease  
DAH: development assistance for health 
DALY: disability-adjusted life-year 
DHS: Demographic and Health Survey 
DPT: diphtheria-pertussis-tetanus 
DSP: Disease Surveillance Points 
ELISA: enzyme-linked immunosorbent assay 
EPEC: enteropathogenic E. coli 
EPP: Estimation and Projection Package 
ETEC: enterotoxigenic E. coli 
GATHER: Guidelines for Accurate and Transparent Health Estimates Reporting 
GBD: Global Burden of Diseases, Injuries, and Risk Factors Study 
GEMS: Global Enteric Multicenter Study 
GHDx: Global Health Data Exchange 
GPRM: Global Price Reporting Mechanism 
HAQ: Healthcare Access and Quality 
HH air poll: household air pollution 
Hib: Haemophilus influenzae type B 
HIV CDR: Crude death rate due to HIV/AIDS 
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IAEG-SDGs: Inter-Agency and Expert Group on Sustainable Development Goal Indicators 
IARC: International Agency for Research on Cancer 
ICD: International Classification of Disease 
IHD: ischemic heart disease 
IHR: International Health Regulations 
IOTF: International Obesity Task Force 
IPV: intimate partner violence 
ISIC: International Standard Industrial Classification 
JMP: Joint Monitoring Programme 
LDI: lag distributed income per capita  
LRI: lower respiratory infection 
MAP: Malaria Atlas Project 
MCCD: Medical Certification of Causes of Death 
MCEE: Maternal and Child Epidemiology Estimation group  
MDG: Millennium Development Goal 
MI: mortality/incidence ratio 
MM: maternal mortality 
MMR: maternal mortality ratio 
MMS: Maternal Mortality Surveillance  
Mort: mortality 
NCD: non-communicable disease 
NN mort: neonatal mortality 
NTDs: neglected tropical diseases 
OECD: Organisation for Economic Co-operation and Development 
Occ risk burden: burden attributable to occupational risks 
ODA: Official development assistance 
PAF: population-attributable fraction 
PCV3: Three-dose pneumococcal conjugate vaccine 
PHE: population health equivalence 
PM2.5: particulate matter <2.5μm in diameter 
RMSE: root mean square error 
RSV: respiratory syncytial virus 
SBA: skilled birth attendance 
SBH: summary birth history 
SCD(R): Survey of Causes of Death (Rural) 
SD: standard deviation 
SDG: Sustainable Development Goals 
SDI: Socio-demographic Index 
SDSN: Sustainable Development Solutions Network 
SEER: Surveillance, Epidemiology, and End Results Program 
SEV: summary exposure variable 
SRS: Sample Registration System 
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ST-GPR: spatiotemporal Gaussian process regression  
TAC: TaqMan Array Card 
TB: tuberculosis 
TRIPS: Agreement on Trade-Related Aspects of Intellectual Property Rights 
UHC: universal health coverage 
UIs: Uncertainty intervals 
UN: United Nations 
UNICEF: United Nations Children’s Fund 
VA: verbal autopsy 
VR: vital registration 
WaSH: water, sanitation, and hygiene 
WHO: World Health Organization 
YLD: years lived with disability 
YLL: years of life lost 
 
1.8 Funding Sources 
Funding for this research was provided by the Bill & Melinda Gates Foundation. 
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Section 2. Nonfatal outcome estimation 
 
The GBD 2016 nonfatal estimation process is visually represented in Appendix Figures 1a and 1b 
illustrating the steps necessary to estimate incidence, prevalence, and YLDs for disease and injury 
sequelae in GBD 2016. Appendix Figure 1a outlines the general process of nonfatal outcome estimation 
from data inputs to finalization of YLD burden results; steps 3b and 3c of that process identify alternative 
modelling approaches employed for certain causes and injuries. Alternative approaches are illustrated in 
greater detail in Appendix Figure 1b. Conceptually, the estimation effort is divided into eight major 
components: (1) compiling data sources through data identification and extraction; (2) data adjustment; 
(3) estimation of prevalence and incidence by cause and sequelae using DisMod-MR 2.1 or alternative 
modelling strategies for selected cause groups; (4) estimation by impairment; (5) severity distributions; 
(6) incorporation of disability weights; (7) comorbidity adjustment; and (8) the estimation of YLDs by 
sequelae and causes. Appendix Section 3 contains additional detail specific to each disease, impairment 
and injury and their sequelae. Nonfatal modelling strategies vary significantly between causes. 
2.1 Data sources, identification and extraction 
 
2.1.1 Systematic reviews 
For GBD 2015, updated systematic reviews were conducted for 101 causes and sequelae using data 
available through January of 2015. For GBD 2016 we conducted literature reviews for 116 causes and 4 
impairments. For other diseases, only a small fraction of the existing data appears in the published 
literature and other sources predominate such as survey data, disease registers, notification data, 
hospital inpatient data, or claims data.  Data were systematically screened from household surveys 
archived in the Global Health Data Exchange (ghdx.healthdata.org), including Demographic and Health 
Surveys, Multiple Indicator Cluster Surveys, Living Standards Measurement Surveys, and Reproductive 
Health Surveys. Other national health surveys were identified based on survey series that had yielded 
usable data for past rounds of GBD, sources suggested to us by in-country collaborators, and surveys 
identified in major multinational survey data catalogs, such as the International Household Survey 
Network and the World Health Organization (WHO) Central Data Catalog, as well as through country 
Ministry of Health and Central Statistical Office websites. Case notifications reported to the WHO were 
updated through 2016. Citations for all data sources used for nonfatal estimation in GBD 2016 are 
provided in searchable form through a web-tool (http://ghdx.healthdata.org/). A description of the search 
terms employed for cause-specific systematic reviews are detailed by cause in Appendix Section 3. 
 
2.1.2 Survey data preparation 
For GBD 2016, survey data for which we had access to the unit record data constituted a substantial part 
of the underlying data used in the estimation process. During extraction, we concentrated on 
demographic variables (such as location, sex, age), survey design variables (such as sampling strategy and 
sampling weights), and the variables used to define the population estimate (such as prevalence or a 
proportion) and a measure of uncertainty (standard error, confidence interval or sample size and number 
of cases).  
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2.1.3 Disease Registers  
For GBD 2016 nonfatal estimation, disease registries were an important source for a select number of 
conditions such as cancers, end-stage renal disease, and congenital disorders. The GHDx source tool 
(http://ghdx.healthdata.org/data-type/disease-registry)2 provides a comprehensive list of registry data 
used in GBD estimation processes. 
 
2.1.4 Estimation of Hospital Envelope 
 
Administrative Data
Separate data with 
one year recall and 
proportion data
Adjust reported 
proportions to 
average number of 
visits or admissions 
One year recall 
adjustment
Separate data 
disaggregated by age 
and all age data
Data 
disaggregated by 
age
DisMod-MR 2.1
Estimated Age 
pattern
Age splitting
Aggregated age 
data
Age split data
DisMod-MR 2.1Final hospital envelope
Covariate Database
Inpatient model:
Study: World Health Survey, World 
Health Survey Multi-country survey 
Country: log Hospital beds per 1,000
Input data ResultsDatabase Process
Survey microdata
Group data into recall 
bins
Reported tabulations
 
 
Input data and methodological summary 
 
Case definition 
 We defined a hospital admission as the overnight admission into a formal healthcare facility but 
excluded admissions to long-term care (>120 days), nursing care facilities, and traditional or spiritual 
healers. 
 
Input Data 
We searched the GHDx for population surveys, administrative records, and censuses from 
January 1990 to September 2016. We applied five secondary data filters: “discharge”, “health facility”, 
“nationally representative”, “household”, or “outpatient.” We also applied ten keyword filters: 
“healthcare access”, “health care costs”, “healthcare economics”, “healthcare expenditure”, “healthcare 
services”, “healthcare use”, “outpatient facilities”, “patient counts”, “hospitals”, or “length of stay”. We 
applied no language restrictions to our search and required all returned records to either contain 
microdata or tabulated reports. We searched the returned records’ metadata looking for measures of 
inpatient care. For inclusion, we required all measures to be nationally or subnationally representative. 
Additionally, we consulted with experts and GBD collaborators to gather data sources that were not 
within the GHDx. In total, we accepted data sources from 2,855 location-years (1,560 from administrative 
records and 1,295 from population surveys). 
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Modelling Strategy 
Data adjustment 
 We classified each of the accepted data sources into four data types: (a) proportion of survey 
respondents who were admitted into the hospital in the past 30 days; (b) proportion of survey 
respondents who were admitted to the hospital in the past year; (c) average number of admissions 
(utilization rate) reported by survey respondents in the past year; and (d) average number of visits 
reported by annual administrative records. We assigned measures reported by annual administrative 
records as our reference group as these data types were free from recall bias and most closely matched 
our case definition. In data sources where microdata was available, we extracted and binned the data 
based on gender and age groups of under-1, 1-4, 4-9, 10-14, through till 95+ years of age.  
 
We crosswalked each of the three non-reference (survey) data types to the reference 
(administrative record) data type through the use of penalized spline regressions to account for non-
systematic differences between the data types. For each non-reference data type and each sex, we 
looked for overlap between the non-reference data type and reference data type on the basis of location, 
year, age group, and sex. With the overlapping data, we calculated the ratio of the point estimate from 
the reference data type, 𝜇𝜇𝑟𝑟𝑟𝑟𝑟𝑟, to the non-reference data type,  𝜇𝜇𝑠𝑠. We fit these ratios with a penalized 
spline regression shown below ln�𝜇𝜇𝑟𝑟𝑟𝑟𝑟𝑟,𝑖𝑖
𝜇𝜇𝑠𝑠,𝑖𝑖 � = ℎ(𝑎𝑎𝑎𝑎𝑎𝑎𝑖𝑖) + 𝜀𝜀𝑖𝑖 (1) 
Where 𝑖𝑖 denotes a given matched observation, ℎ(𝑎𝑎𝑎𝑎𝑎𝑎𝑖𝑖) represents a basis function which estimated a 
cross-validated penalized spline over the population weighted mean age of the age group, and 𝜀𝜀 
represents the  residual. In the below figures, for each non-reference data type, we plot the ratio of 𝜇𝜇𝑟𝑟𝑟𝑟𝑟𝑟 
and  𝜇𝜇𝑠𝑠 across age and by sex and the predictions from the penalized spline regressions 
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Figure. Global age-sex specific crosswalks to equate each non-reference data type top the reference 
data type. For each non-reference data type and each sex, we plot the ratio of reference data points to 
non-reference data points, which were matched based on location, age group, year, and sex. Using a 
penalized spline regression, we estimated the crosswalk between each non-reference data type and the 
reference type. We plot the crosswalk and the associated prediction error below. 
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To crosswalk non-reference data types to reference data types, we multiplied non-reference data 
types by the exponentiated predictions from respective penalized spline regressions. Uncertainty from 
the adjustments were accounted for using the following equation 
𝑠𝑠𝑎𝑎𝑎𝑎 =  �𝑠𝑠𝑎𝑎𝑚𝑚2 ∙ 𝑠𝑠𝑎𝑎𝑠𝑠2 + 𝑠𝑠𝑎𝑎𝑚𝑚2 ∙ 𝜇𝜇𝑠𝑠2 + 𝑠𝑠𝑎𝑎𝑠𝑠2 ∙ 𝜇𝜇𝑚𝑚2  (2) 
Where 𝑠𝑠𝑎𝑎𝑎𝑎, 𝑠𝑠𝑎𝑎𝑚𝑚, and 𝑠𝑠𝑎𝑎𝑠𝑠 are the standard errors of the adjusted non-reference data point, the 
exponentiated crosswalk prediction, and the non-reference data point, respectively. 𝜇𝜇𝑠𝑠 and 𝜇𝜇𝑚𝑚 are the 
means of the non-reference data point and the exponentiated crosswalk predictions from the penalized 
spline regressions.  
 
Age-sex splitting 
DisMod-MR 2.1 is capable of conducting age-integration but its performance degrades while 
integrating across wide age categories (e.g. all ages). To remedy this issue, we ran a DisMod-MR 2.1 
model with data that was disaggregated by age to estimate countries’ age-pattern and then applied the 
estimated age-pattern to split aggregated all age data. This procedure was operationalized by calculating 
a constant, 𝑘𝑘, which was the ratio of the aggregated all age data point, 𝜇𝜇𝑎𝑎𝑎𝑎𝑎𝑎 𝑎𝑎𝑎𝑎𝑟𝑟, to the all age estimated 
utilization rate from the DisMod-MR 2.1 model, 𝜇𝜇𝑑𝑑� 
𝑘𝑘 = 𝜇𝜇𝑎𝑎𝑎𝑎𝑎𝑎 𝑎𝑎𝑎𝑎𝑟𝑟
𝜇𝜇𝑑𝑑�
 (3) 
The constant, 𝑘𝑘, was then multiplied by age specific utilization rates from the DisMod-MR 2.1 model. The 
uncertainty from the data and the age-pattern were propagated following equation 2. The split data were 
then incorporated into the final DisMod-MR 2.1 model. 
 
DisMod Modelling  
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 To help explain variation in locations with little to no data, we used the country level covariate of 
natural log of hospital beds per 1,000. Study level covariates were used to denote World Health Surveys 
and World Health Organization’s Multi-Country Survey Study on Health System Responsiveness. The 
country-level covariate of hospital beds per 1,000 was estimated using ST-GPR on data sourced from the 
World Bank. The study-level covariates were used as these two survey series were systematically higher 
than data points from other sources in the same locations and time period. Coefficients for the covariates 
are presented in below table.  
 
Table. Estimated coefficients of the hospital envelope model.  
Study-level covariates denote global dichotomous covariates that serve to adjust corresponding data 
points 
 
Covariate type Coefficient Exponentiated coefficient 
World Health Survey Study-level 0.44 
(0.39 — 0.48) 
1.55 
(1.48 — 1.61) 
World Health Organization Multi-
country Survey Study on Health 
and Responsiveness 
Study-level 0.49 
(0.42 — 0.55) 
1.63 
(1.52 — 1.73) 
log Hospital beds per 1,000 Country-level 0.17 
(0.16 — 0.19) 
1.19 
(1.17 — 1.20) 
 
 
2.1.5 Claims, inpatient hospital, and outpatient data 
 
For GBD 2016, claims (linkage) data, inpatient hospital, and outpatient data played a key role in the 
nonfatal estimation process of many GBD causes.  
Claims data 
For GBD 2016, we accessed aggregate data derived from claims information in a database of US private 
health insurance and public insurance schemes of Medicaid and Medicare, for the years 2000, 2010, and 
2012, commonly referred to as Marketscan. The population covered in each year was 3.3 million in 2000, 
40.4 million in 2010, and 40.8 million in 2012. For each of these individuals, information on every health 
service encounter was collected and all episodes of care were linked to individuals by unique identifiers, 
which allowed us to aggregate data in multiple ways, including creating counts of claims and individuals 
for inpatient and outpatient care. Marketscan has fifteen diagnosis columns for both inpatient and 
outpatient episodes. We mapped all ICD-9 four- or five-digit-coded diagnoses to GBD causes (see 
Appendix Table 4). GBD conditions were categorized as “long-term” or “short-term” depending on cause 
duration. In a given year, for each individual in the claims data, a long-term case was defined as any 
mention in any diagnostic field associated with any claim, including inpatient and outpatient encounters. 
A short-term case was defined the same way, but assumed that claims within a condition-specific 
duration were the same case. In this way, an individual could have multiple short-term conditions in a 
given year, while avoiding double-counting cases with multiple claims from a single illness episode.  
 
11
In GBD 2015, a subset of available facility types were used for short-term causes in outpatient claims 
data. In GBD 2016, we added more facility types, including the “office visit” facility type, which accounts 
for more than 50% of all outpatient data. 
 
 
Inpatient hospital admissions 
Inpatient hospital data were extracted from 3557 location-years in 41 countries. ICD coding was 
standardized across sources, and versions of ICD (Appendix Table 4).  
 
For GBD 2015, one limitation of our use of hospital data in non-fatal disease estimation was the challenge 
of accessing accurate information on coverage populations for any given data source. Section 2.1.4 of the 
appendix describes the modelling strategy for the hospital envelope, an estimate of hospital utilization, 
i.e. the rate of inpatient episodes per capita by age, sex, year and location.  For GBD 2016, we used this 
hospital utilization envelope in place of information on coverage population. We calculated demographic-
specific (by age, sex, year, and location) cause fractions in each inpatient hospital data source and 
multiplied these by the hospital utilization envelope to produce a rate of incidence/prevalence in 
inpatient admissions. For countries with completed registration of all inpatient episodes, this method 
makes little difference compared to the previous approach of dividing inpatient episode numbers by 
population as the all-cause inpatient rates per population from these sources were inputs to the 
utilization model. For countries with incomplete coverage, where in the past we had to make 
assumptions on the proportion of the population covered or reject the source because of unknown 
catchment population, this method is an improvement. 
 
Using the Marketscan claims data described above (with the exception of Marketscan 2000 data, due to 
the low coverage compared to two later years), we generated three scalars that were applied to the 
product of cause fractions generated by the inpatient hospital data and the utilization envelope on a 
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cause-by-cause basis. The scalars account for bias in inpatient hospital data from sources which were 
aggregated by ICD code and by primary diagnosis only. First, we corrected to account for multiple 
admissions for an individual. Second, we adjusted for non-primary diagnoses. Third, we corrected to 
account for inpatient and outpatient care. Combined with the uncorrected version (no scalar applied), 
this resulted in four types of incidence and prevalence estimates from inpatient hospital data: 1) (un-
corrected) inpatient admissions by episode, primary diagnosis, 2) inpatient admissions by individual, 
primary diagnosis only, 3) inpatient hospital admissions, accounting for all diagnoses, 4) an estimate of 
any inpatient admission or outpatient visit by an individual, accounting for all diagnoses. These data were 
reviewed in conjunction with data from all other sources for each model that utilizes hospital data to 
determine which type of data adjustment was most appropriate as an input to non-fatal disease 
estimation.  
 
The equations we used for each of the three scalars can be found below: 
 
a) Adjustment to account for multiple admissions which gave us inpatient admissions by individual, 
primary diagnosis only 
a. 𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑟𝑟𝑒𝑒𝑖𝑖𝑠𝑠𝑒𝑒𝑑𝑑𝑟𝑟1° ∗ �
𝑀𝑀𝑀𝑀 𝑖𝑖𝑖𝑖𝑒𝑒𝑎𝑎𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖1°
𝑀𝑀𝑀𝑀 𝑖𝑖𝑖𝑖𝑒𝑒𝑎𝑎𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑒𝑒𝑒𝑒𝑖𝑖𝑠𝑠𝑠𝑠𝑖𝑖𝑒𝑒1° � =  𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑𝑖𝑖𝑖𝑖1°  
b) Adjustment for non-primary diagnoses which gave us inpatient admissions by individual, all 
diagnoses 
a. 𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑟𝑟𝑒𝑒𝑖𝑖𝑠𝑠𝑒𝑒𝑑𝑑𝑟𝑟1° ∗ �
𝑀𝑀𝑀𝑀 𝑖𝑖𝑖𝑖𝑒𝑒𝑎𝑎𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑎𝑎𝑎𝑎
𝑀𝑀𝑀𝑀 𝑖𝑖𝑖𝑖𝑒𝑒𝑎𝑎𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑒𝑒𝑒𝑒𝑖𝑖𝑠𝑠𝑠𝑠𝑖𝑖𝑒𝑒1° � =  𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑𝑖𝑖𝑖𝑖𝑎𝑎𝑎𝑎𝑎𝑎  
c) Adjustment to account for inpatient and outpatient care which gave us inpatient admissions and 
outpatient visits by individual, all diagnoses 
a. 𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑟𝑟𝑒𝑒𝑖𝑖𝑠𝑠𝑒𝑒𝑑𝑑𝑟𝑟1° ∗ �
𝑀𝑀𝑀𝑀 𝑖𝑖𝑖𝑖𝑒𝑒𝑎𝑎𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑎𝑎𝑎𝑎 ∪𝑀𝑀𝑀𝑀 𝑒𝑒𝑜𝑜𝑖𝑖𝑒𝑒𝑎𝑎𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑎𝑎𝑎𝑎  
𝑀𝑀𝑀𝑀 𝑖𝑖𝑖𝑖𝑒𝑒𝑎𝑎𝑖𝑖𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑒𝑒𝑒𝑒𝑖𝑖𝑠𝑠𝑠𝑠𝑖𝑖𝑒𝑒1° � = 𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖|𝑜𝑜𝑜𝑜𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑑𝑑𝑖𝑖𝑖𝑖𝑎𝑎𝑎𝑎𝑎𝑎   
 
For maternal causes, a new bundle was created that had every maternity-related ICD code mapped to it. 
At the end of the process, each maternal cause rate was divided by the rate of this all maternity bundle in 
order to adjust the denominators from population to live births. 
 
Congenital and neonatal causes with similar age patterns were aggregated to create correction factors 
because the data in individual causes were too sparse to make them reasonable, and would leave the age 
pattern mostly flat. Injuries used a separate correction factor as well.   
 
These scalars were then smoothed by fitting a Loess curve to the observed data for each combination of 
cause and sex. The span of the Loess smoothing varied depending on how many observable data points 
there were. For cause/sex subsets with 5 or fewer observations a span (fraction of number of points to 
consider when fitting a curve) of 1 was set. For 6 to 10 observations, a span of 0.75 was set, and for 11 or 
more observations, a span of 0.5 was set. 
 
In cases where the third scalar, accounting for inpatient and outpatient care, was greater than 50, we 
determined it to be unstable and did not apply this scalar to the hospital data. Exceptions to this rule 
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were for congenital and neonatal causes (preterm births, neonatal hemoloytic disease, encephalopathy, 
sepsis), where babies hospitalized with these conditions often have comorbid states that make it very 
likely that the given code would not be listed as primary, as well as peripheral arterial disease and 
cirrhosis. For these causes, the exception is 100. 
 
 
 
 
Outpatient 
Outpatient encounter data were available from the US and Sweden for 68 location-years. In GBD 2016, 
Brazil and Mexico were included, but we dropped them this year due to lack of reliability (biases related 
to types of hospitals that were included in the datasets, etc). No changes were made in the processing of 
outpatient data from GBD 2015, aside from updates to the ICD mappings to GBD cause.  
 
Similar to the inpatient hospital data, a scalar was calculated using Marketscan claims data to adjust for 
multiple visits per individual within one year (for long-term conditions), and within a cause-specific 
duration (for short-term causes). However, for the outpatient correction factor, we kept only 3 outpatient 
facility types (office, outpatient hospital, and outpatient NEC).  
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Table: Facility types used in outpatient Marketscan data 
 
Outpatient Facility Name Used in 
GBD 
2015 for 
Incidence 
Used in 
GBD 
2016 for 
Incidence 
Used in 
Outpatient 
Correction 
Factor 
Office no yes yes 
Outpatient Hospital yes yes yes 
Independent Laboratory yes no no 
Emergency Room - Hospital yes yes no 
Patient Home yes yes no 
Inpatient Hospital no yes no 
Ambulatory Surgical Center no yes no 
End-Stage Renal Disease Facil no yes no 
Other Unlisted Facility no yes no 
Outpatient (NEC) no yes yes 
Skilled Nursing Facility no yes no 
Urgent Care Facility no yes no 
Ambulance (land) no yes no 
Independent Clinic no yes no 
Comprehensive Outpt Rehab Fac no yes no 
Nursing Facility no yes no 
Hospice no yes no 
Pharmacy (1) no no no 
Rural Health Clinic no yes no 
State/Local Public Health Clin no yes no 
Birthing Center no yes no 
Community Mental Health Center no yes no 
Federally Qualified Health Ctr no yes no 
Psych Facility Partial Hosp no yes no 
Residential Subst Abuse Facil no yes no 
Mass Immunization Center no yes no 
Custodial Care Facility no yes no 
Comprehensive Inpt Rehab Fac no yes no 
Psych Residential Treatmnt Ctr no yes no 
Inpatient Long-Term Care (NEC) no yes no 
Mobile Unit no yes no 
Assisted Living Facility no yes no 
School no yes no 
Inpatient Psychiatric Facility no yes no 
Walk-in Retail Health Clinic no yes no 
Military Treatment Facility no yes no 
Pharmacy (2) no no no 
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Other Inpatient Care (NEC) no yes no 
Ambulance (air or water) no yes no 
Non-resident Subst Abuse Facil no yes no 
Intermed Care/Mental Retarded no yes no 
Group Home no yes no 
Adult Living Care Facility no yes no 
Temporary Lodging no yes no 
Homeless Shelter no yes no 
MISSING no yes no 
 
 
Table: Durations of causes 
 
Duration in Days GBD Cause 
28 
diarrheal diseases, clostridium difficile, pelvic inflammatory disease, acute otitis 
media, myocardial infarction due to ischemic heart disease, first ever acute 
hemorrhagic stroke, first ever acute ischemic stroke, upper respiratory infections, 
peptic ulcer disease, symptomatic episodes, gastritis and duodenitis, symptomatic 
episodes, appendicitis, vascular intestinal disorders, paralytic ileus and intestinal 
obstruction, gallbladder and biliary diseases, symptomatic episodes, pancreatitis 
cases, interstitial nephritis and urinary tract infections, acute urolithiasis, acute 
myocarditis, pelvic inflammatory disease due to gonococcal infection, 
cerebrovascular disease acute, pelvic inflammatory disease due to chlamydial 
infection 
30 influenza 
60 acute other sense organ diseases, lower respiratory infections 
90 
typhoid fever, paratyphoid fever, abscess and other bacterial skin diseases, other 
meningitis -- viral, gonococcal infection, trichomoniasis infection, adverse effects 
of medical treatment, foreign body in eyes, acute glomerulonephritis, cellulitis, 
impetigo, foreign body in other body part, pulmonary aspiration and foreign body 
in airway, other transport injuries, cyclist road injuries, motor vehicle road 
injuries, motorcyclist road injuries, other road injuries, pedestrian road injuries by 
road vehicle, poisonings, falls, fire, heat, and hot substances, environmental heat 
and cold exposure , other unintentional injuries, venomous animal contact, non-
venomous animal contact, exposure to forces of nature, drowning, unintentional 
suffocation, other exposure to mechanical forces, unintentional firearm injuries, 
self-harm by other specified means, self-harm by firearm, sexual violence, assault 
by other means, assault by firearm, assault by sharp object, executions and police 
conflict, conflict and terrorism, typhoid and paratyphoid fever 
120 acute encephalitis 
180 
endocarditis, early syphilis infection, chlamydial infection, maternal abortive 
outcome 
365 
diphtheria remission, whooping cough, meningitis nonfatal overall, mild 
impairment due to neonatal tetanus, varicella seroprevalence, measles, visceral 
leishmaniasis, cutaneous and mucocutaneous leishmaniasis, symptomatic cystic 
echinococcosis, disfigurement due to basal cell carcinoma, cutaneous squamous 
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cell carcinoma, Guillain-Barré syndrome, ectopic pregnancy incidence ratio, 
maternal hemorrhage, hypertensive disorders of pregnancy, other maternal 
infections, obstructed labor, acute event, puerperal sepsis, decubitus ulcer, 
meningococcal meningitis incidence proportion, other meningitis incidence 
proportion, H influenza type b meningitis incidence proportion, pneumococcal 
meningitis incidence proportion, severe pre-eclampsia, eclampsia 
 
 
 
 
 
2.1.6 Case notifications 
 
Case notifications, active screening, intervention coverage studies, and surveillance contributed to 
estimates of infectious diseases. If available, we extracted data from survey and administrative microdata; 
otherwise, data were extracted from published literature and reports. For many infectious diseases and 
neglected tropical diseases (NTDs), we made use of cases notified by countries to the World Health 
Organization (WHO) and other global monitoring entities. The causes for which we use WHO case 
notification data included tuberculosis (TB), measles, yellow fever, rabies, dengue, cholera, whooping 
cough, human African trypanosomiasis (HAT), meningitis, all sexually transmitted infections (STIs), and 
other infectious and NTDs, such as Ebola. 
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2.2 Data adjustment 
In addition to the corrections applied to claims and hospital data, a number of other adjustments were 
applied to extracted nonfatal sources in order to make the data more consistent and suitable for 
modelling. In this second step of nonfatal estimation, commonly applied adjustments included age-sex 
splitting, adding study-level covariates, bias correction, adjustments for underreporting of notification 
data, and computing expected values of excess mortality.  
Age-sex splitting was commonly applied to literature data reported by age or sex but not by age and sex. 
For GBD2016, we split all data reported in age groups with a width greater than 20 years, using age 
patterns from available survey microdata or regional patterns derived from an initial run of main 
modelling tool, DisMod-MR 2.1. We relied on the meta-regression component of DisMod-MR 2.1 for 
many of the bias correction of data for variations in study attributes such as case definitions and 
measurement method. DisMod-MR 2.1 calculates a single adjustment that is applied regardless of age, 
sex, or location. If enough data were available to differentiate these adjustments by age, sex, or location, 
or if detailed survey data were available to make more precise adjustments between different thresholds 
on a biochemical measure, we applied bias corrections to the data before entry into DisMod-MR 2.1. For 
instance, we crosswalked between 15 different case definitions with different thresholds of fasting 
plasma glucose or glycated hemoglobin levels for diabetes mellitus based on available survey data with 
individual records of the actual measurements. In another example, we corrected data reporting on one-
year prevalence instead of point prevalence of alcohol dependence by age using studies reporting on 
both measures, as the average duration of alcohol dependence is greater in middle-aged and older 
individuals compared to young adults. The correction of notification data for underreporting relied on 
studies that had examined the gap between true incidence and notified cases. 
In GBD 2016, we estimated expected values of excess mortality from prevalence or incidence and cause-
specific mortality rate (CSMR) data for every cause for which deaths were estimated with the exception 
of a few causes with very low mortality rates such as uterine fibroids. We matched every prevalence data 
point (or incidence data for short-duration conditions) with the CSMR value corresponding to the age 
range, sex, year, and location of the data point. We restricted this to data points reporting age-groups 
spanning 20 years or less. The ratio of CSMR to prevalence (or incidence times a short duration) is 
conceptually equivalent to an excess mortality rate. To reflect a gradient in excess mortality, we added in 
all relevant models the log of lag distributed income (LDI) or the health access and quality index (HAQI) as 
a country covariate for excess mortality, with a strong prior that as LDI increases, excess mortality 
declines.  
 
2.3 DisMod-MR 2.1 Estimation 
 
a. Estimation of sequelae and causes 
The most extensively used estimation method was the Bayesian meta-regression method DisMod-MR 2.1. 
For some causes such as HIV/AIDS or hepatitis B and C, disease-specific natural history models have been 
used where the underlying three state model in DisMod-MR 2.1 (susceptible, cases, dead) is insufficient 
to capture the complexity of a disease process. For some diseases with a range of sequelae differentiated 
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by severity, such as chronic obstructive pulmonary disease (COPD) or diabetes mellitus, DisMod-MR 2.1 
was used to meta-analyze the data on overall prevalence with separate DisMod-MR 2.1 models of the 
proportions of cases with different severity levels or sequelae. Likewise, DisMod-MR 2.1 was used to 
meta-analyze data on the proportions of liver cancer and cirrhosis due to underlying etiologies such as 
hepatitis B, hepatitis C, and alcohol use.  
 
b. DisMod-MR 2.1 description 
Until GBD 2010, nonfatal estimates in burden of disease assessments were based on a single data source 
on prevalence, incidence, remission or a mortality risk selected by the researcher as most relevant to a 
particular location and time. For GBD 2010, we set a more ambitious goal: to evaluate all available 
information on a disease that passed a minimum quality standard. That required a different analytical tool 
that would be able to pool disparate information presented in varying age groupings and from data 
sources using different methods. The DisMod-MR 1.0 tool used in GBD 2010 evaluated and pooled all 
available data, adjusted data for systematic bias associated with methods that varied from the reference 
and produced estimates by world regions with uncertainty intervals using Bayesian statistical methods. 
For GBD 2013, the improved DisMod-MR 2.0 had increased computational speed allowing computations 
that were consistent between all disease parameters at the country rather than region level. The 
hundred-fold increase in speed of DisMod-MR 2.0 was partly due to a more efficient rewrite of the code 
in C++ but also by changing to a model specification using log rates rather than a negative binomial model 
used in DisMod-MR 1.0. In cross-validation tests, the log rates specification worked as well or better than 
the negative binomial specification.3 For GBD2015, we rewrote the ‘wrapper’ code that organises the 
flow of data and settings at each level of the analytical cascade. The sequence of estimation occurs at five 
levels: global, super-region, region, country and, where applicable, subnational location. The super-region 
priors are generated at the global level with mixed-effects, nonlinear regression using all available data; 
the super-region fit, in turn, informs the region fit, and so on down the cascade. The wrapper gives 
analysts the choice to branch the cascade in terms of time and sex at different levels depending on data 
density. The default used in most models is to branch by sex after the global fit but to retain all years of 
data until the lowest level in the cascade. Appendix Figure 2 below summarizes the Dismod-MR process. 
 
In updating the ‘wrapper,’ we consolidated the code base into a single language, Python, to make the 
code more transparent and efficient and to better deal with subnational estimation. The computational 
engine is limited to three levels of random effects; we differentiate estimates at the super-region, region 
and country level. In GBD 2013, the subnational units of China, the UK and Mexico were treated as 
‘countries’ such that a random effect was estimated for every location with contributing data. However, 
the lack of a hierarchy between country and subnational units meant that the fit to country data 
contributed as much to the estimation of a subnational unit as the fits for all other countries in the 
region. We found inconsistency between the country fit and the aggregation of subnational estimates 
when the country’s epidemiology varied from the average of the region. Adding an additional level of 
random effects required a prohibitively comprehensive rewrite of the underlying DisMod-MR engine. 
Instead, we added a fifth layer to the cascade, with subnational estimation informed by the country fit 
and country covariates, plus an adjustment based on the average of the residuals between the 
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subnational location’s available data and its prior. This mimicked the impact of a random effect on 
estimates between subnationals.  
 
In GBD 2015, we also improved how country covariates differentiate nonfatal estimates for diseases with 
sparse data. The coefficients for country covariates were re-estimated at each level of the cascade. For a 
given location, country coefficients were calculated using both data and prior information available for 
that location. In the absence of data, the coefficient of its parent location was used, in order to utilize the 
predictive power of our covariates in data sparse situations.  
 
For GBD 2016, the computational engine (DisMod-MR 2.1) remained substantively unchanged from GBD 
2015. We changed the prediction year set to generate fits for the years 1990, 1995, 2000, 2005, 2010, 
and 2016. We updated the age prediction sets to include age groups 80-84, 85-89, 90-94, and 95+, to 
comply with changes across all functional areas of the GBD. We also expanded the set of locations where 
subnational units are modeled; the set now includes: Brazil, China, England, India, Indonesia, Japan, 
Kenya, Mexico, Saudi Arabia, South Africa, Sweden, and the United States.   
 
c. DisMod-MR 2.1 likelihood estimation 
Analysts have the choice of using a Gaussian, log-Gaussian, Laplace or Log-Laplace likelihood function in 
DisMod-MR 2.1. The default log-Gaussian equation for the data likelihood is: 
−𝑙𝑙𝑜𝑜𝑎𝑎�𝑖𝑖�𝑦𝑦𝑗𝑗�𝛷𝛷�� = log�√2𝜋𝜋� + log�𝛿𝛿𝑗𝑗 + 𝑠𝑠𝑗𝑗� + 12�log�𝑎𝑎𝑗𝑗 + 𝜂𝜂𝑗𝑗� − log�𝑚𝑚𝑗𝑗 + 𝜂𝜂𝑗𝑗�𝛿𝛿𝑗𝑗 + 𝑠𝑠𝑗𝑗 �2 
where, yj is a ‘measurement value’ (i.e., data point); Φ denotes all model random variables; ηj is the offset 
value, eta, for a particular ‘integrand’ (prevalence, incidence, remission, excess mortality rate, with-
condition mortality rate, cause-specific mortality rate, relative risk or standardized mortality ratio) and aj 
is the adjusted measurement for data point j, defined by: 
𝑎𝑎𝑗𝑗 = 𝑎𝑎(−𝑜𝑜𝑗𝑗−𝑐𝑐𝑗𝑗)𝑦𝑦𝑗𝑗 
where uj is the total ‘area effect’ (i.e., the sum of the random effects at three levels of the cascade: super-
region, region and country) and cj is the total covariate effect (i.e., the mean combined fixed effects for 
sex, study level and country level covariates), defined by: 
𝑐𝑐𝑗𝑗 = � β𝐼𝐼(𝑗𝑗),𝑘𝑘𝑋𝑋�𝑘𝑘,𝑗𝑗𝐾𝐾[𝐼𝐼(𝑗𝑗)]−1
𝑘𝑘=0
 
with standard deviation  
𝑠𝑠𝑗𝑗 = � ζ𝐼𝐼(𝑗𝑗),𝑎𝑎?̂?𝑍𝑘𝑘,𝑗𝑗𝐿𝐿[𝐼𝐼(𝑗𝑗)]−1
𝑎𝑎=0
 
where k denotes the mean value of each data point in relation to a covariate (also called x-covariate); I(j) 
denotes a data point for a particular integrand, j; βI(j),k is the multiplier of the kth x-covariate for the ith 
integrand; 𝑋𝑋�𝑘𝑘,𝑗𝑗 is the covariate value corresponding to the data point j for covariate k; l denotes the 
standard deviation of each data point in relation to a covariate (also called z-covariate); ζI(j),k is the 
multiplier of the lth z-covariate for the ith integrand; and δj is the standard deviation for adjusted 
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measurement j, defined by: 
𝛿𝛿𝑗𝑗 = 𝑙𝑙𝑜𝑜𝑎𝑎�𝑦𝑦𝑗𝑗 + 𝑎𝑎(−𝑜𝑜𝑗𝑗−𝑐𝑐𝑗𝑗)𝜂𝜂𝑗𝑗 + 𝑐𝑐𝑗𝑗� − 𝑙𝑙𝑜𝑜𝑎𝑎�𝑦𝑦𝑗𝑗 + 𝑎𝑎(−𝑜𝑜𝑗𝑗−𝑐𝑐𝑗𝑗)𝜂𝜂𝑗𝑗� 
Where mj denotes the model for the jth measurement, not counting effects or measurement noise and 
defined by:  
𝑚𝑚𝑗𝑗 = 1𝐵𝐵(𝑗𝑗)−𝐴𝐴(𝑗𝑗)∫ 𝐼𝐼𝑗𝑗𝐵𝐵(𝑗𝑗)𝐴𝐴(𝑗𝑗) (a) da 
where A(j) is the lower bound of the age range for a data point; B(j) is the upper bound of the age range 
for a data point; and Ij denotes the function of age corresponding to the integrand for data point j. 
 
2.4 Impairment and Underlying Cause Estimation 
 
For GBD 2016, as in GBD 2015, we estimated the country-age-sex-year prevalence of nine impairments – 
step 4 of Appendix Figure 1a. Impairments in GBD are conditions or specific domains of functional health 
loss which are spread across many GBD causes as sequelae and for which there are better data to 
estimate the occurrence of the overall impairment than for each sequela based on the underlying cause. 
These impairments included: anaemia, epilepsy, hearing loss, heart failure, developmental intellectual 
disability, infertility, vision loss, Guillain-Barré syndrome, and pelvic inflammatory disease. Overall 
impairment prevalence was estimated using DisMod-MR 2.1. We constrained cause-specific estimates of 
impairments, as in the 19 causes of blindness, to sum to the total prevalence estimated for that 
impairment. Anaemia, epilepsy, hearing loss, heart failure, and developmental intellectual disability were 
estimated at different levels of severity. Estimates were made separately for primary infertility (those 
unable to conceive), secondary infertility (those having trouble conceiving again), and whether the 
impairment affected men and/or women. In the case of epilepsy, we determined the proportions with 
idiopathic and secondary epilepsy as well as the proportions with severe and less severe epilepsy using 
mixed effects regressions. The sparse data for the proportion of seizure-free, treated epilepsy were 
pooled in a random effects meta-analysis. DisMod-MR 2.1 models produced country-, age-, sex-, and 
year-specific severity levels of hearing loss and vision loss. Due to limited information on the severity 
levels of developmental intellectual disability, we assumed a similar distribution of severity globally, based 
on random effects meta-analysis of IQ-specific data for the overall impairment. This was supplemented by 
cause-specific severity distributions for chromosomal causes and iodine deficiency; the severity of 
developmental intellectual disability included in the long-term sequelae of causes including neonatal 
disorders, meningitis, encephalitis, neonatal tetanus, and malaria was estimated in combined health 
states of multiple impairments such as motor impairment, blindness, and/or seizures.14 For GBD 2015, we 
changed the name of the intellectual disability impairment to specify that estimates reflect cases arising 
during the developmental period which we have defined as ages below 20. The severity of heart failure 
was derived from our Medical Expenditure Panel Surveys (MEPS) analysis and therefore was not specific 
for country, year, age, or sex. 
A detailed description of the methods of each impairment can be found at the end of Section 3 of this 
appendix. 
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2.4.1 Impairment squeeze 
For impairments like epilepsy, developmental intellectual disability, and blindness, mentioned above in 
Step 4, we often have better information regarding the total prevalence of the impairment rather than 
the prevalence of said impairment due to its various causes. For example, we have more data and a 
better idea of the total number of blind individuals (which we refer to herein as the 
blindness "envelope") in the world than we do for the number of individuals who are blind due to a 
specific cause like retinopathy of prematurity or cataract. We achieve this consistency by either 
"squeezing" or inflating the individual sequela prevalence values so that their sums fit 
into each appropriate envelope. Blindness, epilepsy and/or developmental intellectual disability appear in 
various combinations with motor impairment levels as sequelae for a number of neonatal disorders and 
infectious diseases like malaria and neonatal tetanus ("Moderate motor impairment with blindness and 
epilepsy due to neonatal tetanus," for example). This present an extra challenge as any squeeze or 
inflation of one of the impairments making up a sequela will affect the others. We set some rules on how 
to do these adjustments sequentially. First, when the envelope of an impairment is smaller than the sum 
of all contributing causes, we redistribute the ‘excess’ prevalent cases of combined impairment sequelae 
onto the sequelae that only have motor impairment (at mild, moderate or severe level) within the same 
cause grouping. Second, we apply the adjustments in a particular order such that we always fit at least 
one of the envelopes exactly where the other one or two envelopes may be exceeded by some amount. 
We first enforce a fit to the developmental intellectual disability impairment envelope, then epilepsy and, 
lastly, blindness. Thus, the developmental intellectual disability envelope will always match exactly, 
whereas the epilepsy and blindness envelopes may occasionally be exceeded on a draw-by-draw basis. 
 
2.5 Severity Distribution 
 
Sequelae were deﬁned in terms of severity for 199 causes at Level 4 of the hierarchy (Appendix Table 3). We 
generally followed the same approach for estimating the distribution of severity as in GBD 2015. For Zika, we 
included sequelae for those with symptomatic acute infection, a small proportion with Guillain-Barré 
syndrome and the number of neonates with congenital Zika as reported to Pan American Health Organization 
(PAHO). For sexual violence, we estimated concurrent physical injuries and the more immediate 
psychological outcomes following sexual violence.  For the added causes that were split from broader cause 
categories, the differentiation between drug-sensitive and drug-resistant tuberculosis, the creation of other 
leukemia, alcoholic and other cardiomyopathy, and self-harm by firearm or other means each follow the 
same pattern of assigning sequelae as for their parent causes. In cases in which severity was related to a 
particular impairment, such as mild, moderate, and severe heart failure due to ischemic heart disease, 
the analysis was driven by impairment estimation methods. Severity levels for conditions such as chronic 
kidney disease and COPD were modelled using DisMod-MR 2.1, while we performed meta-analyses to 
estimate the allocation of severity for causes such as rheumatoid arthritis, dementia, and multiple sclerosis.  
 
For many causes we had inadequate data on severity from surveys or the epidemiological literature. For 
those diseases, we made use of three population surveys: the US Medical Expenditure Panel Survey 
(MEPS) 2000–2014, the [US] National Epidemiological Survey on Alcohol and Related Conditions (NESARC) 
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2000–2001 and 2004–2005, and the Australian National Survey of Mental Health and Wellbeing of Adults 
(NSMHWB) 1997.20–22 Each dataset contained individual-level measurements of functional health status 
using the SF-12 Health Survey as well as diagnostic information on the conditions affecting each 
individual.  
 
In order to use the data collected using SF-12 for measuring the distribution of severity, the individual SF-
12 summary scores were mapped to an equivalent disability weight. A convenience sample of 
respondents was asked to complete SF-12 for the hypothetical individual living in a health state described 
using a selection of 60 of the 235 health states with their lay descriptions from the GBD Disability Weights 
(DW) surveys, reflecting the full range of severity. Each of these health states has a measured disability 
weight associated with it on a zero to one scale. In total, we collected 1,980 usable responses. To deal 
with heterogeneity in responses, we excluded from the statistical analysis responses that were more than 
two median absolute deviations from the median for each health state. After correcting for outliers, the 
rank order correlation between SF-12 scores for the hypothetical individuals in each health state 
characterized by the lay description with the measured disability weight was -0.815. The health states 
served as random effect groups, such that the composite score would be equal to the intercept plus the 
random effect estimated for that health state, or 
 
𝐷𝐷𝐷𝐷𝑖𝑖 = 𝛼𝛼 + 𝑈𝑈ℎ𝑟𝑟𝑎𝑎𝑎𝑎𝑖𝑖ℎ 𝑠𝑠𝑖𝑖𝑎𝑎𝑖𝑖𝑟𝑟. 
 
The final relationship between SF-12 score and disability weight is shown below:  
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To generate a smooth mapping from SF-12 combined scores to the GBD disability weight space, we used 
LOESS regression on the random effects for each health state. Because disability weights are defined in 
the range from 0 to 1, we truncated the function at a combined SF-12 score of 116.36 (any combined 
score above this level was set to 0) and truncated the function at 42.7 so that any combined score less 
than that value was set to 1. All SF-12 survey data were thus transformed into disability weight space.   
 
The second stage of the analysis was to build models predicting the transformed SF-12 scores as a 
function of the number of conditions suffered by each individual. First, variable selection was performed 
using LASSO regression to penalize the regression coefficients of highly correlated conditions. The tuning 
parameter, λ, controls the strength of the least-squares penalty. When λ=0, LASSO regression returns the 
same results as ordinary least-squares regression. Higher values of λ impose a stronger penalty and 
constrain a greater number of model parameters to 0. A 10-fold cross-validation was used to find the 
value of the λ that minimised the mean cross-validated error. This process resulted in a λ value of 0.0013 
and eliminated 10 conditions from the analysis.  Transformed SF-12 scores into the disability weight scale 
for the remaining 190 conditions were then modeled for each measure m of each individual i over n total 
conditions in the survey, as follows: 
 
𝑙𝑙𝑜𝑜𝑎𝑎𝑖𝑖𝑖𝑖(𝐷𝐷𝐷𝐷)𝑖𝑖𝑚𝑚 = 𝛽𝛽0 + 𝛽𝛽1𝐶𝐶𝑜𝑜𝑖𝑖𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖1𝑖𝑖𝑚𝑚 + ⋯+ 𝛽𝛽𝑖𝑖𝐶𝐶𝑜𝑜𝑖𝑖𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖 𝑖𝑖𝑖𝑖𝑚𝑚 
 
This equation effectively assumes that comorbid conditions act to change SF-12 scores in a multiplicative 
fashion rather than an additive fashion.  
 
To estimate the comorbidity-corrected effect of each condition (i.e., in isolation) on total disability, we 
compared the predicted disability weight without the condition of interest (“counterfactual DW”) with 
the predicted disability weight including the condition of interest. Following the multiplicative 
comorbidity equation, the joint effect can be written:  
 
𝐶𝐶𝑜𝑜𝑖𝑖𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖 𝑠𝑠𝑖𝑖𝑎𝑎𝑐𝑐𝑖𝑖𝑠𝑠𝑖𝑖𝑐𝑐𝐷𝐷𝐷𝐷 = 1 − 1 − 𝑖𝑖𝑝𝑝𝑎𝑎𝐶𝐶𝑖𝑖𝑐𝑐𝑖𝑖𝑎𝑎𝐶𝐶𝐷𝐷𝐷𝐷𝑚𝑚1 − 𝑐𝑐𝑜𝑜𝑜𝑜𝑖𝑖𝑖𝑖𝑎𝑎𝑝𝑝𝑠𝑠𝑎𝑎𝑐𝑐𝑖𝑖𝑜𝑜𝑎𝑎𝑙𝑙𝐷𝐷𝐷𝐷𝑚𝑚 
 
The mean of this condition-specific effect over all observations is the population marginal effect of a 
condition. 
 
Using the model above, we estimate a counterfactual disability weight – the total individual disability 
weight excluding the effect of the condition of interest. We compared the observed distribution of 
functional health status with this counterfactual distribution to determine the marginal effect of the 
condition of interest. In other words, we estimate the health state for each individual and for each 
condition as the cumulative individual weight minus the effects of all comorbid conditions. 
 
𝐻𝐻𝑎𝑎𝑎𝑎𝑙𝑙𝑖𝑖ℎ 𝑠𝑠𝑖𝑖𝑎𝑎𝑖𝑖𝑎𝑎 𝐷𝐷𝐷𝐷 = 1 − 1 − 𝑖𝑖𝑖𝑖𝐶𝐶𝑖𝑖𝑖𝑖𝑖𝑖𝐶𝐶𝑜𝑜𝑎𝑎𝑙𝑙 𝑐𝑐𝑜𝑜𝑚𝑚𝑜𝑜𝑙𝑙𝑎𝑎𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝐷𝐷𝐷𝐷𝑚𝑚1 − 𝑐𝑐𝑜𝑜𝑜𝑜𝑖𝑖𝑖𝑖𝑎𝑎𝑝𝑝𝑠𝑠𝑎𝑎𝑐𝑐𝑖𝑖𝑜𝑜𝑎𝑎𝑙𝑙𝐷𝐷𝐷𝐷𝑚𝑚  
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The estimation strategy for health state-specific severity distributions where there are multiple severity 
categories involved binning individuals’ weights into severity cutoffs (e.g., mild, moderate, and severe) for 
which disability weights were derived. These bins were defined using results from the GBD Disability 
Weights Studies23 for conditions which had multiple health states defined. Cutoffs were taken as the 
midpoints between levels of health state and cases distributed into severity bins accordingly. Cases were 
considered asymptomatic if the counterfactual weight was equal to or exceeded the individual 
cumulative weight. 
 
2.6 Disability weights 
To compute YLDs for a particular health outcome in a given population, the number of people living with 
that outcome was multiplied by a disability weight that represents the magnitude of health loss 
associated with the outcome. Disability weights are measured on a scale from 0 to 1, with 0 implying a 
state that is equivalent to full health and 1 a state equivalent to death. 
Disability weights used in GBD studies prior to GBD 2010 have been criticized for the method used 
(person trade-off), the small elite panel of international public health experts who determined the 
weights and the lack of consistency over time as the GBD cause list expanded and additional disability 
weights from a study in the Netherlands24 were added or others derived by ad-hoc methods.  
 
GBD 2010 Disability Weights Measurement Study 
For GBD 2010, a primary data collection effort focused on measuring health loss rather than welfare loss 
using a standardized approach of simple comparison questions directed to the general public across 
diverse communities.  
Household surveys were conducted between Oct 28, 2009 and June 23, 2010 in five countries 
(Bangladesh, Indonesia, Peru, Tanzania and the USA) selected to provide diversity across culture, 
language and socioeconomic status.  
Personal face-to-face computer-assisted interviews were conducted for all household surveys with the 
exception of the survey in the USA which was conducted as computer-assisted telephone interviews. 
Households were randomly selected using a multistage stratified sampling design where the probability 
of selection was proportional to the population size. In all cases, samples were designed to be 
representative for a given geographical area with national representation in the case of the USA.  
For every contacted household, an adult respondent aged 18 years or older was randomly selected by the 
survey programme using the Kish approach. For face-to-face interviews, up to three visits were made to 
selected households to establish contact. When a respondent was identified, up to three return visits 
were made in order to do the survey at a time when the respondent was available. For the US telephone 
surveys, repeat calls were made up to seven times. 
A web based survey was posted at a dedicated URL between July 26, 2010 and May 16, 2011. The survey 
was initially available in English with subsequent availability in Spanish and Mandarin. Recruitment of 
respondents occurred through several channels, such as news items and editorials in scientific journals, 
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announcements at scientific meetings, postings on websites of institutions participating in the GBD, social 
networking and communication mobilization channels as well as direct contact with individuals and 
groups with known global health interests by tapping into the professional networks of the study 
investigators and their colleagues. Participants in the web based survey were required to be aged 18 or 
older. Household surveys obtained oral informed consent from all participants; written informed consent 
was obtained from participants in the web survey. Ethical review board approval was obtained from each 
household survey site and at the University of Washington, Seattle, WA.  
Standardized survey instruments were developed to obtain comparative assessments of the full array of 
disease and injury sequelae, parsimoniously captured in 220 unique health states. Lay descriptions of 
health states formed the basis for all comparisons. These descriptions used simple, non-clinical 
vocabulary that emphasized the major functional consequences and symptoms associated with each 
health state. Development of these descriptions involved an iterative process of detailed consultation 
with experts participating in the GBD 2010 study with the goal of both capturing the most relevant details 
of each health state while avoiding ambiguity and ensuring consistency. Where possible, health states 
were grounded in standard clinical classifications systems, for example, the Canadian Cardiovascular 
Society grading scale was referenced for descriptions of stages of angina,25 while the New York Heart 
Association functional classification was referenced for severity of heart failure.26 Pilot testing indicated 
that the lay descriptions in face-to-face interviews should not exceed 30 words. 
A paired comparison question formed the basis of all surveys. The questions in the survey were framed 
with the following statement, “A person’s health may limit how well parts of his body or mind work. As a 
result, some people are not able to do all of the things in life that others may do, and some people are 
more severely limited than others. I am going to ask you a series of questions about different health 
problems. In each question, I will describe two different people…” Descriptions of two hypothetical 
people, each with a particular health state, were presented to respondents who were then asked which 
person they regarded as “the healthier”. Health pairs in all surveys were selected by a randomizing 
computer algorithm. In the five household surveys, paired comparisons were presented for a subset of 
108 health states pertaining to chronic conditions. The framing of chronic and acute conditions is 
different as they were presented as causing life-long or temporary health loss. We chose to only field 
health states that could be framed as lasting a lifetime in the household surveys as we hypothesized that 
presenting differently framed comparisons would be difficult to convey in face-to-face interviews. In the 
web survey we considered this more feasible as respondents could read and refer to the framing of the 
question for each pair-wise comparison. All 220 health states were thus evaluated in the web survey. 
In addition, the web survey included “population health equivalence” (PHE) questions relating to 
population health and health programmes specifically – such as “Imagine two different health 
programmes. The first programme prevented 1,000 people from getting an illness that causes rapid 
death. The second programme prevented 2,000 people from getting an illness that is not fatal but causes 
lifelong health problems resulting in varying examples of health states at moderate to severe disability. 
Which programme would you say produced the greater overall health benefits?” This information was 
used to anchor the results from the pair-wise comparisons on the 0–1 disability weight scale. 
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 GBD 2013 European Disability Weights Measurement Study 
The GBD 2010 disability weights were critically dependent on the ways that outcomes were described to 
survey respondents. Descriptions for health states were designed to balance validity and parsimony and 
this necessarily meant that some details of different health states had to be omitted. As lay descriptions 
were developed collaboratively through individual expert groups organised around a particular set of 
health issues – some amount of variability in language and detail inevitably occurred. Criticisms and 
suggestions for improvement came from a number of commentators on the GBD 2010 disability weights 
measurement study.27–29 
The GBD 2013 Study expanded the list of disease and injury causes and sequelae which were mapped to 
235 unique health states. Additional data for the European Disability Weights Measurement Study were 
collected between September 23, 2013 and November 11, 2013 in Hungary, Italy, the Netherlands and 
Sweden. The initiation of these surveys was connected to a project sponsored by the European Centre for 
Disease Prevention and Control (the Burden of Communicable Diseases in Europe project).30 The four 
selected countries were chosen to be representative of the four regions of Europe (east, south, middle, 
and north) in terms of age, sex and education of the respondents. Respondents were recruited from 
standing internet panels in each country on the basis of quota sampling with reference to age, sex and 
education in such a way as to maintain population representativeness of these characteristics. Eligible 
participants were aged 18–65 and were preselected in the case of the Netherlands, where age, sex and 
education of respondents were already known, or in the case of the other three countries, invited to 
participate via a web-link and then selected on the basis of their individual characteristics. 
The protocol for the European disability weights measurement study followed the protocol that was 
developed and implemented in the GBD 2010 disability weights measurement study. Lay descriptions for 
some health states that lacked mention of an important symptom or for which consistency of wording 
across different levels of severity had been noted were reworded. The European disability weights 
measurement study included 255 health states, of which 183 were used in the analyses of GBD 2013. 
Those 183 consisted of 135 of the 220 health states that were included in the European disability weights 
measurement study with unmodified lay descriptions; 30 from GBD 2010 for which alternative lay 
descriptions were included. Disability weights were estimated for additional sequelae that were 
incorporated into GBD 2013 but had not been included in GBD 2010.  
Finding high correlation in resulting disability weight values between the country surveys and the web 
survey, we analyzed the results of all surveys together. We ran probit regression analyses on the answers 
to the pair-wise comparison questions, with dummies for each health state with a value of 1 for the first 
state in a pair, –1 for the second of a pair being chosen, and 0 for all states other than the pair being 
considered. This method formalizes the intuition that if two health states in a pair produce similar health 
loss, the answers are likely to be evenly split; a pair of health states with very different health loss, will get 
many more responses favoring one over the other. The statistical methods infer the distances between 
values attached to different health states based on the frequencies of responses to the paired 
comparisons. A second analytic step was needed to anchor the resulting estimates onto the 0–1 disability 
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weights scale. We anchored results from the probit regression analysis onto the 0–1 scale using 
population health equivalence data from the GBD 2010 web survey using a linear regression of the probit 
coefficients from the analysis of paired comparisons on the logit-transformed disability weight estimates 
derived from interval regression of the population health equivalence responses. Using numerical 
integration, we then estimated mean values for disability weights on the natural 0–1 scale. Uncertainty 
was estimated by bootstrapping with 1000 samples. 
A complete listing of the lay descriptions and values for the 235 health states used in GBD 2016 is 
provided in Appendix Table 5. 
 
2.7 Comorbidity correction (COMO) 
The final stage in the estimation of YLDs is a micro-simulation, which adjusts for comorbidity. We refer to 
this micro-simulation process as “COMO”. For GBD 2016, we estimated the co-occurrence of different 
diseases by simulating 40,000 individuals in each location-age-sex-year combination as exposed to the 
independent probability of having any of the sequelae included in GBD 2016 based on disease prevalence. 
We tested the contribution of dependent and independent comorbidity in the US MEPS data, and found that 
independent comorbidity was the dominant factor even though there are well-known examples of dependent 
comorbidity, i.e., clustering of conditions such as diabetes and stroke or anxiety and alcohol use disorders. Age was the 
main predictor of comorbidity such that age-specific microsimulations accommodated most of the required 
comorbidity correction.31  
The two components necessary for the computation of YLDs, prevalence of each disease sequelae and 
disability weights, are the two inputs into COMO. The prevalence values are primarily produced using 
DisMod-MR 2.1. The disability weights have been described above. 
The micro-simulation, as performed for each age-sex-location-year, can best be represented as a four-
step process. First, simulants are exposed to independent probabilities of having each sequela, where the 
probability is equal to the prevalence estimate. For each simulant, the probability of having a disease 
sequela is equal to the estimated prevalence from that draw from the uncertainty distribution. Each 
simulant is determined to have or not have the disease sequelae based on a draw from a binomial 
distribution. From this simulation, simulants end up having from none to multiple disease sequelae. 
Second, the disability weight for each simulant is estimated based on the disease sequelae that they have 
acquired. The formula for the cumulative disability weight for a simulant is one minus the multiplicative 
sum of one minus each disability weight present: 
𝑆𝑆𝑖𝑖𝑚𝑚𝑜𝑜𝑙𝑙𝑎𝑎𝑖𝑖𝑖𝑖 𝐷𝐷𝐷𝐷𝑎𝑎 = 1 −�(1 − 𝐷𝐷𝐷𝐷𝑘𝑘)𝑗𝑗
𝑘𝑘=𝑖𝑖
 
where the 𝐷𝐷𝐷𝐷𝑘𝑘 is the disability weight for the kth disease sequela that the simulant l has acquired. Once 
the simulant disability weight is computed, the disability weight attributable to each sequela for the 
simulant is calculated using the following formula: 
 
𝐴𝐴𝐷𝐷𝐷𝐷𝑎𝑎𝑘𝑘 = 𝐷𝐷𝐷𝐷𝑘𝑘
∑ 𝐷𝐷𝐷𝐷𝑘𝑘
𝑘𝑘=𝑗𝑗
𝑘𝑘=𝑖𝑖
∗ 𝑆𝑆𝑖𝑖𝑚𝑚𝑜𝑜𝑙𝑙𝑎𝑎𝑖𝑖𝑖𝑖 𝐷𝐷𝐷𝐷𝑎𝑎 
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where 𝐴𝐴𝐷𝐷𝐷𝐷𝑎𝑎𝑘𝑘 is the attributable DW for disease sequela k in simulant l; 𝐷𝐷𝐷𝐷𝑘𝑘 is the disability weight for 
disease sequela k, and simulant 𝐷𝐷𝐷𝐷𝑎𝑎 is the disability weight for simulant l from the combination of all 
sequelae that they have acquired. This formula apportions the overall simulant disability weight to each 
condition in proportion to the disability weight of each condition in isolation. 
 
Finally, YLDs per capita in an age-sex-country-year are computed by taking the sum of the attributable 
disability weights for a disease sequela across simulants. 
 
𝑌𝑌𝑌𝑌𝐷𝐷 𝑅𝑅𝑎𝑎𝑖𝑖𝑎𝑎𝑘𝑘 = ∑ 𝐴𝐴𝐷𝐷𝐷𝐷𝑎𝑎𝑘𝑘𝑖𝑖𝑎𝑎=1 𝑖𝑖  
 
The actual number of YLDs from disease sequela k in an age-sex-location-year is then computed as the 
YLD rate k times the appropriate age-sex-location-year population. 
 
By repeating the simulation process for each age-sex-country-year 1,000 times, the uncertainty in the 
prevalence of each disease sequela and the disability weight is propagated into the final comorbidity 
corrected YLD results. We selected 40,000 simulants for each age-sex- location-year group on the basis of 
simulation testing, which has shown that results were stable for YLDs at this number of simulants even in 
the younger age groups when prevalence is relatively low. For any given location-year-age-sex 
group, sequelae with prevalence of less than one in 20,000 were excluded from the microsimulation. 
 
2.8 YLD Computation, Uncertainty & Residual YLDs 
 
For GBD 2016, we computed YLDs by sequela as prevalence multiplied by the disability weight for the 
health state associated with that sequela. The uncertainty ranges reported around YLDs incorporates 
uncertainty in prevalence and uncertainty in the disability weight. To do this, we take the 1,000 samples 
of comorbidity-corrected YLDs and 1,000 samples of the disability weight to generate 1,000 samples of 
the YLD distribution. We assume no correlation in the uncertainty in prevalence and disability weights. 
The 95% uncertainty interval is reported as the 25th and 975th values of the distribution. Uncertainty 
intervals for YLDs at different points in time (1990, 1995, 2000, 2005, 2010, and 2016) for a given disease 
or sequela are correlated because of the shared uncertainty in the disability weight. For this reason, 
changes in YLDs over time can be significant even if the uncertainty intervals of the two estimates of YLDs 
largely overlap as significance is determined by the uncertainty around the prevalence estimates. 
 
Residual YLDs 
 
Despite expanding our list of causes and sequelae in successive GBD iterations, many diseases remain for 
which we do not explicitly estimate disease prevalence and YLDs. Less common diseases and their 
sequelae were included in 35 residual categories (Appendix Table 6). For 22 of these residual categories, 
epidemiological data on incidence or prevalence were available and these were modelled accordingly. For 
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13 residual categories, epidemiological data on incidence and prevalence were not available but sufficient 
cause of death data allowed for cause of death estimates. For these residual categories, we estimated 
YLDs by multiplying the residual YLL estimates by the ratio of YLDs to YLL from the estimates of level 3 
causes in the same disease category that were explicitly modelled. This scaling was undertaken for each 
country-sex-year. This approach made the simplifying assumption that the residual diseases caused 
disability proportionate to the ratio of disability to mortality in explicitly modelled diseases. We did not 
include causes with large disability but no or little mortality in estimating these ratios. For example, we 
estimated the YLDs from other neurological disorders from the YLD to YLL ratios for dementia, multiple 
sclerosis, and Parkinson’s disease, but did not include the YLDs from headaches and epilepsy in the ratio.  
 
2.9 Socio-Demographic Index (SDI) analysis & Epidemiological Transition 
a. Development of revised SDI indicator 
The Socio-demographic Index (SDI) is a composite indicator of development status constructed for GBD 
2015 whose components are strongly correlated with health outcomes. It is the geometric mean of 0 to 1 
indices of total fertility rate, mean education for those aged 15 and older, and lag distributed income per 
capita. 
 
SDI was calculated using the Human Development Index (HDI) methodology, wherein an index value was 
determined for each of the covariate inputs (log LDI, mean educational attainment over age 15, and TFR). 
For GBD 2015 these indices were computed on the basis of a relative scale, in which the upper and lower 
bounds were established by the maximum and minimum observed values, respectively, for each input 
over the entire estimation period of 1980–2015.  
Prompted by the observations that the scales (and by extension SDI) were sensitive to the addition of new 
subnational locations as GBD becomes more granular and to the length of the time period over which SDI 
is computed, for GBD 2016 we implemented fixed scales in determining individual indices. Thus, an index 
score of 0 now represents the minimum level of each covariate input past which selected health 
outcomes can get no worse. An index score of 1 represents the maximum level of each covariate input 
past which selected health outcomes cease to improve. As a composite, a location with an SDI of 0 would 
have a theoretical minimum level of development relevant to these health outcomes, while a location 
with an SDI of 1 would have a theoretical maximum level of development relevant to these health 
outcomes.  
 
We selected the minima and maxima of the scales by examining the relationships each of the inputs had 
with life expectancy at birth and under-5 mortality and identifying points of limiting returns at both high 
and low values, if they occurred prior to theoretical limits (eg, a TFR of 0). The final scales are summarised 
in the table below. 
 
Input Lower bound Upper bound 
TFR 1·5a 8 
LDI per capita 250 USD (5·52 log USD)b 60,000 USD (11·00 log USD) 
Mean educational attainment for 
ages 15 and older 
0 years 17 years 
a The low point of limiting returns for TFR was identified at 1 during GBD 2015; however, incorporating feedback with regard to 
accounting for a pattern of TFR rebound in highly developed countries, we instead set the lower limit of TFR at 1·5. 
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b The minimum for the LDI scale was originally set at the theoretical limit of 0 USD, as we did not observe an asymptotic 
relationship between log(LDI) and E0 or 5q0 at lower values of log(LDI). Empirically, however, we also did not observe an LDI 
below 350 USD (5·86 log USD) for the estimation period 1970–2016. In log-space, this meant that approximately half of our 
scale was not being utilised, compressing the observed variation in LDI and diminishing its meaningful contribution to SDI. 
Accordingly, we set the lower limit on LDI to 250 USD (5·52 log USD) to ensure we were fully utilising the range of the scale to 
capture its variation across space and time, as is the case with the other two inputs. 
 
Using the limits on the scales described above, we computed the index scores underlying SDI analogously 
to GBD 2015 as follows: 
𝐼𝐼𝐶𝐶𝑎𝑎𝐶𝐶 = (𝐶𝐶𝑎𝑎𝐶𝐶 − 𝐶𝐶𝑎𝑎𝑒𝑒𝑙𝑙) (𝐶𝐶ℎ𝑖𝑖𝑎𝑎ℎ − 𝐶𝐶𝑎𝑎𝑒𝑒𝑙𝑙)�  
Where 𝐼𝐼𝑐𝑐𝑎𝑎𝐶𝐶 – the index for covariate C, location l, and year y – is equal to the difference between the 
value of that covariate in that location-year and the lower bound of the covariate divided by the 
difference between the upper and lower bounds for that covariate. If the values of input covariates fell 
outside the upper or lower bounds (eg, LDI per capita greater than 60,000 USD), they were mapped to 
the respective upper or lower bounds. We also note that the index value for TFR was computed as 1 −
𝐼𝐼𝑇𝑇𝑇𝑇𝑇𝑇𝑎𝑎𝐶𝐶, as lower TFRs correspond to higher levels of development, and thus higher index scores. For GBD 
2016 we expanded the computation of SDI to 755 national and subnational locations spanning the time 
period 1970–2016.  
The composite Socio-demographic Index is the geometric mean of these three indices for a given 
location-year. The cutoff values used to determine quintiles for analysis were then computed using 
country-level estimates of SDI for the year 2016, excluding countries with populations less than 1 million. 
 
Example calculation 
Below we present the calculation of SDI for Mexico in the year 2010: 
𝑇𝑇𝑇𝑇𝑅𝑅 = 2.43;  𝑀𝑀𝑎𝑎𝑎𝑎𝑖𝑖 𝑎𝑎𝐶𝐶𝑜𝑜𝑐𝑐 𝑦𝑦𝑝𝑝𝑠𝑠 𝑖𝑖𝑐𝑐 = 9.23;  𝑙𝑙𝑖𝑖𝑌𝑌𝐷𝐷𝐼𝐼 = 9.58  
𝐼𝐼𝑇𝑇𝑇𝑇𝑇𝑇 = 1 −  2.43 − 1.58 − 1.5 =  .855  
𝐼𝐼𝐸𝐸𝑑𝑑𝑜𝑜𝑐𝑐 =  9.23 − 0 17 − 0 =  .543  
𝐼𝐼𝑎𝑎𝑖𝑖𝐿𝐿𝑙𝑙𝐼𝐼 = 9.58 − 5.5211.00 − 5.52 =  .741  
𝑆𝑆𝐷𝐷𝐼𝐼 =  �𝐼𝐼𝑇𝑇𝑇𝑇𝑇𝑇 ∗ 𝐼𝐼𝐸𝐸𝑑𝑑𝑜𝑜𝑐𝑐 ∗ 𝐼𝐼𝑎𝑎𝑖𝑖𝐿𝐿𝑙𝑙𝐼𝐼3 =  √. 855 ∗ .543 ∗  .7413 =  .701   
 
b. Age-sex-specific relationships between SDI and YLD rates  
 
In order to evaluate the relationship between SDI and morbidity, we fit a Gaussian process regression 
using a linear prior to the mean function within a stochastic partial differential equation (SPDE) 
framework. 
 
We first assume the following: ln (𝑌𝑌𝑖𝑖𝑎𝑎𝑠𝑠𝑐𝑐)~𝑁𝑁(𝜇𝜇𝑖𝑖 ,𝜎𝜎2) 
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Where Y,iasc is the cause-specific YLD rate for a given level of SDI (i), age group (a), sex (s), and cause (c).  
We then specify a linear prior to the mean µi,: 
𝜇𝜇𝑖𝑖 =  𝛼𝛼 +  𝛽𝛽(𝑆𝑆𝐷𝐷𝐼𝐼) +  𝑧𝑧𝑖𝑖 
Where  
𝑧𝑧𝑖𝑖 ~ 𝐺𝐺𝐺𝐺(0,𝛴𝛴𝑀𝑀) 
GP refers to a Gaussian processs, and 𝛴𝛴𝑀𝑀 refers to the Matern covariance function. 
 
For causes where the relationship between SDI and YLD rates was markedly non-linear (e.g., many 
neglected tropical diseases), we instead specified a continuous linear piecewise prior to the mean with 
either one or two knots depending on the nature of the distinct changes in direction in the data. 
 
Using SPDE, we specified additional priors on the range, variance, and precision of the mean function, as 
well as selected the number of underlying bases. These hyperparameters were chosen empirically and 
were identical for all age-sex-cause combinations. Values for the selected hyperparameters are displayed 
in the table below. 
Hyperparmeter Value 
Range 0.2 
Variance 1 
Precision 1 x 1010 
Number of bases 2 (mesh points at 0.3, 0.7) 
 
Regressions were run separately by age-sex-cause, using observed cause-specific YLD rates from all years 
1990-2016 to produce predictions per level of SDI from 0 to 1 in increments of .005. We fit models on 
observations from all countries estimated in GBD and included state and province level estimates in lieu 
of national estimates for Brazil, China, and India due to their large populations (> 200 million) and small 
number of state-level units modelled in GBD (BRA – 27, IND – 31, CHN – 33) relative to population. 
Though the United States and Indonesia also fall under the designation of large-population (> 200 
million), we fit models on national-level observations instead of state/province-level observations for 
these two countries as a result of the undue influence from the relatively large number of state-level 
units modelled in GBD relative to population (USA – 51, IDN – 34).  Country and region dummy variables 
used in GBD 2015 were no longer included in this analysis. All models were fit using the INLA package in 
R. 
 
Due to the more reliable estimation at more aggregate levels of cause specificity, we imposed a top-down 
hierarchical scaling scheme, in which the Level 1 causes were scaled to the predictions for all-cause 
morbidity, then Level 2 causes were scaled to their scaled Level 1 parents, and so on.  
 
Having a complete set of age specific YLD rates, we were then able to produce a full set of age-
standardised rates for every SDI level.  In order to produce other age-aggregates of our results, we used 
the same modelling framework as above. In this case, however, we regarded the logit of the share of 
population in each age group as the dependent variable to estimate a smoothed relationship between 
population age-structure and SDI.  Predictions for each age group at each level of SDI were rescaled to 
sum to 100%.   
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Section 3.  Nonfatal cause-specific estimation process 
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Case Definition  
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. The case definition 
includes all forms of TB including pulmonary TB and extrapulmonary TB which are bacteriologically 
confirmed or clinically diagnosed. For TB, the ICD 10 codes are A10-A19.9, B90-B90.9, K67.3, K93.0, 
M49.0, P37.0, and ICD 9 codes are 010-019.9, 137-137.9, 138.0, 138.9, 139.9, 320.4, 730.4-730.6. For 
HIV-TB, the ICD 10 code is B20.0. 
Latent TB infection (a new sequela added for GBD 2016) is defined as an infection with Mycobacterium 
tuberculosis, without any symptoms or signs of active TB disease. 
We have separately estimated the incidence and prevalence of multidrug-resistant tuberculosis and 
extensively drug-resistant tuberculosis by HIV status in GBD 2016. The case definitions of the new 
causes are shown below. 
(1) Multidrug-resistant TB without extensive drug resistance: a form of TB (among HIV-negative 
individuals) that is resistant to the two most effective first-line anti-tuberculosis drugs (isoniazid and 
rifampicin), but is not resistant to any fluoroquinolone and any second-line injectable drugs (amikacin, 
kanamycin, or capreomycin). 
(2) Extensively drug-resistant TB: a form of TB (among HIV-negative individuals) that is resistant to 
isoniazid and rifampicin, plus any fluoroquinolone and any second-line injectable drugs. 
(3) Drug-susceptible TB: TB (among HIV-negative individuals) that is susceptible to isoniazid and 
rifampicin 
(4) Multidrug-resistant HIV-TB without extensive drug resistance: a form of TB (among HIV-positive 
individuals) that is resistant to the two most effective first-line anti-tuberculosis drugs (isoniazid and 
rifampicin), but is not resistant to any fluoroquinolone and any second-line injectable drugs (amikacin, 
kanamycin, or capreomycin). 
(5) Extensively drug-resistant HIV-TB: a form of TB (among HIV-positive individuals) that is resistant 
to isoniazid and rifampicin, plus any fluoroquinolone and any second-line injectable drugs  
(6) Drug-susceptible HIV-TB: TB (among HIV-positive individuals) that is susceptible to isoniazid and 
rifampicin 
 
Input data 
Model Inputs 
Input data for TB include annual case notifications, data from prevalence surveys, and estimated cause-
specific mortality (CSMR) of TB among HIV-positive and HIV-negative individuals. From these inputs, we 
calculated ‘priors’ (expected values) on excess mortality to give more guidance to the model. An 
updated systematic review was done for GBD 2016 (the search terms are shown in the table below). 
Input data for latent TB infection (LTBI) include: (1) population-based tuberculin surveys, and (2) cohort 
studies examining the risk of developing active TB disease as a function of induration size. We searched 
PubMed and Google Scholar, and also manually searched the reference list of relevant studies to aid 
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identification of additional studies. The search terms, number of studies identified, and number of 
studies included are shown in the table below. 
Outcome Search Terms Total 
number of 
studies 
identified  
Number 
of 
studies 
included 
Tuberculosis* PubMed search terms: ("tuberculosis"[MeSH] OR 
tuberculosis[Title/Abstract]) OR TB[Title/Abstract] OR 
Mycobacterium tuberculosis[Title/Abstract] AND 
prevalence[Title/Abstract] AND ("2015/01/01"[PDAT] : 
"2016/11/02"[PDAT]) NOT (animals[MESH] NOT 
humans[MESH]) 
 
1061 3 
LTBI 
(tuberculin 
surveys) 
PubMed search terms: ("tuberculin survey"[tiab] OR 
(("risk"[MeSH Terms] OR "risk"[tiab] OR "risk of"[tiab]) 
AND ("tuberculosis"[MeSH Terms] OR "tuberculosis"[tiab] 
OR "tuberculous"[tiab]) AND ("infection"[MeSH Terms] OR 
"infection"[tiab])) OR (("risk"[MeSH Terms] OR "risk"[tiab] 
OR "risk of"[tiab]) AND TB[tiab] AND ("infection"[MeSH 
Terms] OR "infection"[tiab])) OR "latent tuberculosis 
infection"[tiab] OR "latent TB infection"[tiab] OR "latent 
tuberculosis"[MESH]) AND ("survey"[tiab] OR 
“surveys”[tiab]) NOT (animals[MESH] NOT humans[MESH]) 
 
Google Scholar search terms: ("tuberculin survey") OR 
(("risk of tuberculous infection" OR "risk of tuberculosis 
infection" OR "risk of TB infection" OR "latent tuberculosis 
infection" OR "latent TB infection") AND “survey”) 
 
9029 108 
LTBI (cohort 
studies) 
PubMed search terms: ("tuberculin"[tiab] OR 
("tuberculin"[tiab] AND "positive"[tiab]) OR 
"Mantoux"[tiab] OR ("Mantoux"[tiab] AND 
"positive"[tiab]) OR "induration"[tiab]) AND (active[tiab] 
AND ("tuberculosis"[MeSH] OR "tuberculosis"[tiab])) AND 
("risk"[MeSH] OR "risk"[tiab]) AND ("prospective"[tiab] OR 
"follow up"[tiab] OR "longitudinal"[tiab]) 
 
Google Scholar search terms: (("tuberculin" OR "Mantoux" 
OR “tuberculin reactivity”) AND (“risk of tuberculosis” OR 
“tuberculosis risk”)) -autopsy -autopsies -nosocomial -
qualitative -prison -cancer -malignant -homeless -smoking 
 
3624 27 
* Updated systematic review, covering the period from 2015/01/01 to 2016/11/02 
Input data for multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) include: (i) 
the number of drug-resistant cases by type [MDR-TB, XDR-TB, TB cases with a drug sensitivity testing 
(DST) result for isoniazid and rifampicin, and MDR-TB cases with DST for second-line drugs] from routine 
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surveillance and surveys reported to the World Health Organization, and (ii) the risk of MDR-TB 
associated with HIV infection from the literature.1   
Modeling Strategy 
Overview 
We made major changes to our modelling of TB. First, we estimated risk-weighted prevalence of LTBI by 
location, year, age and sex using data from population-based tuberculin surveys and cohort studies 
reporting on the risk of developing active TB disease as a function of induration size. Next, we divided 
the inputs on prevalence (from surveys in low and middle income countries), incidence (notification data 
from countries with a four or five-star rating, and estimated incidence for countries with a less than 
four-star rating), and CSMR by the risk-weighted LTBI prevalence in order to model TB among those at 
risk in each country. To generate incidence estimates, we first ran a regression using MI ratios (logit 
transformed) from locations with a 4 or 5-star rating on causes of death with SDI as a covariate 
anchoring the lower end of the SDI scale with a data point from the Bangalore study2 reporting that 
49.2% of 126 untreated new pulmonary TB cases were dead at the end of the 5-year follow up period, to 
predict age-sex specific MI ratios for all locations and years. We then estimated age-sex specific 
incidence using the predicted MI ratios and CSMR estimates. We used DisMod-MR 2.1, the GBD 
Bayesian meta-regression tool to generate consistent trends in all parameters. We then multiplied the 
DisMod-MR 2.1 outputs by the risk-weighted prevalence of LTBI to get population-level estimates of 
incidence and prevalence. Because the output from DisMod-MR 2.1 are for all forms of TB, we split them 
into MDR-TB and XDR-TB by HIV status. To do so, we estimated the proportions of TB cases with MDR-
TB for all locations and years, using data from notifications and survey data. We then estimated the 
proportions of MDR-TB among HIV-negative individuals and MDR-TB among HIV-positive individuals 
based on the risk of MDR-TB associated with HIV infection from a meta-analysis1. To split MDR-TB into 
MDR-TB with and without extensive drug resistance, we pooled the limited notification and survey data 
on the proportion of MDR-TB cases who are extremely drug resistant by super-region, and applied these 
proportions to MDR-TB cases among HIV-negative and HIV-positive individuals respectively. 
Modeling risk-weighted latent TB infection prevalence 
Input data for modeling risk-weighted LTBI prevalence were from two sources: (i) population based 
tuberculin skin test (TST) surveys, and (ii) cohort studies examining the risk of developing active TB 
disease as a function of induration size. First, we extracted the prevalence of tuberculin skin testing 
results by induration size using the most detailed induration categories reported by studies. Second, 
from cohort studies reporting on the relative risk of developing active TB disease as a function of 
induration size, we pooled the risk of developing active TB by induration size in millimeters using the 
DisMod Ode computational engine. Third, we multiplied the LTBI prevalence by induration in millimeters 
ranging from 0-20+ with the relative risk of developing active TB at each induration size, and summed 
them up to derive risk-weighted LTBI prevalence for each age group.  
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Available evidence3 suggests that people with very advanced HIV infection (CD4 counts <200 cells/mm3) 
may have a false-negative TST (0mm induration) due to profound immune suppression, but still have 
very high risk for TB. For those who are HIV-positive, but with higher CD4 counts, the risk for active TB 
increases with greater induration size as in HIV-negative individuals (i.e., the shape of the tuberculin 
response curve is similar to that for the general population). To take into account the false-negative TST 
response in HIV cases with profound immune suppression, we first computed the proportion of HIV-
positive individuals with CD4 counts <200 cells/mm  for the 0mm induration group using our HIV 
prevalence estimates for that particular category. We then multiplied that proportion by the relative risk 
of developing active TB disease in the 0mm induration group compared with the 20+ mm induration 
group among HIV positive individuals. The relative risk was computed using data from a prospective, 
multicenter cohort study of HIV-positive people in the United States.3  
Using the risk-weighted LTBI prevalence (adjusting for a false-negative TST among people with 
advanced HIV infection) as input data, we ran a DisMod MR 2.1 model with three location-level 
covariates, namely, Socio-demographic Index (SDI), Summary Exposure Variable (SEV) scalar for TB (a 
summary variable of the exposure levels of TB risk factors weighted by relative risk), and age-
standardized TB mortality rate, to generate risk-weighted LTBI prevalence by location, year, age and sex. 
We included two study covariates (BCG positive, and mixed BCG status) where the reference category is 
BCG negative. We found no statistically significant difference between studies using different dosages of 
tuberculin purified protein derivative (PPD). We therefore did not include different PPD dosages as 
study covariates but added more uncertainty to data points from studies that used dosages larger or 
smaller than the standard dose of 5 tuberculin units per test dose of 0.1 ml, by entering them as z-
covariates in Dismod. 
Modeling TB incidence 
Incidence inputs were from two different sources: (1) incidence from notification data for countries with 
a four or five-star rating on their cause of death data4 as a proxy for the quality of health-related 
administrative data systems, and (2) estimated incidence for countries with a less than four-star rating. 
We used the age and sex-specific notifications (all new and relapse cases combined) in our analysis. 
Prior to 2013, notification data were available by case type (new pulmonary smear-positive, new 
pulmonary smear-negative, and new extra-pulmonary) and there were missing age data especially for 
younger age-groups in some countries. We imputed the missing age-groups for the three forms of TB 
notifications. Smear-positive age-specific notifications were inflated with the proportion smear-
unknown and relapsed cases only reported at the country-year level.  Some countries reported only 
pulmonary smear-positive cases for selected years. Missing smear-negative and extra-pulmonary cases 
were predicted from the adjusted smear-positive cases using a seemingly unrelated regression.  All 
three types of notifications were added together to represent TB-all form incidence for countries with a 
four or five-star rating.  
To generate incidence estimates for locations with a less than four-star rating, we ran a regression using 
MI ratios (logit transformed) from locations with a 4 or 5-star rating on causes of death as input data 
with SDI as a covariate anchoring the lower end of the SDI scale with a data point from a cohort study in 
the 1960s2 reporting that 49.2% of 126 untreated new pulmonary TB cases were dead at the end of the 
5-year follow up period, in order to predict age-sex specific MI ratios for all locations and years. We then 
38
used the predicted MI ratios and cause specific mortality estimates to compute age-sex specific 
incidence estimates for locations with a less than four-star rating. For South Africa, a country with large 
inequality, we decided that the Health Care Access and Quality (HAQ) index would be a better health-
related index than SDI for TB, a health outcome that differentially affects the poor. We therefore used 
the HAQ index instead, to predict incidence for South Africa. While the MI-ratios predicted using the SDI 
covariate were within a reasonable range for most countries with a less than four-star rating, there were 
some outliers with very high MI ratios. We replaced those MI ratios with the MI ratios computed based 
on notifications and CSMR for 2010. For outliers in other years, we assumed a similar proportional 
difference between predicted MI ratios and notifications-based MI ratios as in 2010 and adjusted the 
predicted MI ratios accordingly, which were then used to predict incidence. 
We computed the age-sex specific incidence of TB among the latent TB-infected population, using TB 
incidence as the numerator and our estimated risk-weighted latent TB infection prevalence as the 
denominator. We included location-level covariates, namely, the age-standardized adult underweight 
prevalence, and the log-transformed age-standardized SEV scalar for TB to help inform variation over 
year and geography. We set bounds of 0.75 to 1.25 on the SEV scalar covariate where a value in log 
space of 1 would reflect perfect agreement with our risk factor estimates.  
 
Modeling TB prevalence  
Data from prevalence surveys reporting on pulmonary smear-positive TB and bacteriologically positive 
TB were included. Because incidence data are for all forms of TB, we adjusted prevalence surveys to 
account for extra-pulmonary cases. We ran a spatiotemporal Gaussian process regression to predict 
location-year-age-sex specific proportions of extra-pulmonary TB among all TB cases using data on the 
three forms of TB from the incidence data above. We then computed the extra-pulmonary inflation 
factor as 1+( proportion of extrapulmonary TB /(1- proportion of extrapulmonary TB)), and applied it to 
data from prevalence surveys. We then computed the prevalence of TB among the TB-infected 
population, using TB prevalence as the numerator and our estimated risk-weighted LTBI prevalence as 
the denominator. We included a study covariate indicating whether it was bacteriologically positive TB 
(reference category) or smear-positive TB. We found no systematic bias between studies that used both 
symptoms and chest X-ray as screening methods and studies that used only one of the methods. We 
therefore did not adjust them for systematic bias but added more uncertainty to data points from 
studies that used only one of the screening methods (by using it as a z-covariate in Dismod). We also 
added more uncertainty to data points from sub-national surveys. We included the SEV scalar country-
level covariate with priors that as the SEV scalar increases, prevalence increases.  
 
Modeling TB excess mortality  
We matched each prevalence data point and TB CSMR (TB and HIV-TB combined) by location, year, age, 
and sex to calculate excess mortality rate (EMR) as EMR=CSMR/prevalence. We also matched each 
incidence data point and TB CSMR by location, year, age, and sex to calculate EMR for countries with a 
four or five-star rating on their cause of death data. To reflect a gradient in EMR, we added the HAQ 
index, and adult HIV death rates as country-level covariates. 
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DisMod-MR 2.1 
For each location, we included the following as input in the DisMod model: case notifications for 
locations with a four or five-star rating, predicted MI-ratio-based incidence for locations with a less than 
four-star rating, prevalence survey data where available, excess mortality estimates, and CSMR (TB and 
HIV-TB combined) by age and sex.  
The output from the DisMod model was for all forms of TB in TB-infected population including both HIV-
negative and HIV-positive individuals. We computed the incidence and prevalence of TB among the 
entire population, by multiplying the prevalence of LTBI with the DisMod model estimates. 
Betas and exponentiated values from the DisMod model are shown in the table below. 
Covariate Parameter Beta (95% CI) Exponentiated beta (95% 
CI) 
Smear positive TB Prevalence -0.75 0.47 (0.47 — 0.47) 
Sex (male) Prevalence 0.51 1.66 (1.55 — 1.79) 
Sex (male) Incidence 0.13 1.14 (1.14 — 1.14) 
Age-standardized 
proportion adult 
underweight 
Incidence 2.23 9.35 (8.73 — 9.72) 
Age-standardized 
proportion adult 
underweight 
Prevalence 2.95 19.13 (17.32 — 20.07) 
Age-standardized SEV 
scalar (log-
transformed) 
Prevalence 0.78 2.19 (2.12 — 2.39) 
Age-standardized SEV 
scalar (log-
transformed) 
Incidence 0.75 2.12 (2.12 — 2.12) 
HAQ (log-
transformed) 
Excess mortality -1.58 0.21 (0.19 — 0.22) 
Adult HIV death rate Excess mortality 0.96 2.61 (1.04 — 7.02) 
HIV-TB incidence and prevalence 
To distinguish HIV-TB from all forms of TB, we first estimated the proportions of HIV-TB cases among all 
TB cases using data on the number of TB cases recorded as HIV-positive and the number of TB cases 
with an HIV test result recorded in the WHO TB notifications register. We ran a mixed effects regression 
using the adult HIV death rate as a covariate to predict location-year specific HIV-TB proportions, which 
were then applied to TB incident and prevalent cases from DisMod, to generate HIV-TB incident and 
prevalent cases by location and year. These cases were then age-sex split based on the age-sex pattern 
of estimated HIV prevalence by location-year to generate location-year-age-sex specific HIV-TB incident 
and prevalent cases.  
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Multidrug-resistant TB, extensively drug-resistant TB and drug-susceptible TB  
We ran a spatiotemporal Gaussian process regression to predict the proportions of MDR-TB cases 
among all TB cases for all locations and years. The input data for this regression (i.e., weighted average 
of the proportions of new and previously treated cases with MDR-TB) were based on the number of 
MDR-TB cases among new TB cases, MDR-TB cases among previously treated TB cases, and the number 
of new and previously treated TB cases with drug sensitivity testing for isoniazid and rifampicin from 
routine surveillance and surveys reported to the World Health Organization. We then used the predicted 
proportions to MDR-TB cases among all TB cases, along with the HIV-TB and TB no-HIV incidence 
estimates, and the relative risk of MDR-TB associated with HIV infection from the literature1 to compute 
the proportions of MDR-TB cases among HIV negative TB cases �𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠� by location, year, age, 
and sex using the following formula: 
 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠 = 𝑀𝑀𝑀𝑀𝑀𝑀𝑐𝑐,𝑦𝑦
�1 + �𝑀𝑀𝑀𝑀 𝑃𝑃𝑃𝑃𝑃𝑃𝐻𝐻𝐻𝐻𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠𝐻𝐻𝐻𝐻𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠��  𝐻𝐻𝐻𝐻𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠 
 
where 𝑀𝑀𝑀𝑀𝑀𝑀𝑐𝑐,𝑦𝑦 is the number of all MDR-TB cases among HIV-positive and HIV-negative individuals by 
location and year, RR is the relative risk of MDR-TB associated with HIV infection, 𝑃𝑃𝑃𝑃𝑃𝑃𝐻𝐻𝐻𝐻𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠 is the 
number of HIV-TB incident cases by location, year, age, and sex, and 𝐻𝐻𝐻𝐻𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠 is the number of TB 
no-HIV incident cases by location, year, age, and sex. 
 
We then applied the predicted proportions of MDR-TB cases among HIV negative TB cases to our 
predicted HIV-negative TB incident and prevalent cases to generate MDR-TB incident and prevalent 
cases by location, year, age, and sex. Next, we subtracted MDR-TB cases from all HIV-negative TB cases 
to generate drug-susceptible TB cases by location, year, age, and sex. To distinguish XDR-TB from MDR-
TB, we aggregated the XDR-TB cases and MDR-TB cases (with drug sensitivity testing for second-line 
drugs) up to the super-region level and calculated the super-region level proportions of XDR-TB among 
MDR-TB cases, which were then applied to MDR-TB cases in corresponding countries within the super-
regions to produce XDR-TB cases by location, year, age, and sex. We linearly extrapolated XDR-TB 
prevalence and incidence back assuming the rates were zero in 1992, one year before 1993 when XDR-
TB was first recorded in USA surveillance data.5 Finally, we subtracted XDR-TB cases from MDR-TB cases 
to generate MDR-TB (without XDR) cases by location, year, age, and sex.   
 
 
Multidrug-resistant HIV-TB, extensively drug-resistant HIV-TB and drug-susceptible HIV-TB  
To split HIV-TB into MDR-HIV-TB and drug-susceptible HIV-TB, we first calculated the proportions of 
MDR-HIV-TB among all HIV-TB cases (𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠) for each location, year, age, and sex using the 
following formula: 
 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠 = 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠𝑀𝑀𝑀𝑀 
 
where 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑐𝑐,𝑦𝑦,𝑎𝑎,𝑠𝑠 is the proportions of MDR-TB among all HIV-negative TB cases for each location, 
year, age, and sex and 𝑀𝑀𝑀𝑀 is the relative risk of MDR-TB associated with HIV infection. We then applied 
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the predicted proportions of MDR-TB cases among HIV-TB cases to all HIV-TB case estimates to generate 
MDR-HIV-TB cases by location, year, age, and sex. Next, we subtracted MDR-HIV-TB cases from all HIV-
TB cases to generate drug-susceptible HIV-TB cases by location, year, age, and sex. To separate out XDR- 
HIV-TB from MDR-HIV-TB, we applied the super-region level proportions of XDR-TB among MDR-TB 
cases, to MDR-HIV-TB cases in corresponding countries within the super-regions to produce XDR-HIV-TB 
cases by location, year, age, and sex. We linearly extrapolated XDR-HIV-TB prevalence and incidence 
back assuming the rates were zero in 1992, one year before 1993 when XDR-TB was first recorded in 
USA surveillance data.5 Finally, we subtracted XDR-HIV-TB cases from MDR-HIV-TB cases to generate 
MDR-HIV-TB (without extensive drug resistance) cases by location, year, age, and sex.   
 
Disability weights 
The lay descriptions and disability weights for severity levels derived from the GBD Disability Weights 
study are shown below. 
Health state Name Lay description Disability Weights 
(95% CI) 
Tuberculosis, not 
HIV infected 
has a persistent cough and fever, is short of breath, 
feels weak, and has lost a lot of weight 
0.333 (0.224-0.454) 
Tuberculosis, HIV 
infected 
has a persistent cough and fever, shortness of 
breath, night sweats, weakness and fatigue and 
severe weight loss 
0.408 (0.274-0.549) 
 
For drug-susceptible TB, MDR-TB without extensive drug resistance, and XDR-TB, we used the same 
disability weight [0.333 (0.224-0.454)] as in non-HIV-infected TB. For drug-susceptible HIV-TB, MDR-HIV-
TB without extensive drug resistance, and XDR-HIV-TB, we used the same disability weight [0.408 
(0.274-0.549))] as in HIV-infected TB. 
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Case definition 
Infection with the human immunodeficiency virus (HIV) causes influenza-like symptoms during the acute 
period following infection and can lead to acquired immunodeficiency syndrome (AIDS) if untreated. HIV 
attacks the immune system of its host, leaving infected individuals more susceptible to opportunistic 
infections like tuberculosis. Although there are two different subtypes of HIV, HIV-1 and HIV-2, no 
distinction is made in our estimation process or presentation of results. For HIV, ICD 10 codes are B20-
B24, C46-C469, D84.9; ICD 9 codes are 042-044, 112-118 (after 1980), 130 (after 1980), 136.3-136.8 
(after 1980), 176.0-176.9 (after 1980), 279 (after 1980); and ICD9 BTL codes are B184-B185. 
Input data 
Model inputs 
Household seroprevalence surveys 
Geographically representative HIV seroprevalence survey results were used as inputs to the model for 
countries with generalized HIV epidemics where available.  
 
GBD demographic inputs 
Location-specific population, fertility, and HIV-free survival rates from GBD 2016 and migration data from 
UNAIDS were used as inputs in modeling all locations. 
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UNAIDS data 
The files compiled by UNAIDS for their HIV/AIDS estimation process were our main source of data for 
producing estimates of HIV burden. These files are typically country-specific and contain both 
demographic data (population, fertility, migration, and HIV-free survival rates) and HIV-specific 
information. In all cases except migration, we substituted in our own, internally consistent demographic 
estimates. The HIV-specific information includes what is needed to run both the Spectrum and Estimation 
and Projection Package (EPP) models. Spectrum requires data on AIDS mortality among people living with 
HIV with and without ART, CD4 progression among people living with HIV not on ART, ART coverage 
among adults and children, coverage of breastfeeding among women living with HIV, prevention of 
mother-to-child transmission coverage, and CD4 thresholds for treatment eligibility. EPP uses many of the 
same assumptions as Spectrum but fits a simpler model to HIV prevalence data from surveillance sites 
and large household surveys. Antenatal care, incidence, prevalence, and treatment coverage data from 
UNAIDS were used in modeling for all locations. We extracted all of these data from UNAIDS’ proprietary 
formats. 
For GBD 2016, we received national-level files for 81 countries and subnational-level files for 6 countries. 
For many of the GBD locations not covered by these files, we had UNAIDS files from an earlier year of 
estimation, which we used again. After combining, we were left with a set of 42 countries for which we 
have never received a UNAIDS file, many of them countries with small populations and/or low HIV 
prevalence. In those places, we generated regional averages of all needed inputs. This enabled us to run 
Spectrum for every GBD location. 
In several cases, we have modified the structure or data in the UNAIDS files. In South Africa, which we 
have estimated at the province level since GBD 2015, we split the national-level UNAIDS file into nine 
provincial datasets. We used GBD 2016 demographic inputs for the provinces. These provinces are 
already fit as separate subpopulations in EPP, so we extracted the prevalence data for the individual 
provinces and assumed national rates for all other Spectrum inputs. In some locations that are estimated 
only at the national level in GBD 2016, we received subnational files from UNAIDS. In these cases, we split 
GBD 2016 demographic input data using the subnational relative relationships found in the UNAIDS files. 
Additionally, we identified that the ratio of fertility in HIV-positive women to HIV-negative women was 
negative in Indonesia. We used linear extrapolation to replace this value. 
Vital registration data 
We used all available sources of vital registration and sample registration data from the GBD Causes of 
Death database after garbage code redistribution and HIV/AIDS mis-coding correction, except in Group 
1A countries as described below.1,2 There are two different cause of death data sources for HIV/AIDS in 
China: the Disease Surveillance Point (DSP) system and the Notifiable Infectious Disease Reporting (NIDR) 
system. Both systems are administered by the Chinese Center for Disease Control and Prevention, but the 
reported number of deaths due to HIV is significantly lower in DSP. Therefore, we have used the 
provincial-level ratio of deaths due to HIV/AIDS from NIDR to those from DSP, choosing the larger ratio 
between years 2013 and 2014, and scaled the reported deaths in the DSP system, which is in turn used in 
the Space-Time Gaussian Process Regression (ST-GPR) process. 
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On-ART literature data  
Data were identified by using search terms “HIV,” “mortality,” and “antiretroviral therapy” in PubMed 
searches across the literature. To be included, studies must include only HIV-positive people who receive 
antiretroviral therapy (ART) but who were ART-naïve prior to the study. In addition, studies must report 
either a duration-specific mortality proportion or a hazard ratio across age or sex, and must not include 
children.  
For duration-specific survival data, studies must report uncertainty on mortality estimates or provide 
stratum-specific sample sizes and must include duration-specific data to allow for calculation of 0-6, 7-12, 
or 13-24 month conditional mortality. In addition, studies must either report separate mortality and loss-
to-follow-up (LTFU) curves, be corrected for LTFU using vital registration data, or be conducted in a high-
income setting. Finally, studies must report the percent of participants who are male, the median age of 
participants, and either data with specific data on the number of CD4 T lymphocytes (CD4 counts) or the 
median CD4 count used for the data. 
Hazard ratio data for ages or sexes can only be used if the hazard ratios are controlled for other variables 
of interest (age, sex, and CD4 category).  
In GBD 2013, we identified 102 papers for extraction. For GBD 2015, we included 13 additional studies 
informing the duration-specific mortality estimation process and 26 studies informing the age and sex 
hazard ratio estimation process (some studies were used and counted in both). We also added one study 
to our LTFU analysis. For GBD 2016, we included 12 additional studies informing the duration-specific 
mortality estimation process and 11 studies informing the age and sex hazard ratio estimation process 
(some studies were used and counted in both). 
Off-ART literature data 
In GBD 2013, to characterize uncertainty in the progression and death rates, we systematically reviewed 
the literature on mortality without ART. We searched terms related to pre-ART or ART-naive survival since 
seroconversion.3 After screening, we identified 13 cohort studies that included the cohorts used by 
UNAIDS from which we extracted survival at each one-year point after infection. Screening for additional, 
recently published studies in GBD 2015 and GBD 2016 identified no new cohort studies for inclusion in 
this analysis. 
Severity splits & disability weights 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for HIV/AIDS 
severity levels are shown below. 
Severity level Lay description DW (95% CI) 
Symptomatic HIV has weight loss, fatigue, and frequent infections. 0.274 
(0.184-0.377) 
AIDS with antiretroviral 
treatment 
has occasional fevers and infections. The person 
takes daily medication that sometimes causes 
diarrhea. 
0.078 
(0.052-0.111) 
AIDS without antiretroviral 
treatment 
has severe weight loss, weakness, fatigue, cough 
and fever, and frequent infections, skin rashes, 
and diarrhea. 
0.582 
(0.406-0.743) 
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The proportion of people living with HIV/AIDS who are being treated with anti-retroviral therapy is an 
output of Spectrum, the compartmental model used to make consistent incidence, prevalence, and 
mortality estimates described below.  
 
Modeling strategy  
In GBD 2016, our general modeling strategy for estimating HIV incidence, prevalence, and mortality is 
very similar to the strategy used in GBD 2015. We continue to use the Spectrum program rewritten in 
Python for GBD 2013 to facilitate faster and more flexible execution necessary for our more intensive 
computational needs. We made several changes to Spectrum’s assumptions comparing to the Spectrum 
software used by UNAIDS. We also again ran EPP using an open-source computer program in R written by 
Jeffrey Eaton.4 We ran EPP for all Group 1 countries in order to produce incidence and prevalence 
estimates that were consistent with the demographic and epidemiological assumptions used in 
GBD 2016. 
On-ART 
First, we corrected reported probabilities of death for loss to follow-up using an update of the approach 
developed by Verguet and colleagues.5 Verguet and colleagues used tracing and follow-up studies to 
empirically estimate the relationship between death in LTFU and the rate of LTFU. 
To create estimates of age-specific hazard ratios, we synthesized hazard ratio data in five broad age 
groups: 15-25, 25-35, 35-45, 45-55, 55-100, and modeled the data using DisMod-MR 2.0. 
To create estimates of sex-specific hazard ratios, we use the metan function in Stata to create estimates 
of relative risks separately by region, using female age groups as the reference group.  
The age and sex hazard ratios were applied to the study level mortality rates, accounting for the 
distribution of ages and sexes in the mortality data. We then subtracted HIV-free mortality from the 
model life table process to calculate study level age-sex HIV-specific mortality. 
We used DisMod-MR 2.0 to synthesize the age-sex split study level data into estimates of conditional 
probability of death over initial CD4 count.3 We modeled the data separately by duration, age, and sex 
and added a fixed effect on whether the study was conducted prior to 2002. We estimated all three 
regions together using a fixed effect for each region. 
Changes for GBD 2016 
In GBD 2016, we chose to age-sex split the data at the study level so that we could consider study-specific 
age-sex distributions, whereas previous GBD iterations relied upon region-specific distributions. Another 
change was a switch to estimating all regions together with fixed effects for each region. This allowed us 
to impart a CD4 trend in sub-Saharan Africa and other developing country estimates that led to more 
realistic estimates in the high CD4 categories where little data was available from those regions.  
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Off-ART 
Following UNAIDS assumptions, no-ART mortality is modeled as shown in the figure below.3  
 
 
 
The death and progression rates between CD4 categories vary by age according to four age groups: 15–
24 years, 25–34 years, 35–44 years, and 45 years or older. We modeled the logit of the conditional 
probability of death between years in these studies using the following formula: 
 
In the formula, m is conditional probability of death from year tj to tj+1, ai is an indicator variable for age 
group at seroconversion (15–24 years, 25–34 years, 35–44 years, and 45 years or older), tj is an indicator 
variable of year since seroconversion, and uκ is a study-level random effect.  
By sampling the variance-covariance matrix of the regression coefficients and the study-level random 
effect, we generated 1,000 survival curves for each age group that capture the systematic variation in 
survival across the available studies. For each of the 1,000 survival curves, we used a framework modeled 
after the UNAIDS optimization framework in which we find a set of progression and death rates that 
minimizes the sum of the squared errors for the fit to the survival curve.6,7  
Burden estimation overview 
UNAIDS uses two key analytical components in their epidemiological estimation. EPP is used to estimate 
incidence trajectories that are consistent with prevalence surveys and other prevalence measurements 
such as antenatal clinic serosurveillance. Spectrum is a compartmental HIV progression model used to 
generate age-specific incidence, prevalence, and death rates from the EPP incidence curves and 
assumptions about intervention scale-up and local variation in epidemiology. 
For GBD 2013, we created an exact replica of Spectrum in Python. This enabled us to run thousands of 
iterations of the model at once on our computing cluster and allowed for more flexible input data 
structures. Additionally, in order to generate estimates with more realistic ranges of uncertainty than 
those in UNAIDS 2012, we adjusted all input data by uniformly sampled factors between 0.9 and 1.1. 
These changes, along with our new estimation of with- and without-ART mortality and CD4 progression 
parameters, persist into GBD 2016. 
Due to the substantial differences in the quality and types of data available across different countries, we 
used three different methodologies to produce year-, age-, and sex-specific estimates of HIV incidence, 
prevalence, and mortality. 
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Countries with seroprevalence surveys and antenatal clinic data (Groups 1A and 1B) 
We identified 50 countries – as well as subnational locations in India, Kenya, and South Africa – with at 
least 0.5% adult HIV prevalence and at least one geographically representative HIV seroprevalence survey 
or available antenatal care clinic (ANC) data. In order to ensure that our estimates of incidence and 
prevalence in these places were consistent with our estimates of HIV progression, we used a version of 
EPP written in R and C++ by Jeffrey Eaton to create new fits to the available prevalence data. The version 
of EPP used in GBD 2016 was an updated release from Jeffrey Eaton since completion of GBD 2015. In 
this new version, an ANC prevalence adjustment was included and incorporated with the 2016 lookup 
database and an additional parameter to estimate ANC variance inflation was included as well. In the ANC 
bias adjustment, instead of using the default universal assumption of the prior mean and standard 
deviation (SD) of the distribution that the adjustment follows, we selected the parameters based on each 
sub-population (general population and high risk population) in each location. For sub-populations with 
prevalence survey data, we used the default assumption with mean=0.15 and SD=1. For subpopulations 
without prevalence survey data, we chose the region/epidemic specific mean and SD based on the 
median probit difference and probit difference SD in Table 1 of Marsh et al.8  
India’s HIV epidemic is classified as concentrated in specific subpopulations rather than generalized to the 
full population, and only one prevalence survey, the 2005-2006 National Family Health Survey (NFHS-3), 
was available, so we used modified parameters for Indian states in EPP. We first calculated the mean of 
the median probit difference between men and women for “Countries with concentrated epidemics” in 
Table 1 of March et al as mentioned above, which was 0.245. Then we derived empirical parameters 
based on the difference between the ANC data and the NFHS-3 survey data in probit space to use for the 
general population. Specifically, we calculated the probit difference by taking the median of all raw ANC 
prevalence in years 2004 through 2006 and comparing to the 2005 prevalence survey data in probit space 
for three states with large HIV epidemics: Andhra Pradesh, Karnataka, and Maharashtra. From this 
empirical parameter derivation, we got the mean and SD value based on the three states as 0.124 and 
0.051, respectively. We then used linear interpolation between the prevalence with a prior of 0.245 and 
the new prior of 0.124 to recalculate the mean and keep the SD the same as the empirical estimates. The 
final assumption of the prior mean and SD were 0.182 and 0.051, respectively. We did not make any 
adjustments for high risk populations. 
In the new version of EPP, in addition to the equilibrium prior assumption of the force of infection in 
projection, a random walk approach is available as an alternative method. For locations with two or more 
prevalence surveys and a declining trend between the mean of the most recent two surveys, the random 
walk approach was chosen to project the force of infection. We assumed the change of the log scaled 
force of infection was following a normal distribution with mean equal to the median of the change of the 
modeled force of infection among the years having ART implemented or prevalence data, and the SD was 
equal to the default setting as the mean SD of the change of the modeled force of infections among the 
years having prevalence data. The projection year was chosen from the most recent year between the 
year with the lowest model force of infection and the year of the second latest survey data.  
For Indian states, we used the equally weighted draw-level estimates of the equilibrium prior and random 
walk assumptions since we had no further information to support either assumption for each state. Here, 
the projection year of the random walk was the year with the lowest modeled force of infection because 
no locations had more than one prevalence survey, and the assumption of increasing ART coverage was 
supported by the data available to us. 
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In the new EPP code, an optimization step was added into IMIS function to speed up the parameter 
sampling step based on Raftery and Bao.9 Two optimization methods have been introduced. The main 
algorithm is Broyden–Fletcher–Goldfarb–Shanno (BFGS) optimization. If BFGS fails, Nelder-Mead 
optimum is used instead. In our 2016 EPP model, by substituting in our own assumptions about HIV 
progression rates and on/off ART mortality, we were able to ensure that the implied relationship between 
incidence and mortality/prevalence in EPP is similar to that in Spectrum. 
In Group 1 locations, we expect estimates of HIV burden to exhibit substantial uncertainty. To reflect this, 
we induced a perfect correlation between the previously independent draws of HIV mortality with and 
without ART and CD4 progression. We paired the draws of the three parameter sets internally and with 
each other in the following way: we sorted without-ART mortality and CD4 progression internally by age 
(not CD4), meaning the highest draw of HIV mortality without ART for age ai and CD4 category cl will be 
paired with the highest draw of HIV mortality without ART for age ak and CD4 category cl. In the same 
way, we sorted with-ART mortality internally by age, sex, CD4 count at treatment initiation, and duration 
on treatment. After this sorting process, the lowest indexed draw of each parameter has the highest 
values and vice versa. This means that we will use the most extreme possible parameter sets in EPP and 
Spectrum and should see a commensurate expansion in the range of the uncertainty. 
To ensure that this expanded uncertainty is replicated in EPP, we fit the model once for every set of 
paired draws of the progression parameters for every location. This means that the first iteration of EPP 
for Uganda sees the highest draws of all three sets of progression parameters. Such a procedure is 
necessary because EPP currently has no mechanism for incorporating uncertainty in any inputs except 
prevalence data. This process (Process 1 in the HIV/AIDS Estimation Flowchart), produced 1,000 sets of 
EPP output for each of the locations that make up the 48 countries in the group. Every set of EPP outputs 
contains 500 consistent draws of HIV incidence and prevalence in adults aged 15-49. In many cases, the 
algorithm used to fit EPP, incremental mixture importance sampling, failed, resulting in fewer than 1,000 
sets of EPP results. 
For every location in the group, we sampled one of the 500 incidence/prevalence draws from each of the 
sets of EPP results (Process 2 in the HIV/AIDS Estimation Flowchart). By sampling one draw from each set, 
we ensured that the distribution of progression parameters dictating the relationship between incidence 
and prevalence was exactly the same as the distribution of the sorted parameters generated in the 
previous step. In locations where not all 1,000 iterations of EPP fit successfully, we sampled one draw 
from every iteration that did succeed and then resampled with replacement from that set of draws. To 
maintain the link between the input progression draws and the resulting incidence and prevalence draws 
from EPP, we replaced any parameter draw associated with a failed run of EPP with the parameter draw 
that that failed draw was replaced with. At the end of this process, for every location in the set of 48 
countries, we were left with 1,000 linked draws of adult incidence and prevalence and the exact 
progression parameters that generated those draws. 
We then ran these results, along with the previously described demographic and HIV-specific inputs, 
through Spectrum to produce location-, year-, age-, and sex-specific estimates of HIV incidence, 
prevalence, and mortality (Process 9 in the HIV/AIDS Estimation Flowchart).  
The HIV/mortality reckoning process (Process 11 on the HIV/AIDS Estimation Flowchart) is intended as a 
method of reconciling separate estimates of HIV mortality (and its resulting effect on estimates of HIV-
free and all-cause mortality) in Group 1 countries by averaging estimates of HIV mortality from the model 
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life table process and EPP-Spectrum. Additional details on the reckoning can be found in the GBD 2016 
mortality manuscript.10   
Since Spectrum produces HIV incidence, prevalence, and deaths that are consistent with one another 
over time, the reckoning process results in death numbers that are no longer consistent with the 
incidence and prevalence produced in Spectrum. In order to recreate this consistency, we recalculated 
incidence for all Group 1 locations using reckoned deaths and prevalence produced by Spectrum (Process 
12 on the HIV/AIDS Estimation Flowchart). The updated incidence is calculated by aggregating counts of 
people living with HIV (PLWH), new infections, and deaths (among PLWH from HIV and other causes) at 
the year-sex level and calculating the following ratio for each sex: 
Age-specific counts of new infections are then scaled by their corresponding sex-year ratios. 
Countries with vital registration data (Group 2A and 2B) 
Vital registration is one of the highest-quality sources of data on HIV burden in many countries, so 
generating estimates that are consistent with these data, with necessary adjustment to account for any 
potential underreporting, is critical. We identified 114 countries – as well as 440 subnational locations 
from Brazil, China, Japan, Indonesia, Mexico, Sweden, the United Kingdom, and the United States – with 
at least two usable points of vital registration data, verbal autopsy (VA) data, or sample registration 
system (SRS) data. In India and Indonesia, we used SRS and VA data, respectively, as input mortality for 
CIBA. For India we extracted the resulting age-sex distribution of incidence, but scaled the level to match 
the adult incidence rate estimated from EPP for each state. 
We imputed missing years of data to generate a complete time series for HIV from the estimated start 
year of the epidemic using ST-GPR. We analyzed mortality trends using ST-GPR starting in 1981, the year 
that HIV was first identified in the United States.11 For ST-GPR, we adjusted the lambda (time weight) and 
GPR scale according to the completeness of vital registration data, with 4- and 5-star quality VR using 
parameters designed to follow the data more closely. We produced separate splines by country/age 
group, up to the peak year of death rate. We then ran a linear regression with random effects on region, 
age, and sex. Following this, we ran space-time residual smoothing, in which time, age, and space weights 
are used to inform smoothing of the residuals between data points and the linear regression estimate. 
From this process, we generated space-time estimates with the applied weights, along with the median 
absolute deviation (MAD) of the space-time estimates from the data. The MAD was calculated at various 
levels of the location hierarchy (e.g., subnational and national), and was added into the data variance 
term. The data variance and space-time estimates were then analyzed using Gaussian Process Regression 
to return a final estimate of mortality along with uncertainty.  
Although Spectrum produces HIV mortality estimates that are within the realm of possibility in most 
countries using the incidence curves provided in the UNAIDS country files, it is a deterministic model that 
has not yet been integrated into an optimizable framework. Therefore, in order to “fit” it to vital 
registration data, we need to adjust input incidence.  
50
To improve the fit of this process, in GBD 2015, we restructured Spectrum to add compartments that 
identify groups of people living with HIV by year of infection (Process 5 in the HIV/AIDS Estimation 
Flowchart). With this version of Spectrum we can output, among many other metrics, HIV deaths by year, 
age, sex, and infection cohort. This enables us to adjust incidence to fit to death much more precisely and 
without making any rigid assumptions about the time from HIV infection to HIV death. 
We have incorporated these improvements into a cohort incidence bias adjustment (CIBA) process. First, 
we ran Spectrum normally to produce 1,000 draws of incidence, prevalence and mortality (Process 4 in 
the HIV/AIDS Estimation Flowchart). Then, by year, age, and sex, we took the ratio of VR deaths to 
Spectrum deaths to quantify the amount of bias in Spectrum. Using draw-level duration data from the 
new version of Spectrum, for every year-, age-, and sex-specific infection cohort, we calculated the share 
of all HIV deaths observed over the course of the projection period in that cohort that would occur in 
each year after the year of infection. For example, projecting from 1970 through 2016, we identified the 
cohort of men infected in 1992 at the age of 16, calculated the total number of HIV deaths in that cohort 
in all subsequent years through the end of 2016, and divided the annual number of deaths by that total. 
This showed us the distribution of deaths among that cohort over the projection period. In the most 
extreme case (infections in 2015), we could only produce one point of that distribution (2016), so that 
single value is exactly 1·0; 100% of the deaths observed in that cohort occurred in 2016. 
We then used these distributions of death to weigh the ratio of VR deaths to Spectrum deaths, meaning 
that ratios in the years where we expect the largest share of deaths were weighed most heavily. We then 
multiplied the initial size of that cohort from the normal run of Spectrum by the sum of the combined 
ratios to get a new estimate of new cases in that year/age/sex combination. 
We can write this method mathematically in the following way: 
𝑟𝑡 =
𝑉𝑅𝑡
𝐷𝑡
 
𝜌𝑡
𝑡−𝑖 =
𝑑𝑡
𝑡−𝑖
∑ 𝑑𝑘
𝑡−𝑖𝑛
𝑘=𝑡−𝑖+1
 
𝛼𝑡−𝑖 = ∑ 𝑟𝑘
𝑛
𝑘=𝑡−𝑖+1
∗ 𝜌𝑘
𝑡−𝑖 
𝑛adjusted
𝑡−𝑖 = 𝛼𝑡−𝑖 ∗ 𝑛𝑡−𝑖 
𝑉𝑅𝑡 is the number of HIV/AIDS deaths in year 𝑡 from ST-GPR, and 𝐷𝑡 is the number of HIV/AIDS deaths 
from the first run of Spectrum. In the second equation, 𝑑𝑡
𝑡−𝑖 is the number of HIV/AIDS deaths among 
members of infection cohort 𝑡 − 𝑖 in year 𝑡, with 𝑖 ≥ 1, from the new, duration-tracking version of 
Spectrum, and 𝑛 is final year of the projection. Therefore, 𝜌
𝑡
𝑡−𝑖 is the share of observed deaths in cohort 
𝑡 − 𝑖 that we expect to occur in year 𝑡. It follows that 𝛼𝑡−𝑖 is the weighted adjustment ratio described 
above, which we multiply by the estimated initial size of infection cohort 𝑡 − 𝑖 as calculated in the first-
stage Spectrum run to get the adjusted number of new cases, 𝑛adjusted
𝑡−𝑖 . This process is run separately for 
every sex, single-age, and draw. 
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CIBA (Process 6 in the HIV/AIDS Estimation Flowchart) allows ratios in each year after a given infection 
year to influence the final adjustment to incidence. The size of that influence is determined by the 
relative importance of that year in the cohort-year’s distribution of deaths over time. The result is a new 
set of 1,000 draws of incidence and a set of 1,000 ratios of post-adjustment incidence to pre-adjustment 
incidence. We perform this adjustment using mean durations from the new version of Spectrum in order 
to try to shift the mean of the regular distribution of deaths. 
Finally, to produce location-, year-, age-, and sex-specific estimates of HIV incidence, prevalence, and 
mortality, we ran the new estimates of incidence and all previously input data through Spectrum (Process 
9 in the HIV/AIDS Estimation Flowchart).  
Countries without survey data and vital registration data (Group 2C) 
The remaining 31 countries – as well as 14 subnational locations from China and Saudi Arabia – had 
neither geographically representative seroprevalence surveys nor reliable vital registration systems. To 
produce estimates of HIV burden in these countries, we assumed that Spectrum is similarly biased as in 
other Group 2 countries. This involved running Spectrum (Process 7 in the HIV/AIDS Estimation 
Flowchart), adjusting incidence using 1,000 adjustment ratios randomly sampled from the entire set of 
CIBA results (Process 8), and rerunning Spectrum using the new draws of adjusted incidence (Process 9). 
As above, the estimates of incidence, prevalence, and mortality were incorporated into the rest of the 
machinery via the reckoning process. 
Subnational splitting and aggregation 
Spectrum results for India, Kenya, and UK subnational locations are modeled at higher levels of geography 
than our GBD locations. Spectrum results for India are produced at the state level, while GBD 2016 
estimates were produced at the state urban-rural level; Spectrum models Kenya provinces, while we 
compute Kenyan estimates for 47 counties. Indonesia and the United Kingdom have Spectrum results at 
the national level, while GBD 2016 estimates Indonesian provinces and Upper Tier Local Authorities in the 
UK. To split the Spectrum results into more granular results for processing, we assign each GBD 
subnational unit to a Spectrum modeling unit. From this, we generate age/sex/year-specific proportions 
for population, HIV-specific death, and HIV-free mortality.  
In Cote d’Ivoire, Haiti, Moldova, Mozambique, and Zimbabwe, the country files that we received from 
UNAIDS contained only subnational data without national-level aggregates. In these locations, we 
generated GBD 2016 demographic inputs for the provided subnational units using the proportions 
present in the UNAIDS files and ran the locations through EPP and Spectrum at the subnational level 
before aggregating to generate final national level GBD 2016 estimates. These aggregation and splitting 
steps are shown as Process 10 in the HIV/AIDS Estimation Flowchart. 
HIV/AIDS resulting in other diseases 
There are two Level 4 causes under the HIV/AIDS Level 3 cause in the GBD 2016 cause hierarchy. The 
modeling process for HIV/AIDS-tuberculosis is detailed in another part of this appendix. We computed the 
number of people living with HIV resulting in other diseases by subtracting the number of people living 
with HIV/AIDS-tuberculosis from all people living with HIV/AIDS at the 1,000 draw level. 
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 Diarrheal Diseases 
 
Flowchart 
 
 
Case definition 
We defined diarrheal disease episodes as three or more loose stools in a 24-hour period. In the diarrhea 
models, self-reported prevalence is the reference category for all data adjustments. Hospital input data 
use ICD9 codes 001-009.9 and ICD10 codes A00-A09. We also split diarrhea episodes into three severity 
levels: mild, moderate, and severe.  
Input data 
 Model inputs 
We used two main types of data in the diarrhea non-fatal burden estimation and the attribution of 
diarrheal etiologies. Moreover, we included all data sources used in GBD 2015 and conducted new 
reviews of scientific literature, surveys, and hospitalization data. We presented a summary of the data 
sources in Table Data.  
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The first type of data is the incidence and prevalence of diarrhea in community and hospital settings. 
Hospital data and healthcare utilization data were identified using the ICD9 codes 001-009.9 and ICD10 
codes A00-A09. To be consistent with the survey data, we transformed the hospital and healthcare data 
from incidence to prevalence. A summary of the data sources is found in Table 1. We used data from 
population-representative surveys, such as the Demographic and Health Surveys and the Multiple 
Indicator Cluster Surveys. We converted the prevalence of maternal-reported two-week period from 
surveys to point prevalence in one-year age increments this equation. 
𝑃𝑜𝑖𝑛𝑡 𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 = 𝑃𝑒𝑟𝑖𝑜𝑑 𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 ∗
𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛
(𝑅𝑒𝑐𝑎𝑙𝑙 𝑃𝑒𝑟𝑖𝑜𝑑 + 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 − 1)
Survey data were adjusted for seasonality. An inclusion criterion for scientific literature is a study duration 
longer than 1 year to avoid bias in the seasonal timing of diarrhea. Surveys are frequently conducted over 
several months. To account for seasonal variation in diarrhea prevalence, we fit a simple sine/cosine 
model for each GBD region. The model is mixed-effects with random effects on each site. The model 
accounts for the year of the survey. The percent difference between the monthly model fit diarrhea 
prevalence and the mean fitted diarrheal prevalence is a scalar to adjust survey data by month and 
location. 
Diarrhea duration was updated based on a systematic review with spatial variation (Table 2).1 
The second type of data describes diarrhea etiologies. We extracted data on all etiologies except C. 
difficile from scientific literature that reported the proportion of diarrhea cases that tested positive for 
each pathogen. We completed a systematic literature review covering the years May 2015 to May 2016 
for diarrhea prevalence, incidence, and all diarrhea etiologies. Inclusion criteria included diarrhea as the 
case definition, studies with a sample size of at least 100, and studies with at least one year of follow-up. 
We excluded studies that reported on diarrheal outbreaks exclusively and those that used acute 
gastroenteritis with or without diarrhea. 
We pulled all articles using a PubMed search term that combined non-specific and etiology-specific 
diarrhea on May 24, 2016 (Search string: ((((((diarrhoea[title] OR diarrhoea[MeSH Terms] OR 
diarrhea[title] OR diarrhea[MeSH Terms]) NOT ((colitis[title/abstract] OR enterocolitis[title/abstract] OR 
inflammatory bowel[title/abstract] OR irritable[title/abstract]OR Crohn*[title/abstract] OR HIV[title] OR 
treatment[title] OR therapy[title])) NOT ((appendicitis[title/abstract] OR esophag*[title/abstract] OR 
surger*[title/abstract] OR gastritis[title/abstract] OR liver[title/abstract] OR case report[title] OR case-
report[title] OR therapy[title] OR treatment[title])) AND ( ( 2015/04/01:2016/12/31[PDat] ) AND 
Humans[Mesh]) ))) OR (( (diarrhoea[title] OR diarrhoea[MeSH Terms] OR diarrhea[title] OR 
diarrhea[MeSH Terms]) AND (salmonella[title/abstract] OR salmonella[MeSH Terms] 
aeromonas[title/abstract] OR aeromonas[MeSH Terms] OR shigell*[title/abstract] OR shigell*[MeSH 
Terms] OR enteropathogenic e coli [title/abstract] OR enteropathogenic e coli[MeSH Terms] OR 
enterotoxigenic e coli[title/abstract] OR enterotoxigenic e coli[MeSH Terms] OR 
campylobacter[title/abstract] OR campylobacter[MeSH Terms] OR amoebiasis[title/abstract] OR 
entamoeb*[title/abstract] OR amoebiasis[MeSH Terms] OR entamoeb*[MeSH Terms] OR 
cryptosporidi*[title/abstract] OR cryptosporidi*[MeSH Terms] OR rotavirus[title/abstract] OR 
rotavirus[MeSH Terms] OR norovirus[title/abstract] OR norovirus[MeSH Terms] OR 
adenovirus[title/abstract] OR adenovirus[MeSH Terms]) AND ((etiolog*[title/abstract] OR etiology[MeSH 
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Terms] OR cause[title/abstract] OR pathogen[title/abstract])) NOT ((colitis[title/abstract] OR 
enterocolitis[title/abstract] OR inflammatory bowel[title/abstract] OR irritable[title/abstract]OR 
Crohn*[title/abstract] OR HIV[title] OR treatment[title] OR therapy[title])) NOT 
((appendicitis[title/abstract] OR esophag*[title/abstract] OR surger*[title/abstract] OR 
gastritis[title/abstract] OR liver[title/abstract] OR case report[title] OR case-report[title] OR therapy[title] 
OR treatment[title])) AND ( ( 2015/04/01:2016/12/31[PDat] ) AND Humans[Mesh]))))). 
We identified 442 studies, of which 36 met our inclusion criteria. We extracted data points for location, 
sex, year, and age. For the data that describe proportion of episodes positive for a given pathogen, we 
assigned an age range based on the prevalence-weighted mean age of diarrhea in the appropriate 
year/sex/location if the age of the study participants was not reported.  
We used the Global Enteric Multicenter Study (GEMS), a seven-site, case-control study of moderate-to-
severe diarrhea in children under 5 years,2 to calculate odds ratios for the diarrheal pathogens. We 
analyzed raw data for a systematic reanalysis, representative of the distribution of cases and controls by 
age and site, of roughly half of the 22,000 original GEMS samples that were tested for the presence of 
pathogen using quantitative polymerase chain reaction (qPCR).3  
Severity split inputs 
Diarrheal diseases have three severity levels: mild, moderate, and severe. The proportion of diarrhea 
cases that are assigned to each comes from a systematic review of diarrhea severity.1 Mild cases are the 
proportion of diarrhea cases that did not seek medical care (64.8%); moderate cases are the proportion 
that sought medical care but did not have severe dehydration or bloody stool (28.9%); and severe cases 
are the proportion that sought medical care with severe dehydration or bloody stool (6.9%). These 
proportions are based on the frequency of dehydration and bloody stool among community-based 
studies reported in the systematic review. 
Modeling strategy  
The non-fatal diarrheal disease burden is modeled in DisMod-MR, a Bayesian meta-regression modeling 
framework. DisMod-MR produces estimates of the incidence, prevalence, and remission of diarrhea for 
each age, sex, location, and year. We defined remission, or the time to recovery, as five days average. 
Diarrhoeal disease episodes are characterized as three or more loose stools in a 24 hour period. The 
reference category for our input data is community based diarrhoea episodes such as data from 
population-representative surveys or community cohorts. Input data that are from a different population, 
such as hospital outpatient or inpatient groups, are adjusted by study-level covariates so that they are 
consistent with the reference category. This step occurs in DisMod.  
Country-level covariates also inform the model. These include the proportion of the population that have 
access to improved sanitation, access to improved water sources, health system access, income per 
capita, and the SEV for diarrhea (Table 3). 
We estimated diarrheal disease etiologies separately from overall diarrhea mortality using a 
counterfactual strategy for enteric adenovirus, Aeromonas, Entamoeba histolytica (amoebiasis), 
Campylobacter enteritis, Cryptosporidium, typical enteropathogenic Escherichia coli (t-EPEC), 
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enterotoxigenic Escherichia coli (ETEC), norovirus, non-typhoidal salmonella infections, rotavirus, and 
Shigella. Vibrio cholerae and Clostridium difficile were modeled separately.  
Diarrheal etiologies are attributed to diarrheal deaths using a counter-factual approach. We calculated a 
population attributable fraction (PAF) from the proportion of severe diarrhea cases that are positive for 
each etiology. The PAF represents the relative reduction in diarrhea mortality if there was no exposure to 
a given etiology. As diarrhea can be caused by multiple pathogens and the pathogens may co-infect, PAFs 
can overlap and add up to more than 100%. We calculated the PAF from the proportion of severe 
diarrhea cases that are positive for each etiology. We assumed that hospitalized diarrhea cases are a 
proxy of severe and fatal cases. We used the following formula to estimate PAF:4 
𝑃𝐴𝐹 = 𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 ∗ (1 −
1
𝑂𝑅
) 
Where Proportion is the proportion of diarrhea cases positive for an etiology and OR is the odds ratio of 
diarrhea given the presence of the pathogen. 
We dichotomized the continuous qPCR test result using the value of the cycle threshold (Ct) that most 
accurately discriminated between cases and controls. The Ct values range from 0 to 35 cycles 
representing the relative concentration of the target gene in the stool sample. A low value indicates a 
higher concentration of the pathogen while a value of 35 indicates the absence of the target in the 
sample. We used the lower Ct value when we had multiple Ct values for the cutpoint. The case definition 
for each pathogen is a Ct value that is below the established cutoff point.  
We used a mixed effects conditional logistic regression model to calculate the odds ratio for under 1 year 
and 1-4 years old for each of our pathogens. The odds ratio for 1-4 years was applied to all GBD age 
groups over 5 years. There were three pathogen-age odds ratios that were not statistically significant: 
Aeromonas and Amoebiasis in under 1 year and Campylobacter in 1-4 years. The mean value of the odds 
ratio was above 1 in all three cases so we transformed the odds ratios for these three exceptions only in 
log-space such that exponentiated values could not be below 1. The transformation was: 
Odds ratio = exp(log(or) – 1)) + 1 
We modeled the proportion data using the meta-regression tool DisMod-MR to estimate the proportion 
of positive diarrhea cases for each separate etiology by location/year/age/sex and to adjust for the 
covariates.  
We used the estimated sensitivity and specificity of the laboratory diagnostic technique used in the GEMS 
study compared to the qPCR case definition to adjust our proportion before we computed the PAF:5 
𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛𝑇𝑟𝑢𝑒 =
(𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 + 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 − 1)
(𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 + 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 − 1)
 
We used this correction to account for the fact that the proportions we used are based on a new test that 
is not consistent with the laboratory-based case definition (qPCR versus GEMS conventional laboratory 
testing for pathogens).15 
Our literature review extracted the proportion of any enteropathogenic Escherichia coli (EPEC) without 
differentiating between typical (tEPEC) and atypical (aEPEC). In order to be consistent with the odds ratios 
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that we obtained, we adjusted our proportion estimates of any EPEC to typical EPEC only. This adjustment 
was informed by a subset of our literature review that reported both atypical and typical EPEC. We 
estimated a ratio by super-region of tEPEC to any EPEC and adjusted our proportion estimates 
accordingly. We found that the majority of EPEC diarrhea cases were positive for atypical EPEC, consistent 
with other published work.3  
For Vibrio cholerae (cholera), we used the literature review to estimate expected number of cholera cases 
for each country-year using the incidence of diarrhoea, estimated using DisMod-MR, and the proportion 
of diarrhoea cases that are positive for cholera. We assigned cholera PAF using odds ratios from the qPCR 
results to estimate a number of cholera-attributable cases. We compared this expected number of 
cholera cases to the number reported to the World Health Organization at the country-year level.6 We 
modeled the underreporting fraction to correct the cholera case notification data for all countries using 
health system access and the diarrhoea SEV scalar to predict total cholera cases. We used the age-specific 
proportion of positive cholera samples in DisMod and our incidence estimates to predict the number of 
cholera cases for each age/sex/year/location. Finally, we modeled the case fatality ratio of cholera using 
DisMod-MR and to estimate the number of cholera deaths.  
For C. difficile, we modeled incidence and mortality in DisMod-MR for each age, sex, year, location. 
DisMod-MR is a Bayesian meta-regression tool that uses spatio-temporal information as priors to 
estimate prevalence, incidence, remission, and mortality for C. difficile infection. DisMod-MR uses a 
compartmental model to relate prevalence, incidence, remission, and mortality. We set remission in our 
model to 1 month.  
There are several key updates to the approach to diarrhea etiology estimation in GBD 2016 compared to 
GBD 2015. There are new data used in the diarrhea DisMod-MR models and in the diarrhea proportion 
DisMod-MR models. We changed the age groups used in the odds ratio estimation. In GBD 2015 and 
before, odds ratios were estimated for each age group defined by GEMS: 0-1 year, 1-2 years, and 2-5 
years. For GBD 2016, we have collapsed the last two age groups so that our odds are representative for 
under-1 and over-1 years. We have updated the survey data extraction methodology so that we account 
for the seasonality of diarrhea in each GBD region. We have changed the duration of diarrhea from an 
average of 4.2 days used in GBD 2015 and prior and updated the duration so that there is variation in 
space and uncertainty in the duration estimate. Last, we have updated the proportion severity splits 
based on a literature review.  
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Table 1. Nonfatal input data used in diarrhea modeling.   
Type of data Data points (#) 
Facility - inpatient 14,913 
Facility - other/unknown 6,540 
Survey - cross-sectional 6,474 
Other 2,231 
Total 30,158 
 
Figure 1. The number of data points used in diarrhea non-fatal modeling for each country is shown.
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Table 2. Duration of diarrhea. Values are from a systematic review of diarrhea duration.1  
 
Mean Lower Upper 
Global 4.3 days 4.2 days 4.4 days 
 
Table 3. Severity splits, details on the severity levels for diarrhea in GBD 2015 and the associated disability 
weight (DW) with that severity.  
Severity level Lay description DW (95% CI) 
Mild Has diarrhea defined as 3 or 
more loose stools in a 24-hour 
period with no dehydration 
0.074 (0.049-0.104) 
Moderate Has diarrhea defined as 3 or 
more loose stools in a 24-hour 
period with painful cramps and 
feeling thirsty and any 
dehydration 
0.188 (0.125-0.264) 
Severe Has diarrhea defined as 3 or 
more loose stools in a 24-hour 
period with painful cramps and 
is very thirsty or feels nauseated 
or tired and/or severely 
dehydrated 
0.247 (0.164-0.348) 
 
 
 
 
 
Table 4. Covariates. Summary of covariates used in the diarrhea DisMod-MR meta-regression model  
 
Covariate Type Parameter Exponentiated beta 
(95% Uncertainty 
Interval) 
Low income hospital Study-level  0.62 (0.24-1.08) 
Inpatient population Study-level  0.009 (0.005-0.02) 
Marketscan data Study-level  0.044 (0.028-0.092) 
Diarrhea SEV Country-level Prevalence 0.87 (0.84-0.91) 
Unsafe sanitation SEV Country-level Prevalence 2.36 (2.01-2.64) 
Rotavirus vaccine 
coverage 
Country-level Prevalence 0.76 (0.74-0.79) 
Sex Country-level Prevalence 0.95 (0.93-0.97) 
Healthcare access and 
quality index 
Country-level Excess mortality 0.93 (0.93-0.93) 
Sex Country-level Excess mortality 1.21 (1.18-1.23) 
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 Typhoid and Paratyphoid Fever 
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Case definition 
Typhoid and paratyphoid are acute bacterial infections that most commonly cause febrile illness and 
gastrointestinal symptoms. Severe cases are associated with intestinal bleeding and perforation, altered 
mental state and, in some cases, death. We define a confirmed case as one for which there has been a 
positive blood culture test for either Salmonella enterica typhi or paratyphi. Diagnostic criteria do not 
typically accompany national surveillance reports; however, with blood culture being the standard 
diagnostic, we treat reported cases as confirmed. Given the poor sensitivity of blood culture, however, 
we estimated case definition as simply febrile illness resulting from an infection with Salmonella enterica 
typhi or paratyphi. This is effectively a counterfactual definition in which we attempt to estimate the 
number of true infections regardless of test result. These causes include all ICD-10 codes under the 
heading A01 (Typhoid and paratyphoid fevers). 
Input data  
Model inputs 
Our incidence dataset included a combination of data from prospective cohort studies and national 
surveillance systems. Similarly, data on proportions due to typhoid and paratyphoid included a 
combination of prospective cohort studies and national surveillance systems. 
 
Level Incidence Proportion 
Data points 864 414 
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Studies 89 56 
Locations 59 54 
Regions 14 11 
 
 
Severity splits 
For GBD 2016, we derived severity splits based on a published review of enteric fever outcomes from 
(Azmatullah A, Qamar FN, Thaver D, et al. 2005). 
 
Paratyphoid is split into four sequelae: mild (28.5% [15.6–44.2]), moderate (52.25% [27.2–77.7]), severe 
(14.25% [8.2–21.8]), and abdominal pain and distention (5.0% [2.8–7.6]): 
 
 
Sequela Description 
Disability 
weight 
Mild Has a low fever and mild discomfort , but no 
difficulty with daily activities. 
0.006 
(0.002–0.012) 
Moderate Has a fever and aches, and feels weak, which causes 
some difficulty with daily activities.  
0.051 
(0.032–0.074) 
Severe Has a high fever and pain, and feels very weak, 
which causes great difficulty with daily activities. 
0.133 
(0.088–0.19) 
Abdominal pain & distention 
due to paratyphoid 
Has pain in the belly and feels nauseated. The 
person has difficulties with daily activities.  
0.114 
(0.078–0.159) 
 
 
Similarly, typhoid is split into four sequelae: moderate (35.0% [26.0–44.3]), severe (47.75% [38.0–57.4]), 
severe abdominal pain and distention (17.0% [10.0–25.7]), and intestinal bleeding (0.25% [0–2.0]): 
 
Sequela Description 
Disability 
weight 
Moderate Has a fever and aches, and feels weak, which causes 
some difficulty with daily activities.  
0.051 
(0.032–0.074) 
Severe Has a high fever and pain, and feels very weak, 
which causes great difficulty with daily activities. 
0.133 
(0.088–0.19) 
Gastrointestinal bleeding Vomits blood and feels nauseated. 0.325 
(0.209–0.462) 
Abdominal pain and 
distention (includes intestinal 
perforation) 
Has severe pain in the belly and feels nauseated. The 
person is anxious and unable to carry out daily 
activities. 
0.324 
(0.22–0.442) 
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Modelling strategy 
We first model total incidence of typhoid and paratyphoid combined. Second, we model the proportion 
of this total due to typhoid and the proportion due to paratyphoid. Finally, we split the case estimates 
into sequelae representing different major symptoms and levels of severity. 
 
Total incidence was modelled using DisMod-MR, using the proportion of the population with access to 
clean water, and the proportion of the population living in the Indian Ocean monsoon belt as covariates. 
We performed a crosswalk using a study-level covariate indicating sources that were based on passive 
versus active surveillance, with active surveillance as the reference. This adjusts for incomplete case 
capture by passive surveillance. Incidence data were inflated to account for poor diagnostic sensitivity, 
based on an internal meta-analysis of the sensitivity of blood culture, the most common diagnostic used 
for typhoid. Similarly, we used two DisMod models to estimate etiologic proportions: one for the 
proportion of total incidence due to typhoid, and one for the proportion due to paratyphoid.   
 
Typhoid cases are split between four sequelae: moderate typhoid fever, severe typhoid fever, severe 
typhoid fever with intestinal bleeding, and typhoid fever with abdominal complications. Paratyphoid 
cases are split between four sequelae: mild paratyphoid fever, moderate paratyphoid fever, severe 
paratyphoid fever, and paratyphoid fever with abdominal complications. 
 
Changes from GBD 2015 to GBD 2016 
We made no major changes in our methods between GBD 2015 and 2016. 
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 Other intestinal infectious diseases 
 
In addition to the intestinal infectious diseases described above, there are many diverse types of 
intestinal infectious diseases. Because these intestinal infectious diseases are diverse in their underlying 
causes and risk factors as well as in their associated health outcomes, modelling them together in a 
DisMod-MR model would not produce reliable estimates of prevalence or excess mortality. Instead, we 
calculated the YLDs caused by intestinal infectious diseases directly using a YLD/YLL ratio.  
We calculated the ratio of YLDs to YLLs across the specified intestinal infectious diseases for which 
nonfatal outcomes were modelled, using YLL estimates from the GBD 2016 cause of death (CoD) 
analysis. We then multiplied this YLD/YLL ratio by the YLL estimates for other intestinal infectious 
diseases from the GBD 2016 CoD analysis, providing us with an estimate of the YLDs associated with 
other intestinal infectious diseases. 
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 Lower respiratory infections (LRI) 
 
Flowchart 
 
Case definition 
We used clinician-diagnosed pneumonia or bronchiolitis as our case definition for lower respiratory 
infections (LRI). We included ICD9 codes 073.0-073.6, 079.82, 466-469, 480-489, 513.0, and 770.0 and 
ICD10 codes A48.1, J09-J22, J85.1, P23-P23.9, and U04. LRI etiologies are modeled separately from overall 
LRI incidence and prevalence. The etiologies include influenza, respiratory syncytial virus, Streptococcus 
pneumoniae, and Haemophilus influenzae type b and are episodes of LRI where the etiology is the causal 
pathogen in the infection.  
Input data 
Model inputs 
Input data included all data used in GBD 2015. We used two primary types of input data for lower 
respiratory infections. The first is lower respiratory infection incidence and prevalence data. These data 
come from a systematic literature review, hospital inpatient and outpatient data, claims data from the 
US, and population-representative surveys (Table 1). The second type of data is on the etiologies of LRI. 
Influenza and respiratory syncytial virus (RSV) population attributable fractions were informed by a 
systematic literature review of the proportion of LRI cases that are positive for each pathogen. 
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Haemophilus influenzae type B (Hib) and Streptococcus pneumoniae (pneumococcal pneumonia) are 
informed by a systematic review of vaccine efficacy and effectiveness studies.  
To estimate the non-fatal burden of lower respiratory infections (LRI), we conducted a systematic review 
of scientific literature for LRI incidence and prevalence (Search String: ('lower respiratory' [title/abstract] 
OR pneumonia[title/abstract] AND ('2015/05/01'[PDat] : '2016/6/31'[PDat] )AND Humans[MeSH Terms] 
NOT(autoimmune[title/abstract] OR COPD [title/abstract] OR 'cystic fibrosis'[title/abstract]). Our inclusion 
criteria were studies that were published between May 2015 and June 2016, had a sample size of at least 
100, were at least one year in duration, and included lower respiratory infections, pneumonia, or 
bronchiolitis in the case definition. Our literature review identified 631 articles, of which 48 were included 
and extracted. We also included studies referred by experts and identified through scientific literature 
references. 
We also used self-reported prevalence of LRI symptoms from population-representative surveys, such as 
the Demographic and Health Survey and the Multiple Indicator Cluster Survey. When possible, we 
extracted survey data by 1-year age group and by sex. We converted these data from two-week period 
prevalence to point prevalence. The equation for this adjustment is 
1) 𝑃𝑜𝑖𝑛𝑡 𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 =
𝑃𝑒𝑟𝑖𝑜𝑑 𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 ∗ 𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛
(𝑅𝑒𝑐𝑎𝑙𝑙 𝑃𝑒𝑟𝑖𝑜𝑑+𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛−1)
We performed a systematic review of the duration of symptoms of LRI. We sought consistency with our 
case definition of LRI and defined our duration as the time between the onset of symptoms to the 
resolution of increased work of breathing. Although crucial, there were very limited data on spatial, 
temporal, or age-specific duration which may vary based on severity, etiology, and treatment. We 
identified 485 titles from PubMed and extracted 6 studies which were used in a meta-analysis (mean 
duration 7.79 days, 6.2-9.64 days). 
Survey data were adjusted for seasonality. An inclusion criterion for scientific literature is a study duration 
longer than 1 year to avoid bias in the seasonal timing of LRI. Surveys are frequently conducted over 
several months. To account for seasonal variation in LRI symptom prevalence, we fit a simple sine/cosine 
model for each GBD region. The model is mixed-effects with random effects on each site. The model 
accounts for the year of the survey and the case definition used. The percent difference between the 
monthly model fit diarrhea prevalence and the mean fitted diarrheal prevalence is a scalar to adjust 
survey data by month and location. 
In addition to survey data, hospital inpatient, outpatient data, and US claims data were included in the LRI 
modeling. To make the data more consistent in the modeling process, we converted all incidence data to 
prevalence. 
We updated our systematic review of scientific literature for the proportion of LRI that tested positive for 
influenza and respiratory syncytial virus (RSV) to include all data from GBD 2015 and from studies 
published between May 2015 and May 2016. Inclusion criteria were studies that had a sample size of at 
least 100, studies that were at least one year in duration, and studies describing lower respiratory 
infections, pneumonia, or bronchiolitis as the case definition. During our literature review we identified 
209 studies, of which 7 met our inclusion criteria and were extracted. We excluded studies that described 
pandemic H1N1 influenza solely and studies that used influenza-like illness as the case definition. We 
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assigned an age range based on the prevalence-weighted mean age of LRI in the appropriate 
year/sex/location if the ages of the study participants were not reported.  
We also conducted a systematic literature review of studies on the Hib vaccine and PCV effectiveness 
studies against X-ray-confirmed pneumonia and against pneumococcal and Hib disease until May 2016. 
For PCV studies, we extracted, if available, the distribution of pneumococcal pneumonia serotypes and 
the serotypes included in the PCV used in the study. No new studies were identified for GBD 2016. We 
excluded observational and case-control studies due to implausibly high vaccine efficacy estimates. Hib 
trial data were exclusively from children <5 years so we did not include the effect of Hib on ages over 5 
years of age. PCV trial data are also frequently limited to younger age populations. To understand the 
contribution of pneumococcal pneumonia in older populations, we also included PCV efficacy studies that 
used before-after approaches. 
 
Table 1: Data Inputs 
Type of data Data points (#) 
Facility - inpatient 15,258 
Facility - other/unknown 6,411 
Survey - cross-sectional 7,772 
Other 909 
Total 30,350 
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Figure 1. The number of data points used in the LRI non-fatal modeling by country is shown. 
Severity splits 
The distribution of moderate (85%) and severe (15%) lower respiratory infections is determined by a 
meta-analysis of the ratio of severe to all LRI from studies that report the incidence of moderate and 
severe lower respiratory infections.  
We used the health states of acute infectious disease episode, moderate and severe, with the lay 
descriptions and disability weight values shown in table below: 
Table 2: Severity Splits 
Severity level Lay description DW (95% CI) 
Moderate Has a fever and aches and feels weak which causes some 
difficulty with daily activities. 
0.051 (0.032-0.074) 
Severe Has a high fever and pain and feels very weak, which causes 
great difficulty with daily activities. 
0.133 (0.088-0.19) 
Modeling strategy  
The non-fatal lower respiratory infection burden is modeled in DisMod-MR, a Bayesian meta-regression 
modeling framework. DisMod-MR produces estimates of the incidence, prevalence, and remission of 
LRI for each age, sex, location, and year. We defined the time to recovery as an average of 10 
69
days (9-12 days) which corresponds with a remission 36.5. The models are informed by study-level 
covariates and by country-level covariates.  
Input data are adjusted to our standard case definition. Data are adjusted by study-level binary covariates 
which describe if the source is a hospital or inpatient sample and if the data come from a self-reported 
survey (Table 3). Self-reported prevalence of LRI symptoms from population-representative surveys such 
as the Demographic and Health Survey (DHS) and the Multiple Indicator Cluster Survey (MICS) is used. 
Our case definition from symptom-based prevalence estimates is children in the last 2-weeks with fever 
and cough with difficulty breathing and symptoms located in the chest and/or chest and nose. This is 
consistent with the WHO Integrated Management of Childhood Illness guidelines definition of pneumonia 
and with the DHS and MICS definition of acute respiratory infection (ARI).1 We extracted the prevalence 
of children under 5 years old that had fever and cough with difficulty breathing and included an indicator 
for this less-specific definition. Some surveys did not include the prevalence of LRI symptoms and fever so 
we adjusted survey prevalence estimates that did not include fever by studies that did based on a logistic 
regression. 
Table 3: Model covariates 
Study covariate Type Parameter Exponentiated beta 
Hospital inpatient population Study-level - 0.25 (0.23-0.27) 
Hospital data from middle- or low-
income country 
Study-level - 0.17 (0.16-0.19) 
Self-reported Study-level - 4.05 (3.81-4.27) 
Poor diagnostic validity Study-level - 1.72 (1.63-1.81) 
Marketscan Study-level - 1.95 (1.77-2.12) 
Hib vaccine coverage Country-level Prevalence 0.73 (0.70-0.76) 
LRI SEV Country-level Prevalence 0.98 (0.91-1.07) 
Socio-demographic index Country-level Prevalence 0.77 (0.59-1.06) 
Healthcare access and quality 
index 
Country-level Excess mortality 0.96 (0.96-0.96) 
 
 
 
Etiologies 
We estimated LRI etiologies separately from overall LRI mortality using two distinct counterfactual 
modeling strategies to estimate population attributable fractions (PAFs), described in detail below. The 
PAF represents the relative reduction in LRI mortality if there was no exposure to a given etiology. As LRIs 
can be caused by multiple pathogens and the pathogens may co-infect, PAFs can overlap and add up to 
more than 100%. Separate strategies were used for viral- influenza and respiratory syncytial virus (RSV)- 
and bacterial- Streptococcus pneumoniae and Haemophilus influenzae type B- etiologies. We did not 
attribute etiologies to neonatal pneumonia deaths due to a dearth of reliable data in this age group. We 
calculated uncertainty of our PAF estimates from 1,000 draws of each parameter using normal 
distributions in log space.  
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Influenza and RSV. We calculated the population attributable fraction (PAF) from the proportion of severe 
LRI cases positive for influenza and RSV. We assumed that hospitalized LRI cases are a proxy of severe 
cases. We used the following formula to estimate PAF:2 
PAF = Proportion * (1-1/OR) 
Where Proportion is the proportion of LRI cases that test positive for influenza or RSV and OR is the odds 
ratio of LRI given the presence of the pathogen. We used an odds ratio of 5.1 (3.19 – 8.14) for influenza 
and 9.79 (4.98 – 19.27) for RSV from a recently published meta-analysis.3 These odds ratios are marginally 
different from those used in GBD 2013. 
We modeled the proportion data using the meta-regression tool DisMod-MR to estimate the proportion 
of LRI cases that are positive for influenza and RSV, separately, by location/year/age/sex. We accounted 
for study-level covariates in our models such as PCR as the diagnostic technique, studies that investigated 
RSV or influenza exclusively, and studies from inpatient populations. 
As the case-fatality of viral causes of pneumonia is lower than for bacterial causes, we adjusted for 
differential case-fatality by determining the etiological fractions for mortality attributable to RSV and 
influenza (Table 2). We measured the etiologic fractions by applying a relative case-fatality adjustment 
based on in-hospital case-fatality, which we coded to specific pneumonia etiologies. Hospital admissions 
data of this type were limited to data from the USA, Austria, Brazil, and Mexico. We generated the pooled 
estimate of the case-fatality differential between bacterial (pneumococcus, Hib) and viral etiologies (RSV, 
influenza) using DisMod-MR. 
Pneumococcal pneumonia and Hib. For Streptococcus pneumoniae (pneumococcal pneumonia) and 
Haemophilus influenzae type B (Hib), we calculated the population attributable fraction using a vaccine 
probe design.4,5 The ratio of vaccine effectiveness against nonspecific pneumonia to pathogen-specific 
disease represents the fraction of pneumonia cases attributable to each pathogen.  
To estimate the PAF for Hib and pneumococcal pneumonia, we calculated the ratio of vaccine 
effectiveness against nonspecific pneumonia to pathogen-specific pneumonia (Equations 1 and 3). We 
estimated a study-level estimate of PAF from a meta-analysis of these ratios. To estimate the PAF for Hib, 
we only used randomized controlled trials because of implausibly high values of vaccine efficacy in case-
control studies. To estimate the PAF for pneumococcal pneumonia, we included RCTs and before and 
after vaccine introduction longitudinal studies. 
 We adjusted the study-level PAF estimate by vaccine coverage and expected vaccine performance to 
estimate country- and year-specific PAF values. For pneumococcal pneumonia, we adjusted the PAF by 
the final Hib PAF estimate and by vaccine serotype coverage. Finally, we used an age distribution of PAF 
modeled in DisMod to determine the PAF by age. Because of an absence of data describing vaccine 
efficacy against Hib in children older than two years, we did not attribute Hib to episodes of LRI in ages 
five years and older. 
We used a vaccine probe design to estimate the PAF for pneumococcal pneumonia and (Hib) by first 
calculating the ratio of vaccine effectiveness against nonspecific pneumonia to pathogen-specific 
pneumonia at the study level (Equations 1 and 2).4–6 We then adjusted this estimate by vaccine coverage 
and expected vaccine performance to estimate country- and year-specific PAF values (Equations 3 and 4). 
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1) 𝐻𝑖𝑏𝑃𝐴𝐹𝐵𝑎𝑠𝑒 = 1 −
𝑉𝐸𝑃𝑛𝑒𝑢𝑚𝑜𝑛𝑖𝑎
𝑉𝐸𝐻𝑖𝑏 
 
 
2) 𝑃𝑛𝑒𝑢𝑚𝑜𝑃𝐴𝐹𝐵𝑎𝑠𝑒 = 1 −  
𝑉𝐸𝑃𝑛𝑒𝑢𝑚𝑜𝑛𝑖𝑎 ∗(1−𝑃𝐴𝐹𝐻𝑖𝑏∗𝑉𝐸𝐻𝑖𝑏 𝑂𝑝𝑡𝑖𝑚𝑎𝑙)
𝑉𝐸𝑆𝑡𝑟𝑒𝑝𝑡𝑜𝑐𝑜𝑐𝑐𝑢𝑠∗𝐶𝑜𝑣𝑆𝑒𝑟𝑜𝑡𝑦𝑝𝑒
 
 
 
3) 𝑃𝐴𝐹𝐻𝑖𝑏 =  𝑃𝐴𝐹𝐵𝑎𝑠𝑒 ∗
(1−𝐶𝑜𝑣𝐻𝑖𝑏∗𝑉𝐸𝐻𝑖𝑏 𝑂𝑝𝑡𝑖𝑚𝑎𝑙)
(1−𝑃𝐴𝐹𝐵𝑎𝑠𝑒∗𝐶𝑜𝑣𝐻𝑖𝑏∗𝑉𝐸𝐻𝑖𝑏 𝑂𝑝𝑡𝑖𝑚𝑎𝑙)
 
 
4) 𝑃𝐴𝐹𝑃𝑛𝑒𝑢𝑚𝑜 =
𝑃𝐴𝐹𝐵𝑎𝑠𝑒∗(1−𝐶𝑜𝑣𝑃𝐶𝑉∗𝑉𝐸𝑃𝐶𝑉 𝑂𝑝𝑡𝑖𝑚𝑎𝑙)
(1−𝑃𝐴𝐹𝐻𝑖𝑏∗𝐶𝑜𝑣𝐻𝑖𝑏∗𝑉𝐸𝐻𝑖𝑏 𝑂𝑝𝑡𝑖𝑚𝑎𝑙)∗(1−
𝑃𝐴𝐹𝐵𝑎𝑠𝑒𝐶𝑜𝑣𝑃𝐶𝑉∗𝑉𝐸𝑃𝐶𝑉 𝑂𝑝𝑡𝑖𝑚𝑎𝑙
(1−𝑃𝐴𝐹𝐻𝑖𝑏∗𝐶𝑜𝑣𝐻𝑖𝑏∗𝑉𝐸𝐻𝑖𝑏 𝑂𝑝𝑡𝑖𝑚𝑎𝑙)
)
 
 
Where 𝑉𝐸𝑃𝑛𝑒𝑢𝑚𝑜𝑛𝑖𝑎 is the vaccine efficacy against nonspecific pneumonia, 𝑉𝐸𝐻𝑖𝑏 is the vaccine efficacy 
against invasive Hib disease, 𝑉𝐸𝑆𝑡𝑟𝑒𝑝𝑡𝑜𝑐𝑜𝑐𝑐𝑢𝑠 is the vaccine efficacy against serotype-specific 
pneumococcal pneumonia, 𝐶𝑜𝑣𝑠𝑒𝑟𝑜𝑡𝑦𝑝𝑒 is the serotype-specific vaccine coverage for PCV,
7  𝑉𝐸𝐻𝑖𝑏 𝑂𝑝𝑡𝑖𝑚𝑎𝑙 
is the Hib effectiveness in the community (0.8)8,  𝑃𝐴𝐹𝐻𝑖𝑏 is the final PAF for Hib, 𝐶𝑜𝑣𝑃𝐶𝑉 is the PCV 
coverage, 𝐶𝑜𝑣𝐻𝑖𝑏 is the Hib coverage by country, and 𝑉𝐸𝑃𝐶𝑉 𝑂𝑝𝑡𝑖𝑚𝑎𝑙 is the vaccine effectiveness in the 
community (0.8).9  
For Hib, we assumed that the vaccine efficacy against invasive Hib disease is the same against Hib 
pneumonia. For pneumococcal pneumonia, a recent study in adults 10 found that the vaccine efficacy 
against invasive pneumococcal disease may be significantly higher than against pneumococcal 
pneumonia. We used this ratio to adjust estimates of vaccine efficacy against invasive pneumococcal 
disease from other studies. However, recognizing that the study is unique in that it uses a urine antigen 
test among adults, we added uncertainty around our adjustment using a wide uniform distribution 
(median 0.65, 0.3-1.0).  
There are several important differences in the approach to LRI etiology estimation in GBD 2016 compared 
to GBD 2015. We have added an adjustment for the seasonality of LRI symptom prevalence from 
population-representative surveys. We have performed an update to the average duration of LRI 
symptoms which decreased the mean duration of illness from 10 to 7.79 days. We have changed some of 
the covariates used in the modeling process and updated the input data for the LRI envelope and for its 
etiologies.  
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 Upper respiratory infections 
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Case Definition 
Upper respiratory infections (URI) include acute nasopharyngitis, sinusitis, pharyngitis, tonsillitis, 
laryngitis/tracheitis and epiglottitis. For URI, ICD 10 codes are J00-J02,J02.8-J03,J03.8-J06.9,J36,J36.0, 
and ICD 9 codes are 460-465.9,475-475.9,476.9. 
 
Input data 
 Model Inputs 
For GBD 2013, a systematic review of the prevalence of URI was conducted. The PubMed search terms 
were: ((upper respiratory infection[Title/Abstract] or rhinitis[Title/Abstract] or 
rhinosinusitis[Title/Abstract] or sinusitis[Title/Abstract] or nasopharyngitis[Title/Abstract] or 
rhinopharyngitis[Title/Abstract] or common cold[Title/Abstract] or pharyngitis[Title/Abstract] or 
tonsillitis[Title/Abstract] or epiglottitis[Title/Abstract] or supraglottitis[Title/Abstract] or 
laryngitis[Title/Abstract] or laryngotracheitis[Title/Abstract] or tracheitis[Title/Abstract]) AND 
(prevalence[Title/Abstract] OR incidence[Title/Abstract]) NOT (allergies or allergy or allergic rhinitis or 
asthma) AND (“2009”[Date – Publication] : “2013”[Date – Publication]))  
The exclusion criteria were: 
1. Studies that were not population-based, eg, hospital or clinic-based studies 
2. Studies that did not provide primary data on epidemiological parameters, eg, a 
commentary piece 
3. Studies with a sample size of less than 150 
4. Reviews 
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 Updates to systematic reviews are performed on an ongoing schedule across all GBD causes: an update 
for upper respiratory infections will be performed in the next one to two iterations. The table below 
shows the number of literature studies included in GBD 2016, as well as the number of countries or 
subnational units and GBD world regions represented. 
 Prevalence Incidence Mortality risk 
Studies 11 - - 
Countries/subnationals 10 - - 
GBD world regions 8 - - 
 
In addition, data from nationally representative surveys including United States National Health 
Interview Surveys, Demographic and Health Surveys, and Russia Longitudinal Monitoring Surveys were 
included.  
 Severity Splits 
The table below shows the severity distributions based on the data from Medical Expenditure Panel 
Surveys where we categorized “acute nasopharyngitis or acute uri multi sites/nos” as mild URI and 
“acute sinusitis, acute pharyngitis, acute tonsillitis, and acute laryngitis/tracheitis and epiglottitis” as 
moderate URI.  
Age Mild URI (proportion) Moderate URI 
(proportion) 
Standard error 
0-4 0.8475367 0.1524633 0.0235054 
5-9 0.7957522 0.2042478 0.0214788 
10-14 0.7510127 0.2489873 0.0219692 
15-19 0.7800903 0.2199097 0.0254533 
20-24 0.8277971 0.1722029 0.0340625 
25-29 0.866052 0.133948 0.0372739 
30-34 0.8716526 0.1283474 0.0385933 
35-39 0.8711911 0.1288089 0.0404143 
40-44 0.8723335 0.1276665 0.0413539 
45-49 0.8835218 0.1164782 0.0450838 
50-54 0.8862297 0.1137703 0.0483388 
55-59 0.8882668 0.1117332 0.0532085 
60-64 0.8837538 0.1162462 0.0618551 
65-69 0.8844019 0.1155981 0.0741072 
70-74 0.8912954 0.1087046 0.0867568 
75-79 0.8846442 0.1153558 0.0937314 
80-84 0.9130687 0.0869313 0.104148 
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 The lay descriptions and disability weights for severity levels derived from the GBD Disability Weights 
study are shown below. 
Severity level Lay description DW (95% CI) 
Mild upper respiratory infections has a low fever and mild 
discomfort , but no difficulty with 
daily activities. 
0.006 (0.002–0.012) 
Moderate/severe upper respiratory 
infections 
has a fever and aches, and feels 
weak, which causes some difficulty 
with daily activities. 
0.051 (0.032–0.074) 
 
Modelling Strategy 
URI was modeled using a standard DisMod MR2.2 model. We used the log-transformed age-
standardized SEV scalar for URI as a location-level covariate. 
 
Betas and exponentiated values are shown in the table below: 
Covariate Parameter beta Exponentiated beta 
Log-transformed age-
standardized SEV scalar for URI 
Prevalence 4.69 108.32 (45.02 — 147.82) 
Sex Prevalence -0.029  0.97 (0.95–0.99) 
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 Otitis media 
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Case Definition 
Otitis media is an infection of the middle ear space. We included acute otitis media, chronic otitis media, 
and hearing loss due to otitis media in the GBD non-fatal outcome modelling. (The hearing loss 
estimation is included in the hearing loss report provided separately.) The ICD 10 codes are H65-H75.83, 
and ICD 9 codes are 381-384.9. 
 
Input data 
 Model Inputs 
A systematic review of the prevalence of otitis media was conducted for GBD 2013. The PubMed search 
terms were: (((otitis media[Title/Abstract] AND (incidence[Title/Abstract] OR 
prevalence[Title/Abstract])) AND (“2009”[Date – Publication] : “2013”[Date – Publication])).  
The exclusion criteria were: 
5. Studies that were not population-based, eg, hospital or clinic-based studies 
6. Studies that did not provide primary data on epidemiological parameters, eg 
commentaries 
7. Studies with a sample size of less than 150 
8. Reviews 
9. Case series 
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Updates to systematic reviews are performed on an ongoing schedule across all GBD causes, and an 
update for otitis media will be performed in the next one to two iterations. The table below shows the 
number of literature studies included in GBD 2016, as well as the number of countries or subnational 
units and GBD world regions represented. 
Prevalence Incidence Remission 
Studies 29 12 5 
Countries/subnationals 20 8 4 
GBD world regions 11 5 4 
In addition, data from the United States Medical Expenditure Panel Surveys and Australia National 
Health Surveys were included.  
Severity Splits 
We assume that all acute otitis media cases would experience ear pain. The severity distributions for 
chronic otitis media based on the study by Lin and colleagues (2009) were as follows: (i) vertigo (2.9%, 
95% CI: 2.4 to 3.6%), and (ii) severe infectious complications (0.05%, 95% CI: 0.01 to 0.2%). We 
considered the remaining 97% of chronic otitis media cases as asymptomatic. The lay descriptions and 
disability weights for severity levels derived from the GBD Disability Weights study are shown below. 
Severity level Lay description DW (95% CI) 
Ear pain has an earache that causes some 
difficulty with daily activities 
0.013 
(0.007–0.024) 
Vertigo due to chronic otitis 
media* 
Severe infectious complications 
due to chronic otitis media 
has an earache that causes some 
difficulty with daily activities 
0.013 
(0.007–0.024) 
* See the hearing loss report for the lay descriptions and disability weights for different severity levels.
Modelling Strategy 
We modelled acute and chronic otitis media as separate non-fatal health outcomes using DisMod-
MR 2.1. We assumed that the incidence of acute otitis media decreases after the age of 5 years. Log-
transformed LDI covariate was used as a location-level covariate to model chronic otitis media.  
Betas and exponentiated values are shown in the table below: 
Acute otitis media DisMod model 
Covariate Parameter Beta (95% CI) Exponentiated beta (95% 
CI) 
Sex Prevalence 0.17 1.18 (1.01 – 1.38) 
Sex Incidence -0.20 0.82 (0.76 – 0.88) 
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 Chronic otitis media DisMod model 
Covariate Parameter Beta (95% CI) Exponentiated beta (95% 
CI) 
Log LDI Prevalence -0.41  0.67 (0.61 – 0.76) 
Sex Prevalence 0.046  1.05 (0.75 – 1.46) 
 
 
Reference 
Lin, Y. S., Lin, L. C., Lee, F. P., & Lee, K. J. (2009). The prevalence of chronic otitis media and its 
complication rates in teenagers and adult patients. Otolaryngology-Head and Neck Surgery, 140(2), 165-
170. 
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Case definition 
Meningitis is a disease caused by inflammation of the meninges, the protective membrane surrounding 
the brain and spinal cord, and is typically caused by an infection in the cerebrospinal fluid. Symptoms 
include headache, fever, stiff neck, and sometimes seizures. Included in the GBD modeling were cases 
meeting ICD-10 diagnostic criteria for meningitis due to bacteria, viruses, or other causes (A39-A39.9, 
A87-A87.9, D86.81, G00.0-G00.8, G03-G03.8, Z20.811, and Z22.31) (1). In GBD 2016, meningitis 
encompasses viral meningitis and four bacterial etiologies: pneumococcal, haemophilus influenza type B 
(HiB), meningococcal, and other.  
Input data 
Model inputs 
In the GBD 2010 study, a systematic review of literature was conducted to capture studies of incidence 
and excess mortality rate for all bacterial meningitis cases. For each of the four etiologies, literature 
included excess mortality rate, incidence, proportion, remission, and standardized mortality ratio. The 
inclusion criteria stipulated that: (1) the publication year must be between 1980 and 2010; (2) “caseness” 
was based on diagnoses by antigen test, blood test, cerebrospinal fluid test, polymerase chain reaction 
test, or latex agglutination test; (3) sufficient information must be provided on study method and sample 
characteristics to assess the quality of the study; and (4) study samples must be representative of the 
general population. No limitation was set on the language of publication. For GBD 2013, the search 
strategy was replicated to capture epidemiological studies published between 2010 and 2013. The search 
strategy was repeated in 2015 only to capture excess mortality – updates to systematic reviews are 
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performed on an ongoing schedule across all GBD causes, and a complete update for meningitis will be 
performed in the GBD 2017 iteration.  
Additional sources we included in the acute bacterial meningitis model were inpatient-only hospital data 
and US claims data from 2000, 2010, and 2012, primary diagnosis and inpatient only. Sequelae and 
severity splits were informed by a meta-analysis, Edmond et al (2), while an internal meta-analysis 
informed mortality estimates for long-term moderate to severe impairments (3).  
Data were outliered or excluded if we found them unreasonable when compared to regional, super-
regional, and global rates.  
For GBD 2016, we also included VR proportions for mortality due to the different etiologies of meningitis 
to inform the proportional splits of the meningitis parent model for GBD Cause of Death modeling. 
The tables below show the number of studies included in GBD 2016, as well as the number of countries 
or subnational units and GBD world regions represented for the bacterial meningitis model and each 
model that informs the etiology split. 
Table 1a. Acute bacterial meningitis 
 Prevalence Incidence Mortality risk 
Studies 0 70 70 
Countries/subnationals 0 65/304 44/0 
GBD world regions 0 20 17 
 
Table 1b. Pneumococcal meningitis incidence proportion 
 
 
 
 
 
 
Table 1c. Meningococcal meningitis incidence proportion 
 
 
 
 
 
 
Table 1d. H influenza type B meningitis incidence proportion 
 Proportion 
Studies 68 
Countries/subnationals 42/2 
GBD world regions 18 
 
Table 1e. Other bacterial meningitis incidence proportion 
 Proportion 
Studies 60 
 Proportion 
Studies 67 
Countries/subnationals 42/2 
GBD world regions 18 
 Proportion 
Studies 62 
Countries/subnationals 39/2 
GBD world regions 17 
81
Countries/subnationals 37/2 
GBD world regions 16 
Modeling strategy 
Non-fatal outcomes were modeled using a combination of custom models and DisMod-MR 2.1, with 
minor changes from the GBD 2015 modeling process. First, the overall incidence and prevalence of 
bacterial meningitis was modeled to estimate the short-term morbidity due to acute infection. This 
DisMod model had a set duration (1/remission) of 4 weeks with a range ±2 weeks. Literature and 
surveillance/notification data were flagged with covariates, as were US claims data with year-specific 
covariates to be crosswalked to the reference data, which was GBD 2016 inpatient-only hospital data. We 
used the function in DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) data from our CODEm 
and CODcorrect analyses and matched with prevalence data points for the same location. We calculated 
excess mortality rate to estimate priors by dividing CSMR by prevalence, calculated from remission and 
incidence. To help inform trends where we lack data, we applied a country-level covariate for proportion 
of the population at the subnational and country levels that lives within the meningitis belt in sub-
Saharan Africa. We forced a positive relationship, with a lower bound of 0 and an upper bound of 
2. We also applied a lag-distributed income covariate to excess mortality, log transformed and forced
negative with an upper bound of 0 and a lower bound of -1. Betas and exponentiated values (which can 
be interpreted as an odds ratio) are shown in the tables below for study-level covariates and country-
level covariates.  
Table 2. Study covariates 
Table 3. Country-level covariates 
Incidence of bacterial meningitis were split into four etiologies (pneumococcal, meningococcal, H. 
influenzae type B, and other bacterial meningitis) using four incidence proportion models run in DisMod-
MR 2.1. Results from these models were squeezed to sum to 1 at the draw level for each location, year, 
age, and sex. We applied a Hib3 vaccine coverage covariate to the H. influenzae type B proportion model, 
the proportion of the population living in the meningitis belt covariate to the meningococcal meningitis 
Study covariate Parameter Beta Exponentiated beta 
Surveillance/notification 
data 
Incidence -1.23 (-1.58 to -0.89) 0.29 (0.21 – 0.41) 
Literature Incidence -0.24 (-0.32 to -0.15) 0.79 (0.73 – 0.4286) 
Claims data – 2000 Incidence -0.29 (-0.35 to -0.23) 0.75 (0.71 – 0.79) 
Claims data – 2010 Incidence -0.32 (-0.37 to -0.27) 0.73 (0.69 – 0.76) 
Claims data – 2012 Incidence -0.36 (-0.42 to -0.31) 0.69 (0.66 – 0.73) 
Country-level covariate Parameter Beta Exponentiated beta 
Meningitis belt 
(proportion of 
population) 
Incidence 1.52 (0.95 – 1.97) 4.56 (2.59 – 7.19) 
LDI (log transformed) Excess mortality -0.28 (-0.29 to -0.26) 0.76 (0.74 – 0.77) 
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proportion model, a PCV3 coverage covariate to the pneumococcal meningitis model, and the 
aforementioned 3 covariates to the other meningitis incidence model. 
Data for viral meningitis were only available from hospitals or US claims data, and not from population 
studies, so incidence and prevalence of viral meningitis were extrapolated from bacterial meningitis 
incidence by applying age- and sex-specific ratios between bacterial and viral cases from a combination of 
hospital data and US claims data. In addition to short-term sequelae as a result of acute bacterial and viral 
meningitis, we also modeled the long-term outcomes from bacterial meningitis infection.  
Sequelae splits 
We first split the long-term sequelae among survivors of acute infection. We calculated the acute-phase 
survivors by applying the excess mortality (calculated by the acute meningitis parent DisMod model) to 
the incidence of each etiology (excess mortality was converted to case fatality rate by e(-excess mortality x 1/(excess 
mortality + remission))). The survivors were then subject for long-term sequelae by applying the post-discharge 
proportions of health consequences calculated by a meta-analysis by Edmond et al (2). We calculated the 
ratio of acute meningitis survivors that experience major long-term impairments for all etiologies, and the 
ratio of minor impairments to major impairments for pneumococcal meningitis versus all other etiologies 
(because pneumococcal meningitis showed significantly higher risk of morbidity than other etiologies). 
This ratio was based off a regression of log-transformed GDP and ratio values from Edmonds et al. The 
regression is shown below: 
𝑦 = −0.33590 ln(𝐺𝐷𝑃) + 1.15230 
We used these two ratios to calculate the proportions of survivors who contract a long-term minor 
impairment and those who contract a long-term major impairment. The proportion with major 
impairments were further split (again using pooled proportions from Edmond et al) into specific major 
impairments, which were grouped into vision loss, hearing loss, moderate-to-severe cognitive 
impairments, and epilepsy.  
The calculated incidence of long-term sequelae was then converted to prevalence by two different 
approaches. For the sequelae not associated with excess mortality, which were vision loss, hearing loss, 
intellectual disability, motor impairment, and behavioral problems, the incidence of each age was 
cumulatively added up to the subsequent age (assuming half-cycle) to construct prevalence at each age. 
If the sequela is associated with excess mortality (epilepsy and moderate-to-severe cognitive 
impairments), the calculated incidence was uploaded into DisMod together with the corresponding 
mortality parameters (excess mortality data from the epilepsy envelope DisMod model, and standardized 
mortality ratio data from a neonatal encephalopathy meta-analysis, converted to excess mortality using 
all-cause mortality estimates) to estimate the prevalence. Vision loss, hearing loss, and epilepsy estimates 
were squeezed and severity split centrally.  
 
Disability weights 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for sequelae 
associated with each etiology are shown below. 
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Table 5. Severity splits, lay descriptions, DWs 
Severity split Lay description DW (95% CI) 
Mild behavior problems This person is hyperactive and has difficulty 
concentrating, remembering things, and completing 
tasks. 
0.045 (0.028-0.066) 
Mild hearing loss This person has great difficulty hearing and 
understanding another person talking in a noisy place 
(for example, on an urban street). 
0.01 (0.004-0.019) 
Mild hearing loss with 
ringing 
This person is unable to hear and understand 
another person talking, even in a quiet place, is 
unable to take part in a phone conversation. 
Difficulties with communicating and relating to 
others cause emotional impact at times (for example 
worry or depression). 
0.021 (0.012-0.036) 
Moderate hearing loss This person has great difficulty hearing and 
understanding another person talking in a noisy place 
(for example, on an urban street), and sometimes 
has annoying ringing in the ears. 
0.027 (0.015-0.042) 
Moderate hearing loss 
with ringing 
This person is unable to hear and understand 
another person talking, even in a quiet place, is 
unable to take part in a phone conversation. 
Difficulties with communicating and relating to 
others often cause worry, depression, or loneliness. 
0.074 (0.048-0.107) 
Moderately severe 
hearing loss 
Custom DW from hearing loss impairment envelope  
Severe hearing loss This person is unable to hear and understand 
another person talking, even in a quiet place, and 
unable to take part in a phone conversation. 
Difficulties with communicating and relating to 
others cause emotional impact at times (for example 
worry or depression). 
0.158 (0.105-0.227) 
Profound hearing loss This person is unable to hear and understand 
another person talking, even in a quiet place, is 
unable to take part in a phone conversation, and has 
great difficulty hearing anything in any other 
situation. Difficulties with communicating and 
relating to others often cause worry, depression, or 
loneliness. 
0.204 (0.134-0.288) 
Complete hearing loss This person cannot hear at all in any situation, 
including even the loudest sounds, and cannot 
communicate verbally or use a phone. Difficulties 
with communicating and relating to others often 
cause worry, depression, or loneliness. 
0.215 (0.144-0.307) 
Severe hearing loss with 
ringing 
This person is unable to hear and understand 
another person talking, even in a quiet place, is 
unable to take part in a phone conversation, and has 
annoying ringing in the ears for more than 5 minutes 
0.261 (0.175-0.36) 
84
at a time, almost every day. Difficulties with 
communicating and relating to others cause 
emotional impact at times (for example worry or 
depression), 
Profound hearing loss 
with ringing 
This person is unable to hear and understand 
another person, even in a quiet place, is unable to 
take part in a phone conversation, has great difficulty 
hearing anything in any other situation, and has 
annoying ringing in the ears for more than 5 minutes 
at a time, several times a day. Difficulties with 
communicating and relating to others often cause 
worry, depression, or loneliness, 
0.277 (0.182-0.387) 
Complete hearing loss 
with ringing 
This person cannot hear at all in any situation, 
including even the loudest sounds, and cannot 
communicate verbally or use a phone, and has very 
annoying ringing in the ears for more than half of the 
day. Difficulties with communicating and relating to 
others often cause worry, depression, or loneliness, 
0.316 (0.212-0.435) 
Moderate motor 
impairment 
This person has some difficulty in moving around, 
and difficulty in lifting and holding objects, dressing 
and sitting upright, but is able to walk without help. 
0.061 (0.04-0.089) 
Moderate motor plus 
cognitive impairments 
This person has some difficulty in moving around, 
holding objects, dressing and sitting upright, but can 
walk without help. This person has low intelligence 
and is slow in learning to speak and to do simple 
tasks. 
0.203 (0.134-0.29) 
Long-term mild motor 
impairment 
This person has some difficulty in moving around but 
is able to walk without help. 
0.01 (0.005-0.02) 
Borderline intellectual 
disability 
This person is slow in learning at school. As an adult, 
the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions 
independently. 
0.011 (0.005-0.02) 
Severe motor 
impairment 
This person is unable to move around without help, 
and is not able to lift or hold objects, get dressed or 
sit upright. 
0.402 (0.268-0.545) 
Epilepsy (combined DW) NA 
Blindness Is completely blind, which causes great difficulty in 
some daily activities, worry and anxiety, and great 
difficulty going outside the home without assistance. 
0.187 (0.124-0.26) 
Severe acute episode of 
infectious disease 
This person has a high fever and pain, and feels very 
weak, which causes great difficulty with daily 
activities. 
0.133 (0.088-0.19) 
Mild intellectual 
disability 
This person has low intelligence and is slow in 
learning at school. As an adult, the person can live 
independently, but often needs help to raise children 
and can only work at simple supervised jobs. 
0.043 (0.026-0.065) 
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Monocular distance 
vision loss 
This person is blind in one eye and has difficulty 
judging distances 
0.017 (0.009-0.029) 
Mild motor plus 
cognitive impairments 
This person has some difficulty in moving around but 
is able to walk without help. The person is slow in 
learning at school. As an adult, the person has some 
difficulty doing complex or unfamiliar tasks but 
otherwise functions independently. 
0.031 (0.018-0.05) 
Severe motor plus 
cognitive impairments 
This person cannot move around without help, and 
cannot lift or hold objects, get dressed or sit upright. 
The person also has very low intelligence, speaks few 
words, and needs constant supervision and help with 
all daily activities. 
0.542 (0.37-0.702) 
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Case definition 
Encephalitis is a disease caused by an acute inflammation of the brain. Symptoms of encephalitis can 
include flu-like symptoms like headache, fever, drowsiness, and fatigue, and at times, seizures, 
hallucinations, or stroke. Included in the GBD modeling were cases meeting ICD-10 diagnostic criteria for 
encephalitis (A83-A86.4, B94.1, F07.1, G04-G05.8) (1). 
Input data 
Model inputs 
In the GBD 2010 study, a systematic review of literature was conducted to capture studies of incidence, 
excess mortality rate, remission, and standardized mortality ratio for encephalitis. These data sources 
included hospital data and literature. The inclusion criteria stipulated that: (1) the publication year must 
be between 1980 and 2010; (2) sufficient information must be provided on study method and sample 
characteristics to assess the quality of the study; and (3) study samples must be representative of the 
general population. No limitation was set on the language of publication. For GBD 2013, the GBD 2010 
search strategy was replicated to capture epidemiological studies published between 2010 and 2013. We 
did not do a literature review for GBD 2016. 
Additional sources we included in the acute bacterial meningitis model were inpatient-only hospital data 
and US claims data from 2000, 2010, and 2012, primary diagnosis and inpatient only. Sequelae and 
severity splits were informed by a meta-analysis, Edmond et al (2), while an internal meta-analysis 
informed mortality estimates for long-term moderate-to-severe impairments (3).  
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Data were outliered or excluded if we found they differed significantly when compared to regional, super-
regional, and global rates.  
The tables below show the number studies included in GBD 2016, as well as the number of countries or 
subnational units and GBD world regions represented for the encephalitis. 
Table 1. Acute encephalitis 
Prevalence Incidence 
Studies 0 26 
Countries/subnationals 0 37/291 
GBD world regions 0 16 
Modeling strategy 
Non-fatal outcomes were modeled using a combination of custom models and DisMod-MR 2.1, with 
minor changes from the GBD 2015 modeling process. First, the overall incidence and prevalence of 
encephalitis was modeled to estimate the short-term morbidity due to acute infection. This DisMod 
model had a set duration (1/remission) between 2.9 and 3.1 weeks. We also imposed caps on excess 
mortality for ages 10-50, and a cap on incidence from ages 10-100. US claims data and literature data 
were flagged with year-specific covariates to be crosswalked to the reference data, which were inpatient-
only, primary diagnosis hospital data. We used the function in DisMod-MR 2.1 to pull in cause-specific 
mortality rate (CSMR) data from our CODEm and CODcorrect analyses and match with incidence data 
points for the same location. We calculated excess mortality rate to estimate priors by dividing CSMR by 
prevalence, calculated from remission and incidence. To help inform trends where we lack data, we 
applied a binary country-level covariate at the subnational and country level that indicates if the location 
is in a Japanese Encephalitis endemic area (4). We forced a positive relationship, with a lower bound of 0 
and an upper bound of 0.1. We also applied a lag-distributed income covariate to excess mortality, log 
transformed and forced negative with an upper bound of 0 and a lower bound of -1. Betas and 
exponentiated values (which can be interpreted as an odds ratio) are shown in the tables below for 
study-level covariates and country-level covariates.  
Table 2. Study covariates 
Table 3. Country-level covariates 
Study covariate Parameter beta Exponentiated beta 
Claims data – 2000 Incidence -0.81 (-0.84 to – 0.78) 0.44 (0.43 – 0.46) 
Claims data – 2010 Incidence -0.56 (-0.59 to – 0.54) 0.57 (0.55 – 0.58) 
Claims data – 2012 Incidence -0.45 (-0.47 to -0.42) 0.64 (0.62 – 0.65) 
Literature Incidence -1.23 (-1.36 to -1.13) 0.29 (0.26 – 0.32) 
Country-level covariate Parameter beta Exponentiated beta 
Japanese Encephalitis 
endemic area (binary) 
Incidence 0.068 (0.030 – 0.097) 1.07 (1.03 – 1.10) 
88
 In addition to short-term sequelae as a result of acute encephalitis, we also modeled the long-term 
outcomes from encephalitis.  
Sequelae Splits 
We first split the long-term sequelae among survivors of acute infection. We calculated the acute phase 
survivors by applying the excess mortality (calculated by the acute meningitis DisMod model) to the 
incidence of each etiology (excess mortality was converted to case fatality rate by e(-excess mortality x 1/(excess 
mortality + remission))). The survivors were then subject to long-term sequelae by applying the post-discharge 
proportions of health consequences calculated by a meta-analysis by Edmond et al (2). We calculated the 
ratio of acute encephalitis survivors that result in a major long-term impairment, and the ratio of minor 
impairments to major impairments, based off a regression of log-transformed GDP and ratio values from 
Edmonds et al. The regression is shown below: 
𝑦 = −0.33590 ln(𝐺𝐷𝑃) + 1.15230 
We assumed a similar pattern of health outcomes for encephalitis infection survivors as with other 
bacterial meningitis survivors (except hearing loss, as we could not find evidence of hearing loss as a 
consequence of encephalitis infection). We used these two ratios to calculate the proportions of survivors 
who contract a long-term minor impairment and those who contract a long-term major impairment. The 
proportion with major impairments were further split (again using pooled proportions from Edmond et al) 
into specific major impairments, which were grouped into vision loss, moderate to severe cognitive 
impairments, and epilepsy.  
The calculated incidence of long-term sequelae was then converted to prevalence by two different 
approaches. For the sequelae not associated with excess mortality, which were vision loss, intellectual 
disability, motor impairment, and behavioral problems, the incidence of each age was cumulatively added 
up to the subsequent age (assuming half-cycle) to construct prevalence at each age. If the sequela is 
associated with excess mortality (epilepsy and moderate-to-severe cognitive impairments), the calculated 
incidence was uploaded into DisMod together with the corresponding mortality parameters (excess 
mortality data from the epilepsy envelope DisMod model, and standardized mortality ratio data from a 
neonatal encephalopathy meta-analysis, converted to excess mortality using all-cause mortality 
estimates) to estimate the prevalence. Vision loss and epilepsy estimates were squeezed and severity 
split centrally.  
 Disability weights 
The basis of the GBD disability weight survey assessments is lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for sequelae 
associated with encephalitis are shown below. 
Table 4. Severity splits, lay descriptions, and DWs 
Severity split Lay description DW (95% CI) 
LDI (log transformed) Excess mortality -0.015 (-0.055 to -
0.0002) 
0.99 (0.95 – 1.00) 
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Mild behavior problems This person is hyperactive and has difficulty 
concentrating, remembering things, and completing 
tasks. 
0.045 (0.028-0.066) 
Moderate motor 
impairment 
This person has some difficulty in moving around, 
and difficulty in lifting and holding objects, dressing 
and sitting upright, but is able to walk without help. 
0.061 (0.04-0.089) 
Moderate motor plus 
cognitive impairments 
This person has some difficulty in moving around, 
holding objects, dressing and sitting upright, but can 
walk without help. This person has low intelligence 
and is slow in learning to speak and to do simple 
tasks. 
0.203 (0.134-0.29) 
Long- term mild motor 
impairment 
This person has some difficulty in moving around but 
is able to walk without help. 
0.01 (0.005-0.02) 
Borderline intellectual 
disability 
This person is slow in learning at school. As an adult, 
the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions 
independently. 
0.011 (0.005-0.02) 
Severe motor 
impairment 
This person is unable to move around without help, 
and is not able to lift or hold objects, get dressed, or 
sit upright. 
0.402 (0.268-0.545) 
Epilepsy (combined DW) NA 
Blindness Is completely blind, which causes great difficulty in 
some daily activities, worry and anxiety, and great 
difficulty going outside the home without assistance. 
0.187 (0.124-0.26) 
Acute encephalitis This person has a high fever and pain, and feels very 
weak, which causes great difficulty with daily 
activities. 
0.133 (0.088-0.19) 
Mild intellectual 
disability 
This person has low intelligence and is slow in 
learning at school. As an adult, the person can live 
independently but often needs help to raise children 
and can only work at simple supervised jobs. 
0.043 (0.026-0.065) 
Monocular distance 
vision loss 
This person is blind in one eye and has difficulty 
judging distances 
0.017 (0.009-0.029) 
Mild motor plus 
cognitive impairments 
This person has some difficulty in moving around but 
is able to walk without help. The person is slow in 
learning at school. As an adult, the person has some 
difficulty doing complex or unfamiliar tasks but 
otherwise functions independently. 
0.031 (0.018-0.05) 
Severe motor plus 
cognitive impairments 
This person cannot move around without help, and 
cannot lift or hold objects, get dressed or sit upright. 
The person also has very low intelligence, speaks few 
words, and needs constant supervision and help with 
all daily activities. 
0.542 (0.37-0.702) 
 
No other significant changes were made to the modeling process for GBD 2016. 
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Case definition 
Diphtheria is a bacterial infection caused by Corynebacterium diphtheriae. For diphtheria, ICD 10 codes 
are A36-A36.9, Z22.2, Z23.6, and ICD9 codes are 032-032.9, V02.4, V03.5, and V74.3. 
 
Input data 
 
Model inputs 
For GBD 2016, input data included case fatality rate data from a systematic review of the literature and 
diphtheria mortality estimates from a negative binomial regression model.  
A systematic review of diphtheria case fatality was conducted for GBD 2016 to add to the literature used 
in GBD 2013. The PubMed search terms were: ((diphtheria[Title/Abstract] AND case 
fatality[Title/Abstract])) AND ("2013"[Date - Publication]: "2016"[Date - Publication]). 
 
Severity split & disability weights 
We draw primarily on the literature, as well as patterns in data observed in South Asia and Central Asia, 
to assign the following severity distributions for diphtheria: 70% (95% CI:66.5–73.5%) moderate and 30% 
(95% CI: 26.5–33.5%) severe cases. The lay descriptions and disability weights for diphtheria severity 
levels derived from the GBD Disability Weights study are shown below. 
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 Table 1. Severity splits, lay descriptions, and disability weights (DW) 
Severity level Lay description DW (95% CI) 
Moderate diphtheria 
Has a fever and aches, and feels 
weak, which causes some difficulty 
with daily activities. 
0.051 (0.032–0.074) 
Severe diphtheria 
Has a high fever and pain, and feels 
very weak, which causes great 
difficulty with daily activities. 
0.133 (0.088–0.19) 
 
Modelling strategy 
 
We used DisMod-MR 2.1 as a meta-regression tool to pool the case fatality data and generate location-
year-age-sex-specific case fatality rate estimates. We used lag-distributed income and the IHME health 
care access and quality index as location-level covariates. Diphtheria mortality was modelled using a 
negative binomial regression and data from the cause of death database with the DTP3 coverage 
covariate and age dummy variables. Incidence was then calculated as mortality rate divided by case 
fatality rate. Prevalence was calculated by multiplying incidence and duration, which was estimated to be 
a mean of 27.5 days, based on a meta-analysis of duration data from the literature. 
The table below shows model covariate coefficients and exponentiated values (from the DisMod case-
fatality model), which can be interpreted as odds ratios. 
Table 2. Beta and exponentiated beta values 
Covariate Parameter Coefficient (95% CI) 
Exponentiated 
coefficient (95% CI) 
DTP3 coverage 
(proportion) 
Case fatality  -0.18 (-0.66, -0.01) 0.84 (0.52, 0.99) 
Sex Case fatality 0.15 (-0.58, 0.90) 1.16 (0.56, 2.46) 
 
No other significant changes were made to the modelling strategy for GBD 2016. 
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Case definition 
Pertussis (whooping cough), is a contagious respiratory disease caused by the bacterium Bordetella 
pertussis. For pertussis, ICD 10 codes are A37-A37.91, Z23.7, and ICD 9 codes are 033-033.9, 484.3, V03.6. 
Input data 
Model inputs 
For the GBD 2016 nonfatal estimation process, the primary source of input data was pertussis case 
notifications from the World Health Organization (WHO). We also used historical case notifications for the 
UK back to 1940 to inform the whooping cough natural history model. 
Severity splits 
For GBD 2015, we assumed all pertussis cases were moderate episodes of acute infectious disease 
because of associated symptoms and MEPS data. The lay description and disability weight derived from 
the GBD Disability Weights study are shown below. 
Table 1. Severity splits, lay descriptions, and disability weights 
Severity level Lay description DW (95% CI) 
Moderate Has a fever and aches and feels weak, which 
causes some difficulty with daily activities. 
0.051 
(0.032–0.074) 
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 Modelling strategy 
We modelled log-transformed incidence with a mixed-effects linear regression of case notifications from 
WHO (1985–2015) on diphtheria-tetanus-pertussis dose 3 (DTP3) vaccination coverage. Historical data of 
United Kingdom (UK) pertussis cases and UK DTP3 coverage rates (both back to 1940) were also used to 
inform the incidence model. The random effect by country allowed for registration completeness to vary 
by country. The results of this model were then used to predict incidence as a function of vaccine 
coverage. To correct for underreporting in case notifications, we used a value of the random effect that 
matched the highest random effect in a high income region – Switzerland (which has a pertussis 
monitoring system which captures a high percentage of cases) – to get an implied attack rate assumed to 
be the same for all unvaccinated populations. Uncertainty was estimated by taking 1,000 iterations of the 
predictions based on the variance-covariance matrix. Prevalence was calculated by multiplying incidence 
by an average duration assumed to be 50 days. 
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Case definition 
 
Tetanus is a serious bacterial disease caused by the bacterium Clostridium tetani. For tetanus, the ICD 10 
codes are A33-A35.0, Z23.5, and ICD 9 codes are 037-037.9, 771.3, V03.7. 
 
Input data 
 
Model inputs 
For GBD 2016, input data for the estimation of tetanus included case fatality rate data extracted from a 
systematic review the literature and IHME tetanus mortality estimates calculated with CODEm. 
A systematic review was conducted for GBD 2016. The PubMed search terms were: 
(tetanus[Title/Abstract]) AND (case fatality[Title/Abstract]) AND ("2013"[Date - Publication]: "2016"[Date - 
Publication]). 
Severity split & disability weights 
We assume that all tetanus cases are severe episodes of acute infectious diseases. The lay descriptions 
and disability weights for tetanus derived from the GBD Disability Weights study are shown below. 
Table 1. Severity splits, lay descriptions, and disability weights (DW) 
Severity level Lay description DW (95% CI) 
Severe 
Has a high fever and pain, and feels 
very weak, which causes great 
difficulty with daily activities. 
0.133 
(0.088–0.19) 
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Regarding the severity level of impairment due to neonatal tetanus, we assume the same distribution as 
in neonatal encephalopathy. 
 
Modelling strategy 
 
We used DisMod-MR 2.0 as a meta-regression tool to pool the case fatality data and generate location-
year-age-sex-specific case fatality rate estimates. We used DTP3 coverage as a location-level covariate. 
Mortality was modelled using the standard CODEm tool on neonatal tetanus (ages 0-0.1) and non-
neonatal tetanus (ages 1-80) separately for males and females. Incidence was then calculated as: 
 
Incidence = mortality rate / case fatality rate 
 
Prevalence was then computed based on the estimated incidence and duration draws derived from 
literature review.  
 
To estimate mild and moderate impairment due to neonatal tetanus, we first computed the incidence of 
survival from neonatal tetanus as: 
 
Incidence of survival = incidence * (1 - CFR) 
 
We then conducted a meta-analysis of published studies to estimate the proportion of mild impairment 
due to neonatal tetanus and moderate-to-severe impairment due to neonatal tetanus. We applied these 
proportions to the estimated incidence of survival, to generate incidence of mild impairment due to 
neonatal tetanus and moderate-to-severe impairment due to neonatal tetanus, which were used as input 
data in DisMod 2.0. We ran two separate DisMod models (one for mild impairment due to neonatal 
tetanus, and one for moderate-to-severe impairment due to neonatal tetanus) to generate age-sex-year-
country-specific estimates. 
 
The table below shows betas and exponentiated values for the covariates used in the estimation process 
(from the DisMod case-fatality model), which can be interpreted as an odds ratio. 
 
Table 3. Beta and exponentiated beta values 
Covariate Parameter Beta (95% CI) 
Exponentiated beta 
(95% CI) 
DTP3 coverage 
(proportion) 
Case fatality  0.52 (-0.061 — 1.32) 1.68 (0.94 — 3.76) 
Sex Case fatality -0.12 (-0.35 — 0.10) 0.89 (0.71 — 1.11) 
 
No other significant changes were made to the modelling strategy for GBD 2016. 
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Input data 
Vital registration data from the cause of death database were used for data-rich countries. To inform 
the natural history model, we used data from the following sources: World Health Organization (WHO) 
case notifications from 1995 to 2015; case notifications identified by collaborators; vital registration (VR) 
data in countries in the following three super-regions: high-income, Central Europe/Eastern 
Europe/Central Asia, and Latin America and Caribbean; and case fatality data identified through 
systematic literature reviews for GBD 2010, GBD 2013, and GBD 2016. The PubMed search query for 
GBD 2016 was: (measles [Title/Abstract]) AND (case fatality [Title/Abstract]) AND ("2013"[Date - 
Publication]: "2016"[Date - Publication]). Studies were included if they reported case fatality rate, 
number of deaths, and number of cases. Studies were excluded if they included non-representative 
samples only.  
 
Modelling strategy – data-rich countries 
Mortality was modelled separately for data-rich and other countries. For data-rich countries (ie, 
countries with vital registration more than 95% complete for more than 25 years), we used a general 
CODEm strategy to model VR data with measles-containing vaccination dose one (MCV1) coverage, 
childhood malnutrition, lagged distributed income, the Healthcare Access and Quality Index, and 
education as country-level covariates. We made estimations for the age range post-neonatal to 59 
years. 
 
Modelling strategy – other countries 
Measles mortality in the remaining countries was modelled using a natural-history-based model. First, 
we modelled measles incidence with a mixed-effects linear regression of case notifications from WHO 
(1995–2015) on routine measles vaccination rates and supplementary immunization activities (SIAs). 
More precisely, log-transformed incidence rates were regressed on the log of the proportion 
unvaccinated with first- and second-dose measles-containing vaccine, and additional SIA coverage 
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lagged by one, two, three, four, and five years, with super-region, region, and country-level random 
effects. The results of this mixed-effects regression model were then used to predict location-year-
specific incidence as a function of routine vaccine coverage and SIAs. To correct for underreporting in 
case notifications, we added the effect of a 95% attack rate, assumed to be the same across all 
unvaccinated populations. Uncertainty was estimated by taking 1,000 iterations of the predictions based 
on the variance-covariance matrix. For locations in three super-regions – high-income, Central 
Europe/Eastern Europe/Central Asia, and Latin America and Caribbean – we used reported measles 
cases as incident cases.  
 
Second, the case fatality rate was modelled using a mixed-effects negative binomial regression with the 
child malnutrition covariate and study-level indicators (hospital-based or not; outbreak or not; and rural 
or urban/mixed), with country random effects. Uncertainty was estimated by taking 1,000 iterations of 
the predictions based on the variance-covariance matrix and uncertainty in country random effects. The 
fit of the model was evaluated using diagnostic plots of predicted versus observed values. Finally, 
estimated deaths were calculated at the 1,000-draw level as 
𝑑𝑒𝑎𝑡ℎ𝑠 = 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 ∗ 𝐶𝐹𝑅. 
We estimated overall number of deaths and then assigned an age-sex distribution based on the age- and 
sex-specific patterns found in the cause of death data. We made estimations for the age range post-
neonatal to 59 years. 
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Case definition 
Varicella (also known as chicken pox) is an acute infectious disease caused by varicella zoster virus. 
Herpes zoster (also known as shingles), is caused by the reactivation of the same virus that causes 
varicella. For varicella and herpes zoster, the ICD 10 codes are B01-B02.9, P35.8, Z20.820, and ICD 9 
codes are 052-053.9, V01.71, V01.79, V05.4. 
 
Input data 
Model inputs 
Input data for varicella were from published seroprevalence studies, and that for herpes zoster were from 
published incidence studies. 
A systematic review was done for both varicella and herpes zoster for GBD 2016. The PubMed search 
query for varicella was as follows: (varicella[Title/Abstract] AND seroprevalence[Title/Abstract]) AND 
(incidence[Title/Abstract] OR prevalence[Title/Abstract]) NOT (herpes zoster[Title/Abstract] OR 
shingles[Title/Abstract]) AND ("2013"[Date - Publication] : "2016"[Date - Publication]).  
The PubMed search query for herpes zoster was as follows: ((herpes zoster[Title/Abstract] OR 
shingles[Title/Abstract]) AND (incidence[Title/Abstract)) NOT (varicella[Title/Abstract] OR chicken 
pox[Title/Abstract]) AND ("2013"[Date - Publication] : "2016"[Date - Publication]) 
The exclusion criteria were: 
10. Studies that were not population-based, eg, hospital or clinic-based studies 
11. Studies that did not provide primary data on epidemiological parameters, eg, commentaries  
12. Review articles 
13. Case series 
14. Self-reported cases 
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 Severity splits & disability weights 
We assume all varicella cases are mild episodes of acute infectious disease. Herpes zoster was a sequela 
studied in the GBD disability weight study. The lay descriptions and corresponding disability weights are 
presented in the table below. 
 
Table 1. Severity level, lay description, and disability weights (DW) 
Severity level Lay description DW (95% CI) 
Mild acute 
infectious disease 
Has a low fever and mild discomfort but no difficulty 
with daily activities. 
0.006 
(0.002–0.012) 
Herpes zoster 
Has a blistering skin rash that causes pain, with some 
burning and itching. 
0.058 
(0.035–0.09) 
 
Modelling strategy 
The modelling strategies for varicella and herpes zoster are outlined below: 
I. Varicella seroprevalence data were first run through DisMod-MR 2.0. Detailed steps in the estimation of 
incidence and prevalence are shown below: 
1. Model varicella seroprevalence data as prevalence in DisMod, after specifying zero remission 
and no excess mortality 
2. Pick up incidence draws (which are actually hazards) from DisMod 
3. Calculate population incidence rate = hazard *(1-prevalence) at the draw level 
4. Calculate prevalence as prevalence = population incidence rate*duration (assumed to be 7 
days) 
II. Herpes Zoster morbidity was modeled using a standard DisMod model. We assume no excess mortality 
associated with herpes zoster. 
Betas and exponentiated values (which can be interpreted as an odds ratio) are shown in the tables 
below. 
Table 3a. Varicella DisMod model 
Covariate Parameter Beta (95% CI) Exponentiated beta (95% CI) 
Sex (male) Seroprevalence -0.075 (-0.85 — 0.75) 0.93 (0.43 — 2.12) 
 
Table 3b. Herpes zoster DisMod model 
Covariate Parameter Beta (95% CI) Exponentiated beta (95% CI) 
Sex Incidence -0.14 (-0.28 — -0.0049) 0.87 (0.76 — 1.00) 
 
No other significant changes were made to the GBD 2016 modelling strategy.  
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 Malaria 
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Case definition 
Malaria is an acute parasitic mosquito-borne disease. An individual with uncomplicated malaria 
experiences one to two weeks of persistent fever, chills/shivering, sweating, joint pains and headache.  
The individual will likely be lethargic and feverish, causing loss of daily function during the attack. 
Individuals with an untreated P. falciparum infection may develop severe malaria, which includes the 
symptoms of uncomplicated malaria plus potentially swelling, difficulty breathing, unconsciousness, and 
death. Rapid diagnostic test or microscopy are considered the gold-standard diagnostic approaches for 
the purposes of GBD. The relevant ICD-10 codes are B50-B54. 
 
Data input 
Primary data inputs were: 
(i) Routine malaria case reports from national routine surveillance systems. These were 
obtained at national level from the WHO World Malaria Report and at the subnational 
administrative level, wherever possible, via an exhaustive search of published and grey 
literature sources along with online data portals hosted by national ministries of health. Each 
retained record consisted of an annual count of malaria cases along with breakdown by 
whether confirmed/unconfirmed and by malaria parasite species. 
(ii) Cross-sectional geolocated community-representative observations of infection prevalence 
for Plasmodium falciparum (referred to hereafter as P. falciparum parasite rate, PfPR). 
 
These malaria epidemiological metrics were augmented in the modelling by: 
(iii) Malaria Atlas Project (MAP) modelled estimates of malaria control intervention population 
coverage (ITNs, IRS, antimalarials) resolved to 5 km x 5 km pixel-year level (for Africa) and 
country-year level (outside Africa). 
(iv) A large suite of environmental, sociodemographic, and economic covariates resolved to 5 km 
x 5 km pixel-year level (for Africa) and country-year level (outside Africa). 
 
Modelling strategy 
The suitability, availability, and quality of PfPR and routine case reporting data, as well as detailed 
intervention coverage information, differ markedly inside versus outside Africa. This meant we developed 
separate modelling strategy for countries inside Africa versus those outside. The exceptions were Algeria, 
Egypt, Morocco, Comoros, Mauritius, Cape Verde, Sao Tome, Principe, Rwanda, Botswana, Namibia, 
Eritrea, Djibouti, and South Africa which, despite being part of Africa, have epidemiologies and data 
availability/quality more akin to non-African settings. 
PfPR and case incidence modelling: Africa 
Modelling was conducted in the following steps: 
(i) The large assembly of geolocated PfPR surveys maintained by MAP was used in a Bayesian 
spatiotemporal geostatistical model to predict PfPR for every pixel-year in sub-Saharan Africa, 
representing an update to earlier work (Bhatt et al Nature, Gething et al NEJM). The model 
took into account (i) PfPR survey participant age ranges and diagnostic type; (ii) coverage of 
ITNs, IRS, and effective antimalarial drug coverage and how these changed through time at 
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each data and prediction location; (iii) environmental conditions at each data and prediction 
location (including density of vegetation, temperature, humidity, rainfall, elevation, proximity 
to populated areas). The outcome was a predicted space-time “cube” of PfPR, standardized 
to the 2-10 age range, for each year 1980–2016. 
(ii) The PfPR cube was then converted into an equivalent cube of the predicted incidence rate of 
clinical malaria. This conversion was achieved using an established model (Cameron et al 
Nature Communications) and allowed estimates stratified into three broad age bins (0-5; 5-
15; <15). 
 
PfPR and case incidence modelling: Outside Africa 
Malaria endemic countries outside Africa tend to have less PfPR data than those inside, in part because 
prevalence is generally lower and thus PfPR becomes an inefficient way to measure malaria risk. 
Conversely, routine surveillance systems outside Africa are generally stronger, meaning that reports of 
malaria cases from health systems are more reliable and provide some insight into the total malaria 
burden in the community. Modelling outside Africa was carried out in the following steps: 
(i) National and subnational case reports were first subject to adjustments to identify and 
minimize bias. Bias in reported case numbers arises from various sources. First, a fraction of 
cases in the community will either seek no care or attend only a private or informal health 
care provider who would not provide a record of that case to the routine surveillance system. 
We adjusted for this by modelling the fraction of cases seeking care from different provider 
categories based on data from nationally representative cross-sectional household surveys 
(primarily from the Demographic and Health Survey (DHS) program and the Multiple 
Indicator Cluster Survey program). Second, cases reaching formal clinics may not be subject 
to a confirmatory diagnostic test. We adjusted for this by assuming the fraction of 
unconfirmed cases that were truly malaria would equal the fraction of positives among all 
those tested. Third, many routine surveillance systems fail to capture all case reports, with 
certain facilities/regions missing from the national totals in a given year. We adjusted for this 
based on reporting completeness statistics published nationally by WHO. 
(ii) These adjusted routine case reports were georeferenced using digitized administrative 
boundary data using a large library of such boundaries maintained by MAP. 
(iii) Each case report was converted to an estimate of clinical incidence rate by dividing over the 
estimated population at risk in each unit, with the latter quantity derived by combing high-
resolution gridded population data with MAP models that exclude malaria risk based on 
aridity or temperature ranges not conducive to transmission. 
(iv) The incidence rate for each unit was then converted to an inferred PfPR value using the same 
model described earlier (Cameron et al). This allowed us to then combine these data with the 
true PfPR survey data that existed, albeit sparsely, in many countries outside Africa. 
(v) The combined PfPR survey point data and (pseudo) PfPR administrative unit data were then 
used in a Bayesian spatiotemporal geostatistical model to predict PfPR at pixel-year level 
across all countries. As for the Africa model, PfPR was standardized by age and diagnostic 
type and informed by a wide suite of covariates. An additional mechanism was developed to 
allow polygon (ie, administrative unit) and point (ie, survey) data to be used jointly to infer 
the predicted space-time surfaces. 
(vi) As in Africa, the predicted PfPR cube was then converted into an equivalent cube of the 
predicted incidence rate of clinical malaria.  
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Total malaria cases by country, year, sex 
The pixel-level predictions of clinical incidence rate (both inside and outside Africa) were combined with 
high-resolution gridded population data to estimate total cases per pixel-year. These were then 
aggregated to GBD national/subnational geographies. For countries endemic for P. vivax and P. 
falciparum, we calculated the number of cases due to P. vivax applying the fraction of P. vivax and P. 
falciparum obtained from WHO and literature review. Total cases estimated in the MAP age bins were 
then redistributed to standard GBD age bins using the age pattern learned during the mortality/CoD 
estimation process (discussed in more detail in the GBD 2016 CoD paper). 
Determining YLDs for malaria 
As in GBD 2015, we use a two-step process for determining malaria severity. For acute cases, severity 
splits for mild, moderate, and severe malaria were produced by analysis of MEPS data. These sequelae 
and their associated disability weights are presented below. 
Table 1. Severity level, lay description, and DW 
Severity level Lay description DW (95% CI) 
Mild Has a low fever and mild discomfort but no 
difficulty with daily activities. 
0.006 
(0.002–0.012) 
Moderate Has a fever and aches and feels weak, which causes 
some difficulty with daily activities. 
0.051 
(0.032–0.074) 
Severe Has a high fever and pain and feels very weak, 
which causes great difficulty with daily activities. 
0.133 
(0.088–0.19) 
 
To determine long-term neurological burden due to malaria, we use the work by Roca-Felter et al. (2008) 
that examined the number of uncomplicated cases that led to longer-term impairment. Analytically, this 
means multiplying incidence estimates (described in the section below) for persons under 20 by 0.00029 
(0.000077–0.00057). This subset is then combined with excess mortality rates derived from all-cause 
mortality and standardized mortality ratios for neonatal encephalopathy (NE) in a DisMod model to 
produce prevalence estimates for all estimation years. Implicit in this process is an assumption that the 
disability and trend of impairment due to severe malaria follow NE. The subsequent severity splitting 
follows NE as well. Once the incidence estimation procedures were completed, the results were 
combined and converted to prevalence by matching each draw with a draw of duration. Consistent with 
GBD 2015, we use a uniform distribution between 14 and 28 days for duration. 
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Chagas disease 
Flowchart 
Case definition 
Chagas disease is defined by infection with the protozoa Trypanosoma cruzi, which is transmitted by 
Triatominae insect vectors (most common), blood transfusion, organ transplant, and congenital 
transmission. It includes an acute phase corresponding with the time of infection, and is typically 
asymptomatic. Chronic infection may be latent (ie, asymptomatic), or result in cardiovascular or 
digestive sequelae. It includes all ICD-10 codes under the heading B57 (Chagas disease), with codes 
B57.0-B75.1 corresponding to the acute phase, B57.2 corresponding to chronic cardiovascular sequelae, 
and B57.3 corresponding to chronic digestive sequelae.  
Input data 
Model inputs 
For GBD 2016 estimation, we used seroprevalence data to model Chagas. The table below illustrates the 
geographic distribution of model input data for the estimation process.  
Table 1. Geographies 
Level  Prevalence 
Data points 407 
Studies 56 
Locations 20 
Regions 4 
We also use CSMR estimates in the modeling process, which will be addressed in further detail below. 
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 Modelling strategy  
We modeled Chagas disease using a full DisMod-MR 2.1 Bayesian meta-regression model incorporating 
seroprevalence data, as above, and CSMR estimates. We assume no remission. We eliminate all new 
infections, except those via vertical transmission, in Chile and Uruguay for years after the interruption of 
vector-based transmission (Abad-Franch F, Diotaiuti L, Gurgel-Gonçalves R, Gürtler RE. Certifying the 
interruption of Chagas disease transmission by native vectors: cui bono? Mem Inst Oswaldo Cruz 
2013;108:251–4.; Coura JR. Chagas disease: control, elimination and eradication. Is it possible? Mem 
Inst Oswaldo Cruz 2013;108:962–7.). For non-endemic countries, we estimate the prevalence of 
imported chronic infections based on migration. For each non-endemic country, we estimate the total 
number of people infected with Chagas as the sum of the number of immigrants from each endemic 
country multiplied by the corresponding prevalence of Chagas in that endemic country.  
 
We estimate five sequelae: symptomatic acute infection from incidence; and megaviscera, heart failure, 
atrial fibrillation, and chronic asymptomatic infection from prevalence. We assume that 5% of acute 
infections will be symptomatic (Teixeira AR, Nitz N, Guimaro MC, Gomes C, Santos-Buch CA. Chagas 
disease. Postgrad Med J 2006;82:788–98.). The proportion of chronic infections resulting in a given 
sequela varies by sex and age: the prevalence of megaviscera among those infected with Chagas ranges 
from 0% in children to nearly 10% among older adults (Coura JR, Naranjo MA, Willcox HP. Chagas’ 
disease in the Brazilian Amazon: II. A serological survey. Rev Inst Med Trop São Paulo 1995; 37:103–7.); 
the prevalence of atrial fibrillation attributable to Chagas ranges from 0% among children to 
approximately 10% in men over 80 years of age (Ribeiro AL, Marcolino MS, Prineas RJ, Lima-Costa MF. 
Electrocardiographic abnormalities in elderly Chagas disease patients: 10-year follow-up of the Bambuí 
Cohort Study of Aging. J Am Heart Assoc 2014;3:e000632.); and the prevalence of heart failure 
attributable to Chagas among those who are infected ranges from 0% among young children, to a 
maximum of 23% among men over 80 years of age (Sabino EC, Ribeiro AL, Salemi VM, et al., for the 
National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II (REDS-II), International 
Component. Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-
seropositive former blood donors. Circulation 2013;127:1105–15.). 
 
Severity splits and disability weights 
 
The table below illustrates the sequelae, lay descriptions, and DWs for Chagas disease.  
 
Table 2. Sequelae, lay description and DWs 
 
Sequelae Description 
Disability 
Weight 
Atrial fibrillation and 
flutter due to Chagas 
disease 
 
Has periods of rapid and irregular heartbeats and occasional 
fainting.  
0.224 
(0.151–
0.312) 
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Mild heart failure due 
to Chagas disease 
Is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort. 
 
0.041 
(0.026–
0.062) 
Moderate heart failure 
due to Chagas disease 
Is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity. 
 
0.072 
(0.047–
0.103) 
Severe heart failure 
due to Chagas disease 
Is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems.  
 
0.179 
(0.122–
0.251) 
Mild chronic digestive 
disease due to Chagas 
disease 
 
Has some pain in the belly that causes nausea but does not 
interfere with daily activities. 
0.011 
(0.005–
0.021) 
Moderate chronic 
digestive disease due 
to Chagas disease 
 
Has pain in the belly and feels nauseated. The person has 
difficulties with daily activities.  
 
0.114 
(0.078–
0.159) 
Acute Chagas disease Has a fever and aches, and feels weak, which causes some 
difficulty with daily activities.  
 
0.051 
(0.032–
0.074) 
Asymptomatic Chagas 
disease 
Latent Chagas infection (ie, chronic infection with no 
apparent symptoms) 
NA 
 
 
Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modelling strategy for endemic countries from GBD 2015 
to GBD 2016. 
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 Visceral Leishmaniasis 
Flowchart 
 
Input Data and Methodological Summary  
Case Definition 
Visceral leishmaniasis (VL) is the most serious manifestation of disease caused by the Leishmania 
parasite, transmitted through the bite of phlebotomine sand flies. Those infected typically present with 
fever, weight loss, anaemia, leukopenia, thrombocytopenia, and enlargement of the spleen and liver. If 
left untreated, it can be fatal. Transmission varies by geographic region, as approximately 70 animal 
species have been identified as potential reservoir hosts of the parasite. The ICD9 code related to 
visceral leishmaniasis is 085.0, and the ICD10 code is B55.0. 
 
Input data 
No systematic review of literature was done for VL for GBD 2016; however, WHO country profile 
datasets were updated to include the most recent case reports, and subnational reporting data from 
India, Brazil and Mexico were added.  The table below outlines the number of location-years of 
reporting data, and the number of locations (countries or subnational units) and GBD world regions 
represented. 
 incidence  
Location-years 2,034 
Locations 188 
GBD world regions 14 
 
 
Modelling strategy  
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We inflated VL case reports to account for underreporting, based on underreporting factors that were 
published by Alvar et al.(1) After adjusting for underreporting, we modelled all-age VL incidence using 
Space-Time Gaussian Process Regression (ST-GPR), with four covariates: socio-demographic index, 
leishmaniasis transmission potential (binary), high leishmaniasis endemicity (binary), and migration rate.  
Given that the vast majorty of location-years of case reports are for all ages and both sexes combined, 
mortality data offered the richest source of data on the age/sex distribution of VL.  We modelled age-sex 
patterns using a mixed effects model of the logit-transformed proportion of cases that occur in each 
age/sex category, with fixed effects on age (indicator variables for each GBD age group) and sex, and 
hierarchical random effects region nested within super-region, and random slopes on age category 
within each level of the geographic hierarchy.  Finally, we applied the age/sex patterns from the age-
specific model to the total incidence estimates from the all-age ST-GPR model to estimate incidence by 
location, year, age and sex. Resultant incidence draws are then assumed to have a duration of three 
months, from which prevalence is calculated. Of those three months, three weeks are assumed to be 
spend with severe infection, and nine with moderate infection. 
 
 
Changes from GBD 2015 to GBD 2016 
We have substantially revised this model for GBD 2016.  Whereas GBD 2015 incidence estimates were 
derived from a DisMod model, we now estimate all-age incidence via ST-GPR, and age/patterns via a 
custom mixed-effects model.  This approach has the advantage of being able to estimate trends with 
more detail and accuracy, and of being able to more effectively utilize all-age data, which represent the 
majority of location-years of incidence data for VL.   
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 Cutaneous & Mucocutaneous Leishmaniasis 
Flowchart 
 
Input Data and Methodological Summary  
Case Definition 
Cutaneous leishmaniasis (CL) is the most common manifestation of disease caused by the Leishmania 
parasite, transmitted through the bite of phlebotomine sand flies. It causes the appearance of skin 
lesions, often beginning as papules or nodules and developing into ulcers, on parts of the body exposed 
to the bite of the sand fly. Mucocutaneous leishmaniasis (MCL) is a much more exceptional – and severe 
– presentation. Primarily isolated to Latin America, MCL infections can result in degradation of the 
mucous membranes, typically following an ulcerative sore from CL infection. Transmission varies by 
geographic region, as approximately 70 animal species have been identified as potential reservoir hosts 
of the parasite. 
Input data 
No systematic review of literature was done for Cutaneous and Mucocutaneous Leishmaniasis for GBD 
2016; however, WHO country profile datasets were updated to include the most recent case reports, 
and subnational reporting data from India, Brazil and Mexico were added.  The table below outlines the 
number of location-years of reporting data, and the number of locations (countries or subnational units) 
and GBD world regions represented. 
 incidence  
Location-years 1,368 
Locations 132 
GBD world regions 16 
 
 
Modelling strategy 
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We first compiled two CL datasets: 1) a dataset of all-age annual CL case reports, and 2) a dataset of 
age/sex specific incidence data.  Where countries reported cases by age or sex, those age/sex-specific 
case reports were collapsed to all-age/both sex totals for inclusion the all-age database.  All-age/both-
sex case reports were then inflated to account for underreporting, based on underreporting factors that 
were published by Alvar et al.(1)  
After adjusting for underreporting, we modelled all-age CL incidence using Space-Time Gaussian Process 
Regression (ST-GPR).  Age-sex patterns were modelled using DisMod-MR and the age/sex-specific 
dataset.  Finally, we applied the age/sex patterns from the age-specific DisModel model to the total 
incidence estimates from the all-age ST-GPR model to estimate incidence by location, year, age and sex.  
 
We estimated total prevalence as the sum of the prevalence of acute symptoms and long-term 
sequelae.  The prevalence of acute symptoms was calculated as the product of incidence and duration, 
with duration equal to six-months.(2)  We estimated the prevalence of long-term sequelae based on the 
proportion of cases that would result in lasting facial scars.  To do this, we first obtained the average 
proportion of sores that occur on the face based on a sample‐weighted average of the proportion from 
four studies conducted in North Africa/Middle East (the region with the most data and a fairly high 
incidence of CL).(3–6) The average proportion of facial sores was 0.476. Of these people, we only 
assigned long‐term to sequelae to those who did not have appropriate access to health care, which we 
estimated based on a normalized health system access covariate. We multiplied CL incidence times the 
proportion of people with facial sores (46%), times the proportion of people without health system 
access in each location‐year to obtain incidence of people with long‐term sequelae. Assuming no 
remission or excess mortality, we stream those with long-term sequelae through cohort space to 
estimate prevalence. 
 
Changes from GBD 2015 to GBD 2016 
We have substantially revised this model for GBD 2016.  Whereas GBD 2015 incidence estimates were 
derived from a DisMod model, we now estimate all-age incidence via ST-GPR, and age/patterns via a 
DisMod model.  This approach has the advantage of being able to estimate trends with more detail and 
accuracy, and of being able to more effectively utilize all-age data, which represent the majority of 
location-years of incidence data for CL.  Moreover, previous iterations of GBD estimated prevalence 
from incidence by carrying cases across age groups within a GBD estimation year, rather than carrying 
cases across cohort space.  The previous approach offers a good approximation under relatively stable 
conditions (i.e. relatively stable incidence and health system access), but it performs poorly where there 
are non-trivial trends in incidence.  We have improved our approach here, and now estimate prevalence 
in cohort space. 
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 Human African Trypanosomiasis (HAT) 
 
Flowchart 
 
 
Input Data & Methodological Summary 
 
Case Definition 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a vector-borne disease which 
is transmitted by the bite of the tsetse fly. It is caused by the parasite Trypanosoma brucei with two 
subspecies, namely T.b. rhodesience (makes up less than 5% of total HAT cases) and T.b. gambiense. 
Cases are diagnosed through laboratory methods which rest on finding the parasite in body fluid or 
tissue by microscopy. In highly endemic or epidemic areas where the likelihood of false positives in 
serological tests is deemed lower, a seropositive individual is considered affected even in the absence of 
parasitological confirmation. The ICD-10 codes for HAT are B56.0, B56.1 and B56.9. 
 
Input data 
Model inputs 
A literature search was done for GBD 2013 and for GBD 2015. The GBD 2015 search was conducted 
between 1/1/2013 and 8/10/2015, and the number of initial hits was 87. Of these, five sources were 
extracted for data.  The literature search was updated by reviewing all publications from 2016; of the 
138 sources reviewed, one additional source was identified to describe the age/sex distribution of HAT 
infection.   
Additional input data used to estimate mortality due to HAT included a) population at risk estimates 
from GBD 2010 ArcGIS analysis using geocoded case notifications for 2000 to 2009(1) and population 
Count Grid estimates from Gridded Population of the World 3,(2,3) b) population screened from 1997 to 
2004,(4) c) historical data from GBD 2010 on total number of HAT cases reported(1,4,5) and d) cases 
reported annually to the WHO(6) – for Kenya, a study on cases reported subnationally(7) was used to 
split the national cases into five counties (HomaBay, Migori, Busia, Bungoma, Kakamega). In addition, 
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age-specific incidence data from active screening undertaken in the Democratic Republic of Congo(8) 
and Uganda(9) were used to inform age pattern for deaths. 
Data on the number of cases identified through active screening were obtained from a Weekly 
Epidemiological Record report (4) for T.b. gambiense HAT reported from 1997-2004 which reported 
active case finding data for the following countries: The Gambia, Ghana, Guinea Bissau, Liberia, Niger, 
Sierra Leone, and Senegal.  No active case detection screening coverage data are currently available for 
T.b. rhodesiense HAT-endemic countries.  
National case data from 1990-2015 were obtained from the World Health Organization’s official 
surveillance data (available via the Global Health Observatory).  
The table below shows the number of location-years of reporting data, and the number of locations 
(countries or subnational units) and GBD world regions represented. 
 incidence  
Location-years 805 
Locations 29 
GBD world regions 4 
 
Based on available historical data post-1980, the following countries (years) were included in the 
estimation: Botswana (1983), Ethiopia (1980-1983), Guinea-Bissau (1980-1983, 1985-1987), Rwanda 
(1980, 1982-1988), and Sierra Leone (1981-1982). Five subnational locations (out of 49) for Kenya were 
also added in the estimation for GBD 2016. 
 
Severity splits/sequelae 
The basis of the GBD disability weight (DW) survey assessments are lay descriptions of sequelae 
highlighting major functional consequences and symptoms. The lay descriptions and disability weights 
for sequelae due to HAT are shown below. 
Sequela Lay description DW (95% CI) 
Skin 
disfigurement, 
level 1   
Has a slight, visible physical deformity that is sometimes 
sore or itchy. Others notice the deformity, which causes 
some worry and discomfort. 
0.027 
(0.015–0.042) 
Motor plus 
cognitive 
impairments, 
severe 
Cannot move around without help, and cannot lift or 
hold objects, get dressed or sit upright. The person also 
has very low intelligence, speaks few words, and needs 
constant supervision and help with all daily activities 
0.542 (0.37–0.702) 
 
Modelling strategy 
The nonfatal model for HAT is implemented as follows: 
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1. The incidence of reported HAT cases among the population at risk was calculated as the total 
number of reported cases divided by the population at risk.  
 
2. To estimate the number of cases that were likely undetected by country and year, a multi-level 
mixed-effects linear regression of natural log-transformed incidence rate (ratio of reported HAT 
cases to population at risk) on natural log-transformed screening coverage (ratio of number 
screened for HAT to population at risk), with country random effects, was performed. Gaps were 
then filled using exponential interpolation between years and extrapolation from 2015 to 2016 
for reported cases. This model generates a beta-coefficient which is used to estimate the case 
detection rate (see step 3). 
 
For country-years in which no screening coverage data were reported: 
 Among countries with data reported, 1997-2004, the proportion of the at risk 
population screened from 1997 was used retrospectively for the period 1990-1996 and 
the screening coverage from 2004 was carried forward from 2005-2016. 
 For countries with no screening data reported, the mean screening coverage for the 
region was used to impute a value over time.  
 
3. Using the mean and variance-covariance matrix from the regression as parameters, a 
multivariate normal distribution was used to generate 1,000 draws of case detection rate (CDR), 
given the expected screening coverage. Undetected deaths were then estimated as the 
difference between the ratio of reported cases to CDR and reported cases (reported cases/CDR 
– reported cases). Estimates of incidence were obtained by adding the reported cases to the 
undetected cases. 
 
4. Total HAT cases were split between T.b. gambiense and T.b. rhodesiense.  We assigned all cases 
to T.b. gambiense for Angola, Benin, Burkina Faso, Cameroon, Central African Republic, Chad, 
Congo, Cote d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Gabon, Ghana, 
Guinea, Guinea-Bissau, Mali, Nigeria, Sierra Leone, South Sudan, and Togo.  We assigned all 
cases to T.b. rhodesiense for Botswana, Ethiopia, Kenya, Malawi, Mozambique, Rwanda, 
Tanzania, Zambia, and Zimbabwe.  Cases in Uganda were split by species based on species-
specific case reports. 
 
5. Assuming the same proportion in treated and untreated cases, the incidence estimates were 
then split into the two sequelae, skin disfigurement and sleeping disorder. This was done by 
generating 1,000 draws of the splitting proportion for the sequelae (70%–74% with sleeping 
disorder) based on a study that reported presence of symptoms at admission of patients in 
treatment centers [14] – draws were generated from a beta distribution with alpha parameter = 
1884 and beta parameter = 649. 
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6. To compute prevalence of HAT, we generate 1,000 draws of total duration of symptoms in
untreated cases with a mean duration of 3 years (1.8 – 4.1) for  T.b. gambiense and 0.5 years
(0.46 – 0.54) for T.b. rhodesiense, and an estimated duration of six months for all treated cases
(both species) (10,11). Prevalence of treated and untreated cases were summed.
7. For untreated cases, we assumed that half the duration is spent with sleeping disorder (severe
motor and cognitive impairment) and disfigurement.(12) Treated (ie, reported) cases are
assumed to have been prevalent for 0.5 years, and for the fraction of treated cases that present
with sleeping disorder, it was assumed that this is present for half the total duration and that
the rest of the duration is spent suffering from disfiguring skin disease. Treated cases that don’t
present with sleeping disorder were assigned disfigurement for the entire duration.
8. An age-pattern was applied to the all-age incidence estimates using the incidence studies from
DRC and Uganda.(8,9,13) The age-pattern in GBD 2016 employed a cubic spline to account for
the higher risk of infection among working age adults (as opposed to GBD 2015 in which a step-
function at age 20 years was employed to differentiate risk). Without information on sex-
specific incidence, we assumed equal incidence rates between both sexes.
Changes from GBD 2015 to GBD 2016 
We have made two changes to our modelling strategy between GBD 2015 to GBD 2016.  First, we now 
split nonfatal cases between T.b. gambiense and T.b. rhodesiense, and apply different durations to the 
two.  Second, we have improved our method for estimating the age-pattern of cases and now use cubic 
spline based regression model rather the previous step function. 
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Schistosomiasis
Case definition 
Schistosomiasis, also known as bilharzia or “snail fever,” is a helminth disease caused by infection with 
five species of the parasite Schistosoma, namely, S. mansoni, S. japonicum, S. haematobium, S. mekongi, 
and S. intercalatuma. It is considered a neglected tropical disease (NTD). The first three species cause 
the most infection and the last two rarely cause disease. Diagnosis is made by microscopic exam of stool 
or urine for parasite eggs. For less advanced infections, serologic techniques are used. The ICD-10 codes 
for schistosomiasis are B65-B65.9. 
Input data 
Model inputs 
To model nonfatal outcomes due to schistosomiasis, we conducted a systematic literature review, 
extracting prevalence data from 1980 to 2016 for the five species of schistosomiasis listed above. The 
search string used in the systematic review is (schistosom*[Title/Abstract] OR bilharzia*[Title/Abstract] 
OR "snail fever"[Title/Abstract]) AND ("1990"[Date - Publication] : "3000"[Date - Publication]) AND 
(epidemiolog* OR inciden* OR prevalen* OR seroprevalen*) NOT (animals[mesh] NOT humans[mesh]). 
Additionally, we used data compiled by the Global Atlas of Helminth Infections (GAHI), which includes 
grey literature and unpublished data.    
Population at risk/mass drug administration data 
Population at risk estimates and MDA data were taken from the WHO PCT Databank [1]. 
Severity splits/sequelae 
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The table below shows the list of clinical sequelae (including mild, moderate, and severe anaemia) due 
to schistosomiasis, their lay descriptions, and the associated disease stages and disability weights. Using 
literature [1], a list of eight possible clinical sequelae and anaemia sequelae were defined (mild 
infection, mild diarrhoea, haematemesis (vomiting blood), hepatomegaly, ascites (buildup of fluid in the 
peritoneal cavity), dysuria (painful urination), bladder pathology, hydronephrosis (swelling of kidney due 
to buildup of urine in the kidney), mild anaemia, moderate anaemia, and severe anaemia).  
Table 2. Clinical sequela, lay descriptions, disease stages, and DWs 
Clinical sequela Lay description Disease 
stage 
Disability weights 
(DWs) 
Mild infection has a low fever and mild discomfort , but no 
difficulty with daily activities 
1 0.006 (0.002–
0.012) 
Mild diarrhoea 1 0.056 
Hepatomegaly has some pain in the belly that causes nausea but 
does not interfere with daily activities 
2 0.011 (0.005–
0.021) 
Dysuria has some pain in the belly that causes nausea but 
does not interfere with daily activities 
2 0.011 (0.005–
0.021) 
Hydronephrosis has some pain in the belly that causes nausea but 
does not interfere with daily activities 
2 0.011 (0.005–
0.021) 
Haematemesis vomits blood and feels nauseated 3 0.325 (0.209–
0.463) 
Ascites has pain in the belly and feels nauseated. The 
person has difficulties with daily activities 
3 0.114 (0.078–
0.159) 
Bladder pathology has some pain in the belly that causes nausea but 
does not interfere with daily activities 
3 0.011 (0.005–
0.021) 
Mild anaemia feels slightly tired and weak at times, but this 
does not interfere with normal daily activities 
NA 0.004 (0.001–
0.008) 
Moderate 
anaemia 
feels moderate fatigue, weakness, and shortness 
of breath after exercise, making daily activities 
more difficult 
NA 0.052 (0.034–
0.076) 
Severe anaemia feels very weak, tired, and short of breath, and 
has problems with activities that require physical 
effort or deep concentration 
NA 0.149 (0.101–
0.210) 
Modelling strategy 
The morbidity model for schistosomiasis involved a multi-step process. First, we ran a single-parameter 
prevalence model in DisMod-MR 2.0 using the prevalence data extracted in the systematic review and 
from the GAHI database. We make the assumption that all of our data are measured within a population 
at risk – therefore, the estimates from the DisMod model represent prevalence estimates among the 
population at risk for schistosomiasis. Additionally, we included the MDA treatment data from the WHO 
as a country-level covariate in the DisMod model. Second, we then scaled the prevalence estimates to 
the population at risk estimates from the WHO PCT Databank to get age/sex/location/year all-
schistosomiasis prevalence envelopes. 3) We ran a generalized linear model to get species-specific 
proportional prevalence on data from literature that reported both S. haematobium and S. mansoni 
infection, and 4) literature-informed parameters (a, b, c) for translating infection (x) to morbidity (y): y = 
120
(a + bx^c)/(1 + bx^c) – a [2-4]. We used the species-specific conversion factors calculated in step (3) to 
split the all-schistosomiasis envelope into species-specific schistosomiasis. We then used the parameters 
determined in step (4) to translate infection into morbidity to get age/sex/year/location-specific 
prevalence of sequelae. The burden of anaemia due to schistosomiasis was estimated (see anaemia 
documentation for details). 
Model evaluation was done by separately assessing the fit of the single-parameter DisMod models and 
checking the final estimates produced after age-sex splits. Plots of time trends of prevalence across 
locations and age were used to evaluate the results. In addition, maps of the global distribution of total 
schistosomiasis prevalence and prevalence of sequelae due to schistosomiasis were also assessed across 
time. 
Changes from GBD 2015 to GBD 2016 
The main change made from GBD 2015 was the systematic review and using extracted data in a DisMod 
model to estimate prevalence within the population at risk. In addition, newly updated data from the 
WHO PCT databank were downloaded and used in the model, and geographic restrictions were 
updated. 
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Cysticercosis 
Flowchart 
Input Data & Methodological Summary 
Case Definition 
Cysticercosis, or Neurocysticercosis (NCC), is a parasitic disease caused by the pig tapeworm, Taenia 
solium. It is transmitted via ingestion of eggs or gravid proglottids shed by a human or non-human host 
with an intestinal infection of the same helminth known as Taeniasis. In rare cases, auto-infection is also 
possible among people with intestinal infections. Diagnosis is made by magnetic resonance imaging 
(MRI) or computerized tomography (CT) brain scans to identify cysts. The ICD-10 codes for Cysticercosis 
are B69-B69.9. 
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 Input data 
Systematic Literature Review 
The nonfatal estimation for cysticercosis focused on estimating prevalence of NCC among epileptics at 
risk as well as the prevalence of NCC with epilepsy. A systematic review of literature was conducted in 
PubMed for GBD 2015 using the following search string:  
("cysticercosis"[Title/Abstract] OR "neurocysticercosis"[Title/Abstract] OR 
"cysticerciasis"[Title/Abstract] OR "Taenia solium"[Title/Abstract]) AND (“1990”[Date – 
Publication] : “2015”[Date – Publication]) AND (epidemiology OR prevalence)).  
This yielded 1,038 studies of which 166 were included during the title/abstract screening. Following the 
full-text screening, 17 studies were included and extracted – studies were excluded because of one or 
more of the following reasons: 
15. study not in epileptics 
16. study not population-based 
17. study does not have primary data on prevalence of NCC among epileptics at risk 
18. study not in humans (some studies were on cysticercosis in pigs) 
19. study on comorbidities with NCC (other than epilepsy) 
20. study on sub-population, eg, patients with neurological disorders 
21. review study 
 
We combined the newly extracted studies with studies extracted during GBD 2013. The table below 
shows the number of studies finally included, and the number of countries or subnational units and GBD 
world regions represented. 
 prevalence  
Studies 31 
Countries/subnationals 23 
GBD world regions 8 
 
A study-level covariate was also created in GBD 2015 to indicate the type of diagnosis for each study, ie, 
definitive or probable. Of the 77 rows of country-year-age-sex data, there were 15 rows with definitive 
diagnosis and 62 rows with probable diagnosis. 
Covariates 
Data was ascertained from the PEW Research Center [1] on the proportion of the population that is 
Muslim and incorporated as a continuous covariate with a range between 0 and 1. 
Epilepsy Envelope 
The modelling process incorporates 100 draws of epilepsy envelope prevalence from the GBD 2016 
epilepsy DisMod MR model – details on this modeling process can be found elsewhere. 
Geographic Restrictions 
We conducted a literature review to determine the geographic extent of the disease and classify 
locations based on whether the disease is absent or present in each year.  Locations that were 
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geographically restricted in any given year did not have estimates made for them but could have 
imported cases attributed to them at a later stage. Of note, we did not attempt a complete systematic 
review, since a single high-quality source could offer sufficient evidence of presence. Evidence of 
absence or presence was not available for every location for each year and so assumptions were made 
for missing years by taking into consideration the epidemiological characteristics of the disease.  If 
evidence indicated disease presence for two non-consecutive years, we assumed presence for all years 
between the two. If evidence indicated disease absence for two non-consecutive years, we assumed 
absence for all years between the two. If evidence indicated a change in status (i.e. from absent to 
present, or present to absent) between two non-consecutive years than we conducted targeted 
searches to ascertain the relevant year of introduction or elimination for that location.  In the cases 
where presence or absence information was missing for the start or end years of our study interval 
(1990-2016) without evidence of any introduction or elimination events within the interval, we applied 
the status of the first and last presence/absence observations respectively to all years between the 
interval bound and the observation year. For cysticercosis, we performed targeted searches to classify 
location-years in PubMed and Google Scholar.   Our map was populated by 21 peer-reviewed articles 
and meta-analyses and WHO reports. 
Modelling strategy 
DisMod MR was used to model the prevalence of NCC among epileptics at risk. In the model, pigs per 
capita and religion (binary, >50% Muslim) were used as country-level covariates. In addition, the 
prevalence of “definitive diagnosis” was transformed to that of “probable and definitive diagnosis” so as 
to not underestimate overall prevalence. 
After running DisMod, we adjusted the fraction of people with epilepsy attributable to cysticercosis in 
endemic countries for the population at risk based on the proportion of the population without access 
to sanitation and the proportion of the population that is Muslim. Predicted NCC prevalence among 
epileptics at risk was calculated such that Prevalence=P×(NM-N)/(NM-1), where P = prevalence of all-
cause epilepsy in total population, N = proportion of NCC among epileptics at risk (non-Muslims without 
access to sanitation), and M = proportion of population not at risk of contracting NCC. It was assumed 
that the prevalence of epilepsy due to causes other than NCC is the same regardless of whether a 
population is at risk or not. It was also assumed that Muslims and non-Muslims have equal access to 
sanitation. 
Geographic restrictions were applied to set prevalence to zero in non-endemic locations. 
Model evaluation was done by separately assessing the fit of the DisMod MR model and checking the 
estimates produced after estimating prevalence of NCC with epilepsy. Plots of time trends of prevalence 
across locations and age were used to evaluate the results. In addition, maps of the global distribution of 
prevalence of NCC among epileptics at risk and prevalence of NCC with epilepsy were also assessed 
across time. 
Only minor changes were made to the GBD2015 modeling strategy including slight changes to the model 
parameters in Dismod MR, a change in covariates, new geographic restrictions and an updating of the 
proportion of population with Muslim data by filling in subnational locations with national proportions – 
this was done due to lack of data on this covariate at the subnational level. 
References: 
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 Cystic Echinococcosis 
 
Flowchart 
 
 
Input Data & Methodological Summary 
Case definition 
Cystic echinococcosis is a parasitic disease caused by infection with the Echinococcus granulosis 
tapeworm. It is a natural parasite of canines, with sheep being the most common intermediate host in 
the two-stage lifecycle, but can be spread to humans through ingestion of soil, water, or food 
contaminated with the fecal matter of an infected dog containing infective eggs. Diagnosis is made by 
clinical findings, imaging, serology, and tissue pathology. The ICD-9 and ICD-10 codes for echinococcosis 
are 122.0-122.9 and B67-B67.9, respectively. 
Input data 
Systematic Literature Review 
The nonfatal estimation for cystic echinococcosis (CE) focused on estimating incidence and prevalence 
of CE and its sequelae. A systematic review of literature was conducted in PubMed for GBD 2015 using 
the following search string:  
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("echinococcosis"[Title/Abstract] OR "hydatid disease"[Title/Abstract] OR 
"hydatidosis"[Title/Abstract] OR "echinococcal disease"[Title/Abstract] OR "Echinococcus 
granulosus infection"[Title/Abstract]) AND (“1990”[Date – Publication] : “2015”[Date – 
Publication]) AND (epidemiology OR incidence OR prevalence).  
This yielded 1,619 studies of which 279 were included during the title/abstract screening. Following the 
full-text screening, 77 studies (32 incidence, 43 prevalence and 2 both) were included and extracted – 
studies were excluded because of one or more of the following reasons: 
22. study not population-based 
23. study does not have primary data on prevalence and/or incidence 
24. study not in humans 
25. study on sub-populations 
26. review study 
 
Since we were interested in modelling symptomatic CE cases, we only used data on incidence of patients 
diagnosed by imaging techniques (mainly ultrasonography). Therefore, we excluded prevalence data 
which were mostly from serological studies. 
Data from these extracted studies were combined with data from studies extracted during GBD 2013. 
The table below shows the number of studies finally included, and the number of countries or 
subnational units and GBD world regions represented. 
 incidence 
Studies 84 
Countries/subnationals 137 
 
Hospital Data 
Hospital data prepared by the GBD team. This data was adjusted to account for multiple hospital 
episodes of a single case and non-primary diagnoses. 
 incidence 
Data Sources 59 
Countries/subnationals 319 
 
Geographic Restrictions 
We conducted a literature review to determine the geographic extent of the disease and classify 
locations based on whether the disease is absent or present in each year.  Locations that were 
geographically restricted in any given year did not have estimates made for them but could have 
imported cases attributed to them at a later stage. Of note, we did not attempt a complete systematic 
review, since a single high-quality source could offer sufficient evidence of presence. Evidence of 
absence or presence was not available for every location for each year and so assumptions were made 
for missing years by taking into consideration the epidemiological characteristics of the disease.  If 
evidence indicated disease presence for two non-consecutive years, we assumed presence for all years 
between the two. If evidence indicated disease absence for two non-consecutive years, we assumed 
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absence for all years between the two. If evidence indicated a change in status (i.e. from absent to 
present, or present to absent) between two non-consecutive years than we conducted targeted 
searches to ascertain the relevant year of introduction or elimination for that location.  In the cases 
where presence or absence information was missing for the start or end years of our study interval 
(1990-2016) without evidence of any introduction or elimination events within the interval, we applied 
the status of the first and last presence/absence observations respectively to all years between the 
interval bound and the observation year.  For cystic echinococcosis, we performed targeted searches to 
classify location-years in PubMed and Google Scholar.   Our map was populated by 23 peer-reviewed 
articles and meta-analyses. 
Sequelae due to cystic echinoccocosis 
The table below shows the sequelae due to echinococcosis and their associated disability weights. 
Sequela Lay description DW (95% CI) 
Chronic respiratory disease has cough and shortness of breath after heavy 
physical activity, but is able to walk long 
distances and climb stairs. 
0.019 (0.011–0.033) 
Abdominal problems has pain in the belly and feels nauseated. The 
person has difficulties with daily activities. 
0.114 (0.078–0.159) 
Epilepsy (Combined DW) NA 
 
Modelling strategy 
A Poisson model was used to model cystic echinococcosis incidence. Mortality estimates from the 
custom mortality model were age-standardized and used as a covariate in the model along with age 
splines and sex. One thousand draws were generated from the predicted mean and predicted standard 
error. 
Geographic restrictions were applied to set incidence to zero in location-years where the disease was 
not endemic. 
These incidence draws were used to calculate prevalence at the draw level by drawing a value of 
duration of clinical disease from a uniform distribution between four and six years and assuming that 
each incident case, on average, gets infected in the middle of a five-year age group. In the youngest age 
groups where individuals are less than one year old, prevalence was equal to have of the incidence. For 
all individuals over one year old, half of the incidence-years in each age group were assigned to the 
prevalence in that age bin and the remaining incidence was assigned to the age bin following it.  
After producing all-case prevalence draws, a thousand draws of proportions for abdominal, respiratory, 
and epileptic symptoms among echinococcosis cases adding up to 1 were generated. Uncertainty in the 
splitting proportions was captured by drawing them from a Dirichlet distribution, informed by published 
data on cysts localization [1]. On average, the proportions of abdominal, respiratory, and epileptic 
symptoms due to echinococcosis were 0.8, 0.19, and 0.01, respectively. These proportions were used to 
split the prevalence and incidence from DisMod into the three sequelae. 
Model evaluation was done by separately assessing the fit of the DisMod MR model and checking the 
estimates produced after estimating incidence and prevalence of sequelae due to cystic echinococcosis. 
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Plots of time trends of incidence and prevalence across locations and age were used to evaluate the 
results. In addition, maps of the global distribution of incidence and prevalence were assessed across 
time. 
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 Lymphatic Filariasis 
Flowchart  
 
  
Input Data and Methodological Summary  
Case Definition  
Lymphatic filariasis (LF) is a neglected tropical disease spread in which threadlike nematodes invade the 
lymphatic system. The worms responsible – Wuchereria bancrofti, Brugia malayi, and Brugia timori – are 
spread from human to human via mosquitoes. The most prominent clinical manifestations of LF are 
lymphedema (a swelling of the legs, also known in its more extreme manifestation as elephantiasis) and 
hydrocele (a collection of fluid in the sac around the testicles).  
Input data  
A systematic review of literature for GBD 2016 in the PubMed database was done on October 14, 2016, 
for prevalence and incidence data using the search (Lymphatic filariasis AND prevalence) OR (Lymphatic 
filariasis AND (prevalence OR incidence OR "mass drug administration" OR MDA OR coverage)) OR 
(Lymphedema, hydrocele) OR (Transmission Assessment Survey (TAS)) OR (Lymphatic filariasis AND 
mapping).  
 
Population at risk and MDA coverage data come from the WHO PCT Databank [1]. 
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Modelling strategy  
Data on prevalence of microfilaria is modelled using Dismod-MR 2.1. Due to the focal nature of 
lymphatic filariasis, we make the assumption that data collected are from endemic locations unless 
specifically specified in literature or survey methods. If the data are nationally representative, we adjust 
the data points by multiplying by the inverse of the proportion of the population at risk. Due to the fact 
that data is collected in endemic locations or we adjust it so that it is within the population at risk, we 
then scaled the DisMod-MR 2.1 estimates according to at-risk population in order to attain nationally 
representative values. We developed a new MDA location-level covariate that is used in the DisMod 
model based off WHO PCT Databank data, informing prevalence estimates.   
For lymphedema and hydrocele, we incorporate survey data from the Global LF Atlas in a non-linear 
error-in-variables regression that determines the prevalence of lymphedema and hydrocele as functions 
of microfilaria prevalence, which is then applied to the total microfilaria DisMod model in order to attain 
an envelope of cases by location-year. Separately, all available prevalence data for these conditions is 
modeled in DisMod in order to determine an age-sex pattern.  
In the estimation of lymphedema and hydrocele prevalence, we perform the same population at-risk 
correction that is done on microfilaria prevalence. For hydrocele prevalence after treatment, we take 
the value before MDA rollout in 2000 and reduce that by the same treatment efficacy function described 
for microfilaria prevalence, using dosage-reduction data specific to hydrocele along with the location-
year specific MDA coverage. For lymphedema, we assume no new cases appear among treated 
individuals. As such, we reduce lymphedema prevalence in post-treatment years in accordance with 
MDA coverage.  
Sequela  Data points  Regions   Countries   Subnational units  
Prevalence of detectable 
microfilaria  1,552  
 
10  
 
40  28  
Lymphedema due to lymphatic 
filariasis  511  
 
10  
 
25  15  
Hydrocele due to lymphatic  
filariasis  265  
 
8  
 
22  12  
  
Changes from GBD 2015 to GBD 2016 
We conducted a new literature review, and utilized data from recent years and the MDA covariate to 
predict the time trend rather than last year’s non-linear regression to estimate the reduction of 
microfilaria as a function of treatments per person.  
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 Onchocerciasis 
Flowchart 
 
 
 
Input data & methodological summary 
Case definition 
Onchocerciasis, also known as river blindness, is a parasitic disease caused by the helminth Onchocerca 
volvulus. It is transmitted via the bite of one of several species of Similium blackflies that have 
historically bred in fast-moving freshwater rivers and tributaries throughout sub-Saharan Africa, Central 
America, and South America. Diagnosis can be made by skin snip biopsy to identify larvae, surgical 
removal of nodules and exam for adult worms, slit lamp exam of anterior part of the eye where larvae 
or lesions caused by them are visible, and antibody tests (mostly useful to visitors to areas with 
parasites). The ICD-10 code for onchocerciasis is B73. 
Input data 
Model inputs 
Prevalence data prepared by the GBD 2010 expert group (EG) was used for modelling the nonfatal 
outcomes resulting from onchocerciasis in Africa. This included 1,000 draws of infection and morbidity 
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(visual impairment, blindness, and skin conditions) cases with confidence intervals categorized by 
country, age, and sex for years 1990, 1995, 2000, 2005, and 2010. Details about the materials and 
methods used by the EG to generate these draws can be found elsewhere [1-5]. These data represented 
all African countries included in the African Programme for Onchocerciasis Control (APOC) and the 
Onchocerciasis Control Programme (OCP) for which initial Rapid Epidemiological Mapping of 
Onchocerciasis (REMO) assessments demonstrated a need for Community-Directed Treatment with 
Ivermectin (CDTI) (defined as having a prevalence of skin nodules greater than 20%). Four countries – 
Rwanda, Mozambique, Kenya and Gabon – were designated as hypo-endemic countries after initial 
REMO assessments and not included due to sparsity of cases and paucity of data. Estimates for Sudan 
from GBD 2010 were reassigned to South Sudan in GBD 2013 after its independence in 2011 since REMO 
assessments indicated that the vast majority of cases occurred in that area of the former Sudan. The 
tables below show the countries included in each program and the number of corresponding GBD 
locations they represent.  
 APOC Countries OCP Countries 
Countries included Angola, Burundi, Cameroon, 
Central African Republic, Chad, 
Congo, Democratic Republic of 
Congo, Ethiopia, Equatorial Guinea, 
Liberia, Malawi, Nigeria, South 
Sudan, Tanzania, and Uganda 
Benin, Burkina Faso, Côte d'Ivoire, 
Ghana, Guinea Bissau, Guinea, Mali, 
Niger, Senegal, Sierra Leone, and 
Togo 
Hypo-endemic countries 
not included 
Rwanda, Mozambique, Kenya, 
Gabon, Sudan 
 
GBD countries & 
subnationals 
15 11 
GBD world regions 3 1 
 
Prevalence data for modelling non-fatal outcomes resulting from onchocerciasis in the Americas was 
extracted via a systematic literature review. Web of Science, Scopus, and PubMed were searched with 
the following search strings: 
Database Search string Yield 
PubMed (oncho*[Title/Abstract] OR "river blindness"[Title/Abstract] OR "O. 
volvulus"[Title/Abstract] OR "robles disease"[Title/Abstract] OR "blinding 
filariasis"[Title/Abstract] OR "coast erysipelas"[Title/Abstract] OR “sowda” [Title/Abstract] 
OR “nodding syndrome”[Title/Abstract]) AND (“1980”[Date – Publication] : “2016”[Date – 
Publication]) AND (epidemiology[Title/Abstract] OR prevalence[Title/Abstract] OR 
incidence[Title/Abstract] OR surveillance[Title/Abstract] OR”MDA”[Title/Abstract] OR 
“Mass Drug Administration”[Title/Abstract] OR “Community-directed treatment with 
ivermectin”[Title/Abstract] OR “CDTI”[Title/Abstract] OR “mass treatment”[Title/Abstract] 
OR “multiple ivermectin treatments”[Title/Abstract] OR “monthly doses of 
ivermectin”[Title/Abstract] OR “large scale treatment”[Title/Abstract] OR 
REMO[Title/Abstract] OR “Rapid epidemiological mapping of 
onchocerciasis”[Title/Abstract] OR APOC[Title/Abstract] OR “African Programme for 
Onchocerciasis Control”[Title/Abstract] OR OCP[Title/Abstract] OR “Onchocerciasis Control 
Programme”[Title/Abstract]) NOT(Animals[MeSH] NOT Humans[MeSH]) 
986 
Web of 
Science 
TS=(oncho* OR "river blindness" OR "O. volvulus" OR "robles disease" OR "blinding 
filariasis" OR "coast erysipelas" OR sowda OR “nodding syndrome”) AND TS=(epidemiology 
1,144 
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OR prevalence  OR incidence  OR surveillance OR MDA OR “Mass Drug Administration” OR 
“Community-directed treatment with ivermectin” OR CDTI OR “mass treatment” OR 
“multiple ivermectin treatments” OR “monthly doses of ivermectin” OR “large scale 
treatment” OR REMO OR “Rapid epidemiological mapping of onchocerciasis” OR APOC OR 
“African Programme for Onchocerciasis Control” OR OCP OR “Onchocerciasis Control 
Programme”) NOT TS=((Animals NOT Humans)) 
SCOPUS (TITLE-ABS-KEY(oncho* OR "river blindness" OR "O. volvulus" OR "robles disease" OR 
"blinding filariasis" OR "coast erysipelas")) AND TITLE-ABS-KEY(epidemiology OR 
prevalence OR incidence OR surveillance OR MDA OR "Mass Drug Administration" OR 
"Community-directed treatment with ivermectin" OR CDTI OR "mass treatment" OR 
"multiple ivermectin treatments" OR "monthly doses of ivermectin" OR "large scale 
treatment" OR REMO OR "Rapid epidemiological mapping of onchocerciasis" OR APOC OR 
"African Programme for Onchocerciasis Control" OR OCP OR "Onchocerciasis Control 
Programme") AND NOT KEY(Animals NOT Humans) AND PUBYEAR > 1979 
2,000 
 
This yielded 4,130 results in total which was reduced to 2,502 after removing duplicates. The title and 
abstracts were screened for inclusion or exclusion with the following criteria: 
Exclusion Criteria: 
 Pre-1980 
 Non-original source 
 Non-representative population 
o Vulnerable populations (eg, slum-dwellers, prisoners, orphans, high-risk jobs, etc.) 
o Hospital-based samples (including saved stool samples) 
o Non-native peoples (eg, migrants, expats, nomads, etc.) 
o Immunosuppression/illness (eg, HIV, TB, CA, RA, asthma, malaria, handicap, etc.) 
 Non-human population 
 Does not meet case definition 
 Case-control study 
 
Sixty-one articles were identified for full text screening and extraction from the historically endemic 
American countries: Guatemala, Brazil, Ecuador, Venezuela, Mexico, and Colombia. 
Severity splits/sequelae 
The table below shows the list of common clinical manifestations of onchocerciasis and the sequelae to 
which they have been mapped along with the lay description and the associated disability weight (DW) 
of each sequela. 
Clinical manifestation Sequela name Lay description DW 
Uveitis; Punctate 
keratitis; Optic neuritis; 
Torpid Iritis; 
Onchochorioretinitis 
Moderate vision 
impairment 
has vision problems that make it difficult to 
recognize faces or objects across a room 
0.031 
(0.019–
0.049) 
Sclerosing keratitis; 
Optic neuropathy; 
Optic atrophy; 
Severe vision 
impairment 
has severe vision loss, which causes difficulty 
in daily activities, some emotional impact (for 
0.184 
(0.125–
0.258) 
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Choroidoretinopathy; 
Cataracts 
example worry), and some difficulty going 
outside the home without assistance 
Blindness Blindness is completely blind, which causes great 
difficulty in some daily activities, worry and 
anxiety, and great difficulty going outside the 
home without assistance 
0.187 
(0.124–
0.260) 
Acute papular 
onchodermatitis; 
Onchocercomata 
(subcutaneous 
nodules) 
Mild skin 
disease 
has a slight, visible physical deformity that is 
sometimes sore or itchy. Others notice the 
deformity, which causes some worry and 
discomfort 
0.027 
(0.015–
0.042) 
Chronic papular 
onchodermatitis; 
Lichenified 
obchodermatitis 
(“sowda”); 
Lymphadenopathy 
Mild skin 
disease without 
itch 
has a slight, visible physical deformity that 
others notice, which causes some worry and 
discomfort 
0.011 
(0.005–
0.021) 
Skin atrophy; 
Depigmentation 
(“leopard skin”) 
Moderate skin 
disease 
has a visible physical deformity that is sore 
and itchy. Other people stare and comment, 
which causes the person to worry. The 
person has trouble sleeping and 
concentrating 
0.188 
(0.124–
0.267) 
Hanging groin; 
Lymphoedema 
Severe skin 
disease without 
itch 
has an obvious physical deformity that makes 
others uncomfortable, which causes the 
person to avoid social contact, feel worried, 
sleep poorly, and think about suicide 
0.405 
(0.275–
0.546) 
 Asymptomatic 
onchocerciasis 
NA NA 
 
Modelling strategy 
The nonfatal modelling for onchocerciasis included four major steps. In the first step, GBD 2010 
prevalence was extrapolated to obtain GBD 2016 estimates. Acute skin disease level 2 and chronic skin 
disease level 2 were summed to create the moderate skin disease sequela. Uncertainty was quantified 
and provided by the EG for all estimates except those of visual impairment and blindness. In these cases, 
each of the OCP draws the number of cases were multiplied by a random value (the exponent of a 
normally distributed variable with mean zero and standard deviation 0.1) in order to add uncertainty. 
Within each draw, the same randomly drawn value was applied to all country-year-age-sex estimates. 
Visual impairment was then split into moderate and severe vision impairment by first multiplying the 
visual impairment estimates by a random value (from a normal distribution with mean 0.84 and 
standard deviation 0.0031) to generate moderate vision impairment, and then subtracting the resulting 
estimates from visual impairment to obtain estimates of severe vision impairment. Prevalence of 
sequelae was calculated by dividing the cases by the population. 
The second step in modelling morbidity due to onchocerciasis was the adjustment of uncertainty in the 
conversion of nodule prevalence to microfilaria (mf) prevalence and in the effects of mass drug 
administration (MDA). To adjust for uncertainty in translation of nodule prevalence to mf prevalence, 
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the final OCP draws from the first step were logit transformed and uncertainty was added from a 
random value drawn from a normal distribution to the transformed estimates. The resulting estimates 
were then normalized and scaled using estimates published elsewhere [1]. To adjust for uncertainty due 
to MDA, the year when MDA with Ivermectin started was set according to the table below. 
Country MDA start year 
Angola, Burundi, South Sudan 2005 
Congo, Ethiopia, DRC 2001 
Cameroon, Central African Republic, Equatorial Guinea, Liberia, Nigeria, Uganda 1999 
Chad, Niger, Tanzania 1998 
Malawi 1997 
All others 1990 
The uncertainty in the time trend was then multiplied by the normalized prevalence estimates and the 
final prevalence was obtained by re-expanding the scaled normalized draws and adjusting the scale back 
from logit scale. 
In the third step, prevalence of onchocerciasis in the Americas was modelled separately and combined 
with the Africa model. Onchocerciasis is known to have occurred in six countries of Central and Southern 
America: Mexico, Guatemala, Colombia, Ecuador, Brazil and Venezuela. The epidemiology of 
onchocerciasis is very different in these countries than in Africa because it has only occurred in relatively 
small, well defined foci. These foci have been mapped and thoroughly monitored since the early 1990s 
with the formation of the Onchocerciasis Elimination Program of the Americas (OEPA) and all of the 
prevalence surveys conducted are only representative of these areas. Additionally, certain foci are 
geographically continuous across national boundaries. Therefore, we modelled onchocerciasis in these 
countries at the foci level among the population at risk in each foci instead of at the national level. 
Population at risk for each focus was modelled using data from OEPA on baseline population at risk [6] 
and data from OEPA and peer reviewed studies on dates of elimination in each focus [6-19]. This was 
done with a Poisson model using year splines as a covariate and 1,000 draws of the population are risk 
were drawn from the predicted mean and standard error. The prevalence of disease among the 
population at risk was subsequently modeled using a generalized linear model with a binomial family, 
logit link, no intercept term and random effects on a combined-foci variable created by grouping foci by 
geographic contiguity and nearness when data was sparse. Covariates included an indicator term on the 
foci, the number of years since MDA began and splines on age. One thousand draws of prevalence were 
calculated form one thousand draws of beta values from the variance-covariance matrix and adjusted by 
the estimated population at risk in each foci-year to determine the number of cases. The cases were 
then summed by GBD location and year and divided by national population to find the national 
prevalence. While the model predicted case values very close to zero in the countries where elimination 
has occurred, these were overwritten to zero values for all years after certified elimination. The ratio of 
global all-age, all-sex prevalence of each sequelae to the all-cases prevalence from the Africa estimates 
was applied to all-cases prevalence from the Americas to calculate prevalence of each sequelae. 
Lastly, to estimate the prevalence of asymptomatic onchocerciasis, the prevalence of morbidity (vision 
loss, blindness and skin conditions) was subtracted from the overall onchocerciasis prevalence.  
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Moderate vision impairment, severe vision impairment and blindness estimates were each multiplied by 
a factor of 8/33 before subtraction to account for cases that have concurring symptoms. 
Model evaluation was done by separately assessing plots of time trends of prevalence across locations 
and age for each sequela. In addition, maps of the global distribution of total onchocerciasis prevalence 
and prevalence of sequelae due to onchocerciasis were also assessed across time. 
 
Changes from GBD 2015 to GBD 2016 
Prevalence of onchocerciasis in foci in the Americas was not previously included but is now being 
modelled. 
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 Dengue 
 
Flowchart 
 
 
Case definition 
Dengue is mosquito-borne viral infection that causes febrile illness and, in severe cases, jaundice, 
hemorrhage, and death. It includes all ICD-10 codes under the heading A90 (Dengue fever [classical 
dengue]) and A91 (Dengue hemorrhagic fever). 
Input data 
 Model inputs 
For GBD 2016, we modelled dengue incidence based on officially reported cases. The table below 
illustrates the geographic distribution of data points used in our analysis. 
Table 1. Geographies 
Level Incidence 
Data points 2,920 
Studies 70 
Locations 201 
Regions 15 
  
While no systematic update was conducted, we did incorporate new expansion factor data that were 
provided by collaborators and have updated to the latest available case reports for GBD 2016. 
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Modelling strategy  
The methods used to model dengue incidence remain unchanged from GBD 2015, and are an improved 
variant of the methods used for GBD 2013 that were described by Stanaway et al. Briefly, we derive two 
dengue-specific covariates: first a variable to define the expected spatial distribution of the disease 
based on principal components analysis of dengue CSMR estimates and dengue transmission probability 
and, second, a variable to define the country-specific trends, based on a mixed-effects model of 
reported cases. We then estimate a mixed-effects negative binomial model with number of reported 
cases as the dependent variable, fixed effects on the aforementioned spatial and temporal covariates, 
and random effects on location. These random effects are assumed to correspond to deviations in 
reporting completeness and, calibrating against published expansion factor data (ie, estimates of the 
degree of underreporting), they are inflated to adjust for underreporting estimates. The resulting 
incidence estimates are split into moderate (94.5%) and severe (5.5%) sequelae, based on the 
proportion of reported cases that were severe. We assume that 8.4% of symptomatic infections will 
produce post-acute chronic fatigue lasting an average of six months (Teixeira L de AS, Lopes JSM, 
Martins AG da C, Campos FAB, Miranzi S de SC, Nascentes GAN. Persistence of dengue symptoms in 
patients in Uberaba, Minas Gerais State, Brazil. Cad Saúde Pública 2010; 26: 624–30.). 
 Severity splits and disability weights 
Table 2. Sequelae, lay descriptions, and DWs 
Sequela Lay description 
Disability 
Weight (DW) 
Moderate Has a fever and aches, and feels weak, which causes 
some difficulty with daily activities.  
0.051 
(0.032–0.074) 
Severe Has a high fever and pain, and feels very weak, 
which causes great difficulty with daily activities. 
0.133 
(0.088–0.19) 
Asymptomatic Infection with no apparent illness. NA 
 
Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modelling strategy from GBD 2015 to GBD 2016. 
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 Yellow Fever 
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Case definition 
Yellow fever is mosquito-borne viral infection that causes febrile illness and, in severe cases, jaundice, 
haemorrhage, and death. It is considered a neglected tropical disease (NTD). It includes all ICD-10 codes 
under the heading A95 (yellow fever). 
Input data 
 Model inputs 
Case data for the yellow fever estimate process comes from official case reports filed with the World 
Health Organization. The table below shows the distribution of said data geographically for the GBD 
2016 estimation process. 
 
Table 1. Data spread 
  
Level Incidence 
Data points 909 
Studies 19 
Locations 47 
Regions 9 
 
We have updated to the latest available case reports for GBD 2016. 
 
Severity splits 
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Yellow fever is split into three levels of severity: moderate (33% [13–52]), severe (12% [5–26]), and 
asymptomatic (55% [37–74]). The table below illustrates this breakdown. 
 
Table 2. Sequela, description, and disability weight (DW) 
 
Sequela Description 
Disability 
weight (DW) 
Moderate Has a fever and aches, and feels weak, which causes some 
difficulty with daily activities.  
0.051 
(0.032–0.074) 
Severe Has a high fever and pain, and feels very weak, which 
causes great difficulty with daily activities. 
0.133 
(0.088–0.19) 
Asymptomatic Infection with no apparent illness. NA 
 
 
Modelling strategy  
 
We modelled reported cases of yellow fever using a mixed-effects negative binomial model, with fixed 
effects for year and random effects for super-region, region, and country. We assume that yellow fever 
cases are underreported, and that this underreporting mirrors that for dengue (a disease for which we 
have better data on underreporting). With that, we estimate symptomatic cases as the product of our 
base case estimates and dengue expansion factors (ie, the factor by which you must multiply reported 
cases to derive true cases). Based on published estimates from Johansson et al (2014), we assume that 
27% of symptomatic cases will be severe. 
 
Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modelling strategy for endemic countries from GBD 2015 
to GBD 2016. 
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 Rabies 
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Input data and methodological summary 
 
Case definition 
Rabies is a fatal viral infection, transmitted by animal bites. Without prophylactic vaccination the disease 
is almost universally fatal. The disease has a long incubation period (1-3 months), and early intervention 
with prophylactic vaccination is nearly 100% effective in preventing symptomatic disease. It is considered 
a neglected tropical disease (NTD). We model symptomatic infections, not including those infections in 
which intervention prevented the onset of symptomatic disease, corresponding to the ICD10 code A82. 
Input data 
 Model inputs 
As we derive our estimate of cases from our estimate of deaths, no incidence data are used in the model. 
For GBD 2016, we modelled rabies mortality using all available data in the cause of death database. Data 
points were outliered if they reported an improbable number of rabies deaths (eg, zero rabies deaths in a 
hyperendemic country) or if their inclusion in the model yielded distorted trends. In some cases multiple 
data sources for the same location differed dramatically both in their quality and reported rabies 
mortality (eg, a verbal autopsy and vital registration source). In these cases the lower-quality data source 
was outliered. 
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Modelling strategy  
We derive estimates of the number of symptomatic rabies infections (ie, those not averted through 
prophylactic vaccination) based on rabies mortality estimates, assuming 99% case fatality. All cases are 
assumed to be severe. 
 
We modelled rabies mortality using a two-model hybrid approach 1) a global CODEm model of all 
locations, using all data in the CoD database; and 2) a CODEm model restricted to data-rich countries.     
 
 Sequela description and DW 
 
There is only one sequela and associated disability weight for rabies, which is severe. The lay description 
is included in the table below. 
 
Table 2. Sequela, description, and DW 
 
Sequela Description 
Disability 
Weight  
(95% CI) 
Severe Has a high fever and pain, and feels very weak, which 
causes great difficulty with daily activities. 
0.133 
(0.088–0.19) 
 
 
Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modelling strategy for rabies from GBD 2015.  
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 Ascariasis 
Flowchart 
 
 
Input data and methodological summary 
Case definition 
Ascariasis is a helminthic disease caused by the parasitic roundworm Ascaris lumbricoides. It is one of the 
three intestinal nematode infections (INI), or soil-transmitted helminthiasis (STH), that are modelled in 
GBD. Diagnosis is made by examination of stool by microscope or PCR, with or without concentration 
procedures. The ICD-10 codes for ascariasis are B77-B77.9. 
  
Input data 
Expert Group Data 
Input data for this model was compiled from various sources. Prevalence data prepared by the GBD 
expert group (EG) during GBD 2010 [1, 2] contained mean prevalence with confidence intervals, stratified 
by location, year (1990, 2005, 2010), age group (0-4, 5-9, 10-14, 15+ years) and intensity of infection 
(light, medium, heavy, all). For the model, light infestation was not attributed any disability. The expert 
group also provided data on reduction of prevalence in 2010, stratified by location, age group and Mass 
Drug Administration (MDA) coverage strategy (community/school). The table below shows the number of 
countries or subnational units and GBD world regions represented in the data. 
Table 1a. Geographic Spread of Expert Group Prevalence Data 
 prevalence 
Countries/subnationals 160 
GBD world regions 17 
Mass Drug Administration 
Data on national MDA program coverage was downloaded from the WHO PCT Databank source site [3]. 
This data spanned 119 GBD locations over 13 years beginning in 2003. 
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India Ministry of Health 
Collaborators from the Indian Ministry of Health provided supplementary prevalence data [4] and MDA 
coverage data for India [5]. This data was available for all Indian states but was not available at the most 
detailed GBD location specification for the country: urban and rural. Data on MDA coverage was available 
for the years 2013-2016 while prevalence data was only available for 2015. 
Severe Wasting Estimates 
To inform the wasting model, 1,000 draws of severe wasting prevalence among children under 5 years 
were ascertained from GBD 2016 estimates – the methods used to generate estimates of wasting 
prevalence are detailed elsewhere (part of risk factors documentation) [6]. 
Geographic Restrictions 
We conducted a literature review to determine the geographic extent of the disease and classify locations 
based on whether the disease is absent or present in each year.  Locations that were geographically 
restricted in any given year did not have estimates made for them but could have imported cases 
attributed to them at a later stage. Of note, we did not attempt a complete systematic review, since a 
single high-quality source could offer sufficient evidence of presence. Evidence of absence or presence 
was not available for every location for each year and so assumptions were made for missing years by 
taking into consideration the epidemiological characteristics of the disease.  If evidence indicated disease 
presence for two non-consecutive years, we assumed presence for all years between the two. If evidence 
indicated disease absence for two non-consecutive years, we assumed absence for all years between the 
two. If evidence indicated a change in status (i.e. from absent to present, or present to absent) between 
two non-consecutive years than we conducted targeted searches to ascertain the relevant year of 
introduction or elimination for that location.  In the cases where presence or absence information was 
missing for the start or end years of our study interval (1990-2016) without evidence of any introduction 
or elimination events within the interval, we applied the status of the first and last presence/absence 
observations respectively to all years between the interval bound and the observation year.  Our search 
was done in conjunction with the title/abstract screening portion of a systematic literature review for 
prevalence data. The search strings and yield can be viewed in the table below for each of the databases 
queried. 
Table 1b. Geographic Restriction Search Strings 
Database Search String Yield 
PubMed (Ascariasis[Title/Abstract] OR Ascaris[Title/Abstract] OR "A. 
lumbricoides"[Title/Abstract] OR Ascaris[MeSH] OR Trichuris[Title/Abstract] 
OR Trichuriasis[Title/Abstract] OR "Whip Worm"[Title/Abstract] OR "T. 
trichura"[Title/Abstract] OR Trichuris[MeSH] OR Hookworm[Title/Abstract] OR 
"A. duodenale"[Title/Abstract] OR "Ancylostoma duodenale”[Title/Abstract] 
OR ancylostomiasis[Title/Abstract] OR "N. americanus"[Title/Abstract] OR 
“Necator americanus”[Title/Abstract] OR necatoriasis[Title/Abstract] OR 
Ancylostoma [MeSH] OR Necator[MeSH]) AND (prevalence[Title/Abstract] OR 
incidence[Title/Abstract] OR epidemiology[Title/Abstract] OR 
surveillance[Title/Abstract]) NOT(Animals[MeSH] NOT Humans[MeSH]) 
2376 
Web of 
Science  
 
(Ascariasis OR Ascaris OR A. lumbricoides OR Trichuris OR Trichuriasis OR 
Whip Worm OR T. trichura OR Hookworm OR A. duodenale OR Ancylostoma 
duodenale OR anclyostomiasis OR N. americanus OR Necator americanus OR 
2266 
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necatoriasis) AND TOPIC:(prevalence OR incidence OR epidemiology OR 
surveillance) NOTTOPIC: ((Animals NOT Humans)) 
Timespan: 1980-2016. Indexes: SCI-EXPANDED, SSCI, A&HCI, ESCI. 
SCOPUS TITLE-ABS_KEY (ascariasis OR ascaris OR a. lumbricoides OR trichuris OR 
trichuriasis OR whip worm OR t. trichura OR hookworm OR a. duodenale OR 
ancylostoma duodenale OR anclyostomiasis OR n. americanus OR necator 
americanus OR necatoriasis) AND PUBYEAR>1979 
29 
 
These papers were used to classify location-years for all locations and years present in the literature. 
Additionally, systematic literature reviews, meta-analyses, national health statistics publications and 
collaborator input were used to classify location-years not present in the literature review wherever 
possible. 
Severity splits/sequelae 
The table below shows the list of sequelae due to ascariasis and the associated disability weights (DW). 
Prevalence of medium infection and heavy infection were mapped to mild abdominopelvic problems and 
heavy infestation of ascariasis respectively.  Light infection was not attributed any disability. 
Table 2. Sequelae, lay descriptions, and disability weights (DWs) 
Sequela Lay description DW 
Mild abdominopelvic problems  has some pain in the belly that causes nausea but 
does not interfere with daily activities 
0.011 (0.005–0.021) 
Heavy infestation has cramping pain and a bloated feeling in the belly 0.027 (0.015–0.043) 
Severe wasting is extremely skinny and has no energy 0.128 (0.082–0.183) 
Asymptomatic ascariasis N/A N/A 
 
Modelling strategy 
In the estimation of morbidity due to ascariasis, the EG data were first prepared by formatting the 
location names to be consistent with the GBD 2016 location names and applying the 2010 prevalence to 
1990 and 2005 for sub-Saharan Africa countries – estimates for these two years were missing. This was 
followed by using the data on reductions in 2010 prevalence to adjust the prevalence for locations with 
coverage data. After this adjustment, only data for medium infection, heavy infection, and all infection 
were retained. 
Using the mean prevalence and the upper and lower bounds of the mean provided by the EG, 1,000 
draws of prevalence were generated. This was done by multiplying the mean estimates by the exponent 
of random draws from a normal distribution with mean = 0 and standard deviation = sd, where sd = 
abs(abs(ln(upper)-ln(lower))/(invnormal(0.975)*2). These draws were created for all GBD age-groups, 
assuming the same prevalence in ages 15+ and same prevalence in males and females. 
Since the draws were only at the national level, subnational locations were modelled for Brazil, China, 
Indonesia, Kenya, Mexico, Saudi Arabia, and South Africa. This was done using a generalized linear model 
with a binomial family, logit link and robust standard errors. The predicted cases for all subnational 
locations were summed and scaled to the national case total. India subnationals were separately derived 
by applying the proportion of all national cases in each state from the Indian Ministry of Health data [4] to 
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the national total.  We then applied the modelled proportion of cases in urban or rural locations such that 
the sum of urban and rural cases in a state equals the state total and the sum of all state cases equals the 
national total. 
To get 1995 and 2000 estimates, exponential interpolation of estimates between 1990 and 2005 was 
performed. The draws for 2016 were produced based on 2010 estimates corrected for PCT control 
activities between 2010 and 2016 – this was done by extrapolating the 2004–2010 trend to 2016, given 
cumulative number of treatments per person calculated using data from the WHO PCT Databank [3] and 
the Indian Ministry of Health MDA coverage data[5]. The 2004-2010 trend was applied to all intensities of 
infection. Prevalence was assumed to be zero for the countries with missing input data and also in 
children younger than 28 days. The resulting estimates were 1,000 draws of ascariasis prevalence by GBD 
location, year, age, sex, and intensity level (mild, heavy, overall infection). To estimate the prevalence of 
asymptomatic ascariasis, prevalence of mild and heavy infestation was subtracted from the overall 
ascariasis prevalence. 
The final step in the modelling process was to estimate the prevalence of severe wasting due to ascariasis 
in age groups 28–364 days and 1–4 years. This was done separately using 1,000 draws of prevalence of 
heavy infestation due to ascariasis and the wasting envelope prevalence. The initial step in determining 
prevalence of severe wasting due to ascariasis was generating 1,000 draws of change in weight-for-height 
z-score per heavy prevalent case from a random normal distribution with mean = 0.493826493 and 
standard deviation = 0.04972834 (calculated from upper and lower bounds of the mean estimate). The 
mean, upper, and lower bounds were provided by a GBD collaborator who calculated them based on a 
published article [6]. The prevalence of severe wasting due to ascariasis was then obtained as a function 
of change in weight-for-height z-score (z_change) such that prevalence = p_wasting_env – 
Phi(Phi_inv(p_wasting_env) – z_change*p), where p_wasting_env = wasting envelope prevalence, Phi_inv 
is the inverse standard normal cumulative distribution function (cdf), and p = prevalence of heavy 
ascariasis infestation. Finally, geographic restrictions were applied to set prevalence to zero in countries 
with wasting that are not endemic for ascariasis. 
Model evaluation was done by plotting prevalence of overall ascariasis and that of each sequela against 
year for each location and age group. Maps of the global distribution of total ascariasis prevalence and 
prevalence of sequelae due to ascariasis were also assessed across time and age.  
Only minor changes were made to the GBD 2015 modelling strategy including the incorporation of 
updated data from the WHO PCT databank [3] and data from the Indian Ministry of Health, new 
modelling of subnational prevalence distribution and new geographic restrictions. 
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 Trichuriasis 
 
Flowchart 
 
Input data and methodological summary 
 
Case definition 
Trichuriasis is a helminth diseases caused by the parasitic roundworm Trichuris trichiura. It is one of the 
three intestinal nematode infections (INI), or soil-transmitted helminthiasis (STH), that we model in GBD. 
Diagnosis is made by examination of stool by microscope or PCR, with or without concentration 
procedures. The ICD-10 code for trichuriasis is B79. 
 
Input data 
Expert Group Data 
Input data for this model was compiled from various sources. Prevalence data prepared by the GBD 
expert group (EG) during GBD 2010 [1, 2] contained mean prevalence with confidence intervals, stratified 
by location, year (1990, 2005, 2010), age group (0-4, 5-9, 10-14, 15+ years) and intensity of infection 
(light, medium, heavy, all). For the model, light infestation was not attributed any disability. The expert 
group also provided data on reduction of prevalence in 2010, stratified by location, age group and Mass 
Drug Administration (MDA) coverage strategy (community/school). The table below shows the number of 
countries or subnational units and GBD world regions represented in the data. 
Table 1a. Geographic Spread of Expert Group Prevalence Data 
 prevalence 
Countries/subnationals 160 
GBD world regions 17 
Nonfatal health outcome estimation
Final burden estimation
Legend
YLLs
Comorbidity 
adjusted 
YLDs
DALYs
Input dataInput data
ProcessProcess
ResultsResults
Databaset
Disability weights
Nonfatal
Burden estimation
Cause of death
Covariates
Input Data
Data 
preparation
Model distribution of 
prevalence for subnationals 
and scale to national case 
totals (BRA, CHN, KEN, MEX, 
SAU, ZAF)
Data on reductions in 2010 prevalence by location, age, 
helminth type and coverage(community/school)
Expert group data on prevalence
by location, year (1990, 2005, 2010), age (0-4, 5-9, 10-
14, 15+) and intensity (light, medium, heavy, all) 1000 draws of trichuriasis 
prevalence by location, year 
(1990, 2005, 2010), age, sex: 
assume same prev in ages 15+ 
and same prev in males & 
females
 Adjust prevalence for 
locations with coverage 
data; apply same adjustment 
to 1990 & 2005
Interpolate 
(exponentially) between 
1990 and 2005 to get 
1995 and 2000 estimates
Produce draws for 2016 based on 2010 
estimates corrected for PCT control 
activities between 2010 and 2016; 
Extrapolate trend 2004-2010 to 2016, 
given cumulative number of ttp
Calculate cumulative number of 
treatments per person (tpp) in 
population requiring PCTWHO PCT 
databank data
Overall trichuriasis 
prevalence
Mild abdominal 
pain due to 
trichuriasis
Heavy trichuriasis 
infestation
Estimate prevalence of 
asymptomatic trichuriasis
= overall – (mild + heavy + 
wasting)
Estimate prevalence of 
severe wasting due to 
trichuriasis
Asymptomatic 
trichuriasis
Severe wasting 
due to trichuriasis
Prevalence of severe wasting from 
wasting envelope
Mean (0.493826493)  and bounds 
(0.389863021, 0.584794532) for change 
in weight-for -height z-score
Comorbidity 
correction (COMO)
Disability weights
Unadjusted 
YLD by 
sequelae
Split India subnationals using 
India prevalence survey and 
modeled splits of state 
prevalence into urban and 
rural, scaling to state case 
totals and then national 
totals
India MOH MDA 
data
Apply geographic 
restrictions
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Mass Drug Administration 
Data on national MDA program coverage was downloaded from the WHO PCT Databank source site [3]. 
This data spanned 119 GBD locations over 13 years beginning in 2003. 
India Ministry of Health 
Collaborators from the Indian Ministry of Health provided supplementary prevalence data [4] and MDA 
coverage data for India [5]. This data was available for all Indian states but was not available at the most 
detailed GBD location specification for the country: urban and rural. Data on MDA coverage was available 
for the years 2013-2016 while prevalence data was only available for 2015. 
Severe Wasting Estimates 
To inform the wasting model, 1,000 draws of severe wasting prevalence among children under 5 years 
were ascertained from GBD 2016 estimates – the methods used to generate estimates of wasting 
prevalence are detailed elsewhere (part of risk factors documentation) [6]. 
Geographic Restrictions 
We conducted a literature review to determine the geographic extent of the disease and classify locations 
based on whether the disease is absent or present in each year.  Locations that were geographically 
restricted in any given year did not have estimates made for them but could have imported cases 
attributed to them at a later stage. Of note, we did not attempt a complete systematic review, since a 
single high-quality source could offer sufficient evidence of presence. Evidence of absence or presence 
was not available for every location for each year and so assumptions were made for missing years by 
taking into consideration the epidemiological characteristics of the disease.  If evidence indicated disease 
presence for two non-consecutive years, we assumed presence for all years between the two. If evidence 
indicated disease absence for two non-consecutive years, we assumed absence for all years between the 
two. If evidence indicated a change in status (i.e. from absent to present, or present to absent) between 
two non-consecutive years than we conducted targeted searches to ascertain the relevant year of 
introduction or elimination for that location.  In the cases where presence or absence information was 
missing for the start or end years of our study interval (1990-2016) without evidence of any introduction 
or elimination events within the interval, we applied the status of the first and last presence/absence 
observations respectively to all years between the interval bound and the observation year.  Our search 
was done in conjunction with the title/abstract screening portion of a systematic literature review for 
prevalence data. The search strings and yield can be viewed in the table below for each of the databases 
queried. 
Table 1b. Geographic Restriction Search Strings 
Database Search String Yield 
PubMed (Ascariasis[Title/Abstract] OR Ascaris[Title/Abstract] OR "A. 
lumbricoides"[Title/Abstract] OR Ascaris[MeSH] OR Trichuris[Title/Abstract] 
OR Trichuriasis[Title/Abstract] OR "Whip Worm"[Title/Abstract] OR "T. 
trichura"[Title/Abstract] OR Trichuris[MeSH] OR Hookworm[Title/Abstract] OR 
"A. duodenale"[Title/Abstract] OR "Ancylostoma duodenale”[Title/Abstract] 
OR ancylostomiasis[Title/Abstract] OR "N. americanus"[Title/Abstract] OR 
“Necator americanus”[Title/Abstract] OR necatoriasis[Title/Abstract] OR 
Ancylostoma [MeSH] OR Necator[MeSH]) AND (prevalence[Title/Abstract] OR 
2376 
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incidence[Title/Abstract] OR epidemiology[Title/Abstract] OR 
surveillance[Title/Abstract]) NOT(Animals[MeSH] NOT Humans[MeSH]) 
Web of 
Science  
 
(Ascariasis OR Ascaris OR A. lumbricoides OR Trichuris OR Trichuriasis OR 
Whip Worm OR T. trichura OR Hookworm OR A. duodenale OR Ancylostoma 
duodenale OR anclyostomiasis OR N. americanus OR Necator americanus OR 
necatoriasis) AND TOPIC:(prevalence OR incidence OR epidemiology OR 
surveillance) NOTTOPIC: ((Animals NOT Humans)) 
Timespan: 1980-2016. Indexes: SCI-EXPANDED, SSCI, A&HCI, ESCI. 
2266 
SCOPUS TITLE-ABS_KEY (ascariasis OR ascaris OR a. lumbricoides OR trichuris OR 
trichuriasis OR whip worm OR t. trichura OR hookworm OR a. duodenale OR 
ancylostoma duodenale OR anclyostomiasis OR n. americanus OR necator 
americanus OR necatoriasis) AND PUBYEAR>1979 
29 
 
These papers were used to classify location-years for all locations and years present in the literature. 
Additionally, systematic literature reviews, meta-analyses, national health statistics publications and 
collaborator input were used to classify location-years not present in the literature review wherever 
possible. 
Severity splits/sequelae 
The table below shows the list of sequelae due to trichuriasis and the associated disability weights (DW). 
Prevalence of medium infection and heavy infection were mapped to mild abdominopelvic problems and 
heavy infestation of trichuriasis respectively.  Light infection was not attributed any disability. 
Sequela Lay description DW (95% CI) 
Mild abdominopelvic problems  has some pain in the belly that causes nausea but 
does not interfere with daily activities 
0.011 (0.005–0.021) 
Heavy infestation has cramping pain and a bloated feeling in the belly 0.027 (0.015–0.044) 
Severe wasting is extremely skinny and has no energy 0.128 (0.082–0.183) 
Asymptomatic trichuriasis N/A N/A 
 
In the estimation of morbidity due to trichuriasis, the EG data were first prepared by formatting the 
location names to be consistent with the GBD 2016 location names and applying the 2010 prevalence to 
1990 and 2005 for sub-Saharan Africa countries – estimates for these two years were missing. This was 
followed by using the data on reductions in 2010 prevalence to adjust the prevalence for locations with 
coverage data. After this adjustment, only data for medium infection, heavy infection, and all infection 
were retained. 
Using the mean prevalence and the upper and lower bounds of the mean provided by the EG, 1,000 
draws of prevalence were generated. This was done by multiplying the mean estimates by the exponent 
of random draws from a normal distribution with mean = 0 and standard deviation = sd, where sd = 
abs(abs(ln(upper)-ln(lower))/(invnormal(0.975)*2). These draws were created for all GBD age-groups, 
assuming the same prevalence in ages 15+ and same prevalence in males and females. 
Since the draws were only at the national level, subnational locations were modelled for Brazil, China, 
Indonesia, Kenya, Mexico, Saudi Arabia, and South Africa. This was done using a generalized linear model 
with a binomial family, logit link and robust standard errors. The predicted cases for all subnational 
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locations were summed and scaled to the national case total. India subnationals were separately derived 
by applying the proportion of all national cases in each state from the Indian Ministry of Health data [4] to 
the national total.  We then applied the modelled proportion of cases in urban or rural locations such that 
the sum of urban and rural cases in a state equals the state total and the sum of all state cases equals the 
national total. 
To get 1995 and 2000 estimates, exponential interpolation of estimates between 1990 and 2005 was 
performed. The draws for 2016 were produced based on 2010 estimates corrected for PCT control 
activities between 2010 and 2016 – this was done by extrapolating the 2004–2010 trend to 2016, given 
cumulative number of treatments per person calculated using data from the WHO PCT Databank [3] and 
the Indian Ministry of Health MDA coverage data[5]. The 2004-2010 trend was applied to all intensities of 
infection. Prevalence was assumed to be zero for the countries with missing input data and also in 
children younger than 28 days. The resulting estimates were 1,000 draws of trichuriasis prevalence by 
GBD location, year, age, sex, and intensity level (mild, heavy, overall infection). To estimate the 
prevalence of asymptomatic trichuriasis, prevalence of mild and heavy infestation was subtracted from 
the overall trichuriasis prevalence. 
Erroneous outliers in the original prevalence data in several countries were dealt with by replacing 
national prevalence with the associated regional prevalence and re-assigning all heavy infection cases to 
mild infection in countries with consistently operating MDA programs. This applied to countries where 
original prevalence data produced more than 100 YLDs per 100,000 people including Kiribati, Marshall 
Islands, Malaysia, Philippines, Swaziland and South Africa. These were significant outliers and not thought 
plausible according to available literature. 
The final step in the modelling process was to estimate the prevalence of severe wasting due to 
trichuriasis in age groups 28–364 days and 1–4 years. This was done separately using 1,000 draws of 
prevalence of heavy infestation due to trichuriasis and the wasting envelope prevalence. The initial step 
in determining prevalence of severe wasting due to trichuriasis was generating 1,000 draws of change in 
weight-for-height z-score per heavy prevalent case from a random normal distribution with mean = 
0.493826493 and standard deviation = 0.04972834 (calculated from upper and lower bounds of the 
mean estimate). The mean, upper, and lower bounds were provided by a GBD collaborator who 
calculated them based on a published article [6]. The prevalence of severe wasting due to trichuriasis was 
then obtained as a function of change in weight-for-height z-score (z_change) such that prevalence = 
p_wasting_env – Phi(Phi_inv(p_wasting_env) – z_change*p), where p_wasting_env = wasting envelope 
prevalence, Phi_inv is the inverse standard normal cumulative distribution function (cdf), and p = 
prevalence of heavy trichuriasis infestation. Finally, geographic restrictions were applied to set prevalence 
to zero in countries with wasting that are not endemic for trichuriasis. 
Model evaluation was done by plotting prevalence of overall trichuriasis and that of each sequela against 
year for each location and age group. Maps of the global distribution of total trichuriasis prevalence and 
prevalence of sequelae due to trichuriasis were also assessed across time and age.  
Only minor changes were made to the GBD 2015 modelling strategy including the incorporation of 
updated data from the WHO PCT databank [3] and data from the Indian Ministry of Health, new 
modelling of subnational prevalence distribution and new geographic restrictions. 
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 Hookworm Disease 
 
Flowchart 
 
Input data and methodological summary 
Case Definition 
Hookworm disease is a helminthic disease caused by the parasitic roundworms, Ancylostoma duodenale 
and Necator americanus. It is one of the three intestinal nematode infections (INI), or soil-transmitted 
helminthiasis (STH), that we model in GBD. Diagnosis is made by examination of stool by microscope or 
PCR, with or without concentration procedures. The ICD-10 codes for hookworm disease are B76-B76.9. 
 
Input data 
Expert Group Data 
Input data for this model was compiled from various sources. Prevalence data prepared by the GBD 
expert group (EG) during GBD 2010 [1, 2] contained mean prevalence with confidence intervals, stratified 
by location, year (1990, 2005, 2010), age group (0-4, 5-9, 10-14, 15+ years) and intensity of infection 
(light, medium, heavy, all). For the model, light infestation was not attributed any disability. The expert 
group also provided data on reduction of prevalence in 2010, stratified by location, age group and Mass 
Drug Administration (MDA) coverage strategy (community/school). The table below shows the number of 
countries or subnational units and GBD world regions represented in the data. 
Table 1a. Geographic Spread of Expert Group Prevalence Data 
 prevalence 
Countries/subnationals 160 
GBD world regions 17 
Nonfatal health outcome estimation
Final burden estimation
Legend
YLLs
Comorbidity 
adjusted 
YLDs
DALYs
Input dataInput data
ProcessProcess
ResultsResults
DatabaseDatabase
Disability weights
Nonfatal
Burden estimation
Cause of death
Covariates
Input Data
Data 
preparation
Model distribution of 
prevalence for subnationals 
and scale to national case 
totals (BRA, CHN, KEN, MEX, 
SAU, ZAF)
Data on reductions in 2010 prevalence by location, age, 
helminth type and coverage(community/school)
Expert group data on prevalence
by location, year (1990, 2005, 2010), age (0-4, 5-9, 10-
14, 15+) and intensity (light, medium, heavy, all) 1000 draws of hookworm 
prevalence by location, year 
(1990, 2005, 2010), age, sex: 
assume same prev in ages 15+ 
and same prev in males & 
females
 Adjust prevalence for 
locations with coverage 
data; apply same adjustment 
to 1990 & 2005
Interpolate 
(exponentially) between 
1990 and 2005 to get 
1995 and 2000 estimates
Produce draws for 2016 based on 2010 
estimates corrected for PCT control 
activities between 2010 and 2016; 
Extrapolate trend 2004-2010 to 2016, 
given cumulative number of ttp
Calculate cumulative number of 
treatments per person (tpp) in 
population requiring PCTWHO PCT 
databank data
Overall hookworm 
prevalence
Mild abdominal 
pain due to 
hookworm
Heavy hookworm 
infestation
Estimate prevalence of 
asymptomatic hookworm
= overall – (mild + heavy + 
wasting)
Estimate prevalence of 
severe wasting due to 
hookworm
Asymptomatic 
hookworm
Severe wasting 
due to hookworm
Prevalence of severe wasting from 
wasting envelope
Mean (0.493826493)  and bounds 
(0.389863021, 0.584794532) for change 
in weight-for -height z-score
Comorbidity 
correction (COMO)
Disability weights
Unadjusted 
YLD by 
sequelae
Hookworm
Split India subnationals using 
India prevalence survey and 
modeled splits of state 
prevalence into urban and 
rural, scaling to state case 
totals and then national 
totals
India MOH MDA 
data
Apply geographic 
restrictions
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Mass Drug Administration 
Data on national MDA program coverage was downloaded from the WHO PCT Databank source site [3]. 
This data spanned 119 GBD locations over 13 years beginning in 2003. 
India Ministry of Health 
Collaborators from the Indian Ministry of Health provided supplementary prevalence data [4] and MDA 
coverage data for India [5]. This data was available for all Indian states but was not available at the most 
detailed GBD location specification for the country: urban and rural. Data on MDA coverage was available 
for the years 2013-2016 while prevalence data was only available for 2015. 
Severe Wasting Estimates 
To inform the wasting model, 1,000 draws of severe wasting prevalence among children under 5 years 
were ascertained from GBD 2016 estimates – the methods used to generate estimates of wasting 
prevalence are detailed elsewhere (part of risk factors documentation) [6]. 
Geographic Restrictions 
We conducted a literature review to determine the geographic extent of the disease and classify locations 
based on whether the disease is absent or present in each year.  Locations that were geographically 
restricted in any given year did not have estimates made for them but could have imported cases 
attributed to them at a later stage. Of note, we did not attempt a complete systematic review, since a 
single high-quality source could offer sufficient evidence of presence. Evidence of absence or presence 
was not available for every location for each year and so assumptions were made for missing years by 
taking into consideration the epidemiological characteristics of the disease.  If evidence indicated disease 
presence for two non-consecutive years, we assumed presence for all years between the two. If evidence 
indicated disease absence for two non-consecutive years, we assumed absence for all years between the 
two. If evidence indicated a change in status (i.e. from absent to present, or present to absent) between 
two non-consecutive years than we conducted targeted searches to ascertain the relevant year of 
introduction or elimination for that location.  In the cases where presence or absence information was 
missing for the start or end years of our study interval (1990-2016) without evidence of any introduction 
or elimination events within the interval, we applied the status of the first and last presence/absence 
observations respectively to all years between the interval bound and the observation year.  Our search 
was done in conjunction with the title/abstract screening portion of a systematic literature review for 
prevalence data. The search strings and yield can be viewed in the table below for each of the databases 
queried. 
Table 1b. Geographic Restriction Search Strings 
Database Search String Yield 
PubMed (Ascariasis[Title/Abstract] OR Ascaris[Title/Abstract] OR "A. 
lumbricoides"[Title/Abstract] OR Ascaris[MeSH] OR Trichuris[Title/Abstract] 
OR Trichuriasis[Title/Abstract] OR "Whip Worm"[Title/Abstract] OR "T. 
trichura"[Title/Abstract] OR Trichuris[MeSH] OR Hookworm[Title/Abstract] OR 
"A. duodenale"[Title/Abstract] OR "Ancylostoma duodenale”[Title/Abstract] 
OR ancylostomiasis[Title/Abstract] OR "N. americanus"[Title/Abstract] OR 
“Necator americanus”[Title/Abstract] OR necatoriasis[Title/Abstract] OR 
Ancylostoma [MeSH] OR Necator[MeSH]) AND (prevalence[Title/Abstract] OR 
2376 
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incidence[Title/Abstract] OR epidemiology[Title/Abstract] OR 
surveillance[Title/Abstract]) NOT(Animals[MeSH] NOT Humans[MeSH]) 
Web of 
Science  
 
(Ascariasis OR Ascaris OR A. lumbricoides OR Trichuris OR Trichuriasis OR 
Whip Worm OR T. trichura OR Hookworm OR A. duodenale OR Ancylostoma 
duodenale OR anclyostomiasis OR N. americanus OR Necator americanus OR 
necatoriasis) AND TOPIC:(prevalence OR incidence OR epidemiology OR 
surveillance) NOTTOPIC: ((Animals NOT Humans)) 
Timespan: 1980-2016. Indexes: SCI-EXPANDED, SSCI, A&HCI, ESCI. 
2266 
SCOPUS TITLE-ABS_KEY (ascariasis OR ascaris OR a. lumbricoides OR trichuris OR 
trichuriasis OR whip worm OR t. trichura OR hookworm OR a. duodenale OR 
ancylostoma duodenale OR anclyostomiasis OR n. americanus OR necator 
americanus OR necatoriasis) AND PUBYEAR>1979 
29 
 
These papers were used to classify location-years for all locations and years present in the literature. 
Additionally, systematic literature reviews, meta-analyses, national health statistics publications and 
collaborator input were used to classify location-years not present in the literature review wherever 
possible. 
 
Severity splits/sequelae 
The table below shows the list of sequelae due to hookworm and the associated disability weights (DW). 
Prevalence of medium infection and heavy infection were mapped to mild abdominopelvic problems and 
heavy infestation of hookworm respectively.  Light infection was not attributed any disability. 
Table 2. Sequelae, lay descriptions, and disability weights (DWs) 
Sequela Lay description DW 
Mild abdominopelvic problems  has some pain in the belly that causes nausea but 
does not interfere with daily activities 
0.011 (0.005–0.021) 
Heavy infestation has cramping pain and a bloated feeling in the belly 0.027 (0.015–0.044) 
Severe wasting is extremely skinny and has no energy 0.128 (0.082–0.183) 
Asymptomatic hookworm 
disease 
NA NA 
Mild anaemia feels slightly tired and weak at times, but this does 
not interfere with normal daily activities 
0.004 (0.001–0.008) 
Moderate anaemia feels moderate fatigue, weakness, and shortness of 
breath after exercise, making daily activities more 
difficult 
0.052 (0.034–0.076) 
Severe anaemia feels very weak, tired and short of breath, and has 
problems with activities that require physical effort 
or deep concentration 
0.149 (0.101–0.210) 
 
Modelling strategy 
In the estimation of morbidity due to hookworm disease, the EG data were first prepared by formatting 
the location names to be consistent with the GBD 2016 location names and applying the 2010 prevalence 
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to 1990 and 2005 for sub-Saharan Africa countries – estimates for these two years were missing. This was 
followed by using the data on reductions in 2010 prevalence to adjust the prevalence for locations with 
coverage data. After this adjustment, only data for medium infection, heavy infection, and all infection 
was retained. 
Using the mean prevalence and the upper and lower bounds of the mean provided by the EG, 1,000 
draws of prevalence were generated. This was done by multiplying the mean estimates by the exponent 
of random draws from a normal distribution with mean = 0 and standard deviation = sd, where sd = 
abs(abs(ln(upper)-ln(lower))/(invnormal(0.975)*2). These draws were created for all GBD age groups, 
assuming the same prevalence in ages 15+ and same prevalence in males and females. 
Since the draws were only at the national level, subnational locations were modelled for Brazil, China, 
Indonesia, Kenya, Mexico, Saudi Arabia, and South Africa. This was done using a generalized linear model 
with a binomial family, logit link and robust standard errors. The predicted cases for all subnational 
locations were summed and scaled to the national case total. India subnationals were separately derived 
by applying the proportion of all national cases in each state from the Indian Ministry of Health data [4] to 
the national total.  We then applied the modelled proportion of cases in urban or rural locations such that 
the sum of urban and rural cases in a state equals the state total and the sum of all state cases equals the 
national total. 
To get 1995 and 2000 estimates, exponential interpolation of estimates between 1990 and 2005 was 
performed. The draws for 2016 were produced based on 2010 estimates corrected for PCT control 
activities between 2010 and 2016 – this was done by extrapolating the 2004–2010 trend to 2016, given 
cumulative number of treatments per person calculated using data from the WHO PCT Databank [3] and 
the Indian Ministry of Health MDA coverage data[5]. The 2004-2010 trend was applied to all intensities of 
infection. Prevalence was assumed to be zero for the countries with missing input data and also in 
children younger than 28 days. The resulting estimates were 1,000 draws of hookworm prevalence by 
GBD location, year, age, sex, and intensity level (mild, heavy, overall infection). To estimate the 
prevalence of asymptomatic hookworm, prevalence of mild and heavy infestation was subtracted from 
the overall hookworm prevalence. 
The final step in the modelling process was to estimate the prevalence of severe wasting due to 
hookworm in age groups 28–364 days and 1–4 years. This was done separately using 1,000 draws of 
prevalence of heavy infestation due to hookworm and the wasting envelope prevalence. The initial step in 
determining prevalence of severe wasting due to hookworm was generating 1,000 draws of change in 
weight-for-height z-score per heavy prevalent case from a random normal distribution with mean = 
0.493826493 and standard deviation = 0.04972834 (calculated from upper and lower bounds of the 
mean estimate). The mean, upper, and lower bounds were provided by a GBD collaborator who 
calculated them based on a published article [6]. The prevalence of severe wasting due to hookworm was 
then obtained as a function of change in weight-for-height z-score (z_change) such that prevalence = 
p_wasting_env – Phi(Phi_inv(p_wasting_env) – z_change*p), where p_wasting_env = wasting envelope 
prevalence, Phi_inv is the inverse standard normal cumulative distribution function (cdf), and p = 
prevalence of heavy hookworm infestation. Finally, geographic restrictions were applied to set prevalence 
to zero in countries with wasting that are not endemic for hookworm. 
The burden of anemia due to hookworm disease was estimated seperately (see anemia documentation 
for details). 
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Model evaluation was done by plotting prevalence of overall hookworm disease and that of each 
sequelae against year for each location and age group. Maps of the global distribution of total hookworm 
disease prevalence and prevalence of sequelae due to hookworm disease were also assessed across time 
and age.  
Only minor changes were made to the GBD 2015 modelling strategy including the incorporation of 
updated data from the WHO PCT databank [3] and data from the Indian Ministry of Health, new 
modelling of subnational prevalence distribution and new geographic restrictions. 
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Input Data & Methodological Summary 
Case definition 
Human foodborne trematodiases (FBT) is defined as the infection with parasitic worms of the class 
trematoda, which are also known as flukes. Trematodes are transmitted via contaminated food and 
infection is highly related to food habits. Definitive hosts, including humans, become infected when 
ingesting viable metacercariae by consuming contaminated aquatic products (eg, watercress). In the 
ICD-10, FBT are listed under code B66 [1]. 
 
FBT is subdivided into six types of FBT (see Table 1): 
 Clonorchiasis 
 Fascioliasis 
 Intestinal fluke 
 Opisthorchiasis 
 Paragonimiasis (normal and cerebral infections) 
 
Table 1. Subtypes of FBT 
 Species of FBT Also known as: Carcinogen 
1 Chlonorchiasis (Chinese) Liver fluke Associated with choliangiocarcinoma 
2 Opisthorchiasis 
(O viverrini & O felineus) 
Liver fluke Associated with choliangiocarcinoma 
(O viverrini) 
3 Fascioliasis Liver fluke No available evidence 
4 Intenstinal fluke Liver fluke No available evidence 
5 Paragonimiasis Lung fluke   
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 Thresholds for heavy infection and duration by species of FBT 
The majority of people infected with FBTs are asymptomatic. When symptoms do occur they are often 
non-specific. Among the clinical symptomatic group, severity is associated with worm burden, typically 
measured by fecal egg counts, and the duration of infection. The thresholds for heavy infection and 
duration by species of FBT are shown in Table 2. The clinical presentation of FBT depends on the target 
organs (liver, lung, or intestines). Clonorchiasis and opisthorchiasis patients may suffer from loss of 
appetite, fullness, indigestion, diarrhoea, pain in the right upper quadrant, lassitude, weight loss, ascites, 
and oedema.[2, 3] Cholangitis, obstructive jaundice, intra-abdominal mass, cholecystitis, and gallbladder or 
intrahepatic stones may occur as complications.[3, 4] 
 
Table 2. Thresholds for heavy infection and duration by species of FBT 
 Species of FBT Case thresholds for heavy infection Duration 
1 Chlonorchiasis 10,000 eggs per g of feces lifelong 
2 Opisthorchiasis 10,000 eggs per g of feces lifelong 
3 Fascioliasis 1,000 eggs per g of faces lifelong 
4 Intenstinal fluke 1,000 eggs per g of faces lifelong 
5 Paragonimiasis 100 eggs per 5 ml sputum lifelong 
6 Cerebral paragonimiasis Any infection of the brain with flukes and/or eggs of 
Paragonimus spp. 
lifelong 
 
Input data 
Model inputs 
For GBD 2010, the data came from the expert group and is the result of their analysis. The expert group 
analysis used the results of a systematic literature review performed by Furst et al. as a starting point for 
the analysis.[5] Furst et al. searched PubMed, WHOLIS, FAOBIB, Embase, CAB Abstracts, Literatura 
Latino Americana e do Caribe em Ciências de Saùde (LILACS), ISI Web of Science, BIOSIS preview, Science 
Direct, African Journals OnLine (AJOL), and the System for Information on Grey Literature in Europe 
(SIGLE), period Jan 1, 1980, to 
Dec 31, 2008. The initial number of studies identified through the literature review was ~34,000 
references. The literature review included extracted data from 181 studies. For GBD 2013 and GBD 2015 
the search strategy was replicated to capture epidemiological studies published between 2008 and 
2015. Due to the cyclical nature of systematic review for GBD causes, no data collection was scheduled 
for GBD 2016. As such, foodborne trematodiases will be a priority for the next iteration of the study. 
Input data for the assessment of the total national number of infected people  
Only studies that used countrywide surveys to estimate the national prevalence rates were included (or 
for China, province-wide surveys). Reason for choosing only national studies is that FBT shows a highly 
focal spatial distribution and local cross-sectional surveys would profoundly under- or overestimate true 
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national prevalences. We decided not to model national and subnational together and get a coefficient 
on subnational, because there is not a one-fits-all relationship across the world. Infection is highly 
related to food habits and there are highly varying differences between national and subnational 
prevalence rates. The final GBD 2016 dataset contained 29 prevalence studies from 17 countries. We 
used raw data from the selected studies as input for DisMod. 
Prevalence intestinal fluke infection 
Intestinal fluke is different from the other types of FBT, because there are several pathogens that fall 
under intestinal fluke infection. It can be caused by pathogens, such as Metagonimus spp., Echinostoma 
spp., Neodiplostomatidae.[6] When assessing the prevalence of intestinal fluke infection, we added the 
identified prevalence for each parasite species in order to obtain the overall prevalence of intestinal 
fluke infections. This approach may lead to a certain overestimation of the true prevalence, because 
people may be co-infected with more than one intestinal fluke species. There is no sufficient evidence 
about the proportion of co-infections, but the resulting overestimation of the true prevalence may be 
more than offset by the assumptions made in our previous modelling approach and the many challenges 
in generating the underlying epidemiological parameters (eg, diagnostic inaccuracy in the detection of 
infections with the more than 50 intestinal fluke species). Also of note: the transmission source of 
intestinal fluke infections are species-specific and therefore vary. For instance, Fasciolopsis buski is 
usually transmitted by eating raw water plants with the infective parasite stage attached to the water 
plants, whereas Neodiplostomatidae are transmitted by eating undercooked and infested frogs, snakes, 
and tadpoles. Because of these different transmission pathways, the rate of co-infection might in fact be 
smaller than expected. 
Input data to differentiate between asymptomatic and heavy infections 
We estimated the proportion of heavily infected among all infected in all available national and regional 
cross-sectional surveys. It is expected that heavy infection increases with age and there are data 
available on heavy infection by age group. We therefore decided to include age-dependent rates of 
heavy infection for clonorchiasis, opisthorchiasis, and intenstinal fluke infection. For (cerebral) 
paragonimiasis and fascioliasis there were not sufficient age-dependent data on high intensity FBT 
infection.  
 
Modelling strategy 
We used a three-step process for the disease modelling of FBT. In the first step we used DisMod-MR 2.0 
to estimate assess the prevalence of FBT by age, sex, year, and country. In the second we differentiated 
between asymptomatic and heavy infections. MetaXL (a meta-analysis add in for Microsoft Excel) was 
used to estimate the proportion of heavy infected among all infected by age group for clonorchiasis, 
opisthorchiasis, and intenstinal fluke infection (see Table 3 and 4). These proportions were used to 
estimate the prevalence of heavy FBT infection.  
The third step consisted of deselecting countries that have no autochtonous case reports of FBT (input 
34,000 references from literature review).  
 
Table 3. Percentage of high intensity infection by age group and type of FBT (based on eight FBT 
prevalence studies) 
Age 
category 
Clonorchiasis Opisthorchiasis Intestinal fluke infection 
Mean Low High Mean Low High Mean Low High 
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0-9 30% 17% 44% 10% 0% 29% 8% 3% 14% 
10-19 15% 0% 43% 15% 0% 69% 11% 8% 14% 
20-29 18% 10% 29% 16% 0% 52% 18% 15% 21% 
30-39 17% 5% 34% 21% 0% 56% 22% 17% 28% 
40-49 22% 13% 32% 28% 1% 68% 22% 13% 32% 
50-59 18% 0% 49% 29% 0% 75% 17% 9% 28% 
60+ 32% 18% 47% 25% 0% 64% 15% 8% 23% 
 
 
Table 4. Percentage of high-intensity infection by type of FBT (based on 4 FBT prevalence studies) 
Type of FBT 
 
Mean Low High 
Paragonimiasis 23% 0% 59% 
Fascioliasis 19% 3% 41% 
 
Cerebral paragonimiasis 
It was assumed that 0.8% of paragonimiasis cases have cerebral involvement. This proportion was used 
to estimate the prevalence of cerebral paragonimiasis. This proportion is based on one study. The data 
are from Oh SJ. The rate of cerebral involvement in paragonimiasis: an epidemiologic study. Jpn J 
Parasitol 1969;18:211-14. The study was performed in Paju, South Korea. This is an area with 6,738 
inhabitants and according to the survey, it was estimated that 29.6% of all individuals would react to 
intradermal test (= an immunological reaction indicating previous or current contact to the parasite). 
25% of all “positive reactors” may have eggs in their sputum (= active infection with the parasite 
currently present in the human host). If these rates are applied to the community as a whole, the 
number of patients with active paragonimiasis would be at least 498 (=6,738*0.296*0.250). 
Furthermore, four cases of cerebral paragonimiasis were found in this community. Therefore, four out 
of 498 individuals with active paragonimus infection suffered from cerebral infection (=0.80%; 95% 
confidence interval 0.019%-1.587%).  
Severity splits and disability weights 
For GBD 2016, FBT was not split into health states with different severities. The table below shows the 
GBD 2016 disability weights that were used to calculate the burden of FBT in YLDs. 
  
Table 5. Disability weights that were used to calculate FBT YLDs 
Sequelae  Severity description Health state name Disability weight 
Asymptomatic 
clonorchiasis 
Clonorchiasis, currently without 
symptoms 
N/A 0.000 (0.000–0.000) 
Heavy 
clonorchiasis 
Abdominal pain and nausea reported as 
moderate 
Abdominopelvic problem, 
moderate 
0.114 (0.078–0.159) 
Asymptomatic 
opisthorchiasis 
Opisthorchiasis,  currently without 
symptoms 
N/A 0.000 (0.000–0.000) 
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Heavy 
opisthorchiasis 
Abdominal pain and nausea reported as 
moderate 
Abdominopelvic problem, 
moderate 
0.114 (0.078–0.159) 
Asymptomatic 
fascioliasis 
Fascioliasis, currently without 
symptoms 
N/A 0.000 (0.000–0.000) 
Heavy 
fascioliasis 
Abdominal pain and nausea reported as 
moderate 
Abdominopelvic problem, 
moderate 
0.114 (0.078–0.159) 
Asymptomatic 
intestinal fluke 
infection 
Intestinal fluke infection, currently 
without symptoms 
N/A 0.000 (0.000–0.000) 
Heavy intestinal 
fluke infection 
Abdominal pain and nausea reported as 
moderate 
Abdominopelvic problem, 
moderate 
0.114 (0.078–0.159) 
Asymptomatic 
paragonimiasis 
Paragonimiasis, currently without 
symptoms 
N/A 0.000 (0.000–0.000) 
Heavy 
paragonimiasis 
Cough, fever, and weight loss Tuberculosis, not HIV-infected 0.333 (0.224–0.454) 
Cerebral 
paragonimiasis 
Epilepsy due to cerebral paragonimiasis Epilepsy, less severe (seizures 
< once per month) 
0.263 (0.173–0.367) 
  
Epilepsy, severe (seizures >= 
once per month 
0.552 (0.375–0.710) 
Note. N/A: not applicable 
 
Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modelling strategy from GBD 2015 to GBD 2016. 
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Input Data and Methodological Summary 
Case definition 
Leprosy is a chronic bacterial infection caused by Mycobacterium leprae, primarily affecting the nervous 
system, skin, respiratory tract, and eyes. Transmission is facilitated through contact with fluid from the 
nose and mouth of an infected individual. The ICD-10 codes for leprosy are A30.9.  
Input data  
To model nonfatal outcomes due to leprosy, WHO Weekly Epidemiological Record (WER) case 
notification data were used from 1987 to 2012 to capture incident cases of leprosy. This is the same 
database that was used to model GBD 2015 estimates, and due to the cyclical nature of systematic 
reviews for GBD causes, no data collection was scheduled for GBD 2016. As such, leprosy will be a 
priority for the next iteration of the study. Stage-specific incidence data for grade 1 and grade 2 leprosy 
that are used to define age-sex patterns came from Brazil case notification data.  
Modelling strategy 
We used a multi-step process for the disease modeling of leprosy. In the first step, we ran a single-
parameter model using DisMod-MR 2.0 to estimate the leprosy incidence age pattern by age, sex, year, 
and country. Then, we scaled the incidence outputs to the WHO WER cases, and used the ordinary 
differential equations (ODE) solver to calculate prevalence from the scaled DisMod-MR 2.0 incidence 
outputs.  
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Severity data were prepared by running a generalized ordered logistic regression using Brazil case 
notification data to get the relationship between leprosy incidence and grade 1 and grade 2 incidence by 
age and sex. We then used this relationship to split the parent DisMod-MR 2.0 model, and again scaled 
to WHO WER severity-specific cases. For disfigurement grade 1, we apply a duration of six months to get 
prevalence estimates. For disfigurement grade 2, we again use the ODE solver to get prevalence 
estimates.  
Model evaluation was done by separately assessing the fit of the parent DisMod model and checking the 
final estimates produced after age-sex splits. Plots of time trends of prevalence across locations and age 
were used to evaluate the results. In addition, maps of the global distribution of leprosy prevalence and 
prevalence of sequelae due to leprosy were also assessed across time. 
Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modelling strategy from GBD 2015 to GBD 2016. 
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Input data and methodological summary 
 
Background and case definition 
Ebola virus disease is a relatively rare viral pathogen linked with high case fatality rates in both humans 
and non-human primates. The disease is zoonotic, and while bats have been implicated as reservoirs, 
definitive host species are yet to be identified. Once a human becomes infected after viral transmission 
from animal sources either directly or indirectly, secondary human-to-human transmission is possible, 
primarily through exchange of infectious bodily fluids and secretions. Clinical cases typically present 
initially as a febrile illness, similar to a number of different pathogens, subsequently followed by 
haemorrhagic complications, and often death. Historically there have been a number of outbreaks, 
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usually no more than a few hundred cases and typically constrained to one country, focused in Central 
Africa. The West African outbreak, however, which started in Guinea in 2013, has claimed more lives than 
all previous outbreaks combined, and spread across the region seeding additional outbreaks. There is an 
ICD code for Ebola, A98.4, but no data used in the modelling reference that coding (ie, all the data are 
from literature extractions). Data for Ebola virus disease were only included if the case was identified as 
either “probable” or “confirmed” as per WHO definitions 
[http://www.who.int/csr/resources/publications/ebola/ebola-case-definition-contact-en.pdf]. A 
confirmed case is any suspected or probable case with a positive laboratory result through either 
detection of virus RNA via reverse transcriptase-polymerase chain reaction, or by detection of IgM 
antibodies directed against Ebola. A probable case is any suspected case evaluated by a clinician or any 
deceased suspected case with an epidemiological link to a confirmed case.  
  
Input data 
 Model inputs 
Two distinct sequelae were assigned to Ebola virus disease (EVD) to be incorporated into the YLD 
estimation process: (i) sequela associated with the initial symptomatic phase of the infection (associated 
with all cases of Ebola virus disease) and (ii) sequela characterizing the long-term post-EVD consequences 
of infection. As such, data were required both to ascertain the number of deaths as well as those 
surviving from each outbreak. 
Data on fatal cases were inherited from the GBD 2016 mortality estimation process and were converted 
into incidence of cases of Ebola (with fatal outcomes) by cross-referencing locational annualized 
population estimates. 
In order to calculate the numbers of survivors from each outbreak, two data sources were referenced, 
one based upon modelled estimates of the main three countries in the West African Ebola outbreak 
(namely Sierra Leone, Liberia, and Guinea), supplemented by WHO Situation Reports covering the 
clusters of 2016 cases and literature references covering all other subsequent outbreaks. 
Researchers from Imperial College London (UK), as part of the WHO Ebola response team, provided 
modelled estimates for the number of fatalities that result from a given number of reported cases 
(provided by line lists from WHO). This method was used in a variety of papers to generate baseline 
estimates of case fatality rates and other key epidemiological measures while correcting for the lag period 
between initially reporting a case and the final outcome of that case (whether it be death or survival). The 
full data cleaning and methodology are reported elsewhere.1,2 Bespoke estimates were provided for GBD 
for Liberia, Sierra Leone, and Guinea and were stratified by age, sex, and year. Death data from Guinea 
ranged from February 28, 2014, until September 27, 2015, with data from Liberia ranging from March 20, 
2014, to May 4, 2015, and data from Sierra Leone ranging from May 21 until September 28, 2015. To 
these estimates, calculated case fatality ratios1,2 were applied in order to generate an estimate of the 
total number of cases stratified by age, sex, and country. 
For all other outbreaks, numbers of survivors were directly evaluated based upon numbers published in a 
previous review3,4 and consulting original documents describing these outbreaks. This initial review was 
also updated to include the outbreak that occurred in the Democratic Republic of the Congo in 2014,5 and 
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cases in 2016. This resulted in datasets describing each outbreak with variable degrees of detail: some 
fully describing the age and sex breakdown of all survivors [eg, Rosello et al.6] and others simply providing 
the final total. Only confirmed or probable cases were included as per the case definition. Outbreaks that 
spanned multiple years, in the absence of sufficient data providing an accurate breakdown, were 
apportioned between the years by evenly assigning a uniform number of survivors to each month of the 
outbreak’s duration. An additional search was conducted to identify imported cases from the West 
African outbreak during 2014 and 2015. 
Table 1. Sequelae and disability weights (DWs) associated with Ebola 
Sequelae Description Disability weight 
Infectious disease, acute 
episode, severe 
Has a high fever and pain and 
feels very weak, which causes 
great difficulty with daily 
activities 
 
0.133 (0.088–0.19) 
Infectious disease, post-acute 
consequences (fatigue, 
emotional lability, insomnia) 
Is always tired and easily upset. 
The person feels pain all over 
the body and is depressed 
0.219 (0.148–0.308) 
 
It was not possible to create bespoke disability weights for the more specific sequelae often associated 
with Ebola virus disease (eg, haemorrhaging or ocular complications in survivors), so existing disability 
weights were co-opted. General high fevers and weakness characterize the majority of presenting cases7 
with long-term complications generally related to weakness and arthralgia.8 
 
Modelling strategy  
Data on cases (both survivors and fatalities) resulting from imported cases from 2014 and 2015 were 
used as specific count data as it was assumed to be an accurate representation of the cases and 
outbreaks in these countries, all of which were on high alert for importation of cases.9,10 
The other input data were processed prior to inclusion in GBD to account for any potential 
underreporting of deaths. A meta-analysis of existing underreporting studies from the literature was 
performed, using a random effects model with a DerSimonian-Laird estimator. A variety of sources were 
included, capturing a number of different estimation processes, all identified by literature review. The 
figure below shows the different effect sizes of the different studies, as well as the resulting GBD 2016 
correction factor, with the GBD 2015 correction factor for reference. The correction factor ranged from 
1.5147 to 2.5720 with a mean of 2.0433. 
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 In order to capture this potential variation, all input data were multiplied by the lower and upper limit of 
this estimated correction factor; these numbers then provided the lower and upper bounds from which 
draw values were taken. For outbreaks where no data were supplied for age and/or sex, the pattern 
observed in the West African outbreak (for which there were the most comprehensive data) was used to 
apportion these total values. 
One thousand draws were taken from a normal distribution fitted between these lower and upper bound 
values, which generated mean estimates stratified by age, sex, location, and year along with credible 
intervals for these numbers. For the West African outbreak, this generated total case numbers, from 
which the estimated number of deaths was subtracted in order to provide an estimate for the total 
number of survivors. For all other outbreaks, this data processing directly estimated the total number of 
survivors from each outbreak. These count data were converted into prevalence estimates by cross-
referencing estimates of population size. 
In order to estimate the duration of the sequelae categories, previous modelled assessments of the West 
African outbreak were consulted.1,2 The duration of initial infection for patients was calculated as the 
total time period between onset of symptoms to death or to discharge from hospital (8.2 days [7.9–8.4] 
and 15.1 [14.6–15.6], respectively). These time periods were assumed to be appropriate for 
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characterizing all other outbreaks. This time period was then assigned a disability weight corresponding 
to “infectious disease, acute episode, severe.” 
For long-term sequelae estimation, the proportion of survivors still suffering post-acute consequences 
was modelled using an exponential function with proportions of survivors still reporting poor health 
states (derived from a number of survivor studies8,12–21) reported over different time periods. The average 
duration of post-Ebola sequelae was then calculated as 0.9042 years (0.3673–1.4268). 
The final combination of YLDs associated with prevalent initial onset of disease and prevalent post-EVD 
consequences was then calculated to provide an overall YLD estimate stratified by age, sex, location, and 
year. Estimates were provided for the years 1990, 1995, 2000, 2005, 2010, 2015, and 2016 as per non-
fatal GBD estimation protocols. 
 
Potential limitations 
Data on Ebola outbreaks prior to 2014 are sparse, and as a result many values derived from the West 
African outbreak were assumed to be valid for historic outbreaks as well. This may mask significant 
differences that exist between these outbreaks, some of which were caused by different species of Ebola 
virus. In order to minimize this problem we chose to implement a data-driven approach – for those 
outbreaks where sufficiently detailed historical data could be obtained, this was used in preference to any 
assumed age/sex breakdown.  
Haemorrhagic manifestations are currently not considered as an explicit health state for disability 
weighting, and as a result, the current classification (of infectious disease, acute episode, severe) may be 
an underestimate. In contrast, the post-Ebola disease sequelae disability weighting may overestimate this 
burden, particularly when applied over a long period of time. In both instances, however, these disability 
weightings represent the most relevant linkages in the absence of bespoke values being generated. 
Due to so few historical survivors of Ebola virus disease, only a handful of studies have tracked the long-
term sequelae among cohorts of survivors beyond a two-year period. Given the large number of survivors 
from the West African outbreak, it is likely that future of parameterization of this component will become 
much better data-driven. The current log-linear regression model extends for a period of 20 years and 
therefore could prove to be an overestimate of duration. In addition, ocular manifestations are not 
currently considered within the sequelae envelope – future iterations will consider health states such as 
“Distance vision, severe impairment: has severe vision loss, which causes difficulty in daily activities, some 
emotional impact (for example worry), and some difficulty going outside the home without assistance.” 
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 Zika 
 
 
 
 
Input data 
Data on cases of acute Zika and Congenital Zika Syndrome (CZS) come from official reports, primarily 
from PAHO.  
 
Modeling strategy 
We estimate the all-age incidence of symptomatic Zika as the product of reported Zika cases and 
country-specific expansion factors that adjust for underreporting.  Those expansion factors are derived 
from our dengue model and the methods used for their estimation are detailed in the dengue model 
documentation and by Stanaway et al.(1) A subset of incidence data were age/sex-specific, and we used 
a mixed-effects negative binomial model with cubic splines on age and interaction terms with sex to 
estimate the age/sex distribution of cases.  We then split total incidence based on the age/sex-
distribution model to estimate the incidence of symptomatic Zika by location, year, age, and sex. 
 
We conducted a meta-analysis of three studies(2–4) to estimate the proportion of all Zika infections that 
are symptomatic.  We estimate that 41% of Zika infections are symptomatic (14 – 68%), with 59% being 
asymptomatic.  We then estimated incidence of asymptomatic infections as, 
𝐼𝑎𝑠𝑦𝑚𝑝 =
𝐼𝑠𝑦𝑚𝑝
𝑃𝑟𝑠𝑦𝑚𝑝
− 𝐼𝑠𝑦𝑚𝑝 
Where Iasymp is the incidence of asymptomatic infections, Isymp is the incidence of symptomatic Zika, and 
Prsymp is the proportion of infections that are symptomatic (i.e. 41%). 
 
We assume that the incidence of Zika among pregnant women equals the incidence of Zika among all 
women, within a given location, year, and age group. We then estimate the number of pregnant women 
infected with Zika as the product of incidence of Zika and the number of pregnant women in every 
location, year, and age group.  Finally, we used an intercept only, mixed-effects Poisson regression 
model, with random effects on location, the number of at-risk births as the exposure term, and the 
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number of reported CZS cases as the outcome to estimate proportion of at-risk births (i.e. those in 
which the mother was infected with Zika during pregnancy) resulting in CZS. 
 
 
Changes from GBD 2015 to GBD 2016 
Zika is a new cause for GBD 2016. 
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Background 
Guinea-worm disease is caused by the parasitic worm Dracunculus medinensis.  The transmission cycle 
begins when Guinea worm larvae are released in stagnant water (e.g., ponds, lakes, open wells) where 
they are ingested by freshwater copepods (small crustaceans sometimes called water fleas) of the genus 
Cyclops [1].  When a person consumes water containing Cyclops, the copepods are dissolved by gastric 
acids and intestinal enzymes and the larvae are released.  Larvae then migrate through the intestinal 
wall and travel to the connective tissues.  The larvae mature and mate 60–90 days after infection; 
shortly thereafter, the male dies and the pregnant female worm continues to move through the victim's 
connective tissues.  Approximately 10–14 months post-infection, the adult worm creates a painful 
burning blister on the skin that develops and enlarges over several days, usually from the feet or lower 
limbs. Blister formation may be preceded by a slight fever, itchy rash, nausea, vomiting, and diarrhea.  
To relieve the pain associated with the worm’s emergence, infected persons immerse the infected part 
of their body in local stagnant water sources, such as ponds. Upon entering the water, the female worm 
will expel her larvae and the cycle can begin again [1-4]. 
 
The global campaign to eradicate Guinea worm began in 1980, when the U.S. Centers for Disease 
Control and Prevention (CDC) suggested that Guinea worm eradication would be an ideal indicator of 
the success of the International Drinking Water Supply and Sanitation Decade of 1981–1990; in 1981, 
Guinea worm eradication was adopted as a sub-goal of this United Nations advocacy effort [1, 5].  In 
1986, the World Health Assembly adopted a resolution to eliminate Guinea worm disease and since 
then The Carter Center has led a coalition that includes ministries of health of endemic countries, CDC, 
the World Health Organization (WHO), the United Nations Children’s Fund (UNICEF), thousands of 
village volunteers and supervisory staff supported by numerous donors [5].    
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To break the cycle of transmission, ministries of health in endemic countries implement a suite of 
interventions: case detection and containment; provision of safe water sources; distribution of filter 
cloths and pipe filters; water source treatment with Abate® (a larvacide) and health education.   
 
By design, the Guinea worm eradication programmatic infrastructure covers the entire at-risk 
population in endemic countries. Since case containment[6] is a key intervention designed to not only 
interrupt transmission but also monitor progress towards eradication, incident cases of guinea worm 
disease are nationally representative.  To implement case containment as an intervention, all cases of 
Guinea worm disease are identified.  Containment is defined as: detection within 24 hours of the worm's 
emergence; the patient did not contaminate any water source; the patient received proper wound care 
and health education on not entering any water source; a supervisor verified the case as dracunculiasis 
within 7 days; and Abate® is used if there is any uncertainty about contamination of water sources or 
known contamination of water sources [7].  Case reporting occurs at the village level on a monthly basis; 
case data are then aggregated within the national Guinea Worm Eradication Program and reported to 
the World Health Organization.  In settings where annual case reports are low (suggesting no 
transmission) or transmission has been interrupted, cash rewards are promoted to enhance surveillance 
activities.  
 
Input Data & Methodological Summary 
Case Definition 
A Guinea worm case is defined as an individual with Guinea worm disease. A person is counted as a case 
only once in a calendar year, i.e., when the first Guinea worm emerged from that person, although an 
individual may have more than one worm emerge at a time and/or more than one worm emerge during 
the year.  These cases are confirmed through the Guinea worm eradication program infrastructure by 
clinical exam and verification by local supervisors.  All specimens from all case-patients are sent to the 
U.S. Centers for Disease Control and Prevention (CDC) for laboratory evaluation and confirmation [7]. 
 
Input data 
Model inputs 
Geographic restrictions 
Only the following countries were identified as guinea-worm endemic as of 1990[8]: Benin, Burkina 
Faso, Cameroon, Central African Republic, Chad, Cote d’Ivoire, Ethiopia, Ghana, India, Kenya, Mali, 
Mauritania, Niger, Nigeria, Pakistan, Senegal, Sudan, South Sudan, Togo, Uganda, and Yemen[8]. Any 
country not reporting Guinea worm in 1990 is not included in the GBD model.  
Geographic restrictions by year were also implemented to account for the period post-transmission to 
reflect the accomplishments of the Guinea worm eradication campaign. Geographic restriction for 
countries that were endemic in 1990 was defined based on data reported post-interruption of 
transmission.  In the GBD analysis, Guinea worm disease was no longer modeled for the year that 
followed the last reported case (imported or indigenous) provided that the subsequent years through 
2015 also had no case reports.  To ensure that cases were attributed to burden in the country in which 
the case was detected, both indigenous and imported cases were included. For example, Kenya 
reported its last (imported) case in 2005, and as no other cases were reported through 2015, incidence 
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from 2006 onwards is zero.   For Chad, a country that had years during which no cases were reported, 
the model covers the entire period 1990-2015. 
Data sources  
1) Case data by location, by year
2) Literature review of age/sex distribution
3) Literature review for sequelae (type, duration and proportion)
Case data: Annual case data were reported by the WHO in the Weekly Epidemiological Record. For 
years or locations for which WER reports were not published, the following sources were also used to 
extract case counts: 
1) CDC’s MMWR reports
2) 1990-1999 total country reports from Hopkins et al[8]
3) India subnational estimates: India MOH report (1984-1999)
4) The Carter Center’s Guinea worm wrap-up:  disaggregation of case totals for Sudan and
South Sudan pre-2011 (independence) to ensure case totals from 1990-2010 are consistent
with current national boundaries; 2016 provisional case data.
The number of cases annually was compared to official total numbers published in WER 2016 to ensure 
accuracy of data entry.  
Subnational data 
India: Subnational data for India was obtained from the Ministry of Health for the period 1984-1999; 
cases were reported by year and state: http://www.ncdc.gov.in/index2.asp?slid=329&sublinkid=216  
Kenya: Subnational data from Kenya was requested from the MOH but not obtained. To split cases by 
subnational unit, the Carter Center Guinea Worm Wrap Up was reviewed to identify districts with 
endemic villages.  A national survey conducted 1993/1994 found cases in Turkana and West Pokot 
counties, but case totals were not reported by county. Indigenous transmission was interrupted in 1995, 
with imported cases reported until 2005. WER reports from 1999-2006 document that all imported 
cases from 1998-2005 occurred in Turkana County. All cases in Kenya are currently analyzed in GBD as 
occurring in Turkana County as we are unable to disaggregate the data.  
Accounting for possible under-reporting 
Once national eradication programs were initiated, national case searches were conducted to improve 
the accuracy of national case estimates.  These searches were designed to enumerate prevalent Guinea 
worm disease cases and identify endemic villages to direct intervention and surveillance activities.  For 
the majority of years included in the GBD analysis, the total number of Guinea worm cases reported is 
equivalent to a national census, as all cases are identified and reported.  Nevertheless, not all endemic 
countries were able to initiate full national surveillance as of 1990.  National case searches began as 
follows: India (1980); Pakistan (1987); Cameroon and Nigeria (1988); Ghana (1989); Benin, Burkina Faso, 
Central African Republic, Côte d'Ivoire and Togo (1990); Niger, Mauritania, Mali, Senegal, Uganda and 
Yemen (1991); Ethiopia and Sudan (1992); and Chad and Kenya (1993).  By 1995, all endemic countries 
had begun implementing case-containment strategies[2].   
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 The model does not account for the possibility that cases occurred in communities that were not 
included in routine surveillance or did not achieve 100% reporting coverage over time. However, any 
cases that may have been undetected would likely not have been a significant increase over annual 
totals given the comprehensive nature of Guinea worm disease surveillance activities.  Nevertheless, 
there are years for which the annual case data is inconsistent with preceding/following annual case 
totals and could not be accounted for in our model. For example, Niger reported 500 cases in 1992, 
despite reporting 32,829 cases in 1991 and 25,346 cases in 1993.  In those instances, the following data 
points were identified as outliers and excluded from analysis as follows: 
  
 
 
 
 
 
Table 1. List of reported case data outliered in the analysis to account for possible under-reporting 
Country Year Reported Cases 
Central African Republic 1996 9 
Central African Republic 1997 5 
Ethiopia 1992 303 
Kenya (Turkana County) 1990 6 
Uganda 1990 4,704 
Uganda* 1992 126,369 
Benin 1991 4,006 
Benin 1992 4,315 
Chad 1992 156 
Cote d’Ivoire 1990 1,360 
Mali 1990 884 
Mauritania 1992 1,557 
Niger  1992 500 
Senegal 1990 38 
Togo 1990 3,042 
Togo 1991 5,118 
South Sudan* 1996 116,844 
Sudan 1994 132 
*For these two data points, we do not dispute that over 100,000 cases of Guinea worm likely occurred. However, given the 
amount of missing data in the early time series for these two countries, inclusion of these resulted in implausibly high case 
predictions (over 1 million cases in Uganda in 1990 and over 1.5 million for South Sudan from 1990-1995).   
 
 
Age/Sex distribution 
Generally, the risk of Guinea worm infection varies according to sex or age-specific differences in access 
to safe drinking water. A study in Ethiopia found women were more likely to experience Guinea worm 
disease than men; in India, men experienced greater risk of infection [1].  Exposure to unsafe water 
sources varies largely on mobility patterns and type of water sources: communities in which infected 
180
water is carried in for consumption are more likely to see more Guinea worm disease in children and 
older adults [9].  Once interventions to control the spread of Guinea worm infection are implemented, 
the age and sex distribution likely changes to reflect variation in coverage and uptake of eradication 
interventions, such as larvacide of water sources and case-containment rates; age/sex case data are 
currently not available.   
The evidence base available to describe risk of infection by age is as follows: 
1) Studies from Nigeria: 
a. Adeyeba et al [10]: Guinea worm disease not common among children <1 year of age; 
increase in risk by age 
b. Kale et al [11]: More boys ages 5-9 years than girls were infected (11.9% v. 6.8%); 
Women ages 20-29 years had higher prevalence of infection than men (13.4% v. 4.7%); 
Overall, the prevalence in both men and women was highest in ages 10-14 years and 30 
years or older.   
c. Greenwood et al [12]: The mean age of male cases was 25.8 years (95% CI: 23.9, 27.7) 
and 26.9 years for females (95% CI: 23.7, 30.1).   
2) Other countries: 
a. Sudan [13]: No significant age trend among lower-endemicity villages, higher endemicity 
villages (n=4) had higher prevalence in children and older adults. This study attributes 
the difference in age trends to community-level water source.  
b. Ghana [14]: The trend in age of first infection reported was similar for males and 
females, with more females experiencing first infection between 15-19 years and males 
between 20-24 years of age. The proportion of men with Guinea worm disease was 
much higher than women among ages 25-54 years of age.  Adults >15 years of age were 
more likely to be infected than children.  
The evidence base available to describe the risk of infection by gender is as follows: 
1) Studies from Nigeria: 
a. Adeyeba et al [10]: No difference among males and female 
b. Kale et al [11]: No overall gender difference comparing total males infected to total 
females infected, although gender differences for certain age groups (see notes above). 
c. Greenwood et al [12]: Two-thirds of cases reported among 47 villages from 1971-1974 
were male.  
 
WHO Weekly Epidemiological Record (WER) age reports:  Age and sex data were reported by country for 
2009 onwards; these data capture the age distribution for Chad, Ethiopia, Ghana, Mali, and South 
Sudan.  We excluded these data as the age/sex distribution is only described for children <15 years or 
adults, which does not permit fitting an age trend across multiple categories.   
WER sex-specific data: Sex-specific differences in the burden of Guinea worm disease could reflect 
differing levels of access to eradication program interventions, in addition to risk factors associated with 
local transmission dynamics. Since the data reported from 2009-2015 are the only available data 
nationally representative, we used the overall sex difference to generate sex-specific incidence and 
prevalence, with females experiencing a slightly higher risk (53%) compared to males (47%): 
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Table 2. WHO Weekly Epidemiological Record total worm burden by gender, by year 
Year Female Male Total % Fem % Male 
2009 1699 1490 3189 53% 47% 
2010 976 821 1797 54% 46% 
2011 524 534 1058 50% 50% 
2012 273 269 542 50% 50% 
2013 79 69 148 53% 47% 
2014 63 63 126 50% 50% 
2015 9 13 22 41% 59% 
Total 3623 3259 6882 53% 47% 
 
There is limited evidence to suggest that risk varies jointly by sex and age; however, evidence for this 
modification also suggests that such age and sex specific risks may vary by endemic community within a 
given geography (in some settings, women at higher risk, in others men, but not for all age strata).  
Without additional data sources in which cases are disaggregated by age and sex, this joint relationship 
is not modeled.   
To model age-specific variation, we used data from seven studies with age-specific case data to generate 
an age-trend in a Dismod model.  We further assumed no Guinea worm disease occurred in infants less 
than 1 year of age.  
Severity splits/sequelae 
Sequelae associated with Guinea worm relate to the wound at the site of the worm’s emergence, which 
can include abscesses and chronic ulcerations. Joint and tissue damage can occur, as well as secondary 
infection in connective tissues [15].  During the worm’s emergence, which takes approximately one 
month to exit the body, the ulcer is painful and itchy [1]. The wound is subject to secondary infection 
and scarring.  Possible long-term consequences of Guinea worm infection include arthritis or other 
permanent damage to connective tissues; however, data on this is limited. In the Greenwood study, 
41.7% of all cases experienced infection at the site of emergence and the annual proportion of cases 
with definite arthritis ranged from 1.6% to 7.3% of all cases.  
While an individual experiences Guinea worm disease, they are generally unable to work and have 
limited mobility at the time prior and during emergence and in the subsequent period in which they are 
healing.  Although most worms emerge in the feet and lower legs, there are reports of worms exiting at 
other sites [15], which could cause other disability not accounted for here.   A study in Nigeria found 
that 98% of worms emerged in the lower limbs[16]. The Greenwood study also observed that 88.4% 
emerged in the lower limbs.  Therefore, for the purposes of estimating the burden of Guinea worm 
disease in the GBD, all disability associated with Guinea worm disease is attributed to lower limb 
conditions, pain and lack of mobility.  Due to limited data, we cannot account for differential disability 
based on number of worms emerging at the same time.  
The following evidence base was reviewed to determine the proportion of cases attributed to each 
sequela, as well as duration of sequelae.  
Duration of disability and type of disability: 
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Studies from Nigeria: 
1) Adeyeba et al [10]: 93.4% incapacitated for an average of 26 days 
2) Smith et al [17]: Average disability duration 12.7 weeks; 58% unable to leave the home for a 
mean duration of 4.2 weeks; duration of disability greater among those older than 50 years 
compared to those younger than 50 years 
3) Okoye et al [16]: 21% of cases were totally incapacitated due to their infection (not permanently 
disabled) 
4) Kate et al [11]: A survey of 17 villages from 1971-1975 found that duration of disability was 
approximately 100 days 
5) Greenwood et al [12]: Weekly visits to 47 villages from 1971-1974 reported mean duration of 
illness ranging from 4.2 weeks to 7.2 weeks. 17.4% of cases had an active infection which 
persisted for 10 weeks or more.  
Other countries: 
6) Benin [18]: From two villages in highly endemic areas, estimated that 39-59 days of disability 
experienced after worm emergence. 
7) Ghana [19]: 28.2% experienced pain 12-18 months post emergence; 5% unable to carry out at 
least one daily activity, 0.5% permanently impaired (ligament damage to thumb) 
8) Ghana [14]: Complete disability experienced among males with Guinea worm disease lasted 
approximately 5 weeks among those untreated. Among cases provided supportive care (wound 
management), the duration of disability was 2.5 weeks.  
For all cases, we assume each experiences pain and disfigurement (level 2), and musculoskeletal 
problems lower limb (moderate) for a period of one month, followed by two months of pain and 
disfigurement (mild).  We then assume that 30% of all cases will then experience disfigurement level 1 
with itch/pain for an additional 9 months (approximately a year of disability) to account for longer-term 
disability associated with recovery.    
Table 3. Sequela associated with Guinea worm disease in Global Burden of Disease study 
Sequela Lay description DW (95% CI) 
Disfigurement, 
level 2, with 
itch/pain 
Has a visible physical deformity that is sore and itchy. Other 
people stare and comment, which causes the person to worry. 
The person has trouble sleeping and concentrating. 
0.188 
(0.125-0.267) 
Disfigurement, 
level 1, with 
itch/pain 
Has a slight, visible physical deformity that is sometimes sore or 
itchy. Others notice the deformity, which causes some worry and 
discomfort. 
0.027 
(0.015-0.042) 
Musculoskeletal 
problems, 
lower limbs, 
moderate 
Has moderate pain in the leg, which makes the person limp, and 
causes some difficulty walking, standing, lifting and carrying 
heavy things, getting up and down and sleeping. 
0.079 
(0.054-0.11) 
 
Modeling strategy 
Total incidence 
183
The incidence of Guinea worm disease is modeled in GBD using two approaches: for years and locations 
for which case data were reported, 1,000 draws of incidence were estimated using a beta distribution of 
cases and total population minus cases.  For years and locations for which case data were missing 
(largely the early 1990s) a Poisson regression of all case data was implemented per country, using the 
total population as the offset. The predicted incidence and standard error was used to generate a 
random distribution of 1,000 incidence draws. Incidence is multiplied by duration of sequelae to 
calculate prevalence.  Country-level incidence predictions are shown in the following figures.  
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Figure 1. Overall comparison of model versus reported cases (excluding outliers) 
Sex-specific incidence 
To account for the proportion of cases in females compared to males (53% to 47%), the incidence draws 
were multiplied by the sex proportion and the total population (to estimate number of cases by sex), 
then divided by the sex-specific total population for that year to calculate sex-specific incidence.   
Age-specific incidence 
In order to generate age-specific incidence, a literature search was conducted to identify national and 
subnational data sources in which age-specific prevalence was reported. The only nationally 
representative data available were WER reports from 2009 onwards; however, age was only reported as 
less than 15 years of age or older than 15 years of age. In order to generate a trend over the life course, 
eight subnational data sources were identified. The prevalence of guinea worm disease was extracted by 
age category reported in the original paper. An age trend was then fit using DisMod 2.0, with the 
following model settings: 
Age mesh points: 0 0.01 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 100 
Drill year: 2000; Drill location: Global; no birth prevalence; 30 year time window 
The age data were used to generate one single age trend that we assumed applied to all locations, 
and all estimation periods from 1990-2016.  
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Figure 2. Age-specific prevalence model generated by DisMod 
 
  
To apply this age prevalence curve to the sex-split incidence draws, 1,000 draws of output were 
downloaded from DisMod and applied to the incidence data as follows: 
j indexes the age strata 
i indexes the draw (1 to 1,000) 
sex cases draw is the total number of cases for the sex stratum (all ages) 
𝑎𝑔𝑒 𝑐𝑎𝑠𝑒𝑠𝑗 =  𝐷𝑖𝑠𝑀𝑜𝑑 𝐷𝑟𝑎𝑤𝑖,𝑗 ∗ 𝑎𝑔𝑒 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛𝑗 
𝑎𝑔𝑒 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑑𝑟𝑎𝑤𝑖 =
𝑎𝑔𝑒 𝑐𝑎𝑠𝑒𝑠𝑗 (
𝑠𝑒𝑥 𝑐𝑎𝑠𝑒𝑠 𝑑𝑟𝑎𝑤𝑖
𝑡𝑜𝑡𝑎𝑙 𝑐𝑎𝑠𝑒𝑠 )
𝑎𝑔𝑒 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛𝑗
  
 
 
Under the assumption that Guinea worm disease occurs approximately 1 year post-infection, incidence 
among children aged less than one year was set to zero.  
Sequelae splits 
Prevalence of the sequelae listed in Table 3 was calculated by multiplying the age and sex-specific 
incidence draw by the duration of the health state (in years). 
1) Guinea worm pain associated with worm emergence (Level 2): all cases, 1 month  
2) Guinea worm pain associated with worm emergence (Level 1): all cases, 2 months plus 30% of 
cases for an additional 9 months 
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3) Lower limb musculoskeletal problems: all cases, 1 month  
Estimates were produced for 1990, 1995, 2000, 2005, 2010, and 2016. 
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 Other neglected tropical diseases 
In addition to the neglected tropical diseases described above, there are many diverse types of neglected 
tropical diseases, which are encompassed by the following ICD 10 codes: A68-A68.9, A69.2-A69.5, A75-
A75.9, A77-A79.9, A92-A94.0, A96-A96.9, A98-A98.8, B58, B59-B60.8, B68-B68.9, B70-B72.0, B74.3-B75, 
B78-B78.9, B80-B81.8, B83-B83.8, P37.1. 
Because these neglected tropical diseases are diverse in their underlying causes and risk factors as well as 
in their associated health outcomes, modelling them together in a DisMod-MR model would not produce 
reliable estimates of prevalence or excess mortality. Instead, we calculated the YLDs caused by neglected 
tropical diseases directly using a YLD/YLL ratio.  
We calculated the ratio of YLDs to YLLs across the specified neglected tropical diseases for which nonfatal 
outcomes were modelled, using YLL estimates from the GBD 2015 cause of death (CoD) analysis. We then 
multiplied this YLD/YLL ratio by the YLL estimates for other neglected tropical diseases from the GBD 2015 
CoD analysis, providing us with an estimate of the YLDs associated with other neglected tropical diseases. 
 
Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modelling strategy from GBD 2015 to GBD 2016. 
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 Maternal Disorders 
1) Abortion, ectopic pregnancy, and miscarriage; 2) Obstructed labor and uterine 
rupture; 3) Maternal hemorrhage; 4) Maternal sepsis and other maternal infections; 5) 
Maternal hypertensive disorders; 6) Other maternal disorders 
 
Flowchart 
Inpatient hospital 
data
Nonfatal 
database
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(incidence only 
models)
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(per live birth) by 
location/year/age
Comorbidity 
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Comorbidity 
adjusted 
YLDs
DALYs
Input data
Process
Results
Database
Disability weights
Nonfatal
Burden estimation
Cause of death
Covariates
Claims data – 
inpatient visits
A/M covariates
Study: elective only, ectopic excl, lit, 
not repr,
Country: Abort legality, ANC4, Modern 
contraception prevalence
All data extracted 
with live births as 
denominaator
Apply standard 
duration and 
severity splits
Disability weights 
for each sequela
Unadjusted 
YLD by 
sequela
Literature review
Adjustment from 
primary code to all 
code based on 
Claims data
Adjusted 
inpatient data  
Meta-analyses on sequela severity distribution and symptom duration:
A/E/M: 3 days (2-4), O&UR: 5 days (3-7), Mild Hem: 7 days (4-10), Severe 
Hem: 14 days (10-18), Sep: 7 days (5-10), Inf: 30 days (15-45), Other HDoP: 
3 months (2-4), Severe Preeclam: 7 days (5-10), Eclam: 1 day (0.5-2)
Claims data – 
outpatient visits
Abbreviations
A/M: Abortion and miscarriage; Ect Preg: Ectopic pregnancy; O&UR: Obstructed labor and uterine rupture; Hem: Maternal hemorrhage; Sep: Maternal sepsis; Inf: Other maternal infections; HDoP: Maternal hypertensive disorders; 
Eclam: Eclampsia; Sev pre-eclam: Severe pre-eclampsia; ASFR: Age-specific fertility rate; Stunting <5: Stunting (proportion <2SD height for age, <5 years); MS: Marketscan; ANC4: coverage of 4 visits of antenatal care; SDI: Socio-
Demographic Index; lit: Literature data; inpt: Inpatient data; not repr: Not representative; LN: Natural log; TFR: Total fertility rate; LDI: Lag-distributed income per capita; SBA: Skilled birth attendance (proportion), IFD: In facility 
delivery
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only 
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Input data and methodological summary 
 
Case definition 
Maternal disorders are those complications occurring during pregnancy, childbirth, and the postpartum 
period. Seven different statistical models were completed for GBD 2016. These included 1) abortion, 
ectopic pregnancy, miscarriage, 2) obstructed labor and uterine rupture, 3) maternal hemorrhage 
(including placental disorders), 4) maternal sepsis, 5) other maternal infections, 6) hypertensive disorders 
of pregnancy, 7) eclampsia. Other direct maternal disorders were estimated using a YLD-to-YLL ratio 
approach used for multiple different GBD causes. Late maternal death and indirect maternal disorders, 
including HIV-related maternal death, were not assigned any disability as the disability associated with 
them was assumed to be included in estimates for the underlying conditions. ICD-9 and ICD-10 codes for 
each of the statistical models are contained in the table below.  
Table 1. ICD codes for maternal disorders 
International classification of diseases codes for maternal disorders in GBD 2015 non-fatal analysis 
Model ICD10 code ICD9 code 
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Abortion, miscarriage O01-O08, O36.4 631, 634-639 
Ectopic pregnancy O00 633-633.91 
Maternal hemorrhage 
O20, O43.2, O44-
O46, O62.2, O67, 
O72 
640-641, 661.0, 666 
Eclampsia O15 642.6 
Hypertensive disorders of pregnancy O11-O16 
642.3, 642.4, 642.5, 642.6, 642.7, 
642.9 
Severe Pre-eclampsia O14.1-O14.13 642.5-642.54 
Obstructed labor and uterine rupture 
O64-O66, O71, 
O83 
659-660, 662, 665, 669.5, 669.6 
Other maternal infections 
O23, O41, O75.2-
3, O86, O91 
646.5, 646.6, 659.2, 672.0, 674.1, 
674.2, 674.3, 675 
Maternal sepsis O85 659.3, 670 
Input data 
Systematic literature reviews were completed for GBD 2010, GBD 2013 and GBD 2015. These were 
updated on August 31st 2016 using the combined search string below. In addition, we searched ministry 
of health websites for pregnancy complication data and used from Confidential Enquiry and other sources 
used in our maternal mortality analyses when they presented data on pregnancy complications. We also 
performed snowball searches for abortion reporting and surveillance data systems, finding multiple such 
systems throughout high income countries and several locations in Central and Eastern Europe. Inpatient 
and outpatient data were used, as was claims data from MarketScan in the United States. This data was 
extracted and processed as described in the section on hospital data, including use of primary-to-any 
inpatient ratio to correct for under-reporting of pregnancy complications in hospital datasets that rely 
only on primary discharge codes. All data was extracted in standard fashion, uploaded and stored on a 
centralized SQL database. The final dataset contents for each of the models is shown below as well. 
Maternal Disorders 
(   (    ( "Postpartum Hemorrhage" OR "Uterine Hemorrhage"  ) OR   ( maternal[Title/Abstract] OR 
pregnant[Title/Abstract] OR pregnancy[Title/Abstract] OR mothers )   AND ( haemorrhag*[Title/Abstract] 
OR hemorrhag*[Title/Abstract] )   NOT "case report"[All fields]   )   AND ( 2015/04/30[PDat] : 
2016/12/31[PDat] ) AND humans[MeSH Terms]  )   OR  (  (  ( "induced abortion" OR "Therapeutic 
abortion"  OR "legal Abortion" OR "medical abortion" OR "miscarriage"  OR  "Abortion, Induced"[Mesh] 
OR "Abortion, Therapeutic"[Mesh]  OR "Abortion, Legal"[Mesh]  OR "ectopic Pregnancy"  )  NOT (  "case 
report"[Title/Abstract] OR "birth defect"[Title/Abstract] OR congenital[Title/Abstract]  )  )  AND (  
2015/04/30[PDat] : 2016/12/31[PDat]  ) AND humans[MeSH Terms] )   OR    (    (  "obstructed labour" OR 
"obstructed labor" OR "labour dystocia" OR "labor dystocia" OR dystocia OR "cephalopelvic 
disproportion"  OR "cephalo-pelvic disproportion" ) AND (   2015/03/15[PDAT] : 2016/12/31[PDAT]   ) 
AND (Humans[MeSH Terms])  )   OR   (    (  (   "obstetric fistula" OR "vesicovaginal fistula"  ) OR 
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"rectovaginal fistula"  ) AND (   2015/03/15[PDAT] : 2016/12/31[PDAT]   ) AND humans[MeSH Terms]    )  
OR      (   (  "Puerperal Infection"[Mesh] OR  "Puerperal Infection" OR   (   (maternal[Title/Abstract] OR 
pregnant[Title/Abstract] OR pregnancy[Title/Abstract]   )   AND (   Sepsis OR infection[Title/Abstract]    )   )  
)  NOT "case report" AND (    2015/07/31[PDat] : 2016/12/31[PDat]      ) AND humans[MeSH Terms]  )    OR 
(  (Pre-Eclampsia[Title/Abstract] OR preeclampsia[Title/Abstract] OR Eclampsia[Title/Abstract] OR Pre-
Eclampsia[Mesh] OR Eclampsia[Mesh] OR "Hypertension, Pregnancy-Induced"[Mesh] OR "pregnancy 
induced hypertension"[Title/Abstract] OR "gestational hypertension"[Title/Abstract] OR "Hypertensive 
disorders of pregnancy"[Title/Abstract]) NOT ("case report" OR "kidney don*"[Title/Abstract] OR 
polymorphism*[Title/Abstract] OR endotheli*[Title/Abstract]) AND ( 2015/07/31[PDat] : 
2016/12/31[PDat] ) AND "humans"[MeSH Terms]   ) 2519 hits, 22 new sources extracted.  
Incidence 
Studies 22 
Countries/subnationals 21/3 
GBD world regions 10 
Modeling strategy  
We estimated the incidence ratio of each category of pregnancy complications using DisMod-MR 2.1, 
with the exception of other maternal disorders which we estimated using a YLD-to-YLL ratio approach 
used in multiple causes across the GBD 2016. The reason is that most literature and surveillance data is 
expressed in terms of number of events per live birth rather than per population. Hospital and claims 
data, which was centrally processed for all GBD 2016 causes to have population as the denominator, was 
transformed to have live births as the denominator by dividing by age-specific fertility rate (ASFR; live 
births per population).  
We used the datasets described above to estimate incidence ratio for each age-sex-location-year in the 
GBD 2016 location hierarchy using DisMod-MR 2.1. A number of study-level covariates were used to 
crosswalk from non-standard sub-populations or case definitions. For most conditions, Marketscan claims 
data or literature data were considered to be the closest approximation of the true incidence of 
complications so were identified as the reference category. A series of country covariates were then 
chosen to help drive the magnitude of estimates in areas of sparse or absent data. As fertility rate is 
partially related to the number of cases of a given complication, the natural log of total fertility rate (TFR) 
from our demographics analysis was used in most of the models. No specific age or slope priors were 
used. All models were run with a time window of five years. The quantitative results of study-level and 
country-level covariates for each condition are shown below.  
Abortion and miscarriage 
Study-level covariate Parameter 
Location 
level 
beta Exponentiated beta 
Not representative Incidence Global 
-1.2e-03 (-2.6e-03 — 
-2.6e-04) 
1.00 (1.00 — 1.00) 
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Hospital Inpatient Incidence Global 
-7.9e-04 (-2.4e-03 — 
-3.8e-04) 
1.00 (1.00 — 1.00) 
Elective pregnancy 
terminations only  
Incidence Global 
-9.7e-03 (-0.054 — -
3.8e-05) 
0.99 (0.95 — 1.00) 
Marketscan, year 2000 Incidence Global -1 (-1.99 — -0.03) 0.37 (0.14 — 0.97) 
Marketscan, year 2010 Incidence Global -1.02 (-2 — 0) 0.36 (0.14 — 1.00) 
Marketscan, year 2012 Incidence Global -1.01 (-2 — -0.051) 0.36 (0.14 — 0.95) 
Country-level covariate Parameter 
Location 
level 
beta Exponentiated beta 
Legality of Abortion Incidence Global 
0.020 (0.019 — 
0.021) 
1.02 (1.02 — 1.02) 
Antenatal Care (4 visits) 
Coverage (proportion) 
Incidence Global 
-3.8e-04 (-1.6e-03 — 
-6.0e-06) 
1.00 (1.00 — 1.00) 
Contraception (Modern) 
Prevalence (proportion) 
Incidence Global -0.53 (-0.6 — -0.33) 0.59 (0.55 — 0.72) 
Ectopic pregnancy 
Study-level covariate Parameter 
Location 
level 
beta Exponentiated beta 
Hospital Inpatient Incidence Global 
2.50 (2.50 — 2.50) 
12.18 (12.17 — 
12.18) 
Country-level covariate Parameter 
Location 
level 
beta Exponentiated beta 
Legality of Abortion Incidence Global 
-0.012 (-0.013 — -
0.011) 
0.99 (0.99 — 0.99) 
Maternal hemorrhage 
Study-level covariate Parameter 
Location 
level 
beta Exponentiated beta 
Postpartum hemorrhage 
only 
Incidence Global 
-6.6e-03 (-0.022 — -
3.9 e-04) 
0.99 (0.98 — 1.00) 
Hospital Inpatient Incidence Global 1.00 (1.00 — 1.00) 2.72 (2.71 — 2.72) 
Antepartum 
hemorrhage only 
Incidence Global -0.63 (-0.99 — -0.28) 0.53 (0.37 — 0.76) 
Severe hemorrhage 
excluded 
Incidence Global 
-0.027 (-0.1 — -7.3e-
04) 
0.97 (0.90 — 1.00) 
Severe hemorrhage only Incidence Global 
-0.12 (-0.28 — -7.9e-
03) 
0.89 (0.76 — 0.99) 
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Country-level covariate Parameter 
Location 
level 
beta Exponentiated beta 
Skilled Birth Attendance 
(proportion) 
Incidence Global 
-3.5e-03 (-0.013 — -
3.3e-04) 
1.00 (0.99 — 1.00) 
Sociodemographic Index Incidence Global 
1.8e-03 (5.1e-05 — 
8.3e-03) 
1.00 (1.00 — 1.01) 
Total Fertility Rate Incidence Global -0.1 (-0.11 — -0.1) 0.90 (0.90 — 0.90) 
Hypertensive disorders of pregnancy 
Study-level covariate Parameter 
Location 
level 
beta Exponentiated beta 
Hospital Inpatient Incidence Global 0.40 (0.37 — 0.46) 1.50 (1.45 — 1.58) 
Literature Incidence Global -0.3 (-0.3 — -0.28) 0.74 (0.74 — 0.76) 
Diagnostic criteria for 
severe cases 
Incidence Global -1.84 (-1.88 — -1.78) 0.16 (0.15 — 0.17) 
Includes only 
preeclampsia data (not 
other gestational 
hypertension 
Incidence Global -1.16 (-1.17 — -1.13) 0.31 (0.31 — 0.32) 
Country-level covariate Parameter 
Location 
level 
beta Exponentiated beta 
Antenatal Care (4 visits) 
Coverage (proportion) 
Incidence Global 
-1.5e-04 (-1.5e-04 — 
-1.3e-05) 
1.00 (1.00 — 1.00) 
LDI (I$ per capita) Incidence Global 
-3.6e-0.5(-1.4e-04 
— -9.9e-06) 
1.00 (1.00 — 1.00) 
Total Fertility Rate Incidence Global -1.5 (-1.5 — -1.5) 0.22 (0.22 — 0.22) 
Eclampsia 
Study-level covariate Parameter 
Location 
level 
beta Exponentiated beta 
Hospital Inpatient Incidence Global 1.99 (1.85 — 2.00) 7.28 (6.39 — 7.39) 
Literature Incidence Global -1.34 (-1.54 — -1.25) 0.26 (0.21 — 0.29) 
Country-level covariate Parameter Location 
level 
beta Exponentiated beta 
201
Antenatal Care (4 visits) 
Coverage (proportion) 
Incidence Global -4.11 (-6.08 — -3.14 2.3e-03 — 0.043) 
Total Fertility Rate Incidence Global -0.98 (-1.06 — -0.94) 0.37 (0.35 — 0.39) 
Severe pre-eclampsia 
Study-level covariate Parameter 
Location 
level 
beta Exponentiated beta 
Hospital Inpatient Incidence Global 2.00 (2.00 — 2.00) 7.39 (7.38 — 7.39) 
Country-level covariate Parameter Location 
level 
beta Exponentiated beta 
Antenatal Care (4 visits) 
Coverage (proportion) 
Incidence Global 
-1.6e-03 (-5.2e-03 – 
-5.3e-05) 
1.00 (0.99 — 1.00) 
Total Fertility Rate Incidence Global -1.5 (-1.5 — -1.49) 0.22 (0.22 — 0.23) 
LDI (I$ per capita) Incidence Global 
-3.3e-04(-1.6e-03 – -
1.8e-05) 
1.00 (1.00 — 1.00) 
Obstructed labor and uterine rupture 
Study-level covariate Parameter 
Location 
level 
beta Exponentiated beta 
Under Reported Incidence Global 
-8.8e-03 (-0.04 - -
1.8e-04)  
0.99 (0.96 — 1.00) 
Hospital Inpatient Incidence Global 2.00 (2.00 — 2.00) 7.38 (7.37 — 7.39) 
Marketscan, year 2000 Incidence Global 1.99 (1.95 — 2.00) 7.29 (7.04 — 7.39) 
Marketscan, year 2010 Incidence Global 1.88 (1.80 — 1.95) 6.52 (6.05 — 7.02) 
Marketscan, year 2012 Incidence Global 1.85 (1.77 — 1.91) 6.33 (5.88 — 6.77) 
Country-level covariate Parameter Location 
level 
beta Exponentiated beta 
Stunting (proportion 
<2SD height for age, <5 
years) 
Incidence Global 
0.11 (0.0061 — 
0.36) 
1.11 (1.01 — 1.44) 
Skilled Birth Attendance 
(proportion) 
Incidence Global 
-0.015 (-0.059 — -
5.8e-04) 
0.99 (0.94 — 1.00) 
Maternal sepsis 
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Study-level covariate Parameter 
Location
level 
beta Exponentiated beta 
Hospital Inpatient Incidence Global 3.00 (3.00 — 3.00) 
20.08 (20.07 — 
20.09) 
Diagnostic criteria for 
severe cases 
Incidence Global 
-7.1e-03 (-0.026 - -
4.7e-04) 
0.99 (0.97 — 1.00) 
Marketscan, year 2000 Incidence Global 1.99 (1.97 — 2.00) 7.31 (7.14 — 7.39) 
Marketscan, year 2010 Incidence Global 1.99 (1.96 — 2.00) 7.32 (7.12 — 7.39) 
Marketscan, year 2012 Incidence Global 1.98 (1.93 — 2.00) 7.21 (6.88 — 7.38) 
Other maternal infections: 
Study-level covariate Parameter 
Location 
level 
beta Exponentiated beta 
Hospital Inpatient Incidence Global 0.50 (0.50 — 0.50) 1.65 (1.65 — 1.65) 
Under Reported Incidence Global 
-0.52 (-1.18 — -
0.046) 
0.59 (0.31 — 0.96) 
Marketscan, year 2000 Incidence Global 1.66 (1.43 — 1.79) 5.25 (4.16 — 5.99) 
Marketscan, year 2010 Incidence Global 1.85 (1.62 — 1.98) 6.37 (5.07 — 7.21) 
Marketscan, year 2012 Incidence Global 1.91 (1.68 — 2.00) 6.72 (5.34 — 7.37) 
Country-level covariate Parameter Location 
level 
beta Exponentiated beta 
Socio-demographic 
Index 
Incidence Global 
-7.4e-03 (-0.024 - -
1.7e-04) 
0.99 (0.98 — 1.00) 
Severity splits 
After completion of DisMod-MR 2.1 models, all age-specific ratios were then converted to population 
rates by multiplying by ASFR. Maternal hemorrhage was split between moderate (500-<1000ml blood 
loss) and severe (>1000 blood loss) on the basis of a meta-analysis of 19 studies1. Data on the average 
duration of acute symptoms were not available so, after consultation with clinician collaborators, we 
assigned a duration of 7 days (+/-3) for moderate hemorrhage and 14 days (+/- 4) for severe hemorrhage. 
The total maternal hemorrhage incidence served as input to the causal attribution process of the overall 
anemia envelope, which is described separately. This is a change from GBD 2013, when only the 
prevalence of maternal hemorrhage was considered in anemia causal attribution which was inappropriate 
because the disability from hemorrhage-induced anemia is longer-lasting than the acute hemorrhagic 
event, a situation that was not previously reflected. Acute disability was calculated assuming incident 
cases of abortion, ectopic pregnancy, and miscarriage persist for an average of 3 days (+/-1) and 
obstructed labor was assigned a duration of 5 days (+/-2). Again, these determinations were based on 
clinical expert determination as we could not identify any data to inform this.   
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Hypertensive disorders of pregnancy (HDoP) and maternal sepsis and other maternal infections were 
estimated in two models each. HDoP YLD estimates included severe preeclampsia and other HDoP which 
were derived from two models of total HDoP and severe pre-eclampsia. The duration of severe 
preeclampsia was assigned to be 7 days (+/-2) and other HDoP was assigned a duration of 3 months (2-4). 
Eclampsia was a separate model, assigned a duration of 1 day (+/-1). A large number of those with severe 
preeclampsia go on to have long term sequelae of the condition2, as do those with eclampsia3,4, both of 
which were included in the estimates of HDoP and were a bulk of the YLD for those conditions. Maternal 
sepsis was assigned a duration of 5 days (+/-2) and, based on the same data identified in our review of 
pelvic inflammatory disease (PID; described separately), a proportion of incident cases were estimated to 
continue on to have secondary infertility due to maternal sepsis. Other maternal infections were assigned 
a wide potential duration of 15 to 45 days (mean 30).  
Uncertainty and model selection 
For all maternal disorders, uncertainty bounds include uncertainty due to input data, crosswalks from 
non-reference definitions, uncertainty in numerical solutions (posteriors) of each DisMod-MR 2.1 model, 
duration of symptoms, and proportion of all persons with each type of symptom.  
In consultation with GBD researchers and collaborators, final models were selected on a combination of 
qualitative and quantitative goodness of fit to input data, plausibility of geographic and temporal trends, 
consistency of age pattern, and, when available, comparison with other published studies on the 
epidemiology of pregnancy complications. Directionality, magnitude, and plausibility of study-level and 
country-level covariates was also considered in the process of model development. Of note, due to the 
nature of statistical modeling, final results do not always cover the values reported in input data. 
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Obstetric fistula 
Flowchart 
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Case Definition 
Obstetric fistula is a severe long-term complication of prolonged obstructed labor in which a fistula 
(hole) develops between the birth canal and the bladder and/or rectum. The ICD codes include: 
Input data 
Model Inputs 
A systematic review was conducted for GBD 2015. The PubMed search terms were: (('obstetric 
fistula'[All Fields] OR 'vesicovaginal fistula'[All Fields]) OR 'rectovaginal fistula'[All Fields]) AND 
('2013'[PDAT] : '2015'[PDAT]) AND 'humans'[MeSH Terms]. 
The exclusion criteria were: 
27. Studies that did not provide primary data on epidemiological parameters, e.g.
commentaries
28. Case series
29. Reviews
The table below shows the number of literature studies included in GBD2015, as well as the number of 
countries or subnational units and GBD world regions represented. 
Prevalence Incidence Mortality risk 
Studies 8 3 - 
Countries/subnationals 8 3 - 
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GBD world regions 3 1 - 
In addition to using data from published studies, we also included data from UNFPA reports, and 
nationally representative Demographic and Health Surveys and Multiple Indicator Cluster Surveys. 
Severity Splits 
The following severity distributions were assigned based a meta-analysis of published studies1-4 and 
Pakistan Demographic and Health survey (2006-2007): vesicovaginal fistula (90.8%, 95% CI: 85.0 to 
95.4%); rectovaginal fistula (9.2%, 95% CI: 4.6 to 15.0%. The lay descriptions and disability weights for 
severity levels derived from the GBD Disability Weights study are shown below. 
Severity level Lay description DW (95% CI) 
vesicovaginal 
fistula 
has an abnormal opening between the bladder and the vagina, 
which makes her unable to control urinating. The woman is 
anxious and depressed. 
0.342 
(0.227-0.478) 
rectovaginal 
fistula 
has an abnormal opening between her vagina and rectum 
causing flatulence and feces to escape through the vagina. The 
person gets infections in her vagina, and has pain when 
urinating. 
0.501 
(0.339-0.657) 
Modeling Strategy 
Obstetric fistula was modeled using DisMod-MR 2.1. We used neonatal mortality rate as a country-level 
covariate. We also included a study-level covariate indicating whether it was a hospital-based or 
community-based study. Remission was calculated, using the cure data from 11 Demographic and 
Health surveys, by dividing the number of cured obstetric fistula cases by total person years of follow up 
of all cases (cured, uncured and untreated). The person year of follow up for uncured or untreated 
fistula cases was calculated as the time interval (in year) between the last birth and the date of 
interview. For cured cases, we assumed that the person year of follow up was half the time interval (in 
year) between the last birth and the date of interview. 
Betas and exponentiated values (which can be interpreted as an odds ratio) are shown in the table 
below: 
Covariate Parameter Beta (95% CI) Exponentiated beta 
(95% CI) 
Neonatal mortality rate Prevalence 1.96 (1.85 — 2.00) 7.09 (6.35 — 7.38) 
Neonatal mortality rate Incidence 0.54 (0.026 — 1.14) 1.72 (1.03 — 3.13) 
Neonatal mortality rate Remission -0.-73 (-0.99 — -0.28) 0.48 (0.37 — 0.76) 
Hospital data Prevalence -1.75 (-1.99 — -1.27) 0.17 (0.14 — 0.28) 
Hospital data Incidence -0.65 (-1.86 — 0.85) 0.52 (0.16 — 2.35) 
References 
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Preterm Birth Complications  
Flowchart 
Input data and methodological summary 
Case definition  
Preterm birth is defined as live birth before 37 completed weeks of gestation. In our analysis, we further 
break down this cause into three sub-categories of preterm birth, based on gestational age: extremely 
preterm (<28 weeks), very preterm (28 to <32 weeks), and moderate to late preterm (32 to <37 weeks). 
These categories are based on the World Health Organization (WHO) definition of preterm birth.1  
Input data 
Model inputs 
A systematic review was completed for GBD 2010, and for GBD 2013 and GBD 2016, a review was 
conducted on literature published since the previous addition. The PubMed database was searched using 
the following search string: ((("Infant, Premature"[Mesh] OR ("infant"[All Fields] AND "premature"[All Fields]) OR 
"premature infant"[All Fields] OR ("preterm"[All Fields] AND "infant"[All Fields]) OR "preterm infant"[All Fields] OR 
("infant, newborn"[MeSH Terms] OR ("infant"[All Fields] AND "newborn"[All Fields]) OR "newborn infant"[All Fields] 
OR ("newborn"[All Fields] AND "infant"[All Fields])) AND (premature[All Fields] OR preterm[All Fields]) OR 
"premature birth"[MeSH Terms] OR ("premature"[All Fields] AND "birth"[All Fields]) OR "premature birth"[All Fields] 
OR ("preterm"[All Fields] AND "birth"[All Fields]) OR "preterm birth"[All Fields]) ((("Infant, Premature"[Mesh] OR 
("infant"[All Fields] AND "premature"[All Fields]) OR "premature infant"[All Fields] OR ("preterm"[All Fields] AND 
"infant"[All Fields]) OR "preterm infant"[All Fields] OR ("infant, newborn"[MeSH Terms] OR ("infant"[All Fields] AND 
"newborn"[All Fields]) OR "newborn infant"[All Fields] OR ("newborn"[All Fields] AND "infant"[All Fields])) AND 
(premature[All Fields] OR preterm[All Fields]) OR "premature birth"[MeSH Terms] OR ("premature"[All Fields] AND 
"birth"[All Fields]) OR "premature birth"[All Fields] OR ("preterm"[All Fields] AND "birth"[All Fields]) OR "preterm 
birth"[All Fields]) AND ("2012"[PDAT] : "3000"[PDAT]) AND "humans"[MeSH Terms].  
The exclusion criteria were: 
1 http://www.who.int/mediacentre/factsheets/fs363/en/ 
208
1. Studies that did not provide primary data on epidemiological parameters, e.g., a commentary piece 
2. Non-representative studies (e.g., only high-risk pregnancies) 
3. Reviews 
The table below shows the number of literature studies included in the estimates for GBD 2016, as well as the 
number of countries or subnational units and GBD world regions represented.  
Table 1a-c. Literature Data geographies 
Preterm Birth <28 Weeks 
 Birth prevalence Case fatality   
Studies 219 125 
Geographic locations 281 99 
GBD world regions 16 18 
 
Preterm Birth 28-<32 Weeks 
 Birth prevalence Case fatality   
Studies 227 117 
Geographic locations 290 97 
GBD world regions 18 17 
 
Preterm Birth 32-<37 Weeks 
 Birth prevalence Case fatality   
Studies 86 93 
Geographic locations 244 82 
GBD world regions 14 10 
 
In addition to literature data, data from US claims data for 2010 and 2012 by US state and hospital data from 98 
additional national or subnational locations were considered to inform the estimates of the three gestational age 
preterm categories. Only inpatient data was included from these datasets, as we believed it would be more 
representative of the true prevalence of preterm birth than outpatient data: preterm infants in the countries from 
which hospital data was available are almost sure to be admitted to the hospital, whereas outpatient data is more 
likely to capture repeated visits by the same child as they grow.  
In accordance with methodology from other global estimates of preterm birth2, we have outliered sources reporting 
preterm births (<37 weeks) as less than 3% of all births, as this was determined to be biologically implausible.  
 
Severity splits and disability weights 
 
The basis of the GBD disability weight (DW) survey assessments are lay descriptions of sequelae 
highlighting major functional consequences of symptoms. The lay descriptions and disability weights for 
2 Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller A, Narwal R, Adler A, Vera Garcia C, Rohde S, Say L, Lawn 
J. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 
for selected countries: a systematic analysis and implications. Lancet 2012; 379: 2162–72 
209
preterm birth are shown below. Further severity levels are calculated by combining several of these 
disability weights, e.g., moderate motor plus cognitive impairment with blindness. 
 
Table 2. Severity, lay description, and DWs 
Severity level Lay description 
Motor plus cognitive 
impairments, mild 
has some difficulty in moving around but is able to walk without help. The person is 
slow in learning at school. As an adult, the person has some difficulty doing complex 
or unfamiliar tasks but otherwise functions independently. 
Motor impairment, mild has some difficulty in moving around but is able to walk without help. 
Motor impairment, moderate 
has some difficulty in moving around, and difficulty in lifting and holding objects, 
dressing and sitting upright, but is able to walk without help. 
Motor impairment, severe 
is unable to move around without help, and is not able to lift or hold objects, get 
dressed or sit upright.  
Distance vision, mild 
impairment 
has some difficulty with distance vision, for example reading signs, but no other 
problems with eyesight. 
Distance vision, moderate 
impairment 
has vision problems that make it difficult to recognize faces or objects across a 
room. 
Distance vision, severe 
impairment 
has severe vision loss, which causes difficulty in daily activities, some emotional 
impact (for example worry), and some difficulty going outside the home without 
assistance. 
Distance vision blindness 
is completely blind, which causes great difficulty in some daily activities, worry and 
anxiety, and great difficulty going outside the home without assistance.  
Motor plus cognitive 
impairments, mild Combined DW 
Motor impairment with 
blindness, moderate Combined DW 
Motor impairment with 
epilepsy, moderate  Combined DW 
Motor impairment with 
blindness and epilepsy, 
moderate Combined DW 
Motor plus cognitive 
impairment with blindness, 
moderate Combined DW 
Motor plus cognitive 
impairment with epilepsy, 
moderate Combined DW 
Motor plus cognitive 
impairment with blindness 
and epilepsy, moderate Combined DW 
Motor impairment with 
blindness, severe Combined DW 
Motor impairment with 
epilepsy, severe Combined DW 
Motor impairment with 
blindness and epilepsy, 
severe Combined DW 
Motor impairment with 
blindness and epilepsy, 
severe Combined DW 
Motor plus cognitive 
impairment with epilepsy, 
severe Combined DW 
Motor plus cognitive 
impairment with blindness 
and epilepsy, severe Combined DW 
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To determine the proportion of people within each of these severity levels, one study informed 
moderate-to-severe impairment splits, and for mild impairments cases were divided equally into both 
categories.3 
Modeling strategy  
Burden from each of the gestational age categories of preterm birth (extreme, very, and moderate to 
late) is modeled separately, using similar methods.  
For a given gestational age group, an initial DisMod MR 2.2 model is run using prevalence and case 
fatality data. An initial DisMod MR 2.2 model is also run for all preterm births (<37 weeks). Prior to input 
into DisMod, case fatality ratio (CFR) data is transformed into excess mortality rate (EMR) space using the 
formula: 
𝐸𝐸𝐸𝐸𝐸𝐸 =  − ln(1 − 𝐶𝐶𝐶𝐶𝐸𝐸)28365.25  
which is analogous to the transformation of cumulative incidence to incidence rate. The denominator in 
this equation is derived from the definition of our CFR parameter, which is death in the first 28 days of 
life. The output from this first-step DisMod model is prevalence in the first two neonatal age groups. For 
this model, remission and incidence are both set to zero, as no one can be born prematurely after birth, 
and no one can cease to have been born premature after the fact. Study covariates were created for 
hospital data, US claims data, and literature sources that use non-standard gestational age categories.  
 
 
Preterm Birth <28 Weeks 
Study-level covariate Parameter Geography level beta Exponentiated beta 
Sex Prevalence 
Global 0.068 (0.047 — 
0.090) 1.07 (1.05 — 1.09) 
Hospital data Prevalence Global 0.010 (-2 — 1.98) 1.01 (0.14 — 7.24) 
Birth prevalence of 
preterm birth, 
gestational age < 
32 weeks Prevalence 
Global 
1.04 (1.01 — 1.05) 2.82 (2.76 — 2.86) 
inpatient-only 
Marketscan, year 
2010 Prevalence 
Global 
-2.18 (-3.89 — 0.95) 
 
0.11 (0.020 — 
2.58) 
inpatient-only 
Marketscan, year 
2012 Prevalence 
Global 
-1.01 (-3.95 — 1.90) 
0.36 (0.019 — 
6.71) 
Sex 
Excess 
Mortality 
Global  
0.11 (0.079 — 0.15) 
 1.12 (1.08 — 1.16) 
 
3 Hagberg et al. Acta Paediatrica 1996, 85:954-60 
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Country-level covariate Parameter beta Exponentiated beta 
Healthcare Access & Quality 
Index Prevalence -0.012 (-0.014 — -0.01) 0.99 (0.99 — 0.99) 
LDI (I$ per capita) 
Excess 
Mortality Rate -0.11 (-0.16 — -0.07) 0.90 (0.85 — 0.93) 
Healthcare Access & Quality 
Index 
Excess 
Mortality Rate 
-0.013 (-0.016 — -
0.0099) 0.99 (0.98 — 0.99) 
 
Preterm Birth 28-<32 Weeks 
Study-level covariate Parameter Geography level beta Exponentiated beta 
Sex Prevalence 
Global 0.067 (0.051 — 
0.079) 1.07 (1.05 — 1.08) 
Hospital data Prevalence 
Global  
-0.02 (-2 — 1.93) 0.98 (0.14 — 6.87) 
Birth prevalence of 
preterm birth, 
gestational age < 
32 weeks Prevalence 
Global 
0.45 (0.43 — 0.46) 1.57 (1.54 — 1.59) 
Birth prevalence of 
preterm birth, 
gestational age 28-
37 weeks Prevalence 
Global 
2.20 (2.19 — 2.22) 9.06 (8.92 — 9.21) 
inpatient-only 
Marketscan, year 
2010 Prevalence 
Global 
1.30 (0.36 — 1.97) 
 
3.65 (1.43 — 7.14) 
inpatient-only 
Marketscan, year 
2012 Prevalence 
Global - 
 
-1 (-4 — 1.99) 
 
0.37 (0.018 — 
7.32) 
Sex 
Excess 
Mortality 
Global 0.21 (0.16 — 0.27) 
 1.24 (1.17 — 1.31) 
 
Country-level covariate Parameter beta Exponentiated beta 
Healthcare Access & Quality 
Index Prevalence 
-0.0079 (-0.0097 — -
0.0065) 0.99 (0.99 — 0.99) 
LDI (I$ per capita) 
Excess 
Mortality Rate -0.66 (-0.78 — -0.59) 0.51 (0.46 — 0.56) 
Healthcare Access & Quality 
Index 
Excess 
Mortality Rate 
 
-0.0089 (-0.014 — -
0.0026) 0.99 (0.99 — 1.00) 
 
 
Preterm Birth <37 Weeks 
Study-level covariate Parameter Geography level beta Exponentiated beta 
Sex Prevalence 
Global 0.066 (0.056 — 
0.076) 1.07 (1.06 — 1.08) 
Hospital data Prevalence 
Global  
-0.013 (-2 — 1.97) 0.99 (0.14 — 7.17) 
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Birth prevalence of 
preterm birth, 
gestational age 28-
37 weeks Prevalence 
Global 
0.12 (0.11 — 0.13) 1.13 (1.12 — 1.14) 
inpatient-only 
Marketscan, year 
2010 Prevalence 
Global 
 
-0.9 (-3.6 — 1.53) 
 
 
 
 
0.41 (0.027 — 
4.60) 
 
inpatient-only 
Marketscan, year 
2012 Prevalence 
Global 
-0.99 (-3.94 — 1.96) 
 
0.37 (0.019 — 
7.13) 
 
Sex 
Excess 
Mortality 
Global 
0.13 (0.084 — 0.18) 1.14 (1.09 — 1.19) 
 
Country-level covariate Parameter beta Exponentiated beta 
Healthcare Access & Quality 
Index Prevalence 
-0.0048 (-0.0061 — -
0.0035) 1.00 (0.99 — 1.00) 
LDI (I$ per capita) 
Excess 
Mortality Rate -0.47 (-0.55 — -0.41) 0.62 (0.58 — 0.66) 
Healthcare Access & Quality 
Index 
Excess 
Mortality Rate 
-0.0051 (-0.0091 — -
0.00036) 0.99 (0.99 — 1.00) 
 
 
Using prevalence in the first two neonatal age groups, prevalence at 0-6 days, 7-27 days, and 28 days is 
calculated via interpolation. Functionally, this is birth prevalence minus all those who have died in the first 
28 days, our case fatality parameter.  
Next, using mild impairment proportion and moderate-to-severe impairment proportion data, we ran 
either mixed-effect hierarchical regressions or meta-analyses to generate country-year-sex-specific 
estimates of both parameters (we used a meta-analysis when there was not sufficient data to support a 
regression model). We then calculated the birth prevalence of each severity level. As mild impairment 
and moderate-severe impairment were calculated separately, it was possible that they could sum to a 
value greater than one.  To address this, we checked the sum of the two values in any of the 1,000 
iterations of the uncertainty analysis, and if greater than 0.9, proportionately rescaled both estimates to 
sum to 0.9 in any of the 1,000 iterations of the uncertainty analysis (we picked 0.9 rather than 1 to allow 
at least some probability of a child having no impairment).  We then proceeded with the calculation of 
the birth prevalence of impairment:  
Mild impairment birth prevalence = prevalence at 28 days * proportion mild impairment 
Moderate/severe impairment birth prevalence = prevalence at 28 days * proportion mod-severe 
impairment 
For moderate/severe impairment, results of these latter calculations were then combined with excess 
mortality estimates derived from the standard mortality ratios (SMR) of cerebral palsy and used as inputs 
into a second DisMod MR 2.2 model. For this model, remission and incidence were also set to zero. For 
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mild impairment, we assumed no excess mortality and no remission, and as such simply applied the birth 
prevalence of mild impairment to every age group. 
No other significant changes were made to the modeling strategy for GBD 2016.  
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 Neonatal encephalopathy due to birth asphyxia and birth trauma 
  
Flowchart 
 
Input data and methodological summary 
 
Case definition 
Neonatal encephalopathy (NE) due to birth asphyxia and birth trauma, also called hypoxic-ischemic 
encephalopathy, is defined as injury to the brain in the first few moments or days of life in an infant born 
at term. NE has multiple etiologies, and is defined more by its symptoms – abnormal neurological 
function, including reduced level of consciousness, seizures, depression of tone and reflexes, or difficulty 
maintaining respiration – than its origin. NE can occur when an infant is deprived of oxygen during 
delivery or sustains physical trauma to the head, among other causes.  
Input data 
 Model inputs 
A systematic review was completed for GBD 2010, and for GBD 2013 and GBD 2015, a review was 
conducted on literature published since the previous addition. The PubMed database was searched using 
the following search string: ((("infant"[Title/Abstract] OR "newborn"[Title/Abstract] OR "newborn 
infant"[Title/Abstract]) AND ("encephalopathy"[Title/Abstract] OR "neonatal 
encephalopathy"[Title/Abstract] OR "perinatal asphyxia"[Title/Abstract] OR "asphyxia 
neonatorum"[Title/Abstract] OR "newborn encephalopathy"[Title/Abstract] OR "hypoxic ischaemic 
encephalopathy"[Title/Abstract] OR ("birth trauma"[Title/Abstract] AND "birth asphyxia"[Title/Abstract]))) 
AND ("2012"[PDAT] : "3000"[PDAT]) AND "humans"[MeSH Terms])  
The exclusion criteria were:  
1. Studies that did not provide primary data on epidemiological parameters, e.g., a commentary piece 
2. Non-representative studies (e.g., only high-risk pregnancies) 
3. Reviews 
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The table below shows the number of literature studies included in GBD 2016, as well as the number of 
countries or subnational units and GBD world regions represented. No additional literature searches were 
done for GBD 2016. 
Table 1. Geographic representation 
Birth prevalence Case fatality 
Studies 38 36 
Locations 27 25 
GBD world regions 13 12 
In addition to literature data, data from US claims data for 2000, 2010, and 2012 by US state were 
included. Only inpatient data was included from these datasets, because we believed it would be more 
representative of the true prevalence of neonatal encephalopathy than outpatient data: infants with 
neonatal encephalopathy in the countries from which hospital data was available are almost sure to be 
admitted to the hospital, whereas outpatient data is more likely to capture repeated visits by the same 
child as they grow. 
Severity splits  
The basis of the GBD disability weight (DW) survey assessments are lay descriptions of sequelae 
highlighting major functional consequences of symptoms. The lay descriptions and disability weights for 
neonatal encephalopathy birth are shown below. 
Table 2. Severity level, lay description and DWs 
Severity level Lay description 
Motor plus cognitive 
impairments, mild 
has some difficulty in moving around but is able to walk without help.The person is 
slow in learning at school. As an adult, the person has some difficulty doing complex 
or unfamiliar tasks but otherwise functions independently. 
Motor impairment, mild has some difficulty in moving around but is able to walk without help. 
Motor impairment, moderate 
has some difficulty in moving around, and difficulty in lifting and holding objects, 
dressing and sitting upright, but is able to walk without help. 
Motor impairment, severe 
is unable to move around without help, and is not able to lift or hold objects, get 
dressed or sit upright.  
Distance vision blindness 
is completely blind, which causes great difficulty in some daily activities, worry and 
anxiety, and great difficulty going outside the home without assistance.  
Motor impairment with 
blindness, moderate (combined DW) 
Motor impairment with 
epilepsy, moderate (combined DW) 
Motor impairment with 
blindness and epilepsy, 
moderate (combined DW) 
Motor plus cognitive 
impairment with blindness, 
moderate (combined DW) 
motor plus cognitive 
impairment with epilepsy, 
moderate (combined DW) 
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motor plus cognitive 
impairment with blindness 
and epilepsy (combined DW) 
Motor impairment with 
blindness, severe (combined DW) 
Motor impairment with 
epilepsy, severe (combined DW) 
Motor impairment with 
blindness and epilepsy, 
severe (combined DW) 
Motor plus cognitive 
impairment with blindness, 
severe (combined DW) 
Motor plus cognitive 
impairment with epilepsy, 
severe (combined DW) 
**For disability weights and combined disability weights, please refer to the disability weights table in the 
appendix. 
To determine the proportion of people within each of these severity levels, one study informed 
moderate-to-severe impairment splits, and mild impairments cases were divided equally into both 
categories.3 
Modeling strategy  
An initial DisMod MR 2.2 model is run using prevalence and case fatality data. Prior to input into DisMod, 
case fatality ratio (CFR) data is transformed into excess mortality rate (EMR) space using the formula 
𝐸𝑀𝑅 =  −
ln(1−𝐶𝐹𝑅)
28
365.25
, which is analogous to the transformation of cumulative incidence to incidence rate. 
The denominator in this equation is derived from the definition of our CFR parameter, which is death in 
the first 28 days of life.  The output from this first-step DisMod model is prevalence in the first two 
neonatal age groups. For this model, remission and incidence are both set to zero, as no one can be born 
with encephalopathy after birth, and no one can cease to have been born with encephalopathy after the 
fact. Study covariates were created for hospital data and US claims data. 
Table 3 
Study-level covariate Parameter Location level beta Exponentiated beta 
Sex Prevalence 
Global -0.036 (-0.11 — 
0.047) 0.96 (0.89 — 1.05) 
Inpatient-only 
Marketscan, year 
2000 Prevalence 
Global 
1.64 (1.44 — 1.85) 
5.18 (4.20 — 6.39) 
Inpatient-only 
Marketscan, year 
2010 Prevalence 
Global 
1.91 (1.76 — 2.00) 
6.78 (5.84 — 7.36) 
Inpatient-only 
Marketscan, year 
2012 Prevalence 
Global 
1.96 (1.85 — 2.00) 7.07 (6.39 — 7.38) 
3 Badawi et al Developmental Medicine & Child Neurology, 2005, 47:293-8 
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Hospital data – 
Central Europe, 
Eastern Europe, & 
Central Asia Prevalence 
Global 
 
-1.23 (-1.43 — -1.03) 
 0.29 (0.24 — 0.36) 
Sex 
Excess 
Mortality 
Rate 
Global 
0.16 (-0.58 — 0.93) 1.18 (0.56 — 2.53) 
 
Country-level covariate Parameter beta Exponentiated beta 
Healthcare Access & Quality 
Index Prevalence 
 
 
 
-0.0084 (-0.016 — -
0.0012) 
 0.99 (0.98 — 1.00) 
In-Facility Delivery 
(proportion) Prevalence -0.34 (-0.87 — -0.02) 0.71 (0.42 — 0.98) 
Skilled Birth Attendance 
(proportion) Prevalence -0.63 (-1.47 — -0.041) 0.53 (0.23 — 0.96) 
LDI (I$ per capita) 
Excess 
Mortality Rate -0.23 (-0.37 — -0.086) 0.79 (0.69 — 0.92) 
 
Using prevalence in the first two neonatal age groups, prevalence at 28 days is calculated via 
interpolation. Functionally, this is birth prevalence minus all those who have died in the first 28 days, our 
case fatality parameter.  
Next, using mild impairment proportion and moderate-to-severe impairment proportion data, we ran 
either mixed-effect hierarchical regressions or meta-analyses to generate country-year-sex-specific 
estimates of both parameters (we used a meta-analysis when there was not sufficient data to support a 
regression model). We then calculated the birth prevalence of each severity level. As mild impairment 
and moderate-severe impairment were calculated separately, it was possible that they could sum to a 
value greater than one.  To address this, we checked the sum of the two values in any of the 1,000 
iterations of the uncertainty analysis, and if greater than 0.9, proportionately rescaled both estimates to 
sum to 0.9 in any of the 1,000 iterations of the uncertainty analysis (we picked 0.9 rather than 1 to allow 
at least some probability of a child having no impairment).  We then proceeded with the calculation of 
the birth prevalence of impairment:  
Mild impairment birth prevalence = prevalence at 28 days * proportion mild impairment 
Moderate/severe impairment birth prevalence = prevalence at 28 days * proportion mod-severe 
impairment 
For moderate/severe impairment, results of these latter calculations were then combined with excess 
mortality estimates derived from the standard mortality ratios (SMR) of cerebral palsy and used as inputs 
into a second DIsMod MR 2.1 model. For this model, remission and incidence were also set to zero. For 
mild impairment, we assumed no excess mortality and no remission, and as such simply applied the birth 
prevalence of mild impairment to every age group. 
No other significant changes were made to the GBD 2016 modeling process.  
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 Neonatal sepsis and other neonatal infections 
 
Flowchart 
 
 
 
Input data and methodological summary 
Case definition 
Neonatal sepsis and other neonatal infections are infections during the neonatal period that advance to a 
systemic blood stream infection, the underlying cause of which can be meningitis, gastroenteritis, or 
other etiologies. Neonatal pneumonia, however, is not included – it is captured in our modeling of 
pneumonia as a separate entity. ICD codes associated with these causes include: 
Input data 
Model inputs 
A systematic review was completed for GBD 2010, and for GBD 2013 and GBD 2015, a review was 
conducted on literature published since the previous addition. The PubMed database was searched using 
the following search string: (("infant"[Title/Abstract] OR "newborn"[Title/Abstract] OR "newborn 
infant"[Title/Abstract]) AND ("neonatal sepsis"[All Fields] OR "neonatal septicaemia"[All Fields] OR 
"neonatal meningitis"[All Fields] OR "early sepsis"[All Fields] OR "early septicaemia"[All Fields] OR 
"tetanus"[All Fields] OR "meningitis"[All Fields] OR "sepsis"[All Fields])) AND ("2012"[PDAT] : 
"3000"[PDAT]) AND "humans"[MeSH Terms] 
The exclusion criteria were:  
1. Studies that did not provide primary data on epidemiological parameters, e.g., a commentary piece 
2. Non-representative studies (e.g., only high-risk pregnancies) 
3. Reviews 
The table below shows the number of literature studies included in GBD 2016, as well as the number of 
countries or subnational units and GBD world regions represented. Please note – no literature review was 
conducted for GBD 2016. 
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Table 1. Geographic representation 
Birth prevalence Case fatality  
Studies 2 15 
Locations 2 15 
GBD world regions 2 10 
In addition to literature data, data from US claims data for 2000, 2010, and 2012 by US state were 
included. Only inpatient data was included from these datasets, because we believed it would be more 
representative of the true prevalence of neonatal sepsis than outpatient data: infants with neonatal 
sepsis in the countries from which hospital data was available are almost sure to be admitted to the 
hospital, whereas outpatient data is more likely to capture repeated visits by the same child as they grow. 
Remission was set to 26, as a cause of neonatal sepsis is assumed to last two weeks. Incidence is set to 0 
after 27 days, as by definition, neonatal sepsis must occur within the neonatal period (0-27 days). 
Severity splits 
The basis of the GBD disability weight (DW) survey assessments are lay descriptions of sequelae 
highlighting major functional consequences of symptoms. The lay descriptions and disability weights for 
neonatal sepsis birth are shown below. 
Table 2. Severity level, lay description and DWs 
Severity level Lay description 
Motor plus cognitive 
impairments, mild
has some difficulty in moving around but is able to walk without help. The person is 
slow in learning at school. As an adult, the person has some difficulty doing complex 
or unfamiliar tasks but otherwise functions independently. 
Motor impairment, mild has some difficulty in moving around but is able to walk without help. 
Motor impairment, moderate 
has some difficulty in moving around, and difficulty in lifting and holding objects, 
dressing and sitting upright, but is able to walk without help. 
Motor impairment, severe 
is unable to move around without help, and is not able to lift or hold objects, get 
dressed or sit upright.  
Distance vision blindness 
is completely blind, which causes great difficulty in some daily activities, worry and 
anxiety, and great difficulty going outside the home without assistance.  
Motor impairment with 
blindness, moderate Combined DW 
Motor impairment with 
epilepsy, moderate Combined DW 
Motor impairment with 
blindness, moderate Combined DW 
Motor plus cognitive 
impairment with blindness, 
moderate Combined DW 
Motor plus cognitive 
impairment with epilepsy, 
moderate  Combined DW 
Motor plus cognitive 
impairment with blindness 
and epilepsy, moderate  Combined DW 
Motor impairment with 
blindness, severe Combined DW 
Motor impairment with 
epilepsy, severe Combined DW 
Motor impairment with 
blindness, severe Combined DW 
220
Motor plus cognitive 
impairment, severe Combined DW 
Motor plus cognitive 
impairment with epilepsy, 
severe Combined DW 
Motor plus cognitive 
impairment with blindness 
and epilepsy, severe Combined DW 
Infection due to neonatal 
sepsis, severe Combined DW 
**For disability weights and combined disability weights, please refer to the disability weights table in the 
appendix. 
To determine the proportion of people within each of these severity levels, one study informed 
moderate-to-severe impairment splits, and for mild impairments cases were divided equally into both 
categories.4 
Modeling strategy 
For GBD 2016, we used the same modeling strategy employed for GBD 2015. The methodology is 
outlined below. 
An initial DisMod MR 2.1 model is run using prevalence and case fatality data. Prior to input into DisMod, 
case fatality ratio (CFR) data is transformed into excess mortality rate (EMR) space using the formula: 
𝐸𝑀𝑅 =  −
ln(1 − 𝐶𝐹𝑅)
28
365.25
which is analogous to the transformation of cumulative incidence to incidence rate. The denominator in 
this equation is derived from the definition of our CFR parameter, which is death in the first 28 days of 
life. The output from this first-step DisMod model is prevalence in the first two neonatal age groups. A 
study covariate were created literature. 
Study-level covariate Parameter Location level beta Exponentiated beta 
Sex Prevalence Global 0.12 (0.068 — 0.17) 1.12 (1.07 — 1.18) 
Literature Prevalence 
Global 
1.70 (1.18 — 1.99) 5.47 (3.24 — 7.30) 
Country-level covariate Parameter beta Exponentiated beta 
Healthcare Access & Quality 
Index Prevalence 
0.0051 (-0.0097 — 
0.020) 1.01 (0.99 — 1.02) 
4 Badawi et al Developmental Medicine & Child Neurology, 2005, 47:293-8 
221
LDI (I$ per capita) 
Excess 
Mortality Rate -0.2 (-0.49 — -0.0097) 0.82 (0.61 — 0.99) 
Healthcare Access & Quality 
Index 
Excess 
Mortality Rate 
-0.017 (-0.04 — -
0.00089) 
 
0.98 (0.96 — 1.00) 
SEV Unsafe Water 
 
Prevalence 0.12 (0.0060 — 0.39) 1.13 (1.01 — 1.47) 
SEV Unsafe Sanitation Prevalence 
 
0.12 (0.0018 — 0.45) 
 
1.13 (1.00 — 1.57) 
 
 
Using prevalence in the first two neonatal age groups, prevalence at 28 days is calculated via 
interpolation. Functionally, this is birth prevalence minus all those who have died in the first 28 days, our 
case fatality parameter.  
Next, using mild impairment proportion and moderate-to-severe impairment proportion data, we ran 
either mixed-effect hierarchical regressions or meta-analyses to generate country-year-sex-specific 
estimates of both parameters (we used a meta-analysis when there was not sufficient data to support a 
regression model). We then calculated the birth prevalence of each severity level. As mild impairment 
and moderate-severe impairment were calculated separately, it was possible that they could sum to a 
value greater than one. To address this, we checked the sum of the two values in any of the 1,000 
iterations of the uncertainty analysis, and if greater than 0.9, proportionately rescaled both estimates to 
sum to 0.9 in any of the 1,000 iterations of the uncertainty analysis (we picked 0.9 rather than 1 to allow 
at least some probability of a child having no impairment).  We then proceeded with the calculation of 
the birth prevalence of impairment:  
Mild impairment birth prevalence = prevalence at 28 days * proportion mild impairment 
Moderate/severe impairment birth prevalence = prevalence at 28 days * proportion mod-severe 
impairment 
For moderate/severe impairment, results of these latter calculations were then combined with excess 
mortality estimates derived from the standard mortality ratios (SMR) of cerebral palsy and used as inputs 
into a second DisMod MR 2.1 model. For this model, remission and incidence were also set to zero. For 
mild impairment, we assumed no excess mortality and no remission, and as such simply applied the birth 
prevalence of mild impairment to every age group. 
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Hemolytic disease and other neonatal jaundice 
 
Flowchart 
 
 
 
Case definition 
Hemolytic disease of the newborn and other neonatal jaundice refers to several etiologies by which an 
infant develops extreme hyperbilirunemia (EHB) and can then go on to develop kernicterus. The 
etiologies that we model for GBD are EHB from Rhesus (Rh) disease, preterm birth, glucose-6-phosphate 
dehydrogenase deficiency (G6PD), and other causes.   
Input data 
 Model inputs 
A systematic review was completed for GBD 2010, and for GBD 2013 and GBD 2015, a review was 
conducted on literature published since the previous addition. The PubMed database was searched using 
the following search string: (("infant"[Title/Abstract] OR "newborn"[Title/Abstract] OR "newborn 
infant"[Title/Abstract]) AND ("haemolytic"[All Fields] OR "hyperbilirubinemia"[All Fields] OR "jaundice"[All 
Fields] OR "glucose-6-phosphate dehydrogenase deficiency"[All Fields] OR "G6PD deficiency"[All Fields] 
OR "hyperbilirubinemia"[All Fields] OR "EHB"[All Fields] OR "phototherapy"[All Fields] OR "ABO 
incompatibility"[All Fields] OR "RH incompatibility"[All Fields] OR "rh blood group system"[All Fields] OR 
"Rhesus"[All Fields] OR "Rhesus disease"[All Fields] OR "erythroblastosis fetalis"[All Fields] OR 
"kernicterus"[All Fields])) AND ("2012"[PDAT] : "3000"[PDAT]) Sort by: PublicationDate 
The exclusion criteria were:  
1. Studies that did not provide primary data on epidemiological parameters, e.g., a commentary 
piece 
2. Non-representative studies (e.g., only high-risk pregnancies) 
3. Reviews 
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For hemolytic disease, much of the input data comes from other GBD models, which are described in 
detail in the “modeling strategy” section. However, the modeling process for EHB from Rh disease 
involves literature data for several parameters, the breadth of which are described in the tables below:  
Table 1a. Rh negativity 
 Prevalence 
Studies 48 
Countries/subnationals 47 
GBD world regions 13 
 
Table 1b. Children who are not first-born 
 Prevalence 
Studies 82 
Countries/subnationals 81 
GBD world regions 14 
 
Table 1c. Proportion of Preterm Infants who go on to have ROP 
 Prevalence 
Studies 32 
Countries/subnationals 28 
GBD world regions 12 
 
**Please note that US claims data and hospital data were not included in the hemolytic disease modeling 
process because they are not coded separately by etiology. They could not be slotted into the existing 
modeling framework.  
 
Severity splits & disability weights 
 
The basis of the GBD disability weight (DW) survey assessments are lay descriptions of sequelae 
highlighting major functional consequences and symptoms. The lay descriptions and disability weights for 
hemolytic disease and other neonatal jaundice levels are shown below. 
Table 2. Severity, lay description and DWs  
Severity level Lay description DW (95% CI) 
Motor impairment, moderate 
has some difficulty in moving around, and difficulty in lifting and holding objects, 
dressing and sitting upright, but is able to walk without help. 
0.061 
(0.04-0.089) 
Motor impairment, severe 
is unable to move around without help, and is not able to lift or hold objects, get 
dressed or sit upright.  
0.402 
(0.268-0.545) 
Distance vision blindness 
is completely blind, which causes great difficulty in some daily activities, worry and 
anxiety, and great difficulty going outside the home without assistance.  
0.187 
(0.124-0.26) 
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To determine the proportion of people within each of these severity levels, one study informed 
moderate-to-severe impairment splits, and for mild impairments cases were divided equally into both 
categories.5 
Modeling strategy 
The modeling strategy can be described as two main steps. For each of the four etiologies (Rh disease, 
G6PD deficiency, preterm birth, and other causes) we estimated the prevalence of extreme 
hyperbilirubinemia (EHB or bilirubin>25 or exchange transfusion). Then, we multiplied this prevalence by 
an estimated proportion of EHB cases who go on to develop kernicterus. We used development of 
kernicterus as our criterion for incidence of long-term moderate/severe impairment.  
Rh Disease 
We began with data on the prevalence of Rh negativity in the population, the number of Rhogam (Rh0 
Immune Globulin) doses distributed to countries in 2010, and the proportion of children who are not 
firstborn. Mixed effect regressions were run on Rh negativity and birth order greater than one to 
generate estimates of these values for every country-year. We made the assumptions that the proportion 
of Rhogam doses to Rh-incompatible children stayed constant over time, and that countries with NMR<5 
had complete Rhogam coverage. This yields the following equation for the prevalence of EHB in countries 
with NMR>5: 
EHB Prevalence = Rh negative prevalence * (1 – Rh negative prevalence) * (2010 Rhogam doses / 2010 Rh 
incompatible babies) * (not-firstborn prevalence) * 0.15 
The 0.15 multiplier represents results of previous calculations5 showing the proportion of women 
developing Rh isoimmunization with a risk for anti-Rh antibodies complicating subsequent pregnancies.  
Finally, to generate estimates of kernicterus prevalence, we multiplied the prevalence of EHB by 0.0072 
(0.0038, 0.112) -- the proportion of children with EHB who develop kernicterus (extracted from previously 
published values).6,7   
G6PD, Preterm, and Other 
The other three pathways of kernicterus modeling simply involve multiplication by scalars. For each of 
these, given a complete set of prevalence estimates from other GBD models, we multiplied by a scalar 
representing the proportion of children who are expected to develop EHB (see the table below for the 
values of these scalars). We then adjusted that estimate upward by a factor of 2.45 (1.44, 4.16) for 
countries in which the NMR is greater than 15, a value utilized in previous publications4 to reflect 
heightened risk in those countries where access to phototherapy for prevention of EHB is not standard. 
Finally, these EHB prevalence values were multiplied by a set of NMR-dependent scalars representing the 
proportion of EHB cases that go on to develop kernicterus. See table below, for those values. 
5 Badawi et al. Developmental Medicine & Child Neurology, 2005, 47:293-8 
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Table 3. EHB proportion and CIs 
Cause Source of birth 
prevalence estimates 
EHB proportion 95% CI 
G6PD Congenital DisMod 
model, GBD 2016. 
0.0013 (0.00085, 0.002) 
Preterm birth 
complications 
Custom modeling for 
preterm conditions, 
discussed elsewhere in 
this document 
(summed over all 
gestational ages). 
0.00045 (0.00029, 0.0007) 
Other Global births – (Rh 
disease birth 
prevalence + preterm 
complications birth 
prevalence + G6PD 
birth prevalence) 
0.00038 (0.00033, 0.00163) 
Table 4. EHB proportions used in G6PD, preterm, and other estimates. 
NMR Kernicterus proportion 95% CI 
<5 0.23 (0.099, 0.361) 
5-15 0.35 (0.12, 0.58) 
>=15 0.438 (0.255, 0.621) 
Table 5: NMR-dependent kernicterus proportions applied to G6PD, preterm, and other EHB estimates. 
Final Kernicterus Prevalence 
We estimated preterm kernicterus in order to arrive at a proper value for the number of “other” children 
at risk of kernicterus but we do not actually include our preterm estimates in our measures of kernicterus 
since we assume that its disability is captured in our preterm models. Thus, we generate our final birth 
prevalence of kernicterus by: 
Kernicterus birth prevalence = (kernicterus prevalence from Rh disease) + (kernicterus prevalence from 
G6PD) + (kernicterus prevalence from other disorders). 
These estimates, along with estimates of excess mortality associated with kernicterus, are then used as 
inputs into our disease modeling tool (DisMod) to generate estimates of moderate to severe impairment 
for all ages. 
No other significant changes were made to the GBD 2016 estimation process. 
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 Protein-energy malnutrition 
 
Flowchart 
 
 
Input data and methodological summary 
Case Definition 
For protein energy malnutrition (PEM), ICD 10 codes are E40-E46.9, E64.0, and ICD 9 codes are 260-
263.9. Our assessment of nonfatal PEM includes the quantification of nonfatal health loss associated with 
moderate and severe acute malnutrition, commonly referred to as “wasting,” and was defined in terms of 
weight-for-height Z-scores (WHZ) on the WHO 2006 growth standard for children. We quantified nonfatal 
PEM burden in four mutually-exclusive and collectively exhaustive categories, reflecting distinct 
gradations of disability that can occur: moderate wasting without edema (WHZ < -2SD to < -3 SD), 
moderate wasting with edema (WHZ < -2SD to < -3 SD), severe wasting without edema (WHZ < -3SD), and 
severe wasting with edema (WHZ < -3SD). The aggregate of categories that include “edema” can be 
considered equivalent to the disease state commonly referred to as “kwashiorkor” and severe wasting 
can likewise be considered equivalent to “marasmus.”  
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This classification reflects a moderate shift from GBD 2015, when moderate wasting without edema was 
not included in our nonfatal estimates, and by definition is associated with higher prevalence estimates 
than previously published by GBD. The other GBD 2015 categories—kwashiorkor, marasmus, and severe 
wasting—have unchanged case definitions, but have been renamed for clarity and consistency. This 
revised GBD 2016 case definition more closely aligns with other and allows for better application to the 
international nutrition community’s programming and estimates related to non-fatal PEM.  
Input data  
The input data for this model come in three primary streams. First, we used individual-level and tabulated 
child anthropometry data from health surveys, literature, national reports, and centralized to inform the 
prevalence of WHZ decrement in each category corresponding to our case definitions. Second, to inform 
the proportion of children under 5 years who have signs of organ failure manifested as edema (i.e. 
kwashiorkor), we used a compiled dataset of surveys conducted using Standardized Monitoring and 
Assessment of Relief and Transitions (SMART) methods. Third, we used the cause-specific mortality rate 
(CSMR) results of our causes-of-death GBD analyses to inform spatiotemporal and age patterns in PEM 
mortality, which helped also inform patterns of PEM morbidity. These data sources and modeling process 
are described in other GBD publications on cause-specific mortality. All data was extracted with the most 
detailed standard demographic identifiers available, including age, sex, country, year, and subnational 
location if available.  
Modelling Strategy 
We used five parallel models to inform our estimates, the first two of which were completed in ST-GPR 
and the second three of which were completed in DisMod-MR 2.1: 1) Prevalence of WHZ <-2 in children 
under 5 years, 2) Prevalence of WHZ <-3 in children under 5 years, 3) Proportion of those with WHZ <-2 
who have edema in under 5 years, 4) Proportion of those with WHZ <-3 who have edema in under 5 
years, and 5) Prevalence, incidence, and excess-mortality of WHZ <-2 in all ages. As a final step, we 
subtracted a number of cases of PEM where the underlying etiology is severe worm infestation. 
The results of the first four models were used for children under 5 years. Arithmetic transformations were 
performed to ensure that the final results fit into the mutually-exclusive, collectively-exhaustive 
categories described in the first section above. We assumed zero prevalence of edema in people over 5 
years old. The results of the final model were used for all age groups 5 years and older and the proportion 
of moderate versus severe wasting in each of those age groups was derived from the first set of models.  
The final model represents the first attempt we have made in GBD to estimate incidence for PEM, for 
which there is comparatively little empirical data. Using available information from scientific publications, 
which suggest the mean duration of illness is 9 months, and conversations with collaborators and 
nutrition experts, we applied what we consider a plausible set of remission rate bounds of 0.25-1.25 (# of 
remitted cases of PEM per person-year of illness) to the final of the five models. These bounds allowed 
DisMod-MR 2.1 to mathematically derive an internally-consistent solution for incidence, prevalence, 
remission, excess mortality, and cause-specific mortality using all available data. This could only be done 
for the aggregate PEM definition (prevalence of WHZ <-2) to ensure that the case definition for 
prevalence matched that of the mortality results. The incidence-to-prevalence ratio derived from the final 
model was applied equally across all the categories of nonfatal PEM. Future work in systematically 
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evaluating longitudinal datasets on nutrition and growth failure will allow us to improving the empirical 
basis for PEM incidence estimates, including improved resolution for the component categories.   
We applied disability weights from the GBD disability weight survey to the prevalence of the above 
sequela according to their corresponding health state and severity level. The sequela, along with their lay 
descriptions and disability weights for health states derived from the GBD Disability Weights study are 
shown below. We assumed that those with moderate wasting, but no edema, did not have any direct 
disability due to this condition. 
Table 1. Sequela, severity, lay description, and DWs 
Sequela Health State Name Lay description DW (95% CI) 
Moderate Wasting 
without Edema 
Asymptomatic -- -- 
Moderate Wasting 
with Edema 
Kwashiorkor 
Is very tired and irritable and 
has diarrhea. 
0.051 
(0.031-0.079) 
Severe Wasting 
without Edema 
Severe wasting 
Is extremely skinny and has 
no energy. 
0.128  
(0.082-0.183) 
Severe Wasting 
with Edema 
Kwashiorkor +  
Severe wasting  
Is very tired and irritable and 
has diarrhea. 
0.051 
(0.031-0.079) 
Is extremely skinny and has 
no energy. 
0.128 
(0.082-0.183) 
 
Because both worms and PEM can cause wasting, we needed to divide out the wasting envelope to 
attribute wasting to both PEM and worms. We determined the amount of wasting attributable to worms 
by referencing Hall et al. 20086 to determine the mean and confidence interval estimates of the z-score 
shift. We then calculated the counterfactual wasting prevalence given no worms, according to the z-score 
shift. From this, we calculated the fraction of wasting that is attributable to worms, and assigned the 
remainder of wasting to PEM. We assumed no edema due to worms and the same prevalence-to-
incidence ratio as in each of the other models.  
Following the assignment of disability weights to the various sequelae, the resulting disability adjusted life 
years (YLDs) go through the comorbidity simulator, which accounts for any comorbidity and corrects 
accordingly. The final outputs are comorbidity adjusted YLDs, which are combined with years of life lost 
(YLLs) for final disability-adjusted life years (DALYs).  
 
  
6 Hall A, Hewitt G, Tuffrey V, de Silva N. A review and meta‐analysis of the impact of intestinal worms on child 
growth and nutrition. Maternal and Child Nutrition. 2008. 4. 118-236. 
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Iodine deficiency 
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Input data and methodological summary 
Case definition 
Our assessment of the nonfatal burden of iodine deficiency includes estimates of only the subset of 
iodine deficiency associated with visible goiter (grade 2) and its associated sequelae, including thyroid 
dysfunction, heart failure, and intellectual disability (historically referred to as “cretinism”). It does not 
include estimates of sub-clinical iodine deficiency or non-visible goiter (grade 1) induced by iodine 
deficiency. Expanding to include all forms of subclinical iodine deficiency is a goal of future iterations of 
GBD analyses. The corresponding ICD-10 codes from the causes of death analysis for iodine deficiency are 
E00-E02. Further details of mortality modeling can be found in the GBD 2016 cause-specific mortality 
publication.  
 
Input data 
For GBD 2016, data from the WHO Vitamin and Mineral Nutrition Information System and published 
studies were used. This extraction and an accompanying systematic review were last conducted for GBD 
2013. The PubMed search terms were: ((iodine deficiency[Title/Abstract] AND prevalence[Title/Abstract]) 
AND (“2009”[Date – Publication] : “2013”[Date – Publication])) 
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The exclusion criteria were: 
1. Studies that were not population-based, eg, hospital or clinic-based studies 
2. Studies that did not provide primary data on epidemiological parameters, eg, 
commentaries  
3. Review articles 
4. Case series 
5. Self-reported cases 
Updates to systematic reviews are performed on an ongoing schedule across all GBD causes; an update 
for iodine deficiency will be performed in the next one to two iterations. The table below shows the 
number of literature studies included in GBD 2016, as well as the number of countries or subnational 
units and GBD world regions represented. 
 
Table 1. Geographic representation 
 Prevalence Incidence Mortality risk 
Studies 25 - - 
Countries/subnationals 8 - - 
GBD world regions 5 - - 
 
Modelling strategy 
For GBD 2016, we modelled the prevalence of grade 2 goiter in DisMod-MR 2.1. We chose to model 
grade 2 goiter over grade 1 goiter because of the greater reliability and consistency of the clinical 
diagnosis of grade 2 goiter worldwide. We used a study-level covariate to indicate national and 
subnational observations, where nationally representative studies were set as the reference category. We 
used household iodized salt consumption proportion as a country-level covariate. 
We estimated the prevalence of intellectual disability due to iodine deficiency (cretinism) by regressing 
data points from studies reporting both cretinism and goiter prevalence in the same population. To do so, 
we first transformed cretinism prevalence and goiter prevalence into logit space, regressed the logit 
prevalence of cretinism on the logit prevalence of goiter, and predicted for all locations using the goiter 
estimates from the DisMod model above. We dropped locations with total goiter prevalence less than 
20% and locations with household iodized salt consumption greater than 90%. We kept observations in 
children younger than 5 years and use these data as incidence input in DisMod to generate location-year-
age-sex-specific estimates. We assumed zero remission as the disease is a lifelong condition, and zero 
incidence after age 5. We repeated the dropout criteria of total goiter prevalence and iodized salt 
consumption on the DisMod output. The severity split for intellectual disability due to iodine deficiency is 
presented separately in the section for intellectual disability. 
Heart failure attributable to iodine deficiency was modelled separately, and the methods for this 
outcome are presented separately in the section for heart failure and its etiologies. 
Betas and exponentiated values (which can be interpreted as an odds ratio) for the grade 2 goiter DisMod 
model are shown in the table below. 
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Table 2. Beta and exponentiated beta values 
Covariate Parameter beta Exponentiated beta 
Proportions of households 
using iodized salts 
Prevalence -0.55 (-0.60, -0.41) 0.58 (0.55, 0.66) 
Subnational Prevalence 0.50 (0.48, 0.50) 1.64 (1.62, 1.65) 
Sex Prevalence -0.63 (-0.85, -0.42) 0.53 (0.43, 0.66) 
 
Severity splits & disability weights 
Our approach to apportioning cases of grade 2 goiter was modified in GBD 2016 to improve internal 
consistency of YLD estimates. The primary change was that in GBD 2015, each of the types of symptoms 
(heart failure, thyroid dysfunction, intellectual disability) were considered to be mutually-exclusive, but 
recognizing they are not, we constructed independent joint probabilities for each. Initial severity 
proportions have not changed since GBD 2010: visible goiter without symptoms of thyroid dysfunction 
(proportion=0.915, 95% confidence interval (CI): 0.904-0.926); goiter with symptoms of thyroid 
dysfunction (proportion=0.085, 95% confidence interval (CI): 0.084-0.086). The regression results for 
intellectual disability (ID) were applied to the total estimates of iodine deficiency. All of those with ID 
were assumed to have symptoms of thyroid dysfunction. Heart failure due to iodine deficiency, which was 
estimated separately, was assumed to only occur in the subset of persons with profound ID.   
The lay descriptions and disability weights for severity levels derived from the GBD Disability Weights 
study are shown below. 
Table 3. Severity, health state, lay description, and DWs for sequelae specific to iodine deficiency 
Severity 
level 
Health state Lay description DW (95% CI) 
Visible 
goiter 
without 
symptoms 
Disfigurement, level 2 Has a visible physical deformity that 
causes others to stare and comment. 
As a result, the person is worried and 
has trouble sleeping and 
concentrating. 
0.067 
(0.044–0.096) 
Visible 
goiter with 
symptoms 
Goiter Has a large mass in the front of the 
neck. The person sometimes has 
weakness and fatigue, constipation 
and weight gain. 
0.199 
(0.133–0.276) 
 
No other significant changes were made to the modelling strategy for GBD 2016. 
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Input data and methodological summary 
Case definition 
For GBD 2016, the case assessment of vitamin A deficiency involves the quantification of total Vitamin A 
deficiency (serum retinol < 0.7 µmol/L) as well as blindness and vision loss due to Vitamin A deficiency, 
which are associated with corneal ulcerations and corneal scars. ICD 10 codes are E50-E50.9, E64.1, and 
ICD 9 codes are 264-264.9. 
To ensure we were using as much information as possible, and therefore maximize the data basis of our 
estimates, we modeled Vitamin A deficiency sequentially. The first step was to estimate the coverage of 
Vitamin A supplementation. Although the typical metric on which supplementation is tracked is 2+ 
doses of Vitamin A in the previous 12 months for children under 5 years, most existing health surveys do 
not routinely provide sufficient information to calculate it. Our case definition for the supplementation 
model was therefore the proportion of children 6-59 months of age who received at least one dose of 
Vitamin A in the previous 6 months. Supplementation estimates were then used as a location-level 
covariate to guide incidence and prevalence models of overall Vitamin A deficiency, which was 
subsequently used as a location-level covariate to guide prevalence estimates of vision loss due to 
Vitamin A deficiency. The difference between total Vitamin A deficiency and vision loss due to Vitamin A 
deficiency is considered asymptomatic. Total Vitamin A deficiency is separately considered as a risk 
factor in the GBD 2016 comparative risk assessment analysis.  
Input data 
For GBD 2016, we used data from the WHO Vitamin and Mineral Nutrition Information System, health 
surveys such as DHS and MICS, and studies identified through literature review. A systematic review was 
last conducted for GBD 2013. The PubMed search terms were: ((vitamin A deficiency[Title/Abstract] 
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AND prevalence[Title/Abstract]) AND (“2009”[Date – Publication] : “2013”[Date – Publication])). The 
table below shows the number of data points included in the final datasets. Exclusion criteria were: 
1. Studies that were not population-based, e.g., hospital or clinic-based studies
2. Studies that did not provide primary data on epidemiological parameters, e.g., commentaries
3. Review articles
4. Case series
5. Self-reported cases
Table 1. Geographic representation of datasets used for three stages of Vitamin A deficiency 
nonfatal burden estimation (number of data points per location)
Location
Supplementation 
(proportion) 
Deficiency 
(prevalence) 
Vision Loss 
(Relative 
risk) 
Vision Loss 
(prevalence) 
Global 900 365 1 81 
East Asia 12 10 
Southeast Asia 102 45 21 
Oceania 24 18 
Central Asia 51 31 
Central Europe 2 1 
Australasia 1 
Southern Latin America 1 
High-income North America 4 
Caribbean 17 12 1 
Andean Latin America 25 10 
Central Latin America 33 54 1 
Tropical Latin America 1 2 2 
North Africa and Middle East 49 37 18 
South Asia 61 21 21 
Central Sub-Saharan Africa 60 9 1 
Eastern Sub-Saharan Africa 182 63 10 
Southern Sub-Saharan Africa 49 15 1 
Western Sub-Saharan Africa 232 31 5 
Modelling strategy 
All Vitamin A deficiency estimates were made using DisMod-MR 2.1. As described above, we first 
estimated Vitamin A supplementation coverage. Although all data was from ages 6-59 months, we 
assumed no difference in age pattern of supplementation coverage and used the natural log of lag-
distributed income per capita (LN-LDI) as a location-level covariate to inform estimates where data was 
absent. DHS and MICS data was cross-walked to the reference data source, which came from UNICEF 
(http://data.worldbank.org/indicator/SN.ITK.VITA.ZS). 
Table 2: Covariate effects for Vitamin A supplementation model 
Measure Covariate Type Value Exponentiated 
Prevalence MICS Study-level -0.59 0.56 
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(-0.73 — -0.42) (0.48 — 0.65) 
Prevalence DHS Study-level 
-0.092 
(-0.22 — 0.038) 
0.91 
(0.80 — 1.04) 
Prevalence 
LDI (I$ per 
capita) 
Country-level 
0.0094 
(0.00061 — 0.039) 
1.01 
(1.00 — 1.04) 
 
Second, we estimated the age- and sex-specific prevalence of Vitamin A deficiency (serum retinol < 0.7 
µmol/L). WHO VMNIS was the primary data source for this model and was supplemented with data from 
DHS and other health surveys where testing was performed. We assumed the following in our model: no 
excess mortality, birth prevalence is possible, and that incidence and remission are both decreasing 
after age 5. Incidence estimates were therefore derived from the changing age pattern of prevalence 
with some allowance for remission. Data from subnational locations was crosswalked to the reference 
data sources of nationally-representative data. Females were found to have 1.09 times higher Vitamin A 
deficiency, although the uncertainty in that ratio ranged from 0.97 to 1.24. Location-level covariates 
were used for Vitamin A supplementation coverage from the above model as well as GBD 2016 Socio-
demographic Index (SDI) numbers.  
 
Table 3: Covariate effects for Vitamin A deficiency model 
Measure Covariate Type Value Exponentiated 
Prevalence Sex Study-level 
0.086  
(-0.027 — 0.21) 
1.09  
(0.97 — 1.24) 
Prevalence Subnational Study-level 
0.00074  
(-0.15 — 0.17) 
1.00  
(0.86 — 1.19) 
Prevalence 
Vit A suppl. 
coverage 
Country-level 
-0.38  
(-0.71 — -0.099) 
0.68  
(0.49 — 0.91) 
Prevalence SDI Country-level 
-2.25  
(-2.87 — -1.36) 
0.10  
(0.057 — 0.26) 
 
Third, for models of prevalence of blindness and vision loss due to vitamin A deficiency, this was run as a 
single-parameter meta-regression on prevalence, so incidence estimates were not generated. Data from 
subnational locations was crosswalked to the reference data sources of nationally-representative data. 
Vitamin A deficiency prevalence was used as a location-level covariate. Two covariates that were used in 
GBD 2015 were removed in the GBD 2016 models. These were 1) proportion of children who are 
underweight and 2) year. The first was removed to eliminate a modeling circularity where, because of 
timing of processes, the only available results for this covariate at time of modeling Vitamin A deficiency 
were from the previous round of GBD estimation. The second was removed because it functionally 
assumes a fixed time trend in the prevalence of vision loss, which may not be the case everywhere.  
 
Table 4: Covariate effects for Vision loss due to Vitamin A deficiency model 
Measure Covariate Type Value Exponentiated 
Prevalence Sex Study-level 
0.040  
(-1.44 — 1.53) 
1.04  
(0.24 — 4.60) 
Prevalence Subnational Study-level 0.19  1.20  
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(0.0069 — 0.46) (1.01 — 1.59) 
Prevalence 
Vit A Def Prev 
(age-stdized) 
Country-level 
1.10  
(0.054 — 1.96) 
3.00  
(1.06 — 7.08) 
 
Severity splits and disability weights 
Our GBD 2016 results include explicit estimates of total Vitamin A deficiency, although those without 
vision loss are assumed to be asymptomatic. Description of how our estimates of total vision loss 
described above are parsed into moderate vision loss, severe vision loss, and blindness can be found in 
the modeling description for the “vision loss impairment”. Sequelae and corresponding disability 
weights for each of the health states associated with Vitamin A deficiency are shown in the table below. 
 
Table 5. Severity, lay description and Disability Weight (DW) 
Severity level Lay description DW (95% CI) 
Asymptomatic 
Vitamin A 
deficiency 
 0 
Moderate 
vision loss  
Has vision problems that make it difficult to recognize faces or 
objects across a room. 
0.031 
(0.019-0.049) 
Severe vision 
loss  
Has severe vision loss, which causes difficulty in daily activities, 
some emotional impact (for example worry), and some difficulty 
going outside the home without assistance. 
0.184 
(0.125-0.259) 
Blindness  
Is completely blind, which causes great difficulty in some daily 
activities, worry and anxiety, and great difficulty going outside 
the home without assistance. 
0.187 
(0.124-0.26) 
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 Other nutritional deficiencies  
 
Other nutritional deficiencies encompass a wide variety of causes of morbidity, ranging from vitamin 
deficiencies to other nutritional anemias. GBD 2016 treats these causes as a single category, given their 
relatively limited burden, diversity in underlying causes and risk factors, and data availability. Instead of 
modeling them in a traditional modeling format, we calculate the YLDs associated with other nutritional 
deficiencies using a YLD/YLL ratio.   
The first input for this non-fatal portion of other nutritional deficiencies burden is the YLL estimates from 
the GBD 2016 causes of death (CoD) analysis. The causes and their associated ICD-10 codes that 
constitute other nutritional deficiencies for CoD are listed below. Additionally, CoD includes specific 
models for Protein Energy Malnutrition, another nutritional cause of morbidity and mortality; as Protein 
Energy Malnutrition has a specific non fatal model that results in YLDs, we can calculate the YLD/YLL ratio 
for Protein Energy Malnutrition. We multiply the YLL estimates for other nutritional deficiencies from CoD 
by the YLD/YLL ratio for PEM, providing us with an estimate of the YLDs associated with other nutritional 
deficiencies.  
 
GBD cause ICD-10 code 
Other nutritional 
deficiencies 
D51-D52.0 (vitamin B12 deficiency anemia and folate deficiency anemia) 
Other nutritional 
deficiencies 
D52.8-D53.9 (other nutritional anemias) 
Other nutritional 
deficiencies 
D64.3 (other sideroblastic anemias) 
Other nutritional 
deficiencies 
E51-E61.9 (thiamine, niacin, other B group vitamins, ascorbic acid, vitamin 
D, other vitamin, dietary calcium, dietary selenium, dietary zinc, and other 
nutrient element deficiencies) 
Other nutritional 
deficiencies 
E63-E64.0 (other nutritional deficiencies and sequelae of protein-calorie 
malnutrition) 
Other nutritional 
deficiencies 
E64.2-E64.9 (sequelae of vitamin C deficiency, rickets, other nutritional 
deficiencies, and unspecified nutritional deficiencies) 
Other nutritional 
deficiencies 
M12.1-M12.19 (Kaschin-Beck disease) 
 
  
237
 Sexually transmitted infections (STIs), excluding HIV: 
Chlamydia, gonorrhea, trichomonas, genital herpes due to HSV-2, syphilis (early 
infection and adult tertiary syphilis), and other STIs 
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Input data and methodological summary 
 
Case definition 
For GBD 2016, we estimated the prevalence and incidence of genital and reproductive tract infection with 
several common sexually transmitted infections, including Chlamydia trachomatis, Neisseria gonorrhea, 
Trichomonas vaginalis, Treponema pallidum (syphilis), and genital herpes associated with seroprevalent 
HSV-2. Separate estimates were completed for early syphilis and adult tertiary syphilis. ICD-9 and ICD-10 
codes associated with each cause in the GBD 2016 cause-specific mortality analyses are listed below. Of 
note, mortality was assumed to be zero in trichomoniasis and genital herpes infection, and YLDs due to 
congenital syphilis were not estimated.  
 
Table 1. International classification of diseases codes for sexually transmitted infections in GBD 2015 cause of death 
analysis  
Condition ICD10 code ICD9 code 
Sexually transmitted 
infections (STI) excl HIV 
A50-A60, A63-A64, I98.0, K67.0-K67.2, M73.0-M73.1 090-099,131,614 
Syphilis A50-A53, I98.0, K67.0-K67.2, M73.0-M73.1 090-097 
Congenital syphilis A50 090 
Early syphilis A51 091 
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Adult tertiary syphilis A52, I98.0 093-095 
Chlamydial infection A55-A56,K67.0 099.41,099.5 
Gonococcal infection A54,K67.1 098 
Trichomoniasis A59,K67.0 131 
Genital herpes A60 054.1 
Other STI A57-A58, A63-A64, M73.0 099 (except 099.41, 099.5) 
 
Input data 
 Model inputs 
Systematic literature reviews were completed on April 17, 2015, for chlamydia, gonorrhea, trichomonas, 
genital herpes, and early syphilis. Three related search strings were used as many studies report on 
multiple infections. With the exception of the early syphilis literature review, which was completed in 
GBD 2015, these were the same search strings and strategies as were employed in GBD 2013.  
462 initial hits; 54 sources selected for full text review and data extraction: (((chlamydia[Title/Abstract] OR 
chlamydia tracomatis[Title/Abstract] OR trachoma[Title/Abstract]) AND prevalence[Title/Abstract]) AND 
('2013'[Date - Publication] : '2015'[Date - Publication]))   /// ((gonorrhea[Title/Abstract] OR 
Neisseria[Title/Abstract] OR gonococcal[Title/Abstract]) AND prevalence[Title/Abstract]) AND 
("2013"[PDAT] : "2015"[PDAT]) /// ((trichomonal[Title/Abstract] OR trichomonas[Title/Abstract]) AND 
prevalence[Title/Abstract]) AND ('2013'[PDAT] : '2015'[PDAT])   
1265 initial hits; 178 sources selected for full text review and data extraction: ("syphilis"[MeSH] OR 
"Treponema pallidum"[MeSH]) NOT "Yaws"[MeSH] AND "prevalence"[MeSH] AND "1990"[PDAT] : 
"2015"[PDAT] AND "humans"[MeSH] /// ("syphilis"[MeSH] OR "Treponema pallidum"[Mesh]) NOT 
“Yaws”[MeSH] AND ("incidence"[MeSH]) AND ("1990"[PDAT] : "2015"[PDAT]) AND "humans"[MeSH])  
13 initial hits; 1 selected for full text review and data extraction: herpes"[Title/Abstract] OR "Herpesvirus 2, 
Human"[Mesh]) AND ("Prevalence"[Title/Abstract] OR "Incidence"[Title/Abstract] AND ("2015"[PDAT] : 
"2015"[PDAT]) 
 
The genital herpes dataset was supplemented by those sources contained in recent published estimates 
completed by Looker and colleagues.1,2 For all other STI, most notably early syphilis, we supplemented 
our datasets with manual search of national ministry of health websites, antenatal clinic surveillance 
reports, and case-notification data from locations where centralized reporting is mandatory.  
To be included, a study must report on laboratory-confirmed diagnosis of an STI. For each STI, the 
reference category for diagnostic modality was a DNA-based test (eg, PCR or other nucleic acid 
amplification test) and data using any other diagnostic test were quantitatively crosswalked to the 
reference category using binary study-level covariates in DisMod-MR 2.1 For genital herpes, any sources 
that did not use nucleic acid amplification were excluded.  
For early syphilis, crosswalks were performed in a country-specific manner because non-treponemal 
false-positive rate is dependent on several epidemiological factors, including age, sex, and endemicity of 
other infections. Given the potential variability in immunological reasons for false positives in each of the 
other STI categories, we also did not perform any adjustment for published sensitivity and specificity of 
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tests, as these results are often drawn from particular populations that may not be representative of the 
global experience for each infection.  
For all STI, including genital herpes, sources were excluded if the sample population was drawn 
exclusively from a high-risk group (eg, HIV-positive, men who have sex with men [MSM], or sex workers).  
All surveillance data were considered prevalence when modeling chlamydia and gonorrhea, and all data 
were considered prevalence when modeling early syphilis. 
Data were outliered or excluded if we found them unreasonable when compared to regional, super-
regional, and global rates. These data included European surveillance data, much of which was 
unreasonably low. 
Composition of final datasets are shown below for each of the different STI models.  
Gonococcal infection 
 Prevalence Incidence 
Studies 177 5 
Countries/subnationals 75/240 3 
GBD world regions 20 3 
 
Chlamydial infection 
 Prevalence Incidence 
Studies 203 2 
Countries/subnationals 93/221 1/0 
GBD world regions 21 1 
 
Early syphilis 
 Prevalence 
Studies 409 
Countries/subnationals 167/155 
GBD world regions 21 
 
Adult tertiary syphilis 
 Prevalence 
Studies 34 
Countries/subnationals 17/127 
GBD world regions 7 
 
Trichomoniasis infection 
 Prevalence 
Studies 115 
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Countries/subnationals 62/18 
GBD world regions 20 
Genital herpes 
Prevalence Incidence 
Studies 269 20 
Countries/subnationals 72/38 12/8 
GBD world regions 20 7 
Modelling strategy  
Overall, we have made no substantive changes to the estimation strategy since GBD 2015. We estimated 
the nonfatal burden of STI in three parts. For the first part we estimated the prevalence, incidence, 
remission, and case fatality from acute infection associated with gonococcus, chlamydia, trichomoniasis, 
genital herpes (from herpes simplex virus 2), early syphilis, and adult tertiary syphilis using the data above 
and DisMod-MR 2.1. Not all cases of STI are symptomatic, so we used literature review to guide splitting 
prevalent cases into asymptomatic and symptomatic health states.3,4 Specific modelling considerations in 
DisMod-MR 2.1 for each STI are described below.  
The second part, which is estimation of prevalence, incidence, remission and case fatality from pelvic 
inflammatory disease (PID) and PID-induced primary and secondary infertility, is described in a separate 
section on those conditions. Briefly, for PID we used ICD-9 and ICD-10 coded discharge datasets, 
Marketscan claims database, and systematic literature review to develop a dataset that was 
subsequently modelled for all locations using DisMod-MR 2.1. Processing steps for discharge and claims 
data are described separately. PID was then split into underlying ideologies (chlamydia, gonorrhea, and 
other) using results of supplemental literature review and DisMod-MR 2.1 models of the proportion due 
to each etiology. PID-induced primary and secondary infertility assuming only a fixed subset of incident 
PID cases develop infertility and that there is no remission in these cases.  
The third and final part involved finding the ratio of YLD to YLL ratio for all STI (excluding other STI) and 
then applying that same ratio to other STI YLLs.  
Gonococcal infection 
Prevalence data were the primary input from literature, case notification systems, and surveillance. 
Incidence was restricted to occur only between ages 10 and 69. EMR was set to have a maximum value of 
0.0001. Remission rate bounds were set to be between 2 and 5 (translating to a duration of 10 to 26 
weeks), and are the same as we used in GBD 2015, GBD 2013, and GBD 2010.3,4 Study covariates included 
crosswalks for data where case diagnosis was based on culture or other non-nucleic acid amplification 
tests (PCR is the gold-standard diagnostic method). Surveillance/notification data were also crosswalked 
against the reference definition. Female-to-male ratio of prevalence and incidence was restricted to not 
exceed 2.01:1, an approach that was used to account for relatively sparse data from males. Coverage 
proportion of four visits of antenatal care coverage (ANC4) was the only country covariate and was 
assigned to prevalence.  
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We assigned the proportion of persons who developed symptoms of infection and/or epididymo-orchitis. 
Both were unchanged from GBD 2010 and are the same as used in WHO analyses. Males were assigned 
a fixed proportion of each of the following health states. Epididymo‐orchitis differed for locations with 
long time series of high-quality vital registration data (“data-rich”) compared to locations with poor data 
(“all others”). This split was performed for developed versus developing countries in GBD 2013 and GBD 
2010. Data-rich proportion was 0.03 (0.015–0.045) and all others was 0.0975 (0.0483–0.143). A 
proportion of the remainder, 0.5875 (0.5288–0.6463), were assigned a health state of mild, acute 
infectious disease. The remainder were assumed to be asymptomatic. Females were estimated to have a 
proportion with mild, acute infectious disease of 0.34 (0.306–0.374) and the remainder asymptomatic.3,4 
Females have fewer symptoms of gonorrhea than males, which results in higher YLDs among males, 
despite a lower number of cases.  
Gonococcal infection 
Study-level covariate Parameter Location level beta Exponentiated beta 
Sex prevalence Global 0.37 (0.30 – 0.70) 1.45 (1.29 – 2.01) 
Culture-positive prevalence 
Global -0.0054 (-0.039 to – 
0.000071) 0.99 (0.96 – 1.00) 
Diagnosis other prevalence 
Global -0.0063 (-0.051 to -
0.00019) 0.99 (0.95 – 1.00) 
Country-level covariate Parameter beta Exponentiated beta 
Antenatal Care (4 visits) 
Coverage (proportion) prevalence 
-0.021 (-0.098 to -
0.0000033) 0.98 (0.91 – 1.00) 
Chlamydial infection 
Chlamydia estimation methods were the same as used for gonococcal infection described above, with a 
few exceptions. Remission bounds were set between 0.5 and 0.9599, and the female-to-male sex ratio of 
prevalence and incidence was restricted to not exceed 1.35:1. The proportion of antenatal care coverage 
(4 visits) was applied as a country-level covariate. 
The approach to estimating sequelae was the same as for gonorrhea, although the proportions in each 
state were different. Data- rich proportion was 0.02 (0.01–0.03) and all others was 0.0625 (0.0325–
0.0975). A proportion of the remainder, 0.505 (0.4545–0.5555), were assigned a health state of mild, 
acute infectious disease. The remainder were assumed to be asymptomatic. Females were estimated to 
have proportion with mild, acute infectious disease of 0.17 (0.153–0.187) and the remainder 
asymptomatic.3,4 Again, despite a higher number of cases among females, the YLD-per case among males 
was higher.  
Chlamydial infection 
Study-level covariate Parameter Location 
level 
beta Exponentiated beta 
Diagnosis other prevalence 
Global -0.031 (-0.18 to -
0.00029) 0.97 (0.83 – 1.00) 
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Culture-positive prevalence 
Global -0.024 (-0.12 to -
0.00058) 0.98 (0.89 – 1.00) 
Country-level covariate Parameter beta Exponentiated beta 
Antenatal Care (4 visits) 
Coverage (proportion) prevalence 
-0.024 (-0.093 to -
0.00013) 0.98 (0.91 – 1.00) 
Trichomoniasis 
Trichomoniasis estimation methods were similar to those used for gonococcal and chlamydia infection. 
However, the female-to-male sex ratio was unbounded, and excess mortality rate was assumed to be 
zero. Remission was bounded from 0.7199 and 0.89. Surveillance and case-notification data for 
trichomonas was considered to be unreliable and not used. The reference definition for diagnostic was 
PCR, and wet mount and culture positive were crosswalked against the reference definition.  
Males are assumed to be 100% asymptomatic with trichomoniasis, while 0.34 (0.306–0.374) of prevalent 
females were assigned a health state of mild, acute infectious disease.3,4 
Trichomonas infection 
Study-level covariate Parameter Location 
level 
beta Exponentiated beta 
Diagnostic wet mount prevalence 
Global -0.41 
(-0.5 to -0.24) 0.66 (0.61 – 0.79) 
Culture-positive prevalence 
Global -0.15 
(-0.38 to -0.01) 0.86 (0.68 – 0.99) 
Country-level covariate Parameter beta Exponentiated beta 
Antenatal care (4 visits) 
coverage (proportion) prevalence -0.052 (-0.098 to -0.003) 0.95 (0.91 – 1.00) 
Genital herpes due to HSV-2 
Genital herpes estimation assumed remission and mortality are both zero. Incidence estimates were thus 
based on mathematical integration of age-specific prevalence data. Incidence was restricted to occur 
between ages 10 and 59. After careful analysis, the modeling strategy for genital herpes has evolved to 
exclude high-risk populations. High-risk groups that were excluded included MSM, HIV-positive, prisoners, 
sex workers, drug users, and STI clinic samples. However, blood donor samples were included, and 
crosswalked to the general population assuming the prevalence is lower than that of the general 
population. Data on pregnant populations were also crosswalked, without a priori knowledge of direction. 
Crosswalks were performed at the regional level to allow for variation in the quantitative relationship. A 
single country covariate, age-standardized HIV prevalence, was used to guide estimates in locations with 
sparse data in recognition of the strong relationship between HSV-2 and HIV transmission.  
243
Many with initial genital herpes infection have a painful rash that, while not as severe as that 
accompanying zoster reactivation, is more severe than that associated with recurrent genital herpes 
episodes. A systematic literature review revealed a few studies that informed our estimation that 0.175 
(0.10–0.25) of initial herpes cases have symptoms of moderate, acute infectious disease lasting 3 (2–4) 
weeks and 0.189 have prevalent persons have 6 (5–7) recurrent episodes per year each lasting 2 (1–3) 
weeks.5–7 
Genital herpes 
Study-level covariate Parameter Location 
level 
beta Exponentiated 
beta 
Study Population Blood 
Donors Prevalence Region 
-0.38  
(-0.62 to -0.16) 0.68 (0.54 – 0.86) 
Study Population 
Pregnant Prevalence Region 
-0.11  
(-0.25 to -0.034) 0.90 (0.78 – 1.03) 
Country-level covariate Parameter beta Exponentiated beta 
HIV age-standardized 
prevalence Prevalence 
0.057  
(0.0038 – 0.098) 1.06 (1.00 – 1.10) 
Early syphilis 
For early syphilis estimation methods, data were assumed to be prevalence measures. Age range was 
restricted to be from 10 to 64 years. Excess mortality was assumed to be 0, and incidence rates were 
assumed to be less than 0.3. Remission bounds were between 0.5 and 2. Blood donor samples 
consistently had prevalence values that were lower than that of the general population, and were 
crosswalked accordingly. Data from studies using only treponemal tests, or only non-treponemal tests, 
were additionally crosswalked to the reference definition of both treponemal and non-treponemal 
testing. Crosswalks were performed in a country-specific manner to reflect the variability in false positive 
rate in non-treponemal tests as a function of age, sex, and endemicity of other non-STI infectious 
conditions. The proportion of antenatal care coverage was applied as a country covariate on prevalence.  
Our review of literature on proportion of early syphilis cases with symptoms led to assignment of a 0.686 
(0.627–0.745) of prevalent cases to have a combined duration of primary and secondary symptoms 
lasting 23 (13–44) days.8–11 The remainder were considered asymptomatic. 
Early syphilis infection 
Study-level covariate Parameter Location 
level 
beta Exponentiated beta 
Study Population Blood 
Donors prevalence 
Country -0.2 (-0.2 to -
0.19) 0.82 (0.82 – 0.82) 
Non-trep only prevalence 
Country 0.0021 (0.00008 
– 0.0094) 1.00 (1.00 – 1.01) 
Country-level covariate Parameter beta Exponentiated beta 
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Antenatal Care (4 visits) 
Coverage (proportion) prevalence -0.2 ( -0.2 to -0.2) 0.82 (0.82 to 0.82) 
Adult tertiary syphilis 
Prevalence data were the primary input. Incidence was assumed to not occur until age 15. Excess 
mortality rate was capped at 0.1, which equates to minimum duration of five years, and no remission was 
assumed. Cause-specific mortality rate (CSMR) results from GBD 2016 mortality and causes of death 
analysis were included in the model, which was also used to back-calculate excess mortality rate (EMR) 
data to match each input prevalence datum.12 CSMR priors were not passed on through the cascade so as 
to restrict the utility of these data to back-calculating prevalence at the country level. Study-level 
covariates were used to crosswalk surveillance data to the reference source of hospital data. Natural log 
of lag-distributed income (LN-LDI) was used as a country-level covariate on EMR. Non transformed 
syphilis prevalence was used as used as a country-level covariate on prevalence. An increasing slope prior 
was applied to incidence from ages 30 to 100.  
Two notable differences exist between GBD 2016 and previous estimates of adult tertiary syphilis. First, in 
GBD 2015 all cases of adult tertiary syphilis were assumed to be symptomatic and were assigned the 
same disability that describes a health state of moderate motor and cognitive dysfunction. For GBD 2016, 
there were 8 new sequelae, including asymptomatic adult tertiary syphilis. Second, the reference source 
was hospital data, which was adjusted for the likelihood of tertiary syphilis to appear as an inpatient or 
outpatient case.  
Adult tertiary syphilis 
Study-level covariate Parameter Location 
level 
beta Exponentiated beta 
Surveillance/notification 
data prevalence 
Global -1.1 (-1.23 to -
0.98) 0.33 (0.29 – 0.38) 
Country-level covariate Parameter beta Exponentiated beta 
LDI (I$ per capita) 
excess 
mortality rate -0.24 (-0.29 to -0.2) 0.79 (0.75 – 0.82) 
Syphilis prevalence 
(proportion) Prevalence 0.098 (0.0021 – 0.41) 1.10 (1.00 – 1.51) 
Other sexually transmitted infections 
To calculate YLDs due to acute infection with other STI, we calculated the YLD to YLL ratio for all STI 
(excluding other STI) and then applied that same ratio to other STI YLLs. YLDs were also estimated to 
other STI as a result of the proportion of PID and PID-induced infertility that was not due to gonorrhea or 
chlamydia.  
Uncertainty and model selection 
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For all STI estimates, uncertainty bounds include uncertainty due to input data, including CSMR from GBD 
2016 mortality and causes of death analysis, crosswalks from non-reference definitions, uncertainty in 
numerical solutions (posteriors) of each DisMod-MR 2.1 model, and proportion of all infections with each 
type of symptom.  
In consultation with GBD researchers and collaborators, final models were selected on a combination of 
qualitative and quantitative goodness of fit to input data, plausibility of geographic and temporal trends, 
consistency of age pattern, and, when available, comparison with other published studies on STI 
epidemiology. Directionality, magnitude, and plausibility of study-level and country-level covariates was 
also considered in the process of model development. Of note, due to the nature of statistical modelling, 
final results do not always cover the values reported in input data. 
 
No other changes were made to the modelling strategy for GBD 2016. 
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Case definition 
We define acute hepatitis A as an infection with the hepatitis A virus resulting in anti-HAV IgG 
seroconversion, regardless of symptoms.  It includes all ICD-10 codes under the heading B15 (Acute 
hepatitis A). 
Input data 
 Model inputs 
We use anti-HAV seroprevalence data from population-based studies and surveys for the incidence 
model.   
Level Prevalence 
Data points 3668 
Studies 469 
Locations 175 
Regions 21 
 
Updates to systematic reviews are performed on an ongoing schedule across all GBD causes, an update 
for hepatitis A will be performed in the next 1-2 iterations.   
Severity splits & disability weights 
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Based on information published by Armstrong et al, (Armstrong GL, Bell BP. Hepatitis A Virus Infections 
in the United States: Model-Based Estimates and Implications for Childhood Immunization. Pediatrics. 
2002 May 1;109(5):839–45.) we assume that the probability of symptomatic infection increases with age 
from ~1% in the first year of life to ~85% in adulthood.   
The table below illustrates the sequelae associated with Acute Hep A, as well as the lay descriptions and 
associated disability weights. 
Sequela Description 
Disability 
Weight 
Moderate Has a fever and aches, and feels weak, which causes 
some difficulty with daily activities.  
0.051 
(0.032-0.074) 
Severe Has a high fever and pain, and feels very weak, 
which causes great difficulty with daily activities. 
0.133 
(0.088-0.19) 
Asymptomatic Infection with no apparent illness of NA 
Modelling strategy 
Given its reasonably stable force of infection among susceptible people across age groups, we used a 
catalytic binomial model to estimate incidence of acute hepatitis A based on anti-HAV seroprevalence. 
The catalytic binomial model is a binomial generalized linear model with a complementary log-log link, 
and an offset term for log-age.  Since anti-HAV is a lifetime marker of past infection, and a given 
individual can only be infected once, seroprevalence at age t is equal to the cumulative incidence (CI) 
over t years.  Assuming constant force of infection, we can estimate the incidence rate (IR) as, 
𝐶𝐼 = 1 − 𝑒−𝐼𝑅∙𝑡 
We can rearrange this equation to solve for the log-IR: 
ln (𝐼𝑅) =  
ln (− ln(1 − 𝐶𝐼))
ln (𝑡)
Thus, by using the complimentary log-log link for CI (i.e. ln(-ln(1-CI)) with an offset for log-age, we are 
able to model the incidence rate of infection from seroprevalence data. To inform the model in the 
absence of data we use a predictive covariate derived from principal components analysis of lag-
distributed income (LDI) and the proportion of the population with access to improved water.  We use a 
mixed effects model with fixed effects on the aforementioned PCA-derived covariate, and nested 
hierarchical random effects on super-region, region, country, and sub-national locations. 
Changes from GBD 2015 to GBD 2016 
Our overall approach has not changed from that used in GBD 2016 
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Case definition 
We define acute hepatitis B as the period corresponding to initial infection with the hepatitis B virus, 
regardless of symptoms.  It includes all ICD-10 codes under the heading B16 (Acute hepatitis B). 
Input data 
 Model inputs 
We use hepatitis B surface antigen (HBsAg) seroprevalence data from population-based studies and 
surveys for the incidence model.   
Level Prevalence 
Data points 2987 
Studies 312 
Locations 145 
Regions 19 
 
Updates to systematic reviews are performed on an ongoing schedule across all GBD causes, an update 
for hepatitis A will be performed in the next 1-2 iterations.   
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Modelling strategy 
We model the incidence of chronic HBsAg carriage using a full DisMod model of HBsAg seroprevalence.  
We then convert incidence of chronic carriage to total incidence of hepatitis B infection by dividing age-
specific estimates of the incidence of chronic carriage by age-specific estimates of the probability of 
infection resulting in carriage based on Edmunds et al (Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, 
Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci. 1993 
Aug 23;253(1337):197–201): 
 
𝑃(𝑐𝑎𝑟𝑟𝑖𝑒𝑟 | 𝑎𝑔𝑒 ≤ 6 𝑚𝑜𝑛𝑡ℎ𝑠) =  0.885 
 
𝑃(𝑐𝑎𝑟𝑟𝑖𝑒𝑟 | 6 𝑚𝑜𝑛𝑡ℎ𝑠 ≤ 𝑎𝑔𝑒 < 25 𝑦𝑒𝑎𝑟𝑠) =  𝑒−0.645 ×𝑎𝑔𝑒
0.455
 
 
𝑃(𝑐𝑎𝑟𝑟𝑖𝑒𝑟 | 𝑎𝑔𝑒 ≥ 25 𝑦𝑒𝑎𝑟𝑠) =  𝑒−0.645 ×25
0.455
= 0.061 
 
 
We then split symptomatic cases into moderate (73%) and severe (27%) severities based on data from 
McMahon et al (McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute 
hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent 
development of the carrier state. J Infect Dis. 1985 Apr;151(4):599–603). 
 
 
Sequela Description 
Disability 
Weight 
Moderate Has a fever and aches, and feels weak, which causes 
some difficulty with daily activities.  
0.051 
(0.032-0.074) 
Severe Has a high fever and pain, and feels very weak, 
which causes great difficulty with daily activities. 
0.133 
(0.088-0.19) 
Asymptomatic Infection with no apparent illness of NA 
 
 
Changes from GBD 2015 to GBD 2016 
We have updated the severity splits, but the modeling strategy remains otherwise unchanged from GBD 
2013.  
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Case definition 
We define acute hepatitis C as the period corresponding to initial infection with the hepatitis C virus, 
resulting in anti-HCV IgG seroconversion, regardless of symptoms.  It includes all ICD-10 codes under the 
heading B17.1 (Acute hepatitis C). 
 
Input data 
Model inputs 
To estimate morbidity for HepC, we use anti-HCV seroprevalence data from population-based studies 
and surveys to estimate incidence and prevalence of hepatitis C infection: 
Level Prevalence 
Data points 5242 
Studies 239 
Locations 521 
Regions 21 
 
251
Model 
We model the incidence and prevalence of hepatitis C infection using a full DisMod model of anti-HCV 
seroprevalence data.  We divide incident infections into asymptomatic (75%), moderate (24%), and 
severe (1%) states.  Based on a meta-analysis, we estimate that 75% of anti-HCV positive people are 
chronically infected. 
 
Sequela Description 
Disability 
Weight 
Moderate Has a fever and aches, and feels weak, which causes 
some difficulty with daily activities.  
0.051 
(0.032-0.074) 
Severe Has a high fever and pain, and feels very weak, 
which causes great difficulty with daily activities. 
0.133 
(0.088-0.19) 
Asymptomatic Infection with no apparent illness of NA 
 
Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modeling strategy from GBD 2015.  
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Case definition 
For GBD 2016, we define acute hepatitis E as an infection with the hepatitis E virus resulting in anti-HEV 
IgG seroconversion, regardless of symptoms.  It includes all ICD-10 codes under the heading B17.2 
(Acute hepatitis E). 
 
Input data 
 Model inputs 
For GBD 2016 estimation, we used anti-HEV seroprevalence data from population-based studies and 
surveys to estimate incidence of infection. The table below indicates the number of data points included 
in terms of prevalence by location hierarchy: 
 
Level Prevalence 
Data points 433 
Studies 85 
Locations 56 
Regions 19 
   
253
Modeling Strategy 
The GBD 2016 estimation process for HepE uses a DisMod MR 2.1 model, which is a Bayesian meta-
regression. We model the incidence of Hepatitis E using a full DisMod MR 2.1 model of anti-HEV 
seroprevalence, assuming no remission.   Based on information published by Rein et al1 we assume that 
the probability of symptomatic infection increases with age from ~1% in the first year of life to ~60% in 
adulthood.   
 
The table below illustrates the sequelae associated with Acute HepE, along with their descriptions and 
disability weights. 
 
Sequela Description 
Disability 
Weight 
Moderate Has a fever and aches, and feels weak, which causes 
some difficulty with daily activities.  
0.051 
(0.032-0.074) 
Severe Has a high fever and pain, and feels very weak, 
which causes great difficulty with daily activities. 
0.133 
(0.088-0.19) 
Asymptomatic Infection with no apparent illness of NA 
 
Changes from GBD 2015 to GBD 2016 
We have made no substantive changes in the modeling strategy from GBD 2015.  
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Neoplasms (Cancer) 
All cancers except for non-melanoma skin cancer (basal cell carcinoma and 
squamous cell carcinoma) 
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Input data and methodological appendix 
Case definition 
For GBD 2016, incidence, prevalence, and disability are estimated for all cancers as defined in ICD-10 
(C00-C96). Prevalence for all cancers is estimated for a maximum of 10 years after incidence as in GBD 
2013 and GBD 2015. Prevalence extending beyond the 10 year period is only estimated for permanent 
sequelae from procedures. 
To estimate disability for each cancer, total prevalence is split into four sequelae: 1. diagnosis and primary 
therapy; 2. controlled phase; 3. metastatic phase; and 4. terminal phase. Diagnosis and primary therapy 
are defined as the time from symptoms onset to end of treatment. Controlled phase is defined as the 
time after finishing primary treatment and either cure (defined as survival after 10 years) or metastatic 
phase. Metastatic phase is defined as the time period of intensive treatment for metastatic disease, 
terminal phase is defined as the one month period prior to death. Each of these sequelae has a separate 
disability weight (Error! Reference source not found.). Additional disability is estimated for breast cancer 
(disability due to mastectomy), larynx cancer (disability due to laryngectomy), colon and rectum cancer 
(disability due to stoma), bladder cancer (disability due to incontinence), and prostatectomy (disability 
due to incontinence and impotence). The associated ICD codes for neoplasms estimated for GBD 2016 
are listed below, as well as in Appendix Table 4. 
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Table 1. GBD cancer causes with respective ICD codes 
GBD cause ICD9 ICD10 
Bladder cancer 188.0-188.9 C67-C67.9 
Brain and nervous system cancer 191.0-192.9 C70-C72.9 
Breast cancer 174.0-175.9 C50-C50.929 
Cervical cancer 180.0-180.9 C53-C53.9, D26.0 
Colon and rectum cancer 153.0-154.9, 209.1-
209.17 
C18-C21.9 
Esophageal cancer 150.0-150.9 C15-C15.9 
Gallbladder and biliary tract cancer 156.0-156.9, 209.25-
209.27 
C23-C24.9 
Hodgkin disease 201.0-201.98 C81-C81.99 
Kidney cancer 189.0-189.1, 209.24 C64-C65.9 
Larynx cancer 161.0-161.9 C32-C32.9 
Leukemia 208.0-208.92 C94.1, C94.7-C95.92 
Acute lymphoid leukemia  ALL  204.0-204.02 C91.0-C91.02 
Acute myeloid leukemia AML 205.0-205.02, 205.3-
205.32, 206.0-
206.02, 207.0 
C92.0-C92.02, C92.3-
C92.62, C93.0-C93.02, 
C94.0-C94.02, C94.2-
C94.22, C94.4-C94.5 
Chronic lymphoid leukemia CLL 204.1-204.12 C91.1-C91.12 
Chronic myeloid leukemia CML 205.1-205.12, 206.1-
206.12, 207.1 
C92.1-C92.12 
Other leukemia 204, 204.2, 204.5, 
204.8, 204.9, 205, 
205.2, 205.8, 205.9, 
206, 206.2, 206.8, 
206.9, 207, 207.0-
207.2, 207.8, 207.9, 
208, 208.0-208.2, 
208.4, 208.7, 208.8, 
208.9 
C91, C91.2, C91.3-
C91.9, C92, C92.2, 
C92.7-C92.9, C93, 
C93.1-C93.3, C93.5, 
C93.7-C93.9, C94, 
C94.1, C94.3, C94.6-
C94.8, C95, C95.1-
C95.2, C95.4, C95.6, 
C95.7, C95.9 
Liver cancer 155.0-155.9 C22-C22.9 
Lung, bronchus, and trachea cancer 162.0-162.9, 209.21 C33-C34.92 
Non-Hodgkin lymphoma 200.0-200.9, 202.0-
202.98 
C82-C86.6, C96-C96.9 
Malignant skin melanoma 172.0-172.9 C43-C43.9 
Mesothelioma 158.9, 163.0-163.9 C45-C45.9 
Oral and Lip Cancer 140.0-145.9 C0-C08.9 
Multiple myeloma and immunoproliferative diseases  203.0-203.9 C88-C90.9 
Nasopharynx cancer 147.0-147.9 C11-C11.9 
Non-melanoma skin cancer (Basal cell carcinoma) 173.0-173.01, 
173.09-173.11, 
173.19-173.21, 
173.29-173.31, 
C44.0-C44.01, 
C44.09-C44.119, 
C44.19-C44.219, 
C44.29-C44.319, 
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173.39-173.41, 
173.49-173.51, 
173.59-173.61, 
173.69-173.71, 
173.79-173.81, 
173.89-173.91, 
173.99, 216.0-216.9, 
232.0-232.9, 238.2 
C44.39-C44.41, 
C44.49-C44.519, 
C44.59-C44.619, 
C44.69-C44.719, 
C44.79-C44.80, 
C44.82-C44.91, 
C44.99 
Non-melanoma skin cancer (Squamous-cell carcinoma) 173.02, 173.12, 
173.22, 173.32, 
173.42, 173.52, 
173.62, 173.72, 
173.82, 173.92 
C44.02, C44.12-
C44.129, C44.22-
C44.229, C44.32-
C44.329, C44.42, 
C44.52-C44.529, 
C44.62-C44.629, 
C44.72-C44.729, 
C44.81, C44.92, D04-
D04.9, D49.2 
Other neoplasms 158.0-158.8, 209.4-
209.57, 209.61, 
209.63-209.67, 
210.0-211.8, 212.0-
212.8, 213.0-215.9, 
217.0-221.8, 222.0-
222.8, 223.0-223.89, 
224.0-229.0, 229.8, 
230.1-230.8, 231.0-
231.2, 233.0-233.2, 
233.31-233.32, 
233.4-233.5, 233.7, 
234.0-234.8, 235.0, 
235.4, 235.6-235.8, 
236.1-236.2, 236.4-
236.5, 236.7, 
236.91-237.3, 237.5-
238.1, 238.3-238.5, 
239.2-239.4, 239.6 
D00.00-D00.2, D01.0-
D01.3, D02.0-D02.3, 
D03-D03.9, D05-
D06.9, D07.0-D07.2, 
D07.4-D07.5, D09.0, 
D09.2-D09.3, D09.8, 
D10.0-D10.7, D11-
D12.9, D13.0-D13.7, 
D14.0-D14.32, D15-
D24.9, D27-D27.9, 
D28.0-D28.7, D29.0-
D29.8, D30.0-D30.8, 
D31-D36.7, D37.01-
D37.5, D38.0-D38.5, 
D39.1-D39.2, D39.8, 
D40.0-D40.8, D41.0-
D41.8, D42-D43.9, 
D44.0-D44.8, D45-
D45.9, D47-D47.0, 
D47.2-D47.9, D48.0-
D48.7, D49.3-D49.4, 
D49.6 
Other cancers 152.0-152.9, 160.0-
160.9, 164.0-164.9, 
170.0-171.9, 181.0-
181.9, 182.9, 183.2-
183.8, 184.0-184.4, 
184.8, 187.1-187.8, 
189.2-189.8, 190.0-
190.9, 194.0-194.8, 
209.0-209.03, 
C17-C17.9, C3-C31.9, 
C37-C38.8, C4-C41.9, 
C47-C5, C51-C52.9, 
C57-C57.8, C58-
C58.0, C60-C60.9, 
C63-C63.8, C66-
C66.9, C68.0-C68.8, 
C69-C7, C74-C75.8, 
D49.81 
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209.22, 209.31-
209.36 
Other pharynx cancer 146.0-146.9, 148.0-
148.9 
C09-C10.9, C12-C13.9 
Ovarian cancer 183.0 C56-C56.9 
Pancreatic cancer 157.0-157.9 C25-C25.9 
Prostate cancer 185.0-185.9 C61-C61.9 
Stomach cancer 151.0-151.9, 209.23 C16-C16.9 
Testicular cancer 186.0-186.9 C62-C62.92 
Thyroid cancer 193.0-193.9 C73-C73.9 
Uterine cancer 182.0-182.8 C54-C54.9 
Garbage code 149.0-149.9, 159.0-
159.9, 165.0-165.9, 
169.0, 173.0, 176.0-
179.9, 183.9-184.0, 
184.5, 184.9, 187.0, 
187.9, 189.0, 189.9, 
194.9-199.9, 209.0, 
209.2, 209.29-209.3, 
209.6, 209.62, 
209.69-210.0, 211.0, 
211.9-212.0, 212.9, 
221.0, 221.9-222.0, 
222.9-223.0, 223.9, 
229.0-229.1, 229.9-
230.0, 230.9-231.0, 
231.8-231.9, 233.0, 
233.3, 233.39, 233.6, 
233.9-234.0, 234.9-
235.3, 235.5, 235.9-
236.0, 236.3, 236.6, 
236.9, 237.4, 238.0, 
238.6-239.1, 239.5, 
239.7-239.9 
C14-C14.9, C26-C29, 
C35-C36, C39-C39.9, 
C42, C44, C46-C46.9, 
C55-C55.9, C57.9, 
C59-C6, C63.9, C68, 
C68.9, C75.9-C80.9, 
C87, C97-D00.0, D01, 
D01.4-D02, D02.4-
D02.9, D07, D07.3-
D07.39, D07.6-D09, 
D09.1-D09.19, D09.7, 
D09.9-D10, D10.9, 
D13, D13.9-D14, 
D14.4, D28, D28.9-
D29, D29.9-D30, 
D30.9, D36.9-D37.0, 
D37.6-D38, D38.6-
D39.0, D39.7, D39.9-
D40, D40.9-D41, 
D41.9, D44, D44.9, 
D46-D46.9, D47.1, 
D48, D48.9-D49.1, 
D49.5, D49.7-D49.8, 
D49.89-D49.9 
  
Input data 
Cancer incidence is directly estimated from cancer mortality using mortality to incidence ratios (MIR). 
Data sources for cancer mortality are described in detail elsewhere.1 Data sources to scale countries 
between a hypothetical best- and a hypothetical worst case survival remained the same for the worst 
case survival as in GBD 2015 where we used a combination of the 1950 US Mortality Files with “Cancer 
Survival in Africa, Asia, the Caribbean and Central America” (SurvCan) data.2,3 For mesothelioma, 
gallbladder cancer, and the leukemia subtypes SEER 1973 survival data for the lower boundary was used 
since these cancers are not included in the US Mortality Files from 1950. We updated the hypothetical 
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best case survival using 5-year survival data from the SEER Cancer Statistics Review (CSR), 1975-2013.4 To 
estimate the proportion of cancer patients undergoing procedures we used SEER data form 1983 to 
20085 and Mexico Hospital Data from 2001 to 20097. Data sources used to adjust procedure sequelae will 
be listed below. 
Modeling strategy  
Estimation of cancer mortality and MIR estimation has been described in the GBD 2016 Mortality and 
Causes of Death capstone paper. The final GBD cancer mortality estimates are being transformed to 
incidence estimate by using separately estimated MIR. To summarize the MIR estimation process, 
incidence and mortality data from cancer registries were matched by cancer, age, sex, year, and location 
to generate MI ratios. Compared to GBD 2015 we used more narrow inclusion criteria to select the input 
for the MIR model. Only sources were included that reported both, incidence and mortality. We dropped 
MIR if cases were less than 25. Compared to the outliering process for GBD 2015, which relied on the 
binary classification of “developed” versus “developing” countries, we used SDI quintiles for GBD 2016 for 
dropping unrealistic data in the input dataset. MI ratios from SDI quintiles 1-4 were dropped if they were 
below the median MI ratio of quintile 5. This was done under the assumption that these MI ratios reflect 
incomplete death ascertainment. To not artificially increase the predicted MI ratio, MI ratios from SDI 
quintiles 1-4 were dropped if they were above the third interquartile range (IQR) x 1.5 IQR. MI ratios 
above 2 were dropped. To avoid MIR predictions for all age groups and all years above 1, the MIR input 
data was divided by upper caps. Upper caps were generated using the 95th percentile of MIR in the 
cleaned input dataset for all cancers combined. To avoid too low MIR predictions especially in young age 
groups with little data, the MIR data input was divided by lower caps, which were the 5th percentile of the 
cleaned input dataset by cancer.  
A fixed effect logistic regression was used to fit the model input using the Socio-demographic Index (SDI) 
as a covariate with age and sex as categorical variables. The model was run separately by cancer and 
results were rescaled using the lower and upper caps. 
logit (𝑀𝐼 𝑟𝑎𝑡𝑖𝑜𝑐,𝑎,𝑠,𝑡) = 𝛼 + β1𝑆𝐷𝐼𝑐,𝑡 + ∑ β2𝐼𝑎
𝐴
𝑎
+ β3𝐼𝑠 + ϵ𝑐,𝑎,𝑠,𝑡   
 
c: country, a: age group, t: time (years); s: sex 
SDI: Socio-demographic index (index using log lag dependent income per capita (LDI), average 
educational attainment in the population over age 15, and total fertility rate (TFR)) 
I: indicator variable  
ϵc,a,s,t: error term 
 
Data points were outliered manually if they clearly influenced the model in an unrealistic way. For 
example, a data point was marked as an outlier if it created a single-year, single age group spike in model 
predictions. Results from the final linear model were used as input for space-time smoothing and a 
Gaussian Process Regression (ST-GPR) (Appendix Section 2.9). Compared to GBD 2013 and 2015 the MI 
ratio estimation continues to be revised since the modeling strategy used for GBD 2015 yielded MI ratios 
for low- and low-middle SDI that were very close to MI ratios from high-SDI countries for certain cancers.  
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Final MI ratio estimates at the 1000 draw level were combined with final mortality estimates (as well at 
the 1000 draw level) to generate incidence estimates. It was assumed that uncertainty in the MI ratio is 
independent of uncertainty in the estimated mortality. 
After transforming the final GBD cancer mortality estimates to incidence estimates (step 1 in the 
flowchart), incidence was combined with the relative yearly survival estimates up to 10 years (step 8 in 
the flowchart). To estimate cancer prevalence, relative cancer survival was estimated by scaling cancer 
specific survival between the “best case” and “worst case” survival, using the survival data sources listed 
above (step 2, 3, and 5 in the flowchart). To transform relative to absolute survival (adjusting for 
background mortality), GBD 2016 lifetables were used (step 6 and 7 in the flowchart) to calculate lambda 
values: lambda= (ln(nLxn/nLxn+1))/5 where nLx=person years lived between ages x and x+n (from GBD 
lifetable). Absolute survival was then calculated using an exponential survival function (absolute survival = 
relative survival * elambda*t). 
The access to cancer care variable to scale countries between the best and worst case survival was 
estimated using the same method as for GBD 2013 and GBD 2015 (step 4 in the flowchart)8: 
𝐴𝑐𝑐𝑒𝑠𝑠 𝑡𝑜 𝑐𝑎𝑟𝑒 = 1 −
𝐴𝑔𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑀𝐼𝑅𝑐𝑦𝑠 − 𝐴𝑔𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑀𝐼𝑅𝑚𝑖𝑛
𝐴𝑔𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑀𝐼𝑅𝑚𝑎𝑥 − 𝐴𝑔𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑀𝐼𝑅𝑚𝑖𝑛
 
c=country; y=year; s=sex; Age-standardized MI ratiomin=lowest MIR for all countries and years; Age 
standardized MIRmax=highest MIR for all countries and years 
Survivors beyond 10 years were considered cured. The survivor population prevalence was divided into 
two sequelae (1. diagnosis and primary therapy; 2. controlled phase). The yearly prevalence of the 
population that did not survive beyond 10 years was then divided into the four sequelae by assigning the 
fixed durations for the diagnosis and primary therapy phase, metastatic phase, and terminal phase and 
assigning the remaining prevalence to the controlled phase (step 9 in the flowchart). Duration of the 
treatment sequelae (1. diagnosis and primary therapy; 2. controlled phases; 3. metastatic phase; 4. 
terminal phase) remained the same as for GBD 2013 and GBD 2015.8 Table 3 lists the duration including 
sources used. 
Table 3. Duration of four prevalence sequelae by cancer 
  
Diagnosis/ 
Treatment 
(months)  
Remission 
Disseminated/metastatic 
(months) 
Note 
Terminal 
(months) 
Esophageal 
cancer 
59 Calculated 
based on 
remainder 
of time 
after 
attributing 
other 
sequelae. 
 
4.610 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000  
1 
months 
Stomach cancer 5.29 3.8810 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000  
Liver cancer 4 2.5110 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000  
Larynx cancer 5.39 8.8410 SEER Stage IVc 
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Lung cancer  3.311 4.5110 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000  
Breast cancer 311 17.710 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000  
Cervical cancer 4.89 9.2110 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000  
Uterine cancer 4.69 11.610 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000 
Prostate cancer 411 30.3510 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000 
Colorectal 
cancer 
411 9.6910 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000  
Oral cancer 5.39 9.3310 SEER Stage IVc 
Nasopharyngeal 
cancer 
5.39 13.1910 SEER Stage IVc 
Cancer of other 
part of pharynx 
5.39 7.9110 SEER Stage IVc 
Gallbladder 
cancer 
4 3.4710 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000 
Pancreas 
cancer 
4.19 2.5410 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000 
Melanoma 2.912 7.1810 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000 
Ovarian cancer 3.211 25.610 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000 
Testicular 
cancer 
3.79 19.4710 SEER Stage III 
Kidney cancer 5.39 5.3810 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000 
Bladder cancer 5.19 5.810 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000 
Brain cancer 5 6.9310 
SEER Median age 
standardized survival all 
patients, all years 
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Thyroid cancer 3 19.3910 SEER Stage IVc 
Mesothelioma 4 7.7510 
SEER Summary Stage 1997 
(Distant site/node involved) 
1995-2000 
Hodgkin 
lymphoma 
3.711 2614  
Non Hodgkin 
lymphoma 
3.711 7.714  
Multiple 
myeloma 
79 36.8210 
SEER Median age 
standardized survival all 
patients, all years 
Leukemia9 5 43.6710 
SEER Median age 
standardized survival all 
patients, all years 
ALL 12 7.0210 
SEER Median age 
standardized survival all 
patients, all years 
AML 6 4.610 
SEER Median age 
standardized survival all 
patients, all years 
CLL 6 4815 
SEER Median age 
standardized survival all 
patients, all years 
CML 6 4.610 
SEER Median age 
standardized survival  for 
AML (patients with CML die 
in blast crisis, which is 
treated like AML) all 
patients, all years 
Leukemia other 6 4815 
SEER Median age 
standardized survival all 
patients, all years 
Other 
4.4 (mean of 
other cancer 
durations) 
15.8110 
SEER Median age 
standardized survival all 
patients, all years 
 
For cancer specific procedure sequelae hospital data were used to estimate the number of cancer 
patients undergoing mastectomy, laryngectomy, stoma, prostatectomy, and cystectomy (step 10 in the 
flowchart). These proportions remained the same as in GBD 2013 and GBD 2015.8 Proportions were 
generated by dividing the rate of procedures generated from the diagnostic codes in the hospital dataset 
and the coverage population by the GBD age-, and sex-specific disease incidence rates for that country. 
Diagnostic codes used are listed in table 4: 
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Table 4. Procedure codes used to estimate cancer procedure proportions 
Procedure Cancer Procedure code (ICD-9_CM) 
Mastectomy Breast cancer 854, 8541, 8542, 8543, 8544, 
8545, 
8546, 8547, 8548 
Laryngectomy Larynx cancer 301, 303, 304, 3029 
Stoma Colon and rectum cancer 461, 4610, 4611, 4613, 4862 
Cystectomy Bladder cancer  5771, 5779 
Prostatectomy Prostate  603, 604, 605, 606, 6062 
 
To estimate procedure-related disability for certain cancers, the procedure proportions (proportion of 
cancer population that undergoes procedures) from hospital data was used as input for a proportion 
model in Dismod-MR 2.1 in order to estimate the proportions for all locations, by age, and by sex.  
Since colostomy or ileostomy procedures are done for reasons other than cancer a literature review was 
done to determine the proportion of ostomies due to colorectal cancer. The “all cause” colostomy 
proportions were multiplied by 0.58 based on the results of the literature review showing that on average 
58% of ostomies are done for colorectal cancer.16–18   
The final procedure proportions were applied to the incidence cases of the respective cancers and 
multiplied with the proportion of the incidence population surviving for 10 years to determine the 
incident cases of the cancer population that underwent procedures. These incident cases were used 
again as an input for DisMod-MR 2.1 with a remission specification of zero and an excess mortality rate 
prior of 0 to 0.1. This approach was different compared to GBD 2015 where we used the cause-specific 
mortality of the specific cancer to obtain prevalence of the sequela. The approach was changed since the 
mortality for the population undergoing disease specific procedures (e.g. mastectomy for breast cancer) 
is likely closer to the general population after they have survived for a period of time compared to the 
cause-specific mortality of the underlying disease (e.g. breast cancer).  
Since disability associated with prostatectomy comes from impotence and incontinence and not from the 
prostatectomy itself 18% of the prostatectomy prevalence was assumed to be incontinent and 55% was 
assumed to be impotent based on a literature review done for GBD 2013.19–26 
Since all sequelae for a cause need to be mutually exclusive, the controlled phase for the cancers with 
additional procedure related disability was adjusted to only include the population without procedure 
related disability (= controlled phases prevalence of the total population – controlled phase prevalence of 
the proportion that experienced procedure related disability) (step 11 in the flowchart). The disability 
weight for the prevalence of the population that experiences additional disability was adjusted to reflect 
the combined disability of the controlled phase as well as the procedure.  
Lastly, the procedure sequelae prevalence and general sequelae prevalence were multiplied with 
disability weights (Table 5) for the procedures to obtain the number of YLDs (steps 11, 12, 13 in the 
flowchart). The sum of these YLDs is the final YLD estimate associated with each cancer. 
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Table 5. Lay description and disability weights 
Health state Lay description Estimate Uncertainty interval 
Cancer, diagnosis and 
primary therapy 
(cancer_diagnosis) 
This person has pain, nausea, 
fatigue, weight loss and high anxiety. 
              
0.288  
              
0.193  
              
0.399  
Cancer, controlled phase 
(generic_medication) 
This person has a chronic disease 
that requires medication every day 
and causes some worry but minimal 
interference with daily activities. 
              
0.049  
              
0.031  
              
0.072  
Cancer, metastatic 
(cancer_metastatic) 
This person has severe pain, extreme 
fatigue, weight loss and high anxiety. 
              
0.451  
              
0.307  
              
0.600  
Terminal phase, with 
medication 
(cancer_terminal_treat) 
This person has lost a lot of weight 
and regularly uses strong medication 
to avoid constant pain. The person 
has no appetite, feels nauseous, and 
needs to spend most of the day in 
bed. 
              
0.540  
              
0.377  
              
0.687  
Mastectomy 
(cancer_mastectomy) 
This person had one of her breasts 
removed and sometimes has pain or 
swelling in the arms.  
              
0.036  
              
0.020  
              
0.057  
Stoma (cancer_stoma) This person has a pouch attached to 
an opening in the belly to collect and 
empty stools.  
              
0.095  
              
0.063  
              
0.131  
Laryngectomy 
(speech_problems) 
This person has difficulty speaking, 
and others find it difficult to 
understand.  
              
0.051  
              
0.032  
              
0.078  
Urinary incontinence 
(incontinence) 
This person cannot control urinating.               
0.139  
              
0.094  
              
0.198  
Impotence (impotence) This person has difficulty in 
obtaining or maintaining an erection. 
              
0.017  
              
0.009  
              
0.030  
 
Estimating non-melanoma skin cancer (squamous and basal cell carcinoma) 
Mortality due to squamous cell skin cancer was estimated in the same way that all other cancers were 
estimated using the same methods as in GBD 2015 with the exception that only vital registration system 
data (and not cancer registry data) was the sources for squamous cell cancer mortality. CODEm models 
were run to generate estimates for all countries, years, and age groups by sex. As in GBD 2015 for basal 
cell carcinoma of the skin (BCC) we did not estimate any mortality given that this is a very rare event. 
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We estimated squamous cell and basal cell skin cancer incidence by using cancer registry as well as 
primary literature data for incidence. Only cancer registries that were listed in CI5 VIII as registering 
squamous cell carcinoma or basal cell carcinoma respectively, were included in the analysis.27 For cancer 
registry data reported at the three digit level (C44: Other and unspecified malignant neoplasm of skin), 
proportions from Karagas et al were used to split C44 into squamous cell carcinoma and basal cell 
carcinoma.28 We did not add any new data compared to GBD 2015. DisMod-MR 2.1 was used to model 
incidence and prevalence. Prevalence was calculated as function of two extreme scenarios (duration 1 
versus 5 years). Country, age, sex and year specific duration was estimated using a country-age-sex-year 
specific relative access-to-care-score.  
 
The access to care score was based on the melanoma mortality to incidence ratio: 
 
𝐴𝑐𝑐𝑒𝑠𝑠 𝑡𝑜 𝑐𝑎𝑟𝑒 = 1 −
𝐴𝑔𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑀𝐼𝑅𝑐𝑦𝑠 − 𝐴𝑔𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑀𝐼𝑅𝑚𝑖𝑛
𝐴𝑔𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑀𝐼𝑅𝑚𝑎𝑥 − 𝐴𝑔𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑀𝐼𝑅𝑚𝑖𝑛
 
c=country; y=year; s=sex; Age-standardized MI ratiomin=lowest MIR for all countries and years; Age 
standardized MIRmax=highest MIR for all countries and years 
Remission was calculated as the inverse of the duration estimates and used as additional input for 
DisMod-MR 2.1. 
 
To reflect differing degrees of disability due to squamous cell carcinoma we used three levels of severity 
that were derived from MEPS (more detail on severity splits is found in Appendix Section 2.5). Prevalence 
was multiplied by distinct disability weights (Table 6) to generated YLDs. 
 
Table 6. Lay description and disability weights 
Cause Health state  Estimate 
with 
uncertainty 
interval 
Cutaneous squamous 
cell carcinoma, mild 
Disfigurement, 
level 1 
has a slight, visible physical deformity that 
others notice, which causes some worry and 
discomfort. 
0.011 
(0.005-
0.021) 
Cutaneous squamous 
cell carcinoma, 
moderate 
Disfigurement, 
level 2 
has a visible physical deformity that causes 
others to stare and comment. As a result, the 
person is worried and has trouble sleeping and 
concentrating. 
0.067 
(0.044-
0.096) 
Cutaneous squamous 
cell carcinoma, severe 
Disfigurement, 
level 3, with 
itch/pain 
has an obvious physical deformity that is very 
painful and itchy. The physical deformity makes 
others uncomfortable, which causes the person 
to avoid social contact, feel worried, sleep 
poorly, and think about suicide. 
0.576 
(0.401-
0.731) 
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Disfigurement due to 
basal cell carcinoma 
Disfigurement, 
level 1 
has a slight, visible physical deformity that 
others notice, which causes some worry and 
discomfort. 
0.011 
(0.005-
0.021) 
SR Table 15 contains a comparison of GBD 2016 and GLOBOCAN estimated cancer 
incidence by cause and sex for 2012.  
There are no other significant changes to the GBD 2016 neoplasms modeling 
process. 
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Input data and methodological appendix 
 
Case definition 
Rheumatic heart disease (RHD) was defined as a clinical diagnosis by a physician with or without 
confirmation using echocardiography. This case definition for echocardiographic confirmation of RHD 
follows the World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease 
(1). 
 
Criterion Definition 
1. Echocardiography Prevalent rheumatic heart disease based on echocardiographic assessment 
and clinical confirmation 
2. Clinical diagnosis Prevalent rheumatic heart disease based on physician diagnosis 
 
ICD codes for data included from hospital records can be found in Methods Appendix Table 4. 
 
Input data 
Model inputs 
We did not perform a systematic review for GBD 2016. A systematic review was performed for GBD 2013 
and updated for GBD 2015. The GBD 2015 search information encompassed the following: 
• Search terms: ('rheumatic heart disease' AND epidemiology[MeSH Subheading]) OR  ('acute 
rheumatic fever' AND epidemiology[MeSH Subheading]) OR   ('rheumatic fever' AND 
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epidemiology[MeSH Subheading]) OR   (RHD AND epidemiology[MeSH Subheading]) OR    
('valvular heart disease' AND epidemiology[MeSH Subheading]) OR  (((streptococcus OR 
streptococci) AND heart) AND epidemiology[MeSH Subheading]) OR   (heart AND valve AND 
disease AND epidemiology[MeSH Subheading]) OR   ('mitral valve stenosis' AND 
epidemiology[MeSH Subheading]) OR  (('rheumatic heart disease' OR 'rheumatic fever') AND 
prevalence) OR  (('rheumatic heart disease' OR 'rheumatic fever') AND incidence) OR  
(('rheumatic heart disease' OR 'rheumatic fever') AND ('standardized mortality ratio' OR 
SMR)) OR  ('rheumatic heart disease' OR 'rheumatic fever' AND 'case fatality') 
• Dates included in search: 1/1/2013 – 3/16/2015 
• Number of initial hits: 2,045 
• Number of sources included: 17 
 
These differed from the GBD 2013 search terms: 
• (hasabstract[text] AND Humans[Mesh] AND middle age[MeSH])) OR 21) AND ((rheumatic 
heart disease/epidemiology[Mesh] OR rheumatic heart disease/mortality[Mesh]) AND 
(prevalence[Title/Abstract] OR incidence[Title/Abstract]) AND ("2010"[Date - Publication] : 
"3000"[Date - Publication]) AND (hasabstract[text] AND Humans[Mesh] AND middle 
age[MeSH])) 
 
The table below illustrates the number of literature studies included in GBD 2016, as well as the number 
of countries or subnational units and GBD world regions represented. 
 
Endemic model 
 Prevalence Incidence Mortality risk 
Studies 54 0 0 
Countries/subnationals 29 0 0 
GBD world regions 9 0 0 
 
Non-endemic model 
 Prevalence Incidence Mortality risk 
Studies 8 0 0 
Countries/subnationals 5 0 0 
GBD world regions 5 0 0 
 
We did not include any non-literature-based data types other than the hospital and claims data described 
elsewhere. Hospital and claims data were available only for the non-endemic country model. We used 
uncorrected inpatient hospital data as the correction factors generated using US claims data were 
exceptionally high (~100X) and could not be validated using data sources from other geographies. As 
patterns of disease and access to care vary widely, using uncorrected hospital data avoids inappropriately 
scaling inpatient data in other countries based on the very high use of RHD codes in the US in all-position 
diagnosis and outpatient claims data.  We excluded all outpatient data, as they were implausibly low 
when compared with inpatient data from the same locations and claims data.  
 
For the non-endemic country model, we included study-level covariates for inpatient hospital data and 
claims data from 2000 and 2010 to adjust these data points, using as reference the data obtained from 
literature and claims data from 2012. 
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Severity splits and disability weights 
 
Severity level Lay description DW (95% CI) 
Rheumatic heart disease, not 
including heart failure 
Has a chronic disease that requires 
medication every day and causes some 
worry but minimal interference with daily 
activities. 
0.049 (0.031–0.072) 
 
Modelling strategy  
For GBD 2016 estimation, we ran two models – one for non-endemic countries and one for endemic 
countries. We defined endemicity based on GBD 2016 RHD mortality estimates and the Socio-
demographic Index estimates (SDI) for the year 2016. For mortality, we used a threshold of 0.15/100,000 
deaths in children aged 5-9; for SDI, we used a cutpoint of 0.6. These thresholds were selected using as 
priors expert opinion on locations where RHD is known to be endemic. Locations above the threshold for 
deaths or below the threshold for SDI were categorised as endemic; all other locations were categorised 
as non-endemic. For GBD 2015, these decisions were made at the country level. For GBD 2016, they were 
made at the national level for countries modelled nationally, and at the subnational level for the subset of 
countries modelled subnationally. 
 
Non-endemic model: We included hospital data, claims data, and limited literature data on prevalence. 
We also included CSMR from our mortality estimates of RHD for non-endemic locations only. A prior of no 
remission was set, and excess mortality was capped at 0.1 for all ages. We included study-level covariates 
for claims data from 2000 and 2010, cross-walking them to data from the literature and claims data in 
2012. We also included the log-transformed age-standardised SEV scalar for RHD and the natural log of 
lagged distributed income (lnLDI, I$ per capita) as a country-level covariates for prevalence and excess 
mortality, respectively. 
 
Endemic model: We included prevalence data from surveys published in the literature. As with the high-
income model, we included CSMR from our mortality estimates of RHD for endemic locations only. A 
prior of no remission was set for all ages, and excess mortality was capped at 0.07, the highest observed 
mean excess mortality rate data point observed in this model. We also set priors of 0 on incidence for 
ages 0 to 1 and 50 to 100 to account for patterns of incidence in endemic countries. We used lnLDI as 
fixed-effect country-level covariates on prevalence and excess mortality, enforcing an inverse relationship 
for both. The log-transformed, age-standardized SEV scalar was also used as a fixed-effect country-level 
covariate on prevalence.  
 
We combined estimates from the endemic and non-endemic models, selecting estimates for the 
locations identified as non-endemic from the non-endemic model and estimates for the locations 
identified as endemic from the endemic model. Estimates of heart failure due to RHD were then 
subtracted from the estimates for RHD, giving the overall prevalence of RHD without heart failure. A 
description of the modelling strategy for heart failure due to RHD can be found in the Heart Failure 
appendix. We evaluated models based on comparing estimates with input data as well as estimates from 
previous rounds of GBD. 
 
The table below shows the country covariates, parameters, betas, and exponentiated betas: 
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Covariate Parameter beta Exponentiated beta 
Endemic model 
Log-transformed age-
standardized SEV scalar: RHD 
Prevalence 0.93 (0.76 – 1.22) 2.55 (2.13 – 3.37) 
LDI (I$ per capita) Excess mortality rate -0.28 (-0.48 – -0.11) 0.76 (0.62 – 0.90) 
Non-endemic model 
All Marketscan, year 2000 Study-level 0.19 (0.090 – 0.30) 1.21 (1.09 – 1.34) 
All Marketscan, year 2010 Study-level` 0.44 (0.36 – 0.52) 1.55 (1.43 – 1.68) 
Log-transformed age-
standardized SEV scalar: RHD 
Prevalence 0.78 (0.75 – 0.89) 2.19 (2.12 – 2.43) 
LDI (I$ per capita) Excess mortality rate -0.54 (-0.57 – -0.5) 0.58 (0.57 – 0.61) 
 
 
We changed the process of selecting locations for the endemic and non-endemic models. In previous 
rounds, this decision had been based on country development status and income level, and the models 
were referred to as low-income and high-income. However, because these models are trying to capture 
differences between locations where RHD is endemic and locations where the disease is extremely rare, 
we are now using death data and the Socio-demographic Index to identify which model should be used 
for estimates for each location. In addition, we are now making this determination at the subnational 
level for the relevant countries. 
 
Endemic Locations: North Korea, Cambodia, Laos, the Maldives, Myanmar, the Philippines, Timor-Leste, 
Fiji, Kiribati, Marshall Islands, Federated States of Micronesia, Papua New Guinea, Samoa, Solomon 
Islands, Tonga, Vanuatu, Azerbaijan, Georgia, Tajikistan, Turkmenistan, Uzbekistan, Albania, Belize, 
Dominica, Dominican Republic, Grenada, Guyana, Haiti, Jamaica, Saint Lucia, Saint Vincent and the 
Grenadines, Suriname, Bolivia, Ecuador, Guatemala, Honduras, Nicaragua, Algeria, Egypt, Iran, Iraq, Libya, 
Morocco, Palestine, Syria, Yemen, Afghanistan, Bangladesh, Bhutan, Nepal, Pakistan, Angola, the Central 
African Republic, Congo (Brazzaville), Democratic Republic of the Congo, Burundi, Comoros, Djibouti, 
Eritrea, Ethiopia, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Somalia, Tanzania, Uganda, 
Zambia, Lesotho, Namibia, Swaziland, Zimbabwe, Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Cote 
d'Ivoire, The Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Sao Tome 
and Principe, Senegal, Sierra Leone, Togo, American Samoa, Guam, South Sudan, Eastern Cape, Free 
State, Gauteng, KwaZulu-Natal, Limpopo, Mpumalanga, North-West, Northern Cape, Western Cape, 
Chongqing, Gansu, Guizhou, Hainan, Inner Mongolia, Qinghai, Tibet, Xinjiang, Yunnan, Sudan, Sumatera 
Barat, Bengkulu, Kalimantan Utara, Jawa Tengah, Bali, Nusa Tenggara Barat, Nusa Tenggara Timur, 
Kalimantan Barat, Kalimantan Tengah, Kalimantan Selatan, Kalimantan Timur, Sulawesi Utara, Sulawesi 
Tengah, Sulawesi Tenggara, Gorontalo, Sulawesi Barat, Maluku, Maluku Utara, Papua Barat, Papua, Acre, 
Amapá, Bahia, 
Goiás, Maranhão, Pará, Pernambuco, Piaui, Sergipe, Tocantins, Baringo, Bomet, Bungoma, Busia, Elgeyo-
Marakwet, Embu, Garissa, HomaBay, Isiolo, Kajiado, Kakamega, Kericho, Kilifi, Kirinyaga, Kisii, Kisumu, 
Kitui, Kwale, Laikipia, Lamu, Machakos, Makueni, Mandera, Marsabit, Meru, Migori, Mombasa, Murang’a, 
Nairobi, Nakuru, Nandi, Narok, Nyamira, Nyandarua, Nyeri, Samburu, Siaya, TaitaTaveta, TanaRiver, 
TharakaNithi, TransNzoia, Turkana, UasinGishu, Vihiga, Wajir, WestPokot, Andhra Pradesh, Urban, Assam, 
Urban, Bihar, Urban, Chhattisgarh, Urban, Delhi, Urban, Goa, Urban, Gujarat, Urban, Haryana, Urban, 
Himachal Pradesh, Urban, Jammu and Kashmir, Urban, Jharkhand, Urban, Karnataka, Urban, Kerala, 
Urban, Madhya Pradesh, Urban, Maharashtra, Urban, Manipur, Urban, Meghalaya, Urban, Odisha, Urban, 
Punjab, Urban, Rajasthan, Urban, Tamil Nadu, Urban, Telangana, Urban, Tripura, Urban, Uttar Pradesh, 
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Urban, Uttarakhand, Urban, West Bengal, Urban, Andhra Pradesh, Rural, Arunachal Pradesh, Rural, 
Assam, Rural, Bihar, Rural, Chhattisgarh, Rural, Delhi, Rural, Gujarat, Rural, Haryana, Rural, Himachal 
Pradesh, Rural, Jammu and Kashmir, Rural, Jharkhand, Rural, Karnataka, Rural, Kerala, Rural, Madhya 
Pradesh, Rural, Maharashtra, Rural, Manipur, Rural, Meghalaya, Rural, Nagaland, Rural, Odisha, Rural 
Punjab, Rural, Rajasthan, Rural, Sikkim, Rural, Tamil Nadu, Rural, Telangana, Rural, Tripura, Rural, Uttar 
Pradesh, Rural, Uttarakhand, Rural, West Bengal, Rural, The Six Minor Territories, Rural, The Six Minor 
Territories, Urban 
 
Non-endemic Locations: Taiwan (Province of China), Malaysia, Sri Lanka, Thailand, Vietnam, Armenia, 
Kazakhstan, Kyrgyzstan, Mongolia, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, 
Macedonia, Montenegro, Poland, Romania, Serbia, Slovakia, Slovenia, Belarus, Estonia, Latvia, Lithuania, 
Moldova, Russia, Ukraine, Brunei, South Korea, Singapore, Australia, New Zealand, Andorra, Austria, 
Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, 
Malta, Netherlands, Norway, Portugal, Spain, Switzerland, Argentina, Chile, Uruguay, Canada, Antigua and 
Barbuda, The Bahamas, Barbados, Cuba, Trinidad and Tobago, Peru, Colombia, Costa Rica, El Salvador, 
Panama, Venezuela, Paraguay, Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Tunisia, Turkey, United 
Arab Emirates, Equatorial Guinea, Gabon, Seychelles, Botswana, Bermuda, Greenland, Hong Kong Special 
Administrative Region of China, Macao Special Administrative Region of China, Northern Mariana Islands, 
Puerto Rico, Virgin Islands, U.S., Northern Ireland, Scotland, Anhui, Beijing, Fujian, Guangdong, Guangxi, 
Hebei, Heilongjiang, Henan, Hubei, Hunan, Jiangsu, Jiangxi, Jilin, Liaoning, Ningxia, Shaanxi, Shandong, 
Shanghai, Shanxi, Sichuan, Tianjin, Zhejiang, Alabama, Alaska, Arizona, Arkansas, California, Colorado, 
Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, 
Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, 
Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North 
Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South 
Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, 
Wales, Aguascalientes, Baja California, Baja California Sur, Campeche, Coahuila, Colima, Chiapas, 
Chihuahua, Distrito Federal, Durango, Guanajuato, Guerrero, Hidalgo, Jalisco, México, Michoacán de 
Ocampo, Morelos, Nayarit, Nuevo León, Oaxaca, Puebla, Querétaro, Quintana Roo, San Luis Potosí, 
Sinaloa, Sonora, Tabasco, Tamaulipas, Tlaxcala, Veracruz de Ignacio de la Llave, Yucatán, Zacatecas, Aceh, 
Sumatera Utara, Riau, Jambi, Sumatera Selatan, Lampung, Bangka Belitung, Kepulauan Riau, Jakarta, Jawa 
Barat, Yogyakarta, Jawa Timur, Banten, Sulawesi Selatan, Alagoas, Amazonas, Ceará, Distrito Federal, 
Espírito Santo, Minas Gerais, Mato Grosso do Sul, Mato Grosso, Paraíba, Paraná, Rio de Janeiro, Rio 
Grande do Norte, Rondônia, Roraima, Rio Grande do Sul, Santa Catarina, São Paulo, Sweden except 
Stockholm, Stockholm, Hokkaidō, Aomori, Iwate, Miyagi, Akita, Yamagata, Fukushima, Ibaraki, Tochigi, 
Gunma, Saitama, Chiba, Tōkyō, Kanagawa, Niigata, Toyama, Ishikawa, Fukui, Yamanashi, Nagano, Gifu, 
Shizuoka, Aichi, Mie, Shiga, Kyōto, Ōsaka, Hyōgo, Nara, Wakayama, Tottori, Shimane, Okayama, 
Hiroshima, Yamaguchi, Tokushima, Kagawa, Ehime, Kōchi, Fukuoka, Saga, Nagasaki, Kumamoto, Ôita, 
Miyazaki, Kagoshima, Okinawa, Kiambu, Arunachal Pradesh, Urban, Mizoram, Urban, Nagaland, Urban, 
Sikkim, Urban, Goa, Rural, Mizoram, Rural, Ha'il, Qassim, Riyadh, Tabuk, Madinah, Makkah, Bahah, 
Northern Borders, Jawf, Jizan, 'Asir, Najran, Eastern Province, Darlington, Northumberland, Stockton-on-
Tees, Newcastle upon Tyne, North Tyneside, Redcar and Cleveland, County Durham, Gateshead, 
Middlesbrough, South Tyneside, Sunderland, Hartlepool, Cheshire East, Stockport, Trafford, Cheshire,  
West and Chester, Sefton, Lancashire, Cumbria, Bolton, Wirral, Bury, St Helens, Warrington, Oldham, 
Rochdale, Wigan, Halton, Liverpool, Tameside, Salford, Blackburn with Darwen, Knowsley, Blackpool, 
Manchester, North Yorkshire, East Riding of Yorkshire, York, North East Lincolnshire, Calderdale, North  
Lincolnshire, Bradford, Kirklees, Leeds, Sheffield, Wakefield, Rotherham, Doncaster, Kingston upon Hull, 
City of Barnsley, Northamptonshire, Leicestershire, Lincolnshire, Rutland, Derby, Derbyshire, 
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Nottinghamshire, Nottingham, Leicester, Warwickshire, Herefordshire, County of, Solihull, Shropshire, 
Worcestershire, Staffordshire, Dudley, Coventry, Telford and Wrekin, Stoke-on-Trent, Walsall, 
Wolverhampton, Birmingham, Sandwell, Bedford, Central Bedfordshire, Suffolk, Hertfordshire, Essex, 
Cambridgeshire, Thurrock, Norfolk, Southend-on-Sea, Peterborough, Luton, Richmond upon Thames, 
Kensington and Chelsea, Barnet, Westminster, Bromley, Bexley, Redbridge, Merton, Brent, Hillingdon, 
Havering, Kingston upon Thames, Sutton, Harrow, Enfield, Croydon, Hammersmith and Fulham, Ealing, 
Greenwich, Wandsworth, Waltham Forest, Camden, Lambeth, Lewisham, Hounslow, Southwark, 
Newham, Barking and Dagenham, Haringey, Hackney, Islington, Tower Hamlets, Wokingham, 
Buckinghamshire, Surrey, Windsor and Maidenhead, West Berkshire, Hampshire, Bracknell Forest, West 
Sussex, Oxfordshire, Reading, Kent, Brighton and Hove, Medway, East Sussex, Portsmouth, Isle of Wight, 
Milton Keynes, Southampton, Slough, South Gloucestershire, Dorset, Wiltshire, North Somerset, Devon, 
Poole, Bath and North East Somerset, Gloucestershire, Somerset, Swindon, Torbay, Bristol, City of 
Bournemouth, Cornwall, Plymouth 
 
Other than this update to model assignment, there were no substantive changes in the modelling 
strategy from GBD 2015. 
 
1. Reményi, B. et al. Nat. Rev. Cardiol. 9, 297–309 (2012); published online 28 February 2012 
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Input data and methodological summary 
 
Case definition 
Case definitions: 
1) Acute myocardial infarction (MI): Definite and possible MI according to the third universal 
definition of myocardial infarction: 
a. When there is clinical evidence of myocardial necrosis in a clinical setting consistent with 
myocardial ischemia or  
b. Detection of a rise and/or fall of cardiac biomarker values and with at least one of the 
following: i) symptoms of ischaemia, ii) new or presumed new ST-segment-T wave 
changes or new left bundle branch block, iii) development of pathological Q waves in the 
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ECG, iv) imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality, or v) identification of an intracoronary thrombus by angiography or autopsy. 
c. Sudden (abrupt) unexplained cardiac death, involving cardiac arrest or no evidence of a 
noncoronary cause of death 
d. Prevalent MI is considered to last from the onset of the event to 28 days after the event 
and is divided into an acute phase (0–2 days) and subacute (3–28 days). 
 
2) Chronic IHD 
a. Angina; clinically diagnosed stable exertional angina pectoris or definite angina pectoris 
according to the Rose Angina Questionnaire, physician diagnosis, or taking nitrate 
medication for the relief of chest pain. 
b. Asymptomatic ischemic heart disease following myocardial infarction; survival to 28 days 
following incident MI. The GBD study does not use estimates based on ECG evidence for 
prior MI, due to its limited specificity and sensitivity (1). 
 
ICD codes used for inclusion of hospital and claims data for MI and angina can be found in Methods 
Appendix Table 4. 
 
Input data 
 Model inputs 
Myocardial infarction 
A systematic review for myocardial infarction was not performed for GBD 2016. Updates to systematic 
reviews are performed on an ongoing schedule across all GBD causes; an update for myocardial infarction 
will be performed in the next one to two iterations.  
 
A systematic review was done for myocardial infarction for GBD 2015. The search strings used were 
extensive; a full list will be provided on request. 
 
The dates of the search were 1/1/2009 – 2/3/2015. 38,522 studies were returned; 194 were extracted 
(this number includes extractions that were done for STEMI/NSTEMI models and revascularization models 
that are not currently part of the MI modelling process but may be in the future). 
 
A systematic review for myocardial infarction was also done for GBD 2013. The extensive search terms for 
that review can be found here will be provided on request.  
 
 Prevalence Incidence Mortality risk 
Studies 0 93 61 
Countries/subnationals 0 39 32 
GBD world regions 0 8 10 
 
Apart from inpatient hospital and inpatient claims data, we did not include any data from sources other 
than the literature for myocardial infarction. We excluded data with broad age ranges where it was 
impossible to obtain more granular data, as these data caused the known age pattern for increased risk of 
myocardial infarction to be masked in the estimates generated from DisMod. 
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We corrected inpatient hospital data outside of DisMod to account for the fact that these data sources do 
not capture the out-of-hospital cardiac arrest deaths which are part of the universal definition of MI. 
Using as a model the adjustment factors developed to translate tobacco consumption prevalence to 
tobacco consumption frequency, we matched administrative hospital data to population-based literature 
data based on age group, sex, and super region (1). For the adjustment factor, we developed the 
following generalized additive model on matched data ln�𝜇𝜇𝑟𝑟𝑟𝑟𝑟𝑟,𝑖𝑖� =  𝛽𝛽0 + 𝛽𝛽1 ln�𝜇𝜇𝑏𝑏,𝑖𝑖� + 𝑠𝑠(𝑎𝑎𝑎𝑎𝑎𝑎𝑖𝑖)+𝜀𝜀𝑖𝑖 
Where 𝑖𝑖 represents a given matched observation, 𝑎𝑎𝑎𝑎𝑎𝑎 signifies the data point’s age group, 𝑠𝑠(𝑥𝑥) 
represents a penalized spline where the smoothing parameter is chosen through cross validation and 
𝜇𝜇𝑟𝑟𝑟𝑟𝑟𝑟 and 𝜇𝜇𝑏𝑏 denote the mean of the data point from literature and the mean of the inpatient hospital 
data point, respectively. Predictions from the model were then taken as the adjusted data points. The 
standard error of each corrected data point was adjusted to account for the uncertainty due to the 
correction. 
We included a study-level covariate to correct for the change in diagnostic criteria to include troponin 
measurements within DisMod. This adjustment was applied to data collected before 2000. We also 
included a study-level covariate to adjust data points within DisMod that captured only first-ever MI, 
using studies where all events were included as the reference. We also adjusted estimates within DisMod 
from studies that only included non-fatal cases using study-level covariates with sources that included 
fatal and non-fatal cases as reference. 
 
Angina 
 
A systematic review was not performed for GBD 2016. Updates to systematic reviews are performed on 
an ongoing schedule across all GBD causes; an update for angina will be performed in the next one to two 
iterations.  
 
A systematic review for angina was not done for GBD 2015, but was for GBD 2013. The search terms for 
that are here: (Angina Pectoris/epidemiology[Mesh] OR Angina Pectoris/mortality[Mesh] ) AND 
(prevalence[Title/Abstract] OR incidence[Title/Abstract]) AND ("2010"[Date - Publication] : "3000"[Date - 
Publication]) 
 
Literature data included: Angina 
 
 Prevalence Incidence Mortality risk 
Studies 72 0 7 
Countries/subnationals 73 0 7 
GBD world regions 20 0 5 
 
We included survey data (including NHANES and World Health Study questionnaires) which included the 
RAQ items. Prevalence of angina was calculated using the standard algorithm to determine whether the 
RAQ was positive or negative. 
 
We excluded data with broad age ranges where it was impossible to obtain more granular data, as these 
data caused the known age pattern for increased risk of angina to be masked in the estimates generated 
from DisMod. 
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We included sex- and age-group-specific covariates to adjust prevalence data points obtained from the 
RAQ using the claims data as the reference since the RAQ has been shown to be neither sensitive nor 
specific. 
 
We also included US claims data, but did not include inpatient hospital data from any locations.  Stable 
angina (unstable angina is modeled as part of MI) is expected to be rare in inpatient, but common in 
outpatient data as it is a condition usually managed on an outpatient basis, except for specific surgical 
interventions. This discrepancy leads to implausible correction factors based on inpatient/outpatient 
information from claims data (~150X); thus adjusted data cannot be used. Including uncorrected data in 
the model is likely to lead to incorrect estimates as hospitalization and procedure rates are likely to vary 
between geographies based on access to and patterns of care. All outpatient data was excluded as it was 
implausibly low for all locations when compared with literature and claims data. 
 
 Severity split inputs 
Acute myocardial infarction was split into two severity levels by length of time since the event – days 1 
and 2 versus days 3 through 28. Disability weights were established for these two severities using the 
standard approach for GBD 2015. 
Angina was split into mild, moderate, and severe groups using information from MEPS. Disability weights 
were established for these severities using the standard approach for GBD 2015. 
 
Acute myocardial infarction 
 
Severity level Lay description DW (95% CI) 
Acute myocardial infarction, 
days 1-2 
Has severe chest pain that becomes worse 
with any physical activity. The person feels 
nauseated, short of breath, and very anxious. 
0.432 (0.288–0.579) 
Acute myocardial infarction, 
days 3-28 
Gets short of breath after heavy physical 
activity, and tires easily, but has no problems 
when at rest. The person has to take 
medication every day and has some anxiety. 
0.074 (0.049–0.105) 
 
Angina pectoris 
 
Severity level Lay description DW (95% CI) 
Mild angina Has chest pain that occurs with strenuous 
physical activity, such as running or lifting 
heavy objects. After a brief rest, the pain 
goes away. 
0.033 (0.02 – 0.052) 
Moderate angina Has chest pain that occurs with moderate 
physical activity, such as walking uphill or 
more than half a kilometer (around a 
0.08 (0.052 – 0.113) 
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quarter-mile) on level ground. After a brief 
rest, the pain goes away. 
Severe angina Has chest pain that occurs with minimal 
physical activity, such as walking only a short 
distance. After a brief rest, the pain goes 
away. The person avoids most physical 
activities because of the pain. 
0.167 (0.11 – 0.24) 
 
Modelling strategy  
 
Myocardial infarction 
o We first calculated custom cause-specific mortality estimates using cause of death data 
prior to garbage code redistribution, generating age-sex-country-specific proportions of 
IHD deaths that were due to MI (acute IHD) vs those due to other causes of IHD (chronic 
IHD). Estimates of this proportion for all locations were then generated using a DisMod 
proportion-only model. Due to a high degree of variability in pre-redistribution coding 
practices by location, we used the global age-, sex-, and year-specific proportions of 
acute deaths in subsequent calculations. The global proportions were multiplied by post-
CodCorrect (final GBD estimates) IHD deaths to generate CSMR estimates for MI, even 
though GBD reports only deaths for all IHD taken together. These data, along with 
incidence and excess mortality data, informed a DisMod model to estimate the 
prevalence and incidence of myocardial infarction due to ischemic heart disease. 
o These estimates were split into prevalence and incidence estimates for days 1-2 and days 
3-28 post-event. Disability weights were assigned to each of these two groupings. 
o We set a value prior of one month for remission (11/13) from the MI health state. We 
also set a value prior for the maximum excess mortality rate of 10 for all ages. We 
included lnLDI as a fixed-effect country-level covariate on excess mortality, forcing an 
inverse relationship. 
Study covariate Parameter Beta Exponentiated beta 
Diagnostic blood sample (troponin) Incidence -0.45 (-0.47 – -0.44) 0.64 (0.62 - 0.64) 
LDI (I$ per capita) Excess mortality rate -0.1 (-0.1 – -0.1) 0.9 (0.9 – 0.9) 
First ever MI Incidence -0.66 (-0.67 – -0.65) 0.52 (0.51 – 0.52) 
Non-fatal MI Incidence -0.40 (-0.41 – -0.40) 0.67 (0.66 – 0.67) 
Log-transformed age-standardized 
SEV scalar: IHD 
Incidence 1.24 (1.21 – 1.25) 
 
3.44 (3.34 – 3.49) 
Asymptomatic ischaemic heart disease  
o Excess mortality estimates from the myocardial infarction model were used to generate 
data of the incidence of surviving 28 days post-event. 
o We used these data, along with the estimates of CSMR due to chronic IHD (the other part 
of the proportion described in step 1) and excess mortality data in a DisMod model to 
estimate the prevalence of persons with IHD following myocardial infarction. This 
estimate included subjects with angina and heart failure; a proportion of this prevalence 
was removed in order to avoid double-counting based on evidence from the literature 
(2). The result of this step generates estimates of asymptomatic ischaemic heart disease 
following myocardial infarction. 
o We set a value prior of 0 for remission for all ages. 
o No study- or country-level covariates were included for the model. 
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Angina 
o We used prevalence data from the literature and USA claims databases, along with data 
on mortality risk to estimate the prevalence and incidence of angina for all locations. 
o The proportion of mild, moderate, and severe angina was determined by the standard 
approach for severity splitting for GBD 2015. 
o We included a value prior of 0 for remission for all ages. We also included a value prior of 
1 for excess mortality for all ages. 
o We included age- and sex-specific study-level covariates to adjust data points based on 
RAQ, using data points from the claims database as the reference. 
o We also included the log-transformed, age-standardized SEV scalar for IHD as a fixed 
effect country-level covariate. 
 
Study covariate Parameter Beta Exponentiated beta 
RAQ, female, less than 50 Prevalence 2.33 (2.30 – 2.40) 10.28 (9.98 – 11.06) 
RAQ, male, less than 50 Prevalence 0.94 (0.92 – 0.95) 2.57 (2.51 – 2.59) 
RAQ, female, 50 to 64 Prevalence 1.44 (1.35 – 1.50) 4.22 (3.87 – 4.47) 
RAQ, male, 50 to 64 Prevalence 0.83 (0.80 – 0.90) 2.30 (2.23 – 2.46) 
RAQ, female, 65 plus Prevalence 0.29 (0.27 – 0.30) 1.34 (1.31 – 1.35) 
RAQ, male, 65 plus Prevalence 0.19 (0.11 – 0.29) 1.21 (1.11 – 1.33) 
Log-transformed age-
standardized SEV scalar: IHD 
Prevalence 1.25 (1.23 – 1.25) 
 
3.47 (3.43 – 3.49) 
 
LDI (I$ per capita) Excess mortality rate -0.55 (-1 – -0.1) 0.58 (0.37 – 0.90) 
 
There have been no substantive changes in the modelling strategy for myocardial infarction, 
asymptomatic ischemic heart disease following myocardial infarction, and angina from GBD 2015. 
 
1. Reitsma, Marissa B., et al. "Smoking prevalence and attributable disease burden in 195 countries 
and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015." 
The Lancet. 
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Ischaemic Stroke & Haemorrhagic Stroke  
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Input data and methodological summary 
Case definition 
Stroke was defined according to WHO criteria – rapidly developing clinical signs of focal (at times global) 
disturbance of cerebral function lasting more than 24 hours or leading to death with no apparent cause 
other than that of vascular origin(1). Data on transient ischaemic attack (TIA) were not included. 
 
Acute stroke: Stroke cases are considered acute from the day of incidence of a first-ever stroke 
through day 28 following the event. 
 
Chronic stroke: Stroke cases are considered chronic beginning 28 days following the occurrence 
of an event. Chronic stroke includes the sequelae of an acute stroke AND all recurrent stroke 
events. GBD 2015 adopts this broader definition of chronic stroke than was used in prior 
iterations in order to model acute strokes using only first-ever incident events.  
 
Ischaemic stroke: Incident ischaemic stroke is defined as the occurrence of first-ever ischaemic 
stroke, based on clinical diagnosis by a physician using diagnostic imaging. Ischaemic strokes are 
considered to include all vascular events leading to limited blood flow to brain tissue, with 
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resulting infarction, including atherosclerotic and thromboembolic strokes but excluding strokes 
in which the underlying cause is intracranial haemorrhage. 
 
Haemorrhagic or other strokes: This cause includes all non-ischaemic strokes of a vascular cause 
including subarachnoid and stroke due to intracranial haemorrhage. 
 
ICD codes used for inclusion of hospital and claims data can be found in Appendix Table 4 
Input data 
 Model inputs 
A systematic review was not performed for GBD 2016. Updates to systematic reviews are performed on 
an ongoing schedule across all GBD causes; an update for cerebrovascular disease will be performed in 
the next iteration.  
 
A systematic review of the literature was performed in GBD 2013.  The search terms used were:  
(stroke[Mesh]) AND (prevalence[Title/Abstract] OR incidence[Title/Abstract]) AND ("2010"[Date - 
Publication] : "3000"[Date - Publication]) AND (hasabstract[text] AND Humans[Mesh] AND middle 
age[MeSH])) (hasabstract[text] AND Humans[Mesh] AND middle age[MeSH])) OR 21) AND ((hemorrhagic 
stroke/epidemiology[Mesh] OR hemorrhagic stroke/mortality[Mesh]) AND (prevalence[Title/Abstract] OR 
incidence[Title/Abstract]) AND ("2010"[Date - Publication] : "3000"[Date - Publication]) AND 
(hasabstract[text] AND Humans[Mesh] AND middle age[MeSH])) 
 
The tables below indicate the number of literature studies included in GBD 2016, as well as the number of 
countries or subnational units and GBD world regions represented. 
 
Acute Ischaemic stroke 
 
 Prevalence Incidence Mortality risk 
Studies 0 73 14 
Countries/subnationals 0 55 12 
GBD world regions 0 14 5 
 
Acute Haemorrhagic or other stroke 
 
 Prevalence Incidence Mortality risk 
Studies 0 73 10 
Countries/subnationals 0 51 11 
GBD world regions 0 13 4 
 
Chronic  Ischaemic stroke 
 
 Prevalence Incidence Mortality risk 
Studies 53 0 8 
Countries/subnationals 50 0 4 
GBD world regions 14 0 2 
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Chronic Haemorrhagic or other stroke 
 
 Prevalence Incidence Mortality risk 
Studies 53 0 8 
Countries/subnationals 50 0 4 
GBD world regions 14 0 2 
 
We included inpatient hospital data, adjusted for readmission and primary to any diagnosis using 
correction factors estimated from US claims data. We excluded data for locations where the data points 
were implausibly low (Vietnam, Philippines, India). In addition, we included unpublished stroke registry 
data for acute ischaemic and acute haemorrhagic strokes. We also included survey data for chronic 
cerebrovascular disease. These surveys were identified based on expert opinion and review of major 
survey series focused on world health that included questions regarding self-reported history of stroke. 
 
As with many models in GBD, the diversity of data sources available means that we needed to adjust 
available data to our preferred or reference case definition (2). For the first ever acute stroke models we 
used DisMod to estimate the statistical association between measurements taken using different case 
definitions and then used these estimates to adjust the non-referent datapoints.  We included study-level 
covariates to adjust data points for first and recurrent strokes combined, using data for first strokes only 
as reference. We also included study-level covariates to adjust ischaemic and haemorrhagic strokes 
combined (all stroke), using as reference studies with subtype-specific information. 
  
 Severity split inputs 
The table below illustrates the severity level, lay description, and disability weights for GBD 2016. In 
previous iterations of the GBD, severity splits for stroke were based on the standard approach described 
elsewhere (3). For GBD 2016, we undertook a review to identify epidemiologic literature which reported 
the degree of disability at 28 days (for acute stroke) or one year (for chronic stroke) using the modified 
Rankin scale (mRS) and the Mini-mental State Examination (MMSE) or the Montreal Cognitive Assessment 
(MoCA).  The mRS assesses functional capabilities, while the MMSE and MoCA tests provide evaluations 
of cognitive functioning. We then mapped these measures to the existing GBD categories as indicated 
below. This appproach allowed us to include location-specific information and can be updated as more 
data on functional or cognitive status become available. 
Acute stroke severity splits  
Severity level Lay description Modified 
Rankin Score 
Cognitive 
Status 
DW (95% CI) 
Stroke, mild Has some difficulty in moving 
around and some weakness in one 
hand, but is able to walk without 
help. 
1 N/A 0.019 
(0.01–0.032) 
Stroke, moderate Has some difficulty in moving 
around, and in using the hands for 
lifting and holding things, 
dressing, and grooming. 
2, 3 MoCA>=24 
or 
MMSE>=26 
 
0.07 
(0.046–0.099) 
285
Stroke, moderate 
plus cognition 
problems 
Has some difficulty in moving 
around, in using the hands for 
lifting and holding things, dressing 
and grooming, and in speaking. 
The person is often forgetful and 
confused. 
2, 3 MoCA<24 
or 
MMSE<26 
0.316 (0.206–
0.437) 
Stroke, severe Is confined to bed or a wheelchair, 
has difficulty speaking, and 
depends on others for feeding, 
toileting, and dressing. 
4, 5 MoCA>=24 
or 
MMSE>=26 
0.552 (0.377–
0.707) 
Stroke, severe plus 
cognition 
problems 
Is confined to bed or a wheelchair, 
depends on others for feeding, 
toileting, and dressing, and has 
difficulty speaking, thinking 
clearly, and remembering things. 
 MoCA<24 
or 
MMSE<26 
0.588 (0.411–
0.744) 
 
Chronic stroke severity splits 
Severity level Lay description Modified 
Rankin 
Score 
Cognitive 
Status 
DW (95% CI) 
Stroke, asymptomatic  0 N/A N/A 
Stroke, long-term 
consequences, mild 
Has some difficulty in moving 
around and some weakness in 
one hand, but is able to walk 
without help. 
1 N/A 0.019 
(0.01–0.032) 
Stroke, long-term 
consequences, 
moderate 
Has some difficulty in moving 
around, and in using the hands 
for lifting and holding things, 
dressing, and grooming. 
2, 3 MoCA>=24 
or 
MMSE>=26 
0.07 
(0.046–0.099) 
Stroke, long-term 
consequences, 
moderate plus 
cognition problems 
Has some difficulty in moving 
around, in using the hands for 
lifting and holding things, 
dressing and grooming, and in 
speaking. The person is often 
forgetful and confused. 
2, 3 MoCA<24 or 
MMSE<26 
0.316 
(0.206–0.437) 
Stroke, long-term 
consequences, severe 
Is confined to bed or a 
wheelchair, has difficulty 
speaking, and depends on 
others for feeding, toileting, 
and dressing. 
4, 5 MoCA>=24 
or 
MMSE>=26 
0.552 
(0.377–0.707) 
Stroke, long-term 
consequences, severe 
plus cognition 
problems 
Is confined to bed or a 
wheelchair, depends on others 
for feeding, toileting, and 
dressing, and has difficulty 
speaking, thinking clearly, and 
remembering things. 
4, 5 MoCA<24 or 
MMSE<26 
0.588 
(0.411–0.744) 
286
 Severity split literature data availability 
 Acute Proportion Chronic Proportion 
Studies 6 13 
Countries/subnationals 5 11 
GBD world regions 5 5 
We used DisMod MR 2.1, a Bayesian meta-regression tool, to model the six severity levels, with an 
independent proportion model for each. Reports which grouped mRS scores differently than our mapping 
(e.g. 0-2) were adjusted in DisMod by estimating the association between these alternate groupings and 
our preferred mappings. These statistical associations were used to adjust data points to the referent 
category as necessary. The six models were scaled such that the sum of the proportions for all levels 
equaled 1.   
 
Modelling strategy  
Three general approaches were employed for all of the components of the stroke modelling process, 
detailed in the table below. 
o Data points were adjusted from nonstandard to standard case deinitions using estimates 
from statistical models generated by DisMod for the acute models. Coefficients for these 
crosswalks can be found in the tables for fixed effects located below. 
o The GBD summary exposure value, which is the relative risk-weighted prevalence of 
exposure, for ischaemic or haemorrhagic stroke as appropriate and a covariate for 
country income were used as country-level covariates for all models (4). Coefficients for 
these covariates can be found in the tables for fixed effects located below. 
o Two versions of each stroke model were run, referred to as step 1 and step 2 models. 
First, we ran the step 1 DisMod-MR models for acute and chronic subtype-specific stroke 
using only incidence, prevalence, and case fatality data as inputs. We then used the ratio 
of acute:chronic cause-specific mortality estimated by these models to divide GBD stroke 
deaths into acute and chronic stroke deaths, using the global average for the proportion 
of acute:chronic stroke mortality. The acute and chronic models were then run (step 2) 
using the same incidence, prevalence, and case fatality data as well as the custom cause-
specific mortality rates as input data. 
 
Step 1 
o We generated estimates for first-ever acute ischaemic and first-ever acute haemorrhagic 
stroke using DisMod-MR 2.1 with data collected on stroke incidence and excess 
mortality. We set value priors of 11 to 13 on remission for all ages to establish a one-
month duration for these acute sequelae. 
o We then calculated the rate of surviving until 28 days after an acute event for both 
ischaemic and haemorrhagic stroke using the modelled estimates of excess mortality and 
incidence. 
o These survivor data were then used in the chronic ischaemic and chronic haemorrhagic 
stroke models as incidence inputs. 
o We then ran the chronic stroke models, using the survivor incidence data and excess 
mortality data. Non-subtype-specific prevalence data were split into ischaemic and 
haemorrhagic components using the ratio of 28-day survivors from the first stage acute 
models. We set a value prior of 0 on remission for all ages. 
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o Implausible or extreme outliers in input data were dropped from these estimation 
results. 
o From these four models, we generated the proportions of deaths due to acute ischaemic, 
chronic ischaemic, acute haemorrhagic, and chronic haemorrhagic stroke, and split the 
post-CoDCorrect stroke deaths generated from the GBD mortality estimates into these 
four parts, by multiplying the location-, sex-, age- and year-specific CSMR results by the 
global proportions estimated from the DisMod models. Thus, the mortality rates due to 
acute ischaemic, chronic ischaemic, acute haemorrhagic, and chronic haemorrhagic 
stroke are driven by all available data on incidence, prevalence, and excess mortality data 
for stroke. These CSMR estimates were then uploaded into the non-fatal database and 
used as inputs for models in Step 2.  
Step 2 
o We re-ran the first-ever acute ischaemic and first-ever acute haemorrhagic models with 
CSMR as derived from CoDCorrect and epidemiologic data as described above. Twenty-
eight-day survivorship was recalculated from these models and uploaded into the chronic 
ischaemic and chronic haemorrhagic stroke with CSMR models. These chronic models 
also use CSMR as derived from CoDCorrect and epidemiologic data as described above. 
o Implausible or extreme outliers were dropped from these estimation results. 
 
Models were evaluated based on expert opinion, comparison with previous iterations, and model fit. 
 
Changes in the modelling of stroke for GBD 2016 
Several changes were made to the modelling strategy for stroke for the GBD 2016 study. In GBD 2015 and 
prior, chronic stroke was modelled for both subtypes (ischaemic and haemorrhagic or other) together to 
estimate the total prevalence of chronic stroke. For the GBD 2016 study, each stroke subtype was 
modelled independently, resulting in separate acute and chronic stroke models for each subtype. This 
change was made in order to simplify the stroke modeling process and to ensure that both subtypes were 
estimated correctly. In the GBD2015 and prior studies, severity splits were based on estimates derived 
from standard GBD analysis of the U.S. Medical Expenditure Panel Survey. For the GBD2016 study, a 
review of studies reporting modified Rankin scores following stroke was performed and disability weights 
were applied using a model of modified Rankin level by age and sex as described above. 
 
1) Hatano S. Experience from a mulicentre stroke register: a preliminary report. Bull WHO 54, 541-
553. 1976. 
2) GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and 
national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-
2015: a systematic analysis for the Global Burden of Disease Study 2015. 
Lancet. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6. 
3) Burstein et al. Estimating distributions of health state severity for the global burden of disease 
study. Population Health Metrics  (2015) 13:31 
4) GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment 
of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-
2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 
8;388(10053):1659-1724. doi: 10.1016/S0140-6736(16)31679-8. 
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The tables below indicate the covariates used by cause in the estimation process, as well as the beta and 
exponentiated beta values.  
Step 1:  
Cause Variable name Measure beta Exponentiated beta 
Chronic ischaemic stroke Log-transformed SEV 
scalar: Isch Stroke 
Prevalence 0.83 (0.75 — 1.03) 2.29 (2.12 — 2.80) 
 
Chronic ischaemic stroke LDI (I$ per capita) Excess 
mortality rate 
-0.16 (-0.29 — -0.1) 0.85 (0.75 — 0.90) 
Chronic haemorrhagic 
stroke 
Log-transformed SEV 
scalar: Hem Stroke 
Prevalence 0.79 (0.75 — 0.92) 2.21 (2.12 — 2.50) 
Chronic haemorrhagic 
stroke 
LDI (I$ per capita) Excess 
mortality rate 
-0.12 (-0.16 — -0.1) 0.89 (0.85 — 0.90) 
First ever acute 
haemorrhagic stroke 
Hospital data Incidence 0.54 (0.54 – 0.54) 1.71 (1.71 – 1.72) 
First ever acute 
haemorrhagic stroke 
Any stroke Incidence 1.27 (1.27 – 1.28) 3.57 (3.56 – 3.59) 
First ever acute 
haemorrhagic stroke 
First-ever acute stroke, 
ischemic or hemorrhagic 
Incidence 0.52 (0.52 – 0.53) 1.69 (1.68 – 1.71) 
First ever acute 
haemorrhagic stroke 
Log-transformed age-
standardized SEV scalar: 
hemorrhagic stroke 
Incidence 0.77 (0.75 – 0.82) 2.17 (2.12 – 2.27) 
First ever acute 
haemorrhagic stroke 
Any stroke Excess 
mortality rate 
-0.48 (-0.66 – -
0.32) 
0.62 (0.52 – 0.73) 
First ever acute 
haemorrhagic stroke 
First-ever acute stroke, 
ischemic or hemorrhagic 
Excess 
mortality rate 
-0.081 (-0.3 – 0.16) 0.62 (0.52 – 0.73) 
First ever acute 
ischaemic stroke 
Hospital data Incidence 0.38 (0.37 – 0.38) 1.46 (1.45 – 1.46) 
First ever acute 
ischaemic stroke 
Any stroke Incidence 0.31 (0.29 – 0.33) 1.37 (1.34 – 1.39) 
First ever acute 
ischaemic stroke 
First-ever acute stroke, 
ischemic or hemorrhagic 
Incidence 0.37 (0.36 – 0.38) 1.44 (1.43 – 1.46) 
First ever acute 
ischaemic stroke 
Log-transformed age-
standardized SEV scalar: 
ischemic stroke 
Incidence 1.16 (1.09 – 1.22) 3.21 (2.99 – 3.39) 
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Step 2:  
Cause Variable name Measure beta Exponentiated beta 
Chronic ischemic 
stroke with CSMR 
Log-transformed SEV 
scalar: Ischaemic stroke Prevalence 0.89 (0.75 – 1.19) 2.44 (2.13 – 3.27) 
Chronic ischemic 
stroke with CSMR LDI (I$ per capita) 
Excess 
mortality rate -0.49 (-0.5 – -0.46) 0.61 (0.61 – 0.63) 
Chronic haemorrhagic 
stroke with CSMR 
Log-transformed SEV 
scalar: Haemorrhagic 
stroke Prevalence 0.88 (0.75 – 1.15) 2.40 (2.13 – 3.17) 
Chronic haemorrhagic 
stroke with CSMR LDI (I$ per capita) 
Excess 
mortality rate -0.48 (-0.5 – -0.44) 0.62 (0.61 – 0.64) 
First-ever acute 
haemorrhagic stroke 
with CSMR Any stroke Incidence 1.27 (1.27 – 1.29) 3.58 (3.56 – 3.62) 
First-ever acute 
haemorrhagic stroke 
with CSMR 
First-ever acute stroke, 
ischemic or 
hemorrhagic Incidence 0.52 (0.52 – 0.54) 1.69 (1.68 – 1.71) 
First-ever acute 
haemorrhagic stroke 
with CSMR 
Log-transformed SEV 
scalar: Hem stroke Incidence 1.11 (1.01 – 1.20) 3.03 (2.74 – 3.33) 
First-ever acute 
haemorrhagic stroke 
with CSMR Any stroke 
Excess 
mortality rate -0.37 (-0.49 – -0.27) 0.69 (0.62 – 0.77) 
First-ever acute 
haemorrhagic stroke 
with CSMR 
First-ever acute stroke, 
ischemic or 
hemorrhagic 
Excess 
mortality rate 0.023 (-0.2 – 0.23) 1.02 (0.82 – 1.25) 
First-ever acute 
ischaemic stroke with 
CSMR Any stroke Incidence 0.32 (0.30 – 0.33) 1.38 (1.35 – 1.39) 
First-ever acute 
ischaemic stroke with 
CSMR 
First-ever acute stroke, 
ischemic or 
hemorrhagic Incidence 0.37 (0.36 – 0.38) 1.44 (1.43 – 1.46) 
First-ever acute 
ischaemic stroke with 
CSMR 
Log-transformed age-
standardized SEV 
scalar: Ischemic stroke Incidence 1.11 (1.05 – 1.18) 3.04 (2.86 – 3.26) 
First-ever acute 
ischaemic stroke with 
CSMR Any stroke 
Excess 
mortality rate -0.34 (-0.45 – -0.24) 0.71 (0.64 – 0.79) 
First-ever acute 
ischaemic stroke with 
CSMR 
First-ever acute stroke, 
ischemic or 
hemorrhagic 
Excess 
mortality rate -0.69 (-0.82 – -0.56) 0.50 (0.44 – 0.57) 
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Acute Myocarditis 
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Input data and methodological summary 
 
Case definition 
Myocarditis refers to a heterogenous group of diseases with variable clinical and pathological features. 
Acute myocarditis was defined for GBD as the acute and time-limited symptoms of myocarditis separate 
from its chronic heart failure-related sequelae. Heart failure due to myocarditis is estimated separately in 
GBD (see methods for heart failure). Symptoms of acute myocarditis are nonspecific and include a flu-like 
or gastrointestinal syndrome, followed by anginal-type chest pain, arrhythmias, syncope, or heart failure.  
 
A list of the ICD codes included can be found in Methods Appendix Table 4. 
Input data 
Model inputs 
The preferred data sources for acute myocarditis was hospital admission data and other health facility 
data identifying cases of acute myocarditis. 
 
A systematic review was performed for GBD 2013 and updated for GBD 2015. A systematic review was 
not performed for GBD 2016. 
 
The GBD 2015 search terms included: (cardiomyopathy AND epidemiology[MeSH Subheading]) OR 
(myocarditis AND epidemiology[MeSH Subheading]) OR (cardiomyopathy AND (incidence OR prevalence 
OR “case fatality”)) OR (myocarditis AND (incidence OR prevalence OR “case fatality”)) 
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 Dates included in search: 1/1/2013 – 3/16/2015 
 Number of initial hits: 3,598 
 Number of sources included: 0 
 
The GBD 2013 search terms included: (hasabstract[text] AND Humans[Mesh] AND middle age[MeSH])) 
OR 21) AND ((cardiomyopathy/epidemiology[Mesh] OR cardiomyopathy/mortality[Mesh]) AND 
(prevalence[Title/Abstract] OR incidence[Title/Abstract]) AND ("2010"[Date - Publication] : "3000"[Date - 
Publication]) AND (hasabstract[text] AND Humans[Mesh] AND middle age[MeSH])) 
 
We did not include any non-literature-based data, apart from the hospital and claims data described 
elsewhere. We used inpatient hospital data adjusted for readmission, primary to any diagnosis, and 
inpatient to outpatient utilization based on correction factors generated using US claims data. We 
excluded all outpatient data, as they were implausibly low when compared with inpatient data from the 
same locations and with claims data. Inpatient hospital data points which were more than 5-fold different 
from the mean value for High-income North America, Central Europe and Western Europe for that age-
sex group were excluded. 
 
We included study-level covariates for inpatient hospital data and claims data from 2000 and 2010 to 
adjust these data points, using as reference the claims data from 2012. 
 
Severity splits and disability weights 
 
Severity level Lay description DW (95% CI) 
Acute myocarditis Has a fever and aches, and feels weak, which causes 
some difficulty with daily activities. 
0.051 (0.032–0.074) 
 
Modelling strategy  
For GBD 2016, we estimated myocarditis using a DisMod MR-2.1 Bayesian meta-regression model, setting 
a minimum of 3 and maximum of 5 as value priors on remission to establish an average duration of three 
months. We set a value prior of 0 for all ages on excess mortality. We included study-level covariates on 
incidence for claims data from 2000 and 2010. Country-level covariates used included the 
cardiomyopathy and myocarditis summary exposure variable (SEV) on incidence and lag distributed 
income (LDI) per capita (I$) on excess mortality. 
 
The table below gives the parameters, betas, and exponentiated betas for study-level and country-level 
covariates used in the model 
Study covariate Parameter beta Exponentiated beta 
LDI (I$ per capita) Excess mortality rate -0.3 (-0.49 – -0.11) 0.74 (0.61 – 0.90) 
All MarketScan, year 2000 Incidence 0.0036 (-0.072 – 0.082) 1.00 (0.93 – 1.09) 
All MarketScan, year 2010 Incidence -0.046 (-0.12 – 0.020) 0.96 (0.89 – 1.02) 
Log-transformed age-
standardized SEV scalar: CMP 
Incidence 0.89 (0.75 – 1.18) 2.44 (2.13 – 3.24) 
 
No substantive changes were made to the modelling approach for GBD 2016. 
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Atrial Fibrillation and Flutter 
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Input data and methodological summary 
Case definition 
Atrial fibrillation was defined as a diagnosis with atrial fibrillation or atrial flutter by ECG findings. ICD 
codes used for inclusion of hospital and claims data can be found in Methods Appendix Table 4. 
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Input data 
 Model inputs 
We did not perform a systematic review for GBD 2016. A systematic review was performed for GBD 2015 
with the following search terms: (“atrial fibrillation” AND epidemiology[MeSH Subheading]) OR (“atrial 
flutter” AND epidemiology[MeSH Subheading]) OR (“atrial fibrillation” AND (prevalence OR incidence OR 
“case fatality”)) OR (“atrial flutter” AND (prevalence OR incidence OR “case fatality”)) OR (“heart atrium 
fibrillation” AND epidemiology[MeSH Subheading]) OR (“heart atrium fibrillation” AND (prevalence OR 
incidence OR “case fatality”)) 
 
The dates of the search were 1/1/2013 – 3/15/2016. There were 5,630 studies returned and, of those, 27 
were extracted.  
 
A systematic review was also performed for GBD 2013, with the search terms: (hasabstract[text] AND 
Humans[Mesh] AND middle age[MeSH])) OR 21) AND ((atrial fibrillation/epidemiology[Mesh] OR atrial 
fibrillation/mortality[Mesh]) AND (prevalence[Title/Abstract] OR incidence[Title/Abstract]) AND 
("2010"[Date - Publication] : "3000"[Date - Publication]) AND (hasabstract[text] AND Humans[Mesh] AND 
middle age[MeSH])) 
 
The table below shows the data inputs: 
 
 Prevalence Incidence Mortality risk 
Studies 71 24 15 
Countries/subnationals 42 17 12 
GBD world regions 8 3 6 
 
 
Apart from hospital and claims data points on prevalence, no non-literature-based data were included. 
We included hospital data corrected for readmission, primary to any diagnosis, and inpatient to 
outpatient utilization ratios using adjustment factors calculated from US claims data. We excluded 
hospital data in certain geographies (e.g. Philippines, China, India) where the data were implausibly low, 
as well as any year groupings with where the corrected prevalence value exceeded 0.3 for any age group. 
This threshold was based on the highest reported prevalence in the available literature. We excluded all 
outpatient administrative data as the values for all locations were implausibly low. We included study-
level covariates to adjust the inpatient hospital data and the claims data from 2000 and 2010 within 
DisMod, using as reference literature data and the claims data from 2012. 
 
 Severity splits & disability weights 
Atrial fibrillation is split into symptomatic and asymptomatic based on standard GBD proportion 
information. The table below includes lay descriptions and disability weights for the severity levels of 
atrial fibrillation: 
Severity level Lay description DW (95% CI) 
Asymptomatic No symptoms N/A 
Symptomatic Has periods of rapid and irregular 
heartbeats and occasional fainting 
0.224 (0.151–0.312) 
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Modelling strategy  
In order to address changes in coding practices for atrial fibrillation that resulted in an implausible trend 
of increasing death certificate-based mortality rates, we used a prevalence-based modeling approach that 
combined DisMod-MR and CODEm models to generate estimates for atrial fibrillation and flutter. This 
approach, first used in GBD 2015, allowed us to more generate more accurate estimates, using observed 
prevalence and incidence rates along with modeled excess mortality rates generated from prevalence 
and cause-specific mortality estimates. 
• In Step 1, we estimated deaths for atrial fibrillation using a standard CODEm approach. 
• In Step 2, we estimated prevalence rates in DisMod-MR using data from published reports of 
cross-sectional and cohort surveys and primary care facility data. We also used claims data 
covering inpatient and outpatient visits for the United States along with inpatient hospital 
data from 22 countries. As the inpatient hospital data only included information from the 
primary code for each visit, prevalence rates for these data were adjusted based on the age- 
and sex-specific proportions of atrial fibrillation in the primary codes versus secondary codes 
in the US claims data. 
• In Step 3, we calculated the excess mortality rate (EMR) for 2016 (defined as the cause-
specific mortality rate (CSMR) estimated from CODEm divided by the prevalence rate from 
DisMod-MR). We then selected 27 countries based on four conditions: 1) ranking of 4 or 5 
stars on the newly developed system for assessing the quality of VR data; 2) prevalence data 
available from the literature was included in the DisMod-MR 2.1 estimation; 3) prevalence 
rate ≥ 0.005; and, 4) CSMR ≥ 0.00002. These conditions were set to ensure that the VR data 
were of sufficient quality to generate reasonable estimates, that prevalence estimates for 
that location were informed directly by representative data for that population, and that 
cause-specific mortality and prevalence estimates were high enough to ensure reasonable 
results from the regression. Using information from these countries as input data, we ran a 
linear mixed-effects regression of logEMR on sex, age, and location. Sex and age were treated 
as fixed effects for the regression, while location was considered a random effect. We then 
predicted age- and sex-specific EMR using the results of this regression for all non-selected 
countries. Countries included in the regression were assigned their directly calculated values. 
These EMR data points were assigned to the time period 1990–2016 and uploaded into the 
Nonfatal database. 
• In Step 4, we re-ran DisMod-MR including the EMR estimated in Step 3 and using log-
transformed lagged distributed income (LDI) as a country-level covariate. Based on 
information from other regressions, we set the bounds at -1.5 to -0.25. We also included 
study-level covariates to cross-walk the inpatient hospital and claims data from 2000 and 
2010 to the reference data, which included literature data and claims data from 2012. We 
included a value prior of 0 for remission for all ages. We also set a value prior of 0 for excess 
mortality for ages 0-30. 
 
The prevalence from the DisMod-MR model in Step 4 was used as the finalized output for upload to 
COMO and further processing into YLDs and DALYs. Models were evaluated based on expert opinion, 
comparison with results from previous rounds of GBD, and model fit.  
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The tables below includes the study covariates, parameters, betas, and exponentiated betas. 
 
DisMod Covariates – Step 2 
Study covariate Parameter Beta Exponentiated beta 
Hospital data Prevalence -0.000086 (-0.19 – 0.097) 1.0 (0.82 – 1.10) 
All MarketScan, year 2000 Prevalence -0.47 (-0.5 – -0.44) 0.63 (0.61 – 0.64) 
All MarketScan, year 2010 Prevalence -0.003 (-0.024 – -0.014) 1.0 (0.98 – 1.01) 
Log-transformed age-
standardized SEV scalar: A 
Fib 
Prevalence 0.75 (0.75 – 0.75) 2.12 (2.12 – 2.12) 
LDI (I$ per capita) Excess mortality rate -0.48 (-0.5 – -0.43) 0.62 (0.61 – 0.65) 
 
DisMod Covariates – Step 4 
Study covariate Parameter Beta Exponentiated beta 
All MarketScan, year 2000 Prevalence -0.46 (-0.49 – -0.43) 0.63 (0.62 – 0.65) 
All MarketScan, year 2010 Prevalence -0.0021 (-0.025 – -0.021) 1.0 (0.98 – 1.02) 
Log-transformed age-
standardized SEV scalar: A 
Fib 
Prevalence 0.75 (0.75 – 0.75) 2.12 (2.12 – 2.12) 
LDI (I$ per capita) Excess mortality rate -0.1 (-0.1 – -0.1) 0.9 (0.9 – 0.9) 
 
No substantative changes were made to the modelling strategy for GBD 2016. 
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Peripheral Arterial Disease  
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Case definition 
For GBD 2016, peripheral arterial disease was defined as having an ankle-brachial index (ABI) <0.9. 
Intermittent claudication was defined clinically.  
Specific ICD codes for claims data included can be found in Methods Appendix Table 4. 
Input data 
 Model inputs 
We did not perform a systematic review for GBD 2016. 
 
A systematic review was performed for peripheral arterial disease and intermittent claudication for GBD 
2015. The search terms were: ('peripheral vascular disease'[TIAB] AND 'epidemiology'[Subheading]) OR   
('peripheral arterial disease'[TIAB] AND 'epidemiology'[Subheading]) OR  ('peripheral artery disease'[TIAB] 
AND 'epidemiology'[Subheading]) OR  ('intermittent claudication'[TIAB] AND 'epidemiology'[Subheading]) 
OR   ('ankle-brachial index'[TIAB] AND 'epidemiology'[Subheading]) OR   ('ankle brachial index'[TIAB] AND 
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'epidemiology'[Subheading]) OR   ('peripheral artery occlusive disease'[TIAB] AND 
'epidemiology'[Subheading]) OR ('peripheral obliterative arteriopathy'[TIAB] AND 
'epidemiology'[Subheading]) OR ('peripheral vascular disease'[TIAB] AND 'prevalence'[MeSH Terms]) OR   
('peripheral vascular disease'[TIAB] AND 'incidence'[MeSH Terms]) OR   ('peripheral vascular 
disease'[TIAB] AND 'case fatality'[All Fields]) OR ('symptomatic claudication'[TIAB] AND (proportion[All 
Fields] OR percent[All Fields])) 
 
The search was conducted from 1/1/13 to 3/16/2015. 1,658 results were returned, of which six were 
extracted.  
 
A systematic review was also performed for peripheral arterial disease and intermittent claudication for 
GBD 2013. Search terms can be provided upon request.  
 
The table below shows the number of literature studies included in GBD 2015, as well as the number of 
countries or subnational units and GBD world regions represented. 
 
Peripheral arterial disease 
 Prevalence Incidence Mortality risk 
Studies 16 2 1 
Countries/subnationals 11 2 1 
GBD world regions 7 2 1 
 
Proportion with intermittent claudication 
 Proportion 
Studies 9 
Countries/subnationals 4 
GBD world regions 3 
 
 
Apart from the claims data, we did not include any non-literature-based data types. We did not use 
inpatient hospital data, as peripheral arterial disease is expected to be rare in inpatient data, but common 
in outpatient data as it is a condition usually managed on an outpatient basis, except for specific surgical 
interventions. This discrepancy leads to implausible correction factors based on inpatient/outpatient 
information from claims data (~150X); thus adjusted data cannot be used. Including uncorrected data in 
the model is likely to lead to incorrect estimates as hospitalization and procedure rates are likely to vary 
between geographies based on access to and patterns of care.  
We corrected US claims data outside of DisMod, using as reference literature reports of prevalence. Using 
as a model the adjustment factors developed to translate tobacco consumption prevalence to tobacco 
consumption frequency, we matched administrative claims data to population-based literature data 
based on age group, sex, and super region (1). For the adjustment factor, we developed the following 
generalized additive model on matched data ln�𝜇𝜇𝑟𝑟𝑟𝑟𝑟𝑟,𝑖𝑖� =  𝛽𝛽0 + 𝛽𝛽1 ln�𝜇𝜇𝑏𝑏,𝑖𝑖� + 𝑠𝑠(𝑎𝑎𝑎𝑎𝑎𝑎𝑖𝑖)+𝜀𝜀𝑖𝑖 
Where 𝑖𝑖 represents a given matched observation, 𝑎𝑎𝑎𝑎𝑎𝑎 signifies the data point’s age group, 𝑠𝑠(𝑥𝑥) 
represents a penalized spline where the smoothing parameter is chosen through cross validation and 
𝜇𝜇𝑟𝑟𝑟𝑟𝑟𝑟 and 𝜇𝜇𝑏𝑏 denote the mean of the data point from literature and the mean of the claims data point, 
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respectively. Predictions from the model were then taken as the adjusted data points. The standard error 
of each corrected data point was adjusted to account for the uncertainty due to the correction. 
Outpatient data were not included as the rates were implausibly low for all locations. 
 
 
 Severity splits and disability weights 
We used the proportion of intermittent claudication to split the overall prevalence of peripheral arterial 
disease into symptomatic and asymptomatic peripheral vascular disease. The table below illustrates these 
values: 
Severity level Lay description DW (95% CI) 
Asymptomatic No symptoms No DW assigned 
Symptomatic Has cramping pains in the legs after walking a medium 
distance. The pain goes away after a short rest. 
0.014 (0.007–0.025) 
 
Modelling strategy  
For GBD 2016, we used DisMod MR 2.1 to model the overall prevalence of peripheral arterial disease 
using prevalence data from literature studies and claims data. Claims data were adjusted outside of 
DisMod using the ratio of prevalence reported in literature studies to the prevalence figures in the claims 
data by age and sex. We also included the log-transformed, age-standardized SEV scalar for PAD and log-
transformed LDI as fixed-effect, country-level covariates. We set value priors of 0 for incidence from ages 
0 to 30. We also set a value prior of 0 for remission for all ages. Finally, we set a value prior of a maximum 
value of 0.25 on excess mortality for all ages.  
 
The table below illustrates the study covariates, parameters, beta, and exponentiated beta values for the 
overall peripheral vascular disease model. 
 
Covariate Parameter Beta Exponentiated beta 
Log-transformed age-
standardized SEV scalar: PVD 
Prevalence 1.22 (1.17 – 1.25) 
 
3.40 (3.21 – 3.49) 
 
LDI (I$ per capita) Excess mortality rate -0.30 (-0.50 – -0.1) 0.74 (0.61 – 0.90) 
 
We used DisMod MR-2.1 to model the proportion of peripheral vascular disease with intermittent 
claudication. We set a value prior of 0 for proportion for ages 0 to 40. 
 
Covariate Parameter Beta Exponentiated beta 
Healthcare access and quality index Proportion -0.013 (-0.04 – -0.00034) 0.99 (0.96 – 1.00) 
 
To obtain final estimates for the sequelae of interest, we multiplied the prevalence model by the 
proportion model at the draw level to generate the prevalence of symptomatic and asymptomatic 
peripheral vascular disease. 
  
Models were evaluated based on expert review, comparisons with estimates from prior rounds of GBD, 
and assessing model fit.  
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We corrected an error in the mapping of ICD-coded data for peripheral arterial disease – in previous 
iterations of GBD, unspecified atherosclerosis was assigned to peripheral arterial disease. As this code 
likely represents a mix of central and peripheral atherosclerosis, we excluded these data to ensure 
specificity of diagnosis. Other this correction, there have been no substantive changes from GBD 2015 in 
terms of modelling strategy for peripheral arterial disease. 
 
1. Reitsma, Marissa B., et al. "Smoking prevalence and attributable disease burden in 195 countries 
and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015." 
The Lancet. 
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Acute Endocarditis 
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Input data and methodological appendix 
 
Case definition 
Our case definition for acute endocarditis was a clinical diagnosis of infective endocarditis. The ICD codes 
included can be found in Methods Appendix Table 4. 
 
Input data 
Model inputs 
A systematic review was performed for GBD 2013 and updated for GBD 2015. We did not perform a 
systematic review for GBD 2016. The following search terms were used: ((‘endocarditis’[MeSH Terms] OR 
‘endocarditis’[All Fields]) AND ‘epidemiology’[Subheading]) OR ((‘endocarditis’[MeSH Terms] OR 
‘endocarditis’[All Fields]) AND ((‘epidemiology’[Subheading] OR ‘epidemiology’[All Fields] OR 
‘incidence’[All Fields] OR ‘incidence’[MeSH Terms]) OR (‘epidemiology’[Subheading] OR ‘epidemiology’[All 
Fields] OR ‘prevalence’[All Fields] OR ‘prevalence’[MeSH Terms]) OR ‘case fatality’[All Fields])) OR 
((‘endocardium’[MeSH Terms] OR ‘endocardium’[All Fields]) AND inflammation[TIAB] AND 
‘epidemiology’[Subheading]) OR ((‘endocardium’[MeSH Terms] OR ‘endocardium’[All Fields]) AND 
inflammation[TIAB] AND ((‘epidemiology’[Subheading] OR ‘epidemiology’[All Fields] OR ‘incidence’[All 
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Fields] OR ‘incidence’[MeSH Terms]) OR (‘epidemiology’[Subheading] OR ‘epidemiology’[All Fields] OR 
‘prevalence’[All Fields] OR ‘prevalence’[MeSH Terms]) OR ‘case fatality’[All Fields])) 
 
 Dates included in search: 1/1/2013 – 3/16/2015 
 Number of initial hits: 1,246 
 Number of sources included: 6 
 
The table below shows the number of literature studies included in GBD 2016, as well as the number of 
countries or subnational units and GBD world regions represented. 
 
 Prevalence Incidence Mortality risk 
Studies 0 14 1 
Countries/subnationals 0 7 1 
GBD world regions 0 3 1 
 
 
We did not include any non-literature-based data types, apart from the hospital and claims data 
described elsewhere. We excluded all outpatient data, as they were implausibly low when compared with 
inpatient data from the same locations and claims data. We used hospital data corrected for readmission 
and primary to any diagnosis based on the correction factors generated using US claims data. We 
excluded any inpatient hospital data points which were more than 5-fold different from the mean value 
for High-income North America, Central Europe and Western Europe for that age-sex group. 
 
We included study-level covariates for inpatient hospital data and claims data from 2000 and 2010 to 
adjust these data points, using as reference the data obtained from literature and claims data from 2012. 
 
Severity split inputs 
We used the standard GBD approach, which utilizes MEPS data to split overall estimates of endocarditis 
into moderate and severe categories. The table below includes the severity level, lay descriptions, and 
DWs associated with acute endocarditis. 
 
Severity level Lay description DW (95% CI) 
Moderate Has a fever and aches, and feels weak, which causes some 
difficulty with daily activities. 
0.051 (0.032–0.074) 
Severe Has a high fever and pain, and feels very weak, which causes 
great difficulty with daily activities. 
0.133 (0.088–0.19) 
 
Modelling strategy  
For GBD 2016, we estimated endocarditis using a DisMod MR-2.1 Bayesian meta-regression model, 
setting a minimum of 11 and maximum of 13 as value priors on remission to establish an average 
duration of one month. We included study-level covariates on incidence for inpatient hospital data and 
claims data from 2000 and 2010. Country-level covariates used included the endocarditis summary 
exposure variable (SEV) on incidence and lag distributed income (LDI) per capita (I$) on excess mortality. 
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We evaluated models by comparing model fits with the data and with results from previous GBD 
estimation cycles. In prior iterations of GBD, we used modelled data for remission; based on information 
from the literature and expert review, we have revised this to use an average duration of one month for 
all locations. For GBD 2015, we had restricted claims and inpatient hospital data to primary diagnosis 
position only; as mentioned above, we are now using data with a diagnosis of endocarditis in any 
position. 
 
The table below gives the parameters, betas, and exponentiated betas for study-level and country-level 
covariates used in the model 
Covariate Parameter Beta Exponentiated beta 
Hospital data Incidence 0.70 (0.66 – 0.72) 2.01 (1.93 – 2.06) 
Inpatient-only Marketscan, 
year 2000 
Incidence -0.34 (-0.39 – -0.29) 0.71 (0.68 – 0.75) 
Inpatient-only Marketscan, 
year 2010 
Incidence -0.18 (-0.22 – -0.13) 0.84 (0.80 – 0.88) 
LDI (I$per capita) Excess mortality rate -0.14 (-0.16 – -0.13) 0.87 (0.85 – 0.88) 
Log-transformed age-
standardized SEV scalar: 
endocarditis 
Incidence 0.89 (0.75 – 0.86) 2.20 (2.12 – 2.37) 
 
No other significant changes were made to the modelling strategy from GBD 2015. 
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Other cardiovascular disease 
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Case definition  
Other cardiovascular disease is a residual category resulting from the GBD approach of estimating the 
total burden of all causes. Prevalence estimates are produced in order to provide YLDs consistent with 
the estimated YLLs from the death modeling process and to enable the calculation of DALYs. 
 
Conditions included in this cause, based on ICD codes used for both fatal and nonfatal modeling, are:  
Other diseases of pulmonary vessels, Acute pericarditis, Other diseases of pericardium, Pericarditis in 
diseases classified elsewhere, Nonrheumatic mitral valve disorders, Nonrheumatic aortic valve disorders,  
 Nonrheumatic tricuspid valve disorders, Nonrheumatic pulmonary valve disorders, Paroxysmal 
tachycardia, Cardiac septal defect, acquired, Rupture of chordae tendineae, not elsewhere classified, 
Rupture of papillary muscle, not elsewhere classified, Intracardiac thrombosis, not elsewhere classified, 
Cerebral amyloid angiopathy, Other aneurysm, Other disorders of arteries and arterioles, Diseases of 
capillaries, Disorders of arteries, arterioles and capillaries in diseases classified elsewhere, Phlebitis and 
thrombophlebitis, Portal vein thrombosis, Other venous embolism and thrombosis, Varicose veins of 
lower extremities, Varicose veins of other sites, Other disorders of veins, Nonspecific lymphadenitis, 
Other noninfective disorders of lymphatic vessels and lymph nodes, Other disorders of circulatory system 
in diseases classified elsewhere   
 
Input data  
As this is a residual category, we used data from the Medical Expenditure Panel Survey and modeled 
estimates from heart failure due to other cardiovascular disease to estimate prevalence of other 
cardiovascular disease. 
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Severity split inputs  
The table below includes lay descriptions and disability weights for the severity levels of other 
cardiovascular disease for GBD 2016.  
Severity level  Lay description  DW (95% CI)  
Mild  Is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter‐mile on 
level ground. The person feels comfortable at rest or during 
activities requiring less effort.  
0.041 (0.026–0.062)  
Moderate  Is short of breath and easily tires with minimal physical activity, 
such as walking only a short distance. The person feels 
comfortable at rest but avoids moderate activity.  
0.072 (0.047–0.103)  
Severe  Is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the breathing 
problems.  
0.179 (0.122–0.251)  
 
Modelling strategy   
To obtain prevalence estimates of other cardiovascular disease, we used MEPS data combined with 
prevalence estimates of heart failure due to other CVD for the US in 2005 to estimate the ratio of the 
prevalence of HF due to other CVD causes to to the prevalence of other CVD causes. We then applied this 
ratio to the age‐, sex‐, and year‐specific prevalence estimates for heart failure due to other CVD causes 
for all locations to generate prevalence estimates of other cardiovascular disease.  
 
No significant changes were made to the modelling strategy for GBD 2016. 
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 Hemoglobinopathies and Hemolytic Anaemias 
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Input data and methodological summary 
 
Case definition 
Hemoglobinopathies and hemolytic anaemias span four GBD causes: thalassemias, sickle cell disorders, 
glucose-6-phosphate dehydrogenase (G6PD) deficiency, and other hemoglobinopathies. ICD-9 and ICD-10 
codes for each are contained in Table 1. Within each category, several unique combinations of genetic 
mutations lead to distinct phenotypes with different natural history, which has led us to estimate several 
distinct subtypes of thalassemias and sickle cell disorders. The three thalassemia models included 1) beta-
thalassemia major, 2) hemoglobin E/beta-thalassemia, and 3) hemoglobin H disease. Sickle cell models 
included 1) homozygous sickle cell and severe sickle cell/beta-thalassemia, 2) hemoglobin SC disease, and 
3) “mild” sickle cell-beta thalassemia. We also estimated the burden of glucose-6-phosphate 
dehydrogenase (G6PD) deficiency. Finally, we estimated prevalence and YLD due to other 
hemoglobinopathies and hemolytic anemias assuming the YLD-to-YLL ratio for each age, sex, location, 
and year was similar to that of the aggregate of sickle cell, thalassemias, and G6PD deficiency. This 
approach was used in multiple causes across GBD 2015.  
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 TABLE 1. International classification of diseases codes for hemoglobinopathies and hemolytic anaemias in GBD 2015 
cause of death analysis  
Condition ICD-10 code ICD-9 code 
Total D55-D59 282.0-282.1, 282.7-285.8, 282.2-282.3, 282.5-282.6, 282.4 
Thalassemias D56 282.4 
Sickle cell disorders D57 282.5-282.6 
G6PD deficiency D55 282.2-282.3 
Other hemoglobinopathies 
and hemolytic anemias 
D58-D64.8 282.0-282.1, 282.7-285.8 
 
Input data 
 Model inputs 
Systematic literature reviews were completed for GBD 2010 and GBD 2013. These were updated on May 
1, 2015, using the following search strings: 
(thalassemias[Title/Abstract] AND (prevalence[Title/Abstract] OR survival[Title/Abstract] OR 
mortality[Title/Abstract]) AND ("2008"[PDAT] : "2013"[PDAT])) AND "humans"[MeSH Terms] 
 
(sickle cell[Title/Abstract] AND (mortality[Title/Abstract] OR survival[Title/Abstract] OR 
prevalence[Title/Abstract]) AND ("2008"[PDAT] : "2013"[PDAT])) AND "humans"[MeSH Terms] 
 
(G6PD[Title/Abstract] OR G6PD deficiency[Title/Abstract] OR glucose-6 phosphate 
dehydrogenase[Title/Abstract] OR glucose-6-phosphate dehydrogenase deficiency[Title/Abstract] AND 
(survival[Title/Abstract] OR mortality[Title/Abstract]) AND ("2008"[PDAT] : "2013"[PDAT])) AND 
"humans"[MeSH Terms] 
 
Of note, upon the recommendation from multiple GBD collaborators, we identified and re-extracted all 
primary data that had been used in GBD 2013. In some situations, this process identified cases of sickle 
cell or thalassemia that had been assigned to incorrect subtypes, but mostly the data were correct and 
verified. We excluded any data where the results presented in a study were themselves the result of 
modelling exercises. The most significant change as a result of re-extraction was when we identified that 
much of the literature data used in GBD 2013 from females with G6PD deficiency actually did not 
correspond to our case definition of homozygous disease, but rather included combined case counts for 
homozygotes and hemizygotes. We only included homozygous disease in our datasets for GBD 2015, 
which has led to much lower estimates of G6PD deficiency in females.  
 
We extracted prevalence data from population-level and community surveys as well as with-condition 
mortality and excess-mortality data from cohort studies. Age-specific survival proportions were converted 
to with-condition mortality rates as needed. We also included data from hospital and claims data for a 
subset of hemoglobinopathy models, including beta-thalassemia major, hemoglobin E/beta-thalassemia, 
homozygous sickle cell and severe sickle cell/beta-thalassemia, hemoglobin SC disease, and mild sickle 
cell/beta-thalassemia. The extraction and processing of hospital and claims data is described separately. 
Composition of final datasets are shown below for each of the different hemoglobinopathies and 
hemolytic anaemias models.  
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Data availability 
Homozygous sickle cell and severe sickle cell/beta-thalassemia (2097): 
 Prevalence Mortality risk 
Studies 110 25 
Countries/subnationals 83/44 11/15 
GBD world regions 13 8 
 
Hemoglobin SC disease (2100): 
 Prevalence Mortality risk 
Studies 63 12 
Countries/subnationals 42/21 4/7 
GBD world regions 12 4 
 
Mild sickle cell/beta-thalassemia (2103): 
 Prevalence Mortality risk 
Studies 20 9 
Countries/subnationals 57/7 22/9 
GBD world regions 13 3 
 
Beta-thalassemia major (2085): 
 Prevalence Mortality risk 
Studies 27 6 
Countries/subnationals 86/33 6/1 
GBD world regions 18 3 
 
Hemoglobin E/beta-thalassemia (2087):  
 Prevalence Mortality risk 
Studies 7 1 
Countries/subnationals 23/20 1/1 
GBD world regions 3 1 
 
Hemoglobin H disease (2089):  
 Prevalence 
Studies 11 
Countries/subnationals 19/23 
GBD world regions 9 
 
G6PD deficiency (2112):  
 Prevalence 
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Studies 278 
Countries/subnationals 89/39 
GBD world regions 18 
Modelling strategy  
Besides data re-extraction and addition of hospital and claims data, we have made no substantive 
changes to the estimation strategy since 2013. We estimated the nonfatal burden of hemoglobinopathies 
in three parts.  
First, we used the datasets described above to estimate prevalence for each age-sex-location-year in the 
GBD 2015 location hierarchy using DisMod-MR 2.1. For mild sickle cell/beta-thalassemia models, study-
level covariates were used to identify and crosswalk those data from Marketscan in the year 2000, which 
were systematically lower than later years, to the years 2010 and 2012. The magnitude of prevalence in 
later years of claims data for this model, and in all years for other models, was similar to that of literature 
data from the same locations, so they were considered equivalent and no additional crosswalks were 
performed. In all sickle cell models and beta-thalassemia major, the natural log of lag-distributed income 
per capita (LN-LDI) was used as a sole country covariate on excess mortality, meant to reflect the 
profound impact that health system financial resources can have on survival from these conditions. For 
G6PD deficiency, data where diagnosis was made only on the basis of chemical or reagent testing was 
crosswalked to the reference definition of genetic G6PD deficiency; absolute value of latitude was the 
sole country covariate for this model.  
Second, we calculated prevalence of hemoglobinopathy traits (sickle cell trait, hemoglobin E trait, 
hemoglobin beta trait, G6PD trait) by back-calculating from birth prevalence estimates from 
corresponding DisMod-MR 2.1 models, assuming Hardy-Weinberg equilibrium, and no excess mortality. 
Third, age-specific prevalence for all subtypes of hemoglobinopathies were paired with estimated 
sequelae distributions from a series of cohort studies and clinical data in GBD 2010 and GBD 2013. This 
included consideration of the burden of anaemia associated with homozygous and heterozygous persons 
and ensuring the estimates of hemoglobinopathy-induced anaemia were internally consistent with overall 
estimates for each condition, including prevention of double counting. The anaemia estimation process is 
described separately.  
Third, and finally, we found the ratio of YLD to YLL ratio for all hemoglobinopathies and then applied it to 
YLLs estimated for other hemoglobinopathies and hemolytic anaemias in our cause-specific mortality 
analysis. Quantitative crosswalk results for each model are shown below.  
Covariate, parameter, beta, and exponentiated beta values 
Homozygous sickle cell and severe sickle cell/beta-thalassemia (2097): 
Study-level covariate Parameter Location 
level 
beta Exponentiated beta 
LDI (I$ per capita) 
Excess 
mortality rate 
Global -0.14 0.87 
(0.86 - 0.88) 
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Hemoglobin SC disease (2100): 
Study-level covariate Parameter Location 
level 
beta Exponentiated beta 
LDI (I$ per capita) 
Excess 
mortality rate 
Global -0.03 0.97 
(0.95 – 1.00) 
Mild sickle cell/beta-thalassemia (2103): 
Study-level covariate Parameter Location 
level 
beta Exponentiated beta 
LDI (I$ per capita) 
Excess 
mortality rate 
Global -0.19 0.83 
(0.74 - 0.98) 
All MarketScan, year 
2000 Prevalence 
Global -0.48 .6199 
(0.54 - 0.71) 
Beta-thalassemia major (2085): 
Study-level covariate Parameter Location 
level 
beta Exponentiated beta 
LDI (I$ per capita) 
Excess mortality 
rate 
Global -0.58 0.56 
(0.55 - 0.58) 
Hemoglobin E/beta-thalassemia (2087): 
Study-level covariate Parameter Location 
level 
beta Exponentiated beta 
Year Prevalence 
Global 0.02 
(0.00 - 0.02) 
1.02 
(1.00 - 1.02) 
Hemoglobin H disease (2089): 
Study-level covariate Parameter Location 
level 
beta Exponentiated beta 
Year Prevalence 
Global -0.01 0.99 
(0.98 - 1.02) 
G6PD deficiency (2112): 
Study-level covariate Parameter Location 
level 
beta Exponentiated beta 
Absolute value of 
average latitude Prevalence 
Super region -0.01 0.99 
(0.98 - 1.00) 
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Diagnostic modality 
based on chemical/ 
reagent testing Prevalence 
Super region 
0.322 1.38 
(1.16 - 1.69) 
Year Prevalence 
Super region -0.01 0.99 
(0.98 - 0.99) 
Sequelae 
With the exception of anaemia, only homozygous individuals were considered to experience disability. 
Estimated sequelae of thalassemias included anaemia (described separately), heart failure (described 
separately), and periodic severe infection. Another series of common, but not universal, sequelae also 
occur in those with thalassemias, including splenomegaly, skeletal deformity, delayed growth/puberty, 
diabetes, hypothyroidism, and leg ulcers. Given sparse data on the occurrence of these sequelae, they 
were approximated with a health state named “other combined sequelae of thalassemia,” for which we 
used the disability weight corresponding to a health state of “generic uncomplicated disease, anxiety 
about diagnosis and daily medication” which, of note, was also used to approximate the disability for 
those with cancer in remission. For sickle cell disorders, we similarly estimated YLDs for anaemia 
(described separately), stroke, and pain crises separately and approximated the myriad additional 
complications of sickle cell disease with the health state “other combined sequelae of sickle cell disease.” 
The only sequelae estimated for G6PD deficiency were anaemia (described separately) and heart failure 
(described separately). Notably, however, G6PD deficiency is considered to be asymptomatic for a vast 
majority of those with the condition, with only a very small subset of around 1 in 1,000,000 having 
chronic hemolysis (Class I disease) and approximately 1% having periodic hemolytic episodes (Class II 
disease) with exposure to environmental, pharmaceutical, or food products. Females heterozygous for 
G6PD deficiency exhibit chimerism, as one X chromosome becomes dominant in each of the red blood 
cells, so we estimated half as many heterozygous females will be symptomatic as homozygous females.  
Uncertainty and model selection 
For all hemoglobinopathies estimates, uncertainty bounds include uncertainty due to input data, 
crosswalks from non-reference definitions in study covariates above, uncertainty in numerical solutions 
(posteriors) of each DisMod-MR 2.1 model, and proportion of all persons with each type of symptom.  
In consultation with GBD researchers and collaborators, final models were selected on a combination of 
qualitative and quantitative goodness of fit to input data, plausibility of geographic and temporal trends, 
consistency of age pattern, and, when available, comparison with other published studies on 
hemoglobinopathy epidemiology. Directionality, magnitude, and plausibility of study-level and country-
level covariates was also considered in the process of model development. Of note, due to the nature of 
statistical modelling, final results do not always cover the values reported in input data. 
No other significant changes were made to the GBD 2015 modelling strategy. 
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Chronic Obstructive Pulmonary Disease (COPD) 
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Input data and methodological summary 
 
Case definition 
COPD is defined as in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification: a 
measurement of <0.7 FEV1/FVC (one second of forceful exhalation/total forced expiration) on spirometry 
after bronchodilation. It should be noted that this is the same reference definition as was used for GBD 
2015, but it is different from GBD 2013 where the “Lower Limit of Normal (LLN),” ie, relative to an age- 
and sex-specific norm for the FEV1/FVC ratio, was the reference. We made this decision because the 
severity grading of COPD follows the GOLD Class definition rather than the LLN concept. The definitions of 
the severity classes in the GOLD classification are provided below.  
GOLD CLASS FEV1 Score 
I: Mild >=80% of normal 
II: Moderate 50-79% of normal 
IV: Severe <50% of normal 
 
ICD-10 codes associated with COPD include J40, J41, J42, J43, J44, and J47. The corresponding ICD-9 
codes are 490-492, 494, and 496. 
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Input data 
For GBD 2016, we updated the systematic review from previous iterations. The full search term was: 
(chronic obstructive pulmonary disease[Title/Abstract] AND (prevalence[Title/Abstract] or incidence 
[Title/Abstract] or mortality [Title/Abstract] or death [Title/Abstract]) AND "Cross-Sectional Studies"[MeSH 
Terms])  Filters: Publication date from 04/01/2015 to 11/01/2016; Humans 
 
Twenty-three new sources were extracted. Studies excluding smokers were excluded from the review.  
 
In addition, we include survey data with spirometry measurements, including the National Health and 
Nutrition Examination Study series in the United States. The Study of Aging and Global Health (SAGE) 
series was examined for GBD 2015 but ultimately excluded as the spirometry data had implausible 
FEV1/FVC values (eg, over 1). 
Data using alternative case-definitions of COPD prevalence (i.e. LLN) were crosswalked to the reference 
case-definition with age-specific ratios derived from studies reporting prevalence using both the 
alternative and reference case-definitions. 
Furthermore, claims data for the United States were included. Additional information on the claims data 
collection and pre-corrections are provided elsewhere. Briefly, we determined US national and state-level 
estimates of COPD prevalence from a database of individual level ICD-coded health service encounters. 
Persons with any claim associated with COPD were marked as a prevalent case for that year. 
For GBD 2016, an additional correction was made for COPD US claims data. Under the assumption that 
NHANES estimates are more accurate than claims data estimates because they use spirometry 
measurements, we derived an age-specific crosswalk to adjust US claims data according to the ratio 
between NHANES and the national-level US claims estimates. 
A table describing the density and distribution of the available data informing the COPD estimation 
process is provided below. 
 Proportion by GOLD Class Prevalence Incidence 
Studies 15 80 4 
Countries or 
subnational 
locations 
27 119 4 
Regions 15 16 3 
 
Modelling strategy  
As described above, the estimation of COPD burden occurs in three main steps. The first is the estimation 
of prevalence and incidence using a DisMod-MR 2.1 model. The second is the separate estimation of the 
proportions by three GOLD class groupings in DisMod-MR 2.1. The third is the combination of these two 
processes to derive prevalence by severity. 
 
Step 1: Main COPD model 
Prior settings include remission of 0 and an incidence ceiling of 0.0002 before age 20. The latter was 
necessary to avoid a kick-up of estimates in childhood at an age range with few or no primary data. 
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Similar to other causes, we include estimates of cause-specific mortality rate (CSMR) and derived 
estimates of excess mortality rate (EMR) by dividing every prevalence data point by the CSMR value for 
the corresponding location, age, sex, and year. We did not estimate EMR for data points with an age 
range greater than 20 years. 
 
To assist estimation, each model includes a series of country-level covariates that describe 
spatiotemporal patterns. Where available, we use the COPD standardized exposure variables (SEV), which 
aggregate multiple risk factors into a single variable. We also use the log of LDI on EMR to capture 
country-level variation of EMR, assuming a negative coefficient (ie, lower mortality with rising GDP).  
Step 2: GOLD class models 
The GOLD class models use data from surveys that specified prevalence by GOLD class after expressing 
the values as a proportion of all COPD cases. We use fixed effects from the SEV scalar and the log of lag-
distributed income (LDI) per capita to assist estimation. 
 
Table of model coefficients for COPD and GOLD class models 
Cause Variable_name Measure Beta Exponentiated 
COPD LDI (I$ per capita) excess mortality 
rate 
-0.5 
(-0.5 — -0.5) 
 
 
0.61 
(0.60 — 0.61) 
 
COPD Log age-
standardized SEV 
scalar: COPD 
prevalence 0.75 
(0.75 — 0.76) 
2.12 
(2.12 — 2.15) 
 
GOLD I proportion Socio-demographic 
Index 
proportion 0.93 
(-0.96 — 1.97) 
 
 
2.54 
(0.38 — 7.18) 
 
GOLD I proportion Log age-
standardized SEV 
scalar: COPD 
proportion -0.17 
(-0.62 — 0.33) 
 
0.84 
(0.54 — 1.39) 
 
GOLD II proportion Socio-demographic 
Index 
proportion 0.93 
(-0.96 — 1.97) 
 
 
2.54 
(0.38 — 7.18) 
 
GOLD II proportion Log age-
standardized SEV 
scalar: COPD 
proportion -0.17 
(-0.62 — 0.33) 
 
 
0.84 
(0.54 — 1.39) 
 
GOLD III+IV proportion Socio-demographic 
Index 
proportion 0.35 
(-1.66 — 1.88) 
 
 
1.42 
(0.19 - 6.57) 
GOLD III+IV proportion Log age-
standardized SEV 
scalar: COPD 
proportion 0.018 
(-0.8 — 0.78) 
 
 
1.02 
(0.45 — 2.17) 
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Severity 
The three GOLD class groupings reflect a grading based on a physiological measurement rather than a 
direct measurement of disease severity. In order to map the epidemiological findings by GOLD Class into 
the three COPD health states for which we have disability weights (DW), we used the 2001–2011 Medical 
Expenditure Panel Survey (MEPS) data from the United States. Specifically, we convert the GOLD class 
designations estimated for the USA in 2005 (the midpoint of MEPS years of analyses) into GBD 
classifications of asymptomatic, mild, moderate, and severe COPD.  
The table below shows the three health states of COPD and the corresponding lay descriptions and 
disability weights. The graph shows the average proportion by GOLD Class (after scaling to 100%) across 
all ages for USA in 2005. We also show the proportion of MEPS respondents reporting any health service 
contact in the past year for COPD with a DW value attributable to COPD of 0, mild range (0 to midpoint 
between DWs for mild and moderate), moderate range (midpoint of DW values mild and moderate to 
midpoint of DW values for moderate and severe) and severe range (midpoint between DW values 
moderate and severe or higher). The DW value for COPD was derived from a regression with indicator 
variables for all health states reported by MEPS respondents and their reported overall level of disability 
derived from a conversion of 12-Item Short Form Surveys (SF-12) answers to GBD DW values. This 
analysis gave the severity distribution for each GBD cause reported in MEPS after correcting for any 
comorbid causes individual respondents reported during a year. 
Health state Lay description DW (95% CI) 
Mild COPD This person has cough and shortness of breath after 
heavy physical activity, but is able to walk long 
distances and climb stairs. 
0.019 
(0.011–0.033) 
Moderate COPD This person has cough, wheezing, and shortness of 
breath, even after light physical activity. The person 
feels tired and can walk only short distances or climb 
only a few stairs. 
0.225 
(0.153–0.31) 
Severe COPD This person has cough, wheezing, and shortness of 
breath all the time. The person has great difficulty 
walking even short distances or climbing any stairs, 
feels tired when at rest, and is anxious. 
0.408 
(0.273–0.556) 
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The algorithm to translate GOLD Class to COPD DW categories first assigns GOLD III&IV to severe COPD 
and what remains to moderate. Next, GOLD class I is assigned to the asymptomatic category first and 
what remains goes to mild COPD. This algorithm is repeated for each age and sex category and for all 
1,000 draws from the DisMod models of GOLD classes and the MEPS analyses. We end up with 
proportions of each of the GOLD class categories that map onto GBD COPD health states with uncertainty 
bounds determined by the 25th and 975th values of the 1,000 draws. These values are then applied to the 
estimates of the proportion of cases by GOLD class category, after scaling to 100%, by location, year, age, 
and sex. This assumes that the relationship between GOLD class and GBD COPD health states in the 
United States applies everywhere.  
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 Pneumoconiosis 
Coal Worker’s Pneumoconiosis, Asbestosis, Silicosis, and Other 
Pneumoconiosis 
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Input data and methodological appendix 
Case definition 
Pneumoconiosis is a chronic lung disease typified by lung scarring and other interstitial damage caused by 
exposure to dust and other containments – usually through occupational exposure. For GBD, we model 
pneumoconiosis by exposure type: coal, asbestos, silica, and other.  
Input data 
A systematic review of the literature was conducted for pneumoconiosis using the following search string 
in PubMed: 
(Pneumoconiosis[Title/Abstract] AND prevalence[Title/Abstract]) 
The search was restricted to humans and publications between January 2012 and November 2016. The 
search produced 31 hits, although no sources included useable data. Many studies were excluded on the 
basis of being from non-representative populations (eg, studies of prevalence of pneumoconiosis among 
groups of coal workers). 
Data used to make estimates of pneumoconiosis are predominantly from four main sources. The first is 
literature data from previous systematic reviews – usually from smaller-scale studies or surveys of 
prevalence. The second are occupational exposure reports and registries produced by governmental 
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agencies. The third data format we use are collated hospital inpatient reports. The fourth main category 
of data are claims data – particularly for the United States. Greater detail on the preparation of the 
collated inpatient data and claims data is provided elsewhere. An overview of the data density and 
distribution by measure and location is present below for the four pneumoconiosis variants. 
Silicosis Prevalence Incidence Mortality risk 
Studies 48 3 0 
Locations 214 3 0 
Regions 13 3 0 
 
Coal worker’s Prevalence Incidence Mortality risk 
Studies 45 4 0 
Locations 239 4 0 
Regions 12 3 0 
 
Asbestosis Prevalence Incidence Mortality risk 
Studies 45 3 0 
Locations 263 3 0 
Regions 12 3 0 
 
Other Prevalence Incidence Mortality risk 
Studies 58 0 0 
Locations 299 0 0 
Regions 15 0 0 
 
For all etiologies, we use a sex-specific correction factor of the hospital inpatient data where numbers are 
adjusted upward by the ratio of primary diagnosis to secondary diagnosis present in the claims data.  
Severity split inputs 
Data to inform estimates of the severity gradient due to pneumoconiosis etiologies are derived from 
previous analyses of the Medical Expenditure Panel Survey (MEPS). The disability weights are also shared. 
Severity level Lay description DW (95% CI) 
Mild Has cough and shortness of breath after heavy 
physical activity, but is able to walk long distances 
and climb stairs. 
0.019 
(0.011–0.033) 
Moderate Has cough, wheezing, and shortness of breath, even 
after light physical activity. The person feels tired 
and can walk only short distances or climb only a 
few stairs. 
0.225 
(0.153–0.312) 
Severe Has cough, wheezing, and shortness of breath all 
the time. The person has great difficulty walking 
even short distances or climbing any stairs, feels 
tired when at rest, and is anxious. 
0.408 
(0.273–0.556) 
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 Modelling strategy 
Estimates for the pneumoconiosis etiologies are produced using a standard DisMod-MR 2.1 approach. 
For all etiologies, we use prior settings of zero remission. Additionally, we assume no incidence and 
prevalence before the age of 10. 
Claims data for 2000 and 2010 are adjusted via study covariates to account for systematically low 
estimates relative to the 2012 claims data. Implicit in this adjustment is the assumption that variation 
between years of claims data is a function of data collection inconsistencies and noise. As 
pneumoconiosis is a chronic disease largely caused by long-term occupational exposure and there is no 
evidence of rapid occupational shifts during the period of study, we ascribe observed differences to 
collection noise/error. 
Similar to other causes, we include estimates of cause-specific mortality rate (CSMR) and Excess Mortality 
Rate (EMR) in this. The source and estimation of these rates are discussed elsewhere.  
To assist estimation, each model includes a series of country-level covariates that describe 
spatiotemporal patterns. 
For the most part, the same covariates from GBD 2015 were used. Adjustments were also made to the 
coal and asbestos covariates as follows. 
The coal production covariate was improved to include subnational data for the United States and India. 
United States state-level data for 2001-2015 came from the U.S. Energy Information Administration. India 
state-level data for 2005-2014 came from the Ministry of Coal in India. We scaled these figures to the 
national estimates from the BP Satistical Review of World Energy 2016. For years with missing state-level 
data we split the national-level data according to the proportions by state in the closest year for which we 
did have state-level data. 
We also created a covariate for asbestos consumption per capita with a 30-year lag, and used that instead 
of the GBD 2015 asbestos production covariate. This change is based on the idea that asbestos 
production may be too limited in scope, given that asbestosis may occur in locations where asbestos is 
used and handled but not necessarily mined. To create the asbestos consumption covariate we used data 
from the United States Geological Survey to run a model in DisMod 2.1. A 30-year lag was placed on this 
model to account for the delay between asbestos consumption and occurrence of disease. 
Where available, we use standardized exposure variables (SEV) which aggregates multiple risk factors into 
a single variable. A full accounting is below: 
Cause Measure Variable_Name Beta Exponentiated 
Asbestosis excess 
mortality 
rate 
LDI (I$ per capita) -0.055 
(-0.14 — -0.012) 
0.95 
(0.87 — 0.99) 
Asbestosis prevalence All MarketScan, year 
2010 
-0.00057 
(-0.0013 — -
0.00013) 
 
1.00 
(1.00 — 1.00) 
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Asbestosis prevalence All MarketScan, year 
2000 
-0.00019 
(-0.00087 — -
0.000033) 
 
1.00 
(1.00 — 1.00) 
Asbestosis Prevalence Asbestos Consumption 
(per capita) 
0.0091 
(0.00051 — 0.023) 
1.01 
(1.00 — 1.02) 
Coal worker’s prevalence All MarketScan, year 
2000 
-0.0074 
(-0.025 — -0.00035) 
0.99 
(0.98 — 1.00) 
Coal worker’s prevalence Log-transformed age-
standardized SEV scalar: 
Coal W 
1.00 
(0.76 — 1.24) 
2.72 
(2.14 — 3.46) 
 
Coal worker’s prevalence Coal Production (per 
capita) 
1.19 
(0.086 — 1.97) 
 
3.28 
(1.09 — 7.19) 
 
Coal worker’s prevalence All MarketScan, year 
2010 
-0.011 
(-0.042 — -0.00023) 
) 
0.99 
(0.96 — 1.00) 
Coal worker’s excess 
mortality 
rate 
LDI (I$ per capita)  -1 
(-1 — -1) 
0.37 
(0.37 — 0.37) 
 
Other pneumoconiosis prevalence All MarketScan, year 
2010 
-0.0097 
(-0.035 — -
0.000015) 
 
0.99 
(0.97 — 1.00)) 
Other pneumoconiosis prevalence Log-transformed SEV 
scalar: Oth Pneum 
0.78 
(0.75 — 0.87) 
 
2.19 
(2.12 — 2.39) 
 
Other pneumoconiosis excess 
mortality 
rate 
LDI (I$ per capita) -1 
(-1 — -1) 
0.37 
(0.37 — 0.37) 
 
Other pneumoconiosis prevalence All MarketScan, year 
2000 
-0.0095 
(-0.034 — -0.0002) 
 
0.99 
(0.97 — 1.00) 
Silicosis prevalence All MarketScan, year 
2000 
-0.0069 
(-0.021 — -0.00032) 
0.99 
(0.98 — 1.00) 
Silicosis excess 
mortality 
rate 
LDI (I$ per capita) -0.5 
(-0.5 — -0.5) 
0.61 
(0.61 — 0.61) 
Silicosis prevalence All MarketScan, year 
2010 
-0.0076 
(-0.027 — -0.00037) 
0.99 
(0.97 — 1.00) 
Silicosis prevalence Log-transformed age-
standardized SEV scalar: 
Silicosis 
1.24 
(1.21 — 1.25) 
 
3.45 
(3.36 — 3.49) 
 
Silicosis Prevalence Gold Production (per 
capita) 
2.75 
(0.17 — 4.91) 
 
15.71 
(1.18 — 
135.10) 
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To account for country level differences in excess mortality (perhaps as a function of available medical 
care) we use ln(lag distributed income) as a proxy measure. 
For GBD 2015 prevalence and incidence of coal worker’s pneumoconiosis and asbestosis were set to 
zero in locations without a history of coal mining or asbestosis production given the causal and necessary 
relationship between respective occupational exposure and disease. For GBD 2016 we removed the 
geographical exclusions for asbestosis, given our move to a consumption covariate, as mentioned above. 
321
 Asthma 
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Case definition 
Asthma is a chronic lung disease marked by spasms in the bronchi usually resulting from an allergic 
reaction or hypersensitivity and causing difficulty in breathing. We define asthma as a doctor’s diagnosis 
and wheezing in the past year. The relevant ICD-10 codes are J45 and J46. ICD-9 code is 493. 
Input data 
For GBD 2016, we did a full systematic review of the literature on asthma. We used the following search 
string in PubMed and filtered by studies of humans published between January 2012 and November 
2016. 
(Asthma[Title/Abstract] AND prevalence[Title/Abstract] AND "Cross-Sectional Studies"[MeSH Terms]) 
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From this search, we had 533 hits. Of these, 47 sources were extracted after full-text screening and 
incorporated into the GBD 2016 model. 
Additional survey data added for GBD 2016 were mainly from India: International Study of Asthma and 
Allergies in Childhood (ISAAC); National Family Health Survey; WHO Study on global AGEIng and adult 
health (SAGE); and Indian Study on Epidemiology of Asthma, Respiratory Symptoms and Chronic 
Bronchitis (INSEARCH). 
Surveys carried out as part of the ISAAC collaboration are the most important source of prevalence data 
in children. 
The following table provides a description of the data density and distribution by location and 
epidemiological measure (including the claims data discussed below). 
Prevalence Incidence Mortality risk 
Studies 302 7 6 
Countries/subnational 
locations 
354 5 3 
Regions 21 1 1 
In addition to literature and survey data, we use claims data from the United States from 2000, 2010, and 
2012. Information on the source and preparation of these data are provided in detail elsewhere. Briefly, 
we determined US national and state level estimates of asthma prevalence from a database of individual-
level ICD-coded health service encounters for three years. Persons with any claim associated with asthma 
were marked as a prevalent case for that year. Aggregated estimates were then adjusted using a noise-
reduction algorithm. These corrected data were then used in the modelling process. 
Modelling strategy 
We use DisMod-MR 2.1 as the main modelling tool for asthma. Prior settings include a maximum 
remission of 0.3 (reflecting the upper bound of the highest observed data) and no incidence between the 
ages of 0 and 0.5 year, as a diagnosis cannot be made in young infants. 
Data points from the ISAAC studies were reported for both sexes combined. We sex-split before 
modelling using the ratios derived from the 2012 US claims data (1).  
Data that describe wheezing in the past year, but do not report presence/absence of an accompanying 
diagnosis are crosswalked to the reference category using a study-level covariate in DisMod. As the table 
below shows, studies that only report wheezing are systematically higher than reference data points and 
are adjusted down -- dividing by the exponentiated coefficient. Data that describe prevalence of lifetime 
diagnosis of asthma but not accompanying wheezing in the past year are also crosswalked to the 
reference category using a study-level covariate. 
To account for country-level differences in excess mortality as a function of available medical care we use 
log lag-distributed income (LDI) as a covariate and assume a negative coefficient. The effect size is shown 
below. 
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Claims data for 2000 and 2010 are adjusted via study covariates to account for systematically lower 
estimates relative to the 2012 claims data. Implicit in this adjustment is the assumption that variation 
between years of claims data is a function of data-collection inconsistencies. 
Similar to other causes, we include estimates of cause-specific mortality rate (CSMR) and excess mortality 
rate (EMR) derived as a matched value for each prevalence data point dividing CSMR by prevalence. We 
restrict these EMR calculations to data points of 20-year age span or less. 
 
To assist estimation, the model includes a series of country-level covariates that describe spatiotemporal 
patterns. Specifically, we use log LDI and the asthma standardized exposure variable (SEV), a scalar that 
combines exposure of all GBD risks that influence asthma. A full covariate list, including the study-level 
covariates, described above are presented in the following table with their associated effects: 
Variable_name Measure Beta Exponentiated 
Wheezing only prevalence 0.46 
(0.43 - 0.50) 
 
1.59 
(1.53 — 1.65) 
Physician diagnosed asthma only prevalence -0.091 
(-0.14 — -0.038) 
 
0.91 
(0.87 — 0.96) 
Claims data 2000 prevalence -0.53 
(-0.56 - -0.5) 
 
0.59 
(0.57 — 0.61) 
Claims data 2010 prevalence -0.13 
(-0.15 — -0.1) 
0.88 
(0.86 — 0.90) 
Log SEV scalar: asthma prevalence 1.24 
(1.20 — 1.25) 
 
 
3.44 
(3.33 — 3.49) 
 
Log LDI (I$ per capita) excess mortality rate -0.5 
(-0.5 — -0.5) 
 
0.61 
(0.61 — 0.61) 
 
Severity split inputs 
Lay descriptions and disability weights for the asthma health states are shown in the table below. The 
distribution between the three health states is derived from an analysis of the US Medical Expenditure 
Panel Surveys (MEPS). The methods are described in full in a separate section of this appendix. Briefly, 
MEPS is an ongoing survey of health service encounters with as its main objective to collect data on 
health expenditure. Panels are recruited every year and followed up for a period of two years. Diagnostic 
information provided by respondents on the reasons for any health care contact are coded into three-
digit ICD-9 codes by professional coders. 
Twice over the two-year follow-up period respondents are asked to fill in 12-Item Short Form Surveys (SF-
12). From convenience samples asking respondents to fill in SF-12 for 60 of the GBD health states, IHME 
has created a mapping from SF-12 scores to GBD Disability Weights (DW). We perform a regression with 
indicator variables for all GBD causes that we can identify from the ICD codes in MEPS to derive for each 
individual with a diagnosis the amount of disability that can be attributed to that condition after 
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controlling for any comorbid conditions. Anyone with a diagnosis of asthma in whom the disability 
assigned to asthma is negative or zero we assume is asymptomatic (at the time of asking SF-12 question 
relating to their health status in the past four weeks). Non-zero values we bin into the three health states 
assuming a split between these at the midpoint between DW values. The table below gives the 
proportions in MEPS in each of the health states and an asymptomatic state. 
 
Severity level Lay description DW (95% CI) Severity 
distribution 
Asymptomatic   36.2%  
(35.0–37.3%) 
Controlled This person has wheezing and cough once a 
month, which does not cause difficulty with 
daily activities.  
0.015 
(0.007–0.026) 
 
19.9% 
(13.6–27.8%) 
Partially controlled This person has wheezing and cough once a 
week, which causes some difficulty with daily 
activities. 
 
0.036 
(0.022–0.055) 
 
20.6%  
(15.1–25.8%) 
Uncontrolled This person has wheezing, cough, and 
shortness of breath more than twice a week, 
which causes difficulty with daily activities 
and sometimes wakes the person at night. 
0.133 
(0.086–0.192) 
23.3% 
(18.7–30.3%) 
 
There were no significant changes in modelling approach from GBD 2015. 
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Case definition 
Interstitial lung diseases and pulmonary sarcoidosis are a collection of chronic respiratory diseases that 
impair lung function and oxygen uptake through scarring and/or inflammation. The relevant ICD codes 
are D86 and J84. For interstitial lung disease, we use the American Thoracic Society as the gold standard 
definition. 
Input data 
Model Inputs 
No systematic review of the literature was conducted for ILD for this iteration of the Global Burden of 
Disease. These reviews done on a rotating basis and updates will be made for a future iteration. 
Data used to make estimates of ILD are predominantly from three main sources. The first is literature 
data from previous systematic reviews – usually from smaller-scale studies of prevalence. The second 
main data type is claims data for the United States. The source and preparation of these data is described 
elsewhere. The third main data type is adjusted hospital inpatient records. Because these records only 
report primary diagnosis, we a priori adjust the numbers by a sex-specific factor based on patterns 
observed in the US claims data – that is, the ratio of primary to secondary diagnoses.  
The following table provides a picture of the number of available studies along with their distribution 
globally and by epidemiological profile. In short, the ILD data landscape is rather sparse. The available 
data are largely skewed toward high-income countries like the United States or the member countries of 
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the European Union. The relatively high number of subnational units with data is largely a function of 
claims data in the United States and hospital data from Mexico and Brazil.  
 Prevalence Incidence Mortality risk 
Studies 51 19 0 
Locations 261 15 0 
Regions 11 6 0 
 
Severity splits 
Data to inform estimates of the severity gradient due to ILD are derived from previously analyses of the 
Medical Expenditure Panel Survey (MEPS). The table below illustrates the lay descriptions and disability 
weights associated with different levels of severity of interstitial lung disease. 
 
Severity level Lay description DW (95% CI) 
Mild Has cough and shortness of breath after heavy 
physical activity, but is able to walk long distances 
and climb stairs. 
0.019 
(0.011–0.033) 
Moderate Has cough, wheezing, and shortness of breath, 
even after light physical activity. The person feels 
tired and can walk only short distances or climb 
only a few stairs. 
0.225 
(0.153–0.312) 
Severe Has cough, wheezing, and shortness of breath all 
the time. The person has great difficulty walking 
even short distances or climbing any stairs, feels 
tired when at rest, and is anxious. 
0.408 
(0.273–0.556) 
 
Modelling strategy 
Estimates for ILD are produced using a standard DisMod-MR 2.1 approach. We use prior settings of zero 
remission and we constrain the super-region random effects to -0.5 to 0.5 to ensure model stability. 
As described above, we use an a priori adjustment of hospital inpatient data to correct for secondary 
diagnoses available in the claims data.  
Similar to other causes, we include estimates of cause-specific mortality rate (CSMR) and Excess Mortality 
Rate (EMR). The source and estimation of these rates are discussed elsewhere.  
The GBD ethic is to use all available data sources where reasonable. Because ILD consists of many smaller 
etiologies not broken out here, we make crosswalks to account for measurement, case definition, and 
study design differences. The full list is below: 
Variable_Name Measure Beta Exponentiated 
Only idiopathic pulmonary 
fibrosis and sarcoidosis 
prevalence -1.49 
(-1.96 — -0.88) 
0.22 
(0.14 — 0.41) 
All MarketScan, year 2000 prevalence 1.15 
(1.10 — 1.19) 
3.15 
(3.00 — 3.29) 
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All MarketScan, year 2010 prevalence 1.40 
(1.37 — 1.44) 
 
4.07 
(3.93 — 4.24) 
All MarketScan, year 2012 prevalence 1.40 
(1.35 — 1.43) 
4.04 
(3.88 — 4.19) 
Only idiopathic pulmonary 
fibrosis and sarcoidosis 
incidence -0.87 
(-1.53 — -0.19) 
 
0.42 
(0.22 — 0.83) 
LDI (I$ per capita) excess mortality 
rate 
-0.2 
(-0.2 — -0.2) 
0.82 
(0.82 — 0.82) 
 
To account for country level differences in excess mortality (perhaps as a function of available medical 
care) we use ln(lag distributed income) as a proxy measure. The effect size is shown above. 
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 Other chronic respiratory diseases 
In addition to the chronic respiratory diseases described above, there are many diverse types of chronic 
respiratory diseases with a range of severities and associated sequelae. Because these chronic respiratory 
diseases are diverse in their underlying causes and risk factors as well as in their associated health 
outcomes, modelling them together in a DisMod-MR model would not produce reliable estimates of 
prevalence or excess mortality. Instead, we calculated the YLDs caused by other chronic respiratory 
diseases directly using a YLD/YLL ratio.  
We calculated the ratio of YLDs to YLLs across the specified chronic respiratory diseases for which 
nonfatal outcomes were modelled, using YLL estimates from the GBD 2016 cause of death (CoD) analysis. 
We then multiplied this YLD/YLL ratio by the YLL estimates for other chronic respiratory diseases from the 
GBD 2016 CoD analysis, providing us with an estimate of the YLDs associated with other chronic 
respiratory diseases.  
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 Cirrhosis  
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Input data and methodological summary 
 
Case definition 
Cirrhosis is a chronic liver disease most often caused by alcohol use or chronic infection with hepatitis B 
or C. Early disease is typically asymptomatic as the liver’s resilience compensates for cirrhotic damage. 
Decompensated cirrhosis occurs when the disease progresses beyond the capacity of the liver to 
compensate for the damage, and is marked by profound symptoms, health loss and, often, death. We 
model decompensated cirrhosis, defined by cirrhosis (or a closely related diagnosis code) as the primary 
diagnosis in hospital data. We model total cirrhosis (compensated plus decompensated) when cirrhosis is 
a secondary diagnosis in hospital data. This includes ICD1-0 codes K70-K77, I85, P78.81. 
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Input data 
Model inputs 
For GBD 2016, we modelled cirrhosis prevalence based on hospital data, which have been updated to 
reflect the new estimation cycle. This year, we added data from MarketScan to our prevalence estimation 
process. The table below indicates the number of data points, as well as the location and regional 
breakdown of non-hospital and non-MarketScan data. Decompensated cirrhosis only used inpatient 
MarketScan data, whereas compensated used inpatient and outpatient. 
Table 1. Data inputs for the cirrhosis parent model (not including hospital inpatient data) 
 Prevalence Incidence 
Studies 0 1 
Countries/subnationals 0 1 
Countries 0 1 
GBD world regions 0 1 
GBD super-regions 0 1 
 
We model etiologic proportions based on published estimates of the proportion of cirrhosis due to 
alcohol use, hepatitis B, hepatitis C, and other causes: 
Table 2. Data inputs for the etiologic proportion models  
 Alcohol Hepatitis B Hepatitis C Other 
Studies 54 80 88 41 
Countries/subnationals 27 41 46 21 
Countries 25 35 39 20 
GBD world regions 14 17 18 11 
GBD super-regions 7 7 7 7 
 
For GBD 2016, we conducted a systematic review of the literature to capture studies of the proportion of 
cirrhosis attributable to alcohol, hepatitis B, hepatitis C, and other causes. We searched the peer-
reviewed literature via PubMed and solicited sources from GBD collaborators. 
The inclusion criteria stipulated that: 1) the publication year must be from 1980 onward; 2) the sample 
had to be a representative sample of those with decompensated cirrhosis (eg, studies of patients with 
both HCC and cirrhosis were excluded); 3) sufficient information must be provided on study method and 
sample characteristics to assess the quality of the study; 4) hepatitis B and C were confirmed via HBsAg, in 
the case of hepatitis B, and anti-HCV IgG, in the case of hepatitis C.  
Data were outliered or excluded if we found them unreasonable when compared to regional, super-
regional, and global rates. 
Severity splits  
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms.  
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Table 3. Severity level and lay descriptions 
Sequela name Health state description 
Disability weight 
(95% CI) 
Cirrhosis of the liver due to 
alcohol, decompensated 
Has a swollen belly and swollen legs. The person 
feels weakness, fatigue and loss of appetite. 
0.178 
(0.122-0.25) 
Cirrhosis of the liver due to 
hepatitis B, decompensated 
Has a swollen belly and swollen legs. The person 
feels weakness, fatigue and loss of appetite. 
0.178 
(0.123-0.25) 
Cirrhosis of the liver due to 
hepatitis C, decompensated 
Has a swollen belly and swollen legs. The person 
feels weakness, fatigue and loss of appetite. 
0.178 
(0.122-0.25) 
Cirrhosis of the liver due to 
other cause, decompensated 
Has a swollen belly and swollen legs. The person 
feels weakness, fatigue and loss of appetite. 
0.178 
(0.122-0.25) 
 
Modelling strategy  
We modelled cirrhosis prevalence using hospital data and CSMR estimates, assuming no remission. For 
GBD 2016 we modeled compensated cirrhosis. Compensated cirrhosis was estimated by subtracting year, 
sex, age, and location specific draws of compensated cirrhosis from the corresponding draws of total 
cirrhosis. To estimate the prevalence of cirrhosis due to alcohol, cirrhosis due to hepatitis B, cirrhosis due 
to hepatitis C, and cirrhosis due to other causes, we developed aetiological proportion models using 
DisMod, and used the results of these models to split the compensated and decompensated cirrhosis 
prevalence estimates. 
 
Given the similar etiologies for liver cancer and cirrhosis we integrated the etiology models for these two 
causes. We have more data for liver cancer etiologies than we do for cirrhosis. Therefore, we first 
developed four single-parameter DisMod models, each to estimate the proportion of liver cancer due to a 
given cause (ie, alcohol, hepatitis B, hepatitis C, and other). These models included as covariates alcohol 
consumption (litres per capita), hepatitis B surface antigen (HBsAg) seroprevalence, and hepatitis C (anti-
HCV IgG) seroprevalence. Moreover, the model for the proportion due to alcohol included a binary 
covariate indicating countries with a predominantly Muslim population (thought to be associated with 
very low alcohol consumption). Estimates from these liver cancer models were then used as covariates 
(along with alcohol, HBsAg, and anti-HCV) in the four corresponding cirrhosis aetiology models. Estimates 
from these cirrhosis models were then similarly used as covariates in the corresponding liver cancer 
models. Proportions from the four etiology models were then rescaled to sum to one at the draw level, 
and used to split the parent compensated and decompensated cirrhosis estimates. 
 
Study level covariates were used to adjusted prevalence data from hospital inpatient data and US claims 
data (2000 and 2010) toward the level of other prevalence data points, which were more representative 
of the general population. The healthcare quality and access index was used as a location-level covariate 
on excess mortality to guide estimates for countries with few or no data. 
Table 4. Beta and exponentiated values for total cirrhosis 
Study covariate  Parameter Beta Exp(beta) 
Hospital Inpatient Prevalence 1.40 (1.40 - 1.40) 4.05 (4.05 - 4.06) 
Claims data - 2000 Prevalence -0.70 (-0.74 - -0.66) 0.50 (0.47 - 0.52) 
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Claims data - 2010 Prevalence -0.03 (-0.07 - -0.00) 0.97 (0.93 - 1.00) 
 
Table 5. Location-level beta and exponentiated values for total cirrhosis 
Country-level covariate  Parameter Beta Exp(beta) 
Healthcare access and 
quality index Excess mortality rate -0.08 (-0.09 - -0.07) 0.93 (0.91 - 0.93) 
 
Table 6. Beta and exponentiated values for decompensated cirrhosis 
Study covariate  Parameter Beta Exp(beta) 
Inpatient only claims 
data – 2000 
Incidence 
-0.9 (-0.94 — -0.87) 0.40 (0.39 — 0.42) 
Inpatient only claims 
data  – 2010 
Incidence -0.011 (-0.031 — -
0.00031) 0.99 (0.97 – 1.00) 
Hospital inpatient data Incidence -2.5 (-2.5 — -2.5) 0.082 (0.082 – 0.082) 
 
Table 7. Location-level beta and exponentiated values for decompensated cirrhosis 
Country-level covariate  Parameter Beta Exp(beta) 
Healthcare access and 
quality index 
Excess mortality rate -0.02 (-0.021 — -0.019) 0.98 (0.98 — 0.98) 
 
 
Changes from GBD 2015 to GBD 2016 
We added the MarketScan database to our input data and modeled compensated cirrhosis for the first 
time.  
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Case definition 
Peptic ulcer disease is a digestive disorder involving ulcers in the lining of the stomach (gastric ulcers) or 
the duodenum (duodenal ulcers), diagnosed by endoscopy. Peptic ulcer disease is often asymptomatic 
with periodic symptomatic episodes of heartburn, bloating, nausea, or vomiting, and in severe cases, 
bleeding. ICD codes included are K25, K26, K27, K28, and K31. 
Input data 
Model inputs 
In GBD 2016, chronic peptic ulcer disease was renamed to total peptic ulcer disease, symptomatic and 
asymptomatic (total peptic ulcer). Data inputs were separate for the total peptic ulcer and symptomatic 
episode models. A systematic review of literature was conducted to capture studies of prevalence, 
incidence associated with peptic ulcer disease. For GBD 2016, the search was conducted in peer-reviewed 
literature via PubMed. The inclusion criteria stipulated that (1) “caseness” must be based on clinical 
threshold as established by the ICD; (2) sufficient information must be provided on study methods and 
sample characteristics to assess the quality of the study; and (3) study samples must be representative of 
the general population (ie, samples of patients prescribed gastroscopies due to gastric pain or 
populations with H. pylori bacteria were excluded). 
 For the total peptic ulcer dataset we also included hospital inpatient and US claims data from 2000, 
2010, and 2012 at the US state level, extracted as prevalence. The claims data were extracted using all 
diagnoses, and the hospital data were adjusted for only recording primary diagnoses, using a correction 
factor from claims data. For GBD 2016, we also extracted national surveys for doctor-confirmed, self-
reported diagnoses of peptic ulcer disease and adjusted the data with a study-level covariate. 
334
For the symptomatic episode dataset, we also considered literature sources that specifically referenced 
bleeding, perforations, and hospital visits, and extracted hospital inpatient and US claims data from 2000, 
2010, and 2012 at the US state level, extracted as incidence to capture individual episodes. These data 
were similarly extracted and adjusted to estimate all diagnoses. Data were outliered or excluded if we 
found them unreasonable when compared to regional, super-regional, and global rates.  
The tables below show the number of studies included in GBD 2016, as well as the number of countries 
or subnational units and GBD world regions represented. 
Total peptic ulcer disease, symptomatic and asymptomatic 
Prevalence Incidence 
Studies 31 1 
Countries 41 1 
Countries/subnationals 324 1 
GBD world regions 6 1 
Symptomatic episodes of peptic ulcer disease 
Prevalence Incidence 
Studies 0 7 
Countries 0 17 
Countries/subnationals 0 119 
GBD world regions 0 3 
Severity split & disability weight 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. For GBD 2016, we added a mild sequela to symptomatic 
episodes of peptic ulcer disease with proportions of cases derived from the MEPS. The lay descriptions 
and disability weights for peptic ulcer disease are shown below: 
Severity level Lay description DW (95% CI) 
Mild peptic ulcer 
disease, symptomatic 
episodes 
This person has some pain in the belly that causes 
nausea but does not interfere with daily activities. 
0.011 (0.005-0.021) 
Moderate peptic ulcer 
disease, symptomatic 
episodes 
This person has pain in the belly and feels nauseous. 
The person has difficulties with daily activities. 
0.114 (0.080-0.159) 
*The numerous sequelae generated from exclusive combinations of anemia and peptic ulcer disease each contain custom disability weights. 
More information can be found in the appendix detailing disability weights.  
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The DisMod model for total peptic ulcer disease included bounding remission from 0.1 to 0.5 (a duration 
of two to ten years), zero incidence from 0 to 5 years of age. Reference data were from literature and our 
most complete claims data set (2012). We marked inpatient, other US claims years data, and national 
survey data with study-level covariates. We used the function in DisMod-MR 2.1 to pull in cause-specific 
mortality rate (CSMR) data from our CODEm and CODcorrect analyses and match with prevalence data 
points for the same location. We calculated excess mortality rate to estimate priors by dividing CSMR by 
prevalence. We also applied a lag-distributed income and a healthcare access and quality index country-
covariate to excess mortality, forced negative. Betas and exponentiated values (which can be interpreted 
as an odds ratio) are shown in the tables below for study-level covariates and country-level covariates.  
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level covariate Hospital Inpatient Prevalence 0.73 (0.67 - 0.79) 2.08 (1.96 - 2.20) 
Study-level covariate Self-reported Prevalence 0.60 (0.52 - 0.67) 1.82 (1.69 - 1.95) 
Study-level covariate Claims data - 2000 Prevalence -0.27 (-0.31 - -0.22) 0.77 (0.73 - 0.80) 
Study-level covariate Claims data - 2010 Prevalence 0.05 (0.01 - 0.09) 1.05 (1.01 - 1.10) 
Country covariate LDI (I$ per capita) 
Excess 
mortality rate -0.47 (-0.49 - -0.45) 0.63 (0.61 - 0.64) 
Country covariate 
Healthcare access 
and quality index 
Excess 
mortality rate -0.01 (-0.01 - -0.01) 0.99 (0.99 - 0.99) 
The symptomatic episodes of peptic ulcer disease DisMod model bounded remission from 16.5 to 17.5 (a 
duration of about three weeks). We also assumed no incidence from 0 to 5 years old, and excess 
mortality capped at 0.1 for all ages. The reference data were US claims data from 2012, and we marked 
other US claims years data, inpatient hospital data with study-level covariates. We used the function in 
DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) data from our CODEm and CODcorrect 
analyses and match with prevalence data points for the same location. We calculated excess mortality 
rate to estimate priors by dividing CSMR by prevalence. We also applied a lag-distributed income 
covariate to excess mortality, log transformed and forced negative with an upper bound of -0.1 and a 
lower bound of -1, and a log-transformed age-standardized death rate for stomach cancer to incidence. 
Betas and exponentiated values (which can be interpreted as an odds ratio) are shown in the tables 
below for study-level covariates and country-level covariates. 
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level covariate Hospital Inpatient Incidence 0.77 (0.71 - 0.83) 2.16 (2.03 - 2.30) 
Study-level covariate Claims data - 2000 Incidence 0.04 (-0.01 - 0.09) 1.04 (0.99 - 1.09) 
Study-level covariate Claims data - 2010 Incidence -0.08 (-0.12 - -0.03) 0.93 (0.89 - 0.97) 
Country covariate LDI (I$ per capita) 
Excess 
mortality rate -0.61 (-0.63 - -0.58) 0.55 (0.53 - 0.56) 
To calculate prevalence asymptomatic peptic ulcer disease, we took the estimated prevalence of 
symptomatic episodes, and subtracted it from our estimated prevalence of total peptic ulcer disease. 
Methods for causal attribution of anemia due to peptic ulcer can be found elsewhere in the appendix 
detailing strategies for impairments. Each final combination of sequela of anemia and peptic ulcer disease 
underwent exclusivity adjustments to prevent double counting.  
Modelling strategy 
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 Gastritis and duodenitis 
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Case definition 
Gastritis and duodenitis are digestive disorders involving inflammation of the stomach lining (gastritis) or 
the duodenum (duodenitis). Gastritis and duodenitis can often be asymptomatic with periodic 
symptomatic episodes of nausea, vomiting, indigestion, stomach pain, and in severe cases, internal 
bleeding. ICD code included is K29. 
Input data 
Model inputs 
In GBD 2016, chronic gastritis and duodenitis was renamed to total gastritis and duodenitis, symptomatic 
and asymptomatic (total gastritis). Data inputs were separate for the total gastritis and symptomatic 
episode models. A systematic review of literature was conducted to capture studies of prevalence, and 
incidence associated with gastritis and duodenitis. The inclusion criteria were studies that are 
representative of the national population (ie. excluded populations of patients with H. pylori), and studies 
with sufficient information methods and sample characteristics. Reviews were excluded from the search 
results.  
In addition to literature data, we included hospital inpatient and US claims data from 2000, 2010, and 
2012 at the US state level, extracted as prevalence for the total gastritis dataset. The claims data were 
extracted using all diagnoses, and the hospital data were adjusted for only recording primary diagnoses, 
using a correction factor from claims data. 
For the symptomatic episode dataset, we used extracted hospital inpatient and US claims data from 
2000, 2010, and 2012 at the US state level, extracted as incidence to capture individual episodes. These 
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data were similarly extracted and adjusted to estimate all diagnoses. Data were outliered or excluded if 
we found them unreasonable when compared to regional, super-regional, and global rates.  
The tables below show the number of studies included in GBD 2016, as well as the number of countries 
or subnational units and GBD world regions represented. 
Total gastritis and duodenitis, symptomatic and asymptomatic  
 
 Prevalence Incidence 
Studies 82 1 
Countries   
Countries/subnationals 164 1 
GBD world regions 16 1 
   
Symptomatic episodes of gastritis and duodenitis 
 Prevalence Incidence 
Studies 0 49 
Countries   
Countries/subnationals 0 143 
GBD world regions 0 8 
 
Disability weights 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. For GBD 2016, we added the mild sequela for 
symptomatic episodes of gastritis with proportions of cases derived from the MEPS. The lay descriptions 
and disability weights for gastritis and duodenitis are shown below: 
Severity split Lay description DW (95% CI) 
Mild gastritis and 
duodenitis, symptomatic 
episodes 
This person has some pain in the belly that causes 
nausea but does not interfere with daily activities. 
 
0.011 (0.005-0.021) 
Moderate gastritis and 
duodenitis, symptomatic 
episodes 
This person has pain in the belly and feels nauseated. 
The person has difficulties with daily activities. 
0.114 (0.078 — 
0.159) 
*The numerous sequelae generated from exclusive combinations of anemia and gastritis each contain custom disability weights. More 
information can be found in the appendix detailing disability weights.   
 
Modelling strategy  
The DisMod model for total gastritis and duodenitis included bounding remission from 0 to 1 (a minimum 
duration of one year). Reference data were from literature and our most complete US claims dataset 
(2012). We marked inpatient and other US claims years data with study-level covariates. We used the 
function in DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) data from our CODEm and 
CODcorrect analyses and match with prevalence data points for the same geography. We calculated 
excess mortality rate to estimate priors by dividing CSMR by prevalence. We also applied a country-level 
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covariate for alcohol consumption to prevalence, which we forced positive with a lower bound of 0 and 
an upper bound of 2. Additionally, we applied lag-distributed income and healthcare access and quality 
index covariates to excess mortality, forced negative with an upper bound of 0 and a lower bound of -1. 
Betas and exponentiated values (which can be interpreted as an odds ratio) are shown in the tables 
below for study-level covariates and country-level covariates.  
 
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level covariate Hospital Inpatient Prevalence -0.81 (-0.86 - -0.70) 0.44 (0.42 - 0.50) 
Study-level covariate Outpatient Prevalence -0.28 (-1.23 - 0.79) 0.76 (0.29 - 2.20) 
Study-level covariate Claims data - 2000 Prevalence 0.05 (0.01 - 0.09) 1.05 (1.01 - 1.09) 
Study-level covariate Claims data - 2010 Prevalence 0.23 (0.20 - 0.27) 1.26 (1.22 - 1.31) 
Country covariate 
Alcohol (liters per 
capita) Prevalence 0.00 (0.00 - 0.00) 1.00 (1.00 - 1.00) 
Country covariate LDI (I$ per capita) 
Excess 
mortality rate -0.14 (-0.17 - -0.12) 0.87 (0.85 - 0.89) 
Country covariate 
Healthcare access 
and quality index 
Excess 
mortality rate -0.07 (-0.07 - -0.07) 0.93 (0.93 - 0.93) 
 
The symptomatic episodes of gastritis and duodenitis DisMod models bounded remission from 52 to 54 (a 
duration of about one week). We also assumed no incidence from 0 to 2 years old. The reference data 
were US claims data from 2012, and we marked other US claims years data and inpatient data with 
specific study-level covariates. We used the function in DisMod-MR 2.1 to pull in cause-specific mortality 
rate (CSMR) data from our CODEm and CODcorrect analyses and match with incidence data points for the 
same geography. We calculated excess mortality rate to estimate priors by dividing CSMR by 
incidence/remission. We also applied a country-level covariate for alcohol consumption to incidence, 
which we forced positive with a lower bound of 0 and an upper bound of 2. Additionally, we applied lag-
distributed income and healthcare access and quality index covariates to excess mortality, forced 
negative with an upper bound of 0 and a lower bound of -1. Betas and exponentiated values (which can 
be interpreted as an odds ratio) are shown in the tables below for study-level covariates and country-
level covariates. 
 
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level covariate Hospital Inpatient Incidence -1.00 (-1.00 - -0.99) 0.37 (0.37 - 0.37) 
Study-level covariate Claims data - 2000 Incidence 0.01 (-0.03 - 0.05) 1.01 (0.97 - 1.05) 
Study-level covariate Claims data - 2010 Incidence 0.19 (0.16 - 0.22) 1.21 (1.17 - 1.25) 
Country covariate 
Alcohol (liters per 
capita) Incidence 0.00 (0.00 - 0.01) 1.00 (1.00 - 1.01) 
Country covariate LDI (I$ per capita) 
Excess 
mortality rate -0.14 (-0.16 - -0.12) 0.87 (0.85 - 0.89) 
Country covariate 
Healthcare access 
and quality index 
Excess 
mortality rate -0.04 (-0.04 - -0.03) 0.96 (0.96 - 0.97) 
 
To calculate prevalence of asymptomatic gastritis and duodenitis, we took the estimated prevalence of 
symptomatic episodes, and subtracted it from our estimated prevalence of total gastritis and duodenitis. 
Methods for causal attribution of anemia due to gastritis can be found elsewhere in the appendix 
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detailing strategies for impairments. Each final combination of sequela of anemia and gastritis underwent 
exclusivity adjustments to prevent double counting. 
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Case definition 
Appendicitis is an inflammation of the appendix that causes nausea, vomiting, and sharp pain in the right 
lower abdomen. Appendicitis requires surgery, or septic shock may set in and the patient will be at risk 
for severe complications, including sepsis and death. ICD-10 codes included are K35-K35.3, K35.8, K35.80, 
K35.89, K35.9, K36, K36.0, K37, K37.0, K37.9, and K38.3. 
Input data 
Model inputs 
Since GBD 2010, the data used for appendicitis are hospital inpatient data across 103 separate locations 
and US claims data for 2000, 2010, and 2012 by US state, primary diagnoses only. Descriptions of search 
strategies for hospital and claims data are included elsewhere in the appendix. The agreed-upon 
approach for appendicitis was to rely primarily on these data sources and not conduct a formal literature 
review. Data were outliered or excluded if we found them unreasonable when compared to regional, 
super-regional, and global rates. 
Table 1. Data inputs (not including hospital inpatient data) 
 Prevalence Incidence 
Studies 0 3 
Countries/subnationals 0 319 
Countries 0 40 
GBD world regions 0 15 
GBD super-regions 0 7 
 
341
  
 
Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms.  
Table 2. Severity level and lay description.  
Severity split Lay description DW (95% CI) 
Appendicitis, severe This person has severe pain in the belly and feels 
nauseated. The person is anxious and unable to carry 
out daily activities. 
0.324 (0.219–
0.442) 
 
Modelling strategy  
DisMod-MR 2.1, a Bayesian meta-regression tool, was used to estimate appendicitis prevalence by age, 
sex, year, and geography (subnational [select countries], country, region, super-region). Prior settings in 
the DisMod model included bounding remission from 25 to 27 (a duration of about two weeks) for all age 
groups and capping excess mortality at 0.31. We used study-level covariates to adjust incidence derived 
from MEPS, and US claims data for 2000 and 2010 toward the level of other incidence data points, which 
were more representative of the general population.  
 
We used the function in DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) data from our 
CODEm and CODcorrect analyses and match with prevalence data points for the same geography. We 
calculated excess mortality rate to estimate priors by dividing CSMR by prevalence. We also applied a 
fiber (g per day) country-level covariate to incidence, forcing a positive relationship with a lower bound of 
0. A lag-distributed income (LDI) covariate was applied to excess mortality, log-transformed and forced 
negative with an upper bound of -0.1 and a lower bound of 0. Similarly, a health care access and quality 
index (HAQI) covariate was also forced negative (-2, 0) on excess mortality. 
 
Betas and exponentiated values (which can be interpreted as an odds ratio) are shown in the tables 
below for study-level covariates and country-level covariates: 
 
Table 3. Study-level beta and exponentiated values 
Covariate Parameter beta Exponentiated beta 
MEPS Incidence 0.43 (0.14 - 0.72) 1.53 (1.15 - 2.06) 
inpatient-only 
Marketscan, year 2000 Incidence -0.13 (-0.18 - -0.10) 0.88 (0.84 - 0.91) 
inpatient-only 
Marketscan, year 2010 Incidence -0.06 (-0.10 - -0.02) 0.94 (0.91 - 0.98) 
 
Table 4. Location-level beta and exponentiated values 
Covariate Parameter beta Exponentiated beta 
fiber adjusted(g) Incidence -0.04 (-0.05 - -0.04) 0.96 (0.95 - 0.96) 
LDI (I$ per capita) Excess mortality rate -0.00 (-0.00 - -0.00) 1.00 (1.00 - 1.00) 
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Healthcare access and 
quality index Excess mortality rate -0.00 (-0.00 - -0.00) 1.00 (1.00 - 1.00) 
 
 
  
343
 Paralytic Ileus and Intestinal Obstruction 
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Case definition 
Paralytic ileus and intestinal obstruction is a lack of digestive propulsion caused by failed peristalsis, 
typically requiring surgery. ICD code for paralytic ileus and intestinal obstruction is K56. 
Input data 
Model inputs 
Since GBD 2010, the data used for paralytic ileus and intestinal obstruction have been hospital inpatient 
data and US claims data for 2000, 2010, and 2012 by US state, primary diagnoses only. Descriptions of 
search strategies for hospital and claims data are included elsewhere in the appendix. The agreed-upon 
approach for paralytic ileus and intestinal obstruction was to only use these data sources, and not 
conduct a literature review. Data were outliered or excluded if we found them unreasonable when 
compared to regional, super-regional, and global rates. 
Table 1. Model inputs (not including hospital inpatient data) 
 Prevalence Incidence 
Studies 0 4 
Countries/subnationals 0 347 
Countries 0 42 
GBD world regions 0 16 
GBD super-regions 0 7 
  
Severity splits 
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The basis of the GBD disability weight survey assessments is lay descriptions of sequelae highlighting 
major functional consequences and symptoms.  
Table 2. Severity level and lay description.  
Severity level Lay description DW (95% CI) 
Paralytic ileus and 
intestinal obstruction, 
severe 
This person has severe pain in the belly and feels 
nauseated. The person is anxious and unable to 
carry out daily activities. 
0.324 (0.219–0.442) 
 
Modelling strategy  
DisMod-MR 2.1, a Bayesian meta-regression tool, was used to estimate paralytic ileus and intestinal 
obstruction prevalence by age, sex, year, and geography (subnational [select countries], country, region, 
super-region). 
Paralytic ileus and intestinal obstruction was modelled with remission set between 25 and 26 for all age 
groups, implying a duration of approximately two weeks. We also set a prior for the maximum incidence 
of 0.002 for ages 0 to 5. The reference data were hospital inpatient data, primary diagnosis only. Study-
level covariates were used to adjust incidence derived from the Medical Expenditure Panel Survey (MEPS) 
and US claims data for 2000, 2010, and 2012 toward the levels in hospital inpatient data.  
 
We used the function in DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) data from our 
CODEm and CODcorrect analyses and match with incidence data points for the same geography. We 
calculated the excess mortality rate to estimate priors by dividing CSMR by incidence/remission. We also 
applied location-level covariates: fibre consumption to incidence with an upper bound of 0 and a lower 
bound of -2, a lag-distributed income covariate to excess mortality, log-transformed and forced negative 
with an upper bound of 0 and a lower bound of -1, and a health care access and quality index (HAQI) 
covariate with an upper bound of 0 and lower bound of -2. 
 
Betas and exponentiated values (which can be interpreted as an odds ratio) are shown in the tables 
below for study-level covariates and country-level covariates: 
 
Table 3. Study-level beta and exponentiated values 
Covariate Parameter beta Exponentiated beta 
MEPS Incidence 0.05 (-0.18 - 0.28) 1.05 (0.84 - 1.32) 
inpatient-only 
Marketscan, year 2000 Incidence 0.27 (0.22 - 0.31) 1.30 (1.25 - 1.36) 
inpatient-only 
Marketscan, year 2010 Incidence 0.63 (0.59 - 0.66) 1.88 (1.81 - 1.94) 
inpatient-only 
Marketscan, year 2012 Incidence 0.60 (0.56 - 0.64) 1.82 (1.76 - 1.89) 
 
Table 4. Location-level beta and exponentiated values 
Covariate Parameter beta Exponentiated beta 
fiber adjusted(g) Incidence -0.01 (-0.03 - -0.00) 0.99 (0.97 - 1.00) 
LDI (I$ per capita) Excess mortality rate -0.23 (-0.25 - -0.20) 0.80 (0.78 - 0.82) 
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Healthcare access and 
quality index Excess mortality rate -0.02 (-0.02 - -0.02) 0.98 (0.98 - 0.98) 
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 Inguinal, femoral and abdominal hernias 
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Flowchart 
 
Case definition 
A hernia is a digestive disorder that occurs when an internal organ protrudes through an opening in the 
tissue that holds it in place. Hernias most commonly occur in the inner and outer groin, and in the 
abdomen, and require surgical intervention. However, it can take several months before surgery occurs, 
resulting in a chronic condition. ICD codes used are K40, K41, K42, K44, K45, and K46.  
Input data 
Model inputs 
For GBD 2010 and 2013, the data used for hernias were hospital inpatient data extracted as prevalence 
and remission data calculated based off a regression from a paper describing mean wait times for elective 
surgery in OECD countries. For GBD 2016, we use the same data, but only included regression results for 
OECD countries. We also included US claims data for 2000, 2010, and 2012 by US state. The agreed-upon 
approach for hernias was to use only these data sources, and not conduct a literature review. For GBD 
2016, we renamed chronic inguinal, femoral, and abdominal hernias to total inguinal, femoral, and 
abdominal hernias. 
In GBD 2016 we created a new database and model for inguinal, femoral and abdominal hernias, 
symptomatic episodes, which models prevalence and incidence of symptomatic episodes within inpatient 
settings as a primary diagnosis. The input data for the symptomatic database include the hospital 
inpatient data (primary diagnoses only) extracted as prevalence, US claims data (inpatient only) for 2000, 
2010, and 2012, and the remission data on elective surgery wait times described above.   
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Data were outliered or excluded if we found them unreasonable when compared to regional, super-
regional, and global rates.  
The tables below show the number of studies included in GBD 2016, as well as the number of countries 
or subnational units and GBD world regions represented. These numbers reflect both the total and 
symptomatic databases. 
 
Total inguinal, femoral, and abdominal hernias 
 
 Prevalence Incidence Remission 
Studies 0 0 1 
Countries 39 0 33 
Countries/subnationals 329 0 33 
GBD world regions 7 0 4 
 
Inguinal, femoral, and abdominal hernias, symptomatic episodes 
 
 Prevalence Incidence Remission 
Studies 0 0 1 
Countries 40 0 33 
Countries/subnationals 332 0 33 
GBD world regions 7 0 4 
 
Disability weights 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. For GBD 2016, we added moderate and severe sequela to 
prevalent cases of symptomatic hernias . The lay descriptions and disability weights for inguinal, 
abdominal, and femoral hernias are shown below: 
Severity split Lay description DW (95% CI) 
Mild Inguinal, 
abdominal, and femoral 
hernia, symptomatic 
episodes 
This person has some pain in the belly that causes 
nausea but does not interfere with daily activities. 
0.011 (0.005-0.021) 
Moderate Inguinal, 
abdominal, and femoral 
hernia, symptomatic 
episodes 
This person has pain in the belly and feels nauseous. 
The person has difficulties with daily activities. 
 
0.114 (0.080-0.159) 
Severe Inguinal, 
abdominal, and femoral 
hernia, symptomatic 
episodes 
This person has severe pain in the belly and feels 
nauseated. The person is anxious and unable to carry 
out daily activities. 
0.324 (0.219-0.442) 
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Modelling strategy  
We modelled total hernia and symptomatic hernia using separate DisMod models, informed by 
prevalence and incidence data from hospital and US claims data, paired with the calculated remission 
from the regression described in Siciliani et al1.. Priors were set with a maximum incidence of 0.02 for 
ages 0 to 4, and bounds on remission from 0 to 5 (a minimum duration of about ten weeks) – we also 
assumed prevalence at birth due to umbilical hernias. Reference data were US claims data from 2012, 
and we marked inpatient hospital data and the remaining years of US claims data with separate study-
level covariates. We used the function in DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) 
data from our CODEm and CoDcorrect analyses and match with incidence data points for the same 
geography. We calculated excess mortality rate to estimate priors by dividing CSMR by 
incidence/remission. We also applied a lag-distributed income covariate to both remission and excess 
mortality, log transformed. We forced this covariate negative for excess mortality (bounds from -1 to 0), 
and positive for remission (bounds from 0.5 to 2). Betas and exponentiated values (which can be 
interpreted as an odds ratio) are shown in the tables below for study-level covariates and country-level 
covariates.  
 
Total inguinal, femoral, and abdominal hernias 
 
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level covariate Hospital Inpatient Prevalence -2.02 (-2.06 - -2.00) 0.13 (0.13 - 0.14) 
Study-level covariate Claims data - 2000 Prevalence -0.37 (-0.41 - -0.33) 0.69 (0.67 - 0.72) 
Study-level covariate Claims data - 2010 Prevalence -0.06 (-0.08 - -0.03) 0.95 (0.92 - 0.97) 
Country covariate LDI (I$ per capita) 
Excess mortality 
rate 1.01 (0.90 - 1.11) 2.74 (2.45 - 3.04) 
Country covariate LDI (I$ per capita) 
Excess mortality 
rate -0.00 (-0.00 - -0.00) 1.00 (1.00 - 1.00) 
 
 
Inguinal, femoral, and abdominal hernias, symptomatic episodes  
 
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level covariate Hospital Inpatient Prevalence -1.28 (-1.30 - -1.25) 0.28 (0.27 - 0.29) 
Study-level covariate 
Claims data - 
2000 Prevalence -0.68 (-0.70 - -0.65) 0.51 (0.50 - 0.52) 
Country covariate LDI (I$ per capita) 
Excess mortality 
rate 0.85 (0.51 - 0.98) 2.34 (1.66 - 2.66) 
Country covariate LDI (I$ per capita) 
Excess mortality 
rate -0.00 (-0.00 - -0.00) 1.00 (1.00 - 1.00) 
 
We calculated prevalence of asymptomatic hernias by subtracting the estimated prevalence of 
symptomatic hernias from our estimated prevalence of total hernias. 
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 Inflammatory Bowel Disease 
 
Flowchart 
Survey Data
CSMR from 
CODEm
Nonfatal 
database
Dismod-MR 2.1
Prevalence & 
incidence by 
location/year/
age/sex for IBD 
due to UC
Comorbidity 
correction 
(COMO)
YLLs
Comorbidity 
adjusted 
YLDs
DALYs
Inflammatory Bowel Disease (IBD)
Inpatient data
Computing excess 
mortality from 
available incidence 
& CSMR data
Study-level and country-level covariates
Prevalence of 
symptomatic 
UC
Disability weights 
for each sequela
Unadjusted 
YLD by 
sequela
Adjustment from 
primary code to all 
code based on 
Claims data
Adjusted inpatient 
data
Claims data
Literature
Survey Data
CSMR from 
CODEm
Nonfatal 
database
Dismod-MR 2.1
Prevalence & 
incidence by 
location/year/
age/sex for IBD 
due to CD
Comorbidity 
correction 
(COMO)
Inpatient data
Computing excess 
mortality from 
available incidence 
& CSMR data
Study-level and country-level 
covariates
Adjustment for 
undiagnosed CD
Disability weights 
for each sequela
Unadjusted 
YLD by 
sequela
Adjustment from 
primary code to all 
code based on 
Claims data
Adjusted inpatient 
data
Claims data
Literature
Prevalence of 
symptomatic 
CD
Adjustment for 
undiagnosed UC
Literature
Meta-analysis of % 
undiagnosed as 
indeterminate colitis
Input data
Process
Results
Database
Disability weights
Nonfatal
Burden estimation
Cause of death
Covariates
Input Data
MEPS analysis of 
symptomatic and 
asymptomatic 
proportions
MEPS analysis of 
symptomatic and 
asymptomatic 
proportions
 
 
Case definition 
Inflammatory bowel disease is a type of digestive disorder involving inflammation of the colon and 
gastrointestinal tract, most commonly classified as Crohn’s disease (inflammation of the small and large 
intestine) and ulcerative colitis (inflammation of the colon and rectum). In a significant proportion of 
cases of inflammatory bowel disease, neither Crohn’s disease nor ulcerative colitis is definitively the 
diagnosis, and a diagnosis of indeterminate colitis is applied. ICD codes are K50 for Crohn’s disease, K51 
for ulcerative colitis, and K52 for indeterminate colitis. 
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 Input data 
Model inputs 
Data inputs were separate for ulcerative colitis and Crohn’s disease, but a single systematic review of 
literature was conducted to capture studies of prevalence and incidence for all inflammatory bowel 
diseases for GBD 2016. Studies were excluded if they were not representative of the national population, 
or if they had insufficient study and sampling methods. Reviews were excluded from the search results. In 
addition to literature data, we included US claims data from 2000, 2010, and 2012 at the US state level, 
extracted as prevalence. For GBD 2016 we included inpatient hospital data as model inputs. Data were 
outliered or excluded if we found them unreasonable when compared to regional, super-regional, and 
global rates.  
The tables below show the number of studies included in GBD 2016, as well as the number of countries 
or subnational units and GBD world regions represented. 
Noninfective inflammatory bowel disease due to ulcerative colitis 
 
 Prevalence Incidence 
Studies 15 98 
Countries 41 52 
Countries/subnationals 286 61 
GBD world regions 7 6 
  
Noninfective inflammatory bowel disease due to Crohn’s disease 
 Prevalence Incidence 
Studies 17 84 
Countries 46 47 
Countries/subnationals 292 55 
GBD world regions 7 5 
 
Disability weights 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. For GBD 2016, we used the MEPS to find the proportion 
of asymptomatic prevalence for both ulcerative colitis and crohn’s disease. The lay descriptions and 
disability weights for sequelae associated with inflammatory bowel disease are shown below, and are 
applied to symptomatic cases only: 
Severity split Lay description DW (95% CI) 
Crohn’s disease, 
symptomatic 
This person has cramping abdominal pain, has 
diarrhea several times a day, and feels very tired for 
two months every year. When the person does not 
have symptoms, there is anxiety about them 
returning. 
0.231 (0.156-0.32) 
351
Ulcerative colitis, 
symptomatic  
This person has cramping abdominal pain, has 
diarrhea several times a day, and feels very tired for 
two months every year. When the person does not 
have symptoms, there is anxiety about them 
returning. 
0.231 (0.156-0.32) 
 
Modeling strategy  
The modelling strategy for all inflammatory bowel disease encompasses separate DisMod models for 
ulcerative colitis and Crohn’s disease, which are then adjusted to account for inflammatory bowel disease 
due to indeterminate colitis.  
 
The DisMod model for ulcerative colitis included setting remission to 0 for all age groups and setting 
incidence to 0 for ages 0 to 1. Reference data were US claims data from 2012, and we marked hospital 
inpatient, literature, and the remaining years of US claims data with separate study-level covariates. We 
used lag-distributed income (log-transformed) and healthcare access and quality index country level 
covariates on excess morality (forced negative) to further inform the model. We applied a country-level 
covariate of absolute value of average latitude to prevalence, and a ln-ASDR (age standardized death rate) 
fixed effect on prevalence. The ASDR data are taken from our CODEm and CODcorrect analyses for all 
inflammatory bowel disease. Betas and exponentiated values (which can be interpreted as an odds ratio) 
are shown in the tables below for study-level covariates and country-level covariates. 
 
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level covariate Hospital Inpatient Prevalence 0.40 (0.40 - 0.40) 1.49 (1.49 - 1.49) 
Study-level covariate MEPS Prevalence -0.01 (-0.02 - -0.00) 0.99 (0.98 - 1.00) 
Study-level covariate Literature Prevalence -0.00 (-0.01 - -0.00) 1.00 (0.99 - 1.00) 
Study-level covariate Claims data - 2000 Prevalence -0.00 (-0.01 - -0.00) 1.00 (0.99 - 1.00) 
Study-level covariate Claims data - 2010 Prevalence -0.00 (-0.00 - -0.00) 1.00 (1.00 - 1.00) 
Country covariate 
Absolute value of 
average latitude Prevalence 0.05 (0.05 - 0.06) 1.06 (1.06 - 1.06) 
Country covariate LDI (I$ per capita) 
Excess mortality 
rate -0.50 (-1.00 - -0.02) 0.61 (0.37 - 0.98) 
Country covariate 
Healthcare access 
and quality index 
Excess mortality 
rate -0.50 (-1.00 - 0.00) 0.61 (0.37 - 1.00) 
 
 
The DisMod model for Crohn’s disease included setting remission to 0 for all age groups and setting 
incidence to 0 for ages 0 to 2. Reference data were US claims data from 2012 and inpatient data. We 
marked literature, MEPS, and the remaining years of US claims data with specific study-level covariates. 
We used lag-distributed income (log-transformed) and healthcare access and quality index country level 
covariates on excess morality (forced negative) to further inform the model. We applied a country-level 
ln-ASDR (age standardized death rate) fixed effect on prevalence. The ASDR data are taken from our 
CODEm and COD correct analyses for all inflammatory bowel disease. Betas and exponentiated values 
(which can be interpreted as an odds ratio) are shown in the tables below for study-level covariates and 
country-level covariates. 
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Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level covariate MEPS Prevalence -0.01 (-0.04 - -0.00) 0.99 (0.96 - 1.00) 
Study-level covariate Literature Prevalence -0.00 (-0.01 - -0.00) 1.00 (0.99 - 1.00) 
Study-level covariate Claims data - 2000 Prevalence -0.00 (-0.00 - -0.00) 1.00 (1.00 - 1.00) 
Study-level covariate Claims data - 2010 Prevalence -0.00 (-0.00 - -0.00) 1.00 (1.00 - 1.00) 
Country covariate LDI (I$ per capita) 
Excess mortality 
rate -0.47 (-0.97 - -0.02) 0.62 (0.38 - 0.98) 
Country covariate 
Healthcare access 
and quality index 
Excess mortality 
rate -0.17 (-0.23 - -0.10) 0.84 (0.79 - 0.91) 
 
 
We conducted a meta-analysis to calculate the ratio of inflammatory bowel disease cases that are 
categorized as indeterminate colitis to cases that are characterized as either Crohn’s disease or ulcerative 
colitis. The results of this meta-analysis were a mean ratio of 0.059 (0.047-0.071). We then took the 
prevalence results of the DisMod models for ulcerative colitis and Crohn’s disease and adjusted them by 
multiplying by a normal distribution of draws from 1.059 (1.047-1.071) to encompass all inflammatory 
bowel disease cases. 
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Case definition 
Vascular intestinal disorder, also known as intestinal ischemia, occurs when there is decreased blood 
supply to the gastrointestinal tract causing injury to the bowel. Vascular intestinal disorders typically 
require surgery. The ICD code for vascular intestinal disorders is K55.  
Input data 
Model inputs 
For GBD 2016, the data used for vascular intestinal disorders are hospital inpatient data and US claims 
data for 2000, 2010, and 2012 by US state, primary diagnoses only. Descriptions of search strategies for 
hospital and claims data are included elsewhere in the appendix. The agreed-upon approach for vascular 
intestinal disorders was to use only these data sources and not conduct a literature review. Data were 
outliered or excluded if we found them unreasonable when compared to regional, super-regional, and 
global rates. 
The table below shows the number of literature studies included in GBD 2016, as well as the number of 
countries or subnational units and GBD world regions represented. 
 
Table 1. Data inputs 
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  Incidence 
Studies 0 
Countries 11 
Countries/subnationals 97 
GBD world regions 5 
 
Disability weights 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for vascular 
intestinal disorders are shown below: 
 
Table 2. Severity level and lay descriptions 
 
Severity split Lay description DW (95% CI) 
Vascular intestinal 
disorders, severe 
This person has severe pain in the belly and feels 
nauseated. The person is anxious and unable to carry 
out daily activities. 
0.324 (0.219-0.442) 
 
Modelling strategy  
Prior settings in the DisMod model included bounding remission from 2 to 12 (a duration from about four 
weeks to half a year) for all age groups and capping excess mortality at 10. The reference data were US 
claims data from year 2012, primary diagnosis only, and we marked inpatient US claims data years 2000 
and 2010, and hospital inpatient data with separate study-level covariates.  
 
We used the function in DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) data from our 
CODEm and CoDcorrect analyses and match with incidence data points for the same geography. We 
calculated excess mortality rate to estimate priors by dividing CSMR by incidence/remission. We also 
applied a lag-distributed income covariate (log transformed) and healthcare access and quality index 
covariate to excess mortality, forced negative with an upper bound of 0 and a lower bound of -1. 
 
Betas and exponentiated values (which can be interpreted as an odds ratio) are shown in the tables 
below for study-level covariates and country-level covariates: 
 
Table 3. Study covariate 
 
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level 
covariate Hospital Inpatient Incidence 0.29 (0.21 - 0.34) 1.33 (1.24 - 1.40) 
Study-level 
covariate 
inpatient-only 
Marketscan, year 
2000 Incidence 
-0.56 (-0.61 - -
0.51) 0.57 (0.54 - 0.60) 
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Study-level 
covariate 
inpatient-only 
Marketscan, year 
2010 Incidence 0.01 (-0.04 - 0.05) 1.01 (0.96 - 1.05) 
Country covariate LDI (I$ per capita) 
Excess mortality 
rate 
-0.43 (-0.51 - -
0.35) 0.65 (0.60 - 0.70) 
Country covariate 
Healthcare access 
and quality index 
Excess mortality 
rate 
-0.03 (-0.04 - -
0.03) 0.97 (0.96 - 0.97) 
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Input data and methodological summary 
 
Case definition 
Gallbladder and biliary diseases are digestive disorders including gallstones, cholecystitis, cholangitis, and 
other diseases of the gallbladder and biliary tract. Cholecystitis is an inflammation of the gallbladder, and 
cholangitis is an infection or inflammation of the bile duct, the result of a bacterial infection – both are 
often the result of gallstones. Gallbladder and biliary diseases, especially the presence of gallstones, can 
often be asymptomatic with periodic symptomatic episodes of severe abdominal pain, nausea, vomiting, 
and at times fever. ICD codes included are K80, K81, K82, and K83. 
Input data 
Model inputs 
For GBD 2016, we renamed chronic gallbladder and biliary diseases to total gallbladder and biliary 
diseases (total gallbladder disease). Data inputs were separate for the total gallbladder disease and 
symptomatic episode models. A systematic review of literature was conducted to capture studies of 
prevalence and incidence of gallbladder and biliary diseases. For GBD 2016, we performed a systematic 
literature search using PubMed. Studies not representative of the national population (ie. H. Pylori 
cohorts, patients presenting with pain), studies without sufficient information on study and sampling 
methods, and reviews were excluded. In addition to literature data, we included hospital inpatient and US 
claims data from 2000, 2010, and 2012 at the US state level, extracted as prevalence for the total 
gallbladder model, and extracted an incident case for the symptomatic gallbladder model. Data were 
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outliered or excluded if we found them unreasonable when compared to regional, super-regional, and 
global rates.  
The tables below show the number of studies included in GBD 2016, as well as the number of countries 
or subnational units and GBD world regions represented. 
Total gallbladder and biliary diseases 
 
 Prevalence Incidence 
Studies 28 2 
Countries 45 2 
Countries/subnationals 307 2 
GBD world regions 7 2 
   
Symptomatic episodes of gallbladder and biliary diseases 
 Prevalence Incidence 
Studies 1 1 
Countries 1 38 
Countries/subnationals 1 320 
GBD world regions 1 6 
 
Disability weights 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. For GBD 2016, we included the mild and severe sequela 
and applied the disability weights to prevalent cases in the symptomatic gallbladder model. The lay 
descriptions and disability weights for gallbladder and biliary disease are shown below: 
 
Severity split Lay description DW (95% CI) 
Mild gallbladder and 
biliary disease, 
symptomatic episodes 
This person has some pain in the belly that causes 
nausea but does not interfere with daily activities. 
 
0.011 (0.005-0.021) 
Moderate gallbladder 
and biliary disease, 
symptomatic episodes 
This person has pain in the belly and feels nauseous. 
The person has difficulties with daily activities. 
 
0.114 (0.080-0.159) 
Severe gallbladder and 
biliary disease, 
symptomatic episodes 
This person has severe pain in the belly and feels 
nauseated. The person is anxious and unable to carry 
out daily activities. 
0.324 (0.219-0.442) 
 
Modelling strategy  
The DisMod model for total gallbladder and biliary diseases included bounding remission from 0 to 1 (a 
minimum duration of one year). Reference data were from literature and US claims data year 2012, and 
we marked inpatient hospital and US claims data years 2000 and 2010 with separate year-specific study-
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level covariates. We used the function in DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) 
data from our CODEm and CODcorrect analyses and match with prevalence data points for the same 
geography. We calculated excess mortality rate to estimate priors by dividing CSMR by prevalence. We 
also applied a lag-distributed income covariate to excess mortality, log transformed and forced negative 
with an upper bound of 0 and a lower bound of -1. Betas and exponentiated values (which can be 
interpreted as an odds ratio) are shown in the tables below for study-level covariates and country-level 
covariates.  
 
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level covariate Hospital Inpatient Prevalence 0.60 (0.59 - 0.60) 1.82 (1.81 - 1.82) 
Study-level covariate 
Claims data - 
2000 Prevalence 0.19 (0.15 - 0.23) 1.21 (1.16 - 1.26) 
Study-level covariate 
Claims data - 
2010 Prevalence -0.02 (-0.05 - 0.02) 0.98 (0.95 - 1.02) 
Country covariate LDI (I$ per capita) 
Excess 
mortality rate -0.56 (-0.57 - -0.54) 0.57 (0.56 - 0.58) 
 
 
The symptomatic episodes of gallbladder and biliary diseases DisMod model bounded remission from 9 to 
26 (a duration of about two to six weeks). The reference data were US claims data from 2012, and we 
marked other US claims years data, inpatient data, and literature with specific study-level covariates. We 
used the function in DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) data from our CODEm 
and CODcorrect analyses and match with incidence data points for the same geography. We calculated 
excess mortality rate to estimate priors by dividing CSMR by incidence/remission. We also applied a lag-
distributed income covariate to excess mortality, log transformed and forced negative with an upper 
bound of 0 and a lower bound of -1. Betas and exponentiated values (which can be interpreted as an 
odds ratio) are shown in the tables below for study-level covariates and country-level covariates. 
 
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level covariate 
Hospital 
Inpatient Incidence 0.70 (0.70 - 0.70) 2.01 (2.01 - 2.01) 
Study-level covariate Literature Incidence -0.87 (-1.13 - -0.60) 0.42 (0.32 - 0.55) 
Study-level covariate 
Claims data - 
2000 Incidence -0.34 (-0.37 - -0.30) 0.71 (0.69 - 0.74) 
Study-level covariate 
Claims data - 
2010 Incidence -0.00 (-0.01 - -0.00) 1.00 (0.99 - 1.00) 
Country covariate 
LDI (I$ per 
capita) 
Excess mortality 
rate -0.66 (-0.67 - -0.65) 0.51 (0.51 - 0.52) 
 
To calculate prevalence of asymptomatic gallbladder and biliary diseases, we took the estimated 
prevalence of symptomatic episodes and subtracted it from our estimated prevalence of total gallbladder 
and biliary diseases. 
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 Pancreatitis 
 
Flowchart 
CSMR from 
CODEm
Nonfatal 
database
Dismod-MR 2.1
Prevalence & 
incidence by 
location/year/age/
sex for pancreatitis
Comorbidity 
correction 
(COMO)
YLLs
Comorbidity 
adjusted 
YLDs
DALYs
Pancreatitis
Computing excess 
mortality from 
available incidence & 
CSMR data
Study-level and country-
level covariates
Disability weights 
for each sequela
Unadjusted 
YLD by 
sequela
Adjustment from 
primary code to all 
code based on 
Claims data
Adjusted inpatient 
data
Literature
Survey data
Claims data
Input data
Process
Results
Database
Disability weights
Nonfatal
Burden estimation
Cause of death
Covariates
Input Data
Severity splits
Medical Expenditure 
Panel Survey
Meta-analysis of % 
mild/mod/severe 
pancreatitis
Prevalence 
of mild/
mod/severe 
pancreatitis 
Adjusted inpatient 
data
 
 
Input data and methodological summary 
 
Case definition 
Pancreatitis is the inflammation of the pancreas, and often results in nausea, stomach pain, and vomiting. 
We model acute and chronic pancreatitis together, using ICD codes K85 and K86. 
Input data 
Model inputs 
For GBD 2016, a systematic review of the prevalence and incidence of pancreatitis throughout the world 
was conducted. The exclusion criteria were studies clearly not representative of the national population 
(ie. alcoholics or smokers), self-reported data, and reviews. In addition to literature, we included hospital 
inpatient and US claims data for 2000, 2010, and 2012 by US state. Data were outliered or excluded if we 
found them unreasonable when compared to regional, super-regional, and global rates.  
The table below shows the number of literature studies included in GBD 2016, as well as the number of 
countries or subnational units and GBD world regions represented. 
 
 Prevalence Incidence 
Studies 5 19 
Countries 4 40 
Countries/subnationals 4 318 
GBD world regions 2 6 
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Disability weights 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for pancreatitis 
are shown below: 
Severity split Lay description DW (95% CI) 
Pancreatitis cases, mild This person has some pain in the belly that causes 
nausea but does not interfere with daily activities. 
 
0.011 (0.005-0.021) 
Pancreatitis cases, 
moderate 
This person has pain in the belly and feels 
nauseous. The person has difficulties with daily 
activities. 
 
0.114 (0.080-0.159) 
Pancreatitis cases, severe This person has severe pain in the belly and feels 
nauseated. The person is anxious and unable to 
carry out daily activities. 
0.324 (0.219-0.442) 
 
Modelling strategy  
Prior settings in the DisMod model included bounding remission from 8 to 9 (a duration from about six 
weeks) for all ages. The reference data were literature and US claims data from 2012. We marked 
hospital inpatient and other US claims years data with a separate year-specific study-level covariate. 
Additionally, we marked literature that reported acute pancreatitis only, with an acute study-level 
covariate. 
 
We used the function in DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) data from our 
CODEm and CODcorrect analyses and match with incidence and prevalence data points for the same 
geography. We calculated excess mortality rate to estimate priors by dividing CSMR by 
incidence/remission (or prevalence, if applicable). We also applied a country-level log-transformed age-
standardized SEV scalar covariate for pancreatitis to incidence with bounds of 0.75 to 1.25, and a lag-
distributed income covariate to excess mortality, log-transformed and forced negative with an upper 
bound of 0 and a lower bound of -1. 
 
Betas and exponentiated values (which can be interpreted as an odds ratio) are shown in the tables 
below for study-level covariates and country-level covariates: 
 
 
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level covariate Acute Incidence 
-0.92 (-1.06 - -
0.78) 0.40 (0.35 - 0.46) 
Study-level covariate Hospital Inpatient Incidence 
0.90 (0.90 - 
0.90) 2.46 (2.46 - 2.46) 
Study-level covariate Claims data - 2000 Incidence 
-0.44 (-0.48 - -
0.40) 0.64 (0.62 - 0.67) 
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Study-level covariate Claims data -2010 Incidence 
0.07 (0.03 - 
0.10) 1.07 (1.03 - 1.10) 
Country covariate 
SEV scalar, 
Pancreatitis Incidence 
1.24 (1.21 - 
1.25) 3.45 (3.35 - 3.49) 
Country covariate LDI (I$ per capita) 
Excess mortality 
rate 
-1.00 (-1.00 - -
1.00) 0.37 (0.37 - 0.37) 
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 Other digestive diseases 
 
In addition to the digestive diseases described above, there are many diverse types of digestive diseases 
with a range of severities and associated sequelae. Because these digestive diseases are diverse in their 
underlying causes and risk factors as well as in their associated health outcomes, modelling them 
together in a DisMod-MR model would not produce reliable estimates of prevalence or excess mortality. 
Instead, we calculated the YLDs caused by digestive diseases directly using a YLD/YLL ratio.  
We calculated the ratio of YLDs to YLLs across the specified digestive diseases for which nonfatal 
outcomes were modelled, using YLL estimates from the GBD 2016 cause of death (CoD) analysis. We then 
multiplied this YLD/YLL ratio by the YLL estimates for other digestive diseases from the GBD 2016 CoD 
analysis, providing us with an estimate of the YLDs associated with other digestive diseases. 
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Input data and methodological summary 
Case definition 
Dementia is a progressive, degenerative, and chronic neurological disorder typified by memory 
impairment and other neurological dysfunctions. For the purposes of GBD 2016, we use the Diagnostic 
and Statistical Manual of Mental Disorders III, IV or V, or ICD case definitions as the reference. A wide 
array of diagnostic and screening instruments exists, including Clinical Dementia Rating scale (CDR), Mini 
Mental State Examination (MMSE), and the Geriatric Mental State (GMS). For severity rating purposes we 
use the CDR as the reference. The relevant ICD-10 codes for dementia are F00, F01, F02, F03, G30, and 
G31. The ICD-9 codes are 290, 291.2, 291.8, 294 and 331. 
Unlike most causes in the Global Burden of Disease project, dementia mortality and morbidity estimates 
are modelled jointly. This is because of marked discrepancies between prevalence data and cause of 
death data. Specifically, prevalence data suggest little to no variation over time (eg, 1990–2016) whereas 
age-standardized mortality rates in vital registrations in high-income countries have increased multiple 
times over this same period. Additionally, prevalence variation between countries is much smaller than 
the variation in death rates assigned to dementia in vital registration. We attribute these discrepancies to 
changing coding practices rather than epidemiological change. 
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Because of this joint procedure, descriptions of the mortality estimation process are included where 
relevant. 
Input data 
 Model inputs 
To inform our estimates of burden due to dementia, we use mortality data from vital registration 
systems, as well as prevalence data from surveys, and administrative data such as claims sources.  
An updated systematic review was conducted covering January 2015 to October 2016, and search terms1 
were set to capture studies for all dementia, including its sub-types. The search yielded 1,208 initial hits 
and 27 were marked for extraction. Inclusion criteria comprised studies that reported prevalence, 
incidence, remission rate, excess mortality rate, relative risk of mortality, standardised mortality ratio, or 
with-condition mortality rate. Studies with no clearly defined sample were excluded. A flow chart 
documenting this review is displayed below.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 ((dementia[Title/Abstract]) AND ((incidence[Title/Abstract]) or (prevalence[Title/Abstract])) AND (“2015/01/23”[Date - Publication] : 
“3000”[Date - Publication]) 
1208 Sources 
Identified in 
Systematic Review
169 Sources after 
Title/Abstract 
Screening
2 Articles in Foreign 
Languages
1037 Sources 
Excluded based on 
Title/Abstract 
Screening
43 Sources after 
Full-Text Screening
126 Sources 
Excluded based on 
Full Text Screening
43 Sources 
Extracted
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Additionally, a table describing the density and distribution of the epidemiological data available for GBD 
2016 is presented below: 
 Prevalence Incidence Mortality risk Severity 
Studies 174 60 15 17 
Countries/subnationals 131 37 19 15 
GBD world regions 17 10 9 8 
 
Severity splits 
In GBD 2013 (and still used in GBD 2016), we extracted data from studies reporting on mild, moderate, 
and severe dementia. As the data indicate an age pattern with greater proportions with more severe 
disease in the very old, we restricted our analyses to studies reporting on severity <70, 70-79, and 80+ 
ages. Most of these studies reported severity based on the CDR scale: CDR=1 as mild, CDR=2 as 
moderate, and CDR=3 as severe dementia. Other studies report staging of dementia according to MMSE; 
the Functional capacity scale; the Cambridge Mental Disorders of the Elderly Examination (CAMDEX); the scale 
of Hughes and the Geriatric Mental State (GMS). This year we excluded all studies that used the DSM III 
criteria, as we found that these sources reported systematically higher severities.  We used a random 
effects meta-analysis to pool the data by severity level. 
We multiplied estimations of prevalence (country-year-sex-age-specific) by the fractions of mild, 
moderate, and severe dementia and estimated 95% uncertainty intervals at the 1,000-draw level.  
Severity level Lay description DW (95% CI) Severity distribution 
Mild The person has some trouble remembering 
recent events and finds it hard to 
concentrate and make decisions and plans. 
0.069 
(0.046–0.099) 
<70: 79% (65–86%) 
70-79: 71% (51–84%) 
80+: 61% (44–76%) 
Moderate The person has memory problems and 
confusion, feels disoriented, at times hears 
voices that are not real, and needs help 
with some daily activities. 
0.377 
(0.252–0.508) 
<70: 17% (5–24%) 
70-79: 19% (8–37%) 
80+: 26% (16–34%) 
Severe The person has complete memory loss, no 
longer recognizes close family members, 
and requires help with all daily activities. 
0.449 
(0.304–0.595) 
<70: 4% (2–42%) 
70-79: 9% (8–17%) 
80+: 12% (9–24%) 
 
Modelling strategy  
 
As mentioned above, the estimation of morbidity due to dementia occurs in conjunction with the 
mortality estimation.  
 
First, we ran a CODEm model for dementia and extracted the mortality rates by age, sex, and geography 
for 2016.  
Second, we ran a DisMod-MR 2.1 model with all data on incidence, prevalence, and mortality risk (relative 
risk, standardized mortality ratio, or with-condition mortality rates) and a setting of zero remission and 
366
extracted 2016 prevalence by age, sex, and geography. To account for potential systematic differences 
between claims and survey data, we crosswalked for each year of claims data.  
Third, we selected countries where the sum of cause-specific mortality rate to prevalence ratio for males 
and females exceeded 0.4 (excluding small island nations and those without vital registration). This 
resulted in choosing the United States, Sweden, Finland and Puerto Rico.  The choice to pick fewer 
countries for this regression compared to GBD 2015, which used 30 countries in the EMR regression, was 
motivated by a desire to reduce the spread in EMR values, as countries used in the regression retain their 
original EMR values.   
Fourth, we used a linear effects regression with dummies on age group and sex to predict excess 
mortality (ie, the ratio of cause-specific mortality rate and prevalence) by age and sex, the results of 
which are found in the Tables below.  
Table: Fixed effect coefficients of EMR regression. Outcome: ln(EMR) 
Independent variables     Coef        Std. error     P value 
95% Confidence 
Interval 
Male 0.047 0.054 0.394 -0.06 0.153 
Age 40-59 -3.299 0.115 0.000 -3.524 -3.073 
Age 60-64 -2.627 0.115 0.000 -2.852 -2.401 
Age 65-69 -2.395 0.115 0.000 -2.62 -2.169 
Age 70-74 -2.068 0.115 0.000 -2.293 -1.842 
Age 75- 79 -1.686 0.115 0.000 -1.911 -1.461 
Age 80-84 -1.362 0.115 0.000 -1.587 -1.137 
Age 85-89 -0.949 0.115 0.000 -1.175 -0.724 
Age 90-94 -0.426 0.115 0.001 -0.651 -0.2 
Constant -1.539 0.086 0.000 -1.707 -1.371 
 
Table: Predicted EMR values by age and sex (95% CI) 
 Male Female 
Age 40-59 0.008 (0.007 - 0.01) 0.008 (0.007 - 0.009) 
Age 60-64 0.016 (0.014 - 0.019) 0.016 (0.013 - 0.018) 
Age 65-69 0.021 (0.017 - 0.024) 0.02 (0.017 - 0.023) 
Age 70-74 0.029 (0.024 - 0.034) 0.027 (0.023 - 0.032) 
Age 75- 80 0.042 (0.035 - 0.049) 0.04 (0.034 - 0.047) 
Age 80-84 0.058 (0.049 - 0.068) 0.055 (0.047 - 0.064) 
Age 85-89 0.088 (0.074 - 0.104) 0.084 (0.07 - 0.098) 
Age 90-94 0.147 (0.124 - 0.174) 0.14 (0.118 - 0.165) 
Age 95+ 0.226 (0.19 - 0.268) 0.216 (0.183 - 0.254) 
 
Fifth, these estimates were added to a second DisMod-MR 2.1 model as pertaining to the full 1990–2016 
estimation period. For the four countries included in the regression, we retained their age- and sex-
specific ratios and entered those also as pertaining to the full 1990–2016 estimation period. Thus, the 
model reflects the cause-specific mortality rate if all countries over time would have had the average 
propensity to code to dementia as an underlying cause of death similar to the selected four countries in 
2016. 
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In this model, we assumed zero remission as well as zero excess mortality and incidence until age 40. 
Because of lack of consistency between prevalence and incidence data in locations where the underlying 
data, we excluded incidence data from the final model. In a few locations we found good consistency 
between prevalence and incidence and these were locations where incidence and prevalence were 
collected as part of the same study. In other locations (Beijing, Australia, Italy, Canada, various states in 
the US, Mexico, and Nigeria) we noted that DisMod-MR 2.1 was pushing the fit above the available 
prevalence data and below incidence – “averaging the difference.” In all cases the incidence and 
prevalence data were collected by different studies. We decided to drop the incidence estimates as 
measuring incidence of dementia when symptoms are still mild is more prone to measurement bias than 
measuring prevalence when the diagnosis has become more obvious over time. 
The table below provides additional information on the country covariates used in this model, as well as 
beta and exponentiated beta values. 
Variable Measure Beta Exponentiated 
Beta Value (CI) 
Mean years of education, age-
standardized 
prevalence -0.053 0.95 
(0.85–1.00) 
Smoking prevalence, age-
standardized both sex 
Prevalence 0.11 1.11 
(1.06–1.17) 
US claims data 2000 prevalence -0.69 0.50 
(0.48–0 .55) 
US claims data 2010 prevalence -0.25 0.78 
(0.75–0.86) 
US claims data 2012 prevalence -0.25 0.78 
(0.75–0.86) 
 
As described above, we used crosswalks to standardize the claims data relative to existing literature data.  
Age-standardized education was used as a proxy for general brain health/use that may be protective of 
dementia – specifically Alzheimer’s disease. Smoking prevalence (age-standardised, both sexes) was also 
used as a covariate to guide estimates, as the literature has shown a positive relationship between 
smoking and dementia.   
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Case definition 
Parkinson’s disease is a chronic, degenerative, and progressive neurological condition typified by the loss 
of motor mobility and control – most notably tremors. The corresponding ICD-10 codes are G20, G21, 
and G22. Our case definition for GBD is the presence of at least two of the four primary symptoms: (1) 
tremors/trembling, (2) bradykinesia, (3) stiffness of limbs and torso, and (4) posture instability.  
Unlike most causes in the Global Burden of Disease project, Parkinson’s disease mortality and morbidity 
estimates are modelled jointly. This is because of marked discrepancies between prevalence data and 
cause of death data. Specifically, prevalence data suggest little to no variation over time (eg, 1990–2016) 
whereas age-standardized mortality rates in vital registrations in high-income countries have increased 
multiple times over this same period. Additionally, prevalence variation between countries is much 
smaller than the variation in death rates assigned to Parkinson’s disease in vital registration. We attribute 
these discrepancies to changing coding practices rather than epidemiological change. 
Because of this joint procedure, descriptions of the mortality estimation process are included where 
relevant. 
Input data 
Model inputs 
To inform our estimates of burden due to Parkinson’s disease, we use mortality data from vital 
registration systems, as well as prevalence data from surveys, and administrative data such as claims 
sources.  
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For GBD 2015, a systematic review was conducted from January 2011 to December 2015, and the search 
terms were set to capture studies for Parkinson’s disease.1 This search term resulted in 1,433 initial hits 
with 17 sources marked for extraction. Studies with no clearly defined sample or that drew from specific 
clinic/patient organizations were excluded. 
The following table provides a description of the density and distribution of literature data informing the 
Parkinson’s estimates: 
 
 Prevalence Incidence Mortality risk 
Studies 94 34 10 
Countries/subnationals 134 31 10 
Regions 16 9 3 
 
Beyond the exclusion of studies using non-representative populations, there are no substantial 
adjustment or outliering criteria for the Parksinson’s model. Certain studies have been outliered on a 
case-by-case basis due to subsequent review and exclusion due to inappropriateness of the study design, 
and overly broad age and sex groups that conflict with existing gold-standard age-sex-specific data – 
where possible. 
Severity splits 
As in GBD 2013, we use Hoehn and Yahr stages to determine severity.  However, for GBD 2016, the 
cutpoints were updated in order to more accurately correspond with the lay descriptions of severities.  
Specifically, a Hoehn and Yahr stage 4 now corresponds to a designation of severe, where before it was 
classified as moderate.    
Severity Stage 
Mild ≤2.0 
Moderate 2.5-3.5 
Severe ≥4 
 
For GBD 2016, a literature review was completed to update the severity splits meta-analysis. The 
systematic review covered 1/1/2008 to 11/10/2016 and the search terms were set to capture studies 
reporting prevalence of Parkinson’s by Hoehn and Yahr stage.2 The search term resulted in 234 hits with 
21 marked for extraction.   
The following figures show the results of the meta-analysis on Hoehn and Yahr stage: 
 
 
 
1 (((((Parkinson disease AND epidemiology) AND ( "2011/01/01"[PDat] : "2015/12/31"[PDat] ))) AND ((Parkinson disease AND epidemiology)))) 
2 (("1/1/2008"[Date - Publication] : "2016"[Date - Publication])) AND (parkinson disease[MeSH Terms] OR parkinson disease) AND (epidemiology 
OR prevalence OR incidence) AND (Hoehn) AND (Yahr) AND (stage) 
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Figure 1. Percentage of mild cases of Parkinson’s disease in population-based studies 
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Figure 2. Percentage of moderate cases of Parkinson’s disease in population-based studies 
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Figure 3. Percentage of severe cases of Parkinson’s disease in population-based studies 
 
 
Severity estimates were generated by multiplying estimates of prevalence (country-year-sex-age-specific) 
by the fractions of mild, moderate, and severe PD and estimated 95% confidence intervals by taking 
1,000 draws. 
The following table provides the lay description and disability weights associated with Parkinson’s disease. 
Severity level Lay description DW (95% CI) 
Mild Has mild tremors and moves a little slowly, 
but is able to walk and do daily activities 
without assistance. 
0.01 
(0.005–0.019) 
Moderate Has moderate tremors and moves slowly, 
which causes some difficulty in walking and 
daily activities. The person has some trouble 
swallowing, talking, sleeping, and 
remembering things. 
0.267 
(0.181–0.372) 
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Severe Has severe tremors and moves very slowly, 
which causes great difficulty in walking and 
daily activities. The person falls easily and has 
a lot of difficulty talking, swallowing, sleeping, 
and remembering things. 
0.575 
(0.396–0.73) 
 
Modelling strategy  
First, we ran a CODEm model for Parkinson disease and extracted the mortality rates by age, sex, and 
geography for 2016.  
Second, we ran a DisMod-MR 2.1 model with all data on incidence, prevalence, and mortality risk (relative 
risk, standardized mortality ratio, or with-condition mortality rates) and a setting of zero remission and 
extracted 2016 prevalence by age, sex, and geography. To account for potential systematic differences 
between claims and survey data, we crosswalked for each year of claims data.   
Third, we selected the three countries (United States, Finland, and Austria) with the highest cause-specific 
mortality rate (from step 1) to prevalence (from step two) ratio, which also had prevalence rates above 
0.0005, and a population greater than 1 million.  
Fourth, we used a linear effects regression with dummies on age group and sex to predict excess 
mortality (ie, the ratio of cause-specific mortality rate and prevalence) by age and sex, the results of 
which are found in the tables below.  
Table: Fixed-effect coefficients of EMR regression. Outcome: ln(EMR) 
Independent variables     Coef        Std. error     P value 95% Confidence 
Interval 
Male 0.214 0.074 0.006 0.069 0.359 
Age 40-59 -3.522 0.157 0.000 -3.829 -3.214 
Age 60-64 -2.716 0.157 0.000 -3.024 -2.409 
Age 65-69 -2.236 0.157 0.000 -2.544 -1.929 
Age 70-74 -1.686 0.157 0.000 -1.993 -1.378 
Age 75- 80 -1.194 0.157 0.000 -1.502 -0.887 
Age 80-84 -0.779 0.157 0.000 -1.087 -0.471 
Age 85-89 -0.493 0.157 0.003 -0.800 -0.185 
Age 90-94 -0.203 0.157 0.202 -0.511 0.104 
Constant -2.097 0.117 0.000 -2.326 -1.867 
 
Table: Predicted EMR values by age and sex (95% CI) 
 Male Female 
Age 40-59 0.005 (0.004 - 0.006) 0.004 (0.003 - 0.005) 
Age 60-64 0.01 (0.008 - 0.013) 0.008 (0.006 - 0.01) 
Age 65-69 0.016 (0.013 - 0.02) 0.013 (0.01 - 0.016) 
Age 70-74 0.028 (0.023 - 0.035) 0.023 (0.018 - 0.029) 
Age 75- 80 0.047 (0.037 - 0.059) 0.037 (0.029 - 0.046) 
Age 80-84 0.071 (0.055 - 0.089) 0.057 (0.045 - 0.07) 
Age 85-89 0.093 (0.073 - 0.117) 0.076 (0.06 - 0.093) 
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Age 90-94 0.126 (0.099 - 0.155) 0.101 (0.08 - 0.127) 
Age 95+ 0.154 (0.122 - 0.191) 0.123 (0.097 - 0.153) 
 
Fifth, these estimates were added to a second DisMod-MR 2.1 model as pertaining to the full 1990–2016 
estimation period. For the three countries included in the regression, we retained their age- and sex-
specific ratios and entered those also as pertaining to the full 1990–2016 estimation period. Thus, the 
model reflects the cause-specific mortality rate if all countries over time would have had the average 
propensity to code to dementia as an underlying cause of death similar to the selected three countries in 
2016. 
In this model, we assumed zero remission among all ages, with no incidence or excess mortality for ages 
zero to 20 years old. We ignore data on incidence, relative risk, standardized mortality ratio, and with-
condition mortality as these were shown to be inconsistent with prevalence estimates. We also constrain 
the super-region random effects for prevalence and incidence to -0.25 and 0.25 to account for spurious 
inflation of regional differences.  
 
We make one study-level crosswalk: Diagnostic Criteria. Studies that do not use the gold-standard case 
definition of presence of at least two of the four main symptoms are crosswalked to meet this gold 
standard definition. The table below shows the effect of this crosswalk, which results in a downward 
adjustment of non-standard data points. For GBD 2015, an additional adjustment was made for Case 
Ascertainment, or studies that ascertain cases on clinical record review rather than using live diagnostic 
processes. However, this adjustment was not significant for GBD 2016 and was therefore changed to a z-
cov, which effects the uncertainty of the estimates.   
 
Additionally, claims data for 2000, 2010, and 2012 are adjusted via study covariates to account for 
systematic differences between the claims data and the literature. We use a country-level crosswalk to 
assist DisMod in estimating global patterns. We use Socio-demographic Index as a proxy to capture 
possible social and cultural risk factors or modifiers of Parkinson’s prevalence. 
 
The following table provides an overview of the study-level and country covariates used in the Parkinson’s 
model. 
 
Covariate Measure Beta Exponentiated 
Socio-demographic Index prevalence 1.44 
(1.26 – 1.63) 
4.22 
(3.53 – 5.08) 
All MarketScan, year 2012 prevalence -0.0043 
(-0.016 - -0.00051) 
1.00 
(0.98 – 1.00) 
All MarketScan, year 2010 prevalence -0.0083 
(-0.025 - -0.00021) 
0.99 
(0.97 – 1.00) 
All MarketScan, year 2000 prevalence -0.0086 
(-0.022 - -0.00044) 
0.99 
(0.98 – 1.00) 
(Un)Filled diagnostic criteria prevalence 0.20 
(0.13 - 0.27) 
1.22 
(1.14 – 1.31) 
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 Multiple Sclerosis (MS) 
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Input data and methodological summary 
Case definition 
Multiple sclerosis is a chronic, degenerative, and progressive neurological condition typified by the 
damaging of the myelin sheaths. For GBD, the McDonald’s criteria for diagnosis are considered the gold 
standard, but other definitions such as Poser Committee’s criteria and self-report of a doctor’s diagnosis 
are also included. The ICD-10 code for MS is G35. 
Input data 
A systematic review was conducted for MS for GBD 2015. The search using (multiple sclerosis AND 
epidemiology AND ( "2011/01/01"[PDat] : "2015/12/31"[PDat] ))  from 1/1/2011-7/15/15 yielded 1756 
hits with 28 sources marked for extraction. 
 
The data underpinning estimates of burden due to MS are generally of two types. The first are 
representative, population-based surveys. This includes retrospective case/hospital report analysis, 
nationally representative health studies and the like. Studies with no clearly defined sample or that draw 
from specific clinic/patient organizations were excluded during the systematic review phase. The second 
type are claims data from the United States from 2000, 2010, and 2012. Additional information on the 
source and preparation of these data is provided elsewhere. 
 
The following table provides a description of the density and distribution of literature data informing the 
MS estimates: 
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  Prevalence Incidence Mortality risk 
Studies 132 65 14 
Countries/subnationals 105 26 10 
GBD world regions 11 8 3 
 
Beyond the exclusion of studies using non-representative populations, there are no substantial 
adjustment or outliering criteria for the MS model. Certain studies have been outliered on a case-by-case 
basis due to: (1) subsequent review and exclusion due to inappropriate of the study design, and overly 
broad age and sex groups that conflict with existing gold standard age-sex specific data – where possible. 
 
Severity splits 
For GBD 2016, we updated the meta-analysis of all eligible studies that reported EDSS. The search using 
(("2008"[Date - Publication] : "2016"[Date - Publication])) AND (multiple sclerosis[MeSH Terms] OR 
multiple sclerosis) AND (epidemiology OR prevalence OR incidence) AND (“Kurtzke’s Expanded Disability 
Status Scale”) from 1/1/2008 to 11/14/2016 yielded 355 hits, with 10 marked for extraction.   
As in GBD 2013, we use Kurtzke’s Expanded Disability Status Scale (EDSS) to determine severity splits for 
MS. However, for GBD 2016 we added a category for asymptomatic multiple sclerosis in order to capture 
the initial stages of relapse-remitting multiple sclerosis which has no disability associated.  The EDSS 
scores corresponding to each severity are as follows: 
Asymptomatic: EDSS = 0 
Mild: 0 < EDSS ≤ 3.5 
Moderate: 3.5 < EDSS ≤ 6.5 
Severe: 6.5 < EDSS ≤ 9.5 
 
The table below illustrates severity levels, lay descriptions, and DWs. 
 
Severity level Lay description DW (95% CI) 
Asymptomatic - 0 
(0-0) 
Mild  Has mild loss of feeling in one hand, is a little unsteady 
while walking, has slight loss of vision in one eye, and 
often needs to urinate urgently. 
 
0.183 
(0.124–0.253) 
 
Moderate Needs help walking, has difficulty with writing and arm 
coordination, has loss of vision in one eye and cannot 
control urinating. 
 
0.463 
(0.313–0.613) 
 
Severe Has slurred speech and difficulty swallowing. The person 
has weak arms and hands, very limited and stiff leg 
movement, has loss of vision in both eyes and cannot 
control urinating. 
 
0.719 
(0.534–0.858) 
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 Because not all sources had information on the number of cases with EDSS stage 0, instead reporting on a 
mild category, we implemented a two-step meta-analysis strategy.  First we subsetted the studies to 
those that reported on the number of cases with EDSS stage 0, and did meta-analyses on the proportion 
of asymptomatic and mild cases.  Then, we conducted meta-analyses on the full dataset to get the 
proportion mild, moderate and severe and we squeezed the asymptomatic and mild categories from the 
previous meta-analyses into the mild category established by the meta-analysis on the full dataset.   
The following figures provide the result of the first meta-analysis on the asymptomatic and mild 
categories. 
Figure 1. Asymptomatic cases of MS 
Figure 2. Mild Cases of MS 
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The following figures provide the result of the second meta-analysis on the mild, moderate and severe 
categories. 
Figure 3. Mild Cases of MS (Including both Asymptomatic and Mild Categories) 
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Figure 4. Moderate Cases of MS 
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Figure 5. Severe Cases of MS 
 
Modelling strategy  
We use DisMod 2.1 as the main analytical tool for the MS estimation process. Prior settings include zero 
remission for all ages, and no incidence or excess mortality for persons under 4 years old. We also 
constrain the super-region random effects for prevalence and incidence to -0.5 and 0.5 to account for 
spurious inflation of regional differences.  
 
Claims data for 2000 and 2010 are adjusted via study covariates to account for systematically low 
estimates relative to the 2012 claims data. Implicit in this adjustment is the assumption that variation 
between years of claims data is a function of data collection inconsistencies and noise. 
 
Similar to other cases we use GBD estimates of cause-specific mortality rate (CSMR) and Excess Mortality 
Rate (EMR) in this model.  
 
To assist the estimation process, we use a several country-level covariates. These effects plus those of the 
study covariates are presented below. 
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Covariate Measure Beta Exponentiated Parameter 
Type 
Absolute value of average latitude prevalence .029 
(.026 - .040) 
1.03 
(1.03 - 1.04) 
Country-
level 
Absolute value of average latitude incidence .055 
(.0095 - .061) 
1.06 
(1.01 - 1.06) 
Country-
level 
All MarketScan, year 2000 prevalence -.26 
(-.29 - -.22) 
.77 
(.75 - .80) 
x-cov 
All MarketScan, year 2010 prevalence -.0011 
(-.0034 - -.0017) 
.99 
(.97 – 1.00) 
x-cov 
Healthcare access and quality index excess 
mortality rate 
-.048 
(-.21 - -.035) 
.95 
(.81 - .97) 
Country-
level 
SDI prevalence 1.98 
(1.96- 2.00) 
7.24 
(7.06- 7.38) 
Country-
level 
 
 
As described in the literature, extreme latitude is associated with higher prevalence and incidence of MS. 
While the pathway that affects MS is not fully understood, our results suggest a sizable relationship. Our 
operationalization of latitude is created by a population-weighted average of latitude by country and 
taking the absolute value. The underlying population distribution rasters are part of the Gridded 
Population of the World dataset. 
 
Although there are no known cures for MS, we expect disease management to differ globally – largely as 
a function of available resources. To capture this, we use the healthcare access and quality index 
covariate to capture this relationship in the estimation of excess mortality.  
 
To capture possible social and cultural risk factors or modifiers of MS prevalence, we include SDI as a 
covariate. 
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 Migraine 
 
Flowchart 
 
 
 
Case definition 
Migraine is a class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile 
headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura 
or neurological symptoms). In GBD we do not distinguish subtypes as most epidemiological studies report 
on overall migraine only. The ICD-10 code for migraine is G43 and ICD-9 code is 346.  
Migraine is due to medication overuse headache (MOH) when the additional International Classification 
of Headache Disorders (ICHD) diagnostic criteria for MOH are met. The criteria are: 
A. Headache present on ≥15 days/month fulfilling criteria C and D 
B. Regular overuse (ie, >2 days per week) for ≥3 months of one or more drugs that can be taken for 
acute and/or symptomatic treatment of headache 
C. Headache has developed or markedly worsened during medication overuse 
D. Headache resolves or reverts to its previous pattern within 2 months after discontinuation of 
overused medication 
It also explicitly states that if a person qualifies for chronic migraine or chronic tension-type headache 
(TTH) as well as MOH, both diagnoses should be given. However, our GBD headache collaborators, 
Steiner and Stovner, say that in survey practice, a screening question on chronic headache is used first, 
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followed by questions to determine if medication overuse headache is probable (ie, fitting all criteria but 
criterion D). 
Only one study used in GBD was able to meet criterion D making a final diagnosis after a trial of 
detoxification. Of 25 cases with probably MOH, 15 were confirmed as MOH. 
 
Input data 
 Model inputs 
A systematic reviews of migraine and MOH were conducted for GBD 2010 and updated for GBD 2013. In 
GBD 2015, three new representative surveys conducted by GBD collaborators in Norway; Karnataka, 
India; and Nepal were added. In GBD 2016, four new representative surveys conducted by GBD 
collaborators in Ethiopia, Germany, Denmark, and Sweden were included for migraine, and two surveys in 
Norway and Ethiopia were included for MOH.   
Inclusion criteria of the systematic reviews were: 
o Representative, population-based surveys 
o Reporting of prevalence of migraine headache  
In addition, US claims data for 2000, 2010, and 2012 by US state were used.  
The table below illustrates the geographic distribution of migraine data. 
 Prevalence Incidence Remission Frequency and duration episodes 
Studies 123 4 1 16 
Countries/subnational 
locations 
113 4 1 16 
GBD world regions 16 2 1 9 
 
The table below shows the geographic distribution of MOH data. 
 Prevalence Incidence Remission 
Studies 26 0 7 
Countries/subnational locations 20 0 5 
GBD world regions 8 0 1 
 
 Severity splits 
To determine the proportion of time over a year spent in an episode of migraine headache, 16 studies 
providing data on the frequency of episodes and the average duration of episodes were meta-analyzed. 
As these studies reported frequency and duration of episodes by disparate categories, an assumption was 
made that the mean represented each category. For each study the estimated proportion of time 
symptomatic is 0.085 (0.058–0.112). 
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The basis of GBD disability weight (DW) survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms.  The lay description and DW for migraine are shown 
below. 
Severity level Lay description DW (95% CI) 
Mild  This person has severe, throbbing head pain, and nausea 
that cause great difficulty in daily activities and 
sometimes confine the person to bed. Moving around, 
light, and noise make it worse. 
0.434 (0.285–0.603) 
 
Modelling strategy 
We used a list of binary covariates which are a modified version of quality indicators of epidemiological 
studies on headache (Steiner TJ, Stovner LJ et al [2013]. Improving quality in population surveys of 
headache prevalence, burden, and cost: key methodological considerations. J Headache Pain, 14: 87) and 
shown in the table below. 
Study covariate Notation 
Less desirable (1) Reference (zero) 
Other than one-
year recall period 
Point prevalence One-year prevalence 
Not representative 
 
Selected population  
 
General population or community-based 
sample from whole country OR general 
population or community-based sample 
from defined region within a country, or 
school-based (for children)  
Low-quality 
sampling method 
 
Not stated OR  no (or failed) attempt 
to secure representativeness 
Total defined population, or random 
sample corrected for population 
demographics OR random sample 
uncorrected for population 
demographics 
Poor response Not stated, or <70% 70–100% 
Low-quality survey 
method and type of 
interviewer 
Not stated OR self-administered 
(unsupervised) questionnaire OR  
telephone or face-to-face interview 
by untrained or unspecified 
interviewer(s) 
Face-to-face interview with headache 
expert 
 
Low-quality 
validation of 
diagnostic 
instrument 
 
Instrument not specified or not 
validated OR validated, but 
sensitivity and/or specificity <70%  
OR validated only in screen-positive 
sub-sample, or in clinic or 
unspecified sample, but sensitivity 
and specificity 70% 
Validated in target population or similar, 
and sensitivity and specificity 70%, or 
all diagnoses made in face-to-face or 
telephone interviews by headache 
expert 
Low-quality 
diagnostic criteria 
Not stated OR  stated, other than 
ICHD OR  ICHD (or reasonable 
modification) 
ICHD (or reasonable modification) 
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We added separate covariates for lifetime recall and three years of claims data from MarketScan (2000, 
2010, and 2012). 
Prior settings in the DisMod model included setting incidence to 0 before age 5 based on expert advice. 
We also assume no excess mortality due to migraine. Remission rate is set to be between 0 and 0.1. 
All study covariates were initially evaluated as x-cov (which means that data points are adjusted to the 
reference value if a systematic bias is detected); those that did not have a significant coefficient, were 
entered as z-cov (which means that a multiplier is applied to the standard error of such data points to 
indicate they are less certain values because they did not meet the reference criteria for study quality). 
The table below shows the fixed effect values of the x-covs which are in log space (as DisMod uses an 
offset lognormal model) as well as the exponentiated values which for an x-cov can be interpreted as an 
odds ratio.  
Only the covariate for low quality survey method and type of interviewer, poor response and three years 
of claim data remain as x-covs. 
The covariates for other than one-year recall period, low-quality sampling method, low-quality diagnostic 
criteria, low-quality validation of diagnostic instrument, and not representative studies had non-
significant coefficients as a x-cov and were subsequently used as z-covs. 
Study covariate Parameter beta Exponentiated beta 
Low quality survey method 
and type of interviewer 
Prevalence  0.09  1.09 (0.99 – 1.19) 
Poor response Prevalence - 0.25  0.78 (0.71 – 0.85) 
Claims data US 2000 Prevalence - 2.45  0.086 (0.082 – 0.095) 
Claims data US 2010 Prevalence  - 2.07  0.13 (0.12 – 0.14) 
Claims data US 2012 Prevalence - 1.97  0.14 (0.13 – 0.15) 
 
MOH is initially modelled separately in DisMod, then we include MOH prevalence due to migraine as a 
sequela of migraine. Prior settings in the DisMod model included setting incidence to 0 before age 5 
based on expert advice. We also assume no excess mortality due to MOH. Based on the seven literatures 
on remission (listed in references below), we set bounds of the remission to be between 0 and 0.4     
All study covariates for MOH are evaluated using the same strategy as modelling for migraine.   
The study with recall period other than one year was the only covariate used as a x-covariate; however, 
its coefficient was insignificant: beta = -0.19 and exponentiated beta = 0.83 (0.66 – 1.04). The others were 
subsequently used as z-covariates. 
Study covariate Parameter beta Exponentiated beta 
Low-quality diagnostic criteria Prevalence  0.24  1.27 (1.05–1.59) 
Poor response Prevalence -0.64 0.53 (0.42–0.65) 
 
In GBD 2015, to the prevalence output from DisMod, we first applied the finding from da Silva (2010) that 
60% (40.8–79.2%) of “probable” cases were confirmed cases of MOH. However, headache collaborators 
have argued that this would leave the 40% unaccounted for, as surveys first ask about chronic headache 
and those on medication before applying criteria for those with migraine and TTH. Thus, in GBD 2016, we 
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no longer multiplied the 60% (40.8–79.2%) to the prevalence from DisMod; ie, consider all the “probable” 
cases as MOH cases.  For the severity split, we estimate the proportion of time “symptomatic,” ie, with 
headache, from the Ayzenberg (2012) estimate of 23.1 days a month with headache and multiply 
estimates by 75.9% (72.9–78.8%). 
In addition, we multiplied 73% (64–82%) to the symptomatic MOH prevalence to be symptomatic MOH 
due to migraine and the rest of the prevalent cases are symptomatic MOH due to TTH.  
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 Tension-type Headache 
 
Flowchart 
 
 
 
Case definition 
Tension-type headache (TTH) is characterized by a dull, non-pulsatile, diffuse, band-like (or vice-like) pain 
of mild to moderate intensity in the head, scalp, or neck. The ICD-10 code for migraine is G44.2 and the 
ICD-9 code is 339.1.  
TTH is due to medication overuse headache (MOH) when the additional International Classification of 
Headache Disorders (ICHD) diagnostic criteria for MOH are met. The criteria are: 
E. Headache present on ≥15 days/month fulfilling criteria C and D 
F. Regular overuse (ie, >2 days per week) for ≥3 months of one or more drugs that can be taken for 
acute and/or symptomatic treatment of headache 
G. Headache has developed or markedly worsened during medication overuse 
H. Headache resolves or reverts to its previous pattern within 2 months after discontinuation of 
overused medication 
It also explicitly states that if a person qualifies for chronic migraine or chronic TTH as well as MOH, both 
diagnoses should be given. However, our headache GBD collaborators, Steiner and Stovner, say that in 
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survey practice, a screening question on chronic headache is used first, followed by questions to 
determine if medication overuse headache is probable (ie, fitting all criteria but criterion D). 
Only one study used in GBD was able to meet criterion D making a final diagnosis after a trial of 
detoxification. Of 25 cases with probable MOH, 15 were confirmed as MOH. 
 
Input data 
 Model Inputs 
A systematic review of TTH was conducted for GBD 2010 and updated for GBD 2013. In GBD 2015 three 
new representative surveys conducted by GBD collaborators in Norway; Karnataka, India; and Nepal were 
added. In GBD 2016, two new representative surveys conducted by GBD collaborators in Ethiopia and 
Germany were added. Inclusion criteria of the systematic reviews were: 
o Representative, population-based surveys 
o Reporting of prevalence of TTH headache  
In addition, US claims data for 2000, 2010, and 2012 by US state were included.  
The table below illustrates the geographic distribution of TTH data. 
 Prevalence Incidence Remission Frequency and duration episodes 
Studies 86 1 0 9 
Countries/subnational 
locations 
103 1 0 7 
GBD world regions 15 1 0 6 
 
The table below shows the geographic distribution of MOH data. 
 Prevalence Incidence Remission 
Studies 26 0 7 
Countries/subnational locations 20 0 5 
GBD world regions 8 0 1 
 
 
 Severity splits 
To determine the proportion of time over a year spent in an episode of TTH headache, nine studies 
providing data on the frequency of episodes and the average duration of episodes were meta-analyzed. 
As these studies reported frequency and duration of episodes by disparate categories, an assumption was 
made that the mean represented each category. The estimated proportion of time symptomatic is 0.058 
(0.023–0.092). 
The basis of GBD disability weight (DW) survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay description and DW for TTH are shown below. 
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Severity level Lay description DW (95% CI) 
Mild  This person has a moderate headache that also affects 
the neck, which causes difficulty in daily activities 
0.036 (0.023–0.053) 
 
 
Modelling strategy 
We used a list of binary covariates which are a modified version of quality indicators of epidemiological 
studies on headache (Steiner TJ, Stovner LJ et al (2013). Improving quality in population surveys of 
headache prevalence, burden and cost: key methodological considerations. J Headache Pain, 14: 87) and 
shown in the table below. 
Study covariate Notation 
Less desirable (1) Reference (zero) 
Other than one-
year recall period 
Point prevalence One-year prevalence 
Not representative 
 
selected population  
 
general population or community-based 
sample from whole country OR  general 
population or community-based sample 
from defined region within a country, or 
school-based (for children)  
Low-quality 
sampling method 
 
not stated OR no (or failed) attempt 
to secure representativeness 
total defined population, or random 
sample corrected for population 
demographics OR random sample 
uncorrected for population 
demographics 
Poor response not stated, or <70% 70–100% 
Low-quality survey 
method and type of 
interviewer 
not stated OR self-administered 
(unsupervised) questionnaire OR  
telephone or face-to-face interview 
by untrained or unspecified 
interviewer(s) 
face-to-face interview with headache 
expert 
 
Low-quality 
validation of 
diagnostic 
instrument 
 
instrument not specified or not 
validated OR validated, but 
sensitivity and/or specificity <70%  
OR validated only in screen-positive 
sub-sample, or in clinic or 
unspecified sample, but sensitivity 
and specificity 70% 
validated in target population or similar, 
and sensitivity and specificity 70%, or 
all diagnoses made in face-to-face or 
telephone interviews by headache 
expert 
Low-quality 
diagnostic criteria 
not stated OR stated, other than 
ICHD OR ICHD (or reasonable 
modification) 
ICHD (or reasonable modification) 
 
We added separate covariates for chronic headache, lifetime recall and the three years of claims data 
from MarketScan (2000, 2010, and 2012). 
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Prior settings in the DisMod model included setting incidence to 0 before age 5 based on expert advice. 
We also assume no excess mortality due to TTH. In the absence of any data on remission we set bounds 
between 0 and 0.5, ie, ensuring an average duration of at least two years. 
All study covariates were initially evaluated as x-cov (which means that data points are adjusted to the 
reference value if a systematic bias is detected); those that did not have a significant coefficient were 
entered as z-cov (which means that a multiplier is applied to the standard error of such data points to 
indicate they are less certain values because they did not meet the reference criteria for study quality). 
The table below shows the fixed-effect values of the x-covs which are in log space (as DisMod uses an 
offset lognormal model) as well as the exponentiated values which for a x-cov can be interpreted as an 
odds ratio.  
The covariate for other than one-year recall period and not representative had non-significant 
coefficients as a x-cov and were subsequently used as a z-cov. 
Study covariate Parameter beta Exponentiated beta 
Chronic headache Prevalence -0.37 0.69 (0.41 – 0.98) 
Recall lifetime Prevalence 0.74 2.09 (1.36 – 2.69) 
Claims data US 2000 Prevalence - 4.49 0.011 (0.011 – 0.011) 
Claims data US 2010 Prevalence  - 4.12  0.016 (0.016 – 0.017) 
Claims data US 2012 Prevalence - 4.00 0.018 (0.018 – 0.019) 
 
The very low coefficients in claims data mean that few cases of TTH are included in claims data. Data 
points were crosswalked up by a factor 50 or more. We decided to include the data with such large 
crosswalks as we had no other data for the states of the USA and the crosswalks estimated by DisMod 
were within range of the data from three US studies in Massachusetts, Maryland, and Kentucky. 
 
MOH is initially modelled separately in DisMod, then we include the MOH prevalence due to TTH as a 
sequela of TTH. Prior settings in the DisMod model included setting incidence to 0 before age 5 based on 
expert advice. We also assume no excess mortality due to MOH. Based on seven literature sources on 
remission (listed in references below), we set bounds of the remission to be between 0 and 0.4.  
All study covariates for MOH are evaluated using the same strategy as modelling for TTH.   
The study with recall period other than one year was the only covariate used as a x-covariate; however, 
its coefficient was insignificant: beta = -0.19 and exponentiated beta = 0.83 (0.66 – 1.04). The others were 
subsequently used as z-covariates. 
 
In GBD 2015, to the prevalence output from DisMod, we first applied the finding from da Silva (2010) that 
60% (40.8–79.2) of “probable” cases were confirmed cases of MOH. However, headache collaborators 
have argued that this would leave the 40% unaccounted for, as surveys first ask about chronic headache 
and those on medication before applying criteria for those with migraine and TTH. Thus, in GBD 2016, we 
no longer multiplied the 60% (40.8–79.2) to the prevalence from DisMod; ie, consider all the “probable” 
cases as MOH cases. For the severity split, we estimate the proportion of time “symptomatic,” ie, with 
headache from the Ayzenberg (2012) estimate of 23.1 days a month with headache and multiply 
estimates by 75.9% (72.9–78.8). 
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In addition, we multiplied 73% (64–82) to the symptomatic MOH prevalence to be symptomatic MOH due 
to migraine and the rest of the prevalent cases are symptomatic MOH due to TTH.  
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Case definition 
Motor neuron diseases (MND) are a set of chronic, degenerative, and progressive neurological conditions 
typified by the destruction of motor neurons and the subsequent deterioration of voluntary muscle 
activity. The most common MND is amyotrophic lateral sclerosis. The ICD-10 code corresponding to 
motor neuron diseases is G12. Our gold standard diagnostic criteria are the El Escorial Criteria, with other 
similar criteria (eg, the original set from World Federation of Neurology) if necessary. 
Input data 
A full systematic review was conducted for GBD 2015. The following search string guided our search, 
which resulted in 3,146 hits with 58 sources meeting extraction criteria: (1) the study is a representative 
population-based study, (2) reports on prevalence, incidence, remission, excess mortality, relative risk of 
mortality, standardized mortality ratio, or with-condition mortality rate. Studies with no clearly defined 
sample were excluded. 
(('motor neuron disease'[MeSH Terms] OR ('motor'[All Fields] AND 'neuron'[All Fields] AND 'disease'[All 
Fields]) OR 'motor neuron disease'[All Fields] OR ('motor'[All Fields] AND 'neuron'[All Fields] AND 
'diseases'[All Fields]) OR 'motor neuron diseases'[All Fields]) OR ('amyotrophic lateral sclerosis'[MeSH 
Terms] OR ('amyotrophic'[All Fields] AND 'lateral'[All Fields] AND 'sclerosis'[All Fields]) OR 'amyotrophic 
lateral sclerosis'[All Fields]) OR ALS[All Fields] OR ('motor neuron disease'[MeSH Terms] OR ('motor'[All 
Fields] AND 'neuron'[All Fields] AND 'disease'[All Fields]) OR 'motor neuron disease'[All Fields] OR 
('primary'[All Fields] AND 'lateral'[All Fields] AND 'sclerosis'[All Fields]) OR 'primary lateral sclerosis'[All 
Fields]) OR ('Politics Life Sci'[Journal] OR 'pls'[All Fields]) OR ('muscular atrophy, spinal'[MeSH Terms] OR 
('muscular'[All Fields] AND 'atrophy'[All Fields] AND 'spinal'[All Fields]) OR 'spinal muscular atrophy'[All 
Fields] OR ('progressive'[All Fields] AND 'muscular'[All Fields] AND 'atrophy'[All Fields]) OR 'progressive 
muscular atrophy'[All Fields]) OR PBP[All Fields] OR ('pseudobulbar palsy'[MeSH Terms] OR 
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('pseudobulbar'[All Fields] AND 'palsy'[All Fields]) OR 'pseudobulbar palsy'[All Fields])) AND 
(('epidemiology'[Subheading] OR 'epidemiology'[All Fields] OR 'epidemiology'[MeSH Terms]) OR 
population-based[All Fields]) 
The following table provides an overview of the density and distribution of the data used for GBD 2016. 
Prevalence Incidence Mortality risk 
Studies 11 47 3 
Countries/subnational units 57 46 3 
Regions 5 7 2 
Beyond the literature data, we also make use of claims data from the United States for 2000, 2010, and 
2012. Descriptions of the source and preparation of this data are provided elsewhere. 
Except for excluding studies using non-representative populations, there are no substantial adjustments 
or outliering criteria for the MND model. Certain studies have been outliered on a case-by-case basis due 
to subsequent review and exclusion due to inappropriateness of the study design and case definition. 
Severity splits 
To calculate severity and disability due to MND we analyzed a dataset from Pooled Resource Open-access 
ALS Clinical Trials (PRO-ACT). This dataset contains the largest ALS clinical trials dataset, with a total of 
8,635 ALS patient records from multiple completed clinical trials. Among these, we conducted the final 
analysis with n=4838 (56%) of the patients with complete ALS Function Rating Score (ALSFRS) with 
average follow-up time of 184 days (min: -22, max: 648), in which 2,999 (62%) received experimental 
(medication) treatments and 1,301 (27%) received placebo (in these trials, the medications tested were 
found to be no better than placebo with respect to their effects on ALS progressions). 
The ALSFRS is an instrument for evaluating the functional status of patients with Amyotrophic Lateral 
Sclerosis. It can be used to monitor functional changes in a patient over time. It measures (1) speech, (2) 
salivation, (3) swallowing, (4) handwriting, (5) cutting food and handling utensils (with or without 
gastrostomy), (6) dressing and hygiene, (7) turning in bed and adjusting bed clothes, (8) walking, (9) 
climbing stairs, and (10) breathing. Each task is rated on a 5-point scale from 0 = can’t do, to 4 = normal 
ability. Individual item scores are summed to produce a reported total score of between 0 and 40 (worst 
to best). ALSFRS has been revised to ALSFRS-R, which includes 12 questions (ALSFRS Q10 changes to (10) 
Dyspnea, (11) Orthopnea, and (12) Respiratory insufficiency), with individual item scores summed to a 
score between 0 and 48. 
In order to eliminate any bias from the treatment effects on the ALSFRS, only the first observation at the 
time of trial is selected. If the first observation is missing at the time of trial (or prior), the next non-
missing observation is selected to be included in the final analysis. 
We subsequently mapped ALSFRS scores into GBD severities, and sequelae into different combinations of 
speech problems, chronic obstructive pulmonary disease, and motor impairment using the following 
logic: 
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The ALSFRS assess motor function of the legs through questions on walking (Q8) and stair climbing (Q9). 
Combined score Severity level 
8 None 
5-7 Mild 
2-4 Moderate 
0-1 Severe 
The ALSFRS also assesses motor impairment through questions on handwriting (Q4), cutting food and 
handling utensils (Q5), and dressing and hygiene (Q6).  
Combined score Severity level 
12 None 
9-11 Mild 
3-8 Moderate 
0-2 Severe 
After determining case severity on these two separate metrics, we aggregate by taking the most severe 
ranking (eg, severe + mild = a severe case). 
Respiratory problems: 
Question 10 of the ALSFRS describes breathing difficulty as a function of MND. 
ALSFRS score Description Severity level 
4 Normal None 
3 Shortness of breath with 
minimal exertion 
Mild 
2 Shortness of breath at rest Moderate 
0-1 Intermittent ventilator 
assistance required/ventilator-
dependent 
Severe 
Speech problems 
Speech impairment due to MND is derived from ALSFRS question 1, which describes speech impediments. 
A score of 4 on this question denotes no impairment, while all other values suggest some impairment. 
Creating sequelae 
After determining the severity status of each case for the three symptom umbrellas, we subsequently 
estimated the relative proportion of each combination of symptom class and their respective severities. 
Those without any symptoms (eg, no severity) were categorized as having worry about the diagnosis for 
disability estimation. The following table displays the various sequelae and their associated proportions. 
Motor impairment 
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Mild motor impairment, mild respiratory problems and speech 
problems due to motor neuron disease 
0.01779 0.01658 0.01909 
Mild motor impairment, moderate respiratory problems and 
speech problems due to motor neuron disease 
0.00270 0.00225 0.00324 
Mild motor impairment, severe respiratory problems and 
speech problems due to motor neuron disease 
0.00082 0.00059 0.00113 
Mild motor impairment, and speech problems due to motor 
neuron disease 
0.02052 0.01922 0.02190 
Moderate motor impairment, mild respiratory problems and 
speech problems due to motor neuron disease 
0.03377 0.03210 0.03552 
Moderate motor impairment, moderate respiratory problems 
and speech problems due to motor neuron disease 
0.00715 0.00640 0.00799 
Moderate motor impairment, severe respiratory problems and 
speech problems due to motor neuron disease 
0.00286 0.00240 0.00342 
Moderate motor impairment, and speech problems due to 
motor neuron disease 
0.03041 0.02883 0.03208 
Severe motor impairment, mild respiratory problems and 
speech problems due to motor neuron disease 
0.05242 0.05035 0.05457 
Severe motor impairment, moderate respiratory problems and 
speech problems due to motor neuron disease 
0.02247 0.02111 0.02392 
Severe motor impairment, severe respiratory problems and 
speech problems due to motor neuron disease 
0.01365 0.01259 0.01479 
Severe motor impairment and speech problems due to motor 
neuron disease 
0.04765 0.04567 0.04970 
Mild respiratory problems and speech problems due to motor 
neuron disease 
0.01157 0.01060 0.01263 
Moderate respiratory problems and speech problems due to 
motor neuron disease 
0.00142 0.00111 0.00182 
Severe respiratory problems and speech problems due to 
motor neuron disease 
0.00023 0.00013 0.00043 
Speech problems due to motor neuron disease 0.02457 0.02315 0.02608 
Mild motor impairment and mild respiratory problems due to 
motor neuron disease 
0.02245 0.02109 0.02389 
Mild motor impairment and moderate respiratory problems 
due to motor neuron disease 
0.00275 0.00230 0.00329 
Mild motor impairment and severe respiratory problems due 
to motor neuron disease 
0.00068 0.00047 0.00097 
Mild motor impairment due to motor neuron disease 0.10388 0.10103 0.10681 
Moderate motor impairment and mild respiratory problems 
due to motor neuron disease 
0.06744 0.06511 0.06985 
Moderate motor impairment and moderate respiratory 
problems due to motor neuron disease 
0.01302 0.01199 0.01413 
Moderate motor impairment and severe respiratory problems 
due to motor neuron disease 
0.00412 0.00356 0.00477 
Moderate motor impairment due to motor neuron disease 0.20136 0.19760 0.20518 
Sequela Proportion 
(Mean) 
Proportion 
(Lower) 
Proportion 
(Upper) 
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Severe motor impairment and mild respiratory problems due 
to motor neuron disease 
0.06902 0.06666 0.07146 
Severe motor impairment and moderate respiratory problems 
due to motor neuron disease 
0.02000 0.01872 0.02137 
Severe motor impairment and severe respiratory problems due 
to motor neuron disease 
0.01062 0.00969 0.01163 
Severe motor impairment due to motor neuron disease 0.15037 0.14702 0.15378 
Mild respiratory problems due to motor neuron disease 0.00643 0.00571 0.00723 
Moderate respiratory problems due to motor neuron disease 0.00044 0.00028 0.00069 
Severe respiratory problems due to motor neuron disease 0.00005 0.00001 0.00017 
Asymptomatic, but worry about diagnosis due to motor neuron 
disease 
0.03738 0.03562 0.03921 
 
To determine disability due to these sequelae, we use the standard multiplicative aggregation formula as 
described in the main text. The following table provides description and disability weight assigned to the 
sequelae as appropriate. 
Symptom 
group 
Severity level Lay description DW (95%) 
Respiratory 
problems 
Asymptomatic 
  
Respiratory 
problems 
Mild Has cough and shortness of breath after 
heavy physical activity, but is able to 
walk long distances and climb stairs. 
0.019 
(0.011–0.033) 
Respiratory 
problems 
Moderate Has cough, wheezing, and shortness of 
breath, even after light physical activity. 
The person feels tired and can walk only 
short distances or climb only a few 
stairs. 
0.225 
(0.153–0.31) 
Respiratory 
problems 
Severe Has cough, wheezing, and shortness of 
breath all the time. The person has 
great difficulty walking even short 
distances or climbing any stairs, feels 
tired when at rest, and is anxious. 
0.408 
(0.273–0.556) 
Motor 
impairment 
Asymptomatic 
  
Motor 
impairment 
Mild Has some difficulty in moving around 
but is able to walk without help. 
0.01 
(0.005–0.019) 
Motor 
impairment 
Moderate Has some difficulty in moving around 
and difficulty in lifting and holding 
objects, dressing, and sitting upright, 
but is able to walk without help. 
0.061 
(0.04–0.089) 
Motor 
impairment 
Severe Is unable to move around without help, 
and is not able to lift or hold objects, 
get dressed, or sit upright.  
0.402 
(0.268–0.545) 
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Speech 
problems 
No 
  
Speech 
problems 
Yes Has difficulty speaking, and others find 
it difficult to understand.  
0.051 
(0.032–0.078) 
Asymptomatic, 
but worry 
Yes Has a disease diagnosis that causes 
some worry but minimal interference 
with daily activities. 
0.012 
(0.006–0.023) 
 
Modelling strategy  
We use DisMod 2.1 as the main analytical tool for MND estimation. Prior settings are limited to 0 
remission at all ages. We also constrain the super-region random effects for prevalence and incidence to -
0.5 and 0.5 to account for spurious inflation of regional differences. 
 
Claims data for 2000 and 2010 are adjusted via study covariates to account for systematically low 
estimates relative to the 2012 claims data. Implicit in this adjustment is the assumption that variation 
between years of claims data is a function of data collection inconsistencies and noise. 
 
Similar to other cases we use GBD estimates of cause-specific mortality rate (CSMR) and Excess Mortality 
Rate (EMR) in this model. The source and estimation of these rates are discussed elsewhere. 
 
To assist the estimation process we use several country-level covariates. 
 
Covariate Measure Beta Exponentiated 
Absolute value of average 
latitude 
prevalence .014 
(.012 - .016) 
1.01 
(1.01 - 1.02) 
LDI (I$ per capita) excess 
mortality rate 
-.5 
(-.5 - -.5) 
.61 
(.61 - .61) 
All MarketScan, year 2010 prevalence -.017 
(-.038 - -.0014) 
.98 
(.96 – 1.00) 
All MarketScan, year 2000 prevalence -.026 
(-0.054 - -.0037) 
.97 
(.95 - 1.00) 
 
Although there are no known cures for MND, we expect disease management to differ globally – largely 
as a function of available resources. To capture this, we use the natural log of lagged distributed income 
per capita as a proxy to capture this relationship in the estimation of excess mortality.  
 
As described in the literature, extreme latitude may be associated with higher prevalence and incidence 
of motor neuron disease. While the pathway that affects motor neuron disease is not fully understood, 
our results suggest a relationship. Our operationalization of latitude is created by a population-weighted 
average of latitude by country and taking the absolute value. The underlying population distribution 
rasters are part of the Gridded Population of the World dataset. 
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 Other neurological disorders 
In addition to the neurological disorders described above, there are many diverse types of neurological 
disorders with a range of severities and associated sequelae. Because these neurological disorders are 
diverse in their underlying causes and risk factors as well as in their associated health outcomes, 
modelling them together in a DisMod-MR model would not produce reliable estimates of prevalence or 
excess mortality. Instead, we calculated the YLDs caused by neurological disorders directly using a 
YLD/YLL ratio.  
We calculated the ratio of YLDs to YLLs across the specified neurological disorders for which nonfatal 
outcomes were modelled, using YLL estimates from the GBD 2016 cause of death (CoD) analysis. We then 
multiplied this YLD/YLL ratio by the YLL estimates for other neurological disorders from the GBD 2016 CoD 
analysis, providing us with an estimate of the YLDs associated with other neurological disorders. 
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Case Definition 
Schizophrenia is a chronic psychotic disorder which involves the experience of positive symptoms (eg, 
delusions, hallucinations, thought disorder) and negative symptoms (eg, flat affect, loss of interest, and 
emotional withdrawal). Included in the GBD disease modelling were cases meeting the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV-TR) or the International Classification of Diseases (ICD-
10) diagnostic criteria for schizophrenia (DSM: 295.10-295.30, 295.60, 295.90; ICD: F20.9).1,2 Diagnostic 
criteria are: 
A. Two (or more) of the following, each present for a significant portion of time during a one-
month period (or less if successfully treated):  
1. Delusions 
2. Hallucinations 
3. Disorganized speech 
4. Grossly disorganized or catatonic behavior 
5. Negative symptoms 
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B. Social/occupational dysfunction 
C. Continuous signs of the disturbance persist for at least 6 months. 
D. Exclusions must be met for schizoaffective and mood disorders, substance and general medical 
conditions, and a relationship to a pervasive development disorder. 
 
Input data 
Model Inputs 
For GBD 2015 a systematic review of literature was conducted to capture studies of prevalence, 
incidence, remission, duration, and excess mortality associated with schizophrenia. In summary, the 
search was conducted in three stages involving searches of the peer-reviewed literature (via Medline, 
Embase and PubMed), the grey literature, and expert consultation. The inclusion criteria stipulated that: 
(1) the publication year must be from 1980 onward; (2) “caseness” must be based on clinical threshold 
as established by the DSM or ICD; (3) sufficient information must be provided on study method and 
sample characteristics to assess the quality of the study; and (4) study samples must be representative 
of the general population (ie, inpatient or pharmacological treatment samples, case studies, veterans or 
refugee samples were excluded). No limitation was set on the language of publication. In GBD 2016, a 
complete review of data sources logged in the Global Health Index (GHDx) was undertaken. This led to 
the inclusion of data from an additional 23 data sources. 
The table below shows the number of studies included in GBD 2016, as well as the number of countries 
or subnational units and GBD world regions represented. 
 Prevalence Incidence Duration Excess 
mortality 
Studies 64 30 5 37 
Countries/subnational geographies 52 27 17 35 
GBD world regions 12 7 8 11 
 
Age and sex splitting 
In GBD 2016 reported estimates of prevalence were split by age and sex where possible. Firstly, if 
studies reported prevalence for broad age groups by sex (eg, prevalence in 15 to 65 year old males and 
females separately), and also by specific age groups but for both sexes combined (eg, prevalence in 15 
to 30 year olds, then in 31 to 65 year olds, for males and females combined); age-specific estimates 
were split by sex using the reported sex ratio and bounds of uncertainty. Secondly, where studies 
reported estimates across age groups spanning 20 years or more, these were split into five-year age 
groups using the prevalence age pattern estimated by DisMod-MR.  
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Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for 
schizophrenia severity levels are shown below. 
 
Severity level Lay description DW (95% CI) 
acute state Hears and sees things that are not real and is afraid, confused, 
and sometimes violent. The person has great difficulty with 
communication and daily activities, and sometimes wants to 
harm or kill himself (or herself). 
0.778 
(0.606–0.9) 
residual state Hears and sees things that are not real and has trouble 
communicating. The person can be forgetful, has difficulty 
with daily activities, and thinks about hurting himself (or 
herself). 
0.588 
(0.411–0.754) 
 
Severity splits used in GBD 2016 were consistent with those used in GBD 2013 for schizophrenia. 
Information on the distribution of acute and residual states of schizophrenia was obtained from a 
separate systematic review of the literature.4 Meta-XL (a Microsoft Excel add-in for meta-analysis) was 
used to pool estimates across all studies to calculate the overall proportion of schizophrenia cases in 
each health state – acute 63% (29%–91%) and residual state 37% (9%–71%). 
Modelling strategy 
The GBD 2016 epidemiological modelling strategy for schizophrenia made use of DisMod-MR 2.1 to 
estimate prevalence by age, sex, year, and country. Data across all epidemiological parameters were 
included in the modelling process. We assumed no incidence and prevalence before age 10 and after 
age 80. This minimum age of onset was corroborated with expert feedback and existing literature on 
schizophrenia. Remission was also restricted to a maximum of 0.04 as guided by data available in the 
dataset. 
Study-level covariates can be used in DisMod-MR 2.1 to accommodate for between-study variability in 
the raw prevalence data. In GBD 2016 tested covariates failed to demonstrate significance resulting in a 
model without the inclusion of any covariates.  
A location-level covariate, LDI, was also included. This covariate represents a moving average of gross 
domestic product (GDP) over time. LDI was also applied to excess mortality data with a negative 
relationship assumed. The table below illustrates the covariate, parameter, beta and exponentiated 
beta values for the model. 
 
Location-level covariate Parameter beta Exponentiated beta 
LDI Excess mortality rate -0.55 (-1 — -0.1) 0.58 (0.37 — 0.90) 
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Alcohol dependence 
 
Flowchart 
 
 
Case definition 
Alcohol dependence is a substance-related disorder involving a dysfunctional pattern of alcohol use. 
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for alcohol 
dependence, at least three out of seven of the following criteria must be manifested during a 12-month 
period: 
 Tolerance 
 Withdrawal symptoms or clinically defined alcohol withdrawal syndrome 
 Use in larger amounts or for longer periods than intended 
 Persistent desire or unsuccessful efforts to cut down on alcohol use 
 Time is spent obtaining alcohol or recovering from effects 
 Social, occupational, and recreational pursuits are given up or reduced because of alcohol use 
 Use is continued despite knowledge of alcohol-related harm (physical or psychological) 
The DSM-IV codes for alcohol dependence is 303.90, and the corresponding International Classification 
of Diseases (ICD-10) codes are F10.1 and F10.2.1,2 
 
404
Input data 
Model inputs 
In GBD 2013 and GBD 2016, systematic reviews of literature were conducted to capture studies of 
prevalence, incidence, remission, duration, and excess mortality associated with alcohol dependence. In 
summary, the search was conducted in three stages involving searches of the peer-reviewed literature 
(via Medline, Embase, and PubMed), the grey literature, and expert consultation.  
The inclusion criteria stipulated that (1) “caseness” must be based on clinical threshold as established by 
the DSM and ICD; (2) sufficient information must be provided on study method and sample 
characteristics to assess the quality of the study; and (3) study samples must be representative of the 
general population (ie, inpatient or pharmacological treatment samples (accepted for estimates of 
mortality), case studies, veterans or refugee samples were excluded).  
An adjustment was made outside of DisMod-MR 2.1 to adjust past-year prevalence estimates of alcohol 
dependence toward the level they would have been had the study measured point prevalence, as the 
latter is less susceptible to recall bias. Given that remission from alcohol dependence (and hence, 
average disease duration) vary considerably with age, we also applied an age pattern to this adjustment 
that cannot be replicated within DisMod-MR 2.1 by use of covariates. The first step was to estimate the 
average duration by taking the inverse of remission. Next, we applied an adjustment factor from one-
year to point prevalence using the following formula where average duration is expressed in years: adjustment factor =  average durationaverage duration +  1 
Age-specific adjustment factors were applied to all one-year prevalence estimates propagating sampling 
uncertainty around the prevalence and remission input data through to the final adjusted prevalence 
estimates. 
Prevalence estimates were split by age and sex where possible outside of DisMod-MR 2.1. Firstly if 
studies reported prevalence for broad age groups by sex (eg, prevalence in 15 to 65 year old males and 
females separately), and also by specific age groups but for both sexes combined (eg, prevalence in 15 
to 30 year olds, then in 31 to 65 year olds, for males and females combined); age-specific estimates 
were split by sex using the reported sex ratio and bounds of uncertainty. Secondly, where studies 
reported estimates across age groups spanning 20 years or more, these were split into five-year age 
groups using the regional prevalence age pattern estimated by DisMod-MR 2.1. 
The final dataset for GBD 2016 included 5,140 prevalence estimates, 25 incidence estimates, 14 
remission estimates, and 87 excess mortality estimates. The table below shows the number of studies 
for each parameter as well as the number of countries/subnationals and GBD world regions covered by 
the available data. 
 
 Prevalence Incidence Remission Mortality 
Studies 185 3 4 38 
Countries/subnationals 202 3 4 23 
GBD world regions 19 3 3 6 
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Severity splits & disability weights 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for alcohol 
dependence severity levels are shown below. 
 
Severity level Lay description DW (95% CI) 
Very mild Drinks alcohol daily and has difficulty controlling the 
urge to drink. When sober, the person functions 
normally. 
0.123 
(0.082–0.177) 
Mild  Drinks a lot of alcohol and sometimes has difficulty 
controlling the urge to drink. While intoxicated, the 
person has difficulty performing daily activities. 
0.235 
(0.16–0.327) 
Moderate Drinks a lot, gets drunk almost every week and has 
great difficulty controlling the urge to drink. Drinking 
and recovering cause great difficulty in daily activities, 
sleep loss, and fatigue.  
0.373 
(0.248–0.508) 
Severe Gets drunk almost every day and is unable to control 
the urge to drink. Drinking and recovering replace most 
daily activities. The person has difficulty thinking, 
remembering and communicating, and feels constant 
pain and fatigue. 
0.57 
(0.396–0.732) 
*asymptomatic cases carried no disability weight 
Severity splits used in GBD 2016 were consistent with those used in GBD 2015. The United States’ 
Medical Expenditure Panel Survey (MEPS, conducted in annual waves since 1996)3, the US National 
Epidemiological Survey on Alcohol and Related Conditions (NESARC, conducted in two waves from 
2001–2002 and 2004–2005)4, and the Australian National Survey of Mental Health and Wellbeing of 
Adults (NSMHWB, conducted in 1997)5 were used to estimate the proportion of alcohol dependence 
cases in the asymptomatic 40.9% (38.4%–43.3%); very mild 46.9% (43.7%–50.0%); mild 4.0% (1.8%–
5.8%); moderate 3.4% (2.3%–4.5%); and severe 4.8% (3.0%–7.0%) disease categories. 
 
Modelling strategy 
The GBD 2016 epidemiological modelling strategy for alcohol dependence made use of DisMod-MR 2.1 
to estimate prevalence by age, sex, year, and location. Standardized mortality ratio and relative risk data 
were excluded in the modelling process. Instead we pulled in cause-specific mortality rate (CSMR) data 
from our CODEm and CODcorrect analyses and matched it with prevalence data points for the same 
geography and study year to estimate priors on excess mortality rates (by dividing CSMR by prevalence). 
We assumed no incidence and mortality before age 10. An upper limit of 0.6 was placed on remission (in 
line with data from the US National Epidemiological Survey on Alcohol and Related Conditions (NESARC) 
as well as a declining trend with age to restrict DisMod-MR 2.1 from straying too far from the data 
inputs. 
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Within DisMod-MR 2.1, study-level covariates were used to accommodate for other sources of 
between-study variability in the raw prevalence data. Combined abuse and dependence prevalence 
estimates were crosswalked down toward dependence-only estimates. Similarly, prevalence estimates 
using AUDIT were crosswalked down toward prevalence estimates from diagnostic (non-AUDIT) 
measures.  
Country-level covariates were also included. The LDI covariate represents a moving average of gross 
domestic product (GDP) over time. LDI was also applied to excess mortality data with a negative 
relationship assumed. Alcohol consumption was also represented by a covariate representing this in 
terms of litres of alcohol per capita. 
 
Study/country covariate Parameter beta Exponentiated beta 
Aabuse and dependence Prevalence 0.78 (0.66 — 0.92) 2.19 (1.93 — 2.50) 
AUDIT Prevalence 1.33 (1.24 — 1.41) 3.77 (3.47 — 4.08) 
Alcohol (litres per capita) Prevalence 0.50 (0 — 1.00) 1.65 (1.00 — 2.72) 
LDI (I$ per capita) Excess mortality -0.11 (-0.14 — -0.1) 0.89 (0.87 — 0.90) 
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Fetal alcohol syndrome 
 
Flowchart 
 
Input data and methodological summary 
 
Case definition 
Fetal alcohol syndrome (FAS; ICD-10: Q86.0) is a disorder caused by maternal drinking during pregnancy 
and is the most severe form of fetal alcohol spectrum disorder (FASD). In GBD, only FAS cases were 
included in the model. Other manifestations of FASD including partial fetal alcohol syndrome, alcohol-
related neurodevelopmental disorder, and alcohol-related birth defects were not included. FAS is 
characterized by maternal alcohol exposure which results in certain patterns of facial anomalies such as 
short palpebral fissures and abnormalities in the premaxillary zone (eg, flat upper lip, flattened philtrum, 
and flat midface), growth retardation (eg, decelerating weight over time not due to nutrition), and central 
nervous system neurodevelopmental abnormalities (eg, decreased cranial size at birth) in the offspring.1 
Cases were defined according to diagnostic guidelines set by the US institute of Medicine, the British 
Pediatric Association, and other recognized bodies in the area. 
Input data 
 Model inputs 
A series of systematic literature reviews were conducted to capture studies reporting the prevalence, 
incidence, remission, and excess mortality of FAS. The reviews incorporated searches of peer-reviewed 
literature via electronic databases and consultation with experts. In order for a study to be included, it 
must use recognized classifications of FAS (eg, the US Institute of Medicine) and provide sufficient details 
on study methodology and sample characteristics to determine study quality. No limitation was set on the 
language of publication. Data from the European Surveillance of Congenital Anomalies (EUROCAT) were 
also included and updated where relevant. This methodology was utilized in GBD 2015. Updates to 
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systematic reviews are performed on an ongoing schedule across all GBD causes, an update for FAS will 
be performed in the next 1-2 iterations. The final dataset for GBD 2016 included 175 prevalence 
estimates and 13 excess mortality estimates (from studies of individuals with intellectual disability). 
 Prevalence Mortality 
Studies 81 5 
Countries/subnationals 53 4 
GBD world regions 10 3 
 
 Severity split inputs 
There were no data available which gave prevalence of FAS by severity. As such, severity splits for FAS 
were calculated by matching FAS severity to categories of IQ in children for which prevalence data are 
available. Severe FAS was matched to an IQ of less than 50, moderate FAS to an IQ of 50 to 69, mild FAS 
to an IQ of 74 to 84, and asymptomatic FAS to an IQ of 85 or higher. Prevalence data for these IQ levels 
were then used to calculate severity splits for FAS. 
Severity level Lay description DW (95% CI) 
Mild Is a little slow in developing physically 
and mentally, which causes some 
difficulty in learning but no other 
difficulties in daily activities. 
0.016 (0.008–0.03) 
Moderate Is slow in developing physically and 
mentally, which causes some difficulty in 
daily activities. 
0.056 (0.035–0.083) 
Severe Is very slow in developing physically and 
mentally, which causes great difficulty in 
daily activities. 
0.179 (0.119–0.257) 
 
Modelling strategy  
Prevalence was set to begin from birth. Incidence was set to zero given cases cannot manifest after birth 
(despite the fact they may not be diagnosed immediately at birth). Remission was also set to zero. A 
covariate was included in the model which addressed the heterogeneity introduced by different case-
finding methods, ie, active versus passive case-finding. Estimates from known high-drinking populations 
(eg, indigenous populations) were not considered representative of the general population and were 
excluded. A country-level covariate was included for GBD 2016 representing the log proportion of 
pregnant women who drink during their pregnancy, estimated from a meta-analysis.2 
The table below illustrates the covariate, parameter, beta and exponentiated beta values for the model. 
Study/country  covariate Parameter beta Exponentiated beta 
Passive case finding Prevalence 0.39 (0.0046–1.14) 1.48 (1.00–3.14) 
Maternal drinking Prevalence 0.66 (0.014–1.45) 1.93 (1.01–4.25) 
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Opioid dependence 
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Case Definition 
Opioid dependence is a substance-related disorder involving a dysfunctional pattern of opioid use. 
Included in the GBD disease modelling were cases meeting the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV-TR) or the International Classification of Diseases (ICD-10) diagnostic criteria 
for opioid dependence (DSM: 304.00; ICD: F11.2), excluding those cases due to a general medical 
condition.1,2 According to DSM-IV TR criteria, dependence involves a maladaptive pattern of substance 
use leading to clinically significant impairment or distress. At least three of the following symptoms must 
be experienced within the same 12-month period: 
• Tolerance, characterized by either 
o a need for increased amounts of the substance to achieve intoxication; or 
o markedly diminished effect with continued use of the same amount of the substance;  
• Withdrawal, characterized by either 
o Withdrawal symptoms characteristic to dependence; or 
o the same (or similar) substance is taken to avoid withdrawal symptoms; 
• Substance taken in progressively larger amounts or for longer period; 
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• Persistent desire or unsuccessful efforts to reduce substance use; 
• Disproportionate time dedicated to obtaining the substance; 
• Other important activities are given up because of the substance use; and 
• Substance use is continued despite knowledge of physical or psychological problems occurring as 
a result of the substance. 
 
Input data 
 Model inputs 
A systematic review of the literature was conducted to capture studies of prevalence, incidence, 
remission, and excess mortality associated with opioid dependence. In summary, the search was 
conducted in three stages involving searches of the peer-reviewed literature (via Medline, Embase, and 
Pubmed), the grey literature and, expert consultation. The agreed-upon approach for mental and 
substance use disorders was to conduct electronic database searches on a rolling basis. All three stages of 
GBD 2010’s literature review were repeated for GBD 2013 to capture additional data published up to 
2013. For GBD 2015, stages 2 and 3 of the literature review were updated, and in GBD 2016, the peer-
reviewed database search (stage 1) was conducted via Medline, Embase, and Psycinfo to capture studies 
published from 2013 to 2016.  
 
The inclusion criteria stipulated that 1) the publication year must be from 1980 onward; 2) “caseness” 
must be based on clinical threshold as established by the DSM or ICD; 3) sufficient information must be 
provided on study method and sample characteristics to assess the quality of the study; and (4) study 
samples must be representative of the general population (ie, inpatient or pharmacological treatment 
samples, case studies, veterans or refugee samples were excluded). No limitation was set on the language 
of publication. Methods used for this systematic review have been reported in greater detail elsewhere.3,4 
The table below shows the number of studies included, as well as the number of countries or subnational 
units and GBD world regions represented. 
 Prevalence Remission Mortality 
rate 
Studies 66 8 41 
Countries/subnational geographies 191 25 22 
GBD world regions 10 5 6 
 
Age and sex splitting 
In GBD 2016, reported estimates of prevalence were split by age and sex where possible. First, if studies 
reported prevalence for broad age groups by sex (eg, prevalence in 15 to 65 year old males and females 
separately), and also by specific age groups but for both sexes combined (eg, prevalence in 15 to 30 year 
olds, then in 31 to 65 year olds, for males and females combined); age-specific estimates were split by sex 
using the reported sex ratio and bounds of uncertainty. Second, where studies reported estimates across 
age groups spanning 20 years or more, these were split into five-year age groups using the prevalence 
age pattern estimated by DisMod MR.  
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 Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for opioid 
dependence severity levels are shown below. 
 
Severity level Lay description DW (95% CI) 
Mild Uses heroin (or methadone) daily and has difficulty 
controlling the habit. When not using, the person 
functions normally. 
0.335 (0.221–0.473) 
Moderate to 
severe 
Uses heroin daily and has difficulty controlling the habit. 
When the effects wear off, the person feels severe 
nausea, agitation, vomiting, and fever. The person has a 
lot of difficulty in daily activities. 
0.697 (0.510–0.843) 
 
The proportion of people with opioid dependence within each of the severity levels was determined 
based on available data from US National Epidemiological Survey on Alcohol and Related Conditions 
(NESARC), conducted in two waves from 2001–2002 and 2004–2005,5 and the Comorbidity and Trauma 
study conducted in 2005-2008.6,7 The estimated distribution of opioid dependent cases by severity were 
asymptomatic (16%, 13%–19%), mild (37%, 20%–55%), and moderate/severe (47%, 29%–64%). 
 
Modelling Strategy 
We ran a DisMod-MR model to produce estimates by age, sex, year, and country. We assumed no 
incidence and excess mortality before age 15. This minimum age of onset was corroborated with expert 
feedback and existing literature on opioid dependence. We also assumed no incidence after age 64 as 
supported by data from various sources including the European Monitoring Centre for Drugs and Drug 
Addiction.8 An upper limit of 0.2 was placed on remission consistent with limits in the dataset. Cause-
specific mortality rates (CSMR) from the GBD 2016 cause of death model for opioid use disorders were 
included as data points in the DisMod-MR model.     
The prevalence dataset included data points using “direct” or “indirect” survey methods. “Direct” 
methods of measuring opioid dependence predominantly involve surveys of the general population that 
ask if respondents use or are dependent on opioid. Surveys tend to underestimate the prevalence of the 
most harmful and stigmatized forms of illicit drug use in ways that probably vary between countries and 
cultures.9 “Indirect” methods are considered superior; they use different sources of data to indirectly 
estimate the total number of drug users (methods include “multiplier methods,” back-projection and 
capture-recapture methods). Due to insufficient data on dependence from indirect survey methods 
(considered to be the gold standard for GBD purposes), estimates derived from direct survey methods 
were included in the modelling. The cv_direct covariate was then used to adjust for whether a direct or 
indirect survey method was used. A crosswalk was estimated to convert all dependence estimates 
obtained via direct methods in the dataset, into its equivalent value if the study had measured 
dependence estimates obtained via indirect methods. A direct:indirect dependence ratio of 0.39 (0.22–
0.78) was calculated by DisMod-MR based on comparable direct and indirect dependence estimates in 
the dataset.  
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 Betas and exponentiated values (which can be interpreted as an odds ratio) for each study-level covariate 
are shown in the table below: 
Study covariate Parameter beta Exponentiated beta 
cv_direct Prevalence -0.95 (-0.95 – -0.95) 0.39 (0.39–0.39) 
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Case Definition 
Cocaine dependence is a substance-related disorder involving a dysfunctional pattern of cocaine use. 
Included in the GBD disease modelling were cases meeting the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV-TR) or the International Classification of Diseases (ICD-10) diagnostic criteria 
for cocaine dependence (DSM: 304.20; ICD: F14.2), excluding those cases due to a general medical 
condition.1,2 According to DSM-IV TR criteria, dependence involves a maladaptive pattern of substance 
use leading to clinically significant impairment or distress. At least three of the following symptoms must 
be experienced within the same 12-month period: 
• Tolerance, characterized by either 
o a need for increased amounts of the substance to achieve intoxication; or 
o markedly diminished effect with continued use of the same amount of the substance;  
• Withdrawal, characterized by either 
o Withdrawal symptoms characteristic to dependence; or 
o the same (or similar) substance is taken to avoid withdrawal symptoms; 
• Substance taken in progressively larger amounts or for longer period; 
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• Persistent desire or unsuccessful efforts to reduce substance use; 
• Disproportionate time dedicated to obtaining the substance; 
• Other important activities are given up because of the substance use; and 
• Substance use is continued despite knowledge of physical or psychological problems occurring as 
a result of the substance. 
 
Input data 
 Model inputs 
A systematic review of the literature was conducted to capture studies of prevalence, incidence, 
remission, and excess mortality associated with cocaine dependence. In summary, the search was 
conducted in three stages involving searches of the peer-reviewed literature (via Medline, Embase, and 
Pubmed), the grey literature and, expert consultation. The agreed-upon approach for mental and 
substance use disorders was to conduct electronic database searches on a rolling basis. All three stages of 
GBD 2010’s literature review were repeated for GBD 2013 to capture additional data published up to 
2013. For GBD 2015, stages 2 and 3 of the literature review were updated and in GBD 2016, the peer-
reviewed database search (stage 1) was conducted via Medline, Embase, and Psycinfo to capture studies 
published from 2013 to 2016. 
The inclusion criteria stipulated that 1) the publication year must be from 1980 onward; 2) “caseness” 
must be based on clinical threshold as established by the DSM or ICD; 3) sufficient information must be 
provided on study method and sample characteristics to assess the quality of the study; and (4) study 
samples must be representative of the general population (ie, inpatient or pharmacological treatment 
samples, case studies, veterans or refugee samples were excluded). No limitation was set on the language 
of publication. Methods used for this systematic review have been reported in greater detail elsewhere.3,4 
The table below shows the number of studies included, as well as the number of countries or subnational 
units and GBD world regions represented. 
 Prevalence Remission Standardized 
mortality 
ratio, with-
condition 
mortality 
rate 
Studies 118 3 7 
Countries/subnational geographies 274 3 7 
GBD world regions 15 2 3 
 
Age and sex splitting 
In GBD 2016, reported estimates of prevalence were split by age and sex where possible. First, if studies 
reported prevalence for broad age groups by sex (eg, prevalence in 15 to 65 year old males and females 
separately), and also by specific age groups but for both sexes combined (eg, prevalence in 15 to 30 year 
olds, then in 31 to 65 year olds, for males and females combined); age-specific estimates were split by sex 
using the reported sex ratio and bounds of uncertainty. Second, where studies reported estimates across 
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age groups spanning 20 years or more, these were split into five-year age groups using the prevalence 
age pattern estimated by DisMod-MR.  
 Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for cocaine 
dependence severity levels are shown below. 
 
Severity level Lay description DW (95% CI) 
Mild Uses cocaine at least once a week and has some difficulty 
controlling the habit. When not using, the person 
functions normally. 
0.116 (0.074–0.165) 
Moderate to 
severe 
Uses cocaine and has difficulty controlling the habit. The 
person sometimes has mood swings, anxiety, paranoia, 
hallucinations and sleep problems, and has some 
difficulty in daily activities. 
0.479 (0.324–0.634) 
 
The proportion of people with cocaine dependence within each of the severity levels were determined 
based on available data from US National Epidemiological Survey on Alcohol and Related Conditions 
(NESARC), conducted in two waved from 2001-2002 and 2004-2005 5. The estimated distribution of 
cocaine dependent cases by severity were asymptomatic (50%, 37%—64%), mild (25%, 18%—33%), and 
moderate/severe (25%, 17%—33%). 
 
Modelling Strategy 
We ran a DisMod-MR model to produce estimates by age, sex, year, and country. We assumed no 
incidence, remission, and excess mortality before age 15, and an upper limit of 0.2 on remission. The 
minimum age of onset was corroborated with expert feedback and existing literature from various 
sources including the European Monitoring Centre for Drugs and Drug Addiction.6 Cause-specific 
mortality rates (CSMR) from the GBD 2016 cause of death model for cocaine use disorders was included 
as data points in the DisMod-MR model.    
The prevalence dataset included data points of both use and dependence estimated using “direct” or 
“indirect” survey methods. “Direct” methods of measuring amphetamine dependence predominantly 
involve surveys of the general population that ask if respondents use or are dependent on amphetamine. 
Surveys tend to underestimate the prevalence of the most harmful and stigmatized forms of illicit drug 
use in ways that probably vary between countries and cultures.7 “Indirect” methods are considered 
superior; they use different sources of data to indirectly estimate the total number of drug users 
(methods include “multiplier methods,” back-projection and capture-recapture methods). Due to the lack 
of data available on cocaine dependence from indirect survey methods (considered to be the gold 
standard for GBD purposes), estimates of use and/or estimates from direct survey methods were 
included in the modelling. Study-level covariates were then used to accommodate for between-study 
variability in the raw prevalence data. The cv_direct use covariate was used to adjust for whether direct 
or indirect survey methods were used. This converted all use estimates obtained via direct methods in 
the dataset, into its equivalent value if the study had measured dependence estimates obtained via 
indirect methods. A ratio of direct use:indirect dependence was calculated by comparing similar direct 
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use and indirect dependence estimates in the dataset. To allow for meaningful comparisons, paired direct 
use and indirect dependence estimates needed to be similar in terms of the country they were from, 
year, age group, sex, and prevalence type. To maximize the number of data points available for this ratio 
paired estimates for psychostimulants (ie, both cocaine and amphetamine) were used. Once a dataset 
was set up with paired direct use and indirect dependence estimates, MetaXL (a meta-analysis add-in for 
Microsoft Excel) was utilized to estimate a ratio of direct use:indirect dependence, whereby direct use 
estimates were found to be 3.6 (2.6–5.2) times higher than indirect dependence estimates. This ratio was 
used in DisMod-MR to adjust all use estimates in the dataset downward, toward the level they would 
have been had the study reported indirect dependence. A similar method was used to adjust prevalence 
estimates of cocaine dependence obtained via direct methods toward the level they would have been 
had the study measured cocaine dependence using indirect methods. The estimated ratio of direct 
dependence: indirect dependence was 0.5 (0.2–1.1). 
Betas and exponentiated values (which can be interpreted as an odds ratio) for each study-level covariate 
are shown in the table below: 
Study covariate Parameter beta Exponentiated beta 
cv_direct use Prevalence 1.29 (1.29–1.29) 3.63 (3.63–3.63) 
cv_direct dependence Prevalence -0.68 (-0.68 – -0.68) 0.51 (0.51–0.51) 
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 Amphetamine dependence 
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Case definition 
Amphetamine dependence is a substance-related disorder involving a dysfunctional pattern of 
amphetamine use. Included in the GBD disease modelling were cases meeting the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV-TR) or the International Classification of Diseases (ICD-10) 
diagnostic criteria for amphetamine dependence (DSM: 304.40; ICD: F15.2), excluding those cases due to 
a general medical condition.1,2 According to DSM-IV TR criteria, dependence involves a maladaptive 
pattern of substance use, leading to clinically significant impairment or distress. At least three of the 
following symptoms must be experienced within the same 12-month period: 
 Tolerance, characterized by either 
o a need for increased amounts of the substance to achieve intoxication; or 
o markedly diminished effect with continued use of the same amount of the substance;  
 Withdrawal, characterized by either 
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o Withdrawal symptoms characteristic to dependence; or 
o the same (or similar) substance is taken to avoid withdrawal symptoms; 
 Substance taken in progressively larger amounts or for longer period; 
 Persistent desire or unsuccessful efforts to reduce substance use; 
 Disproportionate time dedicated to obtaining the substance; 
 Other important activities are given up because of the substance use; and 
 Substance use is continued despite knowledge of physical or psychological problems occurring as 
a result of the substance. 
 
Input data 
 Model inputs 
A systematic review of the literature was conducted to capture studies of prevalence, incidence, 
remission, and excess mortality associated with amphetamine dependence. In summary, the search was 
conducted in three stages involving searches of the peer-reviewed literature (via Medline, Embase and 
Pubmed), the grey literature and, expert consultation. The agreed-upon approach for mental and 
substance use disorders was to conduct electronic database searches on a rolling basis. All three stages of 
GBD 2010’s literature review were repeated for GBD 2013 to capture additional data published up to 
2013. For GBD 2015, stages 2 and 3 of the literature review were updated and in GBD 2016, the peer-
reviewed database search (stage 1) was conducted via Medline, Embase and Psycinfo to capture studies 
published from 2013 to 2016. 
The inclusion criteria stipulated that: 1) the publication year must be from 1980 onward; 2) “caseness” 
must be based on clinical threshold as established by the DSM or ICD; 3) sufficient information must be 
provided on study method and sample characteristics to assess the quality of the study; and (4) study 
samples must be representative of the general population (ie, inpatient or pharmacological treatment 
samples, case studies, veterans, or refugee samples were excluded). No limitation was set on the 
language of publication. Methods used for this systematic review have been reported in greater detail 
elsewhere.3,4 The table below shows the number of studies included, as well as the number of countries 
or subnational units and GBD world regions represented. 
 Prevalence Remission Mortality 
rate 
Studies 88 2 6 
Countries/subnational geographies 274 3 7 
GBD world regions 13 2 3 
 
Age and sex splitting 
In GBD 2016, reported estimates of prevalence were split by age and sex where possible. First, if studies 
reported prevalence for broad age groups by sex (eg, prevalence in 15 to 65 year old males and females 
separately), and also by specific age groups but for both sexes combined (eg, prevalence in 15 to 30 year 
olds, then in 31 to 65 year olds, for males and females combined); age-specific estimates were split by sex 
using the reported sex ratio and bounds of uncertainty. Second, where studies reported estimates across 
age groups spanning 20 years or more, these were split into five-year age groups using the prevalence 
age pattern estimated by DisMod MR.  
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Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for 
amphetamine dependence severity levels are shown below. 
 
Severity level Lay description DW (95% CI) 
Mild Uses stimulants (drugs) at least once a week and has 
some difficulty controlling the habit. When not using, the 
person functions normally. 
0.079 (0.051–0.114) 
Moderate to 
severe 
Uses stimulants (drugs) and has difficulty controlling the 
habit. The person sometimes has depression, 
hallucinations, and mood swings, and has difficulty in 
daily activities.  
0.486 (0.329–0.637) 
 
The proportion of people with amphetamine dependence within each of the severity levels was 
determined based on available data from US National Epidemiological Survey on Alcohol and Related 
Conditions (NESARC), conducted in two waves from 2001–2002 and 2004–2005.5 The estimated 
distribution of amphetamine dependent cases by severity were asymptomatic (55%, 40%–71%), mild 
(19%, 12%–27%), and moderate/severe (26%, 16%–35%). 
 
Modelling Strategy 
We ran a DisMod-MR model to produce estimates by age, sex, year, and country. We assumed no 
incidence, remission, and excess mortality before age 15, and an upper limit of 0.35 on remission. The 
minimum age of onset was corroborated with expert feedback and existing literature from various 
sources including the European Monitoring Centre for Drugs and Drug Addiction.6 Cause-specific 
mortality rates (CSMR) from the GBD 2016 cause of death model for amphetamine use disorders was 
included as data-points in the DisMod-MR model.    
The prevalence dataset included data-points of both use and dependence estimated using “direct” or 
“indirect” survey methods. “Direct” methods of measuring amphetamine dependence predominantly 
involve surveys of the general population that ask if respondents use or are dependent on amphetamine. 
Surveys tend to underestimate the prevalence of the most harmful and stigmatized forms of illicit drug 
use in ways that probably vary between countries and cultures.7 “Indirect” methods are considered 
superior; they use different sources of data to indirectly estimate the total number of drug users 
(methods include “multiplier methods,” back-projection and capture-recapture methods). Due to the lack 
of data available on amphetamine dependence from indirect survey methods (considered to be the gold 
standard for GBD purposes), estimates of use and/or estimates from direct survey methods were 
included in the modelling. Study-level covariates were then used to accommodate for between-study 
variability in the raw prevalence data. The cv_direct use covariate was used to adjust for whether direct 
or indirect survey methods were used. This converted all use estimates obtained via direct methods in 
the dataset, into its equivalent value if the study had measured dependence estimates obtained via 
indirect methods. A ratio of direct use:indirect dependence was calculated by comparing similar direct 
use and indirect dependence estimates in the dataset. To allow for meaningful comparisons, paired direct 
use and indirect dependence estimates needed to be similar in terms of the country they were from, 
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year, age group, sex and, prevalence type. To maximize the number of data points available for this ratio 
paired estimates for psychostimulants (ie, both cocaine and amphetamine) were used. Once a dataset 
was set up with paired direct use and indirect dependence estimates, MetaXL (a meta-analysis add-in for 
Microsoft Excel) was utilized to estimate a ratio of direct use:indirect dependence, whereby direct use 
estimates were found to be 3.6 (2.6–5.2) times higher than indirect dependence estimates. This ratio was 
used in DisMod-MR to adjust all use estimates in the dataset downward, toward the level they would 
have been had the study reported indirect dependence. A similar method was used to adjust prevalence 
estimates of amphetamine dependence obtained via direct methods towards the level they would have 
been had the study measured amphetamine dependence using indirect methods. The estimated ratio of 
direct dependence: indirect dependence was 0.5 (0.2–1.1). 
Betas and exponentiated values (which can be interpreted as an odds ratio) for each study level covariate 
are shown in the table below: 
Study covariate Parameter beta Exponentiated beta 
cv_direct use Prevalence 1.29 (1.29–1.29) 3.63 (3.63–3.63) 
cv_direct dependence Prevalence -0.68 (-0.68 – -0.68) 0.51 (0.51–0.51) 
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Cannabis Dependence 
 
Flowchart 
 
Case Definition 
 
Cannabis dependence is a substance-related disorder involving a dysfunctional pattern of cannabis use. 
Included in GBD disease modelling were cases meeting diagnostic criteria for cannabis dependence 
according to the Diagnostic and Statistical Manual of Mental Disorders (DSM), or the equivalent diagnosis 
in the International Classification of Diseases (ICD). These were identified by the following codes: 
DSM:304.30, ICD:F12.2; excluding those cases due to a general medical condition.1,2 
According to DSM-IV-TR criteria, cannabis dependence involves a maladaptive pattern of cannabis use, 
leading to clinically significant impairment or distress. At least three of the following symptoms must be 
experienced within the same 12-month period: 
• Tolerance, characterized by either 
o a need for increased amounts of the substance to achieve intoxication; or 
o markedly diminished effect with continued use of the same amount of the substance;  
• Withdrawal, characterized by either 
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o Withdrawal symptoms characteristic to cannabis dependence; or 
o the same (or similar) substance is taken to avoid withdrawal symptoms; 
• substance taken in progressively larger amounts or for longer period; 
• persistent desire or unsuccessful efforts to reduce substance use; 
• disproportionate time dedicated to obtaining the substance; 
• other important activities are given up because of the substance use; and 
• substance use is continued despite knowledge of physical or psychological problems occurring as 
a result of the substance. 
 
Input data 
 Model inputs 
For GBD 2010, a systematic review of the literature was conducted to capture studies of prevalence, 
incidence, remission, and excess mortality associated with cannabis dependence. In summary, the search 
was conducted in three stages involving electronic searches of the peer-reviewed literature (via Medline, 
Embase, and PubMed), the grey literature and, expert consultation. The agreed-upon approach for 
mental and substance use disorders was to conduct electronic database searches on a rolling basis. All 
three stages of GBD 2010’s literature review were repeated for GBD 2013 to capture additional data 
published up to 2013. For GBD 2015, stages 2 and 3 of the literature review were updated and in GBD 
2016, the peer-reviewed database search (stage 1) was conducted via Medline, Embase, and Psycinfo to 
capture studies published from 2013 to 2016. 
The inclusion criteria stipulated that: (1) the publication year must be from 1980 onward; (2) “caseness” 
must be based on clinical threshold as established by the DSM or ICD; (3) sufficient information must be 
provided on study method and sample characteristics to assess the quality of the study; and (4) study 
samples must be representative of the general population (ie, inpatient or pharmacological treatment 
samples, case studies, veterans or refugee samples were excluded). No limitation was set on the language 
of publication. Methods used for this systematic review have been reported in greater detail elsewhere.3-6 
The table below shows the number of studies included, as well as the number of countries or subnational 
units and GBD world regions represented. 
 Prevalence Remission Mortality 
Studies 236 3 - 
Countries/subnational geographies 315 3 - 
GBD world regions 20 3 - 
 
Age and sex splitting 
In GBD 2016, reported estimates of prevalence were split by age and sex where possible. First, if studies 
reported prevalence for broad age groups by sex (eg, prevalence in 15 to 65 year old males and females 
separately), and also by specific age groups but for both sexes combined (eg, prevalence in 15 to 30 year 
olds, then in 31 to 65 year olds, for males and females combined); age-specific estimates were split by sex 
using the reported sex ratio and bounds of uncertainty. Second, where studies reported estimates across 
age groups spanning 20 years or more, these were split into five-year age groups using the prevalence 
age pattern estimated by DisMod MR.  
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 Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for cannabis 
dependence severity levels are shown below. 
Severity level Lay description DW (95% CI) 
Mild Uses marijuana at least once a week and has some 
difficulty controlling the habit. When not using, the 
person functions normally. 
0.039 (0.024–0.06) 
Moderate to 
severe 
Uses marijuana daily and has difficulty controlling the 
habit. The person sometimes has mood swings, anxiety, 
and hallucinations, and has some difficulty in daily 
activities.  
0.266 (0.178–0.364) 
 
The US National Epidemiological Survey on Alcohol and Related Conditions (NESARC, conducted in two 
waves from 2001-2002 and 2004-2005)7 was used to estimate the proportion of cannabis dependence 
cases asymptomatic (58%, 51%–63%), mild (36%, 31%–42%) and moderate to severe (6%, 4%–8%). 
 
Modelling Strategy 
The epidemiological modelling strategy for cannabis dependence made use of DisMod-MR. Due to 
insufficient data, estimates of any cannabis use and regular (ie, weekly) cannabis use were included in the 
disease modelling of cannabis dependence in a two-step process. At step 1, a crosswalk was estimated to 
convert estimates of any use in the dataset into its equivalent value if the study had measured regular 
use. To do this a ratio of use:regular use was calculated by comparing similar regular use and use 
estimates in the dataset. To allow for meaningful comparisons, paired regular use and use estimates 
needed to be similar in terms of the country they were from, year, age group, sex, and prevalence type.  
Once a dataset was set up with paired regular use and use estimates, MetaXL (a meta-analysis add-in for 
Microsoft Excel) was used to estimate a ratio of use: regular use whereby use estimates were found to be 
2.9 (2.5–3.3) times higher than regular use estimates. This ratio was used to adjust all use estimates in 
the dataset downwards, toward the level they would have been had the study reported regular cannabis 
use. Step 2 involved the DisMod-MR modelling of the regular cannabis use (from step 1) and cannabis 
dependence data. This cannabis regular use/dependence dataset was modelled using a study-level 
covariate which adjusted estimates of regular cannabis use toward the desirable which were estimates of 
cannabis dependence. 
Study-level covariates were used to accommodate for between-study variability in the raw prevalence 
data. As mentioned previously, a cv_regular use covariate adjusted all regular use estimates toward the 
level they would have been if the study had measured cannabis dependence. This covariate was informed 
by a cannabis regular use: dependence ratio (4.1, 3.9–4.6) estimated outside of DisMod-MR using the 
same methodology outlined above for the use:regular use ratio. Based on expert advice, a cv_nesarc 
covariate adjusted all estimates derived from the NESARC toward the level they would have been if they 
had been derived by other surveys. Drug use disorders are not well-captured in household surveys. This is 
especially an issue in NESARC as the sampling strategy used was biased toward less severe cases of drug 
use disorders. We also tested a cv_school survey covariate adjusting estimates derived from school 
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surveys to the level they would have been had the study conducted a fully representative population 
survey; however, this did not have a statistically significant effect on prevalence. Betas and exponentiated 
values (which can be interpreted as an odds ratio) for each study-level covariate are shown in the table 
below. 
 
Study covariate Parameter beta Exponentiated beta 
cv_regular use  Prevalence 1.40 (1.40–1.40)  4.06 (4.06–4.06) 
cv_nesarc Prevalence -0.709 (-0.86 – -0.54) 0.50 (0.42–0.58) 
cv_school survey  Prevalence  
0.03 (-0.05 – 0.12) 1.03 (0.956–1.12) 
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 Other drug use disorders 
 
Flowchart 
 
 
Case definition 
In addition to the four drug use disorders for which we specifically estimate non-fatal burden (opioid, 
cocaine, amphetamine, and cannabis dependence), we also estimate the burden attributable to a residual 
cause of “other drug use disorders.” This is made up of an aggregate group of other forms of drug 
dependence. Included in the GBD disease modelling were cases meeting the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV-TR)1 or the International Classification of Diseases (ICD-10)2 
diagnostic criteria for:   
 Hallucinogen dependence 
 Inhalant or solvent dependence 
 Sedative dependence 
 Tranquilizer dependence 
 Other medicines, drugs, substance dependence 
 
According to DSM-IV TR criteria, dependence involves a maladaptive pattern of substance use, leading to 
clinically significant impairment or distress. At least three of the following symptoms must be experienced 
within the same 12-month period: 
 Tolerance, characterized by either 
o a need for increased amounts of the substance to achieve intoxication; or 
o markedly diminished effect with continued use of the same amount of the substance;  
 Withdrawal, characterized by either 
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o Withdrawal symptoms characteristic to dependence; or 
o the same (or similar) substance is taken to avoid withdrawal symptoms; 
 Substance taken in progressively larger amounts or for longer period; 
 Persistent desire or unsuccessful efforts to reduce substance use; 
 Disproportionate time dedicated to obtaining the substance; 
 Other important activities are given up because of the substance use; and 
 Substance use is continued despite knowledge of physical or psychological problems occurring as 
a result of the substance. 
 
Input data 
 Model inputs 
Prevalence estimates were obtained from the Australian National Survey of Mental Health and Wellbeing 
(NSMHWB) conducted in 19973,and the US National Epidemiological Survey on Alcohol and Related 
Conditions (NESARC), conducted in two waves in 2001–20024 and 2004–2005.5 Given that other forms of 
drug dependence often co-occur with the four types of drug dependence for which we estimate non-fatal 
burden (opioid, cocaine, amphetamine, and cannabis dependence), an adjustment for co-morbidity is 
important so as not to overestimate the overall burden attributable to drug dependence. Participants 
meeting criteria for any other form of drug dependence from each of the surveys used were counted as a 
prevalent case only if they did not simultaneously meet criteria for opioid, cocaine, amphetamine, or 
cannabis dependence. 
Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The average disability weight estimated for cocaine and 
amphetamine dependence was applied to all cases in this residual group of other drug use disorders. The 
cocaine and amphetamine lay descriptions and disability weights are shown below: 
Severity level Lay description DW (95% CI) 
Amphetamine dependence 
Mild Uses stimulants (drugs) at least once a week and has 
some difficulty controlling the habit. When not using, the 
person functions normally. 
0.079 (0.051–0.114) 
Moderate to 
severe 
Uses stimulants (drugs) and has difficulty controlling the 
habit. The person sometimes has depression, 
hallucinations, and mood swings, and has difficulty in 
daily activities.  
0.486 (0.329–0.637) 
Cocaine dependence 
Mild Uses cocaine at least once a week and has some difficulty 
controlling the habit. When not using, the person 
functions normally. 
0.116 (0.074–0.165) 
Moderate to 
severe 
Uses cocaine and has difficulty controlling the habit. The 
person sometimes has mood swings, anxiety, paranoia, 
hallucinations, and sleep problems, and has some 
difficulty in daily activities. 
0.479 (0.324–0.634) 
 
428
 Modelling Strategy 
The GBD 2016 epidemiological modelling strategy made use of DisMod-MR. A number of additional 
expert priors were used in order to run a full parameter model. We assumed no incidence before age 14, 
a maximum of 0.0004 on incidence from the age of 60 years onward, and a maximum remission of 0.2. 
These priors were corroborated with expert feedback and existing literature on drug use disorders 
including the European Monitoring Centre for Drugs and Drug Addiction.6 Finally, cause-specific mortality 
rates (CSMR) from the GBD 2016 cause of death model for other drug use disorders were included as 
data-points in the DisMod-MR model. 
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Major Depressive Disorder 
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Case Definition 
Major depressive disorder (MDD) is an episodic mood disorder involving the experience of one or more 
major depressive episode(s). Included in GBD disease modelling were cases meeting diagnostic criteria 
for MDD according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the equivalent 
diagnosis of recurrent depression in the International Classification of Diseases (ICD). These were 
identified by the following codes: DSM-IV-TR: 296.21–24, 296.31–34; ICD-10: F32.0–9, F33.0–9; 
excluding those cases due to a general medical condition or substance induced cases.1,2 
 
According to DSM-IV-TR criteria, MDD involves the presence of at least one major depressive episode, 
which is the experience of depressed mood almost all day, every day, for at least two weeks. Mood must 
represent a change from the person’s baseline and impaired functioning must be observed across social, 
occupational, and educational domains. Additionally, a total of five out nine criteria must be met to 
make a diagnosis and at least one of the five criteria should either be:   
• “depressed mood” for most of every day; or  
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• “loss of interest in nearly all activities” for most of every day. 
The other seven criteria are:  
• change in eating, appetite or weight;  
• excessive sleeping or insomnia;  
• agitated or slow motor activity;  
• fatigue;  
• feeling worthless or inappropriately guilty;  
• trouble concentrating; and  
• repeated thoughts about death 
MDD was modelled as an episodic disorder with the average length of a major depressive episode (ie, 
duration) specified. This was consistent with previously proposed methodology for the modelling of 
MDD for burden of disease purposes.3-5 
 
Input data 
 Model Inputs 
For GBD 2010, a systematic review of the literature was conducted to capture studies of prevalence, 
incidence, duration, and excess mortality associated with MDD. In summary, the search was conducted 
in three stages involving electronic searches of the peer-reviewed literature (via PsycInfo, Embase and 
PubMed), the grey literature and, expert consultation. The agreed-upon approach for mental and 
substance use disorders was to conduct electronic database searches on a rolling basis. All three stages 
of GBD 2010’s literature review were repeated for GBD 2013 to capture additional data published up to 
2013. In GBD 2015, stages two and three of the literature review were conducted, and in GBD 2016, 
stage 1 was repeated to update our electronic database search to capture data sources published 
between January 2013 and September 2016. 
The inclusion criteria stipulated that: (1) the publication year must be from 1980 onward; (2) “caseness” 
must be based on clinical threshold as established by the DSM or ICD; (3) sufficient information must be 
provided on study method and sample characteristics to assess the quality of the study; and (4) study 
samples must be representative of the general population (ie, inpatient or pharmacological treatment 
samples, case studies, veterans or refugee samples were excluded). No limitation was set on the 
language of publication. Methods used for this systematic review have been reported in greater detail 
elsewhere.6,7 The table below shows the number of studies included in GBD 2016, as well as the number 
of countries or subnational units and GBD world regions represented. 
 Prevalence Incidence Duration Excess mortality 
Studies 344 3 5 22 
Countries/subnational geographies 249 3 2 18 
GBD world regions 20 2 2 5 
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Age- and sex-splitting 
In GBD 2016, reported estimates of prevalence were split by age and sex where possible. First, if studies 
reported prevalence for broad age groups by sex (eg, prevalence in 15 to 65 year old males and females 
separately), and also by specific age groups but for both sexes combined (eg, prevalence in 15 to 30 year 
olds, then in 31 to 65 year olds, for males and females combined); age-specific estimates were split by 
sex using the reported sex ratio and bounds of uncertainty. Second, where studies reported estimates 
across age groups spanning 20 years or more, these were split into five-year age groups using the 
prevalence age pattern estimated by DisMod MR 2.1.  
Attributable suicide estimates 
Given that MDD is an established risk factor for suicide,8 in GBD 2016 we supplemented the available 
data on excess mortality with estimated suicide rates (by age, sex, year, and location) attributable to 
MDD. These were estimated using GBD’s comparative risk assessment methodology whereby the 
current health status was compared with a theoretical-minimum-risk exposure defined as the 
counterfactual status of the absence of MDD in the population. Population attributable fractions (PAFs) 
were estimated using this established formula: 
 
𝑃𝑃𝑃𝑃𝑃𝑃 = 𝑝𝑝 (𝑅𝑅𝑅𝑅 − 1)
𝑝𝑝 (𝑅𝑅𝑅𝑅 − 1) + 1  
P referred to the exposure distribution, which in this case was the DisMod-MR 2.1 prevalence rates of 
MDD by age, sex, location and year. RR referred to the pooled relative-risk of suicide due to MDD 
obtained from an existing systematic review and meta-analysis.8 Age, sex, year, and location-specific 
PAFs were multiplied by their corresponding GBD suicide rate to estimate the proportion of suicide 
cases attributable to MDD. These were entered as cause-specific mortality rates in our epidemiological 
model for MDD. 
 
Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for MDD 
severity levels are shown below. 
Severity level Lay description DW (95% CI) 
Mild  Feels persistent sadness and has lost interest in usual 
activities. The person sometimes sleeps badly, feels 
tired, or has trouble concentrating but still manages to 
function in daily life with extra effort.  
0.145 (0.099–0.209) 
Moderate Has constant sadness and has lost interest in usual 
activities. The person has some difficulty in daily life, 
sleeps badly, has trouble concentrating, and sometimes 
thinks about harming himself (or herself).  
0.396 (0.267-0.531) 
Severe Has overwhelming, constant sadness and cannot 
function in daily life. The person sometimes loses touch 
with reality and wants to harm or kill himself (or herself).  
0.658 (0.477-0.807) 
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To determine the proportion of people with MDD within each of the severity levels, the US National 
Epidemiological Survey on Alcohol and Related Conditions (NESARC, conducted in two waves from 2001 
to 2002 and 2004 to 2005)9 and the  Australian National Survey of Mental Health and Wellbeing of 
Adults (NSMHWB, conducted in 1997)10 were used to estimate the proportion of MDD cases 
asymptomatic (13%, 10%–17%),  mild (59%, 49%–69%), moderate (17%, 13%–22%), and severe (10%, 
3%–20%). 
Modelling Strategy 
The GBD 2016 epidemiological modelling strategy for MDD made use of DisMod-MR 2.1. Data across all 
epidemiological parameters were initially included in the modelling process. However, given that the 
few incidence data points available typically excluded cases of MDD at baseline, new major depressive 
episodes in people with previous episodes were not counted and incidence was underestimated. For 
this reason, we chose to exclude all raw incidence data in the final model and instead, allowed Dismod-
MR 2.1 to calculate incidence based on data from other parameters. We assumed no incidence and 
prevalence before age 3. This minimum age of onset was corroborated with expert feedback and 
existing MDD literature.6 An average remission rate for a major depressive episode of 1.45 (1.3–1.6) was 
used. This was derived from the four longitudinal studies11-14 fitting a lognormal curve with least squared 
differences to data on the proportion of incident cases still fulfilling the case definition for major 
depression at intervals over a one-year period. As data were only available for a follow-up of one year, a 
decision had to be made about the maximum allowable duration of an episode. Setting this at 40 years, 
the average duration implied by the lognormal fit was 0.65 (0.59–0.70) of a year.15  
Study-level covariates were used to accommodate between-study variability in the raw prevalence data. 
A cv_past year recall covariate adjusted all data points derived from past year prevalence toward the 
level they would have been if the study had captured point/past-month prevalence. The latter 
prevalence period is less affected by recall bias. A cv_symptom scale covariate adjusted all data points 
derived using a symptom scale towards the level they would have been if the scale had strictly adhered 
to DSM or ICD thresholds for MDD. A cv_asian data points covariate was used to adjust all estimates 
from East Asia, Southeast Asia and Asia Pacific high-income using a ratio based on a study in China. 
Phillips and collaborators16 reported that the prevalence of MDD in China was 2.07% while the 
prevalence of mood disorders not otherwise specified (NOS) was 2.06%. Of the 808 individuals 
diagnosed with mood disorders NOS, 467 (58%) met criteria for minor depression (defined by DSM-IV-
TR as two to four of nine symptoms of depression lasting for ≥2 weeks). There is evidence to suggest 
that these reported cases of minor depression are likely misdiagnosed cases MDD as DSM/ICD 
diagnostic criteria are not sensitive to cross-cultural presentations of MDD in Asia.16-19 Based on this, a 
ratio of MDD + minor depression: MDD only (1.53, 1.45–1.63) was derived from data presented by 
Phillips and collaborators and used to adjust prevalence estimates from Asia in the model. The aim of 
this adjustment was not to capture sub-syndromal depression but instead, to pick up on diagnoses of 
MDD where there is evidence to suggest that the use of Western-based criteria have underestimated 
prevalence. A cv_school survey covariate adjusted estimates derived from school surveys downwards, to 
the level they would have been had the study conducted a fully representative population survey. A 
cv_World Health Survey covariate was used to adjust all World Health Survey data downwards. The 
World Health Surveys are surveys conducted by the World Health Organization in close to 70 countries. 
While these surveys capture useful information on the prevalence of depression, they make use of a 
symptom scale which does not fully meet DSM and ICD criteria for MDD. This covariate works in 
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essentially the same way as the symptom scale covariate in adjusting World Health Survey estimates 
downwards towards the level they would have been had the study strictly adhered to DSM or ICD 
thresholds for MDD. 
Location-level covariates were also included in the MDD model. A covariate identifying for each GBD 
location, the mean mortality rate in the previous 10 years due to war and terrorism informed the 
estimation of prevalence given existing evidence to show a positive association between conflict status 
and the prevalence of MDD.20,21 An age-standardised SEV scalar was also included. This made use of the 
fraction of MDD burden caused by its relevant risk factors combined to inform the estimation of 
prevalence. Intimate partner violence and childhood sexual violence are the two established risk factors 
of MDD for which attributable burden is estimated in GBD studies. Betas and exponentiated values 
(which can be interpreted as an odds ratio) for each study- and country-level covariate are shown in the 
table below: 
Study/Country  covariate Parameter beta Exponentiated beta 
cv_asian datapoints Prevalence -0.43 (-0.48 — -0.37) 0.65 (0.62 — 0.69) 
cv_past year recall Prevalence 0.63 (0.59 — 0.67) 1.88 (1.80 — 1.96) 
cv_symptom scale Prevalence 1.00 (0.94 — 1.06) 2.72 (2.57 — 2.90) 
cv_school survey Prevalence 0.29 (0.16 — 0.42) 1.33 (1.17 — 1.52) 
cv_world health survey Prevalence 0.78 (0.71 — 0.85) 2.18 (2.04 — 2.35) 
Mean war mortality rate in the 
previous ten years  
Prevalence 0.49 (0.022 — 0.98) 1.63 (1.02 — 2.65) 
Age-standardised SEV scalar: 
Depression 
Prevalence 0.77 (0.75 — 0.82) 2.17 (2.12 — 2.27) 
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Dysthymia 
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Case Definition 
Dysthymia is a mood disorder consisting of chronic depression, demonstrating less severe but longer-
lasting symptoms than major depressive disorder. Included in GBD disease modelling were cases 
meeting diagnostic criteria for dysthymia according to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM), or the equivalent diagnosis in the International Classification of Diseases (ICD). These 
were identified by the following codes: DSM-IV-TR: 300.4, ICD-10: F34.1; excluding those cases due to a 
general medical condition or substance-induced cases.1,2 
 
According to DSM-IV TR criteria, dysthymia involves the experience of chronically depressed mood for 
most of the day, most days that not, for at least two year (or at least one year in children and 
adolescents). During this period, at least two of the following symptoms must also be experienced: 
• poor appetite or overeating; 
• insomnia or hypersomnia; 
• low energy or fatigue; 
• low self-esteem; 
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• poor concentration or indecisiveness; and 
• feelings of hopelessness 
 
Input data 
 Model Inputs 
For GBD 2010, a systematic review of the literature was conducted to capture studies of prevalence, 
incidence, remission, and excess mortality associated with dysthymia. In summary, the search was 
conducted in three stages involving electronic searches of the peer-reviewed literature (via Medline, 
Embase, and PubMed), the grey literature and, expert consultation. The agreed-upon approach for 
mental and substance use disorders was to conduct electronic database searches on a rolling basis. All 
three stages of GBD 2010’s literature review were repeated for GBD 2013 to capture additional data 
published up to 2013. In GBD 2015, stages two and three of the literature review were conducted, and 
in GBD 2016, stage 1 was repeated to update our electronic database search to capture data sources 
published between January 2013 and September 2016. 
The inclusion criteria stipulated that: (1) the publication year must be from 1980 onward; (2) “caseness” 
must be based on clinical threshold as established by the DSM or ICD; (3) sufficient information must be 
provided on study method and sample characteristics to assess the quality of the study; and (4) study 
samples must be representative of the general population (ie, inpatient or pharmacological treatment 
samples, case studies, veterans, or refugee samples were excluded). No limitation was set on the 
language of publication. Methods used for this systematic review have been reported in greater detail 
elsewhere.3,4 The table below shows the number of studies included in GBD 2016, as well as the number 
of countries or subnational units and GBD world regions represented. 
 Prevalence Incidence Remission Excess mortality 
Studies 94 2 2 - 
Countries/subnational geographies 65 2 2 - 
GBD world regions 15 1 2 - 
 
Age- and sex-splitting 
In GBD 2016, reported estimates of prevalence were split by age and sex where possible. First, if studies 
reported prevalence for broad age groups by sex (eg, prevalence in 15 to 65 year old males and females 
separately), and also by specific age groups but for both sexes combined (eg, prevalence in 15 to 30 year 
olds, then in 31 to 65 year olds, for males and females combined); age-specific estimates were split by 
sex using the reported sex ratio and bounds of uncertainty. Second, where studies reported estimates 
across age groups spanning 20 years or more, these were split into five-year age groups using the 
prevalence age pattern estimated by DisMod-MR 2.1.  
 
Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay description and disability weight for a 
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symptomatic state of dysthymia are shown below. Given the milder and more stable presentation of 
dysthymia, it was assigned the same disability weight as that for mild major depressive disorder.  
 
Severity level Lay description DW (95% CI) 
Symptomatic 
dysthymia 
Feels persistent sadness and has lost interest in usual 
activities. The person sometimes sleeps badly, feels 
tired, or has trouble concentrating but still manages to 
function in daily life with extra effort.  
0.145 (0.099–0.209) 
 
To determine the proportion of people with symptomatic and asymptomatic dysthymia, the US National 
Epidemiological Survey on Alcohol and Related Conditions (NESARC, conducted in two waves from 2001 
to 2002 and 2004 to 2005)5 and the Australian National Survey of Mental Health and Wellbeing of Adults 
(NSMHWB, conducted in 1997)6 were used to estimate the proportion of dysthymia  cases 
asymptomatic (29%, 23%–36%) and symptomatic (71%, 64%–77%). 
 
Modelling Strategy 
The GBD 2016 epidemiological modelling strategy for dysthymia made use of DisMod-MR 2.1. Data 
across all epidemiological parameters were initially included in the modelling process. The incidence 
studies reported estimates which were very low relative to the prevalence data. As prevalence studies 
contributed much greater world coverage than incidence studies, we excluded the incidence data, 
relying instead on data from the other parameters. We assumed no incidence and prevalence before 
age 3. This minimum age of onset was corroborated with expert feedback and was consistent with the 
available data. Excess-mortality was set to 0 as there is no epidemiological evidence to suggest that 
dysthymia is associated with a statistically significant risk of mortality.3,4 
Study-level covariates were used to accommodate between-study variability in the raw prevalence data. 
A cv_lay interviewer covariate created a crosswalk between prevalence derived from clinically trained 
interviewers (desirable) and prevalence derived from lay-interviewers. A cv_past year prevalence 
covariate was originally included to adjust all data points derived from past year prevalence toward the 
level they would have been if the study had captured point/past-month prevalence. As the effect of this 
covariate was not statistically significant, it was excluded from the final model. Given that dysthymia is 
being modelled as a chronic disorder with a long duration of between six and 10 years, it was not 
surprising that we did not detect significant variation between point and past-year prevalence. 
Betas and exponentiated values (which can be interpreted as an odds ratio) for each study level 
covariate are shown in the table below: 
Study covariate Parameter beta Exponentiated beta 
cv_lay interviewer Prevalence -0.36 (-0.50 — -0.23) 0.70 (0.61 — 0.79) 
 
Given that there was an overall paucity of epidemiological data available for dysthymia, and the data 
available were very heterogeneous given differences in the data collection methodology used between 
studies, we applied a restriction on location random-effects of -0.3 to 0.3 to further guide the estimation 
of prevalence. 
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Bipolar disorder 
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Case Definition 
Bipolar disorder is a chronic mood disorder with little or no complete remission. Included in GBD disease 
modelling were cases meeting diagnostic criteria for bipolar disorder according to the Diagnostic and 
Statistical Manual of Mental Disorders (DSM), or the equivalent diagnosis in the International 
Classification of Diseases (ICD).1,2 These were identified by the following codes: DSM-IV-TR: 296.0–296.8, 
296.89, 301.13; ICD-10: F31.0–F31.6, F31.8–F31.9, F34.0–F34.1, excluding those cases due to a general 
medical condition or substance induced cases. A diagnosis of bipolar disorder involves the experience of 
one or more manic or hypomanic episode(s), which can be accompanied by a major depressive episode.  
 
According to DSM-IV-TR a manic episode involves the experience of elevated, expansive, or irritable 
mood lasting for at least one week. During this period, at least three (or four if mood is only irritable) of 
the following symptoms must also be experienced; 
 
• inflated self-esteem or grandiosity; 
• decreased need for sleep; 
• more talkative; 
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• flight of ideas or experience that thoughts are racing; 
• distractibility; 
• increase in goal-directed activity; and 
• excessive involvement in pleasurable activities with high potential for painful consequences. 
 
A hypomanic episode involves the experience of elevated, expansive, or irritable mood lasting for at 
least four days. During this period, at least three (or four if mood is only irritable) of the symptoms 
previously listed for a manic episode must also be experienced. 
 
A major depressive episode involves the experience of depressed mood almost all day, every day, for at 
least two weeks. A total of five of nine criteria must be met to make a diagnosis and at least one of the 
five criteria should either be:   
• “depressed mood” for most of every day; or  
• “loss of interest in nearly all activities” for most of every day. 
The other seven criteria are:  
• change in eating, appetite, or weight;  
• excessive sleeping or insomnia;  
• agitated or slow motor activity;  
• fatigue;  
• feeling worthless or inappropriately guilty;  
• trouble concentrating; and  
• repeated thoughts about death. 
Different subtypes of bipolar disorder can be diagnosed depending on the combination of symptoms 
experienced. Bipolar I is characterized by at least one manic episode, which can also alternate with a 
major depressive episode. Bipolar II is characterized by hypomanic episodes alternating with major 
depressive episodes. Cyclothymia is characterized by subsyndromal hypomanic and major depressive 
episode episodes. Bipolar disorder not otherwise specified is characterized by clinically significant 
symptoms of bipolar disorder which do not meet criteria for the other diagnoses.1,2 In GBD 2016 we 
estimated burden for the entire spectrum of bipolar disorder simultaneously, rather than individually for 
each subtype of the disorder. At a minimum, epidemiological studies needed to report on bipolar I and 
bipolar II combined to be included in analyses. 
 
Input data 
 Model inputs 
For GBD 2010, a systematic review of the literature was conducted to capture studies of prevalence, 
incidence, remission, and excess mortality associated with bipolar disorder. In summary, the search was 
conducted in three stages involving electronic searches of the peer-reviewed literature (via Medline, 
Embase and PubMed), the grey literature and, expert consultation. The agreed-upon approach for 
mental and substance use disorders was to conduct electronic database searches on a rolling basis. All 
three stages of GBD 2010’s literature review were repeated for GBD 2013 to capture additional data 
published up to 2013. In GBD 2015, stages two and three of the literature review were conducted, and 
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in GBD 2016, stage 1 was repeated to update our electronic database search to capture data sources 
published between January 2013 and September 2016. 
The inclusion criteria stipulated that: (1) the publication year must be from 1980 onward; (2) “caseness” 
must be based on clinical threshold as established by the DSM or ICD; (3) sufficient information must be 
provided on study method and sample characteristics to assess the quality of the study; and (4) study 
samples must be representative of the general population (ie, inpatient or pharmacological treatment 
samples, case studies, veterans or refugee samples were excluded). No limitation was set on the 
language of publication. Methods used for this systematic review have been reported in greater detail 
elsewhere.3 As previously explained, burden was estimated for the entire spectrum of bipolar disorder 
simultaneously. Combined estimates of all subtypes of bipolar disorders were required. Studies 
reporting separate estimates for bipolar I, bipolar II, cyclothymia, and/or bipolar not otherwise specified 
were accepted if sufficient information was available to sum the disorder-specific estimates. At a 
minimum, studies needed to report on bipolar I and bipolar II. The table below shows the number of 
studies included in GBD 2016, as well as the number of countries or subnational units and GBD world 
regions represented. 
 Prevalence Incidence Remission Excess mortality 
Studies 58 3 - 13 
Countries/subnational geographies 96 2 - 12 
GBD world regions 14 2 - 4 
 
Age- and sex-splitting 
In GBD 2016, reported estimates of prevalence were split by age and sex where possible. First, if studies 
reported prevalence for broad age groups by sex (eg, prevalence in 15 to 65 year old males and females 
separately) and by specific age groups but for both sexes combined (eg, prevalence in 15 to 30 year olds, 
then in 31 to 65 year olds, for males and females combined), age-specific estimates were split by sex 
using the reported sex ratio and bounds of uncertainty. Second, where studies reported estimates 
across age groups spanning 20 years or more, these were split into five-year age groups using the 
prevalence age pattern estimated by DisMod-MR 2.1.  
MarketScan data 
In GBD 2016, we made use of United States (US) MarketScan data in our prevalence dataset for the 
years 2010 and 2012. These were prevalence data for bipolar disorder derived from claims information 
in a database of private and public insurance schemes. Given the sparseness of the bipolar disorder 
prevalence dataset, this allowed us to incorporate detailed prevalence estimates by state, sex, and age 
in our modelling. Evaluation of the age-pattern of MarketScan data revealed that it was consistent to 
what can be observed in population-representative survey estimates; however, given that this data 
source only captures a subset of the population, the actual levels of prevalence and the sex difference in 
prevalence were not and had to be adjusted accordingly. These adjustments are discussed further in the 
section on “Modelling strategy.” 
Severity splits inputs 
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The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for bipolar 
disorder severity levels are shown below. 
 
Severity level Lay description DW (95% CI) 
Manic Is hyperactive, hears and believes things that are not 
real, and engages in impulsive and aggressive behavior 
that endanger the person and others.  
 
0.492 (0.341–0.646) 
Depressive* Has constant sadness and has lost interest in usual 
activities. The person has some difficulty in daily life, 
sleeps badly, has trouble concentrating, and sometimes 
thinks about harming himself (or herself).  
0.396 (0.267–0.531) 
Residual Has mild mood swings, irritability, and some difficulty 
with daily activities.  
0.032 (0.018–0.051) 
Note.*Equivalent to the disability weight estimated for moderate major depressive disorder 
Information on the distribution of manic, depressive, and residual states of bipolar disorder was 
obtained from a separate systematic review of the literature.5 Meta-XL (a Microsoft Excel add-in for 
meta-analysis) was used to pool estimates across all studies to calculate the overall proportion of 
bipolar cases in each health state. Six studies provided information on the proportion of bipolar disorder 
cases in a manic (21%, 12%–33%), depressive (23%, 10%–39%) or residual state (52%, 28%–77%).   
 
Modelling strategy 
The GBD 2016 epidemiological modelling strategy for bipolar disorder made use of DisMod-MR 2.1. Data 
across all epidemiological parameters were initially included in the modelling process. The two studies 
on incidence reported 0% and 0.1% incidence of bipolar disorder and were low relative to the 
prevalence data. They were excluded from the final model where incidence was estimated using data 
from other parameters. We assumed no incidence and prevalence before age 10. Remission was set to a 
maximum of 0.05 in agreement with literature and expert advice suggesting no or very little complete 
remission from bipolar disorder.6,7 
 
Study-level covariates were used to accommodate for between-study variability in the raw prevalence 
data. A cv_point recall covariate adjusted all data points derived from point/past-month prevalence 
toward the level they would have been if the study had captured 12-month prevalence. We set 12-
month prevalence as the desirable level due to the episodic nature of bipolar disorder. Estimates of 
point prevalence surveying symptoms experienced in the past 30 days or less may fail to diagnose cases 
of bipolar disorder in a residual state, thereby underestimating prevalence. Two cv_market scan 
covariates for the years 2010 and 2012 adjusted MarketScan prevalence estimates upward toward the 
level they would have been had they been representative of the general population. The ratio used for 
this upward adjustment was estimated outside of DisMod-MR 2.1 by comparing modelled prevalence 
estimates for the US before MarketScan data were included in the model and corresponding 
MarketScan data points. MetaXL (a meta-analysis add-in for Microsoft Excel) was used to estimate the 
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adjustment ratio whereby Market scan estimates were 1.42 (1.28–1.58) times lower than prevalence 
estimated from survey data representative of the general US population. 
The corresponding beta and exponentiated value (which can be interpreted as an odds ratio) is shown in 
the table below: 
Study covariate Parameter beta Exponentiated beta 
cv_point recall Prevalence -0.60 (-0.90 — -0.42) 0.55 (0.41 — 0.66) 
cv_market scan 2010 Prevalence -0.35 (-0.44 — -0.28) 0.71 (0.64 — 0.76) 
Cv_market scan 2012 Prevalence -0.32 (-0.42 — -0.25) 0.73 (0.66 — 0.78) 
 
An analysis of the sex pattern in MarketScan data also showed that the male: female prevalence ratio 
was 0.68 (0.62–0.76) compared to 0.88 (0.80–0.97) in population-representative survey data. It is likely 
that females are overrepresented in claims data for bipolar disorder as they are more likely to make use 
of such services. So as not to bias our sex pattern in prevalence, the estimated sex ratio in population-
representative survey data was used as a setting to guide the sex pattern in our estimation of 
prevalence.  
Given that there was an overall paucity in epidemiological data available for bipolar disorder, and the 
data available were very heterogeneous given differences in the data-collection methodology used 
between studies, we applied a restriction on location random-effects of -0.3 to 0.3 to further guide the 
estimation of prevalence. 
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Case Definition 
Anxiety disorders are characterized by experiences of intense of fear and distress, typically in 
combination with other physiological symptoms. We aimed to capture all cases of anxiety disorders 
reaching diagnostic threshold defined by the Diagnostic and Statistical Manual of Mental Disorders 
(DSM) or the WHO International Classification of Diseases (ICD-10).1,2 Included disorders are listed below 
and can be identified by the DSM-IV-TR and ICD-10 coding systems as: DSM IV TR: 299.8, 300.0-300.3, 
309.21, 309.81 and ICD-10: F40-42, F43.1, F93.0-93.2, F93.8. Excluded were anxiety disorders due to a 
general medical condition and substance-induced anxiety disorder. 
 
• panic disorder; 
• agoraphobia; 
• specific phobia; 
• social phobia; 
• obsessive-compulsive disorder; 
• post-traumatic stress disorder; 
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• acute stress disorder; 
• generalized anxiety disorder; 
• separation anxiety disorder; and 
• anxiety disorder not otherwise specified 
 
As specific anxiety disorders frequently co-occur, anxiety disorders were modeled as a single cause for 
“any” anxiety disorder in GBD 2016 to avoid the double-counting of individuals meeting criteria for more 
than one anxiety disorder. Epidemiological estimates reporting an outcome for “any” or “total” anxiety 
disorders were included in analyses. 
 
Input data 
 Model inputs 
For GBD 2010, a systematic review of the literature was conducted to capture studies of prevalence, 
incidence, remission, and excess mortality associated with anxiety disorders. In summary, the search 
was conducted in three stages involving electronic searches of the peer-reviewed literature (via 
Medline, Embase, and PubMed), the grey literature and, expert consultation. The agreed-upon approach 
for mental and substance use disorders was to conduct electronic database searches on a rolling basis. 
All three stages of GBD 2010’s literature review were repeated for GBD 2013 to capture additional data 
published up to 2013. In GBD 2015, stages two and three of the literature review were conducted, and 
in GBD 2016, stage 1 was repeated to update our electronic database search to capture data sources 
published between January 2013 and August 2016. 
The inclusion criteria stipulated that: (1) the publication year must be from 1980 onward; (2) “caseness” 
must be based on clinical threshold as established by the DSM or ICD; (3) sufficient information must be 
provided on study method and sample characteristics to assess the quality of the study; and (4) study 
samples must be representative of the general population (ie, inpatient or pharmacological treatment 
samples, case studies, veterans, or refugee samples were excluded). No limitation was set on the 
language of publication. Methods used for this systematic review have been reported in greater detail 
elsewhere.3-5 The table below shows the number of studies included in GBD 2016, as well as the number 
of countries or subnational units and GBD world regions represented. 
 Prevalence Incidence Remission 
Studies 132 3 3 
Countries/subnational geographies 103 2 3 
GBD world regions 18 2 2 
 
Age- and sex-splitting 
In GBD 2016, reported estimates of prevalence were split by age and sex where possible. First, if studies 
reported prevalence for broad age groups by sex (eg, prevalence in 15 to 65 year old males and females 
separately), and also by specific age groups but for both sexes combined (eg, prevalence in 15 to 30 year 
olds, then in 31 to 65 year olds, for males and females combined); age-specific estimates were split by 
sex using the reported sex ratio and bounds of uncertainty. Second, where studies reported estimates 
across age groups spanning 20 years or more, these were split into five-year age groups using the 
prevalence age pattern estimated by DisMod-MR 2.1.  
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  Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for anxiety 
disorder severity levels are shown below. 
 
Severity level Lay description DW (95% CI) 
Mild Feels mildly anxious and worried, which makes it slightly 
difficult to concentrate, remember things, and sleep. The 
person tires easily but is able to perform daily activities.  
0.03 (0.018–0.046) 
Moderate Feels anxious and worried, which makes it difficult to 
concentrate, remember things, and sleep. The person 
tires easily and finds it difficult to perform daily 
activities.  
0.133 (0.091–0.186) 
Severe Constantly feels very anxious and worried, which makes 
it difficult to concentrate, remember things, and sleep. 
The person has lost pleasure in life and thinks about 
suicide.  
0.523 (0.362–0.677) 
 
To determine the proportion of people with anxiety disorders within each of the severity levels, the 
United States’ Medical Expenditure Panel Survey (MEPS, conducted in annual waves since 1996)6, the US 
National Epidemiological Survey on Alcohol and Related Conditions (NESARC, conducted in two waves 
from 2001 to 2002 and 2004 to 2005)7, and the  Australian National Survey of Mental Health and 
Wellbeing of Adults (NSMHWB, conducted in 1997)8 were used to estimate the proportion of anxiety 
disorder cases asymptomatic (28.8%, 27.5%–30.1%),  mild (39.3%, 34.2%–44.2%), moderate (19.1%, 
15.8%–22.7%) and severe (12.7%, 9.2%–16.7%). 
 
Modelling strategy 
The GBD 2016 epidemiological modelling strategy for anxiety disorders made use of DisMod-MR 2.1. 
Data across all epidemiological parameters were initially included in the modelling process. The 
incidence studies reported estimates which were very low relative to the prevalence data. As prevalence 
studies contributed much greater world coverage than incidence studies, we excluded the incidence 
data, relying instead on data from the other parameters. We assumed no incidence and prevalence 
before age 2 and after age 95. This minimum age of onset was corroborated with expert feedback and 
existing literature on anxiety disorders. Remission was set to a maximum of 0.2, consistent with the data 
points available.  
 
Study-level covariates were used to accommodate for between-study variability in the raw prevalence 
data. A cv_past year recall covariate adjusted all data points derived from past year prevalence toward 
the level they would have been if the study had captured point/past-month prevalence. The latter 
prevalence period is less affected by recall bias. A cv_school survey covariate adjusted estimates derived 
from school surveys downward to the level they would have been had the study conducted a fully 
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representative population survey. A country-level covariate identifying for each GBD location the mean 
mortality rate in the previous 10 years due to war and terrorism was also included in the anxiety 
disorders model. This informed the estimation of prevalence given existing evidence to show a positive 
association between conflict status and the prevalence for anxiety disorders.9,10 Betas and 
exponentiated values (which can be interpreted as an odds ratio) for each study-level covariate are 
shown in the table below: 
Study/country covariate Parameter beta Exponentiated beta 
cv_past year recall Prevalence 0.36 (0.30 — 0.42) 1.43 (1.36 — 1.53) 
cv_school survey Prevalence 0.30 (0.15 — 0.46) 1.35 (1.17 — 1.58) 
Mean war mortality rate in the 
previous 10 years  
Prevalence 0.50 (0.030 — 0.97) 1.66 (1.03 — 2.65) 
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Case definition 
According to the Diagnostic and Statistical Manual of Mental Disorders fourth edition, text revision (DSM-
IV-TR),1 anorexia nervosa (AN) is an eating disorder characterized by: 
a) Refusal to maintain body weight at or above a minimally normal weight for age and height (eg,
weight loss leading to maintenance of body weight less than 85% of that expected; or failure to
make expected weight gain during period of growth, leading to body weight less than 85% of that
expected).
b) Intense fear of gaining weight or becoming fat, even though underweight (expanded to include
any behavior that interferes with weight gain in DSM-52).
c) Disturbance in the way in which one’s body weight or shape is experienced, undue influence of
body weight or shape on self-evaluation, or denial of the seriousness of the current low body
weight.
d) In postmenarcheal females, amenorrhea, ie, the absence of at least three consecutive menstrual
cycles (this criterion was removed in DSM-52).
Included in GBD were cases meeting diagnostic criteria according to DSM1 or the International 
Classification of Diseases (ICD).3 These were identified by the following codes: 307.1 (DSM-IV-TR) and 
F50.0 (ICD-10). Different versions of DSM (DSM-III, DSM-III-R, DSM-IV, DSM-IV-TR, and DSM-5) and ICD 
(ICD-9 and ICD-10) were accepted. 
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Input data 
Model inputs 
A series of systematic literature reviews were conducted to capture studies reporting the prevalence, 
incidence, remission, and excess mortality of AN. The reviews incorporated searches of peer-reviewed 
literature via electronic databases, investigations of grey literature, and consultation with experts. In 
order for a study to be included, it must have been published during or after 1980, use DSM or ICD 
criteria to define cases, provide sufficient details on study methodology and sample characteristics to 
determine study quality, and be representative of the general population rather than a special 
population, eg, prison inmates. No limitation was set on the language of publication. Detailed descriptions 
of this methodology have been published elsewhere.4 This methodology was utilized in GBD 2010, GBD 
2013, and GBD 2015. The systematic review will be updated again for GBD 2017. 
The final dataset for GBD 2016 included 110 prevalence estimates, 40 incidence estimates, 20 remission 
estimates, and 28 excess mortality estimates. The table below shows the number of studies for each 
parameter as well as the number of countries/subnationals and GBD world regions covered by the 
available data. 
Prevalence Incidence Remission Mortality 
Studies 49 6 19 22 
Countries/subnationals 35 6 14 15 
GBD world regions 10 2 4 3 
Disability weight 
No severity splits were applied to AN. The lay description and disability weight for AN are shown in the 
table below. 
Lay description DW (95% CI) 
Feels an overwhelming need to starve and exercises 
excessively to lose weight. The person is very thin, weak, 
and anxious. 
0.224 (0.150–0.312) 
Modelling strategy  
We assumed no incidence prior to age 5 or from 50 years onward. These settings are in line with those 
placed on the corresponding cause of death model for anorexia nervosa. A cap of 0.6 was placed on 
remission in order to obtain a more plausible fit of the model. We used the function in DisMod-MR 2.1 to 
pull in cause-specific mortality rate (CSMR) data from our CODEm and CODcorrect analyses. As such, 
other mortality data (standardized mortality ratios and relative risks) were excluded. We also used these 
CSMR data to estimate priors on excess mortality rates (EMR) by matching them with prevalence data 
points for the same geography and study year and dividing CSMR by prevalence. A country-level 
covariate, lagged distributed income (LDI), was included. This covariate represents a moving average of 
gross domestic product (GDP) over time. The limits placed on this covariate meant that prevalence was 
assumed to increase with rising GDP. LDI was also applied to excess mortality data in order to better 
inform regional distribution. The table below illustrates the covariates, parameters, beta and 
exponentiated beta values for AN. 
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Covariate Parameter beta Exponentiated beta 
LDI ($ per capita) Prevalence 0.43 (0.28–0.50) 1.54 (1.32–1.64) 
LDI ($ per capita) Excess mortality -0.36 (-0.49 – -0.13) 0.70 (0.61–0.88) 
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Case definition 
According to the Diagnostic and Statistical Manual of Mental Disorders fourth edition, text revision (DSM-
IV-TR),1 bulimia nervosa (BN) is an eating disorder characterized by: 
a) Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the
following:
1) eating, in a discrete period of time (eg, within any two-hour period), an amount of food
that is definitely larger than most people would eat during a similar period of time and
under similar circumstances
2) a sense of lack of control over eating during the episode (eg, a feeling that one cannot
stop eating or control what or how much one is eating)
b) Recurrent inappropriate compensatory behavior in order to prevent weight gain, such as self-
induced vomiting; misuse of laxatives, diuretics, enemas, or other medications; fasting; or
excessive exercise.
c) The binge eating and inappropriate compensatory behaviors both occur, on average, at least
twice a week for three months (changed to once a week for three months in DSM-52).
d) Self-evaluation is unduly influenced by body shape and weight.
e) The disturbance does not occur exclusively during episodes of anorexia nervosa.
Included in GBD were cases meeting diagnostic criteria according to DSM1 or the International 
Classification of Diseases (ICD).3 These were identified by the following codes: 307.51 (DSM-IV-TR) and 
F50.1 (ICD-10). Different versions of DSM (DSM-III, DSM-III-R, DSM-IV, DSM-IV-TR, and DSM-5) and ICD 
(ICD-9 and ICD-10) were accepted. 
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Input data 
Model inputs 
A series of systematic literature reviews were conducted to capture studies reporting the prevalence, 
incidence, remission, and excess mortality of BN. The reviews incorporated searches of peer-reviewed 
literature via electronic databases, investigations of grey literature, and consultation with experts. In 
order for a study to be included, it must have been published during or after 1980, use DSM or ICD 
criteria to define cases, provide sufficient details on study methodology and sample characteristics to 
determine study quality, and be representative of the general population rather than a special 
population, eg, prison inmates. No limitation was set on the language of publication. Detailed descriptions 
of this methodology have been published elsewhere.4 This methodology was utilized in GBD 2010, GBD 
2013, and GBD 2015. The systematic review will be updated again for GBD 2017. 
The final dataset for GBD 2016 included 148 prevalence estimates, 24 incidence estimates, 14 remission 
estimates, and 11 excess mortality estimates. The table below shows the number of studies for each 
parameter as well as the number of countries/subnationals and GBD world regions covered by the 
available data. 
Prevalence Incidence Remission Mortality 
Studies 49 4 14 11 
Countries/subnationals 36 4 11 9 
GBD world regions 11 1 3 2 
Disability weight 
No severity splits were applied to BN. The lay description and disability weight for BN is shown in the 
table below. 
Lay description DW (95% CI) 
Has uncontrolled overeating followed by guilt, starving, 
and vomiting to lose weight. 
0.223 (0.149–0.311) 
Modelling strategy  
We assumed no incidence prior to 10 years of age or onward from 40 years of age. We used the function 
in DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) data from our CODEm and CODcorrect 
analyses. As such, other mortality data (standardized mortality ratios and relative risks) were excluded. 
We also used CSMR data to estimate priors on excess mortality rates (EMR) by matching them with 
prevalence data points for the same geography and study year and dividing CSMR by prevalence. A study-
level covariate was applied which adjusted estimates based on ICD criteria toward those based on DSM 
criteria. A country-level covariate, lagged distributed income (LDI), was also included. This covariate 
represents a moving average of gross domestic product (GDP) over time. The limits placed on this 
covariate meant that prevalence was assumed to increase with rising GDP. LDI was also applied to excess 
mortality data in order to better inform regional distribution. The table below illustrates the covariates, 
parameters, beta and exponentiated beta values for BN. 
Covariate Parameter beta Exponentiated beta 
ICD classification Prevalence 0.66 (0.015–1.34) 1.93 (1.01–3.80) 
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LDI Prevalence 0.43 (0.26–0.50) 1.53 (1.30–1.65) 
LDI Excess mortality -0.33 (-0.49 – -0.12) 0.72 (0.61–0.89) 
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Autism 
 
Flowchart 
Case definition 
Autism (also known as autistic disorder or childhood autism) is an autistic spectrum disorder (ASD) with 
onset occurring in early childhood. It is characterized by severe and pervasive impairment in several areas 
of development, including social interaction and communication skills, along with restricted and 
repetitive patterns of behaviors and/or interests. As per criteria set by the Diagnostic and Statistical 
Manual of Mental Disorders fourth edition, text revision (DSM-IV-TR),1 diagnosis requires a total of six (or 
more) symptoms, with at least two symptoms of qualitative impairment in social interaction and at least 
one symptom of both qualitative impairment in communication and restricted, repetitive, stereotyped 
behavior. The recognized symptoms include: 
Qualitative impairment in social interaction 
a) marked impairment in the use of multiple nonverbal behaviors such as eye-to-eye gaze, facial 
expression, body postures, and gestures to regulate social interaction  
b) failure to develop peer relationships appropriate to developmental level  
c) a lack of spontaneous seeking to share enjoyment, interests, or achievements with other people  
d) lack of social or emotional reciprocity  
Qualitative impairments in communication  
a) delay in, or total lack of, the development of spoken language (not accompanied by an 
attempt to compensate through alternative modes of communication such as gesture)  
b) in individuals with adequate speech, marked impairment in the ability to initiate or sustain a 
conversation with others  
c) stereotyped and repetitive use of language or idiosyncratic language  
d) lack of varied, spontaneous make-believe play or social imitative play appropriate to 
developmental level  
Restricted repetitive and stereotyped patterns of behavior, interests, and activities  
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a) encompassing preoccupation with one or more stereotyped and restricted patterns of 
interest that is abnormal either in intensity or focus  
b) apparently inflexible adherence to specific, nonfunctional routines or rituals  
c) stereotyped and repetitive motor mannerisms 
d) persistent preoccupation with parts of objects  
Delays or abnormal functioning with onset prior to three years of age in at social interaction, language 
interaction, or symbolic or imaginate play is also required. Included in GBD were cases meeting diagnostic 
criteria according to DSM1 or the International Classification of Diseases (ICD).2 These were identified by 
the following codes: 299.00 (DSM-IV-TR) and F84 (ICD-10). Different versions of DSM (DSM-III, DSM-III-R, 
DSM-IV, DSM-IV-TR, and DSM-5) and ICD (ICD-9 and ICD-10) were accepted. 
Input data 
 Model inputs 
A series of systematic literature reviews were conducted to capture studies reporting the prevalence, 
incidence, remission, and excess mortality of autism. The reviews incorporated searches of peer-reviewed 
literature via electronic databases, investigations of grey literature, and consultation with experts. In 
order for a study to be included, it must have been published during or after 1980, use DSM or ICD 
criteria to define cases, provide sufficient details on study methodology and sample characteristics to 
determine study quality, and be representative of the general population rather than a special population 
eg, prison inmates. No limitation was set on the language of publication. Detailed descriptions of this 
methodology have been published elsewhere.3 This methodology was utilized in GBD 2010, GBD 2013, 
and GBD 2016.  
Prevalence estimates were split by age and sex where possible outside of DisMod-MR 2.1. Firstly if studies 
reported prevalence for broad age groups by sex (eg, prevalence in 15 to 65 year old males and females 
separately), and also by specific age groups but for both sexes combined (eg, prevalence in 15 to 30 year 
olds, then in 31 to 65 year olds, for males and females combined); age-specific estimates were split by sex 
using the reported sex ratio and bounds of uncertainty. Secondly, where studies reported estimates 
across age groups spanning 20 years or more, these were split into five-year age groups using the 
regional prevalence age pattern estimated by DisMod-MR 2.1. 
The final dataset for GBD 2016 included 174 prevalence estimates, 24 incidence estimates, 5 remission 
estimates, and 11 standardized mortality ratio estimates. The table below shows the number of studies 
for each parameter as well as the number of countries/subnationals and GBD world regions covered by 
the available data. 
 Prevalence Incidence Remission Mortality 
Studies 67 3 5 3 
Countries/subnationals 50 3 4 3 
GBD world regions 10 3 2 2 
 Severity split inputs 
Autism is one of the causes that contributes to the intellectual disability (ID) envelope. As such, a 
gradation of autism by level of severity was needed. Meta-analyses were conducted using data from six 
studies reporting information on the IQ level in those with autism in order to calculate the severity splits 
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by six sequelae: autism with 1) no ID, 2) borderline ID, 3) mild ID, 4) moderate ID, 5) severe ID, and 6) 
profound ID. The lay descriptions and disability weights for autism and each level of intellectual disability 
are shown in the table below. 
Health state Lay description DW (95% CI) 
Autism Has severe problems interacting with others and 
difficulty understanding simple questions or directions. 
The person has great difficulty with basic daily activities 
and becomes distressed by any change in routine. 
0.262 (0.176–0.365) 
ID, borderline Is slow in learning at school. As an adult, the person has 
some difficulty doing complex or unfamiliar tasks but 
otherwise functions independently. 
0.011 (0.005–0.024) 
ID, mild Has low intelligence and is slow in learning at school. As 
an adult, the person can live independently, but often 
needs help to raise children and can only work at simple 
supervised jobs. 
0.043 (0.028–0.067) 
ID, moderate Has low intelligence, and is slow in learning to speak and 
to do even simple tasks. As an adult, the person requires 
a lot of support to live independently and raise children. 
The person can only work at the simplest supervised jobs. 
0.098 (0.064–0.142) 
ID, severe Has very low intelligence and cannot speak more than a 
few words, needs constant supervision and help with 
most daily activities, and can do only the simplest tasks. 
0.157 (0.104–0.219) 
ID, profound Has very low intelligence, has almost no language, and 
does not understand even the most basic requests or 
instructions. The person requires constant supervision 
and help for all activities. 
0.196 (0.126–0.272) 
 
Modelling strategy  
We assumed no incidence from 15 years of age onward. A small setting was placed on excess mortality 
whereby only minimal excess mortality was allowed over the lifespan. Remission was set to 0 after expert 
consultation revealed we would not expect remission for autism. Settings for excess mortality and 
remission differ from settings used in GBD 2015 where excess mortality was originally set to 0 and a small 
setting was placed on remission whereby only minimal remission was allowed over the lifespan. The 
mortality data in the autism dataset consist of standardized mortality ratio estimates from high-income 
locations. DisMod MR 2.1 produced good global fit for these data; however, the region fit did not follow 
the data, leading to high estimates of standardised mortality ratio in high-income countries and low 
estimates of standardised mortality ratio in low- and middle-income countries. Excess mortality estimates 
by age, sex, and year were therefore calculated by pulling global estimates of standardised mortality ratio 
from DisMod MR 2.1 and applying the following formula: excess mortality rate =   (standardized mortality ratio − 1)  × all cause mortality rate 
Three study-level covariates were applied which: 1) adjusted estimates using a limited sampling strategy 
towards those using comprehensive sampling strategies (eg, those including private households and 
mainstream schools as well as healthcare and remedial therapy facilities), and 2) adjusted estimates 
based on older diagnostic criteria (prior to DSM-IV and ICD-10) toward estimates made using more 
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current criteria, and 3) adjusted estimates of ASD overall (ie, studies that did not report on the individual 
disorders) toward estimates representing autism. The third covariate is an addition in GBD 2016.  
Study covariate Parameter beta Exponentiated beta 
Non-comprehensive 
sampling strategy 
Prevalence -0.32 (-0.6 – -0.041) 0.73 (0.55–0.96) 
Identifies data classified 
by older criteria (ie, 
before DSM-IV and ICD-
10) 
Prevalence -0.54 (-0.9 – -0.18) 0.58 (0.41–0.83) 
Overall ASD estimates Prevalence 1.25 (0.9–1.60) 3.47 (2.45–4.94) 
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Asperger’s syndrome & other autistic spectrum disorders  
 
Flowchart 
 
 
Case definition 
Asperger’s syndrome is an autistic spectrum disorder (ASD) characterized by severe and sustained 
impairment in social interaction skills along with restricted and repetitive patterns of behavior or 
interests. As per criteria set by the Diagnostic and Statistical Manual of Mental Disorders fourth edition, 
text revision (DSM-IV-TR),1 diagnosis requires at least two symptoms of qualitative impairment in social 
interaction and at least one symptom of restricted, repetitive, stereotyped behavior. The recognized 
symptoms include: 
Qualitative impairment in social interaction 
a) marked impairment in the use of multiple nonverbal behaviors such as eye-to-eye gaze, facial 
expression, body postures, and gestures to regulate social interaction  
b) failure to develop peer relationships appropriate to developmental level  
c) a lack of spontaneous seeking to share enjoyment, interests, or achievements with other people  
d) lack of social or emotional reciprocity  
Restricted repetitive and stereotyped patterns of behavior, interests, and activities  
a) encompassing preoccupation with one or more stereotyped and restricted patterns of 
interest that is abnormal either in intensity or focus  
b) apparently inflexible adherence to specific, nonfunctional routines or rituals  
c) stereotyped and repetitive motor mannerisms 
d) persistent preoccupation with parts of objects  
Unlike autism, there is no clinically significant delay in language acquisition or cognitive development. 
Included in GBD were cases meeting diagnostic criteria according to DSM1 or the International 
Classification of Diseases (ICD).2 These were identified by the following codes: 299.8 (DSM-IV-TR) and 
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F84.5 (ICD-10). Different versions of DSM (DSM-III, DSM-III-R, DSM-IV, DSM-IV-TR, and DSM-5) and ICD 
(ICD-9 and ICD-10) were accepted. Estimates of other ASDs were also included such as Rett’s disorder 
(DSM-IV-TR: 299.8, ICD-10: F84.2), childhood disintegrative disorder (DSM-IV-TR: 299.1, ICD-10: F84.3), 
atypical autism (ICD-10: F84.1), overactive disorder associated with mental retardation and stereotyped 
movements (ICD-10: F84.4), and pervasive disorder not otherwise specified (DSM-IV-TR: 299.8, ICD-10: 
F84.8-F84.9). 
Input data 
 Model inputs 
A series of systematic literature reviews were conducted to capture studies reporting the prevalence, 
incidence, remission, and excess mortality of Asperger’s syndrome and other ASDs. The reviews 
incorporated searches of peer-reviewed literature via electronic databases, investigations of grey 
literature, and consultation with experts. In order for a study to be included, it must have been published 
during or after 1980, use DSM or ICD criteria to define cases, provide sufficient details on study 
methodology and sample characteristics to determine study quality, and be representative of the general 
population rather than a special population, eg, prison inmates. No limitation was set on the language of 
publication. Detailed descriptions of this methodology have been published elsewhere.3 This 
methodology was utilized in GBD 2010, GBD 2013, and GBD 2016.  
Prevalence estimates were split by age and sex where possible outside of DisMod-MR 2.1. Firstly if studies 
reported prevalence for broad age groups by sex (eg, prevalence in 15 to 65 year old males and females 
separately), and also by specific age groups but for both sexes combined (eg, prevalence in 15 to 30 year 
olds, then in 31 to 65 year olds, for males and females combined); age-specific estimates were split by sex 
using the reported sex ratio and bounds of uncertainty. Secondly, where studies reported estimates 
across age groups spanning 20 years or more, these were split into five-year age groups using the 
regional prevalence age pattern estimated by DisMod-MR 2.1. 
The final dataset for GBD 2016 included 78 prevalence estimates, 14 incidence estimates, 2 remission 
estimates, and 1 excess mortality estimate. The table below shows the number of studies for each 
parameter as well as the number of countries/subnationals and GBD world regions covered by the 
available data. 
 Prevalence Incidence Remission Mortality 
Studies 31 2 2 1 
Countries/subnationals 32 2 2 1 
GBD world regions 8 2 1 1 
 
 Disability weight 
No severity splits were applied to autism. The lay description and disability weight for autism are shown in 
the table below. 
Lay description DW (95% CI) 
Has difficulty interacting with other people and is slow to 
understand or respond to questions. The person is often 
preoccupied with one thing and has some difficulty with 
basic daily activities. 
0.104 (0.071–0.147) 
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 Modelling strategy  
We assumed no incidence from 15 years of age onward. This was changed from GBD 2015 where no 
incidence was assumed from 20 years of age onward. A small setting was placed on remission whereby 
only minimal remission was allowed over the lifespan. Excess mortality was set to 0 given the limited data 
demonstrating an association between Asperger’s syndrome and other ASDs and an increased risk of 
death. Only one study reported the excess mortality associated with Asperger’s syndrome and other ASDs 
and found no significantly increased risk of death. Two study-level covariates were applied. The first 
adjusted estimates of Asperger’s syndrome only toward those including both Asperger’s syndrome and 
other ASDs. The second adjusted estimates of ASD overall (ie, studies that did not report on the individual 
disorders) toward estimates representing Asperger’s syndrome and other ASDs. This approach was largely 
consistent with that of GBD 2015 with the exception of the addition of the latter covariate and the earlier 
age in which we assume no incidence onward. 
 
Study covariate Parameter beta Exponentiated beta 
Asperger’s syndrome only Prevalence -0.39 (-0.88 – -0.034)  0.67 (0.42–0.97) 
Overall ASD estimates Prevalence 0.97 (0.53–1.17) 2.65 (1.84–3.67) 
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Case definition 
Attention-deficit/hyperactivity disorder (ADHD) is an externalizing behavior disorder characterized by 
persistent inattention and/or hyperactivity-impulsivity. As per criteria set by the Diagnostic and Statistical 
Manual of Mental Disorders fourth edition, text revision (DSM-IV-TR)1, diagnosis requires six or more 
symptoms of inattention or hyperactivity-impulsivity to have persisted for at least six months in two or 
more settings causing significant impairment to functioning, with at least some impairing symptoms being 
present prior to 7 years of age (12 years of age in DSM-52). Recognized symptoms include: 
Inattention: 
• often fails to give close attention to details or makes careless mistakes in schoolwork, work, or
other activities
• often has difficulty sustaining attention in tasks or play activities
• often does not seem to listen when spoken to directly
• often does not follow through on instructions and fails to finish school work, chores, or duties in
the workplace (not due to oppositional behavior or failure to understand instructions)
• often has difficulty organizing tasks and activities
• often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (such
as schoolwork or homework)
• often loses things necessary for tasks or activities (eg, toys, school assignments, pencils, books, or
tools)
• is often easily distracted by extraneous stimuli
• is often forgetful in daily activities
Hyperactivity 
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• often fidgets with hands or feet or squirms in seat 
• often leaves seat in classroom or in other situations in which remaining seated is expected  
• often runs about or climbs excessively in situations in which it is inappropriate (in adolescents or 
adults, may be limited to subjective feelings of restlessness)  
• often has difficulty playing or engaging in leisure activities quietly  
• is often “on the go” or often acts as if “driven by a motor” 
• often talks excessively 
Impulsivity 
• often blurts out answers before questions have been completed 
• often has difficulty awaiting turn 
• often interrupts or intrudes on others (eg, butts into conversations or games) 
 
Included in GBD were cases meeting diagnostic criteria according to DSM1 or the International 
Classification of Diseases (ICD)3 (called “hyperkinetic disorder” in ICD). These were identified by the 
following codes: 314.0, 314.01 (DSM-IV-TR) and F90 (ICD-10). Different versions of DSM (DSM-III, DSM-III-
R, DSM-IV, DSM-IV-TR, and DSM-5) and ICD (ICD-9 and ICD-10) were accepted.  
Input data 
Model inputs 
A series of systematic literature reviews were conducted to capture studies reporting the prevalence, 
incidence, remission, and excess mortality of ADHD. The reviews incorporated searches of peer-reviewed 
literature via electronic databases, investigations of grey literature, and consultation with experts. In 
order for a study to be included, it must have been published during or after 1980, use DSM or ICD 
criteria to define cases, provide sufficient details on study methodology and sample characteristics to 
determine study quality, and be representative of the general population rather than a special 
population, eg, prison inmates. No limitation was set on the language of publication. Detailed descriptions 
of this methodology have been published elsewhere.4 This methodology was utilized in GBD 2010 and 
GBD 2013. GBD 2015 included additional sources identified by GBD experts and microdata where 
available. The systematic review methodology used in GBD 2010 and 2013 was replicated to update the 
dataset for GBD 2016. 
The final dataset for GBD 2016 included 290 prevalence estimates, five incidence estimates, 20 remission 
estimates, and three excess mortality estimates. The table below shows the number of studies for each 
parameter as well as the number of countries/subnationals and GBD world regions covered by the 
available data. 
 Prevalence Incidence Remission Mortality 
Studies 131 2 14 2 
Countries/subnationals 76 2 12 2 
GBD world regions 16 1 3 2 
 
Reported estimates of prevalence were split by age and sex where possible. If studies reported 
prevalence for broad age groups by sex (eg, prevalence in 5-18 year old males and females separately) 
and by specific age groups but for both sexes combined (eg, prevalence for 5-12 year olds and 13-18 year 
olds, for males and females combined), age-specific estimates were split by sex using the reported sex 
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ratio and bounds of uncertainty. Also, where studies reported estimates across age groups spanning 20 
years or more, these were split into five-year age groups using the prevalence age pattern estimated by 
DisMod-MR 2.1. 
Severity split inputs 
A severity split for the proportion of time spent symptomatic versus asymptomatic was based on data 
from the Great Smoky Mountains Study which assessed the levels of disability found in children and 
adolescents with mental disorders.5 Of those with ADHD, 48% reported disability while 20% of individuals 
with no diagnosis reported disability at the time of survey. Using these as estimates of the proportion of 
time with disability in the “average case,” the proportion of disability in children without a diagnosis was 
subtracted from the proportion with disability for ADHD, giving an adjusted proportion of 28%. Detailed 
descriptions of this methodology have been published elsewhere.6 The lay description and disability 
weight for ADHD is shown in the table below. 
Lay description DW (95% CI) 
Is hyperactive and has difficulty concentrating, 
remembering things, and completing tasks 
0.045 (0.028–0.066) 
 
Modelling strategy  
We assumed no incidence prior to 3 years of age or onward from 12 years of age. The minimum age of 
onset was set in consultation with experts and based on current literature, while the upper age limit on 
incidence was set in line with the latest DSM-5 criteria. Remission was set to zero prior to 12 years, in line 
with the restriction on incidence. Excess mortality was set to zero given only three estimates were found 
for this parameter. Three covariates were included in the model. The first covariate was an informant 
covariate which adjusted estimates not requiring agreement between informants (eg, diagnosis made if 
either a teacher or parent indicates ADHD) toward estimates which required informant agreement. The 
second covariate adjusted estimates not requiring impairment (or those not specifying whether 
impairment was required) for diagnosis toward those which required impairment. The third covariate 
adjusted studies using small, community samples toward studies representative of entire regions or 
countries. Bounds for these covariates were calculated from the epidemiological data and applied in 
DisMod-MR 2.1. 
Study covariate Parameter beta Exponentiated beta 
No informant 
agreement 
Prevalence 0.53 (0.45–0.72) 1.71 (1.57–2.05) 
No impairment Prevalence 0.068 (0.0043–0.21) 1.07 (1.00–1.24) 
Small, community-level 
studies 
Prevalence 0.53 (0.31–0.75) 1.69 (1.36–2.12) 
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Case definition 
Conduct disorder (CD) is an externalizing behavior disorder characterized by a pattern of antisocial 
behavior that violates the basic rights of others or major age-appropriate societal norms. As per criteria 
set by the Diagnostic and Statistical Manual of Mental Disorders fourth edition, text revision (DSM-IV-
TR),1 diagnosis requires three or more of the following symptoms to be present in the past 12 months 
(with at least one present in the last six months) and cause significant impairment in functioning. 
Symptoms include: 
Aggression to people and animals 
• often bullies, threatens, or intimidates others
• often initiates physical fights
• has used a weapon that can cause serious physical harm to others (eg, a bat, brick, broken bottle,
knife, gun)
• has been physically cruel to people
• has been physically cruel to animals
• has stolen while confronting a victim (eg, mugging, purse snatching, extortion, armed robbery)
• has forced someone into sexual activity
Destruction of property 
• has deliberately engaged in fire setting with the intention of causing serious damage
• has deliberately destroyed others’ property (other than by fire setting)
Deceitfulness or theft 
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• has broken into someone else’s house, building, or car  
• often lies to obtain goods or favors or to avoid obligations (ie, “cons” others)  
• has stolen items of nontrivial value without confronting a victim (eg, shoplifting, but without 
breaking and entering; forgery)  
Serious violations of rules  
• often stays out at night despite parental prohibitions, beginning before age 13 years  
• has run away from home overnight at least twice while living in parental or parental surrogate 
home (or once without returning for a lengthy period)  
• is often truant from school, beginning before age 13 years 
 
CD is considered a disorder of childhood but can be diagnosed in adults who display such behaviors yet 
do not meet the criteria for antisocial personality disorder. However, there are almost no studies 
measuring adult CD as existing studies in this area tend to measure adult antisocial behavior rather than 
adult CD.2 As such, only childhood CD (ie, cases prior to 18 years of age) was modeled in GBD. 
Included in GBD were cases meeting diagnostic criteria according to DSM1 or the International 
Classification of Diseases (ICD).3 These were identified by the following codes: 312 (DSM-IV-TR) and F91 
(ICD-10). Different versions of DSM (DSM-III, DSM-III-R, DSM-IV, DSM-IV-TR, and DSM-5) and ICD (ICD-9 
and ICD-10) were accepted. Estimates also including oppositional defiant disorder (ODD; DSM-IV-TR: 
313.81, ICD-10: F91.3) or disruptive behavior disorder not otherwise specified (DDNOS, DSM-IV-TR: 312.9, 
ICD-10: 91.9) were accepted and adjusted with a covariate during the modelling process. 
Input data 
 Model inputs 
A series of systematic literature reviews were conducted to capture studies reporting the prevalence, 
incidence, remission, and excess mortality of CD. The reviews incorporated searches of peer-reviewed 
literature via electronic databases, investigations of grey literature, and consultation with experts. In 
order for a study to be included, it must have been published during or after 1980, use DSM or ICD 
criteria to define cases, provide sufficient details on study methodology and sample characteristics to 
determine study quality, and be representative of the general population rather than a special 
population, eg, prison inmates. No limitation was set on the language of publication. Detailed descriptions 
of this methodology have been published elsewhere.2 This methodology was utilized in GBD 2010 and 
GBD 2013. GBD 2015 included additional sources identified by GBD experts and microdata where 
available. The systematic review methodology used in GBD 2010 and 2013 was replicated to update the 
dataset for GBD 2016. 
The final dataset for GBD 2016 included 176 prevalence estimates, 12 incidence estimates, and 11 
remission estimates. No estimates of excess mortality were found for CD. The table below shows the 
number of studies for each parameter as well as the number of countries/subnationals and GBD world 
regions covered by the available data. 
 Prevalence Incidence Remission Mortality 
Studies 65 4 5 0 
Countries/subnationals 50 6 6 0 
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GBD world regions 14 2 2 0 
 
Reported estimates of prevalence were split by age and sex where possible. If studies reported 
prevalence for broad age groups by sex (eg, prevalence in 5-18 year old males and females separately) 
and by specific age groups but for both sexes combined (eg, prevalence for 5-12 year olds and 13-18 year 
olds, for males and females combined), age-specific estimates were split by sex using the reported sex 
ratio and bounds of uncertainty. 
Severity split inputs 
A severity split for the proportion of time spent symptomatic versus asymptomatic was based on data 
from the Great Smoky Mountains Study which assessed the levels of disability found in children and 
adolescents with mental disorders.4 Of those with CD, 72% reported disability while 20% of individuals 
with no diagnosis reported disability at the time of survey. Using these as estimates of the proportion of 
time with disability in the “average case,” the proportion of disability in children without a diagnosis was 
subtracted from the proportion with disability for CD, giving an adjusted proportion of 52%. Detailed 
descriptions of this methodology have been published elsewhere.5 The lay description and disability 
weight for CD is shown in the table below. 
Lay description DW (95% CI) 
Has frequent behavior problems, which are sometimes 
violent. The person often has difficulty interacting with 
other people and feels irritable 
0.241 (0.159–0.341) 
 
Modelling strategy  
We assumed no incidence or prevalence prior to 5 years of age or after 18 years of age. The minimum 
age of onset was set in consultation with experts while the upper age limit was set in line with DSM 
criteria. Excess mortality was set to zero given the absence of data demonstrating an association between 
CD and an increased risk of death. Remission and incidence were capped between ages 4 and 17 years in 
order to gain more plausible output. A covariate was used to adjust any prevalence estimates which also 
included cases of oppositional defiant disorder and/or disruptive behavior disorder not otherwise 
specified towards those including CD only. 
 
Covariate Parameter beta Exponentiated beta 
Identifies estimates 
also containing ODD 
&/or DDNOS cases 
Prevalence 0.65 (0.41 — 0.89) 1.91 (1.51 — 2.43) 
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Case Definition 
In addition to the individual mental disorders for which we estimate burden, we also estimate the non-
fatal burden attributable to a residual cause of “other mental disorders.” This is made up of an 
aggregate group of personality disorders. Personality disorders are characterized by pervasive, inflexible 
and maladaptive patterns of behaviour and inner experience which are markedly different from what is 
considered to be acceptable in the individual’s culture. These disorders tend to be chronic and are 
associated with significant distress or disability. Included in GBD 2016 were cases meeting diagnostic 
criteria for personality disorders according to the Diagnostic and Statistical Manual of Mental Disorders 
(DSM), or the equivalent diagnosis in the International Classification of Diseases (ICD).1,2 The aggregated 
group of personality disorders used in GBD 2016 captured any of the following; 
 Paranoid personality disorder 
 Schizoid personality disorder 
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 Schizotypal personality disorder 
 Antisocial personality disorder 
 Borderline personality disorder 
 Histrionic personality disorder 
 Narcissistic personality disorder 
 Avoidant personality disorder 
 Dependent personality disorder 
 Obsessive-compulsive personality disorder 
 Personality disorder not otherwise specified 
 
Input data 
 Model inputs 
Prevalence estimates for the above personality disorders were obtained from the US National 
Epidemiological Survey on Alcohol and Related Conditions (NESARC, conducted in two waves from 
2001–2002 and 2004–2005)3 and the Australian National Survey of Mental Health and Wellbeing of 
Adults (NSMHWB, conducted in 1997).4 Given that personality disorders often co-occur with other 
mental and substance use disorders, an adjustment for comorbidity is important so as not to 
overestimate the overall burden attributable to mental and substance use disorders. Participants 
meeting criteria for any type of personality disorders from the NESARC and NSMHWB surveys were 
counted as a prevalent case only if they did not simultaneously meet criteria for another mental and 
substance use disorder featured in GBD 2016.  
Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights applied to the 
personality disorders within this residual group are shown below and were those estimated for anxiety 
disorders. 
Severity level Lay description DW (95% CI) 
Mild Feels mildly anxious and worried, which makes it slightly 
difficult to concentrate, remember things, and sleep. The 
person tires easily but is able to perform daily activities.  
0.03 (0.018–0.046) 
Moderate Feels anxious and worried, which makes it difficult to 
concentrate, remember things, and sleep. The person 
tires easily and finds it difficult to perform daily 
activities.  
0.133 (0.091–0.186) 
Severe Constantly feels very anxious and worried, which makes 
it difficult to concentrate, remember things, and sleep. 
The person has lost pleasure in life and thinks about 
suicide.  
0.523 (0.362–0.677) 
 
To determine the proportion of people with personality disorders within each of the severity levels,  the 
NSMHWB survey was used to estimate the proportion of cases asymptomatic (30%, 28%–32%),  mild 
(41%, 33%–47%), moderate (15%, 11%–20%) and severe (14%, 10%–18%). 
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 Modelling Strategy 
The GBD 2016 epidemiological modelling strategy made use of DisMod-MR 2.1. As we only had 
prevalence data available, a number of expert priors were used in order to run a full-parameter model. 
We assumed no incidence and prevalence before age 14. This minimum age of onset was corroborated 
with expert feedback and DSM criteria highlighting the fact that personality disorders typically become 
recognizable during adolescence and early adulthood. Remission was set to a maximum of 0.01, given 
that these are understood to be chronic disorders with little or no complete remission. Excess mortality 
was set to 0 in this model, in the absence of mortality data required for DisMod-MR 2.1 modelling 
purposes. 
Study-level covariates were used to accommodate for between-study variability in the raw prevalence 
data. A cv_NESARC covariate adjusted all data points derived from NESARC toward the level of data 
points from estimates from the NSMHWB. The latter survey was made up of a more representative list 
of personality disorders and produced estimates along the levels of what we would expect for 
personality disorders. The corresponding beta and exponentiated value (which can be interpreted as an 
odds ratio) is shown in the table below: 
Study covariate Parameter beta Exponentiated beta 
cv_NESARC  Prevalence 0.67 (0.35–0.96) 1.95 (1.42–2.60) 
 
In this model, global prevalence was exclusively estimated using prevalence estimates from two surveys 
from the United States and Australia where we had unit record data available to estimate the 
prevalence of personality disorders, excluding those not simultaneously meeting criteria for another 
mental or substance use disorder. Given the sparsity of data, we applied a restriction on location 
random-effects of -0.1 to 0.1 to further guide prevalence estimation. We are currently undertaking a 
literature review of population-survey data on the epidemiology of personality disorders across low-, 
middle-, and high-income countries with the aim of providing more robust and globally representative 
burden estimates for personality disorders in future GBD studies. 
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Case definition 
The case definitions and diagnostic criteria are presented in the table below. For full accounting 
of associated ICD 9 and ICD 10 codes, please refer to Appendix Table 4. 
Criterion Definition 
1. Diabetes mellitus parent Diabetes mellitus (DM) was defined as fasting plasma glucose 
(FPG) > 126 mg/dL (7 mmol/L) or being on treatment for 
diabetes. 
2. Uncomplicated diabetes mellitus Cases of DM that do not have any of the following 
complications: neuropathy, foot ulcer, leg amputation, or vision 
loss  
3. Diabetic neuropathy Cases of DM that experience diagnosable neuropathy 
4. Diabetic foot due to neuropathy Cases of DM that currently have a foot ulcer 
5. Diabetic neuropathy and
amputation with treatment 
Cases of DM that have had a leg amputation above or below the 
knee, with treatment consisting of a prosthetic limb  
6. Diabetic neuropathy and
amputation without treatment 
Cases of DM that have had a leg amputation above or below the 
knee, with no prosthetic limb  
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7. Moderate vision impairment due 
to diabetes mellitus  
Cases of DM that have moderate vision loss due to diabetic 
retinopathy  
8. Severe vision impairment due to 
diabetes mellitus  
Cases of DM that have severe vision loss due to diabetic 
retinopathy  
9. Blindness due to diabetes 
mellitus  
Cases of DM that have blindness due to diabetic retinopathy  
  
Diabetes mellitus parent: 
Data seeking  
 
1. A systematic review of the literature was done for GBD 2016 with the following search terms:  
  
Diabetes mellitus search string: (diabetes[TI] AND (prevalence[TIAB] OR incidence[TIAB])) OR ('diabetes 
mellitus'[MeSH Terms] AND 'epidemiology'[MeSH Terms]) OR (diabetes[TI] AND 'epidemiology'[MeSH 
Terms]) NOT gestational[All Fields] NOT ('neoplasms'[MeSH Terms] OR 'neoplasms'[All Fields] OR 
'cancer'[All Fields]) NOT ('mice'[MeSH Terms] OR 'mice'[All Fields]) NOT ('schizophrenia'[MeSH Terms] 
OR 'schizophrenia'[All Fields]) NOT ('emigrants and immigrants'[MeSH Terms] OR ('emigrants'[All Fields] 
AND 'immigrants'[All Fields]) OR 'emigrants and immigrants'[All Fields] OR 'immigrants'[All Fields]) NOT 
('pregnancy'[MeSH Terms] OR 'pregnancy'[All Fields] OR 'gestation'[All Fields]) NOT ('rats'[MeSH Terms] 
OR 'rats'[All Fields] OR 'rat'[All Fields]) NOT ('kidney'[MeSH Terms] OR 'kidney'[All Fields]) NOT renal[All 
Fields] NOT ('vitamins'[Pharmacological Action] OR 'vitamins'[MeSH Terms] OR 'vitamins'[All Fields] OR 
'vitamin'[All Fields])  
 
And 
 
FPG search string:  ((“glucose”[Mesh] OR “hyperglycemia”[Mesh] OR “prediabetic state”[Mesh]) AND 
"Geographic Locations"[Mesh] NOT "United States"[Mesh]) AND ("humans"[Mesh] AND "adult"[MeSH]) 
AND ("Data Collection"[Mesh] OR "Health Services Research"[Mesh] OR "Population 
Surveillance"[Mesh] OR "Vital statistics"[Mesh] OR "Population"[Mesh] OR "Epidemiology"[Mesh] OR 
"surve*"[TiAb]) NOT Comment[ptyp] NOT Case Reports[ptyp]) NOT "hospital"[TiAb] 
 
 Search date: January 5, 2017 
  
The search took place for the following dates: 1/1/2016– 12/31/2016. The number of studies returned 
was 1,976, and the number of studies extracted was 26.  
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2. We systematically searched the Global Health Data Exchange (GHDx) for multi-country survey 
programs, national surveys, and longitudinal studies that was tagged with either fasting plasma 
glucose (FPG) or Diabetes mellitus. Each data source we found was tagged with whether the file 
contained microdata and whether the file contained data on FPG (biomarker). In the interest of 
time, we prioritized the data sources we reviewed and extracted based on whether the source was 
tagged with microdata and biomarker information.  
 
3. To capture any remaining sources not identified in the GHDx or in PubMed, we looked to other 
leaders in the field to ensure our datasets were as comprehensive as possible. These included data 
sources used by other research groups that report on the global burden of diabetes3,4, microdata 
from not-yet published national studies, and publications that were not captured in the PubMed 
search string. 
Figure 1: PRISMA diagram of data sources used in GBD 2016 Diabetes mellitus model 
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The table below illustrates the number of data sources used for the GBD 2016 estimation of diabetes 
mellitus parent:  
Prevalence Incidence Mortality risk Relative risk 
Studies 806 132 8 1 
Data inputs 
Purpose: 
To incorporate all available data related to population-representative estimates of diabetes, we 
accepted other measures of blood sugar (hemoglobin A1c, oral glucose tolerance test, post prandial 
glucose test) to define diabetes and mean fasting plasma glucose (FPG) in a population when data on 
diabetes was not available as data inputs.   
Data: 
1. Data inputs come from 4 sources:
 Estimates of diabetes in a representative population
 Estimates of mean FPG in a representative population
 Individual-level data of fasting plasma glucose measured from surveys
 MarketScan, which are insurance claims data from the United States
When a study reported both mean fasting plasma glucose (FPG) and prevalence of diabetes, we used 
the prevalence of diabetes. Where possible, individual-level data from a cohort superseded any data 
described in a study. Individual-level data was collapsed and aggregated to produce estimates for each 
age group, sex, location, and year a survey is conducted. 
2. Covariates
To inform our estimates in data-sparse countries, we systematically tested a range of covariates and 
selected two covariates based on AIC and adjusted R2. These included prevalence of obesity per location 
and lag-distributed income per capita (LDI). 
Data processing 
We perform several processing steps to the data in order to address sampling and measurement 
inconsistencies that will ensure the data are comparable across data sources and between high fasting 
plasma glucose modeling efforts. 
1. Small sample size: Estimates in a sex and age group with a sample size <30 persons was
considered a small sample size. In order to avoid small sample size problems that may bias
estimates, data were collapsed into the next age group in the same study till the sample size
reached at least 30 persons. The intent of collapsing the data is to preserve as much granularity
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between age groups as possible which determined whether the collapse occurred with a 
younger or older age group. If the entire study sample consisted of <30 persons and did not 
include a population-weight, the study was excluded from the modeling process. The estimates 
were re-calculated if case count and sample size were available or the population-weighted 
estimate was calculated when only sample size was available. 
2. Time, Age, and Sex Splitting
a. Time: Prior to modeling in DisMod, any study period that spanned more than 5 years was
duplicated.
b. Age: Prior to modeling in DisMod, data provided in age groups wider than the GBD 5-year
age groups were split using the global age pattern of diabetes mellitus from data that were
in age groups less than 20-year age groups. Uncertainty was propagated by multiplying the
standard error of the data performed by the square root of the number of splits performed.
c. Sex: Prior to modeling in DisMod, data that does not differentiate gender is split into male
and female according to the global male to female ratio from data with sex-specific data.
Uncertainty was propagated by multiplying the standard error of the data performed by the
square root of the number of splits performed.
3. Mean FPG processing: For more details on how datapoints on mean FPG was processed, please 
see the High Fasting Plasma Glucose capstone appendix in the GBD 2016 Risk Factors Paper.
4. Crosswalks
1. Case-definition
We performed adjustments (crosswalks) to datapoints to standardize data to a reference 
definition: fasting plasma glucose (FPG) >126 mg/dL (7 mmol/L) or on treatment. 
a. Prevalence
i. Single-component
Single component case definitions consisted of diabetes defined based on the 
level of only one biomarker (e.g., FPG, HbA1c). 
1. FPG
We used an ensemble distribution to standardized the case definition of 
diabetes in surveys by estimating the prevalence of diabetes under different 
thresholds of FPG. We used individual-level measures of FPG in surveys of a 
representative population. This allowed us to capture the non-systematic 
change in the proportion of population above different levels of FPG. We 
adjusted the datapoint by applying the ratio between FPG above 126 mg/dL 
and the case-definition used in the study. For more details on the approach 
used in the ensemble distribution, please see the GBD 2016 Risk Factors 
Paper. 
2. HbA1c
We assumed that HbA1c >6.5% was equivalent to FPG >126 mg/dL. 
ii. Multi-component
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Multi-component case definition consisted of studies where more than 1 
glucose test was used in the study to identify different segments of the 
population (e.g. FPG and PPG).  
1. Multi-component that includes FPG >126 mg/dL
Multi-component case definitions that consisted of FPG >126 mg/dL 
were assumed to be equivalent to the reference case definition FPG 
>126 mg/dL or Treatment. 
2. Multi-component that does not include FPG >126 mg/dL
Case definitions that did not include FPG >126 mg/dL were excluded 
from the model. 
b. Non-prevalence measure
Data from studies with non-prevalence measures (e.g., incidence, relative risk, excess 
mortality) were marked with the case definition and adjusted to the reference case 
definition within DisMod. 
2. Marketscan
Data from MarketScan were included in the model and a study-level covariate was included in 
the model to adjust them. These datapoints were adjusted to the reference case definition 
within DisMod. 
3. Estimate prevalence of diabetes from mean FPG
We also used the ensemble distribution to estimate the prevalence of diabetes based on mean 
FPG in locations where data on prevalence of diabetes were not available.  For more details 
on the approach used in the ensemble distribution, please see the GBD 2016 Risk Factors 
Paper. 
Amputation due to diabetes mellitus 
Data seeking  
A systematic review of the literature was performed for GBD 2016 with the following search terms: 
(‘diabetes mellitus’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘diabetes 
mellitus’[All Fields]) AND ‘amputation’[All Fields] AND (proportion OR prevalence OR incidence) NOT 
gestational NOT cancer NOT mice NOT schizophrenia NOT immigrants NOT gestation NOT rat NOT 
kidney NOT renal NOT vitamin  
 Dates of search: 1/1/16-12/31/16
 Number of studies returned: 16
 Number of studies extracted: 1
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The table below indicates the data inputs for the GBD 2016 estimation of amputation due to diabetes 
mellitus.  
  
  Prevalence  Incidence  Mortality risk  
Studies  12  32  5  
  
Diabetic neuropathy  
Data seeking  
 
A systematic review of the literature was performed for GBD 2016 with the following search terms:   
 
(“diabetes mellitus”[MeSH Terms] OR (“diabetes”[All Fields] AND “mellitus”[All Fields]) OR “diabetes 
mellitus”[All Fields]) AND neuropathy[All Fields] AND (proportion OR prevalence OR incidence) NOT 
gestational NOT cancer NOT mice NOT schizophrenia NOT immigrants NOT gestation NOT rat NOT 
kidney NOT renal NOT vitamin  
  
 Dates: 1/1/16-12/31/16 
 Number of studies returned: 170 
 Number of studies extracted: 1 
  
The table below illustrates the model inputs for the GBD 2016 estimation process:  
  
  Proportion  
Studies  89  
  
Diabetic foot ulcer  
Data seeking  
 
A systematic review of the literature was performed for GBD 2016 with the following search terms:  
  
((("diabetes mellitus"[MeSH Terms] OR ("diabetes"[All Fields] AND "mellitus"[All Fields]) OR "diabetes 
mellitus"[All Fields] OR "diabetes"[All Fields]) AND ("foot"[MeSH Terms] OR "foot"[All Fields]) AND 
("ulcer"[MeSH Terms] OR "ulcer"[All Fields])) NOT ("neoplasms"[MeSH Terms] OR "neoplasms"[All 
Fields] OR "cancer"[All Fields]) NOT ("mice"[MeSH Terms] OR "mice"[All Fields]) NOT ("emigrants and 
immigrants"[MeSH Terms] OR ("emigrants"[All Fields] AND "immigrants"[All Fields]) OR "emigrants and 
immigrants"[All Fields] OR "immigrants"[All Fields]) NOT ("pregnancy"[MeSH Terms] OR "pregnancy"[All 
Fields] OR "gestation"[All Fields]) NOT ("vitamins"[Pharmacological Action] OR "vitamins"[MeSH Terms] 
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OR "vitamins"[All Fields] OR "vitamin"[All Fields]) NOT renal[All Fields] NOT ("kidney"[MeSH Terms] OR 
"kidney"[All Fields]) AND (proportion[All Fields] OR "incidence"[All Fields] OR "prevalence"[All Fields]) 
NOT ("schizophrenia"[MeSH Terms] OR "schizophrenia"[All Fields]) NOT ("rats"[MeSH Terms] OR 
"rats"[All Fields] OR "rat"[All Fields])) 
  
 Dates: 1/1/16-12/31/16 
 Number of studies returned: 48 
 Number of studies extracted: 0  
  
The table below illustrates the data inputs used for the GBD 2016 modeling process.  
  
  Proportion  
Studies  43  
  
Modeling strategy   
 
DisMod Model 
For GBD 2016, we estimated the overall prevalence of diabetes using DisMod MR‐2.1, a Bayesian 
metaregression. DisMod-MR produces estimates of the prevalence of diabetes for each age, sex, 
geographic location, and year. We also estimated amputation due to diabetes mellitus, diabetic 
neuropathy, and diabetic foot using DisMod. We then multiply all proportion draws from 
neuropathy/foot/amputation models by the parent diabetes model so that all estimates are in the same 
population‐space.  
  
Next, we squeeze (neuropathy + moderate vision loss + severe vision loss) to (90% of parent diabetes) 
prevalence if sum exceeds that 90%. This is to ensure that at least 10% of diabetes cases are 
uncomplicated for all draws. We then squeeze (amputation + foot ulcer) to (90% of neuropathy) 
prevalence if sum exceeds 90%. This is to ensure that at least 10% of diabetic neuropathy cases do not 
have foot ulcer or amputation for all draws. This treats foot ulcer and amputation as mutually exclusive 
categories by assuming a patient won’t have both simultaneously.  
  
From here, we calculate uncomplicated diabetes as the remainder of diabetes cases exclusive of 
neuropathy and vision loss. In addition, we estimate the prevalence of amputation due to diabetes is 
split into with and without treatment using scaled HSA values. For diabetic amputation, we calculated a 
distribution of treated versus untreated amputation, defined as receiving a prosthetic or not. We first 
rescaled the IHME health system access estimates to be between 0 and 0.9, under the assumption that 
10% of amputees will not receive a prosthetic, even in high income countries. We based this assumption 
on the retrospective study by Moore et al, which found that about 80% of patients following major 
lower extremity amputation were fitted with prostheses in the authors’ institutions from 1978 to 1986 
in the USA. We then performed a population‐weighted average of this country‐specific value to obtain a 
proxy for the proportion of amputees that receive a prosthetic by super region. Because these are rough 
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estimates based on large assumptions, we applied confidence intervals of +/‐ 50% of the value to reflect 
our uncertainty.  
 
Diabetes mellitus 
• We set a value prior of 0 for remission for ages 0 to 14  
• We set a value prior of a maximum value of 0.01 for remission for ages 15 to 100  
• We set a value prior of a maximum value of 0.15 for excess mortality for all ages  
• We set a value prior of 0 for incidence for ages 0 to 1  
• We set a value prior of a maximum value of 0.1 for incidence for ages 1 to 100  
 
Study covariate  Parameter  beta  Exponentiated beta  
Sex 
With-condition 
mortality rate 
0.27 (-0.9 — 1.49) 1.31 (0.41 — 4.45)  
LDI (I$ per capita)  Excess mortality rate  -0.24 (-0.25 — -0.22) 0.79 (0.78 — 0.80) 
All MarketScan, year 
2000  
Prevalence  -0.48 (-0.53 — -0.43) 0.62 (0.59 — 0.65) 
All MarketScan, year 
2010 
Prevalence -0.17 (-0.21 — -0.11) 0.85 (0.81 — 0.90)  
All MarketScan, year 
2012  
Prevalence -0.15 (-0.2 — -0.091) 0.86 (0.82 — 0.91) 
Obesity  Prevalence  2.76 (2.46 — 3.07) 15.79 (11.66 — 21.57) 
Sex Prevalence 0.17 (0.15 — 0.19) 1.18 (1.16 — 1.21) 
Sex Incidence 0.035 (-0.042 — 0.11) 1.04 (0.96 — 1.12) 
Sex Excess mortality rate 0.18 (0.15 — 0.20) 1.19 (1.16 — 1.23) 
Sex 
Cause-specific 
mortality rate 
0.00030 (-0.0058 — 
0.0059) 
1.00 (0.99 — 1.01) 
  
Our estimate of the age-standardized global prevalence of diabetes is slightly lower than the estimates 
reported previously by the NCD Risk Factor Collaboration (NCD-RisC) and International Diabetes 
Federation (IDF). IDF reported a prevalence for the year 2013 of 8.3% (7.2–11.3) at ages 20 to 80, 
compared to our estimate for 2016 of 6.0% (5.1–7.0) for the same age range and using the IDF method 
of age-standardization (NCD-Risc: 
http://www.sciencedirect.com/science/article/pii/S0140673616006188 IDF: 
https://www.idf.org/component/attachments/attachments.html?id=1093&task=download.) The NCD-
RisC estimates of prevalence for ages over 18 for the year 2014 were 9.0% (7.2–11.1) in males and 7.9% 
(6.7–9.7) in females, compared to our 2016 estimates of 5.3% (4.5–6.2) and 4.9% (4.1–5.7), respectively. 
Several factors can explain the difference in estimates. We include a greater number of data sources but 
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exclude surveys with self-reported diagnosis of diabetes unlike NCD-RisC. We also define the whole 
distribution of fasting plasma glucose (FPG) and thus have a more accurate way of including surveys that 
report on FPG only in our diabetes disease model.  
Amputation due to diabetes 
• We set a value prior of 0 for incidence for ages 0 to 15
• We set a value prior of 0 for remission for all ages
• We crosswalked the incidence of either above or below knee amputation only to the
incidence of all amputations
DisMod Model 
Study covariate Parameter beta Exponentiated beta 
Above knee amputation only Incidence 
-0.32 (-0.6 — -0.034) 
0.72 (0.55 — 0.97) 
Below knee amputation only Incidence -0.44 (-0.72 — -0.18) 0.64 (0.49 — 0.83) 
Diabetic neuropathy 
• We set a value prior on the proportion of 0 from ages 0 to 1
• We crosswalked data from studies using alternate diagnostic criteria using as reference
studies which used the monofilament test as their diagnostic criteria
DisMod Model 
Study covariate Parameter Beta Exponentiated beta 
Diagnostic vibration perception 
threshold test 
Proportion -0.13 (-0.33 — 0.11) 0.88 (0.72 — 1.12) 
Diagnostic method ‐ nerve conduction 
velocity  
Proportion -0.25 (-0.5 — 0.029) 0.78 (0.61 — 1.03) 
Diagnostic method ‐ clinical exam only Proportion -0.044 (-0.27 — 
0.21) 
0.96 (0.76 — 1.24) 
Diagnostic validated neuropathy scoring Proportion -0.021 (-0.23 — 
0.20) 
0.98 (0.79 — 1.23) 
Diabetic foot ulcer 
• We set a value prior on the proportion of 0 from ages 0 to 10.
• We crosswalked data from studies investigating hospitalized patients only using as
reference studies which captured all diabetic foot ulcers.
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Study covariate Parameter beta Exponentiated beta 
Hospital data Proportion 0.52 (0.13 — 0.87) 1.68 (1.14 — 2.38) 
Severity split inputs  
Severity splits and disability weights were determined by the GBD disability weight survey assessment 
for diabetes mellitus. The table below illustrates the severity levels, lay descriptions, and associated 
disability weights:  
Severity level Lay description DW (95% CI) 
Uncomplicated diabetes mellitus Has a chronic disease that 
requires medication every day 
and causes some worry, but 
minimal interference with daily 
activities  
0.049 (0.031 – 0.072) 
Diabetic neuropathy Has pain, tingling, and 
numbness in the arms, legs, 
hands, and feet. The person 
sometimes gets cramps and 
muscle weakness.  
0.133 (0.089 – 0.187) 
Diabetic neuropathy with 
diabetic foot  
Has a sore on the foot that is 
swollen and causes some 
difficulty in walking.  
a 
Diabetic neuropathy with 
treated amputation  
Has lost part of one leg, leaving 
pain and tingling in the stump. 
The person has an artificial leg 
that helps in moving around.  
a
Diabetic neuropathy with 
untreated amputation  
Has lost part of one leg, leaving 
pain and tingling in the stump. 
The person does not have an 
artificial leg, has frequent sores, 
and uses crutches.  
a
Moderate vision loss due to 
diabetes mellitus  
Has vision problems that make it 
difficult to recognize faces or 
objects across a room.  
0.031 (0.019 – 0.049) 
Severe vision loss due to 
diabetes mellitus  
Has severe vision loss, which 
causes difficulty in daily 
activities, some emotional 
impact (for example worry), and 
0.184 (0.125 – 0.259) 
DisMod Model 
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some difficulty going outside the 
home without assistance. 
Blindness due to diabetes 
mellitus  
Is completely blind, which 
causes great difficulty in some 
daily activities, worry and 
anxiety, and great difficulty 
going outside the home without 
assistance.  
0.187 (0.124 – 0.26)  
a The disability weights are produced from a combination of two health states: neuropathy and diabetic 
foot/amputation 
 
Moore TJ, Barron J, Hutchinson F 3rd, Golden C, Ellis C, Humphries D. Prosthetic usage following 
major lower extremity amputation. Clin Orthop Relat Res. 1989 Jan;(238):219‐24. 
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 Acute Glomerulonephritis 
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Case Definition 
Acute glomerulonephritis (AG) (or post-infectious glomerulonephritis) is an acute episode of hematuria, 
edema, hypertension, and acute kidney injury that typically follows infection with specific strains of group 
A beta-hemolytic streptococcus. As used in the GBD study, this term is synonymous with post-
streptococcal or post-staphylococcal glomerulonephritis. This disease is typically seen in children but can 
demonstrate a bimodal distribution as early life immunity wanes within older years. ICD codes include 
N00, N00.0, N00.1, N00.2, N00.3, N00.4, N00.5, N00.6, N00.7, N00.8, N00.9, N01, N01.1, N01.2, N01.3, 
N01.4, N01.5, N01.6, N01.7, N01.8, and N01.9. 
Input data 
 Model inputs 
For GBD 2010, a systematic review of the prevalence of AG throughout the world was conducted. This 
search was updated for GBD 2013 and GBD 2015. For GBD 2016 a PubMed search was conducted using 
the following search terms: (Acute Glomerulonephritis[Title/Abstract] OR GN [Title/Abstract]) AND 
(Prevalen*[Title/Abstract] OR Inciden*[Title/Abstract]) AND ("2015/01/01"[PDAT] : "3000"[PDAT]) AND 
"humans"[MeSH Terms]. 
 The exclusion criteria were: 
35. Studies clearly not representative of the national population 
36. Studies that did not provide primary data on epidemiological parameters, eg, a 
commentary piece 
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37. Studies that describe non-infectious glomerulonephritis epidemiology 
 
Twenty-eight studies were identified though this search. Two studies were identified for full text 
screening. Neither of these studies was determined to meet inclusion criteria after full-text screening.  
The most recent literature source dates from 2013. Twenty-one articles have been included in total.  
Data from US claims data for 2000, 2010, and 2012 by US state were included. Hospital inpatient data 
was also included. Inpatient data points that exceeded the maximum observed age-standardized rate in 
the US inpatient data by a margin of 25% or greater were excluded from analysis.  
The table below shows the number of studies included in GBD 2016, as well as the number of countries 
and GBD world regions represented by either studies or hospital data. 
 Incidence 
Studies 73 
Geographies 360 
Regions 15 
 
 
 Severity split & disability weight 
The basis of the GBD disability weight assessment is lay descriptions of sequelae highlighting major 
functional consequences and symptoms. Disability weighting (DW) for AG associates with systemic 
symptoms of fever, aches, weakness, and some difficulty with daily activities. The lay description and 
disability weight for acute glomerulonephritis are shown below. 
Cause Lay description DW (95% CI) 
Acute glomerulonephritis Has a fever and aches, and feels weak, which 
causes some difficulty with daily activities. 
0.051 
(0.032–0.074) 
 
Modelling strategy 
We ran a DisMod-MR 2.1 model to produce estimates by age, sex, year, and country. Prior settings in the 
DisMod model included setting remission of three to four weeks. It was assumed that no one was born 
with AG. 
We applied a crosswalk to all US claims data to adjust to 2012 US claims data. Inpatient data was adjusted 
to account for multiple admissions and multiple diagnoses, based on MarketScan data, and was adjusted 
to 2012 US claims data in DisMod. We used the function in DisMod-MR 2.1 to pull in cause-specific 
mortality rate (CSMR) data from our CODEm and CODcorrect analyses and match them with incidence 
data points for the same geography and study year to estimate priors on excess mortality rates (by 
dividing CSMR by incidence). 
We included the covariate Lagged Distributed Income (LDI) as a country-level covariate to inform excess 
mortality, with bounds of -0.5, -0.1.  
Betas and exponentiated values (which can be interpreted as an odds ratio) are shown in the table below: 
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 Covariate Parameter beta Exponentiated beta 
Claims data - 2000 Incidence -0.2 (-0.24 — -0.16) 0.82 (0.79 — 0.86) 
Claims data - 2010 Incidence -0.11 (-0.15 — -0.063) 0.89 (0.86 — 0.94) 
Hospital data  Incidence -0.9 (-0.9 — -0.9) 0.41 (0.41 — 0.41) 
LDI (I$ per capita) Excess mortality rate -0.1 (-0.1 — -0.1) 0.90 (0.90 — 0.90) 
 
Compared to GBD 2015, major changes include inclusion of inpatient data from a greater number of 
geographies.  
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Case definition 
Chronic kidney disease (CKD) is defined as a permanent loss of renal function as indicated by estimated 
glomerular filtration rate (eGFR). The GBD study considers five stages of CKD as defined by degree of loss 
of renal function or receipt of renal replacement therapy: CKD Stage III (eGFR 30-60ml/min/1.73m2), CKD 
Stage IV (eGFR 15-30ml/min/1.73m2), CKD Stage V (eGFR <15ml/min/1.73m2, not on renal replacement 
therapy), maintenance dialysis, and renal transplantation.1 The ICD-10 codes associated with CKD include 
N18.1-N18.9. 
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Input data 
Model inputs 
For GBD 2010, a systematic review of the prevalence of CKD throughout the world was conducted. This 
search was updated for GBD 2013 and GBD 2015. For GBD 2016 this literature search was repeated using 
PubMed search terms: ((((("chronic kidney disease"[Title/Abstract]) AND prevalen*[Title/Abstract]) AND 
("2015/1/1"[Date - Publication] : "3000"[Date - Publication])) NOT ((animals[MeSH] NOT 
humans[MeSH])))).  
 The exclusion criteria were: 
1. Studies clearly not representative of the national population 
2. Studies that did not provide primary data on epidemiological parameters, eg, a 
commentary piece 
3. Studies of a specific etiology of CKD 
4. Studies not reporting on CKD by stage 
 
This literature search was augmented by identification of population-based surveys that measured renal 
function. For maintenance dialysis and renal transplantation, data were largely obtained from registry 
reports. 
 
The next planned PubMed search will be conducted for GBD 2017.  
Disease Number of sources 
CKD Stage III 112 
CKD Stage IV 94 
CKD Stage V 92 
Maintenance dialysis 534 
Renal transplantation 430 
 
Severity splits & disability weights 
Estimates of prevalence and incidence are split using CKD etiology proportion models, resulting in CKD 
estimates by stage and etiology. Then a portion of each etiology split for CKD stages III, IV, and V is 
attributed a disability weight associated with mild, moderate, or severe anemia.2  
Severity level Lay description Disability weight 
(95% CI) 
CKD stage III without 
anemia 
Asymptomatic -- 
CKD stage III with mild 
anemia 
Feels slightly tired and weak at times, but this does not 
interfere with normal daily activities. 
0.004 
(0.001–0.008) 
CKD stage III with 
moderate anemia 
Feels moderate fatigue, weakness, and shortness of breath 
after exercise, making daily activities more difficult. 
0.052 
(0.034–0.076) 
CKD stage III with 
severe anemia 
Feels very weak, tired, and short of breath, and has 
problems with activities that require physical effort or deep 
concentration. 
0.149 
(0.101–0.21) 
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CKD stage IV without 
anemia 
Tires easily, has nausea, reduced appetite, and difficulty 
sleeping. 
0.104 
(0.07–0.147) 
CKD stage IV with mild 
anemia 
 0.108 
(0.072–0.151) 
CKD stage IV with 
moderate anemia 
 0.15 
(0.103–0.207) 
CKD stage IV with 
severe anemia 
 0.237 
(0.165–0.324) 
CKD stage V without 
anemia 
Has lost a lot of weight and has constant pain. The person 
has no appetite, feels nauseated, and needs to spend most 
of the day in bed. 
0.569 
(0.389–0.727) 
CKD stage V with mild 
anemia 
 0.570 
(0.391–0.727) 
CKD stage V with 
moderate anemia 
 0.591 
(0.414–0.743) 
CKD stage V with 
severe anemia 
 0.631 
(0.456–0.782) 
End-stage renal 
disease, on dialysis 
Is tired and has itching, cramps, headache, joint pains, and 
shortness of breath. The person needs intensive medical 
care every other day lasting about half a day. 
0.571 
(0.397–0.725) 
End-stage renal 
disease, with kidney 
transplant 
Sometimes feels tired and down, and has some difficulty 
with daily activities. 
0.024 
(0.014–0.039) 
 
Etiology proportion models are informed by renal registry etiology proportion data. These proportions 
are applied to the CKD stages as described above. Etiologies included in the GBD study include diabetes 
mellitus, hypertension, glomerulonephritis, and “other.” “Other” excludes urologic diseases and 
toxins/poisons as well as cases of unknown etiology. 
Modelling strategy 
We ran a DisMod-MR 2.1 model to produce estimates by age, sex, year, and country for each stage of 
CKD. To account for progression of individuals from stage III to stage IV and stage IV to stage V, we 
informed remission for stages III and IV. Remission data for stage IV was calculated as the ratio of the 
incidence of stage V and prevalence of stage IV at the gender, age, and country-matched level. Remission 
data for stage III were calculated as the ratio of resulting stage IV incidence and stage III prevalence at the 
gender, age, and country-matched level. Remission was set to 0 for stage V and the excess mortality 
parameter was used to account for progression to end-stage renal disease and mortality due to CKD stage 
V. Bounds on excess mortality were informed using a meta-analysis of survival analyses of individuals with 
untreated CKD stage V. 
Data from sources reporting the prevalence of stage III, IV, and V CKD was aggregated to represent the 
prevalence of stage III-V CKD. We ran a DisMod-MR 2.1 model to produce estimates by age, sex, year, and 
country for aggregate stage III-V CKD. We used the function in DisMod-MR 2.1 to pull in cause-specific 
mortality rate (CSMR) data from our chronic kidney disease CODEm and CODcorrect analyses and match 
them with incidence data points for the same geography and study year to estimate priors on excess 
mortality rates (by dividing CSMR by incidence). In order to enforce more consistency between stage 
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models, prevalence of CKD stage III, IV, and V were then scaled to sum to the prevalence and incidence of 
the stage III-V CKD model, at the gender, age, and country-matched level.   
A full description of priors and covariates included in each model can be found in the table below:  
 Priors (min,max) Study-level covariate Country-level covariate 
CKD stage III Remission (0, 0.75) 
Excess mortality (0, 0.05) 
Adjust for estimating 
equation  
Diabetes age-standardised 
prevalence  
Mean Systolic Blood Pressure  
CKD stage IV Remission (0, 0.75) 
Excess mortality (0, 0.05) 
Adjust for estimating 
equation 
Diabetes age-standardised 
prevalence  
Mean Systolic Blood Pressure  
Age-standardised prevalence of 
CKD stage III 
CKD stage V Remission (0, 0) 
Incidence (0, 0.001), age 0-20 
Excess mortality (0.29, 0.54) 
Adjust for estimating 
equation 
Diabetes age-standardised 
prevalence  
Mean Systolic Blood Pressure  
Age-standardised prevalence of 
CKD stage III 
CKD stage 
III-V  
Remission (0, 0) 
Excess mortality (0, 0.54) 
Adjust for estimating 
equation 
Diabetes age-standardised 
prevalence  
Mean Systolic Blood Pressure  
 
We crosswalked data reporting glomerular filtration rate (GFR) estimated with the Modification of Diet in 
Renal Disease (MDRD) equation to data reported using the CKD-Epi equation as our baseline. GFR 
reported for children was estimated using the Schwartz equation as the gold standard among the 
pediatric population. Bounds on the MDRD-CKD-Epi cross walk were informed using a meta-analysis of 
studies reporting prevalence of CKD by stage using both the MDRD and CKD-Epi equations. Betas and 
exponentiated values for this crosswalk are shown in the table below: 
 Study covariate Parameter beta Exponentiated beta 
Stage III eGFR calculated with 
MDRD Equation 
Prevalence 0.27 (0.26 — 0.28) 1.31 (1.30 — 1.32) 
Stage IV eGFR calculated with 
MDRD Equation 
Prevalence -0.0085 (-0.026 — 
0.012) 
0.99 (0.97 — 1.01) 
Stage V  eGFR calculated with 
MDRD Equation 
Prevalence -0.093 (-0.14 — -0.035) 0.91 (0.87 — 0.97) 
Stage III-V eGFR calculated with 
MDRD Equation 
Prevalence 0.24 (0.23 — 0.25) 1.27 (1.26 — 1.28) 
 
The maintenance dialysis and renal transplant models include bounds on location random effects for East 
Asia and High-income Asia Pacific. As Taiwan (Province of China) and Japan have rates of renal 
replacement therapy far out of proportion to other countries in their regions, these bounds prevent renal 
replacement therapy estimates for surrounding countries lacking data from overinflating. Remission data 
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for dialysis was calculated as the ratio of the incidence of renal transplantation to prevalence of dialysis at 
the gender, age, and country-matched level. 
Major changes for GBD 2016 include attribution of anemia to stage V CKD, the switch from the MDRD 
equation to the CKD-Epi equation as our reference, and the use of a CKD envelope to scale individual 
stage estimates.  
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Case definition 
Interstitial nephritis (IN) is defined as a kidney infection that can lead to systemic symptoms such as fever 
and weakness and can cause discomfort and difficulty with daily activities.1 ICD codes include N10, N10.0, 
N10.9, N11, N11.0, N11.1, N11.8, N11.9, N12, N12.0, and N12.9. 
Input data 
 Model inputs 
The interstitial nephritis model is informed by survey data, US state-level claims data, and global hospital 
inpatient and outpatient data. For GBD 2016, a systematic review of the prevalence of IN throughout the 
world was conducted using the following search terms: (((Interstitial Nephritis[Title/Abstract]) OR (Urinary 
Tract Infection[Title/Abstract]))AND (Inciden*[Title/Abstract])) AND ("2013/01/01"[Date - Publication] : 
"3000"[Date - Publication]) NOT (animals[MeSH] NOT humans[MeSH]). 
 The exclusion criteria were: 
42. Studies clearly not representative of the national population 
43. Studies that did not provide primary data on epidemiological parameters, eg, a 
commentary piece 
44. Studies of a specific type of interstitial nephritis  
The table below shows the number of countries and GBD world regions represented. 
 Incidence 
Countries/subnationals 330 
GBD world regions 15 
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Data from US claims data for 2000, 2010, and 2012 by US state were included. Hospital inpatient data 
was also included. Inpatient data points that exceeded the maximum observed age-standardized rate in 
the US claims data by a margin of 25% or greater were excluded from analysis.  
Severity splits & disability weights 
The basis of the GBD disability weight survey assessments is lay descriptions of sequelae highlighting 
major functional consequences and symptoms. Interstitial nephritis is split into mild and moderate 
severity. Mild severity is associated with a disability weight that correlates with low fever, mild 
discomfort, but no difficulty with daily activities. Moderate discomfort is associated with a disability 
weight that correlates with systemic symptoms of fever, aches, weakness, and some difficulty with daily 
activities. The lay descriptions and disability weights for IN are shown below. 
Severity level Lay description DW (95% CI) 
Interstitial nephritis and urinary 
tract infection, mild 
Has a low fever and mild 
discomfort, but no difficulty with 
daily activities. 
0.006 
(0.002, 0.012) 
Interstitial nephritis and urinary 
tract infection, moderate 
Has a fever and aches, and feels 
weak, which causes some 
difficulty with daily activities. 
0.051 
(0.032, 0.074) 
 
The severity distribution of interstitial nephritis was derived from analysis of the Medical Expenditure 
Panel Surveys (MEPS). MEPS is an overlapping panel survey of the non-institutionalized US population 
that collects data on respondents’ health service interactions. Panels are initiated every year. Each panel 
is two years long and consists of five rounds. In 2000, MEPS began using 12-Item Short Form Surveys (SF-
12) to collect data on functional health status. The SF-12 survey is administered twice per panel (about 
once per year).   
In order to translate SF-12 scores into GBD disability weights, 62 lay descriptions for conditions 
representing the full range of disability weight values (from most mild to most severe) were selected. A 
convenience sample of respondents was then asked to complete an SF-12 form for an individual with the 
health state described in the lay descriptions of these conditions. Composite mental and physical SF-12 
score was regressed on GBD disability weight to derive the relationship between disability weight and SF-
12 score. Individual respondent scores were then regressed on reported conditions to obtain a 
comorbidity-corrected condition-specific disability weight. The distribution of these condition-specific 
weights was used derive the proportion of individuals with the conditions that fall within each GBD 
severity category.  
Severity Distribution  
Mild Interstitial Nephritis and UTI 0.362 (0.258, 0.478) 
Moderate Interstitial Nephritis and UTI  0.638 (0.522, 0.742) 
 
Modelling strategy 
We ran a DisMod MR-2.1 model to produce estimates by age, sex, year, and location. Prior settings in the 
IN DisMod 2.1 model included remission after one week between ages 0 and 100. We used the function 
in DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) data from our CODEm and CODcorrect 
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analyses and match them with incidence data points for the same geography and study year to estimate 
priors on excess mortality rates (by dividing CSMR by incidence). 
We applied a crosswalk to all US claims data to adjust to 2012 US claims data. Inpatient data was adjusted 
to account for multiple admissions and multiple diagnoses, based on MarketScan data, and an age-sex-
specific crosswalk was applied to adjust inpatient hospital data to 2012 US claims data. This crosswalk was 
applied by comparing the ratio of prevalence indicated by 2012 US claims data to that indicated by US 
inpatient data and applying these age- and sex-specific adjustment factors to global inpatient hospital 
data. Adjustment factors and their associated standard errors are presented in the table below.  
Sex Age 
start 
Age 
end  
Correction 
Factor 
Standard 
Error  
 Sex Age 
start 
Age 
end  
Correction 
Factor 
Standard 
Error  
Female 0 0.999 8.927 0.117  Male 0 0.999 3.8295 0.0848 
Female 1 4 9.460 0.168  Male 1 4 6.8094 0.1377 
Female 5 9 17.699 0.331  Male 5 9 12.6029 0.2488 
Female 10 14 21.029 0.345  Male 10 14 14.6992 0.2576 
Female 15 19 29.738 0.350  Male 15 19 23.5695 0.2911 
Female 20 24 31.087 0.327  Male 20 24 24.8601 0.3068 
Female 25 29 31.140 0.324  Male 25 29 17.6689 0.2530 
Female 30 34 30.919 0.318  Male 30 34 15.5750 0.2220 
Female 35 39 24.843 0.299  Male 35 39 13.9135 0.2181 
Female 40 44 18.959 0.254  Male 40 44 11.2504 0.1873 
Female 45 49 16.083 0.230  Male 45 49 9.5610 0.1669 
Female 50 54 13.398 0.199  Male 50 54 7.0199 0.1374 
Female 55 59 12.035 0.215  Male 55 59 5.7911 0.1390 
Female 60 64 10.162 0.180  Male 60 64 5.7911 0.1310 
Female 65 69 9.014 0.167  Male 65 69 5.2306 0.1233 
Female 70 74 7.441 0.136  Male 70 74 4.7013 0.1039 
Female 75 79 6.268 0.135  Male 75 79 4.1767 0.0968 
Female 80 84 5.391 0.117  Male 80 84 3.7635 0.0823 
Female 85 89 4.628 0.097  Male 85 89 3.6148 0.0736 
Female 90 94 4.289 0.094  Male 90 94 3.3424 0.0752 
Female 95 99 3.877 0.100  Male 95 99 3.4442 0.0960 
 
We included the covariate Lagged Distributed Income (LDI) as a country-level covariate to inform excess 
mortality, with bounds of -0.5, -0.1. We used this covariate based on the assumption of a higher 
likelihood of mortality based on the developmental status of a country. 
Betas and exponentiated values (which can be interpreted as an odds ratio) are shown in the table below: 
Study covariate Parameter beta Exponentiated beta 
Claims data   ̶ 2000 Incidence -0.042 (-0.072 — -0.01) 0.96 (0.93 — 0.99) 
Claims data   ̶2010 Incidence -0.00074 (-0.0039 — -
0.000091) 
1.00 (1.00 — 1.00) 
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Compared to GBD 2015, major changes include inpatient data from a greater number of geographies and 
an age-sex-specific adjustment of inpatient hospital data to US claims data.  
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Case definition 
Acute urolithiasis (AU) is an acute and usually symptomatic episode of urolithiasis, defined as stone 
formation located anywhere along the genitourinary tract.1 Associated ICD codes include N20, N20.0, 
N20.1, N20.2, N20.9, N21, N21.1, N21.8, N21.9, N22, N22.0, N22.8, N23, and N23.0. 
Input data 
 Model inputs 
For GBD 2010, a systematic review of the prevalence of AU throughout the world was conducted. This 
search was updated for GBD 2013 and again for GBD 2016. A PubMed search was conducted using the 
following search terms: (Urolithiasis[Title/Abstract] OR Kidney Stones[Title/Abstract]) AND 
(Prevalence[Title/Abstract] OR Incidence[Title/Abstract]) AND ("2013/01/01"[PDAT] : "3000"[PDAT]) AND 
"humans"[MeSH Terms]. 
 The exclusion criteria were: 
45. Studies clearly not representative of the national population 
46. Studies that did not provide primary data on epidemiological parameters, eg, a 
commentary piece 
47. Studies of a specific type of urolithiasis 
Four new studies were added based on this systematic review. The below table indicates the number of 
studies included and number of countries/regions represented by either study or hospital data: 
 Prevalence Incidence 
Sources 5 70 
Countries/subnationals 5 329 
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GBD world regions 4 14 
Data from US claims data for 2000, 2010, and 2012 by US state were included. Hospital inpatient and 
outpatient data were also included. Inpatient data points that exceeded the maximum observed age-
standardized rate in the US claims data by a margin of 25% or greater were excluded from analysis. 
Severity splits & disability weights 
The basis of the GBD disability weight survey assessments is lay descriptions of sequelae highlighting 
major functional consequences and symptoms. Urolithiasis is split into mild, moderate, and severe 
categories. The lay descriptions and disability weights for urolithiasis are shown below. 
Severity level  Lay description DW (95% CI) 
Mild acute urolithiasis Has some pain in the belly that causes nausea but 
does not interfere with daily activities. 
0.011 (0.005, 
0.021) 
Moderate acute 
urolithiasis 
Has pain in the belly and feels nauseous. The person 
has difficulties with daily activities. 
0.114 (0.078, 
0.159) 
Severe acute urolithiasis Has severe pain in the belly and feels nauseous. The 
person is anxious and unable to carry out daily 
activities. 
0.324 (0.220, 
0.442) 
 
The severity distribution of urolithiasis was derived from analysis of the Medical Expenditure Panel 
Surveys (MEPS). MEPS is an overlapping panel survey of the non-institutionalized US population that 
collects data on respondents’ health service interactions. Panels are initiated every year. Each panel is 
two years long and consists of five rounds. In 2000, MEPS began using 12-Item Short Form Surveys (SF-
12) to collect data on functional health status. The SF-12 survey is administered twice per panel (about 
once per year).   
In order to translate SF-12 scores into GBD disability weights, 62 lay descriptions for conditions 
representing the full range of disability weight values (from most mild to most severe) were selected. A 
convenience sample of respondents was then asked to complete an SF-12 form for an individual with the 
health state described in the lay descriptions of these conditions. Composite mental and physical SF-12 
score was regressed on GBD disability weight to derive the relationship between disability weight and SF-
12 score. Individual respondent scores were then regressed on reported conditions to obtain a 
comorbidity-corrected condition-specific disability weight. The distribution of these condition-specific 
weights was used derive the proportion of individuals with the conditions that fall within each GBD 
severity category.  
Severity Distribution  
Mild acute urolithiasis 0.642 (0.536, 0.734) 
Moderate acute urolithiasis 0.217 (0.149, 0.296) 
Severe acute urolithiasis 0.141 (0.108, 0.178) 
 
Modelling strategy 
For GBD 2016, we modeled AU using DisMod MR 2.1, a Bayesian meta-regression modelling program. 
Prior settings in the DisMod model included setting remission of two weeks. We applied a crosswalk to all 
US claims data and hospital inpatient data to adjust to 2012 US claims data. We used the function in 
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DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) data from our CODEm and CODcorrect 
analyses and match them with incidence data points for the same geography and study year to estimate 
priors on excess mortality rates (by dividing CSMR by incidence). We set bounds on location random 
effects for incidence due to sparse data.  
Betas and exponentiated values (which can be interpreted as an odds ratio) are shown in the table below: 
Study covariate Parameter beta Exponentiated beta 
Claims data - 2000 Incidence -0.51 (-0.54 — -0.47) 0.60 (0.58 — 0.62) 
Claims data - 2010 Incidence -0.0022 (-0.0065 — -
0.00017) 
1.00 (0.99 — 1.00) 
Hospital, inpatient Incidence -1.76 (-1.8 — -1.74) 0.17 (0.17 — 0.18) 
 
For GBD 2016 we modelled only acute urolithiasis. Chronic urolithiasis estimates were directly derived 
from acute urolithiasis data in previous GBD iterations. Applying this technique for this GBD iteration 
would have required being able to identify acute urolithiasis episodes that repeated within an individual, 
which is a level of detail we currently do not estimate.  
 
Compared to GBD 2015, major changes include inclusion of inpatient data from a greater number of 
geographies, estimation of the severity distribution of acute urolithiasis, and exclusion of chronic cases of 
urolithiasis.   
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Case definition 
Benign prostatic hypertrophy (BPH) is defined as a benign proliferation of prostatic tissue, often leading 
to symptoms such as urinary retention, bladder outlet obstruction, or urinary tract infection.1,2 The ICD 
codes for BPH include N40, N40.0, N40.1, N40.2, N40.3, and N40.9.   
Input data 
 Model inputs 
The BPH model is informed by US state-level claims data and global hospital inpatient data. US claims 
data from years 2000, 2010, and 2012 were included. Inpatient data that exceeded the maximum 
observed age-standardized rate in the US inpatient data by a margin of 25% or greater were excluded 
from analysis.  
 Prevalence 
Sources 62 
Countries/subnationals 355 
GBD world regions 15 
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 Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms of a given cause. BPH is split into symptomatic and 
asymptomatic types. There is no disability weight (DW) assigned to asymptomatic cases of BPH. The DW 
associated with symptomatic BPH regards urinary frequency that is sometimes associated with pain – as 
seen in the table below, which offers further information. 
Severity level Lay description DW (95% CI) 
Asymptomatic N/A 0 
Symptomatic Feels the urge to urinate frequently, but when 
passing urine it comes out slowly and 
sometimes is painful. 
0.067 
(0.043–0.097) 
 
The proportions symptomatic and asymptomatic were derived from analysis of the Medical Expenditure 
Panel Surveys (MEPS). MEPS is an overlapping panel survey of the non-institutionalized US population 
that collects data on respondents’ health service interactions. Panels are initiated every year. Each panel 
is two years long and consists of five rounds. In 2000, MEPS began using 12-Item Short Form Surveys (SF-
12) to collect data on functional health status. The SF-12 survey is administered twice per panel (about 
once per year).   
In order to translate SF-12 scores into GBD disability weights, 62 lay descriptions for conditions 
representing the full range of disability weight values (from most mild to most severe) were selected. A 
convenience sample of respondents was then asked to complete an SF-12 form for an individual with the 
health state described in the lay descriptions of these conditions. Composite mental and physical SF-12 
score was regressed on GBD disability weight to derive the relationship between disability weight and SF-
12 score. Individual respondent scores were then regressed on reported conditions to obtain a 
comorbidity-corrected condition-specific disability weight. The distribution of these condition-specific 
weights was used derive the proportion of individuals with the conditions that fall within each GBD 
severity category.  
Severity Distribution  
Asymptomatic BPH 0.472 (0.459–0.487) 
Symptomatic BPH 0.528 (0.513–0.541) 
 
Modelling strategy 
We ran a DisMod 2.1 model to produce estimates by age, sex, year, and location. Prior settings in the BPH 
DisMod 2.1 model include setting incidence and remission prior to age 40 years to 0. We set an upper 
bound on remission after age 40 to 0.1, corresponding to a maximum duration of 10 years. We also 
determined that there was no excess mortality related to BPH. 
We applied a crosswalk to all US claims data to adjust to 2012 US claims data. Inpatient data was adjusted 
to account for multiple admissions and multiple diagnoses, based on MarketScan data, and an age-
specific crosswalk was applied to adjust inpatient hospital data to 2012 US claims data. This crosswalk was 
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applied by comparing the ratio of prevalence indicated by 2012 US claims data to that indicated by US 
inpatient data and applying these age-specific adjustment factors to global inpatient hospital data. 
Adjustment factors and their associated standard errors are presented in the table below.  
Age start Age end Adjustment 
factor 
Standard 
error 
40 44 21.528 0.402 
45 49 23.031 0.350 
50 54 10.461 0.244 
55 59 6.718 0.232 
60 64 5.402 0.195 
65 69 3.951 0.166 
70 74 3.407 0.132 
75 79 3.172 0.119 
80 84 2.942 0.098 
85 89 3.004 0.085 
90 94 3.874 0.092 
95 99 2.601 0.127 
 
Betas and exponentiated values (which can be interpreted as an odds ratio) are shown in the table below: 
Study covariate Parameter beta Exponentiated beta 
Claims data – 2000 Prevalence  -0.016 (-0.051 — -
0.0014) 
0.98 (0.95 — 1.00)  
Claims data – 2010 Prevalence -0.0047 (-0.018 — -
0.00016) 
1.00 (0.98 — 1.00)  
Mean BMI Prevalence -0.04 (-0.051 — -
0.028) 
0.96 (0.95 — 0.97) 
 
Compared to GBD 2015, major changes include exclusion of literature data on BPH due to issues of 
representativeness and inconsistent case definitions, inclusion of inpatient data from a greater number of 
geographies, and an age-specific adjustment of inpatient hospital data to US claims data.  
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 Other urinary diseases 
In addition to the urinary diseases described above, there are many diverse types of urinary diseases, 
with a range of severities and associated sequelae. Because these urinary diseases are diverse in their 
underlying causes and risk factors as well as in their associated health outcomes, modelling them 
together in a DisMod-MR model would not produce reliable estimates of prevalence or excess mortality. 
Instead, we calculated the YLDs caused by other congenital disorders directly using a YLD/YLL ratio.  
We calculated the ratio of YLDs to YLLs across the specified urinary diseases for which nonfatal outcomes 
were modelled, using YLL estimates from the GBD 2016 cause of death (CoD) analysis. We then multiplied 
this YLD/YLL ratio by the YLL estimates for other urinary diseases from the GBD 2016 CoD analysis, 
providing us with an estimate of the YLDs association with other urinary diseases.  
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 Uterine Fibroids 
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Case definition 
Uterine fibroids, also called uterine myomas or leiomyomas, are non-cancerous, compact tumors that 
occur in the uterus. Fibroids can be diagnosed in a number of ways, including pelvic exam, ultrasound, 
and hysterectomy. Our reference definition is diagnosis by pelvic exam or ultrasound because it is the 
most common. However, we incorporate studies that include diagnosis by self-report, pelvic exam only, 
ultrasound only, hysterectomy only, and all combinations of the three. Refer to the Appendix for ICD 
codes. 
Input data 
 Model inputs 
For GBD 2010, a systematic review of uterine fibroids throughout the world was conducted. Ovid 
MEDLINE, EMBASE, CINAHL, CAB abstracts, WHOLIS, and ISGLE database were searched. The agreed 
approach for uterine fibroids was to conduct a PubMed literature search every three years. A PubMed 
search was conducted as part of the initial review in 2010 and is next due for GBD 2017. Exclusion criteria 
for the initial systematic review were: 
1. Studies that did not provide primary data on epidemiological parameters, e.g., a commentary 
piece 
2. Reviews 
3. Clearly non-representative studies (e.g., only high-risk pregnant women) 
The table below shows the number of literature studies included in GBD 2016, as well as the number of 
countries or subnational units and GBD world regions represented.  
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 Prevalence  Incidence 
Studies 12 4 
Countries/subnationals 16 17 
GBD world regions 7 3 
 
In addition, US claims data for 2000, 2012, and 2012 by US state were included. Inpatient and outpatient 
hospital data were also included.  
 Severity splits 
The basis of the GBD disability weight (DW) survey assessment are lay descriptions of sequelae 
highlighting major functional consequences and symptoms. The lay descriptions and disability weights for 
uterine fibroids are shown below. Further severity levels are calculated by combining several of these 
disability weights, e.g., mild abdominal pain with moderate anemia. It should be noted that anemia alone 
is not ascribed to fibroids, but only in conjunction with mild abdominal pain. The disability weights are 
listed for reference.   
Severity  Lay description DW (95% CI) 
Abdominopelvic 
problem, mild 
has some pain in the belly that causes nausea but does not interfere 
with daily activities. 
0.011 
(0.005-0.021) 
Anemia, mild 
feels slightly tired and weak at times, but this does not interfere with 
normal daily activities. 
0.004 
(0.001-0.008) 
Anemia, 
moderate 
feels moderate fatigue, weakness, and shortness of breath after 
exercise, making daily activities more difficult. 
0.052 
(0.034-0.076) 
Anemia, severe 
feels very weak, tired and short of breath, and has problems with 
activities that require physical effort or deep concentration. 
0.149 
(0.101-0.21) 
 
To determine the proportion of women with uterine fibroids who fall into each severity level, data from 
the Medical Expenditure Panel Survey (MEPS) is used.  
Modeling strategy 
The amount of data included in our model increased significantly with GBD 2015 due to the addition of 
US claims data and hospital data. Our DisMod MR 2.2 settings remained the same as those used in GBD 
2015. 
As in previous GBD iterations, incidence was set to zero prior to 15 years of age and after 51. We assume 
no excess mortality from uterine fibroids.  
Diagnosis by either ultrasound or pelvic exam was set as the reference category. Study-level covariates 
for diagnosis by hysterectomy only and self-report were included.  
 
Study covariate Measure Parameter beta Exponentiated beta 
Hysterectomy only incidence x-cov -1.48 (-1.59 — -
1.37) 0.23 (0.20 — 0.25) 
All MarketScan, year 
2000 
Prevalence x-cov -1.02 (-1.03 — -
1.01) 0.36 (0.36 — 0.36) 
All MarketScan, year 
2012 
Prevalence x-cov -0.73 (-0.77 — -
0.69) 
 
0.48 (0.46 — 0.50) 
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All MarketScan, year 
2010 
Prevalence x-cov -0.76 (-0.79 — -
0.75) 0.47 (0.46 — 0.47) 
Self-reported 
prevalence x-cov -0.23 (-0.26 — -
0.22) 0.79 (0.77 — 0.80) 
 
No other significant changes were made to the GBD 2015 modeling strategy. 
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 Polycystic Ovarian Syndrome (PCOS) 
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Case definition 
Polycystic ovarian syndrome (PCOS) is a condition that affects women’s ovaries and can lead to a variety 
of symptoms. Women with PCOS often have enlarged ovaries that contain pockets of fluid, and symptoms 
include infrequent menstruation, excess hair growth, acne, and obesity.  
Input data 
 Model inputs 
For GBD 2010, a systematic review of PCOS throughout the world was conducted. Ovid MEDLINE, 
EMBASE, CINAHL, CAB abstracts, WHOLIS, and ISGLE database were searched. The agreed approach for 
PCOS was to conduct a PubMed literature search every three years. A PubMed search was conducted as 
part of the initial review in 2010 and is next due for GBD 2017. Exclusion criteria for the initial systematic 
review were: 
1. Studies that did not provide primary data on epidemiological parameters, e.g., a commentary 
piece 
2. Reviews 
3. Clearly non-representative studies (e.g., only high-risk pregnant women) 
The table below shows the number of literature studies included in GBD 2016, as well as the number of 
countries or subnational units and GBD world regions represented.  
 Prevalence  
Studies 21 
Countries/subnationals 17 
GBD world regions 10 
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 In addition, US claims data for 2000, 2012 and 2012 by US state were included. Inpatient and outpatient 
hospital data were also included.  
 Severity splits 
The basis of the GBD disability weight (DW) survey assessment are lay descriptions of sequelae 
highlighting major functional consequences and symptoms. The lay descriptions and disability weights for 
premenstrual syndrome are shown below. Further severity levels are calculated by combining several of 
these disability weights, e.g., mild disfigurement and primary infertility.  
 
Severity  Lay description DW (95% CI) 
Disfigurement, 
level 1 
has a slight, visible physical deformity that others notice, which causes 
some worry and discomfort. 
0.011 
(0.005-0.021) 
Infertility, 
primary 
wants to have a child and has a fertile partner, but the couple cannot 
conceive. 
0.008 
(0.003-0.015) 
Infertility, 
secondary 
has at least one child, and wants to have more children. The person has 
a fertile partner, but the couple cannot conceive.  
0.005 
(0.002-0.011) 
 
To determine the proportion of people within each of these severity levels, one study was consulted.10 
Tehrani et al. included information on the proportion of women who experience primary infertility and 
hyperandrogenism. Percentages were combined to calculate the proportion of women who fall into both 
hyperandrogenism and infertility categories.  
 
Modeling strategy 
The amount of data included in our model increased significantly with GBD 2016 due to the addition of 
US claims data and inpatient and outpatient hospital data. 
The table below illustrates the study covariates, measures, parameters, beta, and exponentiated beta 
values. 
Study covariate Measure parameter beta Exponentiated beta 
All MarketScan, 
year 2000 
Prevalence x-cov 
 
 
-2.51 (-2.55 — -
2.5) 
 
0.081 (0.078 — 
0.082) 
All MarketScan, 
year 2010 
Prevalence x-cov 
-1.41 (-1.44 — -
1.4) 
 
0.24 (0.24 — 0.25) 
 
All MarketScan, 
year 2012 
Prevalence x-cov -1.41 (-1.44 — -
1.4) 0.25 (0.24 — 0.25) 
10 Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F. The prevalence of polycystic ovary syndrome in a 
community sample of Iranian population: Iranian PCOS prevalence study. <i>Reprod Biol Endocrinol</i>. 2011; 9: 39. 
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Androgen Excess 
Society case 
definition 
Prevalence z-cov 
0.47 (0.033 — 
0.96) 1.59 (1.03 — 2.61) 
Rotterdam case 
definition 
Prevalence x-cov 0.31 (0.21 — 
0.40) 1.36 (1.23 — 1.49) 
Self-report prevalence z-cov 0.48 (0.11 — 
0.96) 1.62 (1.12 — 2.62) 
Hospital Inpatient Prevalence x-cov -0.99 (-1.13 — -
0.86) 
 
0.37 (0.32 — 0.42) 
Healthcare access 
and quality index 
Excess 
mortality rate 
Country-level -0.043 (-0.05 — 
-0.034) 0.96 (0.95 — 0.97) 
 
As in previous GBD iterations, incidence was set to zero prior to 15 years of age and after 50. This is 
because a woman must enter puberty before she can get PCOS, and the condition spontaneously goes 
into remission with the onset of menopause.  
Case definitions for PCOS vary widely, including varying rosters of symptoms over various time periods. 
We use as our reference definition the NIH/NICHD criteria, for which three signs must be present: clinical 
or biochemical evidence of hyperandrogenism, oligomenorrhea, and the exclusion of other disorders. We 
include study-level covariates for other common case definitions, including the Rotterdam and Androgen 
Excess Society (AES) definitions, as well as self-report.  
No significant changes took place for GBD 2016. 
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Case definition 
Endometriosis is defined as growth of tissue that usually lies inside the uterus outside of it. Common 
symptoms include chronic pain and infertility. Our reference case definition of endometriosis is diagnosis 
accompanied by pathological confirmation.  
Input data 
 Model inputs 
For GBD 2010, a systematic review of endometriosis throughout the world was conducted. Ovid 
MEDLINE, EMBASE, CINAHL, CAB abstracts, WHOLIS, and ISGLE database were searched. The agreed 
approach for endometriosis was to conduct a PubMed literature search every three years. A PubMed 
search was conducted as part of the initial review in 2010. Exclusion criteria for the initial systematic 
review were: 
1. Studies that did not provide primary data on epidemiological parameters, e.g., a commentary 
piece 
2. Reviews 
3. Clearly non-representative studies (e.g., only high-risk pregnant women) 
The table below shows the number of literature studies included in GBD 2016, as well as the number of 
countries or subnational units and GBD world regions represented.  
 Prevalence  Incidence 
Studies 7 10 
Countries/subnationals 7 8 
GBD world regions 4 2 
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In addition, US claims data for 2000, 2012 and 2012 by US state were included. Inpatient and outpatient 
hospital data were also included.  
Severity splits & disability weights 
The basis of the GBD disability weight (DW) survey assessment are lay descriptions of sequelae 
highlighting major functional consequences and symptoms. The lay descriptions and disability weights for 
endometriosis are shown below. Further severity levels are calculated by combining several of these 
disability weights, e.g., moderate abdominal pain and secondary infertility.  
Severity Lay description DW (95% CI) 
Abdominopelvic 
problem, mild 
has some pain in the belly that causes nausea but does not interfere 
with daily activities. 
0.011 
(0.005-0.021) 
Abdominopelvic 
problem, 
moderate 
has pain in the belly and feels nauseous. The person has difficulties with 
daily activities.  
0.114 
(0.078-0.159) 
Abdominopelvic 
problem, severe 
has severe pain in the belly and feels nauseous. The person is anxious 
and unable to carry out daily activities. 
0.324 
(0.219-0.442) 
Infertility, 
primary 
wants to have a child and has a fertile partner, but the couple cannot 
conceive. 
0.008 
(0.003-0.015) 
Infertility, 
secondary 
has at least one child, and wants to have more children. The person has 
a fertile partner, but the couple cannot conceive.  
0.005 
(0.002-0.011) 
To determine the proportion of people within each of these severity levels, three studies were consulted 
(ALWHS YEAR; Sinaii et al. 2002 & 2008). One addressed the proportion of women who become infertile, 
one addressed the proportion with chronic abdominal pain, and the last one severity of abdominal pain. 
Estimates were combined across studies to calculate the proportion of women who fall into both 
abdominal pain and infertility categories.  
Modeling strategy 
We use DisMod-MR 2.1, a Bayesian meta-regression epidemiological model, to generate estimates 
for Endometriosis by age, sex, year, and country. The amount of data included in our model increased 
significantly with GBD 2015 due to the addition of US claims data and hospital data.  
Diagnosis confirmed by pathology was set as the reference definition. In addition to study-level covariate 
on diagnosis not confirmed by pathology, study-level covariates were added for each year of US claims 
data as well as inpatient and outpatient hospital data. The table below illustrates covariates, measures, 
parameters, beta, and exponentiated beta values. 
Study covariate Measure Parameter beta Exponentiated beta 
Endometriosis not 
confirmed by 
pathology  
incidence x-cov 
-0.56 (-0.9 — -
0.23) 0.57 (0.41 — 0.80) 
All MarketScan, year 
2000 
prevalence x-cov 
-1.5 (-1.96 — -
0.96) 0.21 (0.14 — 0.37) 
All MarketScan, year 
2010 
prevalence x-cov -1.54 (-1.98 — -
0.99) 0.92 (0.85 — 0.99) 
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All MarketScan, year 
2012 
 
prevalence x-cov 
. -1.55 (-1.99 — 
-0.99) 0.21 (0.14 — 0.37) 
Hospital inpatient 
 
prevalence x-cov -1.13 (-1.61 — -
0.58) 0.32 (0.20 — 0.56) 
Healthcare access 
and quality index 
Excess 
mortality rate 
Country-level -0.02 (-0.02 — -
0.02) 0.98 (0.98 — 0.98) 
 
As in previous GBD iterations, incidence was set to zero prior to 15 years of age and after 51. This is 
because a woman must enter puberty before she can get endometriosis, and the condition 
spontaneously goes into remission with the onset of menopause.  
There have been no additional significant changes to the modeling strategy for GBD 2016. 
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Case definition 
Genital prolapse, also called female pelvic organ prolapse, is the clinically relevant descent of one of more 
of the pelvic structures, including the uterus, bladder, rectum, small or large bowl, or vagina. Risk of 
prolapse increases with age, and can be exacerbated by vaginal childbirth or physical strain. ICD codes 
associated with genital prolapse include: N81. 
 
Input data 
 Model inputs 
For GBD 2010, a systematic review of genital prolapse throughout the world was conducted. Ovid 
MEDLINE, EMBASE, CINAHL, CAB abstracts, WHOLIS, and ISGLE database were searched. The agreed 
approach for genital prolapse was to conduct a PubMed literature search every three years. A PubMed 
search was conducted as part of the initial review in 2010 and is next due for GBD 2017. Exclusion criteria 
for the initial systematic review were: 
1. Studies that did not provide primary data on epidemiological parameters, e.g., a commentary 
piece 
2. Reviews 
3. Clearly non-representative studies (e.g., only high-risk pregnant women) 
The table below shows the number of literature studies included in GBD 2016, as well as the number of 
countries or subnational units and GBD world regions represented.  
 Prevalence  
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Studies 13 
Countries/subnationals 12 
GBD world regions 8 
 
In addition, US claims data for 2000, 2010 and 2012 by US state were included. Outpatient and inpatient 
hospital data were also included.  
 Severity splits 
The basis of the GBD disability weight (DW) survey assessment are lay descriptions of sequelae 
highlighting major functional consequences and symptoms. The lay descriptions and disability weights for 
genital prolapse are shown below. Further severity levels are calculated by combining several of these 
disability weights, e.g., mild abdominal pain and stress incontinence.  
Severity  Lay description DW (95% CI) 
Stress 
incontinence 
loses small amounts of urine without meaning to when coughing, 
sneezing, laughing or during physical exercise. 
0.02 
(0.011-0.035) 
Abdominopelvic 
problem, mild 
has some pain in the belly that causes nausea but does not interfere 
with daily activities. 
0.011 
(0.005-0.021) 
 
To determine the proportion of people within each of these severity levels, two studies were 
consulted.11,12 Scherf and Slieker-Ten Hove included information on the proportion of women with 
prolapse who experience a bulging sensation as well as stress incontinence. Percentages were combined 
to calculate the proportion of women who fall into both stress incontinence and bulging sensation 
categories.  
 
Modeling strategy 
The amount of data included in our model increased significantly with GBD 2015 due to the addition of 
US claims data. Our DisMod MR 2.2 settings remained the same as GBD 2015. 
As in previous GBD iterations, incidence was set to zero prior to 15 years of age. This is because it is highly 
unlikely a woman would experience genital prolapse before entering her childbearing years.  
This year we have added covariates for each year of the US claims data as well as the inpatient hospital 
data. The table below illustrates covariates, measures, parameters, beta, and exponentiated beta values. 
Study covariate Measure Parameter beta Exponentiated beta 
All MarketScan, 
year 2000 
prevalence x-cov -1.99 (-2 — -
1.99) 0.14 (0.14 — 0.14) 
All MarketScan, 
year 2010 
prevalence x-cov 
-1.99 (-2 — -
1.97) 
 
0.14 (0.14 — 0.14) 
 
All MarketScan, 
year 2012 
prevalence x-cov -1.99 (-2 — -
1.96) 
 
0.14 (0.14 — 0.14) 
11 Epidemiology of pelvic organ prolapse in rural Gambia, West Africa. Scherf, 2002.  
12 Symptomatic pelvic organ prolapse and possible risk factors in a general population. Slieker-Ten Howe, 2009.  
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 Hospital Inpatient Prevalence x-cov -2.17 (-2.33 — -
2.08) 0.11 (0.097 — 0.13) 
Total fertility rate prevalence Country-level 
covariate 
0.99 (0.97 — 
1.00) 2.69 (2.63 — 2.72) 
 
No other significant changes to modeling strategy were made for GBD 2016. 
 
 
 
  
515
 Premenstrual Syndrome (PMS) 
 
Flowchart 
Input data
Process
Results
Database
Disability weights
Nonfatal
Burden estimation
Cause of death
Covariates
Input Data
Literature data
Nonfatal 
database
Dismod-MR 2.1
Prevalence & 
incidence by 
location/year/
age/sex for PMS, 
adjusted
Comorbidity 
correction 
(COMO)
YLLs
Comorbidity 
adjusted 
YLDs
DALYs
Premenstrual syndrome
Claims data – 
inpatient visits
Study-level covariates: 
1. ICD-10 definition
 2. Moderate-to-severe cases 
3. Period prevalence 
4. Other definitions
Severity splits; 
proportion of time 
in symptomatic 
state
Prevalence of 
mild PMS, 
adjusted
Disability weights 
for each sequela
Unadjusted 
YLD by 
sequela
Outpatient hospital 
data
Adjustment from 
primary code to all 
code based on 
Claims data
Adjusted inpatient 
data
Literature
Meta-analysis of % mild, 
moderate, severe PMS, 
adjusted
Claims data – 
outpatient visits
Prevalence of 
moderate PMS, 
adjusted
Prevalence of 
severe PMS, 
adjusted
Prevalence & 
incidence by 
location/year/
age/sex for PMS, 
unadjusted
Literature data
Nonfatal 
database
Dismod-MR 2.1
Prevalence & 
incidence by 
location/year/
age/sex of 
pregnant women
Pregnancy 
adjustment
Nonfatal 
database
Dismod-MR 2.1
 
Case definition 
Premenstrual syndrome refers to psychological and physical symptoms that occur in the weeks leading up 
to a woman’s period in her menstrual cycle. Symptoms are extremely varied in nature and severity, but 
include tenderness, bloating, irritability, fatigue, abdominal pain, and altered mental states. Symptoms 
cease when a woman is pregnant and once she reaches menopause. 
Input data 
 Model inputs 
For GBD 2010, a systematic review of premenstrual syndrome throughout the world was conducted. Ovid 
MEDLINE, EMBASE, CINAHL, CAB abstracts, WHOLIS, and ISGLE database were searched. The agreed 
approach for premenstrual syndrome was to conduct a PubMed literature search every three years. A 
PubMed search was conducted as part of the initial review in 2010 and is next due for GBD 2017. 
Exclusion criteria for the initial systematic review were: 
1. Studies that did not provide primary data on epidemiological parameters, e.g., a commentary 
piece 
2. Reviews 
3. Clearly non-representative studies (e.g., only high-risk pregnant women) 
The table below shows the number of literature studies included in GBD 2015, as well as the number of 
countries or subnational units and GBD world regions represented. Note that data on the proportion of 
women who are pregnant is used during the pregnancy adjustment, described in detail in the modeling 
strategy section.  
PMS 
 Prevalence  
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Studies 50 
Countries/subnationals 43 
GBD world regions 11 
 
Women who are pregnant  
 Prevalence  
Studies 2 
Countries/subnationals 188 
GBD world regions 21 
 
Inpatient hospital data was not incorporated, as we believed that inpatient data on PMS would fluctuate 
wildly with across geographies and different coding practices, and would not represent the true 
prevalence of PMS in the population.  
 
 Severity splits and disability weights 
The basis of the GBD disability weight (DW) survey assessment are lay descriptions of sequelae 
highlighting major functional consequences and symptoms. The lay descriptions and disability weights for 
premenstrual syndrome are shown below. Further severity levels are calculated by combining several of 
these disability weights, e.g., abdominal pain and depression due to premenstrual syndrome.  
Severity  Lay description DW (95% CI) 
Major depressive 
disorder, mild 
episode 
feels persistent sadness and has lost interest in usual activities. The 
person sometimes sleeps badly, feels tired, or has trouble concentrating 
but still manages to function in daily life with extra effort. 
0.145 
(0.099-0.209) 
Abdominopelvic 
problem, mild 
has some pain in the belly that causes nausea but does not interfere 
with daily activities. 
0.011 
(0.005-0.021) 
 
To determine the proportion of people within each of these severity levels, five studies were consulted. 
Three studies addressed the proportion of women with PMS who experience depression, and two other 
studies addressed the proportion of women with PMS who experience abdominal pain. Estimates were 
pooled across studies to get final proportions, and were combined across studies to calculate the 
proportion of women who fall into both abdominal pain and depression categories.  
 
Modeling strategy 
Our DisMod MR 2.2 settings remained the same as those used in GBD 2015 and, no new data was added 
for GBD 2016. 
As in previous GBD iterations, incidence was set to zero prior to 15 years of age and after 50. This is 
because a woman must enter puberty before she can get premenstrual syndrome, and the condition 
spontaneously goes into remission with the onset of menopause. We assume no excess mortality from 
PMS.  
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Case definitions for PMS vary widely, including varying rosters of symptoms over various time periods. We 
use as our reference definition the American College of Obstetricians and Gynecologists (ACOG) criteria, 
which states that the patient reports at least one of each of the following affective and somatic symptoms 
during the five days before their menses and appear in three consecutive cycles: depression, angry 
outbursts, irritability, anxiety, confusion, social withdrawal; breast tenderness, abdominal bloating, 
headache, or swelling of extremities. We include study-level covariates for other common case 
definitions, including the ICD-10 definition, and the Premenstrual Symptoms Screening Tool (PSST) 
definition. We also include covariates for studies that only examine moderate to severe PMS, or period 
prevalence of PMS.  
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 Other gynaecological conditions  
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Case definition 
Other gynaecological conditions encompasses all disorders that are not menstruation- or bleeding-related 
that do not fall under the heading of any of the other gynaecological causes. They only affect women. 
Input data 
 Model inputs 
No literature data are used to inform models of other gynaecological conditions. Previously, only 
inpatient and outpatient hospital data were used. For GBD 2015, US claims data for 2000, 2012 and 2012 
by US state were added. 
 Severity splits & disability weights 
The basis of the GBD disability weight (DW) survey assessment are lay descriptions of sequelae 
highlighting major functional consequences and symptoms. The lay descriptions and disability weights for 
other gynaecological conditions are shown below.   
Severity  Lay description DW (95% CI) 
Abdominopelvic 
problem, mild 
has some pain in the belly that causes nausea but does not interfere 
with daily activities. 
0.011 
(0.005–0.021) 
Abdominopelvic 
problem, 
moderate 
has pain in the belly and feels nauseated. The person has difficulties 
with daily activities.  
0.114 
(0.078–0.159) 
Abdominopelvic 
problem, severe 
has severe pain in the belly and feels nauseated. The person is anxious 
and unable to carry out daily activities. 
0.324 
(0.219–0.442) 
Anaemia, mild 
feels slightly tired and weak at times, but this does not interfere with 
normal daily activities. 
0.004 
(0.001–0.008) 
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Anaemia, 
moderate 
feels moderate fatigue, weakness, and shortness of breath after 
exercise, making daily activities more difficult. 
0.052 
(0.034–0.076) 
Anaemia, severe 
feels very weak, tired and short of breath, and has problems with 
activities that require physical effort or deep concentration. 
0.149 
(0.101–0.21) 
 
To determine the proportion of women with endometriosis who fall into each severity level, data from 
the Medical Expenditure Panel Survey (MEPS) are used.  
Modelling strategy 
We ran a DisMod MR 2.1 model to estimate the global burden of gynaecological diseases. The amount of 
data included in our model increased significantly with GBD 2015 due to the addition of US claims data. 
Many of our DisMod MR 2.1 settings remained the same, but new study-level covariates were added to 
accommodate the new data. These covariates are shown in the table below, along with measures, 
parameters, beta, and exponentiated beta values. 
Study covariate Measure Parameter  beta Exponentiated beta 
All MarketScan, 
year 2000 
Prevalence x-cov 
 
4.00 (4.00 — 
4.00) 
54.52 (54.43 — 
54.60) 
All MarketScan, 
year 2010 
prevalence x-cov 3.99 (3.98 — 
4.00) 
54.30 (53.57 — 
54.60) 
All MarketScan, 
year 2012 
Prevalence x-cov 3.99 (3.97 — 
4.00) 
53.86 (52.83 — 
54.54) 
Hospital inpatient prevalence x-cov -1.96 (-2.17 — -
1.76) 0.14 (0.11 — 0.17) 
 
As in previous GBD iterations, incidence was set to zero prior to 15 years of age. We assume no excess 
mortality from other gynecological conditions over the same age range.  
No other significant changes were made to the GBD 2016 estimation process. 
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 Endocrine, Metabolic, Blood and Immune Disorders 
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Case definition 
Endocrine, metabolic, blood, and immune disorders (EMBID) is a residual cause consisting of conditions 
that do not map to other causes within the diabetes, urogenital, blood and endocrine disease hierarchy. 
This residual group consists mainly of thyroid disorders, rare metabolic and immune disorders, and blood 
disorders not resulting in anaemia . From the ICD chapter on Endocrine, Metabolic, and Immune 
Disorders (the E chapter) GBD’s definition of EMBID excludes the codes for nutritional deficiencies, 
diabetes and anaemia which are modelled as separate causes; as well as those for obesity and 
hypercholesterolemia which are modeled as risks, not causes. 
 
ICD 10 codes for EMBID include: D64.4, D64.8, D68-D68.6, D68.8-D68.9, D69-D69.4, D69.6, D69.8, D70-
D70.4, D70.8-D70.9, D72-D72.1, D72.8-D72.9, D73- D73.5, D73.8-D73.9, D74.0, D74.8-D74.9, D75-D75.2, 
D75.8-D75.9, D76-D76.3, D80-D80.9, D81-D81.9, D82-D82.4, D82.8-D82.9, D83-D83.2, D83.8-D83.9, D84-
D84.1, D84.8-D84.9, D86.8, D89-D89.3, D89.8-D89.9, E03-E03.1, E03.3-E03.5, E03.8-E03.9, E04-E04.2, 
E04.8-E04.9, E05-E05.5, E05.8-E05.9, E06-E06.3, E06.5, E06.9, E07-E07.1, E07.8-E07.9, E16.1-E16.4, 
E16.8-E16.9, E20-E20.1, E20.8-E20.9, E21-E21.5, E22-E22.2, E22.8-E22.9, E23.0, E23.2-E23.3, E23.6-E23.7, 
E24-E24.1, E24.3-E24.4, E24.8-E24.9, E25.0, E25.8-E25.9, E26-E26.1, E26.8-E26.9, E27-E27.2, E27.4-E27.5, 
E27.8-E27.9, E28-E28.1, E28.3, E28.8-E28.9, E29-E29.1, E29.8-E29.9, E30-E30.1, E30.8-E30.9, E31-E31.2, 
E31.8-E31.9, E32-E32.1, E32.8-E32.9, E34-E34.5, E34.8-E34.9, E67-E67.3, E67.8, E70-E70.5, E70.8-E70.9, 
E71-E71.5, E72-E72.5, E72.8-E72.9, E73-E73.1, E73.8-E73.9, E74-E74.4, E74.8-E74.9, E75-E75.6, E76-
E76.3, E76.8-E76.9, E77-E77.1, E77.8-E77.9, E79-E79.2, E79.8-E79.9, E80-E80.7, E83-E83.9, E84-E84.9, 
E85-E85.9, E88-E88.9. 
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Input data 
 Model inputs 
The EBMID model is informed by global hospital inpatient data. Global inpatient data points that 
exceeded the maximum observed age-standardized rate in the US inpatient data by a margin of 25% or 
greater were excluded from analysis.  
The table below shows the number of countries and GBD world regions represented. 
 Prevalence 
Countries/subnationals 125 
GBD world regions 14 
 
Severity splits & disability weights 
The basis of the GBD disability weight survey assessments is lay descriptions of sequelae highlighting 
major functional consequences and symptoms. EMBID is split into asymptomatic, mild, moderate, and 
severe categories. The lay descriptions and disability weights for EMBID are shown below. 
Severity level Lay description DW (95% CI) 
Asymptomatic endocrine, 
metabolic, blood, and immune 
disorders 
-- -- 
Mild endocrine, metabolic, 
blood, and immune disorders 
Has low energy and feels cold. 
0.019 
(0.01–0.032) 
Moderate endocrine, metabolic, 
blood, and immune disorders 
Feels nervous, has palpitations, 
sweats a lot, and has difficulty 
sleeping. 
0.145 
(0.096–0.202) 
Severe endocrine, metabolic, 
blood, and immune disorders 
Easily bruises and sometimes 
bleeds from the gums and nose; 
feels weak and has some 
difficulty with daily activities. 
0.159 
(0.106–0.226) 
 
The severity distribution of EMBID was derived from analysis of the Medical Expenditure Panel Surveys 
(MEPS). MEPS is an overlapping panel survey of the non-institutionalized US population that collects data 
on respondents’ health service interactions. Panels are initiated every year. Each panel is two years long 
and consists of five rounds. In 2000, MEPS began using 12-Item Short Form Surveys (SF-12) to collect data 
on functional health status. The SF-12 survey is administered twice per panel (about once per year).   
In order to translate SF-12 scores into GBD disability weights, 62 lay descriptions for conditions 
representing the full range of disability weight values (from most mild to most severe) were selected. A 
convenience sample of respondents was then asked to complete an SF-12 form for an individual with the 
health state described in the lay descriptions of these conditions. Composite mental and physical SF-12 
score was regressed on GBD disability weight to derive the relationship between disability weight and SF-
12 score. Individual respondent scores were then regressed on reported conditions to obtain a 
comorbidity-corrected condition-specific disability weight. The distribution of these condition-specific 
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weights was used derive the proportion of individuals with the conditions that fall within each GBD 
severity category.  
Severity Distribution  
Asymptomatic endocrine, metabolic, blood, and 
immune disorders 
0.410 (0.398, 0.423) 
Mild endocrine, metabolic, blood, and immune 
disorders 
0.387 (0.328, 0.430) 
Moderate endocrine, metabolic, blood, and 
immune disorders 
0.061 (0.042, 0.060) 
Severe endocrine, metabolic, blood, and immune 
disorders 
0.142 (0.115, 0.173) 
 
Modelling strategy 
We ran a DisMod MR-2.1 model to produce estimates by age, sex, year, and location. Prior settings in the 
EMBID DisMod model include an upper bound on remission of 0.25, corresponding to a maximum 
duration of four years. We used the function in DisMod-MR 2.1 to pull in cause-specific mortality rate 
(CSMR) data from our CODEm and CODcorrect analyses and match them with incidence data points for 
the same geography and study year to estimate priors on excess mortality rates (by dividing CSMR by 
incidence). 
We included the covariate Lagged Distributed Income (LDI) as a country-level covariate to inform excess 
mortality, with bounds of -0.5, -0.1. 
Compared to GBD 2015, major changes include inclusion of inpatient data from a greater number of 
geographies and placing bounds on remission to reflect the chronic nature of many conditions within the 
endocrine, metabolic, blood, and immune disorders cause grouping.   
 
  
523
 Rheumatoid arthritis 
 
Flowchart 
Case definition 
Rheumatoid arthritis (RA) is a systemic autoimmune disorder that causes pain and swelling of the joints.  
While RA is known to affect internal organs in addition to the joints, these extra-articular effects are not 
factored into the disability weights (DW) used in GBD. The reference case definition for rheumatoid 
arthritis is based on the 1987 criteria by the American College of Rheumatology (ACR 1987)1 which 
stipulate seven diagnostic criteria, of which four need to be satisfied for a diagnosis. Criteria 1 through 4 
must have been present for at least six weeks (see table below). For RA, ICD-10 codes are M05, M06, and 
M08 and ICD-9 codes are 714.0–714.9.  
 
Input data 
 Model inputs 
For GBD 2010, a systematic review of the prevalence of RA throughout the world was conducted. Ovid 
MEDLINE, EMBASE, CINAHL, CAB abstracts, WHOLIS, and SIGLE databases were searched using the 
following search terms: (rheumatoid arthritis OR rheumatic disease* OR rheumatism) AND (prevalen* OR 
inciden* OR cross-sectional OR cross sectional OR epidemiol* OR survey OR population-based OR 
population based OR population study OR population sample OR cohort OR follow-up OR follow up OR 
longitudinal OR regist* OR data collection). 
The exclusion criteria were: 
48. Studies clearly not representative of the national population 
49. Studies that were not population-based, eg, hospital or clinic-based studies 
50. Studies that did not provide primary data on epidemiological parameters, eg, a 
commentary piece 
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51. Studies of a specific type of RA, eg, seropositive RA 
52. Studies with a sample size of less than 150 
53. Reviews 
 
The most recent PubMed search was conducted in GBD 2013 using the above search terms.  
Opportunistically, we added scientific literatures and population surveys encountered for GBD 2015 and 
GBD 2016. The table below shows the number of literature studies included in GBD 2016, as well as the 
number of countries or subnational units and GBD world regions represented. 
 Prevalence Incidence Mortality risk 
Studies 68 25 25 
Countries/subnationals 91 16 16 
GBD world regions 16 6 3 
 
In addition, data from US claims data for 2000, 2010, and 2012 by US state were included. We decided 
not to use hospital inpatient data as we considered they would not be representative of true prevalence 
and that variation between countries in the proportion of true prevalent cases captured in hospital 
inpatient data systems would likely vary more than can be captured by a single crosswalk in DisMod-MR 
2.1. We compared the rates of RA in the outpatient data from Norway, Sweden, Canada, and the USA and 
found implausibly large differences with the rates from the claims data. The US outpatient rates were half 
the value of the claims data and those for the other countries much lower still. For those reasons we 
decided not to use the outpatient data. 
 Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for RA severity 
levels are shown below. 
Severity level Lay description DW (95% CI) 
Mild  This person has moderate pain and stiffness in the arms 
and hands which causes difficulty lifting, carrying, and 
holding things, and trouble sleeping because of the pain. 
0.117 (0.080–0.163) 
Moderate This person has pain and deformity in most joints, 
causing difficulty moving around, getting up and down, 
and using the hands for lifting and carrying. The person 
often feels fatigue. 
0.317 (0.216–0.440) 
Severe This person has severe, constant pain, and deformity in 
most joints, causing difficulty moving around, getting up 
and down, eating, dressing, lifting, carrying, and using the 
hands. The person often feels sadness, anxiety, and 
extreme fatigue. 
0.581 (0.403–0.739) 
 
To determine the proportion of people with RA within each of the severity levels, seven studies from 
three regions provided information on the severity of RA. Severity was classified according to Health 
Assessment Questionnaire scores, with the cutoff scores for each severity level: <1 mild; 1–1.875 
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moderate; and ≥2 severe. Estimates were pooled across studies. We used a random effects meta-analysis 
model. The pooled percentages were mild 48.8% (37.9–59.6), moderate 37.6% (29.3–46.2) and severe 
12.2% (7.8–17.4). After streaming out 1,000 draws assuming a binomial distribution, percentages were 
scaled to sum to 1 at each draw. 
Modelling strategy 
Prior settings in the DisMod model included setting remission to 0.009-0.021, and it was assumed that 
there was no incidence or prevalence of RA before the age of 5 years.  
Data from all sources were re-extracted to better reflect the range of case definitions. We set the 
American College of Rheumatology (ACR) 1987 criteria1 as the reference. We marked studies using the 
Rome 1961,2 American Rheumatology Association (ARA) 1958,3 or European League against Rheumatism 
(EULAR)4 criteria with a single study covariate “non-ACR_1987” as there were inadequate studies with 
each alternative classification system to do separate crosswalks. 
Additional study covariates were created for studies using administrative health system data sources; for 
studies covering regional rather than (sub)-nationally representative populations; and for claims data. 
We used the function in DisMod-MR 2.1 to pull in cause-specific mortality rate (CSMR) data from our 
CODEm and CODcorrect analyses and match it with prevalence data points for the same geography and 
study year to estimate priors on excess mortality rates (by dividing CSMR by prevalence). In GBD 2016, 
CSMR data include the age groups 80-84, 85-89, 90-94, and 95+ years. 
We retained just two RA diagnosis criteria and three years of claims data as x-cov (ie, based on a 
significant coefficient indicating evidence of a systematic bias). Betas and exponentiated values (which 
can be interpreted as an odds ratio) for these covariates are shown in the table below: 
Study covariate Parameter beta Exponentiated beta 
RA criteria other than ACR 1987 Prevalence -0.81 0.45 (0.39 – 0.52) 
RA diagnosis from admin data Prevalence -0.041 0.96 (0.92 – 1.00) 
Claims data - 2000 Prevalence -0.26 0.77 (0.75 – 0.80) 
Claims data - 2010 Prevalence -0.03 0.97 (0.95 – 0.99) 
Claims data - 2012 Prevalence -0.0028 1.00 (0.99 – 1.00) 
The non-representative covariate were used as z-cov, meaning that DisMod estimates a value that gets 
added to the standard deviation of data points to reflect that these were not estimated according to our 
reference case definition/study method. 
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 Osteoarthritis 
 
Flowchart 
 
 
 
Case definition 
The osteoarthritis (OA) reference case definition is symptomatic osteoarthritis of the hip or knee 
radiologically confirmed as Kellgren-Lawrence grade 2-4. Grade 2 symptomatic requires one defined 
osteophyte in hip or knee and pain for at least one month out of the last 12. Grade 3-4 symptomatic 
requires osteophytes and joint space narrowing in hip or knee with deformity also present for grade 4, 
and pain for at least one month out of the last 12 months. 
OA is the most common form of arthritis, involving inflammation and breakdown of joints. For the 
purposes of OA estimates for this GBD study, only hip and knee sites were reviewed. The hip and knee are 
the common sites of OA in the larger joints and are considered to produce the greatest disability. Failure 
of these joints can lead to need for joint replacement surgery, if available, and thus contributes to a 
significant proportion of the high direct health care costs attributable to arthritis. OA of the spine is also 
common; however, it was considered that any symptoms and disability related to the cervical and/or 
lumbar spine would be captured in the estimates of low back pain and neck pain. Hand OA involving the 
fingers and thumbs is another common site for OA, but as it often overlaps with knee OA and could also 
be captured in the “Other Musculoskeletal disorders” category, it was not considered as a separate entity 
in these GBD OA estimates.  
ICD-10 codes for OA of the hip and knee are M16 and M17, respectively. The ICD-9 code for OA is 715, 
without specific codes for hip and knee sites. 
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 Input data 
 Model inputs 
A systematic review of the prevalence, incidence and mortality of OA was performed for the years 1980 
to 2009 on MEDLINE, EMBASE, CINAHL, CAB Abstracts, WHO Library (WHOLIS) and OpenSIGLE for 
GBD2010. For prevalence and incidence, the following search terms were used: (osteoarth* OR 
gonarthr*) AND (prevalen* OR inciden* OR cross-sectional OR cross sectional OR epidemiol* OR survey 
OR population-based OR population based OR population study OR population sample OR cohort OR 
follow-up OR follow up OR longitudinal OR regist*) AND (list of names of all GBD countries). For mortality, 
the following search terms were used: (osteoarth* OR gonarthr*) AND (Mortality OR death OR 
standardised mortality ratio OR standardized mortality ratio OR case fatality OR cross-sectional OR cross 
sectional OR epidemiol* OR survey OR population-based OR population based OR population study OR 
population sample OR cohort OR follow-up OR follow up OR longitudinal OR regist*) AND (list of names of 
all GBD countries). 
Exclusion criteria were: 
54. Sub-populations clearly not representative of the national population 
55. Not a population-based study 
56. Low sample size (less than 150) 
57. Review rather than original studies 
The most recent PubMed search was conducted in GBD 2013 using the above search terms.  
Opportunistically, we added scientific literatures and population surveys encountered during data review 
for GBD 2015 and GBD 2016. The table below shows the number of literature studies included in GBD 
2016, as well as the number of countries or subnational units and GBD world regions represented. 
 Prevalence Incidence Mortality risk Severity 
 OA hip OA knee OA hip OA knee   
Studies 56 82 5 14 3 4 
Countries/subnationals 90 100 5 14 2 3 
GBD world regions 9 10 2 3 2 3 
 
In addition, data from US claims data for 2000, 2010, and 2012 by US state were included. We decided 
not to use hospital inpatient data as we considered it would not be representative of true prevalence, and 
that variation between countries in the proportion of true prevalent cases captured in hospital inpatient 
data system would likely vary more than can be captured by a single crosswalk in DisMod-MR 2.1.  
 Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for OA severity 
levels are shown below. 
Severity level Lay description DW (95% CI) 
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Mild  This person has pain in the leg, which causes some 
difficulty running, walking long distances, and getting up 
and down. 
0.023 (0.013–0.037) 
Moderate This person has moderate pain in the leg, which makes 
the person limp, and causes some difficulty walking, 
standing, lifting and carrying heavy things, getting up and 
down, and sleeping. 
0.079 (0.054–0.110) 
Severe This person has severe pain in the leg, which makes the 
person limp and causes a lot of difficulty walking, 
standing, lifting and carrying heavy things, getting up and 
down, and sleeping. 
0.165 (0.112–0.232) 
 
To determine the proportion of people with OA within each of the severity levels, four studies from three 
regions provided information on the severity of OA. Severity was classified based on the Western Ontario 
and McMaster Universities Arthritis Index (WOMAC) with scores 0-5 taken as mild, 6-13 as moderate, and 
14 and higher as severe. Estimates were pooled across studies using a random effects meta-analysis 
model. The pooled percentages were mild 47.0% (42.2–51.9), moderate 35.9% (31.3–40.7), and severe 
17.1% (12.9–21.6) pooled between patient and physician ratings in a study from Bangladesh which we 
apply to low- and middle-income countries. The pooled proportions from three high-income countries 
were mild 74.3% (64.8–82.7), moderate 24.3% (16.4–33.1), and severe 1.1% (0.6–1.7). After streaming 
out 1,000 draws assuming a binomial distribution, percentages were scaled to sum to 1 at each draw.  
 
Modelling strategy 
Prior settings in the DisMod model included setting remission to 0, and it was assumed that there was no 
incidence or prevalence of OA before the age of 30 years. We assumed in the final model that excess 
mortality is zero. While there are some data on excess mortality risk, the values of hazard ratios or 
standardised mortality ratios are close to one, with some studies reporting mean estimates less than one.  
We used study covariates for studies that reported on X-rays only, self-reported OA with pain, reporting a 
physician diagnosis of OA, and OA with symptoms but no X-ray diagnosis. For each of these covariates we 
estimated the crosswalk prior to DisMod comparing like geographies which had data according to the 
reference case definition and the alternative. In DisMod we set bounds with an upper and lower limit. We 
added covariates for each of three years of claims data in the USA. Betas and exponentiated values 
(which can be interpreted as an odds ratio) for these covariates are shown in the table below: 
Study covariate Parameter OA hip OA knee 
beta Exponentiated beta beta Exponentiated beta 
Self-reported OA with pain Prevalence 1.25  3.48 (3.03 – 3.96)  0.37  1.45 (1.14 – 1.69)  
Reported physician 
diagnosis OA 
Prevalence 
0.97 2.64 (2.45 – 2.72)  0.092 1.10 (0.85 – 1.30)  
Radiography only Prevalence 0.95 2.59 (2.33 – 2.71)  0.12 1.13 (0.88 – 1.32)  
OA with symptoms but no 
radiography confirmation 
Prevalence 
1.18 3.26 (3.01 – 3.77)  0.68 1.97 (1.44 – 2.42)  
Claims data - 2000 Prevalence -0.53  0.59 (0.58 – 0.60)  -1.39 0.40 (0.19 – 0.29)  
Claims data - 2010 Prevalence  not significant -0.91 0.40 (0.29 – 0.47) 
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Claims data - 2012 Prevalence  not significant -0.84 0.43 (0.32 – 0.51) 
Reported physician 
diagnosis OA 
Incidence 0.91 2.49 (2.24 — 2.71) 0.64 1.89 (0.89 – 2.69)  
Radiography only Incidence 0.91 2.47 (2.24 — 2.71) 0.77 2.17 (1.33 – 2.69)  
 
We added mean body mass index (BMI) and the summary exposure variable (SEV) scalar for OA (ie, a 
composite measure of the exposure to risks in GBD that affect OA: BMI) as country-level covariates of 
prevalence measure, and the SEV-OA as a country-level covariate of incidence measure. The coefficient 
for BMI in OA hip model was 0.029 (exponentiated 1.03; 1.01–1.05) meaning that for every unit increase 
in mean BMI in the population OA prevalence increases by 3%. 
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Case definition 
Low back pain (LBP) is defined as low back pain (with or without pain referred into one or both lower 
limbs) that lasts for at least one day. The “low back” is defined as the area on the posterior aspect of the 
body from the lower margin of the twelfth ribs to the lower gluteal folds. 
ICD-10 codes for LBP are M54.3, M54.4 and M54.5. The ICD-9 code is 724. 
 
Input data 
 Model inputs 
Ovid Medline, EMBase, and CINAHL electronic databases were searched for GBD2010. There were no 
age, sex, or language restrictions. The terms “back pain,” “lumbar pain,” “back ache,” “backache,” and 
“lumbago” were used individually and combined with each of the following: “prevalence,” “incidence,” 
“cross-sectional,” and “epidemiology.” The search was updated for GBD 2015 in PUBMED through to 
August 2015.  
Exclusion criteria were: 
58. Sub-populations clearly not representative of the national population 
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59. Not a population-based study 
60. Low sample size (less than 150) 
61. Review rather than original studies 
Additional information was derived from unit record data of surveys in the GHDx, GBD’s repository of 
population health data including the World Health surveys and national health surveys. The table below 
shows the number of studies and surveys included in GBD 2016, as well as the number of countries or 
subnational units and GBD world regions represented. 
 Prevalence Incidence Remission 
Studies/surveys 253 4 4 
Countries/subnationals 172 3 2 
GBD world regions 20 1 1 
 
In addition, data from US claims data for 2000 and 2010 by US state were included.  
 Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for LBP severity 
levels are shown below. 
Severity level Lay description DW (95% CI) 
Low back pain, 
mild 
This person has mild back pain, which causes some difficulty 
dressing, standing, and lifting things. 
0.020 (0.011–0.035) 
Low back pain, 
moderate 
This person has moderate back pain, which causes difficulty 
dressing, sitting, standing, walking, and lifting things. 
0.054 (0.035–0.079) 
Low back pain, 
severe without 
leg pain 
This person has severe back pain, which causes difficulty 
dressing, sitting, standing, walking, and lifting things. The 
person sleeps poorly and feels worried. 
0.272 (0.182–0.373) 
Low back pain, 
severe with leg 
pain 
This person has severe back and leg pain, which causes 
difficulty dressing, sitting, standing, walking, and lifting things. 
The person sleeps poorly and feels worried. 
0.325 0.219–0.446) 
Low back pain, 
most severe 
without leg pain 
This person has constant back pain, which causes difficulty 
dressing, sitting, standing, walking, and lifting things. The 
person sleeps poorly, is worried, and has lost some enjoyment 
in life. 
0.372 (0.250–0.506) 
Low back pain, 
most severe 
with leg pain 
This person has constant back and leg pain, which causes 
difficulty dressing, sitting, standing, walking, and lifting things. 
The person sleeps poorly, is worried, and has lost some 
enjoyment in life. 
0.384 (0.256–0.518) 
 
The severity distributions are derived from an analysis of the Medical Expenditure Panel Surveys (MEPS) 
in the US. MEPS is an overlapping continuous panel survey of the United States non-institutionalized 
population whose primary purpose is to collect information on the use and cost of health care. Panels are 
two years long and are conducted in five rounds, which are conducted every five to six months. A new 
panel begins annually, while the last panel is in its second year 
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(http://www.meps.ahrq.gov/survey_comp/hc_data_collection.jsp). Each panel typically contains about 30,000 to 35,000 
individual respondents.  
MEPS was initiated in 1996 but only began collecting health status data in the form of SF-12 responses in 
2000. For GBD 2016 we used data from 2000–2014. Respondents self-administer the SF-12 twice per 
panel, at rounds 2 and 4, typically about a year apart. Only adults 18 years and older completed the SF-
12. MEPS also usually collects information on diagnoses based on self-report of reasons for encounters 
with health services. In addition, diagnoses are derived through additional questions on “problems that 
bother you” or conditions that led to “disability days,” ie, days out of role due to illness. Professional 
coders translate the verbatim text into three digit ICD-9 codes. The main reason for LBP being measured 
in MEPS relates to health care contact. From MEPS, the severity distribution for LBP without leg pain and 
with leg pain were derived as shown in the below table. 
 
Severity level Distribution without leg pain Distribution with leg pain 
Low back pain, mild 0.41 (0.31–0.53) 0.27 (0.19–0.37) 
Low back pain, moderate 0.35 (0.25–0.44) 0.36 (0.28–0.43) 
Low back pain, severe  0.10 (0.08–0.12) 0.14 (0.10–0.16) 
Low back pain, most severe  0.14 (0.09–0.20) 0.23 (0.15–0.32) 
 
We used US claims data (2012) to derive the proportion of cases with low back pain who report leg pain.  
The proportions were different by age group as shown in Figure 1.  The proportion in each severity level 
in each age group is calculated by multiplying the proportion in the severity level and the proportion with 
or without leg pain. 
 
Figure 1: Proportion of LBP with leg pain 
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20–24 23.2 (23.0–23.4) % 
25–29 28.8 (28.6–28.9) % 
30–34 31.4 (31.3–31.6) % 
35–39 33.1 (32.9–33.2) % 
40–44 34.3 (34.2–34.4) % 
45–49 35.5 (35.4–35.6) % 
50–54 36.4 (36.3–36.5) % 
55–59 37.1 (37.0–37.2) % 
60–64 37.4 (37.3–37.5) % 
65–69 37.1 (36.9–37.3) % 
70–74 36.5 (36.4–36.7) % 
75–79 35.0 (34.8–35.2) % 
80–84 32.1 (31.9–32.4) % 
85–89 28.3 (28.0–28.5) % 
90–94 23.7 (23.2–24.2) % 
95–100 19.2 (18.2–20.2) % 
 
 
Modelling Strategy 
Prior settings in the DisMod model included setting excess mortality to 0, and it was assumed that there 
was no incidence or prevalence of low back pain before the age of 5 years.  
We used study covariates for studies that reported a too broad anatomical region, episode duration of 
greater than three months, recall periods of one week to one month, recall periods between two months 
and one year, activity-limiting LBP, and studies conducted among schoolchildren or otherwise non-
representative samples as studies covering regional rather than (sub)-nationally representative 
populations. The mean and standard error for the coefficient of the covariate of studies among 
schoolchildren population were calculated and used for a constraint in DisMod.  The other covariates 
have their coefficients constraint by reasonable ranges in the direction whether they increased or 
decreased the estimates. We added covariates for each of three years of claims data in the USA. Betas 
and exponentiated values (which can be interpreted as an odds ratio) for these two covariates are shown 
in the table below: 
Study covariate Parameter beta Exponentiated beta1 
Anatomical region too broad Prevalence 0.00049 1.00 (1.00 — 1.00)  
episode duration >= 3 months Prevalence -0.58 0.56 (0.53 — 0.59) 
recall periods of 1 week to 1 
month 
Prevalence 
0.67 1.96 (1.90 – 2.02) 
recall periods between 2 
months and one year 
Prevalence 
0.67 1.95 (1.89 – 2.01) 
Not representative Prevalence 0.17  1.19 (1.14 — 1.25) 
studies among school children Prevalence 1.00  2.72 (2.72 – 2.72)  
Activity-limiting LBP Prevalence -0.82  0.44 (0.42 – 0.46)  
Claims data - 2000 Prevalence -0.55  0.57 (0.56 — 0.59)  
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Claims data - 2010 Prevalence -0.098 0.91 (0.89 – 0.92) 
1 interpretation examples: in DisMod-MR 2.1 activity limiting LBP data points showed a systematic bias downward and were 
adjusted up by dividing by 0.72, while data points of recall greater than two months were adjusted downward dividing by 2.36. 
We dropped the covariate for claims data 2012 as it had a non-significant coefficient close to zero. We 
included the SEV scalar for low back pain as a country covariate. This combines the exposure measures 
for risks estimated to impinge on LBP in GBD: occupational ergonomic exposure and increased BMI. We 
set bounds of 0.75 to 1.25 as the SEV is constructed in a way that if our risk estimates are accurate the 
value should be 1. 
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Case definition 
Neck pain (NP) was defined as: neck pain (+/- pain referred into the upper limb(s)) that lasts for at least 
one day.  
ICD-10 code for neck pain is M54.2. The ICD-9 code is 723.1. 
 
Input data 
 Model inputs 
Ovid MEDLINE, EMBASE, CINAHL, CAB abstracts, WHOLIS, and SIGLE databases were searched for GBD 
2010. There were no age, sex, or language restrictions. The terms neck pain, neck ache, neckache, and 
cervical pain individually and combined with each of the following terms: prevalen*, inciden*, cross-
sectional, cross sectional, epidemiol*, survey, population-based, population based, population study, 
population sample. The search was updated for GBD 2013 and GBD 2015 in PUBMED through to August 
2015.  
Exclusion criteria were: 
62. Sub-populations clearly not representative of the national population 
63. Not a population-based study 
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64. Studies on a specific type of neck pain (eg, following neck fracture) 
65. Low sample size (less than 150) 
66. Review rather than original studies 
Additional information was derived from unit record data of surveys in GHDx, GBD’s repository of 
population health data including NHANES and NHIS in the USA. The table below shows the number of 
studies and surveys included in GBD 2016, as well as the number of countries or subnational units and 
GBD world regions represented. 
 Prevalence Incidence Remission 
Studies/surveys 81 2 1 
Countries/subnationals 91 1 1 
GBD world regions 11 1 1 
 
In addition, data from US claims data for 2000, 2010, and 2012 by US state were included.  
 Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for neck pain 
severity levels are shown below. 
Severity level Lay description DW (95% CI) Proportions 
Neck pain, 
mild  
This person has neck pain, and has difficulty 
turning the head and lifting things 
0.052 (0.036–0.074) 0.67 (0.57–0.75) 
Neck pain, 
moderate 
This person has constant neck pain, and has 
difficulty turning the head, holding arms up, and 
lifting things 
0.112 (0.079–0.162) 0.12 (0.08–0.19) 
Neck pain, 
severe  
This person has severe neck pain, and difficulty 
turning the head and lifting things. The person 
gets headaches and arm pain, sleeps poorly, and 
feels tired and worried 
0.226 (0.147–0.323) 0.06 (0.05–0.07) 
Neck pain, 
most severe 
This person has constant neck pain and arm pain, 
and difficulty turning the head, holding arms up, 
and lifting things. The person gets headaches, 
sleeps poorly, and feels tired and worried 
0.300 0.199–0.434) 0.15 (0.11–0.20) 
 
The severity distributions are derived from an analysis of the Medical Expenditure Panel Surveys (MEPS) 
in the US. MEPS is an overlapping continuous panel survey of the United States non-institutionalized 
population whose primary purpose is to collect information on the use and cost of health care. Panels are 
two years long and are conducted in five rounds, which are conducted every five to six months. A new 
panel begins annually, while the last panel is in its second year 
(http://www.meps.ahrq.gov/survey_comp/hc_data_collection.jsp). Each panel typically contains about 30,000 to 35,000 
individual respondents.  
MEPS was initiated in 1996 but only began collecting health status data in the form of SF-12 responses in 
2000. For GBD 2016 we used data from 2000–2014. Respondents self-administer the SF-12 twice per 
panel, at rounds two and four, typically about a year apart. Only adults 18 years and older completed the 
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SF-12. MEPS also usually collects information on diagnoses based on self-report of reasons for encounters 
with health services. In addition, diagnoses are derived through additional questions on “problems that 
bother you” or conditions that led to “disability days,” ie, days out of role due to illness. Professional 
coders translate the verbatim text into three-digit ICD-9 codes. The main reason for neck pain being 
measured in MEPS relates to health care contact.  
In order to derive a crosswalk of SF-12 values into a scale comparable with that used by the GBD  
disability weights, small studies on convenience samples were conducted asking respondents to fill in SF-
12 to reflect 62 lay descriptions of diverse severity that were used to derive the GBD disability weights. 
From these responses a relationship between SF-12 summary score and the GBD DWs was derived. With 
regression methods, average disability weights were calculated for each of 156 conditions for which there 
were corresponding diagnoses in MEPS, while controlling for any co-morbid other condition by adding 
dummy variables for each condition. As our case definition is for point prevalence of neck pain, we 
ignored the proportion of MEPS respondents with a neck pain diagnosis for whom in our regression we 
found no disability attributable to neck pain. For the remaining cases we binned the amount of DW 
attributed to neck pain across the four health states assuming thresholds at the midpoints between DW 
values. 
Modeling strategy 
Prior settings in the DisMod model included setting excess mortality to 0, and it was assumed that there 
was no incidence or prevalence of neck pain before the age of 5 years.  
We used study covariates for studies that reported a too broad anatomical region, episode duration of 
greater than three months, recall periods of one week to one month, recall periods between two months 
and one year, activity-limiting neck pain, and studies conducted among schoolchildren. We added 
covariates for each of three years of claims data in the USA.  
With exceptions for broad anatomical region, studies among schoolchildren population and activity 
limiting neck pain whose coefficients were consistent with their reasonable ranges, the means and the 
upper and lower bounds for the covariates were calculated by crosswalking with NHANES data as a 
baseline.  The table below shows the prior values for those covariates’ coefficients. 
Study covariate Lower bound Mean Upper bound 
Anatomical region too broad 0  2 
episode duration >= 3 months -0.81 -0.74 -0.67 
recall periods of 1 week to 1 month 0.67 0.77 0.87 
recall periods between 2 months and one year 0.77 0.87 0.97 
studies among school children 0  3 
Activity-limiting neck pain -3  0 
Claims data - 2000 -2.20 -2.08 -1.96 
Claims data - 2010 -1.73 -1.57 -1.41 
Claims data - 2012 -1.65 -1.50 -1.35 
 
Betas and exponentiated values (which can be interpreted as an odds ratio) for these two covariates are 
shown in the table below: 
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Study covariate Parameter beta Exponentiated beta1 
Anatomical region too broad Prevalence 0.52 1.68 (1.53 – 1.84) 
episode duration >= 3 months Prevalence -0.68 0.51 (0.49 – 0.51) 
recall periods of 1 week to 1 month Prevalence 0.86 2.37 (2.32 – 2.39) 
recall periods between 2 months and 
one year 
Prevalence 
0.79 2.21 (2.16 – 2.29) 
studies among school children Prevalence 2.53  12.54 (10.64 – 14.94) 
Activity-limiting neck pain Prevalence -1.42  0.24 (0.19 – 0.31) 
Claims data - 2000 Prevalence -2.19  0.11 (0.11 – 0.11) 
Claims data - 2010 Prevalence -1.60 0.20 (0.20 – 0.21) 
Claims data - 2012 Prevalence -1.51 0.22 (0.22 – 0.23) 
 
1 interpretation examples: in DisMod-MR 2.1 activity-limiting NP data points showed a systematic bias downward and were adjusted up by 
dividing by 0.34 while data points of recall greater than 2 months were adjusted downward dividing by 4.63. 
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Flowchart 
Case definition 
Gout is a rheumatic disease that is characterized by formation of monosodium urate (MSU) crystals in the 
synovial fluid of joints and in other tissues causing inflammation. The crystal formation is caused by 
elevated urate levels in extracellular fluids. It is more common in men. GBD uses the case definition of 
primary gout given by the American College of Rheumatology, generally referred to as ARA 1977 survey 
criteria requiring the presence of MSU crystals in joint fluid or the presence of a tophus proven to contain 
MSU crystals and at least six of 12 gout symptoms or findings (>1 attack of acute arthritis, development of 
maximal inflammation within a day, attack of monarticular arthritis, observation of joint erythema, pain 
or swelling in the first MTP joint, unilaterally attack involving the first MTP joint, unilateral attack involving 
tarsal joint, suspected tophus, hyperuricemia, asymmetrical swelling within a joint on X-ray and negative 
culture of joint fluid for microorganisms during attack of joint inflammation) to make a diagnosis. The ICD-
10 code for gout is M10 and the ICD9 code is 274.  
 
Input data 
 Model Inputs   
For GBD 2010 literature searches were performed for years 1980 to 2009 on MEDLINE, EMBASE, CINAHL, 
CAB Abstracts, WHO Library (WHOLIS), and OpenSIGLE. For prevalence and incidence, the following 
search terms were used: (gout* OR hyperuricemia) AND (prevalen* OR inciden* OR cross-sectional OR 
cross sectional OR epidemiol* OR survey OR population-based OR population based OR population study 
OR population sample OR cohort OR follow-up OR follow up OR longitudinal OR regist*) AND (list of 
names of all GBD countries). For mortality, the following search terms were used: (gout* OR 
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hyperuricemia) AND (Mortality OR death OR standardised mortality ratio OR standardized mortality ratio 
OR case fatality OR cross-sectional OR cross sectional OR epidemiol* OR survey OR population-based OR 
population based OR population study OR population sample OR cohort OR follow-up OR follow up OR 
longitudinal OR regist*) AND (list of names of all GBD countries). 
Exclusion criteria were: 
 Sub-populations clearly not representative of the national population 
 Not a population-based study 
 Low sample size (less than 150) 
 Review 
The most recent PubMed search was conducted in GBD 2013 using the above search terms.  
Opportunistically, additional studies encountered during data review were added for GBD 2015. Since we 
did not add new literature in GBD 2016, the most recent literature source dates from 2014. The table 
below shows the number of literature studies included in GBD 2016, as well as the number of countries 
or subnational units and GBD world regions represented. 
 Prevalence Incidence Mortality risk 
Studies 73 11 3 
Countries/subnationals 90 7 2 
GBD world regions 12 4 1 
 
In addition, data from US claims data for 2000, 2010, and 2012 by state were included.  
 Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for gout 
severity levels are shown below. 
Severity level Lay description DW (95% CI) 
Gout, acute This person has severe pain and swelling in the leg, 
making it very difficult to get up and down, stand, walk, 
lift, and carry heavy things. The person has trouble 
sleeping because of the pain.  
0.295 (0.196–0.409) 
Polyarticular 
gout (same as 
for severe RA) 
This person has severe, constant pain and deformity in 
most joints, causing difficulty moving around, getting up 
and down, eating, dressing, lifting, carrying, and using the 
hands. The person often feels sadness, anxiety, and 
extreme fatigue. 
0.581 (0.403–0.739) 
 
We used three studies on the distribution of the number of gout attacks per year and fitted a lognormal 
curve using a least squared differences method. In the absence of data on the proportion of gout cases 
who have chronic polyarticular gout, we assumed the proportion is equal to those who would have 52 
attacks a year (ie, weekly) or more as implied by the lognormal curve. 
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The average number of attacks was estimated from the lognormal fit: 5.66 (5.14–6.18). From two studies 
we derived an average duration of attacks of 6.1 (5.4–6.8) days by simple averaging. The resulting 
proportion of time symptomatic for acute gout was taken as the multiplication of these two estimates 
divided by the number of days in a year: 9.4% (8.0–10.9%). 
Figure 1: Distribution of cases by frequency 
 
 
Modelling strategy 
Initially we set remission to zero but found this made incidence and prevalence inconsistent. As the ratio 
of prevalence and incidence in similar locations was in the order of 10:1 we decided to allow remission to 
range between 0 and 0.2 and that made incidence and prevalence more consistent. We assumed that 
there was no incidence or prevalence of gout before the age of 15 years.  
We used a covariate for the 2000 US claims data but assumed the latter two years reflect the reference 
case definition. For studies relying on self-reported diagnoses or not stating diagnostic criteria were 
flagged with a covariate for a risk of bias. However, the risk of bias covariate was found to be insignificant; 
thus, it was used as a covariate that affects only uncertainty but not mean estimates. 
Betas and exponentiated values (which can be interpreted as an odds ratio) for the claims covariate are 
shown in the table below: 
Study covariate Parameter beta Exponentiated beta 
    
Claims data – 2000 Prevalence -0.66 0.52 (0.50–0.53) 
 
We added the Summary Exposure Variable (SEV) scalar for gout which summarizes exposure to risks 
estimated in GBD to impinge on gout, ie, low glomerular filtration rate as a country covariate. We set 
bounds of 0.75 to 1.25 as the SEV is constructed in a way that if our risk estimates are accurate the value 
should be 1.  
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Case definition 
Other musculoskeletal (MSK) disorders is a heterogeneous rest category comprising a wide range of 
disorders of muscles, bones, and ligaments that are not included in the five GBD defined musculoskeletal 
diseases rheumatoid arthritis, osteoarthritis, low back and neck pain, and gout, and are not captured as 
long-term sequelae of injuries. 
The table below provides detail of the ICD-10 and ICD-9 codes included in this category. 
ICD-10 codes ICD-9 codes 
 
L93—Lupus erythematosus 
M00-M02—Infectious arthropathies 
M08, M11-M13—Inflammatory polyarthropathies 
M20-M25—Other joint disorders 
M30-M35—Systemic connective tissue disorders 
M40-M43—Deforming dorsopathies 
M45-M46—Spondylopathies 
M60 -M63—Disorders of muscles 
M65-M68—Disorders of synovium and tendon 
M70- M73, M75-M79—Other soft tissue disorders 
M80-M85—Disorders of bone density and structure 
M86—Osteomyelitis 
M87-M90—Other osteopathies 
710.0 
711 
712–713 
716–719 
710.1-710.9 
737 
720–721 
725 
726–728 
729 
733.0-2 
730.1-730.3, 730.7-9 
731, 733.3-9 
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M91-M94—Chondropathies 
M95-M99—Other disorders of the MSK system and 
connective tissue 
732 
734–736, 738–739 
 
 
 
Input data 
 Model Inputs 
The above ICD codes were used to extract other MSK prevalence from US claims data for 2000, 2010, 
and 2012 by US state. The systematic review concentrated on finding health surveys that measured an 
overall amount of musculoskeletal disorders and complaints and reported information to distinguish a 
rest category that was not OA, RA, gout, or low back or neck pain. These data sources are based on self-
reported musculoskeletal conditions or symptoms and not on the listed ICD codes. 
 
The table below shows the number of studies and surveys included in GBD 2016, as well as the number of 
countries or subnational units and GBD world regions represented. 
 Prevalence Incidence Remission 
Studies/surveys 45 2 1 
Countries/subnationals 70 1 1 
GBD world regions 11 1 1 
 
 Severity splits 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The lay descriptions and disability weights for other MSK 
severity levels are shown below. They include the three levels of health states that are used for 
osteoarthritis and rheumatoid arthritis, each. 
Severity level Lay description DW (95% CI) Proportions 
Asymptomatic   0.28 (0.27–0.29) 
Musculoskeletal 
problems, lower 
limbs, mild 
This person has pain in the leg, which 
causes some difficulty running, 
walking long distances, and getting up 
and down. 
0.023 (0.013–0.040) 0.22 (0.15–0.30) 
Musculoskeletal 
problems, upper 
limbs, mild 
This person has mild pain and stiffness 
in the arms and hands. The person has 
some difficulty lifting, carrying, and 
holding things. 
0.028 (0.017–0.046) 0.20 (0.15–0.29) 
Musculoskeletal 
problems, upper 
limbs, moderate  
This person has moderate pain and 
stiffness in the arms and hands, which 
causes difficulty lifting, carrying, and 
holding things, and trouble sleeping 
because of the pain. 
0.115 (0.079–0.163) 0.10 (0.06–0.15) 
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Musculoskeletal 
problems, lower 
limbs, severe 
This person has severe pain in the leg, 
which makes the person limp and 
causes a lot of difficulty walking, 
standing, lifting and carrying heavy 
things, getting up and down, and 
sleeping. 
0.163 0.109–0.224  0.06 (0.04–0.07) 
Musculoskeletal 
problems, 
generalized, 
moderate 
This person has pain and deformity in 
most joints, causing difficulty moving 
around, getting up and down, and 
using the hands for lifting and 
carrying. The person often feels 
fatigue. 
0.312 (0.201–0.438) 0.07 (0.06–0.08) 
Musculoskeletal 
problems, 
generalized, severe 
This person has severe, constant pain 
and deformity in most joints, causing 
difficulty moving around, getting up 
and down, eating, dressing, lifting, 
carrying, and using the hands. The 
person often feels sadness, anxiety, 
and extreme fatigue. 
0.572 (0.370–0.758) 0.07 (0.07–0.08) 
 
The severity distributions are derived from an analysis of the Medical Expenditure Panel Surveys (MEPS) 
in the US. MEPS is an overlapping continuous panel survey of the United States non-institutionalized 
population whose primary purpose is to collect information on the use and cost of health care. Panels are 
two years long and are conducted in five rounds, which are conducted every five to six months. A new 
panel begins annually, while the last panel is in its second year 
(http://www.meps.ahrq.gov/survey_comp/hc_data_collection.jsp). Each panel typically contains about 30,000 to 35,000 
individual respondents.  
MEPS was initiated in 1996, but only began collecting health status data in the form of 12-Item Short 
Form Survey (SF-12) responses in 2000. For GBD 2016 we used data from 2000–2014. Respondents self-
administer the SF-12 twice per panel, at rounds two and four, typically about a year apart. Only adults 18 
years and older completed the SF-12. MEPS also usually collects information on diagnoses based on self-
report of reasons for encounters with health services. In addition, diagnoses are derived through 
additional questions on “problems that bother you” or conditions that led to “disability days,” ie, days out 
of role due to illness. Professional coders translate the verbatim text into three-digit ICD-9 codes. The 
main reason for other MSK being measured in MEPS relates to health care contact.  
In order to derive a crosswalk of SF-12 values into a scale comparable with that used by the GBD  
disability weights, small studies on convenience samples were conducted asking respondents to fill in SF-
12 to reflect 62 lay descriptions of diverse severity that were used to derive the GBD disability weights. 
From these responses a relationship between SF-12 summary score and the GBD DWs was derived. With 
regression methods, average disability weights were calculated for each of 156 conditions for which there 
were corresponding diagnoses in MEPS, while controlling for any comorbid other condition by adding 
dummy variables for each condition. We binned the amount of DW attributed to neck pain across the 
seven health states assuming thresholds at the midpoints between DW values. 
546
Modeling Strategy 
Prior settings in the DisMod model included setting excess mortality to 0, and it was assumed that there 
was no incidence or prevalence of other MSK before the age of 10 years. In the absence of any 
meaningful data on incidence and remission for such a heterogeneous category of disorders, we made a 
rather arbitrary decision of remission 0.5–1, ie, an average duration of 1-2 years. We included cause-
specific mortality rate (CSMR) data for other MSK and estimated priors on excess mortality rate by 
dividing all prevalence data points by the corresponding CSMR. In GBD 2016, new CSMR data include 
older age group, ie, 80-85, 85-90, 90-95, and 95+ years, in addition to 80+ years in GBD 2015. 
We used study covariates for each of the three years of claims data in the USA. Betas and exponentiated 
values (which can be interpreted as an odds ratio) for these two covariates are shown in the table below: 
Study covariate Parameter beta Exponentiated beta1 
Claims data - 2000 Prevalence 0.54  1.72 (1.66 — 1.81)  
Claims data - 2010 Prevalence 0.87 2.40 (2.31 — 2.53)  
Claims data - 2012 Prevalence 0.91 2.49 (2.40 — 2.62)  
1 interpretation examples: in DisMod-MR 2.1 2012 claims data are reduced by a factor 2.71. 
We allow positive coefficients on claims data as all our other data sources are based on other MSK 
disorders in the absence of low back pain, neck pain, OA, RA, and gout, while claims data reflect the one-
year prevalence of having an ICD-coded other MSK condition mentioned. As there are multiple other MSK 
conditions that last less than a year, it is not surprising to find higher one-year prevalence in claims data 
then the point prevalence estimates derived from surveys. 
We use the GBD sociodemographic scalar variable as a covariate with a small coefficient of 0.17 
estimated by DisMod-MR 2.1.  
In order to avoid double counting, we subtract the long-term sequelae of fractures, dislocations, and 
contusions due to injuries from other MSK, as the surveys from which we derive prevalence estimates 
make no distinction between cases with other MSK problems that are or are not due to injuries.  
 
  
547
Congenital Anomalies 
This write-up covers the following causes: congenital heart defects, neural tube defects, cleft lip and cleft 
palate, congenital anomalies of the urogenital system, congenital anomalies of the gastrointestinal tract, 
musculoskeletal congenital anomalies, Down Syndrome, Turner Syndrome, Klinefelter Syndrome, and 
other chromosomal abnormalities, genetic syndromes and micro-deletions  
Flowchart 
Cause-specific 
CSMR estimates 
from CoD 
Nonfatal 
database
Dismod-MR 2.1: full life course 
models for all congenital causes 
and specific sub-cause models
Prevalence of each 
category of 
congenital anomalies  
by location / year / 
sex / age
EPIC (Epi Central 
Computation)
YLLs
Comorbidity
adjusted
YLDs
DALYs
Congenital Anomalies: Overall Methods
Causes included: congenital heart defects, neural tube defects, cleft lip and cleft palate, congenital anomalies of the urogenital system, congenital anomalies of the gastrointestinal 
tract, musculoskeletal congenital anomalies, Down Syndrome, Turner Syndrome, Klinefelter Syndrome, and other chromosomal abnormalities, genetic syndromes and micro-deletions 
Study Level Covariates:
- inclusion of stillbirths
- inclusion of terminations of pregnancy
- exclusion of chromosomal syndromes
- data sources with known under-reporting
- inpatient hospital data sources
- Marketscan claims data sources
Severity splits
Disability weights for each 
sequela, combined when 
applicable
Unadjusted 
YLD by 
sequela
Meta-analysis of health 
states and severities 
associated with each 
congenital condition
International birth defects 
registries
Country-Level Covariates:
- Legality of abortion
- Maternal consumption of alcohol during pregnancy
- Proportion of live births among mothers 35+
- Health access and quality index
- lnLDI
Systematic review of 
the literature for each 
congenital conditon
Inpatient hospital 
data
Literature on long-
term outcomes 
Input data 
preparation & 
processing
Input data
Process
Results
Database
Disability weights
Nonfatal
Burden estimation
Cause of death
Covariates
Input Data
Squeeze sub-cause models for 
congenital heart defects, neural 
tube defects musculoskeletal and 
digestive anomalies to total parent 
cause models
Proportion  Other  for 
congenital heart defects, 
musculoskeletal and 
digestive anomalies
Age- and sex- specific 
prevalence ratios from 
Marketscan inpatient data
Prevalence 
severe 
impairment due 
to  congenital 
cause 
Prevalence of 
moderate 
impairment due 
to  congenital 
cause 
Prevalence of 
mild 
impairment due 
to  congenital 
cause 
Inpatient Marketscan 
claims Data
Mild, moderate and 
severe heart failure 
due to congenital 
heart defects
Split to congenital heart 
sub-cause models using 
CSMR proportions
Case Definitions 
Summary 
The GBD case definition of congenital anomalies includes any condition present at birth that is a result of 
abnormalities of embryonic development, excluding those that are directly the result of infections or 
substance abuse (e.g. fetal alcohol syndrome, congenital syphilis) and excludes minor anomalies as they 
are defined by EUROCAT. Further, our GBD case definition includes only live births and excludes all 
terminations of pregnancy following prenatal diagnosis and stillbirths. 
We have estimated the prevalence and associated disability of the following categories of congenital birth 
defects 
1. Neural tube defects
a. Anencephaly
b. Encephalocele
c. Spina bifida
2. Congenital heart defects
a. Single ventricle and single ventricle pathway defects
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b. Severe congenital heart defects excluding single ventricle and single ventricle pathway 
defects 
c. Critical malformations of great vessels, congenital valvular heart disease and patent 
ductus arteriosis 
d. Ventricular septal defect and atrial septal defect 
e. Other congenital cardiovascular anomalies 
3. Orofacial clefts: Cleft lip and cleft palate 
4. Down Syndrome 
5. Turner Syndrome 
6. Klinefelter Syndrome 
7. Other chromosomal abnormalities, genetic syndromes, and micro-deletions  
a. Edwards Syndrome and Patau Syndrome 
8. Congenital anomalies of the urogenital system 
a. Congenital urinary anomalies 
b. Congenital genital anomalies 
9. Congenital anomalies of the digestive system 
a. Congenital diaphragmatic hernia 
b. Congenital malformations of the abdominal wall 
c.  Congenital atresia and/or stenosis of the gastrointestinal tract 
d. Other congenital malformations of the gastrointestinal tract 
10. Musculoskeletal congenital anomalies 
a. Polydactyly and syndactyly 
b. Limb reduction defects 
c. Other musculoskeletal congenital anomalies 
11. Other congenital anomalies: all birth defects (excluding minor anomalies) not contained in the 
other categories.  
Urogenital, musculoskeletal, and gastrointestinal are all new causes estimated for the first time in GBD 
2016. Previously all were included in the “other congenital anomalies” category.  
This appendix will first describe the input data sources and aspects of the modeling strategy that are 
common to all sub-types of congenital anomalies. We will then provide a description of the case 
definitions, ICD-10 codes, and health states associated with each of the component congenital causes, as 
well as the specific modeling strategies employed in each congenital cause, including the model settings, 
study-level and country-level covariates, and other modeling decisions made.  
Input Data Sources  
Several types of data sources are used in the estimation of congenital anomalies: literature prevalence, 
with-condition mortality and excess mortality data, birth prevalence and neonatal with-condition 
mortality data from a number of international birth defects registries and surveillance systems, inpatient 
hospital and Marketscan claims data prepared internally by the GBD research team, and cause-specific 
mortality estimates produced by the GBD 2016 causes of death analysis. 
We conducted a systematic review of the available literature for all types of congenital anomalies by 
constructing search strings designed to capture information on the prevalence, associated mortality and 
long-term health outcomes associated with each sub-category of congenital anomalies. All results were 
screened – first abstracts, then full-text screenings – to ensure the availability of required information 
and the representativeness of the reported population, and the exclusion of duplicate data also reported 
as part of the birth registry data inputs.  
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We extracted data from a number of international birth defects registries. The International 
Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) reports birth prevalence from a 
number of international member registries. The World Atlas Report also published birth prevalence 
estimates from these international registries prior to the publication of ICBDSR reports. The European 
Surveillance of Congenital Anomalies (EUROCAT) reports the birth prevalence of anomalies as for a 
variety of locations in Western Europe as reported by participating member registries. China’s Maternal 
and Child Health Surveillance survey (MCHS) reports birth prevalence and early neonatal mortality data 
for all subnational locations of China. The National Birth Defects Prevention Network (NBDPN) reports 
birth prevalence estimates as compiled by a number of subnational registries within the United States. 
The Birth Defects Registry of India (BDRI) reports congenital anomalies from participating hospitals 
within India.  
Inpatient hospital and Marketscan claims data for all congenital anomalies causes and sub-cause models 
was prepped centrally by the GBD research team. The inpatient hospital data was adjusted for multiple 
inpatient visits by individuals and for the correction of primary diagnoses to all diagnoses including the 
congenital ICD codes. For more information on the preparation of these data sources, see elsewhere in 
this appendix.  
Modeling Strategy: Overview 
All available input data was utilized in a series DisMod-MR models in order to estimate the prevalence of 
each category of congenital anomalies across the full life course for each location/age/sex combination. 
Incidence was set to 0 for all congenital models, as congenital conditions occur at the time of birth and 
by definition there are no incident cases after birth. Remission was allowed only in the models of a select 
subset of causes for which surgical intervention or spontaneous remission can completely eliminate the 
disability due to that congenital condition: namely, cleft lip and/or palate, polydactyly and syndactyly, 
and ventricular septal defect and atrial septal defect. Cause-specific priors and slope priors were used to 
guide biologically plausible DisMod-MR estimates of excess mortality and remission where applicable. 
For a subset of conditions, a decreasing slope prior on excess mortality rate was applied to capture the 
highest risk of mortality from congenital conditions in the neonatal age groups and a subsequent 
decreasing risk of mortality from congenital conditions later in life. Excess mortality was set to zero after 
70 years of age in all models, in keeping with the GBD cause of death estimates for all congenital causes.  
For each of congenital heart, musculoskeletal and gastrointestinal anomalies, we used as DisMod-MR 
model to estimate the total prevalence of all conditions within that cause category. We then squeezed 
the sum of the specific sub-cause prevalence estimates to these total prevalence estimates in order to 
ensure internal consistency of our cause-level and sub-cause estimates. We used age- and sex-specific 
prevalence ratios derived from the Marketscan inpatient claims data to split off a proportion of other 
heart, musculoskeletal, and gastrointestinal anomalies from the total estimates for each cause. 
 
Study-level Covariates 
A number of the input data sources used for the estimation of congenital birth defects are known to have 
biases leading to under-reporting or over-reporting relative to the true prevalence of congenital 
anomalies among live births and all subsequent age groups. We used study-level covariates in the each 
of the DisMod-MR models to adjust for these under-reporting and over-reporting biases. 
Where necessary, we used a study-level covariate to adjust for the inclusion of stillbirths in the reported 
birth prevalence estimates in literature and registry data sources, as stillbirths are not included in our 
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case definition of prevalence among live births. We also used a study-level covariate to adjust for data 
sources that included terminations of pregnancy in their birth prevalence estimates. In all models except 
for the chromosomal conditions, we also used a study-level covariate to adjust for under-reporting in 
data sources that were extracted to exclude co-occurring chromosomal conditions from the reported 
prevalence estimates. 
For a subset of congenital causes, particularly the congenital heart defects, we noted substantial 
differences in the lists of case definitions being reported to the various congenital registries. Across all 
types of congenital heart defects, the National Birth Defects Prevention Network (NBDPN) had the most 
complete list of reported case definitions – ie, the highest case ascertainment – and was considered the 
gold standard among all birth registry data sources. We used registry-specific crosswalks to adjust all 
other birth defects registries to match the case ascertainment seen in the NBDPN.  
We also included a series of study-level covariates to adjust for under-reporting in the inpatient hospital 
data and Marketscan claims data. This included one study-level covariate used specifically to adjust the 
2010 inpatient Marketscan data and another used specifically to adjust the 2012 Marketscan data to the 
reference literature and registry data sources.   
 
Country-level Covariates 
Country-level covariates were used in each of the congenital DisMod-MR models based on literature 
information about the risk factors for these birth defects. Folic acid availability was used as a covariate 
on prevalence for all neural tube defects models and a subset of the congenital musculoskeletal 
anomalies models. The legality of abortion was used as a covariate on prevalence for conditions in which 
prenatal diagnosis is commonly available and the prognosis is severe enough to cause high rate of 
termination of pregnancy following prenatal diagnosis: these include all chromosomal conditions and a 
subset of the congenital heart defects. Maternal consumption of alcohol during pregnancy, as a 
proportion of all pregnancies, was used as a covariate on prevalence for all congenital heart defects. The 
proportion of live births by mothers age 35+ was used as a covariate on all chromosomal models.  
Across many of the congenital models, the Health Access and Quality Index covariate was used to guide 
the global pattern of with-condition mortality and excess mortality, as was the natural log of the lag-
distributed income per capita (lnLDI). For most of the severe congenital conditions, the mortality 
associated with the condition is highly dependent on access to adequate surgical interventions and other 
medical care during the first hours, weeks, and years of life.  
 
Assigning health states and sequelae for long-term outcomes  
To determine the distribution of health outcomes associated with the congenital causes, we performed a 
review of available literature on the long-term health outcomes of survivors in cohorts born with each 
type of congenital malformation. For conditions requiring surgical intervention shortly after birth to 
ensure survival, the health states included in the disability weight calculations correspond to the post-
surgery outcomes reported in cohorts of individuals born with these life-threatening congenital 
conditions. Where data was available on from multiple cohorts, we pooled these cohorts together to 
calculate the proportion of individuals with each health state. Where data on the joint distribution of the 
long-term health outcomes was not available, we assumed independence of each long-term health 
outcome. Combined disability weights were calculated for all necessary combinations of existing 
disability weights.  
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Case definitions and modeling strategy specifics  
Neural tube defects 
 
Case definitions 
Neural tube defects occur when neural tube fails to close completely during development. The GBD 2016 
case definition includes spina bifida, in which part of the spinal cord and/or meninges are uncovered by 
skin; encephalocele, a congenital defect characterized by sac-like protrusions of the brain and meninges 
through openings in the skull; and anencephaly, the absence of a major portion of the brain, skull, and 
scalp. Spina bifida occulta, a much less severe form of spina bifida where the defect in vertebral column 
remains covered by skin, is excluded from the GBD case definition of spina bifida. All infants born with 
anencephaly die during the first few weeks of life, as there is no remission and no cure for this condition. 
Infants born with spina bifida or encephalocele typically require surgical intervention during the first few 
weeks of life, and thereafter may experience a range of neural and motor complications. Our case 
definitions of spina bifida and encephalocele do not consider surgical intervention for either condition as 
remission.  In GBD 2016, spina bifida, encephalocele, and anencephaly are each modeled separately and 
then fit to a total model of all neural tube defects. Spina bifida corresponds to the ICD-10 codes Q05.0, 
Q05.4,Q05.6, Q05.7, Q05.8, and Q05.9. Encephalocele corresponds to the ICD-10 codes Q01.2, Q01.8, 
and Q01.9. Anencephaly corresponds to the ICD-10 codes Q00.0 and Q00.2.   
Health states associated with neural tube defects 
All infants with anencephaly are assigned the health state of severe motor and cognitive impairment. 
Cases of spina bifida and encephalocele are split into every combination of mild, moderate and severe 
motor impairment, all severities of intellectual disability, and urinary incontinence. These proportions 
were calculated using a pooled analysis of available literature on the long-term outcomes in cohorts of 
individuals born with each sub-type of neural tube defects. The distribution of health states associated 
with encephalocele (references: NIDs 292406, 292320, and 292322) was derived separately from the 
distribution of health states associated with spina bifida (references: NIDs 292324 and 292327), although 
these two categories of neural tube defects are associated with the same list of long-term outcome 
sequela. 
 
Neural tube defects overall modeling strategy and model settings  
In order to ensure internal consistency of the estimates of each sub-type of neural tube defects, we 
developed a model of the total prevalence of neural tube defects and used these location, year, sex and 
age-specific prevalence estimates to scale the estimates of anencepaly, encephalocele and spina bifida 
prevalence. This modeling strategy allowed us to incorporate the cause-specific mortality estimates 
form the GBD 2016 Cause of Death analysis and also allowed us to use literature data where the 
prevalence and mortality estimates were reported for the total of all neural tube defects only. 
The DisMod-MR model of total neural tube defects used cause-specific mortality (CSMR) estimates from 
the GBD cause of death analysis for neural tube defects. This model had a minimum excess mortality of 
3.0 for the first week of age and a decreasing slope prior on excess mortality rate for all ages as the risk 
of death due to neural tube defects is greatest shortly after birth. The model also used an increased 
smoothness (maximum xi=1) on excess mortality rate in order to allow high excess mortality in the early 
neonatal age group. Random effects on prevalence were limited to +- 0.5 in order to limit geographic 
variation in the estimated birth prevalence.  
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 Anencephaly modeling strategy and model settings 
The life expectancy for infants born with anencephaly is on the order of hours or days; none of these 
infants survive past the neonatal age period. Because of the extremely high excess mortality associated 
with this condition and the short age range over which the prevalence varies, we used a custom 
modeling process to estimate the prevalence of anencephaly. We first used DisMod-MR to model the 
prevalence of anencephaly at birth for every location, year, age and sex combination. We then used 
literature data on outcomes largest available cohort of infants born with anencephaly (references: NID 
294812 and NID 296668)), using the precise time of death information from this cohort to create a life 
table that applied the high excess mortality rates to all cases of anencephaly at birth. 
 We applied these mortality rates to both sex and all locations, generating the time lived by infants with 
anencephaly during the early and late neonatal age groups by location, year and sex. We then used GBB 
2016 mortality estimates to calculate the time lived by all infants during the early and late neonatal age 
groups by location, year and sex, and used these two values to calculate the prevalence of anencephaly 
in the early and late neonatal age groups; after one month of age, all available literature indicates that 
no  infants born with anencephaly are still alive. 
The DisMod-MR model for the birth prevalence of anencephaly has random effects on prevalence 
limited to +- 1. As this model was designed to estimate only the prevalence at birth, incidence, remission 
and excess mortality were set to zero for all ages, and the only age mesh points were 0 and 100 years of 
age.  
Encephalocele modeling strategy and model settings 
The DisMod-MR model for encephalocele had a minimum excess mortality of 5.0 for the first week of 
age and a decreasing slope prior on excess mortality rate for all ages. The model also used an increased 
smoothness on excess mortality rate (maximum xi=1).  Random effects on prevalence were limited to +- 
0.5 as we expect limited geographic variation in the birth prevalence of encephalocele. 
Spina bifida modeling strategy and model settings  
The DisMod-MR model for spina bifida had a minimum excess mortality of 3.0 for the first week of age, 
a decreasing slope prior on excess mortality rate for all ages, and a maximum smoothness on excess 
mortality rate of xi=1. Random effects on prevalence were also limited to +- 0.5.  
 
Covariates used in the DisMod-MR total neural tube defects model 
Covariate name Type Measure Beta value Exponentiated value 
Folic acid unadjusted 
(ug) 
Country 
covariate Prevalence -0.000 (-0.000 - -0.000) 1.000 (1.000 - 1.000) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality 
rate -0.101 (-0.104 - -0.100) 0.904 (0.901 - 0.905) 
All MarketScan, year 
2010 
Study-level x-
covariate Prevalence -1.040 (-1.108 - -0.975) 0.353 (0.330 - 0.377) 
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All MarketScan, year 
2012 
Study-level x-
covariate Prevalence -1.023 (-1.096 - -0.958) 0.359 (0.334 - 0.384) 
Chromosomal diagnoses 
excluded 
Study-level x-
covariate Prevalence -0.298 (-0.300 - -0.292) 0.742 (0.741 - 0.746) 
Hospital data for ages 
over 1 year only 
Study-level x-
covariate Prevalence -0.252 (-0.256 - -0.250) 0.778 (0.774 - 0.779) 
Hospital data for the 
under-1 year age group 
Study-level x-
covariate Prevalence 0.249 (0.247 - 0.250) 1.283 (1.280 - 1.284) 
Stillbirths included as 
cases 
Study-level x-
covariate Prevalence 0.298 (0.296 - 0.300) 1.348 (1.345 - 1.349) 
Terminations of 
pregnancy included as 
cases 
Study-level x-
covariate Prevalence 0.008 (0.000 - 0.028) 1.008 (1.000 - 1.028) 
Under Reported 
Study-level x-
covariate Prevalence -0.003 (-0.013 - -0.000) 0.997 (0.987 - 1.000) 
 
- Covariates used in the DisMod-MR birth prevalence model of anencephaly 
Covariate name Type Measure Beta value Exponentiated value 
Folic acid unadjusted 
(ug) 
Country 
covariate Prevalence 
-0.004 (-0.048 - -
0.000) 0.996 (0.954 - 1.000) 
Legality of Abortion 
Country 
covariate Prevalence 
-0.014 (-0.018 - -
0.000) 0.986 (0.982 - 1.000) 
Chromosomal diagnoses 
excluded 
Study-level x-
covariate Prevalence 
-0.156 (-0.254 - -
0.000) 0.855 (0.776 - 1.000) 
Hospital Inpatient 
Study-level x-
covariate Prevalence 
-0.420 (-0.583 - -
0.001) 0.657 (0.558 - 0.999) 
Stillbirths included as 
cases 
Study-level x-
covariate Prevalence 0.797 (0.251 - 0.942) 2.220 (1.286 - 2.564) 
Terminations of 
pregnancy included as 
cases 
Study-level x-
covariate Prevalence 0.184 (0.001 - 0.378) 1.203 (1.001 - 1.459) 
Folic acid unadjusted 
(ug) 
Country 
covariate Prevalence 
-0.004 (-0.048 - -
0.000) 0.996 (0.954 - 1.000) 
 
Covariates used in the DisMod-MR model of encephalocele 
Covariate name Type Measure Beta value Exponentiated value 
Folic acid unadjusted 
(ug) 
Country 
covariate Prevalence -0.002 (-0.037 - -0.000) 0.998 (0.963 - 1.000) 
Healthcare access and 
quality index 
Country 
covariate 
With-
condition 
mortality 
rate -0.005 (-0.018 - -0.000) 0.995 (0.982 - 1.000) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality 
rate -0.626 (-0.996 - -0.250) 0.535 (0.370 - 0.779) 
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Legality of Abortion 
Country 
covariate Prevalence -0.008 (-0.011 - -0.000) 0.992 (0.989 - 1.000) 
All MarketScan, year 
2010 
Study-level 
x-covariate Prevalence -0.712 (-0.877 - -0.130) 0.491 (0.416 - 0.878) 
All MarketScan, year 
2012 
Study-level 
x-covariate Prevalence -0.681 (-0.844 - -0.118) 0.506 (0.430 - 0.888) 
Chromosomal diagnoses 
excluded 
Study-level 
x-covariate Prevalence -0.284 (-0.300 - -0.004) 0.752 (0.741 - 0.996) 
Hospital data for ages 
over 1 year only 
Study-level 
x-covariate Prevalence -0.089 (-0.166 - -0.002) 0.915 (0.847 - 0.998) 
Hospital data for the 
under-1 year age group 
Study-level 
x-covariate Prevalence -0.024 (-0.285 - -0.000) 0.976 (0.752 - 1.000) 
Stillbirths included as 
cases 
Study-level 
x-covariate Prevalence 0.267 (0.005 - 0.299) 1.306 (1.005 - 1.349) 
Terminations of 
pregnancy included as 
cases 
Study-level 
x-covariate Prevalence 0.110 (0.005 - 0.246) 1.116 (1.005 - 1.279) 
 
Covariates used in the DisMod-MR model of spina bifida 
Covariate name Type Measure Beta value Exponentiated value 
Folic acid unadjusted 
(ug) 
Country 
covariate Prevalence -0.002 (-0.029 - -0.000) 0.998 (0.971 - 1.000) 
Healthcare access and 
quality index 
Country 
covariate 
With-
condition 
mortality 
rate -0.013 (-0.059 - -0.001) 0.987 (0.942 - 0.999) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality 
rate -0.625 (-1.000 - -0.250) 0.535 (0.368 - 0.779) 
Legality of Abortion 
Country 
covariate Prevalence -0.007 (-0.009 - -0.000) 0.993 (0.991 - 1.000) 
All MarketScan, year 
2010 
Study-level x-
covariate Prevalence -1.114 (-1.249 - -0.880) 0.328 (0.287 - 0.415) 
All MarketScan, year 
2012 
Study-level x-
covariate Prevalence -1.081 (-1.211 - -0.869) 0.339 (0.298 - 0.419) 
Chromosomal diagnoses 
excluded 
Study-level x-
covariate Prevalence -0.287 (-0.300 - -0.000) 0.750 (0.741 - 1.000) 
Hospital data for ages 
over 1 year only 
Study-level x-
covariate Prevalence -0.006 (-0.019 - -0.000) 0.994 (0.981 - 1.000) 
Hospital data for the 
under-1 year age group 
Study-level x-
covariate Prevalence -0.004 (-0.012 - -0.000) 0.996 (0.988 - 1.000) 
Stillbirths included as 
cases 
Study-level x-
covariate Prevalence 0.011 (0.001 - 0.039) 1.011 (1.001 - 1.040) 
-  
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Congenital heart anomalies 
Case definitions  
There are many distinct types of congenital heart anomalies with a range of anatomical patterns, 
severities, and requirements for medical treatment. For the purposes of estimating nonfatal outcomes, in 
GBD 2016 congenital heart anomalies were split into five-sub categories based on both the anatomical 
characteristics and the treatment requirements of each condition.  
The first sub-cause category, single ventricle and single ventricle pathway defects include tricuspid 
atresia, hypoplastic left heart syndrome, mitral valve atresia, single left ventricle, double outlet right 
ventricle, and pulmonary atresia; the corresponding ICD-10 codes are Q20.1, Q20.2, Q20.4, Q22.4, Q22.6 
and Q23.4. Each of the single ventricle and single ventricle pathway conditions requires surgical 
intervention shortly after birth to ensure infant survival.  
The second sub-cause category, severe congenital heart defects excluding single ventricle and single 
ventricle pathway defects, includes common arterial trunk, common truncus, discordant ventriculoaterial 
connection, transposition of great vessels, atrioventricular septal defect, endocardial cushion defect, 
Tetralogy of fallot, aortopulmonary septal defect, pulmonary valve atresia, congenital stenosis of aortic 
valve, and total anomalous pulmonary venous connection. This category of severe congenital heart 
defects includes ICD-10 codes Q20.0; Q20.3; Q21.2; Q21.3; Q21.4; Q22.0; Q23.0 and Q26.2.  
The third sub-cause category is critical malformations of great vessels, congenital valvular heart disease 
and patent ductus arteriosis. The malformations of vessels and valves in this sub-cause category include 
Ebstein's anomaly, congenital pulmonary valve stenosis, pulmonary valve insufficiency, other 
malformations of the pulmonary valve, malformations of the tricuspid valve, tricuspid atresia or stenosis, 
insufficiency of the aortic valve, mitral stenosis or insufficiency, and other malformations of aortic and 
mitral valves. Patent ductus arteriosis cases are only included among infants of >37 weeks gestational 
age, as premature infants often have minor patent ductus arteriosis that closes shortly after birth.  The 
ICD-10 codes corresponding to the critical malformations of great vessels category include Q22.1, Q22.2, 
Q22.3, Q22.5, Q22.8, Q22.9, Q23.1, Q23.2, Q23.3, Q23.8, Q23, Q25.1, Q25.2, Q25.3, Q25.4, Q25.5, and 
Q25.0. The majority of these conditions require medical attention shortly within the first few weeks of 
life.  
The fourth sub-cause category, ventricular septal defects and atrial septal defects, includes holes in the 
walls separating the chambers of the heart. Many of these septal defects close spontaneously, while 
other require surgical care. The ICD-10 codes corresponding to ventricular septal defect and atrial septal 
defect are Q21.0 and Q21.1, respectively.  
The fifth and final sub-cause category of congenital heart defects is other congenital cardiovascular 
anomalies, which correspond to ICD-10 codes Q27, Q27.1, Q27.2, Q27.3, Q27.30, Q27.31, Q27.32, 
Q27.33, Q27.34, Q27.39, Q27.4, Q27.8, Q27.9, Q28, Q28.0, Q28.1, Q28.2, Q28.3, Q28.8 and Q28.9.  
Health states associated with congenital heart anomalies 
Every case of congenital heart defects was associated with a health state of congenital heart disease, 
except for a proportion of ventricular and atrial septal defects which are considered asymptomatic. All 
congenital heart defects cases were split into a proportion without intellectual disability and a proportion 
with every severity from borderline to profound intellectual disability. The proportion of congenital heart 
anomalies cases experiencing each severity of intellectual disability were calculated using available 
literature sources on the prevalence and severity of intellectual disability in congenital heart defect 
populations (references: NIDs 292230, 292237 and 292240). The proportion of VSD/ASD cases attributed 
to the asymptomatic category was derived from literature sources on the long-term outcomes of patients 
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diagnosed with septal defects at birth (references: NIDs 261403, 292273 and 292275). GBD estimates of 
congenital heart failure were assigned to the congenital heart defect categories according to the 
proportion of total congenital heart cause-specific mortality assigned to each category of congenital heart 
defects.  
 
Modeling strategy and model settings  
 
In order to ensure internally consistent estimates of the prevalence of congenital heart anomalies, we 
developed a model of the total prevalence of congenital heart anomalies and fit the estimates of each 
sub-type of congenital heart anomalies proportionally to these total envelope estimates. The prevalence 
estimates of other congenital heart anomalies were derived as proportions of the total congenital heart 
estimates, using age- and sex-specific proportions from Marketscan claims data. 
The National Birth Defects Prevention Network (NBDPN), the United States state-level birth defects 
reporting system, includes the most comprehensive case reporting of any registry data source. As 
reported in the tables below, the congenital heart models each used registry-specific study-level 
covariate crosswalks to adjust input data from all other birth registries upward according to the 
composition of cases included in the NBDPN. All hospital and Marketscan data were also adjusted using 
study-level covariates with the NBDPN and literature prevalence values as the reference data.  
Total congenital heart anomalies model settings 
In the DisMod model of total congenital heart anomalies, random effects on prevalence were limited to 
+- 0.5 in order to limit geographic variation in the estimates of birth prevalence. The model included a 
decreasing slope prior on excess mortality rate for all ages, as the risk of death due to congenital heart 
anomalies is greatest shortly after birth. The minimum excess mortality rate for the neonatal age range 
was set to 5.0. The smoothness on excess mortality rate was increased to Xi=5.0 in order to allow high 
excess mortality in the neonatal age groups and lower excess mortality rates in older ages.  
During model development, all registry prevalence values below the threshold of 3 per 1,000 were 
marked with a study-level covariate to indicate under-reporting, regardless of whether a comprehensive 
list of ICD codes or cases was included in the input data. These under-reported data sources were then 
adjusted upwards to the reference data.  
Single ventricle and single ventricle pathway defects model settings 
In the DisMod model of single ventricle and single ventricle pathway heart defects, random effects on 
prevalence were limited to +- 0.5 in order to limit the estimated geographic variation in birth 
prevalence. A minimum excess mortality rate of 10.0 was set for the early neonatal period in order to 
capture the high mortality risk, based on expert priors and a review available literature on the mortality 
risk among infants born with single ventricle and single ventricle pathway heart defects. The 
smoothness on excess mortality rate was set to 5.0 in order to fit steep changes in the excess mortality 
rate during the first weeks of life, and a decreasing slope prior on excess mortality rate was applied to all 
ages, as the risk of death due to these congenital heart anomalies is greatest shortly after birth and 
diminishes over the life course.  
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Severe congenital heart defects excluding single ventricle and single ventricle pathway defects model 
settings 
In the DisMod model of congenital heart defects excluding single ventricle and single ventricle pathway 
defects, random effects on prevalence were limited to +- 0.5. A minimum excess mortality rate of 5.0 for 
the early neonatal period was enforced in order to capture the high risk of mortality associated with 
these conditions, and a decreasing slope prior on excess mortality rate was applied for all ages. The 
smoothness on excess mortality rate was set to Xi = 1.0 in order to allow the model to fit steep changes 
in the mortality rate of these conditions in the neonatal age period.  
Critical malformations of great vessels, congenital valvular heart disease and patent ductus arteriosis model 
settings 
In the DisMod model of critical malformations of great vessels, congenital valvular heart disease and 
patent ductus arteriosis, random effects on prevalence were limited to +- 0.5. A minimum excess 
mortality rate of 5.0 was set for the early neonatal period in order to capture the high mortality risk 
associated with these conditions. A decreasing slope prior was applied to excess mortality rate for all 
ages, as the risk of death due to congenital heart anomalies is highest shortly after birth. The 
smoothness on excess mortality was increased to Xi = 3.0 in order to fit steep changes in the mortality 
associated with these conditions during and after the neonatal period.  
Ventricular septal defects and atrial septal defects model settings 
In the DisMod model of ventricular septal defects and atrial septal defects (VSD/ASD), remission was set 
to zero for all ages. Cases of septal defects that spontaneously close over time were considered as part 
of the asymptomatic proportion of VSD/ASD rather than remitted cases.  Random effects on prevalence 
were limited to +- 0.3 in order to limit the random geographic variation in the estimated birth 
prevalence. No minimum excess mortality rate was set in this model, as VSD/ASD cases are not 
associated with excess mortality rates as high as the other subtypes of congenital heart defects. The 
smoothness on excess mortality rate was set to Xi=1.0, and a decreasing slope prior was set on excess 
mortality rate for all ages. 
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Covariates used in the DisMod-MR model of total congenital heart anomalies 
Covariate name Type Measure Beta value Exponentiated value 
Healthcare access and 
quality index 
Country 
covariate Prevalence 0.005 (0.003 - 0.011) 1.005 (1.003 - 1.011) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality 
rate -0.999 (-1.250 - -0.752) 0.368 (0.287 - 0.472) 
Maternal alcohol 
consumption during 
pregnancy (proportion) 
Country 
covariate Prevalence 0.479 (0.398 - 0.499) 1.614 (1.489 - 1.647) 
Chromosomal diagnoses 
excluded 
Study-level 
x-covariate Prevalence -0.009 (-0.021 - -0.001) 0.991 (0.979 - 0.999) 
Hospital data for ages 
over 1 year only 
Study-level 
x-covariate Prevalence -0.000 (-0.002 - -0.000) 1.000 (0.998 - 1.000) 
Hospital data for the 
under-1 year age group 
Study-level 
x-covariate Prevalence -0.080 (-0.133 - -0.034) 0.923 (0.876 - 0.967) 
ICDBSR to NBDPN 
registry case 
composition adjustment 
Study-level 
x-covariate Prevalence -1.168 (-1.212 - -1.122) 0.311 (0.298 - 0.326) 
Stillbirths included as 
cases 
Study-level 
x-covariate Prevalence 0.001 (0.000 - 0.003) 1.001 (1.000 - 1.003) 
Terminations of 
pregnancy included as 
cases 
Study-level 
x-covariate Prevalence 0.000 (0.000 - 0.002) 1.000 (1.000 - 1.002) 
Under Reported 
Study-level 
x-covariate Prevalence -0.910 (-0.942 - -0.873) 0.403 (0.390 - 0.418) 
World Atlas to NBDPN 
registry case 
composition adjustment 
Study-level 
x-covariate Prevalence -1.458 (-1.512 - -1.404) 0.233 (0.220 - 0.246) 
Healthcare access and 
quality index 
Country 
covariate Prevalence 0.005 (0.003 - 0.011) 1.005 (1.003 - 1.011) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality 
rate -0.999 (-1.250 - -0.752) 0.368 (0.287 - 0.472) 
Maternal alcohol 
consumption during 
pregnancy (proportion) 
Country 
covariate Prevalence 0.479 (0.398 - 0.499) 1.614 (1.489 - 1.647) 
 
Covariates used in the DisMod-MR model of single ventricle and single ventricle pathway defects 
Covariate name Type Measure Beta value Exponentiated value 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality rate -0.750 (-1.000 - -0.507) 0.472 (0.368 - 0.602) 
Maternal alcohol 
consumption during 
pregnancy (proportion) 
Country 
covariate Prevalence 0.061 (0.001 - 0.204) 1.063 (1.001 - 1.227) 
559
All MarketScan, year 
2010 
Study-level 
x-covariate Prevalence -0.025 (-0.093 - -0.001) 0.975 (0.912 - 0.999) 
All MarketScan, year 
2012 
Study-level 
x-covariate Prevalence -0.023 (-0.079 - -0.001) 0.977 (0.924 - 0.999) 
Chromosomal 
diagnoses excluded 
Study-level 
x-covariate Prevalence -0.084 (-0.191 - -0.002) 0.919 (0.826 - 0.998) 
EUROCAT to NBDPN 
registry case 
composition 
adjustment 
Study-level 
x-covariate Prevalence -0.989 (-1.000 - -0.953) 0.372 (0.368 - 0.386) 
Hospital data for ages 
over 1 year only 
Study-level 
x-covariate Prevalence -0.001 (-0.004 - -0.000) 0.999 (0.996 - 1.000) 
Hospital data for the 
under-1 year age group 
Study-level 
x-covariate Prevalence -0.449 (-0.725 - -0.316) 0.638 (0.484 - 0.729) 
Stillbirths included as 
cases 
Study-level 
x-covariate Prevalence 0.004 (0.000 - 0.012) 1.004 (1.000 - 1.012) 
Terminations of 
pregnancy included as 
cases 
Study-level 
x-covariate Prevalence 0.058 (0.003 - 0.146) 1.060 (1.003 - 1.157) 
Under Reported 
Study-level 
x-covariate Prevalence -0.994 (-1.000 - -0.979) 0.370 (0.368 - 0.376) 
Under Reported 
Study-level 
z-covariate 
With-condition 
mortality rate 1.530 (1.256 - 1.856) 4.620 (3.511 - 6.398) 
 
Covariates used in the DisMod-MR model of severe congenital heart defects excluding single ventricle and 
single ventricle pathway defects 
Covariate name Type Measure Beta value Exponentiated value 
Healthcare access and 
quality index 
Country 
covariate 
With-
condition 
mortality rate -0.019 (-0.056 - -0.001) 0.981 (0.946 - 0.999) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality rate -0.628 (-0.993 - -0.255) 0.534 (0.370 - 0.775) 
Maternal alcohol 
consumption during 
pregnancy (proportion) 
Country 
covariate Prevalence 0.121 (0.004 - 0.341) 1.128 (1.004 - 1.406) 
Chromosomal diagnoses 
excluded 
Study-level 
x-covariate Prevalence -0.270 (-0.299 - -0.192) 0.764 (0.741 - 0.826) 
EUROCAT to NBDPN 
registry case 
composition adjustment 
Study-level 
x-covariate Prevalence -0.995 (-1.000 - -0.979) 0.370 (0.368 - 0.376) 
Hospital data for ages 
over 1 year only 
Study-level 
x-covariate Prevalence -0.001 (-0.006 - -0.000) 0.999 (0.994 - 1.000) 
Hospital data for the 
under-1 year age group 
Study-level 
x-covariate Prevalence -0.018 (-0.089 - -0.000) 0.982 (0.915 - 1.000) 
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ICDBSR to NBDPN 
registry case 
composition adjustment 
Study-level 
x-covariate Prevalence -0.885 (-0.993 - -0.782) 0.413 (0.371 - 0.458) 
Stillbirths included as 
cases 
Study-level 
x-covariate Prevalence 0.003 (0.000 - 0.012) 1.003 (1.000 - 1.012) 
Terminations of 
pregnancy included as 
cases 
Study-level 
x-covariate Prevalence 0.012 (0.000 - 0.042) 1.012 (1.000 - 1.043) 
Under Reported 
Study-level 
x-covariate Prevalence -0.844 (-0.962 - -0.749) 0.430 (0.382 - 0.473) 
World Atlas to NBDPN 
registry case 
composition adjustment 
Study-level 
x-covariate Prevalence -0.994 (-1.000 - -0.973) 0.370 (0.368 - 0.378) 
 
Covariates used in the DisMod-MR model of critical malformations of great vessels, congenital valvular 
heart disease and patent ductus arteriosis 
Covariate name Type Measure Beta value Exponentiated value 
Healthcare access and 
quality index 
Country 
covariate 
With-
condition 
mortality rate -0.035 (-0.075 - -0.002) 0.965 (0.928 - 0.998) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality rate -0.273 (-0.500 - -0.055) 0.761 (0.607 - 0.946) 
Maternal alcohol 
consumption during 
pregnancy (proportion) 
Country 
covariate Prevalence 0.310 (0.002 - 0.493) 1.364 (1.002 - 1.637) 
All MarketScan, year 
2010 
Study-level 
x-covariate Prevalence -0.003 (-0.010 - -0.000) 0.997 (0.990 - 1.000) 
All MarketScan, year 
2012 
Study-level 
x-covariate Prevalence -0.006 (-0.030 - -0.000) 0.994 (0.971 - 1.000) 
Chromosomal diagnoses 
excluded 
Study-level 
x-covariate Prevalence -0.226 (-0.297 - -0.058) 0.797 (0.743 - 0.944) 
EUROCAT to NBDPN 
registry case 
composition adjustment 
Study-level 
x-covariate Prevalence -0.908 (-0.999 - -0.748) 0.403 (0.368 - 0.473) 
Hospital data for ages 
over 1 year only 
Study-level 
x-covariate Prevalence -0.004 (-0.019 - -0.000) 0.996 (0.981 - 1.000) 
Hospital data for the 
under-1 year age group 
Study-level 
x-covariate Prevalence -0.075 (-0.625 - -0.001) 0.928 (0.535 - 0.999) 
ICDBSR to NBDPN 
registry case 
composition adjustment 
Study-level 
x-covariate Prevalence -0.997 (-1.000 - -0.989) 0.369 (0.368 - 0.372) 
Stillbirths included as 
cases 
Study-level 
x-covariate Prevalence 0.002 (0.000 - 0.007) 1.002 (1.000 - 1.007) 
Terminations of 
pregnancy included as 
cases 
Study-level 
x-covariate Prevalence 0.039 (0.001 - 0.129) 1.040 (1.001 - 1.138) 
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Under Reported 
Study-level 
x-covariate Prevalence -0.985 (-0.999 - -0.944) 0.373 (0.368 - 0.389) 
World Atlas to NBDPN 
registry case 
composition adjustment 
Study-level 
x-covariate Prevalence -0.993 (-1.000 - -0.970) 0.371 (0.368 - 0.379) 
Under Reported 
Study-level 
z-covariate 
With-
condition 
mortality rate 1.400 (1.145 - 1.706) 4.056 (3.142 - 5.507) 
 
Covariates used in the DisMod-MR model of ventricular septal defects and atrial septal defects 
Covariate name Type Measure Beta value Exponentiated value 
Healthcare access and 
quality index 
Country 
covariate 
With-
condition 
mortality rate -0.002 (-0.009 - -0.000) 0.998 (0.991 - 1.000) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality rate -0.025 (-0.050 - 0.000) 0.975 (0.952 - 1.000) 
Maternal alcohol 
consumption during 
pregnancy (proportion) 
Country 
covariate Prevalence 0.014 (0.001 - 0.051) 1.014 (1.001 - 1.052) 
All MarketScan, year 
2010 
Study-level 
x-covariate Prevalence -0.065 (-0.115 - -0.019) 0.937 (0.892 - 0.982) 
All MarketScan, year 
2012 
Study-level 
x-covariate Prevalence -0.014 (-0.045 - -0.001) 0.986 (0.956 - 0.999) 
Hospital data for ages 
over 1 year only 
Study-level 
x-covariate Prevalence -0.004 (-0.014 - -0.000) 0.996 (0.986 - 1.000) 
Hospital data for the 
under-1 year age group 
Study-level 
x-covariate Prevalence -0.005 (-0.017 - -0.000) 0.995 (0.983 - 1.000) 
Stillbirths included as 
cases 
Study-level 
x-covariate Prevalence 0.017 (0.001 - 0.062) 1.017 (1.001 - 1.064) 
Terminations of 
pregnancy included as 
cases 
Study-level 
x-covariate Prevalence 0.012 (0.001 - 0.049) 1.012 (1.001 - 1.050) 
Under Reported 
Study-level 
x-covariate Prevalence -0.529 (-0.707 - -0.323) 0.589 (0.493 - 0.724) 
Healthcare access and 
quality index 
Country 
covariate 
With-
condition 
mortality rate -0.002 (-0.009 - -0.000) 0.998 (0.991 - 1.000) 
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Cleft lip & cleft palate (orofacial clefts) 
Case definition and associated health states  
Orofacial clefts include isolated cleft lip, isolated cleft palate, and combined cleft lip and cleft palate. Cleft 
lip is an opening in the upper lip that may extend into the nose, and with cleft palate, the roof of the 
mouth contains an opening into the nose. Both conditions are the result of the tissues of the face not 
joining properly during development. These conditions can be successfully treated by surgery, which is 
typically done during the first few months or years of life but may occasionally be completed later in life. 
The sequelae associated with orofacial clefts are disfigurement level 1, disfigurement level 2, and 
disfigurement level 2 with speech problems. Additionally, a proportion of the population with orofacial 
clefts is considered to be asymptomatic. The proportion of cleft cases with associated speech problems 
was calculated following a review of available literature on orofacial cleft health outcomes (need 
source(s) from Nick?).  
 The GBD 2016 case definition of orofacial clefts includes isolated cleft palate, which corresponds to ICD-
10 codes Q35.2, Q35.3, Q35.5, Q35.6, Q35.7, Q35.8, and Q35.9, and cleft palate with or without cleft lip, 
which corresponds to ICD-10 codes Q36.0, Q36.1, Q36.9, Q37.1, Q37.5, Q37.8, and Q37.9. 
 
Modeling strategy and model settings  
The DisMod-MR model of orofacial clefts had random effects on prevalence limited to +- 0.5, as we 
expected limited variation in birth prevalence of orofacial clefts.  The model settings allow increased 
smoothness on both excess mortality rate and remission (maximum Xi = 5.0) in order to fit steep changes 
in the rates mortality and remission during the first few years of life. 
Incidence was set to zero for all ages. Remission was set to zero for the first three months of life, as cleft 
lip and/or palate are rarely corrected in the first few months of life. A maximum remission of 0.8 was set 
for ages three months to two years, the age range in which cleft repair is most commonly performed, 
allowing up to 75% of cleft cases to be repaired between three months and 2 years of age. Remission was 
bounded from 0 to 0.07 for ages 2 to 5 years,  0 to 0.004 for ages 5 to 20 years, then bounded from 0 to 
0.002 for ages 20 to 50 years, and set at 0 for ages 50 years +. These limits on remission reflect our priors 
that up to 20% of remaining cleft cases are repaired between 2 and 5 years of age, another 5% may be 
repaired between 5 and 20 years of age, and a maximum 5% of remaining cases are surgically repaired 
between ages 20 and 50 years.  
Priors on excess mortality rate were set at a maximum of 2.5 for the early neonatal period, 0.9 for the 
late neonatal period,  0.24 for the rest of the first year of life, 0.05 for ages 1 to 5 years, and was set to 0 
for ages after 5 years.  These limits on excess mortality reflect our priors that up to 5% of individuals with 
orofacial clefts die in the first week of life, up to 5% die in the following three weeks, up to 20% die in the 
next 11 months, another maximum of 20% before 5 years of ages, and a maximum of 5% of the 
remaining individuals die between ages 5 and 10 years.  
During model development, all birth registry prevalence values below 2 per 10,000 were excluded as 
outliers, as these data are considered low enough to indicate severe under-reporting in the input data.  
 
Covariates used in the DisMod-MR model of orofacial clefts 
Covariate name Type Measure Beta value Exponentiated value 
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Folic acid unadjusted 
(ug) 
Country 
covariate Prevalence -0.000 (-0.000 - -0.000) 1.000 (1.000 - 1.000) 
Healthcare access and 
quality index 
Country 
covariate Prevalence -0.006 (-0.008 - -0.005) 0.994 (0.992 - 0.995) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality 
rate -0.350 (-0.350 - -0.349) 0.705 (0.705 - 0.705) 
Chromosomal diagnoses 
excluded 
Study-level x-
covariate Prevalence -0.202 (-0.237 - -0.167) 0.817 (0.789 - 0.846) 
Hospital data for ages 
over 1 year only 
Study-level x-
covariate Prevalence 0.557 (0.505 - 0.607) 1.746 (1.656 - 1.835) 
Hospital data for the 
under-1 year age group 
Study-level x-
covariate Prevalence -0.192 (-0.242 - -0.144) 0.825 (0.785 - 0.866) 
Stillbirths included as 
cases 
Study-level x-
covariate Prevalence 0.176 (0.142 - 0.211) 1.192 (1.153 - 1.236) 
Under Reported 
Study-level x-
covariate Prevalence -0.519 (-0.592 - -0.454) 0.595 (0.553 - 0.635) 
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Down Syndrome 
Case definition and associated health states  
Down syndrome, also known as Trisomy 21, is the presence of a third copy of chromosome 21, typically 
caused by nondisjunction during the production of gametes. Down syndrome is associated with several 
specific physical characteristics, including decreased muscle tone, flat facial features, an upward slant to 
the eyes, abnormally shaped ears, a single deep crease across the center of the palm, folded skin on the 
inner corners of the eyes, and ability to extend joints beyond the usual, among others. The GBD 2016 
case definition of Down syndrome includes ICD-10 codes Q90.0, Q90.1, Q90.2, and Q90.9. 
 Individuals with Down syndrome may have several combinations of sequelae: those included in the GBD 
sequelae list are intellectual disability, congenital heart disease, and dementia. The joint distribution of 
intellectual disability, congenital heart disease, and dementia associated with cases of Down Syndrome 
was derived from a review of literature on long-term outcomes in cohorts of Down Syndrome individuals. 
To calculate the severity distribution of intellectual disability due to Down Syndrome, we used literature 
values for the IQ distribution of individuals with Down Syndrome (reference: NID 149859) and calculated 
the area under the curve. We obtained age-specific proportions of individuals with Down Syndrome and 
dementia, and thus global age patterns were modeled to calculate the proportion of the population with 
each combination of sequelae for each of the following age ranges: 0-44 years, 45-49 years, 50-54 years, 
55-69 years, 70-79 years, and 80+ years.  
 
Modeling strategy and model settings  
The DisMod-MR model of Down Syndrome excluded all data with a prevalence of zero as outliers, as we 
expect that these low values are indicative of under-reporting in the data sources. The DisMod model 
used cause-specific mortality rate data from the corresponding Down Syndrome model in the GBD 2016 
Cause of Death analysis, and converted these data to excess mortality rate estimates where matching 
prevalence data is available. Random effects on prevalence were limited to +- 0.5 and random effects on 
excess mortality rate are limited to +- 1.0 in order to limit the geographic variation in birth prevalence 
allowed in the model. The maximum smoothness on excess mortality rate was increased to x= 2.0 in 
order to fit the observed steep decline in the mortality risk associated with Down Syndrome after the 
neonatal age range.  
Of note, the use of cause-specific mortality data in the nonfatal model of Down Syndrome is a substantial 
change in the modeling strategy as compared to the previous iterations of the GBD, and results in much 
better-informed excess mortality estimates driving the Down Syndrome prevalence estimates across the 
life course.  
Covariates used in the DisMod-MR model of Down Syndrome 
Covariate name Type Measure Beta value Exponentiated value 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality 
rate -0.337 (-0.368 - -0.304) 0.714 (0.692 - 0.738) 
Legality of Abortion 
Country 
covariate Prevalence -0.001 (-0.002 - -0.000) 0.999 (0.998 - 1.000) 
Live Births 35+ 
(proportion) 
Country 
covariate Prevalence 0.008 (0.001 - 0.025) 1.008 (1.001 - 1.025) 
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Hospital data for ages 
over 1 year only 
Study-level x-
covariate Prevalence 0.140 (0.107 - 0.182) 1.151 (1.113 - 1.199) 
Hospital data for the 
under-1 year age group 
Study-level x-
covariate Prevalence 0.499 (0.497 - 0.500) 1.647 (1.644 - 1.649) 
Stillbirths included as 
cases 
Study-level x-
covariate Prevalence -0.039 (-0.049 - -0.011) 0.962 (0.952 - 0.989) 
Terminations of 
pregnancy included as 
cases 
Study-level x-
covariate Prevalence -0.033 (-0.050 - 0.006) 0.968 (0.952 - 1.006) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality 
rate -0.337 (-0.368 - -0.304) 0.714 (0.692 - 0.738) 
Legality of Abortion 
Country 
covariate Prevalence -0.001 (-0.002 - -0.000) 0.999 (0.998 - 1.000) 
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Turner Syndrome 
Case definitions and associated health states 
Turner syndrome, also known as 45 XO, is a condition in which a female is partly or completely missing an 
X chromosome. Turner syndrome can lead to a variety of medical and developmental problems, including 
short height, failure to start puberty, infertility, heart defects, learning disabilities, and difficulty with 
social adjustment. The GBD case definition of Turner syndrome includes ICD-10 codes Q96.0, Q96.3, and 
Q96.9. The sequelae associated with Turner syndrome are congenital heart disease, infertility, and the 
combination of both congenital heart disease and infertility; additionally, a subset of individuals with 
Turner syndrome are asymptomatic. The distribution of these sequelae was determined by a review of 
existing literature on the long-term health consequences of Turner Syndrome. 
Modeling strategy and model settings  
One of the known limitations to the use of birth prevalence data on Turner Syndrome is that individuals 
with Turner Syndrome are commonly diagnosed later in life rather than prenatally or at birth. Thus, we 
implemented a correction factor to account for under-diagnosis in all birth registry data sources, using 
available literature on the trends in age pattern of Turner Syndrome diagnosis over time (source: NID 
283283); although improvements in diagnoses have occurred over time, only between 15% and 30% of all 
diagnosed Turner Syndrome cases are diagnosed before one year of age. Additionally, the reported 
denominators from all birth registries – the number of live births in each registry catchment area – were 
adjusted to include only female births using the GBD fertility estimates of the age, year, and location-
specific proportion of total live births that are female. Furthermore, all prevalence data with values of 
zero were excluded as outliers, as these low values indicate severe under-reporting in the input data. 
These modeling strategy changes address known causes of under-reporting of Turner Syndrome in the 
previous iterations of the GBD and resulted in higher estimates of Turner Syndrome than were reported 
previously.  
The DisMod-MR model of Turner Syndrome had an excess mortality rate capped at 0.1 (slightly higher 
than the highest available literature estimate of excess mortality rate?). The model did not have a slope 
prior set on excess mortality rate as the risk of mortality associated with Turner Syndrome is not specific 
to the neonatal ages. This model also allows an increased maximum smoothness on excess mortality rate 
and random effects on prevalence limited to +- 0.5 in order to limit random geographic variation in the 
estimated birth prevalence of Turner Syndrome. 
Covariates used in the DisMod-MR model of Turner Syndrome 
Covariate name Type Measure Beta value Exponentiated value 
Healthcare access and 
quality index 
Country 
covariate 
Excess 
mortality 
rate -0.122 (-0.250 - 0.000) 0.885 (0.779 - 1.000) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality 
rate -0.149 (-0.298 - 0.000) 0.861 (0.742 - 1.000) 
Live Births 35+ 
(proportion) 
Country 
covariate Prevalence -0.245 (-0.297 - -0.119) 0.782 (0.743 - 0.887) 
All MarketScan, year 
2010 
Study-level x-
covariate Prevalence -0.958 (-1.061 - -0.856) 0.384 (0.346 - 0.425) 
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All MarketScan, year 
2012 
Study-level x-
covariate Prevalence -0.969 (-1.070 - -0.865) 0.380 (0.343 - 0.421) 
 
 
Klinefelter Syndrome 
Case definitions and associated health states 
Klinefelter syndrome, also known as 47 XXY, is a condition in which a male is born with an extra X 
chromosome in all or some of his cells. We also include other genotypes with supranumary X 
chromosomes, e.g. XXXY, XXXXY, etc. The primary feature of Klinefelter syndrome is sterility, but it can 
cause a variety of other conditions, including weaker muscles, increased height, poor coordination 
abilities, smaller genitals, breast growth, and reduced sexual drive as a result of lower testosterone levels. 
The GBD 2016 case definition of Klinefelter syndrome includes ICD-10 codes Q98.0, Q98.5, and Q99.8. 
The sequelae associated with Klinefelter syndrome are borderline intellectual disability, mild intellectual 
disability, primary infertility, the combination of borderline intellectual disability and infertility, and the 
combination of mild intellectual disability and infertility. In addition, a subset of individuals with 
Klinefelter syndrome are asymptomatic. The distribution of these sequelae was determined by a review 
of existing literature on the long-term health consequences of Turner Syndrome. 
 
Modeling strategy and model settings 
As discussed above for Turner Syndrome, one limitation to the use of birth registry data for the 
estimation of Klinefelter Syndrome is that many individuals with Klinefelter Syndrome are not diagnosed 
prenatally or at birth. To correct this systematic under-reporting in the birth registry data, we applied a 
correction factor to all birth registry input data using available literature on the age pattern of Klinefelter 
Syndrome diagnosis (source: NID 283326). We also adjusted the both-sex live birth denominators 
provided in registry data using location, age, and year-specific proportions of all live births that were 
male. Furthermore, all prevalence data with values of zero were excluded as outliers, as these low values 
indicate severe under-reporting in the input data. These modeling strategy changes address known 
causes of under-reporting in the previous iterations of the GBD and resulted in higher estimates of 
Klinefelter Syndrome than were reported previously. 
The DisMod-MR model of Klinefelter Syndrome had an excess mortality rate maximum limit of 0.075, 
allowing the model to fit estimates of excess mortality up to slightly higher than the highest reported 
literature values. The model did not have a slope prior set on excess mortality and allowed an increased 
smoothness on excess mortality rate. As with several of the other models of chromosomal conditions, 
random effects on prevalence were limited to +- 0.5 in order to limit random geographic variation in the 
estimates of birth prevalence.  
 
Covariates used in the DisMod-MR model of Klinefelter Syndrome 
Covariate name Type Measure Beta value Exponentiated value 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality 
rate -0.150 (-0.300 - 0.000) 0.860 (0.741 - 1.000) 
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Legality of Abortion 
Country 
covariate Prevalence -0.000 (-0.000 - -0.000) 1.000 (1.000 - 1.000) 
Live Births 35+ 
(proportion) 
Country 
covariate Prevalence 0.266 (0.164 - 0.299) 1.304 (1.178 - 1.349) 
All MarketScan, year 
2010 
Study-level x-
covariate Prevalence -2.879 (-3.044 - -2.752) 0.056 (0.048 - 0.064) 
All MarketScan, year 
2012 
Study-level x-
covariate Prevalence -2.848 (-3.010 - -2.727) 0.058 (0.049 - 0.065) 
Hospital data for ages 
over 1 year only 
Study-level x-
covariate Prevalence -1.722 (-1.801 - -1.642) 0.179 (0.165 - 0.194) 
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Other chromosomal abnormalities, genetic syndromes, and microdeletions 
Case definitions and associated health states 
Unbalanced chromosomal rearrangements are genetic anomalies that typically occur due to meiotic 
nondisjunction, when homologous chromosomes do not separate normally in nuclear division during 
gamete formation. The GBD case definition of other chromosomal rearrangements includes 47,XXX 
(Triple X syndrome), other meiotic nondisjunction events, other female sex chromosome abnormalities, 
and other unspecified chromosomal abnormalities. The GBD 2016 case definition corresponds to the ICD-
10 codes Q92.0, Q97.0, Q97.8, and Q99.9. Excluded from this definition are the chromosomal 
abnormalities of Down syndrome, Turner syndrome, Klinefelter syndrome, Edward syndrome and Patau 
syndrome, which are each modeled separately. The sequelae associated with other chromosomal 
rearrangements include intellectual disability, intellectual disability with dementia, intellectual disability 
with congenital heart disease and dementia, and intellectual disability with congenital heart disease. 
Additionally, a proportion of the individuals with unbalanced chromosomal rearrangements are 
asymptomatic. In the absence of available literature on the long-term health outcomes among individuals 
with other chromosomal conditions, the severity distributions associated with Down Syndrome were used 
for the sequela associated with other chromosomal anomalies.  
Edwards Syndrome, also known as Trisomy 18, is the condition in which infants are born with a third copy 
of chromosome 18. Patau syndrome, also known as Trisomy 13, is the condition in which infants are born 
with a third copy of chromosome 13. The GBD estimates the combined prevalence of these two 
conditions in a single model as they present similarly and are associated with similar rates of excess 
mortality. Infants with Edwards syndrome typically have low birthweights and a range of associated 
conditions including a small head and jaw, limb abnormalities, and severe intellectual disability. Infants 
with Patau syndrome have a range of associated defects including musculoskeletal anomalies, 
developmental abnormalities of the nervous system such as microcephaly, congenital heart defects and 
severe intellectual disability. The ICD-10 code for Edwards syndrome is Q91.3 and the ICD-10 code for 
Patau syndrome is Q91.7. In the GBD 2016, all cases of Edwards and Patau syndrome are assigned the 
sequela of severe motor and cognitive impairment, and a proportion of these cases are also associated 
with congenital heart disease. The proportion of cases with associated congenital heart disease was 
0.775, derived by pooling estimates from available literature on the health states associated with the two 
trisomies (references: NID 292226 and NID 292228).  
 
Modeling strategy and model settings 
The DisMod-MR model of other chromosomal abnormalities, genetic syndromes, and microdeletions was 
used to estimate the prevalence and mortality among infants with chromosomal conditions that are not 
explicitly included in any other congenital models. This model used cause-specific mortality estimates 
from the corresponding model of other chromosomal anomalies in the GBD 2016 Cause of Death 
analysis; these cause-specific mortality estimates were then converted to excess mortality where 
overlapping prevalence data were available. Random effects on prevalence were limited to +- 0.5 as 
limited variation in the birth prevalence of chromosomal anomalies is expected across geographies. The 
maximum allowed smoothness on excess mortality rate was set to Xi=2.0 in order to fit high mortality 
rates in the early age groups.  
In the DisMod-MR model of Edwards Syndrome and Patau Syndrome, random effects on prevalence 
were limited to +- 0.5, reflecting the expectation of limited geographic variation in the birth prevalence 
of Edwards Syndrome and Patau Syndrome. An increasing slope prior was set on excess mortality rate 
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for all ages, as individuals with these trisomies generally die within the first few years of life. The model 
allowed a maximum smoothness of Xi = 2.0 in order to fit high excess mortality in the early age groups.   
All input data with birth prevalence values of zero were excluded as outliers, as these values represent 
under-reporting and low case ascertainment in the input data rather than a true lack of these 
chromosomal conditions in the corresponding locations.  
Covariates used in the DisMod-MR model of other chromosomal abnormalities 
Covariate name Type Measure Beta value 
Exponentiated 
value 
Healthcare access and 
quality index 
Country 
covariate 
Excess 
mortality 
rate -0.000 (-0.000 - -0.000) 
1.000 (1.000 - 
1.000) 
Legality of Abortion 
Country 
covariate Prevalence -0.006 (-0.007 - -0.005) 
0.994 (0.993 - 
0.995) 
Live Births 35+ 
(proportion) 
Country 
covariate Prevalence 0.293 (0.279 - 0.299) 
1.340 (1.321 - 
1.349) 
All MarketScan, year 
2010 
Study-level x-
covariate Prevalence -0.388 (-0.455 - -0.320) 
0.679 (0.635 - 
0.726) 
All MarketScan, year 
2012 
Study-level x-
covariate Prevalence -0.278 (-0.353 - -0.206) 
0.757 (0.703 - 
0.814) 
Hospital data for ages 
over 1 year only 
Study-level x-
covariate Prevalence -0.528 (-0.561 - -0.490) 
0.590 (0.571 - 
0.613) 
Hospital data for the 
under-1 year age group 
Study-level x-
covariate Prevalence -0.002 (-0.006 - -0.000) 
0.998 (0.994 - 
1.000) 
Healthcare access and 
quality index 
Country 
covariate 
Excess 
mortality 
rate -0.000 (-0.000 - -0.000) 
1.000 (1.000 - 
1.000) 
Legality of Abortion 
Country 
covariate Prevalence -0.006 (-0.007 - -0.005) 
0.994 (0.993 - 
0.995) 
Live Births 35+ 
(proportion) 
Country 
covariate Prevalence 0.293 (0.279 - 0.299) 
1.340 (1.321 - 
1.349) 
 
Covariates used in the DisMod model of Edwards Syndrome and Patau Syndrome 
Covariate name Type Measure Beta value 
Exponentiated 
value 
Healthcare access and 
quality index 
Country 
covariate 
Excess 
mortality rate 
-0.124 (-0.250 - -
0.004) 
0.883 (0.779 - 
0.996) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality rate 
-0.025 (-0.050 - -
0.000) 
0.975 (0.951 - 
1.000) 
Legality of Abortion 
Country 
covariate Prevalence 
-0.002 (-0.004 - -
0.000) 
0.998 (0.996 - 
1.000) 
Live Births 35+ 
(proportion) 
Country 
covariate Prevalence 0.213 (0.034 - 0.298) 
1.238 (1.034 - 
1.348) 
All MarketScan, year 
2010 
Study-level 
x-covariate Prevalence 
-2.087 (-2.288 - -
1.871) 
0.124 (0.101 - 
0.154) 
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All MarketScan, year 
2012 
Study-level 
x-covariate Prevalence 
-2.022 (-2.233 - -
1.815) 
0.132 (0.107 - 
0.163) 
Hospital data 
Study-level 
x-covariate Prevalence 
-0.003 (-0.010 - -
0.001) 
0.997 (0.990 - 
0.999) 
Stillbirths included as 
cases 
Study-level 
x-covariate Prevalence 0.012 (0.000 - 0.046) 
1.012 (1.000 - 
1.047) 
 
Musculoskeletal congenital anomalies 
Case definitions and associated health states  
The GBD 2016 definition of musculoskeletal congenital anomalies includes any anomalies of the muscles 
or skeletal system present at birth that are not caused by a defined chromosomal syndrome. Within the 
range of congenital musculoskeletal anomalies, we explicitly model three sub-categories: polydactyly and 
syndactyly, limb reduction defects, and all other congenital musculoskeletal anomalies.  
Polydactyly is the condition of being born with at least one extra digit on either the hand or the foot, 
while syndactyly is absence of at least one digit. Our case definition of polydactyly corresponds to ICD-10 
code Q69, and syndactyly corresponds to Q70. The sequela associated with all cases of polydactyly and 
syndactyly is level 1 disfigurement. Limb reduction defects are the condition where a part or all of the 
arm or limb of a fetus fails to form during development, so that the limb is either reduced from its normal 
size or missing entirely. The GBD case definition of limb reduction defects corresponds with ICD-10 codes 
Q71 (all three-digit codes under Q71), Q72 (all three-digit codes), Q73.0, Q73.1 and Q73.8.  
The other congenital musculoskeletal anomalies included within the total estimate of congenital 
musculoskeletal anomalies includes clubfoot, skeletal dysplasias, congenital deformities of the spine, 
congenital dysplasia of the hip, and other congenital musculoskeletal anomalies. This “other” category 
corresponds to ICD-10 codes Q65, Q65.0, Q65.00, Q65.01, Q65.02, Q65.1; Q65.2; Q65.8; Q65.81; Q65.82; 
Q65.89; Q65.9; Q66; Q66.0; Q66.1; Q68; Q68.1; Q68.2; Q68.6; Q68.8; Q74; Q74.1; Q74.2; Q74.3; Q74.9; 
Q75; Q75.0; Q75.5; Q75.9; Q79.8; Q79.9, Q76; Q76.1; Q76.2; Q76.3; Q76.4; Q76.41; Q76.411; Q76.412; 
Q76.413; Q76.414; Q76.415; Q76.419; Q76.42; Q76.425; Q76.426; Q76.427; Q76.428; Q76.429; Q76.49; 
Q76.8; Q76.9, Q77; Q77.0; Q77.1; Q77.2; Q77.3; Q77.4; Q77.5; Q77.6; Q77.7; Q77.8; Q77.9; Q78; Q78.0; 
Q78.1; Q78.2; Q78.3; Q78.4; Q78.5; Q78.6; Q78.8, and Q78.9.  
All cases of polydactyly and syndactyly are assigned the health state of level 1 disfigurement. Remission is 
allowed in the model of polydactyly and syndactyly, as individuals born with these conditions may have 
them surgically corrected and are then no longer considered within our case definition. However, 
remission is not included in the models of limb reduction defects or other congenital musculoskeletal 
defects, as these conditions typically cannot be fully surgically corrected. All cases of limb reduction 
defects are associated with level 2 disfigurement. A proportion of limb reduction defect cases are 
associated with no motor impairment, mild motor impairment with and without pain, and moderate 
motor impairment with and without pain. The distribution of health states associated with congenital 
limb reduction was derived from an analysis of available literature on the long-term outcomes among 
individuals with congenital limb reductions (references: NIDs 292277 and 292279).  
In the absence comprehensive literature on the long-term outcomes associated with the category of 
other congenital musculoskeletal anomalies, prevalence estimates of other congenital musculoskeletal 
anomalies were assigned health states using the proportions derived for limb reduction defects.  
Modeling strategy and model settings  
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As with other categories of congenital anomalies, a model of total musculoskeletal anomalies was used as 
an envelope model and the sub-categories of congenital musculoskeletal anomalies were squeezed 
proportionally to these total estimates. The prevalence of other congenital musculoskeletal anomalies 
was derived from Marketscan claims data as the age- and sex-specific proportion of total musculoskeletal 
congenital anomaly cases that are not included in the polydactyly and syndactyly or limb reduction 
defects categories.  
The DisMod model of total musculoskeletal anomalies used cause-specific mortality estimates from the 
corresponding model in the GBD Causes of Death analysis, and converted these data to excess mortality 
estimates where corresponding prevalence data were available. Random effects on prevalence were 
limited to +- 0.5 in order to limit geographic variation in the birth prevalence of congenital 
musculoskeletal anomalies. Smoothness on excess mortality rate was increased to Xi= 2.0 to allow the 
model to fit a steep decrease in excess mortality rate after the earliest age groups. The model also 
included a decreasing slope prior on excess mortality rate for all ages, as the risk of mortality from 
congenital musculoskeletal anomalies is greatest shortly after birth and decreases over age. 
 
In the DisMod model of limb reduction defects, random effects on prevalence were limited to +- 0.3 in 
order to limit geographic variation in the estimated birth prevalence. The excess mortality rate was set 
to a maximum of 0.5 before 70 years of age in to reflect the relatively low mortality risk of congenital 
limb anomalies, and a decreasing slope prior on excess mortality rate was set for all ages as the risk of 
mortality is highest in the earliest age groups.   
The DisMod model of polydactly and syndactyly limited random effects on prevalence to +- 0.5, as we 
expected limited geographic variation in the birth prevalence estimates. Excess mortality was set to 0 
for all ages. The remission rate was bounded from 0 to 0.02 for the first three months of life, as surgical 
correction of polydactyly or syndactyly rarely occurs in the first few months of life. Remission was 
bounded between 0 and 0.5 for ages 2 to 5 years, the ages during which surgical correction is most likely 
to occur, then set to a maximum of 0.02 after 5 years of age. The smoothness on remission was set to 
Xi= 1.5 in order to facilitate steep changes in remission rates during the first few years of life.  
 
Covariates used in the DisMod-MR model of total musculoskeletal anomalies 
Covariate name Type Measure Beta value Exponentiated value 
Healthcare access and 
quality index 
Country 
covariate 
With-
condition 
mortality 
rate -0.250 (-0.500 - -0.003) 0.779 (0.607 - 0.997) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality 
rate -0.325 (-0.500 - -0.243) 0.722 (0.607 - 0.784) 
Legality of Abortion 
Country 
covariate Prevalence -0.000 (-0.001 - -0.000) 1.000 (0.999 - 1.000) 
All MarketScan, year 
2010 
Study-level x-
covariate Prevalence -0.003 (-0.009 - -0.001) 0.997 (0.991 - 0.999) 
All MarketScan, year 
2012 
Study-level x-
covariate Prevalence -0.004 (-0.010 - -0.000) 0.996 (0.990 - 1.000) 
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Chromosomal diagnoses 
excluded 
Study-level x-
covariate Prevalence -0.007 (-0.025 - -0.000) 0.993 (0.975 - 1.000) 
Hospital data for ages 
over 1 year only 
Study-level x-
covariate Prevalence 0.456 (0.399 - 0.500) 1.577 (1.490 - 1.648) 
Hospital data for the 
under-1 year age group 
Study-level x-
covariate Prevalence 0.496 (0.487 - 0.499) 1.642 (1.627 - 1.648) 
Stillbirths included as 
cases 
Study-level x-
covariate Prevalence 0.001 (0.000 - 0.004) 1.001 (1.000 - 1.004) 
 
Covariates used in the DisMod-MR model of polydactyly and syndactyly 
Covariate name Type Measure Beta value Exponentiated value 
LDI (I$ per capita) 
Country 
covariate Remission 0.999 (0.500 - 1.500) 2.717 (1.649 - 4.482) 
All MarketScan, year 
2010 
Study-level x-
covariate Prevalence -0.774 (-0.899 - -0.646) 0.461 (0.407 - 0.524) 
All MarketScan, year 
2012 
Study-level x-
covariate Prevalence -0.713 (-0.842 - -0.590) 0.490 (0.431 - 0.555) 
Chromosomal diagnoses 
excluded 
Study-level x-
covariate Prevalence -0.019 (-0.049 - -0.001) 0.981 (0.952 - 0.999) 
Hospital data for ages 
over 1 year only 
Study-level x-
covariate Prevalence 0.996 (0.985 - 1.000) 2.709 (2.677 - 2.718) 
Stillbirths included as 
cases 
Study-level x-
covariate Prevalence 0.003 (0.000 - 0.008) 1.003 (1.000 - 1.008) 
Terminations of 
pregnancy included as 
cases 
Study-level x-
covariate Prevalence 0.010 (0.000 - 0.034) 1.010 (1.000 - 1.035) 
Under Reported 
Study-level x-
covariate Prevalence -0.995 (-1.000 - -0.978) 0.370 (0.368 - 0.376) 
LDI (I$ per capita) 
Country 
covariate Remission 0.999 (0.500 - 1.500) 2.717 (1.649 - 4.482) 
 
Covariates used in the DisMod-MR model of limb reduction defects 
Covariate name Type Measure Beta value Exponentiated value 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality 
rate -0.050 (-0.100 - 0.000) 0.952 (0.905 - 1.000) 
Legality of Abortion 
Country 
covariate Prevalence -0.002 (-0.004 - -0.000) 0.998 (0.996 - 1.000) 
All MarketScan, year 
2010 
Study-level x-
covariate Prevalence -0.017 (-0.062 - -0.000) 0.983 (0.940 - 1.000) 
All MarketScan, year 
2012 
Study-level x-
covariate Prevalence -0.086 (-0.282 - -0.001) 0.917 (0.755 - 0.999) 
Chromosomal diagnoses 
excluded 
Study-level x-
covariate Prevalence -0.075 (-0.114 - -0.038) 0.928 (0.893 - 0.963) 
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Hospital data for ages 
over 1 year only 
Study-level x-
covariate Prevalence 0.536 (0.431 - 0.641) 1.709 (1.539 - 1.898) 
Hospital data for the 
under-1 year age group 
Study-level x-
covariate Prevalence 0.543 (0.385 - 0.703) 1.721 (1.469 - 2.020) 
Stillbirths included as 
cases 
Study-level x-
covariate Prevalence 0.126 (0.072 - 0.171) 1.134 (1.075 - 1.186) 
Terminations of 
pregnancy included as 
cases 
Study-level x-
covariate Prevalence 0.015 (0.000 - 0.051) 1.015 (1.000 - 1.053) 
Under Reported 
Study-level x-
covariate Prevalence -0.073 (-0.125 - -0.027) 0.930 (0.883 - 0.973) 
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Urogenital congenital anomalies 
Case definitions and associated health states  
The GBD 2016 case definition of urogenital congenital anomalies include anomalies of the genitals and 
the urinary system that are present at birth. While some types of urogenital congenital anomalies 
encompass both the urinary and genital systems, we have assigned each congenital condition as a 
malformation of either the urinary or the genital system and model anomalies of the urinary and genital 
systems separately. Urinary anomalies include congenital malformation of the collecting system, ureter, 
bladder, and kidney, as well as bladder exstrophy and epispadias. The ICD-10 codes included in the 
category of urinary anomalies are Q64.0, Q64.1, Q60-Q61 and Q62-Q63. Genital anomalies include 
hypospadias, ambiguous or indeterminate sex, other congenital abnormalities of the male genitalia, and a 
variety of female genital malformations. ICD-10 codes Q50-Q52, Q54, Q56, and Q55 (excluding Q55.20-
Q55.21) are included in the case definition of congenital genital anomalies. Undescended testicles are 
excluded from the case definition of genital anomalies, as this is not considered a severe condition. 
Remission is not permitted in the models or either urinary or genital anomalies, as individuals who 
receive surgical corrections of these conditions after birth typically continue to experience health 
consequences as a result of these congenital conditions.  
The total prevalence of congenital urinary anomalies was split into proportions with and without each of 
the following health states: urinary incontinence, impotence, recurrent urinary tract infections and other 
recurring abdominal issues, and atypical genitalia (corresponding to disfigurement, level 1 in the GBD 
Disability Weights Study). Cases of congenital genital anomalies was split into proportions with and 
without primary infertility, impotence, recurrent urinary tract infections and other recurring abdominal 
issues, and atypical genitalia. Estimates were produced for the prevalence of every possible combination 
of those long-term sequela, assuming independence between the outcomes. 
The distribution of these long-term outcomes was derived from a review of available literature on the 
long-term outcomes experienced cohorts of individuals born with a range of congenital urogenital 
anomalies (references: NIDs 292284, 292293, 292295, 292297, 292299, 292316, and 292318).  
Modeling strategy and model settings 
Congenital urogenital anomalies were modeled as two distinct categories, with distinct model 
specifications: urinary congenital anomalies and genital congenital anomalies.In the DisMod model of 
congenital urinary anomalies, random effects on random effects on prevalence were limited to +- 0.5 and 
random effects on with-condition mortality were limited to +- 1.0. The maximum excess mortality rate 
was set to 5.0 for the first year of life and 2.0 for ages 1 year to 70 years. The excess mortality rate set to 
0 for ages 70+ years, consistent with the GBD 2016 Cause of Death models which exclude congenital 
urogenital anomalies as a cause of death after 70 years of age. The smoothness on excess mortality rate 
was set to Xi = 0.6 in order to fit changes in the excess mortality rate during the neonatal period.  
In the DisMod model of congenital genital anomalies, random effects on prevalence were limited to +- 0.5 
in order to limit random geographic variation in the estimates of birth prevalence, and random effects on 
with-condition mortality were limited to +- 1.0. The maximum excess mortality rate was set to 0.5 for all 
ages < 70 years, according to maximum observed excess mortality rates in available literature data on 
congenital genital anomalies. The excess mortality rate set to 0 for ages 70+ years, consistent with the 
GBD 2016 Cause of Death models which exclude congenital urogenital anomalies as a cause of death 
after 70 years of age.  
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Covariates used in the DisMod-MR model of urinary congenital anomalies 
Covariate name Type Measure Beta value Exponentiated value 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality rate -0.498 (-0.750 - -0.256) 0.608 (0.472 - 0.774) 
All MarketScan, year 
2010 
Study-level 
x-covariate Prevalence -0.018 (-0.065 - -0.000) 0.983 (0.937 - 1.000) 
All MarketScan, year 
2012 
Study-level 
x-covariate Prevalence -0.013 (-0.054 - -0.001) 0.987 (0.947 - 0.999) 
Chromosomal diagnoses 
excluded 
Study-level 
x-covariate Prevalence -0.206 (-0.297 - -0.132) 0.814 (0.743 - 0.876) 
Hospital data for ages 
over 1 year only 
Study-level 
x-covariate Prevalence -0.001 (-0.002 - -0.000) 0.999 (0.998 - 1.000) 
Hospital data for the 
under-1 year age group 
Study-level 
x-covariate Prevalence -0.013 (-0.143 - -0.000) 0.987 (0.867 - 1.000) 
Stillbirths included as 
cases 
Study-level 
x-covariate Prevalence 0.002 (0.000 - 0.005) 1.002 (1.000 - 1.005) 
Terminations of 
pregnancy included as 
cases 
Study-level 
x-covariate Prevalence 0.230 (0.142 - 0.294) 1.258 (1.152 - 1.342) 
 
Covariates used in the DisMod-MR model of congenital genital anomalies 
Covariate name Type Measure Beta value Exponentiated value 
LDI (I$ per capita) 
Country 
covariate Remission 0.556 (0.100 - 0.977) 1.743 (1.105 - 2.655) 
All MarketScan, year 
2010 
Study-level 
x-covariate Prevalence -0.309 (-0.436 - -0.181) 0.734 (0.647 - 0.835) 
All MarketScan, year 
2012 
Study-level 
x-covariate Prevalence -0.333 (-0.445 - -0.207) 0.717 (0.641 - 0.813) 
Chromosomal diagnoses 
excluded 
Study-level 
x-covariate Prevalence -0.030 (-0.076 - -0.001) 0.971 (0.927 - 0.999) 
EUROCAT to NBDPN 
registry case 
composition adjustment 
Study-level 
x-covariate Prevalence -0.383 (-0.494 - -0.273) 0.682 (0.610 - 0.761) 
Hospital data for ages 
over 1 year only 
Study-level 
x-covariate Prevalence 0.256 (0.122 - 0.374) 1.291 (1.129 - 1.453) 
Hospital data for the 
under-1 year age group 
Study-level 
x-covariate Prevalence -0.485 (-0.500 - -0.444) 0.616 (0.607 - 0.641) 
ICDBSR to NBDPN 
registry case 
composition adjustment 
Study-level 
x-covariate Prevalence -0.519 (-0.628 - -0.422) 0.595 (0.534 - 0.656) 
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Congenital anomalies of the digestive system 
Case definitions 
Congenital anomalies of the digestive system include any anomalies of the gastrointestinal tract present 
at birth as the result of abnormal embryonic development. As with the other congenital causes, this 
variety of digestive system abnormalities is split into four sub-cause categories. Congenital diaphragmatic 
hernia, a life-threatening malformation of the diaphragm that allows the abdominal organs to push into 
the chest cavity and obstructs proper formation of the lungs, is modeled separately from all other 
congenital malformations of the digestive system. Congenital diaphragmatic hernia corresponds to ICD-
10 code Q79.0.  
All congenital malformations of the abdominal wall are modeled together as a distinct sub-category. The 
primary diagnoses in this category are gastroschisis, omphalocele, and prune belly syndrome, 
corresponding to ICD-10 codes Q79.3, Q79.2, and Q79.4, respectively. All variations of atresia and/or 
stenosis of the digestive tract are modeled together as the third distinct sub-category of digestive 
congenital anomalies. This includes biliary atresia, esophageal atresia and/or stenosis with and without 
tracheoesophageal fistula, and atresia and stenosis of the small intestine, large intestine, rectum and 
anus. The ICD-10 codes included in the atresia and stenosis sub-cause category are Q42.0; Q42.1; Q42.2; 
Q42.3; Q42.4; Q42.8; Q42.9, Q42.8; Q42.9, Q42.0; Q42.1; Q42.2; Q42.3; Q42.4; Q41 (Q41.0; Q41.1; 
Q41.2; Q41.8; Q41.9; ), Q44.2, Q39.0; Q39.1 and Q39.2. The final category of digestive congenital 
anomalies estimated in the GBD is other congenital malformations and diseases of the digestive system. 
This includes ICD-10 codes Q38 (Q38.0; Q38.3; Q38.4; Q38.6; Q38.7; Q38.8);  Q39(Q39.3; Q39.4; Q39.5; 
Q39.6; Q39.8; Q39.9);  Q40(Q40.0; Q40.1; Q40.2; Q40.3; Q40.8; Q40.9);  Q43(Q43.1; Q43.2; Q43.3; 
Q43.4; Q43.5; Q43.6; Q43.7; Q43.8; Q43.9);  Q44(Q44.0; Q44.1; Q44.3; Q44.4; Q44.5; Q44.6; Q44.7);  
Q45(Q45.0; Q45.1; Q45.2; Q45.3; Q45.8; Q45.9); Q79.1, and Q79.5(Q79.51; Q79.59). Inguinal hernias 
present at birth are excluded from the case definition of gastrointestinal congenital anomalies and are 
modeled separately as part of the estimation of inguinal hernias. 
Most congenital anomalies of the gastrointestinal tract require surgical correction early in life in order to 
ensure infant survival. Following surgical intervention, individuals born with these congenital anomalies 
may experience a range of long-term outcomes as a result of their congenital conditions. Thus, we do not 
permit remission in the models of any congenital digestive anomalies and the health states associated 
with the various types of digestive anomalies reflect the long-term outcomes experienced by individuals 
with surgically corrected congenital malformations.  
Health states associated with congenital anomalies of the digestive system 
The health outcomes associated with congenital diaphragmatic hernia include every combination of 
disfigurement, chronic abdominal pain, mild chronic respiratory problems and breathlessness, mild 
intellectual disability, and a proportion of patients who are asymptomatic. The distribution of these long-
term health outcomes was derived from a pooled analysis of available literature on the long-term 
outcomes in surviving patients born with congenital diaphragmatic hernias (references: NIDs 281144, 
292221 and 292224).  
The health outcomes associated with congenital malformations of the abdominal wall include every 
combination of constipation, chronic abdominal pain, and disfigurement and concern about scars. The 
distribution of these outcomes was calculated from a pooled analysis of literature sources on the long-
term outcomes among surviving individuals born with congenital malformations of the abdominal wall 
(references: NIDs 292217 and 292235). Similarly, the outcomes associated with congenital atresia and/or 
stenosis of the abdominal tract include every combination of dysphagia, acid reflux, chronic abdominal 
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pain and/or nausea, and chronic respiratory problems; the distribution of these long-term outcomes was 
also derived from available long-term follow-up studies (references: NIDs 292215 and 292242).  
The distribution of health outcomes associated with other congenital anomalies of the gastrointestinal 
tract was considered to be the same as the health outcomes associated with atresia and/or stenosis of 
the abdominal tract.  
 
Modeling strategy and model settings  
In order to ensure internal consistency in the estimates of each sub-type of congenital digestive 
anomalies, we generated a model to estimate the total prevalence and associated mortality due to all 
congenital digestive anomalies, then fit the estimates of each sub-type of congenital digestive anomalies 
proportionally to the envelope of this total model. The prevalence of other congenital anomalies of the 
digestive tract was calculated as a proportion of the total digestive anomalies estimates, using age- and 
sex-specific proportions derived from Marketscan claims data, which has the most detailed ICD-9 and 
ICD-10 coding information available of any input data sources. This modeling strategy allowed us to utilize 
the GBD 2016 Cause of Death estimates as input to the total congenital digestive anomalies estimates 
and also allowed us to incorporate literature data that reported only the total prevalence of all digestive 
anomalies.  
The DisMod model of total congenital digestive anomalies used cause-specific mortality estimates from 
the corresponding GBD 2016 Cause of Death model of congenital digestive anomalies, and these data 
were converted to excess mortality estimates where corresponding cause-specific mortality estimates 
were available. The model had random effects on prevalence limited to +- 0.5 and a decreasing slope 
prior on excess mortality rate was set for all ages. The smoothness on excess mortality rate was increased 
to Xi = 1.0 in order to fit steep changes in excess mortality rate during the neonatal age period.  
In the DisMod model of congenital diaphragmatic hernia, random effects on prevalence were set to +- 0.5 
and random effects on with-condition mortality were set to +- 1.0. The minimum excess mortality for the 
early neonatal age period was set to 2.0. A decreasing slope prior on excess mortality rate was set for all 
ages, as the risk of mortality due to congenital diaphragmatic hernia is highest shortly after birth and 
diminishes over the life course following surgical correction of the condition. Smoothness on excess 
mortality rate was increased to Xi= 1.0 in order to fit steep changes in excess mortality rate during the 
first weeks of life.  
The DisMod model of congenital malformations of the abdominal wall had random effects on prevalence 
limited to +- 0.5 and random effects on with-condition mortality were limited to +- 1.0. The minimum 
excess mortality rate was set to 3.0 in the early neonatal period according to the range of excess 
mortality estimates observed in literature data. A decreasing slope prior on excess mortality rate was set 
for all ages, and the smoothness on excess mortality rate was set to Xi = 0.8, allowing the model to fit a 
steep decrease in the excess mortality rate after the neonatal age period. 
In the DisMod model of congenital diaphragmatic hernia, random effects on prevalence were set to +- 0.5 
and random effects on with-condition mortality were set to +- 1.0. A decreasing slope prior on excess 
mortality rate was set for all ages, as the risk of mortality due to these congenital digestive anomalies 
highest shortly after birth. The smoothness on excess mortality rate was increased to Xi = 1.0 in order to 
fit steep changes in excess mortality rate during the first weeks of life.  
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Covariates used in the DisMod-MR model of total congenital digestive anomalies 
Covariate name Type Measure Beta value Exponentiated value 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality 
rate -0.158 (-0.195 - -0.124) 0.854 (0.823 - 0.883) 
Chromosomal diagnoses 
excluded 
Study-level x-
covariate Prevalence -0.047 (-0.086 - -0.007) 0.954 (0.917 - 0.993) 
Hospital data for ages 
over 1 year only 
Study-level x-
covariate Prevalence -0.237 (-0.276 - -0.193) 0.789 (0.759 - 0.824) 
Hospital data for the 
under-1 year age group 
Study-level x-
covariate Prevalence 0.381 (0.318 - 0.440) 1.464 (1.375 - 1.552) 
Registry data 
Study-level x-
covariate Prevalence -0.199 (-0.240 - -0.162) 0.819 (0.787 - 0.850) 
Stillbirths included as 
cases 
Study-level x-
covariate Prevalence 0.003 (0.000 - 0.015) 1.003 (1.000 - 1.015) 
Terminations of 
pregnancy included as 
cases 
Study-level x-
covariate Prevalence 0.048 (0.006 - 0.114) 1.049 (1.006 - 1.121) 
Under Reported 
Study-level x-
covariate Prevalence -0.910 (-0.968 - -0.852) 0.403 (0.380 - 0.427) 
Under Reported 
Study-level z-
covariate 
With-
condition 
mortality 
rate 1.657 (1.207 - 1.975) 5.246 (3.343 - 7.207) 
 
Covariates used in the DisMod-MR model of congenital diaphragmatic hernia 
Covariate name Type Measure Beta value Exponentiated value 
Healthcare access and 
quality index 
Country 
covariate 
With-
condition 
mortality rate -0.252 (-0.498 - 0.000) 0.777 (0.608 - 1.000) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality rate -0.627 (-1.000 - -0.250) 0.534 (0.368 - 0.779) 
All MarketScan, year 
2010 
Study-level 
x-covariate Prevalence -1.571 (-1.692 - -1.445) 0.208 (0.184 - 0.236) 
All MarketScan, year 
2012 
Study-level 
x-covariate Prevalence -1.566 (-1.688 - -1.447) 0.209 (0.185 - 0.235) 
Chromosomal diagnoses 
excluded 
Study-level 
x-covariate Prevalence -0.115 (-0.183 - -0.043) 0.892 (0.833 - 0.958) 
Hospital data 
Study-level 
x-covariate Prevalence -0.003 (-0.007 - -0.000) 0.997 (0.993 - 1.000) 
Stillbirths included as 
cases 
Study-level 
x-covariate Prevalence 0.008 (0.000 - 0.024) 1.008 (1.000 - 1.025) 
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 Covariates used in the DisMod-MR model of congenital malformations of the abdominal wall 
Covariate name Type Measure Beta value Exponentiated value 
Healthcare access and 
quality index 
Country 
covariate 
With-
condition 
mortality rate -0.025 (-0.049 - -0.006) 0.975 (0.952 - 0.994) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality rate -0.425 (-0.750 - -0.102) 0.654 (0.472 - 0.903) 
Chromosomal diagnoses 
excluded 
Study-level 
x-covariate Prevalence -0.019 (-0.057 - -0.000) 0.981 (0.945 - 1.000) 
Hospital data for ages 
over 1 year only 
Study-level 
x-covariate Prevalence -0.007 (-0.021 - -0.000) 0.993 (0.979 - 1.000) 
Hospital data for the 
under-1 year age group 
Study-level 
x-covariate Prevalence -0.002 (-0.008 - -0.000) 0.998 (0.992 - 1.000) 
Stillbirths included as 
cases 
Study-level 
x-covariate Prevalence 0.027 (0.001 - 0.077) 1.027 (1.001 - 1.080) 
Terminations of 
pregnancy included as 
cases 
Study-level 
x-covariate Prevalence 0.102 (0.033 - 0.180) 1.107 (1.034 - 1.198) 
Under Reported 
Study-level 
x-covariate Prevalence -0.705 (-0.785 - -0.625) 0.494 (0.456 - 0.535) 
 
Covariates used in the DisMod-MR model of congenital atresia and/or stenosis of the digestive tract 
Covariate name Type Measure Beta value Exponentiated value 
Healthcare access and 
quality index 
Country 
covariate 
Excess 
mortality rate -0.250 (-0.496 - 0.000) 0.779 (0.609 - 1.000) 
LDI (I$ per capita) 
Country 
covariate 
Excess 
mortality rate -0.050 (-0.100 - -0.000) 0.951 (0.905 - 1.000) 
Chromosomal diagnoses 
excluded 
Study-level 
x-covariate Prevalence -0.274 (-0.300 - -0.222) 0.760 (0.741 - 0.801) 
Hospital data for ages 
over 1 year only 
Study-level 
x-covariate Prevalence -0.003 (-0.008 - -0.000) 0.997 (0.992 - 1.000) 
Hospital data for the 
under-1 year age group 
Study-level 
x-covariate Prevalence -0.001 (-0.003 - -0.000) 0.999 (0.997 - 1.000) 
Stillbirths included as 
cases 
Study-level 
x-covariate Prevalence 0.002 (0.000 - 0.005) 1.002 (1.000 - 1.005) 
Terminations of 
pregnancy included as 
cases 
Study-level 
x-covariate Prevalence 0.018 (0.001 - 0.064) 1.019 (1.001 - 1.066) 
Under Reported 
Study-level 
x-covariate Prevalence -0.992 (-1.000 - -0.968) 0.371 (0.368 - 0.380) 
Under Reported 
Study-level 
z-covariate 
With-
condition 
mortality rate 1.544 (1.203 - 1.968) 4.683 (3.330 - 7.156) 
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Other congenital anomalies 
In addition of the specific types of congenital anomalies outlined in the preceding pages, there are a 
number of other types of defects that may be present at birth. These other congenital defects include 
anomalies of the ears, eyes, face and neck, respiratory malformation and diseases, skin disorders, 
phakomatoses and other neurological disorders that are not included in the case definition of neural tube 
defects. Estimates of the YLDs attributable to these other congenital anomalies are derived from a 
YLL:YLD ratio using YLLs from the cause of death (COD) estimates for other congenital anomalies.  
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 Dermatitis 
Flowcharts for Atopic Dermatitis, Contact Dermatitis, & Seborrheic Dermatitis 
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Case definition 
Dermatitis was included in the GBD 2016 cause group of skin and subcutaneous conditions and consists 
of atopic dermatitis, contact dermatitis, and seborrheic dermatitis. Dermatitis, or eczema, refers to an 
inflammation of the skin. Atopic dermatitis is an inflammatory, relapsing, and non-contagious skin 
disorder characterized by an itchy rash (ICD-10: L20) (1). Contact dermatitis is a localized rash or irritation 
of the skin caused by allergens or irritants (ICD: 10: L22-26) (1). Seborrhoeic dermatitis is an inflammatory 
skin disorder affecting the sebaceous-gland-rich areas of skin, generally the scalp, face, and torso (ICD-10: 
L21) (1). It is characterized by scaly, flaky, itchy, and red skin on the affected area. We estimated burden 
separately for atopic dermatitis, contact dermatitis, and seborrheic dermatitis in order to better 
accommodate differences in the epidemiology and burden between the subtypes of dermatitis. 
 
Input data 
Model inputs 
In the GBD 2010, a literature‐based dataset was provided by the skin conditions expert group. Data from 
the Medical Expenditure Panel Survey (MEPS) in the United States in 2000–2009 (2) were also included to 
inform the age pattern of the prevalence output. Data from the NHANES study and the NHIS study (both 
from the US) were not extracted, as questions regarding dermatitis were too broad (ie, asked whether a 
respondent had experienced eczema or any other rash). Dermatitis (known as “eczema”) was modelled as 
a single disorder. For GBD 2013, the literature was updated and dermatitis was disaggregated into 
eczema, contact dermatitis, and seborrheic dermatitis. The agreed-upon approach for dermatitis diseases 
was to undertake a literature review every two years. Therefore, we undertook a new literature review 
for GBD 2016. The data for dermatitis were expanded based on recommendations of research articles 
and reviews by the skin expert group. Additionally, hospital outpatient and US claims data for 2000, 2010, 
and 2012 were used, where appropriate. Data were outliered or excluded if we found them unreasonable 
when compared to regional, super-regional, and global rates. See descriptions of individual modelling 
approaches for more information.  
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Table 1. Model inputs 
  Prevalence Incidence 
Atopic dermatitis Studies 197 0 
Countries/subnationals 227 0 
Countries 96 0 
GBD world regions 19 0 
GBD super-regions 7 0 
Contact dermatitis Studies 24 1 
Countries/subnationals 68 1 
Countries 14 1 
GBD world regions 8 1 
GBD super-regions 6 1 
Seborrheic dermatitis  Studies 24 1 
Countries/subnationals 71 1 
Countries 19 1 
GBD world regions 10 1 
GBD super-regions 7 1 
 
Severity splits and disability weights 
 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. Severity was split into three levels of disfigurement with 
pain/itch. The severity splits and disability weights applied in GBD 2015 were also used for GBD 2016. See 
below for a lay descriptions of the severity levels.  
 
Table 2. Severity level and lay description.  
Sequela Severity level Lay description DW (95% CI) 
Mild atopic dermatitis Disfigurement, level 1 
with itch/pain 
 
The person has a slight, 
visible physical deformity 
that is sometimes sore 
or itchy. Others notice 
the deformity, which 
causes some worry and 
discomfort. 
0.027 (0.015–0.042) 
 
Moderate atopic 
dermatitis  
Disfigurement, level 2, 
with itch/pain 
 
The person has a visible 
physical deformity that is 
sore and itchy. Other 
people stare and 
comment, which causes 
the person to worry. The 
person has trouble 
sleeping and 
concentrating. 
0.188 (0.124–0.267) 
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Severe atopic 
dermatitis 
 
Disfigurement, level 3, 
with itch/pain 
 
The person has an 
obvious physical 
deformity that is very 
painful and itchy. The 
physical deformity 
makes others 
uncomfortable, which 
causes the person to 
avoid social contact, feel 
worried, sleep poorly, 
and think about suicide. 
0.576 (0.401–0.731) 
 
Mild contact dermatitis 
 
Disfigurement, level 1 
with itch/pain 
 
The person has a slight, 
visible physical deformity 
that is sometimes sore 
or itchy. Others notice 
the deformity, which 
causes some worry and 
discomfort. 
0.027 (0.015–0.042) 
 
Moderate contact 
dermatitis 
 
Disfigurement, level 2, 
with itch/pain 
 
The person has a visible 
physical deformity that is 
sore and itchy. Other 
people stare and 
comment, which causes 
the person to worry. The 
person has trouble 
sleeping and 
concentrating. 
0.188 (0.124–0.267) 
 
Symptomatic 
seborrheic dermatitis 
 
Disfigurement, level 1 
with itch/pain 
 
The person has a slight, 
visible physical deformity 
that is sometimes sore 
or itchy. Others notice 
the deformity, which 
causes some worry and 
discomfort. 
0.027 (0.015–0.042) 
 
 
Modelling strategy 
DisMod-MR 2.1 was used to estimate prevalence by age, sex, year, and geography (subnational [select 
countries], country, region, super-region) for atopic dermatitis, contact dermatitis, and seborrheic 
dermatitis. Separate models were run for each cause. 
Atopic dermatitis: Since our available data mostly contained information on prevalence, we specified 
additional expert priors to further inform analyses. Excess mortality was set to zero while a setting of 0-
0.2 (equivalent to five years to life time duration) was placed on remission. Study-level covariates were 
used to adjust prevalence estimates from the Medical Expenditure Panel Survey (MEPS), US claims data 
for 2000, 2010, and 2012, self-reported data, and administrative data toward data based on clinical 
examination. To improve regional and global estimates, the minimum coefficient of variation was set at 
0.4 and location random effects for Paraguay, Sweden, and England were restricted to [-0.25, 0.25], [-
586
0.25, 0.25], and [-0.5, 0.5], respectively. A time window of 10 years was used to determine which data 
points were used for a particular year of fit.  
Contact dermatitis: Similar to atopic dermatitis, mostly prevalence data were available for contact 
dermatitis. Per expert advice, the remission parameter was set from 0.1 to 4, excess mortality was set to 
zero, and incidence was set to zero prior to age 6. Study-level covariates were used to adjust data from 
the Medical Expenditure Panel Survey (MEPS), outpatient data, administrative data, self-reported data, 
data based on a one-year recall, and claims data for 2000 and 2010 toward the values in the 2012 claims 
data. In order to improve model estimates, location random effects were added for Sweden [-2, 2], 
Norway [-2, 2], Denmark [0, 0.5], Italy [-2, 2], Germany [-2, 2], and France [-0.5, 0]. “A time window of 25 
years was used to determine which data points were used for a particular year of fit.  
Seborrheic dermatitis: As with contact dermatitis, the available data were mostly prevalence estimates. 
Per expert advice, settings were placed on incidence as follows: 0-4 years = 0-0.1, and 60-100 = 0-0.01. 
Excess mortality was set to zero while a setting of 0.1-12 was placed on remission, implying a duration of 
one month to 10 years. Study-level covariates were used to adjust prevalence estimates from US claims 
data for 2000 and 2010, MEPS, administrative data, and clinical exam data toward other data points.  
Table 3. Study-level beta and exponentiated values  
 Study covariate Parameter Beta Exp(beta) 
Atopic dermatitis MEPS Prevalence -1.08 (-1.23 - -0.95) 0.34 (0.29 - 0.39) 
Self-reported Prevalence 0.39 (0.34 - 0.44) 1.48 (1.41 - 1.56) 
Administrative data Prevalence -0.33 (-0.54 - -0.12) 0.72 (0.58 - 0.89) 
Claims data - 2000 Prevalence -1.90 (-1.99 - -1.83) 0.15 (0.14 - 0.16) 
Claims data - 2010 Prevalence -1.51 (-1.60 - -1.43) 0.22 (0.20 - 0.24) 
Claims data - 2012 Prevalence -1.47 (-1.56 - -1.40) 0.23 (0.21 - 0.25) 
Contact dermatitis MEPS Prevalence -0.36 (-0.79 - -0.03) 0.69 (0.46 - 0.97) 
Outpatient Prevalence -0.90 (-1.82 - -0.05) 0.41 (0.16 - 0.95) 
Recall 1 year Prevalence -0.18 (-1.02 - 0.86) 0.83 (0.36 - 2.37) 
Self-reported Prevalence 1.65 (0.98 - 1.99) 5.23 (2.68 - 7.30) 
Administrative data Prevalence 1.20 (-0.14 - 1.97) 3.32 (0.87 - 7.16) 
Claims data - 2000 Prevalence 0.32 (0.24 - 0.39) 1.37 (1.27 - 1.48) 
Claims data - 2010 Prevalence 0.53 (0.47 - 0.60) 1.70 (1.59 - 1.81) 
Seborrhoeic dermatitis Diagnosis Physical Exam Prevalence 1.72 (1.03 - 2.00) 5.61 (2.82 - 7.39) 
MEPS Prevalence -1.96 (-2.00 - -1.86) 0.14 (0.14 - 0.16) 
Administrative data Prevalence 1.83 (1.30 - 2.00) 6.22 (3.65 - 7.39) 
Claims data - 2000 Prevalence -0.31 (-0.36 - -0.20) 0.73 (0.69 - 0.82) 
Claims data - 2010 Prevalence 0.14 (0.10 - 0.25) 1.15 (1.10 - 1.28) 
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Case definition 
Psoriasis was included in the GBD 2016 cause group of skin and subcutaneous conditions. According to 
the International Classification of Diseases (ICD-10), it is a skin disease marked by itchy or sore patches of 
thick, red skin with silvery scales (ICD-10: L40, L41) (1,2). 
Input data 
Model inputs 
In the GBD 2010 study, a systematic review of the literature was conducted using PubMed and Google 
Scholar to capture epidemiological data for psoriasis. The literature search also included any relevant data 
from the Medical Expenditure Panel Survey (MEPS) in the United States for 2000–2009, the Australian 
National Health Survey 1995–1996, 2001, 2004–2005, 2007–2008, and the US National Health and 
Nutrition Examination Survey (NHANES) in 2002 and 2005. 
The inclusion criteria stipulated that studies (1) must be published between 1980 and 2012; (2) must 
provide data on the incidence or prevalence of psoriasis; (3) must use samples representative of the 
general population (ie, samples derived from the experimental arm of clinical trials or based in 
dermatology clinics were excluded); (4) must use a sample size larger than 100; and (5) must provide 
sufficient information on study method and sample characteristics to assess the quality of the study. For 
GBD 2013, the GBD 2010 search strategy was replicated to capture epidemiological studies published 
between 2012 and 2014. The agreed-upon approach for psoriasis was to undertake a literature review 
every two years. Therefore, we conducted an updated literature review through October 1, 2016, for GBD 
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2016. Hospital outpatient and US claims data from 2000, 2010, and 2012 were also included in GBD 2016. 
Data were outliered or excluded if we found them unreasonable when compared to regional, super-
regional, and global rates. 
 
 
Table 1. Data inputs 
 Prevalence Incidence 
Studies 72 6 
Countries/subnationals 92 2 
Countries 30 3 
GBD world regions 13 2 
GBD super-regions 6 1 
 
 
Severity splits  
As was the case in GBD 2010, GBD 2013, and GBD 2015, disability weights were estimated for 
disfigurement with itch/pain, levels 1, 2, and 3. The disability weights used for GBD 2015 were also used 
in 2016.  
 
Table 2. Severity level and lay description.  
Sequela Severity level Lay description DW (95% CI) 
Mild psoriasis 
 
Disfigurement, level 1 
with itch/pain 
 
The individual has a slight, 
visible physical deformity that is 
sometimes sore or itchy. Others 
notice the deformity, which 
causes some worry and 
discomfort. 
0.027 (0.015–0.042) 
 
Moderate 
psoriasis 
 
Disfigurement, level 2, 
with itch/pain 
 
The individual has a visible 
physical deformity that is sore 
and itchy. Other people stare 
and comment, which causes the 
person to worry. The person has 
trouble sleeping and 
concentrating. 
0.188 (0.124–0.267) 
 
Severe psoriasis 
 
Disfigurement, level 3, 
with itch/pain 
 
The individual has an obvious 
physical deformity that is very 
painful and itchy. The physical 
deformity makes others 
uncomfortable, which causes 
the person to avoid social 
contact, feel worried, sleep 
poorly, and think about suicide. 
0.576 (0.401–0.731) 
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Modelling strategy 
DisMod-MR 2.1, a Bayesian meta-regression tool, was used to estimate prevalence by age, sex, year, and 
geography (subnational [select countries], country, region, super-region) for psoriasis. 
Psoriasis was modelled with remission set between 0.05 and 0.15, implying a duration between 6.6 and 
20 years. This was in line with the available epidemiological data, expert opinion, and previous GBD work. 
Excess mortality was assumed to be zero. The datasets for psoriasis were sufficiently large to make use of 
a relatively short time window of 10 years to determine which data points were used for a particular year 
of fit.   
Study-level covariates were used to adjust incidence derived from the Medical Expenditure Panel Survey 
(MEPS) and US claims data for 2000, 2010, and 2012, and outpatient data toward the level of other 
prevalence and incidence data points, which were more representative of the general population. 
Additionally, the data were extremely heterogeneous. Therefore, the random effects were constrained 
to (-0.25, 0.25) except in China (0, 0.5) and Taiwan (Province of China) (-0.5, 0). SDI was used as a 
location-level covariate to guide estimates for countries with few or no data.  
Table 3. Study-level beta and exponentiated values 
Covariate Parameter Beta Exp(beta) 
MEPS Prevalence -0.98 (-1.15 - -0.88) 0.37 (0.32 - 0.42) 
Outpatient Prevalence -0.57 (-0.62 - -0.52) 0.56 (0.54 - 0.59) 
Claims data - 2000 Prevalence -1.21 (-1.25 - -1.17) 0.30 (0.29 - 0.31) 
Claims data - 2010 Prevalence -0.96 (-0.98 - -0.92) 0.38 (0.38 - 0.40) 
Claims data - 2012 Prevalence -0.88 (-0.90 - -0.84) 0.42 (0.41 - 0.43) 
Table 4. Location-level beta and exponentiated values 
Covariate Parameter Beta Exp(beta) 
Socio-demographic Index Prevalence 1.91 (1.77 — 1.99) 6.73 (5.90 — 7.34) 
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Case definition 
Cellulitis was included in the GBD 2016 cause group of skin and subcutaneous conditions. Cellulitis is a 
skin disease marked by a bacterial infection that affects and spreads through the skin and soft tissues. 
Symptoms of cellulitis include pain, tenderness, and reddening in the affected area, fever, chills, and 
lymphadenopathy (ICD-10: L03) (1). 
 
Input data 
Model inputs 
In the GBD 2010 study, a systematic review of the literature was conducted using PubMed and Google 
Scholar to capture epidemiological data for cellulitis. Due to lack of published data on the epidemiology of 
cellulitis, the literature search also included relevant incidence data from national inpatient or outpatient 
records in Europe, North America, and Latin America. When years in the national data from the hospital 
records overlapped, inpatient and outpatient data were summed together in an effort to better estimate 
the population incidence of cellulitis. The final dataset also included survey data from the Medical 
Expenditure Panel Survey (MEPS), US claims data, and cause-specific mortality rates for cellulitis 
estimated by CODEm.  
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The inclusion criteria stipulated that studies (1) must be published between 1980 and 2012; (2) must 
provide data on the incidence or prevalence of cellulitis; (3) must use samples representative of the 
general population (ie, samples derived from the experimental arm of clinical trials or based in 
dermatology clinics were excluded); (4) must use a sample size larger than 100; and (5) must provide 
sufficient information on study method and sample characteristics to assess the quality of the study. For 
GBD 2013, the GBD 2010 search strategy was replicated to capture epidemiological studies published 
between 2012 and 2014. In addition, hospital inpatient data and data from US claims for 2000, 2010, and 
2012 by US state were included in GBD 2016. Data were outliered or excluded if we found them 
unreasonable when compared to regional, super-regional, and global rates. 
 
Table 1. Model inputs (not including hospital inpatient data) 
 
 Prevalence Incidence 
Studies 0 3 
Countries/subnationals 0 318 
Countries 0 38 
GBD world regions 0 15 
GBD super-regions 0 7 
 
Severity splits  
 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. Severity splits for cellultis were calculated via the Medical 
Expenditure Panel Survey (MEPS) regression and outlined in the table below. 
 
Table 2. Severity level and lay description.  
 
Sequela Severity level Lay description DW (95% CI) 
Mild cellulitis Infectious disease, acute 
episode, mild 
 
This person has a low 
fever and mild 
discomfort, but no 
difficulty with daily 
activities. 
0.006 (0.002–0.012) 
Moderate cellulitis Infectious disease, acute 
episode, moderate 
 
This person has a fever 
and aches, and feels 
weak, which causes 
some difficulty with daily 
activities. 
0.051 (0.032–0.074) 
Severe cellulitis Infectious disease, acute 
episode, severe 
This person has a high 
fever and pain, and feels 
0.133 (0.088–0.19) 
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 very weak, which causes 
great difficulty with daily 
activities. 
 
 
Modelling strategy 
DisMod-MR 2.1, a Bayesian meta-regression tool, was used to estimate cellulitis prevalence by age, sex, 
year, and geography (subnational [select countries], country, region, super-region). Cellulitis was modeled 
with remission set between 12 and 30, implying a duration of 12 days to one month. This was in line with 
the available epidemiological data, expert opinion, and previous GBD work. The cellulitis dataset was 
sufficiently large to make use of a relatively short time window of five years to determine which data 
points were used for a particular year of fit.  
 
Study-level covariates were used to adjust incidence derived from MEPS, hospital inpatient data, and US 
claims data for 2000 and 2010 toward the level of other incidence data points, which were more 
representative of the general population. US claims data for 2000 and 2010 were set at a maximum of 
zero, whereas MEPS and inpatient data were set with a maximum of two. Log-transformed lagged 
distributed income (LDI) was used as a location-level covariates to guide estimates for locations with little 
or no data. LDI was restricted to a range of -0.5 to -0.1.  
 
 
Table 3. Study-level beta and exponentiated values  
Covariate Parameter Beta Exp(beta) 
MEPS Incidence -1.97 (-2.00 - -1.91) 0.14 (0.14 - 0.15) 
Claims data - 2000 Incidence -0.52 (-0.55 - -0.49) 0.60 (0.58 - 0.61) 
Claims data - 2010 Incidence -0.06 (-0.09 - -0.04) 0.94 (0.92 - 0.97) 
 
Table 4. Location-level beta and exponentiated values  
Covariate Parameter Beta Exp(beta) 
Log (LDI) Excess mortality rate -0.50 (-0.50 — -0.50) 0.61 (0.61 — 0.61) 
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Case definition 
Pyoderma refers to any skin disease that is pyogenic, ie, involves the development of pus. These include 
superficial bacterial conditions such as impetigo, furuncles, ulcers, and abscesses. For GBD 2016, 
pyoderma was modelled as two separate groups: impetigo, and abscess and other bacterial skin diseases. 
Impetigo is a highly contagious bacterial skin infection often characterized by red sores, which eventually 
leak pus or fluid (ICD-10: L01). An abscess is a collection of pus that builds up within the tissue of the 
body, with carbuncles and furuncles being examples of specific types of abscess. The abscess and other 
bacterial skin diseases group included all bacterial skin diseases except impetigo (ICD-10: L00, L02, L04, 
L05, L08). 
Input data 
Model inputs 
For both impetigo and abscess and other bacterial skin diseases in GBD 2010, a literature review was 
conducted using PubMed and Google Scholar. The inclusion criteria were studies which were published 
between 1980 and 2010 and provided data on relevant disease incidence or prevalence. Exclusion criteria 
were studies with no incidence or prevalence data provided, not community- or population-based, 
outside of year range, sample size smaller than 100, experimental arm of clinical trial, papers that 
provided estimates rather than data, and studies that were based in dermatology clinics. The agreed 
approach for pyoderma disease was to undertake a literature review every two years. Therefore, no 
literature review was undertaken for GBD 2015. For GBD 2016, the GBD 2013 search strategy was 
replicated to capture epidemiological studies published between 2014 and 2016. Hospital inpatient data 
were used as model inputs for abscesses and other bacterial skin diseases, but were omitted for 
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impetigo, as the adjustment factor from primary diagnoses codes to all diagnoses codes were found to be 
implausible. 
 
 
Table 1. Data inputs 
 
  Prevalence Incidence 
Impetigo Studies 8 2 
Countries 6 3 
Countries/subnationals 6 53 
GBD world regions 4 1 
Abscess and other 
bacterial skin 
diseases  
Studies 1 0 
Countries 2 38 
Countries/subnationals 2 322 
GBD world regions 1 7 
 
Severity splits and disability weights 
Information on the distribution of cases of impetigo and abscess and other bacterial skin diseases, 
asymptomatic, and within disfigurement levels 1 and 2, were obtained from the MEPS. The symptomatic 
cases were assigned the disability weight of a mild acute infectious disease case.  
 
Table 2. Severity level and lay description 
 
Sequela Severity level Lay description DW (95% CI) 
Impetigo Infectious disease, 
acute episode, mild 
 
The person has a low 
fever and mild 
discomfort, but no 
difficulty with daily 
activities. 
 
0.006 (0.002–0.012) 
 
Abscesses and other 
bacterial skin 
diseases 
Infectious disease, 
acute episode, mild 
 
The person has a low 
fever and mild 
discomfort, but no 
difficulty with daily 
activities. 
 
0.006 (0.002–0.012) 
 
 
 
Modelling strategy 
DisMod-MR 2.1 was used to estimate prevalence by age, sex, year, and geography (country, region, 
super-region) for impetigo and abscess and other bacterial skin diseases. Separate models were run for 
each disease. 
Impetigo: Per expert advice, we assumed a remission of 17 to 20, equating to a duration between 
approximately two and three weeks. A value prior was also placed on incidence, restricting the range 
between zero and one. In addition, study-level covariates were placed on incidence to adjust US claims 
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data for 2000 and 2010 toward the reference literature data and US 2012 claims data. A country-level 
covariate, log transformed lagged distributed income (I$ per capita), which represents a moving average 
of gross domestic product (GDP) over time, was also included to inform prevalence and excess mortality 
estimates. We also used the cause-specific mortality rates for pyoderma estimated using CODEm. We 
used a time window of 5 years to determine which data points were used for a particular year of fit. 
Abscess and other bacterial skin diseases: Per expert advice, a remission setting of 17 to 30 was applied, 
which equated to a duration of two to six weeks. Study-level covariates adjusted incidence estimates 
from US claims data for 2000 and 2010 and hospital inpatient data toward the reference literature data 
and US 2012 claims data. We also used the cause-specific mortality rates for pyoderma estimated using 
CODEm. In addition, we used a log transformed lagged distributed income (I$ per capita) country 
covariates on excess mortality. We used a time window of 5 years to determine which data points were 
used for a particular year of fit. 
Table 3. Beta and exponentiated values  
Impetigo  
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level 
covariate 
Claims data - 
2000 Incidence 
-0.30 (-0.32 - -
0.28) 0.74 (0.72 - 0.75) 
Study-level 
covariate 
Claims data -
2010 Incidence 
-0.09 (-0.10 - -
0.07) 0.92 (0.90 - 0.93) 
Country covariate 
LDI (I$ per 
capita) Prevalence 0.09 (0.00 - 0.33) 1.09 (1.00 - 1.40) 
Country covariate 
LDI (I$ per 
capita) 
Excess mortality 
rate 
-0.20 (-0.20 - -
0.20) 0.82 (0.82 - 0.82) 
 
Abscesses and other bacterial skin diseases 
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level 
covariate 
Hospital 
Inpatient Incidence 
-2.40 (-2.40 - -
2.39) 0.09 (0.09 - 0.09) 
Study-level 
covariate 
Claims data - 
2000 Incidence 
-0.32 (-0.35 - -
0.28) 0.73 (0.70 - 0.76) 
Study-level 
covariate 
Claims data - 
2010 Incidence 
0.02 (-0.01 - 
0.05) 1.02 (0.99 - 1.05) 
Country covariate 
LDI (I$ per 
capita) 
Excess mortality 
rate 
-0.18 (-0.20 - -
0.17) 0.83 (0.82 - 0.85) 
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Case definition 
Scabies was included in the GBD 2016 cause group of skin and subcutaneous conditions. According to the 
International Classification of Diseases (ICD-10), scabies is a skin disease caused by the microscopic mite 
Sarcoptes scabiei. The main symptom is an itchy, pimple-like rash (ICD-10: B86) (1).  
 
Input data 
Model inputs 
In the GBD 2010 study, a systematic review of the literature was conducted using PubMed and Google 
Scholar to capture epidemiological data for scabies. The inclusion criteria stipulated that studies (1) must 
be published between 1980 and 2012; (2) must provide data on the incidence or prevalence of scabies; 
(3) must use samples representative of the general population (ie, samples derived from the 
experimental arm of clinical trials or based in dermatology clinics were excluded); (4) must use a sample 
size larger than 100; and (5) must provide sufficient information on study method and sample 
characteristics to assess the quality of the study. For GBD 2013, the GBD 2010 search strategy was 
replicated to capture epidemiological studies published between 2012 and 2014. The agreed-upon 
approach for scabies was to undertake a literature review every two years. Therefore, we updated the 
systematic review through October 6, 2016, for GBD 2016. Additionally, US claims data from 2000, 2010, 
and 2012 were included in GBD 2016. Data were outliered or excluded if we found them unreasonable 
when compared to regional, super-regional, and global rates. 
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Table 1. Data inputs 
Prevalence Incidence 
Studies 68 20 
Countries/subnationals 85 6 
Countries 33 5 
GBD world regions 17 4 
GBD super-regions 7 3 
Severity splits  
Scabies was assigned the disability weight for disfigurement level 1. The disability weights used for GBD 
2015 were also used for GBD 2016. 
Table 2. Severity level and lay descriptions 
Severity level Lay description DW (95% CI) 
Disfigurement, level 1 with 
itch/pain 
The individual has a slight, visible physical deformity that is 
sometimes sore or itchy. Others notice the deformity, which 
causes some worry and discomfort. 
0.027 (0.015–0.042) 
Modelling strategy 
DisMod-MR 2.1, a Bayesian meta-regression tool, was used to estimate scabies prevalence by age, sex, 
year, and geography (subnational [select countries], country, region, super-region). 
Scabies was modelled with remission set between 2.5 and 3.5, implying four to five months of duration, 
and excess mortality was assumed to be zero. This was in line with the available epidemiological data, 
expert opinion, and previous GBD work.  
The datasets for scabies were sufficiently large to make use of a relatively short time window of five years 
to determine which data points were used for a particular year of fit. Additionally, to improve estimation 
across all regions, we restricted location random effects to (-0.25, 0.25) in Cambodia, Mali, Nepal, Fiji, 
Timor-Leste, Vanuatu, the Oceania, Southeast Asia, and East Asia GBD regions, and the corresponding 
super-region. We also restricted the random effect in Kenya (0, 0.5). We used the unsafe water SEV 
(summary exposure value) as a location-level covariate and set the minimum coefficient of variation at 
0.4. 
Study-level covariates were used to adjust prevalence derived from outpatient data, US claims data for 
2000, 2010, and 2012, and data not based on clinical exams toward the level of other prevalence and 
incidence data points, which were more representative of the general population. 
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Covariate Parameter Beta Exp(beta) 
Claims data - 2000 Prevalence -1.91 (-2.00 — -1.82) 0.15 (0.14 — 0.16) 
Claims data - 2010 Prevalence -1.51 (-1.62 — -1.43) 0.22 (0.20 — 0.24) 
Claims data - 2012 Prevalence -1.29 (-1.39 — -1.20) 0.27 (0.25 — 0.30) 
Data was not based on 
physical examinations 
Prevalence -1.36 (-1.72 — -0.98) 0.26 (0.18 — 0.37) 
Outpatient Prevalence 1.83 (1.70 — 1.97) 6.26 (5.45 — 7.14) 
Table 4. Location-level beta and exponentiated values 
Covariate Parameter Beta Exp(beta) 
Unsafe water (SEV) Prevalence 1.98 (1.94 — 2.00) 7.24 (6.92 — 7.38) 
Table 3. Study-level beta and exponentiated values 
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Case definition 
Fungal diseases were included in the GBD 2016 cause group of skin and subcutaneous conditions and 
consisted of tinea capitis and a residual group of “any” other fungal disease. Similar to GBD 2015, tinea 
capitis was modelled separately from the other fungal skin diseases. This was done to better 
accommodate differences in burden between tinea capitis and other subtypes of fungal skin diseases. 
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Tinea capitis is a fungal infection of the scalp and associated hair. It is characterized by the appearance of 
thickened scaly swellings or as expanding raised red rings (ringworm), mainly caused by species of 
Microsporum, Trichophyton, and Epidermophyton (ICD-10: B35.0) (1). 
The residual group of “any” other fungal skin disease included any fungal skin disease that was specifically 
not tinea capitis or onychomycosis (ie, fungal nail infection). The ICD-10 (1) list of other fungal skin 
diseases includes tinea manuum (ICD-10: B35.2), or hand ringworm; tinea pedis (ICD-10: B35.3), or 
athlete’s foot; tinea corporis (ICD-10:B35.4), or ringworm of the body; tinea imbricata (ICD-10:B35.5), a 
superficial fungal infection limited to parts of Asia and Central America; tinea cruris (ICD-10:B35.6), also 
known as dhobi itch, groin ringworm, or jock itch. In GBD 2016, we added dermatophytosis (ICD-
10:B35.9).  
Input data 
Model inputs 
For GBD 2010, a systematic review of the literature using PubMed and Google Scholar was conducted to 
capture epidemiological data for fungal skin diseases. The literature search also included any relevant 
data from the Medical Expenditure Panel Survey (MEPS) in the United States in 2000–2009. The inclusion 
criteria stipulated that studies (1) must be published between 1980 and 2012; (2) must provide data on 
the incidence or prevalence of fungal  skin diseases; (3) must use samples representative of the general 
population (ie, samples derived from the experimental arm of clinical trials or based in dermatology 
clinics were excluded); (4) must use a sample size larger than 100; and (5) must provide sufficient 
information on study method and sample characteristics to assess the quality of the study. For GBD 2013, 
the GBD 2010 search strategy was replicated to capture epidemiological studies published between 2012 
and 2014. Data were outliered or excluded if we found them unreasonable when compared to regional, 
super-regional, and global rates. 
Table 1. Data inputs  
  Prevalence Incidence 
Tinea capitis Studies 23 0 
Countries/subnationals 68 0 
Countries 17 0 
GBD world regions 7 0 
GBD super-regions 4 0 
Other fungal skin 
diseases 
Studies 30 0 
Countries/subnationals 74 0 
Countries 22 0 
GBD world regions 11 0 
GBD super-regions 6 0 
 
In addition, data from US claims for 2000, 2010, and 2012 by US state were included for both tinea capitis 
and other fungal skin diseases. We also used hospital outpatient data for other fungal skin diseases but 
decided not to use it for tinea capitis because we decided it would not be representative of true 
prevalence, and variation between countries in the proportion of true prevalent cases captured in 
hospital inpatient and outpatient data would likely vary more than can be captured by a single crosswalk 
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in DisMod-MR 2.1. For tinea capitis, we compared the rates in the outpatient data from Norway, Sweden, 
Canada, and the USA and found implausibly large differences with the rates from the claims data.  
Severity splits  
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. The same disability weight was used for both tinea capitis 
and other fungal skin diseases.  
Table 2. Severity level and lay description  
Severity level Lay description DW (95% CI) 
Infectious disease, acute 
episode, mild 
The person has a low fever and mild discomfort but no 
difficulty with daily activities. 
0.006 (0.002–0.012) 
 
Modelling strategy 
DisMod-MR 2.1, a Bayesian meta-regression tool, was used to estimate tinea capitis and other fungal skin 
diseases prevalence by age, sex, year, and geography (subnational [select countries], country, region, 
super-region). Separate models were run for tinea capitis and other fungal skin diseases.  
Tinea capitis. To help inform the distribution of tinea capitis across the lifespan, excess mortality was set 
at zero, remission was set at 0.5 to 4, and incidence was set to zero between 20 and 100 years. This was 
in agreement with the available prevalence data and expert advice. We made use of a relatively long time 
window of 20 years to determine which data points were used for a particular year of fit. This means that 
for the year 2000, for instance, DisMod-MR 2.1 incorporated all data points ranging from 1980 to present 
to estimate prevalence. Study-level covariates in the final model included adjustments for hospital 
outpatient data and US claims data for 2000 and 2010. In addition, we limited random effects for sub-
Saharan Africa (-2,3) and Western Europe (-0.1, 1) to improve model estimates.  
Other fungal skin diseases. The modelling strategy was similar to that for tinea capitis with remission set 
between 0.33 and 4. As Medical Expenditure Panel Survey (MEPS) data points were included in this 
model, we used a study-level covariate to adjust estimates derived from MEPS, outpatient data, and US 
claims data for 2000 and 2010 toward the level of prevalence observed in US claims data from 2012 and 
the literature. We also included a covariate to add uncertainty for data that did not arise from physical 
examination.  
Table 3. Study-level beta and exponentiated values 
Cause  Study covariate Parameter Beta Exp(beta) 
Tinea capitis  Claims data - 2000 Prevalence -0.13 (-0.18 - -0.08) 0.88 (0.84 - 0.92) 
Claims data - 2010 Prevalence -0.10 (-0.14 - -0.06) 0.90 (0.87 - 0.94) 
Other fungal skin 
diseases 
MEPS Prevalence -0.98 (-1.11 - -0.85) 0.37 (0.33 - 0.43) 
Outpatient Prevalence -0.99 (-1.99 - 0.00) 0.37 (0.14 - 1.00) 
Claims data - 2000 Prevalence -0.20 (-0.23 - -0.18) 0.81 (0.80 - 0.83) 
Claims data - 2010 Prevalence -0.05 (-0.07 - -0.03) 0.95 (0.94 - 0.97) 
Data was not based on 
physical 
examinations* Prevalence 1.45 (0.66 - 1.98) 4.28 (1.94 - 7.24) 
* Covariate on the variance.   
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 Viral skin diseases 
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Case definition 
Viral skin diseases consist of viral warts and molluscum contagiosum. Viral warts are raised growths on 
the surface of the skin caused by an infection with the human papillomavirus (ICD-10: B07). Molluscum 
contagiosum is a viral infection of the skin or occasionally of the mucous membranes characterized by the 
appearance of waxy, dome-shaped nodules. It is caused by a DNA poxvirus called the molluscum 
contagiosum virus (ICD-10:  B08.1) (1). In GBD 2016, we modelled viral warts and molluscum contagiosum 
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separately in order to better accommodate differences in burden between the subtypes of viral skin 
diseases. 
Input data 
Model inputs 
In the GBD 2010 study, a systematic review of the literature was conducted using PubMed and Google 
Scholar, to capture epidemiological data for viral skin diseases. Due to lack of published data on the 
epidemiology of viral skin diseases, the literature search also included relevant incidence data from 
national inpatient or outpatient records in the USA. The inclusion criteria stipulated that studies (1) must 
be published between 1980 and 2012; (2) must provide data on the incidence or prevalence of viral warts 
or molluscum contagiosum; (3) must use samples representative of the general population (ie, samples 
derived from the experimental arm of clinical trials or based in dermatology clinics were excluded); (4) 
must use a sample size larger than 100;  and (5) must provide sufficient information on study method and 
sample characteristics to assess the quality of the study. For GBD 2013, the GBD 2010 search strategy was 
replicated to capture epidemiological studies published between 2012 and 2014. Data were outliered or 
excluded if we found them unreasonable when compared to regional, super-regional, and global rates. 
 
Table 1. Input data 
Cause  Prevalence Incidence 
Viral warts Studies 24 1 
Countries/subnationals 71 1 
Countries 20 1 
GBD world regions 12 1 
GBD super-regions 7 1 
Molluscum 
contagiosum 
Studies 11 3 
Countries/subnationals 60 3 
Countries 10 2 
GBD world regions 6 1 
GBD super-regions 4 1 
 
Outpatient data and data from US claims for 2000, 2010, and 2012 by US state were included in GBD 
2016, where appropriate. See descriptions of individual modelling approaches for more information.    
 
Severity splits  
In GBD 2016, cases of both disorders were allocated a distribution between mild acute infectious disease 
and disfigurement level 2. The severity splits and disability weights used in GBD 2015 were also applied in 
GBD 2016.  
 
Table 2. Sequela and disability weight 
Sequela Severity level Lay description DW (95% CI) 
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Mild viral warts 
 
Infectious disease, acute 
episode, mild 
The person has a low 
fever and mild 
discomfort, but no 
difficulty with daily 
activities. 
 
0.006 (0.002–0.012) 
 
Severe viral warts 
 
Disfigurement, level 2 The person has a visible 
physical deformity that 
causes others to stare 
and comment. As a 
result, the person is 
worried and has trouble 
sleeping and 
concentrating. 
0.067 (0.044–0.096) 
Mild molluscum 
contagiosum 
 
Infectious disease, acute 
episode, mild 
 
The person has a low 
fever and mild 
discomfort but no 
difficulty with daily 
activities. 
0.006 (0.002–0.012) 
 
Severe molluscum 
contagiosum 
 
Disfigurement, level 2 
 
The person has a visible 
physical deformity that 
causes others to stare 
and comment. As a 
result, the person is 
worried and has trouble 
sleeping and 
concentrating. 
0.067 (0.044–0.096) 
 
 
Modelling strategy 
For GBD 2016, DisMod-MR 2.1 was used to estimate prevalence, by age, sex, year, and geography 
(subnational [select countries], country, region, super-region) for viral warts and molluscum contagiosum. 
Separate models were run for each disease, as illustrated throughout this cause write-up. 
Viral warts. Viral warts were modelled with excess mortality set to 0 and remission set between 0.25 and 
2, implying a duration of 0.5 to 4 years. This was in line with the levels of prevalence and incidence data, 
as well as expert opinion. A number of additional settings were used to ensure that DisMod-MR 2.1 
sufficiently followed available data points. Incidence was restricted to a maximum of 0.1, and we made 
use of a relatively long time window of 25 years to determine which data points were used for a 
particular year of fit. We limited the prevalence random effects for Andean Latin America (-0.2, 0.2) in 
order to improve model fit. Study-level covariates were used to adjust US claims data for 2000, 2010, and 
2012 toward other data points.  
Molluscum contagiosum. As available data only contained information on prevalence and incidence, we 
specified additional expert priors to further inform analyses. Molluscum contagiosum was modelled with 
excess mortality set to 0 and remission set between 0.5 and 2, implying a duration of 0.5 to 2 years. This 
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was in line with the available epidemiological data, expert opinion, and previous GBD work. We used a 
time window of 25 years to determine which data points to include for a particular year of fit. Due to data 
heterogeneity, we restricted the location random effects to between -0.5 and 0.5 for the Netherlands and 
select GBD regions and super-regions (Southern Latin America, sub-Saharan Africa, high-income, South 
Asia, and Southeast Asia, East Asia, and Oceania). Study-level covariates were used to adjust data not 
based on examination, MEPS, outpatient, and US claims data for 2000 and 2010 toward other data 
points. 
 
 
Table 3. Study-level beta and exponentiated values  
 Covariate Parameter Beta Exp(beta) 
Viral warts Claims data - 2000 Prevalence -0.31 (-0.34 — -0.26) 0.73 (0.71 — 0.77) 
Claims data - 2010 Prevalence -0.19 (-0.22 — -0.14) 0.83 (0.80 — 0.87) 
Claims data - 2012 Prevalence -0.16 (-0.19 — -0.11) 0.85 (0.83 — 0.89) 
Molluscum 
contagiosum 
Claims data - 2000 Prevalence -1.78 (-1.96 - -1.52) 0.17 (0.14 - 0.22) 
Claims data - 2010 Prevalence -1.20 (-1.38 - -0.96) 0.30 (0.25 - 0.38) 
Claims data - 2012 Prevalence -1.06 (-1.23 - -0.82) 0.35 (0.29 - 0.44) 
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Case definition 
Acne vulgaris was included in the GBD 2016 cause group of skin and subcutaneous conditions. Acne 
vulgaris (or acne) is a chronic inflammatory disease of the pilosebaceous unit associated with an increase 
in sebum secretion. Included in the GBD 2016 modelling were cases meeting ICD-10 diagnostic criteria for 
acne vulgaris (ICD-10: l70**).  
 
Input data 
Model inputs 
In the GBD 2010 study, a systematic review of the literature was conducted using PubMed and Google 
Scholar to capture epidemiological data for acne vulgaris. The inclusion criteria stipulated that studies (1) 
must be published between 1980 and 2012; (2) must provide data on the incidence or prevalence of acne 
vulgaris; (3) must use samples representative of the general population (ie, samples derived from the 
experimental arm of clinical trials or based in dermatology clinics were excluded); (4) must use a sample 
size larger than 100; and (5) must provide sufficient information on study method and sample 
characteristics to assess the quality of the study. The agreed-upon approach for acne vulgaris was to 
undertake a literature review every two years. For GBD 2016, the GBD 2010 search strategy was 
replicated in PubMed to capture epidemiological studies published between 2013 and 2016. Additionally, 
US claims data from 2000, 2010, and 2012 were included.  
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Table 1. Input data 
 Prevalence 
Studies 59 
Countries 33 
Countries/subnationals 86 
GBD world regions 7 
 
Severity splits  
The table below illustrates the severity level, lay description, and disability weight for acne. In GBD 2016, 
we added two additional severity levels – disfigurement 2 and disfigurement 3. The disability weight of 
each severity of acne was applied across forty percent of the total prevalence cases to account for biases 
in outpatient utilization. The remaining sixty percent of prevalence cases were considered mild cases 
(disfigurement level 1). These proportions were generated using the ratio of patients seeking care 
captured from claims data, to all individuals from captured in literature surveying the general population.  
 
Table 2. Severity level and lay description 
Sequela Severity level Lay description DW (95% CI) 
Mild acne vulgaris Disfigurement, level 1 
 
The individual has a slight, visible 
physical deformity that others 
notice, which causes some worry 
and discomfort. 
0.011 (0.005–
0.021) 
 
Moderate acne 
vulgaris 
Disfigurement, level 2 The individual has a visible 
physical deformity that causes 
others to stare and comment. As a 
result, the person is worried and 
has trouble sleeping and 
concentrating. 
 
0.067 (0.044–
0.096) 
 
Severe acne vulgaris Disfigurement, level 3 
 
The individual has an obvious 
physical deformity that makes 
others uncomfortable, which 
causes the person to avoid social 
contact, feel worried, sleep poorly, 
and think about suicide. 
 
0.405 (0.275–
0.546) 
 
 
Modelling strategy 
DisMod-MR 2.1 was used to estimate prevalence by age, sex, year, and country for acne vulgaris. 
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Since our available data only contained information on prevalence, we specified additional expert priors 
to further inform analyses. We assumed zero excess mortality and remission from 0.38 to 0.6, implying a 
duration of approximately two to three years. This was in line with the available epidemiological data, 
expert opinion, and previous GBD work. A value prior of zero was set for incidence between the ages of 0 
and 6, and 61 and 100. We used a time window of five years to determine which data points were used 
for a particular year of fit. 
 
Study-level covariates were used to adjust prevalence from US claims data for 2000, 2010, and 2012 
toward the level of other prevalence data points, which were more representative of the general 
population. A study-level covariate was applied to data that were not based on physical examinations.  
 
Furthermore, since the data were extremely heterogeneous, the random effects were constrained to (-
0.3, 0.3) for regions such as East Asia. In addition, sociodemographic status and sugar consumption were 
used as country-level covariates to guide estimates for countries with few or no data.  
 
The table below indicates the study covariates, parameters, beta, and exponentiated beta values used in 
GBD 2016. 
 
 
Table 3. Beta and exponentiated values  
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level 
covariate 
Data was not 
based on physical 
examinations Prevalence 
0.23 (-0.24 - 
0.68) 1.26 (0.79 - 1.97) 
Study-level 
covariate Claims data – 2000  Prevalence 
-1.83 (-1.99 - -
1.62) 0.16 (0.14 - 0.20) 
Study-level 
covariate Claims data – 2010  Prevalence 
-1.69 (-1.85 - -
1.49) 0.18 (0.16 - 0.23) 
Study-level 
covariate Claims data – 2012  Prevalence 
-1.63 (-1.80 - -
1.43) 0.20 (0.17 - 0.24) 
Country covariate 
Socio-
demographic 
Index Prevalence 0.95 (0.84 - 1.00) 2.60 (2.32 - 2.72) 
Country covariate sugar adjusted(g) Prevalence 
0.00 (-0.00 - 
0.00) 1.00 (1.00 - 1.00) 
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 Alopecia Areata 
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Case definition 
Alopecia areata was included in the GBD 2016 cause group of skin and subcutaneous conditions. Alopecia 
areata is an autoimmune disease that results in hair loss on the scalp and other parts of the body. 
Included in the GBD disease modelling were cases meeting ICD-10 diagnostic criteria for alopecia (ICD-10: 
L63).  
Input data 
Model inputs 
In the GBD 2016 study, a systematic review of the literature was conducted using PubMed to expand the 
GBD dataset (1980–2014) with new epidemiological data for Alopecia areata between 2014 and 2016. 
The inclusion criteria stipulated that studies (1) must provide data on the incidence or prevalence of 
alopecia areata; (2) must use samples representative of the general population (ie, samples derived from 
the experimental arm of clinical trials or based in dermatology clinics were excluded); (3) must use a 
sample size larger than 100; and (4) must provide sufficient information on study method and sample 
characteristics to assess the quality of the study. The agreed-upon approach for alopecia areata was to 
undertake a literature review every two years. Additionally, US claims data from 2000, 2010, and 2012 
were included.  
Table 1. Model inputs 
 Prevalence Incidence  
Studies 18 1 
Countries 14 1 
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Countries/subnationals 64 1 
GBD world regions 6 1 
 
Severity splits & disability weights 
The table below illustrates the sequela, severity level, lay description, and disability weights associated 
with Alopecia areata. 
 
Table 2. Severity level and lay description 
Sequela Severity level Lay description DW (95% CI) 
Mild alopecia areata 
 
Disfigurement, level 1 
 
The individual has a slight, 
visible physical deformity 
that others notice, which 
causes some worry and 
discomfort. 
0.011 (0.005–0.021) 
 
Severe alopecia areata 
 
Disfigurement, level 2 
 
The individual has a visible 
physical deformity that 
causes others to stare and 
comment. As a result, the 
person is worried and has 
trouble sleeping and 
concentrating. 
0.067 (0.044–0.096) 
 
 
Modelling strategy 
DisMod-MR 2.1 was used to estimate prevalence by age, sex, year, and country for alopecia areata. We 
assumed zero excess mortality and remission priors implying a minimum duration of seven months. This 
was in line with the available epidemiological data, expert opinion, and previous GBD work. We used a 
time window of 20 years to determine which data points were used for a particular year of fit. 
Study-level covariates were used to adjust prevalence derived from US claims data for 2000 and 2010 
toward the level of other prevalence data, which were more representative of the general population. To 
improve estimation across all regions, the minimum global coefficient of variation was set at 0.1. In 
addition, significant sex differences were observed in the US claims data, resulting in a higher prevalence 
in females compared to males, likely due to more females seeking health consultations for alopecia 
areata compared to males. To minimize this effect, we set the sex covariate to zero, but this had minimal 
impact on the global estimates.  
Table 3. Beta and exponentiated values 
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level 
covariate Claims data - 2000 Prevalence -0.69 (-0.74 - -0.64) 0.50 (0.48 - 0.53) 
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Study-level 
covariate Claims data - 2010 Prevalence -0.07 (-0.11 - -0.02) 0.93 (0.89 - 0.98) 
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Case definition 
Pruritus was included in the GBD 2016 cause group of skin and subcutaneous conditions. Pruritus (or 
itching) can be a symptom of a condition or disease. Included in the GBD disease modelling were cases 
meeting ICD-10 diagnostic criteria for pruritus (ICD-10: L29).  
 
Input data 
Model inputs 
In the GBD 2010 study, a systematic review of the literature was conducted using PubMed and Google 
Scholar to capture epidemiological data for pruritus. The inclusion criteria stipulated that studies (1) must 
be published between 1980 and 2012; (2) must provide data on the incidence or prevalence of pruritus; 
(3) must use samples representative of the general population (ie, samples derived from the 
experimental arm of clinical trials or based in dermatology clinics were excluded); (4) must use a sample 
size larger than 100; and (5) must provide sufficient information on study method and sample 
characteristics to assess the quality of the study. The agreed-upon approach for pruritus was to 
undertake a literature review every two years. For GBD 2016, the GBD 2010 search strategy was 
replicated in PubMed to capture epidemiological studies published between 2013 and 2016. Additionally, 
US claims data from 2000, 2010, and 2012 were included. 
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 Table 1. Data inputs 
  Prevalence 
Pruritus Studies 5 
Countries 5 
Countries/subnationals 56 
GBD world regions 2 
 
Severity splits  
The table below illustrates the severity level, lay description, and disability weight for pruritus. 
 
Table 2. Severity level and lay description 
Sequela Severity level Lay description DW (95% CI) 
Pruritus Disfigurement, level 1 
 
The individual has a 
slight, visible physical 
deformity that others 
notice, which causes 
some worry and 
discomfort. 
0.011 (0.005–0.021) 
 
 
Modelling strategy 
DisMod-MR 2.1 was used to estimate prevalence by age, sex, year, and country for pruritus.  
Per expert advice, remission was set from 0.2 to 1, implying a duration of three months to one years. We 
used a time window of 25 years to determine which data points were used for a particular year of fit.  
Study-level covariates were used to adjust prevalence derived from self-reported literature, MEPS, and 
US claims data for 2000 and 2010 toward the level of US claims data 2012, which were more 
representative of the general population.  
The data were extremely heterogeneous. Therefore, the random effects were constrained to (-0.2, 0.2) 
and lagged distributed income was used as a country-level covariate to guide estimates for countries with 
few or no data.  
Table 3. Beta and exponentiated values  
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level 
covariate MEPS Prevalence -1.33 (-1.65 - -1.07) 0.26 (0.19 - 0.34) 
Study-level 
covariate Self-reported Prevalence 1.61 (0.95 - 1.99) 5.02 (2.59 - 7.32) 
Study-level 
covariate Claims data – 2000  Prevalence -0.74 (-0.78 - -0.71) 0.48 (0.46 - 0.49) 
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Study-level 
covariate Claims data – 2010  Prevalence -0.16 (-0.18 - -0.14) 0.85 (0.84 - 0.87) 
Country covariate LDI (I$ per capita) Prevalence 0.06 (-0.11 - 0.19) 1.06 (0.90 - 1.21) 
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Case definition 
Urticaria was included in the GBD 2016 cause group of skin and subcutaneous conditions. Urticaria (hives) 
refers to a skin reaction that causes itchy, raised bumps. Included in the GBD disease modelling were 
cases meeting ICD-10 diagnostic criteria for urticaria (ICD-10: L50).  
 
Input data 
Model inputs 
In the GBD 2010 study, a systematic review of the literature was conducted using PubMed and Google 
Scholar to capture epidemiological data for urticaria. The inclusion criteria stipulated that studies (1) must 
be published between 1980 and 2012; (2) must provide data on the incidence or prevalence of urticaria; 
(3) must use samples representative of the general population (ie, samples derived from the 
experimental arm of clinical trials or based in dermatology clinics were excluded); (4) must use a sample 
size larger than 100; and (5) must provide sufficient information on study method and sample 
characteristics to assess the quality of the study.  
The agreed-upon approach for urticaria was to undertake a literature review every two years. For GBD 
2016, the GBD 2010 search strategy was replicated to capture epidemiological studies published between 
the previous 2013 and 2016. Additionally, US claims data from 2000, 2010, and 2012 were included in the 
data used for GBD 2016.  
The table below illustrates the data inputs used in GBD 2016 by number of studies, geographic location, 
and prevalence/incidence. 
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Table 1. Data inputs 
Prevalence 
Studies 22 
Countries 21 
Countries/subnationals 72 
GBD world regions 6 
Severity splits & disability weights 
The table below illustrates the severity level, lay description, and disability weight for urticaria. 
Table 2. Severity level and lay descriptions 
Sequela Severity level Lay description DW (95% CI) 
Mild urticaria Disfigurement, level 1 
with itch/pain 
The person has a slight, 
visible physical deformity 
that is sometimes sore 
or itchy. Others notice 
the deformity, which 
causes some worry and 
discomfort. 
0.027 (0.015–0.042) 
Severe urticaria Disfigurement, level 2, 
with itch/pain 
The person has a visible 
physical deformity that is 
sore and itchy. Other 
people stare and 
comment, which causes 
the person to worry. The 
person has trouble 
sleeping and 
concentrating. 
0.188 (0.124–0.267) 
Modelling strategy 
DisMod-MR 2.1 was used to estimate prevalence by age, sex, year, and country for urticaria. 
The available data were mainly composed of prevalence estimates with a few incidence data points. For 
GBD 2016, we made both prevalence and incidence estimates. We used a time window set to 25 years. 
We set excess mortality to zero and remission between 0.5 to 2, implying a duration between ½ and 2 
years. In addition, location random effects were constrained to (-0.3, 0.3). US claims data from year 2000 
and 2010 were adjusted towards the most complete US 2012 set. Specific data points were outliered if 
they were overestimates or underestimates in comparison to country, regional and global patterns.   
The table below illustrates the covariate used in the modelling process, as well as associated parameters, 
beta, and exponentiated beta (confidence interval) values for GBD 2016. 
617
Covariate type Covariate Parameter beta 
Exponentiated 
beta 
Study-level 
covariate Claims data - 2000 Prevalence -0.23 (-0.25 - -0.22) 0.79 (0.78 - 0.80) 
Study-level 
covariate Claims data - 2010 Prevalence -0.06 (-0.08 - -0.05) 0.94 (0.92 - 0.95) 
Table 3. Study covariate 
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 Decubitus Ulcer 
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Case definition 
Decubitus ulcer was included in the GBD 2016 cause group of skin and subcutaneous conditions. 
Decubitus ulcer, also known as pressure ulcer/sore, is an injury to the skin and underlying tissue resulting 
from an obstruction of blood flow due to pressure on the skin. Included in the GBD modelling were cases 
meeting ICD-10 criteria for decubitus ulcer (ICD-10: L89) (1).  
Input data 
Model inputs 
In the GBD 2010 study, a systematic review of the literature was conducted using PubMed and Google 
Scholar to capture epidemiological data for decubitus ulcer. The inclusion criteria stipulated that studies 
(1) must be published between 1980 and 2012; (2) must provide data on the incidence or prevalence of 
decubitus ulcer; (3) must use samples representative of the general population (ie, samples derived from 
the experimental arm of clinical trials or based in dermatology clinics were excluded); (4) must use a 
sample size larger than 100; and (5) must provide sufficient information on study method and sample 
characteristics to assess the quality of the study. The data from literature were sparse but contained both 
prevalence and incidence estimates. For GBD 2013, the GBD 2010 search strategy was replicated to 
capture epidemiological studies published between 2012 and 2014. The available data were from high-
income countries. Hospital inpatient and US claims data from 2000, 2010, and 2012 were also used for 
GBD 2016. The final dataset also included cause-specific mortality rates for decubitus ulcer estimated by 
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CODEm. Data were outliered or excluded if we found them unreasonable when compared to regional, 
super-regional, and global rates. 
 
 
Table 1. Data inputs (not including hospital inpatient data) 
 Prevalence Incidence 
Studies 0 2 
Countries/subnationals 0 308 
Countries 0 34 
GBD world regions 0 15 
GBD super-regions 0 6 
 
 
Severity splits  
For GBD 2016, decubitus ulcer was assigned the disability weight, disfigurement with itch/pain, levels 1, 
2, and 3. The disability weights used for GBD 2015 were based on disfigurement only.  
 
Table 2. Severity level and lay descriptions 
Sequela Severity level Lay description DW (95% CI) 
Mild decubitus ulcer 
 
Disfigurement, level 1 with 
itch/pain 
 
The person has a slight, 
visible physical deformity 
that is sometimes sore or 
itchy. Others notice the 
deformity, which causes 
some worry and 
discomfort. 
0.027 (0.015–0.042) 
 
Moderate decubitus ulcer 
 
Disfigurement, level 2, 
with itch/pain 
 
The person has a visible 
physical deformity that is 
sore and itchy. Other 
people stare and comment, 
which causes the person to 
worry. The person has 
trouble sleeping and 
concentrating. 
0.188 (0.124–0.267) 
 
Severe decubitus ulcer 
 
Disfigurement, level 3, 
with itch/pain 
 
The person has an obvious 
physical deformity that is 
very painful and itchy. The 
physical deformity makes 
others uncomfortable, 
which causes the person to 
avoid social contact, feel 
worried, sleep poorly, and 
think about suicide. 
0.576 (0.401–0.731) 
 
620
 Modelling strategy 
DisMod-MR 2.1 was used to estimate prevalence by age, sex, year, and geography (subnational [select 
countries], country, region, super-region) for decubitus ulcer. Per expert advice, remission was set from 3 
to 4, implying a duration of three to four months. This was based on the assumption that remission does 
not change with treatment. These values were also in line with the available epidemiological data, expert 
opinion, and previous GBD work. The decubitus ulcer dataset was sufficiently large to make use of a 
relatively short time window of five years to determine which data points were used for a particular year 
of fit.  
Study-level covariates were used to adjust incidence derived from hospital inpatient data, MEPS, and US 
claims data for 2000 and 2010 toward the level of other incidence data points, which were more 
representative of the general population. We excluded estimates less than 10E-6. Log-transformed lagged 
distributed income (LDI) was used as a location-level covariate on excess mortality to guide estimates for 
countries with few or no data.  
 
Table 3. Beta and exponentiated values  
Study covariate  Parameter Beta Exp(beta) 
Hospital Inpatient Incidence -0.00 (-0.00 - -0.00) 1.00 (1.00 - 1.00) 
MEPS Incidence -0.08 (-1.12 - 0.85) 0.93 (0.33 - 2.35) 
Claims data - 2000 Incidence -0.52 (-0.56 - -0.47) 0.60 (0.57 - 0.62) 
Claims data - 2010 Incidence -0.30 (-0.34 - -0.26) 0.74 (0.71 - 0.77) 
 
Table 4. Location-level beta and exponentiated values 
Country-level covariate  Parameter Beta Exp(beta) 
LDI (log-transformed) Excess mortality rate -0.50 (-0.50 — -0.49) 0.61 (0.61 — 0.61) 
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 Other skin and subcutaneous diseases 
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Case definition 
The other skin and subcutaneous diseases category encompassed a large group of skin conditions not 
captured in the other skin categories. We included cases meeting the following ICD-10 diagnostic criteria: 
other viral infections characterized by skin and mucous membrane lesions, not elsewhere classified (B08), 
unspecified viral infection characterized by skin and mucous membrane lesions (B09), pediculosis and 
phthiriasis (B85), myiasis (B87), other infestations (B88), sarcoidosis of skin (D86.3), porphyria cutanea 
tarda (E80.1), other and unspecified porphyria (E80.2), pemphigus (L10), other acantholytic disorders 
(L11), pemphigoid (L12), other bullous disorders (L13), bullous disorders in diseases classified elsewhere 
(L14), lichen simplex chronicus and prurigo (L28), pityriasis rosea (L42), lichen planus (L43), other 
papulosquamous disorders (L44), papulosquamous disorders in diseases classified elsewhere (L45), 
exfoliation due to erythematous conditions according to extent of body surface involved (L49), erythema 
multiforme (L51), erythema nodosum (L52), other erythematous conditions (L53), erythema in diseases 
classified elsewhere (L54), other acute skin changes due to ultraviolet radiation (L56), skin changes due to 
chronic exposure to nonionizing radiation (L57), other disorders of skin and subcutaneous tissue related 
to radiation (L59), nail disorders (L60), nail disorders in diseases classified elsewhere (L62), androgenic 
alopecia (L64), other nonscarring hair loss (L65), cicatricial alopecia [scarring hair loss] (L66), hair color 
and hair shaft abnormalities (L67), hypertrichosis (L68), rosacea (L71), follicular cysts of skin and 
subcutaneous tissue (L72), other follicular disorders (L73), eccrine sweat disorders (L74), apocrine sweat 
disorders (L75), vitiligo (L80), other disorders of pigmentation (L81), seborrheic keratosis (L82), acanthosis 
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nigricans (L83), corns and callosities (L84), other epidermal thickening (L85), keratoderma in diseases 
classified elsewhere (L86), transepidermal elimination disorders (L87), atrophic disorders of skin (L90), 
hypertrophic disorders of skin (L91), granulomatous disorders of skin and subcutaneous tissue (L92), 
other localized connective tissue disorders (L94), vasculitis limited to skin, not elsewhere classified (L95), 
and other disorders of skin and subcutaneous tissue in diseases classified elsewhere (L99). 
Input data 
Model inputs 
In the GBD 2010 study, a systematic review of the literature was conducted using PubMed and Google 
Scholar to capture epidemiological data for skin diseases not captured in the other skin categories. The 
inclusion criteria stipulated that studies (1) must be published between 1980 and 2012; (2) must provide 
data on the incidence or prevalence; (3) must use samples representative of the general population (ie, 
samples derived from the experimental arm of clinical trials or based in dermatology clinics were 
excluded); (4) must use a sample size larger than 100; and (5) must provide sufficient information on 
study method and sample characteristics to assess the quality of the study. For GBD 2013, the GBD 2010 
search strategy was replicated to capture epidemiological studies published between 2012 and 2014. 
Hospital outpatient data and data from US claims for 2000, 2010, and 2012 by US state were included in 
GBD 2016. Data were outliered or excluded if we found them unreasonable when compared to regional, 
super-regional, and global rates. 
Table 1. Data inputs (not including hospital inpatient data) 
Prevalence 
Studies 1 
Countries/subnationals 52 
Countries 1 
GBD world regions 1 
GBD super-regions 1 
Severity split & disability weight 
Skin and other subcutaneous diseases were assigned the disability weight for disfigurement level 1. 
Table 2. Severity level and lay description 
Sequela Severity level Lay description DW (95% CI) 
Symptomatic other skin 
and subcutaneous 
diseases 
Disfigurement, level 1 The person has a slight, 
visible physical 
deformity that others 
notice, which causes 
some worry and 
discomfort. 
0.011 (0.005–0.021) 
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DisMod-MR 2.1, a Bayesian meta-regression tool, was used to estimate prevalence by age, sex, year, and 
geography (subnational [select countries], country, region, super-region) for skin and other subcutaneous 
diseases.  
We assumed remission of one, implying a duration of 12 months. Similar to GBD 2015, we used a time 
window of 25 years to determine which data points were used for a particular year of fit. 
Study-level covariates, which were used to adjust prevalence, were derived from the Medical Expenditure 
Panel Survey (MEPS) and US claims data for 2000 and 2010 toward the level of other prevalence data, 
which were more representative of the general population. In addition, log-transformed lagged 
distributed income was used as a location-level covariate to guide estimates for countries with few or no 
data.   
Table 3. Study-level beta and exponentiated values 
Covariate Parameter Beta Exp(beta) 
Claims data – 2000 Prevalence -0.28 (-0.29 — -0.27) 0.76 (0.75 — 0.77) 
Claims data – 2000 Prevalence -0.06 (-0.07 — -0.05) 0.94 (0.93 — 0.95) 
MEPS Prevalence -0.64 (-0.73 — -0.54) 0.53 (0.48 — 0.58) 
Table 4. Location-level beta and exponentiated values 
Covariate Parameter Beta Exp(beta) 
LDI (log-transformed) Prevalence 0.28 (0.27 — 0.30) 1.33 (1.31 — 1.35) 
Modelling strategy 
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 Other sense organ diseases 
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Case definition 
Other sense organ disease is a residual cause capturing both acute and chronic conditions that do not 
map to other causes, but lead to non-trivial morbidity. These include the following ICD codes: 077, 360, 
364, 370-77, 379, 380, 386, and 388, which encompass a plethora of eye and ear disorders and 
conditions. 
077 Other diseases of conjunctiva due to viruses and chlamydiae 
360 Disorders of the globe 
364 Disorders of iris and ciliary body 
370-77 Keratits, Corneal opacity and other disorders of cornea, Disorders of 
conjunctiva, Inflammation of eyelids,  Other disorders of eyelids, Disorders 
of lacrimal system, Disorders of the orbit, Disorders of optic nerve and 
visual pathways 
379 Other disorders of eye 
380 Disorders of external ear 
386 Vertiginous syndromes and other disorders of vestibular system 
388 Other disorders of ear 
 
Input data 
 Model inputs 
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For GBD 2016, we used claims data from US claims data to model other sense organ diseases, since these 
conditions would not appear in inpatient hospital data. ICD-9 codes were assigned at the five-digit level to 
either acute or chronic conditions as listed elsewhere in the Appendix table 4.  
 Severity splits & disability weights 
The basis of the GBD disability weight survey assessments are lay descriptions of sequelae highlighting 
major functional consequences and symptoms. Severity splits for other sense organ diseases were 
calculated via the Medical Expenditure Panel Survey (MEPS) regression and outlined in the table below. 
Chronic:  
Severity Proportion  Health state Disability weight 
Severe 0.21 (0.15–0.28) Vertigo  
Moderate 0.37 (0.30–0.42) This person has slight 
physical deformity which 
causes some worry and 
discomfort 
0.011 (0.005–0.021) 
Asymptomatic 0.42 (0.41–0.44) Asymptomatic N/A 
 
Acute 
Severity Proportion  Health state Disability weight 
Mild 0.30 (0.23–0.37) This person has low fever 
and mild discomfort but 
no difficulty with daily 
activities  
0.006 
(0.002–0.012) 
Moderate 0.25 (0.18–0.32) This person has slight 
physical deformity which 
causes some worry and 
discomfort 
0.011 (0.005–0.021) 
Asymptomatic 0.45 (0.43–0.46) Asymptomatic N/A 
 
Modelling strategy  
For GBD 2016, hospital data were extracted separately for the chronic and acute conditions included in 
other sense organ diseases. The chronic data were extracted as prevalence, and acute as incidence. We 
then ran two separate DisMod-MR 2.1 models. The chronic model, with prevalence data, was run as a 
prevalence-only model. The acute model was run as a full model with incidence data, assuming zero 
excess mortality and duration of one week (remission 52). In both models, to correct for systematically 
lower data from 2000 MarketScan claims, we used a study-level covariate to crosswalk the 2000 data. 
Since the only data source is from the United States, we did not use any country-level covariates in this 
model.  
 
We then aggregated chronic and acute prevalence outputs, resulting in the prevalence of other sense 
organ diseases by country, age, year, and sex.  
 
Results from GBD 2016 are higher for other sense organ diseases because in GBD 2013 we used MEPS 
self-reported claims data, whereas in GBD 2015 and GBD 2016 MarketScan more accurately captures the 
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occurrence of these conditions. In GBD 2016 we were able to separately model acute and chronic 
conditions. 
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 Caries of Deciduous Teeth 
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Case definition 
The case definition for dental caries is “teeth with unmistakable coronal cavity at dentin level, root cavity 
in cementum that feels soft or leathery to probing, temporary or permanent restorations, or missing 
teeth extracted due to a caries lesion.” This definition corresponds to an ICD-9 code of 521.0 and an ICD-
10 code of K02.3 – K02.9. Most caries are subclinical in the sense that they do not cause symptoms a 
majority of the time. Once a carious lesion develops, it will occasionally recede without intervention. 
Generally, however, it worsens with time and eventually requires either filling or extraction. The major 
sequela associated with the condition is symptomatic caries, which is defined as “a toothache which 
causes some difficulty eating.” 
Deciduous teeth are colloquially known by several names throughout the world, including “baby,” “milk,” 
or “fall” teeth. They start erupting in infants around 6 months of age and generally finish by the end of 
year three. Exfoliation of deciduous teeth begins around age 5-6 and usually is complete by age 12-14, 
when only permanent teeth remain. The name of this cause for GBD 2016 has been changes from 
‘deciduous caries’ to ‘caries of deciduous teeth’. 
Dental caries and the DMFT index 
Public health dentists commonly measure dental caries using the dmft/DMFT index, which is an 
incremental measure of the proportion of unhealthy teeth and is also a measure of an individual’s 
lifetime prevalence of caries. Lowercase letters (dmft) are used for deciduous dentition and uppercase 
letters (DMFT) for permanent dentition. D is for decayed, M for missing, F for filled, and T for teeth. The 
maximum dmft score is 20 and the maximum DMFT score is 32. Furthermore, some dentists prefer to 
measure dental caries in terms of tooth surfaces, rather than number of teeth, and report their results 
using an analogous dmfs/DMFS index. The maximum dmfs score is 88, and the maximum DMFS score is 
128 or 148 depending on whether the third molars are counted.  
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The DMFT index is easy to measure and inter-rater reliability is high. However, the primary shortcoming 
of the DMFT is that it does not discriminate well between current and past caries. Strategies we 
employed to maximally utilize dmf/DMF data for estimating the prevalence of burden due to caries of 
deciduous teeth are described below. 
 
Input data 
 Model inputs 
Literature reviews 
A literature review was conducted by the expert group for GBD 2010, and an additional systematic review 
was performed for GBD 2013. The search terms used in the GBD 2013 literature review for deciduous 
caries were (Deciduous caries[Title/Abstract]) OR (milk caries[Title/Abstract]) OR (baby 
caries[Title/Abstract]) OR (caries[Title/Abstract]) OR (dental health[Title/Abstract]) OR (oral 
health[Title/Abstract]) AND (prevalence[Title/Abstract]) AND ( “2010”[Date - Publication] : 
“2013”[Date - Publication]). Updates to systematic reviews are performed on an ongoing 
schedule across all GBD causes; an update for deciduous and permanent caries will be 
performed in the next one to two iterations. 
We eliminated many data points to avoid repetition in the dataset, while striving to maintain as much 
data detail as possible. Redundancy tended to arise in three data descriptors: age, gender, and urbanicity. 
Our order of preference for maintaining detail was age, followed by gender, then urbanicity. Additionally, 
many of the studies presented dmft or DMFT scores, which represent lifetime prevalence and were often 
described as “caries experience.” For the purposes of measuring the burden of disability from dental 
caries, we considered only data on current prevalence to be relevant, and thus converted lifetime 
prevalence data to current prevalence and incidence where possible (see below).  
 
Conversion of dmf/DMF scores to prevalence and incidence 
 
Caries of deciduous teeth 
Many of the studies that reported lifetime prevalence of deciduous caries (dmf scores) provided detail on 
the component breakdown of these scores. We used these data to calculate a d/dmf ratio and convert 
the lifetime prevalence value into one that reflected current prevalence. For example, if the lifetime 
prevalence was reported as 0.8 with d = 1.5 and dmft = 2 (d/dmf ratio = 0.75), we adjusted the 
prevalence value to 0.6. When possible, we used within-study d/dmf ratios to convert lifetime prevalence 
to current prevalence. Otherwise, we converted to current prevalence using a weighted average d/dmf 
ratio at the country, region, super-region, or global level, in that order of preference.  
 
For studies reporting dmf scores for successive age intervals, the increment in the dmf values between 
examinations was considered to be equivalent to the caries incidence over the study duration. We 
extrapolated incidence data from two types of studies. First, for longitudinal or cohort studies, we 
calculated the caries increment over successive ages and time periods as the difference between the 
DMF scores at each time point. Narrow age and time intervals were preferred; most were of three years 
or less. We did not extrapolate incidence data if the age or time interval was greater than 10 years. 
Secondly, if a study only performed a single cross-sectional examination, but reported data in age 
intervals of three years or less, we extrapolated incidence data in the same manner. Narrow age ranges 
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were considered necessary for this incidence extrapolation because the dental health of population 
cohorts has been observed to change in just a few years when preventive measures are instituted.  
 
Data availability for deciduous caries: 
 
 Prevalence Continuous DMF score 
converted to 
prevalence 
Continuous DMF score 
converted to incidence 
Studies 188 119 64 
Countries/subnationals 72/51 57/21 34/167 
GBD world regions 19 19 16 
 
 
Modeling strategy  
Separate estimates for caries of deciduous and permanent teeth 
The natural histories of caries of deciduous teeth and caries of permanent teeth share many similarities, 
but they also share some important differences. Age patterns of decay in permanent and deciduous 
dentition are distinct, and duration of a carious lesion in deciduous teeth also tends to be shorter than an 
untreated episode of permanent caries. Sugar consumption and feeding with formula are both associated 
with development of deciduous carries, but not with permanent caries. Finally, it is unclear whether the 
gender patterns and regional differences are the same for both deciduous and permanent caries. For all 
of these reasons, we elected to model deciduous caries and permanent caries as separate entities and 
then add the estimates together for an overall estimation of the global burden of dental caries. This 
modeling approach was also taken in GBD 2010 and GBD 2013.  
DisMod model development: caries of deciduous teeth 
Serious health consequences of deciduous caries were assumed to be uncommon and death from 
permanent caries very rare. For purposes of modeling, we therefore assigned excess mortality to be zero 
from age 0 to 100. We fixed incidence and prevalence at zero after age 12 when exfoliation is presumed 
to be complete. This age was chosen because 11 was the oldest age of a non-zero prevalence data point. 
We additionally assigned incidence and prevalence to be zero before age 6 months to indicate that this 
condition never begins at birth and is absent in the neonatal and post-neonatal periods. Incidence bounds 
of 0 to 4.0 for ages 1 to 10 years were chosen based on examining the dataset and adding a comfortable 
margin to the highest reported value. An upper remission bound of 1.0 for ages 0 to 5 years was chosen 
in order to fit the sharp increase in prevalence over this age range. As prevalence was assigned to be zero 
after age 14 anyway, we elected to not include a lower remission bounds.  
No country-level covariates were included. We used a study-level covariate to indicate whether a given 
prevalence data point was of “true” current prevalence or calculated from lifetime prevalence using the 
d/dmf ratio. For both incidence and prevalence, we also used study-level covariates to indicate whether 
the dmf scores were for surfaces as opposed to teeth.  
Because no “true” unconverted incidence values were present in the dataset, we could not crosswalk the 
extrapolated incidence values to reference incidence values for deciduous caries. Instead, we used higher 
heterogeneity settings for incidence values than for prevalence (0.7 for incidence, 0.2 for prevalence). We 
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calculated age mesh points at ages 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 100 years. High 
smoothness settings were used for both incidence and prevalence to allow for dynamic age trends.  
Covariate name Type Measure Beta value Exponentiated value 
LDI (I$ per capita) 
Country 
covariate Prevalence -0.101 (-0.142 - -0.067) 0.904 (0.868 - 0.935) 
sugar unadjusted(g) 
Country 
covariate Incidence 0.002 (-0.001 - 0.004) 1.002 (0.999 - 1.004) 
DMF score is for 
surfaces 
Study-level x-
covariate Prevalence 0.266 (0.193 - 0.340) 1.305 (1.213 - 1.405) 
DMF score is for 
surfaces 
Study-level x-
covariate Incidence 1.970 (0.000 - 3.896) 7.173 (1.000 - 49.182) 
d/dmf ratio used to 
convert lifetime 
prevalence 
Study-level x-
covariate Prevalence 0.246 (0.193 - 0.302) 1.279 (1.213 - 1.353) 
 
Models were vetted based on the biological plausibility of the results, the extent to which estimates fit 
the data, and the plausibility of the range of estimates across location hierarchies.  
Correction for edentulism 
One systematic source of bias in the literature was the exclusion of edentate individuals form the study 
populations, which leads to systematic overestimation of caries prevalence when modeled over the entire 
population. To account for this bias, we used our GBD estimates of edentulism and severe tooth 
prevalence to adjust YLD estimates for dental caries. Using the final DisMod estimates for prevalence of 
edentulousness, we calculated the mean prevalence for each age and sex and averaged the 1990 and 
2015 values. We then calculated a population-weighted mean prevalence for each region and each GBD 
super-region. The resulting super-regional averages were used to adjust the DisMod estimates for 
prevalence of permanent caries in calculating years lost due to disability (YLDs). 
Disability weights 
As described above, the GBD definition of disability associated with symptomatic dental caries is “this 
person has a toothache, which causes some difficulty eating.” The disability weight associated with this 
condition is 0.01 (0.005 – 0.019), as derived from the GBD Disability Weights Study.  
Not all those with dental caries experience this disability all the time. We considered only those with 
active dentinal decay to experience symptomatic tooth pain. Those with deciduous caries who had 
undergone exfoliation or had their cavities filled were considered to have no disability. Likewise, those 
with permanent caries who had received fillings, had their cavities extracted, or lost a carious tooth 
altogether were considered to have no disability. Thus, two additional pieces of information are required 
to complete the calculation of years of life lived with disability (YLDs): proportion with symptoms and 
duration of disability. 
To determine duration, we adapted the method employed by the Australian Burden of Disease (AusBoD) 
Study in 1996. For total duration, we used the posterior estimates of duration from final DisMod models. 
For those with symptoms, we split this total duration into two distinct phases of caries disability. The 
“initial” phase is characterized by periodic pain that we assigned to occur an average of one hour per day. 
The “terminal” phase is a period of constant symptoms at the end of an episode. The length of the 
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terminal phase was determined by literature review as described by the AusBoD group. For deciduous 
caries we used a study by Mason, et al. of children in the UK presenting to a casualty ward with tooth pain 
[1]. The length of time each child had been experiencing tooth pain was recorded. Based on the 
distribution of time courses, a log-normal distribution was plotted that approximated the average 
duration of constant symptoms at 27.6 days leading up to seeking care. For permanent caries, a similar 
study of the tooth pain experience of adults in New Zealand who presented to hospital dental 
departments and an emergency clinic resulted in an estimated 55.2 days spent in the terminal phase of 
caries. For those with severe disease, the length of time spent in the terminal phase was subtracted from 
the total duration to determine the amount of time spent in the initial phase. For those with mild disease, 
we considered the entire duration to be spent in the initial phase. 
To determine proportion with symptoms, we completed a supplemental literature review of tooth pain 
and caries. We identified a total of 21 studies with data about the prevalence of pain. The studies were 
grouped according to the type of dentition studied (deciduous or permanent) and the location of the 
study group (high-income or low- and middle-income countries). We extracted data on the proportion in 
each group that described symptoms of pain related to their caries as well as a subset who described 
their symptoms as being severe. The proportions in each group were weighted according to sample size 
to give estimates of the relative sizes of three groups: asymptomatic, mild, and severe.  
We considered asymptomatic individuals to experience no disability. Those with mild disease spent the 
entire duration in the initial phase of disease (one hour of pain per day). Those with severe disease spent 
a majority of the duration in the initial phase followed by a period of time in the terminal phase (constant 
pain). YLDs were calculated by multiplying the prevalence, duration, proportion, and disability weight for 
each age, country, sex, and year.  
No other significant changes were made to the modeling strategy from GBD 2015 to GBD 2016. 
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Case definition 
The case definition for dental caries is “teeth with unmistakable coronal cavity at dentin level, root cavity 
in cementum that feel soft or leathery to probing, temporary or permanent restorations, or missing teeth 
extracted due to a caries lesion.” This definition corresponds to an ICD-9 code of 521.0 and an ICD-10 
code of K02.3 – K02.9. Most caries are subclinical in the sense that they do not cause symptoms a 
majority of the time. Once a carious lesion develops, it will occasionally recede without intervention. 
Generally, however, it worsens with time and eventually requires either filling or extraction. The major 
sequela associated with the condition is symptomatic caries, which is defined as “a toothache, which 
causes some difficulty eating.” 
Dental caries and the DMFT index 
Public health dentists commonly measure dental caries using the dmft/DMFT index, which is an 
incremental measure of the proportion of unhealthy teeth and is also a measure of an individual’s 
lifetime prevalence of caries. Lowercase letters (dmft) are used for deciduous dentition and uppercase 
letters (DMFT) for permanent dentition. D is for decayed, M for missing, F for filled, and T for teeth. The 
maximum dmft score is 20 and the maximum DMFT score is 32. Furthermore, some dentists prefer to 
measure dental caries in terms of tooth surfaces, rather than number of teeth, and report their results 
using an analogous dmfs/DMFS index. The maximum dmfs score is 88, and the maximum DMFS score is 
128 or 148 depending on whether the third molars are counted.  
The DMFT index is easy to measure and inter-rater reliability is high. However, the primary shortcoming 
of the DMFT is that it does not discriminate well between current and past caries. Strategies we 
employed to maximally utilize dmf/DMF data for estimating the prevalence of burden due to permanent 
caries are described below. 
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Input data 
Literature reviews 
A literature review was conducted by the expert group for GBD 2010, and an additional systematic review 
was performed for GBD 2013. The search terms used in the GBD 2013 literature review for permanent 
caries were (Permanent caries[Title/Abstract]) OR (caries prevalence[Title/Abstract]) OR (dental 
health[Title/Abstract]) OR (oral health[Title/Abstract]) AND (prevalence[Title/Abstract]) AND ( 
“2010”[Date - Publication] : “2013”[Date - Publication]). Updates to systematic reviews are 
performed on an ongoing schedule across all GBD causes, an update for deciduous and 
permanent caries will be performed in the next one to two iterations. 
We eliminated many data points to avoid repetition in the dataset, while striving to maintain as much 
data detail as possible. Redundancy tended to arise in three data descriptors: age, gender, and urbanicity. 
Our order of preference for maintaining detail was age, followed by gender, then urbanicity. Additionally, 
many of the studies presented dmft or DMFT scores, which represent lifetime prevalence and were often 
described as “caries experience.” For the purposes of measuring the burden of disability from dental 
caries, we considered only data on current prevalence to be relevant, and thus converted lifetime 
prevalence data to current prevalence and incidence where possible (see below).  
 
Conversion of dmf/DMF scores to prevalence and incidence 
 
Caries of Permanent Teeth 
Whereas in the deciduous dentition, a vast majority of the dmf index is accounted for by caries, tooth loss 
is a major contributor to the DMF index for the permanent dentition. Caries of permanent teeth may not 
necessarily be the primary driver of this tooth loss, as other factors such as periodontal disease and 
trauma may contribute significantly. Thus, we performed the conversions of DMF scores to prevalence 
and incidence values as described above for permanent caries only in individuals ages 20 years or less.  
 
 
Data availability for caries of permanent teeth: 
  
 Prevalence Incidence  Continuous DMF score 
converted to 
prevalence 
Continuous DMF score 
converted to incidence 
Studies 160 4 89 31 
Countries/subnationals 158/68 4/2 46/19 24/11 
GBD world regions 19 3 19 14 
 
Modeling strategy  
Separate estimates of caries of deciduous teeth and caries of permanent teeth 
The natural history of deciduous and permanent caries share many similarities, but they also share some 
important differences. Age patterns of decay in permanent and deciduous dentition are distinct, and 
duration of a carious lesion in deciduous teeth also tends to be shorter than an untreated episode of 
permanent caries. Sugar consumption and feeding with formula are both associated with development of 
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deciduous carries, but not with permanent caries. Finally, it is unclear whether the gender patterns and 
regional differences are the same for both deciduous and permanent caries. For all of these reasons, we 
elected to model deciduous caries and permanent caries as separate entities and then add the estimates 
together for an overall estimation of the global burden of dental caries. This is the modeling approach 
which was also taken in GBD 2010 and GBD 2013.  
DisMod model development: caries of permanent teeth 
Serious health consequences of permanent caries were also assumed to be uncommon and death from 
permanent caries very rare. We therefore assigned excess mortality to be zero from age 0 to 100. The 
dataset suggested that permanent caries are sometimes incident in 5-year-olds, so we fixed incidence 
and prevalence at 0 for ages 0 to 4. Incidence bounds were again chosen based on examining the dataset 
and adding a margin to the highest reported value. In this case, incidence bounds were 0 – 2. Lower 
bounds for remission were set at 0.2 and upper bounds were set at 3. 
As with permanent caries, no country-level covariates were included. We used a study-level covariate to 
indicate whether a given prevalence data point was of “true” current prevalence or calculated from 
lifetime prevalence using the D/DMF ratio, and another study-level covariate to indicate whether a given 
incidence values was extrapolated from DMF scores. For both incidence and prevalence, we also used 
study-level covariates to indicate whether the DMF scores were for surfaces as opposed to teeth.  
We calculated age mesh points at ages 0, 4, 5, 8, 10, 12, 15, 19, 20, 25, 29, 30, 35, 40, 45, 50, 55, 60, 70, 
80, 90, and 100 years. Heterogeneity was set to 0.5 for both incidence and prevalence. High smoothness 
settings were used for both incidence and prevalence to allow for dynamic age trends.  
Covariate name Type Measure Beta value Exponentiated value 
LDI (I$ per capita) 
Country 
covariate Prevalence -0.345 (-0.433 - -0.259) 0.708 (0.648 - 0.772) 
sugar unadjusted(g) 
Country 
covariate Incidence -0.003 (-0.004 - -0.001) 0.997 (0.996 - 0.999) 
DMF score is for 
surfaces 
Study-level x-
covariate Incidence 1.000 (0.000 - 2.000) 2.717 (1.000 - 7.389) 
DMF score is for 
surfaces 
Study-level x-
covariate Prevalence 0.324 (0.185 - 0.453) 1.383 (1.203 - 1.573) 
DMF score used to 
calculate incidence 
Study-level x-
covariate  0.266 (0.160 - 0.299) 1.304 (1.174 - 1.348) 
d/dmf ratio used to 
convert lifetime 
prevalence 
Study-level x-
covariate Prevalence -0.204 (-0.285 - -0.120) 0.815 (0.752 - 0.887) 
 
Although studies were screened carefully during data extraction to ensure that they specified whether 
they were measuring permanent or deciduous caries, some data points were marked as outliers during 
modeling due to their high prevalence values in young ages, as it was deemed likely that some of these 
studies were reporting deciduous in addition to permanent caries.  
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As with deciduous caries, models for permanent caries were vetted based on the biological plausibility of 
the results, the extent to which estimates fit the data, and the plausibility of the range of estimates across 
location hierarchies.  
 
Correction for edentulism 
One systematic source of bias in the literature was the exclusion of edentate individuals from the study 
populations, which leads to systematic overestimation of caries prevalence when modeled over the entire 
population. To account for this bias, we used our GBD estimates of edentulism and severe tooth 
prevalence to adjust YLD estimates for dental caries. Using the final DisMod estimates for prevalence of 
edentulousness, we calculated the mean prevalence for each age and sex and averaged the 1990 and 
2015 values. We then calculated a population-weighted mean prevalence for each region and each GBD 
super-region. The resulting super-regional averages were used to adjust the DisMod estimates for 
prevalence of permanent caries in calculating years lost due to disability (YLDs). 
 
Disability weights 
As described above, the GBD definition of disability associated with symptomatic dental caries is “this 
person has a toothache, which causes some difficulty eating.” The disability weight associated with this 
condition is 0.01 (0.005 – 0.019), as derived from the GBD Disability Weights study.  
Not all those with dental caries experience this disability all the time. We considered only those with 
active dentinal decay to experience symptomatic tooth pain. Those with deciduous caries who had 
undergone exfoliation or had their cavities filled were considered to have no disability. Likewise, those 
with permanent caries who had received fillings, had their cavities extracted, or lost a carious tooth 
altogether were considered to have no disability. Thus, two additional pieces of information are required 
to complete the calculation of years of life lived with disability (YLDs): proportion with symptoms and 
duration of disability. 
To determine duration, we adapted the method employed by the Australian Burden of Disease (AusBoD) 
Study in 1996. For total duration, we used the posterior estimates of duration from final DisMod models. 
For those with symptoms, we split this total duration into two distinct phases of caries disability. The 
“initial” phase is characterized by periodic pain that we assigned to occur an average of one hour per day. 
The “terminal” phase is a period of constant symptoms at the end of an episode. The length of the 
terminal phase was determined by literature review as described by the AusBoD group. For deciduous 
caries we used a study by Mason, et al. of children in the UK presenting to a casualty ward with tooth pain 
[1]. The length of time each child had been experiencing tooth pain was recorded. Based on the 
distribution of time courses, a log-normal distribution was plotted that approximated the average 
duration of constant symptoms at 27.6 days leading up to seeking care. For permanent caries, a similar 
study of the tooth pain experience of adults in New Zealand who presented to hospital dental 
departments and an emergency clinic [2] resulted in an estimated 55.2 days spent in the terminal phase 
of caries. For those with severe disease, the length of time spent in the terminal phase was subtracted 
from the total duration to determine the amount of time spent in the initial phase. For those with mild 
disease, we considered the entire duration to be spent in the initial phase. 
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To determine proportion with symptoms, we completed a supplemental literature review of tooth pain 
and caries. We identified a total of 21 studies with data about the prevalence of pain. The studies were 
grouped according to the type of dentition studied (deciduous or permanent) and the location of the 
study group (high-income or low- and middle-income countries). We extracted data on the proportion in 
each group that described symptoms of pain related to their caries as well as a subset who described 
their symptoms as being severe. The proportions in each group were weighted according to sample size 
to give estimates of the relative sizes of three groups: asymptomatic, mild, and severe.  
We considered asymptomatic individuals to experience no disability. Those with mild disease spent the 
entire duration in the initial phase of disease (one hour of pain per day). Those with severe disease spent 
a majority of the duration in the initial phase followed by a period of time in the terminal phase (constant 
pain). YLDs were calculated by multiplying the prevalence, duration, proportion, and disability weight for 
each age, country, sex, and year.  
No additional changes were made to this modeling strategy. 
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Case definition 
Chronic periodontal disease is caused by chronic bacterial infection around the teeth. Symptoms of 
gingivitis, the mildest form of the disease, include swelling, redness, and propensity of the gums to bleed 
when perturbed. If the infection is not treated appropriately, it will eventually spread below the gum line 
leading to a chronic inflammatory state of the periodontal tissues. Over time, there will be loss of gingival 
tissue and alveolar bone destruction. Teeth will become loose and may need to be extracted.  
The GBD definition of disability associated with symptomatic severe periodontal disease is “bad breath, a 
bad taste in the mouth, and gums that bleed a little from time to time, but which does not interfere with 
daily activities.” The ICD-10 codes for periodontal disease are K05.0 – K05.6, and the ICD-9 codes are 
523.0 – 523.9.  
Defining periodontal disease in a meaningful, reproducible manner has been an ongoing challenge for 
public health dentists. Attachment loss (AL) and pocket depth (PD) have emerged as the most common 
metrics of periodontal health measurement. Attachment loss (AL) is measured as the difference between 
the distance from the gingival margin to the bottom of the pocket and the distance from the cemento-
enamel junction to the bottom of the pocket.  
 
The Community Periodontal Index of Treatment Needs (CPITN) is a classification system that was 
developed by the WHO as a standardized method of periodontal health measurement [1]. CPITN 
classification is based on quantifying the probing depth between teeth and gums. The mouth is divided 
into 6 sections, called sextants. Sextants with fewer than two teeth are excluded. Multiple teeth in each 
sextant are examined. A standard-sized probe is used with depth markings from 3.5 to 5.5 mm. The probe 
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is inserted into the sulcus between a tooth and the gingiva until it meets resistance. The surrounding area 
is then explored with the probe to determine the maximum depth of the pocket. Multiple areas around 
each tooth are probed. Scores range from 0 to 4 in order of increasing severity. When the CPITN method 
was employed, we considered those with Class 4 only. We excluded studies in which the study population 
was reported as the number of sextants rather than the number of individuals surveyed.  
 
In 2007, a new CDC proposal for gold standard diagnosis of severe, chronic periodontitis was published. 
This standard specified that a more strict definition of the condition should be implemented. This more 
exclusive definition of chronic periodontal disease includes > 2 interproximal sites with AL > 6 mm AND > 
1 interproximal site with PD > 5 mm [2]. 
We included the following definitions of severe periodontal disease commonly found in the literature: 
1. Community Periodontal Index of Treatment Needs (CPITN)   ̶ Class 4 only 
2. Clinical Attachment Loss (AL) > 6mm 
3. Clinical Attachment Loss (AL) > 5mm 
4. Clinical Attachment Loss (AL) > 4mm 
5. Gingival Pocket Depth (PD) > 5mm 
If more than one type of data was included in a study, our first preference was for CPITN = 4, followed by 
AL >6 mm, with PD >5 considered the least accurate representation of the GBD case definition. AL > 6mm 
was preferred over AL > 5mm, followed by AL > 4mm. All definitions were extracted for each datum as 
available this time, and a series of study covariates were used to crosswalk non-standard definitions to 
the reference standard of CPITN stage 4 (see below).  
 
Input data 
Model inputs 
For GBD 2010, a review of the literature on periodontal disease prevalence was conducted by the Expert 
Group. A new systematic review was conducted for GBD 2013. The GBD 2013 literature review used the 
following search terms: (Peridontal disease[Title/Abstract]) OR (periodontitis[Title/Abstract]) OR 
(periodontal[Title/Abstract]) AND (prevalence[Title/Abstract]) AND (“2010”[Date - Publication] : 
“2013”[Date - Publication]).  
In both systematic reviews, there was a hierarchical preference for case definitions: if more than one type 
of data was included in a study, our first preference was AL followed by PD, with CPITN considered the 
least accurate representation of the GBD case definition. Updates to systematic reviews are performed 
on an ongoing schedule across all GBD causes; an update for chronic periodontal disease will be 
performed in the next one to two iterations.  
 
 Prevalence Mortality 
Studies 97 4 
Countries/subnationals 48/15 3/1 
GBD world regions 18 2 
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 Modeling strategy  
Overview 
Evidence for chronic periodontal disease being a direct, proximate cause of death is lacking. As such, it 
was not included in overall causes of death analysis. However, there is a developing body of literature to 
suggest that those with chronic periodontal disease may be at increased risk of death from other causes. 
Relative risk data were, therefore, included in modeling of morbidity, but overall years of life lost (YLLs) 
were estimated to be zero. Models of disease burden due to chronic periodontal disease instead focused 
on estimating morbidity (YLDs) associated with the condition, and chronic periodontal disease was not 
included in risk factor analysis of any other condition. 
Correction for edentulism 
Bias in the dataset was felt to be limited, but some systematic bias was present in the definition of the 
study populations. In virtually all studies, edentate persons were excluded from evaluation. This exclusion 
is justified in the context of periodontal disease surveillance because advanced periodontal disease is not 
common in those who are toothless. To account for the systematic bias inherent in excluding those with 
severe tooth loss from the denominator, we discounted the prevalence numbers estimated by DisMod 
MR 2.1. For example, if 40% of 70-74 year old females were estimated to be edentate in a certain region, 
the corresponding estimates for advanced periodontal disease prevalence were reduced to 60% of the 
original value.  
 
DisMod model development 
Mortality was fixed to zero and relative risk was fixed to 1.0 before age 30, as any excess cardiovascular 
events that occur in those with severe tooth loss would not be expected at young ages. Incidence and 
prevalence were assigned to be zero until age 8 as periodontal disease is largely considered to be a 
disease of adulthood. Incidence was allowed to rise beginning at age 9, based on the youngest age at 
which there was a non-zero point estimate for prevalence in the dataset.  
Bounds were assigned for remission and excess mortality to improve plausibility in the DisMod estimates. 
Remission was bounded 0 to 0.05 and excess mortality rate was bounded to 0.0001. We considered both 
bounds to be within reasonable ranges for the observed natural history of the disease.  
Study-level covariates were created for whether the data use a case definition of CPITN class III 
periodontal disease as opposed to the reference definition of class IV, and for whether the data use a 
case definition of attachment loss >=5 mm as opposed to the reference definition of >= 6mm. We did not 
identify any studies for which the only case definition reported was attachment loss >= 4mm. 
Reproductive age-standardized smoking prevalence was used as a country-level covariate.  
Models were vetted based on the biological plausibility of the results, the extent to which estimates fit 
the data, and the plausibility of the range of estimates across location hierarchies.  
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Covariate name Type Measure Beta value Exponentiated value 
Smoking Prevalence 
(Reproductive Age 
Standardized) 
Country 
covariate Prevalence 0.097 (0.004 - 0.194) 1.102 (1.004 - 1.215) 
Data corresponds to 
those with CPITN class 
III periodontal disease 
(class IV is reference) 
Study-level x-
covariate Prevalence 0.211 (0.008 - 0.575) 1.235 (1.008 - 1.777) 
Data corresponds to 
those with 
attachment loss >=5 
mm (reference is >=6 
mm) 
Study-level x-
covariate Prevalence 0.903 (0.657 - 1.126) 2.468 (1.928 - 3.083) 
 
Disability calculation and YLDs 
Because those who are edentate cannot have advanced periodontal disease, we corrected for 
toothlessness as described above. Using the DisMod estimates for prevalence of edentulism, we 
calculated the mean prevalence for each age and sex and averaged the 1990 and 2015 values. We then 
calculated a population-weighted mean prevalence for each region followed by the same for each GBD 
super-region. The resulting super-regional averages were used to adjust the estimates for prevalence of 
advanced periodontal disease in calculating years lost due to disability (YLDs). 
We considered all estimated prevalent cases of chronic periodontal disease to experience the disability 
described by “bad breath, a bad taste in the mouth, and gums that bleed a little from time to time, but 
this does not interfere with daily activities.” The GBD Disability Survey differentiated between those who 
experience pain and those who do not, but the calculated disability weight was the same for both forms 
of the condition, 0.007 (0.003 – 0.014). 
 
No other changes were made for GBD 2016. 
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Case definition 
The case definition of edentulism and severe tooth loss includes any individual with fewer than nine 
remaining permanent teeth; toothlessness of infancy is not included. The assessment of this disease 
includes quantification of the prevalence of the disease as well as estimation of the major sequelae: 
asymptomatic toothlessness and symptomatic toothlessness leading to “great difficulty in eating meat, 
fruits, and vegetables.” A small body of evidence has begun to emerge that implicates edentulousness as 
predisposing individuals to increased risk for ischemic cardiovascular events including myocardial 
infarction and stroke. These data are sparse but have been included in models estimating burden of 
major tooth loss. However, edentulism was not included in the risk factor analysis for ischemic 
cardiovascular diseases.  
Input data 
Model inputs 
An initial literature review was done by the Expert Group for GBD 2010, including published articles as 
well as the results of national and subnational reports. A new systematic review was completed for GBD 
2013. The search terms for this systematic review included: (Edentulism[Title/Abstract]) OR 
(edentulous[Title/Abstract]) OR (endentulousness[Title/Abstract]) OR (severe tooth loss[Title/Abstract]) 
OR (total tooth loss[Title/Abstract]) OR (complete tooth loss[Title/Abstract]) AND 
(prevalence[Title/Abstract]) AND (“2010”[Date - Publication] : “2013”[Date - Publication]).  
While an additional literature review was not performed for GBD 2015, new World Health Survey data 
were added for 47 countries. Updates to systematic reviews are performed on an ongoing schedule 
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across all GBD causes; an update for edentulism and severe tooth loss will be performed in the next one 
to two iterations.  
Bias in the dataset was considered to be negligible. Diagnostic criteria for this condition are very clear (< 9 
teeth). Additionally, all included studies are considered representative of the study population. Thus, 
covariates to account for excess variability were not deemed necessary. Few data points were marked as 
outliers during the modeling process.  
 
 Prevalence Incidence  Mortality 
Sources 151 11 8 
Countries/subnationals 75/11 4/5 5/4 
GBD world regions 20 4 3 
 
 
Modeling strategy  
Overview 
First, estimates for the prevalence of edentulism and severe toothlessness were calculated for each 
location/year/sex/age using DisMod-MR 2.1. Then, estimates of the proportion of the population with 
access to dentures were generated for each location, and the disability weight for “great difficulty in 
eating meat, fruits, and vegetables” was applied to the proportion of the population with edentulism and 
no access to dentures.  
DisMod model development 
As would be expected for an irreversible condition, remission was fixed at zero for all ages. Mortality and 
relative risk were both fixed at zero before age 30, as any excess cardiovascular events resulting from 
severe tooth loss would not be expected at younger ages. We also assigned incidence and prevalence to 
be zero during childhood. Incidence was allowed to rise beginning at age 15, which was chosen based on 
the age at which the permanent dentition is expected to have fully formed in all individuals. The random 
effect limits for all locations were bounded at +/- 1.  
As mentioned above, the criteria for diagnosis of edentulism are straightforward, and bias in the dataset 
was considered negligible. Thus, no study-level covariates were used in modeling the prevalence of 
edentulism. We included lnLDI as a country-level covariate, with a minimum beta value of 0.02; see 
results in the table below. 
Covariate name Type Measure Beta value Exponentiated value 
LDI (I$ per capita) 
Country 
covariate Prevalence 0.026 (0.020 - 0.043) 1.027 (1.021 - 1.044) 
  
Models were vetted based on the biological plausibility of the results, the extent to which estimates fit 
the data, and the plausibility of the range of estimates across location hierarchies. We have made no 
substantive changes in the modeling strategy from GBD 2013. 
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Disability weights 
The disability weight used for symptomatic toothlessness leading to “great difficulty in eating meats, 
fruits, and vegetables” is 0.067 (0.045 – 0.095) as determined by the GBD Disability Survey. We 
considered all those with severe tooth loss and no access to dentures to experience this disability.  
However, the proportion of those with edentulism and severe tooth loss who have dentures has not been 
studied extensively. 
In order to estimate the proportion of edentulous individuals with no access to dentures, we completed a 
supplemental literature review of dentures prevalence. Only six systematic surveys of dentures 
prevalence were identified, all in high- and middle-income countries. All were completed since 2000. 
After extracting the data from the studies, we performed linear regressions of denture presence and 
denture absence against health system access (HSA), a standardized covariate of treatment availability 
used in many disease estimation models. From the results of the regression, the prevalence of no 
dentures was calculated for all super-regions. We then completed a population-weighted average of all 
countries in the super-region based on 2003 populations, the average year of the dentures studies. 
Uncertainties for the prevalence of dentures were calculated by finding the standard deviation and 
standard error of the calculated prevalence values. 
The estimated prevalence of dentures in each location was used to calculate the proportion of individuals 
with asymptomatic edentulism and severe tooth loss (e.g., those who have access to dentures) and 
difficulty eating due to edentulism and severe tooth loss (e.g., those without access to dentures). This 
latter sequela was included as a cause of years lost due to disability (YLDs).   
  
644
 Other Oral Disorders 
 
Other oral disorders encompass a wide variety of dental, tongue, and jaw disorders and malformations, 
including all oral disorders that are not included in the case definitions of permanent or deciduous dental 
caries, periodontal disease, or edentulism and severe tooth loss. All data on the prevalence of other oral 
disorders were obtained from the United States Medical Expenditure Panel Surveys, a nationally 
representative survey conducted yearly from 1996 to 2011 by the US Agency for Healthcare Research and 
Quality.  
 
These data were modelled in DisMod-MR 2.1 using a prevalence-only model with age mesh points set at 
0, 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 years of age. Heterogeneity for prevalence was set 
to the default of 0.5, and smoothness for prevalence was set to the default of 0.3. No study-level or 
country-level covariates were used in this model other than the study-level covariate for sex, which was 
fixed at the super-region level. This model provided us with estimates of the prevalence of other oral 
disorders for every location/age/sex combination.  
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Case definition 
For GBD 2016, the Injuries estimation process for non-fatal health outcomes encompasses a range of 29 
causes, including transport injuries, falls, drowning, self-harm, interpersonal violence, and animal contact. 
Injury incidence is defined using ICD-9 codes E000-E999 and ICD-10 chapters V to Y. For non-fatal 
estimation, Chapters S and T in ICD-10 and codes 800-999 in ICD9 are used to estimate morbidity. Each of 
these 29 causes can result in a variety of physical injury sequelae (i.e. traumatic brain injury), which we 
call the “nature of injury.” Though the initial DisMod models are the “cause of injury” level (ie, drowning), 
each cause of injury is broken out into cause-nature pairs. For the first time in GBD 2016, we report 
incidence, prevalence, and YLDs due to injuries at the cause-nature pair level rather than the cause of 
injury level in aggregate. 
 
We make additional distinctions between inpatient and outpatient injuries, and between short-term and 
long-term injuries. Inpatient injuries are defined as injuries that led to hospitalization, whereas outpatient 
injuries are ones that occurred in outpatient settings or emergency care. We define short-term injuries as 
injuries lasting less than one year, and long-term injuries as those lasting longer than one year, at which 
point we assume lifelong disability. 
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Input data 
Model inputs 
For GBD 2016, to estimate morbidity from injuries, we used data from hospital records, emergency 
department records, and surveys to produce years lost to disability (YLDs) by country, year, sex, age, 
external cause-of-injury, and nature of injury category.  
 
Unfortunately, quite a few countries report their data using a mix of cause of injury and nature of injury 
codes. In order to retain as much of the data as possible, we included all datasets that had at least 15% of 
cases coded to the cause of injury. Previously, we chose 45% as the threshold, but in order to include as 
much data as possible for GBD 2016, we lowered the threshold to 15%. We made this distinction after 
assessing the proportions of major injury causes (road injury and falls) in each of the data sources. We 
concluded that there were no obvious differences between country data with 15%–45% coverage of 
external cause codes and those with more than 45% coverage. Below the 15% threshold, the cause of 
nature coding became more disproportionate when compared to sources with higher cause of nature 
coding. (We assessed the raw hospital data to make sure that there was no disproportionate coding to 
certain causes in the 15%–45% cause of injury coding range. We increased the cause-specific injury cases 
from these datasets proportionately to sum to the total number of injury cases. 
 
Conflict, war and executions and police conflict data were obtained from the Uppsala Conflict Data 
Program [17], the International Institute for Strategic Studies [18], the Armed Conflict Location and Event 
Dataset [TBD] and the Social Conflict Analysis Database [TBD], vital registration systems. Disaster data 
were obtained from the International Disaster Database from the Center for Research on the 
Epidemiology of Disasters [19].   
 
Data searches 
For GBD 2016, hospital and emergency department records were supplemented with more recent and 
available site-years. Additionally, we reviewed a list of sources, which was composed primarily of reports 
and surveys that could be incorporated into non-fatal estimates of injuries prior to estimation. Hospital 
utilization envelopes that gave reliable denominators for hospital data allowed for the use of more data 
sources. We applied correction factors to account for repeat hospital visits within a three-month time 
window (derived from US claims data) to the incidence estimates to avoid double-counting multiple 
health service contacts for the same injury. 
 
Infrequently, data points were marked as outliers. Reasons for this were that the data point did not follow 
the age or time pattern as expected and/or if the incidence rate of people sustaining an injury from a 
certain cause of injury was not plausible. 
 
Modelling strategy 
As in previous GBD iterations, two categories of injury severity were separately modelled: injuries 
warranting inpatient care and injuries warranting other health care. Injuries warranting inpatient care 
refer to injury cases of sufficient severity to require inpatient care, if there are no restrictions in access to 
health care. Injuries warranting other health care refer to injury cases of sufficient severity to require 
health care attention but not hospitalisation. This category includes emergency department visits. In 
order to best measure the burden of injuries, the GBD 2016 estimates excluded trivial injuries by 
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restricting morbidity analysis to cases warranting some form of health care in a system with full access to 
health care. We intended to include cases with injuries that did not receive care in areas with restricted 
access to health care, but that would have warranted some type of health care in a system with full 
access to health care. In some surveys, after asking about recall of injuries in the past month or year 
respondents were further probed whether they sought care and if they did not what the reasons were. 
This allowed us to include cases who cited financial or geographical barriers as reasons for not seeking 
care. 
 
Cause-of-injury incidence 
The list of unique (ie, not counting aggregate categories like road injuries or interpersonal violence) 
cause-of-injury categories has increased to 29 for GBD 2015 following the addition of “self-harm by 
firearm,” and “self-harm by other specified means.” The fatal discontinuities cause-of-injury categories 
now only include “conflict and terrorism” and “exposure to forces of nature, disaster” rather than 
“collective violence and legal intervention,” which encompassed both in GBD 2015. Included previously in 
“collective violence and legal intervention” were injuries due to “executions and police conflict.” For GBD 
2016, we are treating executions and police conflict as a typical cause of injury that has a steady state 
over time rather than as a fatal discontinuity. 
 
The majority of incidence data exist at the external cause-of-injury level. Thus, incidence for cause-of-
injury categories was modelled using DisMod-MR 2.0. DisMod-MR 2.0 is a descriptive epidemiological 
meta-regression tool that produces simultaneous estimates of disease incidence, prevalence, remission, 
and mortality. Multiple datasets from hospital, emergency/outpatient departments, and survey datasets 
were fed into these incidence models. We separately estimated two categories of injury severity: 
inpatient and outpatient injuries. For GBD 2016 we used two covariates in each DisMod-MR model as a 
multiplier from inpatient to outpatient incidence, namely covariates “outpatient,” “in- and outpatient.”  
 
Due to the sporadic nature of the incidence of injuries and a lack of time-trend that results from fatal 
discontinuities, DisMod-MR 2.0 was not used to model incidence due to fatal discontinuities, including 
exposure to forces of nature (ie, natural disaster) and conflict and terrorism. For GBD 2015, to estimate 
incidence that would be expected to occur when there are fatal discontinuities, the mortality rate for 
these cause-of-injury categories was multiplied by the average country-year-age-sex-specific incidence-
to-mortality ratio within several cause-of-injury categories that likely exhibit similar case-fatality ratios. 
This method resulted in some outliers driven by patterns in the cause-of-injury categories used to 
compute the incidence-mortality ratios that did not reflect accurate patterns in the fatal discontinuities. 
For GBD 2016, the incidence-to-mortality ratios were averaged over super-region, year, and sex to limit 
the variability in the ratios applied to fatal discontinuities. For disaster incidence, the incidence-to-
mortality ratio was calculated as an average of the road injuries cause, and drowning if there was a water-
related natural disaster in that specific country-year noted in the International Disaster Database [19]. For 
conflict and terrorism, the incidence-to-mortality ratio was calculated as an average of the road injuries 
and interpersonal violence causes. We treated executions and police conflict as similar to the fatal 
discontinuities in that we imputed the incidence using the incidence-to-mortality ratio of interpersonal 
violence. 
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Follow-up studies 
Similar to GBD 2015, we used follow-up data obtained from a pooled dataset of six follow-up studies from 
China, the Netherlands, and the US, which followed up patients for at least one year after the injury and 
the Medical Expenditure Panel Survey (MEPS) [20-27].  
 
Details of injury follow-up surveys used in GBD 2016 
Dataset Year Type of data 
collected 
Type of patients Setting Sample size* 
and response  
Guangdong follow 
up survey, China# 
2006–
2007 
Follow up survey 
among sample of ISS 
patients  
Patients (15+ years) who  were 
hospitalized that had been injured by 
road traffic injury, fall, blunt or 
penetrating trauma 
Based on three national 
injury surveillance hospitals 
in Zhuhai, Guangdong 
Province in China 
998 (response 
87%) 
LIS follow up 
survey, 
Netherlands1 
2001–
2002 
Follow-up survey 
among stratified 
sample of ISS 
patients 
(oversampling less 
common, severe 
injuries)  
Patients (15+ years) who visited the 
Emergency Department of a hospital 
and were discharged to the home 
environment and patients who were 
admitted to hospital  
Based on 17 public hospitals 
in the Netherlands 
8,564 (response 
37%) 
LIS follow-up 
survey, 
Netherlands2 
2007–
2008 
Follow-up survey 
among stratified 
sample of ISS 
patients 
(oversampling less 
common, severe 
injuries)  
Patients (15+ years)  who visited the 
Emergency Department of a hospital 
and were discharged to the home 
environment and patients who were 
admitted to hospital  
Based on 15 public hospitals 
in the Netherlands 
8,057 (response 
36%) 
NSCOT – National 
study on Costs and 
Outcomes of 
Trauma, USA4 
2001–
2002 
A prospective cohort 
study was conducted 
among a sample of 
adult trauma 
patients treated at 
Level I trauma 
centers and non-
trauma center 
hospitals 
Patients treated for a moderate to 
severe injury (as defined by at least 
one injury of an Abbreviated Injury 
Scale (AIS) score of 3 or greater 
Based on 69 hospitals in 12 
states in the US 
5,191 (response 
61%) 
SCTBIFR – South 
Carolina Traumatic 
Brain injury 
Follow-up 
Registry, USA5 
1999–
2002 
A prospective cohort 
study was conducted 
among injured in-
patients with a 
traumatic brain 
injury-related injury 
Patients (15+ years) who were 
admitted to hospitals and met the 
CDC case definition of TBI – trauma to 
the head associated with altered 
consciousness, amnesia, neurological 
abnormalities, skull fracture, 
intracranial lesion, or death 
Discharged from all 
nonfederal in-state acute 
care hospitals 
7,613 (response 
28%) 
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Dataset Year Type of data 
collected 
Type of patients Setting Sample size* 
and response  
Burns outcome 
study, 
Netherlands6 
2003–
2006 
A multicenter 
prospective cohort 
was conducted 
among adult  
(severe) burn 
patients  
Injury patients who sustained severe 
burns 
Three public hospitals with 
specialized burn units.   
311 (response 
78%) 
*number of patients that met the inclusion criteria; response rate = percentage of patients who responded to the follow-up survey (in case of 
multiple follow-up times the response rate of the first follow-up moment is reported). 
# data from CDC China, jointly analyzed by study authors from IHME and China CDC 
 
MEPS is a large-scale overlapping continuous panel survey of the US non-institutionalized population that 
collects information on use and cost of health care and SF12 responses [28]. SF-12 responses are elicited 
twice over the two-year period that any individual is part of the study. Thus, MEPS offered the benefit of 
including health state measures of non-injured and destined to be injured and the benefit of having pre-
injury and post-injury SF-12 responses. We pooled all available MEPS data over a 19-year span.  
 
The follow-up studies used different patient reported outcome measures to assess health status, namely 
the SF-36, Version 1 SF-12, and the EQ-5D [29-31]. To enable comparison across the six datasets, it was 
necessary to analyse the data in a standardised patient-reported outcome measure. First, we mapped all 
patient-reported outcome measures to Version 2 SF-12 (SF-12v2). Second, we normalised the health 
status measurements by mapping the SF-12 scores to a corresponding disability weight based on several 
opportunistic surveys asking respondents to score SF-12 based on the lay descriptions for a selection of 
60 GBD health states [12]. We ran a regression of logit-transformed disability weight on nature-of-injury 
category and age group and never-injured status. The pooled dataset informed both the nature-of-injury 
category hierarchy and the long-term probability of injuries, discussed below. 
 
Nature-of-injury category hierarchy 
Multiple injuries can occur in one individual. For GBD 2016, a nature-of-injuries severity hierarchy was 
developed to establish a one-to-one relationship between cause-of-injury and nature-of-injury category. 
This means that in case of multiple injury the nature-of-injury category that was likely to be responsible 
for the largest burden was selected. To construct the hierarchy, we used data from the pooled dataset of 
follow-up studies. The output of the regression of logit-transformed disability weight on nature-of-injury 
category and individual characteristics of the follow-up studies were used to calculate the mean long-
term disability attributable each nature-of-injury category. The ranking of nature-of-injury categories by 
their long-term disability weights formed the basis of our severity hierarchy. Hierarchies were developed 
separately, for injuries warranting inpatient care and injuries warranting other health care. 
 
Nature of injury hierarchies: combination of empirical hierarchies estimated from pooled follow-up study 
and expert adjustments, for inpatient and outpatient injuries 
 
Rank Inpatient Hierarchy Outpatient Hierarchy 
1 Spinal cord lesion below neck level Fracture of pelvis 
2 Amputation of lower limbs, bilateral Fracture of patella, tibia or fibula, or ankle 
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3 Amputation of upper limbs, bilateral Fracture of hip 
4 Spinal cord lesion at neck level Fracture of skull 
5 Fracture of hip Amputation of thumb 
6 Fracture of femur, other than femoral neck Fracture of vertebral column 
7 Amputation of upper limb, unilateral Multiple fractures, dislocations, crashes, wounds, 
sprains, and strains 
8 Amputation of lower limb, unilateral Internal hemorrhage in abdomen and pelvis 
9 Multiple fractures, dislocations, crashes, wounds, sprains, 
and strains 
Fracture of femur, other than femoral neck 
10 
11 
Effect of different environmental factors Dislocation of hip 
11 
 
Fracture of patella, tibia or fibula, or ankle Amputation of toe/toes 
12 Moderate-Severe traumatic brain injury Fracture of hand (wrist and other distal part of hand) 
13 Fracture of foot bones except ankle Amputation of fingers (excluding thumb) 
14 Internal hemorrhage in abdomen and pelvis Burns, <20% of total burned surface area without 
lower airway burns 
15 Crush injury Dislocation of knee 
16 Minor traumatic brain injury Contusion in any part of the body 
17 Fracture of pelvis Minor traumatic brain injury 
18 Nerve injury Foreign body in respiratory system 
19 Severe chest injury Severe chest injury 
20 Dislocation of hip Drowning and nonfatal submersion 
21 Burns, >= 20% total burned surface area or >= 10% burned 
surface are if head/neck or hands/wrist involved w/o lower 
airway burns 
Asphyxiation 
22 Lower airway burns Poisoning requiring urgent care 
23 Fracture of skull Effect of different environmental factors 
24 Amputation of thumb Foreign body in GI and urogenital system 
25 Fracture of hand (wrist and other distal part of hand) Fracture of sternum and/or fracture of one or more 
ribs 
26 Fracture of vertebral column Nerve injury 
27 Contusion in any part of the body Fracture of face bones 
28 Open wound(s) Dislocation of shoulder 
29 Amputation of toe/toes Injury to eyes 
30 Dislocation of knee Fracture of clavicle, scapula, or humerus 
31 Amputation of fingers (excluding thumb) Fracture of radius and/or ulna 
32 Drowning and nonfatal submersion Fracture of foot bones except ankle 
33 Asphyxiation Foreign body in ear 
34 Burns, <20% total burned surface area without lower 
airway burns 
Muscle and tendon injuries, including sprains and 
strains lesser dislocations 
35 Muscle and tendon injuries, including sprains and strains 
lesser dislocations 
Superficial injury of any part of the body 
36 Fracture of face bones Open wound(s) 
37 Foreign body in respiratory system Complications following therapeutic procedures 
38 Poisoning requiring urgent care  
39 Foreign body in GI and urogenital system  
40 Fracture of sternum and/or fracture of one or more ribs  
41 Dislocation of shoulder  
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42 Injury to eyes  
43 Fracture of clavicle, scapula, or humerus  
44 Fracture of radius and/or ulna  
45 Foreign body in ear  
46 Superficial injury of any part of the body  
47 Complications following therapeutic procedures  
 
Cause-nature matrices 
Due to the fact that injury disability is linked more to nature-of-injury than to cause-of-injury, matrices 
were generated to map the proportion of each cause-of-injury category that results in a particular nature-
of-injury category. These matrices are based on a collection of dual-coded (eg, both cause-of-injury and 
nature-of-injury coded) hospital and emergency department datasets. The data for this step came from 
inpatient, outpatient, and emergency room discharge data from Argentina, Bulgaria, China, Colombia, 
Cyprus, the Czech Republic, Denmark, Egypt, Estonia, Hungary, Iceland, Iran, Italy, Latvia, Malta, 
Mauritius, Mexico, Mozambique, the Netherlands, Norway, Portugal, Slovenia, Spain, Sweden, 
Macedonia, Uganda, US, and Zambia. We applied our nature-of-injury severity hierarchy above to assert 
that every observation had one cause-of-injury and one nature-of-injury. 
 
In GBD 2015, negative binomial models were used to estimate the probability of each nature-of-injury 
category resulting from each cause-of-injury category. For GBD 2016, Dirichlet models were used instead 
in order to estimate all of the nature-of-injury category proportions for one cause-of-injury 
simultaneously. These models allow for more consistent borrowing of information across age, sex, 
inpatient/outpatient, and high/low-income countries, and assert that the nature-of-injury proportions 
within a cause-of-injury category must add up to 1. One cause-nature matrix was created for each 
combination of injury warranting hospital admission versus injury warranting other health care, high/low-
income countries, male/female, and age category. Applying these matrices to our cause-of-injury 
incidence from DisMod-MR, we produced cases of injury warranting hospital admission and incidence of 
injury warranting other health care by cause and nature of injury. 
 
Probability of permanent health loss 
Disability due to injury was assumed to affect all cases in the short term with a proportion having long-
term (permanent) outcomes. The probability of long-term outcomes was needed to estimate the 
incidence and subsequently the prevalence of cases with permanent health loss. In our conceptual 
model, individuals who suffer a non-fatal injury will, in the long-term, return to either full or partial 
health. If one-year post-injury patients return to a health status with more disability than their pre-injury 
health status, injury patients are assumed to have permanent disability from their injury. The difference 
between the pre-injury health states and health status one year after injury is assumed to be their 
permanent level of injury-related disability. We assessed the probability of developing permanent health 
loss using the pooled dataset of follow-up studies and the Medical Expenditure Panel Survey (MEPS) that 
were also used to generate the nature-of-injury hierarchy. To assess the probability of permanent health 
loss we estimated the effects using a logit-linear mixed effects regression: 
 
𝐿𝑜𝑔𝑖𝑡(𝐷𝑊)𝑖𝑚 =  𝛼 +  𝛽(𝑖𝑛𝑗𝑢𝑟𝑖𝑒𝑠𝑖𝑚) + 𝛽(𝑛𝑒𝑣𝑒𝑟 𝑖𝑛𝑗𝑢𝑟𝑒𝑑𝑖) + 𝛽(𝑛𝑒𝑣𝑒𝑟 𝑖𝑛𝑗𝑢𝑟𝑒𝑑𝑖 ∗ 𝑎𝑔𝑒𝑖)
+ 𝛽(𝑓𝑟𝑎𝑐𝑡𝑢𝑟𝑒 𝑜𝑓 𝑝𝑒𝑙𝑣𝑖𝑠𝑖) + 𝛽(𝑓𝑟𝑎𝑐𝑡𝑢𝑟𝑒 𝑜𝑓 𝑝𝑒𝑙𝑣𝑖𝑠𝑖 ∗ 𝑎𝑔𝑒𝑖) + 𝛽(𝑝𝑜𝑖𝑠𝑜𝑛𝑖𝑛𝑔𝑖 ∗ 𝑎𝑔𝑒𝑖)
+ 𝛽(𝑚𝑜𝑑𝑒𝑟𝑎𝑡𝑒 𝑡𝑜 𝑠𝑒𝑣𝑒𝑟𝑒 𝑇𝐵𝐼𝑖 ∗ 𝑎𝑔𝑒𝑖) + 𝑅𝐸𝑐 + 𝑅𝐸𝑖   
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where we included dummies for all the nature-of-injury categories (𝑖𝑛𝑗𝑢𝑟𝑖𝑒𝑠𝑖𝑚), with the reference 
category being no injury (from MEPS dataset. We also include a dummy for never injured prior to the 
current injury, age, interactions between age and never injured status, and interactions with three long-
term nature-of-injury categories that were found to significantly vary with age: pelvis fractures, 
poisonings, and moderate/severe traumatic brain injuries. In notation, subscript 𝑚 refers to patient-
reported outcome measure, 𝑖 refers to individual and 𝑐refers to country. Random effects (RE) were 
included to control for variation between countries and individuals.  
 
After predicting overall disability at one-year follow-up, we estimated a counterfactual by setting all 
observations to “no injury,” the reference group for 𝛽(𝑖𝑛𝑗𝑢𝑟𝑖𝑒𝑠𝑖𝑚) in our model. The disability 
attributable to the nature-of-injury at one year was assumed to be the difference between our 
counterfactual of no injury and predicted disability with injury. The probability of treated long-term 
outcomes was estimated via the ratio of this attributable disability relative to the long-term disability 
weight for that injury. 
 
𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑙𝑜𝑛𝑔 − 𝑡𝑒𝑟𝑚 𝑑𝑖𝑠𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
𝑤𝑖𝑡ℎ 𝑖𝑛𝑗𝑢𝑟𝑦 𝑑𝑖𝑠𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖𝑚 − 𝑐𝑜𝑢𝑛𝑡𝑒𝑟𝑓𝑎𝑐𝑡𝑢𝑎𝑙 𝑑𝑖𝑠𝑎𝑏𝑖𝑙𝑖𝑡𝑦𝑖𝑚
𝐷𝑊𝑚
 
 
We developed estimates of the probability of permanent health loss by nature-of-injury category, injury 
severity level (injuries warranting inpatient admission and injuries warranting other health care) and age. 
These probabilities are shown in Figure X for three selected age groups (25-30, 50-55, 75-80), and 
selected nature-of-injury categories by inpatient and outpatient. Moderate-severe TBI and spinal cord 
lesions only have inpatient injury long-term probabilities, and nerve injury, open wounds, and severe 
chest injury have long-term probabilities of 0 for outpatient cases. 
 
Figure X. Long-term probabilities derived from the MEPS data for selected nature of injuries and age 
groups 
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Disability associated with treated and untreated cases 
For many nature-of-injury categories GBD 2016 has a separate disability weight for treated and for 
untreated cases [14]. To estimate the percent treated for injuries in a given location-year, we used the 
HAQ Index with the same strategy described for the probability of permanent health loss. In GBD 2015, 
we used a proxy covariate that defined health system access (HSA) based on a combination of vaccination 
rates, proportion of deliveries by a skilled birth attendant, in-facility birth, and antenatal care. We used 
this to estimate the ratio of treated to untreated injuries for each country-year grouping and assigned a 
location-year-specific disability weight equal to a weighted average of the treated and untreated disability 
weights for each nature-of-injury category/severity-level grouping. We assumed that all locations had at 
least 10% of all injuries treated and capped the maximum HSA value at the lowest HSA value for an OECD 
country in a given year. This OECD HSA value for 2015 was used to scale all other location-years between 
10% and 100% treated based on their HSA value. 
 
In GBD 2016, we changed this method significantly. Instead of using the HSA covariate, we use the 
Healthcare Access and Quality (HAQ) Index. The HAQ Index better reflects access to care related to injury 
treatment rather than to maternal and child healthcare. We did not assert that all OECD countries had 
the same value, but rather chose a reasonable cutoff for the HAQ Index (75 on a scale of 0 – 100) as the 
threshold at and above which 100% of injuries were treated. This value captured most OECD countries for 
all years back to 1980, rather than just the most recent year. We then scaled all remaining location-years 
between 10% and 100% treated based on their HAQ Index value and used that as the percent treated in a 
given location-year. This was done at the draw level to propagate uncertainty. Similar to GBD 2015, we 
made the decision to ignore any long-term disability from outpatient injuries from open wound, 
poisoning, and contusion because of implausibly high estimates of long-term disability.   
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Duration of short-term health loss 
To determine the duration for treated cases of short-term injury we analyzed patient responses of two 
Dutch Injury Surveillance System follow-up studies of 2001–2003 and 2007–2009 [20, 21]. These studies 
collected data at 2.5, 5, 9, and 12 months post-injury on whether injury patients were still experiencing 
problems due to their injury [20, 21]. If not, the patients were asked how many days they had 
experienced problems. The injury patients that still reported having problems one year after the injury 
were assumed to be captured in our analysis of permanent disability. The duration for treated cases of 
short-term injury was estimated for injuries warranting inpatient admission and injuries warranting other 
health care separately. The estimates were supplemented by expert-driven estimates of short-term 
duration for nature of injury categories that did not appear in the Dutch dataset and untreated injuries. 
 
Calculation of prevalence from incidence data – short-term injury 
For short-term injury outcomes, which were assumed to be less than one year in duration, the prevalence 
for each cause-of-injury/nature-of-injury/severity-level grouping was approximated by the incidence for 
that grouping multiplied by the associated nature-of-injury/severity-level-specific duration.  
 
Calculation of prevalence from incidence data – permanent health loss 
For permanent health loss, we assumed no remission and thus integrated incidence over time to arrive at 
prevalence estimates. We used DisMod ODE (ie, the “engine” of DisMod-MR 2.1) to carry out this 
integration for each combination of cause of injury and nature of injury by country year and sex. For this 
step we used random effects meta-analysis to pool data on standardized mortality ratios derived from 
literature reviews for spinal cord injury, burns covering more than 20% of the body, moderate to severe 
traumatic brain injury, hip fracture, and multiple significant injuries (see for more detail [12]). Here we 
include examples of these meta-analyses: hip fractures and traumatic brain injuries. 
 
655
Figure XX. Meta-analyses of standardized mortality ratios derived from literature reviews: hip fractures 
and traumatic brain injury. 
 
 
 
 
 
 
For all other nature-of-injury categories, we assumed no long-term excess mortality. For the incidence 
estimates derived from fatal discontinuities – “exposure to forces of nature,” and “conflict and terrorism” 
–  we did not use DisMod as discontinuities by definition violate the assumption of a steady state in 
DisMod to estimate prevalence from incidence. For these two cause-of-injury categories, we coded the 
differential equations from DisMod ODE that determine the relationship between incidence, remission, 
mortality risk, and prevalence into Python and streamed out the prevalence from the incidence in the 
years of war or disaster by integrating over one year at a time. 
No other significant changes were made to the injuries modelling process for GBD 2016. 
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Case definition 
Sexual violence is a new cause for GBD 2016. We estimate the yearly prevalence of sexual violence, ie, 
the proportion of the population that experienced at least one event of sexual violence in the last year. 
We define sexual violence as any sexual assault, including both penetrative sexual violence (rape) and 
non-penetrative sexual violence (other forms of unwanted sexual touching). 
Input data 
 Model inputs 
The majority of the data for sexual violence comes from various health and demographic surveys. We 
include many Demographic and Health Surveys (DHS) and Reproductive Health Surveys (RHS). Other 
survey series include the US Behavioral Risk Factor Surveillance Survey (BRFSS), the British Crime Surveys. 
Table 1 shows the number of unique location-sources for prevalence of sexual violence with a yearly 
recall that we used in the DisMod models. 
Table 1. Unique location-sources for data on sexual violence yearly prevalence used in the DisMod model 
by Global Burden of Disease super-region. 
Super-region name Unique number of sources 
Southeast Asia, East Asia, and Oceania 10 
Central Europe, Eastern Europe, and Central Asia 23 
High-income 55 
Latin America and Caribbean 26 
North Africa and Middle East 7 
South Asia 91 
Sub-Saharan Africa 46 
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 Many other non-survey data sources exist for sexual violence. We explored the use of the United Nations 
Office on Drugs and Crime (UNODC) Statistics [TBD] that covers a wide range of geographies from 2003 to 
2014. However, these estimates are based only on police reports, and their incidence is about 20 times 
lower than the incidence seen in the same location-years from survey data. Although we could include a 
covariate in our models to adjust for this underreporting, we deemed the source unusable because of the 
magnitude of the difference between the police reports and survey data. Survey data typically range 
between 1% and 10% of individuals experiencing sexual violence in the last year. Figure 1 shows the 
incidence estimates from the UNODC data, where most of the estimates are below about 0.05%. The 
geographic pattern is the opposite of what we see in survey data, with higher-income countries having 
higher estimates in the UNODC data. Additionally, the reports were not age-sex-specific, and the 
definition for what constitutes sexual violence varies across countries. 
We also chose not to include the Centers for Disease Control non-fatal injury reports of sexual violence. 
Although this data source includes age- and sex-specific estimates for sexual violence in the United 
States, only sexual violence cases which resulted in physical injury are reported. These estimates are also 
systematically lower than the survey data, to the degree at which any adjustment with covariates would 
be unreliable. Lastly, we excluded a source from the United States Federal Bureau of Investigation: The 
Uniform Crime Reporting (UCR) program. The FBI estimates are produced at the state level for the United 
States, and are meant to be comparable across states. However, police report data for sexual violence are 
systematically lower, similar in magnitude to the UNODC data, so we chose to exclude it. 
Figure 1. United Nations Office of Drugs and Crime Statistics: estimates of sexual violence (incidence per 
person), color by Global Burden of Disease super-regions. 
 
 Data searches 
To find large data sources for sexual violence, we searched through the Global Health Data Exchange 
(GHDx) to identify survey series with relevant questions, and reviewed surveys that were being used for 
intimate partner violence (IPV) already. We identified 107 sources with relevant data that were being 
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used for IPV, and 33 additional surveys with sexual violence questions. We excluded sources that only 
asked about lifetime prevalence of sexual violence because our case definition is specific to the past year. 
We extracted data on the perpetrator of sexual violence where possible (partner versus non-partner). 
We completed a systematic review in PubMed to identify additional sources. We identified 415 sources 
and excluded 314 based on title/abstract screening. Of the 111 sources remaining after title/abstract 
screening, 84 did not have usable data, were of non-representative samples, or referenced data that was 
already being captured from the GHDx. Samples were non-representative if they were only taken among 
high-risk populations (war-afflicted, sex workers, intravenous drug users, etc.), sexually abused 
individuals, or women suffering intimate partner violence. We also excluded studies that only asked 
about sexual violence in the context of alcohol. After full-text screening, 18 sources remained, only two of 
which had yearly recall prevalence. 
 
Modelling strategy 
Prevalence of sexual violence 
To produce estimates of the yearly prevalence of sexual violence, we used DisMod-MR 2.0. DisMod-MR 
2.0 is a descriptive epidemiological meta-regression tool that uses the integrative systems modelling 
approach to produce simultaneous estimates of disease incidence, prevalence, remission, and mortality. 
To preserve variation between male- and female-specific estimates, we have separate models for men 
and women. 
We make various assumptions within DisMod-MR 2.0 including no excess mortality due to sexual violence 
and no incidence between 0–2 and 98–100 years of age. Because of the different ways that questions 
about sexual violence in the last year can be asked, we include multiple study-level covariates (for 
coefficient estimates, see Table 2). We bounded the covariates at logical values to minimize the effect of 
collinearity between the covariates, ie, we expect studies that ask about penetrative sexual violence only 
to have lower estimates of sexual violence overall, so that covariate has an upper bound of 1. 
Table 2. Study- and country-level covariates for DisMod-MR 2.0 yearly recall prevalence models for sexual 
violence. 
Covariate Covariate Bounds Exponentiated Value 
Study-level covariates   
Physically forced sexual violence only Upper: 1 0.94 (0.82 – 1.00) 
Ever-partnered people only None 1.49 (1.16 – 2.01) 
Ever-married people only None 2.19 (1.53 – 2.97) 
Specifies specifically degrading or humiliating sex acts Upper: 1 0.96 (0.87 – 1.00) 
Ever had sex None 1.23 (1.09 – 1.42) 
Ever married or lived with a partner None 1.44 (1.15 – 1.93) 
Does not include coerced or feared sex in definition Upper: 1 0.94 (0.84 – 1.00) 
Penetrative sexual violence only Upper: 1 0.66 (0.56 – 0.75) 
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Does not include non-partner non-penetrative Upper: 1 0.99 (0.97 – 1.00) 
Only includes partner sexual violence Upper: 1 0.85 (0.65 – 0.99) 
Includes attempted sexual violence Lower: 1 1.36 (1.04 – 1.97) 
Country-level covariates   
Alcohol (liters per capita)  1.00 (0.37 – 2.72) 
Socio-demographic Index  0.12 (0.088 – 0.16) 
 
Years lived with disability (YLDs) due to sexual violence 
In our calculations of years lived with disability due to sexual violence, for GBD 2016 we are only 
considering the short-term physical and psychological effects of sexual violence. In future GBD iterations, 
we will be including sexual violence as a risk factor including both sexual violence in the last year and 
lifetime exposure to sexual violence (independent from, and in interaction with, intimate partner 
violence). Including sexual violence as a risk will allow us to capture the long-term mental health 
consequences of sexual violence, which we are unable to capture just considering past yearly recall of 
sexual violence and its consequences for up to one year. 
To calculate the years lived with disability (YLDs) due to having experienced sexual violence in the past 
year, we utilize claims data from the United States from the years 2000, 2010, and 2012 to assess sexual 
violence sequelae. We search through the claims database for the following ICD9 diagnosis codes: 995.53 
(child sexual abuse), 995.83 (adult sexual abuse), and E960.1 (rape). We considered sequelae relating to 
both physical injuries and mental health consequences, in the short-term. 
Physical injury 
For the physical injury sequelae, we looked for any nature-of-injury ICD9 code on the same date of 
contact with medical service providers for a sexual violence ICD9 code (above), and categorized the 
nature-of-injury codes as we do for the general injuries nonfatal modeling process (see appendix: 
nonfatal injuries). We calculate the proportion of individuals with any sexual violence code that result in 
each of the physical injuries categories. This strategy is similar to the strategy that we use for the cause-
nature of injury matrices in the general injuries modeling process, but we have an additional category for 
no physical injury result, since the majority of sexual violence incidents do not result in physical injury in 
the claims database. Additionally, since we only have one data source, we do not model these 
proportions with Dirichlet regression like we do for the injuries cause-nature of injury matrices, but just 
compute them directly from the claims data. To estimate the physical injuries component of YLDs, we 
multiply the DisMod estimates of yearly prevalence of sexual violence by these proportions and then 
multiply by each physical injuries’ respective short-term duration and disability weight that we use in the 
general injuries process (see appendix: nonfatal injuries). 
Acute anxiety and/or reaction to stress 
For the mental and psychological sequelae of sexual violence, we searched an individual being coded to 
any of the following ICD9 codes at any point after a sexual violence incident was noted. The codes are 
meant to reflect conditions relating to an “acute anxiety and/or reaction to stress” condition following a 
traumatic incident, displayed in Table 2. 
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Table 2. ICD9 codes included in the “acute anxiety and/or reaction to stress” condition as a sequela for 
sexual violence. 
ICD9 Code Condition Description 
308 Acute reaction to stress  
308 Predominant disturbance of emotions 
308.1 Predominant disturbance of consciousness 
308.2 Predominant psychomotor disturbance 
308.3 Other acute reactions to stress 
308.4 Mixed disorders as reaction to stress 
308.9 Unspecified acute reaction to stress 
309 Adjustment reaction  
309 Adjustment disorder with depressed mood 
309.1 Prolonged depressive reaction 
309.2 Adjustment reaction with predominant disturbance of other emotions 
309.21 Separation anxiety disorder 
309.22 Emancipation disorder of adolescence and early adult life 
309.23 Specific academic or work inhibition 
309.24 Adjustment disorder with anxiety 
309.28 Adjustment disorder with mixed anxiety and depressed mood 
309.29 Other adjustment reactions with predominant disturbance of other emotions 
309.3 Adjustment disorder with disturbance of conduct 
309.4 Adjustment disorder with mixed disturbance of emotions and conduct 
309.8 Other specified adjustment reactions 
309.81 Posttraumatic stress disorder 
309.82 Adjustment reaction with physical symptoms 
309.83 Adjustment reaction with withdrawal 
309.89 Other specified adjustment reactions 
309.9 Unspecified adjustment reaction 
 
It is possible that the appearance of one of these ICD9 codes is entirely unrelated to the sexual violence 
incident. Additionally, the appearance of one of these codes could be related instead to underlying 
depression and anxiety. To control for these confounding factors, we also searched for these ICD9 codes 
among individuals that were not victims of sexual violence in the past year. We used Poisson regression 
with robust standard errors to model the relative risk of the “acute anxiety and/or reaction to stress” 
comparing individuals with and without sexual violence within the year, controlling for underlying 
diagnoses of depression and anxiety constant: 
log(𝜆) =  𝛽0 + 𝛽1(𝑠𝑒𝑥𝑢𝑎𝑙 𝑣𝑖𝑜𝑙𝑒𝑛𝑐𝑒) +  𝛽2(𝑑𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛) +  𝛽3(𝑎𝑛𝑥𝑖𝑒𝑡𝑦) +  𝛽4(𝑓𝑒𝑚𝑎𝑙𝑒) + 𝛽5(𝑎𝑔𝑒) 
where 𝜆 is the risk of “acute anxiety and/or reaction to stress,” and 𝑒𝛽1 is the relative risk of “acute 
anxiety and/or reaction to stress” comparing those experiencing at least one sexual violence incident to 
those with no sexual violence incidence, holding underlying depression, anxiety, sex, and age constant. 
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We can approximate the risk of “acute anxiety and/or reaction to stress” for each age and sex 
experiencing sexual violence by: 
𝜆𝑎𝑔𝑒,𝑠𝑒𝑥 =  𝑒
𝛽1 ∗  (𝑒𝛽0 ∗ 𝑒𝑠𝑒𝑥∗𝛽4+𝑎𝑔𝑒∗𝛽5) − (𝑒𝛽0 ∗ 𝑒𝑠𝑒𝑥∗𝛽4+𝑎𝑔𝑒∗𝛽5) 
The claims data had n = 70,6707,63 observations (n = 8,331 sexual violence cases). Using the equation 
above, the transformed coefficients and transformed robust standard errors (transformations were 
performed with the Delta method) are shown in Table 3. 
Table 3. Estimates of the risk of “acute anxiety and/or reaction to stress” (𝜆𝑎𝑔𝑒,𝑠𝑒𝑥) among people 
experiencing sexual violence over a year time-period, specific to age and sex. 
Age Male Female 
 Estimate Standard error Estimate Standard error 
0 0.0967 0.0023 0.1205 0.0028 
5 0.0933 0.0021 0.1162 0.0027 
10 0.0899 0.0021 0.1120 0.0026 
15 0.0867 0.0020 0.1080 0.0025 
20 0.0836 0.0020 0.1042 0.0024 
25 0.0806 0.0019 0.1004 0.0024 
30 0.0777 0.0018 0.0968 0.0023 
35 0.0749 0.0018 0.0934 0.0022 
40 0.0722 0.0017 0.0900 0.0021 
45 0.0697 0.0016 0.0868 0.0020 
50 0.0672 0.0016 0.0837 0.0020 
55 0.0648 0.0015 0.0807 0.0019 
60 0.0624 0.0015 0.0778 0.0018 
65 0.0602 0.0014 0.0750 0.0018 
70 0.0581 0.0014 0.0723 0.0017 
75 0.0560 0.0013 0.0697 0.0016 
80 0.0540 0.0013 0.0672 0.0016 
85 0.0520 0.0012 0.0648 0.0015 
90 0.0502 0.0012 0.0625 0.0015 
95 0.0484 0.0011 0.0603 0.0014 
 
We multiplied the prevalence of yearly sexual violence by 𝜆𝑎𝑔𝑒,𝑠𝑒𝑥 to get the prevalence of “acute anxiety 
and/or reaction to stress” due exclusively to sexual violence. To estimate YLDs for this sexual violence 
sequela, we used the average of the disability weights for mild depression and anxiety. For simplicity, we 
assume a duration of one year, thus the YLDs for the mental and psychological stress component of 
sexual violence is the product of the residual probability of “acute anxiety and/or reaction to stress” and 
the disability weight. 
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Input data and methodological summary 
Case definition 
The prevalence of anemia is defined by the following WHO thresholds for hemoglobin in g/L. 
Severity definitions used to calculate GBD 2016 anemia envelope 
 Severity of anemia 
Mild Moderate Severe 
Age < 5 years 
Males 
Females 
100 - 109 g/L 
100 - 109 g/L 
70 - 99 g/L 
70 - 99 g/L 
< 70 g/L 
< 70 g/L 
Age 5 - 14 years 
Males 
Females 
110 - 114 g/L 
110 - 114 g/L 
70 - 99 g/L 
70 - 99 g/L 
< 70 g/L 
< 70 g/L 
Age 15+ years 
Males 
Females, non-pregnant 
Females, pregnant 
110 – 129 g/L 
110 - 119 g/L 
100 – 109 g/L 
80 - 109 g/L 
80 - 109 g/L 
70 - 99 g/L 
< 80 g/L 
< 80 g/L 
< 70 g/L 
663
  
Modelling Strategy Summary:  
As with GBD 2015, the anemia model has two main steps: estimation of the anemia envelope and causal 
attribution. The envelope approach utilizes the main source of anemia data – population mean 
hemoglobin and prevalence of all-cause anemia – to estimate the overall prevalence of anemia 
impairment. The causal attribution assigns all cases of anemia to a specific cause and severity in an 
internally consistent method. 
Input data 
 Model inputs 
The envelope approach to the anemia impairment utilizes data from a variety of sources. Population-
based surveys of hemoglobin concentration were the primary input to our analytic dataset. Examples 
include the Demographic and Health Survey (DHS) and Multiple Indicator Cluster Survey (MICS) series, 
along with other national and subnational surveys that completed hemoglobin testing. We supplemented 
with pertinent sources downloaded from the WHO Vitamin and Mineral Nutrition Information System 
(VMNIS) available at http://www.who.int/vmnis/database/anaemia/countries/en/. A full source list is 
available elsewhere in this appendix. Most used a HemoCue test, adjusted for altitude, and excluded 
those with terminal or acute medical conditions.  Inclusion, exclusion and diagnostic criteria for other 
studies were similar and can be found in each study.  
Modelling strategy 
Anemia Impairment Envelope 
1) Estimation of population mean and standard deviation of hemoglobin  
We ran two Dismod-MR models – one for mean hemoglobin and one for standard deviation of 
hemoglobin. In both models, we included fixed effects on pregnancy status, underweight (proportion 
of children under 5 <2SD weight for age), and sociodemographic index (SDI). A z-cov was used for 
studies not representative of the location modelled. Mean-hemoglobin was used as a fixed effect in 
the standard deviation model.  
2) Estimation of prevalence of anemia by severity  
We modelled the full distribution of hemoglobin for each population (location/age/year/sex), from which 
we applied the WHO thresholds to calculate prevalence of each severity of anemia. In GBD 2015, a 
Weibull distribution was fit using shape and scale parameters estimated from mean hemoglobin. For GBD 
2016, we combine multiple two-parameter distributions to create a more precise and unbiased ensemble 
distribution.  
First, we created a training and testing set of individual-level hemoglobin measurements. The 
training set consisted of 90 DHS surveys, providing 290 group-specific samples of microdata from children 
<5, males 15-45, pregnant females 15-45, and non-pregnant females 15-45 (not all groups were sampled 
in each DHS). A set of two-parameter distributions (gamma, mirror gamma, Weibull, mirror lognormal, 
and mirror gumbel) were fit to the sample’s hemoglobin mean and variance. These distributions were 
combined using weights optimized by a loss function of severity-specific prediction error weighted by the 
ratio of the severity’s disability weight (DW) to mild anemia DW. Weights were constrained to be positive 
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and sum to 1, so that the resultant ensemble distribution is a proper probability density function. All 
permutations of the 5 distributions were tested (ie, we optimized weights for both a mix of all 5 
distributions as well as a gamma-weibull two-way combination).  
 The loss function is  
��
 𝑛𝑛𝑗𝑗
𝑗𝑗=1
� 𝑟𝑟𝑗𝑗|𝑝𝑝𝑖𝑖𝑗𝑗𝑖𝑖 − ?̂?𝑝𝑖𝑖𝑗𝑗𝑖𝑖| 𝑛𝑛𝑘𝑘
𝑖𝑖=1
𝑛𝑛𝑖𝑖
𝑖𝑖=1
 
 Where  
?̂?𝑝𝑖𝑖𝑗𝑗𝑖𝑖 =  �𝑤𝑤𝑧𝑧𝑛𝑛𝑧𝑧
𝑧𝑧=1
� 𝑃𝑃𝑃𝑃𝐹𝐹𝑖𝑖𝑗𝑗𝑧𝑧
𝑡𝑡2𝑗𝑗𝑘𝑘
𝑡𝑡1𝑗𝑗𝑘𝑘
  
 ni is a list of surveys (in either the training or testing set) 
nj is the list of groups: children <5, males 15-45, pregnant females 15-45, non-pregnant 
females 15-45, males >45, and females >45 
nk is the list of severities (mild, moderate, severe) 
nz is the list of distributions (gamma, mirror gamma, Weibull, mirror lognormal, and 
mirror gumbel) 
 r is the ratio of the severity j disability weight to that of mild anemia 
rk = 13 for moderate and rk = 40 for severe  
 PDF is a probability density function fit to the sample mean and variance 
t1 and t2 are the lower and upper bounds to the WHO anemia definition for the group 
 w  is the set of distribution weights (each constrained to be positive) such that 
   ∑ 𝑤𝑤𝑧𝑧
𝑛𝑛𝑧𝑧
𝑧𝑧=1 = 1  and all wz > 0  
Therefore ∑ 𝑤𝑤𝑧𝑧 ∗ 𝑃𝑃𝑃𝑃𝐹𝐹𝑧𝑧
𝑛𝑛𝑧𝑧
𝑧𝑧=1  describes the ensemble probability density function 
that can be integrated to calculate prevalence for any severity  
 
 The testing set consisted of 9 NHANES and 9 DHS surveys not included in the training data. 
Inclusion of NHANES as half the testing set ensured out of sample predictive validity by challenging the 
global weights, as it provided the ensemble distribution with high-income data (DHS is from LMIC 
countries) and data from adults >45 (DHS did not take blood tests from the elderly). We selected the 
combination of distributions (including all individual component distributions) that minimized the loss 
function.  
With a set of component distributions and global weights, we then modelled the distribution  of 
hemoglobin in each location/year/age/sex by fitting each component distribution using modelled mean 
and standard deviation, then weighting to create the ensemble distribution ∑ 𝑤𝑤𝑧𝑧 ∗ 𝑃𝑃𝑃𝑃𝐹𝐹𝑧𝑧
𝑛𝑛𝑧𝑧
𝑧𝑧=1 . We 
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integrated area under the curve for each group-specific WHO threshold to calculate prevalence of anemia 
by severity.  
Because anemia thresholds depend on pregnancy, we separately modelled the distribution of 
pregnant and non-pregnant females. The method for fitting the ensemble distribution to pregnant 
women was identical to that of non-pregnant, but used the mean and variance from the two Dismod 
models adjusted by the estimated beta on the pregnancy status fixed effect. The prevalence of anemia in 
pregnant and non-pregnant women were weighted by the pregnancy rate and combined to estimate 
population prevalence of anemia. The pregnancy rate for each age is estimated as  
𝑝𝑝𝑟𝑟𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 =   (𝐴𝐴𝐴𝐴𝐹𝐹𝐴𝐴 + 𝐴𝐴𝑆𝑆) ∗ 46/52 
Where  
 ASFR is the location- and age-specific fertility rate 
 SB is the location-specific stillbirth rate   
 
Below are some examples of the hemoglobin distributions for various locations and groups, combining 
the sample distribution (histogram), individual distributions, and ensemble distribution.  
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 Causal Attribution 
We performed cause-specific attribution on the anemia envelope using information on cause-specific 
prevalence and hemoglobin shift, which uses the same overall method as in the GBD 2010 with the 
addition of a number of causes and updates to hemoglobin shifts for inputs to causal attribution.  
Total “hemoglobin shift” was determined as the difference between the normal and predicted mean 
hemoglobin levels for each population group. We denoted the normal hemoglobin level as the global 
95th percentile of the distribution of mean-hemoglobin within each age- group, sex, and year. We then 
determined a total shift for each country in the corresponding age-group, sex, and year by finding the 
difference between the global “normal” and the country-specific predicted mean hemoglobin. Our model 
of attribution followed that, because the shift is a disease state experienced by 100% of the population, 
then the sum of cause-specific hemoglobin shifts times the prevalence of each contributing cause should 
add up to the total. We summed shift times prevalence estimates from all causes, compared to the total 
predicted hemoglobin shift, and proportionally assigned. We distributed the residual envelope among 
seven remaining causes.  
Of note, our iron-deficiency anemia (IDA) estimates include acute and chronic hemorrhagic states for 
which supplementation may be helpful, but poor nutritional intake is not the only underlying problem. A 
few causes in this category – hookworm, schistosomiasis, upper gastrointestinal bleeding, and 
gynecologic diseases – were considered separately from IDA because there was enough data from GBD 
prevalence estimation processes to do so. Distribution of anemia burden to IDA only after assignment to 
“known” causes avoided double counting of these cases. Most other causes of anemia not specifically 
considered were included in the “other” categories.  
For all causes with specific population-specific prevalence estimates, we enforced a condition where the 
sum of mild, moderate, and severe anemia would not exceed the total prevalence within each 
population. Additionally, because inherent in our method of determining “normal” hemoglobin is the fact 
that 5% of population groups will have zero, or negative, total shift, we assigned a minimum of 10% of all 
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anemia to be assigned to residual causes based on review of findings from National Health and Nutrition 
Examination Survey (NHANES) in the United states5,6.   
We again used Bayesian contingency table modelling methods developed for GBD 2013 to disaggregate 
marginal estimates of anemia severity and aetiology into a complete set of prevalence estimates for 
aetiology/severity pairs. Marginal estimates of column sums (total anaemia prevalence by severity [mild, 
moderate, severe]) and row sums (total aetiology prevalence for each cause) were paired with priors on 
the etiology-specific hemoglobin shifts (the same as were used for overall etiologic attribution) and rank 
order of variation of severity (e.g. malaria-induced anaemia severity is highly variable while that due to 
homozygous sickle cell disease is less so). Nonlinear optimization methods were then used to populate a 
complete matrix of aetiology-severity estimates from the marginal estimates and distribution priors. We 
found the maximum a posteriori (MAP) point estimate for 5 samples from estimated posterior 
distributions independently for each population group, then scaled the results to ensure row sums were 
non-zero and column sums matched the original draws. We then took the mean of the scaled posteriors 
for each population group. To estimate uncertainty for each scaled posterior mean, we first calculated 
the ratio of each draw to the mean of all draws for the anemia envelope. For non-residual causes, we also 
calculated the ratio of each draws to the mean of all draws. We then multiplied the scaled posterior mean 
by these ratios. 
The anemia causal attribution process produces estimates for mild, moderate, and severe anemia due to 
HIV. Using these estimates, we calculated proportions of HIV with mild, moderate, severe, and no 
anemia for each demographic group. GBD produces estimates for seven HIV sub-causes: early HIV, 
symptomatic HIV, AIDS with antiretroviral treatment, AIDS without antiretroviral treatment, drug-
sensitive HIV/AIDS – Tuberculosis, multidrug-resistant HIV/AIDS – Tuberculosis, and extensively drug-
resistant HIV/AIDS – Tuberculosis. We assumed the anemia severity proportions were equivalent across 
the seven sub-causes, and estimated the anemia severity levels for each by multiplying the HIV sub-
causes by the anemia proportions. 
Priors: Largest* 
Anemia Subtype Expected Largest 
Malaria (PFPR) 0 
Schistosomiasis 0 
Hookworm 0 
Other NTDs 0 
Maternal Hem. 1 
Iron Deficiency 0 
Other Infectious 
Diseases 0 
Peptic Ulcer Disease 
(PUD) 2 
Gastritis 2 
CKD due to 
Diabetes, Stage 3 1 
CKD due to 
Diabetes, Stage 4 1 
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CKD due to 
Diabetes, Stage 5 2 
CKD due to 
Hypertension, Stage 
3 1 
CKD due to 
Hypertension, Stage 
4 1 
CKD due to 
Hypertension, Stage 
5 2 
ckd_glomerulo3 1 
ckd_glomerulo4 1 
ckd_glomerulo5 2 
CKD due to Other, 
Stage 3 1 
CKD due to Other, 
Stage 4 1 
CKD due to Other, 
Stage 5 2 
Uterine Fibroids  0 
Other Gyne 0 
Other 
Hemoglobinopathies 1 
Endocrine, 
Metabolic & Other 
Blood Disorders 0 
hemog_g6pd 1 
hemog_g6pd_hemi 1 
hemog_thalass_btm 2 
hemog_thalass_btt 1 
hemog_thalass_ett 0 
hemog_thalass_hebt 2 
hemog_thalass_hhd 2 
hemog_sickle_hscbt 2 
hemog_sickle_hscd 2 
hemog_sickle_scbt 2 
hemog_sickle_sct 0 
HIV 0 
*0 = mild anemia; 1 = moderate anemia; 2 = severe anemia 
 
 
 
671
Priors: Severity 
Anemia Subtype Expected Variation 
Malaria 1 
Gastritis 2 
Peptic Ulcer Disease 
(PUD) 3 
Maternal Hem. 4 
Endocrine 5 
Other Gyne 6 
Other Infectious 7 
Other NTDs 8 
ckd_other3 9 
ckd_htn3 10 
ckd_diabetes3 11 
ckd_glomerulo3 12 
ckd_other4 13 
ckd_htn4 14 
ckd_diabetes4 15 
ckd_glomerulo4 16 
ckd_other5 17 
ckd_htn5 18 
ckd_diabetes5 19 
ckd_glomerulo5 20 
hemog_thalass_ett 21 
hemog_sickle_sct 22 
hemog_thalass_btt 23 
hemog_g6pd 24 
hemog_g6pd_hemi 25 
Iron Deficiency 26 
Uterine Fibroids 27 
hemog_sickle_hscd 28 
Schistosomiasis 29 
hemog_thalass_hhd 30 
Other 
Hemoglobinopathies 31 
hemog_sickle_scbt 32 
Hookworm 33 
hemog_thalass_hebt 34 
hemog_sickle_hscbt 35 
hemog_thalass_btm 36 
HIV 37 
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Causes for which allocation of residual anemia envelope  
was based on fixed proportion redistribution methods*: 
Iron-deficiency anemia (IDA) 
Uterine fibroids 
Other infectious diseases 
Other gynecological disorders 
Other neglected tropical diseases 
Other endocrine, nutrition, blood and immune disorders 
Other hemoglobinopathies and hemolytic anemias   
 
* A minimum of 10% of all anemia was assigned to residual categories based on analysis of NHANES-III 
data from the United States 
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 Epilepsy Impairment 
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Case definition 
Since GBD 2013, we have used the following definitions from the “Guidelines for Epidemiologic Studies 
on Epilepsy”: 1) Epilepsy: a condition characterized by recurrent (two or more) epileptic seizures, 
unprovoked by any immediate identified cause, and 2) “Active” epilepsy: a prevalent case of active 
epilepsy is defined as a person with epilepsy who has had at least one epileptic seizure in the previous 
five years, regardless of antiepileptic drug (AED) treatment. We also use the following ICD-10 codes for 
epilepsy: G40 (Neuro, epilepsy, total) and G41 (Neuro, epilepsy, status epilepticus). We defined severe 
epilepsy as having seizures one or more times per month.  
Input data 
 Model inputs 
For GBD 2016, we conducted a systematic review covering 10/1/2014 to 10/7/2016 using the following 
search string:  
("2014/10/01"[PDAT] : "2016"[PDAT]) AND ("epilepsy"[MeSH Terms] OR "epilepsy, partial, motor"[MeSH 
Terms] OR "epilepsy, benign neonatal"[MeSH Terms] OR "epilepsy, reflex"[MeSH Terms] OR "myoclonic 
epilepsy, juvenile"[MeSH Terms] OR "epilepsy, frontal lobe"[MeSH Terms] OR "epilepsy, complex 
partial"[MeSH Terms] OR "epilepsy, post-traumatic"[MeSH Terms] OR "epilepsy, temporal lobe"[MeSH 
Terms] OR "epilepsy, absence"[MeSH Terms] OR "epilepsy, tonic-clonic"[MeSH Terms] OR "epilepsies, 
myoclonic"[MeSH Terms] OR "epilepsies, partial"[MeSH Terms] OR epilepsy[Title/Abstract]) AND 
(incidence[Title/Abstract] OR prevalence[Title/Abstract])  NOT(animals[MeSH] NOT humans[MeSH]).  
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Of 952 hits, 32 were marked for extraction. Additional data seeking efforts also led to the addition of 12 
more sources on epilepsy prevalence in India subnationals.  A flow chart documenting the review is 
displayed below.  
 
 
 
 
 
 
 
 
 
 
 
 
We included representative, population-based surveys that reported of prevalence, incidence, remission 
rate, excess mortality rate, relative risk of mortality, standardized mortality ratio, or with-condition 
mortality rate. We excluded studies with no clearly defined sample (eg, among clinic attenders or patient 
organization members with non-specific or non-representative catchment area). The table below details 
the model inputs used to estimate the epilepsy impairment. 
 Prevalence Incidence Mortality risk 
Studies 317 81 23 
Countries/subnationals 192 51 23 
GBD world regions 20 15 10 
 
The inputs for the regressions used to split the epilepsy impairment envelope were also updated for GBD 
2016.  These regressions are used to determine the proportion of epilepsy that is primary or idiopathic, 
the proportion of epilepsy that is severe (one or more fits per month), the proportion of epilepsy that is 
untreated (the treatment gap), and the proportion of treated epilepsy that is treated without fits (no fits 
reported in the preceding year).  
For GBD 2016, a new systematic review was conducted covering 1/1/2006 to 10/17/2016 using the 
search term:  
("2006"[PDAT] : "2016"[PDAT]) AND ("epilepsy"[MeSH Terms] OR "epilepsy, partial, motor"[MeSH Terms] 
OR "epilepsy, benign neonatal"[MeSH Terms] OR "epilepsy, reflex"[MeSH Terms] OR "myoclonic epilepsy, 
juvenile"[MeSH Terms] OR "epilepsy, frontal lobe"[MeSH Terms] OR "epilepsy, complex partial"[MeSH 
Terms] OR "epilepsy, post-traumatic"[MeSH Terms] OR "epilepsy, temporal lobe"[MeSH Terms] OR 
952 Sources 
Identified in 
Systematic Review
94 Sources after 
Title/Abstract 
Screening
858 Sources 
Excluded based on 
Title/Abstract 
Screening
32 Sources after 
Full-Text Screening
62 Sources Excluded 
based on Full Text 
Screening
44 Sources 
Extracted
12 Sources 
identified through 
additional data 
seeking efforts
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"epilepsy, absence"[MeSH Terms] OR "epilepsy, tonic-clonic"[MeSH Terms] OR "epilepsies, 
myoclonic"[MeSH Terms] OR "epilepsies, partial"[MeSH Terms] OR epilepsy[Title/Abstract]) AND 
(incidence[Title/Abstract] OR prevalence[Title/Abstract] OR epidemiology[Title/Abstract]) AND 
(sever*[Title/Abstract] OR treated[Title/Abstract] OR “drug resistant epilepsy”[MeSH] OR “treatment 
resistant”[Title/Abstract] OR proportion[Title/Abstract] OR “clinical characteristics”[Title/Abstracts] OR 
“treatment gap”[Title/Abstract]) NOT(animals[MeSH] NOT humans[MeSH]) 
Of 1,234 hits, 37 were marked for extraction.  Additional data seeking efforts also led to the addition of 
five more sources on the treatment gap in India subnationals.  A flow chart documenting the review is 
displayed below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Severity splits & disability weights 
 
The table below illustrates the severity levels, descriptions, and disability weights associated with 
epilepsy. These are calculated using regressions from literature (ie, frequency of seizures).  
Severity level Lay description Disability weights (95% CI) 
severe (seizures >= once per 
month) 
This person has sudden seizures 
one or more times each month, 
with violent muscle contractions 
and stiffness, loss of  
consciousness, and loss of urine 
or bowel control. Between 
seizures the person has memory 
loss and difficulty concentrating. 
0.552 
(0.375–0.71) 
less severe (seizures < once per 
month) 
This person has sudden seizures 
two to five times a year, with 
0.263 
(0.173–0.367) 
1,234 Sources 
Identified in 
Systematic Review
56 Sources after 
Title/Abstract 
Screening
1,178 Sources 
Excluded based on 
Title/Abstract 
Screening
24 Sources after 
Full-Text Screening
32 Sources Excluded 
based on Full Text 
Screening
29 Sources 
Extracted
5 Sources identified 
through additional 
data seeking efforts
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violent muscle contractions and 
stiffness, loss of consciousness, 
and loss of urine or bowel 
control. 
Treated without fits  This person has a chronic 
disease that requires medication 
every day and causes some 
worry but minimal interference 
with daily activities. 
0.049 
(0.031–0.072) 
 
Modelling strategy  
 
We modelled the prevalence of epilepsy in two steps: first, we created an epilepsy impairment envelope. 
Second, we split the envelope into primary (or idiopathic) and secondary epilepsies. Each of these were 
subdivided into “severe” (on average one or more fits per month) and “non-severe.” Non-severe cases 
were subdivided into “treated” and “un-treated.” Finally, “treated” cases were divided into “treated cases 
with fits” (between one and 11 fits on average in the preceding year) and “treated cases without fits” (no 
fits reported in the preceding year). 
In the first step, we used the DisMod-MR tool for the epilepsy impairment envelope to model a consistent 
fit between incidence, prevalence, remission, and standardized mortality ratio data while using meta-
regression to correct data points with non-reference study quality characteristics. We found no 
systematic bias for the covariate “non-standard case definition” indicating studies that did not define 
“active epilepsy” and additionally the covariate was not significant as a “z-cov”, which acts as a multiplier 
applied to the standard error and thus results in these data points being given less weight in the analysis 
than the “reference” data points. Therefore, we excluded this covariate from the model.  We also 
included data on lifetime prevalence and therefore added a covariate on lifetime prevalence data points. 
We also included country-level covariates on prevalence for the SEV epilepsy scalar, which summarizes 
the epilepsy risk exposure level for each country, and pig meat consumption per capita, which is used as a 
proxy for the level of neurocysticercosis, a common cause of secondary epilepsy.  We included cause-
specific mortality rate (CSMR) results from the epilepsy mortality model as input data to the DisMod 
model. Where age-specific prevalence data was available, we calculated excess mortality rate (EMR) from 
prevalence and CSMR. We included the log of the lag distributed income (LDI) as a covariate on EMR to 
account for lower mortality in developed countries. We included Bayesian priors on remission to account 
for the scarcity of remission data. We set bounds on remission from 0 to 0.25 from age 0-60 and 0 to 0.05 
from age 61-100. The table below indicates the covariates used in the estimation process, as well as 
parameters, betas, and exponentiated betas. 
Measure Variable Name Beta Exponentiated 
prevalence Recall Lifetime 0.18 (0.15 – 0.22) 1.20 (1.17–1.24) 
prevalence All MarketScan, 
year 2000 
-0.89 (-0.94 – -0.83) 0.41 (0.39–0.43) 
prevalence All MarketScan, 
year 2010 
-0.43 (-0.47 – -0.37) 0.65 (0.62–0.69) 
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prevalence All MarketScan, 
year 2012 
-0.35 (-0.41 – -0.30) 0.70 (0.67–0.74) 
prevalence Pig Meat 
Consumption (kg 
per capita) 
0.0054 (0.00012 – 
0.015) 
1.01 (1.00–1.02) 
Prevalence Log-transformed 
age-standardized 
SEV scalar for 
epilepsy 
0.79 (0.75-0.90) 2.21 (2.12-2.46) 
excess mortality 
rate 
LDI (I$ per 
capita) 
-0.55 (-1 – -0.1) 0.58 (1.37–0.90) 
 
In the second step, we used a mixed-effects generalized linear models (binomial family) to predict the 
proportion of idiopathic epilepsy, the proportion of severe epilepsy, the proportion of treated epilepsy 
and the proportion of epilepsy that is treated without fits.  
Because not all of the data on the proportion of idiopathic epilepsy uses optimal case finding methods 
(using CT scans or MRI’s in addition to EEG’s in order to diagnose secondary epilepsy), for GBD 2016 we 
decided to do add a covariate to crosswalk studies with non-optimal case finding methods to those with 
adequate methods. The regression for the proportion of epilepsy that is idiopathic therefore has fixed 
effects on this study quality covariate as well as the under-5 mortality rate, the log of pig meat 
consumption (per capita), and the proportion of a country with access to proper sanitation, as well as a 
random effect on super-region.  
We used similar models to predict the proportion of severe epilepsy and treatment gap based on the 
reported proportions extracted from the systematic review. To predict the proportion of severe epilepsy 
and the treatment gap, we used mixed-effects models with a fixed effect on the log of HAQ Index and a 
random effect on super-region.   
For GBD 2015, a meta-analysis was used to generate two different pooled estimates for proportion of 
treated epilepsy that is seizure-free in developing and developed countries, as there was not enough data 
to run a regression. However, for GBD 2016 the expanded dataset allowed for the implementation of a 
generalized linear model (binomial family) to generate predictions for the proportion of treated epilepsy 
that is seizure-free. We used a fixed effect on the log of HAQ Index.   
We tested a fixed effect on Socio-demographic Index (SDI) and random effects on region and country in 
different models, but they did not improve the model. We generated 1,000 draws of country-specific 
estimates for each year between 1980 and 2016 for each of the models. The table below shows the betas 
from these regressions.  
Regression  covariate beta SE 
Idiopathic Under-5 Mortality -65.82 7.50 
Idiopathic Pig meat consumption -0.12 0.02 
Idiopathic Sanitation 0.45 0.16 
Idiopathic Study Quality 0.88 0.07 
Severe HAQ Index -2.15 0.24 
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Treatment Gap HAQ Index -3.17 0.18 
Treated without fits HAQ Index 3.65 0.21 
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 Infertility Impairment 
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Case definition 
For GBD 2016, the following case definitions were used for infertility: 
1. Primary infertility is defined as a couple who have not had a live birth, who wish to have a child, 
and have been in a union for more than five years without using contraceptives.  
 
2. Secondary infertility is defined in a couple who wish to have a child and have been in a union for 
more than five years without using contraceptives since the last live birth. 
 
Input data 
 Model inputs 
 
We included data for women in five-year age groups between ages 15 and 49 from population-based 
surveys including the Demographic and Health Surveys (DHS), World Fertility Surveys (WFS), Reproductive 
Health Surveys (RHS), Family and Fertility Survey (FFS), and others (EUR, NSF, PCD, PFM). Although these 
surveys only interviewed women, the resultant estimate of prevalence is an indicator of couples’ 
infertility, as it is not possible to determine in a survey which partner is the cause of the infertility. 
Because some surveys ask questions of only ever-married women, we separately estimated the 
prevalence of four parameters:  
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As described below, infertility will be estimated by multiplying prevalence among exposed by the 
exposure. The table below illustrates the extent of data coverage for the infertility impairment for GBD 
2016. 
Table 2: Data coverage 
Model Sources Subnational Country Region 
Super-
region 
primary infertility impairment 314 1 113 20 7 
secondary infertility impairment 315 1 112 19 7 
primary infertility exposure 266 1 101 17 7 
secondary infertility exposure 267 1 101 17 7 
proportion male primary infertility 18 2 15 8 6 
proportion female primary infertility 18 2 15 8 6 
proportion male secondary infertility 18 2 15 8 6 
proportion female secondary infertility 18 2 15 8 6 
Sequelae/disability weights 
Health state name Health state description 
Disability 
weight 
Infertility, primary This person wants to have a child and has a fertile partner, but the couple cannot conceive. 
0.008 
(0.003-
0.015) 
Infertility, secondary 
This person has at least one child, and wants to have more children. The person has a fertile partner, but 
the couple cannot conceive.  
0.005 
(0.002-
0.011) 
Modelling strategy  
For GBD 2016, we estimated the prevalence of primary and secondary infertility by sex and cause in three 
steps.  
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To estimate the prevalence of infertility among couples, we first ran four DisMod-MR 2.1 models to 
estimate the four parameters detailed above. For prevalence of infertility, we tried using the natural log 
of the age-standardized death rate (lnASDR) of STDs, but it was not statistically significant so we did not 
use it in the final model.  
Next, we estimated primary and secondary infertility from DisMod-MR 2.0 models by multiplying the 
estimates for prevalence of infertility among exposed women by the prevalence of exposure to infertility 
to obtain prevalence of infertility among all women and all men. 
2) Estimation of infertility by sex
We ran four DisMod models to estimate the proportion of primary and secondary infertility due to male 
or female causes. Because infertility in some couples is attributable to both partners rather than just one, 
the sum of the proportion of couples’ prevalence due to male factor infertility and due to female factor 
infertility is greater than 1. Again, we tried using lnASDR of STDs as a covariate, but it was not statistically 
significant so we did not use it in the final model. We multiplied our prevalence of primary and secondary 
infertility derived in step 1 by the proportion due to male and female factors to estimate primary and 
secondary infertility by sex.  
3) Causal attribution
There are seven identified causes of female infertility in the GBD 2013 cause list: chlamydia, gonorrhea, 
other sexually transmitted diseases, maternal sepsis, polycystic ovarian syndrome, endometriosis, and 
Turner syndrome. For each of these diseases, we determined the prevalence of infertility by a literature 
review of the probability of becoming infertile due to that disease. For sexually transmitted diseases we 
applied a proportion with infertility derived from Westrom et al. (1992, Sex Transm Dis) to incident cases 
of pelvic inflammatory disease and streamed out prevalence over the fertile age range using DisMod-MR 
2.0.12. We added all the disease-specific estimates of prevalence and assigned the remaining proportion 
to categories of “female primary infertility due to other causes” and “female secondary infertility due to 
other causes.” We assumed all infertility from Turner syndrome is primary infertility and all infertility 
following maternal sepsis is secondary infertility. The only recognized cause of male infertility in the GBD 
2013 cause list is Klinefelter syndrome. We assigned all other male infertility to “male infertility due to 
other causes.” 
We have made no substantive changes in the modelling strategy from GBD 2015. 
1) Estimation of couples’ infertility
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 Developmental Intellectual Disability Impairment 
 
Flowchart 
 
Case definition 
Developmental intellectual disability is a condition of below-average intelligence or mental ability. 
Consistent with the American Association on Intellectual and Developmental Disabilities, we define 
developmental intellectual disability as a condition originating before age 18 (thus, does not include 
impairment due to stroke, Alzheimer’s, etc.). We model the following severities, as measured by 
intelligence quotient (IQ) tests: 
Type of intellectual disability IQ 
Profound 0 to 19 
Severe 20 to 34 
Moderate  35 to 49 
Mild  50 to 69 
Borderline  70 to 85 
 
Input data 
 
Model inputs 
1) Prevalence data: Prevalence of intellectual disability (IQ <70) came from a systematic review starting 
1/1/1990 using the following search string:  
(((intellectual disability[MeSH Terms]) AND prevalence[Title/Abstract]) AND ('1990'[Date - Publication] : 
'3000'[Date - Publication]))   
For GBD 2015, this search had 2,115 hits, of which 13 were extracted that had not been previously 
included in GBD. We included studies that estimate the general population prevalence of intellectual 
disability. We excluded studies that do not use a case definition based on intelligence quotient (IQ) or 
investigated non-representative groups, like hospital patients or people of a specific ethnicity. 
2) IQ mean and standard deviation: Data for mean and SD of IQ came from three source types: 
a. IQ instruments: We conducted a systematic review for IQ scores from standardized tests 
designed to measure intelligence. Given the vast number of instruments that are used to 
measure IQ, we used instrument-specific search strings. In total, our search had 85,000 hits, 
of which 69 were extracted. We excluded non-general populations or non-school populations 
(eg, gifted or impaired populations). We extracted the mean and SD of IQ, in addition to 
whether or not a norming procedure had been applied to the data. Where available, we 
extracted the raw mean and SD as well as the normalized mean and SD.  
b. International Educational Attainment (IEA) surveys: Scores from standardized mathematics, 
reading, and/or science exams were extracted from school-based surveys, given that IEA tests 
measure a closely related concept to IQ in school-age populations.  
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c.  
Survey Country-Years 
Programme for International Student 
Assessment (PISA) 
73 country-years 
Progress in International Reading Literacy 
Study (PIRLS) 
212 country-years 
Trends in International Mathematics and 
Science Study (TIMSS) 
156 country-years 
 
d. Cognitive function surveys: Scores from cognitive function surveys were used where IQ and 
IEA data were unavailable, particularly for older populations and infants.  
Survey Country-Years 
Survey of Health, Ageing, and Retirement in 
Europe (SHARE) 
131 country-years 
WHO Study on Global AGEing and Adult 
Health (SAGE) 
12 country-years 
Longitudinal Study of Ageing (LSA) TBD 
Health and Retirement Survey (HRS) TBD 
Bayley Scales of Infant and Toddler 
Development 
TBD; from literature 
 
 
Severity split/disability weight 
Health state Description 
Disability 
weight 
Borderline intellectual functioning 
This person is slow in learning at school. As an adult, the person has 
some difficulty doing complex or unfamiliar tasks but otherwise 
functions independently. 
0.011 
(0.005–
0.02) 
Intellectual disability/mental 
retardation, mild 
This person has low intelligence and is slow in learning at school. As an 
adult, the person can live independently, but often needs help to raise 
children and can only work at simple supervised jobs. 
0.043 
(0.026–
0.064) 
Intellectual disability/mental 
retardation, moderate 
This person has low intelligence, and is slow in learning to speak and to 
do even simple tasks. As an adult, the person requires a lot of support to 
live independently and raise children. The person can only work at the 
simplest supervised jobs. 
0.1 
(0.066–
0.142) 
Intellectual disability/mental 
retardation, severe 
This person has very low intelligence and cannot speak more than a few 
words, needs constant supervision and help with most daily activities, 
and can do only the simplest tasks. 
0.16 
(0.107–
0.226) 
Intellectual disability/mental 
retardation, profound 
This person has very low intelligence, has almost no language, and does 
not understand even the most basic requests or instructions. The person 
requires constant supervision and help for all activities. 
0.2 
(0.133–
0.283) 
 
 
684
Modelling strategy  
We modelled the prevalence estimates of intellectual disability (ID), both aetiology-specific IDs and 
idiopathic ID, over multiple steps. For GBD 2016, our modelling strategy changed significantly. We 
additionally used IQ distribution data to inform the estimates of ID prevalence, as follows.  
1) Estimate Intellectual Disability Prevalence (IQ <70) 
First, we ran a DisMod-MR 2.1 model to estimate the total prevalence of intellectual disability of level 
IQ <70. We included lag-distributed income and education in the model.  
 
2) Estimate population mean and SD of Intelligence Quotient 
Second, we crosswalked International Educational Attainment data and cognitive function surveys to 
one standard IQ measure. We crosswalked by matching country/age/year sources for which we had 
two or more types of data. Using the IQ data and the data converted to IQ as inputs, we ran a single-
parameter, continuous DisMod-MR 2.1 model estimating the mean and SE of IQ using standardized 
measure. In this model, we included log-transformed LDI (per capita), proportion underweight, and 
log-transformed education (age-standardized) as country-level covariates in this model. We 
additionally included as a covariate an indicator of instrument-type. These instrument-types were 
determined based upon similarity of theoretical constructs and concurrent validity.  
3) Fit parametric distribution to mean and SD of IQ and prevalence of intellectual disability 
We fit a distribution using the mean and SD of IQ, and the prevalence of ID using an ensemble 
approach. The ensemble approach takes a weighted average of multiple distributions, rather than a 
single distribution. The distribution is fit via a Method of Moments, where each potential distribution 
is weighted based upon in-sample fit. This allows us to adapt to different skew over time and 
geographies, and is a highly generalizable approach that does not specify the underlying distribution.  
4) Severity-specific intellectual disability  
We split the total prevalence of idiopathic ID into four severity levels: mild (IQ 50-69), moderate (IQ 
35-49), severe (IQ 20-34), and profound (IQ below 20). 
5) Causal attribution  
We estimated prevalence of each etiology-specific ID by models from the following parent causes. 
Since we are modelling only developmental intellectual disability, causes such as stroke and 
Alzheimer’s are not included in the causal attribution process.  
 
Neonatal preterm birth complications (<28w, 28-32w, 32-36w) 
Neonatal encephalopathy due to birth asphyxia and trauma 
Hemolytic disease and other neonatal jaundice 
Meningitis (pneumococcal, H influenza type B, meningococcal, other bacterial) 
Encephalitis 
Malaria 
Neonatal tetanus 
Iodine deficiency 
African trypanosomiasis 
Down syndrome 
Klinefelter syndrome 
Chromosomal unbalanced rearrangements 
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Neural tube defects 
Hypertensive disorders of pregnancy (eclampsia, preeclampsia) 
Autism  
Fetal alcohol syndrome 
For autism, we identified six studies reporting severity of intellectual disability. We conducted a meta-analysis to 
produce the following severity distribution which we applied to the prevalence of autism to produce severity-
specific ID due to autism.  
ID severity  Mean SE 
None 0.161 0.034 
Borderline 0.161 0.034 
Mild 0.375 0.037 
Moderate 0.190 0.031 
Severe 0.090 0.177 
Profound 0.024 0.134 
 
We calculated prevalence of idiopathic ID by subtracting all severity- and aetiology-specific IDs from the 
severity-specific envelope ID assuming the residuals to represent idiopathic. If the residual was less than 
5% of the severity-specific envelope, the prevalence of all aetiology-specific IDs were proportionally 
squeezed to fit within 95% of the envelope, leaving 5% for idiopathic ID. 
 
As we estimated the prevalence of individual aetiology-specific IDs by models from the respective parent 
causes, the squeezing may result in a distorted balance of prevalence estimates within their parent 
causes. With the aim to maintain consistencies of prevalence within each of the parent causes, we added 
the difference between the original and the squeezed prevalence estimates to the “motor impairment” 
sequela if the squeezed sequela represented “motor and cognitive impairment.” For autism, we obtained 
the fraction of cases that result in ID from literature (0.29; 0.27–0.30 95% CI) and applied to the 
subtraction and squeezing processes. We assume all ID cases due to iodine deficiency (cretinism) to result 
in either severe or profound level, and Klinefelter syndrome cases that result in ID will have either 
borderline or mild level. 
In GBD 2013, all aetiology-specific models were squeezed into the overall (IQ <70) envelope. In 2015, we 
squeeze each model into its discrete severity envelope. GBD 2016 methods are still in development and 
will be finalized later this summer.   
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Guillain–Barré Syndrome (GBS) Impairment 
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Case definition 
Guillain-Barré syndrome is a rare condition that usually occurs as a complication of respiratory or 
gastrointestinal infection. It is considered an immune-mediated nerve dysfunction with rapid onset of 
weakness in feet and hands ascending toward the trunk. In the acute phase about a quarter of cases 
required mechanical ventilation for survival. The majority of cases fully recover within months to a year. 
The following ICD codes are used G61.0 (GBS) and 357.0 (Acute infective polyneuritis). These codes are 
also referenced in Methods Appendix Table 4. 
Input data 
 Model inputs 
A systematic search was performed in Pubmed on 28.01.2010 which produced a systematic review by 
McGrogan A et al. (2009). The search covered 1980-2008 using keywords “Guillain-Barré Syndrome” or 
“polyradiculoneuropathy” and “incidence” or “epidemiology.”  This review included 63 relevant studies 
(published between 1980 and 2008) which reported on Guillain-Barré incidence rate and provided the 
estimated incidence rates for 25 countries in nine GBD regions). There were 35 studies from our 
systematic review that provided information on the underlying cause: 31 mentioning all of the identified 
underlying infectious diseases; 26 providing a proportion for upper respiratory infections, three for 
influenza, 25 for diarrheal disease, and 14 for other diseases. 
An additional search was undertaken for more information on mortality, remission, and duration of GBS. 
As the mortality, remission, and case-fatality rate did not vary significantly across the studies and there 
were  time constraints, instead of doing a systematic search for GBS mortality and remission, a general 
search was carried out. We extracted case fatality rate from five studies, and remission from four studies.  
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measure 
Data 
sources 
Country/Subnational 
Coverage GBD World Regions 
incidence 61 111 9 
 
 
Updates to systematic reviews are performed on an ongoing schedule across all GBD causes, and an 
update for Guillain-Barré syndrome will be performed in the next one to two iterations. Inpatient hospital 
data were extracted using the ICD codes listed above. Only primary diagnoses were considered, with the 
reasoning that Guillain-Barré syndrome should appear as a primary diagnosis and we do not wish to 
include follow-up visits that may be listed as secondary or tertiary codes.  
 
We still had some locations with systematically high or low hospital data.  In order to systematically 
outlier hospital data that was implausible, we outliered all data from any sex-specific country-years where 
the age-standardized rates were higher than 125% of the second highest sex-specific country-year of US 
hospital data or 75% of the second lowest sex-specific country-year of US hospital data.  This assumes US 
hospital data to be the gold standard of hospital data.  
 
 Etiology splits 
 
Information on etiology splits come from a systematic review and meta-analysis of the literature 
completed for GBD 2010. This review searched for articles providing information on the proportion of 
Guillain-Barré cases with any described etiological cause, the proportion of Guillain-Barré cases attributed 
to influenza, the proportion of Guillain-Barré cases attributed to upper respiratory infections, the 
proportion of Guillain-Barré cases attributed to diarrheal diseases and the proportion of Guillain-Barré 
cases attributed to other infections. This review yielded 35 articles; a breakdown of how many articles 
inform each proportion contributing to the split is provided below: 
 
Split Number of Sources 
All specified etiologies 31 
Influenza 3 
Upper respiratory infections 26 
Diarrheal diseases 25 
Other infectious diseases 14 
 
First the envelope for Guillain-Barré cases due to all specified etiologies is established by doing a meta-
analysis on the proportions reported in the studies included. Then, the proportions for each of the other 
splits are squeezed to fit the envelope created in the all specified meta-analysis. Finally, the difference 
between all specified and 100% is attributed to other neurological disorders. The final results of these 
etiology splits are shown below:  
 
Etiology Mean Lower Upper 
Other neurological disorders 0.382 0.331 0.669 
Influenza 0.119 0.071 0.192 
Upper respiratory infections 0.319 0.27 0.372 
Diarrheal diseases 0.109 0.086 0.135 
Other infectious diseases 0.071 0.054 0.093 
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Disability weights 
 
One health state was used for all Guillain-Barré cases. It is described as paralyzed from the waist down, 
cannot feel or move the legs, and has difficulties with urine and bowel control. The person uses a 
wheelchair to move around. The disability weight is 0.296 (0.198–0.414).  
 
Modelling strategy  
All data, from both the literature review and hospital extraction, were corrected for the survival rate. A 
random effects meta-analysis calculated a 95% case fatality rate (95% CI 93–98%). A forest plot showing 
the results of this meta-analysis is displayed below.  As mortality mainly occurs during the acute phase of 
the disease (usually within four weeks of onset), the pooled survival rate was used to get the incidence of 
the people surviving after the acute phase of the GBS. Where surveillance data were reported at age 
groups of over 20 years, we applied the age pattern derived from US Marketscan claims data to age-split 
the data.  
 
 
 
Dismod MR was used to estimate prevalence of Guillain-Barré syndrome for every location, year, age, and 
sex. We included a study-level covariate on hospital data in order to adjust for a potential systematic bias 
in this type of data.  The exponentiated beta for this covariate was 1.30 (1.26-1.33).  We then split the 
overall prevalence of the impairment by underlying etiology (upper respiratory infections, influenza, 
diarrheal diseases, other infections, and other neurological causes). We used random effects meta-
analysis to pool these proportions. We squeeze the proportions for influenza, diarrheal diseases, upper 
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respiratory infections, and other infectious diseases to add to the proportion for all identified infectious 
underlying diseases. We assigned the complement to one of the proportion with any underlying 
infectious disease to a rest category of “idiopathic Guillain-Barre syndrome” that is classified under 
neurological disorders. 
 
There are no substantive modelling changes from GBD 2015.  
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 Pelvic Inflammatory Disease (PID) Impairment 
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Case definition 
Pelvic inflammatory disease (PID) is an infection of the female reproductive organs presenting as a 
complication of infection by a sexually transmitted disease. It can irreversibly damage the uterus, 
fallopian tubes, or other parts of the female reproductive system, leading to infertility.  
 
Input data 
 Model inputs 
A systematic review was completed for GBD 2013 on October 28, 2013, using the following search terms:   
o (("pelvic inflammatory disease"[Title/Abstract] OR "salpingitis"[Title/Abstract]) AND 
(“1994”[Date – Publication] : “2013”[Date – Publication])) 
 
In addition, we included studies with confirmed clinical diagnosis in general population.  
 
No systematic review was conducted for GBD 2015. Updates to systematic reviews are performed on an 
ongoing schedule across all GBD causes, and an update for PID will be performed in the next one to two 
iterations. 
 
Inpatient outpatient MarketScan data were extracted as incidence rates, as per the ICD codes above. We 
also extracted inpatient hospital data and employed two crosswalks derived from MarketScan data. First, 
we adjusted hospital inpatient data using a ratio of primary diagnoses for PID to all diagnoses, since the 
sexually transmitted disease (rather than PID, the consequent syndrome) may appear as the primary 
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diagnosis. Second, we adjusted using a ratio of inpatient/outpatient diagnoses, since not all PID must be 
treated in an inpatient facility. The result is an estimate of total PID incidence.  
 
PID incidence input data  
 
The table below illustrates the data sources used in GBD 2016: 
 
Measure 
Data 
sources 
Subnational 
coverage 
Country 
coverage 
Region 
coverage 
Super-region 
coverage 
Incidence 37 86 22 6 3 
 
A subset of the studies from the systematic review reported the underlying etiology of PID, allowing us to 
estimate the proportion of PID due to chlamydia, gonorrhea, and other sexually transmitted diseases.  
 
Proportion 
of PID due 
to data_sources subnational_coverage country_coverage region_coverage super_region_coverage 
chlamydia 15 5 8 6 3 
gonorrhea 10 5 6 4 2 
other 
STDs 15 5 8 6 3 
 
 Health states and disability weights 
 
Health state name Health state description 
Disability 
weight 
Abdominopelvic 
problem, severe 
This person has severe pain in the belly and feels nauseated. The 
person is anxious and unable to carry out daily activities. 
0.324 
(0.219–
0.442) 
Abdominopelvic 
problem, moderate 
This person has pain in the belly and feels nauseated. The person has 
difficulties with daily activities.  
0.114 
(0.078–
0.159) 
 
Modelling strategy  
 
First, we estimated the total incidence and prevalence of pelvic inflammatory disease using a Dismod-MR 
2.1. We used a study-level covariate on hospital inpatient data. This has the effect of crosswalking 
inpatient incidence (from hospital inpatient facilities) to total PID incidence (derived from MarketScan 
inpatient and outpatient claims data). We used the natural log of the age-standardised death rate 
(lnASDR) of sexually transmitted diseases (excluding HIV) as a location fixed effect, since these diseases 
cause PID and thus their mortality is correlated to PID incidence. We used Bayesian priors on remission 
(13–17) and excess mortality rate (0–0.15).  
 
 
Covariate Parameter beta Exponentiated beta 
Hospital inpatient 
(study-level) 
Incidence  
0.65 (-0.77 – -0.59) 0.52 (0.46–0.56) 
lnASDR STDs (location) Incidence  -0.65(-0.77 – -0.59) 0.52 (0.46–0.56) 
 
692
Second, we ran three separate DisMod models for the proportion of PID due to the following three 
causes: chlamydia, gonorrhea, and other STDs. For each model, we used the lnASDR of the underlying 
STD.  
 
Covariate Parameter Exponentiated beta 
lnASDR chlamydia  Proportion  1.07 (1.00–1.22) 
lnASDR gonorrhea  Proportion  1.19 (1.02–1.34) 
lnASDR STDs  Proportion  1.00 (1.00–1.01) 
 
DisMod estimate for the proportions due to each etiology were proportionally squeezed to sum to 1.  
 
We extracted MarketScan claims data for the first time in GBD 2015. As described in detail above, this 
allowed us to make two crosswalks (from primary diagnosis to all diagnoses, and from inpatient to all 
diagnoses) that we had not previously. In GBD 2013, we only were able to use a ratio of 
inpatient:outpatient diagnoses from one literature source (Rein et al.). The combined effect of these two 
crosswalks is that we estimate substantially more PID cases than estimated in GBD 2013.  
 
No additional changes were made to the estimation process for GBD 2016. 
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Case definition  
Heart failure was diagnosed clinically using structured criteria such as the Framingham or European 
Society of Cardiology criteria. Previous iterations of GBD modelled symptomatic (i.e., NYHA Class II and 
above) episodes of HF only. Beginning in GBD 2016, we used ACC/AHA Stage C and above to capture both 
persons who are currently symptomatic and those who have been diagnosed with heart failure, but are 
currently asymptomatic. 
Framingham Criteria (1): Must fulfill two major criteria or one major and two minor criteria. 
Major criteria: Paroxysmal nocturnal dyspnoea, neck vein distention, rales, radiographic cardiomegaly, 
acute pulmonary oedema, S3 gallop, increased central venous pressure (>16 cm H2O at right atrium), 
hepatojugular reflux; weight loss >4.5 kg in 5 days in response to treatment  
Minor criteria: bilateral ankle oedema, nocturnal cough, dyspnoea on ordinary exertion, hepatomegaly, 
pleural effusion, decrease in vital capacity by one-third from maximum recorded, tachycardia (heart 
rate>120 beats/min).  
European Society of Cardiology (2):  
Typical signs (elevated jugular venous pressure, pulmonary crackles and peripheral oedema) and 
symptoms (e.g. breathlessness, ankle swelling and fatigue) caused by a structural and/or functional 
cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest 
or during stress. 
Input data  
Model inputs  
A systematic review was performed for GBD 2016. The search terms used were: "heart failure"[TIAB] AND 
(epidemiology[MeSH Terms] OR prevalence[TIAB] OR incidence[TIAB] OR mortality[TIAB]) AND 
("1990/01/01"[PDAT] : "2016/09/02"[PDAT]) NOT “animal model” NOT rat NOT mice NOT diabetes[TIAB] 
NOT “renal transplant”[TIAB].  The dates of the search were 01/01/1990 through 09/02/2016. 37,891 
initial hits were returned, and 57 sources were added. An unstructured review of the literature yielded an 
additional 30 sources, of which six were extracted. 
 A systematic review was not performed for GBD 2015 or GBD 2013; however, the GBD 2010 study had 
conducted a systematic literature review for heart failure. 
Overall heart failure prevalence 
Prevalence Incidence Mortality risk 
Studies 22 24 53 
Countries/subnationals 18 20 35 
GBD world regions 7 6 9 
Heart failure due to ischaemic heart disease 
Proportion 
Studies 34 
Countries/subnationals 51 
695
GBD world regions 9 
Heart failure due to hypertensive heart disease 
Proportion 
Studies 35 
Countries/subnationals 38 
GBD world regions 9 
Heart failure due to rheumatic heart disease 
Proportion 
Studies 28 
Countries/subnationals 49 
GBD world regions 11 
Heart failure due to cardiomyopathy 
Proportion 
Studies 32 
Countries/subnationals 51 
GBD world regions 10 
Heart failure due to cardiopulmonary disease 
Proportion 
Studies 12 
Countries/subnationals 10 
GBD world regions 5 
Heart failure due to other cardiovascular and circulatory diseases 
Proportion 
Studies 19 
Countries/subnationals 22 
GBD world regions 6 
Non-literature data included claims data and GBD 2016 death estimates. 
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Severity split inputs  
The table below includes lay descriptions and disability weights for the severity levels of heart failure for 
GBD 2016.  
Severity level Lay description DW (95% CI) 
Mild Is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile on 
level ground. The person feels comfortable at rest or during 
activities requiring less effort.  
0.041 (0.026–0.062) 
Moderate Is short of breath and easily tires with minimal physical activity, 
such as walking only a short distance. The person feels 
comfortable at rest but avoids moderate activity.  
0.072 (0.047–0.103) 
Severe Is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the breathing 
problems.  
0.179 (0.122–0.251) 
Modelling strategy   
The general analytical strategy included estimating the overall prevalence of heart failure using DisMod 
MR 2.1, followed by a multi-step analysis of published literature, claims data, and cause of death data to 
estimate the aetiological fraction for each cause of heart failure. The latter process includes an initial 
assessment of the fraction of heart failure cases attributable to each of the high-level parent cause 
groupings, followed by further division into the detailed causes within each of these groupings, and finally 
a correction factor applied to adjust these proportions. The selection for aetiological causes was based on 
a review of the literature and expert opinion regarding diseases that lead to congestive heart failure. 
We first estimated an overall prevalence of AHA/ACC stage C or D heart failure using literature data, 
hospital data, and claims data. Hospital data were adjusted outside of DisMod, using as reference data 
points reporting prevalence from the literature. Using as a model the adjustment factors developed to 
translate tobacco consumption prevalence to tobacco consumption frequency, we matched 
administrative claims data to population-based literature data based on age group, sex, and super region 
(3). For the adjustment factor, we developed the following generalized additive model on matched data ln�𝜇𝜇𝑟𝑟𝑟𝑟𝑟𝑟,𝑖𝑖� =  𝛽𝛽0 + 𝛽𝛽1 ln�𝜇𝜇𝑏𝑏,𝑖𝑖� + 𝑠𝑠(𝑎𝑎𝑎𝑎𝑎𝑎𝑖𝑖)+𝜀𝜀𝑖𝑖 
Where 𝑖𝑖 represents a given matched observation, 𝑎𝑎𝑎𝑎𝑎𝑎 signifies the data point’s age group, 𝑠𝑠(𝑥𝑥) 
represents a penalized spline where the smoothing parameter is chosen through cross validation and 
𝜇𝜇𝑟𝑟𝑟𝑟𝑟𝑟 and 𝜇𝜇𝑏𝑏 denote the mean of the data point from literature and the mean of the claims data point, 
respectively. Predictions from the model were then taken as the adjusted data points. The standard error 
of each corrected data point was adjusted to account for the uncertainty due to the correction. 
 We set a prior of no remission and capped excess mortality at 1. 
Heart failure due to Chagas was modelled separately as part of the Chagas modelling strategy. We 
subtracted the prevalence of heart failure due to Chagas from the overall heart failure prevalence to give 
an adjusted prevalence of heart failure due to all other aetiologies.  
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Our estimation of the aetiological causes of heart failure makes several assumptions and has several 
limitations. First, we assume that each case of heart failure only has one cause. Second, we rely on claims 
data from the United States, the only country where detailed person-level claims data were available, to 
assess the association between heart failure and underlying aetiologies. Third, we rely on mortality 
estimates due to these underlying causes (regardless of heart failure) to estimate their contribution to 
heart failure deaths in countries where detailed person-level claims data is not yet available. Fourth, we 
utilize the association between claims data and death certificate data in the United States to adjust for 
the differences in coding for ischemic heart disease, the most common cause of heart failure globally, in 
claims data versus death certificates. This approach allows us to produce estimates for all locations and 
can be updated to include more detailed health record and claims data from additional locations as they 
become available. 
To estimate the aetiological fractions for each cause, we calculated the proportion of people with a 
diagnosis of one of the underlying causes of heart failure who also had a diagnosis of heart failure listed 
using claims data from the United States. These proportions were then multiplied by age-, sex-, and 
location-specific deaths (post CoDCorrect) to yield an overall number for each underlying cause of heart 
failure. We then divided these cause-specific totals by the sum of deaths for all aetiologies in order to 
yield a proportion of deaths due to heart failure for each cause. These proportions, along with literature 
data, were used to inform DisMod MR 2.1 models for the six broadest and mutually exclusive and 
collectively exhaustive cause groupings: ischaemic heart disease, hypertensive heart disease, 
cardiomyopathy and myocarditis, rheumatic heart disease, cardiopulmonary disease, and other 
cardiovascular and circulatory diseases. An exception to this approach was made for Sub-Saharan Africa 
where we excluded the proportion estimates generated from claims and death data, relying instead on 
published literature to determine the proportions of heart failure etiologies. This decision was based on 
expert opinion that local patterns differed significantly from what would have been determined from 
claims and death data. The THESUS-HF study, a large-scale, prospective, echocardiographic study of heart 
failure aetiologies in multiple African countries, provided these proportions (3). The results of these six 
proportion models were scaled to sum to one. 
For heart failure due to cardiopulmonary disease, heart failure due to cardiomyopathy and myocarditis, 
and heart failure due to other causes, we calculated the proportion for each sub-cause according to the 
proportion of that cause within each larger aggregate group. 
After the initial splitting and scaling steps, we compared the estimated proportions for the United States 
with the proportions originally calculated from the US claims data. The estimated proportion of HF due to 
IHD was much higher than the proportion of HF due to IHD in the claims data. This difference was due to 
the large number of IHD deaths not related to heart failure. In order to correct this over-estimation, we 
generated a correction factor for HF due to IHD by taking the proportion of HF due to IHD from the claims 
data and dividing it by the proportion of HF due to IHD from the scaled DisMod results. We then 
multiplied the proportion of HF due to IHD from the scaled DisMod results by this correction factor for all 
locations except Sub-Saharan Africa. Since echocardiographic evidence rather than claims data were used 
to model HF etiology proportions in Sub-Saharan Africa, we did not adjust the estimated proportion of HF 
due to IHD for this super region. In the next step, after the proportion of HF due to IHD has been 
corrected, the proportions were all rescaled to sum to one. These final scaled proportions were then 
multiplied by the overall HF envelope (after Chagas adjustment) to yield prevalence estimates of HF due 
to all aetiologies. 
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These estimates were then split into asymptomatic and mild, moderate, and severe heart failure based 
on an analysis of MEPS data.  
Models were evaluated based on expert opinion, comparison of results with other rounds of GBD, and 
model fit.  
Overall heart failure impairment envelope 
Study covariate Parameter beta Exponentiated beta 
All MarketScan, year 2000 Prevalence -0.3 (-0.32 – -0.28) 0.74 (0.72 – 0.76) 
Log-transformed age-
standardised SEV scalar: CVD 
Prevalence 1.06 (0.98 – 1.12) 2.88 (2.67 – 3.07) 
LDI (I$ per capita) Excess mortality rate -0.3 (-0.49 – -0.1) 0.74 (0.61 – 0.90) 
Six main sub-cause proportion envelopes 
Sub-cause Covariate Parameter beta 
Exponentiated 
beta 
Heart failure due to 
cardiomyopathy 
impairment envelope 
Log-transformed 
age-standardised 
SEV scalar: CMP  
Proportion 0.75 (0.75 – 0.76) 2.12 (2.12 – 2.14) 
Heart failure due to 
cardiopulmonary 
disease impairment 
envelope  
Log-transformed 
age-standardised 
SEV scalar: Chr Resp 
Proportion 0.81 (0.79 – 0.83) 2.25 (2.20 – 2.30) 
Heart failure due to 
hypertensive heart 
disease impairment 
envelope 
Systolic blood 
pressure (mmHg) 
Proportion 
0.000010 
(0.0000023 – 
0.000015) 
1.00 (1.00 – 1.00) 
Heart failure due to 
ischaemic heart disease 
impairment envelope  
Log-transformed 
age-standardised 
SEV scalar: IHD  
Proportion 0.75 (0.75 - 0.75) 2.12 (2.12 – 2.12) 
Heart failure due to 
other causes 
impairment envelope 
Log-transformed SEV 
scalar: Oth Cardio  
Proportion 0.75 (0.75 – 0.75) 2.12 (2.12 – 2.12) 
Heart failure due to 
valvular heart disease 
impairment envelope  
Log-transformed 
age-standardised 
SEV scalar: CVD  
Proportion 0.75 (0.75 – 0.75) 2.12 (2.12 – 2.12) 
No other significant changes were made to the modelling strategy for GBD 2016. 
1) http://www.framinghamheartstudy.org/share/protocols/soe0_03s_protocol.pdf
2) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force
for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology 
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(ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart 
J 2016; 37 (27): 2129-2200. 
3) Reitsma, Marissa B., et al. "Smoking prevalence and attributable disease burden in 195 countries and
territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015." The Lancet. 
4) Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, Kouam CK, Suliman A,
Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Davison BA, Cotter G, Sliwa K. The 
Causes, Treatment, and Outcome of Acute Heart Failure in 1006 Africans From 9 Countries. Results of the 
Sub-Saharan Africa Survey of Heart Failure. Arch Intern Med. 2012;172(18):1386-1394. 
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Macular Degeneration
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vis ion loss due to 
trachoma
Principal components 
analysis (PCA)
Proportion by 
location/year/age/
sex of low vision due 
to trachoma
Proportion by 
location/year/age/
sex of blindness  due 
to trachoma
Multiply proportion by 
low vision envelope
Multiply proportion by 
blindness envelope
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Other vision loss
Input data
Process
Results
Database
Disability weights
Nonfatal
Burden estimation
Cause of Death
Covariates
Input Data
Nonfatal database Dismod-MR 2.1
Comorbidity correction 
(COMO)
YLLs
Comorbidity 
adjusted YLDs
DALYs
Other vision loss
Crosswalk data points 
that span multip le 
vis ion loss categories
Survey Data
Location-level covariate: 
SDS
Prevalence by location/
year/age/sex for low 
vis ion due to other 
vis ion loss
Prevalence by location/
year/age/sex for 
blindness due to other 
vis ion loss
Split into moderate and severe 
vis ion loss
Disability weights 
for each sequela
Unadjusted 
YLD by 
sequela
Prevalence by location/
year/age/sex for 
moderate vision loss 
due to other vision loss
Prevalence by location/
year/age/sex for severe 
vis ion loss due to other 
vis ion loss
Squeeze into severity-specific 
vis ion loss envelope
Prevalence by location/
year/age/sex for 
blindness due to other 
vis ion loss
Prevalence by location/
year/age/sex for 
moderate vision loss 
due to other vision loss
Prevalence by location/
year/age/sex for severe 
vis ion loss due to other 
vis ion loss
 
 
Case definition 
We model vision impairment as visual acuity <6/18 according to the Snellen chart. The following 
impairments are modeled:  
Condition Case definition 
Blindness Visual acuity of <3/60 or 
<10% visual field around 
central fixation 
Severe vision impairment  ≥3/60 and <6/60 
Moderate vision impairment  ≥6/60 and <6/18 
Near vision impairment envelope  Near visual acuity of <6/18 
distance equivalent 
  
Near vision impairment describes the progressive inability to focus on near objects as individuals age, and 
is also called presbyopia. This impairs the ability to read. The majority of presbyopia can be corrected by 
the use of reading glasses, contact lenses, or refractive surgery.  
We model vision impairment due to the following causes: uncorrected refractive error, cataract, 
glaucoma, macular degeneration, diabetic retinopathy, trachoma, Vitamin A deficiency, retinopathy of 
prematurity, meningitis, encephalitis, onchocerciasis, and other vision loss. Vision loss due to vitamin A 
deficiency, retinopathy of prematurity, meningitis, encephalitis, and onchocerciasis are modelled as part 
of their underlying cause as described in their respective sections.  
Refractive error is blurry vision due to the lens’s inability to focus. The blurriness caused by refractive 
error can be addressed through the use of contact lenses, glasses, or refractive surgery. Cataract is 
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clouding of the lens of the eye due to protein buildup that impairs vision. Glaucoma is a condition with 
increased intraocular pressure which can lead to damage of the optic nerve. Macular degeneration is a 
deterioration of the macula, leading to central vision loss. Diabetic retinopathy is damage to the retina 
caused by damaged blood vessels that can leak blood into the retina and cause scarring of the retina. 
Trachoma results from a conjunctival bacterial infection (Chlamydia trachomatis) that produces 
inflammation and scarring which leads to an inversion of the eyelids and eyelashes scratching the cornea, 
which eventually leads to scarring of the cornea and vision impairment or blindness. 
 
Input data 
 Model inputs 
Data on overall vision impairment come from surveys measuring visual acuity in representative 
population-based studies, either from publications in peer-reviewed and grey literature or surveys for 
which we had the unit record data. Data were excluded if no test was used of visual acuity that can be 
converted to the Snellen scale, and if a study did not assess “presenting” or “best-corrected” vision. A 
subset of these studies that reported vision loss by cause were used to estimate the prevalence of vision 
loss due to cataract, glaucoma, macular degeneration, diabetic retinopathy, and other causes.  
 
For GBD 2015, we conducted a systematic review for new sources since GBD 2013 (covering 1/1/2013 – 
5/20/2015), using the following search string:  
((((glaucoma[Title/Abstract] OR cataract[Title/Abstract] OR macular[Title/Abstract] OR 'refractive 
error'[Title/Abstract] OR presbyopia[Title/Abstract]) OR (('blindness'[MeSH Terms] OR 'blindness'[All 
Fields]) OR 'vision, low'[MeSH Terms])) AND ('2013'[PDAT] : '3000'[PDAT])) AND 'humans'[MeSH Terms]) 
AND (prevalence[Title/Abstract] OR incidence[Title/Abstract] OR epidemiology[Title/Abstract])   
 
This yielded 1,169 results, of which we extracted 20 sources. Furthermore, we extracted from the 
following nationally representative surveys measuring visual acuity: the WHO Studies on Global Ageing 
and Adult Health (SAGE) and the United States National Health and Examination Surveys (NHANES).  
For GBD 2016, we did a comprehensive extraction of the Rapid Assessment of Avoidable Blindness (RAAB) 
repository (http://raabdata.info/), a database of vision impairment studies in developing settings across 
the world. There are 266 site-years of data, the majority of which have publicly available reports or 
publications of the data. A standardized methodology was used by all sources in the repository, allowing 
inclusion of all available reports. In addition, we added two state-level national surveys from India.  
Due to the sparse literature reporting measured near-vision visual acuity, we also extracted data from the 
following nationally representative studies measuring self-reported near vision loss: SAGE; NHANES; the 
Surveys of Health, Ageing, and Retirement in Europe (SHARE); the Multi-Country Survey Study on Health 
and Responsiveness (MCSS); and the World Health Surveys (WHS).  
Several adjustments were made to raw data.  
1) Where studies reported visual acuity spanning multiple thresholds (eg, <6/60, rather than 
separate severe and blind estimates), we crosswalked using ratios predicted by a linear 
regression on age, using data from studies reporting vision loss by each severity.  
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2) Some studies reported best-corrected vision impairment, but not presenting vision impairment 
(PVI). We crosswalked these data points using a linear regression of logit-transformed PVI 
prevalence with fixed effects on best-corrected VI, healthcare quality and access index (HAQI) 
and Socio-demographic Index (SDI) and super-region random effects. This gave us a predicted PVI 
data points for these studies not explicitly reporting PVI. These crosswalked data points were 
flagged with a study-level covariate that increased standard error in DisMod.  
3) Where data points spanned more than 20 years of age, we age-split using an algorithm that 
applies the age-pattern of the super-region to split the data to five-year age groups.  
 
Whereas other vision impairment aetiologies are modelled based on prevalence data, vision impairment 
due to trachoma is modelled as a proportion of the overall vision impairment envelope, a strategy that 
was chosen based on the nature of available data. 
 
Health states and disability weights 
 
Health state name Health state description Disability weight 
Distance vision, severe 
impairment 
This person has severe vision loss, which causes difficulty in daily activities, some emotional impact (for 
example, worry), and some difficulty going outside the home without assistance. 
0.184 
(0.125–0.259) 
Distance vision, 
moderate impairment This person has vision problems that make it difficult to recognize faces or objects across a room. 
0.031 
(0.019–0.049) 
Distance vision 
blindness 
This person is completely blind, which causes great difficulty in some daily activities, worry and anxiety, 
and great difficulty going outside the home without assistance.  
0.187 
(0.124–0.26) 
Presbyopia 
This person has difficulty seeing things that are nearer than 3 feet, but has no difficulty with seeing 
things at a distance.  
0.011 
(0.005–0.02) 
 
Modelling strategy  
We modelled the prevalence of vision loss in two steps. In the first step, we estimated the total 
prevalence estimates of presenting vision loss: moderate vision impairment, severe vision impairment, 
blindness, and near vision impairment (presbyopia). We directly derived prevalence of near vision 
impairment from this step, whereas the remaining three models that reflect different severity levels of 
distance vision loss continued to the next step.  
1) Estimate severity-specific vision impairment (the “envelopes”) 
First, we ran five DisMod-MR 2.1 models to estimate the total prevalence estimates of presenting vision 
loss: moderate vision impairment, severe vision impairment, blindness, near vision impairment 
(presbyopia), and presenting vision impairment (moderate + severe + blindness). The presenting vision 
impairment model was used as a covariate in the severity-specific models to improve consistency across 
severities.  
Betas and exponentiated values, which can be interpreted as an odds ratio, are shown in the table below 
for each covariate. The best-corrected covariate indicates whether the test measures visual acuity with 
the level of correction the patient presents with (best_corrected = 0) or the ophthalmologist provides 
additional correction via pinhole (best_corrected = 1). Rapid-assessment corrects for potential biases in 
cause-specific vision loss from studies using expedited visual acuity measurement. Socio-demographic 
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Index (SDI) and healthcare access and quality index (HAQI) are used as location covariates as a proxy 
measure of access to eye care such as cataract surgery. Non-representative studies are those not 
representative at the level they are used to model (eg, a state-level survey assigned to a country), 
including a z-cov adjusts for potential bias. Data points that were crosswalked from best-corrected visual 
acuity are flagged with a z-cov to adjust uncertainty in the crosswalk process. Non-standard severity 
definition is used to crosswalk between the self-report questionnaire of SHARE (nonstandard) and the 
other surveys, including SAGE and NHANES, which are crosswalked to examination data using the self-
reported covariate.  
Model Covariate name Type Measure Beta 
value 
Exponentiate
d value 
Vision impairment due to 
glaucoma unsqueezed 
Socio-
demographic 
Index 
Country covariate Prevalence -0.235 (-
0.690 - -
0.008) 
0.791 (0.502 - 
0.992) 
Vision impairment due to 
glaucoma unsqueezed 
diagnostic rapid 
assessment of 
loss 
Study-level x-
covariate 
Prevalence 0.012 
(0.002 - 
0.033) 
1.012 (1.002 - 
1.033) 
Vision impairment due to 
glaucoma unsqueezed 
Not 
representative 
Study-level z-
covariate 
Prevalence 0.022 
(0.003 - 
0.067) 
1.023 (1.003 - 
1.069) 
Blindness due to glaucoma 
unsqueezed 
Socio-
demographic 
Index 
Country covariate Prevalence -0.256 (-
0.690 - -
0.010) 
0.775 (0.501 - 
0.990) 
Blindness due to glaucoma 
unsqueezed 
diagnostic rapid 
assessment of 
loss 
Study-level x-
covariate 
Prevalence 0.010 
(0.000 - 
0.030) 
1.010 (1.000 - 
1.030) 
Blindness due to glaucoma 
unsqueezed 
Not 
representative 
Study-level z-
covariate 
Prevalence 0.024 
(0.000 - 
0.085) 
1.025 (1.000 - 
1.089) 
Vision impairment due to 
cataract unsqueezed 
Elevation Over 
1500m 
(proportion) 
Country covariate Prevalence 0.119 
(0.006 - 
0.319) 
1.127 (1.006 - 
1.376) 
Vision impairment due to 
cataract unsqueezed 
Indoor Air 
Pollution (All 
Cooking Fuels) 
Country covariate Prevalence 0.031 
(0.000 - 
0.111) 
1.032 (1.000 - 
1.118) 
Vision impairment due to 
cataract unsqueezed 
Outdoor Air 
Pollution 
(PM2.5) 
Country covariate Prevalence 0.008 
(0.003 - 
0.014) 
1.008 (1.003 - 
1.014) 
Vision impairment due to 
cataract unsqueezed 
Smoking 
Prevalence 
(Age-
standardized, 
both sexes) 
Country covariate Prevalence 0.776 
(0.035 - 
1.675) 
2.174 (1.036 - 
5.340) 
Vision impairment due to 
cataract unsqueezed 
Socio-
demographic 
Index 
Country covariate Prevalence -0.612 (-
0.962 - -
0.157) 
0.542 (0.382 - 
0.855) 
Vision impairment due to 
cataract unsqueezed 
Systolic Blood 
Pressure 
(mmHg) 
Country covariate Prevalence 0.002 
(0.000 - 
0.007) 
1.002 (1.000 - 
1.007) 
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Vision impairment due to 
cataract unsqueezed 
diagnostic rapid 
assessment of 
loss 
Study-level x-
covariate 
Prevalence 0.031 
(0.009 - 
0.063) 
1.031 (1.009 - 
1.065) 
Vision impairment due to 
cataract unsqueezed 
Not 
representative 
Study-level z-
covariate 
Prevalence 0.014 
(0.003 - 
0.039) 
1.014 (1.003 - 
1.039) 
Blindness due to cataract 
unsqueezed 
Elevation Over 
1500m 
(proportion) 
Country covariate Prevalence 0.641 
(0.420 - 
0.868) 
1.898 (1.522 - 
2.382) 
Blindness due to cataract 
unsqueezed 
Indoor Air 
Pollution (All 
Cooking Fuels) 
Country covariate Prevalence 0.408 
(0.143 - 
0.660) 
1.504 (1.153 - 
1.936) 
Blindness due to cataract 
unsqueezed 
Outdoor Air 
Pollution 
(PM2.5) 
Country covariate Prevalence 0.000 
(0.000 - 
0.001) 
1.000 (1.000 - 
1.001) 
Blindness due to cataract 
unsqueezed 
Smoking 
Prevalence 
(Age-
standardized, 
both sexes) 
Country covariate Prevalence 0.757 
(0.036 - 
1.723) 
2.132 (1.036 - 
5.601) 
Blindness due to cataract 
unsqueezed 
Socio-
demographic 
Index 
Country covariate Prevalence -0.965 (-
1.000 - -
0.864) 
0.381 (0.368 - 
0.421) 
Blindness due to cataract 
unsqueezed 
Systolic Blood 
Pressure 
(mmHg) 
Country covariate Prevalence 0.002 
(0.000 - 
0.008) 
1.002 (1.000 - 
1.009) 
Blindness due to cataract 
unsqueezed 
diagnostic rapid 
assessment of 
loss 
Study-level x-
covariate 
Prevalence 0.002 
(0.000 - 
0.009) 
1.002 (1.000 - 
1.009) 
Blindness due to cataract 
unsqueezed 
Not 
representative 
Study-level z-
covariate 
Prevalence 0.004 
(0.000 - 
0.010) 
1.004 (1.000 - 
1.010) 
Vision impairment due to 
macular degeneration 
unsqueezed 
Socio-
demographic 
Index 
Country covariate Prevalence 0.350 (-
0.432 - 
0.921) 
1.419 (0.650 - 
2.512) 
Vision impairment due to 
macular degeneration 
unsqueezed 
diagnostic rapid 
assessment of 
loss 
Study-level x-
covariate 
Prevalence 0.047 
(0.005 - 
0.126) 
1.049 (1.005 - 
1.134) 
Vision impairment due to 
macular degeneration 
unsqueezed 
Not 
representative 
Study-level z-
covariate 
Prevalence 0.058 
(0.008 - 
0.150) 
1.060 (1.008 - 
1.162) 
Blindness due to macular 
degeneration unsqueezed 
Socio-
demographic 
Index 
Country covariate Prevalence 0.328 (-
0.563 - 
0.959) 
1.389 (0.570 - 
2.609) 
Blindness due to macular 
degeneration unsqueezed 
diagnostic rapid 
assessment of 
loss 
Study-level x-
covariate 
Prevalence 0.016 
(0.002 - 
0.050) 
1.016 (1.002 - 
1.052) 
Blindness due to macular 
degeneration unsqueezed 
Not 
representative 
Study-level z-
covariate 
Prevalence 0.014 
(0.001 - 
0.047) 
1.014 (1.001 - 
1.048) 
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Near vision impairment due 
to presbyopia due to 
uncorrected refractive error 
Socio-
demographic 
Index 
Country covariate Prevalence -1.803 (-
1.999 - -
1.451) 
0.165 (0.135 - 
0.234) 
Near vision impairment due 
to presbyopia due to 
uncorrected refractive error 
Non-standard 
severity 
definition 
Study-level x-
covariate 
Prevalence -0.195 (-
0.200 - -
0.186) 
0.822 (0.819 - 
0.830) 
Near vision impairment due 
to presbyopia due to 
uncorrected refractive error 
Self-reported Study-level x-
covariate 
Prevalence -0.102 (-
0.120 - -
0.089) 
0.903 (0.886 - 
0.915) 
Vision impairment due to 
other vision loss 
unsqueezed 
Socio-
demographic 
Index 
Country covariate Prevalence -0.113 (-
0.351 - -
0.006) 
0.893 (0.704 - 
0.994) 
Vision impairment due to 
other vision loss 
unsqueezed 
diagnostic rapid 
assessment of 
loss 
Study-level x-
covariate 
Prevalence 0.054 
(0.012 - 
0.103) 
1.056 (1.012 - 
1.109) 
Vision impairment due to 
other vision loss 
unsqueezed 
Not 
representative 
Study-level z-
covariate 
Prevalence 0.186 
(0.126 - 
0.239) 
1.205 (1.135 - 
1.270) 
Blindness due to other 
vision loss unsqueezed 
Socio-
demographic 
Index 
Country covariate Prevalence -0.179 (-
0.472 - -
0.005) 
0.836 (0.624 - 
0.995) 
Blindness due to other 
vision loss unsqueezed 
diagnostic rapid 
assessment of 
loss 
Study-level x-
covariate 
Prevalence 0.164 
(0.123 - 
0.211) 
1.178 (1.131 - 
1.235) 
Blindness due to other 
vision loss unsqueezed 
Not 
representative 
Study-level z-
covariate 
Prevalence 0.057 
(0.019 - 
0.107) 
1.059 (1.020 - 
1.113) 
Vision impairment envelope Socio-
demographic 
Index 
Country covariate Prevalence -1.899 (-
1.997 - -
1.605) 
0.150 (0.136 - 
0.201) 
Blindness impairment 
envelope 
Healthcare 
access and 
quality index 
Country covariate Prevalence -0.020 (-
0.024 - -
0.013) 
0.980 (0.976 - 
0.987) 
Blindness impairment 
envelope 
Presenting 
vision 
impairment 
Country covariate Prevalence 0.506 
(0.291 - 
0.743) 
1.659 (1.337 - 
2.102) 
Blindness impairment 
envelope 
Socio-
demographic 
Index 
Country covariate Prevalence -0.115 (-
0.345 - -
0.002) 
0.891 (0.708 - 
0.998) 
Blindness impairment 
envelope 
Not 
representative 
Study-level z-
covariate 
Prevalence 0.000 
(0.000 - 
0.002) 
1.000 (1.000 - 
1.002) 
Blindness impairment 
envelope 
best-corrected 
crosswalk 
Study-level z-
covariate 
Prevalence 0.002 
(0.000 - 
0.007) 
1.002 (1.000 - 
1.007) 
Moderate vision 
impairment envelope 
Presenting 
vision 
impairment 
Country covariate Prevalence 0.775 
(0.668 - 
0.868) 
2.170 (1.951 - 
2.383) 
Moderate vision 
impairment envelope 
Socio-
demographic 
Index 
Country covariate Prevalence -0.041 (-
0.170 - -
0.000) 
0.960 (0.844 - 
1.000) 
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Moderate vision 
impairment envelope 
Not 
representative 
Study-level z-
covariate 
Prevalence 0.000 
(0.000 - 
0.002) 
1.000 (1.000 - 
1.002) 
Moderate vision 
impairment envelope 
best-corrected 
crosswalk 
Study-level z-
covariate 
Prevalence 0.160 
(0.130 - 
0.194) 
1.174 (1.139 - 
1.214) 
Severe vision impairment 
envelope 
Presenting 
vision 
impairment 
Country covariate Prevalence 0.509 
(0.383 - 
0.636) 
1.664 (1.466 - 
1.889) 
Severe vision impairment 
envelope 
Socio-
demographic 
Index 
Country covariate Prevalence -0.018 (-
0.056 - -
0.001) 
0.983 (0.945 - 
0.999) 
Severe vision impairment 
envelope 
Not 
representative 
Study-level z-
covariate 
Prevalence 0.001 
(0.000 - 
0.003) 
1.001 (1.000 - 
1.003) 
Severe vision impairment 
envelope 
best-corrected 
crosswalk 
Study-level z-
covariate 
Prevalence 0.034 
(0.011 - 
0.062) 
1.035 (1.011 - 
1.064) 
Vision impairment due to 
diabetes mellitus 
Diabetes Age-
Standardized 
Prevalence 
(proportion) 
Country covariate Prevalence 1.465 
(0.673 - 
2.255) 
4.328 (1.961 - 
9.535) 
Vision impairment due to 
diabetes mellitus 
Socio-
demographic 
Index 
Country covariate Prevalence -1.192 (-
1.957 - -
0.132) 
0.304 (0.141 - 
0.876) 
Vision impairment due to 
diabetes mellitus 
diagnostic rapid 
assessment of 
loss 
Study-level x-
covariate 
Prevalence 0.011 
(0.000 - 
0.036) 
1.011 (1.000 - 
1.036) 
Vision impairment due to 
diabetes mellitus 
Not 
representative 
Study-level z-
covariate 
Prevalence 0.089 
(0.005 - 
0.239) 
1.093 (1.005 - 
1.270) 
Blindness due to diabetes 
mellitus unsqueezed 
Diabetes Age-
Standardized 
Prevalence 
(proportion) 
Country covariate Prevalence 3.805 
(3.352 - 
3.993) 
44.905 
(28.560 - 
54.217) 
Blindness due to diabetes 
mellitus unsqueezed 
Socio-
demographic 
Index 
Country covariate Prevalence -1.594 (-
1.989 - -
0.597) 
0.203 (0.137 - 
0.550) 
Blindness due to diabetes 
mellitus unsqueezed 
diagnostic rapid 
assessment of 
loss 
Study-level x-
covariate 
Prevalence 0.070 
(0.002 - 
0.230) 
1.072 (1.002 - 
1.259) 
Blindness due to diabetes 
mellitus unsqueezed 
Not 
representative 
Study-level z-
covariate 
Prevalence 0.373 
(0.193 - 
0.586) 
1.453 (1.213 - 
1.796) 
Moderate vision 
impairment due to 
uncorrected refractive error 
unsqueezed 
Socio-
demographic 
Index 
Country covariate Prevalence -0.955 (-
0.998 - -
0.830) 
0.385 (0.369 - 
0.436) 
Severe vision impairment 
due to uncorrected 
refractive error unsqueezed 
Socio-
demographic 
Index 
Country covariate Prevalence -0.899 (-
0.996 - -
0.621) 
0.407 (0.369 - 
0.538) 
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Blindness due to 
uncorrected refractive error 
unsqueezed 
Socio-
demographic 
Index 
Country covariate Prevalence -0.968 (-
1.000 - -
0.870) 
0.380 (0.368 - 
0.419) 
 
 
 
2) Estimate cause-specific vision impairment  
In the second step, we estimated the prevalence of vision loss due to multiple causes: refractive error, 
cataract, glaucoma, macular degeneration, diabetic retinopathy, retinopathy due to prematurity, 
trachoma, vitamin A deficiency, onchocerciasis, meningitis, and other causes not classified elsewhere. The 
vision loss due to retinopathy of prematurity, vitamin A deficiency, onchocerciasis, meningitis, tetanus, 
and neonatal conditions was modeled as part of these underlying causes. Vision loss due to trachoma is 
modelled as a proportion of the envelope, with separate proportion models for vision impairment and 
blindness. For each of cataract, glaucoma, macular degeneration, diabetic retinopathy, and other vision 
loss, we ran two DisMod-MR 2.1 models: one for the combined category of moderate and severe vision 
loss due to the cause, and one for blindness due to the cause. Moderate and severe vision loss were 
modelled together because input data were mostly available for the aggregate. Refractive error was 
modelled in three models, one for each severity. We used the following age restrictions:  
Cause Minimum age  
Cataracts 20 
Glaucoma 45 
Macular degeneration 45 
Diabetic retinopathy 20 
Trachoma 15 
Other vision loss 0 
 
For the cataract model, we used known risk factors – hypertension, smoking, air pollution, and elevation.  
For cataract and refractive error, we used presenting vision impairment as a covariate, as these are the 
main causes of vision impairment and are treatable and thus should have greater covariance with overall 
vision impairment than less common causes such as glaucoma or macular degeneration.  
We estimated the proportions of low vision and blindness due to trachoma using custom mixed-effects 
models. For consistency, the two models (blindness and low vision) were parameterized identically and 
differ only in their input data. Our model included fixed effects on age (using cubic splines with knots at 0, 
40, and 100 years of age), sex, and a covariate derived from a principal components analysis of the 
proportion of the population at risk for trachoma and the proportion of the population with access to 
sanitation. We included nested random effects on super-region, region, and country. Finally, we applied 
geographic and age restrictions to ensure that we estimate zero proportions in non-endemic locations 
and among those younger than 15 year of age (as scarring of the cornea due to trachoma takes decades 
to develop). The prevalence of trachoma at each severity level was calculated by multiplying the 
proportion of vision loss (vision impairment or blindness) due to trachoma by the corresponding best-
corrected vision loss envelope.  
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We split the moderate plus severe vision loss estimates for each cause into moderate and severe using 
the ratio of best-corrected moderate and severe vision loss envelopes. As exceptions, onchocerciasis and 
retinopathy of prematurity were modelled for moderate and severe vision loss as part of the estimation 
process of these causes.  
We scaled the cause-specific vision loss prevalence to the total prevalence of the best-corrected vision 
loss envelopes for each of the three severity levels. The final result is prevalence of vision loss due to each 
cause by severity.  
 
The following changes have been implemented since GBD 2015: 
- DisMod is not designed to handle wide-age data points – by age-splitting the input data we 
improve model fits.  
- In the severity-specific vision impairment models, we use overall presenting vision impairment as 
a covariate, ensuring greater consistency between severities.  
- In GBD 2013 vision impairment models, best-corrected vision data were crosswalked within 
DisMod using a single beta for all ages and locations. By crosswalking the input data, we allow the 
ratio between presenting and best-corrected vision impairment to vary with age and location.   
- In GBD 2013, we estimated the ratio of vision impairment due to refractive error. In 2016, we are 
estimating the prevalence of refractive error, as it shows greater covariance with predictors such 
as SDI and HAQI. This allows the second step (squeezing causes to the envelopes) to include 
refractive error as an input.  
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 Hearing Impairment
Input data
Process
Results
Database
Disability weights
Nonfatal
Burden estimation
Cause of death
Covariates
Input Data
Survey Data
Nonfatal database:
Hearing loss  at 
levels 0-19, 20-34, 
35+, 35-49, 50-64, 
64-79, 80-94, 95+
Dismod-MR 2.1
Unsqueezed prevalence 
by location/year/age/
sex for 35+dB loss
YLLs
Comorbidity 
adjusted YLDs
DALYs
Hearing Impairment
Crosswalk data points 
that span multip le 
hearing  loss  categories
Unsqueezed prevalence 
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Case definition 
For GBD 2016, hearing impairment modeled the following severities of hearing loss: 
Severity thresholds of interest  for hearing loss 
Severity  Threshold (in decibels) 
None 0–19 
Mild  20–34 
Moderate 35–49 
Moderately severe 50–64 
Severe 65–79 
Profound 80–94 
Complete 95+ 
 
We model the following causes of hearing loss: congenital, meningitis, otitis, and age-related and other 
hearing loss. Hearing loss due to meningitis and otitis are modelled as part of their underlying cause as 
described in their respective sections. Congenital hearing loss is defined as hearing loss present at birth. 
Age-related and other hearing loss includes causes not identified as meningitis, otitis, or congenital. This 
includes presbycusis, the gradual increase in hearing loss over age frequently caused by the natural 
breakdown of neurons in the inner ear. For all causes, we estimate hearing loss with and without tinnitus, 
the perception of noise or ringing in the ears.  
 
Input data 
 Model inputs 
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For the estimation of the severity-specific envelopes, we used a series of systematic reviews and survey 
extraction. Data sources up to 2008 were identified by a published systematic review 
(http://www.ncbi.nlm.nih.gov/pubmed/19444763). A systematic review covering 2008–2013 was 
conducted with the following search terms:  
(hearing impairment[Title/Abstract] OR deafness[Title/Abstract] OR hearing loss[Title/Abstract]) 
AND (prevalence[Title/Abstract]) AND ("2008"[PDAT] : "3000"[PDAT]) AND (cross sectional OR 
survey) 
In addition, we extracted hearing loss measurement from the United States National Health and 
Examination Surveys (NHANES). Self-reported data, from both the literature and surveys, were excluded. 
This includes censuses in the Integrated Public Use Microdata Series (IPUMS), the WHO Studies on Global 
Ageing and Adult Health (SAGE), and the WHO Multi-Country Survey Study on Health and Responsiveness 
(MCSS). Systematic reviews and self-reported survey data (including MCSS, SAGE, and NHANES) were 
used to estimate hearing aid coverage.  
For GBD 2016, we conducted a systematic review on November 30, 2016, using the following search 
terms:  
 (hearing impairment[Title/Abstract] OR deafness[Title/Abstract] OR hearing loss[Title/Abstract] 
OR audiometry[Title/Abstract]) AND (prevalence[Title/Abstract]) AND ("2008/11/26"[PDAT] : 
"3000"[PDAT]) AND (cross sectional OR survey) 
This returned 239 results, of which 17 were accepted.  
Where studies reported hearing loss spanning multiple thresholds (eg, 80+, rather than 80-94 and 95+), 
we crosswalked using ratios predicted by a linear regression on age, using NHANES microdata. Where 
studies reported severity categories that did not align with GBD thresholds, we crosswalked using 
NHANES microdata to the nearest GBD severity category, as long as the upper and lower thresholds were 
not more than 10dB different.  
Health states and disability weights 
Health state name Health state description Disability weight 
Hearing loss, mild 
This person has great difficulty hearing and understanding another person talking in a noisy 
place (for example, on an urban street). 
0.01 
(0.004–0.019) 
Hearing loss, mild, with 
ringing 
This person is unable to hear and understand another person talking, even in a quiet place, is 
unable to take part in a phone conversation. Difficulties with communicating and relating to 
others cause emotional impact at times (for example worry or depression). 
0.021 
(0.012–0.036) 
Hearing loss, moderate 
This person has great difficulty hearing and understanding another person talking in a noisy 
place (for example, on an urban street), and sometimes has annoying ringing in the ears. 
0.027 
(0.015–0.042) 
Hearing loss, 
moderate, with ringing 
This person is unable to hear and understand another person talking, even in a quiet place, 
and has great difficulty hearing anything in any other situation. Difficulties with 
communicating and relating to others often cause worry, depression or loneliness. 
0.074 
(0.048–0.107) 
Hearing loss, 
moderately severe (custom DW from hearing loss impairment envelope) 
0.092 
(0.064–0.129) 
Hearing loss, 
moderately severe, 
with ringing (custom DW from hearing loss impairment envelope) 
0.167 
(0.114–0.231) 
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Hearing loss, severe 
This person is unable to hear and understand another person talking in a noisy place (for 
example, on an urban street), and has difficulty hearing another person talking even in a quiet 
place or on the phone. 
0.158 
(0.104–0.227) 
Hearing loss, severe, 
with ringing 
This person is unable to hear and understand another person talking, even in a quiet place, 
has great difficulty hearing anything in any other situation,  Difficulties with communicating 
and relating to others often cause worry, depression, or loneliness. 
0.261 
(0.174–0.361) 
Hearing loss, profound 
This person is unable to hear and understand another person talking in a noisy place, has 
difficulty hearing another person talking even in a quiet place or on the phone, and has 
annoying ringing in the ears for 5 minutes at a time, almost every day. 
0.204 
(0.134–0.288) 
Hearing loss, profound, 
with ringing 
This person cannot hear at all in any situation, including even the loudest sounds, and cannot 
communicate verbally or use a phone. Difficulties with communicating and relating to others 
often cause worry, depression or loneliness. 
0.277 
(0.182–0.388) 
Hearing loss, complete 
This person is unable to hear and understand another person talking, even in a quiet place, 
and unable to take part in a phone conversation. Difficulties with communicating and relating 
to others cause emotional impact at times (for example worry or depression). 
0.215 
(0.143–0.307) 
Hearing loss, complete, 
with ringing 
This person cannot hear at all in any situation, including even the loudest sounds, and cannot 
communicate verbally or use a phone. Difficulties with communicating and relating to others 
often cause worry, depression or loneliness. 
0.316 
(0.211–0.436) 
 
Modelling strategy  
We modelled the prevalence of hearing loss over five steps. First, we ran three DisMod-MR 2.1 models to 
estimate the total prevalence estimates of hearing loss: normal hearing (0–19dB), mild hearing loss (20–
34dB), and moderate hearing loss and above (35+ dB). We squeezed the prevalence estimates from these 
DisMod-MR 2.0 models to fit within the entire population of each country. We estimated prevalence of 
normal hearing for this squeezing purpose only, and hence did not form part of further analysis. Betas 
and exponentiated values, which can be interpreted as an odds ratio, are shown in the table below for 
each covariate. 
Model Covariate name Type Measure Beta value Exponentiated 
value 
Hearing loss impairment at 
35+ dB 
Socio-demographic 
Index 
Country 
covariate 
Prevalence -1.451 (-1.984 
- -0.486) 
0.234 (0.138 - 
0.615) 
Hearing loss impairment at 
95+ dB 
Socio-demographic 
Index 
Country 
covariate 
Prevalence -0.584 (-1.595 
- -0.024) 
0.557 (0.203 - 
0.976) 
Hearing aids (proportion 
of total hearing loss) 
LDI (I$ per capita) Country 
covariate 
Prevalence 0.726 (0.498 - 
0.979) 
2.066 (1.646 - 
2.662) 
Hearing loss impairment at 
0-19 dB 
Socio-demographic 
Index 
Country 
covariate 
Prevalence 0.058 (0.001 - 
0.182) 
1.059 (1.001 - 
1.200) 
 
Second, we ran five additional DisMod-MR 2.1 models for each severity levels of hearing loss above mild: 
moderate (35–49dB), moderately severe (50–64dB), severe (65–79dB), profound (80–94dB), and complete 
(95+). We then squeezed the prevalence estimates from these models to fit within the prevalence that 
were estimated for 35+dB in the first step. By the end of the second step, we had estimated prevalence 
of six severity levels of hearing loss, including mild (20–34dB). We also ran a DisMod-MR 2.0 model for the 
coverage of hearing aids, using (logged) lag distributed income (LDI) as a covariate.  
Third, we adjusted the prevalence of each severity level by accounting for hearing aids. We assumed the 
use of hearing aids reduced the severity by one level. Data obtained from a survey in Norway provided 
detailed information on people with hearing aids, which was used to estimate the proportion of hearing 
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aids for each severity level. We ran a log-linear regression on age with binary indicator for severity levels. 
We calculated country-specific hearing aid coverage by multiplying the severity-specific coverage in 
Norway by the ratio of hearing aid coverage in a given country to that of Norway for each age-sex. We 
shifted the identified fraction of people in each severity level a level below, except for complete hearing 
loss, which we assumed was not correctable by hearing aids. This provided the adjusted prevalence of six 
severity levels of all-cause hearing loss. 
Fourth, we estimated the prevalence of hearing loss due to multiple causes: otitis media, congenital, 
meningitis (pneumococcal, H influenza type B meningitis, meningococcal, and other bacterial), and age-
related and other causes not classified elsewhere. For congenital hearing loss, we assumed that all 
hearing losses occurring at the time of birth are of congenital nature. We assumed that all hearing loss 
due to otitis media is at the mild or moderate level. We implemented proportional squeezes to scale 
cause-specific hearing loss prevalence to the total prevalence of each severity level.  
Finally, we estimated the percent of people experiencing tinnitus for at least five minutes per day by 
severity level using data from the NHANES and two datasets from the United Kingdom. We calculated 
confidence intervals assuming a binomial distribution. We assumed the same distribution of tinnitus 
across all types of hearing loss.  
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Appendix Figure 1a: Overview analytical flowchart for DisMod-MR 2.1 modelling strategies and injuries, GBD 2016
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final results. The flowchart is color-coded by major estimation component: raw data sources, in pink; data adjustments, in yellow; DisMod-MR 2.1 
estimation, in purple; alternative modelling strategies, in light green; injury modeling strategy, in dark green; estimation of impairments and underlying 
causes, in brown; severity distributions and comorbidity correction, in blue; disability weights in orange; and cause of death and demographic inputs, in 
grey. GBD = Global Burden of Disease; TB=tuberculosis; HIV =human immunodeficiency virus; AIDS=acquired immunodeficiency syndrome; SF-12=Short 
Form 12 questions; MEPS=Medical Expenditure Panel Surveys; CSMR=cause-specific mortality rate; SMR=standardized mortality ratio; YLDs=years lived 
with disability; YLLs=years of life lost.
DisMod-MR 2.1
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Appendix Figure 1b: Analytical flowchart for modelling strategies other than DisMod-MR 2.1 and injuries for selected nonfatal cause groups, GBD 2016
Ovals represent data inputs, square boxes represent analytical steps, cylinders represent databases, and parallelograms represent intermediate and 
final results. The flowchart is color-coded by major estimation component: raw data sources, in pink; data adjustments, in yellow; DisMod-MR 2.1 
estimation, in purple; alternative modelling strategies, in light green; injury modeling strategy, in dark green; estimation of impairments and underlying 
causes, in brown; severity distributions and comorbidity correction, in blue; disability weights in orange; and cause of death and demographic inputs, in 
grey. GBD = Global Burden of Disease; TB=tuberculosis; HIV =human immunodeficiency virus; AIDS=acquired immunodeficiency syndrome; SF-12=Short 
Form 12 questions; MEPS=Medical Expenditure Panel Surveys; CSMR=cause-specific mortality rate; SMR=standardized mortality ratio; YLDs=years lived 
with disability; YLLs=years of life lost.
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Appendix Figure 2: DisMod-MR 2.1 analytical cascade
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Appendix Table 1: GATHER checklist of information that should be included in reports of global health 
estimates, with description of compliance and location of information for GBD 2016. Global, regional, and 
national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 
countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 
# GATHER checklist item Description of 
compliance 
Reference 
Objectives and funding 
1 Define the indicators, populations, and time 
periods for which estimates were made. 
Narrative provided in 
paper and methods 
appendix describing 
indicators, definitions, 
and populations 
Manuscript (Methods— 
Overview, Geographic 
units and time periods) 
and methods appendix 
2 List the funding sources for the work. Funding sources listed 
in paper 
Summary (Funding) 
Data Inputs 
For all data inputs from multiple sources that are synthesized as part of the study: 
3 Describe how the data were identified and 
how the data were accessed. 
Narrative description of 
data seeking 
methods provided 
Manuscript (Methods) 
and methods 
appendix Section 2 
4 Specify the inclusion and exclusion criteria. 
Identify all ad-hoc exclusions. 
Narrative about inclusion 
and exclusion criteria by 
data type provided; ad-
hoc exclusions in cause-
specific write ups 
Methods 
appendix Section 
2 and Section 3
5 Provide information on all included data 
sources and their main characteristics. For 
each data source used, report reference 
information or contact name/institution, 
population represented, data collection 
method, year(s) of data collection, sex and age 
range, diagnostic criteria or measurement 
method, and sample size, as relevant. 
An interactive, online 
data source tool that 
provides metadata for 
data sources by 
component, geography, 
cause, risk, or impairment 
has been developed 
Online data citation 
tool 
http://ghdx.health
data.org/global-
burden-disease-
study-2016 
6 Identify and describe any categories of input 
data that have potentially important biases (e.g., 
based on characteristics listed in item 5). 
Summary of known 
biases by cause 
included in methods 
appendix 
Methods appendix 
Section 2 
For data inputs that contribute to the analysis but were not synthesized as part of the study: 
7 Describe and give sources for any other data 
inputs. 
Included in online data 
source tool 
http://ghdx.health
data.org/global-
burden-disease-
study-2016 
For all data inputs: 
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8 Provide all data inputs in a file format from 
which data can be efficiently extracted (e.g., a 
spreadsheet as opposed to a PDF), including all 
relevant meta-data listed in item 5. For any data 
inputs that cannot be shared due to ethical or 
legal reasons, such as third-party ownership, 
provide a contact name or the name of the 
institution that retains the right to the data. 
Downloads of input data 
available through online 
tools, including data 
visualization tools and 
data query tools; input 
data not available in tools 
will be made available 
upon request 
Online data 
visualization tools, 
data query tools, and 
the Global Health Data 
Exchange  
Data analysis 
9 Provide a conceptual overview of the data 
analysis method. A diagram may be helpful. 
Flow diagrams of the 
overall methodological 
processes, as well as 
cause-specific modeling 
processes, have been 
provided 
Manuscript (Methods) 
and methods 
appendix (appendix 
Figure 2)  
10 Provide a detailed description of all steps of the 
analysis, including mathematical formulae. This 
description should cover, as relevant, data 
cleaning, data pre-processing, data adjustments 
and weighting of data sources, and 
mathematical or statistical model(s). 
Flow diagrams and 
corresponding 
methodological write- 
ups for each cause, 
as well as the 
databases and 
modeling processes, 
have been provided 
Manuscript (Methods) 
and methods 
appendix (Appendix 
Figure 1, Appendix 
Section 3) 
11 Describe how candidate models were 
evaluated and how the final model(s) were 
selected. 
Provided in the 
methodological write-
ups 
Appendix section 3 
12 Provide the results of an evaluation of model 
performance, if done, as well as the results of 
any relevant sensitivity analysis. 
Provided in the 
methodological write-
ups 
Appendix section 3 
13 Describe methods for calculating uncertainty of 
the estimates. State which sources of uncertainty 
were, and were not, accounted for in the 
uncertainty analysis. 
Provided in the 
methodological write-
ups 
Appendix section 3 
14 State how analytic or statistical source code used 
to generate estimates can be accessed. 
Access statement 
provided 
Code is provided in an 
online repository 
Results and Discussion 
15 Provide published estimates in a file format from 
which data can be efficiently extracted. 
GBD 2016 results are 
available through online 
data visualization tools, 
the Global Health Data 
Exchange, and the 
online data query tool 
Manuscript, 
supplementary results, 
and online data tools 
(data visualization tools, 
data query tools, and 
the Global Health Data 
Exchange) 
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16 Report a quantitative measure of the 
uncertainty of the estimates (e.g. 
uncertainty intervals). 
Uncertainty intervals 
are provided with all 
results 
Manuscript, 
supplementary results, 
and online data tools 
(data visualization 
tools, data query tools, 
and the Global Health 
Data Exchange); 
htt // hd h lthd t
 17 
Interpret results in light of existing evidence. If 
updating a previous set of estimates, describe 
the reasons for changes in estimates. 
Discussion of 
methodological changes 
between GBD rounds 
provided in the narrative 
of the manuscript and 
methods appendix 
Manuscript (Methods 
and Discussion) and 
methods appendix 
section 3 
 
18 Discuss limitations of the estimates. Include a 
discussion of any modeling assumptions or data 
limitations that affect interpretation of the 
estimates. 
Discussion of limitations 
provided in the 
narrative of the 
manuscript, as well as in 
the methodological 
write-ups in the 
methods appendix 
Manuscript 
(Limitations) and 
methods appendix 
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Location Level
Global 0
Southeast Asia, East Asia, and Oceania 1
East Asia 2
China 3
Anhui 4
Beijing 4
Chongqing 4
Fujian 4
Gansu 4
Guangdong 4
Guangxi 4
Guizhou 4
Hainan 4
Hebei 4
Heilongjiang 4
Henan 4
Hong Kong Special Administrative Region of China 4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
2
3
3
4
4
4
Hubei
Hunan
Inner Mongolia
Jiangsu
Jiangxi
Jilin
Liaoning
Macao Special Administrative Region of China 
Ningxia
Qinghai
Shaanxi
Shandong
Shanghai
Shanxi
Sichuan
Tianjin
Tibet
Xinjiang
Yunnan
Zhejiang
North Korea
Taiwan (Province of China)
Southeast Asia
Cambodia
Indonesia
Aceh
Bali
Bangka Belitung
Banten 4
Appendix Table 2: GBD 2016 location hierarchy with levels
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4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
2
3
3
3
Bengkulu
Gorontalo
Jakarta
Jambi
Cental Java
West Java
East Java
West Kalimantan 
South Kalimantan 
Central Kalimantan 
East Kalimantan 
North Kalimantan 
Riau Islands
Lampung
Maluku
North Maluku
Nusa Tenggara Barat
East Nusa Tenggara
Papua
West Papua
Riau
West Sulawesi
South Sumatera
Central Sulawesi
Southeast Sulawesi
North Sulawesi
West Sumatera
South Sumatera
North Sumatera
Yogyakarta
Laos
Malaysia
Maldives
Mauritius
Myanmar
Philippines
Sri Lanka
Seychelles
Thailand
Timor-Leste
Vietnam
Oceania
American Samoa
Federated States of Micronesia 
Fiji
Guam 3
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Kiribati 3
Marshall Islands 3
Northern Mariana Islands 3
Papua New Guinea 3
Samoa 3
Solomon Islands 3
Tonga 3
Vanuatu 3
Central Europe, Eastern Europe, and Central Asia 1
Central Asia 2
Armenia 3
Azerbaijan 3
Georgia 4
Georgia 3
Kazakhstan 3
Kyrgyzstan 3
Mongolia 3
Tajikistan 3
Turkmenistan 3
Uzbekistan 3
Central Europe 2
Albania 3
Bosnia and Herzegovina 3
Bulgaria 3
Croatia 3
Czech Republic 3
Hungary 3
Macedonia 3
Montenegro 3
Poland 3
Romania 3
Serbia 3
Slovakia 3
Slovenia 3
Eastern Europe 2
Belarus 3
Estonia 3
Latvia 3
Lithuania 3
Moldova 3
Russia 3
Ukraine 3
High-income 1
High-income Asia Pacific 2
Brunei 3
Japan 3
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Aichi 4
Akita 4
Aomori 4
Chiba 4
Ehime 4
Fukui 4
Fukuoka 4
Fukushima 4
Gifu 4
Gunma 4
Hiroshima 4
Hokkaidō 4
Hyōgo 4
Ibaraki 4
Ishikawa 4
Iwate 4
Kagawa 4
Kagoshima 4
Kanagawa 4
Kōchi 4
Kumamoto 4
Kyōto 4
Mie 4
Miyagi 4
Miyazaki 4
Nagano 4
Nagasaki 4
Nara 4
Niigata 4
Ôita 4
Okayama 4
Okinawa 4
Ōsaka 4
Saga 4
Saitama 4
Shiga 4
Shimane 4
Shizuoka 4
Tochigi 4
Tokushima 4
Tōkyō 4
Tottori 4
Toyama 4
Wakayama 4
Yamagata 4
Yamaguchi 4
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Yamanashi 4
South Korea 3
Singapore 3
Australasia 2
Australia 3
New Zealand 3
Western Europe 2
Andorra 3
Austria 3
Belgium 3
Cyprus 3
Denmark 3
Finland 3
France 3
Germany 3
Greece 3
Iceland 3
Ireland 3
Israel 3
Italy 3
Luxembourg 3
Malta 3
Netherlands 3
Norway 3
Portugal 3
Spain 3
Sweden 3
Stockholm 4
Sweden except Stockholm 4
Switzerland 3
United Kingdom 3
England 4
East Midlands 5
Derby 6
Derbyshire 6
Leicester 6
Leicestershire 6
Lincolnshire 6
Northamptonshire 6
Nottingham 6
Nottinghamshire 6
Rutland 6
East of England 5
Bedford 6
Cambridgeshire 6
Central Bedfordshire 6
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Essex 6
Hertfordshire 6
Luton 6
Norfolk 6
Peterborough 6
Southend-on-Sea 6
Suffolk 6
Thurrock 6
Greater London 5
Barking and Dagenham 6
Barnet 6
Bexley 6
Brent 6
Bromley 6
Camden 6
Croydon 6
Ealing 6
Enfield 6
Greenwich 6
Hackney 6
Hammersmith and Fulham 6
Haringey 6
Harrow 6
Havering 6
Hillingdon 6
Hounslow 6
Islington 6
Kensington and Chelsea 6
Kingston upon Thames 6
Lambeth 6
Lewisham 6
Merton 6
Newham 6
Redbridge 6
Richmond upon Thames 6
Southwark 6
Sutton 6
Tower Hamlets 6
Waltham Forest 6
Wandsworth 6
Westminster 6
North East England 5
County Durham 6
Darlington 6
Gateshead 6
Hartlepool 6
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Middlesbrough 6
Newcastle upon Tyne 6
North Tyneside 6
Northumberland 6
Redcar and Cleveland 6
South Tyneside 6
Stockton-on-Tees 6
Sunderland 6
North West England 5
Blackburn with Darwen 6
Blackpool 6
Bolton 6
Bury 6
Cheshire East 6
Cheshire West and Chester 6
Cumbria 6
Halton 6
Knowsley 6
Lancashire 6
Liverpool 6
Manchester 6
Oldham 6
Rochdale 6
Salford 6
Sefton 6
St Helens 6
Stockport 6
Tameside 6
Trafford 6
Warrington 6
Wigan 6
Wirral 6
South East England 5
Bracknell Forest 6
Brighton and Hove 6
Buckinghamshire 6
East Sussex 6
Hampshire 6
Isle of Wight 6
Kent 6
Medway 6
Milton Keynes 6
Oxfordshire 6
Portsmouth 6
Reading 6
Slough 6
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Southampton 6
Surrey 6
West Berkshire 6
West Sussex 6
Windsor and Maidenhead 6
Wokingham 6
South West England 5
Bath and North East Somerset 6
Bournemouth 6
Bristol, City of 6
Cornwall 6
Devon 6
Dorset 6
Gloucestershire 6
North Somerset 6
Plymouth 6
Poole 6
Somerset 6
South Gloucestershire 6
Swindon 6
Torbay 6
Wiltshire 6
West Midlands 5
Birmingham 6
Coventry 6
Dudley 6
Herefordshire, County of 6
Sandwell 6
Shropshire 6
Solihull 6
Staffordshire 6
Stoke-on-Trent 6
Telford and Wrekin 6
Walsall 6
Warwickshire 6
Wolverhampton 6
Worcestershire 6
Yorkshire and the Humber 5
Barnsley 6
Bradford 6
Calderdale 6
Doncaster 6
East Riding of Yorkshire 6
Kingston upon Hull, City of 6
Kirklees 6
Leeds 6
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6
6
6
6
6
6
6
4
4
4
2
3
3
3
2
3
3
3
4
4
4
4
4
4
4
4
4
4
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
North East Lincolnshire 
North Lincolnshire
North Yorkshire 
Rotherham
Sheffield
Wakefield
York
Northern Ireland
Scotland
Wales
Southern Latin America 
Argentina
Chile
Uruguay
High-income North America 
Canada
Greenland
USA
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia 
Florida
Georgia
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana 4
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Nebraska 4
Nevada 4
New Hampshire 4
New Jersey 4
New Mexico 4
New York 4
North Carolina 4
North Dakota 4
Ohio 4
Oklahoma 4
Oregon 4
Pennsylvania 4
Rhode Island 4
South Carolina 4
South Dakota 4
Tennessee 4
Texas 4
Utah 4
Vermont 4
Virginia 4
Washington 4
West Virginia 4
Wisconsin 4
Wyoming 4
Latin America and Caribbean 1
Caribbean 2
Antigua and Barbuda 3
The Bahamas 3
Barbados 3
Belize 3
Bermuda 3
Cuba 3
Dominica 3
Dominican Republic 3
Grenada 3
Guyana 3
Haiti 3
Jamaica 3
Puerto Rico 3
Saint Lucia 3
Saint Vincent and the Grenadines 3
Suriname 3
Trinidad and Tobago 3
Virgin Islands, U.S. 3
Andean Latin America 2
Bolivia 3
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Ecuador 3
Peru 3
Central Latin America 2
Colombia 3
Costa Rica 3
El Salvador 3
Guatemala 3
Honduras 3
Mexico 3
Aguascalientes 4
Baja California 4
Baja California Sur 4
Campeche 4
Chiapas 4
Chihuahua 4
Coahuila 4
Colima 4
Distrito Federal 4
Distrito Federal 4
Durango 4
Guanajuato 4
Guerrero 4
Hidalgo 4
Jalisco 4
México 4
Michoacán de Ocampo 4
Morelos 4
Nayarit 4
Nuevo León 4
Oaxaca 4
Puebla 4
Querétaro 4
Quintana Roo 4
San Luis Potosí 4
Sinaloa 4
Sonora 4
Tabasco 4
Tamaulipas 4
Tlaxcala 4
Veracruz de Ignacio de la Llave 4
Yucatán 4
Zacatecas 4
Nicaragua 3
Panama 3
Venezuela 3
Tropical Latin America 2
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Brazil 3
Acre 4
Alagoas 4
Amapá 4
Amazonas 4
Bahia 4
Ceará 4
Distrito Federal 4
Distrito Federal 4
Espírito Santo 4
Goiás 4
Maranhão 4
Mato Grosso 4
Mato Grosso do Sul 4
Minas Gerais 4
Pará 4
Paraíba 4
Paraná 4
Pernambuco 4
Piaui 4
Rio de Janeiro 4
Rio Grande do Norte 4
Rio Grande do Sul 4
Rondônia 4
Roraima 4
Santa Catarina 4
São Paulo 4
Sergipe 4
Tocantins 4
Paraguay 3
North Africa and Middle East 1
North Africa and Middle East 2
Afghanistan 3
Algeria 3
Bahrain 3
Egypt 3
Iran 3
Iraq 3
Jordan 3
Kuwait 3
Lebanon 3
Libya 3
Morocco 3
Palestine 3
Oman 3
Qatar 3
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Saudi Arabia 3
'Asir 4
Bahah 4
Eastern Province 4
Ha'il 4
Jawf 4
Jizan 4
Madinah 4
Makkah 4
Najran 4
Northern Borders 4
Qassim 4
Riyadh 4
Tabuk 4
Sudan 3
Syria 3
Tunisia 3
Turkey 3
United Arab Emirates 3
Yemen 3
South Asia 1
South Asia 2
Bangladesh 3
Bhutan 3
India 3
Andhra Pradesh 4
Andhra Pradesh, Rural 5
Andhra Pradesh, Urban 5
Arunāchal Pradesh 4
Arunāchal Pradesh, Rural 5
Arunāchal Pradesh, Urban 5
Assam 4
Assam, Rural 5
Assam, Urban 5
Bihār 4
Bihār, Rural 5
Bihār, Urban 5
Chhattīsgarh 4
Chhattīsgarh, Rural 5
Chhattīsgarh, Urban 5
Delhi 4
Delhi, Rural 5
Delhi, Urban 5
Goa 4
Goa, Rural 5
Goa, Urban 5
738
Location Level
Appendix Table 2: GBD 2016 location hierarchy with levels
Gujarāt 4
Gujarāt, Rural 5
Gujarāt, Urban 5
Haryāna 4
Haryāna, Rural 5
Haryāna, Urban 5
Himachal Pradesh 4
Himachal Pradesh, Rural 5
Himachal Pradesh, Urban 5
Jammu and Kashmīr 4
Jammu and Kashmīr, Rural 5
Jammu and Kashmīr, Urban 5
Jharkhand 4
Jharkhand, Rural 5
Jharkhand, Urban 5
Karnātaka 4
Karnātaka, Rural 5
Karnātaka, Urban 5
Kerala 4
Kerala, Rural 5
Kerala, Urban 5
Madhya Pradesh 4
Madhya Pradesh, Rural 5
Madhya Pradesh, Urban 5
Mahārāshtra 4
Mahārāshtra, Rural 5
Mahārāshtra, Urban 5
Manipur 4
Manipur, Rural 5
Manipur, Urban 5
Meghālaya 4
Meghālaya, Rural 5
Meghālaya, Urban 5
Mizoram 4
Mizoram, Rural 5
Mizoram, Urban 5
Nāgāland 4
Nāgāland, Rural 5
Nāgāland, Urban 5
Orissa 4
Orissa, Rural 5
Orissa, Urban 5
Punjab 4
Punjab, Rural 5
Punjab, Urban 5
Rājasthān 4
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5
5
4
5
5
4
5
5
4
5
5
4
5
5
4
5
5
4
5
5
4
5
5
4
5
5
3
3
1
2
3
3
3
3
3
3
2
3
3
3
3
3
3
4
4
Rājasthān, Rural
Rājasthān, Urban
Sikkim
Sikkim, Rural
Sikkim, Urban
Tamil Nādu
Tamil Nādu, Rural
Tamil Nādu, Urban
Telangana
Telangana, Rural
Telangana, Urban
Tripura
Tripura, Rural
Tripura, Urban
Uttar Pradesh
Uttar Pradesh, Rural
Uttar Pradesh, Urban 
Uttarakhand
Uttarakhand, Rural 
Uttarakhand, Urban
West Bengal
West Bengal, Rural
West Bengal, Urban
The Six Minor Territories
The Six Minor Territories, Rural 
The Six Minor Territories, Urban 
Nepal
Pakistan
Sub-Saharan Africa
Central Sub-Saharan Africa 
Angola
the Central African Republic
Congo (Brazzaville)
Democratic Republic of the Congo  
Equatorial Guinea
Gabon
Eastern Sub-Saharan Africa 
Burundi
Comoros
Djibouti
Eritrea
Ethiopia
Kenya
Baringo
Bomet
Bungoma 4
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Busia 4
Elgeyo-Marakwet 4
Embu 4
Garissa 4
HomaBay 4
Isiolo 4
Kajiado 4
Kakamega 4
Kericho 4
Kiambu 4
Kilifi 4
Kirinyaga 4
Kisii 4
Kisumu 4
Kitui 4
Kwale 4
Laikipia 4
Lamu 4
Machakos 4
Makueni 4
Mandera 4
Marsabit 4
Meru 4
Migori 4
Mombasa 4
Murang’a 4
Nairobi 4
Nakuru 4
Nandi 4
Narok 4
Nyamira 4
Nyandarua 4
Nyeri 4
Samburu 4
Siaya 4
TaitaTaveta 4
TanaRiver 4
TharakaNithi 4
TransNzoia 4
Turkana 4
UasinGishu 4
Vihiga 4
Wajir 4
WestPokot 4
Madagascar 3
Malawi 3
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Mozambique 3
Rwanda 3
Somalia 3
South Sudan 3
Tanzania 3
Uganda 3
Zambia 3
Southern Sub-Saharan Africa 2
Botswana 3
Lesotho 3
Namibia 3
South Africa 3
Eastern Cape 4
Free State 4
Gauteng 4
KwaZulu-Natal 4
Limpopo 4
Mpumalanga 4
North-West 4
Northern Cape 4
Western Cape 4
Swaziland 3
Zimbabwe 3
Western Sub-Saharan Africa 2
Benin 3
Burkina Faso 3
Cameroon 3
Cape Verde 3
Chad 3
Cote d'Ivoire 3
The Gambia 3
Ghana 3
Guinea 3
Guinea-Bissau 3
Liberia 3
Mali 3
Mauritania 3
Niger 3
Nigeria 3
Sao Tome and Principe 3
Senegal 3
Sierra Leone 3
Togo 3
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Causes and sequelae 
All causes 
Communicable, maternal, neonatal, and nutritional diseases 
HIV/AIDS and tuberculosis 
Tuberculosis 
Drug-susceptible tuberculosis 
Multidrug-resistant tuberculosis without extensive drug resistance 
Extensively drug-resistant tuberculosis 
Latent tuberculosis infection 
HIV/AIDS 
Drug-susceptible HIV/AIDS - Tuberculosis 
Drug-susceptible HIV/AIDS - Tuberculosis with mild anemia 
Drug-susceptible HIV/AIDS - Tuberculosis with moderate anemia 
Drug-susceptible HIV/AIDS - Tuberculosis with severe anemia 
Drug-susceptible HIV/AIDS - Tuberculosis without anemia 
Multidrug-resistant HIV/AIDS - Tuberculosis without extensive drug resistance 
Multidrug-resistant HIV/AIDS - Tuberculosis without extensive drug resistance with mild anemia 
Multidrug-resistant HIV/AIDS - Tuberculosis without extensive drug resistance with moderate anemia 
Multidrug-resistant HIV/AIDS - Tuberculosis without extensive drug resistance with severe anemia 
Multidrug-resistant HIV/AIDS - Tuberculosis without extensive drug resistance without anemia 
Extensively drug-resistant HIV/AIDS - Tuberculosis 
Extensively drug-resistant HIV/AIDS - Tuberculosis with mild anemia 
Extensively drug-resistant HIV/AIDS - Tuberculosis with moderate anemia 
Extensively drug-resistant HIV/AIDS - Tuberculosis with severe anemia 
Extensively drug-resistant HIV/AIDS - Tuberculosis without anemia 
HIV/AIDS resulting in other diseases 
AIDS with antiretroviral treatment with mild anemia 
AIDS with antiretroviral treatment with moderate anemia 
AIDS with antiretroviral treatment with severe anemia 
AIDS with antiretroviral treatment without anemia 
AIDS without antiretroviral treatment with mild anemia 
AIDS without antiretroviral treatment with moderate anemia 
AIDS without antiretroviral treatment with severe anemia 
AIDS without antiretroviral treatment without anemia 
Early HIV with mild anemia 
Early HIV with moderate anemia 
Early HIV with severe anemia 
Early HIV without anemia 
Symptomatic HIV with mild anemia 
Symptomatic HIV with moderate anemia 
Symptomatic HIV with severe anemia 
Symptomatic HIV without anemia 
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Diarrhea, lower respiratory, and other common infectious diseases 
Diarrheal diseases 
Guillain-Barré syndrome due to diarrheal diseases 
Mild diarrheal diseases 
Moderate diarrheal diseases 
Severe diarrheal diseases 
Intestinal infectious diseases 
Typhoid fever 
Acute typhoid infection 
Gastrointestinal bleeding due to typhoid 
Intestinal perforation due to typhoid 
Severe typhoid fever 
Paratyphoid fever 
Acute paratyphoid infection 
Intestinal perforation due to paratyphoid 
Moderate paratyphoid fever 
Severe paratyphoid fever 
Other intestinal infectious diseases 
Lower respiratory infections 
Guillain-Barré syndrome due to lower respiratory infections 
Moderate lower respiratory infections 
Severe lower respiratory infections 
Upper respiratory infections 
Guillain-Barré syndrome due to upper respiratory infections 
Mild upper respiratory infections 
Moderate upper respiratory infections 
Otitis media 
Acute otitis media 
Mild hearing loss due to chronic otitis media 
Mild hearing loss with ringing due to chronic otitis media 
Moderate hearing loss due to chronic otitis media 
Moderate hearing loss with ringing due to chronic otitis media 
Severe infectious complications due to chronic otitis media 
Vertigo with mild hearing loss and ringing due to chronic otitis media 
Vertigo with mild hearing loss due to chronic otitis media 
Vertigo with moderate hearing loss and ringing due to chronic otitis media 
Vertigo with moderate hearing loss due to chronic otitis media 
Meningitis 
Pneumococcal meningitis 
Acute pneumococcal meningitis 
Blindness due to pneumococcal meningitis 
Borderline intellectual disability due to pneumococcal meningitis 
Complete hearing loss due to pneumococcal meningitis 
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Complete hearing loss with ringing due to pneumococcal meningitis 
Epilepsy due to pneumococcal meningitis 
Mild behavioral problems due to pneumococcal meningitis 
Mild hearing loss due to pneumococcal meningitis 
Mild hearing loss with ringing due to pneumococcal meningitis 
Mild intellectual disability due to pneumococcal meningitis 
Mild motor impairment due to long term due to pneumococcal meningitis 
Mild motor plus cognitive impairments due to pneumococcal meningitis 
Moderate hearing loss due to pneumococcal meningitis 
Moderate hearing loss with ringing due to pneumococcal meningitis 
Moderate motor impairment due to pneumococcal meningitis 
Moderate motor plus cognitive impairments due to pneumococcal meningitis 
Moderate vision impairment due to pneumococcol meningitis 
Moderately severe hearing loss due to pneumococcal meningitis 
Moderately severe hearing loss with ringing due to pneumococcal meningitis 
Monocular distance vision loss due to pneumococcal meningitis 
Profound hearing loss due to pneumococcal meningitis 
Profound hearing loss with ringing due to pneumococcal meningitis 
Severe hearing loss due to pneumococcal meningitis 
Severe hearing loss with ringing due to pneumococcal meningitis 
Severe motor impairment due to pneumococcal meningitis 
Severe motor plus cognitive impairments due to pneumococcal meningitis 
Severe vision impairment due to pneumococcol meningitis 
H influenzae type B meningitis 
Acute H influenzae type B meningitis 
Blindness due to H influenzae type B meningitis 
Borderline intellectual disability due to H influenzae type B meningitis 
Complete hearing loss due to H influenzae type B meningitis 
Complete hearing loss with ringing due to H influenzae type B meningitis 
Epilepsy due to H influenzae type B meningitis 
Mild behavioral problems due to H influenzae type B meningitis 
Mild hearing loss due to H influenzae type B meningitis 
Mild hearing loss with ringing due to H influenzae type B meningitis 
Mild intellectual disability due to H influenzae type B meningitis 
Mild motor impairment due to long term due to H influenzae type B meningitis 
Mild motor plus cognitive impairments due to H influenzae type B meningitis 
Moderate hearing loss due to H influenzae type B meningitis 
Moderate hearing loss with ringing due to H influenzae type B meningitis 
Moderate motor impairment due to H influenzae type B meningitis 
Moderate motor plus cognitive impairments due to H influenzae type B meningitis 
Moderate vision impairment due to H influenza type B meningitis 
Moderately severe hearing loss due to H influenzae type B meningitis 
Moderately severe hearing loss with ringing due to H influenzae type B meningitis 
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Monocular distance vision loss due to H influenzae type B meningitis 
Profound hearing loss due to H influenzae type B meningitis 
Profound hearing loss with ringing due to H influenzae type B meningitis 
Severe hearing loss due to H influenzae type B meningitis 
Severe hearing loss with ringing due to H influenzae type B meningitis 
Severe motor impairment due to H influenzae type B meningitis 
Severe motor plus cognitive impairments due to H influenzae type B meningitis 
Severe vision impairment due to H influenza type B meningitis 
Meningococcal meningitis 
Acute meningococcal meningitis 
Blindness due to meningococcal meningitis 
Borderline intellectual disability due to meningococcal meningitis 
Complete hearing loss due to meningococcal meningitis 
Complete hearing loss with ringing due to meningococcal meningitis 
Epilepsy due to meningococcal meningitis 
Mild behavioral problems due to meningococcal meningitis 
Mild hearing loss due to meningococcal meningitis 
Mild hearing loss with ringing due to meningococcal meningitis 
Mild intellectual disability due to meningococcal meningitis 
Mild motor impairment due to long term due to meningococcal meningitis 
Mild motor plus cognitive impairments due to meningococcal meningitis 
Moderate hearing loss due to meningococcal meningitis 
Moderate hearing loss with ringing due to meningococcal meningitis 
Moderate motor impairment due to meningococcal meningitis 
Moderate motor plus cognitive impairments due to meningococcal meningitis 
Moderate vision impairment due to meningococcal meningitis 
Moderately severe hearing loss due to meningococcal meningitis 
Moderately severe hearing loss with ringing due to meningococcal meningitis 
Monocular distance vision loss due to meningococcal meningitis 
Profound hearing loss due to meningococcal meningitis 
Profound hearing loss with ringing due to meningococcal meningitis 
Severe hearing loss due to meningococcal meningitis 
Severe hearing loss with ringing due to meningococcal meningitis 
Severe motor impairment due to meningococcal meningitis 
Severe motor plus cognitive impairments due to meningococcal meningitis 
Severe vision impairment due to meningococcal meningitis 
Other meningitis 
Acute viral meningitis 
Blindness due to other bacterial meningitis 
Borderline intellectual disability due to other bacterial meningitis 
Complete hearing loss due to other bacterial meningitis 
Complete hearing loss with ringing due to other bacterial meningitis 
Epilepsy due to other meningitis 
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Mild behavioral problems due to other bacterial meningitis 
Mild hearing loss due to other bacterial meningitis 
Mild hearing loss due with ringing to other bacterial meningitis 
Mild intellectual disability due to other bacterial meningitis 
Mild motor impairment due to long term due to other bacterial meningitis 
Mild motor plus cognitive impairments due to other bacterial meningitis 
Moderate hearing loss due to other bacterial meningitis 
Moderate hearing loss with ringing due to other bacterial meningitis 
Moderate motor impairment due to other bacterial meningitis 
Moderate motor plus cognitive impairments due to other bacterial meningitis 
Moderate vision impairment due to other bacterial meningitis 
Moderately severe hearing loss due to other bacterial meningitis 
Moderately severe hearing loss with ringing due to other bacterial meningitis 
Monocular distance vision loss due to other bacterial meningitis 
Other acute bacterial meningitis 
Profound hearing loss due to other bacterial meningitis 
Profound hearing loss with ringing due to other bacterial meningitis 
Severe hearing loss due to other bacterial meningitis 
Severe hearing loss with ringing due to other bacterial meningitis 
Severe motor impairment due to other bacterial meningitis 
Severe motor plus cognitive impairments due to other bacterial meningitis 
Severe vision impairment due to other bacterial meningitis 
Encephalitis 
Acute encephalitis 
Blindness due to encephalitis 
Borderline intellectual disability due to encephalitis 
Epilepsy due to encephalitis 
Mild behavioral problems due to encephalitis 
Mild intellectual disability due to encephalitis 
Mild motor impairment due to long term due to encephalitis 
Mild motor plus cognitive impairments due to encephalitis 
Moderate motor impairment due to encephalitis 
Moderate motor plus cognitive impairments due to encephalitis 
Moderate vision impairment due to encephalitis 
Monocular distance vision loss due to encephalitis 
Severe motor impairment due to encephalitis 
Severe motor plus cognitive impairments due to encephalitis 
Severe vision impairment due to encephalitis 
Diphtheria 
Moderate diphtheria 
Severe diphtheria 
Whooping cough 
Tetanus 
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Mild motor impairment due to neonatal tetanus 
Mild motor plus cognitive impairments due to neonatal tetanus 
Moderate motor impairment due to neonatal tetanus 
Moderate motor impairment with blindness and epilepsy due to neonatal tetanus 
Moderate motor impairment with blindness due to neonatal tetanus 
Moderate motor impairment with epilepsy due to neonatal tetanus 
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal tetanus 
Moderate motor plus cognitive impairment with blindness due to neonatal tetanus 
Moderate motor plus cognitive impairment with epilepsy due to neonatal tetanus 
Severe motor impairment due to neonatal tetanus 
Severe motor impairment with blindness and epilepsy due to neonatal tetanus 
Severe motor impairment with blindness due to neonatal tetanus  
Severe motor impairment with epilepsy due to neonatal tetanus 
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal tetanus 
Severe motor plus cognitive impairment with blindness due to neonatal tetanus 
Severe motor plus cognitive impairment with epilepsy due to neonatal tetanus 
Severe tetanus 
Measles 
Moderate measles 
Severe measles 
Varicella and herpes zoster 
Chickenpox 
Herpes zoster 
Neglected tropical diseases and malaria 
Malaria 
Asymptomatic malaria parasitemia (PfPR) 
Mild anemia due to malaria parasitemia (PfPR) 
Mild malaria 
Mild malaria with mild anemia 
Mild malaria with moderate anemia 
Mild malaria with severe anemia 
Moderate anemia due to malaria parasitemia (PfPR) 
Moderate malaria 
Moderate malaria with mild anemia 
Moderate malaria with moderate anemia 
Moderate malaria with severe anemia 
Moderate motor impairment due to malaria 
Moderate motor impairment with blindness and epilepsy due to malaria 
Moderate motor impairment with blindness due to malaria 
Moderate motor impairment with epilepsy due to malaria 
Moderate motor plus cognitive impairment with blindness and epilepsy due to malaria 
Moderate motor plus cognitive impairment with blindness due to malaria 
Moderate motor plus cognitive impairment with epilepsy due to malaria 
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Severe anemia due to malaria parasitemia (PfPR) 
Severe malaria 
Severe malaria with mild anemia 
Severe malaria with moderate anemia 
Severe malaria with severe anemia 
Severe motor impairment due to malaria 
Severe motor impairment with blindness and epilepsy due to malaria 
Severe motor impairment with blindness due to malaria  
Severe motor impairment with epilepsy due to malaria 
Severe motor plus cognitive impairment with blindness and epilepsy due to malaria 
Severe motor plus cognitive impairment with blindness due to malaria 
Severe motor plus cognitive impairment with epilepsy due to malaria 
Chagas disease 
Acute Chagas disease 
Asymptomatic Chagas disease 
Asymptomatic and mild heart failure due to Chagas disease 
Atrial fibrillation and flutter due to Chagas disease 
Mild chronic digestive disease due to Chagas disease 
Moderate chronic digestive disease due to Chagas disease 
Moderate heart failure due to Chagas disease 
Severe heart failure due to Chagas disease 
Leishmaniasis 
Visceral leishmaniasis 
Moderate visceral leishmaniasis 
Severe visceral leishmaniasis 
Cutaneous and mucocutaneous leishmaniasis 
African trypanosomiasis 
Skin disfigurement due to Trypanosoma brucei gambiense 
Skin disfigurement due to Trypanosoma brucei rhodesiense 
Sleeping sickness due to Trypanosoma brucei gambiense 
Sleeping sickness due to Trypanosoma brucei rhodesiense 
Schistosomiasis 
Ascites due to schistosomiasis 
Bladder pathology due to schistosomiasis 
Dysuria due to schistosomiasis 
Hematemesis due to schistosomiasis 
Hepatomegaly due to schistosomiasis 
Hydronephrosis due to schistosomiasis 
Mild anemia due to schistosomiasis 
Mild diarrhea due to schistosomiasis 
Mild schistosomiasis 
Moderate anemia due to schistosomiasis 
Severe anemia due to schistosomiasis 
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Cysticercosis 
Neurocysticercosis with epilepsy 
Cystic echinococcosis 
Abdominal problems due to cystic echinococcosis 
Chronic respiratory disease due to cystic echinococcosis 
Epilepsy due to echinococcosis 
Lymphatic filariasis 
Acute adenolymphangitis due to lymphatic filariasis 
Hydrocele due to lymphatic filariasis 
Lymphedema due to lymphatic filariasis 
Prevalence of detectable microfiliaria due to lymphatic filariasis 
Onchocerciasis 
Asymptomatic onchocerciasis 
Blindness due to onchocerciasis 
Mild skin disease due to onchocerciasis 
Mild skin disease without itch due to onchocerciasis 
Moderate skin disease due to onchocerciasis 
Moderate vision impairment due to onchocerciasis 
Severe skin disease due to onchocerciasis 
Severe skin disease without itch due to onchocerciasis 
Severe vision impairment due to onchocerciasis 
Trachoma 
Blindness due to trachoma 
Moderate vision impairment due to trachoma 
Severe vision impairment due to trachoma 
Dengue 
Moderate dengue 
Post-dengue chronic fatigue syndrome 
Severe dengue 
Yellow fever 
Asymptomatic yellow fever 
Moderate yellow fever 
Severe yellow fever 
Rabies 
Intestinal nematode infections 
Ascariasis 
Asymptomatic ascariasis 
Heavy infestation of ascariasis 
Mild abdominopelvic problems due to ascariasis 
Severe wasting due to ascariasis 
Trichuriasis 
Asymptomatic trichuriasis 
Heavy infestation of trichuriasis 
750
Mild abdominopelvic problems due to trichuriasis 
Severe wasting due to trichuriasis 
Hookworm disease 
Asymptomatic hookworm disease 
Heavy infestation of hookworm 
Mild abdominopelvic problems due to hookworm disease 
Mild anemia due to hookworm disease 
Moderate anemia due to hookworm disease 
Severe anemia due to hookworm disease 
Severe wasting due to hookworm disease 
Food-borne trematodiases 
Asymptomatic clonorchiasis 
Asymptomatic fascioliasis 
Asymptomatic intestinal fluke infection 
Asymptomatic opisthorchiasis 
Asymptomatic paragonimiasis 
Cerebral paragonimiasis 
Heavy clonorchiasis due to food-borne trematodiases 
Heavy fascioliasis due to food-borne trematodiases 
Heavy intestinal fluke infection due to food-borne trematodiases 
Heavy opisthorchiasis due to food-borne trematodiases 
Mild paragonimiasis due to food-borne trematodiases 
Moderate paragonimiasis due to food-borne trematodiases 
Severe paragonimiasis due to food-borne trematodiases 
Leprosy 
Disfigurement level 1 due to leprosy 
Disfigurement level 2 due to leprosy 
Ebola 
Ebola cases 
Post-Ebola chronic fatigue syndrome 
Zika virus 
Acute Zika infection 
Asymptomatic Zika infection 
Congenital Zika syndrome 
Guillain–Barré syndrome due to Zika infection 
Guinea worm disease 
Mild pain due to Guinea worm emergence 
Moderate pain due to Guinea worm emergence 
Moderate reduced mobility due to Guinea worm emergence 
Other neglected tropical diseases 
Acute infection due to other neglected tropical diseases 
Mild anemia due to other neglected tropical diseases 
Moderate anemia due to other neglected tropical diseases 
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Severe anemia due to other neglected tropical diseases 
Maternal disorders 
Maternal hemorrhage 
Maternal hemorrhage (< 1L blood lost) 
Maternal hemorrhage (> 1L blood lost) 
Mild anemia due to maternal hemorrhage 
Moderate anemia due to maternal hemorrhage 
Severe anemia due to maternal hemorrhage 
Maternal sepsis and other maternal infections 
Infertility due to puerperal sepsis 
Other maternal infections 
Puerperal sepsis 
Maternal hypertensive disorders 
Eclampsia 
Long term sequelae of eclampsia 
Long term sequelae of severe pre-eclampsia 
Other hypertensive disorders of pregnancy 
Severe pre-eclampsia 
Maternal obstructed labor and uterine rupture 
Obstructed labor, acute event 
Rectovaginal fistula 
Vesicovaginal fistula 
Maternal abortion, miscarriage, and ectopic pregnancy 
Ectopic Pregnancy 
Maternal abortive outcome 
Indirect maternal deaths 
Late maternal deaths 
Maternal deaths aggravated by HIV/AIDS 
Other maternal disorders 
Neonatal disorders 
Neonatal preterm birth complications 
Asymptomatic neonatal preterm birth 28-<32 wks 
Asymptomatic neonatal preterm birth 32-<37wks 
Asymptomatic neonatla preterm birth <28wks 
Asymptomatic retinopathy of prematurity 
Blindness due to retinopathy of prematurity 
Mild motor impairment due to neonatal preterm birth complications 28-32wks 
Mild motor impairment due to neonatal preterm birth complications 32-36wks 
Mild motor impairment due to neonatal preterm birth complications <28wks 
Mild motor plus cognitive impairments due to neonatal preterm birth complications 28-32wks 
Mild motor plus cognitive impairments due to neonatal preterm birth complications 32-36wks 
Mild motor plus cognitive impairments due to neonatal preterm birth complications <28wks 
Mild vision impairment due to retinopathy of prematurity 
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Moderate motor impairment due to neonatal preterm birth complications 28-32wks 
Moderate motor impairment due to neonatal preterm birth complications 32-36wks 
Moderate motor impairment due to neonatal preterm birth complications <28wks 
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks 
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks 
Moderate motor impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks 
Moderate motor impairment with blindness due to neonatal preterm birth complications 28-32wks 
Moderate motor impairment with blindness due to neonatal preterm birth complications 32-36wks 
Moderate motor impairment with blindness due to neonatal preterm birth complications <28wks 
Moderate motor impairment with epilepsy due to neonatal preterm birth complications 28-32wks 
Moderate motor impairment with epilepsy due to neonatal preterm birth complications 32-36wks 
Moderate motor impairment with epilepsy due to neonatal preterm birth complications <28wks 
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks 
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks 
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks 
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications 28-32wks 
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications 32-36wks 
Moderate motor plus cognitive impairment with blindness due to neonatal preterm birth complications <28wks 
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 28-32wks 
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 32-36wks 
Moderate motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications <28wks 
Moderate vision impairment due to retinopathy of prematurity 
Severe motor impairment due to neonatal preterm birth complications 28-32wks 
Severe motor impairment due to neonatal preterm birth complications 32-36wks 
Severe motor impairment due to neonatal preterm birth complications <28wks 
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks 
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks 
Severe motor impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks 
Severe motor impairment with blindness due to neonatal preterm birth complications 28-32wks  
Severe motor impairment with blindness due to neonatal preterm birth complications 32-36wks  
Severe motor impairment with blindness due to neonatal preterm birth complications <28wks  
Severe motor impairment with epilepsy due to neonatal preterm birth complications 28-32wks 
Severe motor impairment with epilepsy due to neonatal preterm birth complications 32-36wks 
Severe motor impairment with epilepsy due to neonatal preterm birth complications <28wks 
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 28-32wks 
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications 32-36wks 
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal preterm birth complications <28wks 
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications 28-32wks 
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications 32-36wks 
Severe motor plus cognitive impairment with blindness due to neonatal preterm birth complications <28wks 
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Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 28-32wks 
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications 32-36wks 
Severe motor plus cognitive impairment with epilepsy due to neonatal preterm birth complications <28wks 
Severe vision impairment due to retinopathy of prematurity 
Neonatal encephalopathy due to birth asphyxia and trauma 
Asymptomatic neonatal encephalopathy due to birth asphyxia and trauma  
Mild motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma 
Mild motor plus cognitive impairments due to neonatal encephalopathy due to birth asphyxia and trauma 
Moderate motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma 
Moderate motor impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma 
Moderate motor impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma 
Moderate motor impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma 
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and 
trauma 
Moderate motor plus cognitive impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma 
Moderate motor plus cognitive impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma 
Severe motor impairment due to neonatal encephalopathy due to birth asphyxia and trauma 
Severe motor impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma 
Severe motor impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma  
Severe motor impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma 
Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal encephalopathy due to birth asphyxia and 
trauma 
Severe motor plus cognitive impairment with blindness due to neonatal encephalopathy due to birth asphyxia and trauma 
Severe motor plus cognitive impairment with epilepsy due to neonatal encephalopathy due to birth asphyxia and trauma 
Neonatal sepsis and other neonatal infections 
Asymptomatic neonatal sepsis and other neonatal infections 
Mild motor impairment due to neonatal sepsis and other neonatal infections 
Mild motor plus cognitive impairments due to neonatal sepsis and other neonatal infections 
Moderate motor impairment due to neonatal sepsis and other neonatal infections 
Moderate motor impairment with blindness and epilepsy due to neonatal sepsis and other neonatal infections 
Moderate motor impairment with blindness due to neonatal sepsis and other neonatal infections 
Moderate motor impairment with epilepsy due to neonatal sepsis and other neonatal infections 
Moderate motor plus cognitive impairment with blindness and epilepsy due to neonatal sepsis and other neonatal infections 
Moderate motor plus cognitive impairment with blindness due to neonatal sepsis and other neonatal infections 
Moderate motor plus cognitive impairment with epilepsy due to neonatal sepsis and other neonatal infections 
Severe infection due to neonatal sepsis and other neonatal infections 
Severe motor impairment due to neonatal sepsis and other neonatal infections 
Severe motor impairment with blindness and epilepsy due to neonatal sepsis and other neonatal infections 
Severe motor impairment with blindness due to neonatal sepsis and other neonatal infections   
Severe motor impairment with epilepsy due to neonatal sepsis and other neonatal infections 
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Severe motor plus cognitive impairment with blindness and epilepsy due to neonatal sepsis and other neonatal infections 
Severe motor plus cognitive impairment with blindness due to neonatal sepsis and other neonatal infections 
Severe motor plus cognitive impairment with epilepsy due to neonatal sepsis and other neonatal infections 
Hemolytic disease and other neonatal jaundice 
Moderate motor impairment due to hemolytic disease and other neonatal jaundice 
Moderate motor impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice 
Moderate motor impairment with blindness due to hemolytic disease and other neonatal jaundice 
Moderate motor impairment with epilepsy due to hemolytic disease and other neonatal jaundice 
Moderate motor plus cognitive impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice 
Moderate motor plus cognitive impairment with blindness due to hemolytic disease and other neonatal jaundice 
Moderate motor plus cognitive impairment with epilepsy due to hemolytic disease and other neonatal jaundice 
Severe motor impairment severe due to hemolytic disease and other neonatal jaundice 
Severe motor impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice 
Severe motor impairment with blindness due to hemolytic disease and other neonatal jaundice  
Severe motor impairment with epilepsy due to hemolytic disease and other neonatal jaundice 
Severe motor plus cognitive impairment with blindness and epilepsy due to hemolytic disease and other neonatal jaundice 
Severe motor plus cognitive impairment with blindness due to hemolytic disease and other neonatal jaundice 
Severe motor plus cognitive impairment with epilepsy due to hemolytic disease and other neonatal jaundice 
Other neonatal disorders 
Nutritional deficiencies 
Protein-energy malnutrition 
Moderate wasting with edema 
Moderate wasting without edema 
Severe wasting with edema 
Severe wasting without edema 
Iodine deficiency 
Visible goiter with profound intellectual disability and mild heart failure due to iodine deficiency 
Visible goiter with profound intellectual disability and moderate heart failure due to iodine deficiency 
Visible goiter with profound intellectual disability due to iodine deficiency 
Visible goiter with profound intellectual disability with severe heart failure due to iodine deficiency 
Visible goiter with severe intellectual disability due to iodine deficiency 
Visible goiter with symptoms without intellectual disability or heart failure 
Visible goiter without symptoms 
Vitamin A deficiency 
Asymptomatic vitamin A deficiency 
Blindness due to vitamin A deficiency 
Moderate vision impairment loss due to vitamin A deficiency 
Severe vision impairment loss due to vitamin A deficiency 
Iron-deficiency anemia 
Asymptomatic and mild heart failure due to iron-deficiency anemia 
Mild iron-deficiency anemia 
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Moderate heart failure due to iron-deficiency anemia 
Moderate iron-deficiency anemia 
Severe heart failure due to iron-deficiency anemia 
Severe iron-deficiency anemia 
Other nutritional deficiencies 
Other communicable, maternal, neonatal, and nutritional diseases 
Sexually transmitted diseases excluding HIV 
Syphilis 
Asymptomatic adult tertiary syphilis 
Asymptomatic early syphilis infection 
Cardiovascular complications due to adult tertiary syphilis 
Mild early syphilis infection 
Neurological problems and cardiovascular complications due to adult tertiary syphilis 
Neurological problems due to adult tertiary syphilis 
Severe disfigurement and cardiovascular complications due to adult tertiary syphilis 
Severe disfigurement and neurological problems due to adult tertiary syphilis 
Severe disfigurement due to adult tertiary syphilis 
Severe disfigurement, neurological problems, and cardiovascular complications due to adult tertiary syphilis 
Chlamydial infection 
Asymptomatic chlamydial infection 
Epididymo-orchitis due to chlamydial infection 
Mild chlamydial infection 
Moderate pelvic inflammatory diseases due to chlamydial infection 
Primary infertility due to chlamydial infection 
Secondary infertility due to chlamydial infection 
Severe pelvic inflammatory diseases due to chlamydial infection 
Gonococcal infection 
Asymptomatic gonococcal infection 
Epididymo-orchitis due to gonococcal infection 
Mild gonococcal infection 
Moderate pelvic inflammatory diseases due to gonococcal infection 
Primary infertility due to gonococcal infection 
Secondary infertility due to gonococcal infection 
Severe pelvic inflammatory diseases due to gonococcal infection 
Trichomoniasis 
Acute trichomoniasis infection 
Asymptomatic trichomoniasis infection 
Genital herpes 
Asymptomatic genital herpes 
Moderate infection due to initial genital herpes episode 
Symptomatic genital herpes 
Other sexually transmitted diseases 
Moderate pelvic inflammatory diseases due to other sexually transmitted diseases 
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Primary infertility due to other sexually transmitted diseases 
Secondary infertility due to other sexually transmitted diseases 
Severe pelvic inflammatory diseases due to other sexually transmitted diseases 
Hepatitis 
Acute hepatitis A 
Asymptomatic acute hepatitis A 
Moderate acute hepatitis A 
Severe acute hepatitis A 
Hepatitis B 
Asymptomatic acute hepatitis B 
Chronic hepatitis B 
Moderate acute hepatitis B 
Severe acute hepatitis B 
Hepatitis C 
Asymptomatic acute hepatitis C 
Chronic hepatitis C 
Moderate acute hepatitis C 
Severe acute hepatitis C 
Acute hepatitis E 
Asymptomatic acute hepatitis E 
Moderate acute hepatitis E 
Severe acute hepatitis E 
Other infectious diseases 
Guillain-Barré syndrome due to other infectious diseases 
Mild anemia due to other infectious diseases 
Moderate anemia due to other infectious diseases 
Severe anemia due to other infectious diseases 
Non-communicable diseases 
Neoplasms 
Lip and oral cavity cancer 
Controlled phase of mouth cancer 
Diagnosis and primary therapy phase of mouth cancer 
Metastatic phase of mouth cancer 
Terminal phase of mouth cancer 
Nasopharynx cancer 
Controlled phase of nasopharynx cancer 
Diagnosis and primary therapy phase of nasopharynx cancer 
Metastatic phase of nasopharynx cancer 
Terminal phase of nasopharynx cancer 
Other pharynx cancer 
Controlled phase of other pharynx cancer 
Diagnosis and primary therapy phase of other pharynx cancer 
Metastatic phase of other pharynx cancer 
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Terminal phase of other pharynx cancer 
Esophageal cancer 
Controlled phase of esophageal cancer 
Diagnosis and primary therapy phase of esophageal cancer 
Metastatic phase of esophageal cancer 
Terminal phase of esophageal cancer 
Stomach cancer 
Controlled phase of stomach cancer 
Diagnosis and primary therapy phase of stomach cancer 
Metastatic phase of stomach cancer 
Terminal phase of stomach cancer 
Colon and rectum cancer 
Controlled phase of colon and rectum cancers 
Diagnosis and primary therapy phase of colon and rectum cancers 
Metastatic phase of colon and rectum cancers 
Stoma due to colon and rectum cancer 
Terminal phase of colon and rectum cancers 
Liver cancer 
Liver cancer due to hepatitis B 
Controlled phase of liver cancer due to hepatitis B 
Diagnosis and primary therapy phase of liver cancer due to hepatitis B 
Metastatic phase of liver cancer due to hepatitis B 
Terminal phase of liver cancer due to hepatitis B 
Liver cancer due to hepatitis C 
Controlled phase of liver cancer due to hepatitis C 
Diagnosis and primary therapy phase of liver cancer due to hepatitis C 
Metastatic phase of liver cancer due to hepatitis C 
Terminal phase of liver cancer due to hepatitis C 
Liver cancer due to alcohol use 
Controlled phase of liver cancer due to alcohol use 
Diagnosis and primary therapy phase of liver cancer due to alcohol use 
Metastatic phase of liver cancer due to alcohol use 
Terminal phase of liver cancer due to alcohol use 
Liver cancer due to other causes 
Controlled phase of liver cancer due to other causes 
Diagnosis and primary therapy phase of liver cancer due to other causes 
Metastatic phase of liver cancer due to other causes 
Terminal phase of liver cancer due to other causes 
Gallbladder and biliary tract cancer 
Controlled phase of gallbladder and biliary tract cancer 
Diagnosis and primary therapy phase of gallbladder and biliary tract cancer 
Metastatic phase of gallbladder and biliary tract cancer 
Terminal phase of gallbladder and biliary tract cancer 
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Pancreatic cancer 
Controlled phase of pancreatic cancer 
Diagnosis and primary therapy phase of pancreatic cancer 
Metastatic phase of pancreatic cancer 
Terminal phase of pancreatic cancer 
Larynx cancer 
Controlled phase of larynx cancer 
Diagnosis and primary therapy phase of larynx cancer 
Laryngectomy due to larynx cancer 
Metastatic phase of larynx cancer 
Terminal phase of larynx cancer 
Tracheal, bronchus, and lung cancer 
Controlled phase of lung, bronchus, and trachea cancer 
Diagnosis and primary therapy phase of lung, bronchus, and trachea cancer 
Metastatic phase of lung, bronchus, and trachea cancer 
Terminal phase of lung, bronchus, and trachea cancer 
Malignant skin melanoma 
Controlled phase of malignant skin melanoma 
Diagnosis and primary therapy phase of malignant skin melanoma 
Metastatic phase of malignant skin melanoma 
Terminal phase of malignant skin melanoma 
Non-melanoma skin cancer 
Non-melanoma skin cancer (squamous-cell carcinoma) 
Mild disfigurement due to squamous cell carcinoma 
Moderate disfigurement due to squamous cell carcinoma 
Severe disfigurement due to squamous cell carcinoma 
Non-melanoma skin cancer (basal-cell carcinoma) 
Disfigurement due to basal cell carcinoma 
Breast cancer 
Controlled phase of breast cancer 
Diagnosis and primary therapy phase of breast cancer 
Mastectomy due to breast cancer 
Metastatic phase of breast cancer 
Terminal phase of breast cancer 
Cervical cancer 
Controlled phase of cervical cancer 
Diagnosis and primary therapy phase of cervical cancer 
Metastatic phase of cervical cancer 
Terminal phase of cervical cancer 
Uterine cancer 
Controlled phase of uterine cancer 
Diagnosis and primary therapy phase of uterine cancer 
Metastatic phase of uterine cancer 
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Terminal phase of uterine cancer 
Ovarian cancer 
Controlled phase of ovarian cancer 
Diagnosis and primary therapy phase of ovarian cancer 
Metastatic phase of ovarian cancer 
Terminal phase of ovarian cancer 
Prostate cancer 
Controlled phase of prostate cancer 
Diagnosis and primary therapy phase of prostate cancer 
Impotence due to prostate cancer 
Incontinence due to prostate cancer 
Metastatic phase of prostate cancer 
Terminal phase of prostate cancer 
Testicular cancer 
Controlled phase of testicular cancer 
Diagnosis and primary therapy phase of testicular cancer 
Metastatic phase of testicular cancer 
Terminal phase of testicular cancer 
Kidney cancer 
Controlled phase of kidney cancer 
Diagnosis and primary therapy phase of kidney cancer 
Metastatic phase of kidney cancer 
Terminal phase of kidney cancer 
Bladder cancer 
Controlled phase of bladder cancer 
Diagnosis and primary therapy phase of bladder cancer 
Metastatic phase of bladder cancer 
Terminal phase of bladder cancer 
Urinary incontinence due to bladder cancer 
Brain and nervous system cancer 
Controlled phase of brain and nervous system cancers 
Diagnosis and primary therapy phase of brain and nervous system cancers 
Metastatic phase of brain and nervous system cancers 
Terminal phase of brain and nervous system cancers 
Thyroid cancer 
Controlled phase of thyroid cancer 
Diagnosis and primary therapy phase of thyroid cancer 
Metastatic phase of thyroid cancer 
Terminal phase of thyroid cancer 
Mesothelioma 
Controlled phase of mesothelioma 
Diagnosis and primary therapy phase of mesothelioma 
Metastatic phase of mesothelioma 
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Terminal phase of mesothelioma 
Hodgkin lymphoma 
Controlled phase of Hodgkin disease 
Diagnosis and primary therapy phase of Hodgkin disease 
Metastatic phase of Hodgkin disease 
Terminal phase of Hodgkin disease 
Non-Hodgkin lymphoma 
Controlled phase of non-Hodgkin lymphoma 
Diagnosis and primary therapy phase of non-Hodgkin lymphoma 
Metastatic phase of non-Hodgkin lymphoma 
Terminal phase of non-Hodgkin lymphoma 
Multiple myeloma 
Controlled phase of multiple myeloma 
Diagnosis and primary therapy phase of multiple myeloma 
Metastatic phase of multiple myeloma 
Terminal phase of multiple myeloma 
Leukemia 
Acute lymphoid leukemia 
Controlled phase of acute lymphoid leukemia 
Diagnosis and primary therapy phase of acute lymphoid leukemia 
Metastatic phase of acute lymphoid leukemia 
Terminal phase of acute lymphoid leukemia 
Chronic lymphoid leukemia 
Controlled phase of chronic lymphoid leukemia 
Diagnosis and primary therapy phase of chronic lymphoid leukemia 
Metastatic phase of chronic lymphoid leukemia 
Terminal phase of chronic lymphoid leukemia 
Acute myeloid leukemia 
Controlled phase of acute myeloid leukemia 
Diagnosis and primary therapy phase of acute myeloid leukemia 
Metastatic phase of acute myeloid leukemia 
Terminal phase of acute myeloid leukemia 
Chronic myeloid leukemia 
Controlled phase of chronic myeloid leukemia 
Diagnosis and primary therapy phase of chronic myeloid leukemia 
Metastatic phase of chronic myeloid leukemia 
Terminal phase of chronic myeloid leukemia 
Other leukemia 
Controlled phase of other leukemia 
Diagnosis and primary therapy phase of other leukemia 
Metastatic phase of other leukemia 
Terminal phase of other leukemia 
Other neoplasms 
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Controlled phase of other neoplasms 
Diagnosis and primary therapy phase of other neoplasms 
Metastatic phase of other neoplasms 
Terminal phase of other neoplasms 
Cardiovascular diseases 
Rheumatic heart disease 
Asymptomatic and mild heart failure due to rheumatic heart disease 
Moderate heart failure due to rheumatic heart disease 
Rheumatic heart disease, without heart failure  
Severe heart failure due to rheumatic heart disease 
Ischemic heart disease 
Acute myocardial infarction 3 to 28 days 
Acute myocardial infarction first 2 days 
Asymptomatic and mild heart failure due to ischemic heart disease 
Asymptomatic angina due to ischemic heart disease 
Asymptomatic ischemic heart disease following myocardial infarction 
Mild angina due to ischemic heart disease 
Moderate angina due to ischemic heart disease 
Moderate heart failure due to ischemic heart disease 
Severe angina due to ischemic heart disease 
Severe heart failure due to ischemic heart disease 
Cerebrovascular disease 
Ischemic stroke 
Acute ischemic stroke severity level 1 
Acute ischemic stroke severity level 2 
Acute ischemic stroke severity level 3 
Acute ischemic stroke severity level 4 
Acute ischemic stroke severity level 5 
Asymptomatic chronic ischemic stroke 
Chronic ischemic stroke severity level 1 
Chronic ischemic stroke severity level 2 
Chronic ischemic stroke severity level 3 
Chronic ischemic stroke severity level 4 
Chronic ischemic stroke severity level 5 
Hemorrhagic stroke 
Acute hemorrhagic stroke severity level 1 
Acute hemorrhagic stroke severity level 2 
Acute hemorrhagic stroke severity level 3 
Acute hemorrhagic stroke severity level 4 
Acute hemorrhagic stroke severity level 5 
Asymptomatic chronic hemorrhagic stroke 
Chronic hemorrhagic stroke severity level 1 
Chronic hemorrhagic stroke severity level 2 
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Chronic hemorrhagic stroke severity level 3 
Chronic hemorrhagic stroke severity level 4 
Chronic hemorrhagic stroke severity level 5 
Hypertensive heart disease 
Asymptomatic and mild heart failure due to hypertensive heart disease 
Moderate heart failure due to hypertensive heart disease 
Severe heart failure due to hypertensive heart disease 
Cardiomyopathy and myocarditis 
Myocarditis 
Acute myocarditis 
Asymptomatic and mild heart failure due to myocarditis 
Moderate heart failure due to myocarditis 
Severe heart failure due to myocarditis 
Alcoholic cardiomyopathy 
Asymptomatic and mild heart failure due to alcoholic cardiomyopathy 
Moderate heart failure due to alcoholic cardiomyopathy 
Severe heart failure due to alcoholic cardiomyopathy 
Other cardiomyopathy 
Asymptomatic and mild heart failure due to other cardiomyopathy 
Moderate heart failure due to other cardiomyopathy 
Severe heart failure due to other cardiomyopathy 
Atrial fibrillation and flutter 
Asymptomatic atrial fibrillation and flutter 
Symptomatic atrial fibrillation and flutter 
Aortic aneurysm 
Peripheral artery disease 
Asymptomatic peripheral vascular disease 
Symptomatic claudication due to peripheral vascular disease 
Endocarditis 
Asymptomatic and mild heart failure due to endocarditis 
Moderate endocarditis 
Moderate heart failure due to endocarditis 
Severe endocarditis 
Severe heart failure due to endocarditis 
Other cardiovascular and circulatory diseases 
Asymptomatic and mild heart failure due to other cardiovascular diseases 
Asymptomatic other cardiovascular diseases 
Mild other cardiovascular diseases 
Moderate heart failure due to other cardiovascular diseases 
Moderate other cardiovascular diseases 
Severe heart failure due to other cardiovascular diseases 
Severe other cardiovascular diseases 
Chronic respiratory diseases 
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Chronic obstructive pulmonary disease 
Asymptomatic and mild heart failure due to severe chronic obstructive pulmonary disease 
Asymptomatic chronic obstructive pulmonary disease 
Mild chronic obstructive pulmonary disease 
Moderate chronic obstructive pulmonary disease 
Moderate heart failure due to severe chronic obstructive pulmonary disease 
Severe chronic obstructive pulmonary disease without heart failure 
Severe heart failure due to severe chronic obstructive pulmonary disease 
Pneumoconiosis 
Silicosis 
Asymptomatic and mild heart failure due to severe silicosis 
Asymptomatic silicosis 
Mild silicosis 
Moderate heart failure due to severe silicosis 
Moderate silicosis 
Severe heart failure due to severe silicosis 
Severe silicosis without heart failure 
Asbestosis 
Asymptomatic and mild heart failure due to severe asbestosis 
Asymptomatic asbestosis 
Mild asbestosis 
Moderate asbestosis 
Moderate heart failure due to severe asbestosis 
Severe asbestosis without heart failure 
Severe heart failure due to severe asbestosis 
Coal workers pneumoconiosis 
Asymptomatic and mild heart failure due to severe coal workers pneumoconiosis 
Asymptomatic coal workers pneumoconiosis 
Mild coal workers pneumoconiosis 
Moderate coal workers pneumoconiosis 
Moderate heart failure due to severe coal workers pneumoconiosis 
Severe coal workers pneumoconiosis without heart failure 
Severe heart failure due to severe coal workers pneumoconiosis 
Other pneumoconiosis 
Asymptomatic and mild heart failure due to severe other pneumoconiosis 
Asymptomatic other pneumoconiosis 
Mild other pneumoconiosis 
Moderate heart failure due to severe other pneumoconiosis 
Moderate other pneumoconiosis 
Severe heart failure due to severe other pneumoconiosis 
Severe other pneumoconiosis without heart failure 
Asthma 
Asymptomatic asthma 
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Controlled asthma 
Partially controlled asthma 
Uncontrolled asthma 
Interstitial lung disease and pulmonary sarcoidosis 
Asymptomatic and mild heart failure due to severe interstitial lung disease and pulmonary sarcoidosis 
Asymptomatic interstitial lung disease and pulmonary sarcoidosis 
Mild interstitial lung disease and pulmonary sarcoidosis 
Moderate heart failure due to severe interstitial lung disease and pulmonary sarcoidosis 
Moderate interstitial lung disease and pulmonary sarcoidosis 
Severe heart failure due to severe interstitial lung disease and pulmonary sarcoidosis 
Severe interstitial lung disease and pulmonary sarcoidosis without heart failure 
Other chronic respiratory diseases 
Cirrhosis and other chronic liver diseases 
Cirrhosis and other chronic liver diseases due to hepatitis B 
Cirrhosis and other chronic liver diseases due to hepatitis B, compensated 
Cirrhosis and other chronic liver diseases due to hepatitis B, decompensated 
Cirrhosis and other chronic liver diseases due to hepatitis C 
Cirrhosis and other chronic liver diseases due to hepatitis C, compensated 
Cirrhosis and other chronic liver diseases due to hepatitis C, decompensated 
Cirrhosis and other chronic liver diseases due to alcohol use 
Cirrhosis and other chronic liver diseases due to alcohol, compensated 
Cirrhosis and other chronic liver diseases due to alcohol, decompensated 
Cirrhosis and other chronic liver diseases due to other causes 
Cirrhosis and other chronic liver diseases due to other cause, compensated 
Cirrhosis and other chronic liver diseases due to other cause, decompensated 
Digestive diseases 
Peptic ulcer disease 
Asymptomatic peptic ulcer disease with mild anemia  
Asymptomatic peptic ulcer disease with moderate anemia  
Asymptomatic peptic ulcer disease with severe anemia  
Asymptomatic peptic ulcer disease without anemia 
Mild anemia due to peptic ulcer disease 
Mild symptomatic peptic ulcer disease with mild anemia 
Mild symptomatic peptic ulcer disease with moderate anemia 
Mild symptomatic peptic ulcer disease with severe anemia 
Mild symptomatic peptic ulcer disease without anemia 
Moderate anemia due to peptic ulcer disease 
Moderate symptomatic peptic ulcer disease with mild anemia 
Moderate symptomatic peptic ulcer disease with moderate anemia 
Moderate symptomatic peptic ulcer disease with severe anemia 
Moderate symptomatic peptic ulcer disease without anemia 
Severe anemia due to peptic ulcer disease 
Gastritis and duodenitis 
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Asymptomatic gastritis and duodenitis with mild anemia 
Asymptomatic gastritis and duodenitis with moderate anemia 
Asymptomatic gastritis and duodenitis with severe anemia 
Asymptomatic gastritis and duodenitis without anemia 
Mild anemia due to gastritis and duodenitis 
Mild symptomatic gastritis and duodenitis with mild anemia 
Mild symptomatic gastritis and duodenitis with moderate anemia 
Mild symptomatic gastritis and duodenitis with severe anemia 
Mild symptomatic gastritis and duodenitis without anemia 
Moderate anemia due to gastritis and duodenitis 
Moderate symptomatic gastritis and duodenitis with mild anemia 
Moderate symptomatic gastritis and duodenitis with moderate anemia 
Moderate symptomatic gastritis and duodenitis with severe anemia 
Moderate symptomatic gastritis and duodenitis without anemia  
Severe anemia due to gastritis and duodenitis 
Appendicitis 
Paralytic ileus and intestinal obstruction 
Inguinal, femoral, and abdominal hernia 
Asymptomatic inguinal, femoral, and abdominal hernia 
Mild symptomatic inguinal, femoral and abdominal hernia 
Moderate symptomatic inguinal, femoral and abdominal hernia 
Severe symptomatic inguinal, femoral and abdominal hernia 
Inflammatory bowel disease 
Asymptomatic Crohn's disease 
Asymptomatic ulcerative colitis 
Crohn's disease 
Ulcerative colitis 
Vascular intestinal disorders 
Gallbladder and biliary diseases 
Asymptomatic gallbladder and biliary diseases 
Mild symptomatic episodes gallbladder and biliary diseases 
Moderate symptomatic episodes gallbladder and biliary diseases  
Severe symptomatic episodes gallbladder and biliary diseases 
Pancreatitis 
Mild pancreatitis episodes 
Moderate pancreatitis episodes 
Severe pancreatitis episodes 
Other digestive diseases 
Neurological disorders 
Alzheimer disease and other dementias 
Mild Alzheimer disease and other dementias 
Moderate Alzheimer disease and other dementias 
Severe Alzheimer disease and other dementias 
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Parkinson disease 
Mild Parkinson disease 
Moderate Parkinson disease 
Severe Parkinson disease 
Epilepsy 
Less severe epilepsy 
Seizure-free, treated epilepsy 
Severe epilepsy 
Multiple sclerosis 
Asymptomatic multiple sclerosis 
Mild multiple sclerosis 
Moderate multiple sclerosis 
Severe multiple sclerosis 
Motor neuron disease 
Diagnosis of motor neuron disease 
Mild motor impairment and mild respiratory problems due to motor neuron disease 
Mild motor impairment and severe respiratory problems due to motor neuron disease 
Mild motor impairment and speech problems due to motor neuron disease 
Mild motor impairment due to motor neuron disease 
Mild motor impairment, mild respiratory problems, and speech problems due to motor neuron disease 
Mild motor impairment, moderate respiratory problems, and speech problems due to motor neuron disease 
Mild motor impairment, severe respiratory problems and speech problems due to motor neuron disease 
Mild respiratory problems and speech problems due to motor neuron disease 
Mild respiratory problems due to motor neuron disease 
Moderate motor impairment and mild respiratory problems due to motor neuron disease 
Moderate motor impairment and moderate respiratory problems due to motor neuron disease 
Moderate motor impairment and severe respiratory problems due to motor neuron disease 
Moderate motor impairment and speech problems due to motor neuron disease 
Moderate motor impairment due to motor neuron disease 
Moderate motor impairment, mild respiratory problems, and speech problems due to motor neuron disease 
Moderate motor impairment, moderate respiratory problems, and speech problems due to motor neuron disease 
Moderate motor impairment, severe respiratory problems, and speech problems due to motor neuron disease 
Moderate respiratory problems and speech problems due to motor neuron disease 
Moderate respiratory problems due to motor neuron disease 
Severe motor impairment and mild respiratory problems due to motor neuron disease 
Severe motor impairment and moderate respiratory problems due to motor neuron disease 
Severe motor impairment and severe respiratory problems due to motor neuron disease 
Severe motor impairment and speech problems due to motor neuron disease 
Severe motor impairment due to motor neuron disease 
Severe motor impairment, mild respiratory problems, and speech problems due to motor neuron disease 
Severe motor impairment, moderate respiratory problems, and speech problems due to motor neuron disease 
Severe motor impairment, severe respiratory problems, and speech problems due to motor neuron disease 
Severe respiratory problems and speech problems due to motor neuron disease 
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Severe respiratory problems due to motor neuron disease 
Speech problems due to motor neuron disease 
Migraine 
Asymptomatic medication overuse headache due to migraine 
Asymptomatic migraine 
Symptomatic medication overuse headache due to migraine 
Symptomatic migraine 
Tension-type headache 
Asymptomatic medication overuse headache due to tension-type headache 
Asymptomatic tension-type headache 
Symptomatic medication overuse headache due to tension-type headache 
Symptomatic tension-type headache 
Other neurological disorders 
Guillain-Barré syndrome due to other neurological disorders 
Mental and substance use disorders 
Schizophrenia 
Schizophrenia acute state 
Schizophrenia residual state 
Alcohol use disorders 
Asymptomatic alcohol dependence 
Asymptomatic fetal alcohol syndrome 
Mild alcohol dependence 
Mild fetal alcohol syndrome 
Moderate alcohol dependence 
Moderate fetal alcohol syndrome 
Severe alcohol dependence 
Severe fetal alcohol syndrome 
Very mild alcohol dependence 
Drug use disorders 
Opioid use disorders 
Asymptomatic opioid dependence 
Mild opioid dependence 
Severe opioid dependence 
Cocaine use disorders 
Asymptomatic cocaine dependence 
Mild cocaine dependence 
Severe cocaine dependence 
Amphetamine use disorders 
Asymptomatic amphetamine dependence 
Mild amphetamine dependence 
Severe amphetamine dependence 
Cannabis use disorders 
Asymptomatic cannabis dependence 
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Mild cannabis dependence 
Severe cannabis dependence 
Other drug use disorders 
Depressive disorders 
Major depressive disorder 
Major depressive disorder, currently without symptoms 
Mild major depressive disorder 
Moderate major depressive disorder 
Severe major depressive disorder 
Dysthymia 
Dysthymia, currently without symptoms 
Symptomatic dysthymia 
Bipolar disorder 
Bipolar disorder depressive state 
Bipolar disorder manic state 
Bipolar disorder residual state 
Anxiety disorders 
Anxiety disorders, currently without symptoms 
Mild anxiety disorders 
Moderate anxiety disorders 
Severe anxiety disorders 
Eating disorders 
Anorexia nervosa 
Bulimia nervosa 
Autistic spectrum disorders 
Autism 
Autism with borderline intellectual disability 
Autism with mild intellectual disability 
Autism with moderate intellectual disability 
Autism with profound intellectual disability 
Autism with severe intellectual disability 
Autism without intellectual disability 
Asperger syndrome and other autistic spectrum disorders 
Attention-deficit/hyperactivity disorder 
Attention-deficit/hyperactivity disorder, currently without symptoms 
Symptomatic attention-deficit/hyperactivity disorder 
Conduct disorder 
Conduct disorder, currently without symptoms 
Symptomatic conduct disorder 
Idiopathic developmental intellectual disability 
Borderline idiopathic developmental intellectual disability 
Mild idiopathic developmental intellectual disability 
Moderate idiopathic developmental intellectual disability 
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Profound idiopathic developmental intellectual disability 
Severe idiopathic developmental intellectual disability 
Other mental and substance use disorders 
Mild other mental disorders 
Moderate other mental disorders 
Other mental disorders, currently without symptoms 
Severe other mental disorders 
Diabetes, urogenital, blood, and endocrine diseases 
Diabetes mellitus 
Blindness due to diabetes mellitus 
Diabetic foot due to neuropathy 
Diabetic neuropathy 
Diabetic neuropathy and amputation with treatment 
Diabetic neuropathy and amputation without treatment 
Moderate vision impairment due to diabetes mellitus 
Severe vision impairment due to diabetes mellitus 
Uncomplicated diabetes mellitus 
Acute glomerulonephritis 
Chronic kidney disease 
Chronic kidney disease due to diabetes mellitus 
End-stage renal disease after transplant due to diabetes mellitus 
End-stage renal disease on dialysis due to diabetes mellitus 
Stage III chronic kidney disease and mild anemia due to diabetes mellitus 
Stage III chronic kidney disease and moderate anemia due to diabetes mellitus 
Stage III chronic kidney disease and severe anemia due to diabetes mellitus 
Stage III chronic kidney disease without anemia due to diabetes mellitus 
Stage IV chronic kidney disease untreated and mild anemia due to diabetes mellitus 
Stage IV chronic kidney disease untreated and moderate anemia due to diabetes mellitus 
Stage IV chronic kidney disease untreated and severe anemia due to diabetes mellitus 
Stage IV chronic kidney disease untreated without anemia due to diabetes mellitus 
Stage V chronic kidney disease untreated and mild anemia due to diabetes mellitus 
Stage V chronic kidney disease untreated and moderate anemia due to diabetes mellitus 
Stage V chronic kidney disease untreated and severe anemia due to diabetes mellitus 
Stage V chronic kidney disease untreated without anemia due to diabetes mellitus 
Chronic kidney disease due to hypertension 
End-stage renal disease after transplant due to hypertension 
End-stage renal disease on dialysis due to hypertension 
Stage III chronic kidney disease and mild anemia due to hypertension 
Stage III chronic kidney disease and moderate anemia due to hypertension 
Stage III chronic kidney disease and severe anemia due to hypertension 
Stage III chronic kidney disease without anemia due to hypertension 
Stage IV chronic kidney disease untreated and mild anemia due to hypertension 
Stage IV chronic kidney disease untreated and moderate anemia due to hypertension 
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Stage IV chronic kidney disease untreated and severe anemia due to hypertension 
Stage IV chronic kidney disease untreated without anemia due to hypertension 
Stage V chronic kidney disease untreated and mild anemia due to hypertension 
Stage V chronic kidney disease untreated and moderate anemia due to hypertension 
Stage V chronic kidney disease untreated and severe anemia due to hypertension 
Stage V chronic kidney disease untreated without anemia due to hypertension 
Chronic kidney disease due to glomerulonephritis 
End-stage renal disease after transplant due to glomerulonephritis 
End-stage renal disease on dialysis due to glomerulonephritis 
Stage III chronic kidney disease and mild anemia due to glomerulonephritis 
Stage III chronic kidney disease and moderate anemia due to glomerulonephritis 
Stage III chronic kidney disease and severe anemia due to glomerulonephritis 
Stage III chronic kidney disease without anemia due to glomerulonephritis 
Stage IV chronic kidney disease untreated and mild anemia due to glomerulonephritis 
Stage IV chronic kidney disease untreated and moderate anemia due to glomerulonephritis 
Stage IV chronic kidney disease untreated and severe anemia due to glomerulonephritis 
Stage IV chronic kidney disease untreated without anemia due to glomerulonephritis 
Stage V chronic kidney disease untreated and mild anemia due to glomerulonephritis 
Stage V chronic kidney disease untreated and moderate anemia due to glomerulonephritis 
Stage V chronic kidney disease untreated and severe anemia due to glomerulonephritis 
Stage V chronic kidney disease untreated without anemia due to glomerulonephritis 
Chronic kidney disease due to other causes 
End-stage renal disease after transplant due to other causes 
End-stage renal disease on dialysis due to other causes 
Stage III chronic kidney disease and mild anemia due to other causes 
Stage III chronic kidney disease and moderate anemia due to other causes 
Stage III chronic kidney disease and severe anemia due to other causes 
Stage III chronic kidney disease without anemia due to other causes 
Stage IV chronic kidney disease untreated and mild anemia due to other causes 
Stage IV chronic kidney disease untreated and moderate anemia due to other causes 
Stage IV chronic kidney disease untreated and severe anemia due to other causes 
Stage IV chronic kidney disease untreated without anemia due to other causes 
Stage V chronic kidney disease untreated and mild anemia due to other causes 
Stage V chronic kidney disease untreated and moderate anemia due to other causes 
Stage V chronic kidney disease untreated and severe anemia due to other causes 
Stage V chronic kidney disease untreated without anemia due to other causes 
Urinary diseases and male infertility 
Interstitial nephritis and urinary tract infections 
Mild interstitial nephritis and urinary tract infections 
Moderate interstitial nephritis and urinary tract infections 
Urolithiasis 
Mild urolithiasis episodes 
Moderate urolithiasis episodes 
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Severe urolithiasis episodes 
Benign prostatic hyperplasia 
Asymptomatic benign prostatic hyperplasia 
Symptomatic benign prostatic hyperplasia 
Male infertility 
Primary male infertility 
Secondary male infertility 
Other urinary diseases 
Gynecological diseases 
Uterine fibroids 
Asymptomatic uterine fibroids 
Mild abdominal pain due to uterine fibroids, with mild anemia  
Mild abdominal pain due to uterine fibroids, with moderate anemia  
Mild abdominal pain due to uterine fibroids, with severe anemia  
Mild abdominal pain due to uterine fibroids, without anemia  
Polycystic ovarian syndrome 
Asymptomatic polycystic ovarian syndrome 
Hirsutism and primary infertility due to polycystic ovarian syndrome 
Hirsutism and secondary infertility due to polycystic ovarian syndrome 
Hirsutism due to polycystic ovarian syndrome 
Primary infertility due to polycystic ovarian syndrome 
Secondary infertility due to polycystic ovarian syndrome 
Female infertility 
Idiopathic primary female infertility 
Idiopathic secondary female infertility 
Endometriosis 
Asymptomatic endometriosis 
Mild abdominal pain and primary infertility due to endometriosis 
Mild abdominal pain and secondary infertility due to endometriosis 
Mild abdominal pain due to endometriosis 
Moderate abdominal pain and primary infertility due to endometriosis 
Moderate abdominal pain and secondary infertility due to endometriosis 
Moderate abdominal pain due to endometriosis 
Primary infertility due to endometriosis 
Secondary infertility due to endometriosis 
Severe abdominal pain and primary infertility due to endometriosis 
Severe abdominal pain and secondary infertility due to endometriosis 
Severe endometriosis 
Genital prolapse 
Abdominal pain and stress incontinence due to genital prolapse 
Abdominal pain due to genital prolapse 
Asymptomatic genital prolapse 
Stress incontinence due to genital prolapse 
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Premenstrual syndrome 
Abdominal pain and depression due to premenstrual syndrome 
Abdominal pain due to premenstrual syndrome 
Asymptomatic premenstrual syndrome 
Depression due to premenstrual syndrome 
Other gynecological diseases 
Asymptomatic other gynecological disorders 
Mild anemia due to other gynecological diseases 
Mild other gynecological disorders 
Moderate anemia due to other gynecological diseases 
Moderate other gynecological disorders 
Severe anemia due to other gynecological diseases 
Severe other gynecological disorders 
Hemoglobinopathies and hemolytic anemias 
Thalassemias 
Asymptomatic and mild heart failure due to thalassemias 
Beta-thalassemia major, severe infection with severe anemia  
Beta-thalassemia major, with mild anemia  
Beta-thalassemia major, with moderate anemia  
Beta-thalassemia major, with severe anemia  
Beta-thalassemia major, without anemia 
Hemoglobin E/Beta-thalassemia, without anemia 
Hemoglobin E/beta-thalassemia, severe infection with severe anemia  
Hemoglobin E/beta-thalassemia, with mild anemia  
Hemoglobin E/beta-thalassemia, with moderate anemia  
Hemoglobin E/beta-thalassemia, with severe anemia  
Hemoglobin H disease, severe infection with severe anemia  
Hemoglobin H disease, with mild anemia  
Hemoglobin H disease, with moderate anemia  
Hemoglobin H disease, with severe anemia  
Hemoglobin H disease, without anemia 
Moderate heart failure due to thalassemias 
Severe heart failure due to thalassemias 
Thalassemias trait 
Asymptomatic B-thalassemia trait 
Asymptomatic hemoglobin E trait 
Mild anemia due to B-thalassemia trait 
Mild anemia due to hemoglobin E trait 
Moderate anemia due to B-thalassemia trait 
Moderate anemia due to hemoglobin E trait 
Severe anemia due to B-thalassemia trait 
Severe anemia due to hemoglobin E trait 
Sickle cell disorders 
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Hemoglobin SC disease, with mild anemia  
Hemoglobin SC disease, with moderate anemia  
Hemoglobin SC disease, with severe anemia  
Hemoglobin SC disease, with stroke and severe anemia 
Hemoglobin SC disease, with stroke, without anemia 
Hemoglobin SC disease, with vaso-occlusive crisis and severe anemia 
Hemoglobin SC disease, with vaso-occlusive crisis and stroke, without anemia 
Hemoglobin SC disease, with vaso-occlusive crisis, stroke, and severe anemia 
Hemoglobin SC disease, with vaso-occlusive crisis, without anemia 
Hemoglobin SC disease, without anemia 
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with mild anemia  
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with moderate anemia  
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with severe anemia  
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with stroke and severe anemia 
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with stroke, without anemia 
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis and severe anemia 
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis and stroke, without anemia 
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis, stroke, and severe anemia 
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with vaso-occlusive crisis, without anemia 
Homozygous sickle cell and severe sickle cell/beta-thalassemia, without anemia 
Mild sickle cell/beta-thalassemia, with mild anemia  
Mild sickle cell/beta-thalassemia, with moderate anemia  
Mild sickle cell/beta-thalassemia, with severe anemia  
Mild sickle cell/beta-thalassemia, with stroke and severe anemia 
Mild sickle cell/beta-thalassemia, with stroke, without anemia 
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis and severe anemia 
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis and stroke, without anemia 
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis, stroke, and severe anemia 
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis, without anemia 
Mild sickle cell/beta-thalassemia, without anemia 
Sickle cell trait 
Asymptomatic sickle cell trait 
Mild anemia due to sickle cell trait 
Moderate anemia due to sickle cell trait 
Severe anemia due to sickle cell trait 
G6PD deficiency 
Asymptomatic G6PD deficiency 
Asymptomatic and mild heart failure due to G6PD deficiency 
Mild anemia due to G6PD deficiency 
Moderate anemia due to G6PD deficiency 
Moderate heart failure due to G6PD deficiency 
Severe anemia due to G6PD deficiency 
774
Severe heart failure due to G6PD deficiency 
G6PD trait 
Asymptomatic hemizygous G6PD deficiency 
Mild anemia due to hemizygous G6PD deficiency 
Moderate anemia due to hemizygous G6PD deficiency 
Severe anemia due to hemizygous G6PD deficiency 
Other hemoglobinopathies and hemolytic anemias 
Asymptomatic and mild heart failure due to other hemoglobinopathies and hemolytic anemias 
Mild anemia due to other hemoglobinopathies and hemolytic anemias 
Moderate anemia due to other hemoglobinopathies and hemolytic anemias 
Moderate heart failure due to other hemoglobinopathies and hemolytic anemias 
Severe anemia due to other hemoglobinopathies and hemolytic anemias 
Severe heart failure due to other hemoglobinopathies and hemolytic anemias 
Endocrine, metabolic, blood, and immune disorders 
Asymptomatic and mild heart failure due to endocrine, metabolic, blood, and immune disorders 
Asymptomatic endocrine, metabolic, blood, and immune disorders 
Mild anemia due to endocrine, metabolic, blood, and immune disorders 
Mild endocrine, metabolic, blood, and immune disorders 
Moderate anemia due to endocrine, metabolic, blood, and immune disorders 
Moderate endocrine, metabolic, blood, and immune disorders 
Moderate heart failure due to endocrine, metabolic, blood, and immune disorders 
Severe anemia due to endocrine, metabolic, blood, and immune disorders 
Severe endocrine, metabolic, blood, and immune disorders 
Severe heart failure due to endocrine, metabolic, blood, and immune disorders 
Musculoskeletal disorders 
Rheumatoid arthritis 
Mild rheumatoid arthritis 
Moderate rheumatoid arthritis 
Severe rheumatoid arthritis 
Osteoarthritis 
Mild osteoarthritis of the hip 
Mild osteoarthritis of the knee 
Moderate osteoarthritis of the hip 
Moderate osteoarthritis of the knee 
Severe osteoarthritis of the hip 
Severe osteoarthritis of the knee 
Low back and neck pain 
Low back pain 
Mild low back pain with leg pain 
Mild low back pain without leg pain 
Moderate low back pain with leg pain 
Moderate low back pain without leg pain 
Most severe low back pain with leg pain 
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Most severe low back pain without leg pain 
Severe low back pain with leg pain 
Severe low back pain without leg pain 
Neck pain 
Mild neck pain 
Moderate neck pain 
Most severe neck pain 
Severe neck pain 
Gout 
Asymptomatic gout 
Polyarticular gout 
Symptomatic episodes of gout 
Other musculoskeletal disorders 
Asymptomatic other musculoskeletal disorders 
Other musculoskeletal disorders severity level 1 
Other musculoskeletal disorders severity level 2 
Other musculoskeletal disorders severity level 3 
Other musculoskeletal disorders severity level 4 
Other musculoskeletal disorders severity level 5 
Other musculoskeletal disorders severity level 6 
Other non-communicable diseases 
Congenital birth defects 
Neural tube defects 
Asymptomatic encephalocele following treatment 
Borderline intellectual disability and incontinence due to encephalocele 
Borderline intellectual disability due to encephalocele 
Incontinence due to encephalocele 
Mild intellectual disability and incontinence due to encephalocele 
Mild intellectual disability due to encephalocele 
Mild motor impairment and borderline intellectual disability due to encephalocele 
Mild motor impairment and borderline intellectual disability due to spina bifida 
Mild motor impairment and incontinence due to encephalocele 
Mild motor impairment and incontinence due to spina bifida 
Mild motor impairment and mild intellectual disability due to encephalocele 
Mild motor impairment and mild intellectual disability due to spina bifida 
Mild motor impairment and moderate intellectual disability due to encephalocele 
Mild motor impairment and moderate intellectual disability due to spina bifida 
Mild motor impairment and profound intellectual disability due to encephalocele 
Mild motor impairment and profound intellectual disability due to spina bifida 
Mild motor impairment and severe intellectual disability due to encephalocele 
Mild motor impairment and severe intellectual disability due to spina bifida 
Mild motor impairment due to encephalocele 
Mild motor impairment due to spina bifida 
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Mild motor impairment, borderline intellectual disability and incontinence due to encephalocele 
Mild motor impairment, borderline intellectual disability and incontinence due to spina bifida 
Mild motor impairment, mild intellectual disability and incontinence due to encephalocele 
Mild motor impairment, mild intellectual disability and incontinence due to spina bifida 
Mild motor impairment, moderate intellectual disability and incontinence due to encephalocele 
Mild motor impairment, moderate intellectual disability and incontinence due to spina bifida 
Mild motor impairment, profound intellectual disability and incontinence due to encephalocele 
Mild motor impairment, profound intellectual disability and incontinence due to spina bifida 
Mild motor impairment, severe intellectual disability and incontinence due to encephalocele 
Mild motor impairment, severe intellectual disability and incontinence due to spina bifida 
Moderate intellectual disability and incontinence due to encephalocele 
Moderate intellectual disability due to encephalocele 
Moderate motor impairment and borderline intellectual disability due to encephalocele 
Moderate motor impairment and borderline intellectual disability due to spina bifida 
Moderate motor impairment and incontinence due to encephalocele 
Moderate motor impairment and incontinence due to spina bifida 
Moderate motor impairment and mild intellectual disability due to encephalocele 
Moderate motor impairment and mild intellectual disability due to spina bifida 
Moderate motor impairment and moderate intellectual disability due to encephalocele 
Moderate motor impairment and moderate intellectual disability due to spina bifida 
Moderate motor impairment and profound intellectual disability due to encephalocele 
Moderate motor impairment and profound intellectual disability due to spina bifida 
Moderate motor impairment and severe intellectual disability due to encephalocele 
Moderate motor impairment and severe intellectual disability due to spina bifida 
Moderate motor impairment due to encephalocele 
Moderate motor impairment due to spina bifida 
Moderate motor impairment, borderline intellectual disability and incontinence due to encephalocele 
Moderate motor impairment, borderline intellectual disability and incontinence due to spina bifida 
Moderate motor impairment, mild intellectual disability and incontinence due to encephalocele 
Moderate motor impairment, mild intellectual disability and incontinence due to spina bifida 
Moderate motor impairment, moderate intellectual disability and incontinence due to encephalocele 
Moderate motor impairment, moderate intellectual disability and incontinence due to spina bifida 
Moderate motor impairment, profound intellectual disability and incontinence due to encephalocele 
Moderate motor impairment, profound intellectual disability and incontinence due to spina bifida 
Moderate motor impairment, severe intellectual disability and incontinence due to encephalocele 
Moderate motor impairment, severe intellectual disability and incontinence due to spina bifida 
Profound intellectual disability and incontinence due to encephalocele 
Profound intellectual disability due to encephalocele 
Severe intellectual disability and incontinence due to encephalocele 
Severe intellectual disability due to encephalocele 
Severe motor and cognitive impairment due to anencephaly 
Severe motor impairment and borderline intellectual disability due to encephalocele 
Severe motor impairment and borderline intellectual disability due to spina bifida 
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Severe motor impairment and incontinence due to encephalocele 
Severe motor impairment and incontinence due to spina bifida 
Severe motor impairment and mild intellectual disability due to encephalocele 
Severe motor impairment and mild intellectual disability due to spina bifida 
Severe motor impairment and moderate intellectual disability due to encephalocele 
Severe motor impairment and moderate intellectual disability due to spina bifida 
Severe motor impairment and profound intellectual disability due to encephalocele 
Severe motor impairment and profound intellectual disability due to spina bifida 
Severe motor impairment and severe intellectual disability due to encephalocele 
Severe motor impairment and severe intellectual disability due to spina bifida 
Severe motor impairment due to encephalocele 
Severe motor impairment due to spina bifida 
Severe motor impairment, borderline intellectual disability and incontinence due to encephalocele 
Severe motor impairment, borderline intellectual disability and incontinence due to spina bifida 
Severe motor impairment, mild intellectual disability and incontinence due to encephalocele 
Severe motor impairment, mild intellectual disability and incontinence due to spina bifida 
Severe motor impairment, moderate intellectual disability and incontinence due to encephalocele 
Severe motor impairment, moderate intellectual disability and incontinence due to spina bifida 
Severe motor impairment, profound intellectual disability and incontinence due to encephalocele 
Severe motor impairment, severe intellectual disability and incontinence due to encephalocele 
Severe motor impairment, severe intellectual disability and incontinence due to spina bifida 
profound motor impairment, profound intellectual disability and incontinence due to spina bifida 
Congenital heart anomalies 
Asymptomatic ventricular septal defect and atrial septal defect 
Congenital heart disease and borderline intellectual disability without heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease and borderline intellectual disability without heart failure due to other congenital cardiovascular 
anomalies 
Congenital heart disease and borderline intellectual disability without heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease and borderline intellectual disability without heart failure due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease and borderline intellectual disability without heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease and mild heart failure without intellectual disability due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease and mild heart failure without intellectual disability due to severe congenital heart anomalies excluding 
single ventricle heart defects 
Congenital heart disease and mild heart failure without intellectual disability due to single ventricle and single ventricle pathway 
heart defects 
Congenital heart disease and mild heart failure without intellectual disability due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease and mild intellectual disability  without heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects 
Congenital heart disease and mild intellectual disability without heart failure  due to single ventricle and single ventricle pathway 
heart defects 
Congenital heart disease and mild intellectual disability without heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease and mild intellectual disability without heart failure due to other congenital cardiovascular anomalies 
778
Congenital heart disease and mild intellectual disability without heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease and moderate heart failure without intellectual disability due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease and moderate heart failure without intellectual disability due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease and moderate heart failure without intellectual disability due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease and moderate heart failure without intellectual disability due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease and moderate intellectual disability  without heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease and moderate intellectual disability without heart failure  due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease and moderate intellectual disability without heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease and moderate intellectual disability without heart failure due to other congenital cardiovascular 
anomalies 
Congenital heart disease and moderate intellectual disability without heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease and profound intellectual disability without heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease and profound intellectual disability without heart failure due to other congenital cardiovascular 
anomalies 
Congenital heart disease and profound intellectual disability without heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease and profound intellectual disability without heart failure due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease and profound intellectual disability without heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease and severe heart failure without intellectual disability due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease and severe heart failure without intellectual disability due to severe congenital heart anomalies excluding 
single ventricle heart defects 
Congenital heart disease and severe heart failure without intellectual disability due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease and severe heart without intellectual disability due to ventricular septal defect and atrial septal defect 
Congenital heart disease and severe intellectual disability  without heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease and severe intellectual disability without heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease and severe intellectual disability without heart failure due to other congenital cardiovascular anomalies 
Congenital heart disease and severe intellectual disability without heart failure due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease and severe intellectual disability without heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease without heart failure or intellectual disability due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus 
Congenital heart disease without heart failure or intellectual disability due to ventricular septal defect and atrial septal defect 
Congenital heart disease without intellectual disability or heart failure due to other congenital cardiovascular anomalies 
Congenital heart disease without intellectual disability or heart failure due to severe congenital heart anomalies excluding single 
ventricle heart defects 
Congenital heart disease without intellectual disability or heart failure due to single ventricle and single ventricle pathway heart 
defects 
Congenital heart disease, boderline intellectual disability and mild heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
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Congenital heart disease, boderline intellectual disability and mild heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease, boderline intellectual disability and mild heart failure due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease, boderline intellectual disability and mild heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease, borderline intellectual disability and moderate heart failure due to critical malformations of great 
vessels, congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, borderline intellectual disability and moderate heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease, borderline intellectual disability and moderate heart failure due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease, borderline intellectual disability and moderate heart failure due to ventricular septal defect and atrial 
septal defect 
Congenital heart disease, borderline intellectual disability and severe heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, borderline intellectual disability and severe heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease, borderline intellectual disability and severe heart failure due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease, borderline intellectual disability and severe heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease, mild intellectual disability and mild heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, mild intellectual disability and mild heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects 
Congenital heart disease, mild intellectual disability and mild heart failure due to single ventricle and single ventricle pathway 
heart defects 
Congenital heart disease, mild intellectual disability and mild heart failure due to ventricular septal defect and atrial septal defect 
Congenital heart disease, mild intellectual disability and moderate heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, mild intellectual disability and moderate heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease, mild intellectual disability and moderate heart failure due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease, mild intellectual disability and moderate heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease, mild intellectual disability and severe heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, mild intellectual disability and severe heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects 
Congenital heart disease, mild intellectual disability and severe heart failure due to single ventricle and single ventricle pathway 
heart defects 
Congenital heart disease, mild intellectual disability and severe heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease, moderate intellectual disability and mild heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, moderate intellectual disability and mild heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease, moderate intellectual disability and mild heart failure due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease, moderate intellectual disability and mild heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease, moderate intellectual disability and moderate heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, moderate intellectual disability and moderate heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease, moderate intellectual disability and moderate heart failure due to single ventricle and single ventricle 
pathway heart defects 
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Congenital heart disease, moderate intellectual disability and moderate heart failure due to ventricular septal defect and atrial 
septal defect 
Congenital heart disease, moderate intellectual disability and severe heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, moderate intellectual disability and severe heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease, moderate intellectual disability and severe heart failure due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease, moderate intellectual disability and severe heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease, profound intellectual disability and mild heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, profound intellectual disability and mild heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease, profound intellectual disability and mild heart failure due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease, profound intellectual disability and mild heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease, profound intellectual disability and moderate heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, profound intellectual disability and moderate heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease, profound intellectual disability and moderate heart failure due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease, profound intellectual disability and moderate heart failure due to ventricular septal defect and atrial 
septal defect 
Congenital heart disease, profound intellectual disability and severe heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, profound intellectual disability and severe heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease, profound intellectual disability and severe heart failure due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease, profound intellectual disability and severe heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease, severe intellectual disability and mild heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, severe intellectual disability and mild heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects 
Congenital heart disease, severe intellectual disability and mild heart failure due to single ventricle and single ventricle pathway 
heart defects 
Congenital heart disease, severe intellectual disability and mild heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease, severe intellectual disability and moderate heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, severe intellectual disability and moderate heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects 
Congenital heart disease, severe intellectual disability and moderate heart failure due to single ventricle and single ventricle 
pathway heart defects 
Congenital heart disease, severe intellectual disability and moderate heart failure due to ventricular septal defect and atrial septal 
defect 
Congenital heart disease, severe intellectual disability and severe heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus 
Congenital heart disease, severe intellectual disability and severe heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects 
Congenital heart disease, severe intellectual disability and severe heart failure due to single ventricle and single ventricle pathway 
heart defects 
Congenital heart disease, severe intellectual disability and severe heart failure due to ventricular septal defect and atrial septal 
defect 
Orofacial clefts 
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Asymptomatic orofacial clefts 
Disfigurement level 1 due to orofacial clefts 
Disfigurement level 2 and speech problems due to orofacial clefts 
Disfigurement level 2 due to orofacial clefts 
Down syndrome 
Asymptomatic Down syndrome 
Borderline intellectual disability and mild dementia due to Down syndrome 
Borderline intellectual disability and moderate dementia due to Down syndrome 
Borderline intellectual disability and severe dementia due to Down syndrome 
Borderline intellectual disability due to Down syndrome 
Borderline intellectual disability with congenital heart disease due to Down syndrome 
Borderline intellectual disability, mild dementia, and congenital heart disease due to Down syndrome 
Borderline intellectual disability, moderate dementia, and congenital heart disease due to Down syndrome 
Borderline intellectual disability, severe dementia, and congenital heart disease due to Down syndrome 
Congenital heart disease and mild dementia due to Down syndrome 
Congenital heart disease and moderate dementia due to Down syndrome 
Congenital heart disease and severe dementia due to Down syndrome 
Isolated congenital heart disease due to Down syndrome 
Mild dementia due to Down syndrome 
Mild intellectual disability and mild dementia due to Down syndrome 
Mild intellectual disability and moderate dementia due to Down syndrome 
Mild intellectual disability and severe dementia due to Down syndrome 
Mild intellectual disability due to Down syndrome 
Mild intellectual disability with congenital heart disease due to Down syndrome 
Mild intellectual disability, mild dementia, and congenital heart disease due to Down syndrome 
Mild intellectual disability, moderate dementia, and congenital heart disease due to Down syndrome 
Mild intellectual disability, severe dementia, and congenital heart disease due to Down syndrome 
Moderate dementia due to Down syndrome 
Moderate intellectual disability and mild dementia due to Down syndrome 
Moderate intellectual disability and moderate dementia due to Down syndrome 
Moderate intellectual disability and severe dementia due to Down syndrome 
Moderate intellectual disability due to Down syndrome 
Moderate intellectual disability with congenital heart disease due to Down syndrome 
Moderate intellectual disability, mild dementia, and congenital heart disease due to Down syndrome 
Moderate intellectual disability, moderate dementia, and congenital heart disease due to Down syndrome 
Moderate intellectual disability, severe dementia, and congenital heart disease due to Down syndrome 
Profound intellectual disability and mild dementia due to Down syndrome 
Profound intellectual disability and moderate dementia due to Down syndrome 
Profound intellectual disability and severe dementia due to Down syndrome 
Profound intellectual disability due to Down syndrome 
Profound intellectual disability with congenital heart disease due to Down syndrome 
Profound intellectual disability, mild dementia, and congenital heart disease due to Down syndrome 
Profound intellectual disability, moderate dementia, and congenital heart disease due to Down syndrome 
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Profound intellectual disability, severe dementia, and congenital heart disease due to Down syndrome 
Severe dementia due to Down syndrome 
Severe intellectual disability and mild dementia due to Down syndrome 
Severe intellectual disability and moderate dementia due to Down syndrome 
Severe intellectual disability and severe dementia due to Down syndrome 
Severe intellectual disability due to Down syndrome 
Severe intellectual disability with congenital heart disease due to Down syndrome 
Severe intellectual disability, mild dementia, and congenital heart disease due to Down syndrome 
Severe intellectual disability, moderate dementia, and congenital heart disease due to Down syndrome 
Severe intellectual disability, severe dementia, and congenital heart disease due to Down syndrome 
Turner syndrome 
Asymptomatic Turner syndrome 
Congenital heart disease due to Turner syndrome 
Congenital heart disease with infertility due to Turner syndrome 
Primary infertility due to Turner syndrome 
Klinefelter syndrome 
Asymptomatic Klinefelter syndrome 
Borderline intellectual disability due to Klinefelter syndrome 
Borderline intellectual disability with infertility due to Klinefelter syndrome 
Mild intellectual disability due to Klinefelter syndrome 
Mild intellectual disability with infertility due to Klinefelter syndrome 
Primary infertility due to Klinefelter syndrome 
Other chromosomal abnormalities 
Asymptomatic other chromosomal abnormalities 
Borderline intellectual disability and mild dementia due to other chromosomal abnormalities 
Borderline intellectual disability and moderate dementia due to other chromosomal abnormalities 
Borderline intellectual disability and severe dementia due to other chromosomal abnormalities 
Borderline intellectual disability due to other chromosomal abnormalities 
Borderline intellectual disability with congenital heart disease due to other chromosomal abnormalities 
Borderline intellectual disability, mild dementia, and congenital heart disease due to other chromosomal abnormalities 
Borderline intellectual disability, moderate dementia, and congenital heart disease due to other chromosomal abnormalities 
Borderline intellectual disability, severe dementia, and congenital heart disease due to other chromosomal abnormalities 
Congenital heart disease and mild dementia due to other chromosomal abnormalities 
Congenital heart disease and moderate dementia due to other chromosomal abnormalities 
Congenital heart disease and severe dementia due to other chromosomal abnormalities 
Isolated congenital heart disease due to other chromosomal abnormalities 
Mild dementia due to other chromosomal abnormalities 
Mild intellectual disability and mild dementia due to other chromosomal abnormalities 
Mild intellectual disability and moderate dementia due to other chromosomal abnormalities 
Mild intellectual disability and severe dementia due to other chromosomal abnormalities 
Mild intellectual disability due to other chromosomal abnormalities 
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Mild intellectual disability with congenital heart disease due to other chromosomal abnormalities 
Mild intellectual disability, mild dementia, and congenital heart disease due to other chromosomal abnormalities 
Mild intellectual disability, moderate dementia, and congenital heart disease due to other chromosomal abnormalities 
Mild intellectual disability, severe dementia, and congenital heart disease due to other chromosomal abnormalities 
Moderate dementia due to other chromosomal abnormalities 
Moderate intellectual disability and mild dementia due to other chromosomal abnormalities 
Moderate intellectual disability and moderate dementia due to other chromosomal abnormalities 
Moderate intellectual disability and severe dementia due to other chromosomal abnormalities 
Moderate intellectual disability due to other chromosomal abnormalities 
Moderate intellectual disability with congenital heart disease due to other chromosomal abnormalities 
Moderate intellectual disability, mild dementia, and congenital heart disease due to other chromosomal abnormalities 
Moderate intellectual disability, moderate dementia, and congenital heart disease due to other chromosomal abnormalities 
Moderate intellectual disability, severe dementia, and congenital heart disease due to other chromosomal abnormalities 
Profound intellectual disability and mild dementia due to other chromosomal abnormalities 
Profound intellectual disability and moderate dementia due to other chromosomal abnormalities 
Profound intellectual disability and severe dementia due to other chromosomal abnormalities 
Profound intellectual disability due to other chromosomal abnormalities 
Profound intellectual disability with congenital heart disease due to other chromosomal abnormalities 
Profound intellectual disability, mild dementia, and congenital heart disease due to other chromosomal abnormalities 
Profound intellectual disability, moderate dementia, and congenital heart disease due to other chromosomal abnormalities 
Profound intellectual disability, severe dementia, and congenital heart disease due to other chromosomal abnormalities 
Severe dementia due to other chromosomal abnormalities 
Severe intellectual disability and mild dementia due to other chromosomal abnormalities 
Severe intellectual disability and moderate dementia due to other chromosomal abnormalities 
Severe intellectual disability and severe dementia due to other chromosomal abnormalities 
Severe intellectual disability due to other chromosomal abnormalities 
Severe intellectual disability with congenital heart disease due to other chromosomal abnormalities 
Severe intellectual disability, mild dementia, and congenital heart disease due to other chromosomal abnormalities 
Severe intellectual disability, moderate dementia, and congenital heart disease due to other chromosomal abnormalities 
Severe intellectual disability, severe dementia, and congenital heart disease due to other chromosomal abnormalities 
Severe motor and cognitive impairment due to Edward Syndrome or Patau Syndrome 
Severe motor and cognitive impairment with congenital heart disease due to Edward Syndrome or Patau Syndrome 
Congenital musculoskeletal and limb anomalies 
Disfigurement level 1 due to polydactyly and syndactyly 
Disfigurement level 2 and mild motor impairment due to congenital limb deficiency 
Disfigurement level 2 and mild motor impairment due to other congenital musculoskeletal anomalies 
Disfigurement level 2 and moderate motor impairment due to congenital limb deficiency 
Disfigurement level 2 and moderate motor impairment due to other congenital musculoskeletal anomalies 
Disfigurement level 2 due to congenital limb deficiency 
Disfigurement level 2 due to other congenital musculoskeletal anomalies 
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Disfigurement level 2 with pain and mild motor impairment due to congenital limb deficiency 
Disfigurement level 2 with pain and mild motor impairment due to other congenital musculoskeletal anomalies 
Disfigurement level 2 with pain and moderate motor impairment due to congenital limb deficiency 
Disfigurement level 2 with pain and moderate motor impairment due to other congenital musculoskeletal anomalies 
Disfigurement level 2 with pain due to congenital limb deficiency 
Disfigurement level 2 with pain due to other congenital musculoskeletal anomalies 
Urogenital congenital anomalies 
Asymptomatic congenital anomalies of the urinary tract 
Asymptomatic congenital genital anomalies 
Atypical genital and recurrent urinary tract infections and other abdominal issues due to congenital anomalies of the urinary tract 
Atypical genital and recurrent urinary tract infections and other abdominal issues due to congenital genital anomalies 
Atypical genitalia and impotence due to congenital anomalies of the urinary tract 
Atypical genitalia and impotence due to congenital genital anomalies 
Atypical genitalia and incontinence due to congenital anomalies of the urinary tract 
Atypical genitalia and primary infertility due to congenital genital anomalies 
Atypical genitalia due to congenital anomalies of the urinary tract 
Atypical genitalia due to congenital genital anomalies 
Atypical genitalia, incontinence and impotence due to congenital anomalies of the urinary tract 
Atypical genitalia, incontinence, impotence, and recurrent urinary tract infections or other abdominal issues and impotence due to 
congenital anomalies of the urinary tract 
Atypical genitalia, infertility and impotence due to congenital genital anomalies 
Atypical genitalia, infertility, impotence, and recurrent urinary tract infections or other abdominal issues and impotence due to 
congenital genital anomalies 
Atypical genitalia, recurrent urinary tract infections or other abdominal issues and impotence due to congenital anomalies of the 
urinary tract 
Atypical genitalia, recurrent urinary tract infections or other abdominal issues and impotence due to congenital genital anomalies 
Atypical genitalia, recurrent urinary tract infections or other abdominal issues and incontinence due to congenital anomalies of 
the urinary tract 
Atypical genitalia, recurrent urinary tract infections or other abdominal issues and infertility due to congenital genital anomalies 
Impotence and recurrent urinary tract infections or other abdominal issues due to congenital anomalies of the urinary tract 
Impotence and recurrent urinary tract infections or other abdominal issues due to congenital genital anomalies 
Impotence due to congenital anomalies of the urinary tract 
Impotence due to congenital genital anomalies 
Incontinence and impotence due to congenital anomalies of the urinary tract 
Incontinence and recurrent urinary tract infections or other abdominal issues due to congenital anomalies of the urinary tract 
Incontinence due to congenital anomalies of the urinary tract 
Incontinence, impotence, and recurrent urinary tract infections or other abdominal issues and impotence due to congenital 
anomalies of the urinary tract 
Infertility and impotence due to congenital genital anomalies 
Infertility, impotence, and recurrent urinary tract infections or other abdominal issues and impotence due to congenital genital 
anomalies 
Primary infertility and recurrent urinary tract infections or other abdominal issues due to congenital genital anomalies 
Primary infertility due to congenital genital anomalies 
Recurrent urinary tract infections or other abdominal issues due to congenital anomalies of the urinary tract 
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Recurrent urinary tract infections or other abdominal issues due to congenital genital anomalies 
Digestive congenital anomalies 
 Mild chronic respiratory problems and developmental delay due to congenital diaphragmatic hernia 
Acid reflux, dyspahgia, and/or constipation due to other congenital malformations of the digestive tract 
Asymptomatic congenital atresia and/or stenosis of the digestive tract 
Asymptomatic congenital diaphragmatic hernia 
Asymptomatic congenital malformations of the abdominal wall after treatment 
Asymptomatic other congenital malformations of the digestive tract 
Chronic abdominal pain and concern about scars due to congenital malformations of the abdominal wall 
Chronic abdominal pain and developmental delay due to congenital diaphragmatic hernia 
Chronic abdominal pain and disfigurement due to congenital diaphragmatic hernia 
Chronic abdominal pain and mild chronic respiratory problems due to congenital diaphragmatic hernia 
Chronic abdominal pain and/or nausea due to other congenital malformations of the digestive tract 
Chronic abdominal pain and/or nausea with acid reflux, dyspahgia, and/or constipation  due to other congenital malformations of 
the digestive tract 
Chronic abdominal pain due to congenital atresia and/or stenosis of the digestive tract 
Chronic abdominal pain due to congenital diaphragmatic hernia 
Chronic abdominal pain due to congenital malformations of the abdominal wall 
Chronic abdominal pain, chronic respiratory problems and developmental delay due to congenital diaphragmatic hernia 
Chronic abdominal pain, disfigurement and  chronic respiratory problems due to congenital diaphragmatic hernia 
Chronic abdominal pain, disfigurement and developmental delay due to congenital diaphragmatic hernia 
Chronic abdominal pain, disfigurement, developmental delay and  chronic respiratory problems due to congenital diaphragmatic 
hernia 
Chronic respiratory problems and abdominal pain due to congenital atresia and/or stenosis of the digestive tract 
Chronic respiratory problems and dysphagia or acid reflux due to congenital atresia and/or stenosis of the digestive tract 
Chronic respiratory problems including difficulty breaking and recurrent upper respiratory infections due to atresia and/or 
stenosis of the digestive tract 
Constipation and chronic abdominal pain due to congenital malformations of the abdominal wall 
Constipation and concern about scars due to congenital malformations of the abdominal wall 
Constipation due to congenital malformations of the abdominal wall 
Constipation, chronic abdominal pain and concern about scars due to congenital malformations of the abdominal wall 
Developmental delay or mild intellectual disability due to congenital diaphragmatic hernia 
Disfigurement and developmental delay due to congenital diaphragmatic hernia 
Disfigurement and mild chronic respiratory problems due to congenital diaphragmatic hernia 
Disfigurement due to congenital diaphragmatic hernia 
Disfigurement from scars following treatment for congenital malformations of the abdominal wall 
Disfigurement, chronic respiratory problems and developmental delay due to congenital diaphragmatic hernia 
Dysphagia or acid reflux and chronic abdominal pain due to congenital atresia and/or stenosis of the digestive tract 
Dysphagia or acid reflux due to congenital atresia and/or stenosis of the digestive tract 
Dysphagia or acid reflux, chronic abdominal pain and chronic respiratory problems due to congenital atresia and/or stenosis of 
the digestive tract 
Mild chronic respiratory problems and breathlessness due to congenital diaphragmatic hernia 
Other congenital birth defects 
Complete hearing loss due to other congenital anomalies 
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Complete hearing loss with ringing due to other congenital anomalies 
Mild hearing loss due to other congenital anomalies 
Mild hearing loss with ringing due to other congenital anomalies 
Moderate hearing loss due to other congenital anomalies 
Moderate hearing loss with ringing due to other congenital anomalies 
Moderately severe hearing loss due to other congenital anomalies 
Moderately severe hearing loss with ringing due to other congenital anomalies 
Profound hearing loss due to other congenital anomalies 
Profound hearing loss with ringing due to other congenital anomalies 
Severe hearing loss due to other congenital anomalies 
Severe hearing loss with ringing due to other congenital anomalies 
Skin and subcutaneous diseases 
Dermatitis 
Asymptomatic contact dermatitis 
Asymptomatic seborrhoeic dermatitis 
Mild atopic dermatitis 
Mild contact dermatitis 
Moderate atopic dermatitis 
Moderate contact dermatitis 
Severe atopic dermatitis 
Symptomatic seborrhoeic dermatitis 
Psoriasis 
Mild psoriasis 
Moderate psoriasis 
Severe psoriasis 
Cellulitis 
Mild cellulitis 
Moderate cellulitis 
Severe cellulitis 
Pyoderma 
Abscess and other bacterial skin diseases 
Impetigo 
Scabies 
Fungal skin diseases 
Other fungal skin diseases 
Tinea capitis 
Viral skin diseases 
Mild molluscum contagiosum 
Mild viral warts 
Severe molluscum contagiosum 
Severe viral warts 
Acne vulgaris 
Mild acne vulgaris 
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Moderate acne vulgaris 
Severe acne vulgaris 
Alopecia areata 
Mild alopecia areata 
Severe alopecia areata 
Pruritus 
Urticaria 
Mild urticaria 
Severe urticaria 
Decubitus ulcer 
Mild decubitus ulcer 
Moderate decubitus ulcer 
Severe decubitus ulcer 
Other skin and subcutaneous diseases 
Asymptomatic other skin and subcutaneous diseases 
Symptomatic other skin and subcutaneous diseases 
Sense organ diseases 
Glaucoma 
Blindness due to glaucoma 
Moderate vision impairment due to glaucoma 
Severe vision impairment due to glaucoma 
Cataract 
Blindness due to cataract 
Moderate vision impairment due to cataract 
Severe vision impairment due to cataract 
Macular degeneration 
Blindness due to macular degeneration 
Moderate vision impairment due to macular degeneration 
Severe vision impairment due to macular degeneration 
Refraction and accommodation disorders 
Blindness due to uncorrected refractive error 
Moderate vision impairment due to uncorrected refractive error 
Near vision impairment 
Severe vision impairment due to uncorrected refractive error 
Age-related and other hearing loss 
Complete hearing loss due to age-related and other hearing loss 
Complete hearing loss with ringing due to age-related and other hearing loss 
Mild hearing loss due to age-related and other hearing loss 
Mild hearing loss with ringing due to age-related and other hearing loss 
Moderate hearing loss due to age-related and other hearing loss 
Moderate hearing loss with ringing due to age-related and other hearing loss 
Moderately severe hearing loss due to age-related and other hearing loss 
Moderately severe hearing loss with ringing due to age-related and other hearing loss 
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Profound hearing loss due to age-related and other hearing loss 
Profound hearing loss with ringing due to age-related and other hearing loss 
Severe hearing loss due to age-related and other hearing loss 
Severe hearing loss with ringing due to age-related and other hearing loss 
Other vision loss 
Blindness due to other vision loss 
Moderate vision impairment due to other vision loss 
Severe vision impairment due to other vision loss 
Other sense organ diseases 
Asymptomatic acute sense organ diseases 
Asymptomatic chronic sense organ diseases 
Mild acute sense organ diseases 
Moderate acute sense organ diseases 
Moderate chronic sense organ diseases 
Severe chronic sense organ diseases 
Oral disorders 
Caries of deciduous teeth 
Asymptomatic caries of deciduous teeth 
Pain due to caries of deciduous teeth 
Caries of permanent teeth 
Asymptomatic caries of permanent teeth 
Pain due to caries of permanent teeth 
Periodontal diseases 
Chronic periodontal diseases 
Edentulism and severe tooth loss 
Asymptomatic edentulism and severe tooth loss 
Difficulty eating due to edentulism and severe tooth loss 
Other oral disorders 
Mild other oral disorders 
Severe other oral disorders 
Sudden infant death syndrome 
Injuries 
Transport injuries 
Road injuries 
Pedestrian road injuries 
Cyclist road injuries 
Motorcyclist road injuries 
Motor vehicle road injuries 
Other road injuries 
Other transport injuries 
Unintentional injuries 
Falls 
Drowning 
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Fire, heat, and hot substances 
Poisonings 
Exposure to mechanical forces 
Unintentional firearm injuries 
Unintentional suffocation 
Other exposure to mechanical forces 
Adverse effects of medical treatment 
Animal contact 
Venomous animal contact 
Non-venomous animal contact 
Foreign body 
Pulmonary aspiration and foreign body in airway 
Foreign body in eyes 
Foreign body in other body part 
Environmental heat and cold exposure 
Other unintentional injuries 
Self-harm and interpersonal violence 
Self-harm 
Self-harm by firearm 
Self-harm by other specified means 
Interpersonal violence 
Physical violence by firearm 
Physical violence by sharp object 
Sexual violence 
Physical violence by other means 
Forces of nature, conflict and terrorism, and executions and police conflict 
Exposure to forces of nature 
Conflict and terrorism 
Executions and police conflict 
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Cause ICD10 ICD10 Used in Hospital/Claims Analyses ICD9 ICD9 Used in Hospital/Claims Analyses
Tuberculosis
A10-A14, A15-A18.89, A19-A19.9, B90-
B90.9, K67.3, K93.0, M49.0, N74.0-N74.1, 
P37.0, U84.3, Z03.0, Z11.1, Z20.1, Z23.2
010-019.9, 137-137.9, 320.4, 730.4-730.6, 
V01.1, V03.2, V12.01, V74.1
Drug-susceptible tuberculosis
A10-A14, A15-A18.89, A19-A19.9, B90-
B90.9, K67.3, K93.0, M49.0, N74.0-N74.1, 
P37.0
010-019.9, 137-137.9, 320.4, 730.4-730.6
Multidrug-resistant tuberculosis without extensive 
drug resistance U84.3
Extensively drug-resistant tuberculosis
Latent tuberculosis infection
HIV/AIDS
B20-B23.8, B24-B24.0, B97.81, C46-
C46.52, C46.7-C46.9, O98.7-O98.73, 
Z11.4, Z20.6, Z21, Z22.6, Z83.0
042-044.9, 176-176.9
Drug-susceptible HIV/AIDS-Tuberculosis B20.0
Multidrug-resistant HIV/AIDS-Tuberculosis without 
extensive drug resistance
Extensively drug-resistant HIV/AIDS-Tuberculosis
HIV/AIDS resulting in other diseases B20.1-B23.8, B24-B24.0, B97.81, C46-C46.52, C46.7-C46.9 176-176.9
Diarrheal diseases A00-A00.9, A02-A07, A07.2-A07.4, A08-A08.8, A09, Z22.1, Z23.0 A00-A00.9, A02-A09
001-001.9, 003-009.9, V01.0, V01.83, 
V02.0, V02.2-V02.3, V03.0, V74.0 001-001.9, 003-009.9
Intestinal infectious diseases A01-A01.4, A07.0-A07.1, A07.8-A07.9, Z11.0, Z20.0-Z20.09 002-002.9
Typhoid fever A01.0-A01.09 002.0
Paratyphoid fever A01.1-A01.4 002.1-002.9
Other intestinal infectious diseases A07.0-A07.1, A07.8-A07.9
Lower respiratory infections
A48.1, A70, B96.0-B96.1, B97.21, B97.4-
B97.6, J09-J18.2, J18.8-J18.9, J19.6-J22.9, 
J85.1, P23-P23.9, U04-U04.9, Z25.1
A48.1, A70, B96.0-B97.6, J09-J22.9, 
J85.1, P23-P23.9, U04-U04.9
079.82, 466-469, 470.0, 480-484, 484.1-
489, 510-511.9, 513.0-513.9, 770.0, 
V01.82, V04.7, V04.81
079.82, 466-470.0, 480-484, 484.1-489, 
510-513.9, 770.0
Upper respiratory infections J00-J06.9, J36-J36.0 460-465.9, 475-475.9
Otitis media H65-H70.93 381-383.9
Meningitis A39-A39.9, A87-A87.9, D86.81, G00-G03.9, G06-G09.9, Z20.811, Z22.31
A39-A39.9, A87-A87.9, D86.81, G00-
G03.9
036-036.9, 047-049.9, 054.72, 320-320.3, 
320.5-322.9, 324-326.9, V01.84
036-036.9, 047-049.9, 054.72, 320-320.3, 
320.5-322.9
Pneumococcal meningitis G00.1 320.1
H influenzae type B meningitis G00.0 320.0
Meningococcal meningitis A39-A39.9 036-036.9, 320.5
Other meningitis A87-A87.9, D86.81, G03-G03.9 047-049.9, 054.72, 321-322.9
Encephalitis A83-A85.2, A85.8-A86.0, B94.1, F07.1, G04-G05.8, Z24.1 A83-A86.0, B94.1, F07.1, G04-G05.8
062-064.9, 310.89, 323-323.9, V05.0-
V05.1 062-064.9, 310.89, 323-323.9
Diphtheria A36-A36.9, Z22.2, Z23.6 032-032.9, V02.4, V03.5, V74.3
Whooping cough A37-A37.91, Z23.7 033-033.9, V03.6
Tetanus A33-A35.0, Z23.5 037-037.9, 771.3, V03.7
Measles B05-B05.9, Z24.4 055-055.9, 484.0, V04.2, V73.2
Varicella and herpes zoster B01-B02.9, Z20.820 052-053.9, V01.71-V01.79, V05.4
Malaria B50-B50.0, B50.8-B52.0, B52.8-B53.1, B53.8-B54.0, P37.3-P37.4 084-084.9
Chagas disease B57-B57.5, K93.1 086-086.2, 425.6
Leishmaniasis B55-B55.9, Z26.0 085-085.9, V05.2
Visceral leishmaniasis B55.0 B55.0 085.0 085.1-085.5
Cutaneous and mucocutaneous leishmaniasis B55.1-B55.2 B55.1-B55.2 085.1-085.5 085.0
African trypanosomiasis B56-B56.9 086.3-086.9
Schistosomiasis B65-B65.9 120-120.9
Cysticercosis B69-B69.9 123.1
Cystic echinococcosis B67-B67.4, B67.8-B67.99 B67-B67.99 122-122.4, 122.8-122.9 122-122.9
Lymphatic filariasis B74-B74.2 125.0-125.2
Onchocerciasis B73-B73.1 125.3
Trachoma A71-A71.9, A74.0, B94.0 076-076.9
Dengue A90-A91.0 061-061.8
Yellow fever A95-A95.9, Z24.3 060-060.9, V04.4, V73.4
Rabies A82-A82.9, Z20.3, Z24.2 071-071.9, V01.5, V04.5
Intestinal nematode infections B76-B77.9, B79, Z11.6 126-126.9, 127.0, 127.3, V75.7
Ascariasis B77-B77.9 127.0
Trichuriasis B79 127.3
Hookworm disease B76-B76.9 126-126.9
Food-borne trematodiases B66-B66.9, B72.0 121-121.9
Leprosy A30-A30.9, B92 030-030.9
Ebola A98.4
Zika virus U06-U06.9 066.3
Guinea worm disease B72
Other neglected tropical diseases
A68-A68.9, A69.2-A69.29, A69.8-A69.9, 
A75-A75.9, A77-A79.9, A92-A94.0, A96-
A96.9, A98-A98.3, A98.5-A99.0, B33.0-
B33.1, B60-B60.8, B64, B67.5-B67.7, B68-
B68.9, B70-B71.9, B74.3-B75, B78-B78.9, 
B80-B83.9, B89, P37.1
065-066.2, 066.4-066.9, 080-083.9, 087-
088.9, 122.5-122.7, 123-123.0, 123.2-125, 
125.4-125.9, 127, 127.1-127.2, 127.4-
129.0
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Maternal hemorrhage
O20-O20.9, O43.2-O43.239, O44-O44.00, 
O44.03-O46.93, O62.2, O67-O67.9, O72-
O72.3
O20-O20.9, O43.2-O43.239, O44-O44.00, 
O44.03-O46.93, O62.2-O62.2, O67-O67.9, 
O72-O72.3
640-641.93, 661.2-661.23, 666-666.9 640-641.93, 661.2-661.23, 666-666.9
Maternal sepsis and other maternal infections O23-O23.93, O41.1-O41.93, O85-O86.89, O91-O91.23
O23-O23.93, O41.1-O41.93, O85-O86.89, 
O91-O91.23
646.5-646.64, 658.4-658.93, 659.3-659.33, 
670-670.9, 675-675.94
646.5-646.64, 658.4-658.93, 659.2-659.33, 
670-670.9, 672-672.04, 674.1-674.34, 675-
675.94
Maternal hypertensive disorders O10-O16.9 O10-O16.9 642-642.94 642-642, 642.3-642.94
Maternal obstructed labor and uterine rupture O64-O66.9, O70-O71.9, O83-O84.9 O64-O66.9, O70-O71.9, O83-O84.9 652.7-652.73, 653-653.93, 659.0-659.13, 660-660.93, 664-665.94, 669.5-669.61
652.7-652.73, 653-653.93, 659.0-659.13, 
660-660.93, 664-665.94, 669.5-669.61
Maternal abortion, miscarriage, and ectopic 
pregnancy N96, O00-O08.9, O36.7-O36.73 N96-N96, O00-O08.9, O36.7-O36.73 630-639.9, 656.4-656.43 630-639.9, 656.4-656.43
Other maternal disorders
F53-F54, O09-O09.93, O18.0, O21-
O22.93, O24.4-O24.439, O25-O26.93, 
O28-O36.63, O36.8-O36.93, O38.4, O40-
O41.03, O42-O43.199, O43.8-O43.93, 
O44.01-O44.02, O47-O48.1, O60-O62.1, 
O62.3-O63.9, O68-O69.9, O73-O77.9, 
O80-O82.9, O87-O90.9, O92-O92.79, O94-
O95, O96-O97.9, Z03.7-Z03.79, Z32-
Z37.9, Z39-Z39.2, Z64.0-Z64.3, Z87.5-
Z87.6
643-646.44, 646.7-646.93, 648.1-648.14, 
649.7-652.63, 652.8-652.93, 654-655.23, 
655.7-656.33, 656.5-658.33, 659, 659.4-
659.93, 661-661.13, 661.3-663.93, 667-
669.44, 669.7-669.94, 671-674.94, 676-
679.14, V13.1-V13.21, V15.21-V15.22, 
V22-V24.2, V27-V28.9, V72.4-V72.42, 
V82.4, V91-V91.99
Neonatal preterm birth complications P07.2-P07.39, P22-P22.9, P25-P28.9, P61.2, P77-P77.9 P07.2-P07.39, P77-P77.9
765.21-765.9, 769-770, 770.2-770.9, 
776.6, 777.5-777.53 764-765.9, 777.5-777.53
Neonatal encephalopathy due to birth asphyxia and 
trauma
P02-P03.9, P10-P15.9, P20-P21.9, P24-
P24.9, P90-P91.9
P02-P03.9, P10-P21.9, P24-P24.9, P90-
P91.9
761.7-763.9, 767-768, 768.2-768.9, 779.0-
779.2
761.7-763.9, 767.0-768.9, 772.1-772.2, 
779.0-779.2
Neonatal sepsis and other neonatal infections P36-P36.9, P38-P39.9 P36-P36.9, P38-P39.9 771, 771.4-771.89 771, 771.4-771.89
Hemolytic disease and other neonatal jaundice P55-P59.9 773-774.9
Other neonatal disorders
P00-P01.9, P04-P05.9, P07-P07.18, P08-
P09, P19-P19.9, P29-P29.9, P50-P54.9, 
P60-P61.1, P61.3-P61.9, P70-P72.9, P74-
P74.9, P75.0-P76.9, P78-P78.9, P80-P81.9, 
P83-P84, P92-P92.9, P94-P94.9, P96, 
P96.3-P96.9, P99.9
655.3-655.63, 760-761.6, 764-765.20, 766-
766.9, 771.9-772.9, 775-775.1, 775.4-
776.5, 776.7-777.4, 777.6-779, 779.3-
779.5, 779.7-779.9
Protein-energy malnutrition E40-E46.9, E64.0 260-263.9
Iodine deficiency E00-E02 244.2
Vitamin A deficiency E50-E50.9, E64.1 264-264.9
Iron-deficiency anemia D50-D50.9 280-280.9
Other nutritional deficiencies D51-D53.9, E51-E61.9, E63-E64, E64.2-E64.9 265-269.9, 273-273.9, 281-281.2
Sexually transmitted diseases excluding HIV
A50-A60.9, A63-A64.0, B63, I98.0, K67.0-
K67.2, M73.0-M73.8, N70-N71.9, N73-
N74, N74.2-N74.8, Z11.3, Z20.2, Z22.4
054.1, 054.11-054.19, 090-099.9, 131-
131.9, 613-615.9, V01.6, V02.7-V02.9, 
V73.8, V73.88, V73.9-V73.98, V74.5-
V74.6
Syphilis A50-A53.9, I98.0, K67.2, M73.1-M73.8 A51-A52.9, I98.0 090-097.9 091-092.9, 093.2
Chlamydial infection A55-A56.8, K67.0, N74.4 099.41, 099.5
Gonococcal infection A54-A54.9, K67.1, M73.0, N74.3 098-098.9
Trichomoniasis A59-A59.9 131-131.9
Genital herpes A60-A60.9 054.1, 054.11-054.19
Other sexually transmitted diseases A57-A58, A63-A64.0, B63, N70-N71.9, N73-N74, N74.2, N74.8
099-099.40, 099.49, 099.50-099.9, 613-
615.9
Hepatitis B15-B19.9, B94.2, K71.2, K71.6, P35.3, Z20.5, Z22.5-Z22.59, Z24.6 070-070.9, V02.6-V02.69, V05.3
Acute hepatitis A B15-B15.9 070.0-070.1
Hepatitis B B16-B16.9, B17.0, B18.0-B18.1, B19.1-B19.11, P35.3 070.2-070.31, 070.42, 070.52
Hepatitis C B17.1-B17.11, B18.2, B19.2-B19.21 070.41, 070.44, 070.51, 070.7-070.71
Acute hepatitis E B17.2 070.43, 070.53
Other infectious diseases
A20-A28.9, A31-A32.9, A38-A38.9, A42-
A44.9, A48-A48.0, A48.2-A49.9, A65-
A65.0, A69-A69.1, A74, A74.8-A74.9, 
A80-A81.9, A88-A89.0, B00-B00.9, B03-
B04, B06-B06.9, B10-B10.89, B25-
B27.99, B33, B33.3-B34.9, B37-B37.2, 
B37.5-B47.1, B47.9-B49, B58-B59, B91, 
B94, B94.8-B96, B96.2-B97.2, B97.29-
B97.39, B97.7-B97.8, B97.89, B99-B99.9, 
G14-G14.6, I00, I02, I02.9, I96-I96.9, 
I98.1, J85-J85.0, J85.2-J85.3, J86-J86.9, 
K75.0, K75.3, K76.3, M49.1, M89.6-
M89.69, P35-P35.2, P35.8-P35.9, P37, 
P37.2, P37.5-P37.9, R02-R02.9, U82-U84, 
U85-U89, Z11, Z11.2, Z11.5-Z11.59, 
Z11.8-Z11.9, Z16-Z16.39, Z20, Z20.4, 
Z20.7-Z20.810, Z20.818-Z20.82, Z20.828-
Z20.9, Z22-Z22.0, Z22.3, Z22.32-Z22.39, 
Z22.8-Z22.9, Z23.3-Z23.4, Z24.0, Z24.5, 
Z25.0, Z83.1
020-029, 031-031.9, 034-034.9, 039-039.4, 
039.8-040, 040.1-041.9, 045-046.9, 050-
051.9, 054-054.0, 054.10, 054.2-054.71, 
054.73-054.9, 056-059.9, 072-074.1, 
074.20, 074.3-075.9, 078, 078.2-079.81, 
079.83-079.99, 100-101.6, 104-104.9, 112-
112.0, 112.3-118.9, 130-130.9, 136-136.0, 
136.2-136.9, 138-139.9, 390-390.9, 392, 
392.9, 572.0-572.1, 771.0-771.2, V01, 
V01.2-V01.4, V01.7, V01.8-V01.81, 
V01.89-V02, V02.1, V02.5-V02.59, V03.1, 
V03.3-V03.4, V03.8, V03.9-V04.1, V04.3, 
V04.6, V04.8, V04.89-V05, V05.8-V06, 
V07-V07.3, V09-V09.91, V12.00, V12.02-
V12.09, V18.8, V58.62, V73.0-V73.1, 
V73.3, V73.81, V73.89, V73.99, V74.8-
V74.9, V75.0-V75.4, V75.9
Lip and oral cavity cancer C00-C07, C08-C08.9, Z85.81-Z85.810 140-145.9, V76.42
Nasopharynx cancer C11-C11.9 147-147.9
Other pharynx cancer C09-C10.9, C12-C13.9 146-146.9, 148-148.9
Esophageal cancer C15-C15.9, Z85.01 150-150.9
Stomach cancer C16-C16.9, Z12.0, Z85.02-Z85.028 151-151.9, 209.23, V10.04
Colon and rectum cancer C18-C19.0, C20, C21-C21.8, Z12.1-Z12.13, Z85.03-Z85.048, Z86.010
153-154.9, 209.1-209.17, V10.05-V10.06, 
V76.41, V76.5-V76.52
Liver cancer C22-C22.4, C22.7-C22.9, Z85.05 155-155.9, V10.07
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Liver cancer due to hepatitis B
Liver cancer due to hepatitis C
Liver cancer due to alcohol use
Liver cancer due to other causes
Gallbladder and biliary tract cancer C23, C24-C24.9 156-156.9
Pancreatic cancer C25-C25.9, Z85.07 157-157.9
Larynx cancer C32-C32.9, Z85.21 161-161.9, V10.21
Tracheal, bronchus, and lung cancer C33, C34-C34.92, Z12.2, Z80.1-Z80.2, Z85.1-Z85.20
162-162.9, 209.21, V10.1-V10.20, V16.1-
V16.2, V16.4-V16.40
Malignant skin melanoma C43-C43.9, Z85.82-Z85.828 172-172.9
Non-melanoma skin cancer C44-C44.99 173-173.99, 216-216.9, 232-232.9
Non-melanoma skin cancer (squamous-cell 
carcinoma)
C44.02, C44.12-C44.129, C44.22-
C44.229, C44.32-C44.329, C44.42, C44.52-
C44.529, C44.62-C44.629, C44.72-
C44.729, C44.82, C44.92
C44.02, C44.12-C44.129, C44.22-
C44.229, C44.32-C44.329, C44.42, C44.52-
C44.529, C44.62-C44.629, C44.72-
C44.729, C44.82, C44.92
173.02, 173.12, 173.22, 173.32, 173.42, 
173.52, 173.62, 173.72, 173.82, 173.92
173.02, 173.12, 173.22, 173.32, 173.42, 
173.52, 173.62, 173.72, 173.82, 173.92
Non-melanoma skin cancer (basal-cell carcinoma)
C44.01, C44.11-C44.119, C44.21-
C44.219, C44.31-C44.319, C44.41, C44.51-
C44.519, C44.61-C44.619, C44.71-
C44.719, C44.81, C44.91
173.01, 173.11, 173.21, 173.31, 173.41, 
173.51, 173.60-173.61, 173.71, 173.81, 
173.91
Breast cancer C50-C50.629, C50.8-C50.929, Z12.3-Z12.39, Z80.3, Z85.3, Z86.000 174-175.9, V10.3, V16.3
Cervical cancer C53-C53.9, Z12.4, Z85.41 180-180.9, V10.41, V72.32
Uterine cancer C54-C54.3, C54.8-C54.9, Z85.42, Z86.001 182-182.9
Ovarian cancer C56-C56.2, C56.9, Z80.41, Z85.43 183-183.0, 183.8-183.9, V10.43, V16.41
Prostate cancer C61-C61.9, Z12.5, Z80.42, Z85.46 185-185.9, V10.46, V16.42, V76.44
Testicular cancer C62-C62.92, Z80.43, Z85.47-Z85.48 186-186.9, V10.47-V10.48, V16.43
Kidney cancer C64-C64.2, C64.9-C65.9, Z80.51, Z85.52-Z85.54 189-189.1, 189.5-189.6, 209.24
Bladder cancer C67-C67.9, Z12.6-Z12.79, Z80.52, Z85.51 188-188.9, V10.51, V16.52, V76.3
Brain and nervous system cancer C70-C70.1, C70.9-C72.9, Z85.841-Z85.848, Z86.011 191-191.9
Thyroid cancer C73, Z85.850 193-193.9
Mesothelioma C45-C45.2, C45.7, C45.9
Hodgkin lymphoma C81-C81.49, C81.7-C81.79, C81.9-C81.99, Z85.71-Z85.72 201-201.98, V10.72
Non-Hodgkin lymphoma C82-C85.29, C85.7-C86.6, C96-C96.9 200-200.9, 202-202.98
Multiple myeloma C88-C90.32 203-203.9
Leukemia C91-C93.7, C93.9-C95.2, C95.7-C95.92, Z80.6, Z85.6 204-208.92, V10.59-V10.69, V16.6
Acute lymphoid leukemia C91.0-C91.02 204.0-204.02
Chronic lymphoid leukemia C91.1-C91.12 204.1-204.12
Acute myeloid leukemia
C92.0-C92.02, C92.3-C92.62, C93.0-
C93.02, C94.0-C94.02, C94.2-C94.22, 
C94.4-C94.5
205.0-205.02, 205.3-205.32, 206.0-206.02, 
207.0
Chronic myeloid leukemia C92.1-C92.12 205.1-205.12, 206.1-206.12, 207.1
Other leukemia
Other neoplasms
C17-C17.9, C30-C30.1, C31-C31.9, C37-
C37.0, C38-C38.8, C40-C41.4, C41.8-
C41.9, C47-C4A, C51-C52, C57-C57.8, 
C58-C58.0, C60-C60.9, C63-C63.8, C66-
C66.9, C68.0-C68.8, C69-C69.92, C74-
C75.5, C75.8
152-152.9, 158-158.9, 160-160.9, 163-
164.9, 170-171.9, 181-181.9, 183.2-183.5, 
184-184.9, 187-187.9, 189.2-189.4, 189.8-
190.9, 192-192.9, 194-194.8, 209-209.03, 
209.22, 209.25-209.27, 209.31-209.36
Rheumatic heart disease I01-I01.9, I02.0, I05-I09.9 I01-I09.9 391-391.9, 392.0, 393-398.99 391-398.99
Ischemic heart disease I20-I21.6, I21.9-I25.9, Z82.4-Z82.49 I20-I25.9 410-414.9, V17.3 410-414.9
Cerebrovascular disease G45-G46.8, I60-I64, I64.1, I65-I69.998, Z82.3 430-439.6, V12.54, V17.1
Ischemic stroke G45-G46.8, I63-I63.9, I65-I66.9, I67.2-I67.848, I69.3-I69.4 I63-I63.9, I67.2-I67.848, I69.3-I69.4 433-435.9, 437.0-437.2, 437.4-437.9 434-434.91, 437.0-437.2, 437.4-437.9
Hemorrhagic stroke I60-I62.9, I67.0-I67.1, I69.0-I69.298 I60-I62.9, I67.0-I67.1, I69.0-I69.298 430-432.9, 437.3 430-432.9
Hypertensive heart disease I11-I11.2, I11.9 402-402.91
Cardiomyopathy and myocarditis B33.2-B33.20, B33.22-B33.24, D86.85, I40-I41.8, I42-I43.8, I51.4-I51.6
074.2, 074.23, 422-422.99, 425-425.5, 
425.7-425.9, 429.0-429.1
Myocarditis B33.2-B33.20, B33.22-B33.24, D86.85, I40-I41.8, I51.4-I51.6
B33.2-B33.20, B33.22-B33.24, D86.85, 
I40-I41.8, I51.4-I51.6 074.2, 074.23, 422-422.99, 429.0-429.1 074.2, 074.23, 422-422.99, 429.0-429.1
Alcoholic cardiomyopathy I42.6 425.5
Other cardiomyopathy I42.0-I42.5, I42.7-I43.8 425.0-425.4, 425.7-425.9
Atrial fibrillation and flutter I48-I48.92 I48-I48.92 427.3-427.32 427.3-427.32
Peripheral artery disease I70.2-I70.92, I73-I73.9 I70.2-I73.9 440.2-440.29, 440.4-440.9, 443-443.9 440.2-440.29, 440.4-443.9
Endocarditis B33.21, I33-I33.9, I38-I38.0, I39-I39.9 B33.21, I33-I39.9 074.22, 421-421.9, 424, 424.4-424.99 074.22, 421-421.9, 424-424.99
Other cardiovascular and circulatory diseases
I30-I32.8, I34-I37.9, I51-I51.3, I51.7-I52.8, 
I72-I72.9, I77-I83.93, I86-I89.0, I89.9, 
I95.0-I95.1, I98, I98.8-I99.9, K75.1
074.21, 417-417.9, 420-420.99, 423-423.9, 
424.0-424.3, 429, 429.2-429.9, 442-442.9, 
447-454.9, 456, 456.3-457, 457.1, 457.8-
458.1, 459-459.9
Chronic obstructive pulmonary disease J41-J42.4, J43-J44.9, J47-J47.9 J41-J44.9, J47-J47.9 490-492.9, 494-494.9, 496-499 491-492.9, 494-499
Pneumoconiosis J60-J65.0, J92.0 500-505.9
Silicosis J62-J62.9 J62-J62.9 502-502.9 502-502.9
Asbestosis J61-J61.0, J92.0 J61-J61.0, J92.0 501-501.9 501-501.9
Coal workers pneumoconiosis J60-J60.0 J60-J60.0 500-500.9 500-500.9
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Other pneumoconiosis J63-J65.0 J63-J65.0 503-505.9 503-505.9
Asthma J45-J46.0, Z82.5 J45-J46.0 493-493.92, V17.5 493-493.92
Interstitial lung disease and pulmonary sarcoidosis D86-D86.2, D86.89-D86.9, J84-J84.9 D86-D86.2, D86.89-D86.9, J84-J84.9 135-135.9, 515, 515.9-516.9 135-135.9, 515-516.9
Other chronic respiratory diseases
G47.3-G47.39, J30-J35.9, J37-J39.9, J66-
J68.9, J70.8-J70.9, J82, J90-J90.0, J91-J92, 
J92.9-J93.12, J93.8-J94.9, J96.1-J96.8, J98-
J99.8
278.03, 327.2-327.29, 470, 470.9-474.9, 
476-479, 495-495.9, 506-508.9, 512-513, 
514-514.9, 515.0, 517-518.4, 518.7-519.0, 
519.11-519.9
Cirrhosis and other chronic liver diseases
I85-I85.9, I98.2, K70-K71.11, K71.3-
K71.51, K71.7-K75, K75.2, K75.4-K76.2, 
K76.4-K77.8, Z52.6, Z94.4
I85-I85.9, I98.2, K70-K77.8 456.0-456.21, 570-572, 572.2-573.9, V42.7, V59.6 456.0-456.21, 570-573.9
Cirrhosis and other chronic liver diseases due to 
hepatitis B
Cirrhosis and other chronic liver diseases due to 
hepatitis C
Cirrhosis and other chronic liver diseases due to 
alcohol use
Cirrhosis and other chronic liver diseases due to 
other causes
Peptic ulcer disease K25-K27.7, K28-K28.9 K25-K28.9 531-533.8, 534-534.91 531-534.91
Gastritis and duodenitis K29-K29.91 K29-K29.91 535-535.9 535-535.9
Appendicitis K35-K37.9 K35-K37.9 540-542.9 540-542.9
Paralytic ileus and intestinal obstruction K56-K56.9 K56-K56.9 560-560.39, 560.8-560.9, 569.87 560-560.9, 569.87
Inguinal, femoral, and abdominal hernia K40-K42.9, K44-K46.9 K40-K42.9, K44-K46.9 550-551.1, 551.3-552.1, 552.3-553.1, 553.3-553.9
550-551.1, 551.3-552.1, 552.3-553.1, 
553.3-553.9
Inflammatory bowel disease K50-K51.319, K51.5-K52.9, K58 K50-K51.919, K58 555-556.9, 558-558.9, 564.1, 569.5 555-556.9, 564.1
Vascular intestinal disorders K55-K55.9 K55.0-K55.1 557-557.9, 569.84-569.86 557.0-557.9
Gallbladder and biliary diseases K80-K80.81, K81-K83.9, K87-K87.1 K80-K83.9, K87-K87.1 574-576.9 574-576.9
Pancreatitis K85-K86.9 K85-K86.9 577-577.9 577-577.9
Other digestive diseases
I84-I84.9, K20-K23.8, K30-K31.9, K38-
K38.9, K51.4-K51.419, K57-K57.93, 
K58.0-K62.6, K62.8-K67, K67.8-K68.1, 
K68.12-K68.9, K90-K90.9, K92-K92.9, 
K93.8
455-455.9, 530-530.86, 530.89-530.9, 536-
536.3, 536.8-538, 543-543.9, 562-562.13, 
564-564.09, 564.5-569.49, 569.81-569.83, 
569.89-569.9, 578-579.9
Alzheimer disease and other dementias F00-F03.91, F06.2, G30-G31.1, G31.8-G32.89 F00-F06.2, G30-G31.1, G31.8-G32.89
290-290.9, 294.0-294.9, 331-331.2, 331.6-
331.7, 331.82, 331.89-331.9
290-290.9, 294.0-294.9, 331-331.7, 331.82-
331.9
Parkinson disease G20-G20.9 G20-G20.9 332-332.9 332-332.9
Epilepsy G40-G41.9, Z82.0 345-345.91
Multiple sclerosis G35-G35.0 G35-G35.0 340-340.9 340-340.9
Motor neuron disease 335-335.9
Migraine G43-G43.919 G43-G43.919 346-346.93 346-346.93
Tension-type headache G44-G44.89 G44.2-G44.41 307.81, 339-339.89 307.81, 339.1-339.3
Other neurological disorders
G10-G10.0, G11-G13.8, G21-G21.0, 
G21.2-G24, G24.1-G25.0, G25.2-G25.3, 
G25.5, G25.8-G26.0, G36-G37.9, G50-
G54.1, G54.5-G62, G62.1-G65.2, G70-
G72, G72.1-G73.7, G80-G83.9, G89-
G93.6, G93.8-G95.29, G95.8-G96, G96.1, 
G96.12-G96.9, G98-G99.8, M33-M33.99, 
M60-M60.19, M60.8-M60.9, M79.7
307.8-307.80, 307.89, 330-330.9, 331.3-
331.5, 331.8, 331.83, 333-333.91, 333.93-
338.4, 342-344.9, 348-348.9, 350-353.0, 
353.5-357.5, 357.7-359.23, 359.29-359.9, 
710.3-710.4, 725-725.9, 728-728.85, 
728.87-728.9, 775.2, 780.96
Schizophrenia F20-F20.9, F25-F25.9 295-295.35, 295.5-295.8
Alcohol use disorders F10-F10.99, G31.2, R78.0, X45-X45.9, X65-X65.9, Y15-Y15.9, Z81.1
291-291.9, 303-303.93, 305-305.03, 790.3, 
E860-E860.19, V11.3
Drug use disorders F11-F19.99, P96.1, R78.1-R78.9, Z81.2-Z81.4
292-292.9, 304-304.93, 305.1-305.93, 
E850.0-E850.29, V15.8-V15.86
Opioid use disorders F11-F11.99, R78.1 304.0-304.03, 305.5-305.53, E850.0-E850.29
Cocaine use disorders F14-F14.99, R78.2 304.2-304.23, 305.2-305.23, 305.6-305.63
Amphetamine use disorders F15-F15.99 304.4-304.43, 305.7-305.73
Cannabis use disorders F12-F12.99 304.3-304.33
Other drug use disorders F13-F13.99, F16-F19.99, P96.1, R78.3-R78.9
292-292.9, 304, 304.1-304.13, 304.5-
304.93, 305.1-305.13, 305.3-305.43, 305.8-
305.93
Depressive disorders F32-F33.9, F34.1 296.2-296.36, 300.4, 311-311.9
Major depressive disorder F32-F33.9 296.2-296.36, 311-311.9
Dysthymia F34.1 300.4
Bipolar disorder F30-F31.9, F34.0 F30-F31.9, F34.0 296-296.16, 296.4-296.81 296-296.16, 296.4-296.81
Anxiety disorders F40-F44.9, F93-F93.2 300-300.3, 308-309.9
Eating disorders F50-F50.9 307.1, 307.5-307.59
Anorexia nervosa F50.0-F50.1 307.1
Bulimia nervosa F50.2-F50.5 307.51, 307.54
Autistic spectrum disorders F84-F84.9 299-299.91
Autism F84.0-F84.4 299.0-299.11
Asperger syndrome and other autistic spectrum 
disorders F84, F84.5-F84.9 299, 299.8-299.91
Attention-deficit/hyperactivity disorder F90-F90.9 314-314.9
Conduct disorder F91-F92.9 312-312.9
Idiopathic developmental intellectual disability F70-F79.9, Z81.0 317-319.9, V18.4
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Other mental and substance use disorders
F04-F06.1, F06.3-F07.0, F08-F09.9, F21-
F24, F26-F29.9, F34, F34.8-F34.9, F38-
F39, F45-F49, F51-F52.9, F55-F55.8, F56-
F69.0, F80-F83, F85-F89.0, F93.3-F99.0, 
G47-G47.29, G47.4-G47.9, R40-R40.4, 
R45-R55.0, Z03.2, Z04.6-Z04.72, Z13.4, 
Z64, Z81, Z81.8, Z86.5-Z86.59
293-294, 295.4-295.45, 295.80-295.95, 
296.82-298.9, 300.5-302.9, 306-307.0, 
307.2-307.49, 307.6-307.7, 307.9, 310-
310.1, 313-313.9, 316-316.9, 327-327.19, 
327.3-327.8, 347-347.9, 780-780.2, 
780.93, 780.97, 797-797.9, 799.2-799.29, 
V11.0-V11.2, V11.4-V12.0, V17-V17.0, 
V40-V41.9, V79-V79.9
Diabetes mellitus
E08-E08.11, E08.3-E08.9, E10-E10.11, 
E10.3-E11.1, E11.3-E12.1, E12.3-E13.11, 
E13.3-E14.1, E14.3-E14.9, R73-R73.9
E08-E08.11, E08.3-E08.9, E10-E10.11, 
E10.3-E11.1, E11.3-E12.1, E12.3-E13.11, 
E13.3-E14.1, E14.3-E14.9
249-249.31, 249.5-250.39, 250.5-250.99, 
790.2-790.29 249-249.31, 249.5-250.39, 250.5-250.99
Acute glomerulonephritis N00-N01.9 N00-N01.9 580-580.9 580-580.9
Chronic kidney disease
D63.1, E08.2-E08.29, E10.2-E10.29, E11.2-
E11.29, E12.2, E13.2-E13.29, E14.2, I12-
I13.9, N02-N08.8, N18-N19, Q62-Q62.8, 
Q64.2-Q64.9, Z49-Z49.32, Z52.4, Z99.2
249.4-249.41, 250.4-250.49, 285.21, 403-
404.93, 581-587.9, 753.2-753.29, 753.4, 
753.6-753.9, V13.03-V13.09, V18.6, 
V18.69, V42.0, V45.1-V45.12, V45.73, 
V56-V56.8, V59.4, V81.5-V81.6
Chronic kidney disease due to diabetes mellitus E08.2-E08.29, E10.2-E10.29, E11.2-E11.29, E12.2, E13.2-E13.29, E14.2 249.4-249.41, 250.4-250.49
Chronic kidney disease due to hypertension I12-I13.9 403-404.93
Chronic kidney disease due to glomerulonephritis N03-N06.9, N08-N08.8 581-583.9
Chronic kidney disease due to other causes N02-N02.9, N07-N07.9, Q62-Q62.8, Q64.2-Q64.9 753.2-753.29, 753.4, 753.6-753.9
Urinary diseases and male infertility
N10-N12.9, N15-N16.8, N20-N23.0, N25-
N29, N29.1-N37.8, N39-N46.02, N46.022-
N46.12, N46.122-N49.1, N49.8-N52.1, 
N52.8-N53.9, Z43.7
588-596.8, 596.89-598.1, 598.8-609, 788.3-
788.91, V26.5, V26.52
Interstitial nephritis and urinary tract infections N10-N12.9, N15-N16.8, N30-N30.91, N34-N34.3, N39.0 N10-N12.9, N15-N16.8, N30-N39.0 590-590.9, 595-595.9, 597-597.9, 599.0 590-590.9, 595-595.9, 597-597.9, 599.0
Urolithiasis N20-N23.0 N20-N23.0 592-592.9, 594-594.9 592-594.9
Benign prostatic hyperplasia N40-N40.9 N40-N40.9 600-600.91 600-600.91
Male infertility N46-N46.02, N46.022-N46.12, N46.122-N46.9, Z43.7 606-606.9, V26.5, V26.52
Other urinary diseases
N25-N29, N29.1-N29.8, N31-N33.8, N35-
N37.8, N39, N39.1-N39.9, N41-N45.9, 
N47-N49.1, N49.8-N52.1, N52.8-N53.9
588-589.9, 593-593.9, 596-596.8, 596.89-
596.9, 598-598.1, 598.8-599, 599.1-599.9, 
601-605.9, 607-609, 788.3-788.91
Gynecological diseases
B37.3-B37.49, D25-D28.2, E28.2, N60-
N64.9, N72-N72.0, N75-N77.8, N80-
N95.9, N97-N98.9, Z31-Z31.9
112.1-112.2, 218-218.9, 256.4, 610-611.9, 
616-629.9, V26-V26.49, V26.51, V26.8-
V26.9, V59.7-V59.74
Uterine fibroids D25-D28.2 D25-D28.2 218-218.9 218-218.9
Polycystic ovarian syndrome E28.2 E28.2 256.4 256.4
Female infertility N97-N98.9 628-628.9
Endometriosis N80-N80.9 N80-N80.9 617-617.9 617-617.9
Genital prolapse N81-N81.9 N81-N81.9 618-618.9 618-618.9
Premenstrual syndrome N85.0-N85.1, N92-N93.9, N94.3, N95.0 621.2-621.3, 621.31-621.32, 621.34, 625.4, 626, 626.2-626.9, 627.0-627.1
Other gynecological diseases
B37.3-B37.49, N60-N64.9, N72-N72.0, 
N75-N77.8, N83-N85, N85.2-N91.5, N94-
N94.2, N94.4-N95, N95.1-N95.9, Z31-
Z31.9
B37.3-B37.49, N60-N64.9, N72-N72.0, 
N75-N77.8, N83-N94.2, N94.4-N95.9
112.1-112.2, 610-611.9, 616-616.9, 620-
621.1, 621.30, 621.33, 621.35-625.3, 625.5-
625.9, 626.0-626.1, 627, 627.2-627.9, 629-
629.9, V26-V26.49, V26.51, V26.8-V26.9, 
V59.7-V59.74
112.1-112.2, 610-611.9, 616-616.9, 620-
625.3, 625.5-629.9
Hemoglobinopathies and hemolytic anemias D55-D61.9 282-284.9
Thalassemias D56-D56.3, D56.5-D56.9, D57.4-D57.419 282.4-282.49, 282.6-282.62
Thalassemias trait
Sickle cell disorders D57-D57.3, D57.8-D57.819 282.5, 282.63-282.69
Sickle cell trait
G6PD deficiency D55-D55.2 282.3
G6PD trait
Other hemoglobinopathies and hemolytic anemias D55.3-D55.9, D56.4, D58-D61.9 282-282.2, 282.7-284.9
Endocrine, metabolic, blood, and immune disorders
D66-D69.49, D69.6-D70.0, D70.2-D77, 
D80-D84.9, D86.8, D86.82-D86.84, 
D86.86-D86.87, D89-D89.9, E03-E03.1, 
E03.3-E06.3, E06.5-E07.9, E15-E16, E16.1-
E16.9, E20-E23.0, E23.2-E24.1, E24.3-
E27.2, E27.4-E28.1, E28.3-E32.9, E34-
E35.8, E65-E66.09, E66.2-E68, E70-
E80.09, E80.3-E88.9, E90-E998, Z83.4-
Z83.49
D66-D69.49, D69.6-D70.0, D70.2-D77, 
D80-D84.9, D86.8, D86.82-D86.84, 
D86.86-D86.87, D89-D89.9, E03-E03.1, 
E03.3-E06.3, E06.5-E07.9, E15-E16, E16.1-
E23.0, E23.2-E24.1, E24.3-E27.2, E27.4-
E28.1, E28.3-E35.8, E67-E80.09, E80.3-
E88.9, E90-E998
240-244, 244.8-246.9, 251-256.39, 256.8-
259.9, 270-272.9, 275-278.02, 278.1-
279.9, 286-289.9, 775.3, V12.2-V12.49, 
V18.1-V18.19, V45.86, V77.0, V77.3-
V77.8, V77.91, V85-V85.45, V85.51, 
V85.53-V85.54
240-244, 244.8-246.9, 251-256.39, 256.8-
259.9, 270-271.9, 275-279.9, 285-289.9, 
775.3
Rheumatoid arthritis M05-M06.9 M05-M06.9 714-714.9 714-714.9
Osteoarthritis M16-M17.9 M16-M17.9 715-715.9 715-715.9
Low back and neck pain
G54.2-G54.4, M47-M49, M49.2-M51.9, 
M53-M54.9, M99.0-M99.04, M99.1-
M99.14, M99.2-M99.24, M99.3-M99.34, 
M99.4-M99.44, M99.5-M99.54, M99.6-
M99.64, M99.7-M99.74, M99.8-M99.84
353.1-353.4, 721-724.9
795
Cause ICD10 ICD10 Used in Hospital/Claims Analyses ICD9 ICD9 Used in Hospital/Claims Analyses
Appendix Table 4: ICD-9 and ICD-10 codes by GBD 2016 nonfatal causes, impairments, and nature of injury categories
Low back pain
G54.4, M47.015-M47.019, M47.15-
M47.18, M47.25-M47.28, M47.815-
M47.818, M47.896-M47.899, M48.05-
M48.08, M48.16-M48.19, M48.25-
M48.27, M48.35-M48.38, M48.45-
M48.48, M48.55-M48.58, M49.85-
M49.88, M51.05-M51.07, M51.15-
M51.17, M51.25-M51.27, M51.35-
M51.37, M51.45-M51.47, M51.85-
M51.87, M53.3, M53.85-M53.88, M54.05-
M54.09, M54.15-M54.18, M54.3-M54.5, 
M99.03-M99.04, M99.13-M99.14, M99.23-
M99.24, M99.33-M99.34, M99.43-
M99.44, M99.53-M99.54, M99.63-
M99.64, M99.73-M99.74, M99.83-M99.84
G54.4, M47.015-M47.019, M47.15-
M47.18, M47.25-M47.28, M47.815-
M47.818, M47.896-M47.899, M48.05-
M48.08, M48.16-M48.19, M48.25-
M48.27, M48.35-M48.38, M48.45-
M48.48, M48.55-M48.58, M49.85-
M49.88, M51.05-M51.87, M53.3, M53.85-
M53.88, M54.05-M54.09, M54.15-
M54.18, M54.3-M54.5, M99.03-M99.04, 
M99.13-M99.14, M99.23-M99.24, M99.33-
M99.34, M99.43-M99.44, M99.53-
M99.54, M99.63-M99.64, M99.73-
M99.74, M99.83-M99.84
353.1, 353.4, 721.3, 721.42, 722.10, 
722.32, 722.52, 722.73, 722.83, 722.93, 
724.02-724.03, 724.2-724.3, 724.6-724.79
353.1, 353.4, 721.3-721.42, 722.10-722.52, 
722.73, 722.83, 722.93-724.79
Neck pain
G54.2, M47.011-M47.013, M47.11-
M47.13, M47.21-M47.23, M47.811-
M47.813, M47.892-M47.894, M48.01-
M48.03, M48.12-M48.14, M48.21-
M48.23, M48.31-M48.33, M48.41-
M48.43, M48.51-M48.53, M49.81-
M49.83, M50-M50.93, M53.0-M53.1, 
M53.81-M53.83, M54.01-M54.03, M54.11-
M54.13, M54.2, M54.81, M99.01, M99.11, 
M99.21, M99.31, M99.41, M99.51, 
M99.61, M99.71, M99.81
G54.2, M47.011-M47.013, M47.11-
M47.13, M47.21-M47.23, M47.811-
M47.813, M47.892-M47.894, M48.01-
M48.03, M48.12-M48.14, M48.21-
M48.23, M48.31-M48.33, M48.41-
M48.43, M48.51-M48.53, M49.81-
M49.83, M50-M50.93, M53.0-M53.1, 
M53.81-M53.83, M54.01-M54.03, M54.11-
M54.13, M54.2, M99.01, M99.11, M99.21, 
M99.31, M99.41, M99.51, M99.61, 
M99.71, M99.81
353.2, 721.0-721.1, 722.0, 722.71, 722.81, 
722.91, 723-723.9
353.2, 721.0-721.1, 722.0, 722.71, 722.81, 
722.91
Gout M10-M10.19, M10.3-M10.9 M10-M10.19, M10.3-M10.9 274-274.9, 712.0-712.09 274-274.9, 712.0-712.09
Other musculoskeletal disorders
I27.1, L93-L93.2, M00-M03.6, M07-
M09.8, M11-M15.9, M18-M25.9, M30-
M32.9, M34-M36.8, M40-M43.9, M45-
M46.99, M61-M63.89, M65-M68.8, M70-
M72.4, M72.8-M73, M75-M77.9, M79-
M79.676, M79.8-M87.09, M87.2-M89.59, 
M89.7-M95.9, M99, M99.05-M99.09, 
M99.15-M99.19, M99.25-M99.29, M99.35-
M99.39, M99.45-M99.49, M99.55-
M99.59, M99.65-M99.69, M99.75-
M99.79, M99.85-M99.9
I27.1-I27.1, L93-L93.2, M00-M03.6, M07-
M09.8, M11-M15.9, M18-M25.9, M30-
M46.99, M61-M72.4, M72.8-M87.09, 
M87.2-M95.9, M99, M99.05-M99.09, 
M99.15-M99.19, M99.25-M99.29, M99.35-
M99.39, M99.45-M99.49, M99.55-
M99.59, M99.65-M99.69, M99.75-
M99.79, M99.85-M99.9
416.1, 446-446.9, 710-710.2, 710.5-712, 
712.1-713.8, 715-720.9, 726-727.9, 729-
730.39, 730.7-739.9
416.1-416.1, 446-446.9, 710-712, 712.1-
713.8, 715-720.9, 726-730.39, 730.7-739.9
Congenital birth defects
P96.0, Q00-Q07.9, Q10-Q18.9, Q20-
Q28.9, Q30-Q45.9, Q50-Q61.9, Q63-
Q64.19, Q65-Q87.89, Q89-Q89.8, Q90-
Q93.9, Q95-Q99.9, Z13.7-Z13.79, Z14-
Z15.89, Z82.7-Z82.79, Z87.7-Z87.798
237.7-237.79, 740-753.19, 753.3, 753.5, 
754.3-759.9, V13.6-V13.69, V18.61, 
V18.9, V19.5-V19.8, V82.3
Neural tube defects Q00-Q01.9, Q05-Q05.9, Q07.01, Q07.03 Q00-Q07.03 740-741.93, 742.0 740-742.0
Congenital heart anomalies Q20-Q27, Q27.1-Q28.9 Q20-Q28.9 745-747.9 745-747.9
Orofacial clefts Q35-Q37.9 Q35-Q37.9 749-749.9 749-749.9
Down syndrome Q90-Q90.9 Q90-Q90.9 758.0 758.0
Turner syndrome Q96-Q96.9 Q96-Q96.9 758.6 758.6
Klinefelter syndrome Q98-Q98.9 Q98-Q98.9 758.7 758.7
Other chromosomal abnormalities Q91-Q93.9, Q95, Q95.2-Q95.9, Q97-Q97.9, Q99-Q99.9 Q91-Q95.9, Q97-Q97.9, Q99-Q99.9
758, 758.1-758.2, 758.4-758.5, 758.8-
758.9 758, 758.1-758.5, 758.8-759.89
Congenital musculoskeletal and limb anomalies
Q65-Q65.2, Q65.8-Q66.1, Q68, Q68.1-
Q68.2, Q68.6-Q74, Q74.1-Q75.1, Q75.4-
Q76, Q76.1-Q76.49, Q76.8-Q79, Q79.6-
Q79.9, Q87-Q87.89
Q65-Q79, Q79.6-Q87.89 754.3-756.0, 758.3-758.39, 759.7-759.89 754-756.59, 756.8-756.9
Urogenital congenital anomalies
P96.0, Q50-Q52.2, Q52.4, Q52.6-Q52.9, 
Q54-Q55.2, Q55.22-Q61.9, Q63-Q63.2, 
Q63.8-Q64.19
Q50-Q61.9, Q63-Q64.19 752.0-752.9, 753.0-753.19, 753.3, 753.5 752.0-753.9
Digestive congenital anomalies Q38-Q38.0, Q38.3-Q38.4, Q38.6-Q43, Q43.1-Q45.8, Q79.0-Q79.59 Q38-Q45.8, Q79.0-Q79.59 750-751, 751.1-751.9, 756.6-756.79 750-751.9, 756.6-756.79
Other congenital birth defects
Q02-Q04.9, Q06-Q07.00, Q07.02, Q07.8-
Q07.9, Q10-Q18.9, Q27.0, Q30-Q34.9, 
Q38.1-Q38.2, Q38.5, Q43.0, Q45.9, Q52.3, 
Q52.5, Q53-Q53.9, Q55.20-Q55.21, 
Q63.3, Q65.3-Q65.6, Q66.2-Q67.8, Q68.0, 
Q68.3-Q68.5, Q74.0, Q75.2-Q75.3, Q76.0, 
Q76.5-Q76.7, Q80-Q86.8, Q89-Q89.8, 
Q95.0-Q95.1
237.7-237.79, 742, 742.1-744.9, 748-
748.9, 751.0, 752, 753, 756.2-756.3, 757-
757.9, 759-759.6, 759.9
Skin and subcutaneous diseases
A46-A46.0, A66-A67.3, A67.9, B07-B09, 
B35-B36.9, B85-B88.9, D86.3, E80.1-
E80.29, I89.1-I89.8, L00-L05.92, L08-
L08.9, L10-L14.0, L20-L23.2, L23.4-
L27.0, L27.2-L30.9, L40-L45, L49-L54.0, 
L56, L56.2-L57.9, L59-L60.9, L62-L64, 
L64.8-L68.9, L70-L75.9, L80-L92.9, L94-
L95.9, L97-L99.8, M72.5-M72.6, N49.2-
N49.3
035-035.9, 040.0, 078.0-078.19, 102-
103.9, 110-111.9, 132-134.9, 136.1, 457.2-
457.3, 680-709.3, 709.8-709.9, 728.86, 
785.4
Dermatitis L20-L23.2, L23.4-L27.0, L27.2-L27.9, L30-L30.9 L20-L23.2, L23.4-L25.9 690-692.7, 692.79-692.9 690-692.7, 692.79-692.9
Psoriasis L40-L41.9 L40-L41.9 696-696.9 696-696.9
Cellulitis L03-L03.91, M72.5-M72.6 L03-L03.91, M72.5-M72.6 681-682.9, 728.86
Pyoderma
A46-A46.0, A66-A67.3, A67.9, I89.1-
I89.8, L00-L02.93, L04-L05.92, L08-
L08.9, L88, L97-L98.499, N49.2-N49.3
A46-A46.0, A66-A67.9, I89.1-I89.8, L00-
L02.93, L04-L08.9, L88, L97-L98.499, 
N49.2-N49.3
035-035.9, 040.0, 102-103.9, 457.2-457.3, 
680-680.9, 683-689, 785.4
035-035.9, 040.0, 102-103.9, 457.2-457.3, 
680-689, 785.4
Scabies B86 B86 133-133.6 133-133.6
Fungal skin diseases B35-B36.9 B35-B36.9 110-111.9 110-111.9
Viral skin diseases B07-B07.9, B08.1 B07-B07.9, B08.1 078.0-078.19 078.0-078.19
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Acne vulgaris L70-L70.9 L70-L70.9 706.0-706.1 706.0-706.1
Alopecia areata L63-L63.9 L63-L63.9 704.0-704.09 704.0-704.09
Pruritus L29-L29.9 L29-L29.9 698-699 698-699
Urticaria L50-L50.9 L50-L50.9 708-708.9 708-708.9
Decubitus ulcer L89-L89.95 L89-L89.95 707-707.09, 707.2-707.7 707-707.09, 707.2-707.7
Other skin and subcutaneous diseases
B08-B08.09, B08.2-B09, B85-B85.4, B87-
B88.9, D86.3, E80.1-E80.29, L10-L14.0, 
L28-L28.2, L42-L45, L49-L49.9, L51-
L54.0, L56, L56.2-L57.9, L59-L60.9, L62-
L62.8, L64, L64.8-L68.9, L71-L75.9, L80-
L87.9, L90-L92.9, L94-L95.9, L98.5-L99.8
B08-B08.09, B08.2-B09, B85-B85.4, B87-
B88.9, D86.3, E80.1-E80.29, L10-L14.0, 
L28-L28.2, L42-L49.9, L51-L54.0, L56, 
L56.2-L57.9, L59-L62.8, L64, L64.8-
L68.9, L71-L75.9, L80-L87.9, L90-L92.9, 
L94-L95.9, L98.5-L99.8
132-132.9, 133.8-134.9, 136.1, 692.70-
692.77, 693-695.9, 697-697.9, 700-704, 
704.1-706, 706.2-706.9, 707.1-707.19, 
707.8-707.9, 709-709.3, 709.8-709.9
132-132.9, 133.8-134.9, 136.1, 692.70-
692.77, 693-695.9, 697-697.9, 700-704, 
704.1-706, 706.2-706.9, 707.1-707.19, 
707.8-707.9, 709-709.3, 709.8-709.9
Sense organ diseases
B30-B30.9, H00-H02.8, H02.82-H02.9, 
H03.0-H06.3, H10-H11.9, H13-H13.8, H15-
H22.8, H25-H28.8, H30-H36.8, H40-
H40.9, H42-H44.539, H44.8-H55.89, H57-
H58.9, H60-H62.8, H71-H75.83, H80-
H83.93, H90-H91, H91.1-H94.83, R43-
R44.9, Z01.0-Z01.12, Z13.5, Z41.3, Z52.5, 
Z82.1-Z82.2, Z83.5-Z83.6, Z94.7, Z97.3-
Z97.4
077-077.99, 360-360.44, 360.8-374.85, 
374.87-376.52, 376.8-379.59, 379.8-380.9, 
384-389.9, V19.0-V19.3, V42.5, V43.0-
V43.1, V45.6-V45.69, V45.78, V48.4-
V48.5, V50.3, V58.71, V59.5, V74.4, V80-
V80.0, V80.09-V80.3
Glaucoma H40-H40.9, H42-H42.8 365-365.9
Cataract H25-H26.9, H28-H28.8 366-366.9
Macular degeneration H35.3-H35.389 362.5-362.57
Refraction and accommodation disorders H52-H52.7 367-367.9
Age-related and other hearing loss H71-H75.83, H80-H80.93, H83-H83.93, H90-H91, H91.1-H91.93, H94-H94.83
384-385.9, 387-387.9, 388.1-388.2, 389-
389.9
Other vision loss H27-H27.9, H31-H35.23, H35.4-H36.8, H46-H51.9, H53-H54.9
360.8-362.43, 362.6-363.9, 368-369.9, 377-
378.9
Other sense organ diseases
B30-B30.9, H00-H02.8, H02.82-H02.9, 
H03.0-H06.3, H10-H11.9, H13-H13.8, H15-
H22.8, H30-H30.93, H43-H44.539, H44.8-
H45.8, H55-H55.89, H57-H58.9, H60-
H62.8, H81-H82.9, H92-H93.93, R43-
R44.9
B30-B30.9, H00-H02.8, H02.82-H22.8, 
H30-H30.93, H43-H44.539, H44.8-H45.8, 
H55-H58.9, H60-H62.8, H81-H82.9, H92-
H93.93
077-077.99, 360-360.44, 364-364.9, 370-
374.85, 374.87-376.52, 376.8-376.9, 379-
379.59, 379.8-380.9, 386-386.9, 388-
388.02, 388.3-388.9
380-380.9, 386-388.02, 388.3-388.9
Oral disorders K00-K08.499, K08.8-K14.9, M26-M27.9 520-525.54, 525.8-526.61, 526.69-529.9
Caries of deciduous teeth
Caries of permanent teeth K02-K02.9 521.0-521.09
Periodontal diseases K05-K06.9 523-523.9
Edentulism and severe tooth loss K08.0-K08.499 525.0-525.19, 525.4-525.54
Other oral disorders K00-K01.1, K03-K04.99, K07-K08, K08.8-K14.9, M26-M27.9
520-521, 521.1-522.9, 524-525, 525.2-
525.3, 525.8-526.61, 526.69-529.9
Road injuries V01-V04.99, V06-V80.929, V82-V82.9, V87.2-V87.3
V01-V04.99, V06-V80.929, V82-V82.9, 
V87.2-V87.3
E800.3, E801.3, E802.3, E803.3, E804.3, 
E805.3, E806.3, E807.3-E810.6, E811.0-
E820.6, E821.0-E821.6, E822.0-E826.1, 
E826.3-E827.0, E827.3-E828.0, E828.4-
E829.4
E800.3, E801.3, E802.3, E803.3, E804.3, 
E805.3, E806.3, E807.3-E810.6, E811.0-
E820.6, E821.0-E821.6, E822.0-E826.1, 
E826.3-E827.0, E827.3-E828.0, E828.4-
E829.4
Pedestrian road injuries V01-V04.99, V06-V09.9 V01-V04.99, V06-V09.9
E811.7, E812.7, E813.7, E814.7, E815.7, 
E816.7, E817.7, E818.7, E819.7, E822.7, 
E823.7, E824.7, E825.7-E826.0, E827.0, 
E828.0, E829.0
E811.7, E812.7, E813.7, E814.7, E815.7, 
E816.7, E817.7, E818.7, E819.7, E822.7, 
E823.7, E824.7, E825.7-E826.0, E827.0, 
E828.0, E829.0
Cyclist road injuries V10-V19.9 V10-V19.9
E800.3, E801.3, E802.3, E803.3, E804.3, 
E805.3, E806.3, E807.3, E810.6, E811.6, 
E812.6, E813.6, E814.6, E815.6, E816.6, 
E817.6, E818.6, E819.6, E820.6, E821.6, 
E822.6, E823.6, E824.6, E825.6, E826.1
E800.3, E801.3, E802.3, E803.3, E804.3, 
E805.3, E806.3, E807.3, E810.6, E811.6, 
E812.6, E813.6, E814.6, E815.6, E816.6, 
E817.6, E818.6, E819.6, E820.6, E821.6, 
E822.6, E823.6, E824.6, E825.6, E826.1
Motorcyclist road injuries V20-V29.9 V20-V29.9
E810.2-E810.3, E811.2-E811.3, E812.2-
E812.3, E813.2-E813.3, E814.2-E814.3, 
E815.2-E815.3, E816.2-E816.3, E817.2-
E817.3, E818.2-E818.3, E819.2-E819.3, 
E820.2-E820.3, E821.2-E821.3, E822.2-
E822.3, E823.2-E823.3, E824.2-E824.3, 
E825.2-E825.3
E810.2-E810.3, E811.2-E811.3, E812.2-
E812.3, E813.2-E813.3, E814.2-E814.3, 
E815.2-E815.3, E816.2-E816.3, E817.2-
E817.3, E818.2-E818.3, E819.2-E819.3, 
E820.2-E820.3, E821.2-E821.3, E822.2-
E822.3, E823.2-E823.3, E824.2-E824.3, 
E825.2-E825.3
Motor vehicle road injuries V30-V79.9, V87.2-V87.3 V30-V79.9, V87.2-V87.3
E810.0-E810.1, E811.0-E811.1, E812.0-
E812.1, E813.0-E813.1, E814.0-E814.1, 
E815.0-E815.1, E816.0-E816.1, E817.0-
E817.1, E818.0-E818.1, E819.0-E819.1, 
E820.0-E820.1, E821.0-E821.1, E822.0-
E822.1, E823.0-E823.1, E824.0-E824.1, 
E825.0-E825.1
E810.0-E810.1, E811.0-E811.1, E812.0-
E812.1, E813.0-E813.1, E814.0-E814.1, 
E815.0-E815.1, E816.0-E816.1, E817.0-
E817.1, E818.0-E818.1, E819.0-E819.1, 
E820.0-E820.1, E821.0-E821.1, E822.0-
E822.1, E823.0-E823.1, E824.0-E824.1, 
E825.0-E825.1
Other road injuries V80-V80.929, V82-V82.9 V80-V80.929, V82-V82.9
E810.4-E810.5, E811.4-E811.5, E812.4-
E812.5, E813.4-E813.5, E814.4-E814.5, 
E815.4-E815.5, E816.4-E816.5, E817.4-
E817.5, E818.4-E818.5, E819.4-E819.5, 
E820.4-E820.5, E821.4-E821.5, E822.4-
E822.5, E823.4-E823.5, E824.4-E824.5, 
E825.4-E825.5, E826.3-E826.4, E827.3-
E827.4, E828.4, E829.4
E810.4-E810.5, E811.4-E811.5, E812.4-
E812.5, E813.4-E813.5, E814.4-E814.5, 
E815.4-E815.5, E816.4-E816.5, E817.4-
E817.5, E818.4-E818.5, E819.4-E819.5, 
E820.4-E820.5, E821.4-E821.5, E822.4-
E822.5, E823.4-E823.5, E824.4-E824.5, 
E825.4-E825.5, E826.3-E826.4, E827.3-
E827.4, E828.4, E829.4
Other transport injuries V00-V00.898, V05-V05.99, V81-V81.9, V83-V86.99, V88.2-V98.8
V00-V00.898, V05-V05.99, V81-V81.9, 
V83-V86.99, V88.2-V98.8
E800-E800.2, E801-E801.2, E802-E802.2, 
E803-E803.2, E804-E804.2, E805-E805.2, 
E806-E806.2, E807-E807.2, E810.7, 
E820.7, E821.7, E826.2, E827.2, E828.2, 
E830-E849.9, E929.1
E800-E800.2, E801-E801.2, E802-E802.2, 
E803-E803.2, E804-E804.2, E805-E805.2, 
E806-E806.2, E807-E807.2, E810.7, 
E820.7, E821.7, E826.2, E827.2, E828.2, 
E830-E849.9, E929.1
Falls W00-W19.9 W00-W19.9 E880-E888.9, E929.3 E880-E888.9, E929.3
Drowning W65-W70.9, W73-W74.9 W65-W74.9 E910-E910.99 E910-E910.99
Fire, heat, and hot substances X00-X06.9, X08-X19.9 X00-X19.9 E890-E899.09, E924-E924.99, E929.4 E890-E899.09, E924-E924.99, E929.4
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Poisonings X48-X48.9 X48-X48.9 E863-E863.99 E850.3-E869.99, E929.2
Exposure to mechanical forces W20-W38.9, W40-W43.9, W45.0-W45.2, W46-W46.2, W49-W52, W75-W76.9
W20-W38.9, W40-W43.9, W45.0-W45.2, 
W46-W52, W75-W76.9
E913-E913.19, E916-E922.99, E928.1-
E928.7
E913-E913.19, E916-E922.99, E928.1-
E928.7
Unintentional firearm injuries W32-W34.9 W32-W34.9 E922-E922.99, E928.7 E922-E922.99, E928.7
Unintentional suffocation W75-W76.9 W75-W76.9 E913-E913.19 E913-E913.19
Other exposure to mechanical forces W20-W31.9, W35-W38.9, W40-W43.9, W45.0-W45.2, W46-W46.2, W49-W52
W20-W31.9, W35-W38.9, W40-W43.9, 
W45.0-W45.2, W46-W52 E916-E921.99, E928.1-E928.6 E916-E921.99, E928.1-E928.6
Adverse effects of medical treatment
D69.5-D69.59, D70.1, D78-D78.89, E03.2, 
E06.4, E09-E09.9, E16.0, E23.1, E24.2, 
E27.3, E36-E36.8, E66.1, E89-E89.9, 
G21.1-G21.19, G24.0-G24.09, G25.1, 
G25.4, G25.6-G25.79, G62.0, G72.0, 
G93.7, G96.0, G96.11, G97-G97.9, H59-
H59.89, H91.0-H91.09, H95-H95.9, I95.2-
I95.81, I97-I97.9, J70-J70.5, J95-J95.9, 
K08.5-K08.59, K43-K43.9, K62.7, K68.11, 
K91-K91.9, K94-K95.89, L23.3, L27.1, 
L56.0-L56.1, L64.0, L76-L76.82, M10.2-
M10.29, M87.1-M87.19, M96-M96.9, N14-
N14.4, N46.021, N46.121, N52.2-N52.39, 
N65-N65.1, N99-N99.9, P93-P93.8, P96.2, 
X46-X47.9, Y40-Y84.9, Y88-Y88.3, 
Z21.0, Z42-Z43.0, Z43.8-Z43.9, Z48-
Z48.9, Z51-Z51.9, Z88-Z88.9, Z92-Z94.0, 
Z94.6, Z94.8-Z94.9, Z96-Z96.49, Z96.6-
Z97.2, Z97.8-Z99.12, Z99.3-Z99.9
D69.5-D69.59, D70.1, D78-D78.89, E03.2, 
E06.4, E09-E09.9, E16.0, E23.1, E24.2, 
E27.3, E36-E36.8, E66.1, E89-E89.9, 
G21.1-G25.79, G62.0-G97.9, H59-H59.89, 
H91.0-H91.09, H95-H95.9, I95.2-I97.9, 
J70-J70.5, J95-J95.9, K08.5-K08.59, K43-
K43.9, K62.7, K68.11, K91-K91.9, K94-
K95.89, L23.3, L27.1, L56.0-L56.1, L64.0, 
L76-L76.82, M10.2-M10.29, M87.1-
M87.19, M96-M96.9, N14-N14.4, 
N46.021, N46.121, N52.2-N52.39, N65-
N65.1, N99-N99.9, P93-P96.2, X46-X47.9, 
Y40-Y84.9, Y88-Y88.3, Z21.0, Z42-Z51.9, 
Z88-Z99.9
244.0-244.1, 244.3, 331.81, 333.92, 349-
349.9, 357.6, 359.24, 379.6-379.63, 440.3-
440.32, 457.0, 458.2-458.29, 518.6, 519.00-
519.1, 525.6-525.79, 526.62-526.63, 
530.87, 536.4-536.49, 539-539.9, 551.2-
551.29, 552.2-552.29, 553.2-553.29, 564.2-
564.4, 569.6-569.8, 596.81-596.83, 598.2, 
612-612.1, 780.66, 995.89, E862-E862.99, 
E867-E879.9, E930-E949.9, V44-V45, 
V45.2-V45.4, V45.7, V45.77, V45.79-
V45.8, V45.87-V45.89
244.0-244.1, 244.3, 331.81, 333.92, 349-
349.9, 357.6-359.24, 379.6-379.63, 440.3-
440.32, 457.0, 458.2-458.29, 518.6-519.1, 
525.6-525.79, 526.62-526.63, 530.87, 
536.4-539.9, 551.2-551.29, 552.2-552.29, 
553.2-553.29, 564.2-569.8, 596.81-596.83, 
598.2, 612-612.1, 780.66, 995.89, E870-
E879.9, E930-E949.9, V44-V45.89
Animal contact W52.0-W62.9, W64-W64.9, X20-X29.9 W52.0-W64.9, X20-X29.9 E905-E906.99 E905-E906.99
Venomous animal contact E905-E905.99
Non-venomous animal contact W52.0-W62.9, W64-W64.9, X20-X29.9 W52.0-W64.9, X20-X29.9 E905-E906.99 E906-E906.99
Foreign body
H02.81-H02.819, H44.6-H44.799, M60.2-
M60.28, W44-W45, W45.3-W45.9, W78-
W80.9, W83-W84.9
360.5-360.69, 374.86, 376.6, 709.4, 770.1-
770.18, E911-E912.09, E913.8-E915.09
Pulmonary aspiration and foreign body in airway W78-W80.9, W83-W84.9 W78-W80.9, W83-W84.9 770.1-770.18, E911-E912.09, E913.8-E913.99
770.1-770.18, E911-E912.09, E913.8-
E913.99
Foreign body in eyes H02.81-H02.819, H44.6-H44.799 H02.81-H02.819, H44.6-H44.799 360.5-360.69, 374.86, 376.6, E914-E914.09
360.5-360.69, 374.86, 376.6, E914-
E914.09
Foreign body in other body part M60.2-M60.28, W44-W45, W45.3-W45.9 M60.2-M60.28, W44-W45, W45.3-W45.9 709.4, E915-E915.09 709.4, E915-E915.09
Environmental heat and cold exposure
L55-L55.9, L58-L58.9, W88-W94.9, 
W97.9, W99-W99.9, X30-X32.9, X39-
X39.9
L55-L55.9, L58-L58.9, W88-W99.9, X30-
X32.9, X39-X39.9 E900-E902.99, E926-E926.99, E929.5 E900-E902.99, E926-E926.99, E929.5
Other unintentional injuries W39-W39.9, W77-W77.9, W81-W81.9, X50-X54.9, X57-X58.9
W39-W39.9, W77-W77.9, W81-W81.9, 
X50-X58.9
E903-E904.99, E913.2-E913.39, E923-
E923.99, E927-E928.09, E928.8-E928.89
E903-E904.99, E913.2-E913.39, E923-
E923.99, E927-E928.09, E928.8-E928.89
Self-harm X60-X64.9, X66-X84.9, Y87.0 X60-X64.9, X66-X84.9, Y87.0 E950-E959 E950-E959
Self-harm by firearm X72-X74.9 X72-X74.9 E955-E955.9 E955-E955.9
Self-harm by other specified means X60-X64.9, X66-X67.9, X69-X71.9, X75-X75.9, X77-X84.9, Y87.0
X60-X64.9, X66-X67.9, X69-X71.9, X75-
X75.9, X77-X84.9, Y87.0 E950-E954, E956-E958.0, E958.2-E959 E950-E954, E956-E958.0, E958.2-E959
Interpersonal violence X85-Y08.9, Y87.1-Y87.2 X85-Y08.9, Y87.1-Y87.2 E960-E969 E960-E969
Physical violence by firearm X93-X95.9 X93-X95.9 E965-E965.4 E965-E965.4
Physical violence by sharp object X99-X99.9 X99-X99.9 E966 E966
Sexual violence Y05-Y05.9 E960-E960.1
Physical violence by other means X85-X92.9, X96-X98.9, Y00-Y04.9, Y06-Y08.9, Y87.1-Y87.2
X85-X92.9, X96-X98.9, Y00-Y04.9, Y06-
Y08.9, Y87.1-Y87.2 E961-E964, E965.5-E965.9, E967-E969 E961-E964, E965.5-E965.9, E967-E969
Exposure to forces of nature X33-X38.9 E907-E909.9
Conflict and terrorism U00-U03, Y36-Y38.9, Y89.1 E979-E999.1
Executions and police conflict Y35-Y35.93, Y89.0 E970-E978
NOTE: This is a comprehensive mapping of ICD codes to GBD categories for nonfatal estimation.  Not all causes use hospital data. Detailed case definitions disease by disease are provided in the disease and injury specific write-ups. A 
small number of causes have no corresponding ICD codes.
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Drug-susceptible tuberculosis Tuberculosis, not HIV infected has a persistent cough and fever, is short of breath, feels weak, and has lost a lot of weight.
0.333
(0.224–0.454)
Multidrug-resistant tuberculosis without extensive drug resistance Tuberculosis, not HIV infected has a persistent cough and fever, is short of breath, feels weak, and has lost a lot of weight.
0.333
(0.224–0.454)
Extensively drug-resistant tuberculosis Tuberculosis, not HIV infected has a persistent cough and fever, is short of breath, feels weak, and has lost a lot of weight.
0.333
(0.224–0.454)
Latent tuberculosis infection Asymptomatic -- --
Drug-susceptible HIV/AIDS - Tuberculosis with severe anemia Tuberculosis, HIV infected and anemia, severe (combined DW) 0.495(0.353–0.64)
Drug-susceptible HIV/AIDS - Tuberculosis with moderate anemia Tuberculosis, HIV infected and anemia, moderate (combined DW) 0.439(0.307–0.577)
Drug-susceptible HIV/AIDS - Tuberculosis with mild anemia Tuberculosis, HIV infected and anemia, mild (combined DW) 0.411(0.278–0.551)
Drug-susceptible HIV/AIDS - Tuberculosis without anemia Tuberculosis, HIV infected has a persistent cough and fever, shortness of breath, night sweats, weakness and fatigue and severe weight loss.
0.408
(0.274–0.549)
Multidrug-resistant HIV/AIDS - Tuberculosis without extensive drug 
resistance with severe anemia Tuberculosis, HIV infected and anemia, severe (combined DW)
0.495
(0.353–0.64)
Multidrug-resistant HIV/AIDS - Tuberculosis without extensive drug 
resistance without anemia Tuberculosis, HIV infected
has a persistent cough and fever, shortness of breath, night 
sweats, weakness and fatigue and severe weight loss.
0.408
(0.274–0.549)
Multidrug-resistant HIV/AIDS - Tuberculosis without extensive drug 
resistance with moderate anemia Tuberculosis, HIV infected and anemia, moderate (combined DW)
0.439
(0.307–0.577)
Multidrug-resistant HIV/AIDS - Tuberculosis without extensive drug 
resistance with mild anemia Tuberculosis, HIV infected and anemia, mild (combined DW)
0.411
(0.278–0.551)
Extensively drug-resistant HIV/AIDS - Tuberculosis with mild 
anemia Tuberculosis, HIV infected and anemia, mild (combined DW)
0.411
(0.278–0.551)
Extensively drug-resistant HIV/AIDS - Tuberculosis with severe 
anemia Tuberculosis, HIV infected and anemia, severe (combined DW)
0.495
(0.353–0.64)
Extensively drug-resistant HIV/AIDS - Tuberculosis without anemia Tuberculosis, HIV infected has a persistent cough and fever, shortness of breath, night sweats, weakness and fatigue and severe weight loss.
0.408
(0.274–0.549)
Extensively drug-resistant HIV/AIDS - Tuberculosis with moderate 
anemia Tuberculosis, HIV infected and anemia, moderate (combined DW)
0.439
(0.307–0.577)
Early HIV with severe anemia Anemia, severe; Generic uncomplicated disease anxiety -- --
Symptomatic HIV without anemia HIV cases, symptomatic, pre-AIDS has weight loss, fatigue, and frequent infections. 0.274(0.184–0.377)
Early HIV with mild anemia Anemia, mild; Generic uncomplicated disease anxiety -- --
AIDS without antiretroviral treatment without anemia AIDS cases, not receiving ARV treatment has severe weight loss, weakness, fatigue, cough and fever, and frequent infections, skin rashes and diarrhea. 
0.582
(0.406–0.743)
AIDS with antiretroviral treatment without anemia HIV/AIDS cases, receiving ARV treatment has occasional fevers and infections. The person takes daily medication that sometimes causes diarrhea.
0.078
(0.052–0.111)
Early HIV with moderate anemia Anemia, moderate; Generic uncomplicated disease anxiety -- --
Early HIV without anemia Generic uncomplicated disease: anxiety about diagnosis
has a disease diagnosis that causes some worry but minimal 
interference with daily activities.
0.012
(0.006–0.023)
Symptomatic HIV with moderate anemia HIV cases, symptomatic, pre-AIDS and anemia, moderate (combined DW)
0.312
(0.217–0.418)
Symptomatic HIV with severe anemia HIV cases, symptomatic, pre-AIDS and anemia, severe (combined DW)
0.381
(0.269–0.505)
AIDS with antiretroviral treatment with mild anemia HIV/AIDS cases, receiving ARV treatment and anemia, mild (combined DW)
0.081
(0.054–0.116)
AIDS with antiretroviral treatment with moderate anemia HIV/AIDS cases, receiving ARV treatment and anemia, moderate (combined DW)
0.125
(0.085–0.176)
AIDS with antiretroviral treatment with severe anemia HIV/AIDS cases, receiving ARV treatment and anemia, severe (combined DW)
0.215
(0.148–0.295)
AIDS without antiretroviral treatment with mild anemia AIDS cases, not receiving ARV treatment and anemia, mild (combined DW)
0.583
(0.409–0.743)
AIDS without antiretroviral treatment with moderate anemia AIDS cases, not receiving ARV treatment and anemia, moderate (combined DW)
0.603
(0.43–0.758)
AIDS without antiretroviral treatment with severe anemia AIDS cases, not receiving ARV treatment and anemia, severe (combined DW)
0.642
(0.47–0.792)
Symptomatic HIV with mild anemia HIV cases, symptomatic, pre-AIDS and anemia, mild (combined DW)
0.277
(0.189–0.379)
Mild diarrheal diseases Diarrhea, mild has diarrhea three or more times a day with occasional discomfort in the belly.
0.074
(0.049–0.104)
Guillain-Barré syndrome due to diarrheal diseases Spinal cord lesion below neck level (treated)
is paralyzed from the waist down, cannot feel or move the 
legs and has difficulties with urine and bowel control. The 
person uses a wheelchair to move around.
0.296
(0.198–0.414)
Severe diarrheal diseases Diarrhea, severe
has diarrhea three or more times a day with severe belly 
cramps. The person is very thirsty and feels nauseous and 
tired. 
0.247
(0.164–0.348)
Moderate diarrheal diseases Diarrhea, moderate has diarrhea three or more times a day, with painful cramps in the belly and feeling thirsty
0.188
(0.125–0.264)
Intestinal perforation due to typhoid Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Severe typhoid fever Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Gastrointestinal bleeding due to typhoid Gastric bleeding vomits blood and feels nauseous. 0.325(0.209–0.462)
Appendix Table 5. GBD 2016 sequelae, health states, health state lay descriptions, and disability weights
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Acute typhoid infection Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Acute paratyphoid infection Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Moderate paratyphoid fever Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Intestinal perforation due to paratyphoid Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Severe paratyphoid fever Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Other intestinal infectious diseases Post-COMO calculation for residuals (YLL/YLD ratio, other methods) -- --
Guillain-Barré syndrome due to lower respiratory infections Spinal cord lesion below neck level (treated)
is paralyzed from the waist down, cannot feel or move the 
legs and has difficulties with urine and bowel control. The 
person uses a wheelchair to move around.
0.296
(0.198–0.414)
Severe lower respiratory infections Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Moderate lower respiratory infections Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Mild upper respiratory infections Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Moderate upper respiratory infections Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Guillain-Barré syndrome due to upper respiratory infections Spinal cord lesion below neck level (treated)
is paralyzed from the waist down, cannot feel or move the 
legs and has difficulties with urine and bowel control. The 
person uses a wheelchair to move around.
0.296
(0.198–0.414)
Vertigo with moderate hearing loss and ringing due to chronic otitis 
media Vertigo with moderate hearing loss and ringing -- --
Vertigo with moderate hearing loss due to chronic otitis media Vertigo with moderate hearing loss -- --
Severe infectious complications due to chronic otitis media Ear pain has an ear-ache that causes some difficulty with daily activities.
0.013
(0.007–0.024)
Acute otitis media Ear pain has an ear-ache that causes some difficulty with daily activities.
0.013
(0.007–0.024)
Vertigo with mild hearing loss and ringing due to chronic otitis 
media Vertigo with mild hearing loss and ringing -- --
Vertigo with mild hearing loss due to chronic otitis media Vertigo with mild hearing loss -- --
Moderate hearing loss due to chronic otitis media Hearing loss, moderate
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone.
0.027
(0.015–0.042)
Mild hearing loss due to chronic otitis media Hearing loss, mild has great difficulty hearing and understanding another person talking in a noisy place (for example, on an urban street).
0.01
(0.004–0.019)
Moderate hearing loss with ringing due to chronic otitis media Hearing loss, moderate, with ringing
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone, and has annoying ringing in the ears for 
more than 5 minutes at a time, almost everyday.
0.074
(0.049–0.107)
Mild hearing loss with ringing due to chronic otitis media Hearing loss, mild, with ringing
has great difficulty hearing and understanding another person 
talking in a noisy place (for example, on an urban street), and 
sometimes has annoying ringing in the ears.
0.021
(0.012–0.036)
Epilepsy due to pneumococcal meningitis Epilepsy (combined DW) --
Profound hearing loss due to pneumococcal meningitis Hearing loss, profound
is unable to hear and understand another person talking, even 
in a quiet place, is unable to take part in a phone 
conversation, and has great difficulty hearing anything in any 
other situation. Difficulties with communicating and relating 
to othersoften cause worry, depression, and loneliness.
0.204
(0.134–0.288)
Acute pneumococcal meningitis Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Severe hearing loss with ringing due to pneumococcal meningitis Hearing loss, severe, with ringing
is unable to hear and understand another person talking, even 
in a quiet place, and unable to take part in a phone 
conversation, and has annoying ringing in the ears for more 
than 5 minutes at a time, almost everyday. Difficulties with 
communicating and relating to others cause emotional impact 
at times (for example worry or depression).
0.261
(0.175–0.36)
Moderately severe hearing loss due to pneumococcal meningitis Hearing loss, moderately severe (custom DW from hearing loss impairment envelope) --
Borderline intellectual disability due to pneumococcal meningitis Borderline intellectual functioning
is slow in learning at school. As an adult, the person has 
some difficulty doing complex or unfamiliar tasks but 
otherwise functions independently.
0.011
(0.005–0.02)
Moderate hearing loss with ringing due to pneumococcal meningitis Hearing loss, moderate, with ringing
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone, and has annoying ringing in the ears for 
more than 5 minutes at a time, almost everyday.
0.074
(0.049–0.107)
Profound hearing loss with ringing due to pneumococcal meningitis Hearing loss, profound, with ringing
is unable to hear and understand another person talking, even 
in a quiet place, is unable to take part in a phone 
conversation, has great difficulty hearing anything in any 
other situation, and has annoying ringing in the ears for more 
than 5 minutes at a time, several times a day. Difficulties 
with communicating and relating to others often cause worry, 
depression  or loneliness
0.277
(0.182–0.387)
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Severe hearing loss due to pneumococcal meningitis Hearing loss, severe
is unable to hear and understand another person talking, even 
in a quiet place, and unable to take part in a phone 
conversation. Difficulties with communicating and relating 
to others cause emotional impact at times (for example worry 
or depression).
0.158
(0.105–0.227)
Mild behavioral problems due to pneumococcal meningitis Attention deficit hyperactivity disorder is hyperactive and has difficulty concentrating, remembering things, and completing tasks. 
0.045
(0.028–0.066)
Severe motor plus cognitive impairments due to pneumococcal 
meningitis Motor plus cognitive impairments, severe
cannot move around without help, and cannot lift or hold 
objects, get dressed or sit upright. The person also has very 
low intelligence, speaks few words, and needs constant 
supervision and help with all daily activities.
0.542
(0.374–0.702)
Mild motor impairment due to long term due to pneumococcal 
meningitis Motor impairment, mild
has some difficulty in moving around but is able to walk 
without help.
0.01
(0.005–0.019)
Monocular distance vision loss due to pneumococcal meningitis Distance vision, monocular is blind in one eye and has difficulty judging distances 0.017(0.009–0.029)
Severe vision impairment due to pneumococcol meningitis Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Moderately severe hearing loss with ringing due to pneumococcal 
meningitis Hearing loss, moderately severe, with ringing (custom DW from hearing loss impairment envelope) --
Moderate motor impairment due to pneumococcal meningitis Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Mild hearing loss with ringing due to pneumococcal meningitis Hearing loss, mild, with ringing
has great difficulty hearing and understanding another person 
talking in a noisy place (for example, on an urban street), and 
sometimes has annoying ringing in the ears.
0.021
(0.012–0.036)
Moderate motor plus cognitive impairments due to pneumococcal 
meningitis Motor plus cognitive impairments, moderate
has some difficulty in moving around, holding objects, 
dressing and sitting upright, but can walk without help. The 
person has low intelligence and is slow in learning to speak 
and to do simple tasks.
0.203
(0.134–0.29)
Mild intellectual disability due to pneumococcal meningitis Intellectual disability / mental retardation, mild
has low intelligence and is slow in learning at school. As an 
adult, the person can live independently, but often needs help 
to raise children and can only work at simple supervised jobs.
0.043
(0.026–0.064)
Complete hearing loss with ringing due to pneumococcal meningitis Hearing loss, complete, with ringing
cannot hear at all in any situation, including even the loudest 
sounds, and cannot communicate verbally or use a phone, 
and has very annoying ringing in the ears for more than half 
of the day. Difficulties with communicating and relating to 
others often cause worry, depression or loneliness.
0.316
(0.212–0.435)
Mild motor plus cognitive impairments due to pneumococcal 
meningitis Motor plus cognitive impairments, mild
has some difficulty in moving around but is able to walk 
without help. The person is slow in learning at school. As an 
adult, the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions independently.
0.031
(0.018–0.05)
Moderate hearing loss due to pneumococcal meningitis Hearing loss, moderate
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone.
0.027
(0.015–0.042)
Moderate vision impairment due to pneumococcol meningitis Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Mild hearing loss due to pneumococcal meningitis Hearing loss, mild has great difficulty hearing and understanding another person talking in a noisy place (for example, on an urban street).
0.01
(0.004–0.019)
Severe motor impairment due to pneumococcal meningitis Motor impairment, severe is unable to move around without help, and is not able to lift or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Blindness due to pneumococcal meningitis Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Complete hearing loss due to pneumococcal meningitis Hearing loss, complete
cannot hear at all in any situation, including even the loudest 
sounds, and cannot communicate verbally or use a phone. 
Difficulties with communicating and relating to others often 
cause worry, depression or loneliness.
0.215
(0.144–0.307)
Monocular distance vision loss due to H influenzae type B 
meningitis Distance vision, monocular is blind in one eye and has difficulty judging distances
0.017
(0.009–0.029)
Profound hearing loss due to H influenzae type B meningitis Hearing loss, profound
is unable to hear and understand another person talking, even 
in a quiet place, is unable to take part in a phone 
conversation, and has great difficulty hearing anything in any 
other situation. Difficulties with communicating and relating 
to othersoften cause worry, depression, and loneliness.
0.204
(0.134–0.288)
Complete hearing loss due to H influenzae type B meningitis Hearing loss, complete
cannot hear at all in any situation, including even the loudest 
sounds, and cannot communicate verbally or use a phone. 
Difficulties with communicating and relating to others often 
cause worry, depression or loneliness.
0.215
(0.144–0.307)
Blindness due to H influenzae type B meningitis Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Complete hearing loss with ringing due to H influenzae type B 
meningitis Hearing loss, complete, with ringing
cannot hear at all in any situation, including even the loudest 
sounds, and cannot communicate verbally or use a phone, 
and has very annoying ringing in the ears for more than half 
of the day. Difficulties with communicating and relating to 
others often cause worry, depression or loneliness.
0.316
(0.212–0.435)
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Severe hearing loss with ringing due to H influenzae type B 
meningitis Hearing loss, severe, with ringing
is unable to hear and understand another person talking, even 
in a quiet place, and unable to take part in a phone 
conversation, and has annoying ringing in the ears for more 
than 5 minutes at a time, almost everyday. Difficulties with 
communicating and relating to others cause emotional impact 
at times (for example worry or depression).
0.261
(0.175–0.36)
Profound hearing loss with ringing due to H influenzae type B 
meningitis Hearing loss, profound, with ringing
is unable to hear and understand another person talking, even 
in a quiet place, is unable to take part in a phone 
conversation, has great difficulty hearing anything in any 
other situation, and has annoying ringing in the ears for more 
than 5 minutes at a time, several times a day. Difficulties 
with communicating and relating to others often cause worry, 
depression  or loneliness
0.277
(0.182–0.387)
Severe vision impairment due to H influenza type B meningitis Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Moderate vision impairment due to H influenza type B meningitis Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Mild hearing loss with ringing due to H influenzae type B meningitis Hearing loss, mild, with ringing
has great difficulty hearing and understanding another person 
talking in a noisy place (for example, on an urban street), and 
sometimes has annoying ringing in the ears.
0.021
(0.012–0.036)
Moderate hearing loss with ringing due to H influenzae type B 
meningitis Hearing loss, moderate, with ringing
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone, and has annoying ringing in the ears for 
more than 5 minutes at a time, almost everyday.
0.074
(0.049–0.107)
Severe hearing loss due to H influenzae type B meningitis Hearing loss, severe
is unable to hear and understand another person talking, even 
in a quiet place, and unable to take part in a phone 
conversation. Difficulties with communicating and relating 
to others cause emotional impact at times (for example worry 
or depression).
0.158
(0.105–0.227)
Moderate motor plus cognitive impairments due to H influenzae type 
B meningitis Motor plus cognitive impairments, moderate
has some difficulty in moving around, holding objects, 
dressing and sitting upright, but can walk without help. The 
person has low intelligence and is slow in learning to speak 
and to do simple tasks.
0.203
(0.134–0.29)
Mild intellectual disability due to H influenzae type B meningitis Intellectual disability / mental retardation, mild
has low intelligence and is slow in learning at school. As an 
adult, the person can live independently, but often needs help 
to raise children and can only work at simple supervised jobs.
0.043
(0.026–0.064)
Mild motor plus cognitive impairments due to H influenzae type B 
meningitis Motor plus cognitive impairments, mild
has some difficulty in moving around but is able to walk 
without help. The person is slow in learning at school. As an 
adult, the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions independently.
0.031
(0.018–0.05)
Severe motor impairment due to H influenzae type B meningitis Motor impairment, severe is unable to move around without help, and is not able to lift or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Mild hearing loss due to H influenzae type B meningitis Hearing loss, mild has great difficulty hearing and understanding another person talking in a noisy place (for example, on an urban street).
0.01
(0.004–0.019)
Severe motor plus cognitive impairments due to H influenzae type B 
meningitis Motor plus cognitive impairments, severe
cannot move around without help, and cannot lift or hold 
objects, get dressed or sit upright. The person also has very 
low intelligence, speaks few words, and needs constant 
supervision and help with all daily activities.
0.542
(0.374–0.702)
Moderately severe hearing loss due to H influenzae type B 
meningitis Hearing loss, moderately severe (custom DW from hearing loss impairment envelope) --
Moderate hearing loss due to H influenzae type B meningitis Hearing loss, moderate
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone.
0.027
(0.015–0.042)
Mild behavioral problems due to H influenzae type B meningitis Attention deficit hyperactivity disorder is hyperactive and has difficulty concentrating, remembering things, and completing tasks. 
0.045
(0.028–0.066)
Acute H influenzae type B meningitis Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Mild motor impairment due to long term due to H influenzae type B 
meningitis Motor impairment, mild
has some difficulty in moving around but is able to walk 
without help.
0.01
(0.005–0.019)
Epilepsy due to H influenzae type B meningitis Epilepsy (combined DW) --
Moderately severe hearing loss with ringing due to H influenzae type 
B meningitis Hearing loss, moderately severe, with ringing (custom DW from hearing loss impairment envelope) --
Moderate motor impairment due to H influenzae type B meningitis Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Borderline intellectual disability due to H influenzae type B 
meningitis Borderline intellectual functioning
is slow in learning at school. As an adult, the person has 
some difficulty doing complex or unfamiliar tasks but 
otherwise functions independently.
0.011
(0.005–0.02)
Mild behavioral problems due to meningococcal meningitis Attention deficit hyperactivity disorder is hyperactive and has difficulty concentrating, remembering things, and completing tasks. 
0.045
(0.028–0.066)
Mild hearing loss with ringing due to meningococcal meningitis Hearing loss, mild, with ringing
has great difficulty hearing and understanding another person 
talking in a noisy place (for example, on an urban street), and 
sometimes has annoying ringing in the ears.
0.021
(0.012–0.036)
Complete hearing loss due to meningococcal meningitis Hearing loss, complete
cannot hear at all in any situation, including even the loudest 
sounds, and cannot communicate verbally or use a phone. 
Difficulties with communicating and relating to others often 
cause worry, depression or loneliness.
0.215
(0.144–0.307)
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Severe hearing loss due to meningococcal meningitis Hearing loss, severe
is unable to hear and understand another person talking, even 
in a quiet place, and unable to take part in a phone 
conversation. Difficulties with communicating and relating 
to others cause emotional impact at times (for example worry 
or depression).
0.158
(0.105–0.227)
Mild intellectual disability due to meningococcal meningitis Intellectual disability / mental retardation, mild
has low intelligence and is slow in learning at school. As an 
adult, the person can live independently, but often needs help 
to raise children and can only work at simple supervised jobs.
0.043
(0.026–0.064)
Mild hearing loss due to meningococcal meningitis Hearing loss, mild has great difficulty hearing and understanding another person talking in a noisy place (for example, on an urban street).
0.01
(0.004–0.019)
Moderate hearing loss due to meningococcal meningitis Hearing loss, moderate
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone.
0.027
(0.015–0.042)
Profound hearing loss due to meningococcal meningitis Hearing loss, profound
is unable to hear and understand another person talking, even 
in a quiet place, is unable to take part in a phone 
conversation, and has great difficulty hearing anything in any 
other situation. Difficulties with communicating and relating 
to othersoften cause worry, depression, and loneliness.
0.204
(0.134–0.288)
Borderline intellectual disability due to meningococcal meningitis Borderline intellectual functioning
is slow in learning at school. As an adult, the person has 
some difficulty doing complex or unfamiliar tasks but 
otherwise functions independently.
0.011
(0.005–0.02)
Moderately severe hearing loss due to meningococcal meningitis Hearing loss, moderately severe (custom DW from hearing loss impairment envelope) --
Moderate vision impairment due to meningococcal meningitis Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Blindness due to meningococcal meningitis Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Mild motor plus cognitive impairments due to meningococcal 
meningitis Motor plus cognitive impairments, mild
has some difficulty in moving around but is able to walk 
without help. The person is slow in learning at school. As an 
adult, the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions independently.
0.031
(0.018–0.05)
Epilepsy due to meningococcal meningitis Epilepsy (combined DW) --
Moderate motor impairment due to meningococcal meningitis Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Severe vision impairment due to meningococcal meningitis Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Severe motor impairment due to meningococcal meningitis Motor impairment, severe is unable to move around without help, and is not able to lift or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Moderate motor plus cognitive impairments due to meningococcal 
meningitis Motor plus cognitive impairments, moderate
has some difficulty in moving around, holding objects, 
dressing and sitting upright, but can walk without help. The 
person has low intelligence and is slow in learning to speak 
and to do simple tasks.
0.203
(0.134–0.29)
Moderate hearing loss with ringing due to meningococcal meningitis Hearing loss, moderate, with ringing
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone, and has annoying ringing in the ears for 
more than 5 minutes at a time, almost everyday.
0.074
(0.049–0.107)
Severe motor plus cognitive impairments due to meningococcal 
meningitis Motor plus cognitive impairments, severe
cannot move around without help, and cannot lift or hold 
objects, get dressed or sit upright. The person also has very 
low intelligence, speaks few words, and needs constant 
supervision and help with all daily activities.
0.542
(0.374–0.702)
Monocular distance vision loss due to meningococcal meningitis Distance vision, monocular is blind in one eye and has difficulty judging distances 0.017(0.009–0.029)
Profound hearing loss with ringing due to meningococcal meningitis Hearing loss, profound, with ringing
is unable to hear and understand another person talking, even 
in a quiet place, is unable to take part in a phone 
conversation, has great difficulty hearing anything in any 
other situation, and has annoying ringing in the ears for more 
than 5 minutes at a time, several times a day. Difficulties 
with communicating and relating to others often cause worry, 
depression  or loneliness
0.277
(0.182–0.387)
Mild motor impairment due to long term due to meningococcal 
meningitis Motor impairment, mild
has some difficulty in moving around but is able to walk 
without help.
0.01
(0.005–0.019)
Acute meningococcal meningitis Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Severe hearing loss with ringing due to meningococcal meningitis Hearing loss, severe, with ringing
is unable to hear and understand another person talking, even 
in a quiet place, and unable to take part in a phone 
conversation, and has annoying ringing in the ears for more 
than 5 minutes at a time, almost everyday. Difficulties with 
communicating and relating to others cause emotional impact 
at times (for example worry or depression).
0.261
(0.175–0.36)
Complete hearing loss with ringing due to meningococcal meningitis Hearing loss, complete, with ringing
cannot hear at all in any situation, including even the loudest 
sounds, and cannot communicate verbally or use a phone, 
and has very annoying ringing in the ears for more than half 
of the day. Difficulties with communicating and relating to 
others often cause worry, depression or loneliness.
0.316
(0.212–0.435)
Moderately severe hearing loss with ringing due to meningococcal 
meningitis Hearing loss, moderately severe, with ringing (custom DW from hearing loss impairment envelope) --
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Mild intellectual disability due to other bacterial meningitis Intellectual disability / mental retardation, mild
has low intelligence and is slow in learning at school. As an 
adult, the person can live independently, but often needs help 
to raise children and can only work at simple supervised jobs.
0.043
(0.026–0.064)
Moderate hearing loss with ringing due to other bacterial meningitis Hearing loss, moderate, with ringing
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone, and has annoying ringing in the ears for 
more than 5 minutes at a time, almost everyday.
0.074
(0.049–0.107)
Mild motor plus cognitive impairments due to other bacterial 
meningitis Motor plus cognitive impairments, mild
has some difficulty in moving around but is able to walk 
without help. The person is slow in learning at school. As an 
adult, the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions independently.
0.031
(0.018–0.05)
Borderline intellectual disability due to other bacterial meningitis Borderline intellectual functioning
is slow in learning at school. As an adult, the person has 
some difficulty doing complex or unfamiliar tasks but 
otherwise functions independently.
0.011
(0.005–0.02)
Moderate motor plus cognitive impairments due to other bacterial 
meningitis Motor plus cognitive impairments, moderate
has some difficulty in moving around, holding objects, 
dressing and sitting upright, but can walk without help. The 
person has low intelligence and is slow in learning to speak 
and to do simple tasks.
0.203
(0.134–0.29)
Mild behavioral problems due to other bacterial meningitis Attention deficit hyperactivity disorder is hyperactive and has difficulty concentrating, remembering things, and completing tasks. 
0.045
(0.028–0.066)
Severe motor plus cognitive impairments due to other bacterial 
meningitis Motor plus cognitive impairments, severe
cannot move around without help, and cannot lift or hold 
objects, get dressed or sit upright. The person also has very 
low intelligence, speaks few words, and needs constant 
supervision and help with all daily activities.
0.542
(0.374–0.702)
Severe motor impairment due to other bacterial meningitis Motor impairment, severe is unable to move around without help, and is not able to lift or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Moderately severe hearing loss due to other bacterial meningitis Hearing loss, moderately severe (custom DW from hearing loss impairment envelope) --
Monocular distance vision loss due to other bacterial meningitis Distance vision, monocular is blind in one eye and has difficulty judging distances 0.017(0.009–0.029)
Mild hearing loss due to other bacterial meningitis Hearing loss, mild has great difficulty hearing and understanding another person talking in a noisy place (for example, on an urban street).
0.01
(0.004–0.019)
Moderate hearing loss due to other bacterial meningitis Hearing loss, moderate
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone.
0.027
(0.015–0.042)
Epilepsy due to other meningitis Epilepsy (combined DW) --
Moderately severe hearing loss with ringing due to other bacterial 
meningitis Hearing loss, moderately severe, with ringing (custom DW from hearing loss impairment envelope) --
Severe hearing loss due to other bacterial meningitis Hearing loss, severe
is unable to hear and understand another person talking, even 
in a quiet place, and unable to take part in a phone 
conversation. Difficulties with communicating and relating 
to others cause emotional impact at times (for example worry 
or depression).
0.158
(0.105–0.227)
Blindness due to other bacterial meningitis Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Profound hearing loss due to other bacterial meningitis Hearing loss, profound
is unable to hear and understand another person talking, even 
in a quiet place, is unable to take part in a phone 
conversation, and has great difficulty hearing anything in any 
other situation. Difficulties with communicating and relating 
to othersoften cause worry, depression, and loneliness.
0.204
(0.134–0.288)
Moderate vision impairment due to other bacterial meningitis Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Complete hearing loss with ringing due to other bacterial meningitis Hearing loss, complete, with ringing
cannot hear at all in any situation, including even the loudest 
sounds, and cannot communicate verbally or use a phone, 
and has very annoying ringing in the ears for more than half 
of the day. Difficulties with communicating and relating to 
others often cause worry, depression or loneliness.
0.316
(0.212–0.435)
Complete hearing loss due to other bacterial meningitis Hearing loss, complete
cannot hear at all in any situation, including even the loudest 
sounds, and cannot communicate verbally or use a phone. 
Difficulties with communicating and relating to others often 
cause worry, depression or loneliness.
0.215
(0.144–0.307)
Profound hearing loss with ringing due to other bacterial meningitis Hearing loss, profound, with ringing
is unable to hear and understand another person talking, even 
in a quiet place, is unable to take part in a phone 
conversation, has great difficulty hearing anything in any 
other situation, and has annoying ringing in the ears for more 
than 5 minutes at a time, several times a day. Difficulties 
with communicating and relating to others often cause worry, 
depression  or loneliness
0.277
(0.182–0.387)
Severe hearing loss with ringing due to other bacterial meningitis Hearing loss, severe, with ringing
is unable to hear and understand another person talking, even 
in a quiet place, and unable to take part in a phone 
conversation, and has annoying ringing in the ears for more 
than 5 minutes at a time, almost everyday. Difficulties with 
communicating and relating to others cause emotional impact 
at times (for example worry or depression).
0.261
(0.175–0.36)
Mild hearing loss due with ringing to other bacterial meningitis Hearing loss, mild, with ringing
has great difficulty hearing and understanding another person 
talking in a noisy place (for example, on an urban street), and 
sometimes has annoying ringing in the ears.
0.021
(0.012–0.036)
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Moderate motor impairment due to other bacterial meningitis Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Severe vision impairment due to other bacterial meningitis Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Mild motor impairment due to long term due to other bacterial 
meningitis Motor impairment, mild
has some difficulty in moving around but is able to walk 
without help.
0.01
(0.005–0.019)
Other acute bacterial meningitis Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Acute viral meningitis Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Blindness due to encephalitis Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Epilepsy due to encephalitis Epilepsy (combined DW) --
Monocular distance vision loss due to encephalitis Distance vision, monocular is blind in one eye and has difficulty judging distances 0.017(0.009–0.029)
Severe motor plus cognitive impairments due to encephalitis Motor plus cognitive impairments, severe
cannot move around without help, and cannot lift or hold 
objects, get dressed or sit upright. The person also has very 
low intelligence, speaks few words, and needs constant 
supervision and help with all daily activities.
0.542
(0.374–0.702)
Moderate motor plus cognitive impairments due to encephalitis Motor plus cognitive impairments, moderate
has some difficulty in moving around, holding objects, 
dressing and sitting upright, but can walk without help. The 
person has low intelligence and is slow in learning to speak 
and to do simple tasks.
0.203
(0.134–0.29)
Mild motor plus cognitive impairments due to encephalitis Motor plus cognitive impairments, mild
has some difficulty in moving around but is able to walk 
without help. The person is slow in learning at school. As an 
adult, the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions independently.
0.031
(0.018–0.05)
Mild behavioral problems due to encephalitis Attention deficit hyperactivity disorder is hyperactive and has difficulty concentrating, remembering things, and completing tasks. 
0.045
(0.028–0.066)
Severe motor impairment due to encephalitis Motor impairment, severe is unable to move around without help, and is not able to lift or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Acute encephalitis Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Borderline intellectual disability due to encephalitis Borderline intellectual functioning
is slow in learning at school. As an adult, the person has 
some difficulty doing complex or unfamiliar tasks but 
otherwise functions independently.
0.011
(0.005–0.02)
Moderate motor impairment due to encephalitis Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Mild intellectual disability due to encephalitis Intellectual disability / mental retardation, mild
has low intelligence and is slow in learning at school. As an 
adult, the person can live independently, but often needs help 
to raise children and can only work at simple supervised jobs.
0.043
(0.026–0.064)
Mild motor impairment due to long term due to encephalitis Motor impairment, mild has some difficulty in moving around but is able to walk without help.
0.01
(0.005–0.019)
Moderate vision impairment due to encephalitis Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Severe vision impairment due to encephalitis Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Severe diphtheria Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Moderate diphtheria Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Whooping cough Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Severe motor plus cognitive impairment with blindness due to 
neonatal tetanus
Severe motor plus cognitive impairment with 
blindness (combined DW) --
Severe motor impairment with blindness and epilepsy due to 
neonatal tetanus
Severe motor impairment with blindness and 
epilepsy (combined DW) --
Severe motor impairment with epilepsy due to neonatal tetanus Severe motor impairment with epilepsy (combined DW) --
Severe motor impairment with blindness due to neonatal tetanus Severe motor impairment with blindness (combined DW) --
Moderate motor plus cognitive impairment with blindness and 
epilepsy due to neonatal tetanus
Moderate motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Moderate motor plus cognitive impairment with epilepsy due to 
neonatal tetanus
Moderate motor plus cognitive impairment with 
epilepsy (combined DW) --
Moderate motor impairment with epilepsy due to neonatal tetanus Moderate motor impairment with epilepsy (combined DW) --
Moderate motor impairment with blindness and epilepsy due to 
neonatal tetanus
Moderate motor impairment with blindness and 
epilepsy (combined DW) --
Severe motor impairment due to neonatal tetanus Motor impairment, severe is unable to move around without help, and is not able to lift or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Mild motor impairment due to neonatal tetanus Motor impairment, mild has some difficulty in moving around but is able to walk without help.
0.01
(0.005–0.019)
Moderate motor impairment due to neonatal tetanus Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
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Severe motor plus cognitive impairment with epilepsy due to 
neonatal tetanus
Severe motor plus cognitive impairment with 
epilepsy (combined DW) --
Severe tetanus Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Mild motor plus cognitive impairments due to neonatal tetanus Motor plus cognitive impairments, mild
has some difficulty in moving around but is able to walk 
without help. The person is slow in learning at school. As an 
adult, the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions independently.
0.031
(0.018–0.05)
Moderate motor plus cognitive impairment with blindness due to 
neonatal tetanus
Moderate motor plus cognitive impairment with 
blindness (combined DW) --
Severe motor plus cognitive impairment with blindness and epilepsy 
due to neonatal tetanus
Severe motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Moderate motor impairment with blindness due to neonatal tetanus Moderate motor impairment with blindness (combined DW) --
Moderate measles Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Severe measles Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Chickenpox Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Herpes zoster Herpes zoster has a blistering skin rash that causes pain, with some burning and itching.
0.058
(0.035–0.09)
Moderate motor impairment with epilepsy due to malaria Moderate motor impairment with epilepsy (combined DW) --
Moderate malaria with moderate anemia Infectious disease, acute episode, moderate, with moderate anemia (combined DW)
0.099
(0.065–0.142)
Moderate malaria with severe anemia Infectious disease, acute episode, moderate, with severe anemia (combined DW)
0.192
(0.133–0.263)
Moderate motor plus cognitive impairment with epilepsy due to 
malaria
Moderate motor plus cognitive impairment with 
epilepsy (combined DW) --
Severe malaria Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Severe motor plus cognitive impairment with blindness and epilepsy 
due to malaria
Severe motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Severe motor impairment due to malaria Motor impairment, severe is unable to move around without help, and is not able to lift or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Moderate motor impairment due to malaria Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Mild malaria Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Moderate malaria with mild anemia Infectious disease, acute episode, moderate, with mild anemia (combined DW)
0.054
(0.034–0.079)
Severe motor plus cognitive impairment with epilepsy due to malaria Severe motor plus cognitive impairment with epilepsy (combined DW) --
Moderate malaria Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Mild anemia due to malaria parasitemia (PfPR) Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Moderate anemia due to malaria parasitemia (PfPR) Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Severe motor plus cognitive impairment with blindness due to 
malaria
Severe motor plus cognitive impairment with 
blindness (combined DW) --
Severe motor impairment with blindness due to malaria Severe motor impairment with blindness (combined DW) --
Severe anemia due to malaria parasitemia (PfPR) Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Severe motor impairment with blindness and epilepsy due to malaria Severe motor impairment with blindness and epilepsy (combined DW) --
Moderate motor plus cognitive impairment with blindness and 
epilepsy due to malaria
Moderate motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Mild malaria with severe anemia Infectious disease, acute episode, mild, with severe anemia (combined DW)
0.154
(0.105–0.214)
Severe motor impairment with epilepsy due to malaria Severe motor impairment with epilepsy (combined DW) --
Severe malaria with severe anemia Infectious disease, acute episode, severe, with severe anemia (combined DW)
0.262
(0.184–0.359)
Severe malaria with moderate anemia Infectious disease, acute episode, severe, with moderate anemia (combined DW)
0.178
(0.122–0.247)
Moderate motor impairment with blindness and epilepsy due to 
malaria
Moderate motor impairment with blindness and 
epilepsy (combined DW) --
Moderate motor impairment with blindness due to malaria Moderate motor impairment with blindness (combined DW) --
Mild malaria with mild anemia Infectious disease, acute episode, mild, with mild anemia (combined DW)
0.009
(0.004–0.02)
Severe malaria with mild anemia Infectious disease, acute episode, severe, with mild anemia (combined DW)
0.137
(0.091–0.192)
Asymptomatic malaria parasitemia (PfPR) Asymptomatic -- --
Mild malaria with moderate anemia Infectious disease, acute episode, mild, with moderate anemia (combined DW)
0.057
(0.037–0.085)
Moderate motor plus cognitive impairment with blindness due to 
malaria
Moderate motor plus cognitive impairment with 
blindness (combined DW) --
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Moderate heart failure due to Chagas disease Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Atrial fibrillation and flutter due to Chagas disease Cardiac conduction disorders and cardiac dysrhythmias
has periods of rapid and irregular heartbeats and occasional 
fainting. 
0.224
(0.151–0.312)
Asymptomatic and mild heart failure due to Chagas disease Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Mild chronic digestive disease due to Chagas disease Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Acute Chagas disease Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Severe heart failure due to Chagas disease Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Asymptomatic Chagas disease Asymptomatic -- --
Moderate chronic digestive disease due to Chagas disease Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Moderate visceral leishmaniasis Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Severe visceral leishmaniasis Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Cutaneous and mucocutaneous leishmaniasis Disfigurement, level 2
has a visible physical deformity that causes others to stare 
and comment. As a result, the person is worried and has 
trouble sleeping and concentrating.
0.067
(0.044–0.096)
Sleeping sickness due to Trypanosoma brucei rhodesiense Disfigurement, level 1 with itch/pain
has a slight, visible physical deformity that is sometimes sore 
or itchy. Others notice the deformity, which causes some 
worry and discomfort.
0.027
(0.015–0.042)
Skin disfigurement due to Trypanosoma brucei gambiense Disfigurement, level 1 with itch/pain
has a slight, visible physical deformity that is sometimes sore 
or itchy. Others notice the deformity, which causes some 
worry and discomfort.
0.027
(0.015–0.042)
Skin disfigurement due to Trypanosoma brucei rhodesiense Motor plus cognitive impairments, severe
cannot move around without help, and cannot lift or hold 
objects, get dressed or sit upright. The person also has very 
low intelligence, speaks few words, and needs constant 
supervision and help with all daily activities.
0.542
(0.374–0.702)
Sleeping sickness due to Trypanosoma brucei gambiense Motor plus cognitive impairments, severe
cannot move around without help, and cannot lift or hold 
objects, get dressed or sit upright. The person also has very 
low intelligence, speaks few words, and needs constant 
supervision and help with all daily activities.
0.542
(0.374–0.702)
Mild diarrhea due to schistosomiasis Diarrhea, mild has diarrhea three or more times a day with occasional discomfort in the belly.
0.074
(0.049–0.104)
Severe anemia due to schistosomiasis Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Hematemesis due to schistosomiasis Gastric bleeding vomits blood and feels nauseous. 0.325(0.209–0.462)
Hepatomegaly due to schistosomiasis Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Moderate anemia due to schistosomiasis Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Mild anemia due to schistosomiasis Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Hydronephrosis due to schistosomiasis Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Ascites due to schistosomiasis Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Mild schistosomiasis Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Dysuria due to schistosomiasis Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Bladder pathology due to schistosomiasis Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Neurocysticercosis with epilepsy Epilepsy (combined DW) --
Abdominal problems due to cystic echinococcosis Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Epilepsy due to echinococcosis Epilepsy (combined DW) --
Chronic respiratory disease due to cystic echinococcosis COPD and other chronic respiratory problems, mild
has cough and shortness of breath after heavy physical 
activity, but is able to walk long distances and climb stairs.
0.019
(0.011–0.033)
Lymphedema due to lymphatic filariasis Lymphatic filariasis, symptomatic has swollen legs with hard and thick skin, which causes difficulty in moving around.
0.109
(0.073–0.154)
Hydrocele due to lymphatic filariasis Epididymo-orchitis has swelling and tenderness in the testicles and pain during urination. 
0.128
(0.086–0.18)
Acute adenolymphangitis due to lymphatic filariasis Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Prevalence of detectable microfiliaria due to lymphatic filariasis Asymptomatic -- --
Mild skin disease due to onchocerciasis Disfigurement, level 1 with itch/pain
has a slight, visible physical deformity that is sometimes sore 
or itchy. Others notice the deformity, which causes some 
worry and discomfort.
0.027
(0.015–0.042)
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Severe vision impairment due to onchocerciasis Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Moderate vision impairment due to onchocerciasis Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Asymptomatic onchocerciasis Asymptomatic -- --
Severe skin disease without itch due to onchocerciasis Disfigurement, level 3
has an obvious physical deformity that makes others 
uncomfortable, which causes the person to avoid social 
contact, feel worried, sleep poorly, and think about suicide.
0.405
(0.275–0.546)
Severe skin disease due to onchocerciasis Disfigurement, level 2, with itch/pain
has a visible physical deformity that is sore and itchy. Other 
people stare and comment, which causes the person to worry. 
The person has trouble sleeping and concentrating.
0.188
(0.125–0.267)
Blindness due to onchocerciasis Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Mild skin disease without itch due to onchocerciasis Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Moderate skin disease due to onchocerciasis Disfigurement, level 2, with itch/pain
has a visible physical deformity that is sore and itchy. Other 
people stare and comment, which causes the person to worry. 
The person has trouble sleeping and concentrating.
0.188
(0.125–0.267)
Blindness due to trachoma Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Severe vision impairment due to trachoma Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Moderate vision impairment due to trachoma Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Severe dengue Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Post-dengue chronic fatigue syndrome Infectious disease, post-acute consequences (fatigue, emotional lability, insomnia)
is always tired and easily upset. The person feels pain all over 
the body and is depressed.
0.219
(0.148–0.308)
Moderate dengue Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Asymptomatic yellow fever Asymptomatic -- --
Moderate yellow fever Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Severe yellow fever Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Rabies Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Severe wasting due to ascariasis Severe wasting is extremely skinny and has no energy. 0.128(0.082–0.183)
Asymptomatic ascariasis Asymptomatic -- --
Heavy infestation of ascariasis Intestinal nematode infections, symptomatic has cramping pain and a bloated feeling in the belly. 0.027(0.015–0.043)
Mild abdominopelvic problems due to ascariasis Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Heavy infestation of trichuriasis Intestinal nematode infections, symptomatic has cramping pain and a bloated feeling in the belly. 0.027(0.015–0.043)
Severe wasting due to trichuriasis Severe wasting is extremely skinny and has no energy. 0.128(0.082–0.183)
Mild abdominopelvic problems due to trichuriasis Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Asymptomatic trichuriasis Asymptomatic -- --
Mild anemia due to hookworm disease Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Severe anemia due to hookworm disease Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Asymptomatic hookworm disease Asymptomatic -- --
Mild abdominopelvic problems due to hookworm disease Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Severe wasting due to hookworm disease Severe wasting is extremely skinny and has no energy. 0.128(0.082–0.183)
Heavy infestation of hookworm Intestinal nematode infections, symptomatic has cramping pain and a bloated feeling in the belly. 0.027(0.015–0.043)
Moderate anemia due to hookworm disease Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Asymptomatic fascioliasis Asymptomatic -- --
Heavy clonorchiasis due to food-borne trematodiases Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Heavy fascioliasis due to food-borne trematodiases Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Heavy intestinal fluke infection due to food-borne trematodiases Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Asymptomatic opisthorchiasis Asymptomatic -- --
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Asymptomatic intestinal fluke infection Asymptomatic -- --
Cerebral paragonimiasis Epilepsy (combined DW) --
Asymptomatic paragonimiasis Asymptomatic -- --
Moderate paragonimiasis due to food-borne trematodiases COPD and other chronic respiratory problems, moderate
has cough, wheezing and shortness of breath, even after light 
physical activity. The person feels tired and can walk only 
short distances or climb only a few stairs.
0.225
(0.153–0.31)
Severe paragonimiasis due to food-borne trematodiases COPD and other chronic respiratory problems, severe
has cough, wheezing and shortness of breath all the time. 
The person has great difficulty walking even short distances 
or climbing any stairs, feels tired when at rest, and is 
0.408
(0.273–0.556)
Mild paragonimiasis due to food-borne trematodiases COPD and other chronic respiratory problems, mild
has cough and shortness of breath after heavy physical 
activity, but is able to walk long distances and climb stairs.
0.019
(0.011–0.033)
Heavy opisthorchiasis due to food-borne trematodiases Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Asymptomatic clonorchiasis Asymptomatic -- --
Disfigurement level 2 due to leprosy Disfigurement, level 2
has a visible physical deformity that causes others to stare 
and comment. As a result, the person is worried and has 
trouble sleeping and concentrating.
0.067
(0.044–0.096)
Disfigurement level 1 due to leprosy Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Post-Ebola chronic fatigue syndrome Infectious disease, post-acute consequences (fatigue, emotional lability, insomnia)
is always tired and easily upset. The person feels pain all over 
the body and is depressed.
0.219
(0.148–0.308)
Ebola cases Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Guillain–Barré syndrome due to Zika infection Spinal cord lesion below neck level (treated)
is paralyzed from the waist down, cannot feel or move the 
legs and has difficulties with urine and bowel control. The 
person uses a wheelchair to move around.
0.296
(0.198–0.414)
Asymptomatic Zika infection Asymptomatic -- --
Acute Zika infection Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Congenital Zika syndrome Severe motor plus cognitive impairment with epilepsy (combined DW) --
Mild pain due to Guinea worm emergence Disfigurement, level 1 with itch/pain
has a slight, visible physical deformity that is sometimes sore 
or itchy. Others notice the deformity, which causes some 
worry and discomfort.
0.027
(0.015–0.042)
Moderate pain due to Guinea worm emergence Disfigurement, level 2, with itch/pain
has a visible physical deformity that is sore and itchy. Other 
people stare and comment, which causes the person to worry. 
The person has trouble sleeping and concentrating.
0.188
(0.125–0.267)
Moderate reduced mobility due to Guinea worm emergence Musculoskeletal problems, lower limbs, moderate
has moderate pain in the leg, which makes the person limp, 
and causes some difficulty walking, standing, lifting and 
carrying heavy things, getting up and down and sleeping.
0.079
(0.054–0.11)
Mild anemia due to other neglected tropical diseases Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Moderate anemia due to other neglected tropical diseases Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Acute infection due to other neglected tropical diseases Post-COMO calculation for residuals (YLL/YLD ratio, other methods) -- --
Severe anemia due to other neglected tropical diseases Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Mild anemia due to maternal hemorrhage Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Moderate anemia due to maternal hemorrhage Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Severe anemia due to maternal hemorrhage Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Maternal hemorrhage (> 1L blood lost) Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Maternal hemorrhage (< 1L blood lost) Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Puerperal sepsis Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Other maternal infections Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Infertility due to puerperal sepsis Infertility, secondary has at least one child, and wants to have more children. The person has a fertile partner, but the couple cannot conceive. 
0.005
(0.002–0.011)
Other hypertensive disorders of pregnancy Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Long term sequelae of severe pre-eclampsia Tension-type headaches, mild motor plus cognitive impairment (combined DW) --
Long term sequelae of eclampsia Tension-type headaches, mild motor plus cognitive impairment (combined DW) --
Severe pre-eclampsia Moderate abdominal pain, tension-type headaches, mild motor plus cognitive impairment (combined DW) --
Eclampsia Moderate abdominal pain and severe epilepsy (combined DW) --
Obstructed labor, acute event Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
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Vesicovaginal fistula Vesicovaginal fistula
has an abnormal opening between the bladder and the 
vagina, which makes her unable to control urinating. The 
woman is anxious and depressed.
0.342
(0.227–0.478)
Rectovaginal fistula Rectovaginal fistula
has an abnormal opening between her vagina and rectum 
causing flatulence and feces to escape through the vagina. 
The person gets infections in her vagina, and has pain when 
urinating. 
0.501
(0.339–0.657)
Ectopic Pregnancy Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Maternal abortive outcome Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Other maternal disorders Post-COMO calculation for residuals (YLL/YLD ratio, other methods) -- --
Severe motor plus cognitive impairment with epilepsy due to 
neonatal preterm birth complications <28wks
Severe motor plus cognitive impairment with 
epilepsy (combined DW) --
Severe motor plus cognitive impairment with epilepsy due to 
neonatal preterm birth complications 32-36wks
Severe motor plus cognitive impairment with 
epilepsy (combined DW) --
Severe motor plus cognitive impairment with epilepsy due to 
neonatal preterm birth complications 28-32wks
Severe motor plus cognitive impairment with 
epilepsy (combined DW) --
Mild motor plus cognitive impairments due to neonatal preterm birth 
complications <28wks Motor plus cognitive impairments, mild
has some difficulty in moving around but is able to walk 
without help. The person is slow in learning at school. As an 
adult, the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions independently.
0.031
(0.018–0.05)
Severe motor plus cognitive impairment with blindness and epilepsy 
due to neonatal preterm birth complications <28wks
Severe motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Mild motor plus cognitive impairments due to neonatal preterm birth 
complications 32-36wks Motor plus cognitive impairments, mild
has some difficulty in moving around but is able to walk 
without help. The person is slow in learning at school. As an 
adult, the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions independently.
0.031
(0.018–0.05)
Severe motor plus cognitive impairment with blindness due to 
neonatal preterm birth complications <28wks
Severe motor plus cognitive impairment with 
blindness (combined DW) --
Moderate motor plus cognitive impairment with blindness and 
epilepsy due to neonatal preterm birth complications <28wks
Moderate motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Moderate motor plus cognitive impairment with blindness and 
epilepsy due to neonatal preterm birth complications 32-36wks
Moderate motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Severe motor plus cognitive impairment with blindness and epilepsy 
due to neonatal preterm birth complications 28-32wks
Severe motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Mild motor plus cognitive impairments due to neonatal preterm birth 
complications 28-32wks Motor plus cognitive impairments, mild
has some difficulty in moving around but is able to walk 
without help. The person is slow in learning at school. As an 
adult, the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions independently.
0.031
(0.018–0.05)
Severe motor impairment with epilepsy due to neonatal preterm birth 
complications 32-36wks Severe motor impairment with epilepsy (combined DW) --
Severe motor impairment due to neonatal preterm birth 
complications 32-36wks Motor impairment, severe
is unable to move around without help, and is not able to lift 
or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Severe motor plus cognitive impairment with blindness due to 
neonatal preterm birth complications 32-36wks
Severe motor plus cognitive impairment with 
blindness (combined DW) --
Severe motor impairment with epilepsy due to neonatal preterm birth 
complications <28wks Severe motor impairment with epilepsy (combined DW) --
Severe motor impairment with blindness due to neonatal preterm 
birth complications 32-36wks Severe motor impairment with blindness (combined DW) --
Severe motor impairment with epilepsy due to neonatal preterm birth 
complications 28-32wks Severe motor impairment with epilepsy (combined DW) --
Mild motor impairment due to neonatal preterm birth complications 
<28wks Motor impairment, mild
has some difficulty in moving around but is able to walk 
without help.
0.01
(0.005–0.019)
Mild motor impairment due to neonatal preterm birth complications 
28-32wks Motor impairment, mild
has some difficulty in moving around but is able to walk 
without help.
0.01
(0.005–0.019)
Mild motor impairment due to neonatal preterm birth complications 
32-36wks Motor impairment, mild
has some difficulty in moving around but is able to walk 
without help.
0.01
(0.005–0.019)
Severe motor impairment with blindness due to neonatal preterm 
birth complications <28wks Severe motor impairment with blindness (combined DW) --
Severe motor impairment due to neonatal preterm birth 
complications 28-32wks Motor impairment, severe
is unable to move around without help, and is not able to lift 
or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Severe motor impairment with blindness and epilepsy due to 
neonatal preterm birth complications <28wks
Severe motor impairment with blindness and 
epilepsy (combined DW) --
Moderate motor impairment due to neonatal preterm birth 
complications 28-32wks Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Moderate motor impairment due to neonatal preterm birth 
complications <28wks Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Moderate motor impairment due to neonatal preterm birth 
complications 32-36wks Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Severe motor impairment with blindness due to neonatal preterm 
birth complications 28-32wks Severe motor impairment with blindness (combined DW) --
Severe motor impairment with blindness and epilepsy due to 
neonatal preterm birth complications 32-36wks
Severe motor impairment with blindness and 
epilepsy (combined DW) --
Severe motor plus cognitive impairment with blindness due to 
neonatal preterm birth complications 28-32wks
Severe motor plus cognitive impairment with 
blindness (combined DW) --
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Severe motor impairment due to neonatal preterm birth 
complications <28wks Motor impairment, severe
is unable to move around without help, and is not able to lift 
or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Severe motor impairment with blindness and epilepsy due to 
neonatal preterm birth complications 28-32wks
Severe motor impairment with blindness and 
epilepsy (combined DW) --
Moderate motor plus cognitive impairment with epilepsy due to 
neonatal preterm birth complications 28-32wks
Moderate motor plus cognitive impairment with 
epilepsy (combined DW) --
Blindness due to retinopathy of prematurity Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Severe motor plus cognitive impairment with blindness and epilepsy 
due to neonatal preterm birth complications 32-36wks
Severe motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Moderate motor impairment with blindness and epilepsy due to 
neonatal preterm birth complications 32-36wks
Moderate motor impairment with blindness and 
epilepsy (combined DW) --
Moderate motor impairment with blindness and epilepsy due to 
neonatal preterm birth complications 28-32wks
Moderate motor impairment with blindness and 
epilepsy (combined DW) --
Moderate motor impairment with epilepsy due to neonatal preterm 
birth complications <28wks Moderate motor impairment with epilepsy (combined DW) --
Moderate motor impairment with epilepsy due to neonatal preterm 
birth complications 28-32wks Moderate motor impairment with epilepsy (combined DW) --
Moderate motor impairment with blindness and epilepsy due to 
neonatal preterm birth complications <28wks
Moderate motor impairment with blindness and 
epilepsy (combined DW) --
Moderate motor impairment with epilepsy due to neonatal preterm 
birth complications 32-36wks Moderate motor impairment with epilepsy (combined DW) --
Moderate motor plus cognitive impairment with blindness due to 
neonatal preterm birth complications 28-32wks
Moderate motor plus cognitive impairment with 
blindness (combined DW) --
Moderate motor impairment with blindness due to neonatal preterm 
birth complications 32-36wks Moderate motor impairment with blindness (combined DW) --
Moderate motor impairment with blindness due to neonatal preterm 
birth complications 28-32wks Moderate motor impairment with blindness (combined DW) --
Moderate motor impairment with blindness due to neonatal preterm 
birth complications <28wks Moderate motor impairment with blindness (combined DW) --
Moderate motor plus cognitive impairment with blindness due to 
neonatal preterm birth complications <28wks
Moderate motor plus cognitive impairment with 
blindness (combined DW) --
Moderate motor plus cognitive impairment with blindness due to 
neonatal preterm birth complications 32-36wks
Moderate motor plus cognitive impairment with 
blindness (combined DW) --
Asymptomatic neonatal preterm birth 32-<37wks Asymptomatic -- --
Moderate motor plus cognitive impairment with blindness and 
epilepsy due to neonatal preterm birth complications 28-32wks
Moderate motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Severe vision impairment due to retinopathy of prematurity Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Moderate motor plus cognitive impairment with epilepsy due to 
neonatal preterm birth complications <28wks
Moderate motor plus cognitive impairment with 
epilepsy (combined DW) --
Mild vision impairment due to retinopathy of prematurity Distance vision, mild impairment has some difficulty with distance vision, for example reading signs, but no other problems with eyesight.
0.003
(0.001–0.007)
Moderate vision impairment due to retinopathy of prematurity Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Moderate motor plus cognitive impairment with epilepsy due to 
neonatal preterm birth complications 32-36wks
Moderate motor plus cognitive impairment with 
epilepsy (combined DW) --
Asymptomatic neonatla preterm birth <28wks Asymptomatic -- --
Asymptomatic neonatal preterm birth 28-<32 wks Asymptomatic -- --
Asymptomatic retinopathy of prematurity Asymptomatic -- --
Severe motor impairment due to neonatal encephalopathy due to 
birth asphyxia and trauma Motor impairment, severe
is unable to move around without help, and is not able to lift 
or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Moderate motor impairment due to neonatal encephalopathy due to 
birth asphyxia and trauma Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Moderate motor impairment with blindness due to neonatal 
encephalopathy due to birth asphyxia and trauma Moderate motor impairment with blindness (combined DW) --
Severe motor plus cognitive impairment with epilepsy due to 
neonatal encephalopathy due to birth asphyxia and trauma
Severe motor plus cognitive impairment with 
epilepsy (combined DW) --
Moderate motor impairment with epilepsy due to neonatal 
encephalopathy due to birth asphyxia and trauma Moderate motor impairment with epilepsy (combined DW) --
Moderate motor plus cognitive impairment with blindness and 
epilepsy due to neonatal encephalopathy due to birth asphyxia and 
trauma
Moderate motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Mild motor impairment due to neonatal encephalopathy due to birth 
asphyxia and trauma Motor impairment, mild
has some difficulty in moving around but is able to walk 
without help.
0.01
(0.005–0.019)
Moderate motor plus cognitive impairment with epilepsy due to 
neonatal encephalopathy due to birth asphyxia and trauma
Moderate motor plus cognitive impairment with 
epilepsy (combined DW) --
Severe motor impairment with blindness and epilepsy due to 
neonatal encephalopathy due to birth asphyxia and trauma
Severe motor impairment with blindness and 
epilepsy (combined DW) --
Mild motor plus cognitive impairments due to neonatal 
encephalopathy due to birth asphyxia and trauma Motor plus cognitive impairments, mild
has some difficulty in moving around but is able to walk 
without help. The person is slow in learning at school. As an 
adult, the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions independently.
0.031
(0.018–0.05)
Severe motor plus cognitive impairment with blindness and epilepsy 
due to neonatal encephalopathy due to birth asphyxia and trauma
Severe motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
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Moderate motor impairment with blindness and epilepsy due to 
neonatal encephalopathy due to birth asphyxia and trauma
Moderate motor impairment with blindness and 
epilepsy (combined DW) --
Asymptomatic neonatal encephalopathy due to birth asphyxia and 
trauma Asymptomatic -- --
Moderate motor plus cognitive impairment with blindness due to 
neonatal encephalopathy due to birth asphyxia and trauma
Moderate motor plus cognitive impairment with 
blindness (combined DW) --
Severe motor impairment with epilepsy due to neonatal 
encephalopathy due to birth asphyxia and trauma Severe motor impairment with epilepsy (combined DW) --
Severe motor plus cognitive impairment with blindness due to 
neonatal encephalopathy due to birth asphyxia and trauma
Severe motor plus cognitive impairment with 
blindness (combined DW) --
Severe motor impairment with blindness due to neonatal 
encephalopathy due to birth asphyxia and trauma Severe motor impairment with blindness (combined DW) --
Moderate motor impairment with epilepsy due to neonatal sepsis and 
other neonatal infections Moderate motor impairment with epilepsy (combined DW) --
Moderate motor plus cognitive impairment with epilepsy due to 
neonatal sepsis and other neonatal infections
Moderate motor plus cognitive impairment with 
epilepsy (combined DW) --
Severe motor impairment with blindness due to neonatal sepsis and 
other neonatal infections  Severe motor impairment with blindness (combined DW) --
Severe motor plus cognitive impairment with blindness and epilepsy 
due to neonatal sepsis and other neonatal infections
Severe motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Mild motor impairment due to neonatal sepsis and other neonatal 
infections Motor impairment, mild
has some difficulty in moving around but is able to walk 
without help.
0.01
(0.005–0.019)
Severe motor impairment with epilepsy due to neonatal sepsis and 
other neonatal infections Severe motor impairment with epilepsy (combined DW) --
Asymptomatic neonatal sepsis and other neonatal infections Asymptomatic -- --
Moderate motor impairment with blindness due to neonatal sepsis 
and other neonatal infections Moderate motor impairment with blindness (combined DW) --
Severe motor impairment due to neonatal sepsis and other neonatal 
infections Motor impairment, severe
is unable to move around without help, and is not able to lift 
or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Severe infection due to neonatal sepsis and other neonatal infections Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Moderate motor plus cognitive impairment with blindness and 
epilepsy due to neonatal sepsis and other neonatal infections
Moderate motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Moderate motor impairment due to neonatal sepsis and other 
neonatal infections Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Severe motor plus cognitive impairment with epilepsy due to 
neonatal sepsis and other neonatal infections
Severe motor plus cognitive impairment with 
epilepsy (combined DW) --
Severe motor impairment with blindness and epilepsy due to 
neonatal sepsis and other neonatal infections
Severe motor impairment with blindness and 
epilepsy (combined DW) --
Mild motor plus cognitive impairments due to neonatal sepsis and 
other neonatal infections Motor plus cognitive impairments, mild
has some difficulty in moving around but is able to walk 
without help. The person is slow in learning at school. As an 
adult, the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions independently.
0.031
(0.018–0.05)
Severe motor plus cognitive impairment with blindness due to 
neonatal sepsis and other neonatal infections
Severe motor plus cognitive impairment with 
blindness (combined DW) --
Moderate motor plus cognitive impairment with blindness due to 
neonatal sepsis and other neonatal infections
Moderate motor plus cognitive impairment with 
blindness (combined DW) --
Moderate motor impairment with blindness and epilepsy due to 
neonatal sepsis and other neonatal infections
Moderate motor impairment with blindness and 
epilepsy (combined DW) --
Severe motor impairment with blindness and epilepsy due to 
hemolytic disease and other neonatal jaundice
Severe motor impairment with blindness and 
epilepsy (combined DW) --
Severe motor impairment with epilepsy due to hemolytic disease and 
other neonatal jaundice Severe motor impairment with epilepsy (combined DW) --
Severe motor plus cognitive impairment with blindness and epilepsy 
due to hemolytic disease and other neonatal jaundice
Severe motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Severe motor plus cognitive impairment with blindness due to 
hemolytic disease and other neonatal jaundice
Severe motor plus cognitive impairment with 
blindness (combined DW) --
Severe motor plus cognitive impairment with epilepsy due to 
hemolytic disease and other neonatal jaundice
Severe motor plus cognitive impairment with 
epilepsy (combined DW) --
Moderate motor impairment with blindness and epilepsy due to 
hemolytic disease and other neonatal jaundice
Moderate motor impairment with blindness and 
epilepsy (combined DW) --
Moderate motor plus cognitive impairment with epilepsy due to 
hemolytic disease and other neonatal jaundice
Moderate motor plus cognitive impairment with 
epilepsy (combined DW) --
Moderate motor impairment with epilepsy due to hemolytic disease 
and other neonatal jaundice Moderate motor impairment with epilepsy (combined DW) --
Moderate motor plus cognitive impairment with blindness due to 
hemolytic disease and other neonatal jaundice
Moderate motor plus cognitive impairment with 
blindness (combined DW) --
Moderate motor impairment with blindness due to hemolytic disease 
and other neonatal jaundice Moderate motor impairment with blindness (combined DW) --
Severe motor impairment severe due to hemolytic disease and other 
neonatal jaundice Motor impairment, severe
is unable to move around without help, and is not able to lift 
or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Moderate motor plus cognitive impairment with blindness and 
epilepsy due to hemolytic disease and other neonatal jaundice
Moderate motor plus cognitive impairment with 
blindness and epilepsy (combined DW) --
Moderate motor impairment due to hemolytic disease and other 
neonatal jaundice Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Severe motor impairment with blindness due to hemolytic disease 
and other neonatal jaundice Severe motor impairment with blindness (combined DW) --
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Other neonatal disorders Post-COMO calculation for residuals (YLL/YLD ratio, other methods) -- --
Moderate wasting without edema Asymptomatic -- --
Moderate wasting with edema Kwashiorkor is very tired and irritable and has diarrhea. 0.051(0.031–0.079)
Severe wasting without edema Severe wasting is extremely skinny and has no energy. 0.128(0.082–0.183)
Severe wasting with edema Kwashiorkor and severe wasting (combined DW) 0.172(0.115–0.238)
Visible goiter with profound intellectual disability due to iodine 
deficiency
Intellectual disability / mental retardation, 
profound and Iodine-deficiency goiter (combined DW)
0.358
(0.252–0.475)
Visible goiter with severe intellectual disability due to iodine 
deficiency
Intellectual disability / mental retardation, severe 
and Iodine-deficiency goiter (combined DW)
0.326
(0.233–0.438)
Visible goiter with profound intellectual disability and mild heart 
failure due to iodine deficiency
Intellectual disability / mental retardation, 
profound and Iodine-deficiency goiter and heart 
failure  mild
(combined DW) 0.384(0.276–0.502)
Visible goiter without symptoms Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Visible goiter with profound intellectual disability and moderate 
heart failure due to iodine deficiency
Intellectual disability / mental retardation, 
profound and Iodine-deficiency goiter and heart 
failure, moderate
(combined DW) 0.403(0.293–0.524)
Visible goiter with profound intellectual disability with severe heart 
failure due to iodine deficiency
Intellectual disability / mental retardation, 
profound and Iodine-deficiency goiter and heart 
failure, severe
(combined DW) 0.471(0.344–0.602)
Visible goiter with symptoms without intellectual disability or heart 
failure Iodine-deficiency goiter
has a large mass in the front of the neck. The person 
sometimes has weakness and fatigue, constipation and 
weight gain.
0.199
(0.133–0.276)
Moderate vision impairment loss due to vitamin A deficiency Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Blindness due to vitamin A deficiency Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Severe vision impairment loss due to vitamin A deficiency Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Asymptomatic vitamin A deficiency Asymptomatic -- --
Moderate heart failure due to iron-deficiency anemia Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Mild iron-deficiency anemia Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Asymptomatic and mild heart failure due to iron-deficiency anemia Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Severe iron-deficiency anemia Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Severe heart failure due to iron-deficiency anemia Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Moderate iron-deficiency anemia Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Other nutritional deficiencies Post-COMO calculation for residuals (YLL/YLD ratio, other methods) -- --
Cardiovascular complications due to adult tertiary syphilis Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Severe disfigurement, neurological problems, and cardiovascular 
complications due to adult tertiary syphilis
Level 3 disfigurement, moderate motor plus 
cognitive impairments, and moderate infectious 
disease, acute episode
(combined DW) 0.547(0.402–0.691)
Severe disfigurement and cardiovascular complications due to adult 
tertiary syphilis
Level 3 disfigurement and moderate infectious 
disease, acute episode (combined DW)
0.435
(0.306–0.571)
Neurological problems due to adult tertiary syphilis Motor plus cognitive impairments, moderate
has some difficulty in moving around, holding objects, 
dressing and sitting upright, but can walk without help. The 
person has low intelligence and is slow in learning to speak 
and to do simple tasks.
0.203
(0.134–0.29)
Severe disfigurement due to adult tertiary syphilis Disfigurement, level 3
has an obvious physical deformity that makes others 
uncomfortable, which causes the person to avoid social 
contact, feel worried, sleep poorly, and think about suicide.
0.405
(0.275–0.546)
Asymptomatic early syphilis infection Asymptomatic -- --
Mild early syphilis infection Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Neurological problems and cardiovascular complications due to adult 
tertiary syphilis
Moderate motor plus cognitive impairments and 
moderate infectious disease, acute episode (combined DW)
0.243
(0.168–0.333)
Asymptomatic adult tertiary syphilis Asymptomatic -- --
Severe disfigurement and neurological problems due to adult tertiary 
syphilis
Level 3 disfigurement and moderate motor plus 
cognitive impairments (combined DW)
0.523
(0.378–0.669)
Secondary infertility due to chlamydial infection Infertility, secondary has at least one child, and wants to have more children. The person has a fertile partner, but the couple cannot conceive. 
0.005
(0.002–0.011)
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Asymptomatic chlamydial infection Asymptomatic -- --
Moderate pelvic inflammatory diseases due to chlamydial infection Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Severe pelvic inflammatory diseases due to chlamydial infection Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Epididymo-orchitis due to chlamydial infection Epididymo-orchitis has swelling and tenderness in the testicles and pain during urination. 
0.128
(0.086–0.18)
Primary infertility due to chlamydial infection Infertility, primary wants to have a child and has a fertile partner, but the couple cannot conceive.
0.008
(0.003–0.015)
Mild chlamydial infection Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Primary infertility due to gonococcal infection Infertility, primary wants to have a child and has a fertile partner, but the couple cannot conceive.
0.008
(0.003–0.015)
Epididymo-orchitis due to gonococcal infection Epididymo-orchitis has swelling and tenderness in the testicles and pain during urination. 
0.128
(0.086–0.18)
Severe pelvic inflammatory diseases due to gonococcal infection Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Asymptomatic gonococcal infection Asymptomatic -- --
Mild gonococcal infection Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Secondary infertility due to gonococcal infection Infertility, secondary has at least one child, and wants to have more children. The person has a fertile partner, but the couple cannot conceive. 
0.005
(0.002–0.011)
Moderate pelvic inflammatory diseases due to gonococcal infection Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Asymptomatic trichomoniasis infection Asymptomatic -- --
Acute trichomoniasis infection Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Moderate infection due to initial genital herpes episode Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Asymptomatic genital herpes Asymptomatic -- --
Symptomatic genital herpes Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Primary infertility due to other sexually transmitted diseases Infertility, primary wants to have a child and has a fertile partner, but the couple cannot conceive.
0.008
(0.003–0.015)
Severe pelvic inflammatory diseases due to other sexually 
transmitted diseases Abdominopelvic problem, severe
has severe pain in the belly and feels nauseous. The person is 
anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Other sexually transmitted diseases Post-COMO calculation for residuals (YLL/YLD ratio, other methods) -- --
Secondary infertility due to other sexually transmitted diseases Infertility, secondary has at least one child, and wants to have more children. The person has a fertile partner, but the couple cannot conceive. 
0.005
(0.002–0.011)
Moderate pelvic inflammatory diseases due to other sexually 
transmitted diseases Abdominopelvic problem, moderate
has pain in the belly and feels nauseous. The person has 
difficulties with daily activities. 
0.114
(0.078–0.159)
Asymptomatic acute hepatitis A Asymptomatic -- --
Severe acute hepatitis A Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Moderate acute hepatitis A Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Severe acute hepatitis B Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Moderate acute hepatitis B Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Chronic hepatitis B Asymptomatic -- --
Asymptomatic acute hepatitis B Asymptomatic -- --
Moderate acute hepatitis C Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Severe acute hepatitis C Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Chronic hepatitis C Asymptomatic -- --
Asymptomatic acute hepatitis C Asymptomatic -- --
Asymptomatic acute hepatitis E Asymptomatic -- --
Moderate acute hepatitis E Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Severe acute hepatitis E Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Guillain-Barré syndrome due to other infectious diseases Spinal cord lesion below neck level (treated)
is paralyzed from the waist down, cannot feel or move the 
legs and has difficulties with urine and bowel control. The 
person uses a wheelchair to move around.
0.296
(0.198–0.414)
Mild anemia due to other infectious diseases Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Other infectious diseases Post-COMO calculation for residuals (YLL/YLD ratio, other methods) -- --
Moderate anemia due to other infectious diseases Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Severe anemia due to other infectious diseases Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
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Controlled phase of mouth cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of mouth cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Diagnosis and primary therapy phase of mouth cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Terminal phase of mouth cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Terminal phase of nasopharynx cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Controlled phase of nasopharynx cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of nasopharynx cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Diagnosis and primary therapy phase of nasopharynx cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Controlled phase of other pharynx cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of other pharynx cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Terminal phase of other pharynx cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Diagnosis and primary therapy phase of other pharynx cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Controlled phase of esophageal cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Terminal phase of esophageal cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Metastatic phase of esophageal cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Diagnosis and primary therapy phase of esophageal cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Diagnosis and primary therapy phase of stomach cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Metastatic phase of stomach cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Terminal phase of stomach cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Controlled phase of stomach cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of colon and rectum cancers Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Terminal phase of colon and rectum cancers Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Stoma due to colon and rectum cancer Stoma and generic medication (combined DW) 0.139(0.094–0.192)
Diagnosis and primary therapy phase of colon and rectum cancers Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Controlled phase of colon and rectum cancers Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Controlled phase of liver cancer due to hepatitis B Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Terminal phase of liver cancer due to hepatitis B Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Diagnosis and primary therapy phase of liver cancer due to hepatitis 
B Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety.
0.288
(0.193–0.399)
Metastatic phase of liver cancer due to hepatitis B Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Controlled phase of liver cancer due to hepatitis C Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of liver cancer due to hepatitis C Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Diagnosis and primary therapy phase of liver cancer due to hepatitis 
C Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety.
0.288
(0.193–0.399)
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Terminal phase of liver cancer due to hepatitis C Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Diagnosis and primary therapy phase of liver cancer due to alcohol 
use Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety.
0.288
(0.193–0.399)
Terminal phase of liver cancer due to alcohol use Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Metastatic phase of liver cancer due to alcohol use Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Controlled phase of liver cancer due to alcohol use Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Controlled phase of liver cancer due to other causes Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of liver cancer due to other causes Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Diagnosis and primary therapy phase of liver cancer due to other 
causes Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety.
0.288
(0.193–0.399)
Terminal phase of liver cancer due to other causes Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Diagnosis and primary therapy phase of gallbladder and biliary tract 
cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety.
0.288
(0.193–0.399)
Terminal phase of gallbladder and biliary tract cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Metastatic phase of gallbladder and biliary tract cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Controlled phase of gallbladder and biliary tract cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of pancreatic cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Terminal phase of pancreatic cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Controlled phase of pancreatic cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Diagnosis and primary therapy phase of pancreatic cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Metastatic phase of larynx cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Laryngectomy due to larynx cancer Speech problems and generic medication (combined DW) 0.098(0.063–0.145)
Controlled phase of larynx cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Diagnosis and primary therapy phase of larynx cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Terminal phase of larynx cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Metastatic phase of lung, bronchus, and trachea cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Diagnosis and primary therapy phase of lung, bronchus, and trachea 
cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety.
0.288
(0.193–0.399)
Controlled phase of lung, bronchus, and trachea cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Terminal phase of lung, bronchus, and trachea cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Controlled phase of malignant skin melanoma Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of malignant skin melanoma Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Terminal phase of malignant skin melanoma Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Diagnosis and primary therapy phase of malignant skin melanoma Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Severe disfigurement due to squamous cell carcinoma Disfigurement, level 3, with itch/pain
has an obvious physical deformity that is very painful and 
itchy. The physical deformity makes others uncomfortable, 
which causes the person to avoid social contact, feel worried, 
sleep poorly, and think about suicide.
0.576
(0.401–0.731)
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Moderate disfigurement due to squamous cell carcinoma Disfigurement, level 2
has a visible physical deformity that causes others to stare 
and comment. As a result, the person is worried and has 
trouble sleeping and concentrating.
0.067
(0.044–0.096)
Mild disfigurement due to squamous cell carcinoma Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Disfigurement due to basal cell carcinoma Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Diagnosis and primary therapy phase of breast cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Mastectomy due to breast cancer Mastectomy and generic medication (combined DW) 0.083(0.052–0.124)
Controlled phase of breast cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of breast cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Terminal phase of breast cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Terminal phase of cervical cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Diagnosis and primary therapy phase of cervical cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Controlled phase of cervical cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of cervical cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Controlled phase of uterine cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Terminal phase of uterine cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Diagnosis and primary therapy phase of uterine cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Metastatic phase of uterine cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Diagnosis and primary therapy phase of ovarian cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Controlled phase of ovarian cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of ovarian cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Terminal phase of ovarian cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Diagnosis and primary therapy phase of prostate cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Impotence due to prostate cancer Impotence and generic medication (combined DW) 0.065(0.04–0.1)
Terminal phase of prostate cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Controlled phase of prostate cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of prostate cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Incontinence due to prostate cancer Incontinence and generic medication (combined DW) 0.181(0.124–0.248)
Terminal phase of testicular cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Metastatic phase of testicular cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Diagnosis and primary therapy phase of testicular cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Controlled phase of testicular cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Diagnosis and primary therapy phase of kidney cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Metastatic phase of kidney cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Terminal phase of kidney cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
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Controlled phase of kidney cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Controlled phase of bladder cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Urinary incontinence due to bladder cancer Incontinence and generic medication (combined DW) 0.181(0.124–0.248)
Terminal phase of bladder cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Diagnosis and primary therapy phase of bladder cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Metastatic phase of bladder cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Diagnosis and primary therapy phase of brain and nervous system 
cancers Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety.
0.288
(0.193–0.399)
Terminal phase of brain and nervous system cancers Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Metastatic phase of brain and nervous system cancers Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Controlled phase of brain and nervous system cancers Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Terminal phase of thyroid cancer Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Controlled phase of thyroid cancer Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of thyroid cancer Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Diagnosis and primary therapy phase of thyroid cancer Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Terminal phase of mesothelioma Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Controlled phase of mesothelioma Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Diagnosis and primary therapy phase of mesothelioma Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Metastatic phase of mesothelioma Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Controlled phase of Hodgkin disease Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of Hodgkin disease Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Diagnosis and primary therapy phase of Hodgkin disease Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Terminal phase of Hodgkin disease Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Metastatic phase of non-Hodgkin lymphoma Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Terminal phase of non-Hodgkin lymphoma Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Controlled phase of non-Hodgkin lymphoma Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Diagnosis and primary therapy phase of non-Hodgkin lymphoma Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Terminal phase of multiple myeloma Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Diagnosis and primary therapy phase of multiple myeloma Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Metastatic phase of multiple myeloma Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Controlled phase of multiple myeloma Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Controlled phase of acute lymphoid leukemia Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Diagnosis and primary therapy phase of acute lymphoid leukemia Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
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Metastatic phase of acute lymphoid leukemia Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Terminal phase of acute lymphoid leukemia Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Metastatic phase of chronic lymphoid leukemia Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Terminal phase of chronic lymphoid leukemia Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Diagnosis and primary therapy phase of chronic lymphoid leukemia Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Controlled phase of chronic lymphoid leukemia Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Diagnosis and primary therapy phase of acute myeloid leukemia Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Controlled phase of acute myeloid leukemia Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Terminal phase of acute myeloid leukemia Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Metastatic phase of acute myeloid leukemia Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Diagnosis and primary therapy phase of chronic myeloid leukemia Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Metastatic phase of chronic myeloid leukemia Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Terminal phase of chronic myeloid leukemia Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Controlled phase of chronic myeloid leukemia Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Metastatic phase of other leukemia Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Controlled phase of other leukemia Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Diagnosis and primary therapy phase of other leukemia Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Terminal phase of other leukemia Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Terminal phase of other neoplasms Terminal phase, with medication (for cancers, end-stage kidney/liver disease)
has lost a lot of weight and regularly uses strong medication 
to avoid constant pain. The person has no appetite, feels 
nauseous, and needs to spend most of the day in bed.
0.54
(0.377–0.687)
Diagnosis and primary therapy phase of other neoplasms Cancer, diagnosis and primary therapy has pain, nausea, fatigue, weight loss and high anxiety. 0.288(0.193–0.399)
Metastatic phase of other neoplasms Cancer, metastatic has severe pain, extreme fatigue, weight loss and high anxiety.
0.451
(0.307–0.6)
Controlled phase of other neoplasms Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Severe heart failure due to rheumatic heart disease Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Rheumatic heart disease, without heart failure Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Moderate heart failure due to rheumatic heart disease Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Asymptomatic and mild heart failure due to rheumatic heart disease Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Acute myocardial infarction first 2 days Acute myocardial infarction, days 1-2
has severe chest pain that becomes worse with any physical 
activity,. The person feels nauseous, short of breath, and very 
anxious.
0.432
(0.288–0.579)
Asymptomatic and mild heart failure due to ischemic heart disease Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Asymptomatic angina due to ischemic heart disease Asymptomatic -- --
Severe heart failure due to ischemic heart disease Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
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Acute myocardial infarction 3 to 28 days Acute myocardial infarction, days 3-28
gets short of breath after heavy physical activity, and tires 
easily, but has no problems when at rest. The person has to 
take medication every day and has some anxiety.
0.074
(0.049–0.105)
Moderate angina due to ischemic heart disease Angina pectoris, moderate
has chest pain that occurs with moderate physical activity, 
such as walking uphill or more than half a kilometer (around 
a quarter-mile) on level ground. After a brief rest, the pain 
goes away.
0.08
(0.052–0.113)
Asymptomatic ischemic heart disease following myocardial 
infarction Asymptomatic -- --
Severe angina due to ischemic heart disease Angina pectoris, severe
has chest pain that occurs with minimal physical activity, 
such as walking only a short distance. After a brief rest, the 
pain goes away. The person avoids most physical activities 
because of the pain.
0.167
(0.11–0.24)
Moderate heart failure due to ischemic heart disease Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Mild angina due to ischemic heart disease Angina pectoris, mild
has chest pain that occurs with strenuous physical activity, 
such as running or lifting heavy objects. After a brief rest, the 
pain goes away.
0.033
(0.02–0.052)
Acute ischemic stroke severity level 1 Stroke, long-term consequences, mild has some difficulty in moving around and some weakness in one hand, but is able to walk without help.
0.019
(0.01–0.032)
Chronic ischemic stroke severity level 1 Stroke, long-term consequences, mild has some difficulty in moving around and some weakness in one hand, but is able to walk without help.
0.019
(0.01–0.032)
Acute ischemic stroke severity level 2 Stroke, long-term consequences, moderate has some difficulty in moving around, and in using the hands for lifting and holding things, dressing and grooming.
0.07
(0.046–0.099)
Chronic ischemic stroke severity level 5 Stroke, long-term consequences, severe plus cognition problems
is confined to bed or a wheelchair, depends on others for 
feeding, toileting and dressing, and has difficulty speaking, 
thinking clearly and remembering things.
0.588
(0.411–0.744)
Chronic ischemic stroke severity level 2 Stroke, long-term consequences, moderate has some difficulty in moving around, and in using the hands for lifting and holding things, dressing and grooming.
0.07
(0.046–0.099)
Acute ischemic stroke severity level 5 Stroke, long-term consequences, severe plus cognition problems
is confined to bed or a wheelchair, depends on others for 
feeding, toileting and dressing, and has difficulty speaking, 
thinking clearly and remembering things.
0.588
(0.411–0.744)
Acute ischemic stroke severity level 3 Stroke, long-term consequences, moderate plus cognition problems
has some difficulty in moving around, in using the hands for 
lifting and holding things, dressing and grooming, and in 
speaking. The person is often forgetful and confused.
0.316
(0.206–0.437)
Chronic ischemic stroke severity level 4 Stroke, long-term consequences, severe is confined to bed or a wheelchair, has difficulty speaking and depends on others for feeding, toileting and dressing.
0.552
(0.377–0.707)
Chronic ischemic stroke severity level 3 Stroke, long-term consequences, moderate plus cognition problems
has some difficulty in moving around, in using the hands for 
lifting and holding things, dressing and grooming, and in 
speaking. The person is often forgetful and confused.
0.316
(0.206–0.437)
Acute ischemic stroke severity level 4 Stroke, long-term consequences, severe is confined to bed or a wheelchair, has difficulty speaking and depends on others for feeding, toileting and dressing.
0.552
(0.377–0.707)
Asymptomatic chronic ischemic stroke Asymptomatic -- --
Chronic hemorrhagic stroke severity level 1 Stroke, long-term consequences, mild has some difficulty in moving around and some weakness in one hand, but is able to walk without help.
0.019
(0.01–0.032)
Acute hemorrhagic stroke severity level 5 Stroke, long-term consequences, severe plus cognition problems
is confined to bed or a wheelchair, depends on others for 
feeding, toileting and dressing, and has difficulty speaking, 
thinking clearly and remembering things.
0.588
(0.411–0.744)
Chronic hemorrhagic stroke severity level 5 Stroke, long-term consequences, severe plus cognition problems
is confined to bed or a wheelchair, depends on others for 
feeding, toileting and dressing, and has difficulty speaking, 
thinking clearly and remembering things.
0.588
(0.411–0.744)
Acute hemorrhagic stroke severity level 1 Stroke, long-term consequences, mild has some difficulty in moving around and some weakness in one hand, but is able to walk without help.
0.019
(0.01–0.032)
Acute hemorrhagic stroke severity level 2 Stroke, long-term consequences, moderate has some difficulty in moving around, and in using the hands for lifting and holding things, dressing and grooming.
0.07
(0.046–0.099)
Chronic hemorrhagic stroke severity level 2 Stroke, long-term consequences, moderate has some difficulty in moving around, and in using the hands for lifting and holding things, dressing and grooming.
0.07
(0.046–0.099)
Chronic hemorrhagic stroke severity level 4 Stroke, long-term consequences, severe is confined to bed or a wheelchair, has difficulty speaking and depends on others for feeding, toileting and dressing.
0.552
(0.377–0.707)
Acute hemorrhagic stroke severity level 3 Stroke, long-term consequences, moderate plus cognition problems
has some difficulty in moving around, in using the hands for 
lifting and holding things, dressing and grooming, and in 
speaking. The person is often forgetful and confused.
0.316
(0.206–0.437)
Chronic hemorrhagic stroke severity level 3 Stroke, long-term consequences, moderate plus cognition problems
has some difficulty in moving around, in using the hands for 
lifting and holding things, dressing and grooming, and in 
speaking. The person is often forgetful and confused.
0.316
(0.206–0.437)
Acute hemorrhagic stroke severity level 4 Stroke, long-term consequences, severe is confined to bed or a wheelchair, has difficulty speaking and depends on others for feeding, toileting and dressing.
0.552
(0.377–0.707)
Asymptomatic chronic hemorrhagic stroke Asymptomatic -- --
Asymptomatic and mild heart failure due to hypertensive heart 
disease Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Severe heart failure due to hypertensive heart disease Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Moderate heart failure due to hypertensive heart disease Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
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Asymptomatic and mild heart failure due to myocarditis Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Acute myocarditis Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Severe heart failure due to myocarditis Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Moderate heart failure due to myocarditis Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Asymptomatic and mild heart failure due to alcoholic 
cardiomyopathy Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Moderate heart failure due to alcoholic cardiomyopathy Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Severe heart failure due to alcoholic cardiomyopathy Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Moderate heart failure due to other cardiomyopathy Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Severe heart failure due to other cardiomyopathy Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Asymptomatic and mild heart failure due to other cardiomyopathy Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Asymptomatic atrial fibrillation and flutter Asymptomatic -- --
Symptomatic atrial fibrillation and flutter Cardiac conduction disorders and cardiac dysrhythmias
has periods of rapid and irregular heartbeats and occasional 
fainting. 
0.224
(0.151–0.312)
Asymptomatic peripheral vascular disease Asymptomatic -- --
Symptomatic claudication due to peripheral vascular disease Claudication has cramping pains in the legs after walking a medium distance. The pain goes away after a short rest.
0.014
(0.007–0.025)
Moderate endocarditis Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Asymptomatic and mild heart failure due to endocarditis Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Severe endocarditis Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
Severe heart failure due to endocarditis Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Moderate heart failure due to endocarditis Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Moderate other cardiovascular diseases Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Severe heart failure due to other cardiovascular diseases Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Asymptomatic other cardiovascular diseases Asymptomatic -- --
Mild other cardiovascular diseases Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Asymptomatic and mild heart failure due to other cardiovascular 
diseases Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Severe other cardiovascular diseases Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Moderate heart failure due to other cardiovascular diseases Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Severe heart failure due to severe chronic obstructive pulmonary 
disease
Severe COPD and other chronic respiratory, with 
severe heart failure -- --
Asymptomatic and mild heart failure due to severe chronic 
obstructive pulmonary disease
Severe COPD and other chronic respiratory, with 
mild heart failure -- --
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Moderate chronic obstructive pulmonary disease COPD and other chronic respiratory problems, moderate
has cough, wheezing and shortness of breath, even after light 
physical activity. The person feels tired and can walk only 
short distances or climb only a few stairs.
0.225
(0.153–0.31)
Moderate heart failure due to severe chronic obstructive pulmonary 
disease
Severe COPD and other chronic respiratory, with 
moderate heart failure -- --
Asymptomatic chronic obstructive pulmonary disease Asymptomatic -- --
Mild chronic obstructive pulmonary disease COPD and other chronic respiratory problems, mild
has cough and shortness of breath after heavy physical 
activity, but is able to walk long distances and climb stairs.
0.019
(0.011–0.033)
Severe chronic obstructive pulmonary disease without heart failure COPD and other chronic respiratory problems, severe
has cough, wheezing and shortness of breath all the time. 
The person has great difficulty walking even short distances 
or climbing any stairs, feels tired when at rest, and is 
0.408
(0.273–0.556)
Moderate heart failure due to severe silicosis Severe COPD and other chronic respiratory, with moderate heart failure -- --
Mild silicosis COPD and other chronic respiratory problems, mild
has cough and shortness of breath after heavy physical 
activity, but is able to walk long distances and climb stairs.
0.019
(0.011–0.033)
Moderate silicosis COPD and other chronic respiratory problems, moderate
has cough, wheezing and shortness of breath, even after light 
physical activity. The person feels tired and can walk only 
short distances or climb only a few stairs.
0.225
(0.153–0.31)
Asymptomatic and mild heart failure due to severe silicosis Severe COPD and other chronic respiratory, with mild heart failure -- --
Severe silicosis without heart failure COPD and other chronic respiratory problems, severe
has cough, wheezing and shortness of breath all the time. 
The person has great difficulty walking even short distances 
or climbing any stairs, feels tired when at rest, and is 
0.408
(0.273–0.556)
Asymptomatic silicosis Asymptomatic -- --
Severe heart failure due to severe silicosis Severe COPD and other chronic respiratory, with severe heart failure -- --
Asymptomatic and mild heart failure due to severe asbestosis Severe COPD and other chronic respiratory, with mild heart failure -- --
Moderate heart failure due to severe asbestosis Severe COPD and other chronic respiratory, with moderate heart failure -- --
Mild asbestosis COPD and other chronic respiratory problems, mild
has cough and shortness of breath after heavy physical 
activity, but is able to walk long distances and climb stairs.
0.019
(0.011–0.033)
Severe asbestosis without heart failure COPD and other chronic respiratory problems, severe
has cough, wheezing and shortness of breath all the time. 
The person has great difficulty walking even short distances 
or climbing any stairs, feels tired when at rest, and is 
0.408
(0.273–0.556)
Severe heart failure due to severe asbestosis Severe COPD and other chronic respiratory, with severe heart failure -- --
Moderate asbestosis COPD and other chronic respiratory problems, moderate
has cough, wheezing and shortness of breath, even after light 
physical activity. The person feels tired and can walk only 
short distances or climb only a few stairs.
0.225
(0.153–0.31)
Asymptomatic asbestosis Asymptomatic -- --
Severe coal workers pneumoconiosis without heart failure COPD and other chronic respiratory problems, severe
has cough, wheezing and shortness of breath all the time. 
The person has great difficulty walking even short distances 
or climbing any stairs, feels tired when at rest, and is 
0.408
(0.273–0.556)
Mild coal workers pneumoconiosis COPD and other chronic respiratory problems, mild
has cough and shortness of breath after heavy physical 
activity, but is able to walk long distances and climb stairs.
0.019
(0.011–0.033)
Severe heart failure due to severe coal workers pneumoconiosis Severe COPD and other chronic respiratory, with severe heart failure -- --
Asymptomatic and mild heart failure due to severe coal workers 
pneumoconiosis
Severe COPD and other chronic respiratory, with 
mild heart failure -- --
Asymptomatic coal workers pneumoconiosis Asymptomatic -- --
Moderate heart failure due to severe coal workers pneumoconiosis Severe COPD and other chronic respiratory, with moderate heart failure -- --
Moderate coal workers pneumoconiosis COPD and other chronic respiratory problems, moderate
has cough, wheezing and shortness of breath, even after light 
physical activity. The person feels tired and can walk only 
short distances or climb only a few stairs.
0.225
(0.153–0.31)
Moderate other pneumoconiosis COPD and other chronic respiratory problems, moderate
has cough, wheezing and shortness of breath, even after light 
physical activity. The person feels tired and can walk only 
short distances or climb only a few stairs.
0.225
(0.153–0.31)
Asymptomatic other pneumoconiosis Asymptomatic -- --
Mild other pneumoconiosis COPD and other chronic respiratory problems, mild
has cough and shortness of breath after heavy physical 
activity, but is able to walk long distances and climb stairs.
0.019
(0.011–0.033)
Severe heart failure due to severe other pneumoconiosis Severe COPD and other chronic respiratory, with severe heart failure -- --
Severe other pneumoconiosis without heart failure COPD and other chronic respiratory problems, severe
has cough, wheezing and shortness of breath all the time. 
The person has great difficulty walking even short distances 
or climbing any stairs, feels tired when at rest, and is 
0.408
(0.273–0.556)
Moderate heart failure due to severe other pneumoconiosis Severe COPD and other chronic respiratory, with moderate heart failure -- --
Asymptomatic and mild heart failure due to severe other 
pneumoconiosis
Severe COPD and other chronic respiratory, with 
mild heart failure -- --
Controlled asthma Asthma, controlled has wheezing and cough once a month, which does not cause difficulty with daily activities. 
0.015
(0.007–0.026)
Uncontrolled asthma Asthma, uncontrolled
has wheezing, cough and shortness of breath more than twice 
a week, which causes difficulty with daily activities and 
sometimes wakes the person at night.
0.133
(0.086–0.192)
Asymptomatic asthma Asymptomatic -- --
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Partially controlled asthma Asthma, partially controlled has wheezing and cough once a week, which causes some difficulty with daily activities.
0.036
(0.022–0.055)
Severe heart failure due to severe interstitial lung disease and 
pulmonary sarcoidosis
Severe COPD and other chronic respiratory, with 
severe heart failure -- --
Severe interstitial lung disease and pulmonary sarcoidosis without 
heart failure
COPD and other chronic respiratory problems, 
severe
has cough, wheezing and shortness of breath all the time. 
The person has great difficulty walking even short distances 
or climbing any stairs, feels tired when at rest, and is 
0.408
(0.273–0.556)
Moderate heart failure due to severe interstitial lung disease and 
pulmonary sarcoidosis
Severe COPD and other chronic respiratory, with 
moderate heart failure -- --
Mild interstitial lung disease and pulmonary sarcoidosis COPD and other chronic respiratory problems, mild
has cough and shortness of breath after heavy physical 
activity, but is able to walk long distances and climb stairs.
0.019
(0.011–0.033)
Moderate interstitial lung disease and pulmonary sarcoidosis COPD and other chronic respiratory problems, moderate
has cough, wheezing and shortness of breath, even after light 
physical activity. The person feels tired and can walk only 
short distances or climb only a few stairs.
0.225
(0.153–0.31)
Asymptomatic interstitial lung disease and pulmonary sarcoidosis Asymptomatic -- --
Asymptomatic and mild heart failure due to severe interstitial lung 
disease and pulmonary sarcoidosis
Severe COPD and other chronic respiratory, with 
mild heart failure -- --
Other chronic respiratory diseases Post-COMO calculation for residuals (YLL/YLD ratio, other methods) -- --
Cirrhosis and other chronic liver diseases due to hepatitis B, 
compensated Asymptomatic -- --
Cirrhosis and other chronic liver diseases due to hepatitis B, 
decompensated Decompensated cirrhosis of the liver 
has a swollen belly and swollen legs. The person feels 
weakness, fatigue and loss of appetite.
0.178
(0.123–0.25)
Cirrhosis and other chronic liver diseases due to hepatitis C, 
decompensated Decompensated cirrhosis of the liver 
has a swollen belly and swollen legs. The person feels 
weakness, fatigue and loss of appetite.
0.178
(0.123–0.25)
Cirrhosis and other chronic liver diseases due to hepatitis C, 
compensated Asymptomatic -- --
Cirrhosis and other chronic liver diseases due to alcohol, 
compensated Asymptomatic -- --
Cirrhosis and other chronic liver diseases due to alcohol, 
decompensated Decompensated cirrhosis of the liver 
has a swollen belly and swollen legs. The person feels 
weakness, fatigue and loss of appetite.
0.178
(0.123–0.25)
Cirrhosis and other chronic liver diseases due to other cause, 
compensated Asymptomatic -- --
Cirrhosis and other chronic liver diseases due to other cause, 
decompensated Decompensated cirrhosis of the liver 
has a swollen belly and swollen legs. The person feels 
weakness, fatigue and loss of appetite.
0.178
(0.123–0.25)
Severe anemia due to peptic ulcer disease Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Moderate symptomatic peptic ulcer disease with mild anemia Moderate abdominal pain with mild anemia (combined DW) 0.118(0.081–0.163)
Moderate symptomatic peptic ulcer disease with moderate anemia Moderate abdominal pain with moderate anemia (combined DW) 0.16(0.109–0.22)
Moderate symptomatic peptic ulcer disease without anemia Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Mild anemia due to peptic ulcer disease Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Asymptomatic peptic ulcer disease without anemia Asymptomatic -- --
Mild symptomatic peptic ulcer disease with severe anemia Mild abdominal pain with severe anemia (combined DW) --
Moderate anemia due to peptic ulcer disease Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Moderate symptomatic peptic ulcer disease with severe anemia Mild abdominal pain with severe anemia (combined DW) --
Asymptomatic peptic ulcer disease with moderate anemia Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Asymptomatic peptic ulcer disease with severe anemia Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Mild symptomatic peptic ulcer disease without anemia Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Mild symptomatic peptic ulcer disease with moderate anemia Mild abdominal pain with moderate anemia (combined DW) --
Asymptomatic peptic ulcer disease with mild anemia Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Mild symptomatic peptic ulcer disease with mild anemia Mild abdominal pain with mild anemia (combined DW) --
Mild anemia due to gastritis and duodenitis Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Mild symptomatic gastritis and duodenitis with moderate anemia Mild abdominal pain with moderate anemia (combined DW) --
Asymptomatic gastritis and duodenitis with moderate anemia Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Moderate symptomatic gastritis and duodenitis with severe anemia Moderate abdominal pain with severe anemia (combined DW) 0.246(0.171–0.334)
Moderate anemia due to gastritis and duodenitis Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Asymptomatic gastritis and duodenitis without anemia Asymptomatic -- --
Moderate symptomatic gastritis and duodenitis with moderate 
anemia Moderate abdominal pain with moderate anemia (combined DW)
0.16
(0.109–0.22)
Asymptomatic gastritis and duodenitis with mild anemia Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
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Asymptomatic gastritis and duodenitis with severe anemia Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Mild symptomatic gastritis and duodenitis without anemia Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Mild symptomatic gastritis and duodenitis with severe anemia Mild abdominal pain with severe anemia (combined DW) --
Severe anemia due to gastritis and duodenitis Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Mild symptomatic gastritis and duodenitis with mild anemia Mild abdominal pain with mild anemia (combined DW) --
Moderate symptomatic gastritis and duodenitis with mild anemia Moderate abdominal pain with mild anemia (combined DW) 0.118(0.081–0.163)
Moderate symptomatic gastritis and duodenitis without anemia Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Appendicitis Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Paralytic ileus and intestinal obstruction Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Asymptomatic inguinal, femoral, and abdominal hernia Asymptomatic -- --
Mild symptomatic inguinal, femoral and abdominal hernia Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Moderate symptomatic inguinal, femoral and abdominal hernia Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Severe symptomatic inguinal, femoral and abdominal hernia Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Asymptomatic Crohn's disease Asymptomatic -- --
Asymptomatic ulcerative colitis Asymptomatic -- --
Ulcerative colitis Crohn disease or ulcerative colitis
has cramping abdominal pain, has diarrhea several times a 
day, and feels very tired for two months every year. When the 
person does not have symptoms, there is anxiety about them 
returning.
0.231
(0.156–0.32)
Crohn's disease Crohn disease or ulcerative colitis
has cramping abdominal pain, has diarrhea several times a 
day, and feels very tired for two months every year. When the 
person does not have symptoms, there is anxiety about them 
returning.
0.231
(0.156–0.32)
Vascular intestinal disorders Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Asymptomatic gallbladder and biliary diseases Asymptomatic -- --
Severe symptomatic episodes gallbladder and biliary diseases Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Mild symptomatic episodes gallbladder and biliary diseases Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Moderate symptomatic episodes gallbladder and biliary diseases Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Moderate pancreatitis episodes Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Mild pancreatitis episodes Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Severe pancreatitis episodes Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Other digestive diseases Post-COMO calculation for residuals (YLL/YLD ratio, other methods) -- --
Severe Alzheimer disease and other dementias Dementia, severe has complete memory loss; no longer recognizes close family members; and requires help with all daily activities.
0.449
(0.304–0.595)
Mild Alzheimer disease and other dementias Dementia, mild has some trouble remembering recent events, and finds it hard to concentrate and make decisions and plans.
0.069
(0.046–0.099)
Moderate Alzheimer disease and other dementias Dementia, moderate
has memory problems and confusion, feels disoriented, at 
times hears voices that are not real, and needs help with 
some daily activities.
0.377
(0.252–0.508)
Mild Parkinson disease Parkinson disease, mild has mild tremors and moves a little slowly, but is able to walk and do daily activities without assistance. 
0.01
(0.005–0.019)
Moderate Parkinson disease Parkinson disease, moderate
has moderate tremors and moves slowly, which causes some 
difficulty in walking and daily activities. The person has 
some trouble swallowing, talking, sleeping, and 
0.267
(0.181–0.372)
Severe Parkinson disease Parkinson disease, severe
has severe tremors and moves very slowly, which causes 
great difficulty in walking and daily activities. The person 
falls easily and has a lot of difficulty talking, swallowing, 
sleeping, and remembering things. 
0.575
(0.396–0.73)
Severe epilepsy Epilepsy, seizures >= once a month
has sudden seizures one or more times each month, with 
violent muscle contractions and stiffness, loss of 
consciousness, and loss of urine or bowel control. Between 
seizures the person has memory loss and difficulty 
concentrating.
0.552
(0.375–0.71)
Less severe epilepsy Epilepsy, seizures 1-11 per year
has sudden seizures two to five times a year, with violent 
muscle contractions and stiffness, loss of consciousness, and 
loss of urine or bowel control.
0.263
(0.173–0.367)
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Seizure-free, treated epilepsy Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Mild multiple sclerosis Multiple sclerosis, mild
has mild loss of feeling in one hand, is a little unsteady while 
walking, has slight loss of vision in one eye, and often needs 
to urinate urgently.
0.183
(0.124–0.253)
Severe multiple sclerosis Multiple sclerosis, severe
has slurred speech and difficulty swallowing. The person has 
weak arms and hands, very limited and stiff leg movement, 
has loss of vision in both eyes and cannot control urinating.
0.719
(0.534–0.858)
Moderate multiple sclerosis Multiple sclerosis, moderate
needs help walking, has difficulty with writing and arm 
coordination, has loss of vision in one eye and cannot control 
urinating.
0.463
(0.313–0.613)
Asymptomatic multiple sclerosis Asymptomatic -- --
Severe respiratory problems and speech problems due to motor 
neuron disease Severe respiratory and speech problems (combined DW)
0.438
(0.304–0.581)
Moderate respiratory problems and speech problems due to motor 
neuron disease Moderate respiratory and speech problems (combined DW)
0.265
(0.184–0.36)
Mild respiratory problems and speech problems due to motor neuron 
disease Mild respiratory and speech problems (combined DW)
0.069
(0.043–0.106)
Severe motor impairment and speech problems due to motor neuron 
disease Severe motor impairment and speech problems (combined DW)
0.432
(0.306–0.572)
Moderate motor impairment and speech problems due to motor 
neuron disease Moderate motor impairment and speech problems (combined DW)
0.109
(0.071–0.158)
Mild motor impairment and speech problems due to motor neuron 
disease Mild motor impairment and speech problems (combined DW)
0.061
(0.038–0.094)
Severe motor impairment and severe respiratory problems due to 
motor neuron disease
Severe motor impairment and severe respiratory 
problems (combined DW)
0.641
(0.47–0.796)
Severe motor impairment and mild respiratory problems due to 
motor neuron disease
Severe motor impairment and mild respiratory 
problems (combined DW)
0.413
(0.286–0.553)
Moderate motor impairment, severe respiratory problems, and speech 
problems due to motor neuron disease
Moderate motor impairment with severe 
respiratory problems and speech problems (combined DW)
0.472
(0.339–0.611)
Moderate motor impairment and severe respiratory problems due to 
motor neuron disease
Moderate motor impairment and severe respiratory 
problems (combined DW)
0.414
(0.281–0.559)
Moderate motor impairment and moderate respiratory problems due 
to motor neuron disease
Moderate motor impairment and moderate 
respiratory problems (combined DW)
0.233
(0.16–0.322)
Moderate motor impairment and mild respiratory problems due to 
motor neuron disease
Moderate motor impairment and mild respiratory 
problems (combined DW)
0.029
(0.015–0.051)
Mild motor impairment and severe respiratory problems due to motor 
neuron disease
Mild motor impairment and severe respiratory 
problems (combined DW)
0.443
(0.311–0.587)
Mild motor impairment and mild respiratory problems due to motor 
neuron disease
Mild motor impairment and mild respiratory 
problems (combined DW)
0.079
(0.05–0.117)
Severe motor impairment, severe respiratory problems, and speech 
problems due to motor neuron disease
Severe motor impairment with severe respiratory 
problems and speech problems (combined DW)
0.659
(0.495–0.809)
Severe motor impairment, moderate respiratory problems, and 
speech problems due to motor neuron disease
Severe motor impairment with moderate 
respiratory problems and speech problems (combined DW)
0.557
(0.412–0.705)
Severe motor impairment and moderate respiratory problems due to 
motor neuron disease
Severe motor impairment and moderate respiratory 
problems (combined DW)
0.534
(0.382–0.685)
Moderate motor impairment due to motor neuron disease Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Moderate motor impairment, mild respiratory problems, and speech 
problems due to motor neuron disease
Moderate motor impairment with mild respiratory 
problems and speech problems (combined DW)
0.126
(0.081–0.183)
Mild respiratory problems due to motor neuron disease COPD and other chronic respiratory problems, mild
has cough and shortness of breath after heavy physical 
activity, but is able to walk long distances and climb stairs.
0.019
(0.011–0.033)
Severe respiratory problems due to motor neuron disease COPD and other chronic respiratory problems, severe
has cough, wheezing and shortness of breath all the time. 
The person has great difficulty walking even short distances 
or climbing any stairs, feels tired when at rest, and is 
0.408
(0.273–0.556)
Moderate respiratory problems due to motor neuron disease COPD and other chronic respiratory problems, moderate
has cough, wheezing and shortness of breath, even after light 
physical activity. The person feels tired and can walk only 
short distances or climb only a few stairs.
0.225
(0.153–0.31)
Mild motor impairment due to motor neuron disease Motor impairment, mild has some difficulty in moving around but is able to walk without help.
0.01
(0.005–0.019)
Mild motor impairment, mild respiratory problems, and speech 
problems due to motor neuron disease
Mild motor impairment with mild respiratory 
problems and speech problems (combined dw)
0.079
(0.049–0.123)
Mild motor impairment, moderate respiratory problems, and speech 
problems due to motor neuron disease
Mild motor impairment with moderate respiratory 
problems and speech problems (combined dw)
0.272
(0.191–0.369)
Speech problems due to motor neuron disease Speech problems has difficulty speaking, and others find it difficult to understand. 
0.051
(0.032–0.078)
Severe motor impairment due to motor neuron disease Motor impairment, severe is unable to move around without help, and is not able to lift or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Diagnosis of motor neuron disease Generic uncomplicated disease: anxiety about diagnosis
has a disease diagnosis that causes some worry but minimal 
interference with daily activities.
0.012
(0.006–0.023)
Severe motor impairment, mild respiratory problems, and speech 
problems due to motor neuron disease
Severe motor impairment with mild respiratory 
problems and speech problems (combined DW)
0.443
(0.316–0.58)
Moderate motor impairment, moderate respiratory problems, and 
speech problems due to motor neuron disease
Moderate motor impairment with moderate 
respiratory problems and speech problems (combined DW)
0.309
(0.221–0.414)
Mild motor impairment, severe respiratory problems and speech 
problems due to motor neuron disease
Mild motor impairment with severe respiratory 
problems and speech problems (combined DW)
0.444
(0.311–0.585)
Asymptomatic medication overuse headache due to migraine Asymptomatic -- --
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Symptomatic migraine Headache, migraine
has severe, throbbing head pain and nausea that cause great 
difficulty in daily activities and sometimes confine the person 
to bed. Moving around, light, and noise make it worse.
0.441
(0.294–0.588)
Symptomatic medication overuse headache due to migraine Headache, medication overuse
has daily headaches, felt as dull pain and often lasting all day, 
with poor sleep, nausea and fatigue. The person takes 
medicine for the headaches, which provides little relief but is 
needed to avoid having worse symptoms.
0.223
(0.146–0.313)
Asymptomatic migraine Asymptomatic -- --
Symptomatic medication overuse headache due to tension-type 
headache Headache, medication overuse
has daily headaches, felt as dull pain and often lasting all day, 
with poor sleep, nausea and fatigue. The person takes 
medicine for the headaches, which provides little relief but is 
needed to avoid having worse symptoms.
0.223
(0.146–0.313)
Asymptomatic medication overuse headache due to tension-type 
headache Asymptomatic -- --
Asymptomatic tension-type headache Asymptomatic -- --
Symptomatic tension-type headache Headache, tension-type has a moderate headache that also affects the neck, which causes difficulty in daily activities. 
0.037
(0.022–0.057)
Other neurological disorders Post-COMO calculation for residuals (YLL/YLD ratio, other methods) -- --
Guillain-Barré syndrome due to other neurological disorders Spinal cord lesion below neck level (treated)
is paralyzed from the waist down, cannot feel or move the 
legs and has difficulties with urine and bowel control. The 
person uses a wheelchair to move around.
0.296
(0.198–0.414)
Schizophrenia acute state Schizophrenia, acute state
hears and sees things that are not real and is afraid, confused, 
and sometimes violent. The person has great difficulty with 
communication and daily activities, and sometimes wants to 
harm or kill himself (or herself).
0.778
(0.606–0.9)
Schizophrenia residual state Schizophrenia, residual state
hears and sees things that are not real and has trouble 
communicating. The person can be forgetful, has difficulty 
with daily activities, and thinks about hurting himself (or 
0.588
(0.411–0.754)
Very mild alcohol dependence Alcohol use disorder, very mild drinks alcohol daily and has difficulty controlling the urge to drink. When sober, the person functions normally.
0.123
(0.082–0.177)
Severe fetal alcohol syndrome Fetal alcohol syndrome, severe is very slow in developing physically and mentally, which causes great difficulty in daily activities.
0.179
(0.119–0.257)
Mild alcohol dependence Alcohol use disorder, mild
drinks a lot of alcohol and sometimes has difficulty 
controlling the urge to drink. While intoxicated, the person 
has difficulty performing daily activities.
0.235
(0.16–0.327)
Moderate fetal alcohol syndrome Fetal alcohol syndrome, moderate is slow in developing physically and mentally, which causes some difficulty in daily activities.
0.056
(0.035–0.083)
Asymptomatic fetal alcohol syndrome Asymptomatic -- --
Asymptomatic alcohol dependence Asymptomatic -- --
Mild fetal alcohol syndrome Fetal alcohol syndrome, mild
is a little slow in developing physically and mentally, which 
causes some difficulty in learning but no other difficulties in 
daily activities.
0.016
(0.008–0.03)
Severe alcohol dependence Alcohol use disorder, severe
gets drunk almost every day and is unable to control the urge 
to drink. Drinking and recovering replace most daily 
activities. The person has difficulty thinking, remembering 
and communicating, and feels constant pain and fatigue.
0.57
(0.396–0.732)
Moderate alcohol dependence Alcohol use disorder, moderate
drinks a lot, gets drunk almost every week and has great 
difficulty controlling the urge to drink. Drinking and 
recovering cause great difficulty in daily activities, sleep loss, 
0.373
(0.248–0.508)
Asymptomatic opioid dependence Asymptomatic -- --
Severe opioid dependence Heroin and other opioid dependence
uses heroin daily and has difficulty controlling the habit. 
When the effects wear off, the person feels severe nausea, 
agitation, vomiting and fever. The person has a lot of 
difficulty in daily activities.
0.697
(0.51–0.843)
Mild opioid dependence Heroin and other opioid dependence, mild
uses heroin (or methadone)Â daily and has difficulty 
controlling the habit. When not using, the person functions 
normally.
0.335
(0.221–0.473)
Mild cocaine dependence Cocaine dependence, mild
uses cocaine at least once a week and has some difficulty 
controlling the habit. When not using, the person functions 
normally.
0.116
(0.074–0.165)
Asymptomatic cocaine dependence Asymptomatic -- --
Severe cocaine dependence Cocaine dependence
uses cocaine and has difficulty controlling the habit. The 
person sometimes has mood swings, anxiety, paranoia, 
hallucinations and sleep problems, and has some difficulty in 
daily activities.
0.479
(0.324–0.634)
Severe amphetamine dependence Amphetamine dependence
uses stimulants (drugs) and has difficulty controlling the 
habit. The person sometimes has depression, hallucinations 
and mood swings, and has difficulty in daily activities. 
0.486
(0.329–0.637)
Mild amphetamine dependence Amphetamine dependence, mild
uses stimulants (drugs) at least once a week and has some 
difficulty controlling the habit. When not using, the person 
functions normally.
0.079
(0.051–0.114)
Asymptomatic amphetamine dependence Asymptomatic -- --
Asymptomatic cannabis dependence Asymptomatic -- --
Mild cannabis dependence Cannabis dependence, mild
uses marijuana at least once a week and has some difficulty 
controlling the habit. When not using, the person functions 
normally. 
0.039
(0.024–0.06)
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Severe cannabis dependence Cannabis dependence
uses marijuana daily and has difficulty controlling the habit. 
The person sometimes has mood swings, anxiety and 
hallucinations, and has some difficulty in daily activities.
0.266
(0.178–0.364)
Other drug use disorders Cocaine dependence, mild
uses cocaine at least once a week and has some difficulty 
controlling the habit. When not using, the person functions 
normally.
0.116
(0.074–0.165)
Severe major depressive disorder Major depressive disorder, severe episode
has overwhelming, constant sadness and cannot function in 
daily life. The person sometimes loses touch with reality and 
wants to harm or kill himself (or herself).
0.658
(0.477–0.807)
Moderate major depressive disorder Major depressive disorder, moderate episode
has constant sadness and has lost interest in usual activities. 
The person has some difficulty in daily life, sleeps badly, has 
trouble concentrating, and sometimes thinks about harming 
himself (or herself).
0.396
(0.267–0.531)
Major depressive disorder, currently without symptoms Asymptomatic -- --
Mild major depressive disorder Major depressive disorder, mild episode
feels persistent sadness and has lost interest in usual 
activities. The person sometimes sleeps badly, feels tired, or 
has trouble concentrating but still manages to function in 
daily life with extra effort.
0.145
(0.099–0.209)
Dysthymia, currently without symptoms Asymptomatic -- --
Symptomatic dysthymia Major depressive disorder, mild episode
feels persistent sadness and has lost interest in usual 
activities. The person sometimes sleeps badly, feels tired, or 
has trouble concentrating but still manages to function in 
daily life with extra effort.
0.145
(0.099–0.209)
Bipolar disorder manic state Bipolar disorder, manic episode 
is hyperactive, hears and believes things that are not real, and 
engages in impulsive and aggressive behavior that endanger 
the person and others. 
0.492
(0.341–0.646)
Bipolar disorder residual state Bipolar disorder, residual state has mild mood swings, irritability and some difficulty with daily activities. 
0.032
(0.018–0.051)
Bipolar disorder depressive state Major depressive disorder, moderate episode
has constant sadness and has lost interest in usual activities. 
The person has some difficulty in daily life, sleeps badly, has 
trouble concentrating, and sometimes thinks about harming 
himself (or herself).
0.396
(0.267–0.531)
Anxiety disorders, currently without symptoms Asymptomatic -- --
Moderate anxiety disorders Anxiety disorders, moderate
feels anxious and worried, which makes it difficult to 
concentrate, remember things, and sleep. The person tires 
easily and finds it difficult to perform daily activities.
0.133
(0.091–0.186)
Severe anxiety disorders Anxiety disorders, severe
constantly feels very anxious and worried, which makes it 
difficult to concentrate, remember things and sleep. The 
person has lost pleasure in life and thinks about suicide. 
0.523
(0.362–0.677)
Mild anxiety disorders Anxiety disorders, mild
feels mildly anxious and worried, which makes it slightly 
difficult to concentrate, remember things, and sleep. The 
person tires easily but is able to perform daily activities.
0.03
(0.018–0.046)
Anorexia nervosa Anorexia nervosa
feels an overwhelming need to starve and exercises 
excessively to lose weight. The person is very thin, weak and 
anxious.
0.224
(0.15–0.312)
Bulimia nervosa Bulimia nervosa has uncontrolled overeating followed by guilt, starving, and vomiting to lose weight.
0.223
(0.149–0.311)
Autism with profound intellectual disability Autism with profound intellectual disability (combined DW) --
Autism with moderate intellectual disability Autism with moderate intellectual disability (combined DW) --
Autism with mild intellectual disability Autism with mild intellectual disability (combined DW) --
Autism with borderline intellectual disability Autism with borderline intellectual disability (combined DW) --
Autism without intellectual disability Autism without intellectual disability (combined DW) --
Autism with severe intellectual disability Autism with severe intellectual disability (combined DW) --
Asperger syndrome and other autistic spectrum disorders Asperger syndrome
has difficulty interacting with other people, and is slow to 
understand or respond to questions. The person is often 
preoccupied with one thing and has some difficulty with 
basic daily activities. 
0.104
(0.071–0.147)
Symptomatic attention-deficit/hyperactivity disorder Attention deficit hyperactivity disorder is hyperactive and has difficulty concentrating, remembering things, and completing tasks. 
0.045
(0.028–0.066)
Attention-deficit/hyperactivity disorder, currently without symptoms Asymptomatic -- --
Symptomatic conduct disorder Conduct disorder
has frequent behavior problems, which are sometimes 
violent. The person often has difficulty interacting with other 
people and feels irritable.
0.241
(0.159–0.341)
Conduct disorder, currently without symptoms Asymptomatic -- --
Mild idiopathic developmental intellectual disability Intellectual disability / mental retardation, mild
has low intelligence and is slow in learning at school. As an 
adult, the person can live independently, but often needs help 
to raise children and can only work at simple supervised jobs.
0.043
(0.026–0.064)
Borderline idiopathic developmental intellectual disability Borderline intellectual functioning
is slow in learning at school. As an adult, the person has 
some difficulty doing complex or unfamiliar tasks but 
otherwise functions independently.
0.011
(0.005–0.02)
Profound idiopathic developmental intellectual disability Intellectual disability / mental retardation, profound
has very low intelligence, has almost no language, and does 
not understand even the most basic requests or instructions. 
The person requires constant supervision and help for all 
activities.
0.2
(0.133–0.283)
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Moderate idiopathic developmental intellectual disability Intellectual disability / mental retardation, moderate
has low intelligence, and is slow in learning to speak and to 
do even simple tasks. As an adult, the person requires a lot of 
support to live independently and raise children. The person 
can only work at the simplest supervised jobs.
0.1
(0.066–0.142)
Severe idiopathic developmental intellectual disability Intellectual disability / mental retardation, severe
has very low intelligence and cannot speak more than a few 
words, needs constant supervision and help with most daily 
activities, and can do only the simplest tasks.
0.16
(0.107–0.226)
Other mental disorders, currently without symptoms Asymptomatic -- --
Moderate other mental disorders Anxiety disorders, moderate
feels anxious and worried, which makes it difficult to 
concentrate, remember things, and sleep. The person tires 
easily and finds it difficult to perform daily activities.
0.133
(0.091–0.186)
Severe other mental disorders Anxiety disorders, severe
constantly feels very anxious and worried, which makes it 
difficult to concentrate, remember things and sleep. The 
person has lost pleasure in life and thinks about suicide. 
0.523
(0.362–0.677)
Mild other mental disorders Anxiety disorders, mild
feels mildly anxious and worried, which makes it slightly 
difficult to concentrate, remember things, and sleep. The 
person tires easily but is able to perform daily activities.
0.03
(0.018–0.046)
Moderate vision impairment due to diabetes mellitus Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Diabetic foot due to neuropathy Diabetic neuropathy with diabetic foot -- --
Severe vision impairment due to diabetes mellitus Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Diabetic neuropathy Diabetic neuropathy
has pain, tingling and numbness in the arms, legs, hands and 
feet. The person sometimes gets cramps and muscle 
weakness.
0.133
(0.089–0.187)
Uncomplicated diabetes mellitus Generic uncomplicated disease: worry and daily medication
has a chronic disease that requires medication every day and 
causes some worry but minimal interference with daily 
activities.
0.049
(0.031–0.072)
Diabetic neuropathy and amputation with treatment Diabetic neuropathy with treated amputation -- --
Diabetic neuropathy and amputation without treatment Diabetic neuropathy with untreated amputation -- --
Blindness due to diabetes mellitus Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Acute glomerulonephritis Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Stage V chronic kidney disease untreated and severe anemia due to 
diabetes mellitus
Severe anemia and terminal phase, without 
medication (for cancers, end-stage kidney/liver 
disease)
(combined DW) 0.631(0.456–0.782)
End-stage renal disease after transplant due to diabetes mellitus End-stage renal disease, with kidney transplant sometimes feels tired and down, and has some difficulty with daily activities.
0.024
(0.014–0.039)
Stage IV chronic kidney disease untreated without anemia due to 
diabetes mellitus Chronic kidney disease (stage IV)
tires easily, has nausea, reduced appetite and difficulty 
sleeping.
0.104
(0.07–0.147)
Stage III chronic kidney disease and severe anemia due to diabetes 
mellitus Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Stage III chronic kidney disease and mild anemia due to diabetes 
mellitus Anemia, mild
feels slightly tired and weak at times, but this does not 
interfere with normal daily activities.
0.004
(0.001–0.008)
Stage IV chronic kidney disease untreated and mild anemia due to 
diabetes mellitus Mild anemia with Stage IV CKD -- --
Stage III chronic kidney disease without anemia due to diabetes 
mellitus Asymptomatic -- --
Stage IV chronic kidney disease untreated and moderate anemia due 
to diabetes mellitus Moderate anemia with Stage IV CKD -- --
Stage V chronic kidney disease untreated without anemia due to 
diabetes mellitus
Terminal phase, without medication (for cancers, 
end-stage kidney/liver disease)
has lost a lot of weight and has constant pain. The person has 
no appetite, feels nauseous, and needs to spend most of the 
day in bed.
0.569
(0.389–0.727)
Stage IV chronic kidney disease untreated and severe anemia due to 
diabetes mellitus Severe anemia with Stage IV CKD -- --
Stage V chronic kidney disease untreated and moderate anemia due 
to diabetes mellitus
Moderate anemia and terminal phase, without 
medication (for cancers, end-stage kidney/liver 
disease)
(combined DW) 0.591(0.414–0.743)
End-stage renal disease on dialysis due to diabetes mellitus End-stage renal disease, on dialysis
is tired and has itching, cramps, headache, joint pains and 
shortness of breath. The person needs intensive medical care 
every other day lasting about half a day. 
0.571
(0.398–0.725)
Stage V chronic kidney disease untreated and mild anemia due to 
diabetes mellitus
Mild anemia and terminal phase, without 
medication (for cancers, end-stage kidney/liver 
disease)
(combined DW) 0.57(0.391–0.727)
Stage III chronic kidney disease and moderate anemia due to 
diabetes mellitus Anemia, moderate
feels moderate fatigue, weakness, and shortness of breath 
after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Stage IV chronic kidney disease untreated and moderate anemia due 
to hypertension Moderate anemia with Stage IV CKD -- --
Stage III chronic kidney disease without anemia due to hypertension Asymptomatic -- --
Stage V chronic kidney disease untreated and moderate anemia due 
to hypertension
Moderate anemia and terminal phase, without 
medication (for cancers, end-stage kidney/liver 
disease)
(combined DW) 0.591(0.414–0.743)
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Stage V chronic kidney disease untreated and severe anemia due to 
hypertension
Severe anemia and terminal phase, without 
medication (for cancers, end-stage kidney/liver 
disease)
(combined DW) 0.631(0.456–0.782)
End-stage renal disease on dialysis due to hypertension End-stage renal disease, on dialysis
is tired and has itching, cramps, headache, joint pains and 
shortness of breath. The person needs intensive medical care 
every other day lasting about half a day. 
0.571
(0.398–0.725)
Stage V chronic kidney disease untreated and mild anemia due to 
hypertension
Mild anemia and terminal phase, without 
medication (for cancers, end-stage kidney/liver 
disease)
(combined DW) 0.57(0.391–0.727)
Stage III chronic kidney disease and mild anemia due to hypertension Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Stage IV chronic kidney disease untreated and severe anemia due to 
hypertension Severe anemia with Stage IV CKD -- --
Stage IV chronic kidney disease untreated without anemia due to 
hypertension Chronic kidney disease (stage IV)
tires easily, has nausea, reduced appetite and difficulty 
sleeping.
0.104
(0.07–0.147)
Stage V chronic kidney disease untreated without anemia due to 
hypertension
Terminal phase, without medication (for cancers, 
end-stage kidney/liver disease)
has lost a lot of weight and has constant pain. The person has 
no appetite, feels nauseous, and needs to spend most of the 
day in bed.
0.569
(0.389–0.727)
Stage III chronic kidney disease and severe anemia due to 
hypertension Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Stage IV chronic kidney disease untreated and mild anemia due to 
hypertension Mild anemia with Stage IV CKD -- --
End-stage renal disease after transplant due to hypertension End-stage renal disease, with kidney transplant sometimes feels tired and down, and has some difficulty with daily activities.
0.024
(0.014–0.039)
Stage III chronic kidney disease and moderate anemia due to 
hypertension Anemia, moderate
feels moderate fatigue, weakness, and shortness of breath 
after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
End-stage renal disease after transplant due to glomerulonephritis End-stage renal disease, with kidney transplant sometimes feels tired and down, and has some difficulty with daily activities.
0.024
(0.014–0.039)
Stage IV chronic kidney disease untreated without anemia due to 
glomerulonephritis Chronic kidney disease (stage IV)
tires easily, has nausea, reduced appetite and difficulty 
sleeping.
0.104
(0.07–0.147)
Stage V chronic kidney disease untreated and moderate anemia due 
to glomerulonephritis
Moderate anemia and terminal phase, without 
medication (for cancers, end-stage kidney/liver 
disease)
(combined DW) 0.591(0.414–0.743)
Stage III chronic kidney disease and moderate anemia due to 
glomerulonephritis Anemia, moderate
feels moderate fatigue, weakness, and shortness of breath 
after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Stage III chronic kidney disease and severe anemia due to 
glomerulonephritis Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Stage III chronic kidney disease and mild anemia due to 
glomerulonephritis Anemia, mild
feels slightly tired and weak at times, but this does not 
interfere with normal daily activities.
0.004
(0.001–0.008)
Stage III chronic kidney disease without anemia due to 
glomerulonephritis Asymptomatic -- --
Stage V chronic kidney disease untreated and mild anemia due to 
glomerulonephritis
Mild anemia and terminal phase, without 
medication (for cancers, end-stage kidney/liver 
disease)
(combined DW) 0.57(0.391–0.727)
Stage IV chronic kidney disease untreated and severe anemia due to 
glomerulonephritis Severe anemia with Stage IV CKD -- --
Stage IV chronic kidney disease untreated and moderate anemia due 
to glomerulonephritis Moderate anemia with Stage IV CKD -- --
Stage V chronic kidney disease untreated and severe anemia due to 
glomerulonephritis
Severe anemia and terminal phase, without 
medication (for cancers, end-stage kidney/liver 
disease)
(combined DW) 0.631(0.456–0.782)
Stage V chronic kidney disease untreated without anemia due to 
glomerulonephritis
Terminal phase, without medication (for cancers, 
end-stage kidney/liver disease)
has lost a lot of weight and has constant pain. The person has 
no appetite, feels nauseous, and needs to spend most of the 
day in bed.
0.569
(0.389–0.727)
Stage IV chronic kidney disease untreated and mild anemia due to 
glomerulonephritis Mild anemia with Stage IV CKD -- --
End-stage renal disease on dialysis due to glomerulonephritis End-stage renal disease, on dialysis
is tired and has itching, cramps, headache, joint pains and 
shortness of breath. The person needs intensive medical care 
every other day lasting about half a day. 
0.571
(0.398–0.725)
Stage V chronic kidney disease untreated without anemia due to 
other causes
Terminal phase, without medication (for cancers, 
end-stage kidney/liver disease)
has lost a lot of weight and has constant pain. The person has 
no appetite, feels nauseous, and needs to spend most of the 
day in bed.
0.569
(0.389–0.727)
Stage III chronic kidney disease without anemia due to other causes Asymptomatic -- --
Stage IV chronic kidney disease untreated without anemia due to 
other causes Chronic kidney disease (stage IV)
tires easily, has nausea, reduced appetite and difficulty 
sleeping.
0.104
(0.07–0.147)
Stage III chronic kidney disease and mild anemia due to other causes Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Stage IV chronic kidney disease untreated and mild anemia due to 
other causes Mild anemia with Stage IV CKD -- --
Stage III chronic kidney disease and moderate anemia due to other 
causes Anemia, moderate
feels moderate fatigue, weakness, and shortness of breath 
after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Stage IV chronic kidney disease untreated and moderate anemia due 
to other causes Moderate anemia with Stage IV CKD -- --
Stage V chronic kidney disease untreated and moderate anemia due 
to other causes
Moderate anemia and terminal phase, without 
medication (for cancers, end-stage kidney/liver 
disease)
(combined DW) 0.591(0.414–0.743)
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Stage III chronic kidney disease and severe anemia due to other 
causes Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Stage IV chronic kidney disease untreated and severe anemia due to 
other causes Severe anemia with Stage IV CKD -- --
End-stage renal disease after transplant due to other causes End-stage renal disease, with kidney transplant sometimes feels tired and down, and has some difficulty with daily activities.
0.024
(0.014–0.039)
Stage V chronic kidney disease untreated and severe anemia due to 
other causes
Severe anemia and terminal phase, without 
medication (for cancers, end-stage kidney/liver 
disease)
(combined DW) 0.631(0.456–0.782)
Stage V chronic kidney disease untreated and mild anemia due to 
other causes
Mild anemia and terminal phase, without 
medication (for cancers, end-stage kidney/liver 
disease)
(combined DW) 0.57(0.391–0.727)
End-stage renal disease on dialysis due to other causes End-stage renal disease, on dialysis
is tired and has itching, cramps, headache, joint pains and 
shortness of breath. The person needs intensive medical care 
every other day lasting about half a day. 
0.571
(0.398–0.725)
Mild interstitial nephritis and urinary tract infections Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Moderate interstitial nephritis and urinary tract infections Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Moderate urolithiasis episodes Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Severe urolithiasis episodes Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Mild urolithiasis episodes Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Symptomatic benign prostatic hyperplasia Benign prostatic hypertrophy, symptomatic cases feels the urge to urinate frequently, but when passing urine it comes out slowly and sometimes is painful.
0.067
(0.043–0.097)
Asymptomatic benign prostatic hyperplasia Asymptomatic -- --
Primary male infertility Infertility, primary wants to have a child and has a fertile partner, but the couple cannot conceive.
0.008
(0.003–0.015)
Secondary male infertility Infertility, secondary has at least one child, and wants to have more children. The person has a fertile partner, but the couple cannot conceive. 
0.005
(0.002–0.011)
Other urinary diseases Post-COMO calculation for residuals (YLL/YLD ratio, other methods) -- --
Asymptomatic uterine fibroids Asymptomatic -- --
Mild abdominal pain due to uterine fibroids, with severe anemia Mild abdominal pain with severe anemia (combined DW) --
Mild abdominal pain due to uterine fibroids, with moderate anemia Mild abdominal pain with moderate anemia (combined DW) --
Mild abdominal pain due to uterine fibroids, without anemia Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Mild abdominal pain due to uterine fibroids, with mild anemia Mild abdominal pain with mild anemia (combined DW) --
Secondary infertility due to polycystic ovarian syndrome Disfigurement level 1 and secondary infertility (combined DW) --
Hirsutism due to polycystic ovarian syndrome Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Hirsutism and secondary infertility due to polycystic ovarian 
syndrome Infertility, secondary
has at least one child, and wants to have more children. The 
person has a fertile partner, but the couple cannot conceive. 
0.005
(0.002–0.011)
Asymptomatic polycystic ovarian syndrome Asymptomatic -- --
Hirsutism and primary infertility due to polycystic ovarian syndrome Disfigurement level 1 and primary infertility (combined DW) --
Primary infertility due to polycystic ovarian syndrome Infertility, primary wants to have a child and has a fertile partner, but the couple cannot conceive.
0.008
(0.003–0.015)
Idiopathic secondary female infertility Infertility, secondary has at least one child, and wants to have more children. The person has a fertile partner, but the couple cannot conceive. 
0.005
(0.002–0.011)
Idiopathic primary female infertility Infertility, primary wants to have a child and has a fertile partner, but the couple cannot conceive.
0.008
(0.003–0.015)
Mild abdominal pain and secondary infertility due to endometriosis Mild abdominal pain and secondary infertility (combined DW) --
Moderate abdominal pain and secondary infertility due to 
endometriosis Moderate abdominal pain and secondary infertility (combined DW) --
Severe abdominal pain and secondary infertility due to endometriosis Severe abdominal pain and secondary infertility (combined DW) --
Severe endometriosis Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Primary infertility due to endometriosis Infertility, primary wants to have a child and has a fertile partner, but the couple cannot conceive.
0.008
(0.003–0.015)
Secondary infertility due to endometriosis Infertility, secondary has at least one child, and wants to have more children. The person has a fertile partner, but the couple cannot conceive. 
0.005
(0.002–0.011)
Moderate abdominal pain due to endometriosis Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Asymptomatic endometriosis Asymptomatic -- --
Severe abdominal pain and primary infertility due to endometriosis Severe abdominal pain and primary infertility (combined DW) --
Mild abdominal pain due to endometriosis Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Moderate abdominal pain and primary infertility due to 
endometriosis Moderate abdominal pain and primary infertility (combined DW) --
Mild abdominal pain and primary infertility due to endometriosis Mild abdominal pain and primary infertility (combined DW) --
Abdominal pain due to genital prolapse Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
830
Sequela Health state name Health state lay description Disability weight
Appendix Table 5. GBD 2016 sequelae, health states, health state lay descriptions, and disability weights
Asymptomatic genital prolapse Asymptomatic -- --
Abdominal pain and stress incontinence due to genital prolapse Mild abdominal pain and stress incontinence (combined DW) --
Stress incontinence due to genital prolapse Stress incontinence loses small amounts of urine without meaning to when coughing, sneezing, laughing or during physical exercise.
0.02
(0.011–0.035)
Abdominal pain due to premenstrual syndrome Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Asymptomatic premenstrual syndrome Asymptomatic -- --
Depression due to premenstrual syndrome Major depressive disorder, mild episode
feels persistent sadness and has lost interest in usual 
activities. The person sometimes sleeps badly, feels tired, or 
has trouble concentrating but still manages to function in 
daily life with extra effort.
0.145
(0.099–0.209)
Abdominal pain and depression due to premenstrual syndrome Mild abdominal pain and mild depression (combined DW) --
Severe other gynecological disorders Abdominopelvic problem, severe has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
0.324
(0.22–0.442)
Mild other gynecological disorders Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Moderate anemia due to other gynecological diseases Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Moderate other gynecological disorders Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Severe anemia due to other gynecological diseases Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Asymptomatic other gynecological disorders Asymptomatic -- --
Mild anemia due to other gynecological diseases Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Beta-thalassemia major, with moderate anemia Anemia, moderate; Generic uncomplicated disease anxiety -- --
Asymptomatic and mild heart failure due to thalassemias Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Moderate heart failure due to thalassemias Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Hemoglobin E/beta-thalassemia, with moderate anemia Anemia, moderate; Generic uncomplicated disease anxiety -- --
Hemoglobin H disease, with moderate anemia Anemia, moderate; Generic uncomplicated disease anxiety -- --
Hemoglobin H disease, severe infection with severe anemia Infectious disease, acute episode, severe; Generic uncomplicated disease anxiety; Anemia, severe -- --
Beta-thalassemia major, with severe anemia Anemia, severe; Generic uncomplicated disease anxiety -- --
Hemoglobin E/beta-thalassemia, with severe anemia Anemia, severe; Generic uncomplicated disease anxiety -- --
Beta-thalassemia major, severe infection with severe anemia Infectious disease, acute episode, severe; Generic uncomplicated disease anxiety; Anemia, severe -- --
Hemoglobin H disease, with mild anemia Anemia, mild; Generic uncomplicated disease anxiety -- --
Hemoglobin E/beta-thalassemia, severe infection with severe anemia Infectious disease, acute episode, severe; Generic uncomplicated disease anxiety; Anemia, severe -- --
Hemoglobin E/Beta-thalassemia, without anemia Generic uncomplicated disease: anxiety about diagnosis
has a disease diagnosis that causes some worry but minimal 
interference with daily activities.
0.012
(0.006–0.023)
Hemoglobin E/beta-thalassemia, with mild anemia Anemia, mild; Generic uncomplicated disease anxiety -- --
Beta-thalassemia major, with mild anemia Anemia, mild; Generic uncomplicated disease anxiety -- --
Beta-thalassemia major, without anemia Generic uncomplicated disease: anxiety about diagnosis
has a disease diagnosis that causes some worry but minimal 
interference with daily activities.
0.012
(0.006–0.023)
Hemoglobin H disease, without anemia Generic uncomplicated disease: anxiety about diagnosis
has a disease diagnosis that causes some worry but minimal 
interference with daily activities.
0.012
(0.006–0.023)
Severe heart failure due to thalassemias Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Hemoglobin H disease, with severe anemia Anemia, severe; Generic uncomplicated disease anxiety -- --
Moderate anemia due to B-thalassemia trait Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Asymptomatic B-thalassemia trait Asymptomatic -- --
Asymptomatic hemoglobin E trait Asymptomatic -- --
Moderate anemia due to hemoglobin E trait Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Mild anemia due to B-thalassemia trait Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Mild anemia due to hemoglobin E trait Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
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Severe anemia due to hemoglobin E trait Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Severe anemia due to B-thalassemia trait Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Homozygous sickle cell and severe sickle cell/beta-thalassemia, 
without anemia
Generic uncomplicated disease: anxiety about 
diagnosis
has a disease diagnosis that causes some worry but minimal 
interference with daily activities.
0.012
(0.006–0.023)
Hemoglobin SC disease, without anemia Generic uncomplicated disease: anxiety about diagnosis
has a disease diagnosis that causes some worry but minimal 
interference with daily activities.
0.012
(0.006–0.023)
Mild sickle cell/beta-thalassemia, without anemia Generic uncomplicated disease: anxiety about diagnosis
has a disease diagnosis that causes some worry but minimal 
interference with daily activities.
0.012
(0.006–0.023)
Hemoglobin SC disease, with vaso-occlusive crisis, stroke, and 
severe anemia
Generic uncomplicated disease anxiety; long-term 
consequences due to stroke; severe 
abdominopelvic problem; Anemia, severe
-- --
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis, stroke, 
and severe anemia
Generic uncomplicated disease anxiety; long-term 
consequences due to stroke; severe 
abdominopelvic problem; Anemia, severe
-- --
Mild sickle cell/beta-thalassemia, with stroke, without anemia Generic uncomplicated disease anxiety; long-term consequences due to stroke -- --
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with 
vaso-occlusive crisis and stroke, without anemia
Generic uncomplicated disease anxiety; long-term 
consequences due to stroke; severe 
abdominopelvic problem
-- --
Hemoglobin SC disease, with vaso-occlusive crisis and stroke, 
without anemia
Generic uncomplicated disease anxiety; long-term 
consequences due to stroke; severe 
abdominopelvic problem
-- --
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis and 
stroke, without anemia
Generic uncomplicated disease anxiety; long-term 
consequences due to stroke; severe 
abdominopelvic problem
-- --
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with 
vaso-occlusive crisis and severe anemia
Moderate abdominal pain; Anemia, severe; 
Generic uncomplicated disease anxiety -- --
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with 
mild anemia 
Anemia, mild; Generic uncomplicated disease 
anxiety -- --
Hemoglobin SC disease, with stroke, without anemia Generic uncomplicated disease anxiety; long-term consequences due to stroke -- --
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with 
stroke, without anemia
Generic uncomplicated disease anxiety; long-term 
consequences due to stroke -- --
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis, without 
anemia
Generic uncomplicated disease anxiety and severe 
abdominopelvic problem -- --
Hemoglobin SC disease, with vaso-occlusive crisis, without anemia Generic uncomplicated disease anxiety and severe abdominopelvic problem -- --
Hemoglobin SC disease, with vaso-occlusive crisis and severe 
anemia
Moderate abdominal pain; Anemia, severe; 
Generic uncomplicated disease anxiety -- --
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with 
severe anemia 
Anemia, severe; Generic uncomplicated disease 
anxiety -- --
Hemoglobin SC disease, with severe anemia Anemia, severe; Generic uncomplicated disease anxiety -- --
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with 
stroke and severe anemia
Generic uncomplicated disease anxiety; Long-
term consequences due to stroke; Anemia, severe -- --
Hemoglobin SC disease, with stroke and severe anemia Generic uncomplicated disease anxiety; Long-term consequences due to stroke; Anemia, severe -- --
Hemoglobin SC disease, with mild anemia Anemia, mild; Generic uncomplicated disease anxiety -- --
Mild sickle cell/beta-thalassemia, with vaso-occlusive crisis and 
severe anemia
Moderate abdominal pain; Anemia, severe; 
Generic uncomplicated disease anxiety -- --
Mild sickle cell/beta-thalassemia, with mild anemia Anemia, mild; Generic uncomplicated disease anxiety -- --
Mild sickle cell/beta-thalassemia, with severe anemia Anemia, severe; Generic uncomplicated disease anxiety -- --
Mild sickle cell/beta-thalassemia, with moderate anemia Anemia, moderate; Generic uncomplicated disease anxiety -- --
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with 
vaso-occlusive crisis, stroke, and severe anemia
Generic uncomplicated disease anxiety; long-term 
consequences due to stroke; severe 
abdominopelvic problem; Anemia, severe
-- --
Hemoglobin SC disease, with moderate anemia Anemia, moderate; Generic uncomplicated disease anxiety -- --
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with 
moderate anemia 
Anemia, moderate; Generic uncomplicated disease 
anxiety -- --
Homozygous sickle cell and severe sickle cell/beta-thalassemia, with 
vaso-occlusive crisis, without anemia
Generic uncomplicated disease anxiety and severe 
abdominopelvic problem -- --
Mild sickle cell/beta-thalassemia, with stroke and severe anemia Generic uncomplicated disease anxiety; Long-term consequences due to stroke; Anemia, severe -- --
Asymptomatic sickle cell trait Asymptomatic -- --
Moderate anemia due to sickle cell trait Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Mild anemia due to sickle cell trait Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Severe anemia due to sickle cell trait Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
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Asymptomatic and mild heart failure due to G6PD deficiency Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Mild anemia due to G6PD deficiency Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Severe heart failure due to G6PD deficiency Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Severe anemia due to G6PD deficiency Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Asymptomatic G6PD deficiency Asymptomatic -- --
Moderate heart failure due to G6PD deficiency Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Moderate anemia due to G6PD deficiency Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Mild anemia due to hemizygous G6PD deficiency Anemia, mild feels slightly tired and weak at times, but this does not interfere with normal daily activities.
0.004
(0.001–0.008)
Severe anemia due to hemizygous G6PD deficiency Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Moderate anemia due to hemizygous G6PD deficiency Anemia, moderate feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Asymptomatic hemizygous G6PD deficiency Asymptomatic -- --
Mild anemia due to other hemoglobinopathies and hemolytic 
anemias Anemia, mild
feels slightly tired and weak at times, but this does not 
interfere with normal daily activities.
0.004
(0.001–0.008)
Other hemoglobinopathies and hemolytic anemias Post-COMO calculation for residuals (YLL/YLD ratio, other methods) -- --
Severe heart failure due to other hemoglobinopathies and hemolytic 
anemias Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Asymptomatic and mild heart failure due to other 
hemoglobinopathies and hemolytic anemias Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Moderate heart failure due to other hemoglobinopathies and 
hemolytic anemias Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Moderate anemia due to other hemoglobinopathies and hemolytic 
anemias Anemia, moderate
feels moderate fatigue, weakness, and shortness of breath 
after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Severe anemia due to other hemoglobinopathies and hemolytic 
anemias Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Severe anemia due to endocrine, metabolic, blood, and immune 
disorders Anemia, severe
feels very weak, tired and short of breath, and has problems 
with activities that require physical effort or deep 
concentration.
0.149
(0.101–0.209)
Asymptomatic endocrine, metabolic, blood, and immune disorders Asymptomatic -- --
Severe endocrine, metabolic, blood, and immune disorders Thrombocytopenic purpura easily bruises and sometimes bleeds from the gums and nose; feels weak and has some difficulty with daily activities.
0.159
(0.106–0.226)
Moderate heart failure due to endocrine, metabolic, blood, and 
immune disorders Heart failure, moderate
is short of breath and easily tires with minimal physical 
activity, such as walking only a short distance. The person 
feels comfortable at rest but avoids moderate activity.
0.072
(0.047–0.103)
Asymptomatic and mild heart failure due to endocrine, metabolic, 
blood, and immune disorders Heart failure, mild
is short of breath and easily tires with moderate physical 
activity, such as walking uphill or more than a quarter-mile 
on level ground. The person feels comfortable at rest or 
during activities requiring less effort.
0.041
(0.026–0.062)
Mild anemia due to endocrine, metabolic, blood, and immune 
disorders Anemia, mild
feels slightly tired and weak at times, but this does not 
interfere with normal daily activities.
0.004
(0.001–0.008)
Mild endocrine, metabolic, blood, and immune disorders Hypothyroidism has low energy and feels cold. 0.019(0.01–0.032)
Moderate anemia due to endocrine, metabolic, blood, and immune 
disorders Anemia, moderate
feels moderate fatigue, weakness, and shortness of breath 
after exercise, making daily activities more difficult.
0.052
(0.034–0.076)
Severe heart failure due to endocrine, metabolic, blood, and immune 
disorders Heart failure, severe
is short of breath and feels tired when at rest. The person 
avoids any physical activity, for fear of worsening the 
breathing problems. 
0.179
(0.122–0.251)
Moderate endocrine, metabolic, blood, and immune disorders Hyperthyroidism feels nervous, has palpitations, sweats a lot and has difficulty sleeping.
0.145
(0.096–0.202)
Moderate rheumatoid arthritis Musculoskeletal problems, generalized, moderate
has pain and deformity in most joints, causing difficulty 
moving around, getting up and down, and using the hands 
for lifting and carrying. The person often feels fatigue.
0.317
(0.216–0.44)
Mild rheumatoid arthritis Musculoskeletal problems, upper limbs, moderate
has moderate pain and stiffness in the arms and hands, which 
causes difficulty lifting, carrying, and holding things, and 
trouble sleeping because of the pain.
0.117
(0.08–0.163)
Severe rheumatoid arthritis Musculoskeletal problems, generalized, severe
has severe, constant pain and deformity in most joints, 
causing difficulty moving around, getting up and down, 
eating, dressing, lifting, carrying and using the hands. The 
person often feels sadness, anxiety and extreme fatigue.
0.581
(0.403–0.739)
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Moderate osteoarthritis of the knee Musculoskeletal problems, lower limbs, moderate
has moderate pain in the leg, which makes the person limp, 
and causes some difficulty walking, standing, lifting and 
carrying heavy things, getting up and down and sleeping.
0.079
(0.054–0.11)
Severe osteoarthritis of the hip Musculoskeletal problems, lower limbs, severe
has severe pain in the leg, which makes the person limp and 
causes a lot of difficulty walking, standing, lifting and 
carrying heavy things, getting up and down, and sleeping.
0.165
(0.112–0.232)
Severe osteoarthritis of the knee Musculoskeletal problems, lower limbs, severe
has severe pain in the leg, which makes the person limp and 
causes a lot of difficulty walking, standing, lifting and 
carrying heavy things, getting up and down, and sleeping.
0.165
(0.112–0.232)
Mild osteoarthritis of the knee Musculoskeletal problems, lower limbs, mild has pain in the leg, which causes some difficulty running, walking long distances, and getting up and down.
0.023
(0.013–0.037)
Moderate osteoarthritis of the hip Musculoskeletal problems, lower limbs, moderate
has moderate pain in the leg, which makes the person limp, 
and causes some difficulty walking, standing, lifting and 
carrying heavy things, getting up and down and sleeping.
0.079
(0.054–0.11)
Mild osteoarthritis of the hip Musculoskeletal problems, lower limbs, mild has pain in the leg, which causes some difficulty running, walking long distances, and getting up and down.
0.023
(0.013–0.037)
Mild low back pain without leg pain Low back pain, mild has mild back pain, which causes some difficulty dressing, standing, and lifting things.
0.02
(0.011–0.035)
Moderate low back pain without leg pain Low back pain, moderate has moderate back pain, which causes difficulty dressing, sitting, standing, walking, and lifting things.
0.054
(0.035–0.079)
Most severe low back pain with leg pain Back pain, most severe, with leg pain
has constant back and leg pain, which causes difficulty 
dressing, sitting, standing, walking, and lifting things. The 
person sleeps poorly, is worried, and has lost some 
enjoyment in life.
0.384
(0.256–0.518)
Most severe low back pain without leg pain Back pain, most severe, without leg pain
has constant back pain, which causes difficulty dressing, 
sitting, standing, walking, and lifting things. The person 
sleeps poorly, is worried, and has lost some enjoyment in life.
0.372
(0.25–0.506)
Severe low back pain with leg pain Back pain, severe, with leg pain
has severe back and leg pain, which causes difficulty 
dressing, sitting, standing, walking, and lifting things. The 
person sleeps poorly and feels worried.
0.325
(0.219–0.446)
Severe low back pain without leg pain Back pain, severe, without leg pain
has severe back pain, which causes difficulty dressing, 
sitting, standing, walking, and lifting things. The person 
sleeps poorly and feels worried.
0.272
(0.182–0.373)
Mild low back pain with leg pain Mild low back pain with leg pain (combined DW) 0.02(0.011–0.035)
Moderate low back pain with leg pain Moderate low back pain with leg pain (combined DW) 0.054(0.035–0.079)
Severe neck pain Neck pain, severe
has severe neck pain, and difficulty turning the head and 
lifting things. The person gets headaches and arm pain, 
sleeps poorly, and feels tired and worried.
0.229
(0.153–0.317)
Most severe neck pain Neck pain, most severe
has constant neck pain and arm pain, and difficulty turning 
the head, holding arms up, and lifting things. The person gets 
headaches, sleeps poorly, and feels tired and worried. 
0.304
(0.202–0.415)
Moderate neck pain Neck pain, moderate has constant neck pain, and has difficulty turning the head, holding arms up, and lifting things
0.114
(0.075–0.162)
Mild neck pain Neck pain, mild has neck pain, and has difficulty turning the head and lifting things.
0.053
(0.034–0.078)
Asymptomatic gout Asymptomatic -- --
Polyarticular gout Musculoskeletal problems, generalized, severe
has severe, constant pain and deformity in most joints, 
causing difficulty moving around, getting up and down, 
eating, dressing, lifting, carrying and using the hands. The 
person often feels sadness, anxiety and extreme fatigue.
0.581
(0.403–0.739)
Symptomatic episodes of gout Gout, acute
has severe pain and swelling in the leg, making it very 
difficult to get up and down, stand, walk, lift, and carry 
heavy things. The person has trouble sleeping because of the 
0.295
(0.196–0.409)
Other musculoskeletal disorders severity level 5 Musculoskeletal problems, generalized, moderate
has pain and deformity in most joints, causing difficulty 
moving around, getting up and down, and using the hands 
for lifting and carrying. The person often feels fatigue.
0.317
(0.216–0.44)
Other musculoskeletal disorders severity level 4 Musculoskeletal problems, lower limbs, severe
has severe pain in the leg, which makes the person limp and 
causes a lot of difficulty walking, standing, lifting and 
carrying heavy things, getting up and down, and sleeping.
0.165
(0.112–0.232)
Other musculoskeletal disorders severity level 6 Musculoskeletal problems, generalized, severe
has severe, constant pain and deformity in most joints, 
causing difficulty moving around, getting up and down, 
eating, dressing, lifting, carrying and using the hands. The 
person often feels sadness, anxiety and extreme fatigue.
0.581
(0.403–0.739)
Asymptomatic other musculoskeletal disorders Asymptomatic -- --
Other musculoskeletal disorders severity level 3 Musculoskeletal problems, upper limbs, moderate
has moderate pain and stiffness in the arms and hands, which 
causes difficulty lifting, carrying, and holding things, and 
trouble sleeping because of the pain.
0.117
(0.08–0.163)
Other musculoskeletal disorders severity level 2 Musculoskeletal problems, upper limbs, mild has mild pain and stiffness in the arms and hands. The person has some difficulty lifting, carrying and holding things.
0.028
(0.017–0.045)
Other musculoskeletal disorders severity level 1 Musculoskeletal problems, lower limbs, mild has pain in the leg, which causes some difficulty running, walking long distances, and getting up and down.
0.023
(0.013–0.037)
Severe motor impairment, severe intellectual disability and 
incontinence due to spina bifida
Severe motor impairment with severe intellectual 
disability and incontinence (combined DW)
0.564
(0.418–0.71)
Severe motor impairment, moderate intellectual disability and 
incontinence due to spina bifida
Severe motor impairment with moderate 
intellectual disability and incontinence (combined DW)
0.534
(0.391–0.675)
Severe motor impairment, moderate intellectual disability and 
incontinence due to encephalocele
Severe motor impairment with moderate 
intellectual disability and incontinence (combined DW)
0.534
(0.391–0.675)
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Severe motor impairment, borderline intellectual disability and 
incontinence due to encephalocele
Severe motor impairment, borderline intellectual 
functioning, and urinary incontinence (combined DW)
0.489
(0.353–0.632)
Severe motor impairment, profound intellectual disability and 
incontinence due to encephalocele
Severe motor impairment with severe intellectual 
disability and incontinence (combined DW)
0.564
(0.418–0.71)
Severe motor impairment, mild intellectual disability and 
incontinence due to encephalocele
Severe motor impairment with mild intellectual 
disability and incontinence (combined DW)
0.505
(0.367–0.647)
profound motor impairment, profound intellectual disability and 
incontinence due to spina bifida
Severe motor impairment with profound 
intellectual disability and incontinence (combined DW)
0.584
(0.435–0.73)
Severe motor impairment and mild intellectual disability due to spina 
bifida
Severe motor impairment with mild intellectual 
disability (combined DW)
0.427
(0.3–0.567)
Severe motor impairment and mild intellectual disability due to 
encephalocele
Severe motor impairment with mild intellectual 
disability (combined DW)
0.427
(0.3–0.567)
Severe motor impairment, severe intellectual disability and 
incontinence due to encephalocele
Severe motor impairment with severe intellectual 
disability and incontinence (combined DW)
0.564
(0.418–0.71)
Severe motor impairment, mild intellectual disability and 
incontinence due to spina bifida
Severe motor impairment with mild intellectual 
disability and incontinence (combined DW)
0.505
(0.367–0.647)
Mild motor impairment and incontinence due to spina bifida Mild motor impairment and urinary incontinence (combined DW) 0.148(0.1–0.207)
Mild motor impairment, severe intellectual disability and 
incontinence due to encephalocele
Mild motor impairment, servere intellectual 
functioning, and urinary incontinence (combined DW)
0.284
(0.201–0.385)
Moderate motor impairment, severe intellectual disability and 
incontinence due to spina bifida
Moderate motor impairment, servere intellectual 
functioning, and urinary incontinence (combined DW)
0.32
(0.228–0.429)
Moderate motor impairment, severe intellectual disability and 
incontinence due to encephalocele
Moderate motor impairment, servere intellectual 
functioning, and urinary incontinence (combined DW)
0.32
(0.228–0.429)
Severe motor impairment and moderate intellectual disability due to 
spina bifida
Severe motor impairment with moderate 
intellectual disability (combined DW)
0.461
(0.324–0.603)
Mild motor impairment and incontinence due to encephalocele Mild motor impairment and urinary incontinence (combined DW) 0.148(0.1–0.207)
Moderate motor impairment and incontinence due to spina bifida Moderate motor impairment and urinary incontinence (combined DW)
0.191
(0.132–0.263)
Moderate motor impairment and incontinence due to encephalocele Moderate motor impairment and urinary incontinence (combined DW)
0.191
(0.132–0.263)
Mild motor impairment, profound intellectual disability and 
incontinence due to spina bifida
Mild motor impairment, profound intellectual 
functioning, and urinary incontinence (combined DW)
0.318
(0.224–0.426)
Moderate motor impairment, profound intellectual disability and 
incontinence due to encephalocele
Mild motor impairment, profound intellectual 
functioning, and urinary incontinence (combined DW)
0.318
(0.224–0.426)
Mild motor impairment and profound intellectual disability due to 
spina bifida
Mild motor impairment with profound intellectual 
disability (combined DW)
0.208
(0.142–0.289)
Mild motor impairment, severe intellectual disability and 
incontinence due to spina bifida
Mild motor impairment, servere intellectual 
functioning, and urinary incontinence (combined DW)
0.284
(0.201–0.385)
Severe motor impairment and moderate intellectual disability due to 
encephalocele
Severe motor impairment with moderate 
intellectual disability (combined DW)
0.461
(0.324–0.603)
Severe motor impairment and profound intellectual disability due to 
spina bifida
Severe motor impairment with profound 
intellectual disability (combined DW)
0.519
(0.37–0.668)
Severe motor impairment and severe intellectual disability due to 
encephalocele
Severe motor impairment with severe intellectual 
disability (combined DW)
0.496
(0.355–0.641)
Severe motor impairment, borderline intellectual disability and 
incontinence due to spina bifida
Severe motor impairment, borderline intellectual 
functioning, and urinary incontinence (combined DW)
0.489
(0.353–0.632)
Mild motor impairment, mild intellectual disability and incontinence 
due to encephalocele
Mild motor impairment, mild intellectual 
functioning, and urinary incontinence (combined DW)
0.184
(0.128–0.253)
Moderate motor impairment, borderline intellectual disability and 
incontinence due to encephalocele
Moderate motor impairment, borderline 
intellectual functioning, and urinary incontinence (combined DW)
0.2
(0.139–0.273)
Moderate motor impairment, borderline intellectual disability and 
incontinence due to spina bifida
Moderate motor impairment, borderline 
intellectual functioning, and urinary incontinence (combined DW)
0.2
(0.139–0.273)
Mild motor impairment, borderline intellectual disability and 
incontinence due to encephalocele
Mild motor impairment, borderline intellectual 
functioning, and urinary incontinence (combined DW)
0.157
(0.108–0.218)
Mild motor impairment, borderline intellectual disability and 
incontinence due to spina bifida
Mild motor impairment, borderline intellectual 
functioning, and urinary incontinence (combined DW)
0.157
(0.108–0.218)
Moderate motor impairment and severe intellectual disability due to 
encephalocele
Moderate motor impairment and severe 
intellectual functioning (combined DW)
0.211
(0.145–0.293)
Moderate motor impairment and severe intellectual disability due to 
spina bifida
Moderate motor impairment and severe 
intellectual functioning (combined DW)
0.211
(0.145–0.293)
Moderate motor impairment, mild intellectual disability and 
incontinence due to spina bifida
Moderate motor impairment, mild intellectual 
functioning, and urinary incontinence (combined DW)
0.272
(0.191–0.364)
Mild motor impairment and severe intellectual disability due to spina 
bifida
Mild motor impairment and severe intellectual 
functioning (combined DW)
0.169
(0.113–0.237)
Mild motor impairment and moderate intellectual disability due to 
encephalocele
Mild motor impairment and moderate intellectual 
functioning (combined DW)
0.109
(0.073–0.154)
Mild motor impairment and moderate intellectual disability due to 
spina bifida
Mild motor impairment and moderate intellectual 
functioning (combined DW)
0.109
(0.073–0.154)
Moderate motor impairment and mild intellectual disability due to 
encephalocele
Moderate motor impairment and mild intellectual 
functioning (combined DW)
0.101
(0.066–0.146)
Moderate motor impairment, mild intellectual disability and 
incontinence due to encephalocele
Moderate motor impairment, mild intellectual 
functioning, and urinary incontinence (combined DW)
0.272
(0.191–0.364)
Mild motor impairment, moderate intellectual disability and 
incontinence due to spina bifida
Mild motor impairment, moderate intellectual 
functioning, and urinary incontinence (combined DW)
0.233
(0.161–0.314)
Mild motor impairment, moderate intellectual disability and 
incontinence due to encephalocele
Mild motor impairment, moderate intellectual 
functioning, and urinary incontinence (combined DW)
0.233
(0.161–0.314)
Moderate motor impairment and mild intellectual disability due to 
spina bifida
Moderate motor impairment and mild intellectual 
functioning (combined DW)
0.101
(0.066–0.146)
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Mild motor impairment, mild intellectual disability and incontinence 
due to spina bifida
Mild motor impairment, mild intellectual 
functioning, and urinary incontinence (combined DW)
0.184
(0.128–0.253)
Borderline intellectual disability and incontinence due to 
encephalocele
Borderline intellectual functioning and urinary 
incontinence (combined DW)
0.148
(0.101–0.206)
Moderate motor impairment, moderate intellectual disability and 
incontinence due to encephalocele
Moderate motor impairment, moderate intellectual 
functioning, and urinary incontinence (combined DW)
0.272
(0.191–0.364)
Moderate motor impairment, moderate intellectual disability and 
incontinence due to spina bifida
Moderate motor impairment, moderate intellectual 
functioning, and urinary incontinence (combined DW)
0.272
(0.191–0.364)
Mild intellectual disability and incontinence due to encephalocele Mild intellectual disability and urinary incontinence (combined DW)
0.176
(0.12–0.242)
Moderate intellectual disability and incontinence due to 
encephalocele
Moderate intellectual disability and urinary 
incontinence (combined DW)
0.225
(0.156–0.304)
Severe motor impairment and severe intellectual disability due to 
spina bifida
Severe motor impairment with severe intellectual 
disability (combined DW)
0.496
(0.355–0.641)
Severe intellectual disability and incontinence due to encephalocele Severe intellectual disability and urinary incontinence (combined DW)
0.276
(0.194–0.376)
Mild motor impairment and borderline intellectual disability due to 
spina bifida
Mild motor impairment and borderline intellectual 
functioning (combined DW)
0.021
(0.01–0.039)
Mild motor impairment and borderline intellectual disability due to 
encephalocele
Mild motor impairment and borderline intellectual 
functioning (combined DW)
0.021
(0.01–0.039)
Moderate motor impairment and borderline intellectual disability due 
to spina bifida
Moderate motor impairment and borderline 
intellectual functioning (combined DW)
0.071
(0.045–0.106)
Moderate motor impairment and borderline intellectual disability due 
to encephalocele
Moderate motor impairment and borderline 
intellectual functioning (combined DW)
0.071
(0.045–0.106)
Severe motor impairment and borderline intellectual disability due to 
spina bifida
Severe motor impairment and borderline 
intellectual functioning (combined DW)
0.408
(0.279–0.55)
Severe motor impairment and borderline intellectual disability due to 
encephalocele
Severe motor impairment and borderline 
intellectual functioning (combined DW)
0.408
(0.279–0.55)
Profound intellectual disability and incontinence due to 
encephalocele
Profound intellectual disability and urinary 
incontinence (combined DW)
0.311
(0.217–0.418)
Mild motor impairment and severe intellectual disability due to 
encephalocele
Mild motor impairment and severe intellectual 
functioning (combined DW)
0.169
(0.113–0.237)
Moderate motor impairment, profound intellectual disability and 
incontinence due to spina bifida
Moderate motor impairment with profound 
intellectual disability and incontinence (combined DW)
0.352
(0.254–0.465)
Moderate intellectual disability due to encephalocele Intellectual disability / mental retardation, moderate
has low intelligence, and is slow in learning to speak and to 
do even simple tasks. As an adult, the person requires a lot of 
support to live independently and raise children. The person 
can only work at the simplest supervised jobs.
0.1
(0.066–0.142)
Incontinence due to encephalocele Urinary incontinence cannot control urinating. 0.139(0.094–0.198)
Moderate motor impairment due to spina bifida Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Moderate motor impairment due to encephalocele Motor impairment, moderate
has some difficulty in moving around, and difficulty in lifting 
and holding objects, dressing and sitting upright, but is able 
to walk without help.
0.061
(0.04–0.089)
Borderline intellectual disability due to encephalocele Borderline intellectual functioning
is slow in learning at school. As an adult, the person has 
some difficulty doing complex or unfamiliar tasks but 
otherwise functions independently.
0.011
(0.005–0.02)
Severe motor impairment and incontinence due to spina bifida Severe motor impairment with incontinence (combined DW) --
Severe motor impairment and incontinence due to encephalocele Severe motor impairment with incontinence (combined DW) --
Mild motor impairment and profound intellectual disability due to 
encephalocele Severe motor impairment with incontinence (combined DW) --
Moderate motor impairment and profound intellectual disability due 
to encephalocele Severe motor impairment with incontinence (combined DW) --
Severe motor and cognitive impairment due to anencephaly Motor plus cognitive impairments, severe
cannot move around without help, and cannot lift or hold 
objects, get dressed or sit upright. The person also has very 
low intelligence, speaks few words, and needs constant 
supervision and help with all daily activities.
0.542
(0.374–0.702)
Severe motor impairment and profound intellectual disability due to 
encephalocele Severe motor impairment with incontinence (combined DW) --
Mild intellectual disability due to encephalocele Intellectual disability / mental retardation, mild
has low intelligence and is slow in learning at school. As an 
adult, the person can live independently, but often needs help 
to raise children and can only work at simple supervised jobs.
0.043
(0.026–0.064)
Moderate motor impairment and moderate intellectual disability due 
to encephalocele Motor plus cognitive impairments, moderate
has some difficulty in moving around, holding objects, 
dressing and sitting upright, but can walk without help. The 
person has low intelligence and is slow in learning to speak 
and to do simple tasks.
0.203
(0.134–0.29)
Mild motor impairment and mild intellectual disability due to 
encephalocele Motor plus cognitive impairments, mild
has some difficulty in moving around but is able to walk 
without help. The person is slow in learning at school. As an 
adult, the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions independently.
0.031
(0.018–0.05)
Mild motor impairment and mild intellectual disability due to spina 
bifida Motor plus cognitive impairments, mild
has some difficulty in moving around but is able to walk 
without help. The person is slow in learning at school. As an 
adult, the person has some difficulty doing complex or 
unfamiliar tasks but otherwise functions independently.
0.031
(0.018–0.05)
Severe motor impairment due to encephalocele Motor impairment, severe is unable to move around without help, and is not able to lift or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
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Severe motor impairment due to spina bifida Motor impairment, severe is unable to move around without help, and is not able to lift or hold objects, get dressed or sit upright. 
0.402
(0.268–0.545)
Profound intellectual disability due to encephalocele Intellectual disability / mental retardation, profound
has very low intelligence, has almost no language, and does 
not understand even the most basic requests or instructions. 
The person requires constant supervision and help for all 
activities.
0.2
(0.133–0.283)
Moderate motor impairment and profound intellectual disability due 
to spina bifida
Moderate motor impairment with profound 
intellectual disability (combined DW)
0.249
(0.174–0.338)
Severe intellectual disability due to encephalocele Intellectual disability / mental retardation, severe
has very low intelligence and cannot speak more than a few 
words, needs constant supervision and help with most daily 
activities, and can do only the simplest tasks.
0.16
(0.107–0.226)
Mild motor impairment, profound intellectual disability and 
incontinence due to encephalocele Severe motor impairment with incontinence (combined DW) --
Mild motor impairment due to spina bifida Motor impairment, mild has some difficulty in moving around but is able to walk without help.
0.01
(0.005–0.019)
Asymptomatic encephalocele following treatment Asymptomatic -- --
Mild motor impairment due to encephalocele Motor impairment, mild has some difficulty in moving around but is able to walk without help.
0.01
(0.005–0.019)
Moderate motor impairment and moderate intellectual disability due 
to spina bifida Motor plus cognitive impairments, moderate
has some difficulty in moving around, holding objects, 
dressing and sitting upright, but can walk without help. The 
person has low intelligence and is slow in learning to speak 
and to do simple tasks.
0.203
(0.134–0.29)
Congenital heart disease, boderline intellectual disability and mild 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease, borderline intellectual 
functioning, and mild heart failure (combined DW)
0.052
(0.032–0.081)
Congenital heart disease, boderline intellectual disability and mild 
heart failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease, borderline intellectual 
functioning, and mild heart failure (combined DW)
0.052
(0.032–0.081)
Congenital heart disease, boderline intellectual disability and mild 
heart failure due to ventricular septal defect and atrial septal defect
Congenital heart disease, borderline intellectual 
functioning, and mild heart failure (combined DW)
0.052
(0.032–0.081)
Congenital heart disease, severe intellectual disability and moderate 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease, severe intellectual 
disability, and moderate heart failure (combined DW)
0.22
(0.151–0.302)
Congenital heart disease, borderline intellectual disability and 
moderate heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects
Congenital heart disease, borderline intellectual 
functioning, and moderate heart failure (combined DW)
0.082
(0.053–0.12)
Congenital heart disease, borderline intellectual disability and 
moderate heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus
Congenital heart disease, borderline intellectual 
functioning, and moderate heart failure (combined DW)
0.082
(0.053–0.12)
Congenital heart disease, borderline intellectual disability and 
moderate heart failure due to ventricular septal defect and atrial 
septal defect
Congenital heart disease, borderline intellectual 
functioning, and moderate heart failure (combined DW)
0.082
(0.053–0.12)
Congenital heart disease, boderline intellectual disability and mild 
heart failure due to single ventricle and single ventricle pathway 
heart defects
Congenital heart disease, borderline intellectual 
functioning, and mild heart failure (combined DW)
0.052
(0.032–0.081)
Congenital heart disease, borderline intellectual disability and severe 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease,borderline intellectual 
functioning, and severe heart failure (combined DW)
0.188
(0.13–0.258)
Congenital heart disease, borderline intellectual disability and severe 
heart failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease,borderline intellectual 
functioning, and severe heart failure (combined DW)
0.188
(0.13–0.258)
Congenital heart disease, borderline intellectual disability and severe 
heart failure due to ventricular septal defect and atrial septal defect
Congenital heart disease,borderline intellectual 
functioning, and severe heart failure (combined DW)
0.188
(0.13–0.258)
Congenital heart disease, mild intellectual disability and mild heart 
failure due to single ventricle and single ventricle pathway heart 
defects
Congenital heart disease, mild intellectual 
disability, and mild heart failure (combined DW)
0.082
(0.052–0.121)
Congenital heart disease, mild intellectual disability and mild heart 
failure due to severe congenital heart anomalies excluding single 
ventricle heart defects
Congenital heart disease, mild intellectual 
disability, and mild heart failure (combined DW)
0.082
(0.052–0.121)
Congenital heart disease, borderline intellectual disability and 
moderate heart failure due to single ventricle and single ventricle 
pathway heart defects
Congenital heart disease, borderline intellectual 
functioning, and moderate heart failure (combined DW)
0.082
(0.053–0.12)
Congenital heart disease, borderline intellectual disability and severe 
heart failure due to single ventricle and single ventricle pathway 
heart defects
Congenital heart disease,borderline intellectual 
functioning, and severe heart failure (combined DW)
0.188
(0.13–0.258)
Congenital heart disease and severe heart failure without intellectual 
disability due to severe congenital heart anomalies excluding single 
ventricle heart defects
Congenital heart disease and severe heart failure (combined DW) 0.179(0.122–0.251)
Congenital heart disease and severe heart failure without intellectual 
disability due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease and severe heart failure (combined DW) 0.179(0.122–0.251)
Congenital heart disease, severe intellectual disability and moderate 
heart failure due to single ventricle and single ventricle pathway 
heart defects
Congenital heart disease, severe intellectual 
disability, and moderate heart failure (combined DW)
0.22
(0.151–0.302)
Congenital heart disease, profound intellectual disability and severe 
heart failure due to ventricular septal defect and atrial septal defect
Congenital heart disease, profound intellectual 
disability, and severe heart failure (combined DW)
0.342
(0.239–0.457)
Congenital heart disease, profound intellectual disability and severe 
heart failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease, profound intellectual 
disability, and severe heart failure (combined DW)
0.342
(0.239–0.457)
Congenital heart disease, profound intellectual disability and severe 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease, profound intellectual 
disability, and severe heart failure (combined DW)
0.342
(0.239–0.457)
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Congenital heart disease, profound intellectual disability and severe 
heart failure due to single ventricle and single ventricle pathway 
heart defects
Congenital heart disease, profound intellectual 
disability, and severe heart failure (combined DW)
0.342
(0.239–0.457)
Congenital heart disease, profound intellectual disability and 
moderate heart failure due to ventricular septal defect and atrial 
septal defect
Congenital heart disease, profound intellectual 
disability, and moderate heart failure (combined DW)
0.257
(0.181–0.351)
Congenital heart disease, profound intellectual disability and 
moderate heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus
Congenital heart disease, profound intellectual 
disability, and moderate heart failure (combined DW)
0.257
(0.181–0.351)
Congenital heart disease, profound intellectual disability and 
moderate heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects
Congenital heart disease, profound intellectual 
disability, and moderate heart failure (combined DW)
0.257
(0.181–0.351)
Congenital heart disease, profound intellectual disability and 
moderate heart failure due to single ventricle and single ventricle 
pathway heart defects
Congenital heart disease, profound intellectual 
disability, and moderate heart failure (combined DW)
0.257
(0.181–0.351)
Congenital heart disease, profound intellectual disability and mild 
heart failure due to ventricular septal defect and atrial septal defect
Congenital heart disease, profound intellectual 
disability, and mild heart failure (combined DW)
0.233
(0.162–0.317)
Congenital heart disease, profound intellectual disability and mild 
heart failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease, profound intellectual 
disability, and mild heart failure (combined DW)
0.233
(0.162–0.317)
Congenital heart disease, profound intellectual disability and mild 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease, profound intellectual 
disability, and mild heart failure (combined DW)
0.233
(0.162–0.317)
Congenital heart disease, profound intellectual disability and mild 
heart failure due to single ventricle and single ventricle pathway 
heart defects
Congenital heart disease, profound intellectual 
disability, and mild heart failure (combined DW)
0.233
(0.162–0.317)
Congenital heart disease, severe intellectual disability and severe 
heart failure due to ventricular septal defect and atrial septal defect
Congenital heart disease, severe intellectual 
disability, and severe heart failure (combined DW)
0.31
(0.22–0.419)
Congenital heart disease, severe intellectual disability and severe 
heart failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease, severe intellectual 
disability, and severe heart failure (combined DW)
0.31
(0.22–0.419)
Congenital heart disease, severe intellectual disability and severe 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease, severe intellectual 
disability, and severe heart failure (combined DW)
0.31
(0.22–0.419)
Congenital heart disease, severe intellectual disability and severe 
heart failure due to single ventricle and single ventricle pathway 
heart defects
Congenital heart disease, severe intellectual 
disability, and severe heart failure (combined DW)
0.31
(0.22–0.419)
Congenital heart disease, severe intellectual disability and moderate 
heart failure due to ventricular septal defect and atrial septal defect
Congenital heart disease, severe intellectual 
disability, and moderate heart failure (combined DW)
0.22
(0.151–0.302)
Congenital heart disease, severe intellectual disability and moderate 
heart failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease, severe intellectual 
disability, and moderate heart failure (combined DW)
0.22
(0.151–0.302)
Congenital heart disease and mild heart failure without intellectual 
disability due to single ventricle and single ventricle pathway heart 
defects
Congenital heart disease and mild heart failure (combined DW) 0.041(0.026–0.062)
Congenital heart disease and mild heart failure without intellectual 
disability due to severe congenital heart anomalies excluding single 
ventricle heart defects
Congenital heart disease and mild heart failure (combined DW) 0.041(0.026–0.062)
Congenital heart disease and mild heart failure without intellectual 
disability due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease and mild heart failure (combined DW) 0.041(0.026–0.062)
Congenital heart disease and mild heart failure without intellectual 
disability due to ventricular septal defect and atrial septal defect Congenital heart disease and mild heart failure (combined DW)
0.041
(0.026–0.062)
Congenital heart disease and moderate heart failure without 
intellectual disability due to single ventricle and single ventricle 
pathway heart defects
Congenital heart disease and moderate heart 
failure (combined DW)
0.072
(0.047–0.103)
Congenital heart disease and moderate heart failure without 
intellectual disability due to severe congenital heart anomalies 
excluding single ventricle heart defects
Congenital heart disease and moderate heart 
failure (combined DW)
0.072
(0.047–0.103)
Congenital heart disease and moderate heart failure without 
intellectual disability due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus
Congenital heart disease and moderate heart 
failure (combined DW)
0.072
(0.047–0.103)
Congenital heart disease and moderate heart failure without 
intellectual disability due to ventricular septal defect and atrial septal 
defect
Congenital heart disease and moderate heart 
failure (combined DW)
0.072
(0.047–0.103)
Congenital heart disease and severe heart failure without intellectual 
disability due to single ventricle and single ventricle pathway heart 
defects
Congenital heart disease and severe heart failure (combined DW) 0.179(0.122–0.251)
Congenital heart disease, mild intellectual disability and mild heart 
failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease, mild intellectual 
disability, and mild heart failure (combined DW)
0.082
(0.052–0.121)
Congenital heart disease and severe heart without intellectual 
disability due to ventricular septal defect and atrial septal defect Congenital heart disease and severe heart failure (combined DW)
0.179
(0.122–0.251)
Congenital heart disease, mild intellectual disability and mild heart 
failure due to ventricular septal defect and atrial septal defect
Congenital heart disease, mild intellectual 
disability, and mild heart failure (combined DW)
0.082
(0.052–0.121)
Congenital heart disease, mild intellectual disability and moderate 
heart failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease, mild intellectual 
disability, and moderate heart failure (combined DW)
0.111
(0.072–0.161)
Congenital heart disease, mild intellectual disability and moderate 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease, mild intellectual 
disability, and moderate heart failure (combined DW)
0.111
(0.072–0.161)
Congenital heart disease, moderate intellectual disability and severe 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease, moderate intellectual 
disability, and severe heart failure (combined DW)
0.261
(0.182–0.352)
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Congenital heart disease and mild intellectual disability without heart 
failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease and Intellectual disability 
/ mental retardation, mild (combined DW)
0.043
(0.026–0.064)
Congenital heart disease and mild intellectual disability without heart 
failure due to ventricular septal defect and atrial septal defect
Congenital heart disease and Intellectual disability 
/ mental retardation, mild (combined DW)
0.043
(0.026–0.064)
Congenital heart disease, mild intellectual disability and moderate 
heart failure due to single ventricle and single ventricle pathway 
heart defects
Congenital heart disease, mild intellectual 
disability, and moderate heart failure (combined DW)
0.111
(0.072–0.161)
Congenital heart disease, moderate intellectual disability and severe 
heart failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease, moderate intellectual 
disability, and severe heart failure (combined DW)
0.261
(0.182–0.352)
Congenital heart disease, moderate intellectual disability and severe 
heart failure due to ventricular septal defect and atrial septal defect
Congenital heart disease, moderate intellectual 
disability, and severe heart failure (combined DW)
0.261
(0.182–0.352)
Congenital heart disease and moderate intellectual disability without 
heart failure  due to single ventricle and single ventricle pathway 
heart defects
Congenital heart disease and Intellectual disability 
/ mental retardation, moderate (combined DW)
0.1
(0.066–0.142)
Congenital heart disease, severe intellectual disability and mild heart 
failure due to single ventricle and single ventricle pathway heart 
defects
Congenital heart disease, severe intellectual 
disability, and mild heart failure (combined DW)
0.195
(0.134–0.269)
Congenital heart disease, severe intellectual disability and mild heart 
failure due to severe congenital heart anomalies excluding single 
ventricle heart defects
Congenital heart disease, severe intellectual 
disability, and mild heart failure (combined DW)
0.195
(0.134–0.269)
Congenital heart disease, severe intellectual disability and mild heart 
failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease, severe intellectual 
disability, and mild heart failure (combined DW)
0.195
(0.134–0.269)
Congenital heart disease and moderate intellectual disability  without 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease and Intellectual disability 
/ mental retardation, moderate (combined DW)
0.1
(0.066–0.142)
Congenital heart disease and moderate intellectual disability without 
heart failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease and Intellectual disability 
/ mental retardation, moderate (combined DW)
0.1
(0.066–0.142)
Congenital heart disease and moderate intellectual disability without 
heart failure due to ventricular septal defect and atrial septal defect
Congenital heart disease and Intellectual disability 
/ mental retardation, moderate (combined DW)
0.1
(0.066–0.142)
Congenital heart disease and severe intellectual disability without 
heart failure due to other congenital cardiovascular anomalies
Congenital heart disease and Intellectual disability 
/ mental retardation, severe (combined DW)
0.16
(0.107–0.226)
Congenital heart disease and severe intellectual disability without 
heart failure due to single ventricle and single ventricle pathway 
heart defects
Congenital heart disease and Intellectual disability 
/ mental retardation, severe (combined DW)
0.16
(0.107–0.226)
Congenital heart disease and severe intellectual disability  without 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease and Intellectual disability 
/ mental retardation, severe (combined DW)
0.16
(0.107–0.226)
Congenital heart disease and severe intellectual disability without 
heart failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease and Intellectual disability 
/ mental retardation, severe (combined DW)
0.16
(0.107–0.226)
Congenital heart disease and severe intellectual disability without 
heart failure due to ventricular septal defect and atrial septal defect
Congenital heart disease and Intellectual disability 
/ mental retardation, severe (combined DW)
0.16
(0.107–0.226)
Congenital heart disease and profound intellectual disability without 
heart failure due to other congenital cardiovascular anomalies
Congenital heart disease and Intellectual disability 
/ mental retardation, profound (combined DW)
0.2
(0.133–0.283)
Congenital heart disease and profound intellectual disability without 
heart failure due to single ventricle and single ventricle pathway 
heart defects
Congenital heart disease and Intellectual disability 
/ mental retardation, profound (combined DW)
0.2
(0.133–0.283)
Congenital heart disease and profound intellectual disability without 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease and Intellectual disability 
/ mental retardation, profound (combined DW)
0.2
(0.133–0.283)
Congenital heart disease and profound intellectual disability without 
heart failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease and Intellectual disability 
/ mental retardation, profound (combined DW)
0.2
(0.133–0.283)
Asymptomatic ventricular septal defect and atrial septal defect Asymptomatic -- --
Congenital heart disease and profound intellectual disability without 
heart failure due to ventricular septal defect and atrial septal defect
Congenital heart disease and Intellectual disability 
/ mental retardation, profound (combined DW)
0.2
(0.133–0.283)
Congenital heart disease, severe intellectual disability and mild heart 
failure due to ventricular septal defect and atrial septal defect
Congenital heart disease, severe intellectual 
disability, and mild heart failure (combined DW)
0.195
(0.134–0.269)
Congenital heart disease, moderate intellectual disability and severe 
heart failure due to single ventricle and single ventricle pathway 
heart defects
Congenital heart disease, moderate intellectual 
disability, and severe heart failure (combined DW)
0.261
(0.182–0.352)
Congenital heart disease and mild intellectual disability  without 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease and Intellectual disability 
/ mental retardation, mild (combined DW)
0.043
(0.026–0.064)
Congenital heart disease and moderate intellectual disability without 
heart failure due to other congenital cardiovascular anomalies
Congenital heart disease and Intellectual disability 
/ mental retardation, moderate (combined DW)
0.1
(0.066–0.142)
Congenital heart disease and mild intellectual disability without heart 
failure due to other congenital cardiovascular anomalies
Congenital heart disease and Intellectual disability 
/ mental retardation, mild (combined DW)
0.043
(0.026–0.064)
Congenital heart disease, mild intellectual disability and moderate 
heart failure due to ventricular septal defect and atrial septal defect
Congenital heart disease, mild intellectual 
disability, and moderate heart failure (combined DW)
0.111
(0.072–0.161)
Congenital heart disease, mild intellectual disability and severe heart 
failure due to single ventricle and single ventricle pathway heart 
defects
Congenital heart disease, mild intellectual 
disability, and servere heart failure (combined DW)
0.214
(0.148–0.291)
Congenital heart disease, mild intellectual disability and severe heart 
failure due to severe congenital heart anomalies excluding single 
ventricle heart defects
Congenital heart disease, mild intellectual 
disability, and servere heart failure (combined DW)
0.214
(0.148–0.291)
Congenital heart disease, mild intellectual disability and severe heart 
failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease, mild intellectual 
disability, and servere heart failure (combined DW)
0.214
(0.148–0.291)
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Congenital heart disease, mild intellectual disability and severe heart 
failure due to ventricular septal defect and atrial septal defect
Congenital heart disease, mild intellectual 
disability, and servere heart failure (combined DW)
0.214
(0.148–0.291)
Congenital heart disease without intellectual disability or heart 
failure due to other congenital cardiovascular anomalies Congenital heart disease (custom DW from MEPS) --
Congenital heart disease without intellectual disability or heart 
failure due to single ventricle and single ventricle pathway heart 
defects
Congenital heart disease (custom DW from MEPS) --
Congenital heart disease and mild intellectual disability without heart 
failure  due to single ventricle and single ventricle pathway heart 
defects
Congenital heart disease and Intellectual disability 
/ mental retardation, mild (combined DW)
0.043
(0.026–0.064)
Congenital heart disease without heart failure or intellectual 
disability due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease (custom DW from MEPS) --
Congenital heart disease without heart failure or intellectual 
disability due to ventricular septal defect and atrial septal defect Congenital heart disease (custom DW from MEPS) --
Congenital heart disease, moderate intellectual disability and mild 
heart failure due to single ventricle and single ventricle pathway 
heart defects
Congenital heart disease, moderate intellectual 
disability, and mild heart failure (combined DW)
0.137
(0.093–0.191)
Congenital heart disease and borderline intellectual disability without 
heart failure due to other congenital cardiovascular anomalies
Congenital heart disease and borderline 
intellectual functioning (combined DW)
0.011
(0.005–0.02)
Congenital heart disease without intellectual disability or heart 
failure due to severe congenital heart anomalies excluding single 
ventricle heart defects
Congenital heart disease (custom DW from MEPS) --
Congenital heart disease and borderline intellectual disability without 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease and borderline 
intellectual functioning (combined DW)
0.011
(0.005–0.02)
Congenital heart disease, moderate intellectual disability and 
moderate heart failure due to ventricular septal defect and atrial 
septal defect
Congenital heart disease, moderate intellectual 
disability, and moderate heart failure (combined DW)
0.164
(0.112–0.225)
Congenital heart disease, moderate intellectual disability and 
moderate heart failure due to critical malformations of great vessels, 
congenital valvular heart disease and patent ductus arteriosus
Congenital heart disease, moderate intellectual 
disability, and moderate heart failure (combined DW)
0.164
(0.112–0.225)
Congenital heart disease and borderline intellectual disability without 
heart failure due to single ventricle and single ventricle pathway 
heart defects
Congenital heart disease and borderline 
intellectual functioning (combined DW)
0.011
(0.005–0.02)
Congenital heart disease, moderate intellectual disability and 
moderate heart failure due to single ventricle and single ventricle 
pathway heart defects
Congenital heart disease, moderate intellectual 
disability, and moderate heart failure (combined DW)
0.164
(0.112–0.225)
Congenital heart disease, moderate intellectual disability and mild 
heart failure due to ventricular septal defect and atrial septal defect
Congenital heart disease, moderate intellectual 
disability, and mild heart failure (combined DW)
0.137
(0.093–0.191)
Congenital heart disease, moderate intellectual disability and 
moderate heart failure due to severe congenital heart anomalies 
excluding single ventricle heart defects
Congenital heart disease, moderate intellectual 
disability, and moderate heart failure (combined DW)
0.164
(0.112–0.225)
Congenital heart disease, moderate intellectual disability and mild 
heart failure due to severe congenital heart anomalies excluding 
single ventricle heart defects
Congenital heart disease, moderate intellectual 
disability, and mild heart failure (combined DW)
0.137
(0.093–0.191)
Congenital heart disease and borderline intellectual disability without 
heart failure due to ventricular septal defect and atrial septal defect
Congenital heart disease and borderline 
intellectual functioning (combined DW)
0.011
(0.005–0.02)
Congenital heart disease and borderline intellectual disability without 
heart failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease and borderline 
intellectual functioning (combined DW)
0.011
(0.005–0.02)
Congenital heart disease, moderate intellectual disability and mild 
heart failure due to critical malformations of great vessels, congenital 
valvular heart disease and patent ductus arteriosus
Congenital heart disease, moderate intellectual 
disability, and mild heart failure (combined DW)
0.137
(0.093–0.191)
Disfigurement level 2 and speech problems due to orofacial clefts Speech problems with disfigurement level 2 (combined DW) --
Asymptomatic orofacial clefts Asymptomatic -- --
Disfigurement level 2 due to orofacial clefts Disfigurement, level 2
has a visible physical deformity that causes others to stare 
and comment. As a result, the person is worried and has 
trouble sleeping and concentrating.
0.067
(0.044–0.096)
Disfigurement level 1 due to orofacial clefts Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Severe intellectual disability and moderate dementia due to Down 
syndrome Moderate dementia, severe intellectual disability (combined DW)
0.475
(0.34–0.614)
Profound intellectual disability and moderate dementia due to Down 
syndrome
Moderate dementia, profound intellectual 
disability (combined DW)
0.499
(0.358–0.645)
Borderline intellectual disability and severe dementia due to Down 
syndrome Severe dementia, borderline intellectual disability (combined DW)
0.455
(0.316–0.597)
Mild intellectual disability and severe dementia due to Down 
syndrome Severe dementia, mild intellectual disability (combined DW)
0.472
(0.332–0.615)
Moderate intellectual disability and moderate dementia due to Down 
syndrome
Moderate dementia, moderate intellectual 
disability (combined DW)
0.438
(0.311–0.576)
Severe intellectual disability and severe dementia due to Down 
syndrome Severe dementia, severe intellectual disability (combined DW)
0.535
(0.384–0.681)
Profound intellectual disability and severe dementia due to Down 
syndrome Severe dementia, profound intellectual disability (combined DW)
0.557
(0.401–0.703)
Severe intellectual disability due to Down syndrome Intellectual disability / mental retardation, severe
has very low intelligence and cannot speak more than a few 
words, needs constant supervision and help with most daily 
activities, and can do only the simplest tasks.
0.16
(0.107–0.226)
Profound intellectual disability due to Down syndrome Intellectual disability / mental retardation, profound
has very low intelligence, has almost no language, and does 
not understand even the most basic requests or instructions. 
The person requires constant supervision and help for all 
activities.
0.2
(0.133–0.283)
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Moderate intellectual disability and severe dementia due to Down 
syndrome Severe dementia, moderate intellectual disability (combined DW)
0.503
(0.355–0.646)
Mild intellectual disability and moderate dementia due to Down 
syndrome Moderate dementia, mild intellectual disability (combined DW)
0.403
(0.281–0.536)
Borderline intellectual disability and mild dementia due to Down 
syndrome Mild dementia, borderline intellectual disability (combined DW)
0.079
(0.051–0.115)
Severe intellectual disability, severe dementia, and congenital heart 
disease due to Down syndrome
Congenital heart disease, severe dementia, severe 
intellectual disability (combined DW)
0.535
(0.384–0.681)
Moderate intellectual disability with congenital heart disease due to 
Down syndrome
Moderate intellectual disability with congenital 
heart disease (combined DW)
0.1
(0.066–0.142)
Severe intellectual disability with congenital heart disease due to 
Down syndrome
Severe intellectual disability with congenital heart 
disease (combined DW)
0.16
(0.107–0.226)
Moderate intellectual disability, mild dementia, and congenital heart 
disease due to Down syndrome
Congenital heart disease, mild dementia, moderate 
intellectual disability (combined DW)
0.162
(0.11–0.222)
Profound intellectual disability with congenital heart disease due to 
Down syndrome
Profound intellectual disability with congenital 
heart disease (combined DW)
0.2
(0.133–0.283)
Borderline intellectual disability due to Down syndrome Borderline intellectual functioning
is slow in learning at school. As an adult, the person has 
some difficulty doing complex or unfamiliar tasks but 
otherwise functions independently.
0.011
(0.005–0.02)
Moderate intellectual disability, severe dementia, and congenital 
heart disease due to Down syndrome
Congenital heart disease, severe dementia, 
moderate intellectual disability (combined DW)
0.503
(0.355–0.646)
Mild intellectual disability due to Down syndrome Intellectual disability / mental retardation, mild
has low intelligence and is slow in learning at school. As an 
adult, the person can live independently, but often needs help 
to raise children and can only work at simple supervised jobs.
0.043
(0.026–0.064)
Moderate intellectual disability due to Down syndrome Intellectual disability / mental retardation, moderate
has low intelligence, and is slow in learning to speak and to 
do even simple tasks. As an adult, the person requires a lot of 
support to live independently and raise children. The person 
can only work at the simplest supervised jobs.
0.1
(0.066–0.142)
Congenital heart disease and mild dementia due to Down syndrome Congenital heart disease and mild dementia (combined DW) 0.069(0.046–0.099)
Congenital heart disease and moderate dementia due to Down 
syndrome Congenital heart disease and moderate dementia (combined DW)
0.377
(0.252–0.508)
Mild intellectual disability, severe dementia, and congenital heart 
disease due to Down syndrome
Congenital heart disease, severe dementia, mild 
intellectual disability (combined DW)
0.472
(0.332–0.615)
Borderline intellectual disability, severe dementia, and congenital 
heart disease due to Down syndrome
Congenital heart disease, severe dementia, 
borderline intellectual disability (combined DW)
0.455
(0.316–0.597)
Congenital heart disease and severe dementia due to Down syndrome Congenital heart disease and severe dementia (combined DW) 0.449(0.304–0.595)
Profound intellectual disability, moderate dementia, and congenital 
heart disease due to Down syndrome
Congenital heart disease, moderate dementia, 
profound intellectual disability (combined DW)
0.499
(0.358–0.645)
Severe intellectual disability, moderate dementia, and congenital 
heart disease due to Down syndrome
Congenital heart disease, moderate dementia, 
severe intellectual disability (combined DW)
0.475
(0.34–0.614)
Borderline intellectual disability, mild dementia, and congenital heart 
disease due to Down syndrome
Congenital heart disease, mild dementia, 
borderline intellectual disability (combined DW)
0.079
(0.051–0.115)
Moderate intellectual disability, moderate dementia, and congenital 
heart disease due to Down syndrome
Congenital heart disease, moderate dementia, 
moderate intellectual disability (combined DW)
0.438
(0.311–0.576)
Mild intellectual disability, moderate dementia, and congenital heart 
disease due to Down syndrome
Congenital heart disease, moderate dementia, mild 
intellectual disability (combined DW)
0.403
(0.281–0.536)
Mild intellectual disability, mild dementia, and congenital heart 
disease due to Down syndrome
Congenital heart disease, mild dementia, mild 
intellectual disability (combined DW)
0.109
(0.071–0.159)
Borderline intellectual disability, moderate dementia, and congenital 
heart disease due to Down syndrome
Congenital heart disease, moderate dementia, 
borderline intellectual disability (combined DW)
0.384
(0.262–0.517)
Profound intellectual disability, mild dementia, and congenital heart 
disease due to Down syndrome
Congenital heart disease, mild dementia, profound 
intellectual disability (combined DW)
0.255
(0.178–0.346)
Mild intellectual disability with congenital heart disease due to Down 
syndrome
Mild intellectual disability with congenital heart 
disease (combined DW)
0.043
(0.026–0.064)
Borderline intellectual disability with congenital heart disease due to 
Down syndrome
Borderline intellectual disability with congenital 
heart disease (combined DW)
0.011
(0.005–0.02)
Severe intellectual disability, mild dementia, and congenital heart 
disease due to Down syndrome
Congenital heart disease, mild dementia, severe 
intellectual disability (combined DW)
0.218
(0.149–0.299)
Borderline intellectual disability and moderate dementia due to 
Down syndrome
Moderate dementia, borderline intellectual 
disability (combined DW)
0.384
(0.262–0.517)
Isolated congenital heart disease due to Down syndrome Congenital heart disease (custom DW from MEPS) --
Asymptomatic Down syndrome Asymptomatic -- --
Profound intellectual disability, severe dementia, and congenital 
heart disease due to Down syndrome
Congenital heart disease, severe dementia, 
profound intellectual disability (combined DW)
0.557
(0.401–0.703)
Profound intellectual disability and mild dementia due to Down 
syndrome Mild dementia, profound intellectual disability (combined DW)
0.255
(0.178–0.346)
Severe intellectual disability and mild dementia due to Down 
syndrome Mild dementia, severe intellectual disability (combined DW)
0.218
(0.149–0.299)
Severe dementia due to Down syndrome Dementia, severe has complete memory loss; no longer recognizes close family members; and requires help with all daily activities.
0.449
(0.304–0.595)
Mild dementia due to Down syndrome Dementia, mild has some trouble remembering recent events, and finds it hard to concentrate and make decisions and plans.
0.069
(0.046–0.099)
Moderate intellectual disability and mild dementia due to Down 
syndrome Mild dementia, moderate intellectual disability (combined DW)
0.162
(0.11–0.222)
Mild intellectual disability and mild dementia due to Down syndrome Mild dementia, mild intellectual disability (combined DW) 0.109(0.071–0.159)
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Moderate dementia due to Down syndrome Dementia, moderate
has memory problems and confusion, feels disoriented, at 
times hears voices that are not real, and needs help with 
some daily activities.
0.377
(0.252–0.508)
Congenital heart disease due to Turner syndrome Congenital heart disease (custom DW from MEPS) --
Congenital heart disease with infertility due to Turner syndrome Congenital heart disease with primary infertility (combined DW) --
Primary infertility due to Turner syndrome Infertility, primary wants to have a child and has a fertile partner, but the couple cannot conceive.
0.008
(0.003–0.015)
Asymptomatic Turner syndrome Asymptomatic -- --
Mild intellectual disability due to Klinefelter syndrome Intellectual disability / mental retardation, mild
has low intelligence and is slow in learning at school. As an 
adult, the person can live independently, but often needs help 
to raise children and can only work at simple supervised jobs.
0.043
(0.026–0.064)
Mild intellectual disability with infertility due to Klinefelter 
syndrome Mild intellectual disability with primary infertility (combined DW) --
Asymptomatic Klinefelter syndrome Asymptomatic -- --
Borderline intellectual disability due to Klinefelter syndrome Borderline intellectual functioning
is slow in learning at school. As an adult, the person has 
some difficulty doing complex or unfamiliar tasks but 
otherwise functions independently.
0.011
(0.005–0.02)
Primary infertility due to Klinefelter syndrome Infertility, primary wants to have a child and has a fertile partner, but the couple cannot conceive.
0.008
(0.003–0.015)
Borderline intellectual disability with infertility due to Klinefelter 
syndrome
Borderline intellectual disability with primary 
infertility (combined DW) --
Borderline intellectual disability with congenital heart disease due to 
other chromosomal abnormalities
Borderline intellectual disability with congenital 
heart disease (combined DW)
0.011
(0.005–0.02)
Mild intellectual disability, mild dementia, and congenital heart 
disease due to other chromosomal abnormalities
Congenital heart disease, mild dementia, mild 
intellectual disability (combined DW)
0.109
(0.071–0.159)
Asymptomatic other chromosomal abnormalities Asymptomatic -- --
Mild intellectual disability with congenital heart disease due to other 
chromosomal abnormalities
Mild intellectual disability with congenital heart 
disease (combined DW)
0.043
(0.026–0.064)
Borderline intellectual disability, mild dementia, and congenital heart 
disease due to other chromosomal abnormalities
Congenital heart disease, mild dementia, 
borderline intellectual disability (combined DW)
0.079
(0.051–0.115)
Moderate intellectual disability with congenital heart disease due to 
other chromosomal abnormalities
Moderate intellectual disability with congenital 
heart disease (combined DW)
0.1
(0.066–0.142)
Isolated congenital heart disease due to other chromosomal 
abnormalities Congenital heart disease (custom DW from MEPS) --
Severe dementia due to other chromosomal abnormalities Dementia, severe has complete memory loss; no longer recognizes close family members; and requires help with all daily activities.
0.449
(0.304–0.595)
Borderline intellectual disability due to other chromosomal 
abnormalities Borderline intellectual functioning
is slow in learning at school. As an adult, the person has 
some difficulty doing complex or unfamiliar tasks but 
otherwise functions independently.
0.011
(0.005–0.02)
Severe intellectual disability with congenital heart disease due to 
other chromosomal abnormalities
Severe intellectual disability with congenital heart 
disease (combined DW)
0.16
(0.107–0.226)
Congenital heart disease and moderate dementia due to other 
chromosomal abnormalities Congenital heart disease and moderate dementia (combined DW)
0.377
(0.252–0.508)
Profound intellectual disability with congenital heart disease due to 
other chromosomal abnormalities
Profound intellectual disability with congenital 
heart disease (combined DW)
0.2
(0.133–0.283)
Mild dementia due to other chromosomal abnormalities Dementia, mild has some trouble remembering recent events, and finds it hard to concentrate and make decisions and plans.
0.069
(0.046–0.099)
Congenital heart disease and mild dementia due to other 
chromosomal abnormalities Congenital heart disease and mild dementia (combined DW)
0.069
(0.046–0.099)
Severe motor and cognitive impairment due to Edward Syndrome or 
Patau Syndrome Motor plus cognitive impairments, severe
cannot move around without help, and cannot lift or hold 
objects, get dressed or sit upright. The person also has very 
low intelligence, speaks few words, and needs constant 
supervision and help with all daily activities.
0.542
(0.374–0.702)
Mild intellectual disability due to other chromosomal abnormalities Intellectual disability / mental retardation, mild
has low intelligence and is slow in learning at school. As an 
adult, the person can live independently, but often needs help 
to raise children and can only work at simple supervised jobs.
0.043
(0.026–0.064)
Moderate dementia due to other chromosomal abnormalities Dementia, moderate
has memory problems and confusion, feels disoriented, at 
times hears voices that are not real, and needs help with 
some daily activities.
0.377
(0.252–0.508)
Congenital heart disease and severe dementia due to other 
chromosomal abnormalities Congenital heart disease and severe dementia (combined DW)
0.449
(0.304–0.595)
Moderate intellectual disability due to other chromosomal 
abnormalities
Intellectual disability / mental retardation, 
moderate
has low intelligence, and is slow in learning to speak and to 
do even simple tasks. As an adult, the person requires a lot of 
support to live independently and raise children. The person 
can only work at the simplest supervised jobs.
0.1
(0.066–0.142)
Mild intellectual disability and moderate dementia due to other 
chromosomal abnormalities Moderate dementia, mild intellectual disability (combined DW)
0.403
(0.281–0.536)
Severe intellectual disability, mild dementia, and congenital heart 
disease due to other chromosomal abnormalities
Congenital heart disease, mild dementia, severe 
intellectual disability (combined DW)
0.218
(0.149–0.299)
Severe intellectual disability, severe dementia, and congenital heart 
disease due to other chromosomal abnormalities
Congenital heart disease, severe dementia, severe 
intellectual disability (combined DW)
0.535
(0.384–0.681)
Severe intellectual disability due to other chromosomal abnormalities Intellectual disability / mental retardation, severe
has very low intelligence and cannot speak more than a few 
words, needs constant supervision and help with most daily 
activities, and can do only the simplest tasks.
0.16
(0.107–0.226)
Profound intellectual disability, severe dementia, and congenital 
heart disease due to other chromosomal abnormalities
Congenital heart disease, severe dementia, 
profound intellectual disability (combined DW)
0.557
(0.401–0.703)
Borderline intellectual disability and mild dementia due to other 
chromosomal abnormalities Mild dementia, borderline intellectual disability (combined DW)
0.079
(0.051–0.115)
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Profound intellectual disability and severe dementia due to other 
chromosomal abnormalities Severe dementia, profound intellectual disability (combined DW)
0.557
(0.401–0.703)
Mild intellectual disability and mild dementia due to other 
chromosomal abnormalities Mild dementia, mild intellectual disability (combined DW)
0.109
(0.071–0.159)
Severe intellectual disability and severe dementia due to other 
chromosomal abnormalities Severe dementia, severe intellectual disability (combined DW)
0.535
(0.384–0.681)
Moderate intellectual disability, mild dementia, and congenital heart 
disease due to other chromosomal abnormalities
Congenital heart disease, mild dementia, moderate 
intellectual disability (combined DW)
0.162
(0.11–0.222)
Moderate intellectual disability and severe dementia due to other 
chromosomal abnormalities Severe dementia, moderate intellectual disability (combined DW)
0.503
(0.355–0.646)
Mild intellectual disability and severe dementia due to other 
chromosomal abnormalities Severe dementia, mild intellectual disability (combined DW)
0.472
(0.332–0.615)
Borderline intellectual disability and severe dementia due to other 
chromosomal abnormalities Severe dementia, borderline intellectual disability (combined DW)
0.455
(0.316–0.597)
Severe intellectual disability and mild dementia due to other 
chromosomal abnormalities Mild dementia, severe intellectual disability (combined DW)
0.218
(0.149–0.299)
Profound intellectual disability and moderate dementia due to other 
chromosomal abnormalities
Moderate dementia, profound intellectual 
disability (combined DW)
0.499
(0.358–0.645)
Severe intellectual disability and moderate dementia due to other 
chromosomal abnormalities Moderate dementia, severe intellectual disability (combined DW)
0.475
(0.34–0.614)
Profound intellectual disability and mild dementia due to other 
chromosomal abnormalities Mild dementia, profound intellectual disability (combined DW)
0.255
(0.178–0.346)
Moderate intellectual disability and moderate dementia due to other 
chromosomal abnormalities
Moderate dementia, moderate intellectual 
disability (combined DW)
0.438
(0.311–0.576)
Moderate intellectual disability and mild dementia due to other 
chromosomal abnormalities Mild dementia, moderate intellectual disability (combined DW)
0.162
(0.11–0.222)
Moderate intellectual disability, severe dementia, and congenital 
heart disease due to other chromosomal abnormalities
Congenital heart disease, severe dementia, 
moderate intellectual disability (combined DW)
0.503
(0.355–0.646)
Borderline intellectual disability, moderate dementia, and congenital 
heart disease due to other chromosomal abnormalities
Congenital heart disease, moderate dementia, 
borderline intellectual disability (combined DW)
0.384
(0.262–0.517)
Profound intellectual disability, mild dementia, and congenital heart 
disease due to other chromosomal abnormalities
Congenital heart disease, mild dementia, profound 
intellectual disability (combined DW)
0.255
(0.178–0.346)
Borderline intellectual disability and moderate dementia due to other 
chromosomal abnormalities
Moderate dementia, borderline intellectual 
disability (combined DW)
0.384
(0.262–0.517)
Mild intellectual disability, moderate dementia, and congenital heart 
disease due to other chromosomal abnormalities
Congenital heart disease, moderate dementia, mild 
intellectual disability (combined DW)
0.403
(0.281–0.536)
Moderate intellectual disability, moderate dementia, and congenital 
heart disease due to other chromosomal abnormalities
Congenital heart disease, moderate dementia, 
moderate intellectual disability (combined DW)
0.438
(0.311–0.576)
Severe intellectual disability, moderate dementia, and congenital 
heart disease due to other chromosomal abnormalities
Congenital heart disease, moderate dementia, 
severe intellectual disability (combined DW)
0.475
(0.34–0.614)
Severe motor and cognitive impairment with congenital heart disease 
due to Edward Syndrome or Patau Syndrome
Severe motor plus cognitive impairments and 
congenital heart disease (combined DW)
0.542
(0.374–0.702)
Profound intellectual disability, moderate dementia, and congenital 
heart disease due to other chromosomal abnormalities
Congenital heart disease, moderate dementia, 
profound intellectual disability (combined DW)
0.499
(0.358–0.645)
Borderline intellectual disability, severe dementia, and congenital 
heart disease due to other chromosomal abnormalities
Congenital heart disease, severe dementia, 
borderline intellectual disability (combined DW)
0.455
(0.316–0.597)
Mild intellectual disability, severe dementia, and congenital heart 
disease due to other chromosomal abnormalities
Congenital heart disease, severe dementia, mild 
intellectual disability (combined DW)
0.472
(0.332–0.615)
Profound intellectual disability due to other chromosomal 
abnormalities
Intellectual disability / mental retardation, 
profound
has very low intelligence, has almost no language, and does 
not understand even the most basic requests or instructions. 
The person requires constant supervision and help for all 
activities.
0.2
(0.133–0.283)
Disfigurement level 2 with pain due to other congenital 
musculoskeletal anomalies Disfigurement, level 2, with itch/pain
has a visible physical deformity that is sore and itchy. Other 
people stare and comment, which causes the person to worry. 
The person has trouble sleeping and concentrating.
0.188
(0.125–0.267)
Disfigurement level 2 and mild motor impairment due to congenital 
limb deficiency
Level 2 disfigurement with mild motor 
impairment (combined DW)
0.076
(0.051–0.112)
Disfigurement level 1 due to polydactyly and syndactyly Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Disfigurement level 2 and moderate motor impairment due to other 
congenital musculoskeletal anomalies
Level 2 disfigurement with moderate motor 
impairment (combined DW)
0.124
(0.083–0.175)
Disfigurement level 2 with pain due to congenital limb deficiency Disfigurement, level 2, with itch/pain
has a visible physical deformity that is sore and itchy. Other 
people stare and comment, which causes the person to worry. 
The person has trouble sleeping and concentrating.
0.188
(0.125–0.267)
Disfigurement level 2 due to other congenital musculoskeletal 
anomalies Disfigurement, level 2
has a visible physical deformity that causes others to stare 
and comment. As a result, the person is worried and has 
trouble sleeping and concentrating.
0.067
(0.044–0.096)
Disfigurement level 2 due to congenital limb deficiency Disfigurement, level 2
has a visible physical deformity that causes others to stare 
and comment. As a result, the person is worried and has 
trouble sleeping and concentrating.
0.067
(0.044–0.096)
Disfigurement level 2 with pain and moderate motor impairment due 
to other congenital musculoskeletal anomalies
Level 2 disfigurement with itch/pain and moderate 
motor impairment (combined DW)
0.237
(0.163–0.324)
Disfigurement level 2 with pain and mild motor impairment due to 
other congenital musculoskeletal anomalies
Level 2 disfigurement with itch/pain and mild 
motor impairment (combined DW)
0.196
(0.132–0.275)
Disfigurement level 2 with pain and mild motor impairment due to 
congenital limb deficiency
Level 2 disfigurement with itch/pain and mild 
motor impairment (combined DW)
0.196
(0.132–0.275)
Disfigurement level 2 and mild motor impairment due to other 
congenital musculoskeletal anomalies
Level 2 disfigurement with mild motor 
impairment (combined DW)
0.076
(0.051–0.112)
Disfigurement level 2 with pain and moderate motor impairment due 
to congenital limb deficiency
Level 2 disfigurement with itch/pain and moderate 
motor impairment (combined DW)
0.237
(0.163–0.324)
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Disfigurement level 2 and moderate motor impairment due to 
congenital limb deficiency
Level 2 disfigurement with moderate motor 
impairment (combined DW)
0.124
(0.083–0.175)
Incontinence and impotence due to congenital anomalies of the 
urinary tract urinary incontinence and impotence (combined DW)
0.154
(0.105–0.214)
Atypical genitalia, recurrent urinary tract infections or other 
abdominal issues and incontinence due to congenital anomalies of 
the urinary tract
Mild abdominopelvic problem, urinary 
incontinence, and level 1 disfigurement (combined DW)
0.158
(0.108–0.218)
Atypical genitalia due to congenital genital anomalies Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Atypical genitalia, incontinence and impotence due to congenital 
anomalies of the urinary tract
Mild abdominopelvic problem, urinary 
incontinence, and level 1 disfigurement (combined DW)
0.158
(0.108–0.218)
Atypical genitalia due to congenital anomalies of the urinary tract Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Recurrent urinary tract infections or other abdominal issues due to 
congenital anomalies of the urinary tract Abdominopelvic problem, mild
has some pain in the belly that causes nausea but does not 
interfere with daily activities.
0.011
(0.005–0.021)
Incontinence, impotence, and recurrent urinary tract infections or 
other abdominal issues and impotence due to congenital anomalies 
of the urinary tract
Mild abdominopelvic problem, urinary 
incontinence, and impotence (combined DW)
0.163
(0.112–0.225)
Recurrent urinary tract infections or other abdominal issues due to 
congenital genital anomalies Abdominopelvic problem, mild
has some pain in the belly that causes nausea but does not 
interfere with daily activities.
0.011
(0.005–0.021)
Incontinence and recurrent urinary tract infections or other 
abdominal issues due to congenital anomalies of the urinary tract Level 1 disfigurement and urinary incontinence (combined DW)
0.149
(0.101–0.206)
Atypical genitalia, incontinence, impotence, and recurrent urinary 
tract infections or other abdominal issues and impotence due to 
congenital anomalies of the urinary tract
Mild abdominopelvic problem, urinary 
incontinence, impotence, and level 1 
disfigurement
(combined DW) 0.172(0.118–0.239)
Primary infertility and recurrent urinary tract infections or other 
abdominal issues due to congenital genital anomalies Mild abdominal pain and primary infertility (combined DW) --
Asymptomatic congenital genital anomalies Asymptomatic -- --
Impotence due to congenital anomalies of the urinary tract Impotence has difficulty in obtaining or maintaining an erection. 0.017(0.009–0.03)
Impotence due to congenital genital anomalies Impotence has difficulty in obtaining or maintaining an erection. 0.017(0.009–0.03)
Incontinence due to congenital anomalies of the urinary tract Urinary incontinence cannot control urinating. 0.139(0.094–0.198)
Asymptomatic congenital anomalies of the urinary tract Asymptomatic -- --
Atypical genitalia, infertility, impotence, and recurrent urinary tract 
infections or other abdominal issues and impotence due to congenital 
genital anomalies
Mild abdominopelvic problem,  primary infertility, 
impotence, and level 1 disfigurement (combined DW)
0.046
(0.023–0.083)
Infertility, impotence, and recurrent urinary tract infections or other 
abdominal issues and impotence due to congenital genital anomalies
Mild abdominopelvic problem,  primary infertility, 
and impotence (combined DW)
0.035
(0.018–0.064)
Impotence and recurrent urinary tract infections or other abdominal 
issues due to congenital genital anomalies Mild abdominopelvic problem and impotence (combined DW)
0.028
(0.014–0.05)
Impotence and recurrent urinary tract infections or other abdominal 
issues due to congenital anomalies of the urinary tract Mild abdominopelvic problem and impotence (combined DW)
0.028
(0.014–0.05)
Primary infertility due to congenital genital anomalies Infertility, primary wants to have a child and has a fertile partner, but the couple cannot conceive.
0.008
(0.003–0.015)
Atypical genitalia, recurrent urinary tract infections or other 
abdominal issues and infertility due to congenital genital anomalies
Mild abdominopelvic problem, level 1 
disfigurement and primary infertility (combined DW)
0.029
(0.014–0.055)
Atypical genitalia, infertility and impotence due to congenital genital 
anomalies
Mild abdominopelvic problem, level 1 
disfigurement and primary infertility (combined DW)
0.029
(0.014–0.055)
Atypical genitalia and primary infertility due to congenital genital 
anomalies Disfigurement level 1 and primary infertility (combined DW) --
Atypical genitalia and impotence due to congenital anomalies of the 
urinary tract Level 1 disfigurement and impotence (combined DW)
0.028
(0.014–0.05)
Atypical genitalia, recurrent urinary tract infections or other 
abdominal issues and impotence due to congenital genital anomalies
Mild abdominopelvic problem, level 1 
disfigurement and impotence (combined DW)
0.039
(0.02–0.07)
Atypical genitalia, recurrent urinary tract infections or other 
abdominal issues and impotence due to congenital anomalies of the 
urinary tract
Mild abdominopelvic problem, level 1 
disfigurement and impotence (combined DW)
0.039
(0.02–0.07)
Infertility and impotence due to congenital genital anomalies Primary infertility and impotence (combined DW) 0.025(0.012–0.045)
Atypical genital and recurrent urinary tract infections and other 
abdominal issues due to congenital genital anomalies
Mild abdominopelvic problem and level 1 
disfigurement (combined DW)
0.022
(0.011–0.041)
Atypical genital and recurrent urinary tract infections and other 
abdominal issues due to congenital anomalies of the urinary tract
Mild abdominopelvic problem and level 1 
disfigurement (combined DW)
0.022
(0.011–0.041)
Atypical genitalia and incontinence due to congenital anomalies of 
the urinary tract
Mild abdominopelvic problem and level 1 
disfigurement (combined DW)
0.022
(0.011–0.041)
Atypical genitalia and impotence due to congenital genital anomalies Level 1 disfigurement and impotence (combined DW) 0.028(0.014–0.05)
Chronic abdominal pain and mild chronic respiratory problems due 
to congenital diaphragmatic hernia
Mild abdominopelvic problem and mild COPD 
and other chronic respiratory problems (combined DW)
0.03
(0.016–0.053)
Chronic abdominal pain and disfigurement due to congenital 
diaphragmatic hernia
Level 1 disfigurement with itch/pain and mild 
abdominopelvic problem (combined DW)
0.037
(0.02–0.062)
Disfigurement from scars following treatment for congenital 
malformations of the abdominal wall Disfigurement, level 1
has a slight, visible physical deformity that others notice, 
which causes some worry and discomfort.
0.011
(0.005–0.021)
Chronic abdominal pain due to congenital atresia and/or stenosis of 
the digestive tract Abdominopelvic problem, moderate
has pain in the belly and feels nauseous. The person has 
difficulties with daily activities. 
0.114
(0.078–0.159)
Developmental delay or mild intellectual disability due to congenital 
diaphragmatic hernia Intellectual disability / mental retardation, mild
has low intelligence and is slow in learning at school. As an 
adult, the person can live independently, but often needs help 
to raise children and can only work at simple supervised jobs.
0.043
(0.026–0.064)
844
Sequela Health state name Health state lay description Disability weight
Appendix Table 5. GBD 2016 sequelae, health states, health state lay descriptions, and disability weights
Chronic abdominal pain and/or nausea due to other congenital 
malformations of the digestive tract Abdominopelvic problem, moderate
has pain in the belly and feels nauseous. The person has 
difficulties with daily activities. 
0.114
(0.078–0.159)
Chronic abdominal pain and/or nausea with acid reflux, dyspahgia, 
and/or constipation  due to other congenital malformations of the 
digestive tract
Mild abdominopelvic problem and moderate 
abdominopelvic problem (combined DW)
0.124
(0.085–0.171)
Disfigurement due to congenital diaphragmatic hernia Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Constipation due to congenital malformations of the abdominal wall Abdominopelvic problem, moderate has pain in the belly and feels nauseous. The person has difficulties with daily activities. 
0.114
(0.078–0.159)
Chronic respiratory problems including difficulty breaking and 
recurrent upper respiratory infections due to atresia and/or stenosis of 
the digestive tract
COPD and other chronic respiratory problems, 
mild
has cough and shortness of breath after heavy physical 
activity, but is able to walk long distances and climb stairs.
0.019
(0.011–0.033)
Constipation and chronic abdominal pain due to congenital 
malformations of the abdominal wall
Mild abdominopelvic problem and moderate 
abdominopelvic problem (combined DW)
0.124
(0.085–0.171)
Asymptomatic congenital diaphragmatic hernia Asymptomatic -- --
Asymptomatic congenital atresia and/or stenosis of the digestive tract Asymptomatic -- --
Asymptomatic congenital malformations of the abdominal wall after 
treatment Asymptomatic -- --
Asymptomatic other congenital malformations of the digestive tract Asymptomatic -- --
Chronic respiratory problems and dysphagia or acid reflux due to 
congenital atresia and/or stenosis of the digestive tract
Mild abdominopelvic problem and mild COPD 
and other chronic respiratory problems (combined DW)
0.03
(0.016–0.053)
Acid reflux, dyspahgia, and/or constipation due to other congenital 
malformations of the digestive tract Abdominopelvic problem, mild
has some pain in the belly that causes nausea but does not 
interfere with daily activities.
0.011
(0.005–0.021)
Chronic abdominal pain due to congenital malformations of the 
abdominal wall Abdominopelvic problem, mild
has some pain in the belly that causes nausea but does not 
interfere with daily activities.
0.011
(0.005–0.021)
Dysphagia or acid reflux due to congenital atresia and/or stenosis of 
the digestive tract Abdominopelvic problem, mild
has some pain in the belly that causes nausea but does not 
interfere with daily activities.
0.011
(0.005–0.021)
Chronic abdominal pain due to congenital diaphragmatic hernia Abdominopelvic problem, mild has some pain in the belly that causes nausea but does not interfere with daily activities.
0.011
(0.005–0.021)
Mild chronic respiratory problems and breathlessness due to 
congenital diaphragmatic hernia
COPD and other chronic respiratory problems, 
mild
has cough and shortness of breath after heavy physical 
activity, but is able to walk long distances and climb stairs.
0.019
(0.011–0.033)
Chronic respiratory problems and abdominal pain due to congenital 
atresia and/or stenosis of the digestive tract
Mild abdominopelvic problem and mild COPD 
and other chronic respiratory problems (combined DW)
0.03
(0.016–0.053)
Dysphagia or acid reflux and chronic abdominal pain due to 
congenital atresia and/or stenosis of the digestive tract
Mild abdominopelvic problem and moderate 
abdominopelvic problem (combined DW)
0.124
(0.085–0.171)
Chronic abdominal pain and developmental delay due to congenital 
diaphragmatic hernia
Mild abdominopelvic problem and mild 
intellectual disability (combined DW)
0.053
(0.032–0.083)
Constipation and concern about scars due to congenital 
malformations of the abdominal wall
Mild abdominopelvic problem and level 1 
disfigurement (combined DW)
0.022
(0.011–0.041)
Disfigurement and mild chronic respiratory problems due to 
congenital diaphragmatic hernia
Level 1 disfigurement with itch/pain and mild 
COPD and other chronic respiratory problems (combined DW)
0.045
(0.026–0.073)
Chronic abdominal pain, disfigurement, developmental delay and  
chronic respiratory problems due to congenital diaphragmatic hernia
Mild abdominopelvic problem, mild COPD and 
other chronic respiratory problems, mild 
intellectual disability, and level 1 disfigurement 
(combined DW) 0.096(0.057–0.148)
Disfigurement, chronic respiratory problems and developmental 
delay due to congenital diaphragmatic hernia
Mild COPD and other chronic respiratory 
problems, mild intellectual disability, and level 1 
disfigurement with itch/pain
(combined DW) 0.086(0.052–0.131)
Chronic abdominal pain, disfigurement and developmental delay due 
to congenital diaphragmatic hernia
Mild abdominopelvic problem, mild intellectual 
disability, and level 1 disfigurement with itch/pain (combined DW)
0.078
(0.046–0.12)
Chronic abdominal pain, chronic respiratory problems and 
developmental delay due to congenital diaphragmatic hernia
Mild abdominopelvic problem,  mild COPD and 
other chronic respiratory problems, and level 1 
disfigurement with itch/pain 
(combined DW) 0.056(0.031–0.092)
Chronic abdominal pain and concern about scars due to congenital 
malformations of the abdominal wall
Moderate abdominopelvic problem and level 1 
disfigurement (combined DW)
0.124
(0.085–0.172)
Chronic abdominal pain, disfigurement and  chronic respiratory 
problems due to congenital diaphragmatic hernia
Mild abdominopelvic problem,  mild COPD and 
other chronic respiratory problems, and level 1 
disfigurement with itch/pain 
(combined DW) 0.056(0.031–0.092)
Constipation, chronic abdominal pain and concern about scars due to 
congenital malformations of the abdominal wall
Mild abdominopelvic problem, moderate 
abdominopelvic problem, and level 1 
disfigurement
(combined DW) 0.206(0.143–0.283)
Dysphagia or acid reflux, chronic abdominal pain and chronic 
respiratory problems due to congenital atresia and/or stenosis of the 
digestive tract
Mild abdominopelvic problem, moderate 
abdominopelvic problem, and mild COPD and 
other chronic respiratory problems
(combined DW) 0.141(0.096–0.198)
Disfigurement and developmental delay due to congenital 
diaphragmatic hernia
Level 1 disfigurement with itch/pain and mild 
intellectual disability (combined DW)
0.068
(0.041–0.102)
 Mild chronic respiratory problems and developmental delay due to 
congenital diaphragmatic hernia
Mild intellectual disability and mild COPD and 
other chronic respiratory problem (combined DW)
0.061
(0.037–0.093)
Moderate hearing loss with ringing due to other congenital 
anomalies Hearing loss, moderate, with ringing
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone, and has annoying ringing in the ears for 
more than 5 minutes at a time, almost everyday.
0.074
(0.049–0.107)
Moderately severe hearing loss due to other congenital anomalies Hearing loss, moderately severe (custom DW from hearing loss impairment envelope) --
Mild hearing loss with ringing due to other congenital anomalies Hearing loss, mild, with ringing
has great difficulty hearing and understanding another person 
talking in a noisy place (for example, on an urban street), and 
sometimes has annoying ringing in the ears.
0.021
(0.012–0.036)
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Severe hearing loss due to other congenital anomalies Hearing loss, severe
is unable to hear and understand another person talking, even 
in a quiet place, and unable to take part in a phone 
conversation. Difficulties with communicating and relating 
to others cause emotional impact at times (for example worry 
or depression).
0.158
(0.105–0.227)
Moderate hearing loss due to other congenital anomalies Hearing loss, moderate
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone.
0.027
(0.015–0.042)
Severe hearing loss with ringing due to other congenital anomalies Hearing loss, severe, with ringing
is unable to hear and understand another person talking, even 
in a quiet place, and unable to take part in a phone 
conversation, and has annoying ringing in the ears for more 
than 5 minutes at a time, almost everyday. Difficulties with 
communicating and relating to others cause emotional impact 
at times (for example worry or depression).
0.261
(0.175–0.36)
Mild hearing loss due to other congenital anomalies Hearing loss, mild has great difficulty hearing and understanding another person talking in a noisy place (for example, on an urban street).
0.01
(0.004–0.019)
Complete hearing loss with ringing due to other congenital 
anomalies Hearing loss, complete, with ringing
cannot hear at all in any situation, including even the loudest 
sounds, and cannot communicate verbally or use a phone, 
and has very annoying ringing in the ears for more than half 
of the day. Difficulties with communicating and relating to 
others often cause worry, depression or loneliness.
0.316
(0.212–0.435)
Complete hearing loss due to other congenital anomalies Hearing loss, complete
cannot hear at all in any situation, including even the loudest 
sounds, and cannot communicate verbally or use a phone. 
Difficulties with communicating and relating to others often 
cause worry, depression or loneliness.
0.215
(0.144–0.307)
Profound hearing loss due to other congenital anomalies Hearing loss, profound
is unable to hear and understand another person talking, even 
in a quiet place, is unable to take part in a phone 
conversation, and has great difficulty hearing anything in any 
other situation. Difficulties with communicating and relating 
to othersoften cause worry, depression, and loneliness.
0.204
(0.134–0.288)
Moderately severe hearing loss with ringing due to other congenital 
anomalies Hearing loss, moderately severe, with ringing (custom DW from hearing loss impairment envelope) --
Other congenital birth defects Post-COMO calculation for residuals (YLL/YLD ratio, other methods) -- --
Profound hearing loss with ringing due to other congenital anomalies Hearing loss, profound, with ringing
is unable to hear and understand another person talking, even 
in a quiet place, is unable to take part in a phone 
conversation, has great difficulty hearing anything in any 
other situation, and has annoying ringing in the ears for more 
than 5 minutes at a time, several times a day. Difficulties 
with communicating and relating to others often cause worry, 
depression  or loneliness
0.277
(0.182–0.387)
Symptomatic seborrhoeic dermatitis Disfigurement, level 1 with itch/pain
has a slight, visible physical deformity that is sometimes sore 
or itchy. Others notice the deformity, which causes some 
worry and discomfort.
0.027
(0.015–0.042)
Asymptomatic contact dermatitis Asymptomatic -- --
Asymptomatic seborrhoeic dermatitis Asymptomatic -- --
Severe atopic dermatitis Disfigurement, level 3, with itch/pain
has an obvious physical deformity that is very painful and 
itchy. The physical deformity makes others uncomfortable, 
which causes the person to avoid social contact, feel worried, 
sleep poorly, and think about suicide.
0.576
(0.401–0.731)
Mild contact dermatitis Disfigurement, level 1 with itch/pain
has a slight, visible physical deformity that is sometimes sore 
or itchy. Others notice the deformity, which causes some 
worry and discomfort.
0.027
(0.015–0.042)
Moderate contact dermatitis Disfigurement, level 2, with itch/pain
has a visible physical deformity that is sore and itchy. Other 
people stare and comment, which causes the person to worry. 
The person has trouble sleeping and concentrating.
0.188
(0.125–0.267)
Mild atopic dermatitis Disfigurement, level 1 with itch/pain
has a slight, visible physical deformity that is sometimes sore 
or itchy. Others notice the deformity, which causes some 
worry and discomfort.
0.027
(0.015–0.042)
Moderate atopic dermatitis Disfigurement, level 2, with itch/pain
has a visible physical deformity that is sore and itchy. Other 
people stare and comment, which causes the person to worry. 
The person has trouble sleeping and concentrating.
0.188
(0.125–0.267)
Mild psoriasis Disfigurement, level 1 with itch/pain
has a slight, visible physical deformity that is sometimes sore 
or itchy. Others notice the deformity, which causes some 
worry and discomfort.
0.027
(0.015–0.042)
Moderate psoriasis Disfigurement, level 2, with itch/pain
has a visible physical deformity that is sore and itchy. Other 
people stare and comment, which causes the person to worry. 
The person has trouble sleeping and concentrating.
0.188
(0.125–0.267)
Severe psoriasis Disfigurement, level 3, with itch/pain
has an obvious physical deformity that is very painful and 
itchy. The physical deformity makes others uncomfortable, 
which causes the person to avoid social contact, feel worried, 
sleep poorly, and think about suicide.
0.576
(0.401–0.731)
Moderate cellulitis Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
Mild cellulitis Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Severe cellulitis Infectious disease, acute episode, severe has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
0.133
(0.088–0.19)
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Abscess and other bacterial skin diseases Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Impetigo Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Scabies Disfigurement, level 1 with itch/pain
has a slight, visible physical deformity that is sometimes sore 
or itchy. Others notice the deformity, which causes some 
worry and discomfort.
0.027
(0.015–0.042)
Other fungal skin diseases Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Tinea capitis Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Mild viral warts Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Severe molluscum contagiosum Disfigurement, level 2
has a visible physical deformity that causes others to stare 
and comment. As a result, the person is worried and has 
trouble sleeping and concentrating.
0.067
(0.044–0.096)
Severe viral warts Disfigurement, level 2
has a visible physical deformity that causes others to stare 
and comment. As a result, the person is worried and has 
trouble sleeping and concentrating.
0.067
(0.044–0.096)
Mild molluscum contagiosum Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Mild acne vulgaris Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Moderate acne vulgaris Disfigurement, level 2
has a visible physical deformity that causes others to stare 
and comment. As a result, the person is worried and has 
trouble sleeping and concentrating.
0.067
(0.044–0.096)
Severe acne vulgaris Disfigurement, level 3
has an obvious physical deformity that makes others 
uncomfortable, which causes the person to avoid social 
contact, feel worried, sleep poorly, and think about suicide.
0.405
(0.275–0.546)
Severe alopecia areata Disfigurement, level 2
has a visible physical deformity that causes others to stare 
and comment. As a result, the person is worried and has 
trouble sleeping and concentrating.
0.067
(0.044–0.096)
Mild alopecia areata Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Pruritus Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Severe urticaria Disfigurement, level 2, with itch/pain
has a visible physical deformity that is sore and itchy. Other 
people stare and comment, which causes the person to worry. 
The person has trouble sleeping and concentrating.
0.188
(0.125–0.267)
Mild urticaria Disfigurement, level 1 with itch/pain
has a slight, visible physical deformity that is sometimes sore 
or itchy. Others notice the deformity, which causes some 
worry and discomfort.
0.027
(0.015–0.042)
Moderate decubitus ulcer Disfigurement, level 2, with itch/pain
has a visible physical deformity that is sore and itchy. Other 
people stare and comment, which causes the person to worry. 
The person has trouble sleeping and concentrating.
0.188
(0.125–0.267)
Severe decubitus ulcer Disfigurement, level 3, with itch/pain
has an obvious physical deformity that is very painful and 
itchy. The physical deformity makes others uncomfortable, 
which causes the person to avoid social contact, feel worried, 
sleep poorly, and think about suicide.
0.576
(0.401–0.731)
Mild decubitus ulcer Disfigurement, level 1 with itch/pain
has a slight, visible physical deformity that is sometimes sore 
or itchy. Others notice the deformity, which causes some 
worry and discomfort.
0.027
(0.015–0.042)
Symptomatic other skin and subcutaneous diseases Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Asymptomatic other skin and subcutaneous diseases Asymptomatic -- --
Blindness due to glaucoma Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Severe vision impairment due to glaucoma Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Moderate vision impairment due to glaucoma Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Severe vision impairment due to cataract Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Blindness due to cataract Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Moderate vision impairment due to cataract Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Blindness due to macular degeneration Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Severe vision impairment due to macular degeneration Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Moderate vision impairment due to macular degeneration Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
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Near vision impairment Presbyopia has difficulty seeing things that are nearer than 3 feet, but has no difficulty with seeing things at a distance. 
0.011
(0.005–0.02)
Blindness due to uncorrected refractive error Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Severe vision impairment due to uncorrected refractive error Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Moderate vision impairment due to uncorrected refractive error Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Mild hearing loss due to age-related and other hearing loss Hearing loss, mild has great difficulty hearing and understanding another person talking in a noisy place (for example, on an urban street).
0.01
(0.004–0.019)
Complete hearing loss due to age-related and other hearing loss Hearing loss, complete
cannot hear at all in any situation, including even the loudest 
sounds, and cannot communicate verbally or use a phone. 
Difficulties with communicating and relating to others often 
cause worry, depression or loneliness.
0.215
(0.144–0.307)
Moderate hearing loss due to age-related and other hearing loss Hearing loss, moderate
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone.
0.027
(0.015–0.042)
Moderate hearing loss with ringing due to age-related and other 
hearing loss Hearing loss, moderate, with ringing
is unable to hear and understand another person talking in a 
noisy place (for example, on an urban street), and has 
difficulty hearing another person talking even in a quiet place 
or on the phone, and has annoying ringing in the ears for 
more than 5 minutes at a time, almost everyday.
0.074
(0.049–0.107)
Profound hearing loss due to age-related and other hearing loss Hearing loss, profound
is unable to hear and understand another person talking, even 
in a quiet place, is unable to take part in a phone 
conversation, and has great difficulty hearing anything in any 
other situation. Difficulties with communicating and relating 
to othersoften cause worry, depression, and loneliness.
0.204
(0.134–0.288)
Severe hearing loss due to age-related and other hearing loss Hearing loss, severe
is unable to hear and understand another person talking, even 
in a quiet place, and unable to take part in a phone 
conversation. Difficulties with communicating and relating 
to others cause emotional impact at times (for example worry 
or depression).
0.158
(0.105–0.227)
Severe hearing loss with ringing due to age-related and other hearing 
loss Hearing loss, severe, with ringing
is unable to hear and understand another person talking, even 
in a quiet place, and unable to take part in a phone 
conversation, and has annoying ringing in the ears for more 
than 5 minutes at a time, almost everyday. Difficulties with 
communicating and relating to others cause emotional impact 
at times (for example worry or depression).
0.261
(0.175–0.36)
Mild hearing loss with ringing due to age-related and other hearing 
loss Hearing loss, mild, with ringing
has great difficulty hearing and understanding another person 
talking in a noisy place (for example, on an urban street), and 
sometimes has annoying ringing in the ears.
0.021
(0.012–0.036)
Profound hearing loss with ringing due to age-related and other 
hearing loss Hearing loss, profound, with ringing
is unable to hear and understand another person talking, even 
in a quiet place, is unable to take part in a phone 
conversation, has great difficulty hearing anything in any 
other situation, and has annoying ringing in the ears for more 
than 5 minutes at a time, several times a day. Difficulties 
with communicating and relating to others often cause worry, 
depression  or loneliness
0.277
(0.182–0.387)
Moderately severe hearing loss with ringing due to age-related and 
other hearing loss Hearing loss, moderately severe, with ringing (custom DW from hearing loss impairment envelope) --
Moderately severe hearing loss due to age-related and other hearing 
loss Hearing loss, moderately severe (custom DW from hearing loss impairment envelope) --
Complete hearing loss with ringing due to age-related and other 
hearing loss Hearing loss, complete, with ringing
cannot hear at all in any situation, including even the loudest 
sounds, and cannot communicate verbally or use a phone, 
and has very annoying ringing in the ears for more than half 
of the day. Difficulties with communicating and relating to 
others often cause worry, depression or loneliness.
0.316
(0.212–0.435)
Blindness due to other vision loss Distance vision blindness
is completely blind, which causes great difficulty in some 
daily activities, worry and anxiety, and great difficulty going 
outside the home without assistance. 
0.187
(0.124–0.26)
Severe vision impairment due to other vision loss Distance vision, severe impairment
has severe vision loss, which causes difficulty in daily 
activities, some emotional impact (for example worry), and 
some difficulty going outside the home without assistance.
0.184
(0.125–0.258)
Moderate vision impairment due to other vision loss Distance vision, moderate impairment has vision problems that make it difficult to recognize faces or objects across a room.
0.031
(0.019–0.049)
Asymptomatic acute sense organ diseases Asymptomatic -- --
Asymptomatic chronic sense organ diseases Asymptomatic -- --
Moderate acute sense organ diseases Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Severe chronic sense organ diseases Vertigo -- 0.113(0.074–0.158)
Mild acute sense organ diseases Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Moderate chronic sense organ diseases Disfigurement, level 1 has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
0.011
(0.005–0.021)
Pain due to caries of deciduous teeth Dental caries, symptomatic has a toothache, which causes some difficulty in eating. 0.01(0.005–0.019)
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Asymptomatic caries of deciduous teeth Asymptomatic -- --
Pain due to caries of permanent teeth Dental caries, symptomatic has a toothache, which causes some difficulty in eating. 0.01(0.005–0.019)
Asymptomatic caries of permanent teeth Asymptomatic -- --
Chronic periodontal diseases Periodontitis has minor bleeding of the gums from time to time, with mild discomfort.
0.007
(0.003–0.014)
Asymptomatic edentulism and severe tooth loss Asymptomatic -- --
Difficulty eating due to edentulism and severe tooth loss Severe tooth loss has lost more than 20 teeth including front and back, and has great difficulty in eating meat, fruits, and vegetables.
0.067
(0.045–0.095)
Mild other oral disorders Infectious disease, acute episode, mild has a low fever and mild discomfort , but no difficulty with daily activities.
0.006
(0.002–0.012)
Severe other oral disorders Infectious disease, acute episode, moderate has a fever and aches, and feels weak, which causes some difficulty with daily activities. 
0.051
(0.032–0.074)
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Residual  Method 
 Estimation: YLD to YLL ratio method 
Other intestinal infectious 
diseases 
YLD to YLL ratio of explicitly estimated intestinal infectious diseases by geography, country, sex applied to 
YLL from other intestinal infectious diseases by geography, country, sex  and age.  Causes used for estimation 
include: Typhoid fever, Paratyphoid fever. 
Other neglected tropical 
diseases 
YLD to YLL ratio of explicitly estimated neglected tropical disease causes by geography, country, sex applied 
to YLL from other neglected tropical diseases by geography, country, sex  and age. Causes used for estimation 
include: Chagas disease, Visceral leishmaniasis, Dengue, Yellow fever, Rabies. 
Other maternal disorders 
YLD to YLL ratio of explicitly estimated maternal disorder causes by geography, country, sex applied to YLL 
from other maternal disorders by geography, country, sex  and age.  Causes used for estimation include: 
Maternal hemorrhage, Maternal sepsis and other maternal infections, Maternal hypertensive disorders, Maternal 
obstructed labor and uterine rupture, Maternal abortion, miscarriage, and ectopic pregnancy, Indirect maternal 
deaths, Late maternal deaths, Maternal deaths aggravated by HIV/AIDS. 
Other neonatal disorders 
YLD to YLL ratio of explicitly estimated neonatal disorders by geography, country, sex applied to YLL from 
other neonatal disorders by geography, country, sex  and age.  Causes used for estimation include: Neonatal 
preterm birth complications, Neonatal encephalopathy due to birth asphyxia and trauma, Neonatal sepsis and 
other neonatal infections, Hemolytic disease and other neonatal jaundice. 
Other nutritional 
deficiencies 
YLD to YLL ratio of explicitly estimated nutritional deficiencies by geography, country, sex applied to YLL 
from other nutritional deficiencies by geography, country, sex  and age.  Causes used for estimation include 
Protein-energy malnutrition.   
Other sexually transmitted 
diseases 
YLD to YLL ratio of gonococcal and chlamydial infection by geography, country, sex applied to YLL from 
other sexually transmitted diseases by geography, country, sex  and age.  Causes used for estimation include: 
Chlamydial infection, Gonococcal infection. 
Other infectious diseases 
YLD to YLL ratio of HIV/AIDS and tuberculosis, diarrhea, lower respiratory and other common infectious 
diseases, neglected tropical diseases and malaria, sexually transmitted diseases and hepatitis by geography, 
country, sex applied to YLL from other infectious diseases by geography, country, sex  and age. Causes used for 
estimation include: Typhoid fever, Paratyphoid fever, Lower respiratory infections, Upper respiratory 
infections, Varicella and herpes zoster, Malaria, Acute hepatitis A, Hepatitis B, Hepatitis C, Acute hepatitis E, 
Chlamydial infection, Gonococcal infection, Diphtheria, Whooping cough, Measles, Chagas disease, Visceral 
leishmaniasis, Dengue, Yellow fever, Maternal sepsis and other maternal infections, Pneumococcal meningitis, 
H influenzae type B meningitis, Meningococcal meningitis, Other meningitis, Encephalitis, Tetanus, Ascariasis, 
Neonatal sepsis and other neonatal infections 
Other chronic respiratory 
diseases 
YLD to YLL ratio of COPD, pneumoconiosis and interstitial lung disease and pulmonary sarcoidosis by 
geography, country, sex applied to YLL from other chronic respiratory diseases by geography, country, sex  and 
age.  Causes used for estimation include: Chronic obstructive pulmonary disease, Silicosis, Asbestosis, Coal 
workers pneumoconiosis, Other pneumoconiosis, Interstitial lung disease and pulmonary sarcoidosis 
Other digestive disorders 
YLD to YLL ratio of explicitly estimated  digestive disorders by geography, country, sex applied to YLL from 
other digestive disorders by geography, country, sex  and age.  Causes used for estimation include: Gastritis and 
duodenitis, Appendicitis, Paralytic ileus and intestinal obstruction, Inguinal, femoral, and abdominal hernia, 
Inflammatory bowel disease, Vascular intestinal disorders, Gallbladder and biliary diseases, Pancreatitis 
Other neurological 
disorders 
YLD to YLL ratio of Alzheimer and other dementias, Parkinson disease, multiple sclerosis and motor-neuron 
disease by geography, country, sex applied to YLL from other neurological disorders by geography, country, 
sex  and age.  Causes used for estimation include: Alzheimer disease and other dementias, Parkinson disease, 
Epilepsy, Multiple sclerosis 
Other urinary diseases 
YLD to YLL ratio of explicitly estimated urinary diseases by geography, country, sex applied to YLL from 
other urinary diseases by geography, country, sex  and age.  Causes used for estimation include: Interstitial 
nephritis and urinary tract infections, Urolithiasis 
Other hemoglobinopathies 
and hemolytic anemias 
YLD to YLL ratio of explicitly estimated hemoglobinopathies and hemolytic anemias by geography, country, 
sex applied to YLL from other hemoglobinopathies and hemolytic anemias by geography, country, sex  and age.  
Causes used for estimation include: Thalassemias, Sickle cell disorders, G6PD deficiency 
Other congenital 
anomalies 
YLD to YLL ratio of explicitly estimated congenital anomalies by geography, country, sex applied to YLL from 
other congenital anomalies by geography, country, sex  and age.  Causes used for estimation include: Neural 
tube defects, Congenital heart anomalies 
 
 Estimation: based on epidemiological data 
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Residual  Method 
Meningitis due to other 
causes 
Data on proportion of meningitis due to other causes modelled in DisMod-MR 2.1, forced to sum to 100% at 
1,000 draw level for each geography-year-age-sex with the proportions for pneumococcal, H influenza B and 
meningococcal meningitis, and applied to dismod-MR 2.1 model of all meningitis 
Pelvic inflammatory 
disease due to other 
causes 
DisMod-MR 2.1 model of the proportion of pelvic inflammatory disease due to other causes, constrained to 
100% with proportions of pelvic inflammatory disease due to gonococcal and chlamydial infection and applied 
to the DisMod-MR 2.1 model for all pelvic inflammatory disease 
Other neoplasms 
Similar to all other cancers: mortality to incidence ratio method applied to cancer registry data for other 
neoplasms 
Liver cancer due to other 
causes 
Data on proportion of liver cancer due to other causes modelled in DisMod-MR 2.1, forced to sum to 100% at 
1,000 draw level for each geography, year, age, and sex with the proportions for liver cancer due to hepatitis B, 
hepatitis C and alcohol, and applied to total liver cancer estimates from cancer analyses using mortality to 
incidence ratios 
Other cardiovascular 
diseases 
Ratio of prevalence of ICD-9 coded other cardiovascular diseases in MEPS and 2005 USA outpatient data to 
prevalence of heart failure due to other cardiovascular diseases (estimated as part of the heart failure envelope), 
and applied to prevalence of heart failure due to other CVD estimates for all other locations and years 
Cirrhosis and other 
chronic liver diseases due 
to other causes 
Data on proportion of cirrhosis and other chronic liver diseases due to other causes modelled in DisMod-MR 
2.1, forced to sum to 100% at 1,000 draw level for each geography-year-age-sex with the proportions for 
cirrhosis and other chronic liver diseases due to hepatitis B, hepatitis C and alcohol, and applied to total 
cirrhosis and other chronic liver diseases estimates from DisMod-MR 2.1 analysis 
Other pneumoconiosis  DisMod-MR 2.1 model based on hospital admission and claims data 
Other drug use disorders 
NESARC prevalence of drug dependence other than cannabis, opioids, amphetamines and cocaine multiplied by 
ratio of YLD to prevalence for cocaine and amphetamine by geography, year, age, and sex 
Other mental and 
substance use disorders 
Prevalence of personality disorders not comorbid with GBD mental and substance use disorder categories and 
severity distribution from NESARC and Australian National Survey of Mental Health and Wellbeing 1997 
Chronic kidney disease 
due to other causes  
Data on proportion of chronic kidney disease due to other causes from renal registries modelled in DisMod-MR 
2.1, forced to sum to 100% at 1,000 draw level for each geography-year-age-sex with the proportions of chronic 
kidney disease due to diabetes, hypertension and glomerulonephritis, and applied to total chronic kidney disease 
estimates from DisMod-MR 2.1 analyses 
Other gynecological 
disorders Dismod MR 2.1 using US claims data 
Other musculoskeletal 
disorders 
DisMod-MR 2.1 model of survey and US claims data on prevalence of all musculoskeletal symptoms and 
diseases minus rheumatoid arthritis, osteoarthritis, gout, low back pain and neck pain. Long-term sequelae of 
fractures, dislocations and contusions due to injuries are subtracted out of other musculoskeletal disorders to 
avoid double counting 
Other skin Dismod-MR 2.1 model using outpatient and US claims data 
Age-related and other 
hearing loss 
Survey data on the proportion of hearing loss due to age-related and other hearing loss modelled in dismod MR 
2.1 and forced to sum to total hearing loss by geography, year, age and sex 
Other vision loss 
Survey data on vision loss due to other causes modelled in DisMod-MR 2.1 and forced to sum to total vision 
loss by geography, year, age and sex 
Other sense organ 
disorders DisMod-MR 2.1 model using outpatient and US claims data 
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Residual  Method 
Other oral disorders DisMod-MR 2.1 model using US Medical Expenditure Panel Surveys (MEPS) data 
Other transport injuries DisMod-MR 2.1 model using data from surveys, hospital admission and outpatient/emergency department visits 
Other exposure to 
mechanical forces DisMod-MR 2.1 model using data from surveys, hospital admission and outpatient/emergency department visits 
Foreign body in other part DisMod-MR 2.1 model using data from surveys, hospital admission and outpatient/emergency department visits 
Other unintentional 
injuries DisMod-MR 2.1 model using data from surveys, hospital admission and outpatient/emergency department visits 
Assault by other means DisMod-MR 2.1 model using data from surveys, hospital admission and outpatient/emergency department visits 
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e(0) ln(5q0) ln(35q15) ln(20q50)
0 0.734 0.487 0.655 0.725
1 0.738 0.484 0.657 0.729
2 0.739 0.473 0.654 0.733
3 0.735 0.445 0.646 0.739
4 0.729 0.42 0.636 0.743
5 0.713 0.381 0.626 0.741
6 0.704 0.35 0.61 0.736
7 0.712 0.356 0.614 0.746
8 0.704 0.345 0.607 0.741
9 0.702 0.336 0.601 0.738
10 0.701 0.333 0.598 0.737
Appendix Table 7: Socio-demographic Index R-squared values with lags up to 10 years
Lag
Dependent Variable
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Location SDI Level
Aichi High SDI
Akita High SDI
Alabama High SDI
Alaska High SDI
Andorra High SDI
Aomori High SDI
Arizona High SDI
Arkansas High SDI
Australia High SDI
Austria High SDI
Barking and Dagenham High SDI
Barnet High SDI
Barnsley High SDI
Bath and North East Somerset High SDI
Bedford High SDI
Belgium High SDI
Bexley High SDI
Birmingham High SDI
Blackburn with Darwen High SDI
Blackpool High SDI
Bolton High SDI
Bournemouth High SDI
Bracknell Forest High SDI
Bradford High SDI
Brent High SDI
Brighton and Hove High SDI
Bristol, City of High SDI
Bromley High SDI
Brunei High SDI
Buckinghamshire High SDI
Bury High SDI
Calderdale High SDI
California High SDI
Cambridgeshire High SDI
Camden High SDI
Canada High SDI
Central Bedfordshire High SDI
Cheshire East High SDI
Cheshire West and Chester High SDI
Chiba High SDI
Colorado High SDI
Connecticut High SDI
Cornwall High SDI
County Durham High SDI
Coventry High SDI
Appendix Table 8: Socio-Demographic Index groupings by location, based on 2016 values
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Croatia High SDI
Croydon High SDI
Cumbria High SDI
Cyprus High SDI
Czech Republic High SDI
Darlington High SDI
Delaware High SDI
Denmark High SDI
Derby High SDI
Derbyshire High SDI
Devon High SDI
District of Columbia High SDI
Doncaster High SDI
Dorset High SDI
Dudley High SDI
Ealing High SDI
East Riding of Yorkshire High SDI
East Sussex High SDI
Ehime High SDI
Enfield High SDI
Essex High SDI
Estonia High SDI
Finland High SDI
Florida High SDI
France High SDI
Fukui High SDI
Fukuoka High SDI
Fukushima High SDI
Gateshead High SDI
Georgia High SDI
Germany High SDI
Gifu High SDI
Gloucestershire High SDI
Greece High SDI
Greenwich High SDI
Gunma High SDI
Hackney High SDI
Halton High SDI
Hammersmith and Fulham High SDI
Hampshire High SDI
Haringey High SDI
Harrow High SDI
Hartlepool High SDI
Havering High SDI
Hawaii High SDI
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Herefordshire, County of High SDI
Hertfordshire High SDI
Hillingdon High SDI
Hiroshima High SDI
Hokkaidō High SDI
Hounslow High SDI
Hyōgo High SDI
Ibaraki High SDI
Iceland High SDI
Idaho High SDI
Illinois High SDI
Indiana High SDI
Iowa High SDI
Ireland High SDI
Ishikawa High SDI
Isle of Wight High SDI
Islington High SDI
Italy High SDI
Iwate High SDI
Kagawa High SDI
Kagoshima High SDI
Kanagawa High SDI
Kansas High SDI
Kensington and Chelsea High SDI
Kent High SDI
Kentucky High SDI
Kingston upon Hull, City of High SDI
Kingston upon Thames High SDI
Kirklees High SDI
Knowsley High SDI
Kumamoto High SDI
Kyōto High SDI
Kōchi High SDI
Lambeth High SDI
Lancashire High SDI
Latvia High SDI
Leeds High SDI
Leicester High SDI
Leicestershire High SDI
Lewisham High SDI
Lincolnshire High SDI
Lithuania High SDI
Liverpool High SDI
Louisiana High SDI
Luton High SDI
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Luxembourg High SDI
Maine High SDI
Malta High SDI
Manchester High SDI
Maryland High SDI
Massachusetts High SDI
Medway High SDI
Merton High SDI
Michigan High SDI
Middlesbrough High SDI
Mie High SDI
Milton Keynes High SDI
Minnesota High SDI
Mississippi High SDI
Missouri High SDI
Miyagi High SDI
Miyazaki High SDI
Montana High SDI
Nagano High SDI
Nagasaki High SDI
Nara High SDI
Nebraska High SDI
Netherlands High SDI
Nevada High SDI
New Hampshire High SDI
New Jersey High SDI
New Mexico High SDI
New York High SDI
New Zealand High SDI
Newcastle upon Tyne High SDI
Newham High SDI
Niigata High SDI
Norfolk High SDI
North Carolina High SDI
North Dakota High SDI
North East Lincolnshire High SDI
North Lincolnshire High SDI
North Somerset High SDI
North Tyneside High SDI
North Yorkshire High SDI
Northamptonshire High SDI
Northern Ireland High SDI
Northumberland High SDI
Norway High SDI
Nottingham High SDI
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Nottinghamshire High SDI
Ohio High SDI
Okayama High SDI
Okinawa High SDI
Oklahoma High SDI
Oldham High SDI
Oregon High SDI
Oxfordshire High SDI
Pennsylvania High SDI
Peterborough High SDI
Plymouth High SDI
Poland High SDI
Poole High SDI
Portsmouth High SDI
Puerto Rico High SDI
Reading High SDI
Redbridge High SDI
Redcar and Cleveland High SDI
Rhode Island High SDI
Richmond upon Thames High SDI
Rochdale High SDI
Rotherham High SDI
Rutland High SDI
Saga High SDI
Saitama High SDI
Salford High SDI
Sandwell High SDI
Scotland High SDI
Sefton High SDI
Sheffield High SDI
Shiga High SDI
Shimane High SDI
Shizuoka High SDI
Shropshire High SDI
Singapore High SDI
Slough High SDI
Slovakia High SDI
Slovenia High SDI
Solihull High SDI
Somerset High SDI
South Carolina High SDI
South Dakota High SDI
South Gloucestershire High SDI
South Korea High SDI
South Tyneside High SDI
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Southampton High SDI
Southend-on-Sea High SDI
Southwark High SDI
St Helens High SDI
Staffordshire High SDI
Stockholm High SDI
Stockport High SDI
Stockton-on-Tees High SDI
Stoke-on-Trent High SDI
Suffolk High SDI
Sunderland High SDI
Surrey High SDI
Sutton High SDI
Sweden except Stockholm High SDI
Swindon High SDI
Switzerland High SDI
Taiwan (Province of China) High SDI
Tameside High SDI
Telford and Wrekin High SDI
Tennessee High SDI
Texas High SDI
Thurrock High SDI
Tochigi High SDI
Tokushima High SDI
Torbay High SDI
Tottori High SDI
Tower Hamlets High SDI
Toyama High SDI
Trafford High SDI
Tōkyō High SDI
Utah High SDI
Vermont High SDI
Virgin Islands High SDI
Virginia High SDI
Wakayama High SDI
Wakefield High SDI
Wales High SDI
Walsall High SDI
Waltham Forest High SDI
Wandsworth High SDI
Warrington High SDI
Warwickshire High SDI
Washington High SDI
West Berkshire High SDI
West Sussex High SDI
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West Virginia High SDI
Westminster High SDI
Wigan High SDI
Wiltshire High SDI
Windsor and Maidenhead High SDI
Wirral High SDI
Wisconsin High SDI
Wokingham High SDI
Wolverhampton High SDI
Worcestershire High SDI
Wyoming High SDI
Yamagata High SDI
Yamaguchi High SDI
Yamanashi High SDI
York High SDI
Ôita High SDI
Ōsaka High SDI
'Asir High-middle SDI
Antigua and Barbuda High-middle SDI
Argentina High-middle SDI
Armenia High-middle SDI
Azerbaijan High-middle SDI
Bahah High-middle SDI
Barbados High-middle SDI
Beijing High-middle SDI
Belarus High-middle SDI
Bermuda High-middle SDI
Bulgaria High-middle SDI
Chile High-middle SDI
Cuba High-middle SDI
Delhi, Urban High-middle SDI
Distrito Federal High-middle SDI
Eastern Province High-middle SDI
Georgia High-middle SDI
Goa, Urban High-middle SDI
Greenland High-middle SDI
Guam High-middle SDI
Guangdong High-middle SDI
Ha'il High-middle SDI
Himachal Pradesh, Urban High-middle SDI
Hong Kong Special Administrative Region of China High-middle SDI
Hungary High-middle SDI
Iran High-middle SDI
Israel High-middle SDI
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Jakarta High-middle SDI
Jawf High-middle SDI
Jiangsu High-middle SDI
Jizan High-middle SDI
East Kalimantan High-middle SDI
North Kalimantan High-middle SDI
Kazakhstan High-middle SDI
Riau Islands High-middle SDI
Kuwait High-middle SDI
Lebanon High-middle SDI
Libya High-middle SDI
Macao Special Administrative Region of China High-middle SDI
Macedonia High-middle SDI
Madinah High-middle SDI
Makkah High-middle SDI
Malaysia High-middle SDI
Mauritius High-middle SDI
Montenegro High-middle SDI
Najran High-middle SDI
Northern Borders High-middle SDI
Northern Mariana Islands High-middle SDI
Panama High-middle SDI
Portugal High-middle SDI
Qassim High-middle SDI
Qatar High-middle SDI
Rio de Janeiro High-middle SDI
Riyadh High-middle SDI
Romania High-middle SDI
Russia High-middle SDI
Serbia High-middle SDI
Shanghai High-middle SDI
Spain High-middle SDI
São Paulo High-middle SDI
Tabuk High-middle SDI
The Bahamas High-middle SDI
Tianjin High-middle SDI
Trinidad and Tobago High-middle SDI
Turkey High-middle SDI
Turkmenistan High-middle SDI
Ukraine High-middle SDI
United Arab Emirates High-middle SDI
Zhejiang High-middle SDI
Aceh Middle SDI
Acre Middle SDI
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Aguascalientes Middle SDI
Albania Middle SDI
Algeria Middle SDI
Amapá Middle SDI
Amazonas Middle SDI
American Samoa Middle SDI
Andhra Pradesh, Urban Middle SDI
Anhui Middle SDI
Assam, Urban Middle SDI
Bahia Middle SDI
Bahrain Middle SDI
Baja California Middle SDI
Baja California Sur Middle SDI
Bali Middle SDI
Bangka–Belitung Islands Middle SDI
Banten Middle SDI
Bengkulu Middle SDI
Bosnia and Herzegovina Middle SDI
Botswana Middle SDI
Campeche Middle SDI
Chhattisgarh, Urban Middle SDI
Chiapas Middle SDI
Chihuahua Middle SDI
Chongqing Middle SDI
Coahuila Middle SDI
Colima Middle SDI
Colombia Middle SDI
Costa Rica Middle SDI
Delhi, Rural Middle SDI
Distrito Federal Middle SDI
Dominica Middle SDI
Dominican Republic Middle SDI
Durango Middle SDI
Eastern Cape Middle SDI
Ecuador Middle SDI
Egypt Middle SDI
El Salvador Middle SDI
Equatorial Guinea Middle SDI
Espírito Santo Middle SDI
Fiji Middle SDI
Free State Middle SDI
Fujian Middle SDI
Gauteng Middle SDI
Goa, Rural Middle SDI
Goiás Middle SDI
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Grenada Middle SDI
Guanajuato Middle SDI
Guangxi Middle SDI
Guerrero Middle SDI
Gujarat, Urban Middle SDI
Guyana Middle SDI
Hainan Middle SDI
Haryana, Urban Middle SDI
Hebei Middle SDI
Heilongjiang Middle SDI
Henan Middle SDI
Hidalgo Middle SDI
Himachal Pradesh, Rural Middle SDI
Hubei Middle SDI
Hunan Middle SDI
Inner Mongolia Middle SDI
Jalisco Middle SDI
Jamaica Middle SDI
Jambi Middle SDI
Jammu and Kashmir, Urban Middle SDI
West Java Middle SDI
East Java Middle SDI
Jharkhand, Urban Middle SDI
Jiangxi Middle SDI
Jilin Middle SDI
Jordan Middle SDI
South Kalimantan Middle SDI
Central Kalimantan Middle SDI
Karnataka, Urban Middle SDI
Kerala, Rural Middle SDI
Kerala, Urban Middle SDI
KwaZulu-Natal Middle SDI
Lampung Middle SDI
Liaoning Middle SDI
Limpopo Middle SDI
Madhya Pradesh, Urban Middle SDI
Maharashtra, Urban Middle SDI
Maldives Middle SDI
Manipur, Urban Middle SDI
Mato Grosso Middle SDI
Mato Grosso do Sul Middle SDI
Meghalaya, Urban Middle SDI
Michoacán de Ocampo Middle SDI
Minas Gerais Middle SDI
Mizoram, Urban Middle SDI
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Moldova Middle SDI
Mongolia Middle SDI
Morelos Middle SDI
Mpumalanga Middle SDI
México Middle SDI
Nagaland, Urban Middle SDI
Nayarit Middle SDI
Ningxia Middle SDI
North-West Middle SDI
Northern Cape Middle SDI
Nuevo León Middle SDI
Oaxaca Middle SDI
Oman Middle SDI
West Papua Middle SDI
Paraguay Middle SDI
Paraná Middle SDI
Pernambuco Middle SDI
Peru Middle SDI
Philippines Middle SDI
Puebla Middle SDI
Punjab, Urban Middle SDI
Qinghai Middle SDI
Querétaro Middle SDI
Quintana Roo Middle SDI
Riau Middle SDI
Rio Grande do Norte Middle SDI
Rio Grande do Sul Middle SDI
Rondônia Middle SDI
Roraima Middle SDI
Saint Lucia Middle SDI
Saint Vincent and the Grenadines Middle SDI
San Luis Potosí Middle SDI
Santa Catarina Middle SDI
Sergipe Middle SDI
Seychelles Middle SDI
Shaanxi Middle SDI
Shandong Middle SDI
Shanxi Middle SDI
Sichuan Middle SDI
Sikkim, Urban Middle SDI
Sinaloa Middle SDI
Sonora Middle SDI
Sri Lanka Middle SDI
South Sulawesi Middle SDI
North Sulawesi Middle SDI
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West Sumatra Middle SDI
South Sumatra Middle SDI
North Sumatra Middle SDI
Suriname Middle SDI
Tabasco Middle SDI
Tamaulipas Middle SDI
Tamil Nadu, Urban Middle SDI
Telangana, Urban Middle SDI
Thailand Middle SDI
The Six Minor Territories, Urban Middle SDI
Tlaxcala Middle SDI
Tocantins Middle SDI
Tunisia Middle SDI
Uruguay Middle SDI
Uttarakhand, Urban Middle SDI
Uzbekistan Middle SDI
Venezuela Middle SDI
Veracruz de Ignacio de la Llave Middle SDI
Vietnam Middle SDI
West Bengal, Urban Middle SDI
Western Cape Middle SDI
Xinjiang Middle SDI
Yogyakarta Middle SDI
Yucatán Middle SDI
Yunnan Middle SDI
Zacatecas Middle SDI
Alagoas Low-middle SDI
Andhra Pradesh, Rural Low-middle SDI
Arunachal Pradesh, Rural Low-middle SDI
Arunachal Pradesh, Urban Low-middle SDI
Assam, Rural Low-middle SDI
Bangladesh Low-middle SDI
Baringo Low-middle SDI
Belize Low-middle SDI
Bhutan Low-middle SDI
Bihar, Urban Low-middle SDI
Bolivia Low-middle SDI
Bomet Low-middle SDI
Bungoma Low-middle SDI
Busia Low-middle SDI
Cambodia Low-middle SDI
Cameroon Low-middle SDI
Cape Verde Low-middle SDI
Ceará Low-middle SDI
Chhattisgarh, Rural Low-middle SDI
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Congo (Brazzaville) Low-middle SDI
Elgeyo-Marakwet Low-middle SDI
Embu Low-middle SDI
Federated States of Micronesia Low-middle SDI
Gabon Low-middle SDI
Gansu Low-middle SDI
Garissa Low-middle SDI
Ghana Low-middle SDI
Gorontalo Low-middle SDI
Guatemala Low-middle SDI
Guizhou Low-middle SDI
Gujarat, Rural Low-middle SDI
Haryana, Rural Low-middle SDI
HomaBay Low-middle SDI
Honduras Low-middle SDI
Iraq Low-middle SDI
Isiolo Low-middle SDI
Jammu and Kashmir, Rural Low-middle SDI
Central Java Low-middle SDI
Jharkhand, Rural Low-middle SDI
Kajiado Low-middle SDI
Kakamega Low-middle SDI
West Kalimantan Low-middle SDI
Karnataka, Rural Low-middle SDI
Kericho Low-middle SDI
Kiambu Low-middle SDI
Kilifi Low-middle SDI
Kirinyaga Low-middle SDI
Kisii Low-middle SDI
Kisumu Low-middle SDI
Kitui Low-middle SDI
Kwale Low-middle SDI
Kyrgyzstan Low-middle SDI
Laikipia Low-middle SDI
Lamu Low-middle SDI
Laos Low-middle SDI
Lesotho Low-middle SDI
Machakos Low-middle SDI
Madhya Pradesh, Rural Low-middle SDI
Maharashtra, Rural Low-middle SDI
Makueni Low-middle SDI
Maluku Low-middle SDI
North Maluku Low-middle SDI
Mandera Low-middle SDI
Manipur, Rural Low-middle SDI
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Maranhão Low-middle SDI
Marsabit Low-middle SDI
Marshall Islands Low-middle SDI
Mauritania Low-middle SDI
Meghalaya, Rural Low-middle SDI
Meru Low-middle SDI
Migori Low-middle SDI
Mizoram, Rural Low-middle SDI
Mombasa Low-middle SDI
Morocco Low-middle SDI
Murang’a Low-middle SDI
Myanmar Low-middle SDI
Nagaland, Rural Low-middle SDI
Nairobi Low-middle SDI
Nakuru Low-middle SDI
Namibia Low-middle SDI
Nandi Low-middle SDI
Narok Low-middle SDI
Nepal Low-middle SDI
Nicaragua Low-middle SDI
Nigeria Low-middle SDI
North Korea Low-middle SDI
West Nusa Tenggara Low-middle SDI
East Nusa Tenggara Low-middle SDI
Nyamira Low-middle SDI
Nyandarua Low-middle SDI
Nyeri Low-middle SDI
Odisha, Rural Low-middle SDI
Odisha, Urban Low-middle SDI
Pakistan Low-middle SDI
Papua Low-middle SDI
Paraíba Low-middle SDI
Pará Low-middle SDI
Piaui Low-middle SDI
Punjab, Rural Low-middle SDI
Rajasthan, Rural Low-middle SDI
Rajasthan, Urban Low-middle SDI
Samburu Low-middle SDI
Samoa Low-middle SDI
Siaya Low-middle SDI
Sikkim, Rural Low-middle SDI
Sudan Low-middle SDI
West Sulawesi Low-middle SDI
Central Sulawesi Low-middle SDI
Southeast Sulawesi Low-middle SDI
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Swaziland Low-middle SDI
Syria Low-middle SDI
TaitaTaveta Low-middle SDI
Tajikistan Low-middle SDI
Tamil Nadu, Rural Low-middle SDI
TanaRiver Low-middle SDI
Telangana, Rural Low-middle SDI
TharakaNithi Low-middle SDI
The Six Minor Territories, Rural Low-middle SDI
Tibet Low-middle SDI
Timor-Leste Low-middle SDI
Tonga Low-middle SDI
TransNzoia Low-middle SDI
Tripura, Rural Low-middle SDI
Tripura, Urban Low-middle SDI
Turkana Low-middle SDI
UasinGishu Low-middle SDI
Uttar Pradesh, Rural Low-middle SDI
Uttar Pradesh, Urban Low-middle SDI
Uttarakhand, Rural Low-middle SDI
Vanuatu Low-middle SDI
Vihiga Low-middle SDI
Wajir Low-middle SDI
West Bengal, Rural Low-middle SDI
WestPokot Low-middle SDI
Zambia Low-middle SDI
Zimbabwe Low-middle SDI
Afghanistan Low SDI
Angola Low SDI
Benin Low SDI
Bihar, Rural Low SDI
Burkina Faso Low SDI
Burundi Low SDI
Central African Republic Low SDI
Chad Low SDI
Comoros Low SDI
Cote d'Ivoire Low SDI
Democratic Republic of the Congo Low SDI
Djibouti Low SDI
Eritrea Low SDI
Ethiopia Low SDI
Guinea Low SDI
Guinea-Bissau Low SDI
Haiti Low SDI
Kiribati Low SDI
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Liberia Low SDI
Madagascar Low SDI
Malawi Low SDI
Mali Low SDI
Mozambique Low SDI
Niger Low SDI
Palestine Low SDI
Papua New Guinea Low SDI
Rwanda Low SDI
Sao Tome and Principe Low SDI
Senegal Low SDI
Sierra Leone Low SDI
Solomon Islands Low SDI
Somalia Low SDI
South Sudan Low SDI
Tanzania Low SDI
The Gambia Low SDI
Togo Low SDI
Uganda Low SDI
Yemen Low SDI
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Location 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Global 0.526 0.531 0.535 0.54 0.544 0.549 0.554 0.559 0.564 0.569 0.575 0.58 0.586 0.591 0.596 0.6 0.605 0.609 0.614 0.618 0.622 0.626 0.63 0.634 0.639 0.643 0.648 0.652 0.657 0.662 0.666 0.671 0.676 0.681 0.686 0.691 0.696
Southeast Asia, East Asia, and Oceania 0.438 0.445 0.453 0.461 0.47 0.478 0.486 0.495 0.504 0.512 0.521 0.53 0.539 0.548 0.556 0.565 0.573 0.581 0.587 0.594 0.6 0.606 0.612 0.619 0.626 0.633 0.641 0.65 0.658 0.666 0.675 0.683 0.691 0.699 0.706 0.712 0.719
East Asia 0.436 0.443 0.45 0.458 0.467 0.477 0.486 0.496 0.506 0.515 0.524 0.533 0.543 0.552 0.562 0.571 0.58 0.588 0.594 0.601 0.608 0.614 0.621 0.629 0.636 0.644 0.653 0.661 0.67 0.678 0.686 0.694 0.701 0.709 0.715 0.722 0.729
China 0.42 0.428 0.435 0.444 0.453 0.463 0.473 0.483 0.494 0.503 0.512 0.521 0.531 0.542 0.552 0.562 0.57 0.578 0.585 0.592 0.6 0.607 0.614 0.622 0.63 0.638 0.647 0.657 0.665 0.674 0.682 0.691 0.698 0.706 0.713 0.72 0.727
North Korea 0.471 0.476 0.48 0.485 0.488 0.491 0.494 0.497 0.499 0.502 0.505 0.508 0.51 0.511 0.51 0.506 0.501 0.495 0.489 0.483 0.478 0.473 0.47 0.468 0.468 0.469 0.47 0.471 0.473 0.474 0.476 0.478 0.481 0.484 0.488 0.491 0.494
0.636 0.645 0.657 0.669 0.681 0.695 0.706 0.71 0.718 0.727 0.734 0.743 0.749 0.756 0.762 0.768 0.775 0.788 0.798 0.8 0.808 0.815 0.82 0.824 0.829 0.833 0.837 0.842 0.845 0.849 0.853 0.857 0.86 0.864 0.868 0.871 0.875Taiwan (Province of China)
Hong Kong Special Administrative Region of 
China
0.633 0.643 0.652 0.662 0.671 0.677 0.682 0.688 0.694 0.699 0.704 0.708 0.713 0.718 0.723 0.727 0.731 0.734 0.737 0.74 0.743 0.746 0.749 0.752 0.756 0.761 0.765 0.77 0.775 0.779 0.783 0.787 0.791 0.795 0.798 0.801 0.805
Macao Special Administrative Region of China 0.638 0.646 0.654 0.66 0.667 0.672 0.678 0.684 0.689 0.695 0.7 0.705 0.711 0.716 0.721 0.725 0.728 0.731 0.732 0.734 0.735 0.738 0.742 0.747 0.754 0.761 0.768 0.776 0.784 0.789 0.793 0.796 0.799 0.802 0.806 0.809 0.811
0.413 0.42 0.428 0.436 0.446 0.456 0.467 0.477 0.487 0.497 0.506 0.515 0.525 0.536 0.546 0.556 0.565 0.574 0.581 0.588 0.596 0.603 0.611 0.619 0.627 0.635 0.645 0.654 0.663 0.672 0.68 0.689 0.697 0.704 0.712 0.718 0.725
0.353 0.36 0.367 0.375 0.385 0.396 0.406 0.417 0.427 0.437 0.446 0.455 0.464 0.474 0.483 0.493 0.502 0.51 0.518 0.525 0.532 0.538 0.545 0.552 0.559 0.567 0.576 0.585 0.594 0.603 0.611 0.619 0.626 0.633 0.639 0.645 0.651
0.606 0.612 0.618 0.624 0.631 0.638 0.645 0.653 0.659 0.665 0.671 0.676 0.682 0.689 0.695 0.702 0.709 0.715 0.721 0.726 0.732 0.738 0.744 0.75 0.757 0.764 0.772 0.78 0.787 0.795 0.802 0.809 0.816 0.823 0.829 0.835 0.842
0.367 0.375 0.384 0.394 0.407 0.419 0.431 0.443 0.454 0.464 0.474 0.485 0.496 0.507 0.519 0.53 0.539 0.549 0.557 0.565 0.574 0.582 0.591 0.599 0.607 0.616 0.625 0.635 0.643 0.652 0.66 0.668 0.675 0.682 0.689 0.694 0.7
0.372 0.378 0.386 0.396 0.408 0.42 0.433 0.445 0.458 0.469 0.48 0.492 0.504 0.518 0.531 0.544 0.555 0.564 0.573 0.581 0.59 0.598 0.606 0.615 0.623 0.632 0.642 0.652 0.662 0.671 0.68 0.689 0.698 0.706 0.713 0.72 0.727
0.353 0.358 0.364 0.372 0.382 0.391 0.401 0.411 0.421 0.431 0.438 0.447 0.456 0.465 0.473 0.482 0.49 0.498 0.506 0.513 0.52 0.526 0.533 0.539 0.546 0.553 0.56 0.568 0.575 0.583 0.59 0.597 0.604 0.61 0.616 0.622 0.628
0.444 0.451 0.458 0.467 0.476 0.487 0.497 0.507 0.518 0.527 0.536 0.546 0.557 0.567 0.578 0.588 0.598 0.607 0.615 0.623 0.632 0.64 0.648 0.658 0.667 0.678 0.688 0.7 0.71 0.72 0.729 0.737 0.745 0.753 0.761 0.768 0.775
0.361 0.369 0.376 0.385 0.395 0.406 0.417 0.428 0.439 0.449 0.458 0.468 0.479 0.49 0.501 0.511 0.521 0.531 0.539 0.547 0.555 0.562 0.569 0.577 0.585 0.594 0.603 0.613 0.622 0.632 0.641 0.651 0.661 0.67 0.679 0.686 0.693
0.279 0.287 0.295 0.303 0.314 0.325 0.336 0.347 0.358 0.368 0.376 0.385 0.394 0.403 0.413 0.422 0.431 0.439 0.446 0.454 0.462 0.469 0.477 0.485 0.494 0.503 0.512 0.522 0.531 0.54 0.55 0.559 0.567 0.575 0.581 0.587 0.594
0.438 0.443 0.448 0.454 0.462 0.47 0.478 0.486 0.495 0.502 0.511 0.52 0.529 0.539 0.549 0.558 0.566 0.575 0.582 0.59 0.597 0.604 0.611 0.618 0.625 0.632 0.64 0.648 0.656 0.665 0.672 0.68 0.686 0.693 0.699 0.705 0.711
0.42 0.427 0.435 0.443 0.452 0.462 0.472 0.482 0.492 0.501 0.509 0.517 0.527 0.537 0.547 0.556 0.565 0.573 0.581 0.588 0.596 0.603 0.611 0.619 0.627 0.635 0.644 0.654 0.662 0.671 0.679 0.687 0.695 0.702 0.709 0.716 0.722
0.477 0.482 0.488 0.495 0.504 0.513 0.522 0.531 0.54 0.548 0.557 0.566 0.575 0.582 0.588 0.594 0.6 0.606 0.611 0.617 0.623 0.628 0.634 0.639 0.644 0.649 0.655 0.662 0.668 0.674 0.679 0.685 0.69 0.695 0.7 0.704 0.709
0.368 0.375 0.384 0.394 0.405 0.417 0.429 0.441 0.453 0.463 0.471 0.481 0.491 0.502 0.513 0.525 0.535 0.545 0.554 0.562 0.57 0.578 0.587 0.595 0.604 0.613 0.623 0.633 0.643 0.652 0.661 0.67 0.678 0.685 0.693 0.699 0.706
0.407 0.415 0.423 0.432 0.442 0.452 0.463 0.474 0.484 0.494 0.504 0.514 0.524 0.535 0.545 0.553 0.561 0.569 0.576 0.583 0.59 0.597 0.604 0.611 0.618 0.626 0.635 0.643 0.651 0.659 0.667 0.674 0.681 0.688 0.694 0.7 0.706
0.383 0.391 0.399 0.409 0.42 0.431 0.442 0.454 0.465 0.476 0.485 0.495 0.505 0.516 0.526 0.536 0.546 0.555 0.562 0.569 0.576 0.582 0.59 0.597 0.605 0.613 0.621 0.63 0.639 0.647 0.655 0.663 0.67 0.678 0.684 0.691 0.697
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China (without Hong Kong and Macao) 
Anhui
Beijing
Chongqing
Fujian
Gansu
Guangdong
Guangxi
Guizhou
Hainan
Hebei
Heilongjiang
Henan
Hubei
Hunan
Inner Mongolia
Jiangsu
Jiangxi
Jilin
Liaoning
Ningxia
Qinghai
Shaanxi
Shandong
Shanghai
Shanxi
Sichuan
Tianjin
Tibet
Xinjiang
Yunnan
Zhejiang
Southeast Asia
Cambodia
Indonesia
Laos
Malaysia
Maldives
Myanmar
Philippines
Sri Lanka
Thailand
Timor-Leste
Vietnam
Mauritius
Seychelles
Aceh
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Appendix Table 9: Socio-demographic Index values for all estimated GBD 2016 locations, 1980–2016
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0.261 0.267 0.273 0.279 0.284 0.288 0.292 0.295 0.299 0.303 0.307 0.312 0.316 0.32 0.324 0.328 0.333 0.338 0.345 0.35 0.357 0.363 0.37 0.376 0.383 0.389 0.395 0.401 0.406 0.412 0.416 0.421 0.426 0.431 0.437 0.442 0.446
0.399 0.406 0.413 0.42 0.427 0.432 0.439 0.446 0.453 0.46 0.466 0.47 0.473 0.474 0.475 0.476 0.477 0.479 0.482 0.487 0.492 0.499 0.504 0.51 0.514 0.518 0.522 0.527 0.531 0.536 0.541 0.547 0.553 0.559 0.565 0.571 0.575
0.274 0.292 0.31 0.328 0.346 0.363 0.379 0.394 0.409 0.422 0.434 0.446 0.456 0.466 0.475 0.485 0.495 0.503 0.512 0.521 0.53 0.539 0.547 0.555 0.561 0.568 0.573 0.578 0.582 0.586 0.59 0.595 0.599 0.603 0.607 0.61 0.612
0.256 0.26 0.263 0.267 0.271 0.274 0.278 0.283 0.287 0.292 0.296 0.3 0.304 0.31 0.315 0.32 0.325 0.33 0.334 0.338 0.342 0.345 0.348 0.352 0.355 0.359 0.362 0.367 0.371 0.376 0.382 0.387 0.394 0.4 0.406 0.413 0.418
0.372 0.381 0.389 0.397 0.405 0.412 0.42 0.428 0.435 0.443 0.451 0.458 0.465 0.472 0.477 0.482 0.487 0.492 0.498 0.501 0.504 0.507 0.511 0.514 0.518 0.521 0.525 0.529 0.533 0.537 0.54 0.542 0.545 0.548 0.553 0.558 0.562
0.269 0.275 0.28 0.284 0.289 0.294 0.298 0.303 0.308 0.313 0.318 0.323 0.329 0.335 0.34 0.346 0.352 0.357 0.363 0.368 0.371 0.373 0.374 0.375 0.377 0.379 0.383 0.387 0.393 0.398 0.404 0.411 0.418 0.425 0.432 0.439 0.444
0.382 0.389 0.397 0.403 0.412 0.419 0.427 0.435 0.442 0.448 0.454 0.461 0.466 0.471 0.476 0.481 0.486 0.491 0.496 0.501 0.506 0.511 0.516 0.522 0.527 0.532 0.537 0.541 0.546 0.551 0.555 0.561 0.566 0.571 0.576 0.582 0.586
0.277 0.283 0.288 0.294 0.3 0.306 0.312 0.318 0.324 0.329 0.335 0.341 0.347 0.353 0.359 0.364 0.37 0.376 0.382 0.387 0.393 0.399 0.405 0.41 0.415 0.42 0.426 0.431 0.437 0.443 0.449 0.454 0.46 0.465 0.471 0.476 0.479
0.551 0.561 0.569 0.576 0.583 0.589 0.595 0.601 0.606 0.612 0.617 0.622 0.626 0.631 0.635 0.639 0.643 0.648 0.652 0.656 0.661 0.666 0.671 0.676 0.682 0.688 0.695 0.7 0.705 0.711 0.716 0.721 0.726 0.73 0.735 0.739 0.742
0.718 0.726 0.733 0.738 0.742 0.743 0.743 0.743 0.746 0.75 0.755 0.761 0.765 0.77 0.774 0.778 0.782 0.785 0.788 0.791 0.794 0.797 0.799 0.801 0.802 0.804 0.806 0.807 0.809 0.81 0.812 0.813 0.815 0.817 0.819 0.821 0.822
West Sumatera
Riau
Jambi
South Sumatera
Bengkulu
Lampung
Bangka Belitung
Riau Islands
North Kalimantan
Jakarta
Cental Java
West Java
Yogyakarta
East Java
Banten
Bali
Nusa Tenggara Barat
East Nusa Tenggara 
West Kalimantan 
Central Kalimantan 
South Kalimantan 
East Kalimantan
North Sulawesi
Central Sulawesi
South Sumatera
Southeast Sulawesi 
Gorontalo
West Sulawesi
Maluku
North Maluku
West Papua
Papua
Oceania
Fiji
Kiribati
Marshall Islands
Federated States of Micronesia 
Papua New Guinea
Samoa
Solomon Islands
Tonga
Vanuatu
American Samoa
Guam
Northern Mariana Islands
0.61 0.622 0.633 0.643 0.653 0.662 0.671 0.68 0.689 0.697 0.705 0.713 0.72 0.727 0.733 0.739 0.744 0.75 0.755 0.761 0.766 0.772 0.777 0.782 0.787 0.79 0.792 0.794 0.795 0.795 0.795 0.794 0.793 0.793 0.794 0.796 0.797
Central Europe, Eastern Europe, and Central Asia 0.706 0.708 0.71 0.711 0.714 0.716 0.717 0.721 0.727 0.733 0.739 0.746 0.751 0.754 0.755 0.757 0.758 0.758 0.758 0.758 0.759 0.762 0.765 0.769 0.773 0.778 0.782 0.786 0.79 0.793 0.797 0.801 0.804 0.806 0.809 0.812 0.816
Central Asia 0.576 0.582 0.587 0.591 0.594 0.598 0.602 0.607 0.612 0.618 0.624 0.63 0.635 0.638 0.641 0.642 0.643 0.643 0.643 0.643 0.645 0.647 0.65 0.654 0.66 0.666 0.672 0.679 0.685 0.691 0.697 0.703 0.708 0.714 0.719 0.724 0.729
Armenia 0.602 0.606 0.61 0.615 0.619 0.622 0.626 0.631 0.635 0.64 0.644 0.648 0.648 0.647 0.645 0.643 0.642 0.641 0.642 0.643 0.646 0.651 0.659 0.668 0.676 0.686 0.695 0.705 0.714 0.719 0.724 0.73 0.735 0.74 0.745 0.75 0.755
Azerbaijan 0.606 0.614 0.622 0.63 0.637 0.643 0.648 0.654 0.659 0.664 0.668 0.673 0.676 0.678 0.678 0.677 0.674 0.67 0.667 0.664 0.662 0.662 0.664 0.667 0.671 0.678 0.688 0.7 0.712 0.722 0.731 0.739 0.747 0.753 0.759 0.763 0.767
Georgia 0.679 0.684 0.688 0.691 0.695 0.698 0.702 0.706 0.71 0.715 0.72 0.723 0.722 0.718 0.713 0.705 0.698 0.689 0.682 0.677 0.674 0.676 0.679 0.684 0.69 0.695 0.701 0.708 0.714 0.719 0.723 0.727 0.731 0.736 0.741 0.746 0.751
Kazakhstan 0.629 0.636 0.641 0.645 0.649 0.653 0.658 0.663 0.669 0.675 0.681 0.687 0.692 0.696 0.699 0.701 0.703 0.704 0.704 0.704 0.705 0.706 0.708 0.71 0.712 0.715 0.718 0.721 0.725 0.728 0.731 0.736 0.74 0.744 0.748 0.753 0.757
Kyrgyzstan 0.556 0.562 0.567 0.571 0.575 0.578 0.582 0.587 0.592 0.598 0.604 0.61 0.614 0.618 0.619 0.618 0.617 0.615 0.612 0.609 0.607 0.606 0.605 0.605 0.606 0.606 0.606 0.607 0.608 0.609 0.61 0.612 0.614 0.618 0.622 0.627 0.632
Mongolia 0.403 0.417 0.431 0.445 0.458 0.473 0.489 0.506 0.523 0.539 0.557 0.573 0.586 0.597 0.604 0.611 0.615 0.619 0.623 0.627 0.631 0.635 0.639 0.643 0.647 0.65 0.653 0.656 0.659 0.66 0.662 0.664 0.667 0.67 0.674 0.678 0.683
Tajikistan 0.462 0.469 0.474 0.478 0.481 0.484 0.488 0.494 0.501 0.51 0.519 0.53 0.537 0.542 0.543 0.542 0.537 0.532 0.525 0.519 0.515 0.513 0.515 0.52 0.527 0.535 0.542 0.548 0.552 0.556 0.559 0.561 0.564 0.567 0.571 0.574 0.577
Turkmenistan 0.53 0.536 0.541 0.545 0.548 0.552 0.555 0.56 0.565 0.571 0.577 0.584 0.59 0.598 0.605 0.612 0.618 0.623 0.627 0.63 0.636 0.641 0.647 0.653 0.66 0.668 0.676 0.684 0.692 0.701 0.709 0.717 0.726 0.735 0.743 0.752 0.759
Uzbekistan 0.493 0.498 0.503 0.506 0.51 0.513 0.518 0.523 0.53 0.537 0.544 0.551 0.558 0.565 0.571 0.577 0.582 0.587 0.591 0.594 0.597 0.6 0.604 0.609 0.616 0.623 0.629 0.636 0.642 0.649 0.656 0.664 0.671 0.678 0.685 0.692 0.698
Central Europe 0.701 0.705 0.709 0.711 0.713 0.717 0.72 0.724 0.729 0.736 0.741 0.746 0.75 0.753 0.758 0.763 0.766 0.77 0.773 0.777 0.781 0.785 0.79 0.794 0.799 0.803 0.808 0.814 0.819 0.823 0.828 0.832 0.836 0.839 0.842 0.846 0.849
871
Location 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Appendix Table 9: Socio-demographic Index values for all estimated GBD 2016 locations, 1980–2016
Albania 0.54 0.545 0.55 0.555 0.56 0.564 0.569 0.573 0.577 0.581 0.584 0.585 0.584 0.585 0.588 0.593 0.601 0.607 0.614 0.623 0.633 0.642 0.651 0.659 0.667 0.674 0.68 0.686 0.692 0.697 0.702 0.706 0.711 0.714 0.718 0.721 0.725
Bosnia and Herzegovina 0.502 0.508 0.514 0.518 0.522 0.527 0.532 0.535 0.539 0.542 0.542 0.542 0.543 0.543 0.546 0.552 0.573 0.597 0.619 0.635 0.648 0.658 0.667 0.675 0.682 0.688 0.694 0.699 0.705 0.71 0.714 0.717 0.721 0.724 0.727 0.73 0.733
Bulgaria 0.705 0.71 0.715 0.72 0.724 0.728 0.733 0.738 0.744 0.752 0.76 0.767 0.771 0.771 0.771 0.772 0.771 0.77 0.771 0.771 0.773 0.776 0.779 0.784 0.789 0.794 0.8 0.807 0.813 0.818 0.824 0.828 0.832 0.836 0.839 0.843 0.846
Croatia 0.746 0.751 0.755 0.759 0.763 0.767 0.772 0.775 0.779 0.782 0.786 0.789 0.788 0.785 0.782 0.779 0.779 0.785 0.79 0.793 0.797 0.801 0.806 0.811 0.815 0.819 0.824 0.828 0.833 0.836 0.838 0.841 0.843 0.845 0.846 0.848 0.85
Czech Republic 0.786 0.79 0.793 0.796 0.798 0.8 0.803 0.805 0.807 0.81 0.812 0.816 0.82 0.826 0.829 0.83 0.832 0.834 0.835 0.837 0.839 0.842 0.844 0.847 0.85 0.853 0.856 0.86 0.863 0.866 0.869 0.871 0.873 0.875 0.875 0.878 0.881
Hungary 0.711 0.719 0.727 0.732 0.733 0.735 0.739 0.744 0.748 0.751 0.753 0.756 0.761 0.766 0.77 0.777 0.78 0.783 0.786 0.79 0.794 0.798 0.803 0.807 0.812 0.816 0.821 0.825 0.828 0.831 0.834 0.836 0.838 0.841 0.843 0.846 0.849
Macedonia 0.664 0.669 0.673 0.677 0.681 0.686 0.69 0.695 0.7 0.702 0.7 0.699 0.701 0.701 0.701 0.703 0.708 0.712 0.716 0.718 0.723 0.73 0.737 0.742 0.745 0.749 0.753 0.757 0.762 0.765 0.77 0.775 0.779 0.782 0.786 0.789 0.793
Montenegro 0.725 0.728 0.732 0.734 0.737 0.739 0.742 0.744 0.746 0.748 0.75 0.751 0.75 0.747 0.743 0.74 0.74 0.741 0.743 0.745 0.748 0.753 0.759 0.764 0.769 0.773 0.777 0.781 0.786 0.79 0.795 0.8 0.803 0.806 0.809 0.812 0.815
Poland 0.702 0.702 0.699 0.699 0.703 0.708 0.714 0.719 0.724 0.73 0.735 0.739 0.745 0.751 0.759 0.767 0.773 0.778 0.783 0.789 0.795 0.8 0.805 0.81 0.815 0.82 0.824 0.83 0.835 0.84 0.845 0.85 0.855 0.86 0.864 0.868 0.872
Romania 0.661 0.672 0.684 0.688 0.687 0.688 0.689 0.695 0.703 0.715 0.731 0.738 0.738 0.739 0.74 0.742 0.744 0.747 0.749 0.751 0.755 0.759 0.764 0.769 0.774 0.78 0.786 0.794 0.802 0.808 0.813 0.818 0.822 0.827 0.83 0.833 0.838
Serbia 0.678 0.68 0.682 0.683 0.684 0.686 0.689 0.691 0.694 0.697 0.7 0.703 0.704 0.701 0.699 0.697 0.698 0.702 0.707 0.709 0.712 0.714 0.717 0.722 0.728 0.733 0.737 0.742 0.747 0.752 0.755 0.759 0.761 0.764 0.767 0.769 0.771
Slovakia 0.749 0.753 0.756 0.759 0.762 0.766 0.77 0.774 0.778 0.781 0.785 0.788 0.792 0.797 0.805 0.81 0.812 0.814 0.817 0.819 0.822 0.825 0.828 0.831 0.835 0.839 0.843 0.848 0.854 0.858 0.86 0.865 0.868 0.871 0.874 0.877 0.88
Slovenia 0.766 0.774 0.782 0.789 0.793 0.797 0.801 0.803 0.808 0.813 0.813 0.813 0.812 0.812 0.813 0.815 0.817 0.82 0.823 0.827 0.831 0.835 0.839 0.843 0.847 0.851 0.856 0.86 0.863 0.865 0.867 0.869 0.871 0.873 0.874 0.877 0.881
Eastern Europe 0.737 0.738 0.738 0.739 0.742 0.743 0.744 0.747 0.753 0.76 0.767 0.775 0.782 0.782 0.78 0.777 0.774 0.771 0.768 0.766 0.766 0.768 0.77 0.774 0.78 0.786 0.792 0.8 0.806 0.81 0.813 0.817 0.819 0.821 0.823 0.826 0.829
Belarus 0.703 0.706 0.708 0.711 0.713 0.716 0.719 0.723 0.727 0.733 0.738 0.743 0.748 0.751 0.752 0.748 0.744 0.742 0.741 0.74 0.741 0.744 0.747 0.752 0.758 0.765 0.772 0.78 0.788 0.795 0.8 0.805 0.81 0.814 0.818 0.822 0.826
Estonia 0.775 0.776 0.776 0.776 0.779 0.78 0.779 0.778 0.781 0.788 0.799 0.807 0.813 0.814 0.813 0.812 0.812 0.813 0.816 0.818 0.822 0.827 0.832 0.837 0.843 0.847 0.85 0.854 0.859 0.861 0.866 0.872 0.877 0.88 0.883 0.885 0.887
Latvia 0.759 0.759 0.758 0.758 0.759 0.76 0.762 0.765 0.77 0.776 0.783 0.789 0.793 0.794 0.79 0.786 0.783 0.781 0.781 0.783 0.785 0.79 0.795 0.801 0.808 0.815 0.822 0.831 0.837 0.841 0.843 0.847 0.85 0.851 0.851 0.851 0.853
Lithuania 0.768 0.771 0.772 0.772 0.774 0.776 0.777 0.781 0.787 0.79 0.792 0.795 0.8 0.805 0.805 0.804 0.801 0.801 0.801 0.803 0.805 0.809 0.814 0.819 0.825 0.832 0.838 0.845 0.851 0.853 0.856 0.858 0.862 0.865 0.869 0.872 0.876
Moldova 0.614 0.617 0.619 0.621 0.623 0.625 0.628 0.632 0.636 0.641 0.647 0.651 0.652 0.654 0.652 0.65 0.647 0.643 0.637 0.631 0.626 0.624 0.625 0.629 0.634 0.64 0.646 0.653 0.66 0.665 0.671 0.678 0.683 0.689 0.695 0.699 0.703
Russia 0.745 0.746 0.745 0.745 0.749 0.749 0.748 0.751 0.758 0.766 0.774 0.782 0.788 0.787 0.786 0.784 0.781 0.778 0.775 0.774 0.774 0.775 0.778 0.782 0.787 0.793 0.799 0.806 0.811 0.814 0.818 0.821 0.823 0.824 0.826 0.829 0.832
Ukraine 0.712 0.715 0.717 0.719 0.721 0.724 0.727 0.731 0.737 0.742 0.748 0.753 0.757 0.76 0.758 0.753 0.748 0.742 0.737 0.732 0.729 0.728 0.729 0.733 0.74 0.747 0.755 0.763 0.77 0.774 0.778 0.782 0.785 0.789 0.791 0.792 0.793
High-income 0.773 0.778 0.782 0.787 0.791 0.795 0.799 0.803 0.806 0.809 0.813 0.817 0.822 0.826 0.83 0.834 0.837 0.84 0.843 0.845 0.848 0.852 0.854 0.856 0.859 0.86 0.861 0.863 0.866 0.868 0.871 0.873 0.875 0.877 0.879 0.881 0.882
High-income Asia Pacific 0.745 0.75 0.756 0.763 0.769 0.775 0.781 0.787 0.793 0.799 0.805 0.809 0.816 0.821 0.826 0.831 0.835 0.839 0.841 0.844 0.847 0.849 0.851 0.854 0.856 0.859 0.861 0.864 0.867 0.868 0.871 0.873 0.875 0.877 0.879 0.882 0.884
Brunei 0.674 0.681 0.687 0.694 0.7 0.706 0.713 0.721 0.729 0.737 0.744 0.751 0.756 0.761 0.766 0.772 0.777 0.783 0.789 0.796 0.803 0.809 0.815 0.821 0.827 0.833 0.839 0.844 0.849 0.853 0.856 0.858 0.861 0.863 0.866 0.869 0.871
Japan 0.776 0.779 0.781 0.784 0.788 0.793 0.798 0.803 0.81 0.817 0.822 0.828 0.833 0.837 0.84 0.844 0.847 0.85 0.852 0.854 0.856 0.858 0.859 0.861 0.863 0.865 0.867 0.869 0.871 0.872 0.873 0.875 0.877 0.878 0.88 0.882 0.884
South Korea 0.618 0.631 0.649 0.669 0.684 0.693 0.704 0.714 0.723 0.732 0.738 0.744 0.753 0.764 0.772 0.781 0.791 0.8 0.805 0.81 0.816 0.821 0.826 0.831 0.835 0.84 0.845 0.849 0.853 0.857 0.861 0.864 0.868 0.871 0.874 0.878 0.881
Singapore 0.678 0.686 0.695 0.704 0.711 0.717 0.718 0.711 0.719 0.734 0.741 0.748 0.754 0.76 0.768 0.776 0.784 0.795 0.802 0.805 0.812 0.818 0.823 0.828 0.834 0.84 0.846 0.852 0.858 0.863 0.867 0.869 0.873 0.876 0.879 0.883 0.886
Hokkaidō 0.771 0.775 0.778 0.78 0.784 0.79 0.794 0.799 0.804 0.809 0.813 0.818 0.822 0.826 0.83 0.833 0.836 0.839 0.841 0.843 0.845 0.847 0.848 0.85 0.852 0.853 0.855 0.857 0.859 0.86 0.861 0.862 0.864 0.866 0.867 0.869 0.87
Aomori 0.76 0.764 0.766 0.769 0.773 0.778 0.784 0.789 0.795 0.801 0.805 0.81 0.814 0.818 0.822 0.827 0.831 0.835 0.838 0.84 0.842 0.843 0.845 0.847 0.848 0.85 0.852 0.854 0.855 0.856 0.858 0.859 0.861 0.862 0.864 0.865 0.867
Iwate 0.752 0.756 0.758 0.761 0.766 0.771 0.776 0.78 0.786 0.792 0.797 0.802 0.807 0.811 0.816 0.821 0.826 0.83 0.833 0.835 0.838 0.84 0.842 0.844 0.846 0.848 0.849 0.851 0.853 0.854 0.856 0.857 0.859 0.86 0.862 0.864 0.865
Miyagi 0.763 0.767 0.77 0.773 0.778 0.783 0.789 0.794 0.8 0.807 0.813 0.818 0.824 0.828 0.832 0.836 0.839 0.842 0.844 0.846 0.848 0.85 0.851 0.853 0.855 0.857 0.859 0.861 0.862 0.863 0.865 0.866 0.868 0.869 0.871 0.873 0.874
Akita 0.759 0.763 0.766 0.769 0.773 0.778 0.782 0.787 0.792 0.798 0.802 0.806 0.811 0.815 0.819 0.823 0.828 0.832 0.834 0.836 0.838 0.84 0.842 0.843 0.845 0.847 0.849 0.851 0.852 0.853 0.855 0.856 0.858 0.86 0.861 0.863 0.865
Yamagata 0.75 0.755 0.757 0.76 0.764 0.768 0.772 0.777 0.782 0.788 0.793 0.798 0.803 0.807 0.812 0.817 0.821 0.825 0.829 0.831 0.834 0.837 0.84 0.843 0.845 0.847 0.849 0.851 0.853 0.854 0.855 0.857 0.858 0.86 0.862 0.863 0.865
Fukushima 0.755 0.759 0.761 0.763 0.768 0.773 0.778 0.783 0.79 0.796 0.801 0.806 0.811 0.815 0.82 0.825 0.829 0.833 0.836 0.838 0.841 0.844 0.847 0.85 0.853 0.855 0.857 0.858 0.86 0.861 0.863 0.864 0.865 0.866 0.868 0.87 0.873
Ibaraki 0.768 0.772 0.775 0.777 0.781 0.787 0.792 0.797 0.804 0.811 0.817 0.822 0.828 0.832 0.837 0.842 0.846 0.849 0.851 0.853 0.855 0.857 0.858 0.86 0.862 0.863 0.865 0.867 0.869 0.87 0.872 0.873 0.875 0.876 0.878 0.879 0.881
Tochigi 0.771 0.774 0.776 0.778 0.782 0.787 0.792 0.798 0.805 0.812 0.818 0.823 0.829 0.834 0.839 0.844 0.848 0.851 0.853 0.855 0.857 0.859 0.861 0.862 0.864 0.866 0.868 0.87 0.872 0.873 0.874 0.876 0.877 0.879 0.881 0.882 0.884
Gunma 0.767 0.771 0.773 0.775 0.779 0.784 0.789 0.794 0.8 0.807 0.812 0.818 0.823 0.827 0.832 0.837 0.841 0.845 0.847 0.849 0.851 0.853 0.855 0.856 0.858 0.86 0.862 0.864 0.866 0.867 0.868 0.87 0.871 0.873 0.875 0.876 0.878
Saitama 0.763 0.767 0.769 0.772 0.776 0.781 0.786 0.791 0.798 0.804 0.81 0.815 0.82 0.824 0.827 0.831 0.834 0.837 0.839 0.84 0.842 0.844 0.845 0.847 0.848 0.85 0.852 0.853 0.855 0.856 0.857 0.859 0.86 0.862 0.863 0.865 0.866
Chiba 0.766 0.77 0.771 0.774 0.778 0.784 0.79 0.796 0.803 0.81 0.815 0.82 0.824 0.828 0.831 0.835 0.838 0.841 0.843 0.845 0.847 0.848 0.85 0.851 0.853 0.854 0.856 0.858 0.86 0.861 0.862 0.863 0.865 0.866 0.868 0.869 0.871
Tōkyō 0.824 0.828 0.832 0.835 0.839 0.842 0.846 0.849 0.853 0.858 0.862 0.867 0.871 0.875 0.878 0.881 0.885 0.887 0.89 0.892 0.893 0.895 0.897 0.899 0.901 0.902 0.905 0.906 0.908 0.909 0.911 0.912 0.914 0.915 0.917 0.918 0.92
Kanagawa 0.775 0.779 0.781 0.784 0.788 0.793 0.798 0.803 0.81 0.817 0.821 0.826 0.83 0.834 0.838 0.841 0.844 0.847 0.849 0.851 0.853 0.854 0.856 0.858 0.859 0.861 0.863 0.865 0.866 0.867 0.869 0.87 0.871 0.873 0.875 0.876 0.878
Niigata 0.761 0.765 0.768 0.77 0.774 0.778 0.783 0.788 0.794 0.8 0.805 0.811 0.816 0.821 0.825 0.83 0.835 0.839 0.843 0.845 0.847 0.849 0.851 0.853 0.854 0.856 0.858 0.86 0.862 0.863 0.865 0.866 0.868 0.87 0.871 0.873 0.875
Toyama 0.771 0.774 0.776 0.778 0.782 0.787 0.792 0.798 0.804 0.811 0.817 0.823 0.828 0.832 0.836 0.84 0.844 0.847 0.849 0.851 0.853 0.855 0.857 0.858 0.86 0.862 0.864 0.866 0.868 0.869 0.871 0.872 0.874 0.876 0.877 0.879 0.881
Ishikawa 0.766 0.77 0.773 0.776 0.78 0.786 0.791 0.796 0.802 0.809 0.815 0.82 0.826 0.831 0.836 0.84 0.843 0.846 0.848 0.85 0.852 0.854 0.856 0.857 0.859 0.861 0.863 0.865 0.867 0.868 0.869 0.871 0.873 0.874 0.876 0.878 0.88
Fukui 0.765 0.768 0.77 0.772 0.776 0.781 0.786 0.791 0.798 0.804 0.81 0.815 0.821 0.825 0.829 0.834 0.838 0.842 0.846 0.849 0.851 0.854 0.857 0.859 0.861 0.863 0.864 0.865 0.866 0.866 0.867 0.868 0.869 0.871 0.873 0.876 0.878
Yamanashi 0.763 0.767 0.77 0.772 0.775 0.78 0.785 0.79 0.796 0.803 0.808 0.813 0.818 0.822 0.827 0.832 0.837 0.841 0.844 0.846 0.848 0.85 0.852 0.853 0.855 0.857 0.859 0.861 0.863 0.864 0.865 0.867 0.868 0.87 0.872 0.874 0.875
Nagano 0.761 0.765 0.768 0.77 0.774 0.779 0.783 0.788 0.794 0.8 0.805 0.81 0.816 0.82 0.825 0.83 0.834 0.838 0.841 0.844 0.847 0.849 0.852 0.854 0.856 0.857 0.859 0.861 0.863 0.864 0.866 0.867 0.868 0.869 0.871 0.874 0.876
Gifu 0.764 0.768 0.77 0.772 0.776 0.781 0.787 0.792 0.799 0.806 0.811 0.817 0.822 0.826 0.831 0.835 0.838 0.841 0.843 0.845 0.847 0.849 0.85 0.852 0.854 0.856 0.857 0.859 0.861 0.862 0.864 0.865 0.867 0.868 0.87 0.872 0.873
Shizuoka 0.777 0.78 0.781 0.783 0.787 0.793 0.798 0.803 0.81 0.817 0.823 0.829 0.834 0.839 0.843 0.847 0.851 0.854 0.856 0.858 0.86 0.861 0.863 0.865 0.866 0.868 0.87 0.872 0.874 0.874 0.875 0.876 0.877 0.879 0.881 0.883 0.886
Aichi 0.786 0.79 0.792 0.794 0.797 0.803 0.808 0.813 0.82 0.828 0.833 0.839 0.845 0.849 0.852 0.856 0.859 0.862 0.864 0.866 0.868 0.87 0.871 0.873 0.875 0.877 0.878 0.88 0.882 0.883 0.885 0.886 0.887 0.888 0.89 0.893 0.895
Mie 0.77 0.774 0.776 0.778 0.782 0.788 0.793 0.798 0.805 0.812 0.818 0.824 0.83 0.834 0.839 0.843 0.846 0.849 0.851 0.853 0.855 0.857 0.859 0.86 0.862 0.864 0.866 0.868 0.87 0.871 0.873 0.874 0.875 0.877 0.879 0.881 0.883
Shiga 0.77 0.773 0.775 0.777 0.781 0.787 0.792 0.798 0.805 0.812 0.819 0.825 0.831 0.835 0.84 0.845 0.849 0.853 0.857 0.859 0.862 0.864 0.865 0.867 0.869 0.871 0.873 0.875 0.876 0.877 0.878 0.879 0.88 0.881 0.883 0.886 0.889
Kyōto 0.776 0.779 0.781 0.783 0.787 0.792 0.797 0.803 0.81 0.816 0.821 0.825 0.83 0.834 0.838 0.841 0.845 0.848 0.85 0.852 0.854 0.855 0.857 0.859 0.861 0.862 0.864 0.866 0.868 0.869 0.871 0.872 0.874 0.876 0.877 0.879 0.881
Ōsaka 0.788 0.791 0.793 0.795 0.799 0.804 0.809 0.814 0.821 0.827 0.832 0.836 0.841 0.845 0.848 0.852 0.855 0.858 0.86 0.861 0.863 0.865 0.866 0.868 0.869 0.871 0.873 0.875 0.877 0.878 0.879 0.88 0.882 0.884 0.885 0.887 0.888
Hyōgo 0.765 0.768 0.77 0.773 0.777 0.783 0.788 0.794 0.801 0.808 0.814 0.818 0.823 0.827 0.831 0.834 0.838 0.841 0.843 0.845 0.847 0.848 0.85 0.851 0.853 0.855 0.857 0.859 0.861 0.862 0.863 0.865 0.866 0.868 0.869 0.871 0.873
Nara 0.749 0.753 0.754 0.757 0.762 0.768 0.773 0.779 0.786 0.792 0.797 0.802 0.807 0.811 0.814 0.818 0.821 0.824 0.826 0.828 0.83 0.832 0.833 0.835 0.836 0.838 0.84 0.842 0.843 0.844 0.846 0.847 0.849 0.85 0.852 0.853 0.855
Wakayama 0.757 0.761 0.763 0.766 0.77 0.775 0.781 0.787 0.793 0.8 0.806 0.812 0.817 0.821 0.826 0.829 0.833 0.836 0.838 0.84 0.842 0.844 0.845 0.847 0.849 0.85 0.852 0.854 0.856 0.857 0.859 0.86 0.862 0.864 0.865 0.867 0.869
872
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Appendix Table 9: Socio-demographic Index values for all estimated GBD 2016 locations, 1980–2016
Tottori 0.747 0.751 0.753 0.755 0.759 0.764 0.769 0.774 0.78 0.786 0.791 0.797 0.803 0.807 0.812 0.817 0.822 0.826 0.83 0.832 0.835 0.837 0.84 0.843 0.845 0.847 0.849 0.851 0.853 0.854 0.856 0.857 0.858 0.859 0.861 0.864 0.866
Shimane 0.744 0.748 0.75 0.752 0.756 0.761 0.766 0.771 0.777 0.783 0.788 0.794 0.799 0.803 0.808 0.813 0.818 0.823 0.827 0.83 0.833 0.836 0.839 0.842 0.845 0.847 0.847 0.849 0.85 0.85 0.851 0.852 0.853 0.854 0.856 0.859 0.862
Okayama 0.762 0.765 0.767 0.769 0.773 0.779 0.784 0.79 0.797 0.804 0.809 0.815 0.821 0.825 0.83 0.835 0.839 0.843 0.845 0.847 0.849 0.851 0.853 0.855 0.857 0.859 0.861 0.863 0.865 0.866 0.867 0.869 0.871 0.872 0.874 0.876 0.878
Hiroshima 0.77 0.773 0.775 0.777 0.781 0.787 0.792 0.797 0.804 0.811 0.816 0.822 0.828 0.833 0.837 0.842 0.845 0.848 0.85 0.852 0.854 0.856 0.857 0.859 0.861 0.863 0.865 0.867 0.869 0.869 0.869 0.87 0.871 0.872 0.874 0.877 0.881
Yamaguchi 0.767 0.771 0.773 0.775 0.779 0.784 0.789 0.795 0.801 0.808 0.813 0.818 0.824 0.828 0.832 0.837 0.84 0.843 0.846 0.848 0.85 0.851 0.853 0.855 0.857 0.859 0.861 0.863 0.865 0.866 0.867 0.867 0.868 0.87 0.872 0.875 0.878
Tokushima 0.762 0.765 0.768 0.77 0.774 0.78 0.785 0.79 0.796 0.803 0.808 0.814 0.82 0.824 0.828 0.832 0.835 0.838 0.841 0.843 0.845 0.847 0.849 0.85 0.852 0.854 0.856 0.858 0.86 0.861 0.862 0.864 0.866 0.867 0.869 0.871 0.873
Kagawa 0.764 0.768 0.77 0.772 0.776 0.781 0.786 0.791 0.798 0.805 0.811 0.817 0.822 0.827 0.831 0.835 0.839 0.842 0.844 0.846 0.848 0.85 0.852 0.854 0.855 0.857 0.859 0.861 0.863 0.863 0.864 0.865 0.866 0.867 0.869 0.872 0.875
Ehime 0.757 0.761 0.764 0.767 0.771 0.776 0.781 0.786 0.792 0.799 0.804 0.809 0.815 0.819 0.823 0.828 0.832 0.835 0.837 0.839 0.841 0.843 0.845 0.847 0.849 0.851 0.852 0.855 0.856 0.857 0.859 0.861 0.862 0.864 0.866 0.867 0.869
Kōchi 0.746 0.749 0.751 0.753 0.757 0.763 0.768 0.774 0.78 0.787 0.792 0.796 0.801 0.805 0.81 0.815 0.819 0.823 0.825 0.827 0.829 0.831 0.833 0.835 0.837 0.839 0.84 0.843 0.844 0.845 0.847 0.848 0.85 0.852 0.853 0.855 0.857
Fukuoka 0.769 0.773 0.775 0.777 0.782 0.787 0.792 0.798 0.804 0.811 0.816 0.822 0.826 0.83 0.834 0.837 0.841 0.844 0.846 0.848 0.85 0.852 0.853 0.855 0.857 0.859 0.861 0.863 0.865 0.866 0.867 0.869 0.87 0.872 0.874 0.876 0.877
Saga 0.751 0.755 0.757 0.76 0.764 0.769 0.775 0.78 0.786 0.793 0.798 0.803 0.808 0.812 0.816 0.821 0.825 0.828 0.831 0.834 0.836 0.839 0.843 0.846 0.849 0.85 0.852 0.853 0.854 0.855 0.856 0.857 0.857 0.859 0.861 0.863 0.866
Nagasaki 0.749 0.753 0.755 0.757 0.761 0.767 0.772 0.777 0.783 0.79 0.794 0.799 0.804 0.808 0.813 0.818 0.822 0.826 0.829 0.832 0.834 0.837 0.839 0.841 0.843 0.845 0.847 0.848 0.849 0.849 0.849 0.85 0.851 0.852 0.854 0.857 0.859
Kumamoto 0.75 0.754 0.757 0.759 0.763 0.768 0.773 0.778 0.784 0.791 0.796 0.801 0.806 0.81 0.814 0.819 0.823 0.827 0.83 0.832 0.835 0.837 0.839 0.841 0.843 0.845 0.846 0.846 0.847 0.848 0.849 0.85 0.851 0.852 0.854 0.857 0.86
Ôita 0.761 0.765 0.768 0.771 0.775 0.78 0.785 0.789 0.795 0.802 0.807 0.812 0.817 0.821 0.825 0.83 0.834 0.838 0.841 0.843 0.845 0.847 0.849 0.85 0.852 0.854 0.856 0.858 0.86 0.86 0.861 0.862 0.863 0.865 0.867 0.87 0.872
Miyazaki 0.749 0.752 0.755 0.757 0.762 0.767 0.773 0.778 0.784 0.79 0.795 0.799 0.804 0.808 0.812 0.816 0.821 0.825 0.828 0.831 0.833 0.836 0.839 0.841 0.844 0.845 0.845 0.846 0.847 0.847 0.847 0.848 0.849 0.85 0.853 0.855 0.858
Kagoshima 0.744 0.748 0.751 0.754 0.759 0.765 0.77 0.775 0.782 0.788 0.793 0.799 0.804 0.808 0.813 0.818 0.822 0.826 0.83 0.832 0.834 0.837 0.84 0.842 0.844 0.846 0.846 0.847 0.848 0.849 0.85 0.851 0.852 0.853 0.855 0.858 0.861
Okinawa 0.73 0.734 0.736 0.738 0.743 0.75 0.756 0.762 0.769 0.777 0.782 0.787 0.793 0.797 0.802 0.808 0.812 0.816 0.819 0.821 0.823 0.825 0.828 0.832 0.835 0.836 0.836 0.837 0.837 0.837 0.837 0.838 0.838 0.84 0.842 0.845 0.848
Australasia 0.787 0.79 0.793 0.796 0.799 0.802 0.805 0.808 0.811 0.813 0.815 0.818 0.821 0.824 0.828 0.832 0.836 0.839 0.843 0.846 0.849 0.853 0.856 0.858 0.86 0.862 0.861 0.861 0.864 0.867 0.87 0.872 0.875 0.88 0.884 0.887 0.889
Australia 0.787 0.789 0.792 0.796 0.799 0.802 0.806 0.81 0.813 0.815 0.818 0.82 0.823 0.826 0.83 0.834 0.838 0.842 0.845 0.849 0.853 0.856 0.859 0.862 0.864 0.865 0.865 0.865 0.868 0.872 0.875 0.876 0.879 0.883 0.887 0.89 0.892
New Zealand 0.786 0.79 0.794 0.797 0.799 0.8 0.8 0.8 0.8 0.8 0.803 0.807 0.81 0.813 0.816 0.819 0.822 0.826 0.828 0.828 0.831 0.836 0.839 0.84 0.841 0.843 0.84 0.838 0.841 0.844 0.847 0.851 0.856 0.86 0.863 0.865 0.867
Western Europe 0.754 0.759 0.765 0.771 0.775 0.779 0.784 0.788 0.792 0.797 0.801 0.807 0.812 0.817 0.821 0.825 0.828 0.832 0.835 0.838 0.842 0.845 0.848 0.85 0.852 0.854 0.856 0.858 0.859 0.861 0.864 0.866 0.869 0.871 0.873 0.874 0.876
Andorra 0.845 0.848 0.85 0.852 0.855 0.857 0.859 0.862 0.864 0.866 0.868 0.87 0.872 0.873 0.875 0.876 0.878 0.881 0.884 0.887 0.889 0.891 0.892 0.894 0.896 0.897 0.899 0.901 0.902 0.904 0.906 0.907 0.909 0.91 0.912 0.913 0.915
Austria 0.801 0.803 0.807 0.812 0.816 0.818 0.82 0.822 0.824 0.827 0.83 0.832 0.836 0.838 0.841 0.844 0.846 0.849 0.851 0.854 0.857 0.86 0.862 0.864 0.867 0.869 0.871 0.874 0.876 0.878 0.88 0.882 0.885 0.887 0.889 0.89 0.892
Belgium 0.813 0.818 0.823 0.827 0.831 0.833 0.835 0.837 0.84 0.841 0.843 0.846 0.85 0.855 0.859 0.861 0.862 0.865 0.867 0.869 0.871 0.874 0.877 0.877 0.877 0.878 0.879 0.88 0.882 0.883 0.886 0.89 0.893 0.896 0.897 0.898 0.899
Cyprus 0.692 0.696 0.699 0.704 0.712 0.72 0.726 0.73 0.734 0.739 0.745 0.748 0.754 0.765 0.774 0.783 0.79 0.798 0.806 0.812 0.819 0.826 0.831 0.835 0.839 0.843 0.847 0.852 0.856 0.86 0.863 0.866 0.868 0.869 0.87 0.871 0.872
Denmark 0.866 0.867 0.869 0.871 0.873 0.876 0.879 0.88 0.879 0.879 0.88 0.88 0.88 0.881 0.882 0.885 0.889 0.893 0.895 0.897 0.9 0.903 0.905 0.905 0.906 0.906 0.907 0.908 0.909 0.911 0.914 0.919 0.922 0.925 0.925 0.925 0.925
Finland 0.815 0.816 0.818 0.821 0.826 0.832 0.836 0.837 0.838 0.84 0.841 0.841 0.842 0.843 0.845 0.849 0.852 0.856 0.86 0.863 0.867 0.871 0.874 0.876 0.878 0.88 0.883 0.886 0.888 0.89 0.892 0.896 0.9 0.904 0.906 0.907 0.907
France 0.743 0.749 0.758 0.765 0.769 0.773 0.777 0.783 0.788 0.793 0.799 0.805 0.812 0.817 0.821 0.823 0.826 0.829 0.832 0.833 0.836 0.84 0.843 0.846 0.848 0.849 0.85 0.853 0.855 0.856 0.858 0.861 0.863 0.865 0.867 0.868 0.869
Germany 0.801 0.804 0.807 0.809 0.812 0.814 0.817 0.82 0.822 0.826 0.829 0.832 0.835 0.838 0.841 0.843 0.845 0.847 0.85 0.852 0.854 0.857 0.859 0.86 0.862 0.864 0.866 0.869 0.871 0.873 0.875 0.877 0.88 0.882 0.884 0.886 0.889
Greece 0.699 0.708 0.714 0.722 0.731 0.739 0.745 0.751 0.756 0.761 0.765 0.77 0.775 0.779 0.783 0.787 0.792 0.796 0.801 0.806 0.81 0.815 0.82 0.825 0.829 0.834 0.838 0.843 0.847 0.85 0.852 0.853 0.853 0.852 0.852 0.852 0.853
Iceland 0.808 0.817 0.823 0.83 0.841 0.848 0.847 0.842 0.842 0.844 0.847 0.852 0.852 0.855 0.861 0.862 0.865 0.869 0.873 0.875 0.879 0.886 0.888 0.888 0.889 0.892 0.894 0.895 0.894 0.894 0.901 0.906 0.909 0.914 0.918 0.92 0.921
Ireland 0.684 0.694 0.705 0.717 0.727 0.733 0.74 0.75 0.759 0.764 0.768 0.775 0.784 0.792 0.798 0.802 0.806 0.811 0.818 0.826 0.832 0.836 0.842 0.848 0.856 0.861 0.861 0.861 0.863 0.864 0.867 0.871 0.874 0.877 0.879 0.883 0.885
Israel 0.691 0.698 0.7 0.7 0.702 0.708 0.716 0.723 0.727 0.731 0.736 0.743 0.748 0.753 0.757 0.761 0.764 0.766 0.767 0.769 0.772 0.775 0.777 0.777 0.779 0.781 0.784 0.786 0.786 0.788 0.791 0.794 0.796 0.797 0.798 0.799 0.801
Italy 0.748 0.755 0.761 0.767 0.772 0.776 0.781 0.785 0.789 0.794 0.798 0.803 0.807 0.81 0.814 0.818 0.821 0.824 0.828 0.831 0.834 0.837 0.84 0.843 0.846 0.848 0.85 0.853 0.855 0.857 0.858 0.86 0.862 0.863 0.864 0.865 0.867
Luxembourg 0.848 0.851 0.853 0.855 0.858 0.861 0.864 0.868 0.871 0.873 0.876 0.88 0.882 0.885 0.888 0.891 0.893 0.898 0.9 0.9 0.904 0.909 0.912 0.912 0.913 0.915 0.917 0.919 0.921 0.922 0.924 0.928 0.929 0.932 0.934 0.935 0.936
Malta 0.717 0.723 0.728 0.733 0.738 0.741 0.743 0.743 0.743 0.747 0.752 0.754 0.759 0.768 0.775 0.777 0.778 0.786 0.795 0.803 0.814 0.819 0.822 0.825 0.827 0.829 0.831 0.834 0.836 0.838 0.84 0.842 0.845 0.848 0.85 0.853 0.856
Netherlands 0.825 0.83 0.833 0.835 0.838 0.839 0.84 0.843 0.846 0.848 0.85 0.854 0.859 0.862 0.866 0.871 0.873 0.874 0.876 0.878 0.88 0.884 0.886 0.889 0.893 0.896 0.898 0.9 0.901 0.902 0.905 0.909 0.913 0.915 0.917 0.917 0.918
Norway 0.824 0.828 0.833 0.837 0.84 0.843 0.845 0.845 0.845 0.845 0.847 0.851 0.856 0.859 0.862 0.864 0.868 0.874 0.877 0.88 0.885 0.891 0.894 0.894 0.896 0.897 0.899 0.9 0.901 0.903 0.907 0.912 0.916 0.92 0.922 0.922 0.922
Portugal 0.61 0.618 0.626 0.634 0.643 0.651 0.658 0.665 0.672 0.68 0.687 0.694 0.701 0.708 0.714 0.719 0.725 0.73 0.735 0.74 0.746 0.751 0.755 0.759 0.763 0.766 0.77 0.773 0.777 0.779 0.782 0.785 0.787 0.789 0.791 0.794 0.796
Spain 0.67 0.68 0.689 0.698 0.705 0.713 0.721 0.727 0.733 0.739 0.746 0.752 0.759 0.764 0.77 0.775 0.78 0.786 0.791 0.796 0.801 0.806 0.811 0.816 0.82 0.824 0.828 0.833 0.836 0.838 0.84 0.842 0.843 0.844 0.845 0.847 0.848
Sweden 0.799 0.803 0.806 0.808 0.808 0.808 0.809 0.808 0.807 0.806 0.807 0.81 0.816 0.822 0.829 0.838 0.845 0.849 0.853 0.855 0.857 0.857 0.857 0.857 0.858 0.858 0.858 0.859 0.86 0.859 0.86 0.864 0.867 0.869 0.87 0.871 0.872
Switzerland 0.867 0.867 0.868 0.868 0.869 0.869 0.869 0.869 0.869 0.869 0.869 0.87 0.872 0.874 0.874 0.874 0.874 0.874 0.875 0.875 0.876 0.877 0.878 0.879 0.88 0.881 0.883 0.885 0.887 0.888 0.889 0.891 0.893 0.895 0.896 0.899 0.901
United Kingdom 0.711 0.717 0.722 0.727 0.732 0.737 0.742 0.746 0.753 0.758 0.763 0.769 0.775 0.781 0.787 0.793 0.797 0.802 0.808 0.815 0.822 0.827 0.83 0.831 0.834 0.837 0.838 0.84 0.842 0.843 0.846 0.849 0.853 0.857 0.86 0.862 0.863
Sweden except Stockholm 0.774 0.778 0.782 0.784 0.784 0.784 0.785 0.785 0.784 0.783 0.784 0.788 0.794 0.801 0.809 0.819 0.826 0.831 0.834 0.837 0.839 0.84 0.839 0.84 0.841 0.841 0.841 0.843 0.845 0.844 0.846 0.85 0.854 0.856 0.858 0.86 0.861
Stockholm 0.866 0.868 0.87 0.871 0.873 0.875 0.877 0.879 0.88 0.879 0.879 0.882 0.885 0.889 0.891 0.892 0.893 0.895 0.897 0.899 0.901 0.903 0.905 0.906 0.908 0.909 0.908 0.907 0.906 0.904 0.904 0.905 0.906 0.906 0.905 0.905 0.905
Northern Ireland 0.718 0.726 0.732 0.737 0.742 0.747 0.752 0.759 0.768 0.775 0.782 0.788 0.795 0.802 0.807 0.811 0.815 0.82 0.826 0.832 0.838 0.842 0.846 0.848 0.85 0.852 0.852 0.851 0.853 0.855 0.856 0.857 0.859 0.863 0.866 0.87 0.872
Scotland 0.706 0.712 0.718 0.724 0.728 0.732 0.737 0.742 0.748 0.752 0.755 0.759 0.764 0.77 0.775 0.779 0.782 0.786 0.792 0.797 0.801 0.805 0.809 0.811 0.813 0.815 0.816 0.816 0.818 0.821 0.823 0.826 0.83 0.832 0.834 0.835 0.837
Wales 0.681 0.686 0.692 0.697 0.702 0.708 0.713 0.718 0.726 0.733 0.737 0.742 0.749 0.755 0.762 0.767 0.772 0.778 0.785 0.792 0.8 0.807 0.811 0.813 0.816 0.819 0.821 0.822 0.825 0.827 0.829 0.833 0.837 0.842 0.845 0.847 0.848
England 0.712 0.718 0.723 0.729 0.733 0.738 0.743 0.747 0.753 0.759 0.765 0.771 0.777 0.783 0.789 0.794 0.799 0.804 0.81 0.817 0.824 0.829 0.832 0.834 0.837 0.839 0.841 0.842 0.844 0.846 0.848 0.851 0.855 0.86 0.863 0.865 0.866
Darlington 0.695 0.701 0.708 0.714 0.719 0.725 0.731 0.735 0.741 0.744 0.746 0.75 0.756 0.764 0.772 0.779 0.785 0.791 0.796 0.802 0.808 0.812 0.813 0.814 0.817 0.82 0.823 0.824 0.824 0.825 0.831 0.836 0.841 0.846 0.848 0.848 0.849
Northumberland 0.683 0.689 0.695 0.701 0.707 0.713 0.72 0.726 0.733 0.738 0.742 0.746 0.75 0.756 0.762 0.769 0.775 0.781 0.787 0.792 0.797 0.8 0.802 0.804 0.806 0.808 0.81 0.812 0.815 0.817 0.819 0.821 0.825 0.828 0.83 0.831 0.832
Stockton-on-Tees 0.692 0.698 0.703 0.708 0.714 0.721 0.727 0.733 0.74 0.745 0.748 0.753 0.759 0.766 0.774 0.78 0.786 0.792 0.798 0.806 0.812 0.815 0.817 0.818 0.82 0.822 0.824 0.825 0.827 0.829 0.831 0.833 0.835 0.84 0.843 0.846 0.848
Newcastle upon Tyne 0.705 0.711 0.717 0.722 0.726 0.731 0.737 0.743 0.75 0.756 0.763 0.771 0.78 0.787 0.792 0.798 0.802 0.806 0.811 0.819 0.827 0.833 0.84 0.846 0.852 0.858 0.861 0.865 0.868 0.871 0.873 0.876 0.879 0.882 0.885 0.887 0.889
North Tyneside 0.682 0.687 0.692 0.697 0.701 0.706 0.711 0.718 0.725 0.731 0.737 0.742 0.749 0.756 0.762 0.768 0.772 0.778 0.784 0.79 0.797 0.802 0.805 0.807 0.811 0.816 0.82 0.824 0.827 0.828 0.831 0.834 0.837 0.84 0.842 0.844 0.846
Redcar and Cleveland 0.659 0.665 0.67 0.676 0.68 0.686 0.691 0.697 0.704 0.71 0.714 0.718 0.723 0.727 0.733 0.739 0.744 0.75 0.757 0.766 0.774 0.779 0.782 0.783 0.786 0.789 0.791 0.793 0.795 0.795 0.796 0.797 0.802 0.808 0.813 0.816 0.819
County Durham 0.673 0.679 0.685 0.69 0.696 0.702 0.708 0.713 0.719 0.724 0.728 0.733 0.74 0.746 0.753 0.759 0.764 0.771 0.777 0.784 0.791 0.796 0.799 0.8 0.803 0.805 0.807 0.809 0.812 0.813 0.816 0.818 0.822 0.827 0.83 0.832 0.833
Gateshead 0.687 0.692 0.698 0.703 0.708 0.713 0.719 0.725 0.732 0.738 0.744 0.749 0.755 0.761 0.768 0.774 0.779 0.785 0.791 0.797 0.803 0.808 0.811 0.814 0.818 0.821 0.824 0.826 0.828 0.83 0.833 0.837 0.84 0.844 0.847 0.849 0.851
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Appendix Table 9: Socio-demographic Index values for all estimated GBD 2016 locations, 1980–2016
Middlesbrough 0.668 0.674 0.68 0.686 0.69 0.695 0.699 0.705 0.713 0.72 0.727 0.735 0.741 0.748 0.755 0.761 0.767 0.772 0.778 0.785 0.791 0.794 0.795 0.795 0.8 0.804 0.808 0.813 0.816 0.817 0.818 0.819 0.821 0.824 0.826 0.827 0.829
South Tyneside 0.657 0.662 0.666 0.669 0.672 0.675 0.68 0.686 0.694 0.701 0.707 0.713 0.719 0.725 0.731 0.736 0.741 0.746 0.753 0.761 0.768 0.775 0.78 0.784 0.789 0.793 0.796 0.799 0.802 0.803 0.805 0.807 0.81 0.814 0.817 0.818 0.82
Sunderland 0.676 0.683 0.689 0.694 0.7 0.706 0.712 0.718 0.725 0.731 0.736 0.742 0.748 0.754 0.761 0.767 0.772 0.778 0.785 0.791 0.798 0.804 0.809 0.812 0.816 0.82 0.823 0.826 0.829 0.83 0.831 0.832 0.835 0.838 0.841 0.844 0.845
Hartlepool 0.672 0.678 0.683 0.687 0.691 0.695 0.7 0.704 0.711 0.718 0.723 0.728 0.734 0.74 0.746 0.753 0.759 0.765 0.77 0.777 0.782 0.785 0.787 0.788 0.79 0.793 0.795 0.799 0.802 0.805 0.807 0.81 0.814 0.819 0.82 0.821 0.821
Cheshire East 0.726 0.732 0.737 0.742 0.747 0.753 0.758 0.764 0.769 0.774 0.778 0.783 0.788 0.795 0.802 0.809 0.815 0.821 0.826 0.832 0.837 0.842 0.845 0.845 0.847 0.848 0.848 0.847 0.848 0.851 0.854 0.858 0.863 0.869 0.872 0.873 0.874
Stockport 0.702 0.708 0.714 0.719 0.724 0.73 0.734 0.74 0.747 0.753 0.757 0.763 0.77 0.778 0.784 0.789 0.794 0.8 0.806 0.813 0.82 0.825 0.828 0.829 0.831 0.833 0.835 0.836 0.837 0.838 0.839 0.841 0.844 0.849 0.853 0.855 0.857
Trafford 0.726 0.732 0.737 0.741 0.745 0.75 0.755 0.76 0.767 0.772 0.777 0.784 0.791 0.799 0.806 0.812 0.816 0.821 0.828 0.835 0.841 0.846 0.849 0.851 0.854 0.855 0.855 0.856 0.858 0.86 0.864 0.868 0.872 0.877 0.88 0.882 0.883
Cheshire West and Chester 0.714 0.72 0.726 0.731 0.736 0.741 0.747 0.751 0.756 0.761 0.766 0.773 0.78 0.787 0.792 0.795 0.796 0.799 0.803 0.812 0.822 0.831 0.837 0.839 0.841 0.843 0.845 0.846 0.847 0.849 0.852 0.857 0.862 0.866 0.868 0.869 0.869
Sefton 0.682 0.688 0.693 0.698 0.704 0.709 0.715 0.72 0.725 0.73 0.734 0.74 0.747 0.754 0.761 0.767 0.771 0.777 0.783 0.789 0.795 0.8 0.803 0.805 0.809 0.811 0.812 0.813 0.813 0.814 0.816 0.818 0.82 0.823 0.824 0.825 0.826
Lancashire 0.694 0.7 0.705 0.711 0.716 0.721 0.727 0.732 0.738 0.744 0.749 0.755 0.761 0.768 0.775 0.781 0.786 0.792 0.798 0.804 0.81 0.815 0.817 0.819 0.822 0.824 0.826 0.827 0.829 0.83 0.832 0.834 0.838 0.842 0.845 0.847 0.848
Cumbria 0.702 0.707 0.713 0.718 0.723 0.73 0.736 0.741 0.747 0.751 0.754 0.757 0.763 0.77 0.777 0.783 0.789 0.794 0.8 0.804 0.809 0.812 0.814 0.815 0.818 0.82 0.821 0.821 0.823 0.825 0.828 0.832 0.837 0.842 0.845 0.846 0.848
Bolton 0.678 0.684 0.69 0.695 0.701 0.707 0.713 0.719 0.725 0.73 0.735 0.741 0.747 0.754 0.761 0.766 0.77 0.774 0.78 0.786 0.791 0.795 0.797 0.798 0.8 0.8 0.8 0.8 0.802 0.804 0.807 0.81 0.814 0.819 0.821 0.823 0.824
Wirral 0.677 0.682 0.687 0.692 0.696 0.7 0.705 0.71 0.716 0.722 0.727 0.733 0.739 0.746 0.753 0.76 0.765 0.771 0.777 0.783 0.787 0.79 0.791 0.792 0.795 0.797 0.798 0.798 0.799 0.8 0.803 0.808 0.812 0.817 0.819 0.82 0.82
Bury 0.683 0.688 0.693 0.697 0.7 0.704 0.709 0.714 0.72 0.727 0.733 0.739 0.747 0.754 0.761 0.766 0.77 0.774 0.78 0.787 0.793 0.797 0.799 0.8 0.803 0.806 0.807 0.806 0.806 0.805 0.808 0.812 0.818 0.824 0.828 0.83 0.831
St Helens 0.67 0.675 0.681 0.686 0.691 0.697 0.703 0.709 0.715 0.72 0.722 0.725 0.731 0.738 0.745 0.75 0.755 0.76 0.766 0.772 0.78 0.786 0.79 0.792 0.796 0.799 0.801 0.804 0.806 0.808 0.81 0.812 0.816 0.822 0.826 0.828 0.83
Warrington 0.719 0.724 0.73 0.735 0.741 0.747 0.753 0.759 0.766 0.771 0.774 0.777 0.783 0.789 0.796 0.802 0.807 0.812 0.817 0.824 0.83 0.836 0.841 0.844 0.847 0.85 0.852 0.852 0.852 0.854 0.858 0.862 0.867 0.873 0.875 0.877 0.878
Oldham 0.669 0.674 0.679 0.684 0.689 0.694 0.699 0.704 0.71 0.715 0.72 0.725 0.731 0.738 0.743 0.747 0.751 0.754 0.758 0.763 0.769 0.773 0.775 0.776 0.778 0.78 0.782 0.784 0.787 0.789 0.792 0.796 0.8 0.804 0.806 0.807 0.808
Rochdale 0.668 0.673 0.679 0.684 0.688 0.694 0.7 0.705 0.712 0.716 0.72 0.725 0.731 0.737 0.744 0.75 0.755 0.76 0.767 0.773 0.779 0.783 0.784 0.785 0.787 0.788 0.788 0.788 0.789 0.791 0.795 0.8 0.805 0.81 0.813 0.814 0.815
Wigan 0.671 0.676 0.682 0.687 0.692 0.698 0.704 0.71 0.716 0.722 0.727 0.733 0.739 0.746 0.752 0.758 0.763 0.769 0.774 0.779 0.785 0.789 0.791 0.793 0.795 0.797 0.798 0.799 0.8 0.801 0.804 0.807 0.811 0.816 0.82 0.822 0.824
Halton 0.69 0.695 0.7 0.704 0.707 0.711 0.715 0.72 0.727 0.734 0.739 0.745 0.752 0.759 0.767 0.773 0.778 0.782 0.786 0.792 0.8 0.806 0.81 0.811 0.812 0.814 0.816 0.818 0.82 0.822 0.827 0.832 0.836 0.842 0.847 0.85 0.853
Liverpool 0.688 0.693 0.698 0.702 0.705 0.709 0.712 0.716 0.722 0.729 0.738 0.75 0.76 0.767 0.773 0.777 0.781 0.787 0.794 0.803 0.812 0.818 0.824 0.83 0.836 0.839 0.842 0.844 0.848 0.852 0.855 0.859 0.862 0.865 0.867 0.868 0.87
Tameside 0.672 0.678 0.683 0.688 0.692 0.697 0.702 0.707 0.713 0.719 0.724 0.73 0.737 0.744 0.751 0.756 0.761 0.766 0.771 0.778 0.786 0.792 0.795 0.797 0.8 0.802 0.801 0.801 0.8 0.8 0.802 0.805 0.809 0.813 0.816 0.818 0.82
Salford 0.691 0.696 0.701 0.706 0.71 0.714 0.719 0.723 0.728 0.732 0.737 0.744 0.752 0.761 0.769 0.775 0.78 0.784 0.791 0.799 0.807 0.814 0.818 0.821 0.825 0.828 0.831 0.832 0.834 0.835 0.839 0.843 0.848 0.853 0.856 0.859 0.861
Blackburn with Darwen 0.669 0.675 0.68 0.685 0.689 0.694 0.698 0.702 0.709 0.715 0.72 0.726 0.733 0.739 0.745 0.75 0.755 0.76 0.765 0.77 0.775 0.779 0.781 0.782 0.784 0.786 0.786 0.787 0.791 0.794 0.798 0.802 0.807 0.812 0.816 0.818 0.82
Knowsley 0.665 0.672 0.678 0.683 0.689 0.694 0.7 0.704 0.71 0.715 0.72 0.727 0.733 0.739 0.744 0.75 0.755 0.762 0.768 0.774 0.781 0.787 0.791 0.792 0.795 0.799 0.803 0.807 0.811 0.813 0.816 0.819 0.822 0.828 0.832 0.834 0.837
Blackpool 0.667 0.673 0.679 0.685 0.688 0.69 0.691 0.693 0.699 0.704 0.711 0.722 0.732 0.74 0.746 0.751 0.754 0.759 0.766 0.773 0.778 0.782 0.782 0.78 0.782 0.786 0.788 0.788 0.787 0.788 0.792 0.796 0.799 0.801 0.803 0.806 0.809
Manchester 0.715 0.721 0.726 0.731 0.734 0.739 0.744 0.749 0.755 0.761 0.768 0.775 0.781 0.789 0.796 0.801 0.806 0.812 0.819 0.829 0.839 0.847 0.853 0.857 0.862 0.866 0.869 0.872 0.875 0.878 0.882 0.884 0.888 0.892 0.895 0.897 0.899
North Yorkshire 0.707 0.712 0.718 0.724 0.73 0.736 0.742 0.747 0.754 0.759 0.762 0.765 0.769 0.774 0.78 0.785 0.79 0.796 0.802 0.808 0.815 0.819 0.821 0.822 0.826 0.829 0.831 0.833 0.834 0.835 0.838 0.841 0.844 0.848 0.849 0.849 0.85
East Riding of Yorkshire 0.696 0.702 0.708 0.714 0.72 0.724 0.727 0.726 0.73 0.738 0.746 0.752 0.758 0.765 0.771 0.777 0.782 0.788 0.793 0.799 0.804 0.808 0.81 0.811 0.815 0.818 0.819 0.821 0.823 0.825 0.827 0.828 0.831 0.834 0.836 0.837 0.839
York 0.729 0.735 0.74 0.745 0.749 0.753 0.756 0.76 0.766 0.773 0.781 0.79 0.799 0.804 0.81 0.815 0.819 0.824 0.831 0.836 0.842 0.848 0.854 0.86 0.865 0.87 0.873 0.877 0.88 0.881 0.883 0.885 0.886 0.888 0.89 0.892 0.894
North East Lincolnshire 0.693 0.698 0.703 0.706 0.709 0.714 0.721 0.728 0.736 0.74 0.743 0.748 0.755 0.762 0.769 0.773 0.776 0.779 0.784 0.789 0.795 0.801 0.802 0.802 0.803 0.805 0.808 0.813 0.817 0.822 0.825 0.828 0.831 0.833 0.834 0.834 0.834
Calderdale 0.688 0.694 0.699 0.704 0.709 0.716 0.722 0.729 0.736 0.741 0.746 0.75 0.755 0.761 0.767 0.773 0.777 0.783 0.788 0.795 0.801 0.805 0.806 0.807 0.81 0.814 0.816 0.818 0.82 0.821 0.824 0.828 0.833 0.839 0.842 0.845 0.847
North Lincolnshire 0.691 0.696 0.701 0.706 0.71 0.715 0.72 0.724 0.731 0.736 0.741 0.746 0.751 0.757 0.763 0.769 0.775 0.781 0.787 0.792 0.796 0.8 0.802 0.802 0.803 0.804 0.805 0.806 0.809 0.812 0.816 0.821 0.826 0.831 0.833 0.834 0.835
Bradford 0.669 0.675 0.681 0.686 0.69 0.696 0.702 0.707 0.714 0.72 0.726 0.732 0.738 0.744 0.75 0.755 0.759 0.763 0.767 0.773 0.779 0.784 0.786 0.787 0.79 0.792 0.795 0.798 0.802 0.805 0.808 0.81 0.812 0.815 0.817 0.818 0.819
Kirklees 0.676 0.682 0.688 0.694 0.699 0.705 0.711 0.716 0.723 0.729 0.735 0.741 0.747 0.753 0.759 0.763 0.768 0.772 0.778 0.785 0.79 0.795 0.796 0.797 0.8 0.803 0.805 0.807 0.81 0.812 0.814 0.817 0.821 0.825 0.828 0.83 0.832
Leeds 0.707 0.713 0.719 0.724 0.729 0.734 0.739 0.743 0.75 0.756 0.763 0.771 0.778 0.785 0.791 0.796 0.802 0.807 0.814 0.822 0.83 0.836 0.842 0.847 0.852 0.857 0.861 0.865 0.869 0.869 0.869 0.868 0.869 0.872 0.874 0.876 0.878
Sheffield 0.702 0.707 0.713 0.718 0.723 0.727 0.732 0.737 0.743 0.748 0.753 0.759 0.764 0.77 0.776 0.781 0.786 0.792 0.798 0.805 0.812 0.818 0.823 0.826 0.831 0.835 0.838 0.843 0.848 0.851 0.853 0.855 0.857 0.861 0.863 0.865 0.867
Wakefield 0.68 0.685 0.691 0.696 0.701 0.706 0.711 0.716 0.723 0.728 0.733 0.738 0.744 0.75 0.756 0.761 0.766 0.771 0.777 0.784 0.792 0.797 0.8 0.801 0.804 0.806 0.807 0.808 0.809 0.81 0.812 0.815 0.82 0.825 0.828 0.831 0.833
Rotherham 0.667 0.673 0.678 0.684 0.689 0.694 0.699 0.704 0.71 0.715 0.72 0.725 0.731 0.737 0.743 0.749 0.753 0.758 0.763 0.769 0.776 0.781 0.785 0.788 0.791 0.794 0.795 0.797 0.799 0.801 0.804 0.807 0.809 0.813 0.816 0.818 0.82
Doncaster 0.663 0.668 0.674 0.679 0.683 0.689 0.694 0.7 0.707 0.712 0.716 0.721 0.725 0.73 0.736 0.741 0.745 0.75 0.756 0.763 0.769 0.774 0.777 0.779 0.782 0.785 0.787 0.79 0.793 0.796 0.801 0.805 0.809 0.813 0.816 0.818 0.819
Kingston upon Hull, City of 0.675 0.68 0.685 0.688 0.69 0.694 0.7 0.709 0.718 0.721 0.725 0.731 0.74 0.747 0.754 0.759 0.764 0.77 0.776 0.783 0.791 0.797 0.8 0.803 0.808 0.812 0.817 0.821 0.825 0.826 0.825 0.825 0.827 0.831 0.835 0.838 0.84
Barnsley 0.66 0.665 0.671 0.676 0.681 0.687 0.692 0.697 0.703 0.708 0.712 0.718 0.724 0.73 0.737 0.742 0.747 0.753 0.76 0.766 0.772 0.776 0.778 0.78 0.782 0.784 0.786 0.789 0.791 0.792 0.794 0.797 0.801 0.806 0.81 0.812 0.814
Northamptonshire 0.698 0.704 0.71 0.716 0.72 0.725 0.73 0.734 0.74 0.746 0.751 0.757 0.764 0.771 0.777 0.783 0.788 0.793 0.799 0.805 0.811 0.816 0.818 0.819 0.821 0.824 0.825 0.827 0.828 0.83 0.833 0.835 0.839 0.843 0.845 0.845 0.846
Leicestershire 0.705 0.711 0.717 0.723 0.728 0.733 0.739 0.744 0.75 0.756 0.76 0.765 0.77 0.776 0.782 0.787 0.792 0.798 0.804 0.81 0.816 0.821 0.823 0.826 0.829 0.833 0.836 0.839 0.842 0.843 0.845 0.847 0.85 0.854 0.857 0.859 0.861
Lincolnshire 0.687 0.693 0.699 0.705 0.71 0.716 0.722 0.727 0.733 0.738 0.741 0.744 0.749 0.755 0.761 0.768 0.773 0.779 0.784 0.79 0.796 0.802 0.805 0.808 0.81 0.811 0.811 0.811 0.812 0.813 0.816 0.819 0.823 0.828 0.831 0.832 0.833
Rutland 0.703 0.709 0.715 0.721 0.728 0.736 0.744 0.751 0.76 0.765 0.771 0.772 0.776 0.784 0.79 0.796 0.801 0.806 0.811 0.815 0.82 0.814 0.802 0.782 0.776 0.788 0.797 0.804 0.809 0.817 0.831 0.839 0.839 0.839 0.838 0.839 0.84
Derby 0.689 0.696 0.703 0.71 0.716 0.723 0.728 0.733 0.738 0.743 0.748 0.756 0.764 0.773 0.782 0.789 0.794 0.798 0.803 0.81 0.816 0.822 0.826 0.829 0.834 0.837 0.838 0.841 0.844 0.845 0.846 0.846 0.849 0.855 0.858 0.861 0.864
Derbyshire 0.683 0.689 0.695 0.7 0.705 0.711 0.716 0.722 0.728 0.733 0.737 0.742 0.747 0.754 0.76 0.766 0.772 0.777 0.784 0.79 0.796 0.801 0.803 0.805 0.807 0.81 0.812 0.814 0.815 0.816 0.818 0.822 0.826 0.832 0.836 0.839 0.841
Nottinghamshire 0.68 0.686 0.692 0.698 0.703 0.709 0.714 0.719 0.725 0.731 0.735 0.74 0.745 0.751 0.757 0.762 0.766 0.771 0.778 0.786 0.794 0.8 0.805 0.807 0.811 0.814 0.816 0.817 0.819 0.819 0.82 0.821 0.824 0.828 0.831 0.834 0.835
Nottingham 0.705 0.711 0.718 0.724 0.729 0.733 0.737 0.741 0.746 0.753 0.76 0.769 0.777 0.785 0.793 0.801 0.807 0.815 0.822 0.828 0.834 0.84 0.846 0.85 0.855 0.86 0.863 0.867 0.87 0.871 0.871 0.87 0.871 0.873 0.875 0.877 0.878
Leicester 0.674 0.68 0.686 0.692 0.696 0.702 0.707 0.711 0.717 0.724 0.733 0.744 0.753 0.761 0.768 0.774 0.778 0.781 0.786 0.793 0.8 0.807 0.811 0.814 0.818 0.822 0.825 0.828 0.831 0.834 0.836 0.837 0.84 0.843 0.845 0.847 0.849
Warwickshire 0.714 0.72 0.725 0.731 0.735 0.741 0.746 0.75 0.756 0.761 0.766 0.772 0.778 0.784 0.791 0.796 0.801 0.806 0.812 0.819 0.825 0.83 0.833 0.836 0.838 0.84 0.841 0.842 0.844 0.846 0.849 0.852 0.856 0.861 0.863 0.864 0.865
Herefordshire, County of 0.692 0.698 0.704 0.709 0.715 0.72 0.725 0.729 0.733 0.738 0.741 0.746 0.752 0.759 0.765 0.77 0.775 0.78 0.786 0.793 0.801 0.807 0.809 0.811 0.813 0.815 0.815 0.814 0.815 0.816 0.821 0.828 0.836 0.842 0.846 0.848 0.85
Solihull 0.723 0.728 0.733 0.738 0.742 0.746 0.751 0.755 0.761 0.765 0.768 0.773 0.779 0.787 0.794 0.801 0.807 0.814 0.82 0.826 0.83 0.834 0.836 0.839 0.842 0.846 0.849 0.851 0.852 0.851 0.852 0.853 0.857 0.861 0.863 0.864 0.864
Shropshire 0.694 0.7 0.705 0.71 0.716 0.722 0.727 0.733 0.738 0.743 0.746 0.75 0.755 0.761 0.768 0.773 0.778 0.783 0.79 0.796 0.802 0.805 0.808 0.81 0.814 0.817 0.818 0.818 0.82 0.824 0.829 0.834 0.839 0.843 0.845 0.846 0.847
Worcestershire 0.688 0.694 0.699 0.705 0.71 0.716 0.721 0.727 0.733 0.738 0.742 0.747 0.753 0.759 0.765 0.77 0.775 0.78 0.787 0.796 0.804 0.81 0.813 0.815 0.819 0.821 0.822 0.823 0.824 0.825 0.828 0.832 0.836 0.841 0.844 0.846 0.847
Staffordshire 0.69 0.695 0.701 0.706 0.711 0.716 0.721 0.727 0.733 0.739 0.744 0.749 0.756 0.762 0.768 0.773 0.778 0.783 0.79 0.796 0.802 0.806 0.809 0.81 0.813 0.816 0.818 0.821 0.824 0.826 0.829 0.832 0.835 0.839 0.841 0.842 0.843
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Appendix Table 9: Socio-demographic Index values for all estimated GBD 2016 locations, 1980–2016
Dudley 0.677 0.682 0.688 0.693 0.698 0.703 0.708 0.714 0.721 0.726 0.731 0.736 0.741 0.747 0.753 0.757 0.762 0.767 0.772 0.778 0.784 0.789 0.792 0.794 0.797 0.8 0.802 0.804 0.806 0.806 0.807 0.808 0.81 0.814 0.816 0.817 0.818
Coventry 0.697 0.702 0.707 0.711 0.715 0.719 0.724 0.729 0.735 0.742 0.75 0.757 0.764 0.771 0.777 0.782 0.787 0.792 0.797 0.805 0.812 0.819 0.823 0.826 0.83 0.833 0.835 0.836 0.837 0.838 0.84 0.843 0.848 0.855 0.86 0.863 0.866
Telford and Wrekin 0.698 0.704 0.71 0.716 0.721 0.726 0.731 0.736 0.742 0.747 0.752 0.757 0.763 0.769 0.775 0.78 0.785 0.792 0.798 0.804 0.81 0.815 0.817 0.817 0.818 0.818 0.818 0.818 0.821 0.822 0.824 0.828 0.833 0.838 0.842 0.845 0.846
Stoke-on-Trent 0.67 0.676 0.681 0.686 0.691 0.697 0.701 0.705 0.71 0.716 0.724 0.733 0.742 0.749 0.756 0.761 0.766 0.772 0.777 0.783 0.788 0.79 0.789 0.788 0.789 0.791 0.791 0.79 0.793 0.796 0.8 0.804 0.809 0.815 0.819 0.823 0.827
Walsall 0.667 0.672 0.677 0.682 0.686 0.691 0.697 0.702 0.709 0.714 0.718 0.722 0.728 0.735 0.741 0.744 0.746 0.747 0.752 0.759 0.766 0.771 0.773 0.773 0.776 0.779 0.781 0.784 0.786 0.788 0.792 0.796 0.8 0.804 0.807 0.808 0.809
Wolverhampton 0.678 0.684 0.689 0.693 0.698 0.703 0.707 0.712 0.717 0.723 0.728 0.734 0.741 0.747 0.753 0.757 0.761 0.766 0.772 0.78 0.788 0.795 0.799 0.8 0.803 0.806 0.807 0.808 0.809 0.81 0.813 0.816 0.821 0.825 0.827 0.829 0.83
Birmingham 0.68 0.686 0.691 0.696 0.7 0.705 0.71 0.714 0.72 0.727 0.733 0.742 0.75 0.757 0.763 0.767 0.771 0.775 0.781 0.788 0.795 0.801 0.805 0.808 0.812 0.817 0.819 0.822 0.826 0.829 0.832 0.833 0.836 0.84 0.843 0.845 0.847
Sandwell 0.666 0.671 0.677 0.682 0.686 0.691 0.696 0.701 0.708 0.714 0.719 0.725 0.732 0.739 0.745 0.749 0.753 0.758 0.763 0.768 0.773 0.778 0.781 0.782 0.785 0.787 0.788 0.789 0.79 0.791 0.794 0.797 0.803 0.808 0.812 0.813 0.815
Bedford 0.711 0.717 0.723 0.728 0.733 0.739 0.745 0.75 0.757 0.764 0.771 0.776 0.781 0.784 0.788 0.791 0.795 0.801 0.807 0.814 0.822 0.828 0.831 0.833 0.836 0.839 0.841 0.842 0.843 0.844 0.845 0.846 0.848 0.85 0.85 0.851 0.851
Central Bedfordshire 0.709 0.715 0.72 0.725 0.73 0.735 0.741 0.747 0.754 0.759 0.765 0.77 0.775 0.781 0.788 0.794 0.8 0.806 0.811 0.815 0.818 0.82 0.822 0.823 0.827 0.829 0.83 0.831 0.831 0.831 0.832 0.834 0.838 0.844 0.848 0.85 0.853
Suffolk 0.703 0.709 0.715 0.72 0.725 0.731 0.736 0.74 0.746 0.752 0.757 0.763 0.768 0.773 0.78 0.786 0.791 0.797 0.802 0.807 0.811 0.814 0.814 0.814 0.817 0.82 0.822 0.823 0.824 0.825 0.827 0.83 0.833 0.837 0.838 0.839 0.84
Hertfordshire 0.731 0.737 0.743 0.748 0.753 0.757 0.76 0.764 0.769 0.775 0.781 0.788 0.795 0.801 0.806 0.812 0.816 0.822 0.828 0.836 0.843 0.848 0.851 0.853 0.855 0.858 0.858 0.859 0.861 0.862 0.864 0.866 0.869 0.874 0.876 0.878 0.879
Essex 0.701 0.706 0.712 0.717 0.722 0.726 0.73 0.734 0.739 0.745 0.75 0.757 0.763 0.768 0.774 0.779 0.784 0.79 0.796 0.802 0.808 0.812 0.814 0.816 0.819 0.823 0.825 0.828 0.83 0.83 0.831 0.833 0.836 0.84 0.842 0.844 0.845
Cambridgeshire 0.728 0.734 0.74 0.745 0.749 0.755 0.76 0.765 0.771 0.777 0.783 0.789 0.796 0.801 0.807 0.814 0.82 0.827 0.833 0.838 0.844 0.849 0.854 0.856 0.86 0.862 0.862 0.862 0.862 0.863 0.867 0.87 0.874 0.878 0.88 0.881 0.882
Thurrock 0.702 0.708 0.711 0.715 0.717 0.72 0.723 0.726 0.733 0.741 0.75 0.759 0.765 0.77 0.775 0.78 0.783 0.787 0.793 0.799 0.806 0.811 0.812 0.812 0.813 0.813 0.813 0.814 0.816 0.819 0.821 0.822 0.823 0.825 0.826 0.825 0.824
Norfolk 0.702 0.708 0.714 0.719 0.723 0.728 0.733 0.737 0.743 0.749 0.754 0.759 0.764 0.77 0.775 0.781 0.786 0.792 0.798 0.804 0.81 0.814 0.817 0.818 0.821 0.824 0.826 0.828 0.83 0.831 0.832 0.833 0.836 0.841 0.844 0.846 0.848
Southend-on-Sea 0.683 0.688 0.693 0.696 0.699 0.703 0.709 0.716 0.724 0.731 0.736 0.742 0.749 0.757 0.765 0.772 0.778 0.785 0.79 0.794 0.796 0.797 0.798 0.799 0.802 0.804 0.804 0.806 0.809 0.813 0.817 0.819 0.822 0.825 0.827 0.827 0.828
Peterborough 0.713 0.719 0.724 0.728 0.732 0.737 0.742 0.747 0.753 0.759 0.763 0.767 0.773 0.778 0.785 0.79 0.794 0.798 0.803 0.809 0.815 0.819 0.818 0.816 0.816 0.816 0.816 0.816 0.816 0.818 0.823 0.828 0.831 0.835 0.837 0.838 0.839
Luton 0.692 0.698 0.703 0.707 0.71 0.713 0.715 0.717 0.725 0.733 0.743 0.752 0.759 0.765 0.771 0.775 0.779 0.783 0.787 0.793 0.798 0.803 0.804 0.804 0.806 0.808 0.811 0.816 0.823 0.829 0.834 0.837 0.84 0.843 0.844 0.844 0.845
Richmond upon Thames 0.76 0.766 0.771 0.775 0.779 0.783 0.787 0.791 0.798 0.805 0.813 0.82 0.827 0.833 0.839 0.845 0.85 0.855 0.861 0.868 0.873 0.878 0.882 0.885 0.887 0.888 0.887 0.887 0.888 0.888 0.889 0.891 0.895 0.9 0.905 0.908 0.91
Kensington and Chelsea 0.798 0.804 0.809 0.815 0.82 0.826 0.832 0.837 0.84 0.848 0.855 0.861 0.866 0.871 0.875 0.88 0.884 0.889 0.894 0.9 0.906 0.91 0.914 0.917 0.921 0.924 0.927 0.929 0.932 0.934 0.936 0.938 0.94 0.941 0.942 0.943 0.945
Barnet 0.729 0.735 0.742 0.748 0.753 0.759 0.764 0.769 0.775 0.782 0.787 0.792 0.797 0.803 0.81 0.816 0.823 0.829 0.835 0.841 0.846 0.851 0.853 0.854 0.855 0.855 0.854 0.853 0.855 0.857 0.86 0.865 0.87 0.875 0.878 0.879 0.88
Westminster 0.808 0.812 0.817 0.821 0.825 0.829 0.831 0.832 0.837 0.844 0.853 0.86 0.865 0.869 0.873 0.877 0.882 0.886 0.891 0.896 0.901 0.906 0.91 0.914 0.918 0.921 0.924 0.927 0.929 0.931 0.933 0.935 0.936 0.938 0.939 0.941 0.943
Bromley 0.73 0.736 0.741 0.746 0.749 0.753 0.757 0.761 0.767 0.774 0.779 0.784 0.789 0.793 0.799 0.804 0.809 0.815 0.821 0.829 0.835 0.839 0.842 0.844 0.846 0.847 0.848 0.85 0.851 0.851 0.851 0.851 0.853 0.857 0.86 0.862 0.863
Bexley 0.701 0.707 0.713 0.718 0.722 0.726 0.73 0.733 0.739 0.744 0.749 0.756 0.762 0.768 0.774 0.778 0.781 0.784 0.789 0.795 0.801 0.806 0.809 0.811 0.814 0.815 0.815 0.817 0.819 0.821 0.823 0.824 0.828 0.833 0.836 0.838 0.84
Redbridge 0.702 0.708 0.713 0.718 0.723 0.729 0.734 0.74 0.746 0.752 0.757 0.761 0.767 0.772 0.777 0.782 0.787 0.792 0.797 0.804 0.81 0.815 0.818 0.82 0.822 0.823 0.824 0.827 0.83 0.83 0.831 0.831 0.834 0.837 0.84 0.841 0.843
Merton 0.726 0.732 0.737 0.74 0.743 0.747 0.752 0.757 0.765 0.773 0.782 0.792 0.8 0.807 0.813 0.818 0.823 0.828 0.836 0.845 0.852 0.857 0.859 0.861 0.863 0.865 0.866 0.867 0.869 0.87 0.87 0.871 0.874 0.879 0.881 0.882 0.884
Brent 0.724 0.73 0.736 0.741 0.746 0.752 0.759 0.765 0.773 0.779 0.784 0.788 0.792 0.797 0.802 0.807 0.811 0.815 0.82 0.826 0.834 0.841 0.845 0.846 0.847 0.846 0.843 0.836 0.832 0.832 0.84 0.85 0.858 0.864 0.866 0.865 0.865
Hillingdon 0.756 0.762 0.767 0.772 0.776 0.78 0.784 0.788 0.795 0.801 0.807 0.814 0.821 0.827 0.834 0.84 0.844 0.848 0.853 0.859 0.864 0.866 0.868 0.869 0.871 0.871 0.87 0.87 0.872 0.874 0.876 0.878 0.882 0.888 0.892 0.895 0.897
Havering 0.703 0.709 0.715 0.72 0.724 0.728 0.732 0.735 0.74 0.745 0.75 0.756 0.762 0.768 0.774 0.778 0.783 0.787 0.792 0.798 0.803 0.808 0.81 0.812 0.815 0.818 0.82 0.822 0.825 0.827 0.828 0.829 0.83 0.833 0.835 0.836 0.837
Kingston upon Thames 0.746 0.752 0.758 0.762 0.766 0.77 0.774 0.779 0.788 0.796 0.804 0.811 0.818 0.823 0.828 0.832 0.837 0.842 0.85 0.858 0.864 0.869 0.874 0.878 0.881 0.884 0.886 0.888 0.891 0.892 0.892 0.892 0.895 0.898 0.9 0.901 0.902
Sutton 0.714 0.72 0.726 0.73 0.734 0.737 0.739 0.743 0.749 0.756 0.762 0.769 0.776 0.783 0.79 0.796 0.802 0.807 0.814 0.821 0.828 0.832 0.834 0.834 0.836 0.838 0.84 0.842 0.845 0.846 0.847 0.847 0.85 0.854 0.856 0.857 0.858
Harrow 0.719 0.726 0.732 0.737 0.741 0.745 0.749 0.751 0.757 0.764 0.772 0.781 0.789 0.796 0.802 0.806 0.81 0.814 0.821 0.829 0.836 0.84 0.841 0.842 0.844 0.847 0.847 0.848 0.849 0.849 0.851 0.852 0.854 0.856 0.856 0.856 0.856
Enfield 0.716 0.722 0.728 0.732 0.736 0.741 0.745 0.749 0.755 0.761 0.767 0.773 0.778 0.783 0.787 0.79 0.793 0.798 0.804 0.812 0.82 0.826 0.828 0.828 0.828 0.827 0.826 0.826 0.828 0.831 0.837 0.842 0.847 0.851 0.853 0.853 0.854
Croydon 0.721 0.727 0.732 0.737 0.741 0.745 0.749 0.753 0.759 0.765 0.772 0.78 0.787 0.794 0.801 0.806 0.81 0.815 0.82 0.826 0.832 0.836 0.839 0.841 0.843 0.843 0.841 0.84 0.841 0.841 0.843 0.845 0.848 0.85 0.85 0.849 0.849
Hammersmith and Fulham 0.784 0.789 0.795 0.801 0.807 0.814 0.82 0.826 0.833 0.841 0.849 0.856 0.862 0.867 0.872 0.877 0.883 0.887 0.891 0.897 0.901 0.906 0.909 0.912 0.916 0.919 0.92 0.922 0.924 0.927 0.932 0.936 0.937 0.938 0.94 0.941 0.942
Ealing 0.729 0.736 0.743 0.749 0.757 0.765 0.773 0.779 0.786 0.791 0.795 0.8 0.805 0.81 0.816 0.822 0.827 0.833 0.839 0.847 0.853 0.858 0.86 0.86 0.861 0.86 0.859 0.858 0.857 0.857 0.859 0.863 0.868 0.873 0.876 0.877 0.879
Greenwich 0.701 0.707 0.713 0.719 0.723 0.727 0.732 0.735 0.74 0.746 0.753 0.76 0.768 0.775 0.78 0.784 0.788 0.793 0.798 0.806 0.814 0.821 0.825 0.826 0.826 0.824 0.821 0.82 0.822 0.825 0.83 0.835 0.841 0.846 0.848 0.848 0.848
Wandsworth 0.746 0.752 0.758 0.764 0.77 0.777 0.784 0.791 0.799 0.808 0.816 0.825 0.833 0.839 0.844 0.849 0.854 0.86 0.865 0.872 0.879 0.885 0.89 0.895 0.899 0.902 0.906 0.907 0.909 0.911 0.912 0.915 0.919 0.922 0.924 0.926 0.928
Waltham Forest 0.681 0.687 0.694 0.699 0.705 0.71 0.715 0.72 0.726 0.733 0.739 0.746 0.753 0.76 0.766 0.771 0.774 0.777 0.783 0.79 0.797 0.803 0.806 0.806 0.807 0.805 0.802 0.798 0.798 0.8 0.807 0.814 0.822 0.828 0.832 0.834 0.835
Camden 0.81 0.815 0.819 0.823 0.828 0.833 0.838 0.843 0.848 0.852 0.857 0.862 0.867 0.872 0.876 0.881 0.883 0.884 0.888 0.897 0.904 0.909 0.912 0.915 0.919 0.922 0.924 0.927 0.929 0.931 0.933 0.935 0.937 0.939 0.94 0.942 0.943
Lambeth 0.738 0.745 0.751 0.756 0.761 0.766 0.771 0.773 0.779 0.787 0.798 0.811 0.821 0.828 0.834 0.838 0.842 0.847 0.853 0.86 0.867 0.871 0.872 0.873 0.876 0.881 0.885 0.891 0.898 0.903 0.908 0.914 0.919 0.921 0.922 0.924 0.926
Lewisham 0.702 0.708 0.714 0.719 0.724 0.728 0.732 0.736 0.741 0.747 0.755 0.766 0.775 0.782 0.787 0.79 0.793 0.796 0.802 0.81 0.819 0.826 0.828 0.828 0.829 0.83 0.832 0.833 0.835 0.836 0.84 0.844 0.85 0.856 0.86 0.863 0.865
Hounslow 0.745 0.75 0.753 0.755 0.755 0.757 0.761 0.766 0.773 0.784 0.795 0.805 0.81 0.815 0.818 0.822 0.825 0.829 0.836 0.847 0.857 0.864 0.866 0.864 0.864 0.865 0.867 0.869 0.872 0.874 0.876 0.878 0.883 0.889 0.891 0.891 0.892
Southwark 0.753 0.76 0.766 0.772 0.778 0.782 0.787 0.791 0.798 0.806 0.816 0.825 0.833 0.838 0.841 0.844 0.845 0.848 0.854 0.864 0.875 0.883 0.885 0.885 0.888 0.892 0.896 0.9 0.904 0.907 0.911 0.916 0.923 0.929 0.933 0.935 0.937
Newham 0.69 0.696 0.701 0.705 0.708 0.712 0.716 0.722 0.728 0.734 0.74 0.747 0.754 0.759 0.76 0.759 0.758 0.76 0.765 0.775 0.79 0.803 0.808 0.808 0.81 0.811 0.809 0.803 0.795 0.795 0.813 0.833 0.844 0.85 0.852 0.853 0.853
Barking and Dagenham 0.692 0.698 0.702 0.705 0.707 0.711 0.715 0.719 0.724 0.728 0.733 0.739 0.745 0.752 0.758 0.763 0.765 0.768 0.775 0.784 0.793 0.799 0.801 0.798 0.794 0.79 0.787 0.787 0.791 0.794 0.798 0.8 0.804 0.81 0.814 0.815 0.815
Haringey 0.73 0.736 0.741 0.745 0.747 0.748 0.75 0.752 0.758 0.765 0.777 0.79 0.799 0.805 0.809 0.813 0.817 0.821 0.825 0.831 0.837 0.843 0.846 0.847 0.849 0.851 0.85 0.849 0.848 0.848 0.855 0.865 0.872 0.878 0.88 0.88 0.88
Hackney 0.755 0.761 0.766 0.771 0.777 0.782 0.784 0.787 0.794 0.8 0.806 0.814 0.822 0.828 0.832 0.832 0.829 0.829 0.834 0.844 0.855 0.863 0.866 0.866 0.868 0.871 0.875 0.881 0.887 0.894 0.902 0.91 0.915 0.92 0.923 0.923 0.924
Islington 0.786 0.792 0.797 0.802 0.807 0.813 0.817 0.821 0.827 0.831 0.837 0.844 0.851 0.858 0.864 0.869 0.873 0.877 0.882 0.888 0.894 0.898 0.902 0.905 0.909 0.912 0.915 0.919 0.922 0.925 0.927 0.93 0.932 0.934 0.936 0.938 0.94
Tower Hamlets 0.727 0.732 0.736 0.74 0.747 0.757 0.768 0.777 0.785 0.79 0.794 0.797 0.801 0.805 0.809 0.813 0.819 0.826 0.834 0.847 0.859 0.869 0.876 0.88 0.885 0.891 0.896 0.902 0.907 0.912 0.916 0.919 0.924 0.927 0.929 0.931 0.933
Wokingham 0.758 0.763 0.768 0.773 0.778 0.784 0.79 0.796 0.803 0.806 0.809 0.81 0.812 0.815 0.817 0.82 0.824 0.829 0.836 0.846 0.857 0.865 0.87 0.872 0.875 0.879 0.881 0.883 0.884 0.883 0.882 0.88 0.882 0.887 0.891 0.893 0.895
Buckinghamshire 0.74 0.746 0.752 0.758 0.763 0.768 0.773 0.776 0.781 0.786 0.79 0.795 0.801 0.806 0.812 0.818 0.823 0.828 0.834 0.839 0.845 0.849 0.85 0.851 0.854 0.856 0.856 0.856 0.856 0.856 0.858 0.861 0.865 0.869 0.872 0.873 0.874
Surrey 0.749 0.755 0.76 0.764 0.767 0.77 0.773 0.775 0.781 0.787 0.793 0.8 0.806 0.811 0.816 0.821 0.825 0.831 0.837 0.846 0.854 0.859 0.861 0.863 0.865 0.866 0.867 0.868 0.869 0.87 0.871 0.872 0.875 0.88 0.882 0.884 0.886
Windsor and Maidenhead 0.76 0.766 0.77 0.774 0.776 0.779 0.782 0.783 0.786 0.79 0.799 0.809 0.817 0.824 0.83 0.837 0.841 0.846 0.85 0.856 0.861 0.865 0.868 0.872 0.876 0.879 0.88 0.881 0.883 0.884 0.885 0.888 0.891 0.896 0.9 0.903 0.905
West Berkshire 0.755 0.76 0.765 0.77 0.774 0.78 0.786 0.791 0.798 0.803 0.809 0.814 0.82 0.827 0.833 0.838 0.842 0.846 0.851 0.858 0.865 0.868 0.869 0.869 0.869 0.869 0.866 0.863 0.862 0.863 0.868 0.873 0.878 0.883 0.885 0.886 0.887
Hampshire 0.725 0.731 0.737 0.742 0.747 0.752 0.756 0.76 0.766 0.771 0.776 0.781 0.786 0.791 0.797 0.803 0.808 0.813 0.819 0.824 0.83 0.834 0.836 0.837 0.839 0.841 0.842 0.842 0.844 0.845 0.847 0.85 0.855 0.859 0.862 0.864 0.866
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Appendix Table 9: Socio-demographic Index values for all estimated GBD 2016 locations, 1980–2016
0.733 0.74 0.746 0.753 0.76 0.766 0.771 0.777 0.784 0.791 0.796 0.799 0.804 0.808 0.814 0.82 0.824 0.828 0.833 0.842 0.849 0.855 0.858 0.86 0.863 0.866 0.868 0.87 0.871 0.872 0.873 0.875 0.878 0.882 0.885 0.887 0.888
0.72 0.726 0.731 0.737 0.741 0.746 0.75 0.753 0.759 0.764 0.769 0.774 0.78 0.786 0.792 0.797 0.803 0.808 0.814 0.819 0.824 0.827 0.828 0.829 0.831 0.832 0.834 0.835 0.836 0.838 0.841 0.844 0.847 0.852 0.854 0.855 0.856
0.745 0.751 0.757 0.762 0.767 0.773 0.778 0.782 0.786 0.79 0.794 0.799 0.805 0.81 0.816 0.822 0.827 0.832 0.838 0.845 0.851 0.856 0.858 0.86 0.863 0.865 0.866 0.866 0.867 0.868 0.87 0.874 0.879 0.884 0.887 0.889 0.89
0.753 0.759 0.764 0.769 0.772 0.775 0.779 0.783 0.79 0.798 0.806 0.815 0.822 0.827 0.832 0.837 0.842 0.847 0.853 0.861 0.869 0.876 0.88 0.882 0.885 0.886 0.884 0.883 0.884 0.886 0.89 0.893 0.897 0.901 0.904 0.905 0.906
0.71 0.716 0.721 0.726 0.729 0.733 0.736 0.74 0.745 0.75 0.755 0.76 0.765 0.771 0.776 0.781 0.786 0.791 0.797 0.803 0.808 0.812 0.815 0.816 0.819 0.822 0.823 0.824 0.826 0.827 0.829 0.832 0.835 0.839 0.842 0.844 0.845
0.73 0.735 0.74 0.743 0.745 0.748 0.751 0.755 0.763 0.771 0.781 0.79 0.797 0.803 0.808 0.813 0.819 0.824 0.829 0.834 0.839 0.845 0.851 0.857 0.862 0.867 0.872 0.874 0.877 0.88 0.884 0.887 0.889 0.891 0.894 0.896 0.899
0.686 0.691 0.697 0.701 0.706 0.71 0.715 0.72 0.727 0.733 0.738 0.744 0.749 0.753 0.758 0.763 0.769 0.774 0.78 0.785 0.791 0.796 0.799 0.801 0.804 0.807 0.81 0.811 0.813 0.813 0.815 0.816 0.82 0.824 0.827 0.829 0.831
0.696 0.702 0.708 0.713 0.718 0.723 0.728 0.732 0.737 0.742 0.746 0.75 0.755 0.759 0.765 0.77 0.776 0.781 0.786 0.791 0.796 0.799 0.8 0.801 0.803 0.806 0.807 0.808 0.809 0.81 0.813 0.817 0.821 0.826 0.83 0.832 0.834
0.728 0.734 0.74 0.744 0.746 0.748 0.751 0.754 0.76 0.768 0.776 0.784 0.791 0.797 0.802 0.806 0.81 0.815 0.821 0.828 0.836 0.843 0.849 0.853 0.858 0.861 0.864 0.867 0.869 0.87 0.87 0.868 0.869 0.871 0.873 0.876 0.878
0.695 0.7 0.706 0.71 0.714 0.719 0.724 0.73 0.737 0.741 0.744 0.746 0.748 0.751 0.756 0.762 0.768 0.774 0.78 0.787 0.795 0.804 0.809 0.811 0.812 0.813 0.814 0.816 0.818 0.819 0.821 0.823 0.826 0.829 0.831 0.833 0.835
0.757 0.761 0.762 0.762 0.763 0.768 0.775 0.783 0.79 0.795 0.796 0.799 0.804 0.811 0.818 0.825 0.83 0.835 0.839 0.843 0.847 0.85 0.85 0.85 0.853 0.855 0.856 0.855 0.855 0.856 0.862 0.868 0.873 0.878 0.88 0.88 0.88
0.728 0.734 0.739 0.743 0.746 0.748 0.749 0.75 0.754 0.761 0.771 0.782 0.79 0.798 0.804 0.81 0.814 0.819 0.825 0.832 0.84 0.845 0.849 0.854 0.858 0.863 0.866 0.868 0.869 0.868 0.867 0.866 0.867 0.871 0.874 0.876 0.878
0.749 0.753 0.756 0.757 0.759 0.762 0.766 0.771 0.779 0.787 0.795 0.805 0.812 0.818 0.824 0.83 0.836 0.84 0.844 0.847 0.852 0.855 0.854 0.851 0.848 0.846 0.843 0.845 0.85 0.855 0.861 0.866 0.871 0.874 0.875 0.874 0.873
0.731 0.737 0.742 0.747 0.751 0.756 0.762 0.767 0.774 0.779 0.783 0.787 0.791 0.795 0.799 0.803 0.809 0.816 0.824 0.832 0.839 0.844 0.846 0.848 0.851 0.855 0.858 0.861 0.865 0.866 0.867 0.868 0.871 0.875 0.878 0.88 0.882
0.704 0.71 0.715 0.721 0.726 0.731 0.737 0.742 0.747 0.752 0.754 0.757 0.762 0.768 0.775 0.781 0.788 0.794 0.801 0.807 0.811 0.813 0.814 0.813 0.815 0.816 0.815 0.814 0.814 0.816 0.821 0.827 0.833 0.837 0.839 0.841 0.842
0.713 0.719 0.725 0.731 0.736 0.741 0.746 0.75 0.756 0.761 0.766 0.77 0.775 0.781 0.787 0.793 0.798 0.804 0.81 0.815 0.821 0.825 0.826 0.827 0.829 0.829 0.828 0.826 0.825 0.826 0.83 0.835 0.84 0.844 0.846 0.846 0.847
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West Sussex
Oxfordshire
Reading
Kent
Brighton and Hove 
Medway
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Isle of Wight
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Hawaii 0.843 0.844 0.845 0.848 0.85 0.852 0.855 0.855 0.854 0.853 0.854 0.857 0.86 0.863 0.866 0.869 0.872 0.874 0.875 0.875 0.875 0.876 0.874 0.873 0.874 0.875 0.875 0.877 0.881 0.885 0.889 0.891 0.894 0.896 0.898 0.9 0.901
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Appendix Table 9: Socio-demographic Index values for all estimated GBD 2016 locations, 1980–2016
Idaho 0.809 0.813 0.816 0.822 0.825 0.829 0.833 0.834 0.834 0.832 0.833 0.835 0.837 0.84 0.842 0.845 0.846 0.847 0.848 0.849 0.851 0.854 0.854 0.854 0.855 0.854 0.853 0.854 0.859 0.864 0.867 0.869 0.87 0.871 0.872 0.872 0.872
Illinois 0.843 0.846 0.849 0.852 0.854 0.856 0.857 0.858 0.856 0.855 0.856 0.858 0.86 0.863 0.866 0.868 0.871 0.872 0.874 0.875 0.878 0.881 0.883 0.884 0.886 0.888 0.888 0.891 0.895 0.899 0.902 0.903 0.905 0.906 0.907 0.908 0.908
Indiana 0.833 0.837 0.84 0.843 0.844 0.846 0.848 0.849 0.848 0.847 0.848 0.85 0.853 0.855 0.858 0.859 0.86 0.86 0.86 0.861 0.863 0.866 0.867 0.867 0.869 0.869 0.868 0.869 0.872 0.875 0.878 0.879 0.88 0.881 0.882 0.883 0.883
Iowa 0.834 0.838 0.842 0.845 0.848 0.85 0.853 0.854 0.854 0.853 0.854 0.856 0.858 0.86 0.862 0.864 0.865 0.866 0.867 0.868 0.87 0.873 0.874 0.875 0.876 0.876 0.874 0.876 0.88 0.884 0.887 0.888 0.89 0.891 0.891 0.892 0.893
Kansas 0.835 0.839 0.842 0.846 0.848 0.851 0.854 0.855 0.856 0.855 0.857 0.859 0.861 0.862 0.864 0.865 0.866 0.866 0.866 0.866 0.868 0.871 0.873 0.874 0.875 0.875 0.874 0.875 0.879 0.883 0.886 0.888 0.89 0.892 0.893 0.895 0.895
Kentucky 0.805 0.81 0.814 0.818 0.821 0.824 0.827 0.828 0.828 0.829 0.83 0.833 0.836 0.839 0.841 0.843 0.845 0.846 0.847 0.849 0.851 0.855 0.856 0.857 0.858 0.858 0.857 0.859 0.862 0.865 0.868 0.869 0.87 0.87 0.871 0.873 0.874
Louisiana 0.796 0.801 0.806 0.811 0.814 0.817 0.82 0.822 0.822 0.822 0.824 0.827 0.83 0.833 0.837 0.84 0.842 0.844 0.846 0.847 0.85 0.854 0.856 0.857 0.86 0.86 0.861 0.864 0.869 0.873 0.876 0.878 0.88 0.882 0.883 0.885 0.885
Maine 0.832 0.834 0.836 0.839 0.841 0.844 0.848 0.85 0.853 0.855 0.858 0.862 0.866 0.869 0.872 0.874 0.876 0.877 0.878 0.88 0.882 0.885 0.886 0.887 0.889 0.89 0.891 0.893 0.896 0.899 0.901 0.902 0.902 0.903 0.904 0.905 0.906
Maryland 0.865 0.867 0.868 0.87 0.871 0.872 0.875 0.875 0.875 0.875 0.877 0.88 0.883 0.886 0.889 0.891 0.892 0.892 0.892 0.893 0.895 0.897 0.899 0.899 0.901 0.902 0.901 0.903 0.907 0.912 0.915 0.917 0.919 0.92 0.92 0.921 0.92
Massachusetts 0.865 0.868 0.871 0.874 0.877 0.88 0.882 0.884 0.886 0.886 0.889 0.892 0.895 0.897 0.9 0.902 0.904 0.905 0.906 0.907 0.91 0.913 0.915 0.916 0.918 0.919 0.919 0.921 0.923 0.926 0.928 0.929 0.931 0.932 0.933 0.935 0.935
Michigan 0.845 0.847 0.849 0.852 0.853 0.855 0.857 0.857 0.856 0.854 0.855 0.858 0.861 0.864 0.867 0.87 0.871 0.872 0.873 0.875 0.877 0.88 0.882 0.883 0.886 0.887 0.887 0.888 0.89 0.891 0.892 0.893 0.893 0.894 0.895 0.896 0.897
Minnesota 0.839 0.844 0.848 0.852 0.856 0.859 0.863 0.866 0.867 0.868 0.87 0.873 0.875 0.877 0.879 0.88 0.882 0.882 0.883 0.884 0.886 0.889 0.89 0.89 0.891 0.891 0.89 0.892 0.896 0.9 0.903 0.904 0.905 0.906 0.907 0.909 0.909
Mississippi 0.784 0.789 0.794 0.799 0.803 0.806 0.81 0.811 0.811 0.811 0.813 0.816 0.82 0.824 0.828 0.831 0.833 0.835 0.836 0.838 0.841 0.845 0.847 0.848 0.848 0.847 0.846 0.848 0.853 0.859 0.864 0.867 0.869 0.871 0.872 0.873 0.874
Missouri 0.826 0.83 0.833 0.837 0.839 0.842 0.845 0.846 0.846 0.846 0.847 0.85 0.853 0.856 0.859 0.86 0.862 0.863 0.864 0.865 0.868 0.871 0.872 0.873 0.875 0.875 0.874 0.876 0.879 0.883 0.886 0.887 0.888 0.89 0.891 0.892 0.893
Montana 0.829 0.831 0.834 0.837 0.838 0.84 0.843 0.845 0.844 0.844 0.845 0.847 0.849 0.852 0.855 0.858 0.86 0.862 0.863 0.865 0.866 0.868 0.869 0.869 0.872 0.872 0.873 0.875 0.879 0.882 0.885 0.886 0.888 0.889 0.891 0.892 0.893
Nebraska 0.832 0.835 0.838 0.842 0.845 0.848 0.852 0.853 0.854 0.853 0.855 0.858 0.86 0.862 0.863 0.865 0.866 0.867 0.867 0.867 0.868 0.87 0.87 0.871 0.873 0.873 0.871 0.873 0.877 0.881 0.884 0.886 0.888 0.888 0.889 0.89 0.89
Nevada 0.855 0.857 0.858 0.86 0.86 0.86 0.86 0.857 0.854 0.85 0.85 0.853 0.855 0.857 0.858 0.859 0.861 0.862 0.862 0.863 0.865 0.868 0.868 0.868 0.869 0.867 0.865 0.868 0.875 0.882 0.887 0.889 0.889 0.889 0.888 0.887 0.886
New Hampshire 0.852 0.856 0.859 0.862 0.864 0.866 0.869 0.871 0.873 0.876 0.879 0.882 0.885 0.887 0.889 0.891 0.893 0.894 0.896 0.897 0.9 0.903 0.904 0.905 0.908 0.91 0.911 0.914 0.916 0.919 0.921 0.922 0.924 0.926 0.928 0.93 0.931
New Jersey 0.858 0.861 0.864 0.867 0.868 0.87 0.872 0.873 0.873 0.873 0.875 0.878 0.881 0.883 0.885 0.887 0.889 0.891 0.891 0.892 0.894 0.896 0.896 0.897 0.899 0.9 0.899 0.9 0.904 0.908 0.912 0.914 0.915 0.916 0.917 0.918 0.918
New Mexico 0.809 0.812 0.814 0.818 0.819 0.822 0.825 0.826 0.826 0.824 0.825 0.826 0.829 0.832 0.835 0.838 0.841 0.843 0.844 0.845 0.847 0.85 0.852 0.852 0.854 0.855 0.855 0.858 0.862 0.867 0.871 0.873 0.875 0.877 0.879 0.88 0.881
New York 0.854 0.856 0.858 0.861 0.862 0.864 0.866 0.866 0.866 0.866 0.868 0.871 0.874 0.877 0.879 0.882 0.885 0.887 0.888 0.89 0.892 0.895 0.896 0.897 0.899 0.899 0.899 0.901 0.904 0.907 0.91 0.912 0.915 0.916 0.918 0.919 0.92
North Carolina 0.825 0.829 0.832 0.835 0.837 0.84 0.842 0.842 0.842 0.841 0.844 0.848 0.851 0.855 0.858 0.86 0.86 0.86 0.86 0.86 0.861 0.865 0.867 0.868 0.869 0.868 0.866 0.868 0.873 0.878 0.883 0.885 0.886 0.886 0.887 0.887 0.887
North Dakota 0.816 0.818 0.822 0.827 0.83 0.835 0.839 0.842 0.842 0.843 0.846 0.848 0.85 0.852 0.854 0.857 0.86 0.863 0.866 0.869 0.871 0.874 0.874 0.875 0.875 0.874 0.872 0.874 0.879 0.883 0.887 0.888 0.891 0.892 0.893 0.895 0.896
Ohio 0.838 0.841 0.844 0.847 0.848 0.85 0.853 0.853 0.853 0.852 0.854 0.856 0.858 0.86 0.863 0.865 0.866 0.866 0.867 0.868 0.87 0.874 0.875 0.876 0.878 0.879 0.879 0.88 0.883 0.885 0.887 0.888 0.889 0.89 0.891 0.892 0.893
Oklahoma 0.82 0.824 0.828 0.833 0.836 0.84 0.843 0.844 0.843 0.842 0.843 0.844 0.846 0.847 0.848 0.849 0.849 0.849 0.85 0.85 0.853 0.856 0.857 0.858 0.86 0.861 0.861 0.862 0.866 0.869 0.872 0.874 0.877 0.879 0.88 0.882 0.883
Oregon 0.85 0.852 0.854 0.857 0.857 0.858 0.859 0.858 0.857 0.856 0.857 0.86 0.863 0.866 0.868 0.869 0.87 0.871 0.873 0.875 0.878 0.882 0.884 0.885 0.887 0.887 0.886 0.887 0.89 0.894 0.897 0.898 0.899 0.9 0.901 0.903 0.903
Pennsylvania 0.842 0.845 0.847 0.85 0.851 0.853 0.855 0.856 0.856 0.856 0.858 0.861 0.864 0.867 0.87 0.873 0.875 0.877 0.878 0.879 0.881 0.884 0.885 0.885 0.887 0.887 0.887 0.888 0.892 0.896 0.899 0.9 0.902 0.904 0.905 0.907 0.908
Rhode Island 0.847 0.851 0.853 0.857 0.859 0.861 0.863 0.864 0.865 0.865 0.867 0.87 0.873 0.877 0.88 0.883 0.885 0.886 0.887 0.889 0.89 0.893 0.894 0.895 0.898 0.9 0.9 0.902 0.906 0.909 0.912 0.913 0.915 0.916 0.918 0.92 0.921
South Carolina 0.814 0.818 0.821 0.825 0.828 0.83 0.833 0.833 0.832 0.831 0.834 0.839 0.844 0.849 0.853 0.855 0.856 0.857 0.857 0.858 0.86 0.864 0.866 0.866 0.866 0.864 0.862 0.863 0.868 0.874 0.879 0.881 0.883 0.884 0.884 0.885 0.886
South Dakota 0.806 0.81 0.814 0.818 0.822 0.825 0.83 0.832 0.832 0.832 0.834 0.836 0.839 0.842 0.846 0.849 0.852 0.853 0.855 0.857 0.859 0.861 0.861 0.862 0.863 0.862 0.861 0.863 0.868 0.872 0.876 0.877 0.878 0.879 0.88 0.881 0.882
Tennessee 0.818 0.822 0.825 0.829 0.831 0.833 0.836 0.836 0.836 0.835 0.837 0.841 0.844 0.848 0.851 0.853 0.855 0.856 0.857 0.858 0.861 0.864 0.866 0.866 0.867 0.867 0.865 0.867 0.871 0.875 0.879 0.88 0.882 0.882 0.883 0.884 0.885
Texas 0.815 0.819 0.823 0.827 0.829 0.831 0.834 0.834 0.834 0.832 0.832 0.834 0.835 0.837 0.839 0.84 0.842 0.843 0.843 0.844 0.846 0.849 0.85 0.851 0.853 0.853 0.853 0.855 0.86 0.866 0.87 0.873 0.875 0.876 0.877 0.878 0.878
Utah 0.779 0.786 0.794 0.803 0.809 0.814 0.819 0.82 0.82 0.819 0.822 0.827 0.831 0.833 0.834 0.835 0.834 0.834 0.834 0.836 0.839 0.843 0.846 0.847 0.849 0.849 0.848 0.85 0.855 0.859 0.863 0.864 0.866 0.867 0.869 0.87 0.87
Vermont 0.843 0.846 0.848 0.851 0.853 0.855 0.859 0.861 0.863 0.866 0.869 0.872 0.876 0.879 0.882 0.885 0.887 0.889 0.89 0.893 0.895 0.898 0.899 0.9 0.902 0.904 0.905 0.907 0.909 0.912 0.913 0.915 0.916 0.917 0.918 0.919 0.92
Virginia 0.849 0.852 0.855 0.858 0.86 0.862 0.864 0.866 0.866 0.867 0.868 0.871 0.874 0.877 0.88 0.882 0.883 0.883 0.884 0.884 0.885 0.888 0.888 0.888 0.89 0.891 0.891 0.894 0.899 0.903 0.907 0.909 0.91 0.911 0.912 0.913 0.913
Washington 0.857 0.859 0.862 0.865 0.866 0.867 0.869 0.869 0.868 0.867 0.868 0.87 0.873 0.876 0.878 0.88 0.882 0.883 0.885 0.887 0.891 0.894 0.896 0.896 0.898 0.897 0.896 0.897 0.899 0.902 0.904 0.906 0.907 0.908 0.91 0.911 0.912
West Virginia 0.809 0.813 0.818 0.822 0.824 0.827 0.83 0.831 0.831 0.83 0.832 0.834 0.837 0.84 0.843 0.845 0.847 0.849 0.85 0.851 0.852 0.854 0.856 0.857 0.859 0.859 0.859 0.859 0.862 0.865 0.867 0.869 0.87 0.872 0.873 0.875 0.876
Wisconsin 0.836 0.839 0.842 0.845 0.847 0.85 0.853 0.855 0.856 0.857 0.859 0.861 0.864 0.867 0.869 0.871 0.873 0.874 0.875 0.876 0.878 0.88 0.881 0.882 0.884 0.884 0.884 0.885 0.888 0.892 0.894 0.895 0.897 0.898 0.899 0.901 0.902
Wyoming 0.824 0.827 0.83 0.835 0.837 0.842 0.847 0.85 0.851 0.851 0.852 0.854 0.857 0.86 0.863 0.865 0.867 0.868 0.871 0.874 0.876 0.878 0.878 0.878 0.878 0.877 0.877 0.879 0.886 0.893 0.898 0.901 0.902 0.903 0.904 0.905 0.905
Latin America and Caribbean 0.467 0.477 0.486 0.494 0.503 0.511 0.519 0.526 0.533 0.54 0.546 0.554 0.561 0.568 0.575 0.581 0.588 0.595 0.602 0.608 0.615 0.621 0.627 0.632 0.638 0.643 0.649 0.655 0.661 0.666 0.672 0.678 0.684 0.689 0.695 0.7 0.705
Caribbean 0.532 0.538 0.543 0.551 0.557 0.563 0.569 0.573 0.578 0.583 0.588 0.594 0.599 0.602 0.605 0.608 0.61 0.613 0.617 0.621 0.626 0.631 0.635 0.64 0.645 0.651 0.656 0.66 0.663 0.667 0.671 0.675 0.679 0.683 0.688 0.692 0.696
Antigua and Barbuda 0.611 0.619 0.627 0.634 0.64 0.647 0.654 0.662 0.67 0.678 0.684 0.691 0.696 0.7 0.704 0.707 0.71 0.713 0.716 0.719 0.722 0.723 0.725 0.728 0.731 0.735 0.74 0.746 0.752 0.756 0.759 0.761 0.765 0.767 0.771 0.774 0.778
The Bahamas 0.659 0.666 0.674 0.681 0.689 0.697 0.704 0.709 0.713 0.716 0.719 0.72 0.721 0.722 0.724 0.728 0.733 0.739 0.745 0.751 0.757 0.761 0.765 0.767 0.769 0.77 0.771 0.773 0.774 0.775 0.775 0.776 0.777 0.779 0.78 0.781 0.783
Barbados 0.662 0.668 0.673 0.679 0.685 0.691 0.699 0.706 0.713 0.72 0.726 0.732 0.737 0.741 0.744 0.748 0.751 0.755 0.759 0.762 0.766 0.769 0.771 0.772 0.773 0.776 0.779 0.782 0.784 0.786 0.788 0.789 0.79 0.791 0.793 0.795 0.797
Belize 0.344 0.348 0.353 0.36 0.369 0.379 0.391 0.404 0.419 0.435 0.452 0.469 0.487 0.502 0.515 0.525 0.532 0.537 0.542 0.546 0.552 0.557 0.563 0.569 0.574 0.58 0.585 0.589 0.593 0.596 0.6 0.604 0.608 0.612 0.617 0.621 0.625
Cuba 0.631 0.634 0.637 0.645 0.65 0.658 0.666 0.668 0.673 0.679 0.685 0.693 0.698 0.697 0.696 0.695 0.695 0.692 0.693 0.694 0.697 0.701 0.705 0.712 0.719 0.725 0.732 0.739 0.739 0.743 0.747 0.751 0.757 0.761 0.766 0.772 0.778
Dominica 0.529 0.534 0.541 0.548 0.556 0.563 0.57 0.577 0.584 0.59 0.596 0.6 0.605 0.612 0.62 0.629 0.637 0.645 0.653 0.659 0.665 0.67 0.674 0.678 0.682 0.686 0.69 0.695 0.701 0.705 0.71 0.714 0.718 0.721 0.725 0.729 0.734
Dominican Republic 0.435 0.449 0.463 0.477 0.49 0.499 0.506 0.513 0.519 0.524 0.527 0.53 0.535 0.54 0.545 0.551 0.558 0.566 0.574 0.582 0.589 0.596 0.603 0.609 0.615 0.622 0.629 0.637 0.643 0.649 0.656 0.662 0.668 0.675 0.682 0.69 0.696
Grenada 0.442 0.448 0.453 0.458 0.463 0.468 0.473 0.479 0.485 0.492 0.5 0.51 0.519 0.527 0.536 0.544 0.552 0.561 0.571 0.581 0.591 0.6 0.609 0.618 0.627 0.637 0.646 0.654 0.662 0.668 0.674 0.679 0.684 0.688 0.694 0.699 0.704
Guyana 0.496 0.503 0.509 0.514 0.517 0.518 0.519 0.519 0.519 0.518 0.517 0.518 0.52 0.525 0.53 0.537 0.545 0.552 0.559 0.565 0.569 0.573 0.576 0.579 0.582 0.584 0.587 0.592 0.596 0.601 0.607 0.614 0.621 0.628 0.636 0.643 0.649
Haiti 0.257 0.261 0.264 0.267 0.271 0.275 0.279 0.284 0.29 0.297 0.303 0.31 0.315 0.319 0.321 0.325 0.329 0.334 0.339 0.346 0.352 0.358 0.363 0.368 0.372 0.376 0.381 0.386 0.391 0.397 0.402 0.407 0.413 0.418 0.424 0.428 0.432
Jamaica 0.557 0.563 0.568 0.573 0.578 0.58 0.583 0.587 0.591 0.595 0.599 0.604 0.609 0.615 0.62 0.625 0.629 0.633 0.636 0.64 0.643 0.647 0.651 0.655 0.659 0.664 0.669 0.674 0.679 0.682 0.685 0.688 0.691 0.694 0.696 0.699 0.701
Saint Lucia 0.453 0.464 0.473 0.482 0.492 0.502 0.513 0.523 0.534 0.544 0.555 0.565 0.574 0.583 0.591 0.598 0.606 0.614 0.621 0.629 0.635 0.641 0.647 0.654 0.662 0.668 0.674 0.679 0.684 0.689 0.693 0.697 0.7 0.703 0.707 0.71 0.713
Saint Vincent and the Grenadines 0.418 0.428 0.438 0.449 0.46 0.471 0.48 0.489 0.499 0.508 0.516 0.524 0.533 0.541 0.547 0.555 0.562 0.569 0.576 0.583 0.589 0.595 0.602 0.608 0.615 0.621 0.627 0.633 0.638 0.642 0.645 0.648 0.651 0.655 0.659 0.663 0.667
Suriname 0.51 0.515 0.519 0.524 0.528 0.535 0.541 0.546 0.553 0.56 0.566 0.569 0.572 0.574 0.575 0.577 0.58 0.583 0.587 0.589 0.592 0.597 0.601 0.607 0.614 0.621 0.628 0.636 0.643 0.651 0.659 0.666 0.673 0.68 0.686 0.691 0.696
Trinidad and Tobago 0.592 0.595 0.599 0.603 0.608 0.615 0.624 0.633 0.642 0.649 0.655 0.659 0.663 0.666 0.668 0.669 0.671 0.675 0.68 0.687 0.694 0.7 0.706 0.713 0.719 0.725 0.731 0.738 0.745 0.75 0.755 0.758 0.76 0.762 0.764 0.765 0.766
Bermuda 0.68 0.687 0.692 0.698 0.703 0.708 0.713 0.719 0.724 0.729 0.733 0.737 0.741 0.745 0.749 0.752 0.756 0.76 0.763 0.767 0.77 0.774 0.777 0.781 0.785 0.789 0.793 0.796 0.799 0.801 0.803 0.806 0.808 0.811 0.813 0.816 0.819
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Appendix Table 9: Socio-demographic Index values for all estimated GBD 2016 locations, 1980–2016
Puerto Rico 0.699 0.71 0.719 0.727 0.733 0.739 0.743 0.748 0.753 0.76 0.767 0.774 0.781 0.788 0.793 0.799 0.805 0.81 0.817 0.822 0.828 0.834 0.84 0.845 0.85 0.854 0.858 0.86 0.863 0.864 0.866 0.867 0.868 0.87 0.871 0.873 0.875
Virgin Islands, U.S. 0.723 0.732 0.738 0.743 0.749 0.755 0.76 0.764 0.767 0.771 0.777 0.782 0.789 0.796 0.802 0.808 0.814 0.82 0.825 0.829 0.833 0.836 0.839 0.842 0.845 0.85 0.855 0.861 0.864 0.868 0.871 0.874 0.875 0.876 0.876 0.877 0.877
Andean Latin America 0.45 0.457 0.465 0.473 0.481 0.488 0.496 0.504 0.511 0.518 0.524 0.53 0.536 0.541 0.548 0.555 0.561 0.568 0.575 0.582 0.588 0.594 0.6 0.605 0.61 0.615 0.62 0.625 0.63 0.635 0.64 0.644 0.649 0.653 0.657 0.662 0.666
Bolivia 0.354 0.361 0.368 0.376 0.383 0.39 0.397 0.405 0.412 0.418 0.425 0.432 0.439 0.446 0.453 0.461 0.469 0.477 0.485 0.494 0.502 0.51 0.518 0.525 0.531 0.539 0.546 0.553 0.56 0.567 0.573 0.58 0.586 0.593 0.599 0.605 0.61
Ecuador 0.45 0.458 0.467 0.475 0.484 0.493 0.501 0.509 0.516 0.523 0.53 0.537 0.543 0.55 0.556 0.563 0.569 0.576 0.583 0.588 0.593 0.598 0.603 0.608 0.613 0.619 0.624 0.629 0.635 0.64 0.645 0.65 0.655 0.66 0.665 0.67 0.674
Peru 0.478 0.485 0.493 0.5 0.507 0.514 0.521 0.529 0.537 0.543 0.548 0.553 0.558 0.563 0.569 0.576 0.582 0.59 0.597 0.603 0.61 0.615 0.621 0.626 0.63 0.634 0.639 0.644 0.648 0.652 0.656 0.66 0.663 0.666 0.67 0.674 0.678
Central Latin America 0.466 0.476 0.485 0.493 0.502 0.51 0.518 0.525 0.531 0.537 0.544 0.551 0.56 0.568 0.575 0.581 0.588 0.595 0.602 0.609 0.615 0.622 0.627 0.633 0.639 0.645 0.652 0.659 0.665 0.671 0.676 0.682 0.689 0.695 0.701 0.707 0.711
Colombia 0.485 0.493 0.5 0.506 0.513 0.519 0.526 0.532 0.538 0.544 0.55 0.556 0.562 0.568 0.574 0.581 0.588 0.595 0.601 0.606 0.611 0.616 0.62 0.624 0.629 0.634 0.639 0.645 0.652 0.658 0.664 0.672 0.679 0.686 0.694 0.701 0.707
Costa Rica 0.527 0.532 0.535 0.537 0.539 0.541 0.546 0.552 0.557 0.563 0.57 0.577 0.584 0.591 0.598 0.603 0.608 0.614 0.62 0.627 0.634 0.64 0.646 0.651 0.657 0.662 0.668 0.674 0.679 0.685 0.691 0.697 0.704 0.71 0.716 0.722 0.726
El Salvador 0.383 0.392 0.401 0.408 0.414 0.419 0.424 0.429 0.434 0.439 0.444 0.451 0.458 0.465 0.472 0.48 0.488 0.496 0.504 0.513 0.521 0.529 0.537 0.545 0.552 0.56 0.568 0.576 0.584 0.592 0.6 0.609 0.617 0.625 0.632 0.639 0.645
Guatemala 0.325 0.33 0.335 0.338 0.342 0.345 0.348 0.351 0.355 0.36 0.365 0.37 0.376 0.383 0.389 0.396 0.404 0.412 0.42 0.429 0.438 0.446 0.455 0.463 0.472 0.48 0.489 0.498 0.506 0.514 0.522 0.53 0.537 0.543 0.55 0.556 0.561
Honduras 0.295 0.304 0.313 0.321 0.329 0.337 0.345 0.353 0.362 0.372 0.381 0.39 0.4 0.409 0.418 0.427 0.435 0.443 0.451 0.459 0.466 0.474 0.481 0.488 0.495 0.502 0.508 0.515 0.522 0.527 0.533 0.539 0.545 0.551 0.556 0.562 0.567
Mexico 0.458 0.47 0.481 0.491 0.501 0.511 0.521 0.53 0.538 0.547 0.555 0.564 0.573 0.582 0.591 0.598 0.606 0.614 0.622 0.629 0.637 0.644 0.651 0.657 0.664 0.671 0.678 0.684 0.691 0.695 0.701 0.706 0.712 0.718 0.723 0.729 0.734
Nicaragua 0.409 0.412 0.415 0.418 0.421 0.424 0.427 0.43 0.431 0.433 0.434 0.436 0.438 0.44 0.443 0.447 0.453 0.459 0.466 0.473 0.481 0.488 0.496 0.502 0.509 0.516 0.523 0.53 0.537 0.543 0.549 0.555 0.562 0.569 0.576 0.583 0.588
Panama 0.542 0.552 0.56 0.568 0.574 0.581 0.588 0.594 0.597 0.6 0.603 0.607 0.611 0.615 0.62 0.624 0.628 0.633 0.64 0.647 0.653 0.66 0.666 0.67 0.674 0.679 0.683 0.688 0.693 0.698 0.704 0.71 0.718 0.726 0.735 0.744 0.752
Venezuela 0.533 0.54 0.547 0.557 0.568 0.577 0.583 0.588 0.594 0.592 0.59 0.602 0.619 0.628 0.629 0.632 0.637 0.642 0.647 0.65 0.654 0.657 0.66 0.662 0.667 0.673 0.681 0.688 0.696 0.702 0.708 0.714 0.721 0.728 0.734 0.738 0.742
Aguascalientes 0.49 0.502 0.512 0.521 0.53 0.538 0.548 0.558 0.567 0.576 0.586 0.597 0.608 0.617 0.624 0.631 0.639 0.648 0.656 0.663 0.67 0.675 0.681 0.687 0.693 0.699 0.705 0.711 0.715 0.719 0.723 0.728 0.733 0.739 0.744 0.749 0.754
Baja California 0.523 0.536 0.548 0.56 0.572 0.585 0.597 0.608 0.617 0.624 0.629 0.635 0.642 0.65 0.658 0.666 0.672 0.676 0.68 0.687 0.695 0.703 0.709 0.713 0.715 0.718 0.722 0.728 0.735 0.74 0.745 0.751 0.758 0.764 0.769 0.773 0.776
Baja California Sur 0.535 0.547 0.559 0.571 0.584 0.596 0.605 0.615 0.627 0.635 0.644 0.654 0.663 0.669 0.674 0.679 0.686 0.691 0.692 0.689 0.689 0.694 0.698 0.701 0.707 0.712 0.711 0.707 0.706 0.71 0.718 0.729 0.738 0.744 0.748 0.753 0.757
Campeche 0.437 0.449 0.459 0.468 0.477 0.485 0.494 0.503 0.511 0.52 0.53 0.541 0.551 0.56 0.567 0.574 0.582 0.593 0.603 0.614 0.625 0.635 0.643 0.651 0.658 0.665 0.671 0.677 0.682 0.685 0.688 0.693 0.7 0.707 0.713 0.72 0.726
Coahuila 0.499 0.512 0.523 0.533 0.543 0.552 0.562 0.572 0.582 0.593 0.605 0.617 0.63 0.64 0.649 0.656 0.663 0.671 0.679 0.685 0.691 0.697 0.702 0.708 0.714 0.72 0.726 0.733 0.739 0.743 0.747 0.751 0.754 0.758 0.761 0.766 0.77
Colima 0.472 0.485 0.496 0.506 0.517 0.528 0.54 0.553 0.565 0.579 0.591 0.604 0.616 0.625 0.632 0.638 0.645 0.652 0.659 0.666 0.672 0.678 0.683 0.689 0.695 0.7 0.706 0.712 0.716 0.719 0.723 0.727 0.732 0.737 0.742 0.748 0.753
Chiapas 0.3 0.313 0.323 0.332 0.338 0.342 0.345 0.345 0.342 0.339 0.342 0.355 0.375 0.393 0.41 0.427 0.444 0.459 0.472 0.483 0.491 0.499 0.508 0.517 0.527 0.536 0.546 0.555 0.563 0.57 0.577 0.585 0.593 0.6 0.608 0.616 0.622
Chihuahua 0.49 0.503 0.513 0.523 0.531 0.54 0.549 0.559 0.568 0.578 0.587 0.597 0.607 0.614 0.62 0.623 0.628 0.634 0.639 0.645 0.651 0.658 0.666 0.673 0.682 0.689 0.697 0.705 0.713 0.719 0.726 0.734 0.743 0.75 0.758 0.764 0.769
Distrito Federal 0.592 0.605 0.615 0.624 0.631 0.635 0.638 0.642 0.649 0.66 0.671 0.68 0.686 0.692 0.702 0.713 0.723 0.729 0.733 0.738 0.743 0.749 0.755 0.761 0.766 0.771 0.776 0.779 0.782 0.783 0.785 0.79 0.796 0.802 0.808 0.814 0.819
Durango 0.459 0.47 0.48 0.488 0.495 0.502 0.509 0.516 0.522 0.529 0.536 0.544 0.553 0.559 0.563 0.568 0.576 0.586 0.596 0.605 0.615 0.624 0.632 0.641 0.65 0.657 0.665 0.672 0.678 0.681 0.684 0.688 0.691 0.696 0.7 0.705 0.709
Guanajuato 0.384 0.396 0.407 0.417 0.427 0.437 0.448 0.461 0.472 0.485 0.497 0.511 0.524 0.534 0.543 0.551 0.562 0.573 0.583 0.593 0.603 0.611 0.619 0.627 0.634 0.642 0.65 0.658 0.666 0.671 0.677 0.683 0.688 0.694 0.7 0.706 0.711
Guerrero 0.355 0.367 0.378 0.387 0.395 0.404 0.413 0.423 0.431 0.437 0.441 0.444 0.445 0.442 0.438 0.439 0.445 0.454 0.464 0.473 0.483 0.494 0.505 0.517 0.529 0.54 0.551 0.562 0.57 0.577 0.585 0.595 0.606 0.617 0.626 0.634 0.639
Hidalgo 0.383 0.395 0.406 0.416 0.426 0.437 0.449 0.46 0.47 0.48 0.49 0.501 0.513 0.521 0.527 0.533 0.541 0.55 0.56 0.569 0.577 0.585 0.593 0.6 0.608 0.616 0.624 0.633 0.64 0.646 0.651 0.656 0.662 0.668 0.674 0.68 0.685
Jalisco 0.463 0.475 0.486 0.496 0.505 0.514 0.524 0.535 0.544 0.554 0.565 0.577 0.589 0.599 0.607 0.615 0.624 0.633 0.642 0.65 0.658 0.664 0.671 0.677 0.684 0.69 0.697 0.703 0.709 0.712 0.716 0.719 0.723 0.727 0.732 0.736 0.741
México 0.447 0.463 0.481 0.502 0.528 0.554 0.571 0.582 0.592 0.595 0.597 0.598 0.6 0.616 0.637 0.646 0.651 0.655 0.66 0.666 0.673 0.679 0.684 0.687 0.692 0.697 0.701 0.703 0.706 0.711 0.717 0.723 0.728 0.733 0.739 0.745 0.75
Michoacán de Ocampo 0.368 0.38 0.391 0.401 0.41 0.42 0.431 0.443 0.453 0.464 0.476 0.488 0.5 0.51 0.517 0.525 0.535 0.547 0.558 0.568 0.579 0.588 0.597 0.607 0.616 0.624 0.633 0.641 0.648 0.653 0.657 0.661 0.665 0.67 0.675 0.681 0.685
Morelos 0.479 0.492 0.503 0.513 0.523 0.533 0.543 0.554 0.564 0.576 0.587 0.599 0.611 0.62 0.627 0.634 0.64 0.647 0.653 0.659 0.664 0.67 0.675 0.68 0.686 0.692 0.698 0.705 0.71 0.714 0.718 0.722 0.726 0.73 0.734 0.737 0.741
Nayarit 0.428 0.442 0.454 0.464 0.473 0.482 0.491 0.501 0.511 0.522 0.533 0.545 0.557 0.567 0.575 0.582 0.592 0.602 0.612 0.621 0.63 0.638 0.645 0.652 0.658 0.664 0.67 0.675 0.679 0.683 0.687 0.692 0.698 0.705 0.711 0.718 0.723
Nuevo León 0.582 0.594 0.603 0.612 0.619 0.626 0.632 0.638 0.644 0.652 0.66 0.668 0.678 0.686 0.692 0.697 0.703 0.709 0.715 0.72 0.725 0.73 0.734 0.739 0.744 0.749 0.755 0.76 0.765 0.767 0.77 0.772 0.775 0.777 0.78 0.784 0.787
Oaxaca 0.351 0.362 0.371 0.38 0.388 0.396 0.406 0.417 0.427 0.437 0.446 0.456 0.466 0.471 0.474 0.476 0.481 0.487 0.494 0.501 0.508 0.515 0.523 0.533 0.544 0.555 0.568 0.581 0.592 0.601 0.609 0.617 0.623 0.629 0.634 0.639 0.643
Puebla 0.404 0.416 0.426 0.436 0.445 0.454 0.465 0.475 0.485 0.495 0.505 0.515 0.526 0.532 0.537 0.54 0.545 0.552 0.558 0.565 0.572 0.578 0.586 0.595 0.604 0.614 0.625 0.637 0.647 0.655 0.662 0.669 0.674 0.679 0.683 0.688 0.692
Querétaro 0.445 0.456 0.463 0.465 0.461 0.453 0.452 0.47 0.495 0.515 0.53 0.54 0.549 0.558 0.572 0.589 0.606 0.619 0.627 0.636 0.649 0.661 0.669 0.673 0.677 0.682 0.687 0.693 0.699 0.705 0.71 0.715 0.722 0.728 0.734 0.74 0.744
Quintana Roo 0.49 0.503 0.514 0.524 0.532 0.54 0.547 0.553 0.559 0.567 0.576 0.586 0.598 0.609 0.617 0.625 0.634 0.642 0.65 0.658 0.665 0.671 0.677 0.683 0.688 0.693 0.698 0.704 0.709 0.713 0.718 0.724 0.731 0.738 0.744 0.75 0.755
San Luis Potosí 0.375 0.39 0.403 0.414 0.425 0.436 0.449 0.462 0.474 0.487 0.5 0.513 0.526 0.536 0.544 0.552 0.561 0.572 0.583 0.593 0.604 0.613 0.622 0.631 0.64 0.648 0.656 0.665 0.672 0.678 0.685 0.694 0.703 0.711 0.72 0.728 0.734
Sinaloa 0.491 0.503 0.514 0.523 0.531 0.539 0.547 0.556 0.564 0.573 0.581 0.589 0.597 0.603 0.607 0.613 0.62 0.629 0.639 0.649 0.658 0.666 0.674 0.682 0.689 0.697 0.704 0.712 0.718 0.723 0.727 0.732 0.736 0.74 0.744 0.748 0.751
Sonora 0.528 0.541 0.552 0.561 0.569 0.577 0.584 0.592 0.598 0.606 0.614 0.623 0.632 0.64 0.645 0.65 0.656 0.663 0.67 0.677 0.683 0.69 0.696 0.702 0.709 0.716 0.723 0.731 0.737 0.742 0.746 0.751 0.756 0.761 0.767 0.772 0.777
Tabasco 0.42 0.432 0.443 0.452 0.461 0.469 0.478 0.487 0.496 0.506 0.515 0.525 0.536 0.545 0.552 0.561 0.572 0.584 0.597 0.607 0.616 0.624 0.63 0.636 0.642 0.648 0.654 0.66 0.665 0.669 0.674 0.68 0.685 0.691 0.696 0.701 0.706
Tamaulipas 0.504 0.516 0.526 0.535 0.544 0.553 0.562 0.572 0.582 0.593 0.605 0.617 0.629 0.638 0.646 0.653 0.66 0.668 0.674 0.68 0.685 0.689 0.693 0.697 0.701 0.706 0.712 0.719 0.726 0.732 0.738 0.744 0.751 0.756 0.761 0.766 0.77
Tlaxcala 0.359 0.371 0.384 0.397 0.413 0.432 0.455 0.479 0.499 0.514 0.524 0.533 0.538 0.545 0.559 0.573 0.585 0.593 0.599 0.605 0.612 0.62 0.628 0.635 0.644 0.651 0.657 0.664 0.672 0.677 0.681 0.685 0.693 0.701 0.708 0.715 0.72
Veracruz de Ignacio de la Llave 0.408 0.42 0.431 0.44 0.449 0.458 0.467 0.477 0.484 0.493 0.501 0.51 0.519 0.526 0.531 0.537 0.545 0.554 0.564 0.573 0.582 0.59 0.597 0.605 0.613 0.621 0.63 0.638 0.646 0.653 0.659 0.665 0.67 0.675 0.68 0.686 0.69
Yucatán 0.466 0.477 0.486 0.493 0.501 0.508 0.515 0.522 0.528 0.536 0.545 0.555 0.566 0.575 0.582 0.59 0.599 0.608 0.617 0.625 0.633 0.641 0.647 0.654 0.661 0.667 0.674 0.68 0.685 0.689 0.693 0.697 0.701 0.706 0.71 0.715 0.719
Zacatecas 0.381 0.393 0.405 0.415 0.425 0.435 0.446 0.459 0.471 0.484 0.498 0.512 0.526 0.537 0.546 0.554 0.564 0.574 0.583 0.592 0.601 0.608 0.615 0.622 0.629 0.635 0.641 0.647 0.652 0.656 0.66 0.666 0.672 0.679 0.686 0.693 0.699
Tropical Latin America 0.449 0.461 0.471 0.48 0.489 0.498 0.507 0.515 0.524 0.532 0.539 0.546 0.553 0.56 0.568 0.576 0.583 0.591 0.598 0.605 0.613 0.62 0.626 0.631 0.637 0.642 0.648 0.654 0.66 0.666 0.672 0.679 0.684 0.69 0.696 0.702 0.707
Brazil 0.449 0.461 0.471 0.48 0.49 0.499 0.508 0.516 0.525 0.533 0.54 0.548 0.554 0.562 0.569 0.577 0.585 0.592 0.6 0.607 0.614 0.621 0.627 0.633 0.638 0.644 0.65 0.656 0.662 0.667 0.673 0.68 0.686 0.691 0.697 0.703 0.708
Paraguay 0.437 0.444 0.448 0.451 0.454 0.456 0.459 0.461 0.465 0.469 0.473 0.478 0.484 0.49 0.496 0.504 0.511 0.519 0.527 0.535 0.543 0.55 0.558 0.565 0.573 0.58 0.588 0.596 0.604 0.611 0.62 0.628 0.636 0.645 0.653 0.661 0.668
Acre 0.332 0.346 0.358 0.369 0.38 0.392 0.404 0.416 0.428 0.439 0.449 0.459 0.467 0.474 0.483 0.492 0.501 0.509 0.517 0.522 0.528 0.534 0.539 0.543 0.548 0.555 0.563 0.57 0.578 0.586 0.595 0.604 0.612 0.621 0.629 0.636 0.642
Alagoas 0.314 0.325 0.334 0.342 0.35 0.358 0.368 0.378 0.388 0.397 0.406 0.414 0.422 0.431 0.441 0.452 0.461 0.469 0.477 0.485 0.493 0.501 0.508 0.515 0.522 0.529 0.536 0.544 0.553 0.56 0.569 0.577 0.584 0.592 0.599 0.605 0.61
Amazonas 0.367 0.382 0.394 0.405 0.416 0.427 0.439 0.452 0.464 0.475 0.486 0.497 0.506 0.513 0.523 0.534 0.544 0.552 0.56 0.569 0.578 0.586 0.592 0.597 0.603 0.609 0.615 0.622 0.63 0.637 0.645 0.652 0.659 0.666 0.674 0.68 0.686
Amapá 0.352 0.366 0.38 0.393 0.406 0.419 0.432 0.445 0.457 0.468 0.477 0.486 0.494 0.501 0.509 0.517 0.528 0.54 0.554 0.567 0.577 0.586 0.594 0.603 0.611 0.617 0.623 0.63 0.638 0.645 0.652 0.66 0.666 0.67 0.675 0.679 0.684
Bahia 0.356 0.365 0.373 0.381 0.389 0.397 0.406 0.417 0.428 0.438 0.447 0.456 0.464 0.472 0.481 0.49 0.498 0.507 0.517 0.524 0.532 0.539 0.545 0.552 0.558 0.564 0.571 0.578 0.584 0.591 0.598 0.606 0.613 0.62 0.627 0.633 0.638
Ceará 0.346 0.355 0.362 0.369 0.376 0.382 0.392 0.406 0.417 0.429 0.439 0.448 0.455 0.463 0.472 0.481 0.492 0.501 0.509 0.516 0.523 0.53 0.538 0.545 0.552 0.558 0.565 0.573 0.581 0.588 0.596 0.604 0.612 0.619 0.626 0.632 0.637
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Appendix Table 9: Socio-demographic Index values for all estimated GBD 2016 locations, 1980–2016
Distrito Federal 0.597 0.607 0.617 0.625 0.634 0.643 0.652 0.659 0.666 0.673 0.68 0.686 0.692 0.698 0.704 0.71 0.717 0.723 0.729 0.735 0.741 0.747 0.753 0.758 0.764 0.769 0.775 0.781 0.787 0.793 0.8 0.806 0.812 0.818 0.824 0.829 0.832
Espírito Santo 0.459 0.47 0.481 0.49 0.499 0.509 0.518 0.527 0.536 0.545 0.553 0.561 0.568 0.577 0.584 0.592 0.6 0.607 0.614 0.621 0.628 0.635 0.642 0.648 0.654 0.66 0.665 0.671 0.677 0.682 0.688 0.694 0.699 0.705 0.711 0.717 0.721
Goiás 0.396 0.411 0.425 0.437 0.45 0.462 0.473 0.483 0.493 0.502 0.511 0.52 0.528 0.537 0.546 0.555 0.565 0.574 0.582 0.59 0.597 0.604 0.611 0.617 0.623 0.628 0.635 0.641 0.647 0.653 0.659 0.665 0.67 0.676 0.682 0.689 0.693
Maranhão 0.309 0.314 0.319 0.324 0.329 0.333 0.341 0.352 0.361 0.371 0.38 0.387 0.393 0.403 0.413 0.424 0.435 0.446 0.457 0.468 0.479 0.488 0.496 0.503 0.511 0.517 0.525 0.533 0.541 0.549 0.557 0.566 0.574 0.581 0.588 0.595 0.6
Minas Gerais 0.45 0.462 0.473 0.483 0.493 0.503 0.512 0.518 0.525 0.532 0.539 0.546 0.552 0.559 0.566 0.574 0.582 0.589 0.596 0.603 0.609 0.615 0.621 0.627 0.632 0.638 0.643 0.65 0.656 0.661 0.668 0.674 0.68 0.686 0.692 0.697 0.702
Mato Grosso do Sul 0.401 0.418 0.432 0.445 0.457 0.471 0.481 0.489 0.498 0.506 0.514 0.522 0.53 0.539 0.548 0.558 0.567 0.576 0.584 0.591 0.598 0.604 0.61 0.615 0.62 0.626 0.632 0.638 0.644 0.649 0.654 0.659 0.664 0.669 0.675 0.681 0.686
Mato Grosso 0.419 0.433 0.445 0.456 0.467 0.48 0.49 0.498 0.507 0.516 0.524 0.532 0.54 0.549 0.559 0.569 0.578 0.587 0.595 0.602 0.609 0.615 0.621 0.626 0.631 0.636 0.642 0.647 0.653 0.658 0.664 0.67 0.675 0.68 0.687 0.693 0.699
Pará 0.364 0.375 0.385 0.393 0.402 0.411 0.42 0.428 0.436 0.444 0.451 0.458 0.465 0.473 0.483 0.493 0.503 0.511 0.519 0.526 0.532 0.537 0.541 0.545 0.549 0.554 0.56 0.566 0.574 0.581 0.589 0.597 0.605 0.612 0.619 0.625 0.63
Paraíba 0.325 0.337 0.347 0.356 0.365 0.372 0.384 0.399 0.412 0.424 0.436 0.444 0.451 0.459 0.467 0.476 0.486 0.495 0.504 0.512 0.519 0.527 0.533 0.54 0.546 0.553 0.559 0.567 0.574 0.581 0.589 0.596 0.603 0.61 0.616 0.622 0.627
Paraná 0.443 0.458 0.471 0.483 0.494 0.507 0.517 0.524 0.533 0.541 0.548 0.556 0.564 0.572 0.58 0.589 0.597 0.606 0.614 0.622 0.629 0.636 0.643 0.649 0.654 0.66 0.665 0.671 0.677 0.682 0.688 0.694 0.7 0.706 0.712 0.718 0.722
Pernambuco 0.364 0.377 0.387 0.396 0.405 0.414 0.425 0.437 0.448 0.458 0.468 0.477 0.485 0.492 0.5 0.508 0.516 0.523 0.53 0.536 0.543 0.549 0.555 0.561 0.567 0.573 0.579 0.585 0.592 0.598 0.605 0.611 0.617 0.623 0.63 0.636 0.64
Piaui 0.321 0.329 0.337 0.344 0.351 0.358 0.367 0.378 0.388 0.398 0.408 0.415 0.421 0.428 0.436 0.445 0.455 0.464 0.473 0.482 0.49 0.498 0.505 0.512 0.519 0.526 0.533 0.54 0.548 0.555 0.563 0.571 0.578 0.585 0.591 0.598 0.602
Rio de Janeiro 0.531 0.545 0.557 0.567 0.577 0.587 0.595 0.602 0.608 0.615 0.62 0.626 0.631 0.637 0.642 0.648 0.653 0.659 0.665 0.67 0.676 0.682 0.688 0.692 0.696 0.701 0.705 0.71 0.714 0.718 0.723 0.727 0.732 0.736 0.74 0.745 0.749
Rio Grande do Norte 0.357 0.369 0.38 0.39 0.4 0.409 0.42 0.431 0.442 0.452 0.461 0.469 0.477 0.485 0.494 0.504 0.515 0.524 0.531 0.539 0.546 0.554 0.562 0.568 0.575 0.582 0.589 0.596 0.603 0.61 0.618 0.625 0.632 0.639 0.645 0.651 0.656
Rondônia 0.358 0.373 0.386 0.398 0.41 0.422 0.434 0.446 0.457 0.467 0.477 0.486 0.494 0.502 0.511 0.519 0.528 0.536 0.545 0.552 0.56 0.568 0.575 0.582 0.589 0.597 0.604 0.612 0.619 0.626 0.633 0.64 0.646 0.653 0.66 0.666 0.671
Roraima 0.401 0.411 0.421 0.43 0.44 0.45 0.461 0.472 0.483 0.493 0.503 0.512 0.52 0.527 0.535 0.542 0.548 0.552 0.554 0.558 0.569 0.581 0.589 0.595 0.604 0.612 0.62 0.628 0.636 0.644 0.651 0.657 0.661 0.666 0.672 0.678 0.683
Rio Grande do Sul 0.506 0.516 0.525 0.533 0.541 0.549 0.557 0.565 0.572 0.579 0.585 0.592 0.598 0.604 0.61 0.617 0.622 0.628 0.635 0.641 0.647 0.654 0.66 0.665 0.671 0.676 0.682 0.688 0.693 0.698 0.703 0.708 0.712 0.717 0.722 0.727 0.732
Santa Catarina 0.477 0.489 0.499 0.508 0.517 0.526 0.536 0.544 0.553 0.561 0.569 0.577 0.584 0.592 0.6 0.609 0.617 0.624 0.632 0.639 0.647 0.654 0.66 0.665 0.671 0.676 0.681 0.687 0.693 0.698 0.704 0.711 0.716 0.722 0.729 0.735 0.74
Sergipe 0.336 0.35 0.361 0.372 0.382 0.391 0.403 0.417 0.43 0.442 0.453 0.463 0.472 0.481 0.49 0.501 0.511 0.52 0.529 0.537 0.546 0.554 0.562 0.569 0.576 0.582 0.589 0.596 0.604 0.611 0.619 0.627 0.634 0.641 0.648 0.654 0.659
São Paulo 0.53 0.542 0.552 0.561 0.571 0.581 0.589 0.596 0.602 0.609 0.615 0.621 0.628 0.634 0.64 0.647 0.653 0.659 0.666 0.672 0.679 0.686 0.692 0.697 0.702 0.706 0.711 0.716 0.721 0.726 0.73 0.736 0.74 0.745 0.75 0.756 0.76
Tocantins 0.38 0.389 0.398 0.406 0.415 0.424 0.434 0.443 0.452 0.461 0.469 0.477 0.486 0.494 0.502 0.511 0.521 0.53 0.539 0.547 0.556 0.563 0.571 0.577 0.584 0.591 0.597 0.604 0.612 0.619 0.626 0.634 0.642 0.649 0.656 0.663 0.668
North Africa and Middle East 0.382 0.392 0.401 0.41 0.418 0.427 0.436 0.446 0.455 0.465 0.475 0.485 0.495 0.505 0.513 0.522 0.531 0.539 0.548 0.556 0.564 0.571 0.578 0.586 0.593 0.601 0.608 0.615 0.622 0.628 0.634 0.64 0.647 0.654 0.661 0.669 0.674
North Africa and Middle East 0.382 0.392 0.401 0.41 0.418 0.427 0.436 0.446 0.455 0.465 0.475 0.485 0.495 0.505 0.513 0.522 0.531 0.539 0.548 0.556 0.564 0.571 0.578 0.586 0.593 0.601 0.608 0.615 0.622 0.628 0.634 0.64 0.647 0.654 0.661 0.669 0.674
Algeria 0.356 0.367 0.379 0.39 0.401 0.412 0.423 0.433 0.443 0.453 0.463 0.472 0.479 0.485 0.49 0.495 0.5 0.505 0.51 0.516 0.523 0.53 0.538 0.549 0.559 0.57 0.581 0.591 0.602 0.612 0.622 0.632 0.642 0.651 0.66 0.669 0.676
Bahrain 0.498 0.513 0.526 0.536 0.54 0.542 0.55 0.559 0.565 0.571 0.586 0.599 0.605 0.613 0.623 0.633 0.641 0.644 0.646 0.65 0.663 0.681 0.694 0.699 0.701 0.703 0.707 0.711 0.716 0.719 0.72 0.719 0.718 0.721 0.726 0.732 0.738
Egypt 0.347 0.358 0.369 0.38 0.391 0.402 0.413 0.425 0.435 0.446 0.458 0.469 0.48 0.49 0.499 0.509 0.518 0.527 0.535 0.543 0.551 0.558 0.566 0.573 0.579 0.585 0.591 0.596 0.601 0.607 0.612 0.617 0.623 0.629 0.637 0.645 0.653
Iran 0.379 0.387 0.395 0.404 0.412 0.422 0.434 0.449 0.466 0.487 0.51 0.536 0.562 0.585 0.607 0.625 0.642 0.656 0.667 0.676 0.683 0.689 0.695 0.701 0.707 0.713 0.719 0.725 0.731 0.736 0.742 0.748 0.752 0.757 0.762 0.766 0.769
Iraq 0.289 0.299 0.31 0.32 0.331 0.341 0.351 0.361 0.372 0.381 0.391 0.398 0.405 0.412 0.418 0.423 0.429 0.437 0.447 0.459 0.472 0.485 0.495 0.498 0.498 0.492 0.485 0.475 0.461 0.447 0.434 0.429 0.432 0.44 0.45 0.463 0.474
Jordan 0.264 0.294 0.322 0.346 0.369 0.389 0.409 0.428 0.448 0.466 0.483 0.497 0.511 0.524 0.536 0.548 0.558 0.568 0.577 0.586 0.595 0.603 0.61 0.615 0.621 0.626 0.632 0.637 0.643 0.649 0.656 0.663 0.669 0.676 0.683 0.689 0.694
Kuwait 0.46 0.476 0.494 0.515 0.54 0.566 0.59 0.611 0.628 0.642 0.652 0.657 0.66 0.659 0.653 0.649 0.655 0.671 0.689 0.702 0.711 0.717 0.721 0.726 0.732 0.738 0.747 0.758 0.77 0.781 0.791 0.8 0.808 0.816 0.823 0.829 0.832
Lebanon 0.51 0.525 0.536 0.547 0.561 0.575 0.588 0.602 0.613 0.621 0.627 0.636 0.645 0.653 0.661 0.669 0.678 0.687 0.697 0.706 0.715 0.723 0.73 0.738 0.744 0.751 0.757 0.763 0.77 0.777 0.785 0.792 0.797 0.801 0.804 0.807 0.81
Libya 0.565 0.57 0.575 0.579 0.583 0.588 0.591 0.595 0.598 0.601 0.605 0.611 0.617 0.623 0.63 0.636 0.643 0.651 0.659 0.667 0.675 0.684 0.692 0.702 0.712 0.723 0.734 0.746 0.757 0.768 0.781 0.785 0.793 0.8 0.804 0.807 0.806
Morocco 0.287 0.295 0.303 0.312 0.321 0.329 0.339 0.349 0.359 0.37 0.381 0.393 0.404 0.415 0.427 0.438 0.449 0.46 0.471 0.481 0.49 0.499 0.507 0.516 0.524 0.531 0.54 0.548 0.557 0.565 0.573 0.581 0.589 0.597 0.604 0.611 0.617
Palestine 0.328 0.341 0.351 0.36 0.369 0.376 0.384 0.391 0.397 0.404 0.411 0.417 0.424 0.43 0.437 0.446 0.457 0.467 0.478 0.488 0.497 0.504 0.51 0.513 0.51 0.502 0.49 0.472 0.452 0.432 0.418 0.413 0.412 0.416 0.425 0.438 0.45
Oman 0.107 0.109 0.111 0.113 0.115 0.135 0.156 0.176 0.194 0.214 0.234 0.256 0.277 0.298 0.318 0.337 0.356 0.376 0.396 0.417 0.438 0.458 0.479 0.499 0.52 0.54 0.561 0.581 0.602 0.621 0.639 0.658 0.676 0.691 0.704 0.714 0.72
Qatar 0.52 0.54 0.558 0.575 0.587 0.596 0.601 0.605 0.609 0.615 0.622 0.631 0.64 0.65 0.659 0.669 0.676 0.684 0.69 0.696 0.702 0.708 0.715 0.722 0.728 0.735 0.74 0.745 0.75 0.756 0.761 0.765 0.769 0.774 0.779 0.784 0.788
Saudi Arabia 0.21 0.225 0.242 0.26 0.277 0.293 0.308 0.323 0.338 0.353 0.368 0.383 0.398 0.414 0.429 0.445 0.462 0.479 0.497 0.515 0.533 0.551 0.569 0.587 0.605 0.623 0.642 0.66 0.679 0.696 0.713 0.73 0.746 0.761 0.775 0.788 0.797
Syria 0.28 0.29 0.301 0.311 0.32 0.33 0.339 0.348 0.357 0.366 0.376 0.386 0.397 0.408 0.419 0.43 0.441 0.451 0.462 0.472 0.483 0.493 0.503 0.514 0.525 0.537 0.549 0.56 0.571 0.582 0.593 0.603 0.611 0.618 0.625 0.632 0.638
Tunisia 0.353 0.364 0.376 0.388 0.4 0.412 0.425 0.437 0.45 0.462 0.476 0.489 0.502 0.515 0.527 0.539 0.551 0.563 0.573 0.583 0.591 0.599 0.606 0.612 0.618 0.623 0.629 0.635 0.64 0.646 0.653 0.659 0.667 0.674 0.682 0.69 0.696
Turkey 0.479 0.489 0.498 0.508 0.517 0.527 0.537 0.547 0.557 0.566 0.576 0.584 0.592 0.599 0.605 0.612 0.619 0.627 0.634 0.641 0.649 0.656 0.663 0.67 0.677 0.684 0.691 0.698 0.705 0.711 0.717 0.724 0.731 0.738 0.746 0.754 0.762
United Arab Emirates 0.34 0.365 0.389 0.413 0.436 0.458 0.48 0.501 0.521 0.539 0.557 0.574 0.59 0.606 0.62 0.633 0.645 0.656 0.667 0.677 0.686 0.695 0.703 0.71 0.716 0.721 0.725 0.729 0.732 0.736 0.74 0.745 0.751 0.756 0.762 0.768 0.772
Yemen 0.155 0.159 0.163 0.166 0.168 0.168 0.168 0.167 0.168 0.17 0.173 0.177 0.185 0.195 0.206 0.217 0.229 0.24 0.252 0.264 0.276 0.288 0.302 0.317 0.335 0.351 0.362 0.367 0.371 0.374 0.379 0.386 0.398 0.417 0.434 0.445 0.45
Afghanistan 0.134 0.136 0.139 0.142 0.145 0.147 0.15 0.153 0.154 0.156 0.158 0.16 0.163 0.165 0.165 0.166 0.166 0.167 0.168 0.169 0.17 0.171 0.175 0.181 0.188 0.195 0.203 0.211 0.22 0.229 0.238 0.247 0.255 0.262 0.269 0.276 0.281
Sudan 0.24 0.245 0.252 0.258 0.263 0.268 0.274 0.279 0.285 0.29 0.295 0.3 0.304 0.309 0.313 0.317 0.32 0.326 0.332 0.34 0.351 0.361 0.372 0.383 0.393 0.404 0.415 0.426 0.437 0.448 0.459 0.47 0.48 0.49 0.501 0.51 0.518
Ha'il 0.205 0.22 0.236 0.252 0.267 0.283 0.297 0.312 0.326 0.341 0.355 0.369 0.384 0.399 0.414 0.429 0.446 0.463 0.479 0.496 0.514 0.532 0.549 0.567 0.585 0.603 0.621 0.639 0.657 0.674 0.691 0.708 0.724 0.739 0.752 0.765 0.774
Qassim 0.15 0.169 0.19 0.211 0.231 0.251 0.269 0.288 0.306 0.324 0.341 0.357 0.373 0.389 0.405 0.422 0.439 0.458 0.476 0.495 0.515 0.534 0.554 0.573 0.592 0.61 0.629 0.647 0.666 0.684 0.701 0.717 0.733 0.748 0.762 0.776 0.785
Riyadh 0.185 0.203 0.223 0.244 0.264 0.283 0.301 0.319 0.337 0.353 0.369 0.385 0.401 0.417 0.434 0.451 0.468 0.486 0.505 0.523 0.543 0.562 0.58 0.599 0.618 0.637 0.656 0.675 0.693 0.711 0.727 0.742 0.756 0.769 0.783 0.795 0.804
Tabuk 0.194 0.21 0.229 0.248 0.267 0.285 0.301 0.316 0.332 0.347 0.361 0.376 0.391 0.406 0.422 0.438 0.454 0.471 0.489 0.507 0.525 0.543 0.562 0.58 0.598 0.62 0.64 0.659 0.678 0.695 0.712 0.729 0.745 0.76 0.775 0.79 0.8
Madinah 0.199 0.215 0.232 0.251 0.269 0.285 0.3 0.316 0.331 0.347 0.362 0.377 0.392 0.408 0.424 0.44 0.457 0.474 0.492 0.51 0.528 0.547 0.565 0.583 0.601 0.62 0.638 0.656 0.675 0.693 0.71 0.727 0.744 0.76 0.773 0.786 0.795
Makkah 0.231 0.246 0.261 0.277 0.293 0.308 0.323 0.337 0.352 0.367 0.382 0.396 0.411 0.427 0.442 0.458 0.474 0.491 0.508 0.525 0.543 0.56 0.577 0.594 0.611 0.628 0.645 0.662 0.679 0.695 0.71 0.726 0.741 0.755 0.768 0.779 0.788
Bahah 0.219 0.232 0.246 0.26 0.273 0.287 0.299 0.312 0.325 0.338 0.351 0.364 0.378 0.392 0.406 0.42 0.436 0.452 0.468 0.484 0.5 0.516 0.532 0.549 0.565 0.582 0.599 0.616 0.634 0.65 0.666 0.683 0.699 0.714 0.726 0.737 0.746
Northern Borders 0.264 0.278 0.293 0.308 0.323 0.337 0.351 0.364 0.378 0.392 0.406 0.42 0.434 0.45 0.465 0.48 0.497 0.513 0.53 0.546 0.563 0.58 0.596 0.612 0.629 0.647 0.665 0.681 0.698 0.713 0.728 0.742 0.755 0.766 0.779 0.79 0.797
Jawf 0.236 0.253 0.272 0.291 0.311 0.33 0.347 0.364 0.381 0.398 0.414 0.431 0.448 0.465 0.482 0.499 0.517 0.536 0.555 0.573 0.592 0.61 0.628 0.645 0.663 0.681 0.699 0.717 0.735 0.752 0.768 0.784 0.799 0.814 0.826 0.838 0.846
Jizan 0.202 0.212 0.223 0.234 0.245 0.255 0.265 0.275 0.285 0.296 0.306 0.317 0.329 0.341 0.353 0.365 0.379 0.393 0.407 0.421 0.436 0.45 0.465 0.48 0.496 0.513 0.53 0.546 0.564 0.581 0.597 0.614 0.63 0.645 0.658 0.67 0.679
'Asir 0.167 0.181 0.197 0.213 0.229 0.243 0.258 0.272 0.286 0.301 0.314 0.327 0.341 0.355 0.369 0.384 0.401 0.417 0.434 0.451 0.469 0.487 0.504 0.522 0.541 0.559 0.578 0.598 0.617 0.636 0.654 0.672 0.69 0.706 0.721 0.735 0.744
Najran 0.187 0.199 0.212 0.224 0.237 0.249 0.261 0.273 0.285 0.297 0.309 0.32 0.332 0.345 0.357 0.371 0.385 0.4 0.415 0.431 0.447 0.463 0.479 0.496 0.513 0.53 0.548 0.566 0.585 0.602 0.62 0.637 0.654 0.671 0.685 0.699 0.709
Eastern Province 0.209 0.225 0.243 0.261 0.28 0.297 0.313 0.329 0.346 0.362 0.377 0.393 0.409 0.425 0.441 0.458 0.475 0.493 0.511 0.529 0.548 0.566 0.584 0.603 0.621 0.639 0.658 0.676 0.694 0.711 0.728 0.745 0.761 0.776 0.79 0.803 0.813
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Appendix Table 9: Socio-demographic Index values for all estimated GBD 2016 locations, 1980–2016
South Asia 0.288 0.293 0.298 0.303 0.309 0.314 0.32 0.327 0.334 0.341 0.349 0.356 0.364 0.371 0.378 0.386 0.394 0.402 0.409 0.417 0.425 0.432 0.44 0.447 0.455 0.464 0.473 0.482 0.491 0.5 0.51 0.519 0.529 0.539 0.549 0.56 0.569
South Asia 0.288 0.293 0.298 0.303 0.309 0.314 0.32 0.327 0.334 0.341 0.349 0.356 0.364 0.371 0.378 0.386 0.394 0.402 0.409 0.417 0.425 0.432 0.44 0.447 0.455 0.464 0.473 0.482 0.491 0.5 0.51 0.519 0.529 0.539 0.549 0.56 0.569
Bangladesh 0.254 0.258 0.263 0.269 0.275 0.281 0.287 0.294 0.3 0.307 0.315 0.323 0.331 0.339 0.347 0.355 0.363 0.37 0.377 0.384 0.39 0.396 0.402 0.407 0.414 0.42 0.427 0.434 0.442 0.45 0.459 0.467 0.476 0.485 0.494 0.503 0.511
Bhutan 0.237 0.242 0.247 0.253 0.259 0.265 0.272 0.279 0.286 0.293 0.301 0.31 0.318 0.327 0.337 0.348 0.359 0.37 0.382 0.394 0.406 0.418 0.431 0.444 0.457 0.47 0.482 0.494 0.506 0.518 0.53 0.541 0.552 0.563 0.572 0.581 0.588
India 0.298 0.303 0.308 0.313 0.318 0.324 0.329 0.336 0.342 0.35 0.357 0.364 0.371 0.378 0.385 0.393 0.401 0.408 0.416 0.424 0.432 0.44 0.447 0.455 0.464 0.473 0.482 0.492 0.502 0.512 0.522 0.533 0.543 0.553 0.564 0.575 0.584
Nepal 0.194 0.198 0.202 0.206 0.21 0.214 0.219 0.224 0.23 0.236 0.242 0.25 0.258 0.266 0.276 0.285 0.293 0.302 0.31 0.319 0.328 0.337 0.345 0.354 0.362 0.37 0.377 0.384 0.391 0.398 0.404 0.411 0.417 0.424 0.433 0.443 0.452
Pakistan 0.216 0.218 0.22 0.223 0.227 0.234 0.243 0.255 0.268 0.282 0.297 0.309 0.32 0.33 0.339 0.349 0.36 0.371 0.383 0.392 0.4 0.408 0.416 0.424 0.431 0.438 0.443 0.448 0.453 0.458 0.464 0.471 0.478 0.488 0.499 0.51 0.519
Andhra Pradesh 0.276 0.281 0.285 0.29 0.294 0.299 0.303 0.309 0.315 0.322 0.329 0.337 0.345 0.354 0.363 0.373 0.383 0.393 0.403 0.414 0.424 0.434 0.444 0.453 0.463 0.472 0.481 0.493 0.503 0.514 0.525 0.536 0.546 0.556 0.566 0.577 0.585
Arunachal Pradesh 0.263 0.269 0.274 0.28 0.286 0.292 0.3 0.307 0.315 0.322 0.33 0.338 0.346 0.354 0.362 0.371 0.38 0.389 0.397 0.405 0.413 0.422 0.43 0.438 0.447 0.457 0.466 0.477 0.487 0.5 0.513 0.526 0.539 0.552 0.565 0.578 0.589
Assam 0.292 0.298 0.304 0.311 0.318 0.325 0.332 0.339 0.346 0.353 0.361 0.367 0.373 0.378 0.383 0.389 0.394 0.4 0.405 0.413 0.421 0.429 0.437 0.446 0.454 0.462 0.471 0.479 0.487 0.496 0.504 0.514 0.523 0.532 0.542 0.552 0.562
Bihar 0.25 0.255 0.26 0.264 0.27 0.275 0.281 0.287 0.294 0.3 0.306 0.312 0.317 0.318 0.319 0.318 0.318 0.319 0.317 0.317 0.318 0.321 0.325 0.329 0.334 0.338 0.346 0.354 0.363 0.371 0.38 0.39 0.4 0.411 0.421 0.431 0.44
Chhattisgarh 0.256 0.26 0.264 0.269 0.273 0.277 0.282 0.287 0.292 0.298 0.304 0.31 0.316 0.323 0.329 0.336 0.344 0.352 0.36 0.369 0.376 0.386 0.395 0.405 0.414 0.425 0.436 0.449 0.461 0.473 0.485 0.497 0.509 0.521 0.534 0.547 0.558
Delhi 0.471 0.478 0.484 0.49 0.495 0.5 0.505 0.51 0.515 0.52 0.524 0.529 0.533 0.538 0.544 0.55 0.557 0.565 0.573 0.582 0.592 0.602 0.612 0.623 0.633 0.643 0.653 0.664 0.674 0.684 0.694 0.705 0.715 0.724 0.734 0.744 0.752
Goa 0.394 0.401 0.409 0.416 0.424 0.432 0.44 0.448 0.456 0.465 0.473 0.481 0.49 0.5 0.511 0.523 0.535 0.547 0.561 0.573 0.586 0.597 0.608 0.616 0.623 0.631 0.638 0.645 0.654 0.664 0.673 0.686 0.696 0.707 0.718 0.729 0.738
Gujarat 0.319 0.326 0.331 0.338 0.345 0.352 0.359 0.365 0.373 0.38 0.389 0.395 0.403 0.411 0.42 0.429 0.439 0.448 0.457 0.465 0.473 0.48 0.487 0.495 0.503 0.512 0.522 0.532 0.542 0.551 0.561 0.571 0.58 0.589 0.598 0.607 0.615
Haryana 0.317 0.324 0.331 0.338 0.345 0.353 0.361 0.368 0.377 0.386 0.395 0.405 0.413 0.422 0.431 0.439 0.449 0.458 0.467 0.475 0.484 0.494 0.503 0.513 0.524 0.534 0.545 0.557 0.569 0.58 0.591 0.602 0.613 0.624 0.635 0.646 0.655
Himachal Pradesh 0.289 0.296 0.303 0.311 0.318 0.326 0.334 0.343 0.353 0.363 0.374 0.385 0.396 0.407 0.419 0.43 0.443 0.456 0.469 0.483 0.496 0.508 0.52 0.531 0.541 0.553 0.564 0.575 0.587 0.598 0.61 0.622 0.633 0.644 0.654 0.662 0.669
Jammu and Kashmir 0.276 0.282 0.288 0.295 0.301 0.308 0.316 0.322 0.329 0.336 0.343 0.349 0.353 0.361 0.369 0.377 0.384 0.395 0.405 0.417 0.429 0.441 0.452 0.464 0.475 0.486 0.497 0.507 0.518 0.528 0.539 0.549 0.559 0.569 0.579 0.589 0.598
Jharkhand 0.259 0.262 0.266 0.269 0.273 0.277 0.281 0.285 0.29 0.295 0.3 0.306 0.311 0.316 0.322 0.329 0.334 0.342 0.35 0.358 0.365 0.373 0.381 0.389 0.397 0.406 0.415 0.424 0.433 0.442 0.453 0.464 0.475 0.487 0.499 0.512 0.523
Karnataka 0.296 0.301 0.306 0.312 0.318 0.324 0.33 0.337 0.344 0.352 0.36 0.368 0.376 0.385 0.395 0.405 0.415 0.425 0.436 0.447 0.457 0.465 0.474 0.481 0.49 0.499 0.509 0.521 0.532 0.543 0.554 0.565 0.576 0.586 0.596 0.606 0.614
Kerala 0.369 0.374 0.379 0.385 0.391 0.396 0.403 0.409 0.415 0.422 0.429 0.436 0.444 0.454 0.464 0.476 0.488 0.5 0.512 0.524 0.535 0.545 0.553 0.562 0.57 0.58 0.589 0.599 0.608 0.619 0.628 0.638 0.648 0.657 0.667 0.676 0.683
Madhya Pradesh 0.271 0.275 0.28 0.286 0.291 0.297 0.303 0.309 0.317 0.324 0.332 0.339 0.345 0.35 0.355 0.36 0.365 0.37 0.375 0.38 0.385 0.391 0.397 0.404 0.411 0.418 0.425 0.433 0.441 0.45 0.459 0.47 0.481 0.494 0.507 0.52 0.532
Maharashtra 0.339 0.346 0.353 0.36 0.368 0.375 0.383 0.391 0.399 0.408 0.418 0.426 0.435 0.444 0.454 0.464 0.475 0.485 0.494 0.503 0.512 0.519 0.526 0.534 0.543 0.553 0.564 0.576 0.588 0.599 0.61 0.62 0.63 0.639 0.648 0.658 0.666
Manipur 0.28 0.288 0.295 0.302 0.31 0.318 0.326 0.336 0.346 0.355 0.364 0.372 0.38 0.386 0.391 0.395 0.4 0.406 0.413 0.423 0.433 0.444 0.455 0.467 0.48 0.494 0.507 0.518 0.529 0.54 0.549 0.56 0.571 0.581 0.591 0.601 0.61
Meghalaya 0.287 0.291 0.296 0.3 0.305 0.31 0.316 0.323 0.328 0.335 0.342 0.348 0.353 0.358 0.36 0.363 0.367 0.372 0.379 0.389 0.402 0.417 0.431 0.443 0.455 0.467 0.477 0.488 0.498 0.508 0.519 0.53 0.541 0.552 0.563 0.575 0.585
Mizoram 0.334 0.34 0.346 0.352 0.359 0.369 0.378 0.39 0.399 0.407 0.414 0.422 0.429 0.436 0.44 0.446 0.453 0.459 0.465 0.473 0.482 0.492 0.502 0.511 0.52 0.528 0.537 0.545 0.553 0.562 0.572 0.581 0.591 0.601 0.611 0.621 0.63
Nagaland 0.343 0.348 0.354 0.36 0.366 0.371 0.377 0.383 0.389 0.395 0.401 0.406 0.409 0.413 0.416 0.419 0.422 0.428 0.434 0.442 0.456 0.473 0.49 0.505 0.519 0.533 0.545 0.559 0.572 0.585 0.597 0.61 0.622 0.634 0.645 0.654 0.661
Odisha 0.251 0.255 0.259 0.264 0.269 0.274 0.28 0.285 0.292 0.299 0.305 0.312 0.318 0.324 0.33 0.338 0.344 0.351 0.359 0.368 0.376 0.385 0.393 0.402 0.413 0.422 0.433 0.445 0.457 0.468 0.48 0.491 0.503 0.514 0.526 0.537 0.547
Punjab 0.329 0.337 0.344 0.352 0.359 0.367 0.375 0.383 0.392 0.401 0.409 0.418 0.427 0.436 0.445 0.455 0.465 0.474 0.484 0.493 0.503 0.511 0.519 0.527 0.535 0.545 0.555 0.566 0.576 0.587 0.598 0.608 0.618 0.627 0.636 0.643 0.65
Rajasthan 0.254 0.259 0.263 0.27 0.275 0.28 0.286 0.292 0.299 0.306 0.315 0.322 0.329 0.335 0.341 0.348 0.355 0.362 0.368 0.375 0.382 0.39 0.397 0.405 0.414 0.422 0.43 0.44 0.449 0.457 0.468 0.479 0.49 0.5 0.511 0.521 0.53
Sikkim 0.268 0.273 0.279 0.284 0.29 0.297 0.304 0.313 0.321 0.329 0.337 0.346 0.352 0.361 0.369 0.378 0.388 0.398 0.408 0.418 0.43 0.441 0.453 0.466 0.478 0.49 0.501 0.511 0.52 0.536 0.551 0.565 0.579 0.593 0.607 0.62 0.632
Tamil Nadu 0.309 0.315 0.319 0.325 0.33 0.337 0.343 0.351 0.359 0.367 0.376 0.385 0.395 0.405 0.417 0.428 0.44 0.452 0.464 0.476 0.487 0.496 0.505 0.513 0.521 0.531 0.541 0.552 0.563 0.575 0.587 0.599 0.61 0.621 0.632 0.64 0.648
Telangana 0.265 0.269 0.273 0.278 0.282 0.286 0.291 0.296 0.302 0.309 0.317 0.325 0.333 0.342 0.352 0.362 0.373 0.383 0.395 0.406 0.417 0.428 0.438 0.449 0.459 0.47 0.482 0.495 0.509 0.521 0.535 0.549 0.562 0.574 0.587 0.599 0.609
Tripura 0.315 0.319 0.324 0.328 0.331 0.335 0.339 0.343 0.348 0.353 0.358 0.362 0.366 0.372 0.378 0.386 0.395 0.404 0.412 0.425 0.438 0.451 0.462 0.47 0.478 0.485 0.491 0.497 0.504 0.511 0.518 0.527 0.536 0.545 0.554 0.564 0.573
Uttar Pradesh 0.265 0.269 0.273 0.278 0.282 0.287 0.293 0.299 0.306 0.312 0.32 0.326 0.332 0.336 0.34 0.344 0.348 0.351 0.355 0.358 0.362 0.368 0.374 0.382 0.39 0.398 0.407 0.415 0.423 0.432 0.441 0.451 0.462 0.473 0.485 0.498 0.508
Uttarakhand 0.257 0.262 0.267 0.272 0.277 0.283 0.289 0.295 0.302 0.309 0.317 0.324 0.332 0.34 0.349 0.358 0.368 0.379 0.389 0.4 0.412 0.424 0.436 0.449 0.463 0.477 0.491 0.505 0.519 0.535 0.551 0.568 0.583 0.598 0.613 0.628 0.639
West Bengal 0.324 0.328 0.331 0.335 0.339 0.343 0.347 0.352 0.356 0.361 0.366 0.371 0.376 0.382 0.389 0.396 0.404 0.412 0.42 0.429 0.438 0.446 0.454 0.462 0.47 0.478 0.486 0.496 0.506 0.516 0.526 0.536 0.546 0.555 0.565 0.573 0.58
The Six Minor Territories 0.38 0.388 0.397 0.405 0.413 0.42 0.429 0.437 0.445 0.452 0.461 0.468 0.475 0.482 0.49 0.498 0.506 0.516 0.525 0.534 0.543 0.552 0.562 0.572 0.581 0.592 0.602 0.613 0.623 0.634 0.644 0.654 0.663 0.672 0.682 0.691 0.698
Andhra Pradesh, Urban 0.377 0.382 0.387 0.392 0.397 0.403 0.408 0.413 0.42 0.427 0.434 0.441 0.447 0.454 0.462 0.47 0.479 0.488 0.498 0.51 0.521 0.532 0.541 0.55 0.559 0.567 0.576 0.586 0.595 0.604 0.613 0.623 0.632 0.641 0.65 0.66 0.668
Andhra Pradesh, Rural 0.239 0.242 0.246 0.249 0.253 0.257 0.261 0.265 0.271 0.277 0.284 0.291 0.298 0.307 0.317 0.327 0.337 0.347 0.358 0.368 0.379 0.389 0.398 0.407 0.417 0.425 0.435 0.445 0.455 0.465 0.475 0.485 0.495 0.506 0.516 0.528 0.537
Arunachal Pradesh, Urban 0.405 0.411 0.416 0.421 0.427 0.433 0.439 0.445 0.452 0.457 0.463 0.469 0.474 0.481 0.486 0.493 0.499 0.506 0.511 0.516 0.52 0.525 0.528 0.532 0.536 0.541 0.546 0.552 0.557 0.565 0.573 0.582 0.59 0.599 0.61 0.621 0.631
Arunachal Pradesh, Rural 0.251 0.256 0.261 0.265 0.271 0.276 0.283 0.289 0.296 0.302 0.309 0.316 0.323 0.331 0.338 0.346 0.353 0.361 0.369 0.376 0.384 0.392 0.401 0.409 0.419 0.428 0.438 0.45 0.46 0.474 0.488 0.501 0.515 0.528 0.541 0.554 0.565
Assam, Urban 0.443 0.449 0.454 0.46 0.467 0.473 0.478 0.484 0.489 0.494 0.499 0.504 0.508 0.513 0.519 0.525 0.531 0.536 0.541 0.549 0.556 0.564 0.571 0.579 0.586 0.592 0.599 0.606 0.612 0.618 0.624 0.63 0.636 0.643 0.65 0.657 0.663
Assam, Rural 0.274 0.28 0.286 0.292 0.299 0.306 0.313 0.32 0.327 0.334 0.342 0.348 0.353 0.358 0.363 0.368 0.374 0.379 0.384 0.391 0.399 0.407 0.415 0.423 0.432 0.44 0.449 0.457 0.466 0.474 0.483 0.492 0.501 0.511 0.521 0.532 0.542
Bihar, Urban 0.37 0.377 0.384 0.391 0.399 0.406 0.413 0.42 0.428 0.434 0.441 0.447 0.453 0.456 0.459 0.46 0.463 0.466 0.467 0.468 0.471 0.474 0.479 0.482 0.487 0.491 0.498 0.505 0.513 0.52 0.529 0.537 0.546 0.554 0.561 0.568 0.575
Bihar, Rural 0.231 0.235 0.239 0.243 0.248 0.253 0.258 0.264 0.27 0.275 0.281 0.287 0.292 0.294 0.294 0.294 0.294 0.296 0.295 0.295 0.297 0.299 0.304 0.308 0.313 0.317 0.325 0.333 0.342 0.35 0.359 0.368 0.379 0.389 0.4 0.41 0.419
Chhattisgarh, Urban 0.456 0.462 0.468 0.472 0.477 0.481 0.485 0.489 0.492 0.496 0.5 0.503 0.507 0.51 0.513 0.517 0.521 0.527 0.533 0.539 0.543 0.55 0.557 0.565 0.572 0.581 0.59 0.601 0.611 0.62 0.628 0.637 0.645 0.653 0.661 0.669 0.677
Chhattisgarh, Rural 0.203 0.206 0.21 0.214 0.218 0.223 0.228 0.233 0.238 0.244 0.251 0.257 0.264 0.271 0.278 0.286 0.294 0.302 0.31 0.319 0.328 0.337 0.346 0.356 0.365 0.376 0.387 0.399 0.412 0.424 0.435 0.448 0.461 0.474 0.488 0.502 0.514
Delhi, Urban 0.478 0.485 0.491 0.497 0.502 0.506 0.512 0.517 0.521 0.526 0.53 0.535 0.539 0.543 0.549 0.555 0.561 0.569 0.577 0.586 0.596 0.606 0.616 0.626 0.636 0.646 0.656 0.666 0.676 0.686 0.696 0.706 0.716 0.726 0.736 0.746 0.753
Delhi, Rural 0.388 0.395 0.402 0.409 0.415 0.422 0.429 0.436 0.443 0.45 0.457 0.464 0.471 0.477 0.483 0.49 0.497 0.505 0.515 0.525 0.536 0.547 0.558 0.569 0.58 0.591 0.603 0.614 0.624 0.636 0.647 0.658 0.669 0.681 0.692 0.703 0.713
Goa, Urban 0.459 0.464 0.471 0.476 0.483 0.489 0.495 0.501 0.507 0.514 0.52 0.526 0.533 0.541 0.551 0.561 0.572 0.582 0.595 0.606 0.616 0.626 0.635 0.642 0.648 0.654 0.66 0.665 0.672 0.681 0.69 0.701 0.711 0.721 0.732 0.744 0.753
Goa, Rural 0.365 0.372 0.38 0.386 0.394 0.401 0.409 0.417 0.424 0.433 0.441 0.449 0.458 0.468 0.479 0.491 0.503 0.515 0.529 0.542 0.554 0.566 0.577 0.585 0.592 0.6 0.608 0.616 0.625 0.636 0.646 0.658 0.669 0.679 0.69 0.701 0.71
Gujarat, Urban 0.408 0.415 0.422 0.431 0.439 0.446 0.454 0.459 0.467 0.474 0.482 0.487 0.494 0.501 0.51 0.519 0.529 0.538 0.547 0.555 0.562 0.569 0.575 0.581 0.587 0.594 0.602 0.611 0.618 0.627 0.635 0.643 0.65 0.657 0.664 0.671 0.677
Gujarat, Rural 0.273 0.278 0.283 0.289 0.294 0.3 0.306 0.312 0.319 0.326 0.334 0.341 0.349 0.356 0.364 0.373 0.382 0.39 0.399 0.407 0.414 0.421 0.428 0.435 0.443 0.452 0.461 0.471 0.48 0.49 0.5 0.51 0.52 0.53 0.541 0.552 0.561
Haryana, Urban 0.428 0.436 0.444 0.452 0.46 0.468 0.476 0.483 0.491 0.498 0.506 0.514 0.521 0.528 0.536 0.543 0.552 0.56 0.567 0.575 0.582 0.59 0.596 0.603 0.61 0.617 0.626 0.635 0.645 0.655 0.665 0.674 0.683 0.691 0.7 0.709 0.717
Haryana, Rural 0.284 0.29 0.296 0.302 0.308 0.315 0.322 0.329 0.337 0.346 0.354 0.364 0.372 0.38 0.389 0.397 0.407 0.416 0.424 0.433 0.441 0.45 0.459 0.469 0.478 0.488 0.499 0.511 0.523 0.535 0.547 0.559 0.57 0.581 0.592 0.604 0.614
Himachal Pradesh, Urban 0.433 0.441 0.449 0.457 0.464 0.472 0.48 0.488 0.497 0.505 0.514 0.522 0.531 0.54 0.549 0.558 0.569 0.579 0.59 0.602 0.614 0.624 0.635 0.645 0.655 0.665 0.675 0.685 0.692 0.699 0.708 0.715 0.723 0.729 0.736 0.743 0.75
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Appendix Table 9: Socio-demographic Index values for all estimated GBD 2016 locations, 1980–2016
0.275 0.282 0.289 0.297 0.304 0.312 0.32 0.329 0.339 0.349 0.36 0.37 0.381 0.393 0.404 0.416 0.429 0.442 0.455 0.469 0.482 0.495 0.506 0.517 0.528 0.539 0.551 0.563 0.574 0.585 0.598 0.61 0.621 0.632 0.643 0.652 0.659
0.366 0.374 0.383 0.392 0.401 0.411 0.42 0.428 0.437 0.444 0.451 0.457 0.462 0.47 0.478 0.486 0.494 0.506 0.516 0.528 0.54 0.551 0.562 0.572 0.581 0.59 0.599 0.607 0.615 0.623 0.629 0.636 0.643 0.65 0.657 0.664 0.671
0.247 0.252 0.258 0.263 0.269 0.275 0.282 0.287 0.294 0.301 0.307 0.312 0.317 0.324 0.332 0.339 0.346 0.357 0.366 0.378 0.389 0.4 0.412 0.423 0.435 0.446 0.458 0.468 0.479 0.49 0.5 0.511 0.522 0.532 0.543 0.553 0.562
0.453 0.457 0.462 0.466 0.469 0.472 0.476 0.479 0.483 0.487 0.492 0.497 0.502 0.508 0.514 0.521 0.527 0.536 0.545 0.554 0.561 0.569 0.577 0.584 0.591 0.599 0.607 0.615 0.622 0.63 0.638 0.646 0.653 0.659 0.666 0.673 0.679
0.233 0.236 0.239 0.242 0.245 0.248 0.251 0.255 0.259 0.264 0.269 0.274 0.279 0.285 0.292 0.299 0.305 0.313 0.321 0.33 0.338 0.346 0.354 0.362 0.37 0.379 0.387 0.397 0.405 0.415 0.425 0.436 0.448 0.459 0.472 0.485 0.496
0.391 0.398 0.404 0.412 0.42 0.427 0.434 0.441 0.449 0.456 0.463 0.471 0.478 0.486 0.495 0.505 0.515 0.525 0.536 0.546 0.557 0.565 0.574 0.581 0.589 0.598 0.607 0.616 0.624 0.631 0.639 0.647 0.655 0.664 0.672 0.681 0.688
0.251 0.256 0.26 0.264 0.269 0.274 0.28 0.286 0.292 0.299 0.306 0.314 0.322 0.33 0.339 0.348 0.357 0.367 0.377 0.387 0.397 0.406 0.415 0.423 0.432 0.442 0.453 0.464 0.475 0.485 0.496 0.507 0.518 0.529 0.54 0.552 0.561
0.408 0.412 0.417 0.422 0.428 0.432 0.438 0.443 0.448 0.454 0.46 0.466 0.474 0.483 0.494 0.506 0.518 0.53 0.542 0.554 0.565 0.574 0.582 0.589 0.597 0.605 0.613 0.621 0.629 0.638 0.646 0.655 0.664 0.673 0.683 0.692 0.699
0.358 0.363 0.368 0.374 0.38 0.385 0.391 0.397 0.404 0.411 0.418 0.425 0.433 0.442 0.452 0.464 0.476 0.488 0.5 0.513 0.524 0.534 0.543 0.551 0.559 0.568 0.577 0.586 0.595 0.605 0.613 0.623 0.632 0.642 0.653 0.662 0.669
0.403 0.409 0.415 0.422 0.428 0.435 0.441 0.448 0.455 0.461 0.469 0.476 0.483 0.49 0.497 0.504 0.511 0.517 0.522 0.527 0.531 0.535 0.538 0.541 0.545 0.55 0.557 0.564 0.572 0.581 0.591 0.6 0.609 0.618 0.626 0.635 0.643
0.229 0.232 0.236 0.24 0.245 0.249 0.254 0.26 0.266 0.272 0.28 0.286 0.292 0.296 0.3 0.305 0.309 0.314 0.318 0.322 0.325 0.331 0.336 0.342 0.349 0.355 0.362 0.37 0.378 0.388 0.399 0.411 0.423 0.436 0.451 0.465 0.478
0.421 0.428 0.436 0.444 0.451 0.458 0.465 0.472 0.478 0.486 0.493 0.499 0.506 0.514 0.522 0.531 0.54 0.55 0.558 0.568 0.576 0.584 0.591 0.598 0.606 0.616 0.627 0.638 0.648 0.658 0.669 0.678 0.687 0.695 0.703 0.712 0.719
0.288 0.295 0.301 0.308 0.314 0.322 0.329 0.337 0.345 0.354 0.364 0.373 0.382 0.391 0.4 0.41 0.421 0.43 0.439 0.449 0.457 0.464 0.472 0.48 0.488 0.498 0.51 0.522 0.533 0.544 0.556 0.567 0.577 0.586 0.596 0.607 0.615
0.346 0.353 0.361 0.369 0.378 0.385 0.393 0.402 0.411 0.419 0.427 0.434 0.441 0.447 0.453 0.458 0.465 0.472 0.479 0.489 0.498 0.509 0.519 0.53 0.541 0.554 0.564 0.574 0.582 0.592 0.6 0.609 0.618 0.627 0.636 0.643 0.65
0.265 0.272 0.278 0.285 0.292 0.299 0.306 0.315 0.324 0.332 0.341 0.349 0.356 0.362 0.367 0.371 0.375 0.381 0.387 0.397 0.408 0.419 0.43 0.442 0.455 0.469 0.482 0.494 0.504 0.515 0.525 0.535 0.545 0.555 0.565 0.575 0.585
0.456 0.459 0.46 0.462 0.463 0.465 0.466 0.468 0.469 0.471 0.473 0.474 0.474 0.476 0.479 0.484 0.49 0.498 0.506 0.516 0.529 0.545 0.559 0.572 0.584 0.595 0.605 0.613 0.621 0.63 0.638 0.648 0.657 0.667 0.677 0.687 0.696
0.25 0.254 0.258 0.263 0.268 0.273 0.279 0.286 0.292 0.299 0.307 0.313 0.319 0.323 0.325 0.328 0.331 0.336 0.342 0.352 0.365 0.379 0.393 0.406 0.417 0.429 0.44 0.451 0.461 0.472 0.483 0.495 0.505 0.516 0.528 0.54 0.55
0.383 0.389 0.395 0.401 0.408 0.417 0.426 0.437 0.446 0.453 0.459 0.466 0.472 0.479 0.485 0.492 0.5 0.508 0.514 0.522 0.531 0.54 0.548 0.555 0.562 0.568 0.575 0.581 0.587 0.593 0.601 0.608 0.616 0.625 0.633 0.643 0.651
0.292 0.298 0.303 0.309 0.315 0.325 0.334 0.346 0.355 0.363 0.37 0.378 0.385 0.392 0.395 0.398 0.404 0.408 0.413 0.42 0.43 0.44 0.451 0.461 0.472 0.482 0.491 0.502 0.512 0.523 0.535 0.546 0.557 0.568 0.58 0.591 0.6
0.446 0.451 0.458 0.466 0.473 0.48 0.486 0.494 0.501 0.507 0.513 0.517 0.521 0.525 0.527 0.53 0.532 0.536 0.54 0.544 0.553 0.564 0.576 0.586 0.595 0.604 0.612 0.622 0.632 0.641 0.65 0.66 0.67 0.68 0.691 0.702 0.711
0.328 0.333 0.338 0.343 0.348 0.353 0.357 0.363 0.368 0.374 0.379 0.383 0.387 0.39 0.393 0.395 0.399 0.405 0.412 0.42 0.435 0.452 0.469 0.484 0.498 0.512 0.524 0.537 0.55 0.563 0.575 0.588 0.6 0.611 0.622 0.629 0.637
0.37 0.376 0.382 0.389 0.396 0.403 0.411 0.417 0.424 0.432 0.438 0.444 0.45 0.455 0.461 0.469 0.474 0.481 0.488 0.496 0.504 0.512 0.519 0.527 0.536 0.544 0.552 0.561 0.569 0.575 0.583 0.591 0.599 0.608 0.617 0.627 0.635
0.233 0.237 0.24 0.245 0.248 0.253 0.259 0.263 0.269 0.276 0.281 0.287 0.293 0.299 0.305 0.312 0.318 0.325 0.333 0.341 0.35 0.358 0.366 0.376 0.387 0.397 0.408 0.42 0.432 0.443 0.455 0.467 0.479 0.49 0.502 0.514 0.524
0.441 0.449 0.456 0.463 0.47 0.477 0.484 0.491 0.498 0.506 0.513 0.519 0.526 0.533 0.541 0.548 0.556 0.564 0.571 0.578 0.585 0.592 0.598 0.605 0.611 0.619 0.627 0.636 0.645 0.654 0.662 0.671 0.679 0.688 0.696 0.703 0.709
0.286 0.293 0.3 0.307 0.314 0.322 0.33 0.338 0.346 0.355 0.364 0.373 0.381 0.39 0.399 0.408 0.418 0.427 0.437 0.447 0.457 0.466 0.474 0.483 0.492 0.502 0.513 0.524 0.535 0.546 0.556 0.566 0.577 0.587 0.596 0.604 0.611
0.374 0.379 0.384 0.39 0.396 0.401 0.407 0.412 0.419 0.425 0.433 0.44 0.446 0.452 0.459 0.465 0.473 0.481 0.489 0.499 0.507 0.516 0.523 0.531 0.539 0.546 0.554 0.561 0.569 0.576 0.585 0.594 0.602 0.61 0.618 0.626 0.632
0.218 0.222 0.226 0.232 0.236 0.241 0.246 0.251 0.258 0.265 0.273 0.28 0.286 0.292 0.299 0.305 0.312 0.318 0.324 0.331 0.337 0.345 0.352 0.36 0.368 0.376 0.385 0.395 0.404 0.412 0.423 0.434 0.445 0.456 0.467 0.478 0.487
0.371 0.377 0.386 0.394 0.404 0.414 0.426 0.437 0.448 0.459 0.469 0.477 0.483 0.491 0.498 0.504 0.511 0.518 0.525 0.533 0.542 0.551 0.56 0.57 0.579 0.588 0.595 0.601 0.605 0.618 0.628 0.639 0.649 0.66 0.672 0.685 0.695
0.257 0.261 0.266 0.271 0.276 0.283 0.29 0.297 0.305 0.313 0.321 0.329 0.335 0.343 0.352 0.36 0.37 0.38 0.39 0.4 0.411 0.422 0.434 0.445 0.457 0.469 0.479 0.489 0.496 0.513 0.527 0.542 0.555 0.569 0.584 0.598 0.61
0.391 0.398 0.403 0.408 0.413 0.419 0.425 0.432 0.439 0.446 0.453 0.459 0.467 0.476 0.486 0.495 0.505 0.515 0.526 0.537 0.547 0.557 0.565 0.573 0.581 0.59 0.599 0.609 0.617 0.627 0.636 0.646 0.656 0.667 0.678 0.686 0.693
0.264 0.27 0.274 0.279 0.285 0.292 0.299 0.307 0.315 0.324 0.333 0.341 0.35 0.359 0.369 0.379 0.389 0.399 0.411 0.422 0.433 0.443 0.453 0.462 0.472 0.483 0.494 0.506 0.516 0.528 0.539 0.551 0.562 0.574 0.586 0.595 0.603
0.37 0.376 0.382 0.389 0.396 0.402 0.409 0.416 0.424 0.432 0.44 0.449 0.457 0.465 0.474 0.483 0.494 0.503 0.514 0.526 0.539 0.55 0.56 0.569 0.578 0.587 0.596 0.607 0.618 0.626 0.637 0.647 0.658 0.668 0.679 0.689 0.698
0.225 0.228 0.231 0.234 0.237 0.24 0.244 0.248 0.253 0.259 0.265 0.272 0.28 0.289 0.298 0.308 0.32 0.33 0.342 0.353 0.364 0.375 0.385 0.396 0.406 0.417 0.429 0.441 0.454 0.466 0.48 0.493 0.506 0.519 0.533 0.547 0.558
0.447 0.45 0.453 0.455 0.456 0.458 0.459 0.46 0.463 0.465 0.467 0.469 0.469 0.474 0.479 0.485 0.493 0.501 0.507 0.519 0.53 0.542 0.549 0.555 0.559 0.563 0.567 0.57 0.574 0.579 0.584 0.592 0.599 0.608 0.617 0.627 0.635
0.294 0.298 0.302 0.306 0.31 0.313 0.317 0.321 0.326 0.331 0.336 0.34 0.344 0.351 0.357 0.365 0.373 0.382 0.39 0.403 0.416 0.429 0.439 0.448 0.455 0.461 0.467 0.472 0.479 0.486 0.493 0.501 0.509 0.518 0.528 0.538 0.546
0.367 0.371 0.377 0.382 0.387 0.393 0.399 0.404 0.41 0.417 0.423 0.43 0.435 0.44 0.446 0.451 0.457 0.463 0.468 0.473 0.478 0.484 0.49 0.496 0.502 0.509 0.516 0.524 0.531 0.538 0.546 0.554 0.562 0.57 0.578 0.587 0.594
0.24 0.243 0.247 0.251 0.255 0.259 0.264 0.27 0.276 0.282 0.289 0.295 0.3 0.304 0.308 0.311 0.314 0.317 0.32 0.323 0.327 0.332 0.339 0.347 0.355 0.364 0.372 0.381 0.389 0.398 0.407 0.417 0.429 0.441 0.454 0.468 0.479
0.401 0.406 0.412 0.417 0.422 0.427 0.432 0.437 0.442 0.448 0.454 0.459 0.464 0.469 0.476 0.482 0.489 0.496 0.503 0.511 0.519 0.528 0.537 0.547 0.556 0.567 0.578 0.589 0.6 0.615 0.628 0.642 0.656 0.669 0.682 0.695 0.706
0.223 0.227 0.231 0.235 0.24 0.245 0.25 0.256 0.263 0.269 0.277 0.284 0.292 0.3 0.309 0.318 0.328 0.338 0.349 0.36 0.372 0.385 0.397 0.411 0.424 0.439 0.453 0.468 0.482 0.499 0.515 0.531 0.547 0.562 0.577 0.592 0.604
0.44 0.444 0.45 0.455 0.461 0.466 0.471 0.476 0.481 0.486 0.491 0.496 0.501 0.507 0.513 0.52 0.527 0.535 0.543 0.552 0.56 0.568 0.574 0.58 0.586 0.591 0.597 0.604 0.612 0.619 0.625 0.632 0.638 0.644 0.651 0.658 0.665
0.275 0.279 0.281 0.284 0.288 0.291 0.295 0.299 0.303 0.307 0.312 0.317 0.323 0.329 0.335 0.343 0.351 0.358 0.367 0.376 0.384 0.392 0.4 0.407 0.414 0.422 0.43 0.441 0.451 0.462 0.473 0.483 0.493 0.504 0.514 0.525 0.533
0.293 0.299 0.306 0.312 0.319 0.326 0.333 0.34 0.348 0.355 0.363 0.371 0.379 0.387 0.397 0.406 0.416 0.428 0.439 0.451 0.462 0.474 0.487 0.499 0.512 0.525 0.538 0.552 0.565 0.579 0.591 0.603 0.61 0.617 0.623 0.63 0.637
0.477 0.483 0.488 0.493 0.497 0.501 0.506 0.51 0.514 0.519 0.523 0.528 0.533 0.538 0.544 0.55 0.557 0.565 0.572 0.579 0.586 0.593 0.6 0.607 0.614 0.622 0.63 0.638 0.645 0.654 0.661 0.669 0.677 0.685 0.693 0.702 0.71
0.263 0.268 0.272 0.277 0.282 0.287 0.291 0.295 0.298 0.302 0.307 0.311 0.316 0.321 0.325 0.329 0.334 0.339 0.343 0.346 0.35 0.354 0.358 0.362 0.366 0.371 0.377 0.383 0.389 0.395 0.401 0.408 0.416 0.423 0.43 0.437 0.442
0.259 0.262 0.266 0.271 0.275 0.28 0.283 0.287 0.291 0.295 0.298 0.302 0.305 0.306 0.307 0.308 0.31 0.312 0.314 0.315 0.316 0.317 0.32 0.322 0.327 0.332 0.338 0.345 0.352 0.359 0.366 0.374 0.382 0.388 0.394 0.401 0.406
0.218 0.22 0.223 0.225 0.229 0.232 0.235 0.239 0.243 0.248 0.252 0.256 0.26 0.262 0.265 0.268 0.272 0.276 0.281 0.286 0.289 0.294 0.299 0.305 0.312 0.32 0.329 0.339 0.349 0.357 0.366 0.377 0.388 0.4 0.411 0.422 0.431
0.212 0.216 0.22 0.222 0.226 0.23 0.233 0.236 0.24 0.243 0.247 0.25 0.252 0.254 0.258 0.261 0.263 0.266 0.269 0.273 0.276 0.279 0.283 0.285 0.288 0.291 0.295 0.299 0.303 0.307 0.311 0.316 0.322 0.32 0.319 0.318 0.316
0.3 0.308 0.317 0.326 0.335 0.344 0.351 0.358 0.365 0.372 0.379 0.386 0.393 0.399 0.404 0.41 0.415 0.421 0.426 0.43 0.434 0.439 0.444 0.45 0.456 0.462 0.467 0.471 0.475 0.48 0.487 0.495 0.503 0.511 0.519 0.526 0.531
0.246 0.249 0.253 0.257 0.262 0.267 0.271 0.274 0.277 0.281 0.283 0.284 0.285 0.284 0.282 0.28 0.277 0.273 0.268 0.264 0.257 0.251 0.246 0.243 0.242 0.243 0.242 0.241 0.242 0.244 0.251 0.26 0.27 0.282 0.292 0.304 0.312
0.242 0.252 0.26 0.268 0.275 0.279 0.282 0.284 0.286 0.289 0.29 0.292 0.297 0.303 0.311 0.321 0.343 0.382 0.409 0.433 0.459 0.486 0.509 0.528 0.548 0.565 0.579 0.592 0.605 0.614 0.624 0.633 0.643 0.651 0.658 0.665 0.669
0.38 0.389 0.397 0.406 0.414 0.422 0.429 0.435 0.442 0.45 0.458 0.466 0.474 0.482 0.49 0.498 0.506 0.514 0.521 0.527 0.531 0.534 0.539 0.545 0.551 0.558 0.564 0.57 0.576 0.581 0.586 0.592 0.599 0.605 0.611 0.617 0.622
0.176 0.181 0.185 0.19 0.196 0.201 0.207 0.212 0.217 0.222 0.228 0.234 0.239 0.244 0.249 0.254 0.259 0.264 0.268 0.273 0.277 0.282 0.286 0.291 0.296 0.302 0.308 0.314 0.321 0.329 0.337 0.345 0.354 0.363 0.371 0.38 0.387
0.131 0.137 0.142 0.148 0.154 0.16 0.166 0.172 0.178 0.183 0.188 0.193 0.197 0.2 0.202 0.202 0.202 0.201 0.202 0.202 0.204 0.205 0.208 0.21 0.214 0.217 0.221 0.224 0.229 0.234 0.24 0.246 0.252 0.259 0.266 0.272 0.277
0.208 0.213 0.219 0.225 0.232 0.239 0.246 0.253 0.26 0.268 0.275 0.282 0.289 0.297 0.303 0.309 0.315 0.321 0.325 0.33 0.335 0.34 0.346 0.352 0.359 0.366 0.373 0.381 0.388 0.395 0.403 0.41 0.419 0.427 0.436 0.443 0.449
0.089 0.1 0.11 0.121 0.135 0.148 0.16 0.171 0.181 0.19 0.199 0.207 0.215 0.223 0.23 0.237 0.244 0.252 0.258 0.265 0.272 0.28 0.288 0.296 0.304 0.312 0.321 0.331 0.34 0.35 0.359 0.369 0.379 0.389 0.399 0.409 0.416
0.143 0.146 0.15 0.154 0.158 0.163 0.167 0.172 0.177 0.182 0.187 0.193 0.2 0.208 0.218 0.229 0.241 0.254 0.267 0.279 0.29 0.3 0.309 0.315 0.321 0.326 0.33 0.335 0.338 0.342 0.346 0.352 0.359 0.367 0.375 0.383 0.389
Himachal Pradesh, Rural
Jammu and Kashmir, Urban 
Jammu and Kashmir, Rural 
Jharkhand, Urban
Jharkhand, Rural
Karnataka, Urban
Karnataka, Rural
Kerala, Urban
Kerala, Rural
Madhya Pradesh, Urban 
Madhya Pradesh, Rural 
Maharashtra, Urban 
Maharashtra, Rural
Manipur, Urban
Manipur, Rural
Meghalaya, Urban
Meghalaya, Rural
Mizoram, Urban
Mizoram, Rural
Nagaland, Urban
Nagaland, Rural
Odisha, Urban
Odisha, Rural
Punjab, Urban
Punjab, Rural
Rajasthan, Urban
Rajasthan, Rural
Sikkim, Urban
Sikkim, Rural
Tamil Nadu, Urban
Tamil Nadu, Rural
Telangana, Urban
Telangana, Rural
Tripura, Urban
Tripura, Rural
Uttar Pradesh, Urban
Uttar Pradesh, Rural 
Uttarakhand, Urban 
Uttarakhand, Rural
West Bengal, Urban
West Bengal, Rural
The Six Minor Territories, Rural 
The Six Minor Territories, Urban 
Sub-Saharan Africa
Central Sub-Saharan Africa 
Angola
the Central African Republic
Congo (Brazzaville)
Democratic Republic of the Congo 
Equatorial Guinea
Gabon
Eastern Sub-Saharan Africa 
Burundi
Comoros
Djibouti
Eritrea
Ethiopia 0.122 0.125 0.128 0.132 0.136 0.139 0.142 0.145 0.148 0.15 0.153 0.156 0.158 0.161 0.163 0.166 0.171 0.175 0.179 0.182 0.187 0.192 0.196 0.2 0.205 0.212 0.22 0.229 0.239 0.25 0.26 0.272 0.284 0.295 0.306 0.317 0.326
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Appendix Table 9: Socio-demographic Index values for all estimated GBD 2016 locations, 1980–2016
Kenya 0.22 0.232 0.245 0.257 0.269 0.28 0.291 0.302 0.313 0.323 0.335 0.346 0.357 0.367 0.376 0.384 0.393 0.4 0.405 0.41 0.415 0.42 0.425 0.429 0.434 0.44 0.446 0.452 0.459 0.465 0.473 0.481 0.489 0.498 0.506 0.514 0.52
Madagascar 0.195 0.201 0.207 0.213 0.219 0.226 0.232 0.238 0.244 0.249 0.255 0.26 0.264 0.267 0.269 0.272 0.275 0.278 0.282 0.286 0.289 0.294 0.297 0.302 0.306 0.311 0.315 0.319 0.323 0.327 0.331 0.338 0.344 0.35 0.355 0.361 0.365
Malawi 0.143 0.149 0.155 0.161 0.167 0.175 0.182 0.188 0.194 0.199 0.205 0.21 0.215 0.219 0.223 0.227 0.232 0.238 0.243 0.249 0.254 0.258 0.263 0.268 0.273 0.279 0.284 0.29 0.296 0.302 0.308 0.314 0.32 0.326 0.334 0.342 0.348
Mozambique 0.131 0.133 0.135 0.136 0.137 0.138 0.138 0.139 0.14 0.142 0.145 0.149 0.151 0.153 0.157 0.158 0.165 0.172 0.18 0.186 0.193 0.2 0.207 0.214 0.22 0.226 0.231 0.236 0.242 0.247 0.253 0.26 0.268 0.277 0.287 0.297 0.306
Rwanda 0.065 0.067 0.068 0.069 0.07 0.071 0.089 0.12 0.144 0.164 0.181 0.197 0.208 0.217 0.22 0.223 0.226 0.23 0.234 0.237 0.24 0.244 0.25 0.256 0.263 0.272 0.282 0.293 0.305 0.318 0.33 0.342 0.354 0.365 0.374 0.383 0.39
Somalia 0.161 0.162 0.164 0.166 0.168 0.171 0.173 0.176 0.18 0.183 0.187 0.19 0.192 0.194 0.195 0.196 0.197 0.198 0.199 0.2 0.201 0.203 0.205 0.208 0.212 0.216 0.22 0.225 0.23 0.235 0.24 0.245 0.251 0.256 0.26 0.265 0.268
Tanzania 0.176 0.183 0.19 0.197 0.205 0.213 0.22 0.226 0.233 0.239 0.245 0.251 0.256 0.259 0.263 0.271 0.279 0.288 0.295 0.302 0.308 0.314 0.32 0.326 0.332 0.339 0.345 0.352 0.359 0.367 0.375 0.384 0.392 0.402 0.411 0.421 0.428
Uganda 0.101 0.11 0.117 0.125 0.134 0.142 0.149 0.156 0.163 0.17 0.177 0.184 0.19 0.196 0.203 0.209 0.215 0.22 0.226 0.232 0.238 0.244 0.251 0.257 0.265 0.272 0.28 0.289 0.298 0.308 0.317 0.328 0.338 0.348 0.359 0.37 0.377
Zambia 0.193 0.205 0.216 0.228 0.239 0.251 0.261 0.271 0.281 0.291 0.299 0.307 0.315 0.321 0.326 0.331 0.336 0.34 0.343 0.346 0.35 0.354 0.357 0.362 0.366 0.371 0.377 0.385 0.393 0.401 0.41 0.419 0.428 0.437 0.446 0.454 0.46
South Sudan 0.053 0.054 0.054 0.055 0.056 0.056 0.057 0.062 0.07 0.077 0.082 0.088 0.092 0.095 0.098 0.102 0.105 0.108 0.111 0.114 0.117 0.12 0.123 0.127 0.13 0.134 0.138 0.143 0.148 0.152 0.158 0.164 0.17 0.176 0.182 0.188 0.192
Central 0.292 0.305 0.318 0.33 0.343 0.356 0.368 0.379 0.39 0.401 0.413 0.425 0.435 0.444 0.453 0.462 0.47 0.476 0.482 0.487 0.492 0.497 0.501 0.505 0.51 0.515 0.521 0.527 0.533 0.54 0.546 0.553 0.56 0.566 0.573 0.58 0.585
Coast 0.146 0.16 0.172 0.185 0.196 0.205 0.214 0.222 0.231 0.241 0.252 0.264 0.275 0.286 0.296 0.305 0.313 0.321 0.327 0.332 0.337 0.343 0.348 0.354 0.361 0.368 0.376 0.385 0.394 0.403 0.413 0.423 0.434 0.444 0.455 0.465 0.473
Eastern 0.196 0.209 0.221 0.233 0.245 0.256 0.266 0.277 0.287 0.298 0.31 0.322 0.333 0.344 0.353 0.362 0.371 0.379 0.385 0.391 0.396 0.401 0.407 0.412 0.418 0.424 0.431 0.438 0.445 0.452 0.46 0.467 0.475 0.483 0.49 0.498 0.503
Nairobi 0.42 0.431 0.442 0.453 0.464 0.475 0.486 0.496 0.506 0.516 0.526 0.536 0.545 0.553 0.56 0.567 0.574 0.58 0.585 0.589 0.593 0.598 0.602 0.607 0.611 0.617 0.623 0.63 0.637 0.644 0.652 0.66 0.669 0.677 0.685 0.694 0.701
North Eastern 0.049 0.05 0.051 0.052 0.053 0.053 0.054 0.055 0.056 0.057 0.058 0.059 0.061 0.062 0.067 0.075 0.08 0.081 0.076 0.068 0.069 0.07 0.071 0.072 0.073 0.074 0.075 0.077 0.078 0.079 0.08 0.081 0.083 0.084 0.092 0.112 0.124
Nyanza 0.204 0.216 0.229 0.241 0.253 0.264 0.274 0.285 0.295 0.306 0.318 0.331 0.343 0.353 0.364 0.373 0.383 0.391 0.398 0.404 0.411 0.417 0.423 0.429 0.436 0.443 0.45 0.458 0.466 0.475 0.483 0.491 0.5 0.508 0.516 0.524 0.53
Rift Valley 0.173 0.188 0.202 0.216 0.228 0.239 0.249 0.259 0.269 0.28 0.292 0.305 0.316 0.327 0.337 0.347 0.356 0.363 0.37 0.375 0.381 0.386 0.392 0.397 0.403 0.41 0.417 0.424 0.432 0.44 0.448 0.457 0.465 0.474 0.482 0.491 0.497
Western 0.228 0.24 0.251 0.263 0.274 0.284 0.294 0.303 0.312 0.322 0.332 0.343 0.353 0.362 0.37 0.378 0.385 0.391 0.396 0.4 0.404 0.408 0.412 0.416 0.421 0.426 0.431 0.437 0.443 0.45 0.456 0.463 0.47 0.477 0.484 0.491 0.496
Kiambu 0.313 0.327 0.341 0.355 0.368 0.382 0.394 0.406 0.418 0.429 0.441 0.452 0.462 0.47 0.478 0.486 0.493 0.498 0.503 0.507 0.511 0.515 0.519 0.523 0.527 0.531 0.536 0.541 0.547 0.553 0.559 0.566 0.574 0.581 0.588 0.596 0.601
Kirinyaga 0.28 0.292 0.303 0.314 0.326 0.337 0.348 0.358 0.369 0.379 0.389 0.399 0.408 0.417 0.427 0.437 0.446 0.454 0.461 0.467 0.473 0.479 0.484 0.49 0.495 0.501 0.508 0.514 0.521 0.527 0.533 0.54 0.546 0.552 0.558 0.564 0.569
Murang’a 0.278 0.29 0.303 0.315 0.328 0.34 0.352 0.363 0.374 0.384 0.395 0.406 0.415 0.424 0.432 0.44 0.447 0.454 0.461 0.466 0.472 0.477 0.482 0.487 0.492 0.497 0.503 0.509 0.515 0.52 0.526 0.531 0.537 0.542 0.547 0.552 0.556
Nyandarua 0.263 0.275 0.287 0.3 0.312 0.325 0.337 0.348 0.36 0.371 0.383 0.395 0.405 0.415 0.423 0.431 0.439 0.446 0.452 0.457 0.462 0.466 0.47 0.474 0.479 0.484 0.489 0.496 0.503 0.51 0.518 0.526 0.534 0.542 0.55 0.558 0.564
Nyeri 0.292 0.305 0.318 0.332 0.345 0.358 0.37 0.382 0.394 0.407 0.419 0.432 0.443 0.453 0.462 0.47 0.477 0.483 0.488 0.492 0.496 0.5 0.503 0.507 0.512 0.517 0.524 0.531 0.538 0.546 0.553 0.56 0.566 0.572 0.577 0.583 0.587
Kilifi 0.085 0.086 0.087 0.088 0.089 0.09 0.098 0.111 0.122 0.134 0.15 0.166 0.182 0.197 0.212 0.226 0.238 0.249 0.258 0.266 0.273 0.28 0.286 0.291 0.295 0.301 0.306 0.313 0.321 0.33 0.341 0.352 0.364 0.375 0.387 0.398 0.406
Kwale 0.13 0.141 0.151 0.161 0.17 0.177 0.185 0.192 0.2 0.209 0.221 0.234 0.246 0.255 0.261 0.266 0.271 0.275 0.278 0.28 0.281 0.283 0.285 0.289 0.294 0.3 0.306 0.314 0.324 0.334 0.346 0.357 0.369 0.381 0.393 0.404 0.412
Lamu 0.168 0.181 0.193 0.205 0.215 0.224 0.233 0.241 0.249 0.255 0.262 0.269 0.276 0.283 0.292 0.3 0.309 0.317 0.325 0.332 0.338 0.344 0.349 0.355 0.36 0.365 0.371 0.376 0.381 0.388 0.397 0.406 0.415 0.425 0.434 0.444 0.45
Mombasa 0.246 0.259 0.271 0.283 0.294 0.305 0.316 0.326 0.337 0.347 0.36 0.372 0.384 0.394 0.404 0.413 0.421 0.429 0.435 0.44 0.444 0.448 0.452 0.457 0.463 0.47 0.477 0.484 0.491 0.499 0.508 0.518 0.529 0.539 0.549 0.56 0.568
TaitaTaveta 0.156 0.172 0.186 0.2 0.212 0.223 0.233 0.242 0.252 0.263 0.276 0.29 0.303 0.315 0.327 0.339 0.349 0.359 0.367 0.374 0.38 0.386 0.392 0.399 0.408 0.417 0.426 0.435 0.444 0.453 0.464 0.474 0.484 0.494 0.504 0.513 0.52
TanaRiver 0.064 0.065 0.066 0.077 0.084 0.088 0.09 0.092 0.093 0.097 0.107 0.12 0.132 0.145 0.157 0.167 0.176 0.183 0.188 0.189 0.187 0.185 0.182 0.179 0.175 0.172 0.169 0.168 0.171 0.178 0.191 0.204 0.219 0.234 0.248 0.261 0.271
Embu 0.237 0.25 0.262 0.274 0.287 0.298 0.31 0.32 0.331 0.342 0.353 0.365 0.375 0.386 0.396 0.407 0.417 0.426 0.434 0.441 0.449 0.456 0.463 0.469 0.474 0.48 0.486 0.493 0.499 0.506 0.514 0.521 0.529 0.536 0.543 0.55 0.555
Isiolo 0.205 0.212 0.219 0.226 0.233 0.24 0.246 0.252 0.258 0.264 0.27 0.277 0.284 0.289 0.295 0.3 0.306 0.311 0.315 0.32 0.325 0.33 0.334 0.336 0.336 0.335 0.334 0.334 0.336 0.339 0.343 0.348 0.354 0.36 0.366 0.372 0.377
Kitui 0.145 0.158 0.171 0.183 0.195 0.207 0.217 0.227 0.237 0.246 0.255 0.265 0.274 0.283 0.293 0.302 0.311 0.319 0.327 0.333 0.339 0.345 0.351 0.357 0.364 0.371 0.378 0.386 0.394 0.402 0.411 0.42 0.429 0.438 0.447 0.455 0.461
Machakos 0.194 0.21 0.225 0.24 0.253 0.266 0.278 0.29 0.302 0.315 0.33 0.345 0.358 0.371 0.382 0.393 0.403 0.412 0.42 0.426 0.432 0.437 0.442 0.447 0.453 0.459 0.466 0.474 0.482 0.49 0.497 0.505 0.512 0.519 0.526 0.533 0.538
Makueni 0.154 0.175 0.193 0.21 0.225 0.239 0.252 0.264 0.276 0.288 0.301 0.314 0.325 0.336 0.344 0.351 0.358 0.363 0.367 0.369 0.369 0.369 0.37 0.373 0.378 0.385 0.393 0.402 0.411 0.422 0.432 0.442 0.451 0.46 0.468 0.475 0.48
Marsabit 0.184 0.189 0.193 0.198 0.203 0.207 0.212 0.216 0.22 0.224 0.229 0.234 0.238 0.242 0.246 0.25 0.254 0.257 0.261 0.264 0.268 0.272 0.277 0.282 0.288 0.293 0.299 0.304 0.308 0.312 0.315 0.318 0.322 0.326 0.33 0.335 0.339
Meru 0.209 0.221 0.232 0.243 0.254 0.264 0.274 0.284 0.294 0.305 0.318 0.332 0.345 0.356 0.367 0.377 0.386 0.395 0.402 0.408 0.413 0.419 0.425 0.43 0.435 0.44 0.445 0.451 0.455 0.461 0.467 0.475 0.482 0.49 0.498 0.505 0.512
TharakaNithi 0.204 0.216 0.227 0.238 0.25 0.26 0.271 0.282 0.293 0.303 0.315 0.327 0.338 0.349 0.359 0.368 0.377 0.386 0.393 0.4 0.407 0.413 0.42 0.428 0.435 0.444 0.452 0.462 0.471 0.48 0.489 0.497 0.506 0.514 0.522 0.53 0.536
Nairobi 0.42 0.431 0.442 0.453 0.464 0.475 0.486 0.496 0.506 0.516 0.526 0.536 0.545 0.553 0.56 0.567 0.574 0.58 0.585 0.589 0.593 0.598 0.602 0.607 0.611 0.617 0.623 0.63 0.637 0.644 0.652 0.66 0.669 0.677 0.685 0.694 0.701
Garissa 0.052 0.053 0.054 0.055 0.056 0.057 0.058 0.059 0.06 0.061 0.062 0.064 0.065 0.069 0.075 0.077 0.077 0.074 0.073 0.074 0.075 0.077 0.078 0.079 0.08 0.081 0.083 0.084 0.106 0.127 0.141 0.154 0.166 0.178 0.19 0.202 0.21
Mandera 0.045 0.046 0.047 0.048 0.049 0.05 0.051 0.052 0.053 0.054 0.055 0.057 0.065 0.079 0.088 0.095 0.1 0.103 0.102 0.095 0.086 0.074 0.07 0.072 0.073 0.074 0.075 0.076 0.077 0.077 0.079 0.08 0.081 0.083 0.085 0.087 0.089
Wajir 0.048 0.049 0.05 0.05 0.051 0.052 0.052 0.053 0.054 0.055 0.056 0.057 0.058 0.059 0.06 0.061 0.062 0.062 0.063 0.064 0.065 0.065 0.066 0.067 0.067 0.068 0.069 0.07 0.071 0.072 0.073 0.074 0.075 0.083 0.101 0.115 0.124
HomaBay 0.173 0.188 0.202 0.216 0.229 0.24 0.251 0.261 0.271 0.281 0.291 0.301 0.311 0.32 0.329 0.338 0.347 0.354 0.361 0.368 0.374 0.38 0.385 0.39 0.395 0.401 0.408 0.416 0.425 0.435 0.445 0.455 0.464 0.473 0.481 0.488 0.493
Kisii 0.206 0.218 0.23 0.242 0.254 0.264 0.275 0.285 0.296 0.308 0.322 0.336 0.349 0.362 0.375 0.387 0.399 0.409 0.417 0.425 0.432 0.439 0.447 0.454 0.462 0.47 0.478 0.487 0.495 0.502 0.51 0.518 0.526 0.534 0.542 0.55 0.556
Kisumu 0.214 0.228 0.241 0.254 0.266 0.278 0.29 0.301 0.313 0.326 0.341 0.355 0.369 0.38 0.388 0.396 0.403 0.409 0.413 0.417 0.421 0.425 0.43 0.435 0.441 0.448 0.456 0.465 0.475 0.485 0.495 0.504 0.512 0.521 0.529 0.536 0.542
Migori 0.18 0.194 0.208 0.22 0.233 0.244 0.255 0.264 0.274 0.283 0.294 0.304 0.314 0.324 0.334 0.343 0.353 0.362 0.37 0.378 0.386 0.395 0.404 0.411 0.417 0.422 0.428 0.435 0.44 0.445 0.451 0.458 0.465 0.473 0.48 0.488 0.494
Nyamira 0.268 0.28 0.292 0.304 0.316 0.328 0.34 0.351 0.363 0.374 0.385 0.397 0.409 0.419 0.43 0.44 0.449 0.458 0.464 0.47 0.476 0.483 0.49 0.496 0.501 0.507 0.514 0.521 0.528 0.537 0.545 0.555 0.563 0.572 0.58 0.588 0.594
Siaya 0.166 0.176 0.186 0.196 0.206 0.215 0.225 0.234 0.244 0.253 0.264 0.275 0.285 0.295 0.305 0.314 0.324 0.333 0.34 0.347 0.355 0.363 0.371 0.38 0.39 0.401 0.411 0.422 0.432 0.442 0.451 0.46 0.47 0.479 0.489 0.498 0.505
Baringo 0.151 0.169 0.185 0.2 0.213 0.225 0.236 0.247 0.258 0.268 0.28 0.292 0.304 0.313 0.322 0.329 0.337 0.344 0.351 0.358 0.366 0.373 0.379 0.383 0.385 0.387 0.39 0.393 0.398 0.406 0.414 0.422 0.432 0.441 0.45 0.458 0.465
Bomet 0.099 0.108 0.143 0.169 0.189 0.204 0.218 0.231 0.243 0.254 0.268 0.281 0.293 0.305 0.316 0.327 0.338 0.348 0.357 0.366 0.377 0.388 0.398 0.409 0.418 0.427 0.436 0.446 0.454 0.462 0.47 0.479 0.488 0.497 0.506 0.514 0.521
Elgeyo-Marakwet 0.149 0.167 0.183 0.198 0.211 0.223 0.234 0.245 0.255 0.266 0.278 0.291 0.303 0.313 0.322 0.331 0.34 0.348 0.355 0.362 0.371 0.379 0.388 0.395 0.401 0.408 0.415 0.424 0.433 0.444 0.453 0.463 0.473 0.483 0.492 0.501 0.508
Kajiado 0.197 0.213 0.227 0.241 0.254 0.266 0.278 0.29 0.301 0.313 0.325 0.338 0.35 0.36 0.368 0.376 0.383 0.389 0.393 0.395 0.399 0.403 0.409 0.416 0.426 0.437 0.448 0.46 0.471 0.48 0.489 0.498 0.506 0.515 0.524 0.533 0.539
Kericho 0.094 0.096 0.108 0.135 0.154 0.169 0.183 0.196 0.208 0.224 0.242 0.261 0.278 0.295 0.313 0.328 0.343 0.356 0.368 0.378 0.388 0.397 0.406 0.413 0.42 0.428 0.436 0.445 0.455 0.466 0.476 0.487 0.498 0.509 0.519 0.529 0.536
Laikipia 0.229 0.241 0.253 0.265 0.276 0.287 0.297 0.307 0.317 0.327 0.338 0.349 0.36 0.372 0.386 0.398 0.41 0.42 0.428 0.435 0.442 0.449 0.456 0.463 0.47 0.478 0.487 0.496 0.507 0.518 0.527 0.537 0.547 0.556 0.566 0.575 0.582
Nakuru 0.208 0.221 0.232 0.244 0.255 0.266 0.277 0.287 0.298 0.309 0.321 0.333 0.345 0.355 0.365 0.373 0.382 0.389 0.394 0.398 0.403 0.408 0.413 0.42 0.43 0.441 0.453 0.466 0.479 0.492 0.503 0.515 0.526 0.537 0.546 0.556 0.563
Nandi 0.099 0.124 0.152 0.173 0.191 0.206 0.219 0.232 0.244 0.256 0.27 0.285 0.299 0.313 0.327 0.339 0.35 0.36 0.368 0.374 0.382 0.39 0.399 0.408 0.417 0.427 0.436 0.446 0.455 0.465 0.474 0.483 0.491 0.5 0.508 0.516 0.522
Narok 0.106 0.125 0.141 0.155 0.168 0.178 0.188 0.198 0.208 0.219 0.231 0.244 0.257 0.269 0.282 0.293 0.305 0.315 0.323 0.328 0.332 0.336 0.339 0.345 0.353 0.361 0.368 0.375 0.381 0.387 0.394 0.402 0.41 0.418 0.427 0.435 0.441
Samburu 0.169 0.175 0.181 0.187 0.192 0.196 0.201 0.205 0.209 0.212 0.216 0.22 0.224 0.227 0.229 0.231 0.233 0.235 0.235 0.235 0.236 0.238 0.241 0.245 0.251 0.257 0.264 0.27 0.275 0.281 0.286 0.292 0.297 0.302 0.308 0.313 0.316
882
Location 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Appendix Table 9: Socio-demographic Index values for all estimated GBD 2016 locations, 1980–2016
TransNzoia 0.103 0.137 0.161 0.18 0.197 0.21 0.222 0.234 0.246 0.26 0.278 0.296 0.313 0.328 0.341 0.353 0.364 0.374 0.382 0.39 0.398 0.405 0.412 0.418 0.422 0.427 0.432 0.438 0.445 0.453 0.462 0.471 0.48 0.489 0.498 0.506 0.513
Turkana 0.185 0.19 0.195 0.2 0.205 0.209 0.213 0.217 0.22 0.223 0.227 0.231 0.235 0.238 0.241 0.244 0.247 0.249 0.251 0.25 0.249 0.248 0.248 0.249 0.251 0.253 0.256 0.26 0.265 0.268 0.271 0.273 0.276 0.279 0.283 0.287 0.289
UasinGishu 0.183 0.202 0.22 0.237 0.252 0.266 0.279 0.291 0.303 0.316 0.329 0.342 0.355 0.366 0.376 0.386 0.395 0.404 0.413 0.422 0.432 0.443 0.453 0.462 0.47 0.478 0.486 0.495 0.504 0.513 0.522 0.53 0.539 0.548 0.556 0.564 0.57
WestPokot 0.153 0.16 0.168 0.176 0.183 0.19 0.196 0.203 0.211 0.219 0.23 0.24 0.25 0.258 0.264 0.27 0.275 0.279 0.28 0.281 0.283 0.284 0.286 0.289 0.292 0.296 0.301 0.308 0.314 0.321 0.328 0.335 0.343 0.351 0.359 0.367 0.373
Bungoma 0.199 0.214 0.228 0.242 0.254 0.266 0.277 0.287 0.296 0.305 0.316 0.327 0.336 0.345 0.354 0.362 0.37 0.378 0.385 0.392 0.399 0.406 0.413 0.42 0.426 0.432 0.438 0.444 0.45 0.456 0.462 0.469 0.477 0.484 0.492 0.499 0.505
Busia 0.235 0.246 0.256 0.266 0.276 0.285 0.294 0.303 0.312 0.321 0.331 0.341 0.35 0.359 0.365 0.371 0.377 0.382 0.385 0.387 0.39 0.393 0.396 0.399 0.402 0.406 0.41 0.415 0.421 0.427 0.433 0.44 0.447 0.454 0.461 0.468 0.473
Kakamega 0.23 0.241 0.252 0.263 0.273 0.283 0.292 0.302 0.311 0.321 0.332 0.344 0.355 0.365 0.374 0.383 0.39 0.397 0.402 0.405 0.408 0.411 0.414 0.417 0.421 0.426 0.431 0.438 0.444 0.45 0.457 0.463 0.47 0.477 0.484 0.491 0.496
Vihiga 0.258 0.27 0.281 0.293 0.304 0.315 0.325 0.334 0.344 0.352 0.361 0.37 0.378 0.385 0.391 0.397 0.401 0.405 0.408 0.409 0.41 0.412 0.415 0.418 0.422 0.428 0.436 0.446 0.456 0.467 0.476 0.485 0.493 0.5 0.507 0.513 0.517
Southern Sub-Saharan Africa 0.505 0.511 0.516 0.521 0.527 0.531 0.536 0.541 0.546 0.552 0.558 0.564 0.57 0.577 0.583 0.589 0.595 0.601 0.606 0.611 0.615 0.62 0.625 0.63 0.635 0.64 0.646 0.651 0.656 0.661 0.666 0.672 0.677 0.681 0.685 0.689 0.691
Botswana 0.404 0.414 0.423 0.432 0.441 0.451 0.461 0.471 0.484 0.497 0.508 0.518 0.527 0.536 0.544 0.552 0.56 0.569 0.578 0.587 0.595 0.602 0.609 0.616 0.623 0.631 0.638 0.645 0.65 0.656 0.662 0.669 0.675 0.682 0.689 0.695 0.701
Lesotho 0.323 0.328 0.333 0.337 0.341 0.345 0.349 0.353 0.358 0.364 0.37 0.376 0.383 0.39 0.397 0.403 0.41 0.417 0.423 0.429 0.435 0.442 0.448 0.455 0.462 0.469 0.475 0.482 0.489 0.496 0.504 0.513 0.521 0.529 0.538 0.545 0.552
Namibia 0.374 0.38 0.385 0.39 0.395 0.399 0.404 0.41 0.416 0.422 0.427 0.433 0.441 0.45 0.459 0.469 0.478 0.488 0.497 0.505 0.514 0.522 0.531 0.539 0.547 0.555 0.563 0.569 0.575 0.58 0.586 0.591 0.597 0.604 0.611 0.618 0.624
South Africa 0.542 0.548 0.554 0.559 0.564 0.569 0.574 0.579 0.584 0.59 0.596 0.601 0.606 0.613 0.619 0.624 0.63 0.636 0.64 0.645 0.649 0.653 0.658 0.663 0.669 0.675 0.682 0.688 0.695 0.701 0.707 0.714 0.719 0.724 0.727 0.73 0.734
Swaziland 0.384 0.391 0.398 0.404 0.41 0.415 0.421 0.429 0.437 0.446 0.454 0.462 0.47 0.477 0.484 0.491 0.498 0.504 0.509 0.514 0.518 0.522 0.525 0.528 0.531 0.534 0.537 0.538 0.538 0.539 0.544 0.553 0.562 0.571 0.578 0.584 0.589
Zimbabwe 0.357 0.364 0.37 0.377 0.384 0.39 0.397 0.403 0.412 0.422 0.432 0.443 0.452 0.461 0.47 0.477 0.486 0.493 0.498 0.502 0.505 0.507 0.508 0.506 0.503 0.498 0.492 0.485 0.477 0.472 0.469 0.47 0.474 0.479 0.485 0.491 0.497
Eastern Cape 0.495 0.501 0.506 0.511 0.516 0.521 0.524 0.528 0.533 0.538 0.543 0.547 0.551 0.557 0.562 0.567 0.573 0.578 0.583 0.587 0.591 0.596 0.601 0.606 0.612 0.618 0.626 0.633 0.64 0.647 0.653 0.66 0.665 0.67 0.673 0.676 0.679
Free State 0.546 0.551 0.556 0.56 0.564 0.568 0.572 0.576 0.581 0.586 0.591 0.597 0.602 0.609 0.617 0.624 0.631 0.637 0.641 0.645 0.649 0.652 0.656 0.661 0.666 0.672 0.678 0.684 0.69 0.696 0.702 0.708 0.714 0.718 0.721 0.724 0.727
Gauteng 0.656 0.66 0.664 0.667 0.671 0.674 0.677 0.681 0.684 0.688 0.692 0.695 0.698 0.702 0.705 0.707 0.709 0.712 0.715 0.718 0.721 0.724 0.728 0.731 0.735 0.74 0.744 0.749 0.754 0.759 0.763 0.768 0.773 0.775 0.778 0.78 0.782
KwaZulu-Natal 0.521 0.527 0.532 0.537 0.542 0.546 0.551 0.555 0.56 0.566 0.571 0.576 0.581 0.588 0.594 0.599 0.605 0.61 0.615 0.619 0.624 0.629 0.634 0.639 0.645 0.651 0.658 0.665 0.672 0.679 0.685 0.692 0.698 0.702 0.706 0.71 0.713
Limpopo 0.447 0.454 0.461 0.467 0.473 0.479 0.484 0.49 0.497 0.504 0.511 0.518 0.524 0.532 0.54 0.547 0.554 0.562 0.568 0.572 0.577 0.582 0.588 0.594 0.602 0.61 0.618 0.627 0.636 0.643 0.651 0.659 0.665 0.671 0.675 0.679 0.682
Mpumalanga 0.495 0.502 0.508 0.514 0.52 0.525 0.531 0.537 0.543 0.55 0.557 0.563 0.57 0.577 0.584 0.589 0.595 0.601 0.606 0.61 0.615 0.62 0.625 0.631 0.637 0.644 0.652 0.659 0.667 0.674 0.681 0.688 0.695 0.7 0.703 0.707 0.71
North-West 0.523 0.529 0.534 0.539 0.545 0.55 0.555 0.56 0.565 0.571 0.576 0.58 0.585 0.59 0.594 0.597 0.6 0.604 0.608 0.613 0.618 0.623 0.628 0.633 0.639 0.645 0.651 0.658 0.664 0.671 0.677 0.683 0.689 0.693 0.696 0.699 0.702
Northern Cape 0.545 0.55 0.555 0.559 0.564 0.568 0.572 0.576 0.58 0.585 0.59 0.594 0.598 0.603 0.607 0.61 0.614 0.619 0.623 0.626 0.63 0.633 0.637 0.641 0.646 0.652 0.658 0.664 0.67 0.675 0.681 0.688 0.693 0.697 0.7 0.704 0.707
Western Cape 0.653 0.657 0.66 0.662 0.665 0.668 0.67 0.672 0.675 0.678 0.681 0.684 0.687 0.691 0.695 0.698 0.703 0.708 0.711 0.713 0.715 0.717 0.72 0.722 0.725 0.728 0.732 0.736 0.74 0.744 0.748 0.752 0.756 0.758 0.76 0.762 0.764
Western Sub-Saharan Africa 0.254 0.259 0.263 0.268 0.272 0.276 0.279 0.281 0.282 0.285 0.287 0.29 0.293 0.297 0.301 0.305 0.31 0.314 0.318 0.322 0.326 0.33 0.335 0.339 0.345 0.351 0.357 0.364 0.37 0.376 0.383 0.391 0.399 0.407 0.415 0.423 0.428
Benin 0.171 0.175 0.178 0.182 0.187 0.192 0.197 0.202 0.207 0.212 0.217 0.222 0.227 0.233 0.237 0.242 0.247 0.252 0.257 0.262 0.267 0.273 0.278 0.283 0.288 0.293 0.298 0.304 0.31 0.315 0.32 0.326 0.33 0.335 0.34 0.346 0.351
Burkina Faso 0.103 0.106 0.108 0.109 0.111 0.113 0.115 0.117 0.12 0.123 0.125 0.13 0.136 0.141 0.146 0.15 0.155 0.16 0.165 0.169 0.173 0.178 0.182 0.186 0.191 0.195 0.2 0.206 0.212 0.217 0.225 0.234 0.244 0.253 0.262 0.269 0.274
Cameroon 0.283 0.289 0.296 0.302 0.309 0.316 0.322 0.327 0.332 0.337 0.341 0.345 0.349 0.353 0.356 0.36 0.364 0.369 0.374 0.379 0.383 0.388 0.392 0.396 0.4 0.403 0.406 0.409 0.412 0.415 0.419 0.423 0.428 0.433 0.439 0.445 0.451
Cape Verde 0.241 0.248 0.256 0.263 0.271 0.279 0.287 0.294 0.302 0.31 0.317 0.325 0.332 0.34 0.349 0.358 0.367 0.377 0.387 0.399 0.41 0.421 0.431 0.442 0.452 0.462 0.473 0.484 0.495 0.505 0.514 0.524 0.534 0.542 0.551 0.559 0.566
Chad 0.158 0.159 0.159 0.161 0.163 0.166 0.169 0.172 0.175 0.179 0.183 0.187 0.191 0.194 0.197 0.2 0.203 0.206 0.209 0.212 0.214 0.217 0.219 0.222 0.228 0.235 0.241 0.247 0.252 0.257 0.262 0.268 0.274 0.28 0.285 0.29 0.295
Cote d'Ivoire 0.225 0.226 0.227 0.228 0.23 0.234 0.241 0.249 0.258 0.267 0.277 0.287 0.297 0.306 0.313 0.32 0.327 0.332 0.337 0.341 0.345 0.348 0.351 0.353 0.355 0.358 0.36 0.363 0.366 0.369 0.373 0.377 0.382 0.388 0.394 0.401 0.407
The Gambia 0.205 0.21 0.215 0.221 0.226 0.232 0.237 0.242 0.247 0.251 0.254 0.255 0.255 0.255 0.254 0.254 0.255 0.259 0.264 0.269 0.274 0.28 0.285 0.29 0.295 0.3 0.305 0.31 0.315 0.32 0.325 0.329 0.334 0.339 0.344 0.349 0.352
Ghana 0.309 0.313 0.315 0.317 0.32 0.323 0.326 0.33 0.338 0.347 0.356 0.366 0.375 0.384 0.392 0.401 0.409 0.416 0.421 0.426 0.429 0.431 0.433 0.436 0.438 0.44 0.443 0.446 0.448 0.449 0.451 0.457 0.466 0.477 0.486 0.494 0.499
Guinea 0.181 0.184 0.188 0.191 0.194 0.197 0.2 0.203 0.207 0.21 0.213 0.217 0.22 0.223 0.226 0.23 0.233 0.237 0.24 0.243 0.246 0.249 0.251 0.254 0.257 0.26 0.264 0.268 0.273 0.277 0.282 0.288 0.293 0.299 0.305 0.311 0.316
Guinea-Bissau 0.176 0.179 0.182 0.184 0.187 0.19 0.193 0.197 0.2 0.204 0.208 0.213 0.217 0.222 0.226 0.231 0.236 0.242 0.246 0.25 0.254 0.258 0.262 0.266 0.27 0.274 0.279 0.283 0.288 0.293 0.298 0.305 0.31 0.316 0.322 0.328 0.333
Liberia 0.198 0.201 0.203 0.205 0.207 0.209 0.211 0.213 0.216 0.219 0.218 0.218 0.215 0.211 0.204 0.196 0.186 0.183 0.184 0.19 0.204 0.218 0.234 0.241 0.247 0.253 0.258 0.264 0.27 0.276 0.282 0.289 0.298 0.307 0.314 0.321 0.327
Mali 0.114 0.117 0.118 0.12 0.122 0.124 0.127 0.129 0.131 0.135 0.138 0.142 0.146 0.15 0.153 0.157 0.161 0.164 0.168 0.172 0.176 0.18 0.185 0.19 0.195 0.2 0.205 0.211 0.217 0.223 0.23 0.237 0.243 0.249 0.256 0.262 0.267
Mauritania 0.273 0.279 0.283 0.288 0.293 0.297 0.302 0.307 0.312 0.317 0.322 0.327 0.332 0.338 0.344 0.349 0.356 0.361 0.366 0.372 0.376 0.381 0.386 0.391 0.396 0.402 0.41 0.417 0.424 0.431 0.438 0.445 0.452 0.46 0.468 0.475 0.482
Niger 0.119 0.121 0.123 0.126 0.127 0.129 0.131 0.133 0.135 0.136 0.138 0.139 0.14 0.141 0.141 0.141 0.142 0.143 0.145 0.146 0.148 0.149 0.152 0.154 0.156 0.158 0.161 0.163 0.166 0.169 0.172 0.175 0.179 0.183 0.188 0.192 0.195
Nigeria 0.289 0.296 0.303 0.309 0.314 0.32 0.323 0.323 0.323 0.322 0.322 0.322 0.324 0.327 0.33 0.333 0.337 0.341 0.345 0.349 0.353 0.358 0.364 0.369 0.377 0.385 0.392 0.4 0.407 0.414 0.423 0.433 0.443 0.454 0.464 0.473 0.479
Sao Tome and Principe 0.237 0.243 0.248 0.254 0.259 0.265 0.27 0.275 0.279 0.284 0.289 0.294 0.299 0.304 0.31 0.315 0.32 0.326 0.331 0.336 0.34 0.346 0.351 0.357 0.363 0.369 0.376 0.382 0.388 0.393 0.398 0.403 0.408 0.413 0.42 0.427 0.434
Senegal 0.197 0.2 0.204 0.208 0.211 0.216 0.22 0.225 0.23 0.235 0.24 0.245 0.251 0.257 0.263 0.27 0.276 0.283 0.29 0.295 0.299 0.302 0.304 0.307 0.309 0.312 0.314 0.317 0.32 0.324 0.327 0.331 0.336 0.34 0.345 0.35 0.354
Sierra Leone 0.186 0.189 0.192 0.195 0.198 0.201 0.204 0.207 0.21 0.214 0.217 0.222 0.225 0.229 0.233 0.237 0.241 0.243 0.246 0.247 0.249 0.252 0.257 0.262 0.268 0.273 0.279 0.286 0.292 0.299 0.306 0.313 0.322 0.332 0.341 0.348 0.352
Togo 0.208 0.212 0.215 0.218 0.222 0.225 0.228 0.232 0.236 0.242 0.248 0.255 0.261 0.267 0.273 0.28 0.288 0.296 0.301 0.307 0.312 0.317 0.321 0.326 0.331 0.336 0.341 0.346 0.351 0.356 0.361 0.367 0.373 0.379 0.385 0.392 0.397
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